{"meta":{"query_hash":"b064781980c7","filters":{"topic":"Biosimilars and Bioanalytical Methods"},"cohort_total":876,"direct_labels_cover":4,"predictions_cover":876,"exported":876,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/b064781980c7","api":"https://metacan.xera.ac/api/v1/cohort?topic=Biosimilars+and+Bioanalytical+Methods"},"results":[{"id":"W1424849964","doi":"10.2165/11593730-000000000-00000","title":"Biosimilars of Biological Drug Therapies","year":2011,"lang":"en","type":"review","venue":"Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Biosimilar; Risk analysis (engineering); Medicine; Immunogenicity; Drug; Pharmacology; Intensive care medicine; Immune system; Immunology","score_opus":0.10087913348773116,"score_gpt":0.349562527575078,"score_spread":0.24868339408734685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1424849964","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007784657,0.9935172,0.000010546931,0.000060606162,0.0006700474,0.0003347086,0.0001976025,0.000057972327,0.0051435097],"genre_scores_gemma":[0.00002850444,0.9966502,0.0006026501,0.00017125005,0.000043317483,0.00002846509,0.00008317368,0.00003039878,0.0023620476],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756205,0.0007977711,0.0007431851,0.00047216652,0.000029495759,0.00039531637],"domain_scores_gemma":[0.99851835,0.00047467678,0.0004128721,0.0005064698,0.000055749635,0.000031883654],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006083546,0.00046150276,0.0021694836,0.00017674599,0.00006554337,0.0000067497626,0.0006251435,0.0010823202,0.0027960918],"category_scores_gemma":[0.000075948126,0.00026546372,0.00093745906,0.00026943977,0.000759275,0.000022680684,0.00019941683,0.0005917846,0.0003382288],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014085675,0.00012236442,0.000005901209,0.0014461188,0.0006606467,0.0000017025443,0.00015833309,6.879328e-10,0.000035332247,0.0020329019,0.010020307,0.9855023],"study_design_scores_gemma":[0.00014323325,0.00007865229,0.0000049611926,0.0015382675,0.00051504286,0.000018834811,0.00005544397,1.7624124e-8,0.00035595387,0.0003893808,0.9965847,0.00031551087],"about_ca_topic_score_codex":0.000013453385,"about_ca_topic_score_gemma":9.4033015e-7,"teacher_disagreement_score":0.9865644,"about_ca_system_score_codex":0.000020532023,"about_ca_system_score_gemma":0.00008606008,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W146525475","doi":"","title":"LDP-02 (Millenium).","year":2001,"lang":"en","type":"article","venue":"PubMed","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Inflammatory bowel disease; Ulcerative colitis; Inflammatory Bowel Diseases; Monoclonal antibody; Family medicine; Internal medicine; Immunology; Antibody; Disease","score_opus":0.03578358900087965,"score_gpt":0.24695762472079252,"score_spread":0.2111740357199129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W146525475","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45724642,0.018632766,0.0016458186,0.021198543,0.007976079,0.0016214366,0.000052451338,0.0006742039,0.49095228],"genre_scores_gemma":[0.9684985,0.00026328312,0.00024083798,0.0012601349,0.00008614884,0.00019855081,0.000006955675,0.000010423959,0.029435122],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907017,0.000106324616,0.00015554033,0.00020660424,0.000021860205,0.00043951187],"domain_scores_gemma":[0.99959254,0.00011841239,0.000021949072,0.0002019433,0.000026322723,0.000038806662],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003261936,0.00010200216,0.00016593952,0.000049178892,0.00007581986,0.000011136998,0.0001583968,0.00020778907,0.0012219093],"category_scores_gemma":[0.00015670656,0.00007661499,0.0000854383,0.00014389957,0.00013737536,0.000035045417,0.000055520195,0.00017953597,0.00030136874],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001457149,0.00016448824,0.012792503,0.000007351076,0.00018043861,0.000013763137,0.00002692925,2.1939375e-7,0.006020198,0.0022718548,0.062271643,0.9161049],"study_design_scores_gemma":[0.0004602818,0.000020463714,0.1581168,0.0000016167394,0.000032814347,0.00006262806,0.000018075809,8.249576e-7,0.018926326,0.0003741249,0.8218557,0.00013032678],"about_ca_topic_score_codex":0.000013885447,"about_ca_topic_score_gemma":0.00000667594,"teacher_disagreement_score":0.91597456,"about_ca_system_score_codex":0.00001767612,"about_ca_system_score_gemma":0.00000661216,"threshold_uncertainty_score":0.9996911},"labels":[],"label_agreement":null},{"id":"W1502370099","doi":"10.4161/mabs.28831","title":"Antibody biosimilars: Fears or opportunities?","year":2014,"lang":"en","type":"article","venue":"mAbs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"Genentech","keywords":"Biosimilar; Pharmacovigilance; Context (archaeology); Agency (philosophy); Session (web analytics); European union; Business; Quality (philosophy); Competitor analysis; General partnership; Marketing; Public relations; Medicine; Political science; Finance; Pharmacology; International trade; Advertising; Sociology","score_opus":0.07391033678415444,"score_gpt":0.3336394204290503,"score_spread":0.2597290836448959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1502370099","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32447985,0.008925414,0.05402748,0.1034416,0.014893528,0.0019617865,0.0005263486,0.0021571175,0.4895869],"genre_scores_gemma":[0.914534,0.0004553213,0.0041952943,0.017326677,0.000205189,0.000014371844,0.00018691734,0.000047124635,0.06303516],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989254,0.00023779369,0.00021414961,0.0002479175,0.00003243894,0.0003422856],"domain_scores_gemma":[0.9993653,0.0001856636,0.000058603244,0.0003011751,0.00004821019,0.000040996132],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004710082,0.00015092109,0.00025328572,0.000074733885,0.00012336575,0.000022203541,0.00021177038,0.00026448048,0.0049572038],"category_scores_gemma":[0.00019633902,0.00010066345,0.000090093694,0.00011160199,0.00024518912,0.000046973608,0.000087647815,0.00020438955,0.00040419478],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055324845,0.00039034913,0.0031625405,0.000095694144,0.00038264276,0.000055991783,0.00017768674,5.8984017e-7,0.62935966,0.02128345,0.15253103,0.19200708],"study_design_scores_gemma":[0.00062456744,0.00029029918,0.0027175632,0.00002891279,0.00004759314,0.000051971743,0.00012582402,0.000021092841,0.02406858,0.00065354124,0.97115755,0.00021248896],"about_ca_topic_score_codex":0.000009641369,"about_ca_topic_score_gemma":0.000006411221,"teacher_disagreement_score":0.8186265,"about_ca_system_score_codex":0.000012035214,"about_ca_system_score_gemma":0.00002930202,"threshold_uncertainty_score":0.9959524},"labels":[],"label_agreement":null},{"id":"W1515542254","doi":"10.1023/a:1007669411738","title":"Bioanalytical Method Validation—A Revisit with a Decade of Progress","year":2000,"lang":"en","type":"article","venue":"Pharmaceutical Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1571,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada); University of Saskatchewan","funders":"","keywords":"Bioanalysis; Data science; Computer science; Computational biology; Nanotechnology; Biochemical engineering; Engineering ethics; Biology; Engineering; Materials science","score_opus":0.17049249684697565,"score_gpt":0.5186894285672768,"score_spread":0.3481969317203012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1515542254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5000344,0.05729895,0.02821009,0.11017964,0.0007020214,0.007987886,0.00045777316,0.0008053263,0.29432392],"genre_scores_gemma":[0.9450496,0.0006183241,0.040629245,0.00045926048,0.00009762941,0.0000688241,0.000018404166,0.000041961895,0.013016772],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996249,0.0017404447,0.00040861938,0.0004883847,0.00030172558,0.0008118228],"domain_scores_gemma":[0.99753916,0.0015120201,0.000036598518,0.00037132078,0.000382692,0.00015822306],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037922987,0.00017489895,0.00041430054,0.00019814487,0.00016722028,0.00003129094,0.0004418785,0.00026908453,0.024017887],"category_scores_gemma":[0.0004006419,0.00011469895,0.00011698436,0.001014595,0.0016637295,0.00007210963,0.00011283053,0.0010853859,0.00045946857],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034150449,0.001147942,0.005621872,0.00023259716,0.0007445969,0.000049735907,0.00012493128,0.0000037176012,0.054199297,0.018963423,0.0062556644,0.9092412],"study_design_scores_gemma":[0.0017289915,0.0006483043,0.0014169322,0.000108919776,0.00019200057,0.000093337134,0.000055323835,0.0005703649,0.5946772,0.0011900299,0.3990651,0.0002534979],"about_ca_topic_score_codex":0.000013775417,"about_ca_topic_score_gemma":9.1472305e-7,"teacher_disagreement_score":0.9089877,"about_ca_system_score_codex":0.000039632134,"about_ca_system_score_gemma":0.00011845004,"threshold_uncertainty_score":0.9768743},"labels":[],"label_agreement":null},{"id":"W1546223511","doi":"10.18433/j39014","title":"The Success Rate of New Drug Development in Clinical Trials: Crohn’s Disease","year":2010,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Government of Canada","keywords":"Crohn's disease; Medicine; Drug; Disease; Clinical trial; Drug development; Drug trial; Internal medicine; Intensive care medicine; Pharmacology","score_opus":0.2474602037292657,"score_gpt":0.5358302856649946,"score_spread":0.2883700819357289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1546223511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721973,0.0073536546,0.0001516378,0.015423174,0.0043499,0.00023234932,0.000005351048,0.000007633201,0.00027903065],"genre_scores_gemma":[0.99523115,0.0016171485,0.0013373658,0.0010489611,0.00029487352,0.00000218238,3.3414943e-7,0.0000057832194,0.00046220914],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943749,0.0024920907,0.0022418352,0.00024626832,0.00017983443,0.00046508707],"domain_scores_gemma":[0.99342686,0.0051380494,0.00081412937,0.00012736273,0.00017367,0.0003199511],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.03632537,0.00017307182,0.0006262628,0.00013170138,0.0002640309,0.000066251836,0.0010498636,0.00008305205,0.0011183368],"category_scores_gemma":[0.00523885,0.000087309505,0.00035426085,0.0004424196,0.0017307332,0.00021378683,0.00015160022,0.0013454987,0.00001747395],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028129602,0.00064417836,0.0824893,0.000024786521,0.00021535553,0.00006628374,0.00015963177,0.0000058983205,0.10089393,0.0015927993,0.009538261,0.80155665],"study_design_scores_gemma":[0.0036268604,0.00006144551,0.06839559,0.00004467684,0.00018376083,0.000027955224,0.00006910239,0.00023091816,0.18026118,0.0009872864,0.74594414,0.00016705734],"about_ca_topic_score_codex":0.000023630731,"about_ca_topic_score_gemma":0.000034344608,"teacher_disagreement_score":0.8013896,"about_ca_system_score_codex":0.000020009122,"about_ca_system_score_gemma":0.00108019,"threshold_uncertainty_score":0.9997948},"labels":[],"label_agreement":null},{"id":"W1557131311","doi":"10.1159/000421658","title":"Effects of Staphylococcal Toxins on T-Cell Activity in vivo","year":2015,"lang":"en","type":"article","venue":"Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"In vivo; Microbial toxins; Microbiology; Chemistry; Biology; Toxin; Genetics","score_opus":0.013310787383914538,"score_gpt":0.26016310512663704,"score_spread":0.2468523177427225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1557131311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9501334,0.044435937,0.00004618931,0.0010866204,0.0009130417,0.00069995906,0.000029104393,0.00015933932,0.0024963978],"genre_scores_gemma":[0.9945637,0.003016038,0.0010131755,0.0004575111,0.00007342835,0.00027463492,0.0000548535,0.0000998289,0.00044682124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99366903,0.0008086806,0.0015712784,0.0017379216,0.00023931894,0.0019737696],"domain_scores_gemma":[0.9968076,0.0012202917,0.0005060871,0.001023375,0.00021330689,0.00022939022],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00073477847,0.0011529594,0.0021094533,0.00080069184,0.00011501147,0.00003607534,0.0012563135,0.0030702162,0.00026153916],"category_scores_gemma":[0.000488626,0.0010636102,0.00041530762,0.00096289197,0.0035946704,0.00024919404,0.0011257926,0.0029452061,0.00004563622],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005232282,0.0043368675,0.0016602061,0.00013330362,0.0015865405,0.00030108867,0.00043148504,0.0000048772577,0.96684724,0.003034626,0.0014298147,0.0150016695],"study_design_scores_gemma":[0.011658372,0.000973247,0.003839154,0.00031794686,0.000059293976,0.00013739831,0.00027390907,0.000058484173,0.96418625,0.0014760708,0.015884137,0.0011357099],"about_ca_topic_score_codex":0.00013530994,"about_ca_topic_score_gemma":0.000043564247,"teacher_disagreement_score":0.044430297,"about_ca_system_score_codex":0.00021906997,"about_ca_system_score_gemma":0.00022766278,"threshold_uncertainty_score":0.999355},"labels":[],"label_agreement":null},{"id":"W1557591541","doi":"10.1016/j.semarthrit.2015.04.005","title":"Biosimilar safety factors in clinical practice","year":2015,"lang":"en","type":"article","venue":"Seminars in Arthritis and Rheumatism","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Biosimilar; Interchangeability; Medicine; Pharmacovigilance; Comparability; Risk analysis (engineering); Infliximab; Pharmacology; Drug; Immunology","score_opus":0.03552871885710963,"score_gpt":0.33889712554891854,"score_spread":0.3033684066918089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1557591541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7139602,0.27056867,0.00013054104,0.0037409705,0.0017309304,0.00034849867,0.000055435037,0.000049387585,0.00941536],"genre_scores_gemma":[0.7912968,0.20104285,0.0065043797,0.0006588745,0.000016926877,0.0000068674935,0.000020510946,0.00001494212,0.00043789225],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99767834,0.0007264932,0.0007953545,0.00037521034,0.000058469734,0.00036611492],"domain_scores_gemma":[0.9985903,0.00094678195,0.0001255903,0.0002084629,0.000046794896,0.00008206795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026604843,0.00018490088,0.0005136885,0.00012783108,0.000060008068,0.000021142756,0.00013299723,0.0004744043,0.00014911477],"category_scores_gemma":[0.0021285843,0.00015107616,0.000065383974,0.00021581669,0.00038729017,0.00017458988,0.00012578955,0.00059244863,0.00003206649],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002461986,0.00033506987,0.112181574,0.00000991054,0.000040222665,0.00007802469,0.001048451,9.581023e-7,0.00023664952,0.0025757249,0.008592548,0.87465465],"study_design_scores_gemma":[0.015850129,0.0019633158,0.57639104,0.011842447,0.00006083302,0.000904651,0.009888284,0.000114923656,0.0041929134,0.008933691,0.36839074,0.0014670404],"about_ca_topic_score_codex":0.00018590617,"about_ca_topic_score_gemma":0.00025090706,"teacher_disagreement_score":0.8731876,"about_ca_system_score_codex":0.000036115885,"about_ca_system_score_gemma":0.000057059155,"threshold_uncertainty_score":0.61607075},"labels":[],"label_agreement":null},{"id":"W1569497166","doi":"10.1002/9780470571224.pse304","title":"Unexpected Benefits of a Formulation: Case Study with Erythropoetin","year":2010,"lang":"en","type":"other","venue":"Pharmaceutical Sciences Encyclopedia","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Erythropoietin; Recombinant DNA; Medicine; Concomitant; Dialysis; Anemia; Chronic renal failure; Glycoprotein; Pharmacology; Internal medicine; Chemistry; Biochemistry; Gene","score_opus":0.0515299663339278,"score_gpt":0.3692711278659384,"score_spread":0.3177411615320106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1569497166","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05228582,0.006379999,0.00015130317,0.00044650616,0.0017417013,0.0016849387,0.00016446508,0.0002609684,0.9368843],"genre_scores_gemma":[0.61314636,0.0013623805,0.012806357,0.000457447,0.0007336909,0.00011969852,0.000032054686,0.0003697142,0.3709723],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998156,0.00024008988,0.00037415404,0.000601726,0.00015614131,0.00047186797],"domain_scores_gemma":[0.9990651,0.0002673289,0.00022976544,0.00028499428,0.000066498906,0.00008631635],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054088695,0.00032982253,0.000529482,0.0002201454,0.00016844546,0.000019121446,0.00039235665,0.00048486114,0.013390389],"category_scores_gemma":[0.00008650249,0.00020460384,0.00008308767,0.0006484187,0.001312731,0.000046122488,0.00014312801,0.0006757128,0.00005709965],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001395248,0.011596881,0.12713361,0.000855612,0.0038002313,0.003200397,0.003471352,0.00002087197,0.012787672,0.01522235,0.26898193,0.5515338],"study_design_scores_gemma":[0.00254384,0.0022848973,0.0009219201,0.0001437714,0.000814941,0.0016473634,0.000986347,0.000038711347,0.0029173961,0.000057177327,0.98680645,0.0008371583],"about_ca_topic_score_codex":0.00053692755,"about_ca_topic_score_gemma":0.0011705345,"teacher_disagreement_score":0.7178245,"about_ca_system_score_codex":0.000012035062,"about_ca_system_score_gemma":0.00010648645,"threshold_uncertainty_score":0.9875115},"labels":[],"label_agreement":null},{"id":"W1572535247","doi":"","title":"Collaborative study for the establishment of erythropoietin BRP batch 3.","year":2007,"lang":"en","type":"article","venue":"PubMed","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erythropoietin; Context (archaeology); Bioassay; Pharmacopoeia; Computer science; Biotechnology; Operations research; Biochemical engineering; Biology; Engineering; Medicine; Genetics","score_opus":0.02504603255670758,"score_gpt":0.2953780402006099,"score_spread":0.27033200764390236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1572535247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85610795,0.022262787,0.033490956,0.026297282,0.011788204,0.028337322,0.0006417683,0.00023274505,0.020840961],"genre_scores_gemma":[0.99652994,0.000028291299,0.0005866865,0.00021050312,0.000043329936,0.0004957815,0.000003728008,0.000007483936,0.0020942488],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99902177,0.00013192264,0.0002797798,0.00018154937,0.00003813224,0.00034682383],"domain_scores_gemma":[0.9980956,0.0014009048,0.000102986494,0.00021575284,0.00016366494,0.000021098582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023770432,0.00009844774,0.00021272787,0.00003990322,0.00011682894,0.000010236007,0.00019328117,0.00011160986,0.00008892518],"category_scores_gemma":[0.00048903894,0.00005636403,0.00006879172,0.00027059665,0.0002520225,0.000024954505,0.000060642236,0.000119949575,0.0000031820714],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021549743,0.0025426643,0.0344045,0.000043638556,0.0018117827,0.000004358819,0.0020669126,0.0000018839181,0.0062215747,0.0032614602,0.057319265,0.890167],"study_design_scores_gemma":[0.0024473397,0.00046338103,0.63255817,0.0000039762103,0.0002788839,0.0000034483082,0.0077677765,0.000001531887,0.11241996,0.00028540604,0.24359086,0.00017925707],"about_ca_topic_score_codex":0.000032000386,"about_ca_topic_score_gemma":0.00008484887,"teacher_disagreement_score":0.8899877,"about_ca_system_score_codex":0.000022744478,"about_ca_system_score_gemma":0.000019271587,"threshold_uncertainty_score":0.22984585},"labels":[],"label_agreement":null},{"id":"W1572610401","doi":"10.1155/2015/427235","title":"Physicochemical and Biological Characterization of a Biosimilar Trastuzumab","year":2015,"lang":"en","type":"article","venue":"BioMed Research International","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Consejo Nacional de Ciencia y Tecnología","keywords":"Biosimilar; Trastuzumab; Medicine; Biological drugs; Pharmacodynamics; Pharmacology; Comparability; Computational biology; Pharmacokinetics; Cancer; Biology; Internal medicine; Rheumatoid arthritis; Breast cancer","score_opus":0.19161386733534402,"score_gpt":0.4119554068363072,"score_spread":0.2203415395009632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1572610401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99264693,0.00030403543,0.00044787794,0.0038735908,0.0007116921,0.00015391658,0.00015240455,0.000024168427,0.0016853699],"genre_scores_gemma":[0.99831975,0.00012889529,0.00058241683,0.00008088804,0.000119816716,0.000012385839,0.00016152607,0.000005580366,0.0005887672],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989141,0.00027105893,0.00021169597,0.00023300647,0.0001380195,0.00023211776],"domain_scores_gemma":[0.99931014,0.00015309006,0.000049334645,0.00010911703,0.00031637988,0.00006194282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095770904,0.000083135514,0.0001619092,0.00020405638,0.000042305062,0.000015872,0.0002315616,0.00020126381,0.00027363605],"category_scores_gemma":[0.0004375448,0.000059691734,0.000043711658,0.00018987175,0.0008184623,0.000054706215,0.00018432002,0.00023119136,0.000032467924],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019237114,0.0001899406,0.0013242995,0.0000045748934,0.00007918888,0.0000018464433,0.00008338022,1.0577815e-8,0.9845432,0.0016399692,0.002855657,0.009085573],"study_design_scores_gemma":[0.0012734217,0.00045513595,0.019649476,0.000030062434,0.000006447009,0.000031433858,0.00019641031,0.00007349966,0.84562457,0.0018409556,0.13068922,0.0001293715],"about_ca_topic_score_codex":0.0000107702,"about_ca_topic_score_gemma":3.820895e-7,"teacher_disagreement_score":0.13891862,"about_ca_system_score_codex":0.000046059376,"about_ca_system_score_gemma":0.00005521899,"threshold_uncertainty_score":0.30156583},"labels":[],"label_agreement":null},{"id":"W1586431308","doi":"10.1002/rcm.5182","title":"Pre‐cut dried blood spot (PCDBS): an alternative to dried blood spot (DBS) technique to overcome hematocrit impact","year":2011,"lang":"en","type":"article","venue":"Rapid Communications in Mass Spectrometry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum","funders":"","keywords":"Dried blood spot; Chemistry; Hematocrit; Chromatography; Analyte; Spotting; Dried blood; Analytical Chemistry (journal); Artificial intelligence; Internal medicine; Computer science","score_opus":0.048363609722493324,"score_gpt":0.34663324032089143,"score_spread":0.2982696305983981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1586431308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94034916,0.0030471033,0.020569306,0.0034723065,0.0004410389,0.0037515445,0.00042093516,0.0005767915,0.027371792],"genre_scores_gemma":[0.81897664,0.00038379058,0.17915066,0.00047872032,0.000037292382,0.00032276678,0.00006493249,0.000055848257,0.0005293257],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961375,0.0011962912,0.0008654448,0.0007649903,0.00013285199,0.0009029177],"domain_scores_gemma":[0.9949579,0.00053842965,0.00021992515,0.0038797567,0.00017230163,0.000231687],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001503356,0.00049607956,0.0008416165,0.0012130204,0.0003152671,0.00006041668,0.003100677,0.00052817434,0.0024965378],"category_scores_gemma":[0.00046926548,0.0004673125,0.00027520934,0.0020785898,0.00041247514,0.00026016813,0.0009444569,0.0013004624,0.00017457412],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047003847,0.0035608716,0.008437427,0.00002838283,0.0009117611,0.000022947916,0.0018422286,0.0000032249961,0.95642275,0.02621388,0.00042606107,0.0016604391],"study_design_scores_gemma":[0.0019338425,0.0028337294,0.038172413,0.00017459501,0.00036590509,0.00021808887,0.0004520139,0.000031237494,0.9352249,0.016589293,0.0030000126,0.0010039506],"about_ca_topic_score_codex":0.00054305064,"about_ca_topic_score_gemma":0.00021289018,"teacher_disagreement_score":0.15858135,"about_ca_system_score_codex":0.00020755974,"about_ca_system_score_gemma":0.00011382449,"threshold_uncertainty_score":0.99977785},"labels":[],"label_agreement":null},{"id":"W1599424821","doi":"10.1002/9780470249031.ch3","title":"Protein–Protein Interactions","year":2007,"lang":"en","type":"other","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chemistry; Computational biology; Biology","score_opus":0.026356078868901404,"score_gpt":0.3202403659035627,"score_spread":0.2938842870346613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1599424821","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000690524,0.0015110314,0.004689325,0.00043850136,0.0006338322,0.00046317605,0.000038010916,0.00029443338,0.99192476],"genre_scores_gemma":[0.00026914035,0.000011993442,0.0065910346,0.00038836626,0.0001430441,0.000026659427,0.000032007763,0.00016136449,0.9923764],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990709,0.0000989249,0.00019989542,0.00030479144,0.000023897544,0.0003016038],"domain_scores_gemma":[0.999506,0.00003034149,0.00010483656,0.00031300267,0.000020835143,0.000025014971],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00017363582,0.00022898703,0.0003063238,0.00030970474,0.000042680767,0.000010008472,0.00018033426,0.0007898292,0.18673648],"category_scores_gemma":[0.000047275793,0.0001631497,0.00013776656,0.000138674,0.00018405795,0.000012090506,0.000068965826,0.00054556516,0.004744],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001976278,0.00008389015,0.0000033902074,0.000026572852,0.00023113712,0.0000047755034,0.000002751663,1.2012172e-9,0.065315925,0.009604638,0.90604115,0.018666016],"study_design_scores_gemma":[0.00019137231,0.00004795945,0.0000052595783,0.00014236463,0.000034882356,0.000011830905,0.00000927319,1.2633963e-7,0.04850248,0.00022139693,0.95062286,0.00021020975],"about_ca_topic_score_codex":0.00017349211,"about_ca_topic_score_gemma":0.00012785326,"teacher_disagreement_score":0.18199249,"about_ca_system_score_codex":0.00002051328,"about_ca_system_score_gemma":0.000024873167,"threshold_uncertainty_score":0.9960309},"labels":[],"label_agreement":null},{"id":"W1604483245","doi":"10.1002/9780470571224.pse270","title":"Clinical Validation and Biomarker Translation","year":2010,"lang":"en","type":"other","venue":"Pharmaceutical Sciences Encyclopedia","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biomarker; Clinical trial; Biomarker discovery; Translation (biology); Translational medicine; Medicine; Data science; Computer science; Computational biology; Medical physics; Pathology; Biology; Proteomics","score_opus":0.12680046885027085,"score_gpt":0.4418950329190001,"score_spread":0.31509456406872927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1604483245","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003701086,0.009291903,0.0007103383,0.0013885525,0.00332414,0.0003642175,0.000050359202,0.00016529298,0.98433506],"genre_scores_gemma":[0.013264194,0.047174994,0.0400268,0.0031636613,0.0017819606,0.000059552265,0.00016400842,0.0003959113,0.89396894],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814624,0.00040422258,0.00037351664,0.00061125855,0.00008771749,0.00037706151],"domain_scores_gemma":[0.9991403,0.00046379765,0.00012651221,0.00015366985,0.000017193046,0.00009851653],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014507507,0.00023881246,0.0003545401,0.0001434802,0.00012960298,0.000045706172,0.00026801252,0.00097291643,0.014421327],"category_scores_gemma":[0.00017618714,0.00016964503,0.00010656123,0.00023547752,0.001985619,0.000069978974,0.00007733774,0.0007277997,0.00023668338],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025931888,0.000113238275,0.0031429406,0.000038760445,0.000088888955,0.0000020192563,0.000014402523,1.4437023e-8,0.0038980658,0.00078544015,0.14012392,0.8517664],"study_design_scores_gemma":[0.0004549876,0.00005900787,0.0008505015,0.00003082563,0.00015571357,0.00001232517,0.0000062983827,0.000047633042,0.00074482267,0.0002686034,0.99711686,0.00025243883],"about_ca_topic_score_codex":0.000030434403,"about_ca_topic_score_gemma":0.000027866974,"teacher_disagreement_score":0.8569929,"about_ca_system_score_codex":0.0000054721067,"about_ca_system_score_gemma":0.000055637476,"threshold_uncertainty_score":0.98647964},"labels":[],"label_agreement":null},{"id":"W1673822629","doi":"10.1002/jps.23663","title":"Development of a Human Antibody Tolerant Mouse Model to Assess the Immunogenicity Risk Due to Aggregated Biotherapeutics","year":2013,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"Amgen","keywords":"Immunogenicity; Antibody; Immune system; Antigen; Immunology; Biology; Immunoglobulin G","score_opus":0.14904415070760563,"score_gpt":0.43766471659895856,"score_spread":0.28862056589135293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1673822629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98170924,0.0005923923,0.014368232,0.002692432,0.00022358981,0.00024768693,0.000010335808,0.000007992718,0.00014809672],"genre_scores_gemma":[0.9647812,0.00006296951,0.03339325,0.0015812179,0.000026278363,0.0000033389726,3.575448e-7,0.000006068653,0.00014526972],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814016,0.00034245363,0.0007371664,0.00018841791,0.00019202252,0.0003998029],"domain_scores_gemma":[0.99890906,0.00024028984,0.0003075343,0.0001354928,0.00027717854,0.00013042221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025024356,0.00015577568,0.00038081035,0.00013685922,0.00041503325,0.000057715974,0.0008064461,0.00011739732,0.00041137869],"category_scores_gemma":[0.00015863597,0.00007991951,0.00013771279,0.0004714107,0.00053434283,0.000110010464,0.00016393255,0.00042166063,0.000033262477],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006849971,0.00019174589,0.00069703924,0.000006117376,0.00015320028,0.0000011162743,0.00043977675,0.0001511767,0.9781722,0.0002392563,0.0002255205,0.019654367],"study_design_scores_gemma":[0.00048969744,0.00038308918,0.003834797,0.00004686838,0.000094040995,0.000036329868,0.00027743858,0.0019104186,0.986238,0.0003258769,0.0061999783,0.00016348583],"about_ca_topic_score_codex":0.000026378353,"about_ca_topic_score_gemma":0.000007384709,"teacher_disagreement_score":0.019490883,"about_ca_system_score_codex":0.000040265015,"about_ca_system_score_gemma":0.0001636378,"threshold_uncertainty_score":0.4504308},"labels":[],"label_agreement":null},{"id":"W1732176471","doi":"10.1016/s0065-230x(06)96010-2","title":"Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development: Quantification of Emerging Protein Biomarkers","year":2006,"lang":"en","type":"review","venue":"Advances in cancer research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"American Association of Pharmaceutical Scientists","keywords":"Biomarker discovery; Drug development; Biomarker; Bioanalysis; Drug discovery; Proteomics; Computational biology; Identification (biology); Medicine; Bioinformatics; Drug; Biology; Pharmacology; Nanotechnology","score_opus":0.4573813166261274,"score_gpt":0.6054037194228601,"score_spread":0.14802240279673268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1732176471","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00078506593,0.9955448,0.00027385494,0.0003313439,0.0009127909,0.0017302883,0.00026939905,0.000012405034,0.00014007969],"genre_scores_gemma":[0.000934593,0.99461627,0.0020310942,0.000013557884,0.00007314701,0.0013860213,0.00012486456,0.00003652494,0.0007839494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928628,0.0033814523,0.0018849296,0.0009875253,0.00023128856,0.0006519745],"domain_scores_gemma":[0.99642676,0.002555207,0.00038437967,0.00039679275,0.00020093124,0.00003595332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006128129,0.00036562482,0.001742342,0.0008828027,0.000105675914,0.00002135068,0.0005445521,0.00051868224,0.0001143962],"category_scores_gemma":[0.0005288888,0.00027820517,0.00022954372,0.0019088379,0.00075958326,0.00026012782,0.00017676405,0.0010315517,0.000013709005],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020569882,0.00018478972,0.0012855564,0.0037268251,0.00040087616,0.000004328647,0.00017267518,0.0000058440455,0.00042253267,0.000031896732,0.00047557635,0.9930834],"study_design_scores_gemma":[0.00048185748,0.000038951835,0.00060848956,0.01968949,0.000085546955,3.8189324e-7,0.00016750259,0.0000039710067,0.0016064427,0.00020242727,0.97676826,0.0003466775],"about_ca_topic_score_codex":0.002181763,"about_ca_topic_score_gemma":0.014258064,"teacher_disagreement_score":0.9927367,"about_ca_system_score_codex":0.0005846353,"about_ca_system_score_gemma":0.00072067574,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W1821112997","doi":"10.1039/c5ay01514f","title":"Dried blood spots (DBS) in doping controls: a complementary matrix for improved in- and out-of-competition sports drug testing strategies","year":2015,"lang":"en","type":"article","venue":"Analytical Methods","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency","keywords":"Dried blood; Spots; Matrix (chemical analysis); Competition (biology); Sample (material); Drug; Doping; Biomedical engineering; Medicine; Nanotechnology; Materials science; Pharmacology; Chromatography; Chemistry; Optoelectronics; Pathology; Composite material; Biology","score_opus":0.0805760713186288,"score_gpt":0.4047184799974043,"score_spread":0.3241424086787755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1821112997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83960307,0.0052712625,0.14145611,0.0052471794,0.0013517614,0.0025159398,0.00018336975,0.00013149285,0.004239823],"genre_scores_gemma":[0.6674341,0.000023809745,0.33213225,0.00020111253,0.00004188438,0.000024449018,0.000026291586,0.000015593618,0.00010054964],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9975968,0.00070103316,0.0007830315,0.0004150288,0.00004888848,0.000455246],"domain_scores_gemma":[0.9972395,0.0021906372,0.00017236208,0.00019517308,0.00013063932,0.00007174159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036992182,0.00021739147,0.0007785093,0.00022102383,0.00004523453,0.00002648574,0.0001447354,0.00021436758,0.000049311413],"category_scores_gemma":[0.0013213949,0.00018578311,0.00009923092,0.0003070953,0.0002944831,0.00011478177,0.00009783575,0.0003185995,8.9926766e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034855518,0.0020838373,0.10015334,0.00079384446,0.0011397402,0.00008838185,0.002311578,0.00008365709,0.54171365,0.15503469,0.00034203642,0.19276968],"study_design_scores_gemma":[0.06794515,0.0048994087,0.15346327,0.002285834,0.0033691153,0.00022570434,0.026009236,0.10853055,0.1736438,0.42781153,0.027779361,0.0040370408],"about_ca_topic_score_codex":0.00021806743,"about_ca_topic_score_gemma":0.00014367777,"teacher_disagreement_score":0.36806986,"about_ca_system_score_codex":0.000035339217,"about_ca_system_score_gemma":0.00010645117,"threshold_uncertainty_score":0.7576015},"labels":[],"label_agreement":null},{"id":"W1851453522","doi":"10.1111/apt.13402","title":"Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases","year":2015,"lang":"en","type":"review","venue":"Alimentary Pharmacology & Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"UCB Pharma; Genentech; Vlaamse regering; Hellenic Society of Gastroenterology; Norgine; Agentschap voor Innovatie door Wetenschap en Technologie; Fonds Wetenschappelijk Onderzoek; Celltrion; European Crohn's and Colitis Organisation; National Institute for Health and Care Research; Janssen Biotech; Teva Pharmaceutical Industries; Celgene; Pfizer; Biogen; Ablynx; Gilead Sciences; Amgen; ActoGeniX; Sanofi; Tillotts Pharma; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ironwood Pharmaceuticals, Incorporated","keywords":"Biosimilar; Medicine; Infliximab; Adalimumab; Inflammatory bowel disease; Ulcerative colitis; Bioequivalence; Rheumatoid arthritis; Pharmacokinetics; Drug; Pharmacology; Crohn's disease; Pharmacodynamics; Ankylosing spondylitis; Internal medicine; Immunology; Tumor necrosis factor alpha; Disease","score_opus":0.08557301642064606,"score_gpt":0.4069166715807467,"score_spread":0.3213436551601006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1851453522","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022209225,0.993986,0.000001560567,0.0010984174,0.0019880831,0.0019322499,0.00045181785,0.00007989355,0.00023986674],"genre_scores_gemma":[0.00015129666,0.9760308,0.00007532741,0.023050018,0.0001264817,0.00017361887,0.0002445239,0.00007003,0.00007785216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934002,0.0029639723,0.0017660869,0.0008323728,0.00013140621,0.0009059181],"domain_scores_gemma":[0.9977746,0.0007032743,0.0007912051,0.00044788368,0.00013423926,0.0001488238],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001124364,0.0008751964,0.003196184,0.0003316675,0.00008930987,0.000011171993,0.00094678876,0.0009838981,0.003103543],"category_scores_gemma":[0.000003511319,0.000661906,0.0007554326,0.0006331071,0.0010580639,0.000103469116,0.00040421326,0.0013959392,0.00018378362],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005128403,0.006029531,0.0009130871,0.043238495,0.068127304,0.0006048735,0.000104355946,0.0000029556882,0.017947853,0.00019922043,0.096916415,0.7654031],"study_design_scores_gemma":[0.0016075672,0.00032072628,0.00004823797,0.0051444992,0.06251662,0.00010174953,0.0000149016305,0.0000030901044,0.0030746837,0.00010359799,0.9264272,0.0006371501],"about_ca_topic_score_codex":0.000006261509,"about_ca_topic_score_gemma":0.0000020463904,"teacher_disagreement_score":0.82951075,"about_ca_system_score_codex":0.00025756483,"about_ca_system_score_gemma":0.0005639981,"threshold_uncertainty_score":0.99958324},"labels":[],"label_agreement":null},{"id":"W1866311263","doi":"10.18433/j38s3h","title":"Subsequent Entry Biologics in Canada: Current State of the Science","year":2015,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Toronto","funders":"","keywords":"Interchangeability; Biosimilar; Reimbursement; Medicine; Quality (philosophy); Product (mathematics); Family medicine; Political science; Engineering; Health care; Law","score_opus":0.16899970475495696,"score_gpt":0.4227012602694879,"score_spread":0.25370155551453094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1866311263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795359,0.013229337,0.000035345467,0.0033484953,0.003226453,0.00011982526,0.000014043581,0.000002776884,0.00048784868],"genre_scores_gemma":[0.99843985,0.0008345137,0.00018891235,0.0004761219,0.00003616789,7.2285815e-7,9.6956185e-8,0.0000022439854,0.000021386504],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99788696,0.0004162452,0.00066497386,0.00019177844,0.0003527189,0.00048729996],"domain_scores_gemma":[0.9988708,0.00023260711,0.0003531837,0.000098245706,0.00028425618,0.00016089542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040487433,0.00012625298,0.00028798194,0.00013088735,0.00012280689,0.00001904732,0.0011382711,0.000020538304,0.000108044886],"category_scores_gemma":[0.0005713942,0.00006395396,0.000093117946,0.0011046005,0.002417124,0.00018198347,0.00023494473,0.00060769374,0.0000027067356],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035708304,0.0003983019,0.19371337,0.00002858238,0.00004882926,0.000023000131,0.00019266387,0.00032023576,0.40901354,0.00054130645,0.0028013585,0.39256173],"study_design_scores_gemma":[0.0018669826,0.00015506518,0.019133491,0.000070101385,0.000061192426,0.00013296593,0.0001640095,0.0007948287,0.8450032,0.0009152585,0.13153608,0.0001668336],"about_ca_topic_score_codex":0.010540217,"about_ca_topic_score_gemma":0.005941308,"teacher_disagreement_score":0.43598965,"about_ca_system_score_codex":0.00038270417,"about_ca_system_score_gemma":0.005211633,"threshold_uncertainty_score":0.9960487},"labels":[],"label_agreement":null},{"id":"W1916224281","doi":"10.1002/bmc.2745","title":"Dried blood spot on‐card derivatization: an alternative form of sample handling to overcome the instability of thiorphan in biological matrix","year":2012,"lang":"en","type":"article","venue":"Biomedical Chromatography","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Thiorphan; Chemistry; Chromatography; Derivatization; Matrix (chemical analysis); Elution; High-performance liquid chromatography; Organic chemistry","score_opus":0.039243246029639064,"score_gpt":0.322696027232027,"score_spread":0.2834527812023879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1916224281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955071,0.00037921444,0.0028023582,0.000354785,0.00031779218,0.00033285233,0.00020751618,0.000025427193,0.00007295557],"genre_scores_gemma":[0.995977,0.00004431958,0.0035394486,0.0002776663,0.000061048675,0.000018285726,0.00007088569,0.000008299756,0.000003069633],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981864,0.00041779137,0.0005929771,0.00027057593,0.00012466896,0.00040757848],"domain_scores_gemma":[0.99851257,0.00080675445,0.00015958992,0.00034714973,0.000068528076,0.00010542821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011870146,0.00018214934,0.00048160538,0.00026715343,0.00007522874,0.000005988302,0.00037705587,0.00034592304,0.00030364472],"category_scores_gemma":[0.00055331324,0.00010696684,0.00018568303,0.0009818674,0.00096138037,0.00006897038,0.00013171932,0.00024406283,0.0000042466795],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000462062,0.0029096422,0.46005166,0.0000818372,0.00035420794,0.000001865667,0.0019901115,4.867944e-7,0.5182444,0.010633141,0.00009108908,0.0051795407],"study_design_scores_gemma":[0.0020630446,0.002033132,0.61954385,0.00013110985,0.000099255565,0.000015194093,0.0005185424,0.000016916607,0.36396927,0.0034984837,0.0077817384,0.00032948778],"about_ca_topic_score_codex":0.00014418908,"about_ca_topic_score_gemma":0.000014888125,"teacher_disagreement_score":0.15949218,"about_ca_system_score_codex":0.000015670063,"about_ca_system_score_gemma":0.00003111957,"threshold_uncertainty_score":0.43619815},"labels":[],"label_agreement":null},{"id":"W1952729546","doi":"10.1517/17530059.1.1.147","title":"Highlights of the Third Annual Biomarker World Congress: biomarkers for molecular diagnostics","year":2007,"lang":"en","type":"article","venue":"Expert Opinion on Medical Diagnostics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Biomarker; Biomarker discovery; Drug development; Medicine; Molecular biomarkers; Profiling (computer programming); Computational biology; Bioinformatics; Proteomics; Drug; Oncology; Biology; Pharmacology; Computer science","score_opus":0.025113352939593214,"score_gpt":0.3398107779558041,"score_spread":0.3146974250162109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1952729546","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048416007,0.25605866,0.20576763,0.27010906,0.17800842,0.012052382,0.0050066975,0.0010417291,0.023539418],"genre_scores_gemma":[0.8503108,0.058995202,0.018233918,0.066377714,0.0019750774,0.00037505836,0.0006467004,0.00030193749,0.002783567],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997563,0.00031696016,0.0007504352,0.00043741436,0.00031610366,0.0006160815],"domain_scores_gemma":[0.9889299,0.009912995,0.00022653941,0.0005217122,0.000233919,0.00017489714],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0013665656,0.00030044623,0.0004703491,0.00017291828,0.00018520553,0.000011559565,0.0006713821,0.0006801059,0.0004324042],"category_scores_gemma":[0.013344362,0.00019132945,0.00031880892,0.0004519355,0.0011661714,0.000033045813,0.00020148573,0.00039827952,0.000028785205],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078192895,0.0013245137,0.0025213505,0.0000645583,0.0007165767,0.000043584376,0.00020711003,8.341413e-7,0.010026173,0.059236355,0.8663861,0.058690898],"study_design_scores_gemma":[0.0017943846,0.0003791315,0.008598669,0.00044634924,0.000032531996,0.0000133859085,0.00012512118,0.00002628182,0.15236191,0.0007873551,0.83513093,0.00030394117],"about_ca_topic_score_codex":0.000024295365,"about_ca_topic_score_gemma":0.000026946323,"teacher_disagreement_score":0.80189484,"about_ca_system_score_codex":0.000044724773,"about_ca_system_score_gemma":0.00012074478,"threshold_uncertainty_score":0.9949667},"labels":[],"label_agreement":null},{"id":"W1960922507","doi":"10.1111/bjd.14267","title":"Biosimilars for psoriasis: preclinical analytical assessment to determine similarity","year":2015,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"AbbVie; Wyeth; Cilag; Amgen","keywords":"Biosimilar; Psoriasis; Medicine; Quality (philosophy); Risk analysis (engineering); Product (mathematics); Similarity (geometry); Biological drugs; Pharmacology; Intensive care medicine; Business; Computer science; Immunology; Disease; Artificial intelligence; Internal medicine","score_opus":0.15495882730655608,"score_gpt":0.4507569827974371,"score_spread":0.295798155490881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1960922507","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012973878,0.990321,0.0032460531,0.0016827581,0.002903483,0.0010228528,0.00050114223,0.00002872046,0.00028106422],"genre_scores_gemma":[0.000049594317,0.9813063,0.01674026,0.0010311696,0.00037530577,0.00006462067,0.00007911727,0.00007659927,0.0002770447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932492,0.0018790524,0.0031766437,0.000651213,0.00016553751,0.00087837677],"domain_scores_gemma":[0.9948943,0.0020745944,0.0013755983,0.0004320562,0.0008599381,0.000363466],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022274514,0.00060229894,0.005572343,0.00045670272,0.0001615141,0.00009341212,0.0011293315,0.0022262365,0.0002909686],"category_scores_gemma":[0.0026335854,0.0005312144,0.0019287415,0.00040586526,0.00042932376,0.0001031286,0.00031377567,0.0020058986,0.000044635857],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115479146,0.00037570114,0.000018922945,0.0015194656,0.001329724,0.0008361845,0.0000074906993,1.4157436e-7,0.0000023150806,0.000085119704,0.14103465,0.8546748],"study_design_scores_gemma":[0.0016261657,0.00063433655,0.0000166181,0.0041023213,0.0038540948,0.07254885,0.000019016912,0.0000068232175,0.00001900591,0.0003080683,0.9163666,0.00049810094],"about_ca_topic_score_codex":0.0000039801143,"about_ca_topic_score_gemma":0.00001611481,"teacher_disagreement_score":0.8541767,"about_ca_system_score_codex":0.00019614173,"about_ca_system_score_gemma":0.0012570062,"threshold_uncertainty_score":0.99971396},"labels":[],"label_agreement":null},{"id":"W1964320194","doi":"10.2146/ajhp110632","title":"Stability of alemtuzumab solutions at room temperature","year":2013,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Barrick Gold (Canada)","funders":"National Institutes of Health","keywords":"Pharmacy; Library science; Health science; Clinical pharmacy; Service (business); Medicine; Management; Medical education; Family medicine; Business; Computer science","score_opus":0.038461987896847585,"score_gpt":0.3292774448784525,"score_spread":0.29081545698160494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964320194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.946487,0.01542012,0.0005637718,0.034916613,0.0014607501,0.0005265638,0.000117366806,0.000037802416,0.00046999904],"genre_scores_gemma":[0.9973223,0.0002740548,0.0014256785,0.00075270224,0.00007173313,0.0000069234675,0.0000039319943,0.00001420769,0.00012847416],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99617326,0.0016467618,0.0013604461,0.00020087353,0.00010671613,0.00051195966],"domain_scores_gemma":[0.9973322,0.0003509298,0.0014532441,0.00026994414,0.00045368713,0.00013999375],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001741957,0.0001923834,0.00096831995,0.00012705303,0.00025259142,0.000011291748,0.00031757212,0.00007099398,0.0012216704],"category_scores_gemma":[0.0000948916,0.00013520777,0.0002871915,0.00032631852,0.0004696262,0.0001298088,0.00008834649,0.0005334136,0.00006239157],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007247484,0.00062979886,0.020537196,0.0005348654,0.00093842397,0.000010870872,0.00085858634,0.000005659192,0.73025453,0.0003923769,0.05460725,0.19050568],"study_design_scores_gemma":[0.011975874,0.008027246,0.0551294,0.0013054627,0.0006781261,0.0052664056,0.013424195,0.00014951026,0.4978884,0.0001659818,0.40468672,0.0013026726],"about_ca_topic_score_codex":0.0007560676,"about_ca_topic_score_gemma":0.000011519433,"teacher_disagreement_score":0.35007948,"about_ca_system_score_codex":0.00033119405,"about_ca_system_score_gemma":0.00037662784,"threshold_uncertainty_score":0.99969137},"labels":[],"label_agreement":null},{"id":"W1964595219","doi":"10.1208/s12248-014-9685-5","title":"Recommendations for Validation of LC-MS/MS Bioanalytical Methods for Protein Biotherapeutics","year":2014,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":174,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"Genentech; Biogen; GlaxoSmithKline; Pfizer; Novartis Institutes for BioMedical Research; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Bioanalysis; Chemistry; Liquid chromatography–mass spectrometry; Chromatography; Context (archaeology); Harmonization; Biochemical engineering; Computational biology; Mass spectrometry; Engineering; Biology","score_opus":0.08423505718237441,"score_gpt":0.4061848771733993,"score_spread":0.3219498199910249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964595219","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024698102,0.0005122479,0.96994716,0.025497895,0.0005943921,0.00056333875,0.00004878204,0.000015631835,0.00035071728],"genre_scores_gemma":[0.10644458,0.00015412856,0.88766146,0.0016319634,0.00047901354,0.00007556201,0.000042474076,0.00004372085,0.0034671095],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982256,0.0008391471,0.00048244323,0.00014517535,0.000031430638,0.0002761636],"domain_scores_gemma":[0.99810416,0.0011056486,0.00028982898,0.00022659099,0.00024188613,0.000031896463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041331905,0.00012781478,0.0002965878,0.00008723243,0.00032844744,0.000031299795,0.0002973929,0.00020380568,0.00037576194],"category_scores_gemma":[0.0007576872,0.00007503819,0.0002619464,0.0001328067,0.00025173044,0.00004884785,0.000033146225,0.00028081145,0.000005583703],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003943079,0.00018894736,0.000048456157,0.000039439543,0.00059179805,4.5675357e-8,0.00013840005,0.0000036183203,0.66869795,0.031536605,0.007437995,0.29092243],"study_design_scores_gemma":[0.0010107522,0.0005652182,0.000057571106,0.000033882792,0.00027315598,0.000035933626,0.000051244657,0.00065277447,0.48859358,0.044532757,0.46408057,0.00011255936],"about_ca_topic_score_codex":0.0000036739063,"about_ca_topic_score_gemma":0.0000011789098,"teacher_disagreement_score":0.45664257,"about_ca_system_score_codex":0.000023449795,"about_ca_system_score_gemma":0.00004450024,"threshold_uncertainty_score":0.41143298},"labels":[],"label_agreement":null},{"id":"W1964883357","doi":"10.1208/s12248-012-9321-1","title":"Ligand Binding Assays in the 21st Century Laboratory: Platforms","year":2012,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"PerkinElmer Biosignal","funders":"","keywords":"Computer science; Pharmaceutical industry; Engineering management; Automation; Data science; Engineering; Nanotechnology; Engineering ethics; Medicine; Pharmacology","score_opus":0.02952217528318389,"score_gpt":0.2879060362327815,"score_spread":0.2583838609495976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964883357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717267,0.014829159,0.000044340555,0.004714406,0.0020118274,0.00013524156,0.000020026995,0.000015335982,0.006502921],"genre_scores_gemma":[0.99683285,0.0010917294,0.00011813629,0.001410119,0.00031755364,0.0000020092314,0.0000021529072,0.000007958897,0.0002174664],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99886805,0.0003211386,0.00022292245,0.00007290545,0.00005688521,0.0004581066],"domain_scores_gemma":[0.99936473,0.0002822338,0.000107689324,0.00018373053,0.000030247325,0.000031366882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003358543,0.00011252882,0.00015516028,0.000060984403,0.0003708123,0.000049011247,0.00040324227,0.00016353023,0.00031166285],"category_scores_gemma":[0.0001418524,0.000045576744,0.00007735291,0.00023720402,0.00017203779,0.00014066324,0.000057062614,0.0010008349,0.00015688986],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005130859,0.000980923,0.10300476,0.000028689321,0.0008251322,0.00005835577,0.012186224,0.0000023711611,0.6853576,0.06073665,0.07283968,0.06346657],"study_design_scores_gemma":[0.0019543315,0.000246858,0.05128779,0.000095137584,0.0002024244,0.0020946856,0.013335522,0.0000030218018,0.07175774,0.003085741,0.8555225,0.00041423016],"about_ca_topic_score_codex":0.0000033319072,"about_ca_topic_score_gemma":0.0000030871229,"teacher_disagreement_score":0.78268284,"about_ca_system_score_codex":0.000029851813,"about_ca_system_score_gemma":0.00002954652,"threshold_uncertainty_score":0.43481854},"labels":[],"label_agreement":null},{"id":"W1967226659","doi":"10.1016/j.aca.2011.11.041","title":"High resolution separation methods for the determination of intact human erythropoiesis stimulating agents. A review","year":2011,"lang":"en","type":"review","venue":"Analytica Chimica Acta","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Comisión Sectorial de Investigación Científica; Consejo Superior de Investigaciones Científicas; Ministerio de Ciencia e Innovación","keywords":"Chemistry; Chromatography; Erythropoietin; High-performance liquid chromatography; Capillary electrophoresis; Erythropoiesis; Internal medicine","score_opus":0.13512565000182006,"score_gpt":0.4662266425138192,"score_spread":0.3311009925119991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967226659","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.038482e-7,0.9897213,0.006972322,0.00036877318,0.00038280152,0.0019374238,0.00012036996,0.000040172676,0.00045595854],"genre_scores_gemma":[0.00008121035,0.97082525,0.027400827,0.00021418431,0.000080415615,0.00015795951,0.00042279332,0.000050065166,0.00076728547],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99577165,0.0015871334,0.0015568599,0.0006016455,0.00006401956,0.00041870124],"domain_scores_gemma":[0.9950336,0.0024874879,0.0013437818,0.0008638307,0.00023430662,0.000036982925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025123896,0.0005178161,0.0023285996,0.0002231455,0.00036138634,0.000022930872,0.00067054946,0.0007503588,0.000869998],"category_scores_gemma":[0.0013236671,0.0003172941,0.0012266627,0.0005105271,0.00038128582,0.000092412425,0.00018908076,0.0005718042,0.000018681912],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023341909,0.00012633638,5.586189e-7,0.013754186,0.0010970664,2.3790003e-7,0.000035562964,1.9191653e-8,0.0006782663,0.0023929903,0.006876809,0.9750146],"study_design_scores_gemma":[0.00024749473,0.00028943125,0.000011281548,0.011627764,0.0123680085,0.000019795087,0.000008647761,0.00016787792,0.00035439123,0.00065547356,0.9738574,0.00039245398],"about_ca_topic_score_codex":0.000030791347,"about_ca_topic_score_gemma":0.000009880634,"teacher_disagreement_score":0.9746222,"about_ca_system_score_codex":0.00011383675,"about_ca_system_score_gemma":0.00012027989,"threshold_uncertainty_score":0.99992794},"labels":[],"label_agreement":null},{"id":"W1967607156","doi":"10.1016/j.jval.2011.08.460","title":"PMS74 Use of Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis in Quebec, Canada","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier de l'Université Laval; Canadian Arthritis Patient Alliance; Université de Montréal","funders":"","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Cohort; Hydroxychloroquine; Logistic regression; Comorbidity; Rheumatology; Disease","score_opus":0.07496639590177324,"score_gpt":0.2898749092248766,"score_spread":0.21490851332310335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967607156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860399,0.010454037,0.00040097785,0.00155474,0.0006152728,0.00071529206,0.00015330742,0.000018292596,0.000048180824],"genre_scores_gemma":[0.9938468,0.002546582,0.0029033916,0.00049446116,0.00000453405,0.000026165608,0.000016814063,0.00001386635,0.00014740587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980462,0.00044824558,0.0007438321,0.0002540408,0.000042712385,0.00046495718],"domain_scores_gemma":[0.99889976,0.0005692182,0.0001903804,0.00023652389,0.000035564342,0.00006854425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007185493,0.00013855698,0.0005210582,0.00013164486,0.000058476446,0.0000056046183,0.000137018,0.00012105321,0.000093611496],"category_scores_gemma":[0.00035691285,0.00012507424,0.00006507966,0.00018974638,0.000112404334,0.00007092031,0.000037381305,0.00019809877,0.0000022350546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033817876,0.0034914932,0.5994311,0.00840292,0.00054616545,0.00008288636,0.01605059,0.00076565973,0.005878211,0.044392206,0.02860175,0.28897527],"study_design_scores_gemma":[0.016025972,0.0010484401,0.8588519,0.013519885,0.00004998858,0.00003235595,0.0034504072,0.005203536,0.021445723,0.0114151025,0.06689059,0.0020661186],"about_ca_topic_score_codex":0.9500903,"about_ca_topic_score_gemma":0.7506966,"teacher_disagreement_score":0.28690913,"about_ca_system_score_codex":0.00016734978,"about_ca_system_score_gemma":0.0009551699,"threshold_uncertainty_score":0.5100379},"labels":[],"label_agreement":null},{"id":"W1968059729","doi":"10.1016/j.jpba.2008.03.028","title":"Blood sampling without blood draws for in vivo pharmacokinetic studies in rats","year":2008,"lang":"en","type":"article","venue":"Journal of Pharmaceutical and Biomedical Analysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; Memorial University of Newfoundland","funders":"","keywords":"Bioanalysis; In vivo; Chemistry; Solid-phase microextraction; Pharmacokinetics; Blood sampling; Sampling (signal processing); Chromatography; Sample preparation; Pharmacology; Computer science; Medicine; Biotechnology; Gas chromatography–mass spectrometry; Biology; Mass spectrometry","score_opus":0.12655300672035685,"score_gpt":0.4295228783949239,"score_spread":0.30296987167456707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968059729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97591335,0.019753594,0.0010776168,0.0026931236,0.0003293244,0.00016165324,0.00002789733,0.000009013495,0.000034435507],"genre_scores_gemma":[0.9878196,0.007319065,0.003747523,0.00070324616,0.00015575574,0.0000074184272,0.0000034487487,0.000008882913,0.00023505618],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99776256,0.00026121773,0.00106715,0.00029942777,0.00014263992,0.00046702637],"domain_scores_gemma":[0.9986212,0.0007509488,0.00022258777,0.00008716913,0.00015275815,0.00016533147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014358583,0.00022509278,0.0010904346,0.0008113836,0.00010215702,0.000010129252,0.00020829024,0.00024490338,0.0004148689],"category_scores_gemma":[0.00039707785,0.00014389437,0.0003859393,0.0012411022,0.0010219126,0.000074313946,0.00008759777,0.00063029904,0.0000015548412],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013091662,0.0030741906,0.10479119,0.00022877012,0.011726094,0.00054946105,0.00059050025,0.000014209793,0.8658307,0.00009430398,0.0009018345,0.010889535],"study_design_scores_gemma":[0.04959563,0.0039572795,0.030841058,0.00076553976,0.048251208,0.0040093376,0.0014039947,0.0032340903,0.74533457,0.0026213562,0.10817671,0.0018092016],"about_ca_topic_score_codex":0.000009687201,"about_ca_topic_score_gemma":0.000012371703,"teacher_disagreement_score":0.120496154,"about_ca_system_score_codex":0.000024611454,"about_ca_system_score_gemma":0.00005750911,"threshold_uncertainty_score":0.5867842},"labels":[],"label_agreement":null},{"id":"W1971595431","doi":"10.1007/s10067-013-2177-7","title":"A biologic pharmacosurveillance program for rheumatoid arthritis: a single-center experience","year":2013,"lang":"en","type":"article","venue":"Clinical Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta Hospital; Alberta Hospital Edmonton; University of Alberta","funders":"","keywords":"Medicine; Rheumatoid arthritis; Rheumatology; Single Center; Internal medicine; Center (category theory); Physical therapy","score_opus":0.07580749448703382,"score_gpt":0.39536770260858684,"score_spread":0.319560208121553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971595431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794012,0.00686105,0.002607292,0.0031062348,0.004039978,0.0023597986,0.000067823035,0.0005112242,0.0010454035],"genre_scores_gemma":[0.9822714,0.0037831615,0.01026074,0.0017962895,0.000032323576,0.0013662669,0.00006058242,0.000029568488,0.00039970977],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99618965,0.0007169908,0.0013467107,0.0008092799,0.000036515154,0.00090083503],"domain_scores_gemma":[0.9965991,0.0023146865,0.00032429176,0.00042492306,0.00021549826,0.00012154329],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00079461915,0.00031853223,0.0010413022,0.00006724054,0.00018028666,0.00004188948,0.00050199614,0.0008143071,0.0022357425],"category_scores_gemma":[0.0017567478,0.0002389454,0.00041677745,0.00016902348,0.0015219493,0.000097865945,0.00013681807,0.00046830447,0.00086624554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005258899,0.0034611046,0.2366997,0.00005940541,0.00043591793,0.000006629236,0.00013072371,1.30412e-7,0.014927268,0.0025470306,0.06775422,0.67345196],"study_design_scores_gemma":[0.011683566,0.0037783764,0.013726058,0.0002286038,0.000023135406,0.0009170493,0.00028674005,0.00021855129,0.0072184796,0.004172184,0.95672023,0.0010270219],"about_ca_topic_score_codex":0.000029294182,"about_ca_topic_score_gemma":0.000014201212,"teacher_disagreement_score":0.888966,"about_ca_system_score_codex":0.000019712626,"about_ca_system_score_gemma":0.000053593805,"threshold_uncertainty_score":0.99991167},"labels":[],"label_agreement":null},{"id":"W1972881945","doi":"10.4155/bio.14.33","title":"Choosing The Appropriate Matrix to Perform A Scientifically Meaningful Lipemic Plasma Test in Bioanalytical Method Validation","year":2014,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Bioanalysis; Matrix (chemical analysis); Test (biology); Computer science; Chromatography; Biochemical engineering; Chemistry; Data science; Engineering; Biology","score_opus":0.01678577786401319,"score_gpt":0.30813255352583485,"score_spread":0.29134677566182166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972881945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7123094,0.0023746146,0.22263515,0.043036982,0.0030618377,0.0022835222,0.00017416272,0.0005463147,0.013578008],"genre_scores_gemma":[0.96593136,0.000023613264,0.030504268,0.0005511479,0.00011002826,0.00002856424,0.000029115374,0.000025476087,0.002796459],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967299,0.0008337493,0.00076448877,0.000812173,0.00017762701,0.0006820494],"domain_scores_gemma":[0.99748117,0.0013347521,0.0001799501,0.0007383495,0.00016314468,0.00010265435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004817701,0.00031797565,0.0006290701,0.00060214644,0.0003632746,0.000160199,0.00067239086,0.00037024298,0.0007631077],"category_scores_gemma":[0.002566114,0.00020114858,0.000351536,0.0022464762,0.000319746,0.00009150639,0.00023199017,0.0005211708,0.00049429806],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040392598,0.0009929987,0.04483578,0.00008969569,0.0013795212,0.000009952433,0.0010375252,0.00057395716,0.5089042,0.0096718725,0.0019537588,0.43014678],"study_design_scores_gemma":[0.0050993,0.0012113631,0.040464748,0.00032074217,0.0051367003,0.00013943802,0.0016095255,0.1946516,0.4553379,0.0048616757,0.28826556,0.0029014393],"about_ca_topic_score_codex":0.00014101944,"about_ca_topic_score_gemma":0.00011645577,"teacher_disagreement_score":0.42724535,"about_ca_system_score_codex":0.0001228459,"about_ca_system_score_gemma":0.000055731907,"threshold_uncertainty_score":0.8355494},"labels":[],"label_agreement":null},{"id":"W1974422323","doi":"10.1208/s12248-015-9756-2","title":"Calculations for Adjusting Endogenous Biomarker Levels During Analytical Recovery Assessments for Ligand-Binding Assay Bioanalytical Method Validation","year":2015,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Intertek (Canada)","funders":"","keywords":"Bioanalysis; Biomarker; Endogeny; Detection limit; Multiplex; Chemistry; Matrix (chemical analysis); Computational biology; Chromatography; Bioinformatics; Biology; Biochemistry","score_opus":0.25110774262656504,"score_gpt":0.4197907791111759,"score_spread":0.16868303648461086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974422323","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10033017,0.0007073292,0.88976175,0.005005478,0.0018962532,0.00088293717,0.0002686058,0.00006485201,0.0010826527],"genre_scores_gemma":[0.8564159,0.000037977108,0.13723417,0.00044075877,0.0007187626,0.000060591054,0.000088286775,0.00007135656,0.004932174],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973084,0.0008135126,0.00071213784,0.00033289456,0.00013325442,0.00069983315],"domain_scores_gemma":[0.9967364,0.0020994951,0.0003270666,0.00026430015,0.00042644146,0.00014629493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067897122,0.0002488865,0.00045873108,0.00021116066,0.000894414,0.00015812916,0.0003551974,0.0003295857,0.00010667005],"category_scores_gemma":[0.0026442984,0.0001619343,0.0004262655,0.00029487995,0.00015471493,0.00019269066,0.00010505074,0.00049727754,0.000020316706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024259775,0.0005107882,0.0018189083,0.00010723588,0.004187743,0.000027471171,0.0003968963,0.00057032803,0.8896762,0.006208935,0.009637891,0.08443161],"study_design_scores_gemma":[0.021822099,0.0027158828,0.0085444795,0.00047609807,0.008536917,0.008958977,0.0030076378,0.066913076,0.7829896,0.040168226,0.0535259,0.00234107],"about_ca_topic_score_codex":0.0000071900404,"about_ca_topic_score_gemma":0.0000022169156,"teacher_disagreement_score":0.75608575,"about_ca_system_score_codex":0.00022331419,"about_ca_system_score_gemma":0.00021229101,"threshold_uncertainty_score":0.68792003},"labels":[],"label_agreement":null},{"id":"W1980282196","doi":"10.1016/j.biologicals.2014.05.005","title":"The challenge of indication extrapolation for infliximab biosimilars","year":2014,"lang":"en","type":"review","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; University of British Columbia; University of Toronto; University of Calgary; University of Alberta; Robarts Clinical Trials; Université de Montréal","funders":"Genentech; Celltrion; UCB; LEO Pharma; Ironwood Pharmaceuticals, Incorporated; Teva Pharmaceutical Industries; Gilead Sciences; ActoGeniX; Sanofi; Celgene; Biogen; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biosimilar; Infliximab; Medicine; Extrapolation; Pharmacology; Internal medicine; Mathematics; Tumor necrosis factor alpha; Statistics","score_opus":0.12163158240022143,"score_gpt":0.40752275257993253,"score_spread":0.2858911701797111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980282196","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000012922433,0.99617213,0.00088377466,0.00052941893,0.0004332872,0.0011345648,0.0001831884,0.000035573714,0.00062676024],"genre_scores_gemma":[0.00011997245,0.9983253,0.00053668214,0.000094341995,0.00009106662,0.0002471995,0.0002372153,0.000016566817,0.00033167427],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973971,0.0008431506,0.0009626529,0.00042167632,0.00003289187,0.00034253317],"domain_scores_gemma":[0.99545014,0.0030761044,0.00089535007,0.00046070744,0.000095092415,0.00002260678],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017466575,0.00032132806,0.0014480674,0.00008839345,0.00021123138,0.000013695041,0.000533536,0.0014928888,0.00012151113],"category_scores_gemma":[0.0010773212,0.00014717988,0.00069938006,0.0001698857,0.00054440927,0.000016079512,0.00009476535,0.0003179532,0.00003960123],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023205384,0.000054786815,0.0000016639374,0.0011046545,0.0002285342,5.5787016e-8,0.000004619934,1.0918239e-8,0.00008380033,0.008323904,0.0019661237,0.98820865],"study_design_scores_gemma":[0.00019472672,0.00039567612,0.000011722463,0.00069384306,0.00040581397,0.000003296011,0.0000037477444,0.0000011443503,0.00011254522,0.0024663971,0.99551564,0.00019545537],"about_ca_topic_score_codex":7.2404833e-7,"about_ca_topic_score_gemma":0.0000011420452,"teacher_disagreement_score":0.9935495,"about_ca_system_score_codex":0.0000271287,"about_ca_system_score_gemma":0.000057883477,"threshold_uncertainty_score":0.99980336},"labels":[],"label_agreement":null},{"id":"W1982237827","doi":"10.1080/10543406.2014.948961","title":"Scientific Factors and Current Issues in Biosimilar Studies","year":2014,"lang":"en","type":"article","venue":"Journal of Biopharmaceutical Statistics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interchangeability; Comparability; Biosimilar; Risk analysis (engineering); Bioequivalence; Computer science; Selection (genetic algorithm); Quality (philosophy); Management science; Reliability engineering; Biochemical engineering; Medicine; Mathematics; Pharmacology; Engineering; Machine learning","score_opus":0.1002988965490811,"score_gpt":0.43187349052087487,"score_spread":0.3315745939717938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982237827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85184294,0.12487462,0.011618938,0.0039460966,0.00714262,0.0002325818,0.00024096367,0.00002277936,0.0000784684],"genre_scores_gemma":[0.9846112,0.005176179,0.009738022,0.00022414081,0.00009461679,7.266579e-7,0.00000446771,0.000011135334,0.00013947625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855083,0.0003448317,0.00055870507,0.00017261998,0.0000883841,0.00028464335],"domain_scores_gemma":[0.99857986,0.0008402553,0.00017816704,0.00008847035,0.000233076,0.00008016603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012586579,0.0001590932,0.00046273856,0.00018348462,0.00010423665,0.000045037883,0.00014528188,0.00010904737,0.0001256013],"category_scores_gemma":[0.0014293058,0.00010034744,0.000058056205,0.00018689736,0.00086960295,0.000065755754,0.000083182975,0.0005009636,0.000009816863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007987977,0.0015149037,0.16308561,0.0007379585,0.0010472437,0.000097027536,0.0017142004,0.0000053754147,0.24107352,0.038562514,0.07054021,0.48082262],"study_design_scores_gemma":[0.0034033582,0.0009766112,0.053414535,0.00030710924,0.0004921052,0.00011746884,0.00060006225,0.0004061212,0.13648444,0.016387837,0.7868848,0.00052556186],"about_ca_topic_score_codex":0.0000016571818,"about_ca_topic_score_gemma":0.0000037941732,"teacher_disagreement_score":0.7163446,"about_ca_system_score_codex":0.00003462898,"about_ca_system_score_gemma":0.000029121893,"threshold_uncertainty_score":0.40920496},"labels":[],"label_agreement":null},{"id":"W1986001121","doi":"10.1007/s10637-012-9899-2","title":"Clinical trial design in biosimilar drug development","year":2012,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Biosimilar; Clinical trial; Drug development; Immunogenicity; Medicine; Drug; Risk analysis (engineering); Pharmacology; Intensive care medicine; Drug approval; Immune system; Immunology; Internal medicine","score_opus":0.2911499705476818,"score_gpt":0.4276049626942675,"score_spread":0.13645499214658569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986001121","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000127620815,0.9948462,0.00026828135,0.00050708035,0.0024627168,0.0013178047,0.000027290145,0.0000567716,0.0005010569],"genre_scores_gemma":[0.0000054942197,0.9451759,0.044303857,0.0010155808,0.00080761,0.00013840427,0.00036614412,0.000059616166,0.008127391],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936763,0.002637643,0.002197897,0.0007165468,0.0001360424,0.0006355863],"domain_scores_gemma":[0.99611276,0.0026504733,0.0005861329,0.00037952908,0.000054725777,0.00021640013],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004074731,0.0005934998,0.0020223167,0.00031824358,0.00011755749,0.00003061293,0.0006063663,0.0013851915,0.0010740043],"category_scores_gemma":[0.00063482113,0.00044987182,0.00056575413,0.00048085023,0.0005224441,0.00009366431,0.000201636,0.0013520176,0.0013370386],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043337492,0.00024108888,0.000017268543,0.000557891,0.00034696207,0.0000041473018,0.00009222729,2.0619046e-7,0.0000017307553,0.00085637067,0.030259239,0.9671895],"study_design_scores_gemma":[0.006260193,0.00006973541,0.000022360467,0.0019956147,0.0004827426,0.000018682806,0.0000064511405,5.030798e-7,0.000050990766,0.00095367397,0.9896124,0.0005266602],"about_ca_topic_score_codex":0.00001743463,"about_ca_topic_score_gemma":0.0000070057854,"teacher_disagreement_score":0.9666628,"about_ca_system_score_codex":0.00017124062,"about_ca_system_score_gemma":0.0029954533,"threshold_uncertainty_score":0.99991125},"labels":[],"label_agreement":null},{"id":"W1988128449","doi":"10.1007/s10067-012-2066-5","title":"Subsequent entry biologics/biosimilars: a viewpoint from Canada","year":2012,"lang":"en","type":"review","venue":"Clinical Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Penticton Regional Hospital; University of British Columbia; Stornoway Diamond (Canada); Calgary General Hospital; Brampton Civic Hospital; Vancouver Coastal Health; University of Calgary; Université de Montréal; Saskatoon Medical Imaging; University of Alberta","funders":"","keywords":"Biosimilar; Medicine; Rheumatoid arthritis; Rheumatology; Intensive care medicine; Family medicine; Internal medicine","score_opus":0.17353770010207678,"score_gpt":0.40593910589382715,"score_spread":0.23240140579175037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988128449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005493685,0.9855379,0.00005083559,0.0010114996,0.010820488,0.0006946142,0.00097456924,0.000115373754,0.0007398075],"genre_scores_gemma":[0.00009906938,0.9948675,0.00061221974,0.0025769875,0.00017684344,0.00009422014,0.0010167268,0.00007833527,0.00047809345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98873645,0.0045076916,0.0037636505,0.0014398171,0.000088609726,0.0014638071],"domain_scores_gemma":[0.98882335,0.008010773,0.001426123,0.0013342147,0.00010893215,0.00029658846],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.001815044,0.0010845253,0.007029967,0.00012242187,0.00017973715,0.000022061926,0.0013487781,0.0048501315,0.0061805076],"category_scores_gemma":[0.0021140927,0.00072667416,0.0016788237,0.00029664635,0.0012454452,0.000042954445,0.0007354174,0.003049936,0.0014840033],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004382353,0.0003160091,0.0007902102,0.0014208094,0.001866604,0.000045672514,0.000005704194,6.0390395e-9,0.0000013686118,0.0007284664,0.06302214,0.9317592],"study_design_scores_gemma":[0.00059278734,0.0001346482,0.00008676797,0.0025666065,0.0021331245,0.0003143175,0.000013895177,2.5544074e-7,0.000010061076,0.00050386484,0.9928283,0.00081534794],"about_ca_topic_score_codex":0.043860286,"about_ca_topic_score_gemma":0.04230278,"teacher_disagreement_score":0.93094385,"about_ca_system_score_codex":0.00026787608,"about_ca_system_score_gemma":0.0019195033,"threshold_uncertainty_score":0.99951845},"labels":[],"label_agreement":null},{"id":"W1989818439","doi":"10.1016/j.nano.2006.10.088","title":"Nanomedicine research in Canada","year":2006,"lang":"en","type":"article","venue":"Nanomedicine Nanotechnology Biology and Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nanomedicine; Medicine; Nanotechnology; Materials science","score_opus":0.03392572038921663,"score_gpt":0.34743569627344106,"score_spread":0.3135099758842244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989818439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8101721,0.069192104,0.00019589551,0.10773655,0.002564781,0.00077613315,0.00003201696,0.0001620141,0.009168412],"genre_scores_gemma":[0.99474233,0.0013562617,0.00019068125,0.0017197969,0.00027153883,0.00004947446,0.00008502577,0.000021754433,0.0015631563],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962761,0.0005572762,0.0009281895,0.000859415,0.00012695213,0.0012520667],"domain_scores_gemma":[0.9978761,0.0012151669,0.00015073741,0.0005128848,0.00016419525,0.00008091734],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.002516492,0.00037537073,0.0010982931,0.0011006246,0.00026173636,0.0000022826862,0.00044985279,0.0010772647,0.00082279707],"category_scores_gemma":[0.0005769053,0.0002527026,0.00003557339,0.001414858,0.0045606005,0.000037935977,0.00021665529,0.0017191361,0.000024145907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043405427,0.00023440589,0.27222607,0.00011473793,0.00014774136,0.0003469548,0.000092497976,7.156963e-7,0.47923604,0.07005568,0.05021049,0.12690063],"study_design_scores_gemma":[0.013523361,0.003124187,0.15833627,0.00067984004,0.00014334595,0.0009877738,0.0022426606,0.000027033397,0.02702158,0.054182623,0.73892283,0.00080848264],"about_ca_topic_score_codex":0.6957619,"about_ca_topic_score_gemma":0.5446377,"teacher_disagreement_score":0.68871236,"about_ca_system_score_codex":0.00035736867,"about_ca_system_score_gemma":0.0006345605,"threshold_uncertainty_score":0.99999255},"labels":[],"label_agreement":null},{"id":"W1989847611","doi":"10.1016/j.biologicals.2011.06.015","title":"Quality, safety and efficacy of follow-on biologics in Japan","year":2011,"lang":"en","type":"review","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Comparability; Harmonization; Medicine; Quality (philosophy); Product (mathematics); Scientific evidence; Drug approval; Pharmacovigilance; Risk analysis (engineering); Business; Pharmacology; Adverse effect; Internal medicine; Drug","score_opus":0.22196667777815177,"score_gpt":0.4229495287818701,"score_spread":0.20098285100371832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989847611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047562938,0.99441075,0.00001003626,0.000031395084,0.00029449837,0.00064091134,0.00025505078,0.000037520884,0.0038441902],"genre_scores_gemma":[0.00066410884,0.99814415,0.00032627606,0.00013404344,0.000028395412,0.000019573601,0.00012210128,0.000014413639,0.0005469318],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952464,0.002139224,0.0014135707,0.00072245,0.00002590793,0.0004524097],"domain_scores_gemma":[0.9961551,0.0027457264,0.0005660819,0.0004567117,0.00003368955,0.00004271639],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001913332,0.0005062629,0.0032135702,0.0001986637,0.000053765507,0.0000058208243,0.00046625253,0.0022920263,0.00061411096],"category_scores_gemma":[0.0014156954,0.0002660542,0.000562725,0.00030059417,0.0007862872,0.000012663361,0.00031788525,0.000703184,0.00009599307],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018488857,0.00028423735,0.00029250872,0.0008123011,0.00020333363,0.0000021310655,0.000011043973,7.4300686e-9,0.000115445604,0.012224985,0.00011336904,0.98575574],"study_design_scores_gemma":[0.00064456335,0.00089212187,0.003185656,0.0017088626,0.00017364103,0.000014802055,0.000010241717,2.2480947e-8,0.000051220162,0.00055883796,0.99236566,0.00039437177],"about_ca_topic_score_codex":0.000026724521,"about_ca_topic_score_gemma":0.0000052352852,"teacher_disagreement_score":0.9922523,"about_ca_system_score_codex":0.000032025888,"about_ca_system_score_gemma":0.000047235204,"threshold_uncertainty_score":0.99997914},"labels":[],"label_agreement":null},{"id":"W1989943185","doi":"10.1208/s12248-014-9696-2","title":"Workshop Report: Crystal City V—Quantitative Bioanalytical Method Validation and Implementation: The 2013 Revised FDA Guidance","year":2014,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Agence Française de Sécurité Sanitaire des Produits de Santé; Health Canada; CHDI Foundation; Amgen; Pfizer; U.S. Food and Drug Administration; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Session (web analytics); Bioanalysis; Agency (philosophy); Library science; Plenary session; Medical education; Political science; Computer science; Engineering ethics; Medicine; Engineering; Nanotechnology; Sociology; World Wide Web","score_opus":0.04574924758621939,"score_gpt":0.3867140678480431,"score_spread":0.3409648202618237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989943185","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09654078,0.012243445,0.6817914,0.20288701,0.0020940132,0.00089462625,0.000041730305,0.0000765212,0.0034304368],"genre_scores_gemma":[0.9326431,0.001216415,0.057439797,0.0035340132,0.00062256405,0.000018168563,0.00002681194,0.00003259974,0.0044665365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968788,0.0019294685,0.0005571962,0.00023081913,0.00009704619,0.00030664846],"domain_scores_gemma":[0.9976488,0.0014011541,0.00038964523,0.00032562672,0.00018720393,0.00004756641],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0061748913,0.00016334146,0.00027559174,0.000047871326,0.0007011682,0.00012477684,0.00029910821,0.00012935634,0.0011645063],"category_scores_gemma":[0.00077778724,0.000078730256,0.00013455092,0.00020103776,0.00046174333,0.000112397436,0.00011660771,0.0006373413,0.000021838565],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015275818,0.0003587792,0.013089241,0.000081374805,0.004135901,0.00009536991,0.004007231,0.000072640076,0.18840209,0.105954595,0.4049497,0.2773255],"study_design_scores_gemma":[0.004953423,0.001094763,0.048143502,0.00024788297,0.0023824887,0.0147147,0.005296827,0.0017881449,0.07138494,0.07500575,0.7738829,0.0011046596],"about_ca_topic_score_codex":0.000022782857,"about_ca_topic_score_gemma":0.000016567077,"teacher_disagreement_score":0.8361023,"about_ca_system_score_codex":0.000026141497,"about_ca_system_score_gemma":0.000041380263,"threshold_uncertainty_score":0.9997486},"labels":[],"label_agreement":null},{"id":"W1993767835","doi":"10.1208/s12248-013-9553-8","title":"Large Molecule Run Acceptance: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team","year":2014,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"","keywords":"Harmonization; Bioanalysis; Computer science; Chemistry; Chromatography","score_opus":0.04197405020057763,"score_gpt":0.3379829816867706,"score_spread":0.29600893148619295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993767835","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15345454,0.008969711,0.7428763,0.089260705,0.0018420038,0.0007599804,0.00047401062,0.00006264293,0.0023001272],"genre_scores_gemma":[0.9913501,0.0012955373,0.003349027,0.0030880666,0.00032926383,0.000009917864,0.00013976863,0.000012764966,0.00042554614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843484,0.0007713246,0.00031659912,0.00019320508,0.00004935254,0.00023464934],"domain_scores_gemma":[0.998343,0.00062199024,0.0006190891,0.00018183823,0.00020372806,0.00003036222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015728218,0.00013122072,0.00018747979,0.000025170448,0.00083763123,0.00017194849,0.00024756996,0.00015124722,0.0004914193],"category_scores_gemma":[0.0013437951,0.000070045324,0.00008673856,0.00020455635,0.00015862809,0.00017897881,0.00006915834,0.00028701793,0.000019718582],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019828647,0.0010559646,0.12585877,0.000042834166,0.004248392,0.0000023921543,0.0019773643,0.00004434503,0.12826394,0.016843054,0.105728984,0.6139511],"study_design_scores_gemma":[0.0039190524,0.00049886736,0.022346498,0.00006052239,0.0025078442,0.00020772734,0.0029391972,0.0071893926,0.033717114,0.014317759,0.91182274,0.0004732754],"about_ca_topic_score_codex":0.000041775882,"about_ca_topic_score_gemma":0.00006781554,"teacher_disagreement_score":0.8378956,"about_ca_system_score_codex":0.000037162816,"about_ca_system_score_gemma":0.000032312888,"threshold_uncertainty_score":0.6442467},"labels":[],"label_agreement":null},{"id":"W1997030467","doi":"10.1136/bmj.38797.635012.47","title":"Learning from the TGN1412 trial","year":2006,"lang":"en","type":"editorial","venue":"BMJ","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Psychology","score_opus":0.02532472513244346,"score_gpt":0.32445613248522465,"score_spread":0.2991314073527812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997030467","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000097676166,0.002898386,0.00005695534,0.0016576716,0.98584646,0.00045624506,0.0002375772,0.000071886265,0.008677121],"genre_scores_gemma":[0.00015288756,0.000088713685,0.00023890751,0.00018495234,0.9355986,0.00004027672,0.0013090031,0.000031520718,0.062355105],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766254,0.0010141031,0.000457608,0.00041184694,0.00010401042,0.0003499076],"domain_scores_gemma":[0.9948364,0.0043724393,0.00027463693,0.00041646927,0.000085051404,0.000015002762],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010769151,0.00027395846,0.0005150729,0.000028771532,0.00023559343,0.000047104826,0.00048741323,0.0023349323,0.0013687843],"category_scores_gemma":[0.0028875994,0.00015957328,0.00029780148,0.00008553678,0.00025132953,0.000018092443,0.00015942121,0.0022970496,0.00052151893],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003023129,0.000041247065,0.000011522482,0.0000037881177,0.00022511583,0.000004702441,0.000018908333,4.663367e-7,0.0003148737,0.00002063404,0.9925166,0.0038190477],"study_design_scores_gemma":[0.008934956,0.00026830897,0.00003484918,0.00004179772,0.00024108565,8.635771e-7,0.000022648386,0.0000010088281,0.00026359165,0.00024407923,0.989714,0.00023275708],"about_ca_topic_score_codex":0.00072133436,"about_ca_topic_score_gemma":0.00007818562,"teacher_disagreement_score":0.053677984,"about_ca_system_score_codex":0.000033278826,"about_ca_system_score_gemma":0.00016563474,"threshold_uncertainty_score":0.9995441},"labels":[],"label_agreement":null},{"id":"W1997256514","doi":"10.1002/sim.5572","title":"Comments on the FDA draft guidance on biosimilar products","year":2012,"lang":"en","type":"article","venue":"Statistics in Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interchangeability; Biosimilar; Food and drug administration; Risk analysis (engineering); Computer science; Scientific evidence; Management science; Operations research; Business; Medicine; Engineering; Statistics","score_opus":0.051552394930830296,"score_gpt":0.3530185489860644,"score_spread":0.3014661540552341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997256514","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08312262,0.0266742,0.019589946,0.6809264,0.03233122,0.0049509103,0.0023119813,0.00033860747,0.14975417],"genre_scores_gemma":[0.9589822,0.0002848642,0.006378428,0.030342268,0.00039174155,0.000028770242,0.000073015515,0.000024961812,0.0034937442],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985976,0.00039937353,0.0002966531,0.00020799368,0.00008565185,0.000412683],"domain_scores_gemma":[0.9982163,0.0012347243,0.00008318775,0.00037881208,0.00005333646,0.00003364727],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013876302,0.00016735088,0.00026762873,0.00007071803,0.000110563684,0.0000036077179,0.00022175988,0.00012586782,0.0011132498],"category_scores_gemma":[0.0023133478,0.000088683315,0.000016045366,0.00020162467,0.0005309199,0.000016817006,0.00004628768,0.0004825779,0.00019287984],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017449782,0.00040640615,0.005972241,0.000036857327,0.00008801292,0.000009326332,0.0004753926,5.6212303e-7,0.013778676,0.16994135,0.7977748,0.011341886],"study_design_scores_gemma":[0.0021342032,0.001518454,0.07288233,0.00045510428,0.00010942255,0.000015266769,0.00036789503,0.00002228575,0.039740358,0.0073299897,0.87506235,0.0003623716],"about_ca_topic_score_codex":0.000019653464,"about_ca_topic_score_gemma":0.0000068059744,"teacher_disagreement_score":0.8758596,"about_ca_system_score_codex":0.000042796873,"about_ca_system_score_gemma":0.000015113326,"threshold_uncertainty_score":0.99979985},"labels":[],"label_agreement":null},{"id":"W1997675256","doi":"10.1016/s0828-282x(09)71048-7","title":"Searching for ‘omic’ biomarkers","year":2009,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Prevention of Organ Failure","funders":"","keywords":"Medicine; Computational biology","score_opus":0.0809628964523419,"score_gpt":0.3625329963601318,"score_spread":0.2815700999077899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997675256","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.9945635e-7,0.9914812,0.0018809718,0.00042170667,0.0022394084,0.0003237637,0.00019273088,0.000004800778,0.0034549257],"genre_scores_gemma":[0.000030218558,0.9973318,0.0010102417,0.00021038696,0.000808907,0.000006227463,0.00004815681,0.000031645963,0.0005224434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972221,0.0009316497,0.0008699559,0.00025474533,0.000024252175,0.00069729553],"domain_scores_gemma":[0.99807143,0.00073941576,0.00049950206,0.00025256336,0.00018464788,0.0002524124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015761976,0.00033159318,0.0027447667,0.00071468676,0.00016019444,0.000024475094,0.000610301,0.0011893146,0.000062159736],"category_scores_gemma":[0.00065212225,0.00023858297,0.0017332121,0.000178979,0.0003950492,0.000033561573,0.000017381473,0.0009206555,0.000026593996],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016491991,9.913157e-7,0.0000029470032,0.00046273044,0.0016342431,0.000044395303,0.000006654143,9.688407e-7,0.0000065707595,0.00046741244,0.05478651,0.9425701],"study_design_scores_gemma":[0.00032602958,0.00033079792,0.0000073223273,0.001222964,0.0014558545,0.0020024856,0.000013174562,1.09816135e-7,0.0000052050455,0.00053763966,0.9938633,0.00023510348],"about_ca_topic_score_codex":0.000083730316,"about_ca_topic_score_gemma":0.00015063713,"teacher_disagreement_score":0.94233495,"about_ca_system_score_codex":0.00021415159,"about_ca_system_score_gemma":0.0027308746,"threshold_uncertainty_score":0.97291315},"labels":[],"label_agreement":null},{"id":"W1998811802","doi":"10.1208/s12249-014-0133-8","title":"Challenges and Opportunities to Use Biowaivers to Compare Generics in China","year":2014,"lang":"en","type":"article","venue":"AAPS PharmSciTech","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Drug Research and Development; University of Alberta","funders":"","keywords":"Bioequivalence; Metronidazole; Biopharmaceutics Classification System; Biopharmaceutics; Amoxicillin; Pharmacology; Equivalence (formal languages); Medicine; Chemistry; Mathematics; Drug; Pharmacokinetics; In vitro; Antibiotics","score_opus":0.14524598230140096,"score_gpt":0.3250212529864427,"score_spread":0.17977527068504173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998811802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95826143,0.004301018,0.0015118512,0.028618522,0.0006957043,0.00048699154,0.00007137891,0.00012989898,0.0059232274],"genre_scores_gemma":[0.98917353,0.0014865638,0.0027918862,0.005402145,0.000025488423,0.000013466797,0.000009194857,0.00001293377,0.0010847617],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989775,0.00017901383,0.00017723445,0.00032289172,0.00003198037,0.00031138622],"domain_scores_gemma":[0.9995111,0.00013298263,0.00002818086,0.0002092862,0.000030603784,0.000087796616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004057798,0.00015557611,0.00027139642,0.00020608593,0.000060909122,0.000021526637,0.00017295839,0.00009975528,0.000098453565],"category_scores_gemma":[0.00010613589,0.00012961093,0.000032919805,0.00010690709,0.000111045054,0.00006901124,0.0001661173,0.00016764882,0.000045333283],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023811877,0.00021456416,0.006439084,0.00006470914,0.00011177123,0.00002356502,0.0023710516,0.000008098773,0.16101111,0.011159416,0.017149318,0.8012092],"study_design_scores_gemma":[0.00077475165,0.00030075986,0.10926725,0.00005837404,0.000032249507,0.000027496142,0.0003996941,0.000033445856,0.03644467,0.00048493585,0.85178196,0.00039443932],"about_ca_topic_score_codex":0.000055770368,"about_ca_topic_score_gemma":0.00011757881,"teacher_disagreement_score":0.83463264,"about_ca_system_score_codex":0.000021122421,"about_ca_system_score_gemma":0.000011339028,"threshold_uncertainty_score":0.528538},"labels":[],"label_agreement":null},{"id":"W2000963673","doi":"10.1016/j.jval.2011.08.401","title":"PMS15 Costs of Tumor Necrosis Factor Blockers per Treated Patient Across Adult Indications Using Real-World Data in US Commercially-Insured Population","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Intelligent Mechatronic Systems (Canada)","funders":"","keywords":"Medicine; Adalimumab; Etanercept; Infliximab; Psoriatic arthritis; Rheumatoid arthritis; Ankylosing spondylitis; Internal medicine; Discontinuation; Psoriasis; Population; Surgery; Tumor necrosis factor alpha; Dermatology","score_opus":0.14651859472891726,"score_gpt":0.3822495205097888,"score_spread":0.23573092578087151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000963673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997819,0.0001785091,0.000027023021,0.00039834122,0.00019439685,0.0004713054,0.0008392749,0.000021445429,0.000050723895],"genre_scores_gemma":[0.99410623,0.000116413816,0.0050838604,0.00037067308,0.000007972438,0.000007718028,0.000276177,0.000015184512,0.000015751059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740076,0.000891015,0.0008406868,0.00037294047,0.000059394668,0.0004352303],"domain_scores_gemma":[0.9987231,0.0001802367,0.0004258981,0.00054556155,0.00007226801,0.00005291656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064507703,0.00016111527,0.00047245662,0.00023753151,0.00011989849,0.0000068646727,0.00027919078,0.00015083657,0.0000759457],"category_scores_gemma":[0.00020111284,0.00014268742,0.000046126286,0.0005831918,0.00019000977,0.00008298174,0.00013847073,0.0003083839,0.0000054513007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022449467,0.00048127852,0.98733586,0.000047220452,0.000036023786,0.000001847906,0.0016437484,0.000010139739,0.0026325902,0.00033303504,0.00007678243,0.007176965],"study_design_scores_gemma":[0.0008163556,0.0002207184,0.9938716,0.00020095352,0.000017056209,0.0000035130938,0.00025172136,0.00064254366,0.003596743,0.0000771154,0.00014885252,0.00015281083],"about_ca_topic_score_codex":0.30971995,"about_ca_topic_score_gemma":0.03163941,"teacher_disagreement_score":0.27808052,"about_ca_system_score_codex":0.0002866105,"about_ca_system_score_gemma":0.00013493116,"threshold_uncertainty_score":0.98603064},"labels":[],"label_agreement":null},{"id":"W2006040865","doi":"10.1016/s1063-4584(09)60547-1","title":"526 PROTECTION AGAINST LIPOPOLYSACCHARIDE-INDUCED CARTILAGE INFLAMMATION AND DEGRADATION PROVIDED BY A BIOLOGICAL EXTRACT OF MENTHA SPICATA","year":2009,"lang":"en","type":"article","venue":"Osteoarthritis and Cartilage","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Mentha spicata; Lipopolysaccharide; Inflammation; Cartilage; Chemistry; Medicine; Essential oil; Immunology; Anatomy; Chromatography","score_opus":0.02071472655362881,"score_gpt":0.25397657651020034,"score_spread":0.23326184995657154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006040865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947021,0.0030552235,0.00015877839,0.00095091533,0.00009763089,0.0005431203,0.00005179673,0.000046607587,0.0003938481],"genre_scores_gemma":[0.99893785,0.00040182835,0.00023626816,0.0001304491,0.000029107901,0.000028822991,0.000060739178,0.000007360774,0.00016758841],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99868685,0.00021545679,0.00041213594,0.00036787713,0.00005709589,0.00026055452],"domain_scores_gemma":[0.9994923,0.00004004939,0.0001784489,0.00018298505,0.000053646232,0.000052598985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036735303,0.00019166927,0.00032971278,0.00006950426,0.00015008464,0.000038218957,0.000075316115,0.00033882787,0.000052678286],"category_scores_gemma":[0.00012433052,0.0001557437,0.00006392405,0.00009919683,0.00014431252,0.0001763944,0.000040315736,0.00019837751,0.0000046037508],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000869895,0.000037254336,0.00011847518,0.000011057844,0.0000037246105,0.000002095049,0.000061381375,2.5074844e-8,0.74222213,0.00025570567,0.00007425696,0.2571269],"study_design_scores_gemma":[0.0010060304,0.001274808,0.0010105877,0.00005903104,0.000033143715,0.000030393363,0.00011371527,0.0000053534727,0.99389976,0.0002868719,0.0021016872,0.00017860522],"about_ca_topic_score_codex":0.000015354652,"about_ca_topic_score_gemma":0.000030839496,"teacher_disagreement_score":0.2569483,"about_ca_system_score_codex":0.00001532849,"about_ca_system_score_gemma":0.000014840794,"threshold_uncertainty_score":0.6351044},"labels":[],"label_agreement":null},{"id":"W2007200590","doi":"10.1038/clpt.2012.55","title":"Translational Bioinformatics: Data-driven Drug Discovery and Development","year":2012,"lang":"en","type":"editorial","venue":"Clinical Pharmacology & Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"U.S. National Library of Medicine; National Cancer Institute; David and Lucile Packard Foundation","keywords":"Translational bioinformatics; Clinical pharmacology; Data sharing; Translational research; Data science; Drug reaction; Drug discovery; Drug development; Computer science; The Internet; Clinical trial; Medicine; Bioinformatics; Computational biology; Drug; Genomics; Pharmacology; World Wide Web; Genome; Biology; Alternative medicine; Pathology","score_opus":0.12859080116938446,"score_gpt":0.43442698686586195,"score_spread":0.3058361856964775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007200590","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004791277,0.01614832,0.0017374333,0.0032320216,0.9758764,0.00055213674,0.0016265578,0.0001063761,0.00024161856],"genre_scores_gemma":[0.0008882053,0.023226785,0.039047092,0.035644453,0.8781104,0.00007800139,0.013106744,0.00022083521,0.009677478],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959722,0.0009358656,0.0015141417,0.000720813,0.00015352166,0.0007034274],"domain_scores_gemma":[0.9929945,0.0056585367,0.000498036,0.00057573937,0.00015666163,0.00011651808],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002174485,0.00053788244,0.0010800259,0.00010661008,0.00026401549,0.00005241125,0.00108429,0.0024621782,0.00076280546],"category_scores_gemma":[0.00008602785,0.00041836806,0.00017269877,0.00009164284,0.0014480684,0.00029458862,0.0006746437,0.0027700597,0.0002873301],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031386563,0.00043413747,0.00037856746,0.000088516485,0.0031427296,0.0000028963539,0.00016540373,4.2618709e-7,0.00024834185,0.0000066430853,0.9675978,0.02762072],"study_design_scores_gemma":[0.0021945508,0.000102033926,0.0003501749,0.000034188466,0.002159098,0.00000561715,0.000031847525,0.00008840298,0.000350571,0.00003307488,0.99414563,0.0005048016],"about_ca_topic_score_codex":0.0000027121062,"about_ca_topic_score_gemma":0.000008509917,"teacher_disagreement_score":0.097766005,"about_ca_system_score_codex":0.000040585994,"about_ca_system_score_gemma":0.00072188076,"threshold_uncertainty_score":0.9998268},"labels":[],"label_agreement":null},{"id":"W2008998024","doi":"10.1007/s00216-015-8674-6","title":"Determination of Synacthen® in dried blood spots for doping control analysis using liquid chromatography tandem mass spectrometry","year":2015,"lang":"en","type":"article","venue":"Analytical and Bioanalytical Chemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency","keywords":"Dried blood; Chromatography; Dried blood spot; Liquid chromatography–mass spectrometry; Chemistry; Mass spectrometry; Whole blood; Tandem mass spectrometry; Newborn screening; Medicine; Surgery","score_opus":0.026843869174766055,"score_gpt":0.29477416379092736,"score_spread":0.2679302946161613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008998024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92873675,0.0016859464,0.066755764,0.0006349379,0.000080028476,0.00034566934,0.00013440415,0.00005064925,0.001575866],"genre_scores_gemma":[0.992637,0.000038887567,0.006930778,0.00011816922,0.00005601583,0.0000073695933,0.00003264231,0.000015862066,0.00016331038],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99766916,0.00012159929,0.00084882195,0.00061944907,0.00014765906,0.000593331],"domain_scores_gemma":[0.998465,0.0005937269,0.00020710168,0.0003091122,0.00022133735,0.00020372268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00097066874,0.0003235268,0.0011322388,0.0003881213,0.00006896503,0.000031975876,0.00023488358,0.0005941493,0.00019025688],"category_scores_gemma":[0.00068058394,0.00026608314,0.0005238765,0.0015530486,0.00070176774,0.00007921568,0.000068295776,0.00033759067,0.0000016639256],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002126613,0.0014807367,0.111169696,0.0005460942,0.0073141675,0.00007402833,0.000088518726,0.00004004275,0.87210584,0.003655291,0.0000734947,0.0013254862],"study_design_scores_gemma":[0.014797035,0.0015103468,0.010846518,0.00030056675,0.025092997,0.00016392175,0.0008357867,0.14930128,0.787564,0.0070843697,0.0006015937,0.0019016343],"about_ca_topic_score_codex":0.000032539938,"about_ca_topic_score_gemma":0.0000066868206,"teacher_disagreement_score":0.14926122,"about_ca_system_score_codex":0.000060105278,"about_ca_system_score_gemma":0.000087270084,"threshold_uncertainty_score":0.99997914},"labels":[],"label_agreement":null},{"id":"W2010222138","doi":"10.1007/s00216-011-5655-2","title":"Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer","year":2012,"lang":"en","type":"article","venue":"Analytical and Bioanalytical Chemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":157,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thermo Fisher Scientific (Canada)","funders":"","keywords":"Chemistry; Chromatography; Orbitrap; Mass spectrometry; Analyte; Sample preparation","score_opus":0.012881393480291143,"score_gpt":0.2720874130105445,"score_spread":0.25920601953025335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010222138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98376733,0.001584312,0.008827861,0.0014001877,0.000112548616,0.00066697336,0.0005153304,0.000037740403,0.0030877013],"genre_scores_gemma":[0.99628776,0.00005808493,0.002694515,0.00012841634,0.000059057158,0.000012257369,0.00007506555,0.000015931522,0.00066892727],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977882,0.00011990853,0.0008504068,0.00043964412,0.00012606445,0.00067576097],"domain_scores_gemma":[0.99830115,0.0009295248,0.00021824193,0.00023097305,0.0001760385,0.00014407333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008110479,0.00030374742,0.00092378457,0.00011446483,0.000048997805,0.000012954191,0.00015362569,0.00054366305,0.00020451297],"category_scores_gemma":[0.0005326753,0.00024279652,0.0003031196,0.0003878327,0.0007956924,0.00009129827,0.00006527906,0.00035731815,0.0000020760779],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046636476,0.0007518518,0.0067389393,0.00037705482,0.000465319,0.0000029892633,0.00009510574,9.150592e-8,0.98607713,0.0024768137,0.00008873402,0.0024596185],"study_design_scores_gemma":[0.0024283149,0.00019206817,0.0025558793,0.00013440714,0.00093787396,0.000020392843,0.00023218924,0.0017519329,0.9902722,0.00069464557,0.00043210268,0.00034797788],"about_ca_topic_score_codex":0.000028428669,"about_ca_topic_score_gemma":0.0000025501981,"teacher_disagreement_score":0.012520401,"about_ca_system_score_codex":0.00003560378,"about_ca_system_score_gemma":0.00003915321,"threshold_uncertainty_score":0.9900955},"labels":[],"label_agreement":null},{"id":"W2012758044","doi":"10.1159/000097889","title":"Prevalence of Anti-Erythropoietin Antibodies in Hemodialysis Patients without Clinical Signs of Pure Red Cell Aplasia","year":2006,"lang":"en","type":"article","venue":"Nephron Clinical Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Medicine; Pure red cell aplasia; Erythropoietin; Hemodialysis; Epoetin alfa; Dialysis; Antibody; Internal medicine; Hemoglobin; Anemia; Gastroenterology; Aplasia; Nephrology; Immunology","score_opus":0.0377837893285429,"score_gpt":0.38129744746666844,"score_spread":0.3435136581381255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012758044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894398,0.001272537,0.00030418878,0.0013928651,0.0008679551,0.0004444678,0.00008626223,0.000029816927,0.0061621307],"genre_scores_gemma":[0.98464173,0.0015429821,0.012432511,0.00048364955,0.00010222638,0.000004099362,0.000025292411,0.000020350739,0.0007471736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99265724,0.0032683844,0.0028255335,0.0006775344,0.00016547689,0.00040584637],"domain_scores_gemma":[0.9897351,0.007605247,0.0015653376,0.0006066751,0.00043757484,0.000050050247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046706554,0.00026630858,0.0012060937,0.00011049954,0.000061821294,0.000009804021,0.0004119046,0.000988466,0.00044844797],"category_scores_gemma":[0.00817219,0.00021749309,0.00046551076,0.0003437273,0.0012995056,0.0002210134,0.00020670734,0.0010946463,0.000054483637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014293217,0.0059686704,0.9598165,0.00021974983,0.00017848231,0.000006440099,0.000032257307,0.000006267929,0.01810735,0.00012167337,0.008355169,0.005758111],"study_design_scores_gemma":[0.005957457,0.0025849056,0.9283002,0.00015822191,0.0010512889,0.0000060776147,0.00015019737,0.000037865113,0.023709645,0.00035581965,0.037269652,0.0004186799],"about_ca_topic_score_codex":0.00011945475,"about_ca_topic_score_gemma":0.000027962618,"teacher_disagreement_score":0.031516314,"about_ca_system_score_codex":0.000021002834,"about_ca_system_score_gemma":0.00011665023,"threshold_uncertainty_score":0.97834647},"labels":[],"label_agreement":null},{"id":"W2013459857","doi":"10.1016/j.cyto.2004.07.015","title":"Patient perspectives on cytokine medicines","year":2004,"lang":"en","type":"article","venue":"Cytokine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Society","funders":"","keywords":"Cytokine; Medicine; Intensive care medicine; Traditional medicine; Internal medicine","score_opus":0.015780284693072615,"score_gpt":0.2776718813450753,"score_spread":0.2618915966520027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013459857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.861359,0.011504784,0.00328307,0.04314791,0.0030593514,0.000877656,0.0002429131,0.0005347623,0.07599053],"genre_scores_gemma":[0.99565685,0.000110997156,0.0012242619,0.0020883498,0.00011826843,0.000009998864,0.000017439856,0.0000151418735,0.0007586655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99902195,0.00007390199,0.00021922636,0.00033259572,0.000051189367,0.00030116332],"domain_scores_gemma":[0.9994591,0.000089216985,0.00006205975,0.00027856822,0.000072894625,0.000038166276],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014503741,0.00018294994,0.0002705756,0.000094409086,0.00011125174,0.000007726738,0.00012909317,0.00019003518,0.0010739255],"category_scores_gemma":[0.00020331163,0.00012295798,0.000100903526,0.0001793915,0.00030393252,0.000030530435,0.000039273502,0.00028272282,0.00032727825],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007018668,0.0012858304,0.00043381998,0.000025489391,0.00037616678,0.00008534462,0.0027845483,0.000030868654,0.9061956,0.038255274,0.016183285,0.033641927],"study_design_scores_gemma":[0.003024737,0.0023300585,0.004407387,0.000115305425,0.00009164803,0.00010549463,0.0024999592,0.0000011426201,0.73950815,0.0025178771,0.2450274,0.0003708441],"about_ca_topic_score_codex":0.000020110341,"about_ca_topic_score_gemma":0.000005211014,"teacher_disagreement_score":0.2288441,"about_ca_system_score_codex":0.00006845103,"about_ca_system_score_gemma":0.000028546174,"threshold_uncertainty_score":0.99983925},"labels":[],"label_agreement":null},{"id":"W2014423310","doi":"10.1002/sim.5569","title":"On the interchangeability of biologic drug products","year":2012,"lang":"en","type":"article","venue":"Statistics in Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Interchangeability; Bioequivalence; Drug; Risk analysis (engineering); Biosimilar; Tilmicosin; Medicine; Equivalence (formal languages); Pharmacology; Computer science; Mathematics; Chemistry; Pharmacokinetics","score_opus":0.06153093761929549,"score_gpt":0.3525918014453326,"score_spread":0.2910608638260371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014423310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.916323,0.009970704,0.010761071,0.04144058,0.0067320615,0.0014176762,0.00060099136,0.00005770966,0.012696181],"genre_scores_gemma":[0.9960617,0.000068994304,0.002546742,0.0007716276,0.000056748082,0.00000682694,0.000017326527,0.000003655133,0.00046640623],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9989577,0.00043398576,0.00024350145,0.00011981185,0.00003254873,0.00021247579],"domain_scores_gemma":[0.9978645,0.0017677605,0.000069665206,0.00022920509,0.00005525791,0.000013636844],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001963177,0.00008494389,0.00022792016,0.00004726886,0.000027223905,5.975754e-7,0.00013874249,0.00007193337,0.0012850767],"category_scores_gemma":[0.00450298,0.00003942324,0.000012805708,0.00015082415,0.00084515975,0.000008955562,0.000044347787,0.00027173304,0.000024361716],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000305597,0.00063500553,0.049480923,0.0001584504,0.000114951,0.0000028220593,0.0028531405,2.467433e-7,0.0706361,0.68652594,0.16000395,0.0292829],"study_design_scores_gemma":[0.002990299,0.002810057,0.5509533,0.0005923295,0.00024994023,0.000029989164,0.003078138,0.000029265157,0.1475122,0.20836276,0.08280278,0.0005889315],"about_ca_topic_score_codex":0.000061362785,"about_ca_topic_score_gemma":0.000028349772,"teacher_disagreement_score":0.5014724,"about_ca_system_score_codex":0.000017647566,"about_ca_system_score_gemma":0.000009972572,"threshold_uncertainty_score":0.9996279},"labels":[],"label_agreement":null},{"id":"W2014804582","doi":"10.4155/fmc.11.168","title":"Global Financial Challenge: Opportunities for Strengthening R&amp;D Research in Targeted Drug Delivery","year":2011,"lang":"en","type":"editorial","venue":"Future Medicinal Chemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Business; Drug; Pharmacology; Finance; Medicine","score_opus":0.08930842523626,"score_gpt":0.3556195216305758,"score_spread":0.2663110963943158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014804582","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031533022,0.06448974,0.000048947717,0.0034781499,0.9126871,0.00067152956,0.0033697276,0.00012732111,0.01197419],"genre_scores_gemma":[0.003255694,0.005242549,0.0011357404,0.0001385782,0.97136223,0.00020892148,0.0043406556,0.00007985621,0.014235772],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965052,0.0003900599,0.00071214006,0.00087271084,0.0003370202,0.0011828712],"domain_scores_gemma":[0.99720347,0.0012629493,0.00023798906,0.0005265307,0.0006334107,0.00013563676],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002691586,0.00055420655,0.0009938307,0.00012385877,0.00024462433,0.00002093348,0.00084286986,0.0038507471,0.0010475485],"category_scores_gemma":[0.0016445692,0.000463979,0.00026645765,0.000275328,0.0007652782,0.0000466558,0.00025364,0.0033527045,0.000014532965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010047555,0.00015921766,0.000013221174,0.0008187961,0.00013036885,0.00007404426,0.00020849968,3.5149412e-8,0.0010979488,0.000057894016,0.98304963,0.01338556],"study_design_scores_gemma":[0.0015201666,0.00016324152,0.00001651991,0.000613136,0.0001367925,0.000012650434,0.0013183033,5.200449e-7,0.0023095887,0.0010870752,0.99236995,0.00045204148],"about_ca_topic_score_codex":0.0001843216,"about_ca_topic_score_gemma":0.00029798306,"teacher_disagreement_score":0.05924719,"about_ca_system_score_codex":0.00032431516,"about_ca_system_score_gemma":0.0014481181,"threshold_uncertainty_score":0.99986565},"labels":[],"label_agreement":null},{"id":"W2019992046","doi":"10.4155/bio.13.339","title":"Isr: Background, Evolution and Implementation, with Specific Consideration for Ligand-Binding Assays","year":2014,"lang":"en","type":"review","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Agency (philosophy); Christian ministry; Regulatory science; Guideline; Political science; Regulatory agency; Interim; Public administration; Business; Public relations; Medicine; Law; Sociology; Pathology","score_opus":0.06367978857397234,"score_gpt":0.37091634729390804,"score_spread":0.3072365587199357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019992046","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019309113,0.9816353,0.016887149,0.0001242598,0.00021554613,0.0007265344,0.00023671353,0.000036159454,0.000119030614],"genre_scores_gemma":[0.00038122069,0.99214256,0.005107651,0.000051988303,0.00012819203,0.0001295725,0.0010614448,0.000038676124,0.00095867156],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977428,0.00042525085,0.0007382431,0.0006670393,0.000060889437,0.0003658058],"domain_scores_gemma":[0.99831945,0.0006146286,0.0005324997,0.0003334068,0.00015630518,0.00004370798],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009226866,0.00042514104,0.0016427684,0.00037665822,0.0003546102,0.0001101821,0.00013840527,0.0005746308,0.00029919174],"category_scores_gemma":[0.00004599536,0.0002879825,0.0004655478,0.0004259462,0.0002340891,0.00007511189,0.000049900067,0.00023724041,0.000057349884],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003198468,0.000045804067,0.00012336673,0.0024526233,0.0032161877,0.0000014506136,0.000021399701,1.03922105e-7,0.00016260838,0.006557442,0.003916999,0.98347],"study_design_scores_gemma":[0.0005764621,0.00017623766,0.000014659382,0.00058832165,0.005969392,0.00004244542,0.00015697976,0.0000035188657,0.00012194542,0.00014101525,0.9918088,0.00040027063],"about_ca_topic_score_codex":0.00002578719,"about_ca_topic_score_gemma":0.00010516527,"teacher_disagreement_score":0.98789173,"about_ca_system_score_codex":0.00015411754,"about_ca_system_score_gemma":0.00010829913,"threshold_uncertainty_score":0.9999572},"labels":[],"label_agreement":null},{"id":"W2021252522","doi":"10.1016/j.aca.2014.01.036","title":"Impact of calibrator concentrations and their distribution on accuracy of quadratic regression for liquid chromatography–mass spectrometry bioanalysis","year":2014,"lang":"en","type":"article","venue":"Analytica Chimica Acta","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Bioanalysis; Chemistry; Chromatography; Mass spectrometry; Quadratic equation; Regression; Regression analysis; Liquid chromatography–mass spectrometry; Calibration; Analytical Chemistry (journal); Linear regression; Statistics; Mathematics","score_opus":0.015054097202907778,"score_gpt":0.2993352588317176,"score_spread":0.2842811616288098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021252522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937629,0.0001536584,0.0036565068,0.0009775228,0.00006974068,0.00030144342,0.00078476383,0.000027414764,0.00026602906],"genre_scores_gemma":[0.9985787,0.00016461246,0.0008910062,0.00006310398,0.000026287904,0.000006746041,0.00022844457,0.000012250671,0.000028807277],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985118,0.0002607892,0.00053533993,0.00033537232,0.0000521516,0.00030457493],"domain_scores_gemma":[0.99766463,0.0013420531,0.00039191355,0.00041686688,0.00011817737,0.00006636426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036104792,0.00024506857,0.00069195003,0.00019092948,0.000116236915,0.000015659842,0.0002001665,0.00025648635,0.00015676666],"category_scores_gemma":[0.0007767446,0.00014934989,0.0005107223,0.0005424245,0.00046489463,0.00007898453,0.000037948368,0.00017033148,0.0000014474728],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004890938,0.00026701376,0.0026046317,0.000051963925,0.0009814319,8.6652435e-8,0.000046000456,5.217651e-7,0.98942035,0.0048886104,0.000891829,0.0003584369],"study_design_scores_gemma":[0.00140217,0.0035750726,0.020922935,0.00017570955,0.00078539515,0.000006331755,0.000095595,0.0030134392,0.96716964,0.0013121043,0.0012090673,0.00033255495],"about_ca_topic_score_codex":0.000016903225,"about_ca_topic_score_gemma":0.0000035226774,"teacher_disagreement_score":0.022250755,"about_ca_system_score_codex":0.000030158682,"about_ca_system_score_gemma":0.000061671846,"threshold_uncertainty_score":0.60903114},"labels":[],"label_agreement":null},{"id":"W2022901467","doi":"10.4161/hv.27657","title":"Screening vaccine formulations for biological activity using fresh human whole blood","year":2014,"lang":"en","type":"article","venue":"Human Vaccines & Immunotherapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Disability Prevention and Rehabilitation","funders":"","keywords":"Adjuvant; Immune system; Antigen; Monoclonal antibody; Immunology; Whole blood; Vaccine adjuvant; Medicine; Computational biology; Antibody; Biology","score_opus":0.10141643511212178,"score_gpt":0.35972569749469896,"score_spread":0.2583092623825772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022901467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9094346,0.0014287228,0.087241225,0.00040772828,0.0003258992,0.0005995056,0.0000665743,0.00019482139,0.0003008946],"genre_scores_gemma":[0.98696667,0.000018875882,0.010838592,0.00068603473,0.00022285905,0.000021793023,0.00010020845,0.00005574008,0.0010892254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979724,0.0003227936,0.0005297024,0.00048514223,0.000049652983,0.0006402613],"domain_scores_gemma":[0.99860805,0.00038343857,0.0002583497,0.00056114106,0.00014891516,0.00004009411],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007247818,0.00037726088,0.0005914588,0.00015528974,0.0010599284,0.00006335429,0.0004023074,0.00053612015,0.000635396],"category_scores_gemma":[0.0000677202,0.00030230713,0.00031813994,0.00019825812,0.000100128775,0.00012045649,0.00012718566,0.0003920924,0.000015193467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014877574,0.00031870333,0.007259821,0.000021003487,0.00047094026,3.7045916e-7,0.00006119614,0.000011246444,0.9778965,0.0050276797,0.0002475152,0.008536244],"study_design_scores_gemma":[0.01756603,0.0033238544,0.17109345,0.00018738394,0.0016978412,0.00009923921,0.0001346667,0.0021097907,0.52243936,0.016902922,0.26241833,0.002027161],"about_ca_topic_score_codex":0.000057118763,"about_ca_topic_score_gemma":0.00005681573,"teacher_disagreement_score":0.45545715,"about_ca_system_score_codex":0.000028164492,"about_ca_system_score_gemma":0.000016374403,"threshold_uncertainty_score":0.9999429},"labels":[],"label_agreement":null},{"id":"W2026885880","doi":"10.1016/j.jchromb.2014.12.030","title":"Large-scale retrospective evaluation of regulated liquid chromatography–mass spectrometry bioanalysis projects using different total error approaches","year":2015,"lang":"en","type":"article","venue":"Journal of Chromatography B","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Bioanalysis; Chemistry; Chromatography; Statistics; Scale (ratio); Mathematics","score_opus":0.07960083632024043,"score_gpt":0.3135306692841182,"score_spread":0.2339298329638778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026885880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859588,0.0078105605,0.0045764875,0.00013527043,0.00057871355,0.0003425492,0.000046608497,0.000029337585,0.0005216321],"genre_scores_gemma":[0.99175084,0.00005429467,0.008005939,0.000020433838,0.00010331855,0.000004778837,0.000013675769,0.000028224813,0.000018512254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962365,0.0010837781,0.0012024062,0.00038366715,0.00057859416,0.00051507395],"domain_scores_gemma":[0.99678224,0.00008560153,0.0014162466,0.00042020628,0.0011516312,0.0001440533],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033493536,0.00037655464,0.001231237,0.0015652303,0.00012167088,0.00003213281,0.00034502594,0.0004747313,0.00021925927],"category_scores_gemma":[0.00024857154,0.00026965345,0.0011164845,0.0022017919,0.00047693888,0.00022653893,0.000079314705,0.00053666567,0.0000019890742],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018751193,0.0024612863,0.074596085,0.0001438135,0.008282115,0.000019399618,0.0018803803,0.00013682232,0.9086379,0.00058183144,0.0008722941,0.00051299436],"study_design_scores_gemma":[0.0113185,0.0059609134,0.15002498,0.0005760788,0.008364098,0.0010839349,0.008188433,0.005158422,0.80360395,0.004461267,0.0001906881,0.0010687228],"about_ca_topic_score_codex":0.0000138979885,"about_ca_topic_score_gemma":0.000008871428,"teacher_disagreement_score":0.105033904,"about_ca_system_score_codex":0.00017422841,"about_ca_system_score_gemma":0.00023711237,"threshold_uncertainty_score":0.99997556},"labels":[],"label_agreement":null},{"id":"W2028730671","doi":"10.1016/s1098-3015(10)70711-7","title":"PDB23 COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INJECTION VS. MULTIPLE DAILY INJECTIONS IN TYPE I DIABETES PATIENTS: A CANADIAN PERSPECTIVE","year":2008,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Perspective (graphical); Medicine; Type 2 diabetes; Insulin; Subcutaneous injection; Diabetes mellitus; Internal medicine; Type 1 diabetes; Intensive care medicine; Endocrinology; Computer science; Artificial intelligence","score_opus":0.034423426643432516,"score_gpt":0.2995289651068589,"score_spread":0.2651055384634264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028730671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963755,0.0017573192,0.00003238601,0.00024711955,0.00047412212,0.0007392656,0.00017721581,0.00002164939,0.00017541848],"genre_scores_gemma":[0.9991186,0.00031769954,0.0001568692,0.0002413429,0.000010075103,0.00003229935,0.0000718087,0.000012780556,0.00003849815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99710506,0.0013967952,0.0005426459,0.00038751963,0.00005305803,0.0005149076],"domain_scores_gemma":[0.9984928,0.0007734479,0.00017283493,0.00021930668,0.00026008746,0.000081565515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007868661,0.00017245412,0.00071908743,0.0012849917,0.0001583606,0.0000048355546,0.00012242328,0.00029630252,0.00007227063],"category_scores_gemma":[0.0010088076,0.00016459958,0.00011935443,0.002642239,0.00021232529,0.00005397433,0.000028454704,0.0003897625,0.000008521204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004452347,0.00053637265,0.9906725,0.000038004648,0.00037710974,0.000010628094,0.0016951921,0.0031648513,0.00047548255,0.00025995472,0.00009179268,0.0022328603],"study_design_scores_gemma":[0.0015404491,0.0017132406,0.9920735,0.00008719966,0.00010160557,0.000012859806,0.0006440372,0.0018894303,0.0007089584,0.00015410618,0.00085874903,0.00021589066],"about_ca_topic_score_codex":0.5624056,"about_ca_topic_score_gemma":0.23323955,"teacher_disagreement_score":0.32916602,"about_ca_system_score_codex":0.0010530702,"about_ca_system_score_gemma":0.00051528617,"threshold_uncertainty_score":0.7807518},"labels":[],"label_agreement":null},{"id":"W2029930411","doi":"10.1007/s40259-014-0099-9","title":"Similar Names for Similar Biologics","year":2014,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Amicus Therapeutics; Amgen","keywords":"Biosimilar; Pharmacovigilance; Interchangeability; Medicine; Product (mathematics); Pharmacology; Computer science; Adverse effect","score_opus":0.022341485618954108,"score_gpt":0.2784489941231749,"score_spread":0.2561075085042208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029930411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4015887,0.04277906,0.2887388,0.12480361,0.02718434,0.0078818565,0.0034305085,0.0038887693,0.09970435],"genre_scores_gemma":[0.9499135,0.00023024001,0.029784257,0.009940424,0.00036820752,0.00007618874,0.00017217667,0.000045701974,0.009469297],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985956,0.00021212343,0.00028252008,0.0004071515,0.000026265638,0.00047634382],"domain_scores_gemma":[0.99888146,0.00055816263,0.000089680296,0.00034262467,0.00008589441,0.000042154603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076197437,0.00022255727,0.00036233614,0.00006401271,0.00019616829,0.00001958278,0.00029445524,0.00047788268,0.0005089776],"category_scores_gemma":[0.0005686913,0.00015739347,0.00022194028,0.00012004379,0.0003162359,0.000035546942,0.000080966805,0.00018022534,0.00020271953],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005442615,0.00048569954,0.0050324854,0.00014273301,0.00056242244,0.0000024461817,0.00020057421,0.0000051682105,0.47323257,0.05878359,0.29074103,0.17026705],"study_design_scores_gemma":[0.0008044739,0.00037010282,0.00080272794,0.000012346111,0.000066463144,0.0000064303654,0.00005108788,0.00009696518,0.10155871,0.0060550086,0.8899129,0.00026278858],"about_ca_topic_score_codex":0.000005714773,"about_ca_topic_score_gemma":0.0000030020124,"teacher_disagreement_score":0.5991719,"about_ca_system_score_codex":0.00001785701,"about_ca_system_score_gemma":0.000022250611,"threshold_uncertainty_score":0.641832},"labels":[],"label_agreement":null},{"id":"W2031889731","doi":"10.1056/nejmoa040528","title":"Pure Red-Cell Aplasia and Epoetin Therapy","year":2004,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":432,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hotel Dieu Hospital","funders":"National Cancer Institute; Amgen","keywords":"Pure red cell aplasia; Medicine; Epoetin alfa; Aplasia; Erythropoietin; Incidence (geometry); Anemia; Surgery; Gastroenterology; Red Cell; Pediatrics; Internal medicine","score_opus":0.01967450259997798,"score_gpt":0.2759597915158539,"score_spread":0.25628528891587593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031889731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8327084,0.0671555,0.001361029,0.09187605,0.0018372298,0.00014175686,0.0000031867437,0.000018455883,0.0048983814],"genre_scores_gemma":[0.9894038,0.005270085,0.0016903466,0.0015033559,0.000954339,2.3083132e-7,0.0000016948308,0.000008762706,0.0011673918],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99921435,0.00012941542,0.00033602404,0.000100502126,0.00005700567,0.00016271265],"domain_scores_gemma":[0.9994042,0.00017137273,0.00018227386,0.00009091299,0.00007071676,0.000080541475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008111037,0.00011572592,0.000341946,0.00008662816,0.000049879327,0.0000048577876,0.00011298224,0.00015317643,0.0005493476],"category_scores_gemma":[0.00017368048,0.000062382736,0.000048455462,0.000082258666,0.0002080964,0.000035537756,0.000014959655,0.0004366546,0.000005284649],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015329914,0.00015838994,0.0023902622,0.00002077164,0.00021380397,0.00021912897,0.001144583,0.0000035771236,0.4673392,0.0007600019,0.028154362,0.49806294],"study_design_scores_gemma":[0.10461093,0.0052019833,0.0073213433,0.00028229065,0.0001592523,0.00557071,0.0003313429,4.504773e-7,0.0797298,0.012216579,0.78437835,0.00019697261],"about_ca_topic_score_codex":0.000019130517,"about_ca_topic_score_gemma":0.000005284772,"teacher_disagreement_score":0.756224,"about_ca_system_score_codex":0.0000125417555,"about_ca_system_score_gemma":0.000060135128,"threshold_uncertainty_score":0.6014971},"labels":[],"label_agreement":null},{"id":"W2032836693","doi":"10.1053/j.seminoncol.2014.03.009","title":"Pharmacoeconomics of Cancer Therapies: Considerations With the Introduction of Biosimilars","year":2014,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Pharmacoeconomics; Innovator; Health care; Risk analysis (engineering); Reimbursement; Product (mathematics); Intensive care medicine; Business","score_opus":0.03854655976674012,"score_gpt":0.4049752124438392,"score_spread":0.3664286526770991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032836693","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000074316165,0.9939678,0.000028543556,0.0041261544,0.0007120429,0.00053107337,0.00010384827,0.000007994831,0.00044826767],"genre_scores_gemma":[0.0001328856,0.9980108,0.00078844,0.0004426111,0.0001269368,0.00010848409,0.000029330298,0.000022174578,0.00033830391],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975797,0.0010348014,0.0007837566,0.00033487318,0.000025304063,0.00024159906],"domain_scores_gemma":[0.99703413,0.0016899359,0.0008217755,0.00035121175,0.00008931832,0.000013636962],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000955297,0.00026974778,0.0018724533,0.00019224048,0.00005613933,0.0000034156537,0.0002609872,0.0006985953,0.001123181],"category_scores_gemma":[0.00010993303,0.00015195181,0.0002219146,0.00022964743,0.0011722571,0.000021358695,0.00007067719,0.00063945004,0.0000062344384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007205743,0.00015764886,0.000027815848,0.0014476901,0.0008917652,0.000002031202,0.00021723013,0.0000052189207,0.00044849713,0.0011561913,0.046151664,0.9494222],"study_design_scores_gemma":[0.00039997435,0.00040194427,0.0000042416227,0.00092731946,0.0009304295,0.000064704625,0.00011701663,0.0000013606609,0.0010717366,0.00012789358,0.99579716,0.00015619407],"about_ca_topic_score_codex":0.00003760195,"about_ca_topic_score_gemma":0.00026869136,"teacher_disagreement_score":0.9496455,"about_ca_system_score_codex":0.00013258377,"about_ca_system_score_gemma":0.000449282,"threshold_uncertainty_score":0.99978995},"labels":[],"label_agreement":null},{"id":"W2033051200","doi":"10.1016/j.biologicals.2012.09.010","title":"Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012","year":2012,"lang":"en","type":"article","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Canada; University of Toronto; University Health Network; Health Sciences Centre; Mount Sinai Hospital; Western University","funders":"Health Canada","keywords":"Biosimilar; Summit; Medicine; Pharmacovigilance; Comparability; Product (mathematics); Interchangeability; Health care; Family medicine; Pharmacology; Political science; Drug","score_opus":0.040734856054130394,"score_gpt":0.31990770629134835,"score_spread":0.27917285023721794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033051200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8395081,0.026032584,0.000033223056,0.12049186,0.007695685,0.0012943877,0.0011367983,0.00015165539,0.0036557086],"genre_scores_gemma":[0.95027846,0.00085990335,0.00067877537,0.04237476,0.00019554907,0.000013799598,0.00012157863,0.000020182239,0.005456981],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954409,0.0013638962,0.001070301,0.00070429174,0.00012463587,0.0012959853],"domain_scores_gemma":[0.9977721,0.00078140845,0.00028665506,0.0005338937,0.00008184298,0.0005441014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020708404,0.0004332809,0.0009309805,0.00006156209,0.00031574766,0.000014539696,0.0003901902,0.0009814674,0.00072352786],"category_scores_gemma":[0.0008468038,0.00028869175,0.00013082335,0.00022850245,0.00038828244,0.000041520365,0.00021856284,0.0008049542,0.000027095726],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013073653,0.00021910058,0.15192847,0.000020281075,0.00026102565,0.000017471082,0.000011912546,0.0000010632986,0.0012864412,0.004415338,0.812427,0.029281162],"study_design_scores_gemma":[0.00038673138,0.00049615814,0.2954852,0.00002976612,0.00002968637,0.000017732827,0.000049208382,7.8775406e-7,0.0022603176,0.00006348085,0.7008303,0.00035065],"about_ca_topic_score_codex":0.63262194,"about_ca_topic_score_gemma":0.94935834,"teacher_disagreement_score":0.31673637,"about_ca_system_score_codex":0.0005449878,"about_ca_system_score_gemma":0.0010858044,"threshold_uncertainty_score":0.99995655},"labels":[],"label_agreement":null},{"id":"W2035140756","doi":"10.1208/s12248-012-9347-4","title":"Nonclinical Dose Formulation: Out of Specification Investigations","year":2012,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nuclear Laboratories","funders":"","keywords":"Good laboratory practice; Medicine; Risk analysis (engineering); Medical physics; Computer science; Quality assurance; External quality assessment","score_opus":0.12799970891062892,"score_gpt":0.3693151611841914,"score_spread":0.24131545227356246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035140756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8739242,0.011754873,0.031583063,0.04485094,0.009518467,0.0005804421,0.000045083725,0.00007106758,0.027671875],"genre_scores_gemma":[0.99489456,0.00009920189,0.0032465123,0.00035336555,0.0003496677,0.0000011522587,0.000004060476,0.0000045821266,0.0010468942],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99910533,0.0002773696,0.00035143967,0.000052152856,0.000038512626,0.00017516736],"domain_scores_gemma":[0.9992285,0.00028752186,0.00019694053,0.00016925199,0.00007951435,0.000038316055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012713005,0.0000619314,0.00012925707,0.000032994616,0.00018364089,0.000009437601,0.0001683028,0.00011604325,0.0008919902],"category_scores_gemma":[0.00027746096,0.00003421197,0.00009700003,0.00008051697,0.00022397719,0.000101927464,0.00003383095,0.00035514493,0.00013029977],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039349974,0.0008483686,0.07020629,0.000021092503,0.0006670952,0.0000013148931,0.003699138,0.000010657782,0.6510412,0.12382959,0.06958708,0.07969467],"study_design_scores_gemma":[0.0017891378,0.0002976554,0.38218307,0.00005852519,0.00036270128,0.0004067055,0.0004974984,0.000043244843,0.13001512,0.027864216,0.45620778,0.00027430503],"about_ca_topic_score_codex":0.0000011811165,"about_ca_topic_score_gemma":9.831986e-7,"teacher_disagreement_score":0.5210261,"about_ca_system_score_codex":0.000013887558,"about_ca_system_score_gemma":0.000029069399,"threshold_uncertainty_score":0.97666675},"labels":[],"label_agreement":null},{"id":"W2036463891","doi":"10.1111/j.1537-2995.2008.01749.x","title":"Epoetin‐associated pure red cell aplasia: past, present, and future considerations","year":2008,"lang":"en","type":"review","venue":"Transfusion","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":188,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Hotel Dieu Hospital","funders":"National Cancer Institute; Johnson and Johnson; Amgen","keywords":"Pure red cell aplasia; Medicine; Epoetin alfa; Erythropoietin; Hemodialysis; Darbepoetin alfa; Anemia; Etiology; Internal medicine; Food and drug administration; Intensive care medicine; Surgery; Pharmacology","score_opus":0.0363049522753764,"score_gpt":0.3013012127299262,"score_spread":0.2649962604545498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036463891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012218843,0.9922418,0.000029276094,0.0018932724,0.0006840695,0.0007920408,0.00023072636,0.000086024804,0.0040305834],"genre_scores_gemma":[0.000013605156,0.9960748,0.00026812308,0.00009642167,0.00042498132,0.000036320496,0.0003242435,0.00003829258,0.0027232342],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975544,0.0008712337,0.000577713,0.0005646587,0.000054855307,0.00037710095],"domain_scores_gemma":[0.9989382,0.0004527905,0.00018718834,0.00029758076,0.00006719005,0.000057074958],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000190532,0.0004621953,0.0013954238,0.00012636164,0.00040879365,0.000023448105,0.00013102112,0.0018405752,0.0011727558],"category_scores_gemma":[0.000022089507,0.00032851062,0.00043193562,0.0002211881,0.00025097918,0.00003794835,0.000047914396,0.0010146567,0.000052114734],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030345245,0.00034992746,0.0000112280395,0.002160144,0.0005129739,0.000066682485,0.00015662286,3.9304215e-8,0.0004802371,0.00017453087,0.15510492,0.84095234],"study_design_scores_gemma":[0.0006170656,0.000121721554,0.000022303037,0.000783427,0.00084668485,0.00038256124,0.000019164174,3.5827316e-7,0.00011915669,0.00008421177,0.99666804,0.0003352755],"about_ca_topic_score_codex":0.0000124001945,"about_ca_topic_score_gemma":0.000014089258,"teacher_disagreement_score":0.84156317,"about_ca_system_score_codex":0.000032898293,"about_ca_system_score_gemma":0.00010663068,"threshold_uncertainty_score":0.9999167},"labels":[],"label_agreement":null},{"id":"W2037238429","doi":"10.4155/bio.12.213","title":"Conference Report: 6Th Gcc Focus on Lba: Critical Reagents, Positive Controls And Reference Standards; Specificity For Endogenous Compounds; Biomarkers; Biosimilars","year":2012,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Council of Ontario Universities","funders":"","keywords":"Biosimilar; Bioanalysis; Guideline; Political science; Agency (philosophy); Pharmacology; Medicine; Chemistry; Internal medicine; Chromatography; Pathology","score_opus":0.07433232041568684,"score_gpt":0.33670530562854756,"score_spread":0.26237298521286073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037238429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2422005,0.21163316,0.17249005,0.0834,0.011049086,0.012586378,0.06542261,0.0017617017,0.19945653],"genre_scores_gemma":[0.9948126,0.00044536215,0.0033347271,0.00065680937,0.00010325814,0.00004727557,0.00015463876,0.000027808563,0.00041752573],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966488,0.00060601055,0.0007682623,0.0008171217,0.00019851967,0.000961284],"domain_scores_gemma":[0.9966579,0.0016345185,0.00027985947,0.00062470953,0.0005823536,0.00022062598],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019180225,0.00046023502,0.0010045333,0.00025369777,0.00049149606,0.000094752344,0.00028011625,0.0005537934,0.0006101522],"category_scores_gemma":[0.0014853417,0.00035922587,0.000367363,0.0003397461,0.0010424796,0.00014144754,0.00013157418,0.00036731138,0.000030514982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009176235,0.0047123404,0.028827025,0.00029803152,0.017714115,0.00045302196,0.000872307,0.0000010915757,0.71062636,0.09925332,0.027367545,0.100698575],"study_design_scores_gemma":[0.00930539,0.003938009,0.029166313,0.00039358955,0.010252596,0.0016560137,0.0019999268,0.00020190128,0.57393056,0.0073919096,0.35827377,0.0034900252],"about_ca_topic_score_codex":0.000115612645,"about_ca_topic_score_gemma":0.000053246567,"teacher_disagreement_score":0.7526121,"about_ca_system_score_codex":0.00017140423,"about_ca_system_score_gemma":0.00010377666,"threshold_uncertainty_score":0.999886},"labels":[],"label_agreement":null},{"id":"W2038145760","doi":"10.1007/s10198-014-0589-1","title":"Statistical and regulatory considerations in assessments of interchangeability of biological drug products","year":2014,"lang":"en","type":"article","venue":"The European Journal of Health Economics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interchangeability; Biosimilar; Risk analysis (engineering); Computer science; Generic drug; Product (mathematics); Biochemical engineering; Similarity (geometry); Drug; Equivalence (formal languages); Bioequivalence; Medicine; Mathematics; Pharmacology; Artificial intelligence; Engineering; Pharmacokinetics","score_opus":0.08751189569677449,"score_gpt":0.33603329492938466,"score_spread":0.24852139923261019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038145760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931123,0.0010505501,0.0011218452,0.004016054,0.00023101199,0.00010280154,0.000022170765,0.0000016393107,0.00034159547],"genre_scores_gemma":[0.9947616,0.00023789673,0.004661435,0.00029805416,0.00002311316,1.8488778e-7,0.0000012426709,0.0000040861114,0.00001238996],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99567753,0.0032678926,0.00083037233,0.00009636359,0.000011451069,0.00011636479],"domain_scores_gemma":[0.9985563,0.00070035853,0.0005169087,0.00013870616,0.00006518708,0.000022521604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008127744,0.00006288559,0.00035692763,0.000050190534,0.000037721373,0.0000034636512,0.00010141461,0.000025734465,0.000035450226],"category_scores_gemma":[0.0005589853,0.00003850083,0.000029401892,0.000027229855,0.0004817188,0.000026171765,0.00006052307,0.00022596815,0.0000011978447],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015774585,0.0023818358,0.18152784,0.001046007,0.0006775942,0.0000133878175,0.005708297,0.00010657433,0.04026535,0.14870462,0.011456249,0.6065348],"study_design_scores_gemma":[0.0016947057,0.0017793446,0.97048074,0.00012491416,0.000034004843,0.00014723513,0.0004458577,0.000051396637,0.0064934203,0.013659552,0.004960609,0.00012819238],"about_ca_topic_score_codex":0.000008702409,"about_ca_topic_score_gemma":0.000009001925,"teacher_disagreement_score":0.78895295,"about_ca_system_score_codex":0.00002222785,"about_ca_system_score_gemma":0.000084498344,"threshold_uncertainty_score":0.281693},"labels":[],"label_agreement":null},{"id":"W2042850239","doi":"10.4103/0975-7406.106569","title":"Biosimilars: Current regulatory perspective and challenges","year":2013,"lang":"en","type":"article","venue":"Journal of Pharmacy And Bioallied Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Bioequivalence; Pharmacology; Medicine; Business; Pharmacokinetics; Internal medicine","score_opus":0.09754136608418014,"score_gpt":0.3602832840119084,"score_spread":0.2627419179277283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042850239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5416113,0.42175266,0.00003097602,0.033978123,0.0009409255,0.00015337997,0.000005446671,0.000013493586,0.0015136409],"genre_scores_gemma":[0.9538051,0.04477222,0.00080257386,0.0004607238,0.00009623006,0.0000013653872,1.07715856e-7,0.000003242638,0.000058427006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990643,0.00016216759,0.00028349317,0.00019908251,0.000074391755,0.0002165239],"domain_scores_gemma":[0.9993621,0.00016320858,0.0001947155,0.00005365142,0.0001573655,0.000068977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009417583,0.00012392704,0.00023466091,0.00014563157,0.00019538542,0.000053027976,0.00018499335,0.00005995263,0.00025782792],"category_scores_gemma":[0.00008058649,0.00007343882,0.00006211647,0.000117438445,0.0012939636,0.00027432153,0.00006967927,0.00026116156,0.0000069368593],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019534666,0.0004551806,0.0083209155,0.0001355908,0.00034030245,0.000011570878,0.0019151933,6.283512e-7,0.38783044,0.019913483,0.009219271,0.57166207],"study_design_scores_gemma":[0.0075164563,0.0028484191,0.09435104,0.00044545275,0.0005677037,0.0019182845,0.017415851,0.0002337602,0.2972121,0.042353857,0.5339194,0.0012177071],"about_ca_topic_score_codex":0.00000951828,"about_ca_topic_score_gemma":0.0000019344611,"teacher_disagreement_score":0.57044435,"about_ca_system_score_codex":0.000013731115,"about_ca_system_score_gemma":0.000054189324,"threshold_uncertainty_score":0.4767663},"labels":[],"label_agreement":null},{"id":"W2043483799","doi":"10.1016/j.jpba.2012.08.021","title":"Qualitative and quantitative assessment of marketed erythropoiesis-stimulating agents by capillary electrophoresis","year":2012,"lang":"en","type":"article","venue":"Journal of Pharmaceutical and Biomedical Analysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Chemistry; Capillary electrophoresis; Chromatography; Active ingredient; Dosage form; Erythropoietin; Distribution (mathematics); Pharmacology; Internal medicine","score_opus":0.06195798701266202,"score_gpt":0.4611201032812678,"score_spread":0.39916211626860576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043483799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9638032,0.021351926,0.010982816,0.0033589706,0.00018294239,0.00008769245,0.00009732969,0.00000706525,0.00012810374],"genre_scores_gemma":[0.9891307,0.0023387338,0.008087266,0.00029471455,0.00003768117,0.0000010173454,0.000016386824,0.000006579301,0.000086931344],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972832,0.0011216413,0.000833379,0.00017871163,0.00020141187,0.00038163742],"domain_scores_gemma":[0.9976683,0.0014123287,0.00041084862,0.00007456447,0.00018067726,0.00025324317],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024246967,0.0001878681,0.00082971697,0.00033201577,0.00010849487,0.000012652582,0.000116651434,0.00022077715,0.0010681511],"category_scores_gemma":[0.00040885812,0.00011759799,0.00027730118,0.0007673045,0.001075686,0.000110204295,0.00009468405,0.00045936153,0.0000011703511],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076788286,0.0015309341,0.052015603,0.00018177445,0.016470263,0.000015323405,0.0016376328,9.568768e-7,0.89956737,0.001184026,0.00711256,0.019515662],"study_design_scores_gemma":[0.020789688,0.012719387,0.39320976,0.0006211327,0.077446096,0.00071719656,0.02899362,0.020462226,0.30050686,0.0029832243,0.13848124,0.0030695456],"about_ca_topic_score_codex":0.000017919385,"about_ca_topic_score_gemma":7.73843e-7,"teacher_disagreement_score":0.59906054,"about_ca_system_score_codex":0.000031919768,"about_ca_system_score_gemma":0.000035319492,"threshold_uncertainty_score":0.999845},"labels":[],"label_agreement":null},{"id":"W2043592207","doi":"10.1016/j.drudis.2014.07.011","title":"Channeling postmarketing patient data into pharmaceutical regulatory systems","year":2014,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Guelph","keywords":"Postmarketing surveillance; Pharmacovigilance; License; Enforcement; Business; Medicine; Biosimilar; Pharmacology; Risk analysis (engineering); Drug; Adverse effect; Computer science; Political science","score_opus":0.06591256133947182,"score_gpt":0.3687567047639956,"score_spread":0.30284414342452376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043592207","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000237818,0.99246293,0.0002730825,0.00008645642,0.0047327247,0.000745029,0.0004360775,0.00009007318,0.0011498483],"genre_scores_gemma":[0.00036961233,0.9940465,0.00013398827,0.0002832321,0.0004452842,0.000053125124,0.0016533799,0.00009162317,0.002923248],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99387276,0.0026698778,0.001301078,0.0013063217,0.00013345559,0.0007164767],"domain_scores_gemma":[0.9961241,0.0013080515,0.00058481185,0.0018280237,0.000061301296,0.00009372261],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002236766,0.00073512126,0.0024508722,0.00019940351,0.00027066297,0.00015560618,0.0014173546,0.0009182518,0.00016340426],"category_scores_gemma":[0.0005173971,0.0005137939,0.00052391295,0.00025998772,0.0003419417,0.00025236167,0.0015606941,0.0012664173,0.00034176646],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003997975,0.00013881263,0.0000029436285,0.012211996,0.0009286056,0.000016599251,0.00007017496,0.0000015081654,0.00004656151,0.0006829214,0.029156495,0.9567034],"study_design_scores_gemma":[0.00020167664,0.000040711882,6.456055e-7,0.009068347,0.0013612742,0.00006590071,0.00009946804,0.00008333878,0.000039904124,0.000021542346,0.9883715,0.00064568507],"about_ca_topic_score_codex":0.000037606704,"about_ca_topic_score_gemma":0.0000034788127,"teacher_disagreement_score":0.959215,"about_ca_system_score_codex":0.00013227889,"about_ca_system_score_gemma":0.00021166126,"threshold_uncertainty_score":0.99973136},"labels":[],"label_agreement":null},{"id":"W2046974419","doi":"10.1208/s12248-014-9599-2","title":"Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations","year":2014,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":339,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"European Commission; European Federation of Pharmaceutical Industries and Associations; American Association of Pharmaceutical Scientists","keywords":"Immunogenicity; Terminology; Medicine; Clinical trial; Biosimilar; Pharmacology; Immunology; Pathology; Internal medicine; Antibody","score_opus":0.1269396769028942,"score_gpt":0.42468766487898396,"score_spread":0.29774798797608976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046974419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886723,0.001207206,0.0011411492,0.008374824,0.00021843406,0.0001633909,0.0000037760394,0.0000038476737,0.00021506041],"genre_scores_gemma":[0.9957203,0.0006163755,0.0032553168,0.00028691415,0.000029833458,0.000002047337,4.024252e-7,0.0000047558824,0.000084021834],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972512,0.0014184838,0.0010156778,0.00012788254,0.00003554446,0.00015120457],"domain_scores_gemma":[0.9976634,0.00087557634,0.0011523945,0.00020450325,0.00008017,0.000023964256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004470032,0.000089750894,0.00038348342,0.000025741587,0.0002626586,0.000015323572,0.00013851424,0.0001450092,0.000057734633],"category_scores_gemma":[0.0009569918,0.00004231294,0.00009322672,0.000050901293,0.0009999857,0.000033184275,0.00017608453,0.0006594971,2.4790265e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028475755,0.0002399413,0.20534958,0.000033405555,0.00076300435,0.0000017768002,0.00028006374,1.4342366e-7,0.46361855,0.005566858,0.00018361375,0.3236783],"study_design_scores_gemma":[0.0016939476,0.00065628137,0.9581638,0.000079821715,0.0004001868,0.0018886831,0.00023555962,0.00009261626,0.022157561,0.010417533,0.004102653,0.00011137849],"about_ca_topic_score_codex":0.000011136113,"about_ca_topic_score_gemma":0.0000032288274,"teacher_disagreement_score":0.7528142,"about_ca_system_score_codex":0.0000072198704,"about_ca_system_score_gemma":0.00005222105,"threshold_uncertainty_score":0.3684489},"labels":[],"label_agreement":null},{"id":"W2050903060","doi":"10.4155/bio.11.192","title":"2011 White Paper on Recent Issues in Bioanalysis and Regulatory Findings from Audits and Inspections","year":2011,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; BioPhage Pharma (Canada)","funders":"U.S. Food and Drug Administration","keywords":"Bioanalysis; Excellence; White paper; Audit; Engineering ethics; Computer science; Political science; Nanotechnology; Business; Engineering; Accounting","score_opus":0.030898355705104373,"score_gpt":0.2620523035579235,"score_spread":0.23115394785281915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050903060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93630177,0.050350342,0.000084467414,0.005933048,0.0004386284,0.00026405917,0.00018461313,0.00012609265,0.0063169687],"genre_scores_gemma":[0.9827346,0.010294936,0.002296178,0.00077271013,0.000036454065,0.000014214548,0.000038539292,0.000019582265,0.0037927937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982383,0.00028613606,0.00042531476,0.0006590221,0.000064857304,0.00032635714],"domain_scores_gemma":[0.9991986,0.00013166587,0.000105766114,0.00042830635,0.000064455926,0.00007116652],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041837702,0.0002659652,0.0005753991,0.0005324913,0.00017161423,0.000026431431,0.00015127435,0.00038694256,0.0069500054],"category_scores_gemma":[0.00010041141,0.00020920664,0.0001543779,0.00056900847,0.00046101413,0.00010785253,0.00011261784,0.0002911999,0.00011812642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052003894,0.0009287056,0.86286616,0.00002567252,0.0054259445,0.00003505617,0.0026681067,0.0000012888906,0.025814665,0.0029001255,0.006379346,0.09243487],"study_design_scores_gemma":[0.00083362096,0.00018463601,0.9163269,0.0000394057,0.0013255145,0.0000059857953,0.0006928627,0.000025858437,0.011027284,0.0016498258,0.067416444,0.0004716882],"about_ca_topic_score_codex":0.0016755764,"about_ca_topic_score_gemma":0.0015452596,"teacher_disagreement_score":0.09196318,"about_ca_system_score_codex":0.00004862272,"about_ca_system_score_gemma":0.00001575932,"threshold_uncertainty_score":0.99395776},"labels":[],"label_agreement":null},{"id":"W2051968298","doi":"10.1159/000367833","title":"Biosimilars: Are They Bioequivalent?","year":2014,"lang":"en","type":"review","venue":"Digestive Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Infliximab; Interchangeability; Bioequivalence; Clinical trial; Pharmacovigilance; Intensive care medicine; Disease; Pharmacology; Adverse effect; Internal medicine","score_opus":0.059143897164916075,"score_gpt":0.3651647460213913,"score_spread":0.30602084885647524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051968298","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000026366715,0.99429846,0.000038645365,0.00014280296,0.00097608374,0.00062363036,0.0026106492,0.0001787084,0.0011283645],"genre_scores_gemma":[0.00004372207,0.99583995,0.00005850874,0.0005132195,0.00018717824,0.00012135415,0.0006836237,0.00007994904,0.0024725087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99658376,0.0010689714,0.00067981385,0.00090607017,0.00007695994,0.0006843993],"domain_scores_gemma":[0.9973898,0.0010546475,0.0005775132,0.00072743214,0.0001189127,0.00013170709],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00023028567,0.00081965845,0.0026927802,0.00024733238,0.00020380819,0.000055295826,0.0006908117,0.0009375851,0.00092697336],"category_scores_gemma":[0.00080827577,0.00054114667,0.0014422598,0.00025431745,0.0005515243,0.00005716442,0.00027757077,0.00060301065,0.0013496813],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032661836,0.0003858499,0.00048405668,0.006763577,0.001260856,0.000032624896,0.000009747203,5.2096375e-8,0.0000050583544,0.00063201005,0.028243644,0.96214986],"study_design_scores_gemma":[0.00023413112,0.00011496737,0.00044491852,0.008053201,0.0034626788,0.000024623978,0.000019837838,1.9864031e-7,0.000013217925,0.00016101176,0.9867906,0.00068058586],"about_ca_topic_score_codex":0.0000065429917,"about_ca_topic_score_gemma":0.0000018848009,"teacher_disagreement_score":0.9614693,"about_ca_system_score_codex":0.00008416519,"about_ca_system_score_gemma":0.0001685901,"threshold_uncertainty_score":0.9999863},"labels":[],"label_agreement":null},{"id":"W2057583503","doi":"10.1517/17530050902929214","title":"Protein biomarker quantification by mass spectrometry","year":2009,"lang":"en","type":"article","venue":"Expert Opinion on Medical Diagnostics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada)","funders":"","keywords":"Biomarker; Biomarker discovery; Mass spectrometry; Selected reaction monitoring; Proteomics; Computational biology; Chemistry; Chromatography; Tandem mass spectrometry; Biology","score_opus":0.03386889004991104,"score_gpt":0.34366317529021606,"score_spread":0.309794285240305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057583503","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014064858,0.14415713,0.4204069,0.3696696,0.016689826,0.0033527166,0.00043201682,0.0013132874,0.029913692],"genre_scores_gemma":[0.8791282,0.04284288,0.020793635,0.049722157,0.0011213506,0.00016149538,0.0012646227,0.00009420764,0.0048714373],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828655,0.000305967,0.00038877196,0.00041336834,0.00020387214,0.00040145512],"domain_scores_gemma":[0.99867624,0.00071241235,0.00008614213,0.0003368288,0.000051438314,0.00013692121],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005430595,0.00021334567,0.00028285722,0.0001005134,0.00012381682,0.000021956053,0.00031765347,0.000631208,0.003938617],"category_scores_gemma":[0.003962266,0.00016047717,0.00010013758,0.00026510117,0.00024722586,0.00003684937,0.00002701397,0.0004602681,0.00045818617],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010554085,0.0007453016,0.000082078746,0.0000050706562,0.000048835373,0.000008823633,0.000023459024,4.3687503e-8,0.34293738,0.011877231,0.54366183,0.10050439],"study_design_scores_gemma":[0.00098275,0.0008356053,0.0029493757,0.00017874513,0.0000050389654,0.000012483165,0.000042066396,0.00007101484,0.22015099,0.0013808464,0.77306426,0.00032683575],"about_ca_topic_score_codex":0.0000071808977,"about_ca_topic_score_gemma":2.2584123e-7,"teacher_disagreement_score":0.86506337,"about_ca_system_score_codex":0.000042107247,"about_ca_system_score_gemma":0.00004798725,"threshold_uncertainty_score":0.9969719},"labels":[],"label_agreement":null},{"id":"W2059799806","doi":"10.4155/bio.11.47","title":"Conference Report: The 1St Conference in Asia-Pacific on Recent Issues in Bioanalysis","year":2011,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BioPhage Pharma (Canada)","funders":"U.S. Food and Drug Administration; Korea Food and Drug Administration","keywords":"Excellence; Asia pacific; Political science; Library science; Bioanalysis; Business; Computer science; Nanotechnology; International trade; Law","score_opus":0.0883064087309833,"score_gpt":0.31238306512355657,"score_spread":0.22407665639257326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059799806","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.320222,0.06796341,0.0024644914,0.111818284,0.0036905352,0.0032525351,0.0004002362,0.00060759,0.48958093],"genre_scores_gemma":[0.9885751,0.0031349356,0.0007667133,0.0002815794,0.000022658372,0.000038596303,0.00004402918,0.000015460753,0.0071209506],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965463,0.0009354324,0.00096655334,0.00081648363,0.00013290555,0.0006023031],"domain_scores_gemma":[0.99812853,0.00023104898,0.00031921334,0.0010664593,0.00019845975,0.000056279558],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016890316,0.00036363694,0.00084506825,0.0006412431,0.00013138949,0.000050892195,0.0006587304,0.0004389979,0.006726981],"category_scores_gemma":[0.0004967382,0.0002304294,0.00030924045,0.0019511543,0.00066241855,0.000080172664,0.00013579281,0.00062509597,0.00026956343],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018547466,0.0054469304,0.41891032,0.000095253614,0.006669653,0.0019847136,0.007995088,0.000020277384,0.030083062,0.052432403,0.007141285,0.46736625],"study_design_scores_gemma":[0.0031760507,0.0008850996,0.2767444,0.0003612257,0.0025390415,0.00018282625,0.013573977,0.0008728924,0.10598798,0.00970889,0.5835362,0.0024314064],"about_ca_topic_score_codex":0.0016061573,"about_ca_topic_score_gemma":0.0029183645,"teacher_disagreement_score":0.6683531,"about_ca_system_score_codex":0.00009837479,"about_ca_system_score_gemma":0.00009037394,"threshold_uncertainty_score":0.994181},"labels":[],"label_agreement":null},{"id":"W2063375919","doi":"10.1016/j.jchromb.2012.06.002","title":"Impact of hemolysis during sample collection: How different is drug concentration in hemolyzed plasma from that of normal plasma?","year":2012,"lang":"en","type":"article","venue":"Journal of Chromatography B","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Hemolysis; Chemistry; Drug; Chromatography; Plasma concentration; Plasma; Pharmacology; Red blood cell; Biochemistry; Internal medicine; Medicine","score_opus":0.015641050810686345,"score_gpt":0.26275744940232004,"score_spread":0.2471163985916337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063375919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748987,0.001576815,0.00013673064,0.00016662665,0.00038302885,0.00009159552,0.00009947601,0.000005150249,0.00005069892],"genre_scores_gemma":[0.99859476,0.00027520317,0.0010179132,0.000014059693,0.000059154107,0.0000013349774,0.000007795665,0.000008745783,0.000021050848],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986501,0.0002479219,0.00058272656,0.00011157728,0.00010991232,0.00029776807],"domain_scores_gemma":[0.99856406,0.00036393155,0.0007572625,0.00014404925,0.000106763524,0.000063939275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027879505,0.00018078626,0.0006861617,0.0003061489,0.000055204833,0.000012011153,0.00015895563,0.00020874778,0.00060247985],"category_scores_gemma":[0.00006176147,0.00012627928,0.0006518111,0.0004063095,0.00018008267,0.00021502224,0.000034131757,0.00028549324,6.388128e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006218967,0.0003869277,0.6535299,0.000027087885,0.0007499992,0.0000016771213,0.0005377647,0.000001867387,0.34320304,0.000007553582,0.0005279054,0.00040436492],"study_design_scores_gemma":[0.0018967176,0.0001614031,0.46939972,0.00007156337,0.00012042571,0.00004645511,0.00015390627,0.000014644724,0.52797544,0.000032335312,0.00004829694,0.0000790834],"about_ca_topic_score_codex":0.00017524637,"about_ca_topic_score_gemma":0.000030164778,"teacher_disagreement_score":0.18477239,"about_ca_system_score_codex":0.000053593954,"about_ca_system_score_gemma":0.00004530674,"threshold_uncertainty_score":0.6596732},"labels":[],"label_agreement":null},{"id":"W2063895202","doi":"10.4155/bio.13.1","title":"Analytical and Bioanalytical Assay Challenges to Support Comparability Studies for Biosimilar Drug Development","year":2013,"lang":"en","type":"editorial","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Intertek (Canada)","funders":"","keywords":"Biosimilar; Biopharmaceutical; Comparability; Business; Pharmacology; Biotechnology; Medicine; Biology","score_opus":0.08291979931937664,"score_gpt":0.3721319578502333,"score_spread":0.28921215853085663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063895202","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014924763,0.20903231,0.002050607,0.029515117,0.74733925,0.0050663827,0.0029962107,0.000635483,0.0018721762],"genre_scores_gemma":[0.04089705,0.06656879,0.13570307,0.005143683,0.6016861,0.004824851,0.0074939574,0.00116648,0.13651599],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.993387,0.0008547227,0.0017557933,0.0022775833,0.00041080007,0.0013141071],"domain_scores_gemma":[0.99070215,0.006021343,0.00041802568,0.0011324798,0.0013562931,0.00036970156],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0037663726,0.001166465,0.0034127277,0.0008123405,0.00045901956,0.00013017954,0.0008575529,0.0020967913,0.0006993839],"category_scores_gemma":[0.005864907,0.000877518,0.00084184273,0.0006284723,0.0012229147,0.000097746466,0.00076915673,0.0010524066,0.00037332965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018165873,0.00033169493,0.000121709934,0.0005198108,0.00879464,0.0000059930157,0.0003087716,5.498605e-7,0.000074989715,0.00032221226,0.9510628,0.038275175],"study_design_scores_gemma":[0.0009142156,0.0003945873,0.00019726597,0.00012241333,0.0040686517,0.0000030712883,0.0005903834,0.00006328113,0.0010816068,0.00025466274,0.9911867,0.0011232039],"about_ca_topic_score_codex":0.000043423384,"about_ca_topic_score_gemma":0.0002695324,"teacher_disagreement_score":0.1456531,"about_ca_system_score_codex":0.00038155227,"about_ca_system_score_gemma":0.0004410353,"threshold_uncertainty_score":0.99936754},"labels":[],"label_agreement":null},{"id":"W2064641168","doi":"10.3810/pgm.2014.05.2760","title":"Biosimilar Insulins Are Coming: The Top 10 Things you Should Know","year":2014,"lang":"en","type":"review","venue":"Postgraduate Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada","funders":"Sanofi; Cilag; GlaxoSmithKline; AstraZeneca","keywords":"Biosimilar; Medicine; Drug; Intensive care medicine; Internet privacy; Risk analysis (engineering); Pharmacology; Internal medicine; Computer science","score_opus":0.12174559899454297,"score_gpt":0.3836425135444827,"score_spread":0.26189691454993974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064641168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000024260462,0.9627643,0.000096084696,0.031142658,0.0022266603,0.0009048055,0.00012235218,0.00014045327,0.0026002522],"genre_scores_gemma":[0.000024731586,0.97871506,0.00014111854,0.0061783455,0.00065811997,0.00005111147,0.00037482803,0.00009498461,0.013761694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99526066,0.0014654113,0.0013432804,0.00090181426,0.0001816697,0.00084714714],"domain_scores_gemma":[0.9956428,0.0017876975,0.0009144277,0.0013194589,0.00021647531,0.000119141005],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0024851323,0.0009865506,0.0038111908,0.00029632912,0.0004211051,0.00003230532,0.0013408221,0.00142612,0.0021901315],"category_scores_gemma":[0.0019203278,0.00046241604,0.0007613537,0.00065933866,0.0015334465,0.00005317502,0.0003781319,0.0022139389,0.0008360245],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048324877,0.000090106034,0.000013321974,0.003007199,0.0008489899,0.000018284263,0.000115030845,1.4128688e-8,0.000023769446,0.00064993347,0.13814822,0.8570368],"study_design_scores_gemma":[0.0007428655,0.00033565372,0.000026650792,0.009368858,0.0032242546,0.00013152993,0.000060410763,0.000002717172,0.00003721057,0.00020499836,0.98532313,0.00054169114],"about_ca_topic_score_codex":0.00006305353,"about_ca_topic_score_gemma":0.000008654877,"teacher_disagreement_score":0.85649514,"about_ca_system_score_codex":0.00008559684,"about_ca_system_score_gemma":0.0001258198,"threshold_uncertainty_score":0.99994195},"labels":[],"label_agreement":null},{"id":"W2070196919","doi":"10.1021/ac3018229","title":"Reusable Solid-Phase Microextraction Coating for Direct Immersion Whole-Blood Analysis and Extracted Blood Spot Sampling Coupled with Liquid Chromatography–Tandem Mass Spectrometry and Direct Analysis in Real Time–Tandem Mass Spectrometry","year":2012,"lang":"en","type":"article","venue":"Analytical Chemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Chemistry; Chromatography; Solid-phase microextraction; Mass spectrometry; Detection limit; Tandem mass spectrometry; DART ion source; Dried blood spot; Whole blood; Analytical Chemistry (journal); Gas chromatography–mass spectrometry","score_opus":0.016688188013482697,"score_gpt":0.3097533677512081,"score_spread":0.2930651797377254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070196919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852261,0.0024176098,0.0100912,0.0001582598,0.000038275055,0.00029134555,0.00014311267,0.000101825164,0.0015323064],"genre_scores_gemma":[0.9836095,0.0005369334,0.014435647,0.000045518795,0.00012070981,0.000021605776,0.0004239125,0.000044652286,0.00076150056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964301,0.00019318903,0.00093409535,0.0010766521,0.00018564357,0.0011802941],"domain_scores_gemma":[0.99734825,0.0012719699,0.00042917207,0.0005170316,0.00014564014,0.00028796104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016150348,0.0005959476,0.0017187133,0.00083248096,0.0003261547,0.0001079502,0.00022066657,0.00081699993,0.0006251699],"category_scores_gemma":[0.0003527299,0.0005071061,0.0005709959,0.0040354636,0.0004370111,0.00023747138,0.0000868447,0.00072831206,0.000004261019],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071030605,0.000727834,0.11846705,0.00009419768,0.009966311,0.000018436993,0.00002606745,0.000008161723,0.86988205,0.000009052428,0.000024337658,0.00006620067],"study_design_scores_gemma":[0.005423145,0.00075756735,0.03743931,0.0001124748,0.03868481,0.000098781566,0.00034108595,0.004238094,0.9117168,0.000034223063,0.00012516504,0.0010285286],"about_ca_topic_score_codex":0.00009906121,"about_ca_topic_score_gemma":0.000021234106,"teacher_disagreement_score":0.08102774,"about_ca_system_score_codex":0.00010340532,"about_ca_system_score_gemma":0.000052874373,"threshold_uncertainty_score":0.99973804},"labels":[],"label_agreement":null},{"id":"W2072330286","doi":"10.1208/s12248-014-9679-3","title":"Survey of International Regulatory Bioequivalence Recommendations for Approval of Generic Topical Dermatological Drug Products","year":2014,"lang":"en","type":"review","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; Food and Drug Administration; U.S. Food and Drug Administration; Ministry of Health, Labour and Welfare; European Commission; Ministry of Food and Drug Safety; World Health Organization","keywords":"Bioequivalence; Medicine; Pharmacology; Drug; Drug development; Clinical pharmacology; Generic drug; Clinical trial; New drug application; Pharmacokinetics; Pathology","score_opus":0.17579006375231992,"score_gpt":0.3976035920854215,"score_spread":0.22181352833310158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072330286","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000104680046,0.99428314,0.0013554052,0.0017326194,0.001894431,0.00034368597,0.00019731912,0.0000072706484,0.000081476406],"genre_scores_gemma":[0.00051971624,0.9945171,0.0037771587,0.00008434633,0.00019983112,0.0000147020055,0.00012256361,0.000015299918,0.0007492804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99672085,0.0017314224,0.0010254228,0.00022434727,0.00007185606,0.00022608157],"domain_scores_gemma":[0.997113,0.0011605244,0.0009772603,0.00033170445,0.00039132664,0.000026199596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029227335,0.00021003307,0.0011561095,0.00010896489,0.00012192926,0.000013083034,0.0008696289,0.00032649352,0.00021066211],"category_scores_gemma":[0.0011892699,0.00011011517,0.00041519845,0.00018228639,0.0005209117,0.000030609946,0.00016263903,0.000622564,0.0000065992626],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000668543,0.00021796097,0.00009292813,0.0017079532,0.00085123687,8.9344286e-7,0.00002994665,2.1365223e-7,0.00015839472,0.0014951202,0.041400697,0.9539778],"study_design_scores_gemma":[0.00028149594,0.00008082376,0.00033563425,0.0008256497,0.00046310585,0.00045239486,0.000007991,0.000004318474,0.00037108,0.00021960092,0.99682075,0.00013715649],"about_ca_topic_score_codex":0.000006132047,"about_ca_topic_score_gemma":0.0000024098035,"teacher_disagreement_score":0.9554201,"about_ca_system_score_codex":0.00003096238,"about_ca_system_score_gemma":0.00020912636,"threshold_uncertainty_score":0.44903663},"labels":[],"label_agreement":null},{"id":"W2075123435","doi":"10.1007/s10067-014-2835-4","title":"Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists","year":2015,"lang":"en","type":"article","venue":"Clinical Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame; University of British Columbia; Western University; Mount Sinai Hospital; Southlake Regional Health Center; University of Toronto","funders":"University of Toronto; Johns Hopkins University","keywords":"Medicine; Biosimilar; Family medicine; Rheumatology; Alternative medicine; Pharmacist; Internal medicine; Pharmacy; Pathology","score_opus":0.2622206964662622,"score_gpt":0.40882839137349575,"score_spread":0.14660769490723352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075123435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708658,0.010408038,0.00026859742,0.004324621,0.005440075,0.00050608395,0.00048452042,0.00016190254,0.00754038],"genre_scores_gemma":[0.99422616,0.0026105782,0.0015708373,0.0010797787,0.0000103408875,0.000015163674,0.00017889147,0.000023859751,0.0002843774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934771,0.002834516,0.0018605427,0.0007730016,0.000081524195,0.0009733062],"domain_scores_gemma":[0.99564534,0.0020796517,0.0004915204,0.00075252407,0.00059600663,0.00043496955],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0053677754,0.00038269942,0.0017113662,0.0004706661,0.000103844075,0.000016233002,0.0008606708,0.0017642273,0.0006362852],"category_scores_gemma":[0.013186254,0.00029048856,0.00032419665,0.0007985944,0.0024443024,0.000058586837,0.00028482804,0.000823539,0.00040015558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039407262,0.00038992643,0.9390739,0.000037268837,0.00040615644,0.000024604537,0.000044739852,8.896432e-7,0.00014162355,0.0047152983,0.049572803,0.0051986678],"study_design_scores_gemma":[0.0033482902,0.001169229,0.92310995,0.00012204563,0.000088253335,0.00040855052,0.00010363461,0.000017228564,0.002734067,0.001507383,0.066775896,0.000615478],"about_ca_topic_score_codex":0.101464204,"about_ca_topic_score_gemma":0.09733801,"teacher_disagreement_score":0.02336039,"about_ca_system_score_codex":0.00008559048,"about_ca_system_score_gemma":0.001297514,"threshold_uncertainty_score":0.9999547},"labels":[],"label_agreement":null},{"id":"W2075758441","doi":"10.2174/157489109788490307","title":"Social Leverage of Intellectual Property: Road to the Development of Better Therapy for Tuberculosis","year":2009,"lang":"en","type":"review","venue":"Recent Patents on Anti-Infective Drug Discovery","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Johnson and Johnson; University of British Columbia","keywords":"Intellectual property; Leverage (statistics); Tuberculosis; Clinical trial; Drug development; Medicine; Investment (military); Business; Risk analysis (engineering); Engineering ethics; Drug; Intensive care medicine; Political science; Engineering; Pharmacology; Computer science; Law; Pathology","score_opus":0.0934556450456633,"score_gpt":0.3615809840344358,"score_spread":0.2681253389887725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075758441","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009191671,0.980243,0.0013480461,0.0009335508,0.001138825,0.005630854,0.00071669987,0.000037658952,0.0007596681],"genre_scores_gemma":[0.0025159633,0.995213,0.0001891466,0.0006064448,0.00008927564,0.0001846994,0.0002236772,0.000054450775,0.0009233494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968336,0.0008725031,0.0010480013,0.00063020794,0.00013178002,0.0004838695],"domain_scores_gemma":[0.9983692,0.00053708,0.0005049364,0.00033873427,0.00021881836,0.0000311986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008511281,0.00059362553,0.0020572196,0.00024399198,0.00022554859,0.000029763456,0.00048485308,0.0004803476,0.00012533132],"category_scores_gemma":[0.00025112045,0.00028079387,0.0009440647,0.00043452086,0.00019583745,0.00006968805,0.00015055038,0.00049319706,0.000048464164],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021602087,0.0008935587,0.000025667567,0.00078046776,0.0016308655,3.7702208e-7,0.0005841266,2.840827e-7,0.00040990338,0.000030191051,0.0042491043,0.9911794],"study_design_scores_gemma":[0.0006683174,0.000422571,0.00070479035,0.0021899277,0.00043682326,0.0000019257734,0.00005841964,3.6643542e-7,0.01690204,0.00002059691,0.97816277,0.0004314783],"about_ca_topic_score_codex":0.00001394335,"about_ca_topic_score_gemma":0.000008616605,"teacher_disagreement_score":0.9907479,"about_ca_system_score_codex":0.00016722381,"about_ca_system_score_gemma":0.00030625155,"threshold_uncertainty_score":0.9999644},"labels":[],"label_agreement":null},{"id":"W2077342035","doi":"10.1007/s10227-004-2003-6","title":"Incorporating Biologics into the Treatment of Psoriasis","year":2004,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada)","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Intensive care medicine","score_opus":0.08390719442168929,"score_gpt":0.3563719371492195,"score_spread":0.2724647427275302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077342035","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021980892,0.9975992,0.000025997379,0.00074536336,0.0011626091,0.00013688004,0.000006156497,0.000004332156,0.00009966268],"genre_scores_gemma":[0.00024175909,0.99883115,0.00026848377,0.00010930258,0.00034564306,0.0000020122245,0.000008999315,0.000013230618,0.00017942411],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975308,0.0005655162,0.0014873215,0.00015668788,0.000070890994,0.00018877734],"domain_scores_gemma":[0.99347943,0.0044161337,0.0017207538,0.00019347708,0.00014485554,0.000045366625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010859137,0.00031102935,0.0029417474,0.00026536075,0.000095065996,0.00000559711,0.00016237884,0.00049070275,0.00010500192],"category_scores_gemma":[0.00064539077,0.00012056164,0.0006846988,0.00023976793,0.00072440703,0.000017454695,0.000022182427,0.00039100277,0.000002288328],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048816957,0.00010600459,0.000027577953,0.0013616617,0.00085959025,0.00022063256,0.0002421746,1.07972326e-7,0.000036505375,0.000078484925,0.0011400216,0.9958784],"study_design_scores_gemma":[0.00021520718,0.0015472898,0.0000013392291,0.008037195,0.002109291,0.006523772,0.00018762381,9.290071e-8,0.00004225913,0.0006511807,0.9805612,0.00012357322],"about_ca_topic_score_codex":0.000037503967,"about_ca_topic_score_gemma":0.0000037580437,"teacher_disagreement_score":0.99575484,"about_ca_system_score_codex":0.00007505736,"about_ca_system_score_gemma":0.00035948935,"threshold_uncertainty_score":0.4916361},"labels":[],"label_agreement":null},{"id":"W2077952077","doi":"10.1016/j.biologicals.2011.09.005","title":"Biosimilars – Global issues, national solutions","year":2011,"lang":"en","type":"review","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Biochemical engineering; Biotechnology; Biology; Engineering","score_opus":0.31092367599587706,"score_gpt":0.43790269373568413,"score_spread":0.12697901773980708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077952077","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.5453526e-7,0.9804271,0.000070261354,0.00023836932,0.0009878441,0.00047564032,0.0016423233,0.00016750224,0.01599081],"genre_scores_gemma":[0.000003021698,0.9942403,0.0013852943,0.00064884964,0.00016638146,0.000088862,0.0004665422,0.000017108192,0.0029836586],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99656653,0.0010602764,0.00081346184,0.000776398,0.000053065007,0.0007302653],"domain_scores_gemma":[0.9987481,0.00033004105,0.00033884752,0.00037564244,0.00014011408,0.00006722994],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00096480723,0.00058493647,0.001875475,0.00009833097,0.00023980967,0.000023553313,0.0007278225,0.0024374174,0.006149478],"category_scores_gemma":[0.0006297686,0.0003440834,0.0009628044,0.00043967183,0.00070608547,0.000032705564,0.0003913339,0.00057046,0.0029776662],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001050281,0.00021510152,0.000006221886,0.00046085726,0.0006357212,0.0000049338337,0.0000020425482,7.1728943e-9,0.000011524927,0.03190018,0.13513187,0.83162105],"study_design_scores_gemma":[0.00012372833,0.00014742756,0.000026849551,0.0007202913,0.0004901838,0.00011889866,0.000002410273,7.1164635e-8,0.0000060556313,0.0035636749,0.99433994,0.00046046343],"about_ca_topic_score_codex":0.0000123407835,"about_ca_topic_score_gemma":0.0000034066104,"teacher_disagreement_score":0.85920805,"about_ca_system_score_codex":0.00015739295,"about_ca_system_score_gemma":0.00022602512,"threshold_uncertainty_score":0.9999011},"labels":[],"label_agreement":null},{"id":"W2079795261","doi":"10.1371/journal.pone.0103391","title":"Compatibility of Stabilized Whole Blood Products with CD4 Technologies and Their Suitability for Quality Assessment Programs","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"Public Health Agency; Public Health Agency of Canada","keywords":"Enumeration; External quality assessment; Standardization; Computer science; Reliability engineering; Medicine; Operating system; Mathematics; Pathology; Engineering","score_opus":0.09368302177439002,"score_gpt":0.30629889337356503,"score_spread":0.212615871599175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079795261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952311,0.00044276702,0.0008050006,0.0018626644,0.000020260815,0.001294817,0.00011069795,0.00013911826,0.00009355651],"genre_scores_gemma":[0.9558351,0.000011093092,0.043904077,0.00002191651,0.0000065451627,0.00010823965,0.000039273942,0.000008669629,0.000065089655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838024,0.00042733972,0.00038142872,0.00047536506,0.000053618234,0.00028201137],"domain_scores_gemma":[0.998251,0.00061834854,0.00017644062,0.0006044815,0.00033167092,0.00001805164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018907338,0.00017904353,0.00068159174,0.000031659652,0.00009053877,0.000011820865,0.0001727534,0.00021273062,0.000017304454],"category_scores_gemma":[0.0010008585,0.00010734892,0.00005288499,0.00014424449,0.001036984,0.000043455537,0.000111155234,0.00021631867,7.1880623e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043090174,0.007521218,0.18350855,0.0011337856,0.00072913105,4.9752174e-8,0.00012723553,5.32441e-8,0.77949274,0.0015934104,0.0000110902965,0.025451845],"study_design_scores_gemma":[0.0020116358,0.0024079566,0.05875019,0.00010317783,0.00028960305,0.0000011407241,0.00056757877,0.000033680397,0.93088704,0.0042837397,0.00045394897,0.000210322],"about_ca_topic_score_codex":0.000024131852,"about_ca_topic_score_gemma":0.000051049083,"teacher_disagreement_score":0.1513943,"about_ca_system_score_codex":0.00001585543,"about_ca_system_score_gemma":0.000044732562,"threshold_uncertainty_score":0.43775618},"labels":[],"label_agreement":null},{"id":"W2080183440","doi":"10.4155/bio.13.38","title":"Bioanalysis of Antibody–Drug Conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group Position Paper","year":2013,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bell (Canada)","funders":"","keywords":"Bioanalysis; Antibody-drug conjugate; Conjugate; Drug; Linker; Pharmacology; Pharmaceutical industry; Computational biology; Chemistry; Computer science; Combinatorial chemistry; Antibody; Medicine; Monoclonal antibody; Biology; Chromatography; Mathematics; Immunology","score_opus":0.012675531054162727,"score_gpt":0.30853421304471434,"score_spread":0.2958586819905516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080183440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97314835,0.012830383,0.0026780036,0.0071163443,0.00083181786,0.0007045973,0.00032093364,0.00014266983,0.002226883],"genre_scores_gemma":[0.9936143,0.0013558207,0.002485796,0.0005958081,0.000051386403,0.000013243421,0.0003191248,0.00002677452,0.001537748],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957928,0.0010896152,0.0013259657,0.0007478321,0.00032498813,0.00071879936],"domain_scores_gemma":[0.9966903,0.00069001695,0.0013195984,0.0005684934,0.00061009417,0.000121502904],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018211699,0.00040581718,0.0014202293,0.0007225683,0.00023037195,0.00007204554,0.0005019174,0.0002569735,0.003082624],"category_scores_gemma":[0.00031643372,0.00033236938,0.00091704266,0.0025404103,0.0012377927,0.00026094523,0.00018119976,0.00039856113,0.0001536277],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009518872,0.0005029348,0.15800402,0.00006821934,0.004098837,0.0000036771091,0.00011485142,0.0000062254076,0.818183,0.00068877614,0.00081351644,0.017420733],"study_design_scores_gemma":[0.0047491663,0.0005189527,0.23337711,0.0005654065,0.016469007,0.000028997965,0.0018522643,0.0037393752,0.68639386,0.0011713512,0.04900842,0.0021260856],"about_ca_topic_score_codex":0.0019142333,"about_ca_topic_score_gemma":0.00015765373,"teacher_disagreement_score":0.13178916,"about_ca_system_score_codex":0.0001476237,"about_ca_system_score_gemma":0.000058184865,"threshold_uncertainty_score":0.99991286},"labels":[],"label_agreement":null},{"id":"W2080876607","doi":"10.1208/s12248-009-9091-6","title":"Antidrug Antibody Assay Validation: Industry Survey Results","year":2009,"lang":"en","type":"review","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"American Association of Pharmaceutical Scientists","keywords":"Bioanalysis; Immunogenicity; Biopharmaceutical; Pharmacy; Computer science; Antibody; Medicine; Biotechnology; Immunology; Chemistry; Biology","score_opus":0.1314733355119067,"score_gpt":0.4270096119201458,"score_spread":0.2955362764082391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080876607","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009593776,0.9941651,0.000110369976,0.0008126378,0.0016537765,0.00022752758,0.00031467396,0.000026522297,0.0026797475],"genre_scores_gemma":[0.000037828413,0.9904673,0.00015911541,0.00025327713,0.0005227935,0.0000015151277,0.00041308987,0.000028166105,0.008116906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9906789,0.007168769,0.0011655599,0.00035150602,0.000104970066,0.0005302689],"domain_scores_gemma":[0.9966848,0.0014883017,0.0009708138,0.0006189227,0.00016912162,0.000068066496],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.010148624,0.0004563023,0.001526637,0.00016310165,0.0005193939,0.00014611421,0.0010542108,0.0018802705,0.00067479507],"category_scores_gemma":[0.0012723409,0.00022852041,0.00061953336,0.00047444217,0.00029560048,0.00007694279,0.00014085895,0.005575802,0.00036069492],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052805608,0.00008172957,0.000017342438,0.00014630024,0.0006063341,0.000033298118,0.00001529487,1.6899375e-7,0.000028679657,0.00005413303,0.05685715,0.9421068],"study_design_scores_gemma":[0.0003791626,0.00010805492,0.00039348772,0.0020050502,0.0008304561,0.0025664556,0.000007671749,1.7906434e-7,0.000060369028,0.00016086931,0.9931822,0.0003060664],"about_ca_topic_score_codex":0.000014808737,"about_ca_topic_score_gemma":0.0000022408333,"teacher_disagreement_score":0.9418007,"about_ca_system_score_codex":0.000065261054,"about_ca_system_score_gemma":0.00034444575,"threshold_uncertainty_score":0.9994155},"labels":[],"label_agreement":null},{"id":"W2084850904","doi":"10.1128/jmbe.v11i2.220","title":"Clinical Microbiology in Pharmacy Education: A Practice-based Approach","year":2010,"lang":"en","type":"article","venue":"Journal of Microbiology and Biology Education","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"","keywords":"Pharmacy; Clinical pharmacy; Pharmacy practice; Medicine; Clinical microbiology; Microbiology; Medical education; Family medicine; Biology","score_opus":0.0472595657495568,"score_gpt":0.4181054035135419,"score_spread":0.3708458377639851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084850904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613089,0.012867777,0.0005734927,0.010960042,0.011729858,0.00040781952,0.000036545905,0.000020602774,0.0020949908],"genre_scores_gemma":[0.961574,0.0005847372,0.029502511,0.0071316534,0.000579616,0.000016887137,0.0001607752,0.000015921472,0.00043390723],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99640423,0.0015408373,0.0012080165,0.00044068627,0.000009555121,0.0003966678],"domain_scores_gemma":[0.99733603,0.0009998686,0.0008546526,0.000257757,0.0004696931,0.00008199843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028915647,0.0002683673,0.00068777136,0.0004389771,0.00011472132,0.000014504042,0.00038446556,0.0010512974,0.00032317912],"category_scores_gemma":[0.001150605,0.0001977145,0.000198207,0.00024721274,0.0012644355,0.0001324392,0.000070378235,0.0019058124,0.00002621266],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065538636,0.0025786788,0.06956351,0.000022181408,0.00015449172,0.0000012925647,0.0000715483,2.6712613e-7,0.8437003,0.0019547024,0.007634848,0.07366279],"study_design_scores_gemma":[0.0028728736,0.0007755948,0.007560898,0.000050512743,0.00022848585,0.0055322074,0.00053888117,0.0000038859957,0.02368175,0.0008262401,0.95756793,0.00036076186],"about_ca_topic_score_codex":0.00003711028,"about_ca_topic_score_gemma":0.00002896245,"teacher_disagreement_score":0.94993305,"about_ca_system_score_codex":0.00003709351,"about_ca_system_score_gemma":0.0019548952,"threshold_uncertainty_score":0.82799125},"labels":[],"label_agreement":null},{"id":"W2085714200","doi":"10.1208/s12248-013-9484-4","title":"Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment","year":2013,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"Amgen","keywords":"Bioanalysis; Pharmacokinetics; Dosing; Pharmacology; Immunogenicity; Drug; Monoclonal antibody; Antibody; Chemistry; Medicine; Chromatography; Immunology","score_opus":0.045610785405261756,"score_gpt":0.4208263597374018,"score_spread":0.37521557433214003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085714200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438643,0.0015410774,0.00008459386,0.002330347,0.00035842892,0.00013067445,0.0000058028163,0.0000061762057,0.0011564861],"genre_scores_gemma":[0.99797744,0.0007175682,0.000665095,0.00014141825,0.000057452893,0.0000020173238,0.000001076196,0.000006235778,0.0004317038],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984674,0.00064804044,0.00045428006,0.000106018,0.00004489867,0.00027938662],"domain_scores_gemma":[0.9991855,0.00036356124,0.00017996682,0.0001585837,0.00008231194,0.000030089928],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010888953,0.000115012284,0.00031537385,0.00007301651,0.000080619866,0.000022214437,0.00030285417,0.00008936924,0.0037413307],"category_scores_gemma":[0.000091176764,0.000055276818,0.0002157113,0.00011769152,0.00029975158,0.00007180801,0.00008141795,0.0007379168,0.000053795775],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009522971,0.0005141372,0.36508295,0.000011997672,0.00057515147,0.00000888662,0.00020249924,0.000039647803,0.5818322,0.00014834543,0.023494935,0.027994055],"study_design_scores_gemma":[0.0010768952,0.00022560537,0.9850563,0.000041639843,0.00006888228,0.00020126255,0.00006600197,0.00008883724,0.010407576,0.0020615866,0.00061036425,0.00009506401],"about_ca_topic_score_codex":0.000085028776,"about_ca_topic_score_gemma":0.000002342445,"teacher_disagreement_score":0.6199733,"about_ca_system_score_codex":0.00002804772,"about_ca_system_score_gemma":0.00006837559,"threshold_uncertainty_score":0.9971694},"labels":[],"label_agreement":null},{"id":"W2087287783","doi":"10.1016/j.biologicals.2007.11.004","title":"WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19–20 April 2007","year":2008,"lang":"en","type":"article","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Terminology; Innovator; Product (mathematics); Medicine; Business; Quality (philosophy); Regulatory science; Political science; Intellectual property; Law","score_opus":0.1320325286439629,"score_gpt":0.3391617240837612,"score_spread":0.20712919543979832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087287783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98718584,0.0075768162,0.00010863453,0.0011459544,0.00049320434,0.00075596,0.00006998104,0.0000698494,0.0025937585],"genre_scores_gemma":[0.9950498,0.00058075966,0.00033799288,0.0022736138,0.0001281606,0.00004080308,0.00016419166,0.00000851973,0.0014161941],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968617,0.0012582277,0.0006912543,0.0005280093,0.00019824987,0.00046255544],"domain_scores_gemma":[0.9981635,0.0006481498,0.00032364146,0.0003897702,0.00040652373,0.000068367015],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025537687,0.00029374857,0.00063246064,0.00009399363,0.00026479608,0.0000050018034,0.00024842913,0.0007783324,0.001726993],"category_scores_gemma":[0.001386179,0.00017406014,0.00014673313,0.00025463628,0.0013599362,0.000054007036,0.00008393221,0.00029821388,0.00015569404],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032969771,0.00075992907,0.042562615,0.000063977626,0.00056154,0.00001187384,0.0006631205,0.00003298176,0.84604424,0.0036028607,0.031516608,0.07088328],"study_design_scores_gemma":[0.0044414415,0.0051199645,0.65542626,0.000102752434,0.00023314364,0.00020504846,0.0002315324,0.00014608992,0.25434366,0.00076501665,0.07833256,0.00065251417],"about_ca_topic_score_codex":0.0000088759125,"about_ca_topic_score_gemma":0.0000024468754,"teacher_disagreement_score":0.61286366,"about_ca_system_score_codex":0.000087394124,"about_ca_system_score_gemma":0.00012513432,"threshold_uncertainty_score":0.99918556},"labels":[],"label_agreement":null},{"id":"W2088112231","doi":"10.4155/bio.12.172","title":"Recommendations on Isr in Multi Analyte Assays, Qa/Bioanalytical Consultants And Gcp By Global Cro Council For Bioanalysis (Gcc)","year":2012,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"","keywords":"Bioanalysis; Analyte; Chromatography; Chemistry; Medical physics; Nanotechnology; Medicine; Materials science","score_opus":0.14828855073909972,"score_gpt":0.3539644401417944,"score_spread":0.20567588940269468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088112231","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2688268,0.3494326,0.13290717,0.13820125,0.009036487,0.009537918,0.04943527,0.0017605734,0.04086194],"genre_scores_gemma":[0.9799195,0.0014505113,0.010326658,0.0019005131,0.000079979945,0.00008394358,0.00035872278,0.000040068153,0.0058401097],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99601185,0.00060115504,0.0010613431,0.0009316337,0.00022994554,0.0011640721],"domain_scores_gemma":[0.9972493,0.0010173749,0.0003196779,0.00064647844,0.00051120773,0.00025598542],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026554766,0.0005617412,0.0012172092,0.0003654139,0.00034827273,0.00008782697,0.0003842571,0.0007295787,0.0013163649],"category_scores_gemma":[0.002076411,0.0004597728,0.00051556877,0.002251915,0.00066326,0.0002001841,0.0001429834,0.00041160203,0.0001124067],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001897779,0.0075757653,0.5677303,0.00017031316,0.01963235,0.000019528125,0.0005329747,0.000020027835,0.013308755,0.009290831,0.14788659,0.23193476],"study_design_scores_gemma":[0.009401232,0.0006101709,0.044168822,0.00013042234,0.009511116,0.00003726217,0.0017256091,0.0060361414,0.0074007795,0.0005426513,0.91811,0.002325797],"about_ca_topic_score_codex":0.00062550465,"about_ca_topic_score_gemma":0.000966937,"teacher_disagreement_score":0.7702234,"about_ca_system_score_codex":0.0006491565,"about_ca_system_score_gemma":0.00017135417,"threshold_uncertainty_score":0.9997854},"labels":[],"label_agreement":null},{"id":"W2089309745","doi":"10.4155/bio.14.276","title":"Challenges in Application of Bioanalytical Method on Different Populations and Effect of Population on Pk","year":2014,"lang":"en","type":"review","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bioanalysis; Population; Audit; Biostatistics; Medicine; Business; Nanotechnology; Accounting; Public health; Environmental health; Pathology","score_opus":0.10363702715418749,"score_gpt":0.42140085736490174,"score_spread":0.31776383021071425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089309745","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001637137,0.9980356,0.0005871389,0.00012156618,0.000097236145,0.000550669,0.00007012867,0.000015633548,0.00035830645],"genre_scores_gemma":[0.042590242,0.9562462,0.0006787091,0.00001169446,0.00002815586,0.00006133317,0.00029448452,0.00002744956,0.000061750965],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99574345,0.002114714,0.0011367318,0.00066987344,0.000103715895,0.0002315148],"domain_scores_gemma":[0.9966769,0.0018764675,0.00071478594,0.0006524164,0.00004176287,0.00003767134],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013220698,0.0004508901,0.003295506,0.0009994132,0.000040132443,0.0000055951623,0.00021778334,0.00086414034,0.0000408438],"category_scores_gemma":[0.00038819778,0.0002822161,0.00077537616,0.0005590762,0.00014769132,0.000015919095,0.00006862767,0.00038671787,0.0000107777405],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048890655,0.00015849614,0.00062571163,0.0031770095,0.00063917437,2.7802506e-7,0.000006098195,0.000002597575,0.000018506238,0.0063659134,0.0000050626727,0.9889523],"study_design_scores_gemma":[0.004907952,0.0087382225,0.051976252,0.026303692,0.065810576,0.000044237597,0.000066750545,0.0025769523,0.0022736979,0.0034692464,0.8301603,0.0036720966],"about_ca_topic_score_codex":0.00011630695,"about_ca_topic_score_gemma":0.00010449198,"teacher_disagreement_score":0.98528016,"about_ca_system_score_codex":0.000074080956,"about_ca_system_score_gemma":0.000010145581,"threshold_uncertainty_score":0.999963},"labels":[],"label_agreement":null},{"id":"W2094323797","doi":"10.1002/jcph.339","title":"Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation","year":2014,"lang":"en","type":"review","venue":"The Journal of Clinical Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Monoclonal antibody; Perspective (graphical); Medicine; Extrapolation; Pharmacology; Antibody; Internal medicine; Immunology; Computer science; Mathematics; Statistics; Artificial intelligence","score_opus":0.1412695353166486,"score_gpt":0.5070305994950575,"score_spread":0.36576106417840887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094323797","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005482782,0.97818804,0.00014607016,0.011449867,0.003035783,0.0007895792,0.00008242099,0.000007348765,0.00081809174],"genre_scores_gemma":[0.034725778,0.96248215,0.00029789403,0.0018943552,0.00049368455,0.000005807334,0.0000039648567,0.000018414556,0.000077936704],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98773277,0.008390196,0.0031430698,0.00028888672,0.00013179024,0.0003132697],"domain_scores_gemma":[0.97772014,0.017562602,0.0039253403,0.00030858073,0.00035686433,0.00012645817],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.013325244,0.00032854083,0.0024419646,0.00024675153,0.00022291312,0.000011742962,0.0007965656,0.000948249,0.00040719696],"category_scores_gemma":[0.001889001,0.0001462632,0.00073550374,0.00018242712,0.0018856486,0.000035603312,0.00010181106,0.0026927786,0.000008153429],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016843446,0.0012801897,0.0042792014,0.0016677344,0.011936996,0.000023252387,0.00043074714,0.0000027465135,0.0003511398,0.015990738,0.048274506,0.9140784],"study_design_scores_gemma":[0.0016044657,0.0039667026,0.020549294,0.0024160186,0.007981744,0.00025642585,0.00024207217,0.000057869674,0.00003661818,0.0027020562,0.9597843,0.00040241203],"about_ca_topic_score_codex":0.00013640778,"about_ca_topic_score_gemma":0.00011923459,"teacher_disagreement_score":0.91367596,"about_ca_system_score_codex":0.000115685216,"about_ca_system_score_gemma":0.0013275222,"threshold_uncertainty_score":0.99960804},"labels":[],"label_agreement":null},{"id":"W2095055612","doi":"10.3109/00498254.2012.744113","title":"Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling approaches for small molecules and biologics: applicability to biosimilar development","year":2012,"lang":"en","type":"article","venue":"Xenobiotica","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Allometry; Biosimilar; Scaling; Exponent; Similarity (geometry); Computational biology; Range (aeronautics); Biological system; Statistics; Chemistry; Mathematics; Statistical physics; Biology; Computer science; Physics; Materials science; Artificial intelligence; Biotechnology; Ecology","score_opus":0.12410019834425061,"score_gpt":0.3323444460951144,"score_spread":0.20824424775086375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095055612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8648821,0.008751977,0.11891137,0.004233574,0.00037188944,0.0019442908,0.00008654017,0.00011699743,0.00070123863],"genre_scores_gemma":[0.9265393,0.000036278718,0.07255993,0.0006353387,0.000054871223,0.00007737599,0.000016226984,0.000013271355,0.00006739094],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857575,0.00016862577,0.0003287714,0.00039731574,0.00002944266,0.00050011766],"domain_scores_gemma":[0.99902225,0.00059418613,0.000060318926,0.00014907267,0.000065317654,0.00010887422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009854214,0.00021851792,0.00031018307,0.00008141635,0.00023721755,0.000032588905,0.00012141121,0.00020301569,0.00006462958],"category_scores_gemma":[0.00051585597,0.00016830872,0.0000477158,0.00011083894,0.00036066675,0.0000316973,0.00018144645,0.00015887352,0.00000952611],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021248106,0.00042938857,0.006058969,0.00021906359,0.00035799068,3.2388357e-7,0.0017841842,0.0000094366,0.73905355,0.0053114737,0.00029752002,0.2462656],"study_design_scores_gemma":[0.0023265653,0.0005644095,0.089668356,0.00014703449,0.00060220883,0.000057124354,0.0020102994,0.0010882512,0.8436993,0.0010673391,0.057738587,0.0010305424],"about_ca_topic_score_codex":0.0000017607848,"about_ca_topic_score_gemma":0.0000025771542,"teacher_disagreement_score":0.24523506,"about_ca_system_score_codex":0.000032454413,"about_ca_system_score_gemma":0.000020342006,"threshold_uncertainty_score":0.686343},"labels":[],"label_agreement":null},{"id":"W2097109066","doi":"10.1111/j.1365-2885.2012.01376.x","title":"Estimating product bioequivalence for highly variable veterinary drugs","year":2012,"lang":"en","type":"article","venue":"Journal of Veterinary Pharmacology and Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Bioequivalence; Veterinary Drugs; Pharmacology; Veterinary drug; Medicine; Product (mathematics); Veterinary medicine; Mathematics; Pharmacokinetics; Chemistry; Chromatography","score_opus":0.08166669538535094,"score_gpt":0.3881280151996901,"score_spread":0.30646131981433916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097109066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9504983,0.030945834,0.007820661,0.0017383654,0.008339896,0.00032229096,0.000033616023,0.000028409066,0.00027262155],"genre_scores_gemma":[0.942259,0.0007145414,0.05447275,0.0016028561,0.0006439057,0.0000096499825,0.0000025612835,0.000018472507,0.00027626258],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985634,0.00034561174,0.00045256253,0.00015358564,0.000037948128,0.00044687887],"domain_scores_gemma":[0.9988912,0.00048656375,0.00032851612,0.00010107878,0.00012838685,0.00006425255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013337292,0.00018797307,0.0003749974,0.0000998241,0.00020429467,0.000012445824,0.00020375372,0.00018954393,0.00017856766],"category_scores_gemma":[0.000030298801,0.00014253052,0.00010694697,0.0000990638,0.00030294224,0.00023035498,0.000090493915,0.00038332018,0.0000048447105],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014640383,0.0003512084,0.0004662969,0.000115702605,0.00063630147,0.000009581067,0.00031153264,0.0000037787556,0.9638658,0.00044533395,0.00089979713,0.0314306],"study_design_scores_gemma":[0.004264114,0.009370482,0.0015306593,0.000096475196,0.001544924,0.005996761,0.00018399126,0.00030939994,0.14304769,0.0013575413,0.8318025,0.0004954477],"about_ca_topic_score_codex":7.569821e-7,"about_ca_topic_score_gemma":7.4133606e-9,"teacher_disagreement_score":0.8309027,"about_ca_system_score_codex":0.0000258664,"about_ca_system_score_gemma":0.0000478375,"threshold_uncertainty_score":0.5812226},"labels":[],"label_agreement":null},{"id":"W2099574851","doi":"10.2217/14622416.9.2.157","title":"Case–Control Study of the Association Between Select <i>HLA</i> Genes and Anti-Erythropoietin Antibody-Positive Pure Red-Cell Aplasia","year":2008,"lang":"en","type":"article","venue":"Pharmacogenomics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pure red cell aplasia; Erythropoietin; Antibody; Human leukocyte antigen; Gene; Aplasia; Immunology; Medicine; Biology; Genetics; Internal medicine; Antigen; Anemia","score_opus":0.01933551872073616,"score_gpt":0.2843752701214194,"score_spread":0.26503975140068325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099574851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608314,0.0019043359,0.00008057258,0.0003495832,0.00030130043,0.00058063114,0.0003719518,0.000021361937,0.00030709754],"genre_scores_gemma":[0.9986546,0.00057561934,0.00010404799,0.00024853752,0.00009100941,0.0000053019116,0.000010776894,0.000018535866,0.00029154134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981746,0.00076620106,0.00037616745,0.00031048802,0.000058832862,0.00031371135],"domain_scores_gemma":[0.99891675,0.00044050044,0.00031052652,0.00017947027,0.00011949659,0.000033276097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056657084,0.00020277275,0.0004378879,0.000049161896,0.0004047525,0.000010357403,0.00018323658,0.00022719945,0.000056859266],"category_scores_gemma":[0.00004838689,0.00014790683,0.00011346535,0.00018573119,0.00017722706,0.00004728706,0.00011065445,0.00038536405,0.000008065496],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007112229,0.00030245064,0.37852356,0.000012549381,0.0007587014,0.000051146188,0.00045203313,0.0000046761197,0.61791927,0.000004286367,0.0005731227,0.0013271006],"study_design_scores_gemma":[0.005539712,0.00042942233,0.13612095,0.00000977395,0.0019062322,0.00091223844,0.00036905223,0.000028978988,0.8507223,0.00002123352,0.0035881891,0.0003519139],"about_ca_topic_score_codex":0.00005216315,"about_ca_topic_score_gemma":0.000009901138,"teacher_disagreement_score":0.24240261,"about_ca_system_score_codex":0.00005834537,"about_ca_system_score_gemma":0.00004589971,"threshold_uncertainty_score":0.60314655},"labels":[],"label_agreement":null},{"id":"W2100941840","doi":"10.4155/bio.11.165","title":"Case Studies from the Use of Commercial Biomarker/Protein Test Kits","year":2011,"lang":"en","type":"review","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Inro Consultants (Canada)","funders":"","keywords":"Biomarker; Computational biology; Computer science; Biochemical engineering; Nanotechnology; Chemistry; Biology; Engineering; Biochemistry; Materials science","score_opus":0.40700866938896024,"score_gpt":0.4029132351517365,"score_spread":0.0040954342372237496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100941840","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000056302826,0.9967682,0.000025246667,0.00009995815,0.00036084407,0.00046623134,0.0021229286,0.000030263394,0.000070072965],"genre_scores_gemma":[0.00024248604,0.9971818,0.0009476968,0.00012043702,0.00007462923,0.000053473777,0.00018311167,0.000036718622,0.0011596482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99607253,0.0016289966,0.0012194572,0.0006277932,0.000060065635,0.00039118508],"domain_scores_gemma":[0.99348205,0.0042221677,0.00087708223,0.0011620988,0.00021514512,0.000041434956],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006883404,0.00061049947,0.003162209,0.00023200254,0.00025570532,0.00002751516,0.0006296012,0.00094734883,0.0010286627],"category_scores_gemma":[0.0017749362,0.00031407076,0.0017423687,0.00095106795,0.0012201619,0.00005206889,0.00044148878,0.00053543184,0.00014620106],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000151720205,0.00017321469,0.000053971777,0.0006700805,0.011841944,0.00015823777,0.00006001547,4.50174e-9,0.000041266292,0.00010125314,0.0033897022,0.9834951],"study_design_scores_gemma":[0.0001558008,0.00006706246,0.000018419632,0.0015129424,0.018213341,0.00019954388,0.00005581409,5.519814e-7,0.00010137959,0.000043302054,0.9792657,0.000366144],"about_ca_topic_score_codex":0.0010653809,"about_ca_topic_score_gemma":0.0004229537,"teacher_disagreement_score":0.98312896,"about_ca_system_score_codex":0.00005418046,"about_ca_system_score_gemma":0.00009491818,"threshold_uncertainty_score":0.99993116},"labels":[],"label_agreement":null},{"id":"W2108743111","doi":"10.4155/bio.14.258","title":"Justifying The Lack of Incurred Sample Reproducibility in A Study: Considerations and Strategies","year":2015,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"","keywords":"Guideline; Sample (material); Agency (philosophy); Accounting; Reproducibility; Business; Medicine; Pathology; Chemistry","score_opus":0.22936858192533266,"score_gpt":0.4036808878470402,"score_spread":0.17431230592170754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108743111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98852617,0.0068436246,0.00036170828,0.0030941276,0.00014315259,0.000348003,0.00005108937,0.00002203625,0.00061011285],"genre_scores_gemma":[0.9985656,0.000027075368,0.001232811,0.000081054495,0.000008899256,0.000008862489,0.000004519491,0.0000030263402,0.00006814179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984047,0.00061364786,0.00036551824,0.0004397305,0.00003991308,0.00013649488],"domain_scores_gemma":[0.9985112,0.00059279945,0.000095943346,0.00066445913,0.000116236726,0.000019354926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027459513,0.00009329768,0.00031871392,0.00009532342,0.00007720418,0.000025339587,0.00008964122,0.00008650332,0.00010545983],"category_scores_gemma":[0.00284178,0.000057085796,0.000058343783,0.0003771973,0.0003881052,0.000054314838,0.00009727578,0.00014624154,0.00000283148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023014112,0.0016351623,0.94496113,0.000060972634,0.0017120773,0.000009726323,0.009191048,0.00011110361,0.011032334,0.010934923,0.0012789047,0.018842464],"study_design_scores_gemma":[0.0060112374,0.0012548439,0.75670815,0.000062131716,0.0034551935,0.000035914625,0.13870613,0.0008883177,0.0140239,0.06581345,0.012132931,0.00090778986],"about_ca_topic_score_codex":0.0015488093,"about_ca_topic_score_gemma":0.0020579174,"teacher_disagreement_score":0.18825299,"about_ca_system_score_codex":0.000017492184,"about_ca_system_score_gemma":0.0000841245,"threshold_uncertainty_score":0.3402081},"labels":[],"label_agreement":null},{"id":"W2114126081","doi":"10.1186/1476-511x-12-22","title":"Butylated hydroxytoluene can protect polyunsaturated fatty acids in dried blood spots from degradation for up to 8 weeks at room temperature","year":2013,"lang":"en","type":"article","venue":"Lipids in Health and Disease","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Butylated hydroxytoluene; Polyunsaturated fatty acid; Docosahexaenoic acid; Chemistry; Eicosapentaenoic acid; Chromatography; Food science; Antioxidant; Gas chromatography; Fatty acid; Biochemistry","score_opus":0.016286966556633375,"score_gpt":0.2787651924834691,"score_spread":0.26247822592683573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114126081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983279,0.0029232088,0.000037298534,0.010966795,0.00042525143,0.0018807375,0.00043053296,0.00004299417,0.00001417899],"genre_scores_gemma":[0.99109215,0.00007626327,0.0011017565,0.0055433055,0.0000646637,0.00030047333,0.0004899336,0.000019620658,0.0013118179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797595,0.0004235383,0.00048063233,0.0005143132,0.000041617408,0.00056393363],"domain_scores_gemma":[0.9989819,0.00016524248,0.000092635004,0.00025139016,0.00005548327,0.00045333075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029318465,0.00022631003,0.00039849014,0.0001516343,0.00016763744,0.000032095795,0.00011620283,0.00035137823,0.00018882148],"category_scores_gemma":[0.00066015276,0.00018519399,0.000055008943,0.0003231984,0.00006777132,0.00006664151,0.00006103612,0.0003621414,0.000017057957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012904639,0.0013420944,0.46626756,0.0011617639,0.0002642015,0.000024416291,0.0026261287,0.00001797154,0.46149445,0.0005609607,0.015623633,0.037712198],"study_design_scores_gemma":[0.014603497,0.0015359368,0.9139864,0.0007763465,0.00012910724,0.000009700465,0.0006323429,0.00046482697,0.051289964,0.0050011445,0.010403016,0.0011677279],"about_ca_topic_score_codex":0.0021545251,"about_ca_topic_score_gemma":0.000622718,"teacher_disagreement_score":0.44771883,"about_ca_system_score_codex":0.000084487525,"about_ca_system_score_gemma":0.00021742898,"threshold_uncertainty_score":0.75519913},"labels":[],"label_agreement":null},{"id":"W2114127266","doi":"10.1136/gutjnl-2012-303824","title":"Biosimilars in IBD: hope or expectation?","year":2013,"lang":"en","type":"review","venue":"Gut","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Robarts Clinical Trials","funders":"National Institute for Health and Care Research","keywords":"Biosimilar; Table (database); Medicine; Family medicine; Computer science; Internal medicine; Data mining","score_opus":0.11332932590538132,"score_gpt":0.3981912986020346,"score_spread":0.2848619726966533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114127266","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003102548,0.9957383,0.000022048464,0.00018873383,0.00075317273,0.00064676563,0.000058254842,0.00004666234,0.0025429472],"genre_scores_gemma":[0.0000028204443,0.98463887,0.0010059618,0.00034277866,0.00006129865,0.00015692093,0.00009959363,0.000035086825,0.013656687],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977861,0.00056547497,0.0006801448,0.0004884519,0.000033964214,0.00044583538],"domain_scores_gemma":[0.99888474,0.00042345803,0.00021063499,0.00041094862,0.000036897003,0.00003332761],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029352997,0.00039979996,0.0015252077,0.00028346718,0.000059280417,0.000025810434,0.00040480273,0.0011139966,0.006059188],"category_scores_gemma":[0.00021428148,0.00023832405,0.00034649804,0.0004424768,0.00017667383,0.000050735474,0.00012942683,0.0006710326,0.0025254514],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009764838,0.00007159494,0.0000061009587,0.0013083381,0.00016197875,0.000016316451,0.00002619019,1.056324e-8,0.000033943266,0.000092646114,0.03485639,0.96341676],"study_design_scores_gemma":[0.00024755052,0.00007602819,0.000020713645,0.0020033845,0.0002597349,0.0000561532,0.00002934899,2.2145838e-7,0.000031145242,0.000047766713,0.99689656,0.0003313685],"about_ca_topic_score_codex":0.000027659406,"about_ca_topic_score_gemma":0.000038347447,"teacher_disagreement_score":0.96308535,"about_ca_system_score_codex":0.000070763,"about_ca_system_score_gemma":0.00017238286,"threshold_uncertainty_score":0.9982512},"labels":[],"label_agreement":null},{"id":"W2124630617","doi":"10.2147/bs.s20577","title":"Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics","year":2011,"lang":"en","type":"article","venue":"Biosimilars","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Amgen","keywords":"Interchangeability; Drug; Medicine; Pharmacology; Business; Biosimilar; Risk analysis (engineering); Intensive care medicine; Computer science; Internal medicine","score_opus":0.15432901733991708,"score_gpt":0.32945311233849545,"score_spread":0.17512409499857837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124630617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946797,0.00081347814,0.00071937847,0.0005608752,0.0014496477,0.0005276343,0.00034915408,0.000072613024,0.0008275075],"genre_scores_gemma":[0.9931535,0.00003239744,0.006101344,0.00038859766,0.000015681335,0.000015429941,0.000035326764,0.000016367445,0.00024137206],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981504,0.0002890458,0.0004361516,0.0006302283,0.00005309603,0.0004410992],"domain_scores_gemma":[0.9984977,0.00063428585,0.00019471972,0.0004349527,0.0001781749,0.000060166985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013331734,0.00027904168,0.0004884123,0.00019213614,0.00029134197,0.00003935373,0.00030750924,0.000400411,0.00021131837],"category_scores_gemma":[0.0008168115,0.00019817971,0.0002326035,0.0002484244,0.0013623154,0.00011567304,0.00016432363,0.00024070413,0.0000038933413],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000976597,0.0016562958,0.2695998,0.00038871914,0.00054130494,0.000003305402,0.0032741711,1.3162096e-7,0.68012697,0.004854627,0.0189925,0.01958557],"study_design_scores_gemma":[0.0009547884,0.0005437481,0.077749014,0.000087972,0.0001532731,0.000003824205,0.000931576,0.000011441941,0.9044167,0.0036936665,0.011069913,0.00038408831],"about_ca_topic_score_codex":0.000020108137,"about_ca_topic_score_gemma":0.000028346009,"teacher_disagreement_score":0.22428972,"about_ca_system_score_codex":0.000031657804,"about_ca_system_score_gemma":0.000043906726,"threshold_uncertainty_score":0.8081534},"labels":[],"label_agreement":null},{"id":"W2126408079","doi":"10.1097/01.asn.0000140219.28618.9f","title":"Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia after Treatment with Recombinant Erythropoietin Products","year":2004,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université Laval; St. John’s Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary; Ottawa Hospital; University Health Network; Ontario Institute for Cancer Research; McGill University Health Centre; University of Ottawa; Hospital for Sick Children; Queen's University","funders":"U.S. Food and Drug Administration","keywords":"Medicine; Pure red cell aplasia; Erythropoietin; Internal medicine; Kidney disease; Incidence (geometry); Pharmacokinetics; Gastroenterology; Anemia; Urology; Endocrinology; Surgery","score_opus":0.010483935027210914,"score_gpt":0.2591399298025255,"score_spread":0.24865599477531458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126408079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9458343,0.0017605287,0.000191021,0.05144636,0.0004206556,0.00025003986,0.000022349115,0.0000151361155,0.00005964646],"genre_scores_gemma":[0.9810238,0.0024969734,0.01218405,0.0037360892,0.00012245103,0.0000049514642,0.0000065996787,0.000031923624,0.00039315462],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787295,0.0004826776,0.0006873216,0.00032201526,0.000120972,0.0005140589],"domain_scores_gemma":[0.997527,0.0001749102,0.0014791031,0.00045416522,0.000306952,0.000057884452],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0004840248,0.00032500568,0.0010994121,0.000063581174,0.00014852514,0.000009895854,0.0003999319,0.00024736268,0.00013304476],"category_scores_gemma":[0.00004423802,0.00017150061,0.00059593347,0.0005590604,0.002947639,0.00006313534,0.00010747092,0.00060717104,0.000012663298],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017560999,0.0012971538,0.009980265,0.00004310294,0.0011653636,0.000031989843,0.0006748294,0.000017375229,0.96458566,0.000012578316,0.018969962,0.0014656201],"study_design_scores_gemma":[0.0139942905,0.027935063,0.2552017,0.00027865547,0.0017140851,0.0031145408,0.0035399096,0.0000068437726,0.37040618,0.0005858136,0.3223472,0.00087573455],"about_ca_topic_score_codex":0.00009157991,"about_ca_topic_score_gemma":0.000010553931,"teacher_disagreement_score":0.59417945,"about_ca_system_score_codex":0.00013839907,"about_ca_system_score_gemma":0.00032144602,"threshold_uncertainty_score":0.99976575},"labels":[],"label_agreement":null},{"id":"W2128159233","doi":"10.1096/fasebj.28.1_supplement.981.8","title":"Protein quantification in dried blood spots by MRM mass spectrometry (981.8)","year":2014,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Victoria","funders":"Genome Canada","keywords":"Dried blood spot; Analyte; Dried blood; Chemistry; Triple quadrupole mass spectrometer; Chromatography; Selected reaction monitoring; Mass spectrometry; Small molecule; Multiplex; Computational biology; Tandem mass spectrometry; Bioinformatics; Biochemistry; Biology","score_opus":0.01678481887829675,"score_gpt":0.25990512111692554,"score_spread":0.2431203022386288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128159233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784913,0.0015173579,0.011250524,0.005351905,0.00045622047,0.00023314886,0.0000145185,0.00002746516,0.0026575488],"genre_scores_gemma":[0.9949933,0.000058471174,0.0019164074,0.00030083663,0.00008758099,0.000004621959,0.000007181827,0.000010652367,0.0026208907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838823,0.0007091624,0.00033226932,0.00017348012,0.000056414807,0.0003404283],"domain_scores_gemma":[0.9993654,0.00015429346,0.00016152016,0.00024430943,0.000039026425,0.000035488334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018969871,0.00012911078,0.00021740147,0.00010431359,0.00019345937,0.00004341877,0.0003328448,0.00019457401,0.0005974486],"category_scores_gemma":[0.0002317617,0.00007965166,0.00008899593,0.00023481999,0.0001879875,0.000052500447,0.000029360615,0.00077392644,0.00011619899],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078019395,0.000108105334,0.0009407697,0.000004188134,0.00006481738,0.0000033743531,0.000035248897,5.8729904e-7,0.9908772,0.0017888857,0.0012075152,0.004891259],"study_design_scores_gemma":[0.000987949,0.00017918683,0.0035002527,0.000033205535,0.0000596205,0.00015548682,0.00008431043,0.000028245571,0.9852616,0.0034517809,0.0061256196,0.00013269363],"about_ca_topic_score_codex":0.000012257265,"about_ca_topic_score_gemma":0.000004595362,"teacher_disagreement_score":0.016502045,"about_ca_system_score_codex":0.000026975658,"about_ca_system_score_gemma":0.000026702372,"threshold_uncertainty_score":0.6541643},"labels":[],"label_agreement":null},{"id":"W2132071446","doi":"10.1023/b:pham.0000003390.51761.3d","title":"Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules","year":2003,"lang":"en","type":"article","venue":"Pharmaceutical Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":614,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Greenfield Research (Canada)","funders":"American Association of Pharmaceutical Scientists; Eli Lilly and Company","keywords":"Bioanalysis; Acceptance testing; Computer science; Process (computing); Biochemical engineering; Computational biology; Chemistry; Engineering; Chromatography; Biology; Software engineering","score_opus":0.35160811898357314,"score_gpt":0.574760009449789,"score_spread":0.22315189046621586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132071446","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.073466755,0.0021728892,0.81623167,0.067164674,0.0027155257,0.007828717,0.0014711884,0.00011136502,0.02883721],"genre_scores_gemma":[0.9557057,0.00019097861,0.04157087,0.00041951746,0.00003147298,0.00013279392,0.000027299688,0.000025069696,0.0018962899],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99650365,0.001682544,0.00058623956,0.00036101555,0.00023251105,0.000634034],"domain_scores_gemma":[0.99256814,0.006407159,0.000086694716,0.0002838564,0.00053877156,0.00011536634],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0084683625,0.00015111583,0.00035023157,0.00027052165,0.00022847518,0.000023982018,0.00042809354,0.0001676138,0.0021544117],"category_scores_gemma":[0.0025643716,0.000104228246,0.00018034906,0.0008081951,0.00041562069,0.000048181242,0.00015927319,0.00057830155,0.000047347497],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035761535,0.00045161202,0.00045273206,0.0000973741,0.00047305154,0.000001260679,0.000062504405,0.000008838871,0.917374,0.018921997,0.011388445,0.050410535],"study_design_scores_gemma":[0.0008877222,0.00040459132,0.000052624528,0.00002354336,0.00020600417,0.000008348428,0.00016033219,0.0004460244,0.852,0.0009904641,0.14472267,0.00009766746],"about_ca_topic_score_codex":0.000010596443,"about_ca_topic_score_gemma":7.8086725e-7,"teacher_disagreement_score":0.8822389,"about_ca_system_score_codex":0.000054612094,"about_ca_system_score_gemma":0.0001491152,"threshold_uncertainty_score":0.9987578},"labels":[],"label_agreement":null},{"id":"W2133707942","doi":"10.1002/sim.5567","title":"Impact of variability on the choice of biosimilarity limits in assessing follow‐on biologics","year":2012,"lang":"en","type":"article","venue":"Statistics in Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Biosimilar; Bioequivalence; Econometrics; Limit (mathematics); Statistics; Computer science; Economics; Mathematics; Pharmacology; Medicine; Biotechnology; Biology","score_opus":0.09628629694275934,"score_gpt":0.42570780713145306,"score_spread":0.3294215101886937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133707942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98393077,0.00061574794,0.0063035903,0.0013964304,0.0008768417,0.00040390878,0.00041731226,0.000011273718,0.006044106],"genre_scores_gemma":[0.99664974,0.000071478906,0.0028895158,0.0002961229,0.00003576353,0.0000034463053,0.000021966234,0.0000056241734,0.0000263699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978195,0.0011226328,0.00051228434,0.00017053961,0.000065579174,0.0003094956],"domain_scores_gemma":[0.9913574,0.008047066,0.00019456126,0.0003029967,0.00007235072,0.000025630938],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004035743,0.00015000631,0.00049475866,0.00012080837,0.000031985095,0.0000016276457,0.00018386391,0.00024923825,0.00052772975],"category_scores_gemma":[0.011854044,0.00007605228,0.000050693932,0.00032892879,0.00070321985,0.00002284088,0.000036824324,0.0005260926,0.0000025624508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024012427,0.0009704657,0.8854852,0.00006342313,0.00011174692,0.000002155762,0.00029956983,0.0000059644894,0.062303297,0.035958737,0.003107935,0.01145141],"study_design_scores_gemma":[0.00085967046,0.0009921208,0.9857866,0.00017835772,0.000044329932,0.0000013005208,0.0000897976,0.00004977328,0.0064764256,0.0051796315,0.0002509,0.00009105986],"about_ca_topic_score_codex":0.00025408753,"about_ca_topic_score_gemma":0.00003447762,"teacher_disagreement_score":0.10030147,"about_ca_system_score_codex":0.000068616304,"about_ca_system_score_gemma":0.000042774926,"threshold_uncertainty_score":0.99646956},"labels":[],"label_agreement":null},{"id":"W2135773482","doi":"10.1093/ndt/gfu297","title":"Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)","year":2014,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Pfizer; Cilag; Amgen","keywords":"Medicine; Darbepoetin alfa; Pure red cell aplasia; Incidence (geometry); Epoetin alfa; Internal medicine; Kidney disease; Surgery; Anemia","score_opus":0.006396821213232355,"score_gpt":0.2469350739106032,"score_spread":0.24053825269737086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135773482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98282266,0.000963065,0.011244779,0.002289266,0.0003676218,0.00042735055,0.000153231,0.00008263794,0.001649381],"genre_scores_gemma":[0.99731547,0.0010530284,0.0004934748,0.0005450621,0.000049821825,0.000024107288,0.0003670551,0.000015031531,0.00013692326],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9971225,0.001358212,0.0005786304,0.00047082006,0.00009418134,0.0003756358],"domain_scores_gemma":[0.99768317,0.0012139755,0.00040061004,0.0004892556,0.00018663604,0.000026383543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012123426,0.00024916805,0.0005734963,0.00009694632,0.00023363912,0.0000123575155,0.00042017555,0.0006029479,0.00027014015],"category_scores_gemma":[0.00022052809,0.0001743761,0.00022577078,0.00044865883,0.0009203644,0.000071619215,0.000032769472,0.00049708143,0.000047316156],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010743053,0.00015920181,0.07401959,0.00007021203,0.0003344617,0.000004220622,0.00044933808,0.0000252833,0.92222404,0.00043403017,0.00049682264,0.000708468],"study_design_scores_gemma":[0.003104751,0.000546679,0.5963644,0.000030509973,0.0007542843,0.000091443006,0.00013096194,0.00015830112,0.39387447,0.0009509307,0.003623646,0.0003696705],"about_ca_topic_score_codex":0.00013558991,"about_ca_topic_score_gemma":0.00028484222,"teacher_disagreement_score":0.5283496,"about_ca_system_score_codex":0.000026711747,"about_ca_system_score_gemma":0.0000531684,"threshold_uncertainty_score":0.7110851},"labels":[],"label_agreement":null},{"id":"W2137961216","doi":"10.1111/joim.12432","title":"Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibody","year":2015,"lang":"en","type":"review","venue":"Journal of Internal Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Roche; Novartis; AstraZeneca; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Abbott Laboratories","keywords":"Biosimilar; Medicine; Monoclonal antibody; Tumor necrosis factor alpha; Immune system; Antibody; Monoclonal; Pharmacology; Anti-inflammatory; Immunology; Internal medicine","score_opus":0.06397075564297561,"score_gpt":0.3878844270974023,"score_spread":0.3239136714544267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137961216","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010263668,0.98598343,0.00007713101,0.006546974,0.004459282,0.0005772999,0.0011863407,0.000027044849,0.00011611573],"genre_scores_gemma":[0.0023260892,0.99387807,0.00010927147,0.0018653807,0.0013882134,0.000016950331,0.00023528522,0.0000963457,0.000084381274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99338496,0.0013671386,0.0035112451,0.0005874792,0.00040768742,0.0007414731],"domain_scores_gemma":[0.9929696,0.0027539341,0.002910716,0.000611053,0.00050118787,0.0002535087],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018676479,0.001002188,0.004631913,0.00070946186,0.00015187579,0.00006313847,0.0020925866,0.0011955899,0.0009284779],"category_scores_gemma":[0.002679334,0.00051675254,0.0012527227,0.0006321475,0.0012024308,0.00019815366,0.00042863216,0.0034185566,0.00006380137],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036058102,0.0027187832,0.012355541,0.007208782,0.017474886,0.0042365803,0.002306892,0.000002966947,0.011971755,0.00011353465,0.25268692,0.6853175],"study_design_scores_gemma":[0.0032207984,0.00075066055,0.0049723643,0.028260155,0.0024739318,0.00052838784,0.00022888859,0.0000067009423,0.00017812118,0.00011426373,0.9586937,0.0005720412],"about_ca_topic_score_codex":0.00019830633,"about_ca_topic_score_gemma":0.00005254308,"teacher_disagreement_score":0.70600677,"about_ca_system_score_codex":0.00035086923,"about_ca_system_score_gemma":0.00081110105,"threshold_uncertainty_score":0.9999848},"labels":[],"label_agreement":null},{"id":"W2139470111","doi":"10.4155/bio.09.108","title":"Incurred Sample Reproducibility: Views and Recommendations by the European Bioanalysis Forum","year":2009,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada)","funders":"","keywords":"Bioanalysis; Sample (material); Safeguarding; Reproducibility; Computer science; Process (computing); Data science; Medicine; Chromatography; Chemistry","score_opus":0.03759757155892282,"score_gpt":0.3136246980115632,"score_spread":0.2760271264526404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139470111","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026069865,0.23414895,0.033938006,0.6583844,0.0014614582,0.001830444,0.0022973295,0.0007531194,0.041116428],"genre_scores_gemma":[0.9840834,0.0019979316,0.004091328,0.0048370278,0.00007037025,0.000010656511,0.00037940827,0.000020154608,0.0045097005],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99629146,0.0015758119,0.0006150017,0.0010422837,0.00006477044,0.0004106717],"domain_scores_gemma":[0.997646,0.00043498605,0.00021897398,0.0015420611,0.00009711623,0.000060911538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034763438,0.00025918166,0.000506134,0.0001683032,0.00053148763,0.00008066509,0.0004010586,0.00014634267,0.00089889794],"category_scores_gemma":[0.0011498474,0.0001595866,0.00035366206,0.00099015,0.00037934602,0.000086789696,0.0001440747,0.00030158018,0.00006881385],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022589682,0.00022076599,0.004360099,0.000004126298,0.00093361153,0.0000010311937,0.00011187695,4.0341956e-7,0.010028478,0.00048476862,0.04704575,0.9367865],"study_design_scores_gemma":[0.00045585682,0.00014319229,0.008160989,0.000012135468,0.0015831589,0.000012103079,0.00052559806,0.00007476847,0.0050528883,0.002094799,0.981526,0.00035848276],"about_ca_topic_score_codex":0.00020616203,"about_ca_topic_score_gemma":0.00014046227,"teacher_disagreement_score":0.95801353,"about_ca_system_score_codex":0.000034231885,"about_ca_system_score_gemma":0.00001549499,"threshold_uncertainty_score":0.98423016},"labels":[],"label_agreement":null},{"id":"W2140319246","doi":"10.1093/ndt/gfi018","title":"Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone","year":2005,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Prednisone; Pure red cell aplasia; Erythropoiesis; Erythropoietin; Internal medicine; Discontinuation; Dialysis; Anemia; Gastroenterology; Surgery","score_opus":0.007883944796515725,"score_gpt":0.23475731076618406,"score_spread":0.22687336596966834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140319246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904831,0.0016475049,0.0044081626,0.0024406896,0.00023350536,0.0004437422,0.00007833638,0.00007505518,0.0001898973],"genre_scores_gemma":[0.99490273,0.001530598,0.0022083812,0.00051011576,0.00016372955,0.00015125291,0.0002179878,0.000032747546,0.0002824564],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99739575,0.0006671574,0.00069894374,0.0006516684,0.00012423545,0.00046225288],"domain_scores_gemma":[0.9988639,0.00023523605,0.00030253924,0.0004029458,0.00014776365,0.000047617614],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000306194,0.00038279474,0.00069038995,0.0002541035,0.0001387844,0.000020277996,0.00018098614,0.00060140685,0.0015833621],"category_scores_gemma":[0.000014215168,0.0002750204,0.00023422166,0.00032237085,0.00044122746,0.00020825176,0.000019267469,0.0004079023,0.000026160662],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036389258,0.0018155617,0.1691778,0.00031665384,0.0019113729,0.000061734565,0.0034674911,0.00089729734,0.76555437,0.000093427414,0.00044445504,0.019870581],"study_design_scores_gemma":[0.012300145,0.0028391923,0.3031849,0.00012886523,0.0033159207,0.00016436377,0.00027395872,0.00034344275,0.6715922,0.000237045,0.0047023185,0.00091767655],"about_ca_topic_score_codex":0.000038249942,"about_ca_topic_score_gemma":0.00040766736,"teacher_disagreement_score":0.13400711,"about_ca_system_score_codex":0.000051457446,"about_ca_system_score_gemma":0.000030867457,"threshold_uncertainty_score":0.9999702},"labels":[],"label_agreement":null},{"id":"W2142071363","doi":"10.1053/j.ajkd.2004.04.031","title":"A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario renal centers","year":2004,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Humber River Regional Hospital; York Central Hospital; The Scarborough Hospital; Institute of Kidney Lifescience Technologies; HalTech; Credit Valley Hospital","funders":"","keywords":"Medicine; Epoetin alfa; Hemodialysis; Pure red cell aplasia; Erythropoietin; Internal medicine; Anemia; Antibody; Kidney disease; Peritoneal dialysis; Gastroenterology; Nephrology; Dialysis; Immunology","score_opus":0.017450758491324044,"score_gpt":0.3095496788360742,"score_spread":0.29209892034475016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142071363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988782,0.00024158301,0.00003554115,0.00014990573,0.00040540507,0.00015474016,0.00008005457,0.000005488449,0.00004908142],"genre_scores_gemma":[0.99933493,0.00004506276,0.00024618927,0.00028589202,0.00001858368,0.0000020967382,0.00001770884,0.000011641712,0.000037883317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977256,0.00047588244,0.0010560123,0.00025800115,0.0001424255,0.0003420471],"domain_scores_gemma":[0.99852633,0.00017751814,0.0007751884,0.00017706481,0.00019851411,0.00014535918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041774494,0.00019647741,0.0006878825,0.00032261846,0.000061416664,0.000020942245,0.00030228694,0.000072861294,0.00021622368],"category_scores_gemma":[0.0011061026,0.00016076303,0.00018826834,0.0004043063,0.0004765342,0.00013966225,0.000077092176,0.0004809827,0.0000025240397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081399357,0.0029414962,0.9817099,0.000008352042,0.00019041981,0.000042925516,0.00039184408,0.00009638614,0.012490344,0.0000032844969,0.00003992092,0.0012711548],"study_design_scores_gemma":[0.0051163197,0.001882192,0.9911652,0.0001972622,0.00003436203,0.000030965468,0.0003400907,3.7471176e-7,0.00082202174,0.00004861243,0.00019843223,0.00016411737],"about_ca_topic_score_codex":0.011127212,"about_ca_topic_score_gemma":0.0025073783,"teacher_disagreement_score":0.011668323,"about_ca_system_score_codex":0.00025180506,"about_ca_system_score_gemma":0.0006383564,"threshold_uncertainty_score":0.99545777},"labels":[],"label_agreement":null},{"id":"W2142933086","doi":"10.1586/17474124.2015.1091306","title":"The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13","year":2015,"lang":"en","type":"review","venue":"Expert Review of Gastroenterology & Hepatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Health Canada","keywords":"Biosimilar; Infliximab; Medicine; Inflammatory bowel disease; Disease; Extrapolation; Intensive care medicine; Internal medicine","score_opus":0.0740358983480155,"score_gpt":0.38111940964334506,"score_spread":0.30708351129532957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142933086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00075435406,0.9890008,0.00014505697,0.004661054,0.0010090865,0.004268517,0.00011585122,0.000023104027,0.00002218685],"genre_scores_gemma":[0.0013856883,0.9931433,0.00028645946,0.0031480223,0.000072186966,0.0016326923,0.00019365658,0.00003701667,0.00010098038],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99278885,0.004289475,0.0014582211,0.0008167538,0.00012593421,0.000520777],"domain_scores_gemma":[0.9950485,0.0022283487,0.0011464186,0.0011763279,0.00033832205,0.00006208013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00489589,0.00053314905,0.002265283,0.00022544576,0.00073585263,0.00003284954,0.0006410479,0.00035883288,0.00011073077],"category_scores_gemma":[0.0007686777,0.0002749863,0.00052602286,0.00028966556,0.002097483,0.00004334055,0.00017690979,0.0005867651,0.000012392592],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006798668,0.002067812,0.0019910892,0.020365546,0.0029806744,0.00023827706,0.00041609217,3.6616007e-7,0.0000374977,0.0022754897,0.20426622,0.7646811],"study_design_scores_gemma":[0.0007835358,0.001323604,0.000014752121,0.0030343079,0.0009152262,0.0024391972,0.00012976107,0.000024744768,0.000008147911,0.000044231154,0.99111533,0.00016717253],"about_ca_topic_score_codex":0.000008966466,"about_ca_topic_score_gemma":0.000058839574,"teacher_disagreement_score":0.7868491,"about_ca_system_score_codex":0.00008548779,"about_ca_system_score_gemma":0.00039069098,"threshold_uncertainty_score":0.99997026},"labels":[],"label_agreement":null},{"id":"W2145734950","doi":"10.1007/s13361-013-0678-x","title":"Comparison of Proteins in Whole Blood and Dried Blood Spot Samples by LC/MS/MS","year":2013,"lang":"en","type":"article","venue":"Journal of the American Society for Mass Spectrometry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; University of Victoria","funders":"Genome Canada","keywords":"Dried blood spot; Chemistry; Chromatography; Dried blood; Biomarker discovery; Isoelectric focusing; Whole blood; Blood proteins; Population; Mass spectrometry; Liquid chromatography–mass spectrometry; Sample preparation; Repeatability; Biomarker; Proteomics; Biochemistry; Immunology; Enzyme","score_opus":0.019362954845950263,"score_gpt":0.29670383079131935,"score_spread":0.2773408759453691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145734950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091285,0.0030476998,0.0013063203,0.0041717812,0.00010604215,0.00031346994,0.00006138819,0.000006264909,0.00007416299],"genre_scores_gemma":[0.9533934,0.00017309215,0.045623355,0.00037404877,0.000051607873,0.0000074754616,0.0000024075896,0.000015088285,0.00035954532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865115,0.00015125834,0.00060090004,0.0001687058,0.00009119004,0.00033680227],"domain_scores_gemma":[0.99833673,0.00036361124,0.00094694906,0.00020243305,0.00010697675,0.00004331329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057398767,0.00016581472,0.00078380154,0.00007428956,0.0000931613,0.00002135094,0.0003677209,0.00013418688,0.0001246121],"category_scores_gemma":[0.00017680487,0.0001062942,0.000568914,0.0004860409,0.00080228416,0.00007106288,0.00008268343,0.00054366194,0.0000011961264],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006145679,0.00044102164,0.041522287,0.000030280018,0.00072799233,2.6180368e-7,0.00015091652,4.77986e-7,0.94630545,0.000088075336,0.009754252,0.0009175169],"study_design_scores_gemma":[0.0027620608,0.002597945,0.08459224,0.00008368762,0.00066318404,0.00006117819,0.002616935,0.000017130054,0.8975471,0.0022855704,0.0065207114,0.0002522586],"about_ca_topic_score_codex":0.00011730997,"about_ca_topic_score_gemma":0.000005229222,"teacher_disagreement_score":0.04875836,"about_ca_system_score_codex":0.000034682336,"about_ca_system_score_gemma":0.00004573459,"threshold_uncertainty_score":0.43345517},"labels":[],"label_agreement":null},{"id":"W2147506537","doi":"10.1002/sim.5571","title":"Scientific considerations for assessing biosimilar products","year":2012,"lang":"en","type":"article","venue":"Statistics in Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Biosimilar; Interchangeability; Risk analysis (engineering); Bioequivalence; Drug approval; Business; Computer science; Drug; Medicine; Management science; Pharmacology; Engineering; Pharmacokinetics","score_opus":0.09295416366638011,"score_gpt":0.3965204339961872,"score_spread":0.3035662703298071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147506537","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049930353,0.038219288,0.7732834,0.070927165,0.046697617,0.0045278654,0.0026085938,0.00031088953,0.013494825],"genre_scores_gemma":[0.73930067,0.000026519605,0.2575055,0.0010554412,0.00025483713,0.000028511802,0.00014930815,0.0000142935405,0.0016649301],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894184,0.00014057649,0.0002968216,0.00020746802,0.000042534615,0.0003707653],"domain_scores_gemma":[0.9983035,0.0012263047,0.000067155735,0.00018631815,0.00018403318,0.000032739823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016159851,0.00010463328,0.00023773439,0.00013025585,0.0002198661,0.00002079152,0.00006321355,0.00010950671,0.00069411466],"category_scores_gemma":[0.0060628997,0.00007690838,0.000014375819,0.00019745197,0.00075419346,0.00007571087,0.000024104866,0.00017618737,0.000018172772],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031222164,0.0002868486,0.008546891,0.00014846171,0.000077275734,0.000004781913,0.0010038562,8.1847634e-7,0.25820583,0.21370734,0.5065666,0.011420072],"study_design_scores_gemma":[0.0057071806,0.00055434945,0.06990846,0.0003964531,0.0005339351,0.00012727191,0.0017361596,0.00025817886,0.11159884,0.14642283,0.6619162,0.0008401112],"about_ca_topic_score_codex":0.0000070160304,"about_ca_topic_score_gemma":0.000013984588,"teacher_disagreement_score":0.6893703,"about_ca_system_score_codex":0.000027232152,"about_ca_system_score_gemma":0.00006367779,"threshold_uncertainty_score":0.76000684},"labels":[],"label_agreement":null},{"id":"W2148343772","doi":"10.4155/bio.11.22","title":"How to Manage Having No Incurred Sample Reanalysis Evaluation Failures","year":2011,"lang":"en","type":"editorial","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Bioanalysis; Library science; Computer science; Operations research; Nanotechnology; Engineering; Materials science","score_opus":0.032864163258693915,"score_gpt":0.3088959156710293,"score_spread":0.2760317524123354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148343772","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000104801344,0.01854107,0.010813412,0.002392052,0.9567478,0.0013922439,0.0034160726,0.000344093,0.006248476],"genre_scores_gemma":[0.015919538,0.0029527612,0.05726478,0.000828937,0.7411216,0.0007962607,0.020174876,0.00047612825,0.16046512],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946469,0.0014054204,0.0008833877,0.0016095333,0.0005948352,0.0008599385],"domain_scores_gemma":[0.99433875,0.0015324384,0.000658295,0.0016941597,0.0016234098,0.00015292306],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030962746,0.00081903354,0.00177654,0.0013199348,0.00035257265,0.00027890172,0.0011712156,0.0025323362,0.006106397],"category_scores_gemma":[0.010653009,0.00067374704,0.0012828481,0.001595526,0.0002709765,0.00015586427,0.0004978901,0.0011112409,0.00076212926],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115449075,0.00013083084,0.00008956058,0.00006581296,0.0055553257,0.0000056185345,0.00008515566,0.0000016623559,0.0011816408,0.00004083625,0.94732875,0.045399357],"study_design_scores_gemma":[0.00052157155,0.00016053085,0.00007350056,0.00008130145,0.012377758,6.8198966e-7,0.000101873055,0.000065439024,0.0009165318,0.00030137517,0.9845814,0.0008180384],"about_ca_topic_score_codex":0.0026126052,"about_ca_topic_score_gemma":0.0013807914,"teacher_disagreement_score":0.21562618,"about_ca_system_score_codex":0.0003442513,"about_ca_system_score_gemma":0.00017959782,"threshold_uncertainty_score":0.9995714},"labels":[],"label_agreement":null},{"id":"W2154473763","doi":"10.4155/bio.14.279","title":"2014 White Paper on Recent Issues in Bioanalysis: A Full Immersion in Bioanalysis (Part 2 – Hybrid LBA/LCMS, ELN &amp; Regulatory Agencies’ Input)","year":2014,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical; Health Canada; Armand Frappier Museum","funders":"","keywords":"Bioanalysis; Biopharmaceutical; Computer science; White paper; Nanotechnology; Engineering ethics; Political science; Engineering; Materials science; Biotechnology; Biology","score_opus":0.020253452279761195,"score_gpt":0.27524898724939006,"score_spread":0.25499553496962885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154473763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7268579,0.17838687,0.0029051944,0.061211772,0.0036978186,0.0023273756,0.0006844494,0.00079198217,0.023136666],"genre_scores_gemma":[0.95984876,0.014296508,0.002967878,0.0042440845,0.0002768649,0.00009474799,0.0007249095,0.000109782006,0.017436441],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99184275,0.0025008512,0.0019725787,0.0018975551,0.00040927433,0.001376974],"domain_scores_gemma":[0.9963183,0.00046238778,0.0006297441,0.0021073115,0.00027181927,0.00021048056],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0039829235,0.00091446994,0.0021900956,0.0027655796,0.00028412792,0.00010148623,0.0009662784,0.00085774553,0.010363684],"category_scores_gemma":[0.00054925896,0.00074776064,0.0011930984,0.003970024,0.0006807445,0.00024444924,0.00033237587,0.0009722834,0.0017145596],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040406277,0.0063158562,0.21386532,0.0003624957,0.018762153,0.00020511234,0.0017423389,0.0016062068,0.16213171,0.001958673,0.17275152,0.416258],"study_design_scores_gemma":[0.0023285367,0.00045324894,0.016571956,0.00021965658,0.0029417365,0.000018684086,0.0009022023,0.0009904826,0.013065111,0.00040207946,0.96048725,0.0016190618],"about_ca_topic_score_codex":0.0009169363,"about_ca_topic_score_gemma":0.004129523,"teacher_disagreement_score":0.78773576,"about_ca_system_score_codex":0.0005410758,"about_ca_system_score_gemma":0.00011377009,"threshold_uncertainty_score":0.99949735},"labels":[],"label_agreement":null},{"id":"W2155591144","doi":"10.3390/ph5040353","title":"On the Regulatory Approval Pathway of Biosimilar Products","year":2012,"lang":"en","type":"article","venue":"Pharmaceuticals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Harmonization; Innovator; Scope (computer science); Medicine; Drug approval; Product (mathematics); Business; Risk analysis (engineering); Pharmacology; Computer science; Finance; Drug","score_opus":0.0880573224176878,"score_gpt":0.34090842852924785,"score_spread":0.25285110611156003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155591144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8855742,0.026914697,0.00040612504,0.038291276,0.0046977582,0.0018260629,0.00017569755,0.00023439214,0.041879766],"genre_scores_gemma":[0.99530244,0.00005425879,0.00036586847,0.0030610056,0.00010492496,0.000015662814,0.0000037552059,0.000013585127,0.0010784947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984848,0.00050129974,0.00027853958,0.00020415854,0.000068426525,0.00046280888],"domain_scores_gemma":[0.9987687,0.00064458844,0.00008432149,0.00038580468,0.000064891734,0.000051686307],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015650045,0.00015900025,0.00024809953,0.00004512037,0.00009973322,0.0000051130382,0.00024256138,0.00017008735,0.0017280789],"category_scores_gemma":[0.00052375783,0.00008771672,0.00010419217,0.00019712622,0.00053826335,0.000046706074,0.000087273234,0.00036070234,0.0002455632],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014471811,0.00051298295,0.0006895329,0.000044438424,0.00019002639,6.3224167e-7,0.00011236912,2.35234e-7,0.8624097,0.10335891,0.022955399,0.009581039],"study_design_scores_gemma":[0.00025958123,0.000052122286,0.0013064136,0.000013722925,0.00006069624,0.000009024304,0.000028846787,0.0000041678422,0.8058739,0.0006180538,0.19166994,0.00010354478],"about_ca_topic_score_codex":8.279357e-7,"about_ca_topic_score_gemma":5.081249e-8,"teacher_disagreement_score":0.16871454,"about_ca_system_score_codex":0.000014783076,"about_ca_system_score_gemma":0.00002748688,"threshold_uncertainty_score":0.9991845},"labels":[],"label_agreement":null},{"id":"W2156344403","doi":"10.1074/mcp.m112.022442","title":"Multiplexed Quantitation of Endogenous Proteins in Dried Blood Spots by Multiple Reaction Monitoring - Mass Spectrometry","year":2012,"lang":"en","type":"article","venue":"Molecular & Cellular Proteomics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; University of Victoria","funders":"","keywords":"Dried blood; Analyte; Chromatography; Chemistry; Selected reaction monitoring; Mass spectrometry; Dried blood spot; Biomarker discovery; Quantitative proteomics; Tandem mass spectrometry; Label-free quantification; Population; Small molecule; Whole blood; Multiplex; Sample preparation; Immunoassay; Blood sampling; Proteomics; Bioinformatics; Biochemistry; Biology; Medicine","score_opus":0.02608756240591608,"score_gpt":0.2511941104659813,"score_spread":0.2251065480600652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156344403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791361,0.0035590844,0.0155784385,0.000044961344,0.00036917365,0.0010809931,0.000029045084,0.000042330146,0.00015986107],"genre_scores_gemma":[0.93443346,0.000054241864,0.065201715,0.000015886182,0.000038845825,0.00007218589,0.00006673224,0.00003609942,0.00008081422],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980848,0.00039773688,0.00052131835,0.0003308502,0.00009528476,0.0005700395],"domain_scores_gemma":[0.999194,0.00008403259,0.00025235108,0.00034797328,0.00006748526,0.000054158794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076009665,0.0002451693,0.00040802333,0.00020814907,0.000075813434,0.000012622583,0.00019305563,0.0004493594,0.00003094886],"category_scores_gemma":[0.000324847,0.00024632705,0.0001490015,0.00036180625,0.00011982621,0.000119815246,0.000057454003,0.00044813752,0.00002097655],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015111749,0.00055028696,0.0136866765,0.00005983003,0.00013465359,0.000012194562,0.00014841302,0.000004546568,0.9845923,0.00020074077,0.0000043829787,0.00045481228],"study_design_scores_gemma":[0.0016077372,0.00017274973,0.0021152457,0.000043135897,0.00009827762,0.000019424731,0.00011629983,0.00002962025,0.9952408,0.000119846474,0.00018132543,0.00025555133],"about_ca_topic_score_codex":0.00018367803,"about_ca_topic_score_gemma":0.0000027725398,"teacher_disagreement_score":0.049623277,"about_ca_system_score_codex":0.00007852227,"about_ca_system_score_gemma":0.000033555767,"threshold_uncertainty_score":0.9999989},"labels":[],"label_agreement":null},{"id":"W2156981877","doi":"10.1128/jcm.00842-12","title":"Promise versus Reality: Optimism Bias in Package Inserts for Tuberculosis Diagnostics","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Microbiology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; University of Alberta; McGill University","funders":"European and Developing Countries Clinical Trials Partnership; Canadian Institutes of Health Research; U.S. Food and Drug Administration","keywords":"Food and drug administration; Medical physics; Package insert; Optimism; Tuberculosis; Medicine; R package; Diagnostic accuracy; Computer science; Statistics; Pathology; Psychology; Internal medicine; Risk analysis (engineering); Mathematics; Pharmacology","score_opus":0.44009669424978926,"score_gpt":0.505177077479671,"score_spread":0.06508038322988174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156981877","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001724615,0.9894275,0.00011063359,0.0006546398,0.008022787,0.0009283841,0.00051271135,0.000014202296,0.00015667775],"genre_scores_gemma":[0.00007009198,0.994608,0.0033477452,0.00035798058,0.0009389532,0.00003503709,0.00023430261,0.00006728538,0.0003406309],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.989014,0.0039162603,0.005515786,0.00058501115,0.000035927987,0.0009330005],"domain_scores_gemma":[0.97559184,0.020063808,0.0032793812,0.0005638808,0.00032348133,0.00017763309],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.007969342,0.00069242186,0.0063791666,0.00041387609,0.000076055694,0.000021999645,0.00089801755,0.004192556,0.00036005062],"category_scores_gemma":[0.011149114,0.0004507612,0.0029078664,0.0003146451,0.00073372596,0.0000844066,0.00026431907,0.0029022626,0.00009287636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011792476,0.0011665156,0.00016556315,0.0024346043,0.0022799042,0.000038232974,0.000020946416,1.2817158e-7,0.0001081527,0.00016278605,0.023075817,0.9693681],"study_design_scores_gemma":[0.003861368,0.001768584,0.000059504513,0.002478231,0.0040559936,0.00052410545,0.000011642487,1.7488767e-7,0.000064986685,0.00011676479,0.9865841,0.0004745242],"about_ca_topic_score_codex":0.000007931618,"about_ca_topic_score_gemma":0.000026477943,"teacher_disagreement_score":0.9688936,"about_ca_system_score_codex":0.00013656732,"about_ca_system_score_gemma":0.00062267005,"threshold_uncertainty_score":0.9997944},"labels":[],"label_agreement":null},{"id":"W2168810930","doi":"10.1177/1740774511431280","title":"On-site management of investigational products and drug delivery systems in conformity with Good Clinical Practices (GCPs)","year":2012,"lang":"en","type":"article","venue":"Clinical Trials","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université du Québec à Chicoutimi","funders":"Canadian Institutes of Health Research","keywords":"Investigational Drugs; Medicine; Conformity; Clinical trial; Drug; Delivery system; Business; Pharmacology; Medical physics; Internal medicine; Psychology","score_opus":0.31989869612022465,"score_gpt":0.4841618447633599,"score_spread":0.16426314864313524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168810930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898159,0.004081149,0.000034425397,0.0014404745,0.0018946463,0.00087907765,0.00004662419,0.000018626779,0.0017890801],"genre_scores_gemma":[0.99359983,0.00083601935,0.0038628688,0.0005763896,0.0002549651,0.000021953569,0.00001974612,0.000009537608,0.0008186613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921099,0.005078146,0.0020497213,0.00037845375,0.00008306601,0.00030073398],"domain_scores_gemma":[0.9868862,0.011109688,0.0014808503,0.00031415568,0.00011039332,0.00009868769],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.035538327,0.00016055608,0.0010807068,0.00005928156,0.00004481674,0.00001560271,0.00013942087,0.00035084947,0.00006280991],"category_scores_gemma":[0.009658801,0.00009944174,0.0001263298,0.00015596356,0.0007461909,0.00014006298,0.00010469573,0.00051596825,0.000044902226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058162767,0.0032680754,0.8440682,0.000523832,0.0018259065,0.000014149229,0.00010090679,0.000002731174,0.00096483476,0.0911421,0.011162264,0.04111067],"study_design_scores_gemma":[0.014977039,0.002018579,0.88296896,0.00096487545,0.0013009384,0.000035439036,0.00045716885,0.000025793284,0.0037081023,0.002051873,0.09088551,0.00060573156],"about_ca_topic_score_codex":0.000033458662,"about_ca_topic_score_gemma":0.000007712398,"teacher_disagreement_score":0.08909023,"about_ca_system_score_codex":0.0000117953905,"about_ca_system_score_gemma":0.00007736123,"threshold_uncertainty_score":0.9986833},"labels":[],"label_agreement":null},{"id":"W2169181615","doi":"10.1002/cyto.b.20397","title":"African regional external quality assessment for CD4 T-cell enumeration: Development, outcomes, and performance of laboratories","year":2008,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Centre for Infectious Diseases","funders":"","keywords":"External quality assessment; Statistics; Standard deviation; Coefficient of variation; Human immunodeficiency virus (HIV); Cd4 t cell; Enumeration; Mathematics; Reproducibility; Medicine; Immunology; Combinatorics; Pathology","score_opus":0.15831449281662327,"score_gpt":0.42282068298459424,"score_spread":0.26450619016797094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169181615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902735,0.0015721136,0.00597981,0.0003281442,0.00084908126,0.00031466884,0.00010703598,0.000050211635,0.00052546454],"genre_scores_gemma":[0.9585214,0.00047136203,0.038170397,0.00067247846,0.0001297092,0.000038851274,0.000054339707,0.000020352083,0.0019210948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669814,0.00048108,0.0015783209,0.00060239463,0.0001831093,0.00045694943],"domain_scores_gemma":[0.9960258,0.0025208145,0.0005469801,0.0004125572,0.0003626232,0.00013124594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028594458,0.00030463428,0.0010070434,0.0002639117,0.00037856397,0.000019589661,0.000312264,0.0005241158,0.00026089413],"category_scores_gemma":[0.0009334343,0.00024309427,0.00024065112,0.0008328481,0.0010118232,0.00014404618,0.00016969819,0.00053744885,0.00002151016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046034157,0.0006369363,0.98433924,0.0001377563,0.00023479981,0.0000024927817,0.000052912514,1.4747191e-7,0.0061993455,0.00042575205,0.001966771,0.0055435137],"study_design_scores_gemma":[0.0025328738,0.000802731,0.8929684,0.00003943102,0.000074180905,0.000021961692,0.00009267896,0.000008396504,0.032449577,0.000059051115,0.07057557,0.0003751133],"about_ca_topic_score_codex":0.000004462625,"about_ca_topic_score_gemma":0.000001896475,"teacher_disagreement_score":0.0913708,"about_ca_system_score_codex":0.000049395047,"about_ca_system_score_gemma":0.00033890182,"threshold_uncertainty_score":0.99130964},"labels":[],"label_agreement":null},{"id":"W2172721945","doi":"10.1074/mcp.o115.049957","title":"Multiple Reaction Monitoring Enables Precise Quantification of 97 Proteins in Dried Blood Spots","year":2015,"lang":"en","type":"article","venue":"Molecular & Cellular Proteomics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; University of Victoria","funders":"","keywords":"Dried blood; Spots; Chromatography; Chemistry","score_opus":0.042979629438320094,"score_gpt":0.2689062182088691,"score_spread":0.22592658877054902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172721945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97568816,0.0018228348,0.020719757,0.0000955531,0.00033728615,0.001096873,0.000007707606,0.000039061688,0.00019274309],"genre_scores_gemma":[0.9738824,0.000030052686,0.025550557,0.000015252138,0.00002624903,0.000102200574,0.000029675892,0.000025745385,0.00033786005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840397,0.0003607735,0.00047171421,0.0003722109,0.00008463844,0.0003067115],"domain_scores_gemma":[0.9991107,0.0000506076,0.00021565791,0.00042622027,0.00014941538,0.000047378086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007629879,0.00018795444,0.00032866493,0.00015404548,0.000045820958,0.00001531876,0.00021312728,0.00040074778,0.000008167933],"category_scores_gemma":[0.00052911555,0.00018109416,0.00010134364,0.00027141013,0.00012729559,0.00007896199,0.00007710435,0.00032601535,0.00002439647],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018033679,0.00036183832,0.004074797,0.00005930745,0.00006859122,0.00001888426,0.00014452488,0.000032034455,0.99236614,0.00029727,0.0000062296194,0.002390041],"study_design_scores_gemma":[0.0015013912,0.00015070137,0.0011404692,0.0000858175,0.00007669651,0.000008341497,0.00010595219,0.00010586763,0.9950794,0.0007321848,0.00082127255,0.0001918792],"about_ca_topic_score_codex":0.00019024083,"about_ca_topic_score_gemma":0.000007929649,"teacher_disagreement_score":0.004830801,"about_ca_system_score_codex":0.000056591056,"about_ca_system_score_gemma":0.00008813727,"threshold_uncertainty_score":0.73848057},"labels":[],"label_agreement":null},{"id":"W2181230016","doi":"10.1111/cei.12742","title":"From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals","year":2015,"lang":"en","type":"review","venue":"Clinical & Experimental Immunology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary; University of Alberta","funders":"","keywords":"Immunogenicity; Context (archaeology); Medicine; Clinical trial; Bench to bedside; Intensive care medicine; Risk analysis (engineering); Immunology; Biology; Medical physics; Pathology; Immune system","score_opus":0.605593475497232,"score_gpt":0.5769736681339371,"score_spread":0.028619807363294836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2181230016","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024651585,0.9893226,0.000075076445,0.0041870438,0.0034890252,0.0021232986,0.00013295296,0.000048199327,0.00037528054],"genre_scores_gemma":[0.0010813343,0.99349636,0.0022813703,0.0020697995,0.00053678564,0.0003444219,0.00005090154,0.000060762864,0.0000782739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.988783,0.0063575758,0.0027152328,0.0012242182,0.00009440157,0.0008255721],"domain_scores_gemma":[0.9541013,0.04404092,0.0007271379,0.0008858472,0.00014608272,0.000098706536],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009068485,0.00066978566,0.002925512,0.000090111695,0.00037031117,0.00007104145,0.0012159741,0.0019222663,0.000076658456],"category_scores_gemma":[0.0111755505,0.00036001537,0.00075409276,0.00029418452,0.0029187566,0.00009272982,0.001318188,0.0024796587,0.00008214896],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007184066,0.00076849567,0.00004560422,0.00015060458,0.002311409,0.000012662613,0.00072378083,6.514855e-8,0.00012476677,0.005131795,0.0018087478,0.98820364],"study_design_scores_gemma":[0.0016432357,0.0016775742,0.0001125927,0.0011002024,0.0010931243,0.00008922142,0.007948202,0.0000032283133,0.00004466879,0.0021489598,0.9836448,0.00049418554],"about_ca_topic_score_codex":0.00013212205,"about_ca_topic_score_gemma":0.000022502281,"teacher_disagreement_score":0.98770946,"about_ca_system_score_codex":0.0002704791,"about_ca_system_score_gemma":0.0003393611,"threshold_uncertainty_score":0.9998852},"labels":[],"label_agreement":null},{"id":"W2184990075","doi":"10.1002/dta.1927","title":"Quantitative determination of opioids in whole blood using fully automated dried blood spot desorption coupled to on‐line SPE‐LC‐MS/MS","year":2015,"lang":"en","type":"article","venue":"Drug Testing and Analysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency; Partnership for Clean Competition","keywords":"Dried blood spot; Hydrocodone; Chromatography; Codeine; Whole blood; Oxycodone; Hydromorphone; Solid phase extraction; Matrix (chemical analysis); Extraction (chemistry); Medicine; Chemistry; Morphine; Opioid; Pharmacology; Surgery","score_opus":0.06849297977756455,"score_gpt":0.3416201090951506,"score_spread":0.2731271293175861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2184990075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957985,0.0002315693,0.0033857925,0.00023021817,0.00004435032,0.000116711046,0.000034401055,0.00007620261,0.0000822048],"genre_scores_gemma":[0.9467796,0.000004735924,0.052887473,0.00007459338,0.000013838389,0.0000034690736,0.00004533487,0.000009584152,0.00018138853],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985658,0.00030702836,0.0004612239,0.0003473188,0.00007254042,0.0002461182],"domain_scores_gemma":[0.9987583,0.00054240524,0.00020977881,0.00017453848,0.00025487808,0.000060108043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010223478,0.00017423723,0.00052156905,0.0005460867,0.00008116962,0.000023174733,0.00010542087,0.00015356869,0.00002170435],"category_scores_gemma":[0.001586629,0.00015023444,0.00009306119,0.0016024692,0.00012566832,0.000053962656,0.000055720404,0.0001654065,0.000005914659],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019970223,0.0006181068,0.061658006,0.000039138635,0.0007664456,0.000019369618,0.00074266247,0.002515512,0.92958176,0.00010686672,0.000026442392,0.0037260063],"study_design_scores_gemma":[0.003807395,0.001605271,0.03516902,0.00033312786,0.0057705264,0.000030101502,0.0009810062,0.7350701,0.21589984,0.0006835043,0.000036942365,0.000613149],"about_ca_topic_score_codex":0.0006492797,"about_ca_topic_score_gemma":0.00017658531,"teacher_disagreement_score":0.7325546,"about_ca_system_score_codex":0.00002450426,"about_ca_system_score_gemma":0.000044818393,"threshold_uncertainty_score":0.6126383},"labels":[],"label_agreement":null},{"id":"W2185272193","doi":"10.4155/bio.15.226","title":"2015 White Paper on Recent Issues in Bioanalysis: Focus on New Technologies and Biomarkers (Part 3 – Lba, Biomarkers and Immunogenicity)","year":2015,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; Genentech; Angelini Pharma; Bundesinstitut für Arzneimittel und Medizinprodukte; Amgen; Pfizer; U.S. Food and Drug Administration; Bristol-Myers Squibb; Eli Lilly and Company; Agence Nationale de Sécurité du Médicament et des Produits de Santé; Biogen","keywords":"Bioanalysis; Biopharmaceutical; Immunogenicity; Computer science; Nanotechnology; Medicine; Biotechnology; Biology","score_opus":0.03360566082740423,"score_gpt":0.29413662647527855,"score_spread":0.2605309656478743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185272193","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14841798,0.6272829,0.0002236462,0.2054143,0.0015488762,0.0015441804,0.00029901415,0.00097639806,0.014292723],"genre_scores_gemma":[0.94093525,0.04473338,0.0046171583,0.0015239838,0.00009122991,0.000055273264,0.000099108875,0.00008220508,0.007862402],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996938,0.00051174563,0.00073073915,0.0010096745,0.00016108436,0.00064875087],"domain_scores_gemma":[0.99847865,0.0002317333,0.00023524565,0.0007905877,0.00011870518,0.00014504863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012289408,0.0005206344,0.0009655296,0.0012440642,0.00014120844,0.00008964619,0.00037648636,0.0007440275,0.0003672856],"category_scores_gemma":[0.0006267567,0.0003873155,0.00024868897,0.0019402528,0.0007863593,0.00013284328,0.0002545792,0.0003973584,0.000089981375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027905689,0.0007771153,0.046816774,0.00003248313,0.011816069,0.00007074198,0.0003884001,0.000009848982,0.020264039,0.0011280804,0.04622514,0.86968076],"study_design_scores_gemma":[0.0070154974,0.0021904432,0.013754525,0.00030549083,0.0035732973,0.000053137224,0.007753562,0.00016278807,0.0667488,0.005487919,0.8908935,0.0020610455],"about_ca_topic_score_codex":0.0010013983,"about_ca_topic_score_gemma":0.00087131775,"teacher_disagreement_score":0.8676197,"about_ca_system_score_codex":0.00013876856,"about_ca_system_score_gemma":0.000082437466,"threshold_uncertainty_score":0.9998579},"labels":[],"label_agreement":null},{"id":"W2189370726","doi":"","title":"Biosimilars and Reference Biologics: Decisions on Biosimilar Interchangeability Require the Involvement of Dermatologists Biosimilares y biológicos de referencia: la intercambiabilidad de los biosimilares requiere la participación del dermatólogo","year":2015,"lang":"es","type":"article","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Infliximab; Innovator; Interchangeability; Medicine; Food and drug administration; European union; Business; Pharmacology; Disease; Finance; Engineering","score_opus":0.1266267748429847,"score_gpt":0.373611186097269,"score_spread":0.2469844112542843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2189370726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93217254,0.016767632,0.0022321893,0.038731936,0.0006450494,0.0019825024,0.002542593,0.00034933735,0.004576202],"genre_scores_gemma":[0.97509634,0.010607266,0.0048148045,0.008923411,0.00006621094,0.0001859815,0.000083613915,0.00008527571,0.00013707156],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.985146,0.008325984,0.0022610903,0.0018298358,0.00038123105,0.0020558913],"domain_scores_gemma":[0.98817956,0.007335155,0.0009064536,0.0021341406,0.0007698561,0.00067484606],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0074609546,0.0014356789,0.0019751955,0.000518573,0.00058396015,0.00028600052,0.0019935714,0.0031636248,0.00031984545],"category_scores_gemma":[0.006096279,0.00091372686,0.00057024544,0.0009955992,0.0065657627,0.00033099277,0.0019940555,0.0022243608,0.00003741662],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012099619,0.012473172,0.34612375,0.0039000614,0.007483136,0.00087034976,0.0105297845,0.000056834793,0.24880788,0.101915635,0.18000573,0.07573405],"study_design_scores_gemma":[0.009757373,0.011389305,0.07898273,0.008880814,0.0033032487,0.0018583038,0.02812322,0.0015511272,0.59074324,0.04155499,0.2189748,0.004880829],"about_ca_topic_score_codex":0.00020412286,"about_ca_topic_score_gemma":0.0003080535,"teacher_disagreement_score":0.34193537,"about_ca_system_score_codex":0.00048115844,"about_ca_system_score_gemma":0.00066874037,"threshold_uncertainty_score":0.9998393},"labels":[],"label_agreement":null},{"id":"W2190255689","doi":"10.4155/bio.15.211","title":"From Low- to High-Throughput Analysis","year":2015,"lang":"en","type":"review","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"","keywords":"Throughput; Drug discovery; High-throughput screening; Computer science; Turnaround time; Drug; Risk analysis (engineering); Biochemical engineering; Chemistry; Pharmacology; Business; Medicine; Engineering; Operating system","score_opus":0.07109437566144682,"score_gpt":0.3866871325642364,"score_spread":0.3155927569027896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2190255689","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004368405,0.9941365,0.0014628337,0.00021432833,0.0008432315,0.0003989703,0.002152793,0.00011962489,0.0006673544],"genre_scores_gemma":[0.000029305846,0.983024,0.0047565615,0.00031159818,0.0003194666,0.00007883623,0.002740119,0.000066468085,0.008673619],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947227,0.0012746603,0.001434805,0.001611535,0.00018207729,0.00077420886],"domain_scores_gemma":[0.9965344,0.0005241659,0.000577631,0.0018646736,0.00025764084,0.00024147065],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010013465,0.00094798405,0.0065610763,0.0016305877,0.0001462399,0.000093006674,0.0011974947,0.0017393518,0.006766683],"category_scores_gemma":[0.00030488693,0.0006642231,0.0037045926,0.0064477553,0.00024554427,0.000057165154,0.00051635905,0.0007155377,0.004916874],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013528493,0.0001355819,0.000011266343,0.00034485938,0.04139602,0.000018975641,0.00003446367,0.0000019774957,0.0000051122033,0.000074807795,0.010186196,0.9477772],"study_design_scores_gemma":[0.00017373907,0.00005681232,0.000009082289,0.0005049188,0.10082327,0.000002600189,0.000028919585,0.000002702845,0.000019924928,0.000117565556,0.897522,0.00073848834],"about_ca_topic_score_codex":0.0015732859,"about_ca_topic_score_gemma":0.00018568296,"teacher_disagreement_score":0.9470387,"about_ca_system_score_codex":0.00031139207,"about_ca_system_score_gemma":0.00026763108,"threshold_uncertainty_score":0.9995809},"labels":[],"label_agreement":null},{"id":"W2198610527","doi":"10.1517/14712598.2015.1083552","title":"Biosimilar monoclonal antibodies: the scientific basis for extrapolation","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Infliximab; Medicine; Pharmacology; Disease; Internal medicine","score_opus":0.38047339994214074,"score_gpt":0.4642009020635223,"score_spread":0.08372750212138158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2198610527","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004732711,0.9913839,0.000314013,0.001090107,0.004740006,0.0016687475,0.00039440615,0.00010545839,0.00029862276],"genre_scores_gemma":[0.00001025442,0.9957363,0.000984482,0.0012071069,0.00055823196,0.00040221727,0.000746049,0.00003817083,0.0003171729],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961921,0.001344939,0.0007476025,0.0010065492,0.00010524963,0.0006035911],"domain_scores_gemma":[0.99673396,0.001965756,0.00036259918,0.00069825916,0.00017036314,0.00006903111],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0020477504,0.0006602573,0.00157235,0.0001759363,0.0006638306,0.00011305295,0.00086791354,0.0015218303,0.0007911781],"category_scores_gemma":[0.00039036822,0.00029006758,0.0010855331,0.00040928114,0.0010540873,0.0000427884,0.00010261812,0.0005917656,0.00015755963],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023046558,0.0002024001,0.0000019072586,0.000035471625,0.0002872174,3.3794393e-7,0.000049171802,4.9681685e-8,0.00022964155,0.0015280901,0.053983293,0.94345194],"study_design_scores_gemma":[0.00047410818,0.0008645308,0.0000064103197,0.0006598818,0.000007014437,0.00001414719,0.000035462344,0.0000027533613,0.0002839856,0.00054302893,0.99666584,0.0004428625],"about_ca_topic_score_codex":0.0000027107885,"about_ca_topic_score_gemma":2.606316e-7,"teacher_disagreement_score":0.9430091,"about_ca_system_score_codex":0.00009628548,"about_ca_system_score_gemma":0.0001646403,"threshold_uncertainty_score":0.9999551},"labels":[],"label_agreement":null},{"id":"W2210363578","doi":"10.1016/s1470-2045(15)00381-2","title":"Postmarket policy considerations for biosimilar oncology drugs","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biosimilar; Context (archaeology); Authorization; Business; Marketing authorization; Competition (biology); Interchangeability; Medicine","score_opus":0.240915421907452,"score_gpt":0.4804593703366855,"score_spread":0.23954394842923352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2210363578","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.5711562e-7,0.93067616,0.00007306386,0.0340464,0.0021096494,0.0018939092,0.0012371973,0.00012181561,0.029841451],"genre_scores_gemma":[0.000003760084,0.9793897,0.004257005,0.008932823,0.0018827011,0.0006093778,0.00028666185,0.00007141024,0.0045665475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926233,0.0044249254,0.001080475,0.0007003582,0.00006141521,0.0011094834],"domain_scores_gemma":[0.9893931,0.008473861,0.0007344183,0.0010035303,0.00029634198,0.00009870868],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004796681,0.0006431379,0.0046013086,0.00028426433,0.00042643287,0.00003508813,0.00090988807,0.002610071,0.00084541045],"category_scores_gemma":[0.0023632296,0.00037421013,0.0007909953,0.0003980369,0.00120564,0.000040331503,0.0003844149,0.0014198485,0.0004406415],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012418903,0.00014589209,2.1041085e-7,0.0008357193,0.00075650733,0.000009183063,0.00012945234,7.448681e-8,0.000012825953,0.020572986,0.35445058,0.6229624],"study_design_scores_gemma":[0.001663195,0.0010324909,6.3057894e-7,0.00034381374,0.001974369,0.0006749211,0.00007628737,0.0000013191501,0.000014290273,0.00851815,0.9852737,0.00042681853],"about_ca_topic_score_codex":0.00003812011,"about_ca_topic_score_gemma":0.000057352372,"teacher_disagreement_score":0.63082314,"about_ca_system_score_codex":0.0007656778,"about_ca_system_score_gemma":0.0042316355,"threshold_uncertainty_score":0.99987096},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2217300526","doi":"10.1016/j.semarthrit.2014.10.015","title":"Introduction and commentary: Biosimilars—clinical trial and safety considerations","year":2014,"lang":"en","type":"article","venue":"Seminars in Arthritis and Rheumatism","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Biosimilar; Medicine; Comparability; Risk analysis (engineering); Interchangeability; Clinical trial; Product (mathematics); Quality (philosophy); Pharmacovigilance; Drug development; Pharmacology; Drug; Computer science","score_opus":0.019020554455282168,"score_gpt":0.29924154458513785,"score_spread":0.2802209901298557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2217300526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8323743,0.105023265,0.00033324392,0.059000537,0.001922288,0.0006159278,0.000061808394,0.000046377652,0.0006222498],"genre_scores_gemma":[0.70584106,0.28527278,0.005386635,0.0031349522,0.00015023752,0.0000144191235,0.00002987883,0.000011175451,0.00015884396],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983903,0.00053762004,0.00049877266,0.00035098317,0.000026147347,0.00019615915],"domain_scores_gemma":[0.9989829,0.00072911143,0.00007985606,0.0001432629,0.000018425377,0.00004643765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001351977,0.0001392299,0.0003922342,0.00006764309,0.00022915196,0.000037677823,0.000032292002,0.00025924307,0.00027026032],"category_scores_gemma":[0.00047295223,0.00011909914,0.00003253813,0.00005266725,0.0006975924,0.00008040371,0.000090136404,0.0003031179,0.0000037366092],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008377734,0.00011822097,0.0048879874,0.0000134732045,0.00004853876,0.0000027537421,0.00017157076,1.0293087e-7,0.00081704534,0.008193011,0.067200854,0.9177087],"study_design_scores_gemma":[0.18143314,0.0074464916,0.16961312,0.0064349165,0.00022195232,0.0020049114,0.0012269658,0.00053232507,0.0040686713,0.06352639,0.5616319,0.0018591939],"about_ca_topic_score_codex":0.000031492527,"about_ca_topic_score_gemma":0.000121845005,"teacher_disagreement_score":0.91584945,"about_ca_system_score_codex":0.0000072952525,"about_ca_system_score_gemma":0.000008318041,"threshold_uncertainty_score":0.4856722},"labels":[],"label_agreement":null},{"id":"W2217660800","doi":"10.1186/s13063-015-1123-1","title":"Making smart investment decisions in clinical research","year":2015,"lang":"en","type":"article","venue":"Trials","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Arthritis Research Centre of Canada; Research Canada; St. Paul's Hospital; University of British Columbia","funders":"National Institutes of Health; Office of Research and Development; Canadian Institutes of Health Research; U.S. Department of Veterans Affairs","keywords":"Medicine; Clinical trial; Alternative medicine; Clinical research; Rheumatoid arthritis; Intensive care medicine; Investment (military); Pathology; Immunology","score_opus":0.8398231400302498,"score_gpt":0.6343544987436722,"score_spread":0.2054686412865776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2217660800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.674679,0.034501188,0.0046516694,0.028368426,0.01949089,0.0065657394,0.0001468917,0.00033120083,0.23126504],"genre_scores_gemma":[0.98253214,0.00024928452,0.009249358,0.002685574,0.0002763312,0.000052909978,0.000009199876,0.00001688724,0.004928286],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901127,0.0080772545,0.0010639286,0.00029268465,0.00008069644,0.00037269507],"domain_scores_gemma":[0.9894927,0.009898384,0.00010277237,0.00032249023,0.0001232999,0.000060316146],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.049299933,0.00008819482,0.0006020374,0.00017487806,0.000060490533,0.00001874437,0.00023556723,0.00038119976,0.0004218426],"category_scores_gemma":[0.04153055,0.000059149726,0.00013882537,0.00031195328,0.00031366272,0.000029073435,0.00017846303,0.000577143,0.00068126066],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049350485,0.0019148228,0.03264965,0.000010542287,0.000516499,0.000109113775,0.0006949959,0.000016823815,0.016615411,0.048830863,0.48902234,0.4046839],"study_design_scores_gemma":[0.004351995,0.000577724,0.010463026,0.000095774594,0.00004386881,0.00000923054,0.00031487082,0.000024687693,0.004116625,0.036206577,0.94362277,0.00017283132],"about_ca_topic_score_codex":0.000031933956,"about_ca_topic_score_gemma":0.00004051802,"teacher_disagreement_score":0.45460045,"about_ca_system_score_codex":0.00005009438,"about_ca_system_score_gemma":0.00016340615,"threshold_uncertainty_score":0.9789458},"labels":[],"label_agreement":null},{"id":"W2219577168","doi":"10.1155/2015/971858","title":"Digging for New Solutions","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Inland Hospital; University of Calgary; Université de Sherbrooke","funders":"","keywords":"Incentive; Business; Risk analysis (engineering); Identification (biology); Order (exchange); Notice; Marketing; Industrial organization; Operations management; Economics; Finance; Political science; Law; Market economy","score_opus":0.025989162202690073,"score_gpt":0.27629275819292914,"score_spread":0.25030359599023905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2219577168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5169147,0.30845314,0.07811493,0.06446655,0.025316847,0.0013144958,0.0013549926,0.00013518908,0.003929162],"genre_scores_gemma":[0.9953691,0.00024731026,0.00035933498,0.0030066343,0.00044096218,0.000003197082,0.000025313526,0.000013537225,0.0005346098],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99897987,0.00012247734,0.00031864652,0.00013414216,0.000017886283,0.00042699682],"domain_scores_gemma":[0.9983729,0.0002263949,0.000116894385,0.00007699518,0.00018459109,0.001022217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043983446,0.000117758755,0.00032349635,0.00017013932,0.00015912962,0.000017003127,0.0001415657,0.0003058944,0.00045202515],"category_scores_gemma":[0.0019527936,0.00008751848,0.0001398306,0.000085363565,0.00047764162,0.00004285619,0.000023292634,0.00024761906,0.000009443781],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026871607,0.0001903551,0.043840062,0.00005923139,0.00095162285,0.00014023265,0.00040205035,0.0000055816577,0.01128268,0.013728439,0.7412997,0.18783134],"study_design_scores_gemma":[0.0036771514,0.0011843109,0.0021989304,0.00008693051,0.0002819657,0.00367461,0.00017769303,0.0000068387094,0.00034256896,0.0066430215,0.9815041,0.00022191844],"about_ca_topic_score_codex":0.0012488631,"about_ca_topic_score_gemma":0.0028870504,"teacher_disagreement_score":0.47845438,"about_ca_system_score_codex":0.00008026749,"about_ca_system_score_gemma":0.0026041018,"threshold_uncertainty_score":0.49493584},"labels":[],"label_agreement":null},{"id":"W2245303227","doi":"","title":"Будущее технологий биофармацевтического производства","year":2011,"lang":"ru","type":"article","venue":"Биофармацевтический журнал","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.08372434923710434,"score_gpt":0.2866673650347424,"score_spread":0.20294301579763804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245303227","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07400807,0.06823468,0.006977416,0.006696658,0.030730033,0.004430895,0.0019330685,0.002196241,0.80479294],"genre_scores_gemma":[0.8607657,0.0036373367,0.0131943105,0.0071987524,0.0015517817,0.00015917914,0.0002074253,0.00047359243,0.11281191],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9883748,0.0019143915,0.002638,0.0028641522,0.00047152466,0.0037370762],"domain_scores_gemma":[0.99400663,0.0005949058,0.0010321259,0.0029932407,0.00059632806,0.0007767886],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0024279375,0.0021209444,0.0025982233,0.00081702246,0.0011004028,0.00019198046,0.0025840737,0.0035821004,0.06115762],"category_scores_gemma":[0.0006913295,0.0019204835,0.0015344572,0.0015991066,0.0028654574,0.0005771416,0.0012731412,0.0032406368,0.014217254],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072825938,0.012844379,0.034599174,0.0016651115,0.010869698,0.0015239415,0.012509223,0.000004656823,0.13998814,0.12485193,0.40765586,0.24620529],"study_design_scores_gemma":[0.0077109174,0.0036829622,0.04636873,0.00090583524,0.0029793568,0.00092155876,0.002517694,0.00013889847,0.17792332,0.012414802,0.7391178,0.005318126],"about_ca_topic_score_codex":0.00081123615,"about_ca_topic_score_gemma":0.00017216864,"teacher_disagreement_score":0.78675765,"about_ca_system_score_codex":0.00031671237,"about_ca_system_score_gemma":0.00057293073,"threshold_uncertainty_score":0.9998482},"labels":[],"label_agreement":null},{"id":"W2256209496","doi":"10.1016/j.jval.2015.03.931","title":"The Economic Value of Tofacitinib 5 Mg Bid In The Treatment of Moderate To Severe Rheumatoid Arthritis: A Canadian Analysis","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute; St Joseph's Health Care; Pfizer (Canada)","funders":"","keywords":"Tofacitinib; Medicine; Rheumatoid arthritis; Adverse effect; Internal medicine; Quality of life (healthcare); Physical therapy","score_opus":0.05176418846745655,"score_gpt":0.3124097995938347,"score_spread":0.26064561112637813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256209496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823472,0.009056652,0.000031824293,0.0071038846,0.00018935688,0.00047391822,0.0003364013,0.000004580597,0.00045621165],"genre_scores_gemma":[0.9954388,0.003595758,0.00036763895,0.00047863572,0.0000074418745,0.00002525281,0.00001567859,0.000005508253,0.0000652501],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99782234,0.0009910073,0.0005777592,0.00019800101,0.000033498058,0.0003773969],"domain_scores_gemma":[0.9990771,0.00036093238,0.00012582513,0.00032649186,0.000028621771,0.00008102301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016330979,0.00011636518,0.0004775497,0.00024510646,0.000075938806,0.000009278602,0.00020302052,0.000118603966,0.000039427592],"category_scores_gemma":[0.00006904634,0.00006878275,0.00010929223,0.00040307455,0.00011099547,0.000018863388,0.000014130778,0.00011085506,0.000012343431],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033401276,0.0023199362,0.26323712,0.00020746724,0.004664568,0.0000593627,0.068986595,0.20121188,0.0009662942,0.12374383,0.010553098,0.3207097],"study_design_scores_gemma":[0.02439221,0.014925763,0.19710939,0.0011732538,0.00048355525,0.00025583303,0.029806247,0.05691726,0.016897775,0.030093754,0.6257821,0.0021628756],"about_ca_topic_score_codex":0.42456454,"about_ca_topic_score_gemma":0.28841445,"teacher_disagreement_score":0.615229,"about_ca_system_score_codex":0.0003835111,"about_ca_system_score_gemma":0.0008395844,"threshold_uncertainty_score":0.72457016},"labels":[],"label_agreement":null},{"id":"W2258101701","doi":"10.1200/jco.2009.27.15_suppl.567","title":"Evaluation of the false-negative rate of standardized and quantitative measurement of estrogen receptor (ER) in tissue using AQUA technology","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reproducibility; Concordance; Medicine; Estrogen receptor; Kappa; Breast cancer; Gold standard (test); Nuclear medicine; Internal medicine; Cancer; Pathology; Oncology; Chromatography; Chemistry; Mathematics","score_opus":0.275148876913577,"score_gpt":0.5129683890879859,"score_spread":0.23781951217440894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258101701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98951274,0.004439177,0.0008723563,0.0039856583,0.0006450043,0.00032353762,0.000017568827,0.0000018607439,0.00020210502],"genre_scores_gemma":[0.9842631,0.00033866867,0.015259574,0.000100776604,0.000023573724,9.19018e-7,2.199992e-7,0.000004141811,0.000009024793],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99238497,0.004703461,0.0023841374,0.00015396324,0.00021233218,0.00016114388],"domain_scores_gemma":[0.9931433,0.0017733811,0.002855375,0.00015296496,0.0020469648,0.000027968954],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.023252374,0.00011352936,0.0014040131,0.00019120445,0.000027327176,0.000001379146,0.00021743933,0.00059425866,0.00008389136],"category_scores_gemma":[0.018738769,0.000068681904,0.00021255572,0.00028503148,0.0009952997,0.000057774145,0.000055482767,0.0006359993,5.457587e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004275955,0.0011747038,0.0077581615,0.000022166021,0.00081633957,0.0000028921456,0.0002694959,0.000072663635,0.7628078,0.0026033097,0.00017073115,0.22002582],"study_design_scores_gemma":[0.015704485,0.020369958,0.06853198,0.0005339033,0.0017205662,0.000045994686,0.0011875781,0.00020324442,0.8390625,0.04726466,0.005190811,0.00018428265],"about_ca_topic_score_codex":0.000025120891,"about_ca_topic_score_gemma":0.00004123651,"teacher_disagreement_score":0.21984154,"about_ca_system_score_codex":0.00011773442,"about_ca_system_score_gemma":0.0011015543,"threshold_uncertainty_score":0.9895268},"labels":[],"label_agreement":null},{"id":"W2262409806","doi":"10.1159/000381581","title":"Potential Concerns and Questions","year":2015,"lang":"en","type":"book-chapter","venue":"Frontiers of gastrointestinal research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psychology","score_opus":0.11202770117132642,"score_gpt":0.3797711858043469,"score_spread":0.26774348463302045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262409806","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002643158,0.07162413,0.014092644,0.0034567993,0.0014443584,0.0011422237,0.001061081,0.0001177465,0.9067967],"genre_scores_gemma":[0.005841131,0.0004696406,0.031409584,0.000024013441,0.0002077414,0.0000067633296,0.00006189559,0.000052960128,0.9619263],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982141,0.00022617515,0.0003812892,0.0004482067,0.00021887536,0.0005113465],"domain_scores_gemma":[0.99822253,0.00020809335,0.00014580197,0.0003359039,0.00095906,0.00012863419],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0015297752,0.00025550227,0.00056782825,0.00034712983,0.0001388067,0.000020882442,0.00034213084,0.00037646372,0.00080527697],"category_scores_gemma":[0.00080983323,0.00022067504,0.00013433419,0.00005216742,0.0027392327,0.000038580092,0.00034583622,0.0015040901,0.00007298757],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005826675,0.00006059356,0.00055676245,0.00006968981,0.00021926367,0.00008666512,0.000021100861,8.741939e-7,0.0059634815,0.045479428,0.93725336,0.009706125],"study_design_scores_gemma":[0.0014705001,0.0039059783,0.00052585785,0.0010437687,0.00029493208,0.0012154878,0.00023870697,0.000053298598,0.0007543143,0.074209325,0.91573244,0.0005553736],"about_ca_topic_score_codex":0.000063654654,"about_ca_topic_score_gemma":0.000009448032,"teacher_disagreement_score":0.07115448,"about_ca_system_score_codex":0.000092216025,"about_ca_system_score_gemma":0.00032793728,"threshold_uncertainty_score":0.9999747},"labels":[],"label_agreement":null},{"id":"W2274414307","doi":"10.4155/ppa-2016-0001","title":"Biologics and Biosimilars: a Legal Perspective From Canada","year":2016,"lang":"en","type":"editorial","venue":"Pharmaceutical Patent Analyst","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Library science; Christian ministry; Family medicine; Political science; Internal medicine; Law; Computer science","score_opus":0.04711475273903797,"score_gpt":0.33904405110552555,"score_spread":0.29192929836648757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274414307","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000881643,0.040970936,0.00019767534,0.013085975,0.93009675,0.000542705,0.011055575,0.00015604607,0.0030126814],"genre_scores_gemma":[0.10531021,0.01818711,0.00067669677,0.008167501,0.85369927,0.00010939792,0.0030363444,0.00025587744,0.010557589],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962872,0.00069518754,0.00065225497,0.0012495719,0.0002391949,0.00087658357],"domain_scores_gemma":[0.99637944,0.0022885962,0.0002499975,0.00043252777,0.0004328184,0.0002166032],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050346705,0.0007027547,0.0011794325,0.0001382148,0.00022811633,0.000069501366,0.0005325312,0.0016997046,0.0022369046],"category_scores_gemma":[0.0013182143,0.00044944236,0.00029582015,0.00021385649,0.00080427894,0.000071941504,0.00040795346,0.001789767,0.00008766559],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033099085,0.00009118563,0.00030572276,0.000026588226,0.0017729134,0.0000859321,0.0000130126855,6.493018e-8,0.009929046,0.00019435906,0.98533696,0.0019132342],"study_design_scores_gemma":[0.0014489084,0.00011635779,0.00010695179,0.00010223559,0.0013657442,0.000005154901,0.00009738085,0.000015368525,0.007030377,0.0005392072,0.9884824,0.0006898918],"about_ca_topic_score_codex":0.15277022,"about_ca_topic_score_gemma":0.07297825,"teacher_disagreement_score":0.10442857,"about_ca_system_score_codex":0.00052690954,"about_ca_system_score_gemma":0.00075273734,"threshold_uncertainty_score":0.99979573},"labels":[],"label_agreement":null},{"id":"W2280270666","doi":"10.4155/bio.16.16","title":"9th GCC Closed Forum: Capa in Regulated Bioanalysis; Method Robustness, Biosimilars, Preclinical Method Validation, Endogenous Biomarkers, Whole Blood Stability, Regulatory Audit Experiences and Electronic Laboratory Notebooks","year":2016,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical; BioPhage Pharma (Canada); Caprion (Canada)","funders":"","keywords":"Bioanalysis; Biosimilar; Audit; Attendance; Medicine; Pharmacology; Political science; Business; Chemistry; Internal medicine; Accounting; Chromatography","score_opus":0.028617019286196404,"score_gpt":0.2961344516991059,"score_spread":0.2675174324129095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280270666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83859026,0.07290155,0.06560277,0.016735123,0.0013310391,0.002489532,0.0010690908,0.0007234174,0.0005571957],"genre_scores_gemma":[0.9617521,0.0011419369,0.035350367,0.00046580832,0.00007660847,0.00017307705,0.00010408567,0.00007702298,0.0008589907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9899998,0.0044141575,0.0018321718,0.002006794,0.00030314954,0.0014439467],"domain_scores_gemma":[0.99522203,0.0019070378,0.0007216423,0.0015013848,0.00043035563,0.00021751951],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005363924,0.00078254496,0.0017682626,0.0009475976,0.0004168228,0.000094937,0.0007971172,0.0012456547,0.0014281768],"category_scores_gemma":[0.0011675784,0.00054798735,0.00066757196,0.0022119584,0.0013780673,0.0003054495,0.0003657228,0.00055956596,0.000025794643],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000768684,0.0011490375,0.037231017,0.000089883266,0.008755351,0.00004766131,0.0008265131,0.00001796916,0.87122065,0.0006011758,0.00096761686,0.07832442],"study_design_scores_gemma":[0.0056196013,0.0007116,0.004631739,0.0001568655,0.0057619913,0.00008714456,0.0027459944,0.00060787896,0.9504858,0.0014023837,0.026052117,0.001736853],"about_ca_topic_score_codex":0.00022064323,"about_ca_topic_score_gemma":0.00061672286,"teacher_disagreement_score":0.12316182,"about_ca_system_score_codex":0.0002704499,"about_ca_system_score_gemma":0.00048262547,"threshold_uncertainty_score":0.99969715},"labels":[],"label_agreement":null},{"id":"W2292784915","doi":"10.1177/1932296816629488","title":"In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin?","year":2016,"lang":"en","type":"article","venue":"Journal of Diabetes Science and Technology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Insulin; Medicine; Insulin glargine; Business; Internet privacy; Computer science; Hypoglycemia; Internal medicine","score_opus":0.021262089114250367,"score_gpt":0.2769691283930955,"score_spread":0.25570703927884514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292784915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84892416,0.0030887544,0.00017756043,0.14687482,0.0003212278,0.00012687295,0.000008310382,0.000013738095,0.00046455904],"genre_scores_gemma":[0.99429953,0.00035064603,0.001305681,0.0038816528,0.000032068143,0.0000037457341,5.3975185e-8,0.000005290846,0.000121349396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987421,0.00009028415,0.00034501823,0.000232708,0.00011519367,0.00047469823],"domain_scores_gemma":[0.99898523,0.00032224593,0.0001617119,0.00025269945,0.00023600637,0.00004213383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002792333,0.00013197726,0.0002951491,0.0006222538,0.00015686902,0.000025907397,0.0008860376,0.00026349598,0.000091350244],"category_scores_gemma":[0.0013921119,0.00005877192,0.000047955742,0.0011487005,0.0016402738,0.00025907645,0.00018708293,0.00036302666,0.000011504025],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003784596,0.00010423228,0.022339972,0.0000054721686,0.00003353916,0.000011891772,0.000114503666,6.167337e-8,0.91620314,0.0060699945,0.006640047,0.048439287],"study_design_scores_gemma":[0.0019314716,0.0026497392,0.02554265,0.00022021186,0.000075537704,0.0002701204,0.00141238,0.0000038822004,0.59915954,0.02893941,0.33942688,0.00036819428],"about_ca_topic_score_codex":0.0000011372524,"about_ca_topic_score_gemma":0.0000053292233,"teacher_disagreement_score":0.33278683,"about_ca_system_score_codex":0.000044274184,"about_ca_system_score_gemma":0.00010933109,"threshold_uncertainty_score":0.6043657},"labels":[],"label_agreement":null},{"id":"W2296997770","doi":"10.1016/j.clinthera.2016.02.023","title":"Biosimilars: A Multidisciplinary Perspective","year":2016,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Amgen Canada; Teva Pharmaceutical Industries","keywords":"Biosimilar; Medicine; Pharmacovigilance; Multidisciplinary approach; Intensive care medicine; Pharmacology; Adverse effect; Internal medicine","score_opus":0.1402305023316203,"score_gpt":0.4411171042591477,"score_spread":0.30088660192752736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296997770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40917763,0.04290963,0.07833032,0.36887124,0.021047523,0.0027543707,0.0007183859,0.0019910794,0.0741998],"genre_scores_gemma":[0.97451866,0.00210899,0.0050951503,0.007757757,0.00029290305,0.0000133682415,0.000003054594,0.000042331332,0.010167782],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798447,0.00061080896,0.00051663234,0.0004597559,0.00004045787,0.00038790514],"domain_scores_gemma":[0.99761504,0.0016236193,0.00011467765,0.0004455174,0.0001478897,0.00005324308],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009806433,0.00019227443,0.0003779862,0.000046120258,0.00011861142,0.0000100871475,0.00031129483,0.00053605984,0.0011004674],"category_scores_gemma":[0.0003220598,0.000100807425,0.0003276497,0.00013583609,0.0010286929,0.00005264817,0.00015421814,0.00033187546,0.0005511149],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015021126,0.0024460917,0.070010275,0.000013987109,0.00244259,0.000032306783,0.00040722694,1.3515303e-7,0.29933342,0.03607286,0.014460759,0.57327825],"study_design_scores_gemma":[0.008817505,0.0028956793,0.09073418,0.0001984774,0.00065611734,0.00007376583,0.000987303,0.00003098614,0.09082961,0.063180186,0.7403694,0.0012268091],"about_ca_topic_score_codex":0.0000016915241,"about_ca_topic_score_gemma":0.0000024496724,"teacher_disagreement_score":0.72590864,"about_ca_system_score_codex":0.000045516,"about_ca_system_score_gemma":0.00005438814,"threshold_uncertainty_score":0.99981266},"labels":[],"label_agreement":null},{"id":"W2313241643","doi":"10.4155/bio-2015-0031","title":"Comparison of Blood Microsampling with DBS and Conventional Blood Collection Techniques Used in A Midazolam Biostudy","year":2016,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"","keywords":"Venipuncture; Midazolam; Blood collection; Dried blood; Whole blood; Medicine; Anesthesia; Chemistry; Chromatography; Surgery; Emergency medicine","score_opus":0.02791949676562281,"score_gpt":0.318356737326129,"score_spread":0.2904372405605062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313241643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389195,0.0036821673,0.0014746512,0.00052083365,0.00004059081,0.00021052953,0.000041726562,0.000038098002,0.00009945511],"genre_scores_gemma":[0.99386495,0.00014978816,0.005558397,0.000023813267,0.0000070635965,0.000015850026,0.000008429698,0.000008607339,0.0003630744],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987854,0.00018742011,0.00043408416,0.0003294093,0.000053058244,0.00021063803],"domain_scores_gemma":[0.9992818,0.00023894383,0.00019169037,0.00017071221,0.000093409566,0.000023406827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040823795,0.00015660709,0.00052185537,0.0003398838,0.000080183316,0.000010467004,0.00010245125,0.00021815699,0.00019037753],"category_scores_gemma":[0.00006892725,0.00009446258,0.00010668292,0.00056360743,0.00039376484,0.00004318548,0.000051162275,0.00011290658,0.000002613629],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001052674,0.00046599552,0.45034268,0.000013291221,0.000754007,0.0000014955065,0.000044279514,5.7440605e-8,0.54576784,0.0002002746,0.000019519548,0.0022853054],"study_design_scores_gemma":[0.002264165,0.0005768718,0.057014063,0.00012475505,0.0014791266,0.000020307585,0.00019258141,0.000007523309,0.9372425,0.00010762252,0.00076954655,0.00020093303],"about_ca_topic_score_codex":0.00013352452,"about_ca_topic_score_gemma":0.0003152582,"teacher_disagreement_score":0.3933286,"about_ca_system_score_codex":0.000015403386,"about_ca_system_score_gemma":0.00003225919,"threshold_uncertainty_score":0.3852072},"labels":[],"label_agreement":null},{"id":"W2313540769","doi":"10.1177/171516350613900105","title":"Making the Most of Opportunities in Veterinary Pharmacy","year":2006,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmacy; Veterinary medicine; Business; Medicine; Family medicine","score_opus":0.13946071612484165,"score_gpt":0.33209863140872337,"score_spread":0.19263791528388172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313540769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97727287,0.009893593,0.000059335212,0.0009612295,0.0030721857,0.00033880828,0.00063268153,0.000018759672,0.0077505293],"genre_scores_gemma":[0.99417317,0.002002374,0.00011214964,0.0021415155,0.00024496386,0.000008113363,0.00001925577,0.000026734555,0.0012716964],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997592,0.0004839782,0.0007155725,0.00024775515,0.00010740824,0.0008532998],"domain_scores_gemma":[0.99886256,0.00022767413,0.00026335524,0.00019733755,0.0002331834,0.00021588273],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092094095,0.00028085982,0.00037872794,0.00032296169,0.00050304603,0.000054485106,0.00065965735,0.00007723683,0.0017422703],"category_scores_gemma":[0.00008678236,0.00022596458,0.00012976237,0.00049146166,0.0005587127,0.00016140586,0.00006064145,0.00077486853,0.000004425231],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008852936,0.00031342515,0.01297232,0.00047616486,0.0007908258,0.10146484,0.0012542895,0.0008755095,0.22523533,0.0018150568,0.2678516,0.38606536],"study_design_scores_gemma":[0.0029331937,0.00008257227,0.00028698842,0.000061003226,0.00018958033,0.34291968,0.00006748764,0.0005560516,0.024742594,0.00033165785,0.62719965,0.00062956754],"about_ca_topic_score_codex":0.051530886,"about_ca_topic_score_gemma":0.055381276,"teacher_disagreement_score":0.3854358,"about_ca_system_score_codex":0.00067480083,"about_ca_system_score_gemma":0.0020109152,"threshold_uncertainty_score":0.99917024},"labels":[],"label_agreement":null},{"id":"W2315305182","doi":"10.1136/annrheumdis-2013-eular.1127","title":"THU0599 From Bad to Worse? The Impact of Switching Biologic Agents Multiple Times on Work Productivity and Health-Related Quality of Life for Patients with RA.","year":2013,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Golimumab; Adalimumab; Abatacept; Etanercept; Rheumatoid arthritis; Tocilizumab; Physical therapy; Infliximab; Internal medicine; Cohort; Work productivity; Quality of life (healthcare); Certolizumab pegol; Rheumatology; Productivity; Rituximab; Disease","score_opus":0.0866449699528848,"score_gpt":0.3585350082056694,"score_spread":0.2718900382527846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315305182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943649,0.0012017605,0.000041041352,0.0028409364,0.00008783242,0.0010878724,0.0003583563,0.000008260227,0.000009052333],"genre_scores_gemma":[0.99945986,0.000032806915,0.00017547427,0.00023103002,0.000003839344,0.000027279459,0.000019841431,0.000007238984,0.00004261434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837536,0.0006214764,0.0005267983,0.00020353962,0.0000617512,0.00021104995],"domain_scores_gemma":[0.99746937,0.0013390253,0.0005862884,0.00040546758,0.00014510241,0.000054756114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057803106,0.00015387802,0.000564941,0.000035499404,0.000106443294,0.0000073059437,0.00024751198,0.00007373003,0.000117000855],"category_scores_gemma":[0.0021670249,0.00006347658,0.0001966198,0.00016035755,0.00023854277,0.000044431974,0.00010117927,0.0000864101,0.0000031020588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017527587,0.0014361524,0.9522723,0.0001498452,0.0013549442,1.26438175e-8,0.00048505777,0.000061581864,0.000589926,0.00007200116,0.007674961,0.034150448],"study_design_scores_gemma":[0.00067839294,0.00061264634,0.99503726,0.00035136874,0.000041123516,4.4504247e-8,0.0000796418,0.000018486517,0.0010718814,0.0020205986,0.0000068470026,0.00008172512],"about_ca_topic_score_codex":0.0019491024,"about_ca_topic_score_gemma":0.000016541513,"teacher_disagreement_score":0.042764932,"about_ca_system_score_codex":0.00000749274,"about_ca_system_score_gemma":0.000051214098,"threshold_uncertainty_score":0.29464728},"labels":[],"label_agreement":null},{"id":"W2315805964","doi":"10.1615/jlongtermeffmedimplants.v18.i1.360","title":"Abstract of \"Ethical Challenges with the Development of Biotechnology-Derived Allergy Therapeutics\"","year":2008,"lang":"en","type":"article","venue":"Journal of Long-Term Effects of Medical Implants","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Polytechnique Montréal","funders":"","keywords":"Biotechnology; Commercialization; Quality (philosophy); Government (linguistics); Business; Pharmaceutical industry; Risk analysis (engineering); Medicine; Biology; Marketing","score_opus":0.04138569666678272,"score_gpt":0.31617020327561457,"score_spread":0.27478450660883186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315805964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848137,0.007833215,0.00082253694,0.006069994,0.0002755711,0.00012869065,0.0000032534067,0.0000069331395,0.00004608747],"genre_scores_gemma":[0.99325716,0.005515154,0.00097537274,0.00019864501,0.000031869546,0.00000162509,0.0000013946499,0.000010462918,0.000008333965],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998038,0.00030543143,0.0008623746,0.00014677728,0.00036874562,0.0002786968],"domain_scores_gemma":[0.997079,0.0016320415,0.0008344685,0.00021922527,0.00016531984,0.00006992684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014144438,0.00019040954,0.00079922273,0.00013833548,0.00006839559,0.000001863273,0.0006936013,0.0010454096,0.00011876574],"category_scores_gemma":[0.0003217061,0.00009383952,0.00016120082,0.00010266133,0.0014734396,0.000030799754,0.00011036336,0.001171734,0.0000020184852],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012828048,0.00091802084,0.0018471072,0.00062373275,0.0029931809,0.00042113074,0.0011517502,4.888186e-7,0.8104096,0.0001546268,0.0002448384,0.1799527],"study_design_scores_gemma":[0.0019466401,0.0011412926,0.20759647,0.0008244208,0.000103440536,0.0016743122,0.00008058528,0.000001008321,0.7862208,0.000029288902,0.00027661314,0.000105118466],"about_ca_topic_score_codex":0.0000033710123,"about_ca_topic_score_gemma":0.000020388752,"teacher_disagreement_score":0.20574936,"about_ca_system_score_codex":0.000014147028,"about_ca_system_score_gemma":0.00032017494,"threshold_uncertainty_score":0.8063156},"labels":[],"label_agreement":null},{"id":"W2316442292","doi":"10.1016/j.jid.2016.01.040","title":"A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution","year":2016,"lang":"en","type":"letter","venue":"Journal of Investigative Dermatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Ixekizumab; Medicine; Secukinumab; Immunogenicity; Antibody; Pharmacology; Drug; Monoclonal antibody; Psoriasis; Immunology; Psoriatic arthritis","score_opus":0.03639446385851493,"score_gpt":0.3022155856390985,"score_spread":0.2658211217805836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316442292","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11595357,0.004773936,0.033482414,0.8417357,0.0023273546,0.00073381036,0.00082519854,0.000043728276,0.00012425883],"genre_scores_gemma":[0.39697817,0.0005630593,0.068356775,0.5282302,0.0037118103,0.000018288769,0.00045563918,0.00023605485,0.0014500082],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944421,0.0028394465,0.0012235777,0.0005494048,0.00013235,0.0008131015],"domain_scores_gemma":[0.9943152,0.0023359722,0.001983934,0.00025105788,0.0010088313,0.0001049954],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0012348832,0.0006388718,0.0019546428,0.00052517676,0.00036927516,0.000044856442,0.0003288881,0.0018799715,0.00002942206],"category_scores_gemma":[0.0009777063,0.0004364256,0.00047909658,0.00018417054,0.0024089592,0.00023279032,0.00015046365,0.0029365588,0.0000065839977],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032528146,0.00005895812,0.0002175771,0.0003440551,0.0021417097,0.001323692,0.00072288315,0.000003189663,0.348346,0.00035107898,0.64508235,0.0010832109],"study_design_scores_gemma":[0.0043519405,0.00027982998,0.00081778195,0.0018703202,0.0017194197,0.020913718,0.0005284086,0.00018169369,0.5662167,0.003939751,0.39804187,0.0011385847],"about_ca_topic_score_codex":0.000038760954,"about_ca_topic_score_gemma":0.0000076176484,"teacher_disagreement_score":0.31350553,"about_ca_system_score_codex":0.000108212145,"about_ca_system_score_gemma":0.00037118106,"threshold_uncertainty_score":0.9998087},"labels":[],"label_agreement":null},{"id":"W2317098257","doi":"10.1136/annrheumdis-2012-eular.523","title":"AB0523 Lower than expected levels of DMARD acquisition immediately pre and post biologic initiation in RA patients","year":2012,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Cohort; Rheumatoid arthritis; Internal medicine; Concomitant; Hydroxychloroquine; Biologic Agents; Rheumatology; Coronavirus disease 2019 (COVID-19); Disease","score_opus":0.04458665874057759,"score_gpt":0.312101203567964,"score_spread":0.2675145448273864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317098257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955551,0.003205659,0.000009164849,0.00035738456,0.0002461922,0.0002121038,0.00034948744,0.0000084824405,0.000056435998],"genre_scores_gemma":[0.99941367,0.00017825648,0.000044908895,0.00025055144,0.000007654025,0.000008160552,0.000041424246,0.0000052633254,0.0000501252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989141,0.00035814068,0.00035903492,0.00011043504,0.00004761004,0.00021067544],"domain_scores_gemma":[0.99914575,0.000287118,0.00024508263,0.00017712315,0.00011487798,0.000030037807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025759373,0.00011260188,0.00027686232,0.00007127591,0.00003882358,0.0000041820604,0.00013263924,0.00012618053,0.0002087201],"category_scores_gemma":[0.0006179873,0.00006791077,0.000101617035,0.00013395419,0.00022567873,0.00011629542,0.00009386225,0.000066376866,0.0000048458382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096236856,0.0025281878,0.90112174,0.00037415803,0.0003567987,3.166853e-7,0.0015623186,0.0000017794063,0.028001625,0.00062822975,0.0011070931,0.06335537],"study_design_scores_gemma":[0.0004908757,0.00017941502,0.9781432,0.00022035334,0.00004986794,7.11768e-7,0.00014882119,0.0000022944807,0.020021603,0.0006431116,0.000018572264,0.00008117433],"about_ca_topic_score_codex":0.000029473786,"about_ca_topic_score_gemma":0.0000022361128,"teacher_disagreement_score":0.07702145,"about_ca_system_score_codex":0.000005689715,"about_ca_system_score_gemma":0.000015906313,"threshold_uncertainty_score":0.2769321},"labels":[],"label_agreement":null},{"id":"W2319909929","doi":"10.1136/annrheumdis-2014-eular.2728","title":"FRI0371 A Comparison of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) TRIAL Design: Ways to Improve Positive Trials in Sle","year":2014,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto","funders":"","keywords":"Medicine; Rheumatoid arthritis; Randomized controlled trial; Internal medicine; Clinical trial; Methotrexate; Concomitant; Rheumatology; Hydroxychloroquine; Physical therapy; Disease","score_opus":0.07883867541139963,"score_gpt":0.34628323411167306,"score_spread":0.2674445587002734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319909929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9599813,0.025384078,0.008104392,0.0014648697,0.001960404,0.0025440615,0.00036182237,0.00003352869,0.00016554266],"genre_scores_gemma":[0.9980308,0.0009585431,0.00067032495,0.00017452388,0.000014160856,0.000065482775,0.00000623153,0.000015486592,0.000064465734],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995612,0.0021115937,0.0015114967,0.0003087169,0.00011027897,0.0003458627],"domain_scores_gemma":[0.9944078,0.004164232,0.0007722427,0.00045102896,0.0001264094,0.00007829739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029553564,0.0002473373,0.0018325015,0.00014260493,0.00008903052,0.000021783757,0.00034616503,0.00019600555,0.00007386079],"category_scores_gemma":[0.006198409,0.00015815353,0.00036528287,0.00021512008,0.00031622525,0.00005995904,0.00014383321,0.00014573906,0.000010676454],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12347841,0.007931598,0.015924403,0.0032995502,0.005269977,0.0000071649706,0.0077131866,0.00024225512,0.12073381,0.03723357,0.07486343,0.60330266],"study_design_scores_gemma":[0.11909054,0.013639068,0.011661067,0.027216101,0.001010774,0.00029741763,0.0051346733,0.001954849,0.76478165,0.051254936,0.0017602943,0.0021986447],"about_ca_topic_score_codex":0.000092089474,"about_ca_topic_score_gemma":0.000012333259,"teacher_disagreement_score":0.6440478,"about_ca_system_score_codex":0.000011630465,"about_ca_system_score_gemma":0.000063638305,"threshold_uncertainty_score":0.74205226},"labels":[],"label_agreement":null},{"id":"W2320641439","doi":"10.3821/1913-701x-143.3.134","title":"An Introduction to Biologics and Biosimilars. Part I: Biologics: What are They and Where Do They Come from?","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Biosimilar; Medicine; Internal medicine","score_opus":0.025066765941180146,"score_gpt":0.27738859051507825,"score_spread":0.2523218245738981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320641439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802602,0.0064747217,0.00001812266,0.0052115563,0.0064793597,0.0003206771,0.0011266833,0.000035500096,0.00007319447],"genre_scores_gemma":[0.97455895,0.01719482,0.00064215297,0.005993208,0.0013896858,0.000010398132,0.00005238405,0.000032390704,0.00012602824],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972894,0.00048278604,0.00050038187,0.0007250791,0.00008102346,0.0009213011],"domain_scores_gemma":[0.9976967,0.0001872793,0.00023521006,0.00036122813,0.00032240324,0.0011971627],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009917702,0.0004317148,0.0005295631,0.00025869088,0.00092640443,0.00042185298,0.00053315284,0.0003318807,0.001195854],"category_scores_gemma":[0.00028263286,0.00035204634,0.00008343563,0.00021746152,0.0005037085,0.0004419653,0.00009046054,0.0013100557,0.0000099369645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040883588,0.00012910331,0.033216964,0.000081349644,0.0006155446,0.0042137066,0.0012343649,0.000029774157,0.5839855,0.00025954584,0.08219387,0.29363143],"study_design_scores_gemma":[0.002426443,0.000423893,0.0013263302,0.000053929984,0.00037938557,0.12396442,0.00031627202,0.00011508662,0.030921953,0.002156241,0.83641595,0.0015001198],"about_ca_topic_score_codex":0.0057834783,"about_ca_topic_score_gemma":0.18559043,"teacher_disagreement_score":0.75422204,"about_ca_system_score_codex":0.000269241,"about_ca_system_score_gemma":0.00044806543,"threshold_uncertainty_score":0.9998931},"labels":[],"label_agreement":null},{"id":"W2320750953","doi":"10.5639/gabij.2014.0303.033","title":"Subsequent entry biologics (biosimilars) in Canada: approaches to interchangeability and the extrapolation of indications and uses","year":2014,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Interchangeability; Extrapolation; Business; Medicine; Computer science; Mathematics; Internal medicine","score_opus":0.14093827632215705,"score_gpt":0.2574729309045367,"score_spread":0.11653465458237966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320750953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8827823,0.011968497,0.00794601,0.09509326,0.00049788016,0.0007064041,0.0002455387,0.00001093047,0.0007492256],"genre_scores_gemma":[0.983778,0.002496481,0.0023221725,0.011345522,0.000031245247,0.000010291373,0.000006721511,0.000006218883,0.000003378123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822205,0.000777609,0.00044919297,0.00024536156,0.000059671438,0.00024608918],"domain_scores_gemma":[0.99890256,0.0005982154,0.000228049,0.00012803236,0.00007298473,0.00007018448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015239815,0.00017155948,0.00037055617,0.00012394373,0.00019470441,0.000028987542,0.00013389332,0.00015262565,0.000021016518],"category_scores_gemma":[0.0004557069,0.000102923674,0.000041098694,0.0002104317,0.00068033533,0.000055567987,0.00015297637,0.00036370818,1.5923091e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017265507,0.0004242773,0.7534044,0.0002362489,0.0010095423,0.000011371398,0.007081868,0.000030559815,0.038702358,0.009543218,0.02751872,0.1603109],"study_design_scores_gemma":[0.0050855046,0.0009357042,0.90608007,0.00021249415,0.00033473474,0.0003383326,0.004973345,0.0010640493,0.039301064,0.020833561,0.020099068,0.0007420559],"about_ca_topic_score_codex":0.00062583614,"about_ca_topic_score_gemma":0.025264857,"teacher_disagreement_score":0.15956883,"about_ca_system_score_codex":0.00007367395,"about_ca_system_score_gemma":0.00014925556,"threshold_uncertainty_score":0.9925215},"labels":[],"label_agreement":null},{"id":"W2323198410","doi":"10.1016/j.cyto.2010.07.407","title":"PS3-68 Low volume, highly sensitive immunoassays for detecting cytokines in animal fluids","year":2010,"lang":"en","type":"article","venue":"Cytokine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"PerkinElmer Biosignal","funders":"","keywords":"Medicine; Cytokine; Inflammatory bowel disease; Inflammation; Interleukin 17; Interleukin 23; Crohn's disease; Gastroenterology; Periodontitis; Tumor necrosis factor alpha; Interleukin; Proinflammatory cytokine; Internal medicine; Immunology; Disease","score_opus":0.01314199923928084,"score_gpt":0.2712818165346948,"score_spread":0.25813981729541396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323198410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925919,0.00038523343,0.0019842423,0.0013754277,0.001512272,0.0004515239,0.00020377009,0.0001181255,0.001377459],"genre_scores_gemma":[0.99073464,0.000022262235,0.0066020973,0.0004076191,0.00022846115,0.000037216098,0.000055988065,0.000034585268,0.0018771603],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982455,0.00014871471,0.00044721618,0.00048403812,0.00004620463,0.0006283746],"domain_scores_gemma":[0.99888664,0.0004294731,0.0001068685,0.00034346763,0.00019198857,0.000041581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090161903,0.00027965367,0.00048091362,0.00017366603,0.00019272443,0.000028862149,0.00023798055,0.00065307156,0.0002794337],"category_scores_gemma":[0.0007559482,0.00023638393,0.00018421098,0.00029577775,0.00030917532,0.00009371175,0.00012575986,0.0008171596,0.00011226818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047321166,0.000109161134,0.0023125405,0.000022854612,0.00007086396,0.000013855968,0.00011156548,5.5269817e-7,0.9820647,0.0006190599,0.0010945785,0.013107036],"study_design_scores_gemma":[0.0019281087,0.00046084134,0.02761319,0.00004112396,0.000061165934,0.000088223765,0.00012719484,0.00028679977,0.9069963,0.00023856408,0.061793245,0.00036520275],"about_ca_topic_score_codex":0.000095429896,"about_ca_topic_score_gemma":0.00016587904,"teacher_disagreement_score":0.07506838,"about_ca_system_score_codex":0.000036520076,"about_ca_system_score_gemma":0.000052961994,"threshold_uncertainty_score":0.9639457},"labels":[],"label_agreement":null},{"id":"W2323815622","doi":"10.1136/annrheumdis-2013-eular.731","title":"THU0203 Equal Retention and Drug Survival Between Females and Males Requiring Biologic Therapy for Rheumatoid Arthritis","year":2013,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Etanercept; Adalimumab; Internal medicine; Rheumatoid arthritis; Infliximab; Population; Rheumatology; Survival analysis; Drug; Disease; Pharmacology","score_opus":0.10996718372254957,"score_gpt":0.33125836062105857,"score_spread":0.221291176898509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323815622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96049994,0.03546715,0.0001597555,0.003015184,0.00015194294,0.00048160687,0.00015352975,0.00002628815,0.00004458055],"genre_scores_gemma":[0.98258,0.016716678,0.00029972152,0.00015798263,0.000013373237,0.000041206204,0.000021071844,0.000010490386,0.00015947495],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987282,0.0003507701,0.0003773328,0.00023419151,0.000043013988,0.00026649947],"domain_scores_gemma":[0.9984635,0.0009821047,0.00020269217,0.00022031034,0.000086759,0.000044603574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048731308,0.00016870142,0.00042992923,0.000043805605,0.00020077701,0.00003867393,0.00018242953,0.000111628906,0.000116351184],"category_scores_gemma":[0.00044948526,0.00009910808,0.00016066975,0.00006616844,0.0006243204,0.00011324443,0.00012531887,0.00007707213,0.0000055909745],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002331345,0.00025016116,0.28205374,0.0004162412,0.001046193,3.2968399e-7,0.00034145868,6.454419e-7,0.010024209,0.0077325,0.005273855,0.69262755],"study_design_scores_gemma":[0.0016406578,0.00040625318,0.91106373,0.000907328,0.00007188829,0.000008786561,0.00077151274,0.000029390518,0.01724153,0.06616364,0.0013212262,0.0003740685],"about_ca_topic_score_codex":0.00006381689,"about_ca_topic_score_gemma":0.000005281767,"teacher_disagreement_score":0.6922535,"about_ca_system_score_codex":0.0000024379756,"about_ca_system_score_gemma":0.000015959055,"threshold_uncertainty_score":0.40415102},"labels":[],"label_agreement":null},{"id":"W2324757506","doi":"10.1089/bio.2014.0052","title":"Funding Sources for Canadian Biorepositories: The Role of User Fees and Strategies to Help Fill the Gap","year":2014,"lang":"en","type":"article","venue":"Biopreservation and Biobanking","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Ontario Institute for Cancer Research; CancerCare Manitoba; Canadian Women's Health Network","funders":"Canadian Institutes of Health Research","keywords":"Business; User fee; Quality (philosophy); Best practice; Accounting; Environmental resource management; Management; Economics; Political science","score_opus":0.029361149955614275,"score_gpt":0.27404786938906295,"score_spread":0.24468671943344866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324757506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98566735,0.0024227768,0.00092293933,0.0091573475,0.00028510942,0.00039219085,0.000043963497,0.000019473266,0.0010888525],"genre_scores_gemma":[0.9983322,0.000034429577,0.00056212785,0.0006412241,0.00007749189,0.000013864976,0.0000066941984,0.0000050714984,0.00032687106],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937844,0.000090513066,0.00015533809,0.00015195439,0.000027842158,0.00019591888],"domain_scores_gemma":[0.99941224,0.0002894157,0.000062324565,0.00013563356,0.00007190307,0.000028475612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053716573,0.0000908613,0.00012066915,0.00005346217,0.00045997885,0.00009320012,0.00014903728,0.00011828059,0.000022061726],"category_scores_gemma":[0.00013653685,0.000046661404,0.000031582582,0.00010856619,0.00019697862,0.0000647856,0.000058145135,0.00007002879,9.1397203e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013105736,0.000022984706,0.138818,0.00006871745,0.00018227784,1.3784232e-7,0.0025723549,0.0000036808547,0.6531523,0.16935463,0.0024510098,0.033242855],"study_design_scores_gemma":[0.00030887735,0.00022176107,0.09227797,0.000054110824,0.00007132627,0.000006351342,0.0059383474,0.00018249014,0.13237517,0.0069088354,0.76146996,0.00018478626],"about_ca_topic_score_codex":0.0084300935,"about_ca_topic_score_gemma":0.008079069,"teacher_disagreement_score":0.75901896,"about_ca_system_score_codex":0.000008042814,"about_ca_system_score_gemma":0.000025696365,"threshold_uncertainty_score":0.9981729},"labels":[],"label_agreement":null},{"id":"W2326320320","doi":"10.5639/gabij.2015.0401.009","title":"Health Canada’s perspective on the clinical development of biosimilars and related scientific and regulatory challenges","year":2015,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Perspective (graphical); Regulatory science; Business; Medicine; Computer science; Internal medicine; Pathology","score_opus":0.15669981788227194,"score_gpt":0.3526119372573578,"score_spread":0.19591211937508585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326320320","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3654431,0.14415894,0.00011147054,0.48310456,0.003090831,0.00059222366,0.00014465864,0.000027198663,0.0033269955],"genre_scores_gemma":[0.9533316,0.01263697,0.0037117447,0.030093515,0.00008731461,0.000005166627,0.000007694051,0.000028152946,0.000097845],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758947,0.0008438134,0.000675603,0.00039320727,0.00015510798,0.00034279685],"domain_scores_gemma":[0.99844027,0.00037759054,0.00043901915,0.00017302402,0.00037159433,0.000198495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038417608,0.00022515206,0.0004744995,0.000120576115,0.00068110414,0.000050211787,0.00015201845,0.00021469773,0.000022300543],"category_scores_gemma":[0.00044133601,0.00013705566,0.000055452292,0.00016329868,0.0013007665,0.000055620745,0.00016150769,0.00061418524,6.336227e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006465577,0.0006012478,0.0082795415,0.00009651573,0.0021410822,0.000054778575,0.014028037,0.0000021520225,0.0042167353,0.0073948707,0.85412127,0.10841724],"study_design_scores_gemma":[0.0077817226,0.0049634753,0.3357602,0.0008513947,0.00040972137,0.001835141,0.066248804,0.00010751078,0.030544685,0.023763979,0.52600414,0.0017291899],"about_ca_topic_score_codex":0.00003707498,"about_ca_topic_score_gemma":0.0040201317,"teacher_disagreement_score":0.5878885,"about_ca_system_score_codex":0.00014621008,"about_ca_system_score_gemma":0.0016270148,"threshold_uncertainty_score":0.5588967},"labels":[],"label_agreement":null},{"id":"W2328684823","doi":"10.1136/annrheumdis-2012-eular.1363","title":"AB1369 What is the evidence-based for future policy decisions regarding biologics in sle? A structured review of the literature","year":2012,"lang":"en","type":"review","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Reimbursement; Evidence-based medicine; Intensive care medicine; Evidence-based practice; Alternative medicine; Health care; Economic growth","score_opus":0.17991787852311159,"score_gpt":0.4281669185035638,"score_spread":0.24824903998045222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328684823","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013980588,0.97832584,0.00000846134,0.017418426,0.0010810625,0.0020279821,0.0011042742,0.000008115286,0.000011826605],"genre_scores_gemma":[0.0002210528,0.99412364,0.00012666117,0.005041004,0.0000985448,0.00013039606,0.000047169426,0.000022922093,0.00018863533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955478,0.0023258608,0.0012160445,0.00033922077,0.00013449167,0.00043663388],"domain_scores_gemma":[0.99181867,0.004933723,0.0013677531,0.0015513122,0.00028294994,0.00004556791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015821885,0.00047164512,0.002031996,0.00013203785,0.00020370487,0.00004798755,0.001854236,0.0005904949,0.00013227105],"category_scores_gemma":[0.006754169,0.00016117781,0.0025412436,0.0011259449,0.0005412414,0.00014334646,0.00036003735,0.00053177157,0.0000030422163],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038177783,0.00008847823,0.000015809608,0.04762856,0.00047726167,1.2832801e-7,0.000076087366,2.0527847e-7,0.0000022526915,0.0010735397,0.013062723,0.9375368],"study_design_scores_gemma":[0.00013303231,0.00004245634,0.00016550552,0.47922838,0.0016659285,0.000008542136,0.00005435774,7.061474e-7,0.00006528503,0.0028480145,0.51560676,0.0001810414],"about_ca_topic_score_codex":0.000008518003,"about_ca_topic_score_gemma":0.0000034922657,"teacher_disagreement_score":0.93735576,"about_ca_system_score_codex":0.000028970217,"about_ca_system_score_gemma":0.0004683938,"threshold_uncertainty_score":0.8085859},"labels":[],"label_agreement":null},{"id":"W2329300970","doi":"10.3821/1913-701x-143.4.184","title":"An Introduction to Biologics and Biosimilars. Part II: Subsequent Entry Biologics: Biosame or Biodifferent?","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Biosimilar; Medicine; Internal medicine","score_opus":0.038143750199736266,"score_gpt":0.2922062271496131,"score_spread":0.2540624769498768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329300970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98210454,0.00085628737,0.00005172975,0.0052369586,0.009757811,0.0004475314,0.0013341698,0.000054654254,0.00015631042],"genre_scores_gemma":[0.98226255,0.0036971709,0.0011151745,0.010072174,0.0018974802,0.000019065808,0.00017073908,0.000037524056,0.00072812143],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965786,0.00043695446,0.000701039,0.000813943,0.000105157254,0.0013643502],"domain_scores_gemma":[0.99721485,0.00012642969,0.00023598938,0.0004266507,0.00038280286,0.0016132722],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001052948,0.00053879054,0.00057591056,0.00045539648,0.0014508667,0.00017642912,0.00073592016,0.00038251223,0.0057700356],"category_scores_gemma":[0.00051575527,0.00040665604,0.00012876808,0.0006020955,0.00074218155,0.00022471245,0.000118151394,0.0014606677,0.00001688336],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005472567,0.0001853721,0.0037224279,0.000057408215,0.00036085877,0.004118432,0.00032929666,0.000012945396,0.692306,0.00023437268,0.19117808,0.10694756],"study_design_scores_gemma":[0.0014826177,0.0005991844,0.0001712649,0.0000107562855,0.00019771811,0.15778223,0.000027635124,0.00009648342,0.11916632,0.00015468456,0.71943253,0.0008785484],"about_ca_topic_score_codex":0.002227684,"about_ca_topic_score_gemma":0.05327686,"teacher_disagreement_score":0.57313967,"about_ca_system_score_codex":0.0005404742,"about_ca_system_score_gemma":0.0012667582,"threshold_uncertainty_score":0.9998491},"labels":[],"label_agreement":null},{"id":"W2329699817","doi":"10.1097/mpg.0000000000001149","title":"Time for Personalized Biologic Therapy","year":2016,"lang":"en","type":"letter","venue":"Journal of Pediatric Gastroenterology and Nutrition","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Infliximab; Ulcerative colitis; Inflammatory bowel disease; Dosing; Disease; Crohn's disease; Internal medicine; Vedolizumab; Adalimumab; Clinical trial; Drug; Immunology; Pharmacology","score_opus":0.022543188166109788,"score_gpt":0.26913096006229886,"score_spread":0.24658777189618908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329699817","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051189452,0.034759954,0.0021443756,0.907773,0.0026926994,0.0007632276,0.00061668706,0.00003074179,0.000029863355],"genre_scores_gemma":[0.0042430246,0.085896015,0.006441969,0.85140574,0.04236568,0.0001282407,0.00048472598,0.000119369375,0.008915207],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99803066,0.0005720891,0.00061251223,0.00026858153,0.00004801234,0.0004681134],"domain_scores_gemma":[0.99824977,0.0005932408,0.00076941104,0.000113345784,0.00024333315,0.00003090217],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007060001,0.0002825224,0.00079195097,0.00034111165,0.000099470846,0.000011592906,0.00022553843,0.0014803719,0.00045354257],"category_scores_gemma":[0.00009733938,0.00017212144,0.00043206246,0.000051962717,0.00040801027,0.00006273091,0.00003156263,0.0010160329,0.000017075865],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030356012,0.00011131029,0.00094628107,0.000091733345,0.0003628125,0.000033660544,0.000009841657,4.458769e-9,0.004384721,0.0000069394127,0.98966205,0.0013550702],"study_design_scores_gemma":[0.007649675,0.00711113,0.0003118257,0.000049523045,0.0004993204,0.0008321771,0.0000073486253,3.6801632e-7,0.0002875531,0.001275613,0.98182255,0.00015292526],"about_ca_topic_score_codex":2.889066e-7,"about_ca_topic_score_gemma":9.552104e-8,"teacher_disagreement_score":0.056367233,"about_ca_system_score_codex":0.000028574977,"about_ca_system_score_gemma":0.000033034623,"threshold_uncertainty_score":0.99981594},"labels":[],"label_agreement":null},{"id":"W2333047333","doi":"10.1097/01206501-200606000-00020","title":"PATCH TESTING PATIENTS ON ETANERCEPT","year":2006,"lang":"en","type":"article","venue":"Dermatitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Etanercept; Patch testing; Dermatology; Internal medicine; Contact dermatitis; Immunology; Rheumatoid arthritis; Allergy","score_opus":0.017981115747095214,"score_gpt":0.24492952743104543,"score_spread":0.22694841168395022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333047333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7557337,0.0004877076,0.00057031814,0.0032928588,0.0012056162,0.00028127845,0.00014847818,0.00022909878,0.23805092],"genre_scores_gemma":[0.99219316,0.0000041904677,0.0018183858,0.0035115588,0.000039396065,0.0000054424568,0.000060242313,0.000009039373,0.0023586063],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9993122,0.000104425155,0.00018646357,0.00014907296,0.000029992414,0.0002178269],"domain_scores_gemma":[0.99957883,0.00017373578,0.00005064378,0.00013376444,0.000050849998,0.000012187921],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000073011324,0.00010050818,0.00013388637,0.000038874947,0.00010602865,0.0000136765575,0.0000888284,0.00014423612,0.00094886974],"category_scores_gemma":[0.000097727236,0.000080132566,0.00004593617,0.00011145831,0.000075220516,0.0000311287,0.000027226828,0.00014553766,0.0006179259],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000083901405,0.00041063872,0.3008653,0.00002594843,0.00005016716,0.000015193217,0.00004568508,0.000004340696,0.0062723383,0.0018007059,0.563652,0.1268493],"study_design_scores_gemma":[0.0006515674,0.00015188928,0.73793447,0.000032712353,0.00002211928,0.000014332165,0.00000832346,0.000016394379,0.02949197,0.0011119054,0.23038018,0.00018416511],"about_ca_topic_score_codex":0.00019230071,"about_ca_topic_score_gemma":0.000027564209,"teacher_disagreement_score":0.43706915,"about_ca_system_score_codex":0.000015553898,"about_ca_system_score_gemma":0.0000067949713,"threshold_uncertainty_score":0.9999644},"labels":[],"label_agreement":null},{"id":"W2335213851","doi":"10.3899/jrheum.140717","title":"Arthritis Clinical Trials at a Crossroad","year":2015,"lang":"en","type":"editorial","venue":"The Journal of Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Southlake Regional Health Center; University of Ottawa; University of Toronto; St Joseph's Health Care; Mount Sinai Hospital; Structural Genomics Consortium; Western University","funders":"Coastal Response Research Center, University of New Hampshire","keywords":"Medicine; Clinical trial; Alternative medicine; Population; Clinical research; Intensive care medicine; Internal medicine; Pathology","score_opus":0.09920535094333738,"score_gpt":0.4351547482758436,"score_spread":0.3359493973325062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335213851","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044679223,0.07139214,0.00011755383,0.0017079931,0.92149544,0.00020780416,0.0002050648,0.000019133999,0.00038693624],"genre_scores_gemma":[0.008082991,0.38152742,0.002367233,0.0012459753,0.56998134,0.000021037215,0.00029112614,0.00032038082,0.0361625],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97927946,0.01531204,0.0042961943,0.00029069363,0.00024055521,0.0005810545],"domain_scores_gemma":[0.9643721,0.02933052,0.0044992017,0.00059399166,0.0010795494,0.0001246577],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.048636757,0.0004270402,0.0040863687,0.00017062892,0.00021495557,0.000026934236,0.001245583,0.004036144,0.001371723],"category_scores_gemma":[0.052819062,0.00022494004,0.0011166132,0.0001364343,0.0016990815,0.0000537392,0.00041542447,0.0040117623,0.000416255],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026745542,0.00011682636,0.00044921043,0.000025566576,0.001485138,0.000020288888,0.00007527157,2.4567007e-7,0.00014240062,0.00004250489,0.98058504,0.01438296],"study_design_scores_gemma":[0.0040208735,0.0010914599,0.00002044956,0.00029307892,0.00075126707,0.00420631,0.000053821503,6.00868e-7,0.0001490752,0.001152028,0.98802173,0.00023932362],"about_ca_topic_score_codex":0.00008689473,"about_ca_topic_score_gemma":0.00013688872,"teacher_disagreement_score":0.35151413,"about_ca_system_score_codex":0.00011504032,"about_ca_system_score_gemma":0.0010803504,"threshold_uncertainty_score":0.99954116},"labels":[],"label_agreement":null},{"id":"W2335692146","doi":"10.1159/000443128","title":"Anti-TNFs: Originators and Biosimilars","year":2016,"lang":"en","type":"review","venue":"Digestive Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Comparability; Infliximab; Pharmacovigilance; Health care; Interchangeability; Marketing; Disease; Pharmacology; Drug; Business; Economics; Pathology","score_opus":0.03270455841404569,"score_gpt":0.35078025408758623,"score_spread":0.31807569567354055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335692146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016253627,0.9958849,0.000015675221,0.00015467676,0.0006307454,0.00044442018,0.0021471533,0.000099150275,0.0006070228],"genre_scores_gemma":[0.000036862413,0.99769497,0.000040978564,0.00023940687,0.00007439901,0.000059215632,0.00015410599,0.000049439685,0.0016506005],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781495,0.0004661859,0.00043154822,0.0007335421,0.000047915815,0.00050582504],"domain_scores_gemma":[0.99832296,0.0008721426,0.00024232588,0.00037033562,0.00007223914,0.00012000387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013324864,0.0006050266,0.0019320702,0.00020947993,0.0001670998,0.000037354483,0.00030048896,0.0006538136,0.0006883999],"category_scores_gemma":[0.00039860306,0.00034496916,0.0005225386,0.0002249674,0.00087550876,0.000075496944,0.00019175536,0.00032122634,0.00036338376],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012019895,0.000106563326,0.00064772763,0.001996864,0.00064981554,0.000030195235,0.0000042134493,1.3446823e-9,0.0000082053975,0.00095849734,0.009603355,0.98598254],"study_design_scores_gemma":[0.00023734133,0.00007646205,0.0007153832,0.006382457,0.0016799012,0.000038862705,0.0000078996045,3.098324e-8,0.000026738437,0.00014817191,0.99017715,0.00050960295],"about_ca_topic_score_codex":0.0000020700525,"about_ca_topic_score_gemma":1.7630666e-7,"teacher_disagreement_score":0.9854729,"about_ca_system_score_codex":0.00005468767,"about_ca_system_score_gemma":0.00019007815,"threshold_uncertainty_score":0.9999002},"labels":[],"label_agreement":null},{"id":"W2342581896","doi":"10.1016/j.biologicals.2016.03.006","title":"Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health","year":2016,"lang":"en","type":"review","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Infliximab; Medicine; Public health; Intensive care medicine; Internal medicine; Pathology; Disease","score_opus":0.3128732576127962,"score_gpt":0.5311404830159735,"score_spread":0.21826722540317728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342581896","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010120148,0.99482495,0.00034750215,0.001162961,0.0006212369,0.0014992729,0.00035495698,0.00006838168,0.00010874521],"genre_scores_gemma":[0.008792261,0.9897298,0.0003405392,0.00086536945,0.00011439496,0.00005812127,0.000022140483,0.000030192045,0.000047156995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9870169,0.008679417,0.0021482755,0.0012076378,0.00008271605,0.00086505734],"domain_scores_gemma":[0.98413855,0.013653951,0.0010724976,0.00074501894,0.000113059454,0.0002769289],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0107166255,0.0007517555,0.005522726,0.00029056618,0.00018819253,0.000030649808,0.0007185815,0.0011580536,0.00038404984],"category_scores_gemma":[0.006730298,0.00033669308,0.0012140425,0.00043702888,0.0005248542,0.00006236429,0.0005862455,0.0009222496,0.00019640443],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020557735,0.00019977336,0.00032623575,0.0021419488,0.0005525938,0.0000051581915,0.000004400147,3.0529357e-8,0.00020039824,0.0003969586,0.00043971193,0.9955272],"study_design_scores_gemma":[0.0005557043,0.0043212087,0.005314175,0.028498562,0.00017454562,0.00007162812,0.0000036638603,1.3259428e-7,0.00007344166,0.00013613387,0.9603161,0.0005347115],"about_ca_topic_score_codex":0.000019318437,"about_ca_topic_score_gemma":0.0000010911009,"teacher_disagreement_score":0.9949925,"about_ca_system_score_codex":0.00016691096,"about_ca_system_score_gemma":0.00046465528,"threshold_uncertainty_score":0.9999085},"labels":[],"label_agreement":null},{"id":"W2343568188","doi":"10.1038/nbt.3474","title":"Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars","year":2016,"lang":"en","type":"letter","venue":"Nature Biotechnology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Robustness (evolution); Medicine; Chemistry; Internal medicine; Biochemistry","score_opus":0.011040293627113732,"score_gpt":0.3051033070369849,"score_spread":0.2940630134098712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343568188","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041779303,0.015729854,0.017820204,0.94752413,0.004179444,0.0019454898,0.0082773,0.00017239046,0.00017325708],"genre_scores_gemma":[0.22938792,0.007324534,0.39795005,0.34675473,0.0050626467,0.00030031896,0.0040522367,0.00071288785,0.008454669],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975914,0.00020565478,0.0006958365,0.0008419718,0.00009995042,0.0005652235],"domain_scores_gemma":[0.9972816,0.0009415327,0.0006896094,0.00078576995,0.0002825514,0.000018922885],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00036605127,0.0005028517,0.0013305574,0.0005825133,0.00007772518,0.000006338846,0.00070590316,0.019767543,0.00029690494],"category_scores_gemma":[0.00044246778,0.00032705415,0.00027496216,0.00027115745,0.0013768243,0.0000319405,0.00032811347,0.0039868853,6.545793e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012994015,0.000038766982,0.00006962174,0.0005703871,0.00056821504,0.0000059468825,0.0000036484487,6.789168e-7,0.27558726,0.0011239401,0.6883078,0.033593804],"study_design_scores_gemma":[0.0010250125,0.00065289886,0.0002076579,0.00027801294,0.00031249636,0.00006407349,0.0000075290986,0.00002199352,0.27035224,0.0017751659,0.72496337,0.000339559],"about_ca_topic_score_codex":0.0000021264427,"about_ca_topic_score_gemma":0.0000042195065,"teacher_disagreement_score":0.6007694,"about_ca_system_score_codex":0.000048094043,"about_ca_system_score_gemma":0.000116886695,"threshold_uncertainty_score":0.99991816},"labels":[],"label_agreement":null},{"id":"W2344298048","doi":"10.1016/j.jval.2015.03.974","title":"Canadian Public Reimbursement of Subsequent Entry Biologics (Sebs) / Biosimilars","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Infliximab; Biosimilar; Reimbursement; Formulary; Medicine; Family medicine; Health care; Internal medicine; Disease; Political science","score_opus":0.1314074851867528,"score_gpt":0.3296436078192548,"score_spread":0.19823612263250198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344298048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7152494,0.05616772,0.00038802685,0.20668396,0.006090959,0.0020937847,0.00058481796,0.00016042088,0.012580895],"genre_scores_gemma":[0.99330544,0.0008182275,0.0018647219,0.0035385964,0.000028654862,0.000010220198,0.00004616946,0.000011497975,0.00037648578],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974294,0.0008562258,0.00062078814,0.00030572334,0.00005910863,0.0007288067],"domain_scores_gemma":[0.9990322,0.00012192381,0.00017055323,0.00032254477,0.000097419885,0.0002553785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024148761,0.00016005254,0.000408075,0.00030935675,0.00007172907,0.000008780177,0.00027451437,0.00032824243,0.0002152982],"category_scores_gemma":[0.0003895185,0.00012815821,0.00007338194,0.00040607277,0.00019309379,0.000038342216,0.0000616806,0.00032836548,0.00004007342],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048027004,0.0020488573,0.5377393,0.0006643149,0.0006198277,0.00010433917,0.0020947687,0.0003889373,0.016464626,0.15309891,0.20453785,0.081757985],"study_design_scores_gemma":[0.0037166548,0.0025757884,0.0206564,0.0003471122,0.000040156905,0.00008269189,0.0016930772,0.00035982748,0.021731758,0.009460282,0.9385576,0.0007786144],"about_ca_topic_score_codex":0.09299151,"about_ca_topic_score_gemma":0.021571873,"teacher_disagreement_score":0.73401976,"about_ca_system_score_codex":0.0006304943,"about_ca_system_score_gemma":0.0016205945,"threshold_uncertainty_score":0.99628186},"labels":[],"label_agreement":null},{"id":"W2345015506","doi":"10.18433/j3bc7h","title":"Proceedings of the 10th Canadian Society for Pharmaceutical Sciences, 64th Association of Faculties of Pharmacy of Canada and 18th Pharmaceutical &amp; Biomedical Analysis Annual meetings","year":2007,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Pharmaceutical sciences; Medicine; Family medicine; Pharmacology","score_opus":0.055353792745026796,"score_gpt":0.3926697499226312,"score_spread":0.33731595717760443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345015506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865516,0.003855415,0.00034926855,0.0065727667,0.00084157794,0.00049397955,0.0006419422,0.000008895321,0.00068457937],"genre_scores_gemma":[0.9941673,0.00065618707,0.004004319,0.0008869125,0.00011797505,0.000003014874,0.0000032067348,0.0000109923685,0.00015005433],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99504524,0.00024387379,0.0020420502,0.00046021998,0.0010923385,0.0011162788],"domain_scores_gemma":[0.99447805,0.001809224,0.0016899182,0.0000998581,0.001415784,0.000507172],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.011807378,0.00035486682,0.0011511168,0.00051809597,0.00045438428,0.000028999264,0.0011526584,0.00021877913,0.0003961738],"category_scores_gemma":[0.0012726337,0.00023278737,0.00084291917,0.0027342455,0.0047011403,0.00033516737,0.0002242235,0.00087682094,3.0652268e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010106494,0.0006658174,0.27137533,0.0005476922,0.0028685327,0.0000026645394,0.0010149524,0.000026820182,0.6990176,0.0015804864,0.01092136,0.01096813],"study_design_scores_gemma":[0.0041919844,0.00029825268,0.007070787,0.00010126295,0.003534241,0.000059626982,0.0011336387,0.0018444578,0.7772597,0.00012729717,0.20406651,0.00031226428],"about_ca_topic_score_codex":0.033143647,"about_ca_topic_score_gemma":0.018413104,"teacher_disagreement_score":0.26430455,"about_ca_system_score_codex":0.00025517144,"about_ca_system_score_gemma":0.0022658042,"threshold_uncertainty_score":0.9994983},"labels":[],"label_agreement":null},{"id":"W2368483922","doi":"","title":"New Development of Pharmaceutical Technologies","year":2009,"lang":"en","type":"article","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Pharmaceutical industry; Emerging technologies; Biochemical engineering; Chemistry; Nanotechnology; Pharmacology; Materials science; Medicine; Engineering","score_opus":0.04193995333551561,"score_gpt":0.34411324091510587,"score_spread":0.3021732875795903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2368483922","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10141998,0.026415948,0.52318794,0.05598538,0.0017808188,0.0010000272,0.000010677683,0.0025531554,0.2876461],"genre_scores_gemma":[0.81072104,0.00003528746,0.18252781,0.00041395632,0.000005545508,6.63047e-7,0.0000017736852,0.0000023767332,0.006291543],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994999,0.000020384361,0.00018568277,0.000114865565,0.00001658816,0.0001625882],"domain_scores_gemma":[0.99980444,0.000036341415,0.000025553654,0.00010351708,0.000018620445,0.000011546154],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012299707,0.0000707211,0.0001452795,0.00004581856,0.00003150009,0.000002230399,0.0001375347,0.00017547238,0.001278114],"category_scores_gemma":[0.00004397913,0.00004683324,0.000037491358,0.00010320058,0.000075210155,0.000015972319,0.000035190817,0.000121152974,0.000069894406],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022924776,0.000048079895,0.000087447814,0.0000018118266,0.000026910006,3.7413758e-7,0.000018126739,1.7638122e-8,0.33470443,0.010413055,0.005590077,0.6490867],"study_design_scores_gemma":[0.0002513951,0.000059324433,0.0014755039,0.0000041774856,0.000011038146,0.0000049439705,0.000050433435,9.527761e-7,0.81108874,0.001920701,0.18507312,0.000059692036],"about_ca_topic_score_codex":0.0000010637601,"about_ca_topic_score_gemma":7.3654616e-7,"teacher_disagreement_score":0.70930105,"about_ca_system_score_codex":0.0000073654955,"about_ca_system_score_gemma":0.00004591727,"threshold_uncertainty_score":0.99963486},"labels":[],"label_agreement":null},{"id":"W2388297494","doi":"10.1016/j.cgh.2016.05.010","title":"Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results","year":2016,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary; Dalhousie University","funders":"","keywords":"Medicine; Interpretation (philosophy); Antibody; Tumor necrosis factor alpha; Pathology; Internal medicine; Immunology","score_opus":0.05960277583349324,"score_gpt":0.36382989532633325,"score_spread":0.30422711949284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2388297494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873227,0.00039533206,0.010217161,0.0013003456,0.00029790276,0.00021933964,0.00022344416,0.00000971723,0.0000140549755],"genre_scores_gemma":[0.9957808,0.00032139142,0.0034514132,0.00037931735,0.000014581655,0.0000080807795,0.000012763212,0.000005947885,0.000025653711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980491,0.00045962038,0.00085077545,0.0003758224,0.000015758324,0.00024894634],"domain_scores_gemma":[0.9971321,0.0021695592,0.00039326417,0.00013021518,0.00013057956,0.00004423563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063493784,0.0001334087,0.0006796983,0.000054719258,0.000058964848,0.000003226302,0.000077659264,0.00029765154,0.000012782424],"category_scores_gemma":[0.001369101,0.00008659627,0.00006801678,0.000034189306,0.0017618896,0.000040345698,0.00009870042,0.00012931983,5.3342524e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023369286,0.00011502544,0.864776,0.00006469712,0.0001482036,0.0000012045189,0.00004119872,3.4125208e-8,0.116293736,0.00058100116,0.00006182931,0.015580095],"study_design_scores_gemma":[0.0070898714,0.0060473797,0.97174466,0.0001313767,0.00023065221,0.0001225053,0.00006129099,0.00032545885,0.01264658,0.0010826034,0.00038765298,0.0001299837],"about_ca_topic_score_codex":0.0000118254475,"about_ca_topic_score_gemma":0.00001534186,"teacher_disagreement_score":0.1069686,"about_ca_system_score_codex":0.0000038340777,"about_ca_system_score_gemma":0.000024367358,"threshold_uncertainty_score":0.6491755},"labels":[],"label_agreement":null},{"id":"W2396704791","doi":"10.1016/j.jval.2016.03.1129","title":"COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; Southlake Regional Health Center; Montreal Clinical Research Institute; Centre Hospitalier Universitaire de Sherbrooke; Amgen (Canada)","funders":"","keywords":"Adalimumab; Medicine; Etanercept; Infliximab; Rheumatoid arthritis; Internal medicine; Gastroenterology; Tumor necrosis factor alpha","score_opus":0.06546985798292254,"score_gpt":0.33879417816226476,"score_spread":0.2733243201793422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396704791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973099,0.0011132625,0.0005253956,0.0002939921,0.000041037252,0.0005385984,0.000119627715,0.000017477501,0.000040679915],"genre_scores_gemma":[0.9960255,0.0008460449,0.0030005854,0.00003158692,0.000007146386,0.000012125367,0.00005627862,0.000010847205,0.000009868118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801826,0.00063967134,0.00072799163,0.00027529622,0.0000653917,0.00027337074],"domain_scores_gemma":[0.99837416,0.00080519065,0.00052103144,0.00016743457,0.0000882568,0.000043897642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004365865,0.00017966615,0.00068167207,0.0001322956,0.00007288146,0.0000044464346,0.00006117795,0.00020210407,0.000044573102],"category_scores_gemma":[0.00009472384,0.00008991236,0.000029629166,0.00021093065,0.00028753545,0.000078378594,0.000027887465,0.00011187526,0.0000018553567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009229589,0.00032198304,0.7745377,0.000042042782,0.000061793806,3.8118876e-7,0.00036345248,0.000015014676,0.0011625951,0.00013821266,0.000004621537,0.22242928],"study_design_scores_gemma":[0.012015925,0.011447867,0.96657497,0.0018519394,0.000030337049,0.000005612847,0.00023655395,0.00013566912,0.007179897,0.00010261337,0.0001856174,0.00023302247],"about_ca_topic_score_codex":0.00076526444,"about_ca_topic_score_gemma":0.00020232974,"teacher_disagreement_score":0.22219625,"about_ca_system_score_codex":0.00014088105,"about_ca_system_score_gemma":0.00011595991,"threshold_uncertainty_score":0.36665198},"labels":[],"label_agreement":null},{"id":"W2397751589","doi":"10.1093/jn/134.7.1844","title":"Comments on Use of Combined Measures from Capillary Blood to Assess Iron Deficiency in Rural Kenyan Children","year":2004,"lang":"en","type":"letter","venue":"Journal of Nutrition","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Dried blood spot; Sample (material); Iron deficiency; Medicine; Kenya; Filter paper; Chromatography; Chemistry; Internal medicine; Biology","score_opus":0.0485092082344069,"score_gpt":0.28547580552329266,"score_spread":0.23696659728888575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397751589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8315737,0.0030153724,0.00009544734,0.16324076,0.0010961705,0.00049862807,0.00043105264,0.000010234278,0.00003858636],"genre_scores_gemma":[0.7026025,0.002287146,0.006207318,0.28623617,0.0013863199,0.000014785089,0.0010206455,0.00008275067,0.00016235543],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9979339,0.0005908332,0.00083081104,0.00018876107,0.00017009642,0.00028554894],"domain_scores_gemma":[0.99866223,0.00033310006,0.0005841416,0.00021203078,0.00017623538,0.00003228572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003433913,0.00025529435,0.00075199135,0.00045152468,0.00004716372,0.000025420673,0.00031230476,0.0010154794,0.00008389512],"category_scores_gemma":[0.00015195592,0.0002028553,0.00026179792,0.0001740164,0.00010080093,0.00009189504,0.00004615583,0.0017311192,0.0000073477536],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018007517,0.00647926,0.016298002,0.00023898263,0.00072268484,0.0003275351,0.0001132876,0.0000151034465,0.17049262,0.00004348043,0.801053,0.0024153057],"study_design_scores_gemma":[0.04447156,0.021157648,0.4122261,0.016953388,0.0035850105,0.0012037441,0.00019203547,0.0000016772273,0.33482155,0.0064031496,0.156661,0.0023231052],"about_ca_topic_score_codex":0.00019080995,"about_ca_topic_score_gemma":0.000014335718,"teacher_disagreement_score":0.644392,"about_ca_system_score_codex":0.00012548383,"about_ca_system_score_gemma":0.000057120575,"threshold_uncertainty_score":0.8272199},"labels":[],"label_agreement":null},{"id":"W2398081229","doi":"10.1016/j.jval.2016.03.1155","title":"SUBCUTANEOUS TOCILIZUMAB: A COST-MINIMIZATION ANALYSIS BASED ON THE POPULATION OF QUEBEC","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Tocilizumab; Medicine; Population; Formulary; Cost-minimization analysis; Tofacitinib; Internal medicine; Pharmacology; Rheumatoid arthritis; Environmental health","score_opus":0.042142510521503945,"score_gpt":0.30883726459955646,"score_spread":0.26669475407805254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398081229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.869479,0.0014197599,0.030575857,0.09367566,0.0009064786,0.0024066272,0.00031048665,0.00011626938,0.0011098516],"genre_scores_gemma":[0.99826264,0.00003963421,0.0003983666,0.000831369,0.000008218371,0.000009901894,0.000018561339,0.000005036161,0.0004262676],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99822676,0.0009637742,0.00038568382,0.00018082066,0.00004647635,0.00019646477],"domain_scores_gemma":[0.99845207,0.0010697705,0.00017177562,0.00025209328,0.00003675029,0.000017563316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079573755,0.000083603314,0.00026239263,0.0001818546,0.000059289305,0.0000033871445,0.00010180587,0.00013389018,0.00043515422],"category_scores_gemma":[0.0003362617,0.000042491647,0.000095975694,0.0005132277,0.00008318828,0.00001719066,0.000012103079,0.00009329771,0.000011326674],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038337936,0.0015163164,0.3722824,0.00030095622,0.0010229447,0.000015371674,0.0007565964,0.022839382,0.014502222,0.10487632,0.003671115,0.47438258],"study_design_scores_gemma":[0.0060999673,0.003739061,0.8711254,0.0010617684,0.0006722045,0.000021948501,0.00026517778,0.071012765,0.020802487,0.0070681907,0.01720027,0.0009307687],"about_ca_topic_score_codex":0.014986895,"about_ca_topic_score_gemma":0.0027744267,"teacher_disagreement_score":0.49884298,"about_ca_system_score_codex":0.00013923847,"about_ca_system_score_gemma":0.00008755968,"threshold_uncertainty_score":0.9915724},"labels":[],"label_agreement":null},{"id":"W2398661632","doi":"10.1016/j.yrtph.2016.05.034","title":"Advantages of using an abbreviated dossier for drug master file applications in Taiwan","year":2016,"lang":"en","type":"article","venue":"Regulatory Toxicology and Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada","keywords":"Certification; Library science; Computer science; Medicine; Family medicine; Political science","score_opus":0.03862957217481222,"score_gpt":0.3479942009354864,"score_spread":0.30936462876067417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398661632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993549,0.0021318318,0.001414327,0.0010200787,0.00039441988,0.0007406829,0.0006141018,0.000030191655,0.00010538588],"genre_scores_gemma":[0.9957277,0.00007860564,0.0019674418,0.0005637712,0.00006631765,0.00015105287,0.000043994383,0.000017582772,0.0013834871],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99843264,0.00045305584,0.0003750816,0.00036302055,0.000016811568,0.00035937745],"domain_scores_gemma":[0.99902564,0.0005491186,0.00015361795,0.00016283088,0.00005976155,0.00004901203],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000442822,0.00016917917,0.0004273885,0.00015563791,0.00010469591,0.0000022922216,0.00015511627,0.00040946723,0.0056853374],"category_scores_gemma":[0.00002853397,0.000116390285,0.00006912247,0.00013256408,0.00078302965,0.000086619344,0.000064439155,0.00013820344,0.000005017339],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028259202,0.00029647705,0.00821061,0.000049422393,0.000108178596,0.0000014743363,0.00008531799,0.0000017807337,0.97615767,0.001315434,0.0029902817,0.010500758],"study_design_scores_gemma":[0.005763364,0.0005754361,0.052478652,0.000051979463,0.00030670126,0.000058920625,0.00021933657,0.00009368397,0.7563944,0.0026483042,0.18096538,0.00044385702],"about_ca_topic_score_codex":0.0000027639446,"about_ca_topic_score_gemma":0.000015543625,"teacher_disagreement_score":0.2197633,"about_ca_system_score_codex":0.000033585166,"about_ca_system_score_gemma":0.000060165898,"threshold_uncertainty_score":0.9952236},"labels":[],"label_agreement":null},{"id":"W2402339939","doi":"","title":"State of Pharmaceutical Research and Development in Canada. Bioequivalence of Drug Products with Special Characteristics. Report of the February 13-14, 1998 Canadian Society for Pharmaceutical Sciences Symposium.","year":2000,"lang":"en","type":"other","venue":"PubMed","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Bioequivalence; Pharmaceutical sciences; Pharmaceutical drug; Drug; Medicine; Pharmacology; Pharmacokinetics","score_opus":0.07050487294175384,"score_gpt":0.3214421824816812,"score_spread":0.2509373095399274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402339939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8423231,0.019053247,0.000023193319,0.020109044,0.0066520274,0.01908679,0.008095746,0.000053130494,0.08460372],"genre_scores_gemma":[0.88663405,0.003365198,0.004350361,0.00061045785,0.00056010473,0.0008828267,0.00014457238,0.00023728084,0.103215165],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979507,0.00019024852,0.00052854116,0.00044816567,0.00019431608,0.00068805186],"domain_scores_gemma":[0.9991181,0.00024116297,0.00023741546,0.00021470127,0.00009439778,0.000094228926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016915257,0.00018964264,0.000505109,0.000166705,0.00009290647,0.0000066576345,0.0003682833,0.00015941278,0.00009694123],"category_scores_gemma":[0.0001143509,0.0001222487,0.00004737832,0.00040206834,0.002316664,0.000017565117,0.000099217774,0.00042739933,2.7841853e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021329476,0.0010131582,0.16632734,0.0056167087,0.0025161111,0.00013540145,0.0012891457,0.0000018685963,0.0094330935,0.00021657033,0.45542836,0.3558893],"study_design_scores_gemma":[0.0010348991,0.000062670726,0.10798048,0.00029735485,0.000114816794,0.000063761014,0.0000752509,0.0000032762873,0.11076083,0.000022077807,0.77926946,0.00031510415],"about_ca_topic_score_codex":0.45435834,"about_ca_topic_score_gemma":0.82276297,"teacher_disagreement_score":0.36840466,"about_ca_system_score_codex":0.00016584383,"about_ca_system_score_gemma":0.00432609,"threshold_uncertainty_score":0.85358447},"labels":[],"label_agreement":null},{"id":"W2406104579","doi":"10.18433/j3rg78","title":"Modifications of the Method for Calculating Absolute Drug Bioavailability","year":2016,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Absolute (philosophy); Bioavailability; Drug; Chemistry; Pharmacology; Medicine; Philosophy","score_opus":0.12723839910721263,"score_gpt":0.45327085947045376,"score_spread":0.32603246036324113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406104579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66062003,0.0118725635,0.17947973,0.137766,0.005916536,0.0014141893,0.0002927722,0.00004997587,0.0025881683],"genre_scores_gemma":[0.97451097,0.00015570583,0.024184152,0.00059936155,0.00009429182,0.0000030082053,1.15069334e-7,0.0000053630433,0.00044704942],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800324,0.0005981614,0.00071620406,0.00020779822,0.00014113102,0.00033348837],"domain_scores_gemma":[0.9970459,0.0019974164,0.00045004007,0.00014109169,0.00029283084,0.00007272385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004309714,0.00012308215,0.00029354883,0.00007243207,0.00028793642,0.000014522925,0.0007115504,0.000054631775,0.0005987707],"category_scores_gemma":[0.000952825,0.00005245245,0.0003606241,0.00037344682,0.0013692381,0.000165104,0.00010689576,0.00023160606,0.0000054695506],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012300166,0.00014198424,0.00254288,0.000020366731,0.00008496716,2.676249e-7,0.00005497104,0.000007552714,0.8661975,0.0021418205,0.0022613667,0.12642331],"study_design_scores_gemma":[0.0014602342,0.000071062605,0.001188929,0.000047224567,0.00020765289,0.000041214684,0.00005366407,0.0013426464,0.791771,0.0017675395,0.2019487,0.000100157755],"about_ca_topic_score_codex":0.000011136392,"about_ca_topic_score_gemma":0.0000015645684,"teacher_disagreement_score":0.3138909,"about_ca_system_score_codex":0.000038984053,"about_ca_system_score_gemma":0.00016849121,"threshold_uncertainty_score":0.65561193},"labels":[],"label_agreement":null},{"id":"W2407069932","doi":"10.1016/j.jval.2015.09.1616","title":"Biosimilar Substitution Policies: An Overview","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Interchangeability; Legislation; European union; Medicine; Public economics; Business; International trade; Political science; Law; Economics; Engineering","score_opus":0.25185676392897954,"score_gpt":0.41127787069361604,"score_spread":0.1594211067646365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2407069932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7331237,0.20823574,0.0014705877,0.04393826,0.0053884923,0.0015513023,0.0001729912,0.0004562247,0.0056626555],"genre_scores_gemma":[0.97969955,0.0038092637,0.00479299,0.010884573,0.00014036433,0.000015548729,0.000054660002,0.000023850156,0.0005791828],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808145,0.00084741786,0.0003664202,0.00024784586,0.00004295558,0.00041392635],"domain_scores_gemma":[0.9994246,0.0000781907,0.00008216423,0.000269615,0.000041240954,0.00010420676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016793648,0.00012224843,0.0002909202,0.00012062832,0.000073567564,0.000010356987,0.00016342252,0.00021261242,0.00010570501],"category_scores_gemma":[0.00018160047,0.000098833014,0.000045178687,0.00030779224,0.0001465141,0.00008290234,0.000039043025,0.00024603985,0.00010273652],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011531346,0.0032454017,0.050241612,0.0010110285,0.00022466849,0.00004864811,0.0071270545,0.001573109,0.016953161,0.7797058,0.05680639,0.08190997],"study_design_scores_gemma":[0.003360177,0.0020488407,0.020087218,0.00041187558,0.000030182093,0.00011941395,0.00083020394,0.0012084577,0.01160853,0.0172926,0.9423724,0.0006300909],"about_ca_topic_score_codex":0.0036699867,"about_ca_topic_score_gemma":0.000083703344,"teacher_disagreement_score":0.885566,"about_ca_system_score_codex":0.00015604323,"about_ca_system_score_gemma":0.0002799557,"threshold_uncertainty_score":0.55479467},"labels":[],"label_agreement":null},{"id":"W2407561517","doi":"","title":"Biomarker World Congress 2005.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Biomarker; Drug development; Biomarker discovery; Personalized medicine; Engineering ethics; Data science; Medicine; Computer science; Drug; Engineering; Bioinformatics; Pharmacology; Biology; Proteomics","score_opus":0.041447070748195175,"score_gpt":0.27401598685776685,"score_spread":0.23256891610957167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2407561517","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.095700525,0.03738009,0.0007698655,0.103545465,0.0168419,0.00319579,0.00024704717,0.0010514598,0.74126786],"genre_scores_gemma":[0.8182805,0.00005167536,0.0007671544,0.0022429123,0.00012490565,0.00024607856,0.000010698668,0.000013430732,0.17826264],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892217,0.000121813515,0.00018957825,0.0002171108,0.000023692914,0.00052562554],"domain_scores_gemma":[0.99952495,0.00015510619,0.000045422814,0.00020014586,0.000024348157,0.000050041257],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004603673,0.00011531855,0.00017679243,0.00009966056,0.00006879498,0.000016157677,0.00016607848,0.00014842195,0.0023635083],"category_scores_gemma":[0.000098828816,0.00008623985,0.000084524734,0.00014390309,0.00020197842,0.00005556217,0.00005909018,0.00016635087,0.000389192],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007593943,0.000101868645,0.0022623865,0.000004150908,0.00014732729,0.0000026379223,0.000004982112,1.8249679e-7,0.0026686948,0.0013295398,0.2293263,0.764076],"study_design_scores_gemma":[0.00046091582,0.0000039740694,0.10577058,0.000002159964,0.00003102987,0.000011126729,0.0000039301626,0.0000035118471,0.029229058,0.00007180009,0.8642948,0.000117104624],"about_ca_topic_score_codex":0.0000063139246,"about_ca_topic_score_gemma":0.00008458925,"teacher_disagreement_score":0.7639589,"about_ca_system_score_codex":0.000029523453,"about_ca_system_score_gemma":0.000008310306,"threshold_uncertainty_score":0.99854845},"labels":[],"label_agreement":null},{"id":"W2408973406","doi":"10.1136/ejhpharm-2016-000875.343","title":"DI-077 Effectiveness and safety of biosimilar infliximab in ulcerative colitis","year":2016,"lang":"en","type":"article","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Infliximab; Medicine; Ulcerative colitis; Biosimilar; Azathioprine; Concomitant; Internal medicine; Adverse effect; Inflammatory bowel disease; Mercaptopurine; Retrospective cohort study; Surgery; Disease","score_opus":0.012906500439972596,"score_gpt":0.2779384932599088,"score_spread":0.2650319928199362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2408973406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98083967,0.00090707344,0.0047186534,0.0021725548,0.00029494986,0.0005890519,0.00015487889,0.00004314417,0.010280046],"genre_scores_gemma":[0.99865353,0.00023937543,0.0003732938,0.00013921928,0.0000059086897,0.000009912363,0.0000015080433,0.00000587083,0.0005713988],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99875236,0.0005377508,0.00024531563,0.0002309291,0.000019637986,0.00021400223],"domain_scores_gemma":[0.9988596,0.00088501716,0.000049034054,0.00013613056,0.000050232462,0.000019978166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005575425,0.00012105795,0.00033804716,0.000078252844,0.00003498259,0.000003204948,0.000079680256,0.00022501811,0.00057069375],"category_scores_gemma":[0.00017706273,0.00006716323,0.000047530575,0.0001236602,0.00045598162,0.00005789269,0.0000804439,0.00009254791,0.00001216468],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031021028,0.0002578691,0.08786613,0.00009009551,0.00024617347,0.000007787144,0.00015746134,2.0886783e-7,0.7467443,0.03799791,0.00038123602,0.12314873],"study_design_scores_gemma":[0.002731768,0.00024029615,0.55392057,0.00012224361,0.0000177285,0.000010143364,0.000041004398,0.0000016406929,0.43728548,0.001279028,0.0042261016,0.00012401209],"about_ca_topic_score_codex":0.000041641695,"about_ca_topic_score_gemma":0.000097111624,"teacher_disagreement_score":0.4660544,"about_ca_system_score_codex":0.00002839394,"about_ca_system_score_gemma":0.000022391243,"threshold_uncertainty_score":0.62486964},"labels":[],"label_agreement":null},{"id":"W2410405443","doi":"10.1021/acs.analchem.6b01190","title":"Hematocrit-Independent Quantitation of Stimulants in Dried Blood Spots: Pipet versus Microfluidic-Based Volumetric Sampling Coupled with Automated Flow-Through Desorption and Online Solid Phase Extraction-LC-MS/MS Bioanalysis","year":2016,"lang":"en","type":"article","venue":"Analytical Chemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency; Partnership for Clean Competition","keywords":"Bioanalysis; Chromatography; Chemistry; Dried blood spot; Dried blood; Pipette; Whole blood; Blood sampling; Sample preparation; Solid phase extraction; Hematocrit; Microfluidics; Sampling (signal processing); Extraction (chemistry); Biomedical engineering; Analytical Chemistry (journal); Nanotechnology; Computer science; Surgery; Materials science","score_opus":0.0434164969134294,"score_gpt":0.37233420844782744,"score_spread":0.328917711534398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410405443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96802723,0.0013564394,0.02971438,0.0003365139,0.000064447246,0.0001653067,0.0001942799,0.00009654366,0.000044856184],"genre_scores_gemma":[0.9928067,0.0003253544,0.0063807773,0.000048301405,0.000028688584,0.000008816518,0.00024163458,0.000022984972,0.00013674628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793804,0.00010170934,0.0007627373,0.00059794023,0.0001534274,0.00044616152],"domain_scores_gemma":[0.9981734,0.0009121367,0.00026042905,0.00033696464,0.00023134552,0.00008569097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041461093,0.00030887767,0.0007053618,0.00019934228,0.00008416634,0.000023612045,0.0001653089,0.0004747501,0.0006297736],"category_scores_gemma":[0.0006947695,0.00022311173,0.00014762228,0.0008282308,0.00044152257,0.00012618989,0.00004434487,0.00029692592,0.000009730219],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002342163,0.0016207854,0.0043109506,0.00014990683,0.0007207082,0.000030891028,0.00001789663,0.000053228963,0.98907495,0.000020018735,0.00007331742,0.0015852166],"study_design_scores_gemma":[0.01962947,0.0005846913,0.0037286386,0.0003912549,0.0017614638,0.00005702312,0.00016981675,0.05782691,0.9150137,0.000064911714,0.0002274847,0.0005446493],"about_ca_topic_score_codex":0.00014933135,"about_ca_topic_score_gemma":0.000037934024,"teacher_disagreement_score":0.07406123,"about_ca_system_score_codex":0.00009237636,"about_ca_system_score_gemma":0.000114939605,"threshold_uncertainty_score":0.90982324},"labels":[],"label_agreement":null},{"id":"W2410869977","doi":"10.7326/acpjc-2007-147-2-042","title":"Review: The addition of infliximab and etanercept to methotrexate was effective in the long term for rheumatoid arthritis","year":2007,"lang":"en","type":"article","venue":"ACP Journal Club","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Etanercept; Infliximab; Rheumatoid arthritis; Methotrexate; Biosimilar; Term (time); Internal medicine; Physical therapy; Tumor necrosis factor alpha","score_opus":0.01830174818551942,"score_gpt":0.3324890799910284,"score_spread":0.31418733180550895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410869977","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47589228,0.47750363,0.014688392,0.02587288,0.0010486717,0.0035160105,0.00012222958,0.00002147145,0.0013344359],"genre_scores_gemma":[0.8970744,0.08887821,0.0019957146,0.01175793,0.00010164575,0.000055371176,0.000013929188,0.000016411479,0.00010636441],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856013,0.0006388076,0.00039407567,0.00012555452,0.00004089154,0.00024052347],"domain_scores_gemma":[0.9979077,0.0016690652,0.00016461688,0.00014363474,0.00009034689,0.000024657167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047069397,0.000110305074,0.0002986274,0.00006739306,0.0001595941,0.000015953454,0.00019380247,0.00011892742,0.00010574966],"category_scores_gemma":[0.00075696816,0.00005424105,0.00011538088,0.00017254167,0.00016177914,0.000053449192,0.000041630225,0.00042162975,0.00000516625],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044892033,0.000102183076,0.0013037327,0.0001276572,0.00017652182,0.000016047923,0.00088771095,3.4387736e-7,0.034791537,0.0003982446,0.027370038,0.9343771],"study_design_scores_gemma":[0.00618275,0.0031186184,0.3564571,0.007639243,0.00034085475,0.0059700334,0.0011705693,0.000004988141,0.13820483,0.006035985,0.47421965,0.00065536203],"about_ca_topic_score_codex":0.000007781097,"about_ca_topic_score_gemma":0.00006975352,"teacher_disagreement_score":0.9337217,"about_ca_system_score_codex":0.000018143743,"about_ca_system_score_gemma":0.000011903652,"threshold_uncertainty_score":0.22118858},"labels":[],"label_agreement":null},{"id":"W2411053118","doi":"10.2533/chimia.2010.91","title":"Biotech Research: Bringing Better Therapies to the People The Olten Meeting 2009","year":2010,"lang":"en","type":"article","venue":"CHIMIA International Journal for Chemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Biotechnology; Political science; Engineering ethics; Medicine; Library science; Engineering; Biology; Computer science","score_opus":0.04241733087109759,"score_gpt":0.3717437234873384,"score_spread":0.3293263926162408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411053118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8342189,0.0007752289,0.00087631494,0.155976,0.0041669975,0.00023385024,0.00006744931,0.000030723306,0.0036545102],"genre_scores_gemma":[0.98878783,0.000069324706,0.0022649013,0.0018717331,0.0019366276,0.000026154736,0.000011696064,0.000019633077,0.0050121206],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990187,0.00007884391,0.0002414401,0.00018016672,0.00014178063,0.0003390435],"domain_scores_gemma":[0.9986651,0.0006163863,0.00008942475,0.0002126928,0.00037772357,0.000038692426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020625156,0.0001151,0.00011596897,0.00004539897,0.0006725949,0.0001849976,0.0011157115,0.00018195952,0.0007755766],"category_scores_gemma":[0.00096367055,0.00005905511,0.0001658163,0.000112537826,0.00018818266,0.00004349444,0.0001964866,0.001439672,0.000036040958],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075886484,0.000029836172,0.00045708247,0.000004765645,0.00024211583,0.0000020041193,0.00044385783,0.0000035720675,0.9531156,0.0001478792,0.031608377,0.013869041],"study_design_scores_gemma":[0.00033357128,0.00002433605,0.0020221802,0.000041083025,0.00002084089,0.00034743026,0.0005397798,0.000056308934,0.43133175,0.001249851,0.56392115,0.00011171519],"about_ca_topic_score_codex":0.00001532215,"about_ca_topic_score_gemma":0.000024488892,"teacher_disagreement_score":0.53231275,"about_ca_system_score_codex":0.000032852946,"about_ca_system_score_gemma":0.000047882495,"threshold_uncertainty_score":0.84920204},"labels":[],"label_agreement":null},{"id":"W2411663029","doi":"","title":"BioPartnering North America--Programs from Pharma in Europe and the Middle East.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"British Columbia Centre on Substance Use","funders":"","keywords":"Middle East; Political science; Library science; Geography; Ancient history; Medicine; History; Law; Computer science","score_opus":0.053843753373642736,"score_gpt":0.245554812450633,"score_spread":0.19171105907699026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411663029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938032,0.0012443506,0.000033912536,0.0020952872,0.000699997,0.0003463958,0.000016532505,0.000037663976,0.0017226432],"genre_scores_gemma":[0.9982696,0.0000928469,0.00031229825,0.0005905149,0.00006054463,0.00018983753,0.000016163554,0.000008634597,0.00045952556],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99908197,0.00018002957,0.00016955115,0.00022022828,0.000020811556,0.00032743005],"domain_scores_gemma":[0.9995341,0.00017546663,0.000048839407,0.00018298789,0.000023913393,0.000034721907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000310534,0.000107856926,0.00019851547,0.000031554653,0.00006494334,0.000028096441,0.00017986169,0.000088907094,0.00009519658],"category_scores_gemma":[0.00022407049,0.00006298087,0.000037236976,0.00024109031,0.00064961554,0.0000355241,0.00011813989,0.00042462366,0.00002847948],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026277287,0.00010310063,0.03816341,0.000004626261,0.00009068186,0.0000071559725,0.00030466466,1.5459435e-7,0.007842757,0.00028169478,0.00025598583,0.952683],"study_design_scores_gemma":[0.003238685,0.00002452035,0.58176357,0.000005701575,0.00007675637,0.000017241142,0.00013559315,0.000049012815,0.004535308,0.00019325025,0.40971747,0.00024288059],"about_ca_topic_score_codex":0.00018099713,"about_ca_topic_score_gemma":0.00026070923,"teacher_disagreement_score":0.95244014,"about_ca_system_score_codex":0.0000033087288,"about_ca_system_score_gemma":0.0000059333884,"threshold_uncertainty_score":0.25682855},"labels":[],"label_agreement":null},{"id":"W2413901462","doi":"","title":"Cost-effectiveness estimates reported for tumor necrosis factor blocking agents in rheumatoid arthritis refractory to methotrexate--a brief summary.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Rheumatoid arthritis; Tumor necrosis factor α; Methotrexate; Refractory (planetary science); Tumor necrosis factor alpha; Intensive care medicine; Blocking (statistics); Internal medicine","score_opus":0.09780772954519465,"score_gpt":0.3418194651569669,"score_spread":0.24401173561177222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413901462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98390776,0.003941628,0.003046583,0.001254404,0.0014162624,0.0052923015,0.000339333,0.00022900765,0.00057270896],"genre_scores_gemma":[0.98946345,0.0002278203,0.0050479877,0.00077818596,0.000044547378,0.0038373307,0.000059587826,0.000046104968,0.0004949688],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99736,0.00038540683,0.00064235943,0.0006475441,0.00006296533,0.0009017087],"domain_scores_gemma":[0.9977781,0.001433169,0.00020014406,0.00035590702,0.000110389396,0.00012227202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014664382,0.00030586275,0.0006777022,0.00022724434,0.00014386623,0.00004966793,0.00024737805,0.00029101784,0.00017092514],"category_scores_gemma":[0.0025810283,0.00027556476,0.00018546176,0.00033402548,0.00012544365,0.00014224372,0.00011914322,0.00030624066,0.000020154768],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088623643,0.0004883077,0.03199943,0.00006473805,0.00035438561,0.000038663646,0.000147079,0.0000160723,0.026073126,0.00008092173,0.0037470618,0.936104],"study_design_scores_gemma":[0.0027233767,0.000092286864,0.53616863,0.00015046129,0.00003908419,0.00007308939,0.000025403857,0.000049429298,0.2700944,0.00014113678,0.18997452,0.0004682031],"about_ca_topic_score_codex":0.00016500225,"about_ca_topic_score_gemma":0.00017854174,"teacher_disagreement_score":0.93563575,"about_ca_system_score_codex":0.00019944146,"about_ca_system_score_gemma":0.000038760183,"threshold_uncertainty_score":0.99996966},"labels":[],"label_agreement":null},{"id":"W2414307865","doi":"10.1200/jco.2015.33.15_suppl.e13534","title":"Development of a proposed biosimilar product based on the demonstration of physicochemical, pharmacologic and clinical similarity to pegfilgrastim.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Biosimilar; Medicine; Pegfilgrastim; Cmax; Filgrastim; Oncology; Phases of clinical research; Confidence interval; Pharmacology; Internal medicine; Clinical trial; Pharmacokinetics; Chemotherapy; Neutropenia","score_opus":0.2740587639147554,"score_gpt":0.490525259223902,"score_spread":0.21646649530914658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2414307865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777657,0.00024979893,0.0012536474,0.018372009,0.0011928725,0.00046035415,0.0000114818,0.000008237404,0.000685938],"genre_scores_gemma":[0.95652044,0.000050092873,0.040705502,0.0025200343,0.00016571858,0.0000029241482,0.0000020604293,0.000008111897,0.000025109644],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9942197,0.0020024362,0.0030808402,0.0002906009,0.00016827375,0.00023814231],"domain_scores_gemma":[0.9923624,0.004563234,0.0019082341,0.00022449676,0.0007555901,0.0001860663],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012170269,0.00018369654,0.0014066035,0.000096622214,0.00005871584,0.000005301743,0.0003733305,0.00053778634,0.00009001058],"category_scores_gemma":[0.009115195,0.00010052701,0.00035599415,0.0002290378,0.0010674688,0.000042636257,0.000115213305,0.0011201928,0.000006321792],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02807922,0.020756401,0.05648147,0.0001726762,0.002454755,0.000050269147,0.0005114586,0.00005783556,0.45588976,0.00092441996,0.05591215,0.37870958],"study_design_scores_gemma":[0.015355317,0.03609084,0.09627247,0.00032614678,0.001410888,0.00007258333,0.0005688611,0.0006285869,0.75479096,0.0011285815,0.0928192,0.00053559174],"about_ca_topic_score_codex":0.0000019325696,"about_ca_topic_score_gemma":0.000005073711,"teacher_disagreement_score":0.378174,"about_ca_system_score_codex":0.00004719237,"about_ca_system_score_gemma":0.001837942,"threshold_uncertainty_score":0.99923146},"labels":[],"label_agreement":null},{"id":"W2418122615","doi":"","title":"The comparability conundrum: biosimilars in the United States, Europe and Canada.","year":2011,"lang":"en","type":"article","venue":"PubMed","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Comparability; Discretion; Member states; Business; Pharmacovigilance; Member state; Medicine; European union; Pharmacology; Public economics; Drug; International trade; Political science; Law; Economics","score_opus":0.05189076657167164,"score_gpt":0.23384829287735,"score_spread":0.18195752630567838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418122615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961232,0.0029821182,0.000021881628,0.027075633,0.00084702484,0.0010300522,0.00008298919,0.000034554458,0.006693733],"genre_scores_gemma":[0.99436337,0.00040215437,0.000029055842,0.0046203043,0.000008088885,0.000109549015,0.000014334973,0.0000058402798,0.00044727942],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9984365,0.0007513536,0.00021089509,0.00017715553,0.000033617624,0.00039048088],"domain_scores_gemma":[0.998865,0.00074740837,0.000048342,0.00026507114,0.000045584078,0.000028573797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012308409,0.00010621381,0.0001423747,0.000028137409,0.00018060804,0.000019022173,0.00030067522,0.00007515542,0.00003008579],"category_scores_gemma":[0.00028725268,0.000051161805,0.000019908572,0.00023645448,0.0005384115,0.000018273595,0.00006770952,0.00028033386,0.0000021547728],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015403919,0.0009886903,0.38468188,0.00007366992,0.00074334914,0.00010176404,0.0026561422,0.0000025728282,0.0004068298,0.019773383,0.43426934,0.15476198],"study_design_scores_gemma":[0.00027324984,0.000014815238,0.55182135,0.000001436115,0.000019312827,0.000012641113,0.00027572946,0.0000055158353,0.00065176014,0.00030340726,0.4465475,0.00007323482],"about_ca_topic_score_codex":0.11688977,"about_ca_topic_score_gemma":0.3597618,"teacher_disagreement_score":0.24287203,"about_ca_system_score_codex":0.000023160741,"about_ca_system_score_gemma":0.000041034105,"threshold_uncertainty_score":0.88899094},"labels":[],"label_agreement":null},{"id":"W246017335","doi":"10.1021/es4044648","title":"Sewage-Based Drug Epidemiology","year":2014,"lang":"en","type":"article","venue":"Sound Ideas (University of Puget Sound)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sewage; Epidemiology; Environmental science; Drug; Environmental health; Environmental planning; Environmental engineering; Medicine; Pharmacology","score_opus":0.027225020878548608,"score_gpt":0.26277182942324184,"score_spread":0.23554680854469323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W246017335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.866253,0.0010295827,0.11764533,0.0040188865,0.0007597181,0.00019777185,0.000060750874,0.00015153535,0.00988338],"genre_scores_gemma":[0.9844471,0.000021438966,0.007414842,0.0010258277,0.000041509666,2.712194e-7,0.000044450688,0.000012697711,0.0069918693],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9977488,0.0010539705,0.0002483206,0.00042314938,0.000046858597,0.00047893458],"domain_scores_gemma":[0.99786437,0.0012581727,0.00023327825,0.00045389205,0.00011523536,0.00007506379],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015554428,0.00020404208,0.00060744013,0.00015856222,0.00033784308,0.0000062029585,0.00046525674,0.0003917277,0.001951288],"category_scores_gemma":[0.0005419202,0.00020709506,0.00031763496,0.0002179037,0.0010991525,0.00008916874,0.00013697782,0.0003596864,0.00038107124],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034207926,0.00025942686,0.037125655,0.00009593794,0.00038146562,0.000007529033,0.00039628297,0.000050613253,0.0014250942,0.9351924,0.023516802,0.0012067119],"study_design_scores_gemma":[0.0013005768,0.00016933553,0.0077414,0.00001910689,0.00014268969,0.00000914029,0.0005294665,0.00019517064,0.00009611959,0.95210075,0.03744124,0.0002550238],"about_ca_topic_score_codex":0.00030461146,"about_ca_topic_score_gemma":0.00023951114,"teacher_disagreement_score":0.11819405,"about_ca_system_score_codex":0.00004901314,"about_ca_system_score_gemma":0.000052318243,"threshold_uncertainty_score":0.9989611},"labels":[],"label_agreement":null},{"id":"W2483943775","doi":"10.1016/b978-1-4832-8304-3.50020-1","title":"DERMATITIS MEDICAMENTOSA (Contact Type, from Penicillin)","year":2013,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut d'Histoire de l'Amérique Française","funders":"","keywords":"Penicillin; Dermatology; Medicine; Microbiology; Biology; Antibiotics","score_opus":0.02255785528922682,"score_gpt":0.25666333017753046,"score_spread":0.23410547488830363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2483943775","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007562851,0.012383626,0.00001049905,0.0005126476,0.0017380533,0.00044293015,0.00024528973,0.0000886461,0.9845027],"genre_scores_gemma":[0.0011343391,0.0008075964,0.00086526613,0.0033669237,0.00025939528,0.000018002715,0.00025721593,0.00007197125,0.9932193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981219,0.00011949143,0.0006344529,0.0005825951,0.000101775775,0.00043975972],"domain_scores_gemma":[0.9985396,0.00027512977,0.00029750695,0.00066338194,0.00012958016,0.000094769435],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00020641989,0.0005326058,0.0009137159,0.00010221933,0.00012347625,0.00004008291,0.00045868495,0.0014666831,0.049264036],"category_scores_gemma":[0.000055927336,0.00041512743,0.00033195462,0.000012718311,0.00032671742,0.000036114165,0.0002123564,0.0010419087,0.008316948],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016764006,0.000013343912,0.0000078637995,0.000024729761,0.00080150884,0.000023446966,0.000057659363,4.573662e-9,0.0023757468,0.0046372,0.023047023,0.96899474],"study_design_scores_gemma":[0.00046801296,0.00012781235,0.000097996664,0.00030651403,0.0004252165,0.000023348119,0.000006719273,9.02556e-7,0.002032633,0.011006351,0.9850146,0.0004898863],"about_ca_topic_score_codex":0.000015233876,"about_ca_topic_score_gemma":0.00003981045,"teacher_disagreement_score":0.96850485,"about_ca_system_score_codex":0.00006823841,"about_ca_system_score_gemma":0.00011468089,"threshold_uncertainty_score":0.99983007},"labels":[],"label_agreement":null},{"id":"W2488281113","doi":"10.5639/gabij.2016.0502.016","title":"Biosimilars patent litigation in Canada and Japan: a comparative strategic overview and EU and US update","year":2016,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Amgen Canada","keywords":"Biosimilar; Business; International trade; Law and economics; Economics; Medicine; Internal medicine","score_opus":0.12163815628710273,"score_gpt":0.28716337448201146,"score_spread":0.16552521819490873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488281113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94992435,0.026133234,0.00009540003,0.022867702,0.0002834744,0.00020895811,0.00027511799,0.000008373385,0.00020339314],"genre_scores_gemma":[0.92906857,0.04626919,0.00076443347,0.023818964,0.00003993197,0.0000066561297,0.000008141542,0.000012822439,0.000011310882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812454,0.0004484861,0.0004953631,0.00040916094,0.000085771935,0.00043669465],"domain_scores_gemma":[0.999118,0.00024673017,0.0002494528,0.000103280174,0.00012404252,0.00015854338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055127364,0.0003119419,0.0005262751,0.0001386053,0.00026063411,0.00008344513,0.00009030852,0.00019914987,0.000095127805],"category_scores_gemma":[0.000045031324,0.00019560075,0.000037781785,0.00018240574,0.0005189302,0.00016862074,0.00014250142,0.00036924725,8.645315e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012010386,0.00042739822,0.5381275,0.00038429757,0.0018464322,0.0003965144,0.0023698166,0.0000041398384,0.2941873,0.0029683118,0.0658994,0.092187874],"study_design_scores_gemma":[0.0094507495,0.0017079695,0.8718889,0.0011279562,0.00045105722,0.002450103,0.004599051,0.0004035135,0.04522825,0.01368828,0.047165673,0.0018385086],"about_ca_topic_score_codex":0.0008760661,"about_ca_topic_score_gemma":0.046359237,"teacher_disagreement_score":0.33376142,"about_ca_system_score_codex":0.00011335711,"about_ca_system_score_gemma":0.00027392188,"threshold_uncertainty_score":0.9710422},"labels":[],"label_agreement":null},{"id":"W2488880313","doi":"10.1201/b14271-22","title":"Monitoring the Impact of Asthma Drug Therapy: Database Studies","year":2005,"lang":"en","type":"book-chapter","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Asthma; Database; Medicine; Drug; Computer science; Pharmacology; Internal medicine","score_opus":0.08408470216292835,"score_gpt":0.37359298931575197,"score_spread":0.2895082871528236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488880313","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032207693,0.42431477,0.00005044784,0.00179678,0.00183165,0.00076845515,0.0004894122,0.00011900951,0.56740874],"genre_scores_gemma":[0.018533146,0.036363762,0.00073760975,0.00014024097,0.00036290858,0.000005952822,0.000021938567,0.00004183152,0.9437926],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989517,0.00009286697,0.00037347124,0.00028899885,0.00004529577,0.00024769016],"domain_scores_gemma":[0.9986361,0.00046899062,0.00020276473,0.000545331,0.0001284334,0.000018332918],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048896426,0.0003472179,0.0006162732,0.000073437826,0.000107890104,0.000007737265,0.00033629182,0.00034093056,0.0033457335],"category_scores_gemma":[0.00004264768,0.00015747889,0.00045428512,0.000026349795,0.00057181803,0.000035682166,0.00018963398,0.0005775678,0.000100348654],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008589269,0.00031139492,0.0007413717,0.000108421285,0.021514287,0.000021198091,0.00092733244,0.000004351275,0.0719753,0.0504219,0.19017936,0.66293615],"study_design_scores_gemma":[0.0013830913,0.0006575764,0.0011642568,0.0005987711,0.0003434098,0.000057293957,0.00036962755,0.0000020543946,0.099725306,0.005252368,0.8895607,0.00088553736],"about_ca_topic_score_codex":0.000061861596,"about_ca_topic_score_gemma":0.000008879516,"teacher_disagreement_score":0.69938135,"about_ca_system_score_codex":0.00004773691,"about_ca_system_score_gemma":0.00005279705,"threshold_uncertainty_score":0.9975653},"labels":[],"label_agreement":null},{"id":"W2504972888","doi":"10.1093/toxsci/kfw146","title":"Effects of Capillary Microsampling on Toxicological Endpoints in Juvenile Rats","year":2016,"lang":"en","type":"article","venue":"Toxicological Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"WiLAN (Canada)","funders":"","keywords":"Juvenile; Tail vein; Jugular vein; Blood collection; Blood sampling; Hematology; Medicine; Vein; Internal medicine; Physiology; Biology; Andrology; In vivo; Emergency medicine","score_opus":0.038403863739107855,"score_gpt":0.31210724759349423,"score_spread":0.27370338385438636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2504972888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936913,0.000773644,0.00014327475,0.0018982239,0.00040493745,0.0002582788,0.000007954651,0.000039408,0.0027829462],"genre_scores_gemma":[0.9972989,0.00011813447,0.0011766315,0.0009276311,0.000022204013,0.000018074226,5.0962177e-7,0.0000033542433,0.00043455203],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979528,0.00051200687,0.00039336,0.000505194,0.000085809676,0.00055082154],"domain_scores_gemma":[0.99678445,0.002897296,0.00011602116,0.00012881088,0.000023800865,0.00004964859],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011448424,0.00017767677,0.00044717424,0.00011177965,0.00013648943,0.000011436401,0.00045177375,0.0004360974,0.0013115607],"category_scores_gemma":[0.0013518573,0.00008228588,0.00011500642,0.00037112428,0.0017036415,0.000057027166,0.0001653045,0.00021258807,0.00011120244],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011432648,0.00043798587,0.0031011058,0.000009871925,0.000009755373,0.000018200988,0.000017810275,0.0000011622242,0.975152,0.004442262,0.00036235453,0.01633317],"study_design_scores_gemma":[0.0007101652,0.0021744117,0.049393002,0.00008494803,0.00000981136,0.000010240591,0.000025176318,0.0000021847334,0.94083166,0.003883493,0.0027098597,0.00016504207],"about_ca_topic_score_codex":0.0000060798584,"about_ca_topic_score_gemma":0.000009366011,"teacher_disagreement_score":0.046291895,"about_ca_system_score_codex":0.00004944316,"about_ca_system_score_gemma":0.00004364848,"threshold_uncertainty_score":0.99960136},"labels":[],"label_agreement":null},{"id":"W2516865243","doi":"10.1016/j.jchromb.2016.08.019","title":"Self-initiated and concentration-dependent degradation of tetracaine in neat standard solutions: A trouble-shooting story","year":2016,"lang":"en","type":"article","venue":"Journal of Chromatography B","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nucro Technics","funders":"","keywords":"Chemistry; Tetracaine; Trouble shooting; Bioanalysis; Degradation (telecommunications); Chromatography; Reliability engineering; Surgery","score_opus":0.02565278999865105,"score_gpt":0.27344599573355544,"score_spread":0.24779320573490438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516865243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98529744,0.008108,0.004751648,0.0011933745,0.00027862893,0.00013149006,0.000033478445,0.0000149347015,0.00019097811],"genre_scores_gemma":[0.9957129,0.0010447865,0.0031468347,0.000047648104,0.000020003963,0.0000011459872,0.0000014475756,0.000005650997,0.000019581528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875873,0.00032782607,0.00054364896,0.00010536828,0.000073525385,0.00019090861],"domain_scores_gemma":[0.9989415,0.0003496814,0.0004108949,0.000077617646,0.00018774263,0.000032592958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010452335,0.000101077174,0.0003240571,0.00023375668,0.000064278174,0.000009034071,0.00008621984,0.00015472111,0.000074989526],"category_scores_gemma":[0.00017026678,0.000063504805,0.00011185199,0.00021869349,0.00018568532,0.0001834813,0.000018510265,0.00021857806,6.050798e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078833615,0.00043581147,0.17743146,0.00010366239,0.000718115,0.000028410253,0.00031676644,0.0000013742704,0.7943492,0.003072408,0.0009903446,0.021764103],"study_design_scores_gemma":[0.028878044,0.0045529376,0.33311364,0.0022223806,0.00084573944,0.0010014239,0.0019358982,0.000055069824,0.6040929,0.003740149,0.018723618,0.00083823904],"about_ca_topic_score_codex":0.0000048279735,"about_ca_topic_score_gemma":0.000013670902,"teacher_disagreement_score":0.19025634,"about_ca_system_score_codex":0.000039130347,"about_ca_system_score_gemma":0.00010628798,"threshold_uncertainty_score":0.25896508},"labels":[],"label_agreement":null},{"id":"W2519144724","doi":"","title":"Biosimilars? pricing policies in Canada: A new challenge to provincial governments","year":2013,"lang":"en","type":"article","venue":"Journal of Bioequivalence & Bioavailability","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Business; Medicine; Internal medicine","score_opus":0.024892823770357595,"score_gpt":0.2675882434322147,"score_spread":0.24269541966185712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519144724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794034,0.0017672965,0.00013123329,0.016468408,0.0008918689,0.0005045537,0.000041972216,0.000011465703,0.0007797977],"genre_scores_gemma":[0.9952904,0.00015104961,0.0019766765,0.001857345,0.00012619472,0.000005687568,7.2234195e-7,0.000013329734,0.00057862274],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99736094,0.0002916774,0.0010935186,0.00035559156,0.00023412103,0.0006641715],"domain_scores_gemma":[0.99855685,0.00022150963,0.00042646023,0.00035998746,0.00021951713,0.00021569432],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009820679,0.0002760289,0.0006366172,0.00016483541,0.00007412785,0.00003312883,0.0006141973,0.00022888638,0.001266835],"category_scores_gemma":[0.0008449968,0.00020412735,0.00016117327,0.00043661843,0.00020368297,0.0002478967,0.0002116221,0.00055583066,0.00009034159],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067981024,0.00097654987,0.3600122,0.00018613484,0.00025873937,0.000060141156,0.0011978002,0.00000817392,0.3935517,0.00025199566,0.088901944,0.15391482],"study_design_scores_gemma":[0.002524165,0.0021619962,0.7289162,0.00042980973,0.0001306118,0.00013812282,0.0022762008,0.000019461473,0.20177919,0.0010610335,0.059671514,0.00089167454],"about_ca_topic_score_codex":0.3787658,"about_ca_topic_score_gemma":0.32319453,"teacher_disagreement_score":0.36890402,"about_ca_system_score_codex":0.001320859,"about_ca_system_score_gemma":0.0018608968,"threshold_uncertainty_score":0.9996461},"labels":[],"label_agreement":null},{"id":"W2519311317","doi":"10.2533/chimia.2016.662","title":"Thematic Platform in vitro Diagnostics Technological Progress with a Powerful Network","year":2016,"lang":"en","type":"article","venue":"CHIMIA International Journal for Chemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Thematic map; Population; Business; Biotechnology; Engineering; Data science; Nanotechnology; Medicine; Computer science; Biology; Geography; Environmental health; Cartography","score_opus":0.016183531657442605,"score_gpt":0.2910298786039191,"score_spread":0.27484634694647647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519311317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97135234,0.002300224,0.010650112,0.011707736,0.0014531466,0.0004252278,0.000139742,0.00009977126,0.001871678],"genre_scores_gemma":[0.991967,0.00020552815,0.0062050777,0.0001701621,0.00023278125,0.000028769875,0.000016522647,0.000015582194,0.0011585244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903995,0.000019042245,0.00032664012,0.00019565037,0.000081206286,0.00033749477],"domain_scores_gemma":[0.9990439,0.00047911325,0.00017179216,0.000119009215,0.00014823621,0.00003795534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003635859,0.00015982447,0.00022767592,0.000040479532,0.00006687714,0.00003386618,0.0004679226,0.00029054206,0.0003834329],"category_scores_gemma":[0.0004980508,0.000081464,0.00011142165,0.000076057535,0.00037132084,0.00006666688,0.00007872945,0.00035585556,0.000012719775],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042111487,0.0007890417,0.016534526,0.00007262267,0.0011706434,0.0002341361,0.000051747993,0.0000048381785,0.7866615,0.0021873973,0.008477457,0.17960495],"study_design_scores_gemma":[0.0046700398,0.00019620892,0.0016740852,0.0007653324,0.00007260921,0.0022095232,0.00013049235,0.000024698305,0.95100874,0.012273035,0.026585143,0.00039011805],"about_ca_topic_score_codex":2.4670646e-7,"about_ca_topic_score_gemma":5.7187617e-7,"teacher_disagreement_score":0.17921484,"about_ca_system_score_codex":0.000108379645,"about_ca_system_score_gemma":0.000052104853,"threshold_uncertainty_score":0.41983214},"labels":[],"label_agreement":null},{"id":"W2519779602","doi":"10.1111/bjd.15067","title":"Biosimilars for psoriasis: clinical studies to determine similarity","year":2016,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"Cilag; Galderma; Dermira; Celgene; Amgen; Pfizer; Eli Lilly and Company","keywords":"Biosimilar; Psoriasis; Similarity (geometry); Medicine; Dermatology; MEDLINE; Intensive care medicine; Computer science; Internal medicine; Artificial intelligence; Chemistry","score_opus":0.19206551971016245,"score_gpt":0.46453267096096384,"score_spread":0.2724671512508014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519779602","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013306492,0.98944986,0.0012460452,0.0021168212,0.0059426036,0.0007236671,0.0004321314,0.000024914587,0.000050645547],"genre_scores_gemma":[0.000016664173,0.9922893,0.0052975505,0.0013568021,0.0005303408,0.000048063437,0.0000128216,0.000061672734,0.00038675178],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99311644,0.0019770938,0.0034872093,0.00057557644,0.000080903555,0.0007627507],"domain_scores_gemma":[0.9925782,0.0044145156,0.0017303064,0.0003605115,0.00074174185,0.00017469199],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017852244,0.000542914,0.005930086,0.0003749675,0.0001989144,0.000040184997,0.00095456676,0.0018356479,0.0001699777],"category_scores_gemma":[0.0055169957,0.0004005306,0.0023056043,0.0002386245,0.00067856855,0.00009251699,0.0002934646,0.0011778878,0.00008420829],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092498514,0.00014054523,0.000011710451,0.0018627475,0.002489409,0.00066365686,0.0000075462317,4.1485317e-9,0.000004373452,0.000037165246,0.15259922,0.84209114],"study_design_scores_gemma":[0.0014537418,0.0004413165,0.000007988324,0.014377168,0.0023987181,0.06731814,0.000022452341,5.910818e-8,0.000078760466,0.00040507465,0.91307247,0.00042409357],"about_ca_topic_score_codex":0.0000010335697,"about_ca_topic_score_gemma":0.000013973825,"teacher_disagreement_score":0.84166706,"about_ca_system_score_codex":0.00008576896,"about_ca_system_score_gemma":0.0003998191,"threshold_uncertainty_score":0.9998447},"labels":[],"label_agreement":null},{"id":"W2522289024","doi":"","title":"Regulatory consideration of the assessment of biosimilar products","year":2013,"lang":"en","type":"article","venue":"Journal of Bioequivalence & Bioavailability","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Harmonization; Scope (computer science); Interchangeability; Risk analysis (engineering); Business; Product (mathematics); Order (exchange); Bioequivalence; Medicine; Biotechnology; Pharmacology; Computer science; Finance; Pharmacokinetics","score_opus":0.023726712127593898,"score_gpt":0.2906560368767194,"score_spread":0.2669293247491255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522289024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912695,0.0017061571,0.00014636932,0.0050814734,0.0009297299,0.0003928946,0.000029631152,0.0000067946808,0.00043741692],"genre_scores_gemma":[0.99393153,0.00009823721,0.0055061025,0.0001667384,0.000039288796,0.0000024174171,7.6678316e-7,0.0000064628225,0.00024844796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974708,0.00070005405,0.0012017591,0.00022400272,0.00017654727,0.00022683927],"domain_scores_gemma":[0.9966766,0.00028082187,0.0012306538,0.0006111822,0.0011642991,0.00003643556],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021906125,0.00016630016,0.00053468323,0.000090891,0.00007982073,0.000011478696,0.00044097932,0.0002488533,0.00092401035],"category_scores_gemma":[0.001041458,0.00009405659,0.0002859154,0.00032774959,0.0016782793,0.0001887304,0.000127014,0.000390498,0.000007396566],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034727105,0.00034327636,0.07160776,0.0001409044,0.00011198262,4.1573531e-7,0.000056846693,0.0000014212877,0.9189083,0.00061102957,0.0049275206,0.0032558062],"study_design_scores_gemma":[0.00035096984,0.0003820289,0.30186695,0.00009625162,0.00009798387,0.000032707605,0.00010795313,0.000008643961,0.6943923,0.00079856615,0.0017799045,0.00008568986],"about_ca_topic_score_codex":0.000022123972,"about_ca_topic_score_gemma":0.0000028105278,"teacher_disagreement_score":0.2302592,"about_ca_system_score_codex":0.000063876214,"about_ca_system_score_gemma":0.00036860062,"threshold_uncertainty_score":0.9999893},"labels":[],"label_agreement":null},{"id":"W2524206199","doi":"10.1097/01.jto.0000283072.85701.98","title":"WS-07: Designs for vaccine and immunotherapy trials","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Immune system; Medicine; Immunotherapy; Immunology; Cancer; Innate immune system; Mechanism (biology); Acquired immune system; Cancer immunotherapy; Cancer vaccine; Internal medicine","score_opus":0.10621394388018486,"score_gpt":0.4933764924582765,"score_spread":0.3871625485780917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524206199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46888956,0.06868,0.42082494,0.02662929,0.010020409,0.0015270062,0.00006441665,0.000056683784,0.0033076655],"genre_scores_gemma":[0.8155305,0.0025421553,0.17149732,0.0047629518,0.0012288777,0.000010269221,0.0000069830476,0.000052362793,0.00436859],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975217,0.0008135921,0.0011352855,0.00014956946,0.00003657265,0.00034329234],"domain_scores_gemma":[0.9949498,0.0037629544,0.00086082995,0.00012552766,0.00024321991,0.000057660527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01318796,0.00015324833,0.0010481176,0.000204806,0.000107191314,0.000012019669,0.00019589913,0.00052056863,0.00052134844],"category_scores_gemma":[0.0012539398,0.0000994417,0.00029475644,0.00010313633,0.000128237,0.00006631856,0.000030969048,0.00039457704,0.000009278198],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008377924,0.00020554973,0.000317913,0.000018441558,0.00051313,0.000023480436,0.0001022008,2.8573444e-7,0.3800425,0.00038968932,0.009195562,0.6008133],"study_design_scores_gemma":[0.0037073418,0.005951333,0.005032046,0.000045204728,0.0005135611,0.0015279108,0.00031758595,0.0000032803898,0.21187072,0.005180155,0.7656489,0.00020196436],"about_ca_topic_score_codex":0.0000026055827,"about_ca_topic_score_gemma":0.0000072317175,"teacher_disagreement_score":0.75645334,"about_ca_system_score_codex":0.00007193635,"about_ca_system_score_gemma":0.00011865108,"threshold_uncertainty_score":0.57084},"labels":[],"label_agreement":null},{"id":"W2525897054","doi":"","title":"Some statistical issues on the evaluation of the similarity and interchangeability of biologics","year":2013,"lang":"en","type":"article","venue":"Journal of Bioequivalence & Bioavailability","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interchangeability; Biosimilar; Bioequivalence; Risk analysis (engineering); Biochemical engineering; Computer science; Pharmacology; Biotechnology; Computational biology; Business; Medicine; Engineering; Pharmacokinetics; Biology","score_opus":0.10810246180928541,"score_gpt":0.357205385288697,"score_spread":0.2491029234794116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525897054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866003,0.0033438213,0.000057407797,0.0089143785,0.0004330447,0.00045646998,0.00010655663,0.0000039655047,0.00008406245],"genre_scores_gemma":[0.9987293,0.0002839325,0.00064604473,0.0002484744,0.00004074252,0.000004686484,9.2251526e-7,0.0000038145577,0.00004210131],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9961249,0.0023576813,0.00085374404,0.00022272812,0.00023054314,0.00021037321],"domain_scores_gemma":[0.99658847,0.0012955796,0.0006532079,0.000503041,0.00092428277,0.00003543463],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0077824965,0.0001615414,0.00045973837,0.000050289113,0.00009085216,0.00001229167,0.0004790429,0.0002554963,0.0011577652],"category_scores_gemma":[0.005772903,0.0000704892,0.00018888526,0.00017536654,0.0031001293,0.000108458196,0.00019701988,0.00050066545,0.000007793876],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078924454,0.0020152393,0.17512433,0.00036942033,0.0004958382,7.7430843e-7,0.00094363367,0.0000036018957,0.6788097,0.016138684,0.009312877,0.11599667],"study_design_scores_gemma":[0.0006692266,0.0017039112,0.568595,0.00015162892,0.00033831448,0.000020367148,0.00072599604,0.00013206234,0.36605328,0.06033556,0.0011122752,0.00016235905],"about_ca_topic_score_codex":0.00008079335,"about_ca_topic_score_gemma":0.000008947777,"teacher_disagreement_score":0.39347067,"about_ca_system_score_codex":0.00006121876,"about_ca_system_score_gemma":0.00010916821,"threshold_uncertainty_score":0.9997553},"labels":[],"label_agreement":null},{"id":"W2529176780","doi":"","title":"Biologics and biosimilars: The current litigation landscape in Canada","year":2015,"lang":"en","type":"article","venue":"Journal of Bioanalysis & Biomedicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Current (fluid); Medicine; Internal medicine; Engineering","score_opus":0.029159983543221465,"score_gpt":0.27849653819930187,"score_spread":0.2493365546560804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529176780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6941334,0.2158969,0.0005286998,0.08592487,0.0026816477,0.000251808,0.000055422213,0.000012438753,0.0005148091],"genre_scores_gemma":[0.99615806,0.0022584999,0.00020968396,0.0011861111,0.0001302316,0.0000010662361,0.000010840379,0.0000048624224,0.000040630526],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840856,0.00034142908,0.0007223296,0.00015360207,0.00013254517,0.00024155171],"domain_scores_gemma":[0.99884206,0.0002515138,0.0004135016,0.0001662442,0.00023310028,0.00009355031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018381691,0.00015108018,0.00050634146,0.00030491798,0.000048186484,0.000012498102,0.00023777293,0.00009719914,0.00007600289],"category_scores_gemma":[0.00043374248,0.000073123534,0.00008945002,0.0007676511,0.0002984173,0.000052340318,0.000058854752,0.0004483899,0.0000022451754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048103798,0.00027040136,0.25850537,0.00004598854,0.0011366885,0.00009441776,0.0005038794,0.000011343582,0.01626261,0.00012645475,0.096566014,0.6259958],"study_design_scores_gemma":[0.007455403,0.0017759964,0.20074235,0.0004427026,0.0020243817,0.00067025167,0.007405433,0.0006125406,0.011288978,0.0022961968,0.7646187,0.00066707307],"about_ca_topic_score_codex":0.016665129,"about_ca_topic_score_gemma":0.074396014,"teacher_disagreement_score":0.6680527,"about_ca_system_score_codex":0.00014661142,"about_ca_system_score_gemma":0.0005544427,"threshold_uncertainty_score":0.989883},"labels":[],"label_agreement":null},{"id":"W2529543677","doi":"10.1208/s12249-016-0641-9","title":"Assessment Methodology for Process Validation Lifecycle Stage 3A","year":2016,"lang":"en","type":"review","venue":"AAPS PharmSciTech","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Process validation; Computer science; Quality by Design; Process (computing); Risk analysis (engineering); Process capability; New product development; Quality (philosophy); Robustness (evolution); Process management; Product lifecycle; Product (mathematics); Critical quality attributes; Systems engineering; Work in process; Verification and validation; Engineering; Operations management; Business; Mathematics","score_opus":0.23416419311955464,"score_gpt":0.5176860847881523,"score_spread":0.28352189166859765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529543677","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000042735614,0.9626446,0.031524446,0.00022518726,0.0016439181,0.0018294464,0.0009261589,0.00014252953,0.0010594614],"genre_scores_gemma":[0.00001303239,0.97379625,0.014526646,0.00022520631,0.00023515844,0.00074213656,0.00042038603,0.000081582926,0.0099595925],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959876,0.0014535122,0.00089189486,0.0009096324,0.00007069989,0.00068668876],"domain_scores_gemma":[0.99636775,0.0022349686,0.0006144115,0.00054759084,0.00017387838,0.00006142279],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026048163,0.0005813283,0.0021059003,0.0002846018,0.00020118477,0.00003700222,0.00067201065,0.0013499662,0.0024937086],"category_scores_gemma":[0.00050838396,0.0003603151,0.00074128434,0.0003271175,0.00024421417,0.000098545126,0.0001543093,0.00064555695,0.0002128687],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002103216,0.0001064608,0.000003728654,0.005527094,0.0006377291,0.0000023513862,0.000009207185,3.0505067e-8,0.0010468267,0.0020669831,0.00277483,0.9878037],"study_design_scores_gemma":[0.00066855596,0.00019064642,0.0000022132053,0.0017700078,0.0010977429,0.00003615085,0.000008895798,8.2052543e-7,0.004951378,0.0015597459,0.989219,0.00049481686],"about_ca_topic_score_codex":0.0000033152764,"about_ca_topic_score_gemma":5.4506353e-7,"teacher_disagreement_score":0.9873089,"about_ca_system_score_codex":0.0001291656,"about_ca_system_score_gemma":0.00035892104,"threshold_uncertainty_score":0.9999465},"labels":[],"label_agreement":null},{"id":"W2539474267","doi":"10.4212/cjhp.v69i5.1601","title":"How Should Canadian Pharmacy Departments Utilize Idarucizumab?","year":2016,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Regina Qu'Appelle Health Region","funders":"","keywords":"Pharmacy; Medicine; Family medicine; Business","score_opus":0.05671716549935148,"score_gpt":0.3152804587764905,"score_spread":0.25856329327713906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539474267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49565336,0.01908896,0.00019236005,0.46183273,0.012602559,0.0008210146,0.00076358864,0.000038828355,0.009006608],"genre_scores_gemma":[0.9922844,0.00021631602,0.00010281536,0.002899579,0.00027261474,0.0000039514866,0.000003335812,0.000027864027,0.004189109],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980425,0.0003040446,0.00040650638,0.00021449602,0.000098936376,0.0009335026],"domain_scores_gemma":[0.99824786,0.0001702846,0.00024497125,0.0002737929,0.00027727007,0.0007858172],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000717237,0.00027465055,0.0003579553,0.0002763966,0.0005441919,0.00012948406,0.00087907456,0.000113674134,0.0027148596],"category_scores_gemma":[0.00030147602,0.00014238837,0.00028035967,0.00021518617,0.0006557095,0.00031866357,0.000031156014,0.0005774268,0.0001456401],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043096993,0.00017824431,0.067882195,0.000026782767,0.0027643358,0.0015297767,0.00086472044,0.0000011213599,0.046996858,0.0036039872,0.5264373,0.34928373],"study_design_scores_gemma":[0.0026373332,0.00023325134,0.002843684,0.000042404477,0.0002119503,0.00033884813,0.00008485214,0.0000018321645,0.044294145,0.0009593585,0.9480663,0.00028607133],"about_ca_topic_score_codex":0.10097688,"about_ca_topic_score_gemma":0.35099024,"teacher_disagreement_score":0.49663106,"about_ca_system_score_codex":0.00044042547,"about_ca_system_score_gemma":0.0022875317,"threshold_uncertainty_score":0.9981968},"labels":[],"label_agreement":null},{"id":"W2544596691","doi":"10.1373/clinchem.2016.263434","title":"Dried Blood Spot Reference Intervals for Steroids and Amino Acids in a Neonatal Cohort of the National Children's Study","year":2016,"lang":"en","type":"article","venue":"Clinical Chemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"AACC International","keywords":"Percentile; Cohort; Newborn screening; Medicine; Amino acid; Reference values; Testosterone (patch); Pediatrics; Physiology; Internal medicine; Statistics; Biology; Mathematics","score_opus":0.052844984846431964,"score_gpt":0.36301743426448757,"score_spread":0.3101724494180556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544596691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986509,0.00013936586,0.000021762839,0.00044170246,0.00008110973,0.00026002206,0.00013553748,0.000007640985,0.00026197731],"genre_scores_gemma":[0.9982684,0.000022237311,0.00012691198,0.00013213989,0.000038127237,0.00002064239,0.0000065564086,0.000005366187,0.0013795821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988178,0.0001402583,0.0005270603,0.00031538107,0.000045874942,0.00015360367],"domain_scores_gemma":[0.9986736,0.00090265734,0.00012983006,0.0001874303,0.00008308674,0.000023361281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010097313,0.000106351494,0.00031062114,0.000010470629,0.000032792523,0.0000045270167,0.00025902537,0.0003000633,0.0001272961],"category_scores_gemma":[0.00144303,0.000057405327,0.000102554484,0.00005539535,0.0005410529,0.000021274273,0.00018867459,0.00023554172,0.0000017417927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001848252,0.00036012745,0.9336412,0.000013592672,0.00018407272,3.640645e-7,0.000014942373,5.349284e-9,0.062121756,0.000047230395,0.00013879631,0.0032930672],"study_design_scores_gemma":[0.0033822572,0.00023322443,0.8023509,0.00006111036,0.000095851276,0.000012254767,0.000030186087,5.635414e-7,0.19269592,0.00052353187,0.00051211833,0.000102123966],"about_ca_topic_score_codex":0.000002114875,"about_ca_topic_score_gemma":0.0000034842103,"teacher_disagreement_score":0.13129036,"about_ca_system_score_codex":0.000010304496,"about_ca_system_score_gemma":0.000041677158,"threshold_uncertainty_score":0.23409213},"labels":[],"label_agreement":null},{"id":"W2546620177","doi":"","title":"Evolution of the global biosimilars market: Lessons learned","year":2015,"lang":"en","type":"article","venue":"Journal of Bioanalysis & Biomedicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Innovator; Medicine; Competition (biology); Business; Marketing; Finance","score_opus":0.05121388532853729,"score_gpt":0.34175962962560275,"score_spread":0.2905457442970655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2546620177","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33676097,0.1837265,0.01878931,0.41964048,0.0132353725,0.0008796327,0.00056416437,0.00009893792,0.026304638],"genre_scores_gemma":[0.9970379,0.00032748864,0.0008988916,0.00052970025,0.00015168781,5.999488e-7,0.0000027541078,0.000007990641,0.0010430173],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976402,0.00060852466,0.000995728,0.00019574336,0.00026419663,0.00029561165],"domain_scores_gemma":[0.9976983,0.00012597188,0.001020196,0.00040351914,0.0006371858,0.000114834496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025625592,0.00019636168,0.0007620983,0.00030866737,0.000080586404,0.000009098317,0.0005942839,0.00029781376,0.00041678574],"category_scores_gemma":[0.0008754254,0.000102142316,0.0005646874,0.0017916064,0.0009306007,0.0000717731,0.0001258687,0.00035341005,0.000009447505],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033081418,0.001901967,0.1615557,0.00011920454,0.009471402,0.00006735456,0.00041878998,0.000030528285,0.3715258,0.0033917103,0.29139185,0.15681756],"study_design_scores_gemma":[0.013374183,0.0038606075,0.22002307,0.0008036405,0.0118337255,0.0014590931,0.005477993,0.00033312684,0.08462796,0.015889516,0.6414317,0.00088535994],"about_ca_topic_score_codex":0.00006628982,"about_ca_topic_score_gemma":0.00003186813,"teacher_disagreement_score":0.6602769,"about_ca_system_score_codex":0.0002696343,"about_ca_system_score_gemma":0.00030347717,"threshold_uncertainty_score":0.45635116},"labels":[],"label_agreement":null},{"id":"W2547846819","doi":"10.5639/gabij.2016.0503.032","title":"Are the perspectives regarding the use of biosimilars in the setting of haematology and blood and marrow transplant changing?","year":2016,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Hematology; Medicine; Internal medicine; Intensive care medicine","score_opus":0.06043340861617394,"score_gpt":0.27414360920156383,"score_spread":0.2137102005853899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547846819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88615847,0.014735357,0.00064820173,0.09782127,0.00016022591,0.0002537235,0.00017234794,0.000005180607,0.000045214085],"genre_scores_gemma":[0.98102266,0.0103908,0.0006099934,0.007918469,0.000035668632,0.000005428416,6.7650853e-7,0.000009687638,0.00000659743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979889,0.000959235,0.0004218788,0.00022419628,0.00007823803,0.00032758966],"domain_scores_gemma":[0.9976731,0.0015105695,0.0004938637,0.00016656316,0.00012935748,0.000026579974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016301429,0.00019623288,0.00041450234,0.00015584056,0.0003865729,0.000040041345,0.00021226301,0.00018392627,0.000016307775],"category_scores_gemma":[0.000368821,0.00007382371,0.0000916412,0.00026957178,0.0012799547,0.000098273216,0.00010909626,0.0003917039,9.47918e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087767333,0.0005046506,0.49130753,0.00024232134,0.0023514698,0.0002785777,0.047998823,0.000003744227,0.41569272,0.002336043,0.022429563,0.015976902],"study_design_scores_gemma":[0.010465171,0.00235633,0.49325812,0.002816594,0.0028268718,0.023615858,0.15549763,0.00022550875,0.27430415,0.007530812,0.02556584,0.001537114],"about_ca_topic_score_codex":8.646553e-7,"about_ca_topic_score_gemma":0.00002502526,"teacher_disagreement_score":0.14138858,"about_ca_system_score_codex":0.000008511905,"about_ca_system_score_gemma":0.000025377069,"threshold_uncertainty_score":0.47160465},"labels":[],"label_agreement":null},{"id":"W2548570873","doi":"10.1016/s1470-2045(16)30312-6","title":"21st century pharmacovigilance: efforts, roles, and responsibilities","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pharmacovigilance; Biosimilar; Medicine; Agency (philosophy); Patient safety; Under-reporting; Business; Adverse effect; Pharmacology; Health care; Political science","score_opus":0.08451045535989471,"score_gpt":0.4112558686540705,"score_spread":0.3267454132941758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548570873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009090669,0.984086,0.000005092745,0.001968736,0.0012500468,0.00058224157,0.00037879875,0.00008413191,0.011635906],"genre_scores_gemma":[0.00000774653,0.99048054,0.00020252801,0.0013350263,0.00072379684,0.00009554048,0.00004486242,0.000035940182,0.0070740446],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952571,0.0028024884,0.0006055993,0.0005590733,0.000046118595,0.00072961295],"domain_scores_gemma":[0.9961235,0.002745235,0.00036206076,0.0006758789,0.000046745474,0.000046599787],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023526466,0.0004636403,0.0027780493,0.000101369,0.00021546955,0.000020565536,0.0006672798,0.0011202553,0.00097354053],"category_scores_gemma":[0.00026148878,0.00021269613,0.00030713927,0.00013982176,0.0012105197,0.00003505042,0.00039851834,0.0010885512,0.00032656323],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017662656,0.000050090766,0.0000066566486,0.0017273648,0.0005225161,0.000012644384,0.000040951516,1.783393e-9,0.00006393489,0.007633544,0.020076757,0.9696889],"study_design_scores_gemma":[0.000782102,0.00020589001,0.000006347567,0.0018779564,0.0008135959,0.00034808018,0.00003835348,5.515898e-8,0.00003554572,0.0005212221,0.9950723,0.00029853455],"about_ca_topic_score_codex":0.0000049115984,"about_ca_topic_score_gemma":0.000008326218,"teacher_disagreement_score":0.97499555,"about_ca_system_score_codex":0.00014000291,"about_ca_system_score_gemma":0.00031933983,"threshold_uncertainty_score":0.9999397},"labels":[],"label_agreement":null},{"id":"W2550512372","doi":"10.4155/bio-2016-4988","title":"2016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV): (Part 2 – Hybrid LBA/LCMS and Input from Regulatory Agencies)","year":2016,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; Caprion (Canada)","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Health Canada; World Health Organization; Bristol-Myers Squibb; U.S. Food and Drug Administration; Sanofi; Angelini Pharma","keywords":"Bioanalysis; Biopharmaceutical; Immunogenicity; Excellence; White paper; Biosimilar; Computer science; Nanotechnology; Medicine; Political science; Biotechnology; Biology","score_opus":0.026456623429340666,"score_gpt":0.2739332351796624,"score_spread":0.24747661175032173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550512372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73711026,0.10035108,0.0025989828,0.13143691,0.0036219887,0.0017996513,0.002621803,0.00065245625,0.019806877],"genre_scores_gemma":[0.9759498,0.009652526,0.00069073157,0.0014558095,0.00014152261,0.00004034568,0.00016327962,0.000045663764,0.011860281],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99580973,0.001373398,0.0008676614,0.0011425159,0.00020877493,0.0005979232],"domain_scores_gemma":[0.99776345,0.00065348693,0.00032427063,0.0010050809,0.0001426993,0.0001110144],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016297505,0.0004925755,0.00091329287,0.0007428457,0.00017428874,0.000061131395,0.00034245852,0.0004946475,0.005945827],"category_scores_gemma":[0.0004796433,0.00030234127,0.00037836842,0.000823674,0.00047526992,0.00018171323,0.00014340309,0.0002593388,0.000524933],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010026407,0.00071629917,0.029669425,0.00001764605,0.0049498533,0.000044828663,0.00016429013,0.000004349535,0.17909247,0.000669938,0.035644684,0.74802357],"study_design_scores_gemma":[0.0031876275,0.0005099248,0.06346767,0.00046235038,0.0022706261,0.000008120935,0.00029222376,0.00008588841,0.2979816,0.0028836392,0.62748474,0.0013655843],"about_ca_topic_score_codex":0.00031417375,"about_ca_topic_score_gemma":0.00022882293,"teacher_disagreement_score":0.746658,"about_ca_system_score_codex":0.00022840158,"about_ca_system_score_gemma":0.000059834365,"threshold_uncertainty_score":0.9999429},"labels":[],"label_agreement":null},{"id":"W2550644244","doi":"10.1136/annrheumdis-2016-eular.3359","title":"THU0140 Efficacy and Safety Analysis by Overall anti-Drug Antibody Results Up To Week 30 in Patients with Rheumatoid Arthritis Treated with Sb2 (An Infliximab Biosimilar) or Infliximab Reference Product in Phase III Study","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Rheumatoid arthritis; Biosimilar; Infliximab; Internal medicine; Methotrexate; Immunogenicity; Gastroenterology; Clinical efficacy; Safety profile; Drug; Surgery; Antibody; Adverse effect; Pharmacology; Immunology; Disease","score_opus":0.026809171790200426,"score_gpt":0.3187931148104403,"score_spread":0.2919839430202399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550644244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521244,0.00088946545,0.00001944672,0.0010070436,0.000035220237,0.0014792889,0.0012991986,0.000034457265,0.000023443976],"genre_scores_gemma":[0.99819905,0.0011667503,0.000066206485,0.00019139932,0.0000025388315,0.000038434067,0.00014078892,0.000023598039,0.00017125397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965032,0.00090041576,0.0010690624,0.0007823145,0.00020549458,0.0005395573],"domain_scores_gemma":[0.9977795,0.00049191224,0.00044469134,0.00093014067,0.0002222406,0.00013153713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006387439,0.00043226746,0.0012632844,0.00036839143,0.00013514186,0.000041140225,0.0004728235,0.00010186423,0.00014867864],"category_scores_gemma":[0.00069193146,0.00020001022,0.00009088154,0.0010963937,0.0004344558,0.00027928565,0.00018900876,0.00017491104,0.000005229327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060949977,0.020411968,0.8406995,0.00010540955,0.003375405,0.000016066067,0.002137834,0.000040133225,0.0017194563,0.00004304908,0.0019575346,0.06854367],"study_design_scores_gemma":[0.041390356,0.0036151079,0.94794995,0.0016117609,0.0003342206,0.000002337844,0.0003462873,0.00001498914,0.0039421474,0.000028627108,0.00026652068,0.0004977192],"about_ca_topic_score_codex":0.0005823613,"about_ca_topic_score_gemma":0.00051504845,"teacher_disagreement_score":0.10725043,"about_ca_system_score_codex":0.000026344072,"about_ca_system_score_gemma":0.00009493505,"threshold_uncertainty_score":0.81561804},"labels":[],"label_agreement":null},{"id":"W2550819725","doi":"10.1136/annrheumdis-2016-eular.2021","title":"THU0138 Secondary Efficacy Results Up To Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimiar) with Adalimumab Reference Product in Patients with Moderate To Severe Rheumatoid Arthritis despite Methotrexate Therapy","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Clinical endpoint; Internal medicine; Methotrexate; Surrogate endpoint; Physical therapy; Clinical trial","score_opus":0.06699277095954076,"score_gpt":0.3212752334356977,"score_spread":0.25428246247615693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550819725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932134,0.0013884366,0.00012467032,0.0015951357,0.00018296798,0.0020391378,0.0013404156,0.0000635755,0.000052264728],"genre_scores_gemma":[0.9980449,0.00035028317,0.00060468883,0.0006226479,0.000008825077,0.00010146647,0.00006759571,0.000045338053,0.00015425912],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959779,0.0012673567,0.00095391663,0.00091336,0.00025190925,0.00063558214],"domain_scores_gemma":[0.9971434,0.0006031757,0.00043113416,0.0012863212,0.00032997294,0.0002060247],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055810704,0.00051240105,0.0011166318,0.00019680918,0.00022110737,0.00006672202,0.00079310004,0.00010555013,0.00018748498],"category_scores_gemma":[0.00041808034,0.00025383072,0.00012080678,0.00050133804,0.00026767814,0.00029011627,0.00025348237,0.00025132508,0.00002509324],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1965766,0.021434646,0.05529324,0.000104506544,0.0038179364,0.00001875001,0.010789396,0.00030059856,0.0033336983,0.000102819984,0.0052807387,0.7029471],"study_design_scores_gemma":[0.12375866,0.016577758,0.8007909,0.008073902,0.00026633698,0.000010045744,0.0024147467,0.00005469154,0.044126663,0.0008737465,0.0011461884,0.0019063835],"about_ca_topic_score_codex":0.0005743366,"about_ca_topic_score_gemma":0.00043820275,"teacher_disagreement_score":0.74549764,"about_ca_system_score_codex":0.000031729487,"about_ca_system_score_gemma":0.00017562309,"threshold_uncertainty_score":0.9999914},"labels":[],"label_agreement":null},{"id":"W2551418231","doi":"10.1136/annrheumdis-2016-eular.4314","title":"FRI0184 Increasing Treatment Time on Infliximab Is Predictive of Incrementally Better Long-Term Retention in Stable Infliximab Rheumatology Patients in Canada","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Infliximab; Discontinuation; Internal medicine; Biosimilar; Confidence interval; Population; Cohort; Odds ratio; Rheumatology; Surgery; Demography; Disease","score_opus":0.022186357770935874,"score_gpt":0.26327808073861825,"score_spread":0.2410917229676824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551418231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973809,0.00044728504,0.0000043414398,0.0009854961,0.00012040834,0.0003894766,0.0005139558,0.0000060387547,0.0001520695],"genre_scores_gemma":[0.9991854,0.00029358215,0.000024756917,0.00033048852,0.0000017359166,0.000022209859,0.00002700158,0.000010806915,0.000104064195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979521,0.0006310316,0.0007184857,0.0002458481,0.000116491756,0.00033605174],"domain_scores_gemma":[0.99854404,0.0005899148,0.00038407935,0.000350594,0.00009495191,0.000036433652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024222519,0.00020498697,0.0005692772,0.0001342614,0.00004107729,0.0000047521953,0.0002560646,0.000109157925,0.00049500103],"category_scores_gemma":[0.00040849292,0.00011488704,0.00013200592,0.00016655622,0.00022788908,0.00010826458,0.00012116918,0.000076272714,0.00001017983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011477708,0.0008594549,0.9726351,0.00010737983,0.00030401067,0.0000016002115,0.00013382923,0.000002830356,0.0012537946,0.000032870368,0.00074657926,0.022774775],"study_design_scores_gemma":[0.0026748606,0.00039515982,0.9625564,0.0016461,0.000061653765,0.0000019076454,0.000042194693,0.00001684319,0.032023735,0.0004229543,0.000023338262,0.00013485433],"about_ca_topic_score_codex":0.13673969,"about_ca_topic_score_gemma":0.031055609,"teacher_disagreement_score":0.10568407,"about_ca_system_score_codex":0.0002211968,"about_ca_system_score_gemma":0.00028949068,"threshold_uncertainty_score":0.9866251},"labels":[],"label_agreement":null},{"id":"W2551983394","doi":"10.4155/bio-2016-4989","title":"2016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV): (Part 3 – Lba, Biomarkers and Immunogenicity)","year":2016,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Health Canada; U.S. Food and Drug Administration; Ministry of Health, Labour and Welfare; World Health Organization; Sanofi","keywords":"Bioanalysis; Immunogenicity; Biopharmaceutical; Biosimilar; Excellence; Computer science; Nanotechnology; Medicine; Political science; Biotechnology; Biology","score_opus":0.026761797942422585,"score_gpt":0.28505471707237995,"score_spread":0.2582929191299574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551983394","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3472396,0.21050557,0.0037176195,0.3577669,0.0060044066,0.0040097125,0.0020959345,0.0011730717,0.067487165],"genre_scores_gemma":[0.96216017,0.020291278,0.0007748503,0.0012376796,0.00009421394,0.000066944405,0.000098615346,0.00006237008,0.015213901],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955839,0.0014716021,0.00095201103,0.0011010267,0.00018605242,0.00070543034],"domain_scores_gemma":[0.9978528,0.0006541445,0.00032719685,0.00090599235,0.00015690428,0.00010297446],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020755278,0.0005283015,0.0008986374,0.0011302605,0.00019570209,0.00006843492,0.00036765734,0.00064048223,0.0047061252],"category_scores_gemma":[0.00055623334,0.00031907344,0.00046476882,0.0015499204,0.00050934334,0.00018028611,0.000138468,0.0002411868,0.0005176108],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001567022,0.00085312664,0.02739771,0.000020451362,0.006806134,0.000025027806,0.00007602037,0.0000017504719,0.23649873,0.0007846835,0.010569844,0.7153995],"study_design_scores_gemma":[0.004843192,0.00083417376,0.043433107,0.00051340694,0.0025538285,0.000015540183,0.00027152474,0.000046812787,0.2621569,0.0014880638,0.6822808,0.0015626652],"about_ca_topic_score_codex":0.00028128654,"about_ca_topic_score_gemma":0.0002402509,"teacher_disagreement_score":0.71383685,"about_ca_system_score_codex":0.00019296524,"about_ca_system_score_gemma":0.00004972616,"threshold_uncertainty_score":0.99992615},"labels":[],"label_agreement":null},{"id":"W2552475238","doi":"10.1136/annrheumdis-2016-eular.3760","title":"AB1040 Comparison of Adherence and Dosing Interval of Subcutaneous anti-TNF Biologics in Inflammatory Arthritis from A Canadian Administrative Database","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Université Laval","funders":"","keywords":"Medicine; Golimumab; Adalimumab; Psoriatic arthritis; Certolizumab pegol; Etanercept; Rheumatoid arthritis; Infliximab; Dosing; Internal medicine; Database; Arthritis; Vial; Ankylosing spondylitis; Tumor necrosis factor alpha","score_opus":0.07874937164161133,"score_gpt":0.3501252070028586,"score_spread":0.27137583536124726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552475238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902674,0.0071880203,0.0000205761,0.00055390224,0.000097538876,0.00014200794,0.0016784495,0.0000041938733,0.000047919602],"genre_scores_gemma":[0.9988556,0.0008960211,0.00013960426,0.00007281511,0.000002636649,0.0000029456662,0.0000125073,0.0000041174776,0.000013767532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874675,0.00032853396,0.0005374924,0.0001598601,0.000039220886,0.00018815616],"domain_scores_gemma":[0.99856275,0.00073589274,0.00031777206,0.0002610771,0.00007124404,0.00005126416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019601393,0.00011912191,0.00048256398,0.00006921687,0.000034346886,0.0000047032236,0.00024012962,0.000102244594,0.00019750322],"category_scores_gemma":[0.0007256403,0.00006677735,0.00009168376,0.000085877924,0.0008206656,0.000051018924,0.00009755076,0.00007724943,0.0000020823595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007703046,0.0007055431,0.5679182,0.00037121726,0.0006285318,0.000020922847,0.0011085244,0.0000016612023,0.08617231,0.0018525205,0.0017239153,0.33872637],"study_design_scores_gemma":[0.0017063635,0.0011941182,0.5979787,0.008758244,0.00016886706,0.000024129911,0.0021085106,0.00005514477,0.38174164,0.0054758606,0.00038515805,0.00040323831],"about_ca_topic_score_codex":0.0059266808,"about_ca_topic_score_gemma":0.007419869,"teacher_disagreement_score":0.33832315,"about_ca_system_score_codex":0.0000074437207,"about_ca_system_score_gemma":0.000141989,"threshold_uncertainty_score":0.89594084},"labels":[],"label_agreement":null},{"id":"W2555526897","doi":"10.1182/blood.v118.21.1024.1024","title":"The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Biosimilar; Clinical trial; Receipt; Family medicine; Internal medicine; Computer science","score_opus":0.1733591990452234,"score_gpt":0.3415105808589491,"score_spread":0.1681513818137257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555526897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98872656,0.005294336,0.0000519865,0.00050843245,0.0005453987,0.00036101084,0.00001838079,0.000060893628,0.0044330326],"genre_scores_gemma":[0.9896824,0.0002741874,0.0034798253,0.00013250216,0.000029541556,0.000020352012,0.000010230321,0.000015408707,0.006355573],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806815,0.00057452335,0.00033780246,0.00033140686,0.00009146789,0.00059665926],"domain_scores_gemma":[0.9985172,0.0008221873,0.000063626394,0.00028933169,0.00024408744,0.0000635797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021659283,0.00016272021,0.00022442792,0.00014529575,0.00068030425,0.000051776682,0.00033739518,0.0002367884,0.00035854813],"category_scores_gemma":[0.0006836309,0.00010111296,0.000043419597,0.0004874807,0.00065466913,0.000051847008,0.00030854528,0.0005348767,0.00012424459],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019624103,0.0034312117,0.27426392,0.0001151885,0.0038210445,0.00011306924,0.010353401,6.323875e-8,0.39614928,0.008567308,0.063750766,0.23747233],"study_design_scores_gemma":[0.0020301885,0.0001367105,0.071533754,0.000013538566,0.000072357485,0.000035601977,0.0010814801,0.0000035020792,0.77317053,0.00030034315,0.15140551,0.00021645451],"about_ca_topic_score_codex":0.00006226346,"about_ca_topic_score_gemma":0.00014040974,"teacher_disagreement_score":0.37702125,"about_ca_system_score_codex":0.000018365126,"about_ca_system_score_gemma":0.0001335014,"threshold_uncertainty_score":0.52324194},"labels":[],"label_agreement":null},{"id":"W2555804000","doi":"10.1136/annrheumdis-2016-eular.4242","title":"AB0191 Durability of First Biologic Disease-Modifying Antirheumatic Drug Is Not Influenced by Initial/early DAS28","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University","funders":"","keywords":"Medicine; Antirheumatic drugs; Internal medicine; Population; Drug; Rheumatology; Antirheumatic Agents; Surgery; Pharmacology","score_opus":0.051465725922420984,"score_gpt":0.3293689553802522,"score_spread":0.2779032294578312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555804000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841646,0.0040027653,0.00009389483,0.009499834,0.00024209688,0.00037710503,0.001490715,0.000043354543,0.0000856353],"genre_scores_gemma":[0.99790955,0.00093781704,0.000053860877,0.0007220186,0.0000056833546,0.000018383003,0.000010408281,0.000015287189,0.0003269987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976177,0.0005658609,0.00088499393,0.00037243596,0.00013574198,0.0004232218],"domain_scores_gemma":[0.9967355,0.0014999242,0.0005742532,0.0008957011,0.00019116815,0.0001034262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005443004,0.00028142935,0.00069764646,0.000071869836,0.00019016828,0.00001563724,0.00078007975,0.00014274231,0.0008837274],"category_scores_gemma":[0.0021832304,0.00014012327,0.0004943239,0.000194638,0.0014286661,0.00015601832,0.0002763557,0.00011500602,0.000044286204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042673815,0.0056847804,0.5751442,0.006197906,0.0042859167,0.000005934263,0.0021811863,0.000010380114,0.09633438,0.0038897914,0.112581804,0.1894164],"study_design_scores_gemma":[0.0023727755,0.00033547054,0.6926719,0.004226331,0.0005493332,0.0000044699195,0.00019767198,0.000037781214,0.268601,0.028813908,0.0014818168,0.0007075355],"about_ca_topic_score_codex":0.000111523215,"about_ca_topic_score_gemma":0.0000036888266,"teacher_disagreement_score":0.18870886,"about_ca_system_score_codex":0.000013711855,"about_ca_system_score_gemma":0.0000652128,"threshold_uncertainty_score":0.96761954},"labels":[],"label_agreement":null},{"id":"W2560748104","doi":"10.18433/j3nk60","title":"Evaluation and Optimization of Blood Micro-Sampling Methods: Serial Sampling in a Cross-Over Design from an Individual Mouse","year":2016,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Blood sampling; Medicine; Sampling (signal processing); Pharmacokinetics; Pharmacology; Surgery; Internal medicine; Computer science","score_opus":0.27429125980053976,"score_gpt":0.5212408303691027,"score_spread":0.24694957056856298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560748104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84127116,0.0048275217,0.15266356,0.00046666205,0.00050897646,0.00020278801,0.00003929781,0.000007893565,0.000012159372],"genre_scores_gemma":[0.6524948,0.0007321475,0.34637624,0.000250851,0.00012665798,0.0000029012976,0.0000017550777,0.000008489579,0.0000061817086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963057,0.0019830663,0.00080986274,0.00030769568,0.0002610202,0.00033263204],"domain_scores_gemma":[0.9975108,0.0015935041,0.00041961728,0.00008132647,0.00028998224,0.00010476939],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011711272,0.00016601018,0.00037119808,0.0002218412,0.00013516653,0.00007308331,0.0003853473,0.00012839267,0.0012444062],"category_scores_gemma":[0.0011334432,0.00010187763,0.000084887695,0.00031123645,0.000803471,0.0006467374,0.00010008168,0.00029414578,0.0000010628229],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005308405,0.00021332993,0.0071006534,0.00000602888,0.0001440503,0.0000013951982,0.000167858,0.0018997865,0.8671831,0.00002517014,0.000007232954,0.12272059],"study_design_scores_gemma":[0.006880254,0.0003408157,0.0023395768,0.00008358622,0.0007286082,0.00004294827,0.00007790613,0.0077911564,0.9798574,0.00088312704,0.0007915473,0.0001830656],"about_ca_topic_score_codex":0.000028455011,"about_ca_topic_score_gemma":0.000002189751,"teacher_disagreement_score":0.19371268,"about_ca_system_score_codex":0.000036779944,"about_ca_system_score_gemma":0.00021425405,"threshold_uncertainty_score":0.9996686},"labels":[],"label_agreement":null},{"id":"W2561655163","doi":"","title":"Subsequent entry biologic (biosimilar) monoclonal antibodies in Canada: A review of key regulatory issues and lessons learned","year":2016,"lang":"en","type":"review","venue":"Immunome Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Monoclonal antibody; Key (lock); Computer science; Computational biology; Medicine; Antibody; Immunology; Biology; Computer security; Internal medicine","score_opus":0.23960199445565342,"score_gpt":0.4691900245388563,"score_spread":0.22958803008320286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561655163","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009788206,0.99467975,5.5382276e-7,0.002884482,0.00023113626,0.00089270866,0.00048400453,0.00001368612,0.0007158111],"genre_scores_gemma":[0.00008889946,0.99630994,0.0001007822,0.00009552958,0.00003593008,0.00008760166,0.00008461116,0.000037140606,0.0031595624],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925369,0.0039682966,0.0013544192,0.00083762343,0.00023047498,0.0010722853],"domain_scores_gemma":[0.9966536,0.0017255933,0.00037915228,0.0008713393,0.00029647272,0.00007383507],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0049489983,0.0005227117,0.00306483,0.00051341957,0.000154059,0.000018729115,0.0008695916,0.0007806483,0.0010620661],"category_scores_gemma":[0.0010634852,0.00032395998,0.00036169656,0.00066155224,0.0013765027,0.000055802804,0.00070594775,0.0016018356,0.000052289437],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005260758,0.00008606296,0.00015159568,0.051099777,0.00057319395,0.000047824364,0.000014353715,4.1930845e-9,0.00070816994,0.001006234,0.009389913,0.9368703],"study_design_scores_gemma":[0.0002747875,0.00012086328,0.00047447276,0.09922501,0.00012016117,0.00006404105,0.000029966253,6.6087004e-8,0.0002774959,0.00019046168,0.8988836,0.00033912735],"about_ca_topic_score_codex":0.07575391,"about_ca_topic_score_gemma":0.016609676,"teacher_disagreement_score":0.9365311,"about_ca_system_score_codex":0.0007368607,"about_ca_system_score_gemma":0.0035103108,"threshold_uncertainty_score":0.99992126},"labels":[],"label_agreement":null},{"id":"W2561702912","doi":"10.1017/s0266462316000532","title":"ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS","year":2016,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Reimbursement; Agency (philosophy); Business; Regulatory agency; Health technology; Adverse effect; Cost–benefit analysis; Public economics; Medicine; Actuarial science; Health care; Political science; Economic growth; Economics; Pharmacology","score_opus":0.02529258073609672,"score_gpt":0.40451086535328457,"score_spread":0.3792182846171879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561702912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76862943,0.015304722,0.004057604,0.20302312,0.007237584,0.0004597793,0.00023381367,0.00008562229,0.0009682964],"genre_scores_gemma":[0.99359274,0.0030203105,0.0019961835,0.0012646349,0.000067925575,0.0000040514824,0.0000051361017,0.000009462963,0.00003955244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99853873,0.00018376436,0.00069867563,0.00017577628,0.00013373328,0.00026931844],"domain_scores_gemma":[0.99894804,0.00038192506,0.00040972373,0.00012831668,0.00009207936,0.000039927363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000522651,0.00012854225,0.0002946411,0.0005198034,0.000055318913,0.00000835161,0.00047759173,0.00023618017,0.00038939403],"category_scores_gemma":[0.00019139168,0.00008552351,0.0000875152,0.000087635155,0.00024308095,0.00007366708,0.00012116725,0.00058978697,0.000021997508],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031726828,0.0006689331,0.1769481,0.000027447148,0.00034591532,0.00016279804,0.00010856629,0.0000097385655,0.051477414,0.019583866,0.0026496605,0.7477003],"study_design_scores_gemma":[0.01536553,0.0051313685,0.25335225,0.003601859,0.0000950544,0.0014616831,0.0050433227,0.000020954238,0.19525169,0.007706033,0.5121487,0.00082156115],"about_ca_topic_score_codex":0.000003464844,"about_ca_topic_score_gemma":0.000002878342,"teacher_disagreement_score":0.74687874,"about_ca_system_score_codex":0.0008340975,"about_ca_system_score_gemma":0.0001257279,"threshold_uncertainty_score":0.42635918},"labels":[],"label_agreement":null},{"id":"W2564798600","doi":"10.1080/10543406.2017.1272396","title":"Guest editor’s note: Special issue on biosimilarity assessment","year":2016,"lang":"en","type":"article","venue":"Journal of Biopharmaceutical Statistics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Biopharmaceutical; Management science; Computer science; Economics","score_opus":0.030998349117601735,"score_gpt":0.3864592903826578,"score_spread":0.35546094126505606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564798600","genre_codex":"methods","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042922525,0.0019096495,0.5451886,0.09307758,0.31870183,0.0012078824,0.0073114024,0.00016907167,0.028141696],"genre_scores_gemma":[0.2810482,0.0058461074,0.32470182,0.018916287,0.35654965,0.00001307088,0.000052297582,0.0002052584,0.012667305],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979278,0.00040058146,0.0007755563,0.00022967615,0.00021110728,0.0004553124],"domain_scores_gemma":[0.9976279,0.0013419349,0.00034460082,0.00018454966,0.00032320694,0.00017781013],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00095549144,0.00024371948,0.0004964066,0.00012456665,0.00012574047,0.000030722444,0.00033259633,0.00036185593,0.007246601],"category_scores_gemma":[0.00070161576,0.00013626428,0.00016484891,0.00013471929,0.0005242819,0.00007626665,0.00008434914,0.0007618628,0.00035341264],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006749577,0.00060784625,0.0004459785,0.000021785616,0.00020796533,0.00011939179,0.000013388917,3.2697434e-7,0.10641933,0.004915387,0.7781118,0.10846185],"study_design_scores_gemma":[0.0020609424,0.001015162,0.0022731326,0.00007262709,0.00019912643,0.00007992451,0.000010231567,0.000013389921,0.08884852,0.0010983763,0.9041175,0.00021104855],"about_ca_topic_score_codex":0.0000015258929,"about_ca_topic_score_gemma":0.0000012394794,"teacher_disagreement_score":0.27675593,"about_ca_system_score_codex":0.00017106063,"about_ca_system_score_gemma":0.0001400909,"threshold_uncertainty_score":0.9936609},"labels":[],"label_agreement":null},{"id":"W2579016047","doi":"10.1016/j.jcjo.2016.11.012","title":"Long-term in vitro functional stability of compounded ranibizumab and aflibercept","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Ophthalmology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ranibizumab; Aflibercept; Compounding; Vial; Medicine; Drug; Pharmacology; Surgery; Chromatography; Chemistry; Bevacizumab; Chemotherapy","score_opus":0.05963969846710465,"score_gpt":0.3047843099171201,"score_spread":0.24514461145001543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579016047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99373734,0.0014296856,0.000029648916,0.0006110609,0.0007975506,0.00006988063,0.00003652363,8.450099e-7,0.003287474],"genre_scores_gemma":[0.9993823,0.0000065520935,0.000303452,0.000026587235,0.000029540963,6.8681305e-7,0.0000041033336,0.000006273759,0.00024049701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882984,0.00026049922,0.00043995213,0.00015337423,0.000027652555,0.00028866617],"domain_scores_gemma":[0.99897206,0.00016824322,0.00033798942,0.0002539569,0.00013940487,0.00012833657],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006654733,0.00011572486,0.00046360816,0.00018426287,0.00016851089,0.000018400497,0.00028567328,0.0002828891,0.002699396],"category_scores_gemma":[0.000345881,0.000097611985,0.00009918563,0.000041870993,0.0012028662,0.00009053806,0.000035213583,0.00038878893,0.000004023403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010297174,0.00010941172,0.8621303,0.000045759713,0.0002111925,0.0029339413,0.0001832017,4.7404401e-7,0.12935688,0.00033009457,0.00020058491,0.003468461],"study_design_scores_gemma":[0.0015372961,0.00027849758,0.9419884,0.000026773638,0.000036510195,0.030334925,0.00004851869,0.0000010731317,0.02480113,0.0007219966,0.00012526098,0.00009962392],"about_ca_topic_score_codex":0.0012092011,"about_ca_topic_score_gemma":0.0005648085,"teacher_disagreement_score":0.10455575,"about_ca_system_score_codex":0.00007052482,"about_ca_system_score_gemma":0.00043026728,"threshold_uncertainty_score":0.9982123},"labels":[],"label_agreement":null},{"id":"W2586314633","doi":"10.1093/ecco-jcc/jjx002.706","title":"P582 The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016","year":2017,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Infliximab; Quarter (Canadian coin); European market; Business; Internal medicine; Commerce; Geography","score_opus":0.02207139971678883,"score_gpt":0.3367554119111692,"score_spread":0.31468401219438036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586314633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987403,0.00418368,0.000015640995,0.006101111,0.0006786983,0.00012282681,0.00016344809,0.0000023634573,0.0013292467],"genre_scores_gemma":[0.99620926,0.002112458,0.00015301851,0.000609539,0.0001198647,0.0000014740922,0.0000014705645,0.000008989662,0.0007839131],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99883485,0.00020203087,0.0005357466,0.00014078984,0.000037448222,0.00024915583],"domain_scores_gemma":[0.9988409,0.00017896401,0.00048084784,0.00027510928,0.00015058344,0.00007355547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006317151,0.00014646698,0.00049434864,0.00009909187,0.00013986473,0.000059943315,0.000445135,0.000087937005,0.00049217406],"category_scores_gemma":[0.00017761982,0.00008482044,0.00016458675,0.000060099603,0.00030678112,0.00015471542,0.00015199515,0.00033614592,0.000020539395],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011573645,0.00086692616,0.07048588,0.00005547046,0.00217784,0.0006262707,0.0012533511,0.00003072486,0.17712557,0.000553717,0.598551,0.1366996],"study_design_scores_gemma":[0.0018036601,0.00036460054,0.88499236,0.00011215417,0.00010042323,0.00015334495,0.00006104028,0.0000075046223,0.019786874,0.0004798767,0.09200352,0.00013464337],"about_ca_topic_score_codex":0.00048702385,"about_ca_topic_score_gemma":0.00006838323,"teacher_disagreement_score":0.8145065,"about_ca_system_score_codex":0.000033847908,"about_ca_system_score_gemma":0.00014794634,"threshold_uncertainty_score":0.5388961},"labels":[],"label_agreement":null},{"id":"W2587213758","doi":"10.1093/ecco-jcc/jjx002.058","title":"DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study","year":2017,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Robarts Clinical Trials; Western University","funders":"","keywords":"Vedolizumab; Medicine; Internal medicine; Adverse effect; Ulcerative colitis; Inflammatory bowel disease; Disease","score_opus":0.02820483236420604,"score_gpt":0.32261327643189747,"score_spread":0.2944084440676914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587213758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978293,0.0012762491,0.000061356404,0.00010242292,0.00012482787,0.0005320454,0.000034610457,0.0000010797846,0.00003807443],"genre_scores_gemma":[0.9995454,0.00017259158,0.00020437273,0.000027513048,0.000014131492,0.0000038445605,0.000001999177,0.000008620136,0.00002152255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986014,0.00045757636,0.0004907387,0.00018896208,0.00009353729,0.00016781845],"domain_scores_gemma":[0.9983196,0.00037661273,0.00067359995,0.00027208813,0.0003061327,0.0000519556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008568822,0.00015032459,0.00061578845,0.000067186826,0.000252462,0.0000536435,0.00031748394,0.00009365983,0.000020265341],"category_scores_gemma":[0.0001770672,0.000087093504,0.000046456105,0.00005606232,0.00058816076,0.00017334471,0.00026263593,0.00024581634,1.4657019e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036235493,0.0009556826,0.9294199,0.000111854235,0.00038601458,0.000091433,0.000953656,0.000002616478,0.00028285384,0.000112629925,0.000013893007,0.031433977],"study_design_scores_gemma":[0.010516227,0.0021022235,0.9855317,0.0006333554,0.00018848329,0.0000115330995,0.0003281106,0.000003909058,0.00036468383,0.00018626827,0.000027266327,0.00010627973],"about_ca_topic_score_codex":0.00010022617,"about_ca_topic_score_gemma":0.00005101033,"teacher_disagreement_score":0.056111764,"about_ca_system_score_codex":0.00002319218,"about_ca_system_score_gemma":0.000052533982,"threshold_uncertainty_score":0.355157},"labels":[],"label_agreement":null},{"id":"W2587668874","doi":"10.1093/ecco-jcc/jjx002.551","title":"P426 Supra-therapeutic infliximab levels are not associated with a higher risk of infection in IBD patients","year":2017,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Infliximab; Internal medicine; Cohort; Retrospective cohort study; Logistic regression; Adverse effect; Gastroenterology; Cohort study; Surgery; Tumor necrosis factor alpha","score_opus":0.030663579121408067,"score_gpt":0.29060670604098,"score_spread":0.25994312691957194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587668874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986477,0.0003290024,0.000028822677,0.0002889184,0.0002487127,0.00007292028,0.00006256427,0.0000025161162,0.00031885918],"genre_scores_gemma":[0.99911803,0.000253143,0.00006337657,0.00014352916,0.000021352673,9.5317944e-7,0.0000011051071,0.0000064495043,0.00039204667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908644,0.00022651508,0.00036077542,0.000096279044,0.00005746717,0.00017254667],"domain_scores_gemma":[0.9985216,0.00012719008,0.00094438315,0.00012261973,0.00025661496,0.000027592721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044634,0.0001033539,0.00038871728,0.000086039865,0.00013401783,0.000032543852,0.000095126285,0.0002074225,0.00012623181],"category_scores_gemma":[0.0002318264,0.00006956159,0.000079920224,0.000053134863,0.00023677257,0.00013464608,0.000033881213,0.0003201623,9.878919e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017302266,0.00034275462,0.9829922,0.000017055721,0.00041176175,0.000015815756,0.00008530469,6.576726e-7,0.00043920573,0.00019150671,0.0001738921,0.0135996435],"study_design_scores_gemma":[0.0029178674,0.0007052787,0.98863983,0.00017211035,0.00013821038,0.000014855765,0.00001318631,0.0000016713449,0.0040248353,0.00051860604,0.0027647342,0.00008878964],"about_ca_topic_score_codex":0.00017885979,"about_ca_topic_score_gemma":0.00025299488,"teacher_disagreement_score":0.013510854,"about_ca_system_score_codex":0.000032784577,"about_ca_system_score_gemma":0.0000364308,"threshold_uncertainty_score":0.28366393},"labels":[],"label_agreement":null},{"id":"W2587775289","doi":"10.1080/09537325.2016.1274391","title":"The special issue of the journal <i>Technology Analysis &amp; Strategic Management</i> on biosimilar: capabilities, regulations and affordable healthcare","year":2017,"lang":"en","type":"article","venue":"Technology Analysis and Strategic Management","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Biosimilar; Business; Health care; Strategic management; Knowledge management; Industrial organization; Marketing; Economics; Computer science; Medicine; Economic growth","score_opus":0.024381531467195943,"score_gpt":0.2927091402520469,"score_spread":0.26832760878485096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587775289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7412358,0.008879793,0.0006787018,0.10194937,0.0010394321,0.0015186609,0.00016055114,0.00020421892,0.1443335],"genre_scores_gemma":[0.9846973,0.005446895,0.0011397552,0.00018633952,0.000060497707,0.000025323121,0.000012768325,0.000011561279,0.008419561],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.997686,0.00030518515,0.00072007626,0.00056066277,0.00014455878,0.0005834851],"domain_scores_gemma":[0.9972291,0.000113542694,0.0006801064,0.0017891709,0.00013783586,0.00005025721],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00129926,0.00034307514,0.00077128445,0.0012343088,0.002874544,0.0001609171,0.0011564152,0.00054764724,0.0003369122],"category_scores_gemma":[0.00002485793,0.00020235016,0.00033736852,0.0020720672,0.002639851,0.000057511676,0.0005890866,0.00069954817,0.000007622895],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014839448,0.00017885248,0.0209393,0.00009321215,0.015517957,0.000013282305,0.000054691613,0.000036789927,0.00029442745,0.9498311,0.00094596454,0.011946029],"study_design_scores_gemma":[0.0023017346,0.00070413045,0.039569475,0.000117764415,0.03349824,0.000078025914,0.023877086,0.00034140662,0.002225878,0.8218821,0.0744479,0.00095624314],"about_ca_topic_score_codex":0.000092304035,"about_ca_topic_score_gemma":0.0021238998,"teacher_disagreement_score":0.24346153,"about_ca_system_score_codex":0.000048611855,"about_ca_system_score_gemma":0.000025571855,"threshold_uncertainty_score":0.9984236},"labels":[],"label_agreement":null},{"id":"W2588037807","doi":"10.1093/ndt/gfw163.19","title":"SP238BTP ASSAYS-A COMPARISON BETWEEN NEPHELOMETRIC AND ELISA METHODOLOGIES","year":2016,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Queen's University","funders":"","keywords":"Medicine","score_opus":0.059705777008460054,"score_gpt":0.33288879264494375,"score_spread":0.27318301563648373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588037807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81955755,0.0023120674,0.17193787,0.0042700544,0.00038538652,0.0002663693,0.00017363623,0.00020695348,0.00089010625],"genre_scores_gemma":[0.98678046,0.0016048567,0.010411561,0.0006516477,0.00007942016,0.000021020009,0.000082831786,0.000014648882,0.00035352673],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99730104,0.0012202548,0.00050275977,0.00049210404,0.000059774306,0.00042404357],"domain_scores_gemma":[0.9960357,0.0034610087,0.0001651768,0.00022692769,0.000065037384,0.00004618173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011350979,0.00023975724,0.00066460547,0.00040670641,0.00016458135,0.000016803766,0.00019128202,0.0006232129,0.00053437165],"category_scores_gemma":[0.00026506934,0.0001523014,0.00013780141,0.00044973334,0.00054231193,0.00013416503,0.00003323459,0.00022460453,0.00011651654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004192881,0.00006047736,0.19934955,0.000035203964,0.00078601675,0.000006362537,0.00027098556,0.0000013091307,0.44889012,0.0011371234,0.0011408837,0.34790266],"study_design_scores_gemma":[0.0030703787,0.00043083282,0.7807073,0.000026606818,0.0019101179,0.00004681362,0.000075771146,0.0000057353395,0.19031721,0.003613513,0.019369679,0.00042603991],"about_ca_topic_score_codex":0.00003886082,"about_ca_topic_score_gemma":0.000040620816,"teacher_disagreement_score":0.5813577,"about_ca_system_score_codex":0.000025058565,"about_ca_system_score_gemma":0.00002005624,"threshold_uncertainty_score":0.6210671},"labels":[],"label_agreement":null},{"id":"W2589812281","doi":"","title":"Les biosimilaires : réglementation, développement, et methodes.","year":2011,"lang":"fr","type":"dissertation","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Philosophy","score_opus":0.11166035340870205,"score_gpt":0.4284344786754868,"score_spread":0.3167741252667847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589812281","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022720803,0.055736728,0.10136746,0.031282306,0.021535698,0.0037943155,0.0010973724,0.00073836936,0.761727],"genre_scores_gemma":[0.0465615,0.014524477,0.40018,0.010216361,0.0002590275,0.0002591517,0.0050250385,0.00024036424,0.5227341],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950662,0.0017877407,0.0012062965,0.0009955522,0.00011384964,0.0008303446],"domain_scores_gemma":[0.99779785,0.0006216619,0.00057002675,0.0005070514,0.0003915247,0.000111874484],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015789557,0.0008246856,0.00095035566,0.00033210003,0.0005108812,0.0000656921,0.0005842005,0.0019341434,0.07193108],"category_scores_gemma":[0.00028459085,0.00068645336,0.00048718075,0.00037525973,0.00046289485,0.0001502385,0.00013834122,0.0010194416,0.00075216225],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010295641,0.0014463371,0.014170035,0.0010699659,0.0045295847,0.000026327518,0.0075565805,0.0000012889838,0.20180438,0.31140932,0.076609254,0.38034737],"study_design_scores_gemma":[0.0018102434,0.0007200209,0.05860878,0.00049567595,0.0017406299,0.000030164496,0.005734512,0.00001905845,0.66999954,0.009802975,0.24949442,0.0015439856],"about_ca_topic_score_codex":0.003108751,"about_ca_topic_score_gemma":0.0041579274,"teacher_disagreement_score":0.46819514,"about_ca_system_score_codex":0.00012694983,"about_ca_system_score_gemma":0.00024328285,"threshold_uncertainty_score":0.9995587},"labels":[],"label_agreement":null},{"id":"W2589910009","doi":"10.1007/s40265-017-0693-5","title":"Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview","year":2017,"lang":"en","type":"review","venue":"Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Medicine; Drug; Inflammatory bowel disease; Therapeutic drug monitoring; Pharmacology; Immunogenicity; Monoclonal antibody; Antibody; Pharmacokinetics; Dosing; Immunology; Therapeutic index; Sensitization; Pharmacotherapy; Therapeutic approach; Disease; Internal medicine","score_opus":0.08333870628314687,"score_gpt":0.41256987934238293,"score_spread":0.32923117305923605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589910009","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00071861345,0.9969149,0.000009670601,0.00015232713,0.0003105326,0.00090274244,0.00006588152,0.000025027886,0.0009002967],"genre_scores_gemma":[0.0008103475,0.99696094,0.00038610818,0.00005784616,0.000023482995,0.00004772914,0.00007622744,0.000028445389,0.0016088991],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972697,0.000830006,0.0008621146,0.00056211016,0.00009486896,0.00038119708],"domain_scores_gemma":[0.9982568,0.0002819046,0.0007262592,0.00063647237,0.000050825103,0.000047709982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011256484,0.0004582856,0.0016219753,0.00025241196,0.00014622594,0.000052097195,0.00035648275,0.00039378376,0.000050984778],"category_scores_gemma":[0.00008126993,0.00033716613,0.00041573506,0.00011588837,0.0006768404,0.00016731839,0.0004464544,0.0005144114,0.0000297641],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004088608,0.00024787473,0.0019205216,0.049082354,0.0011257622,0.000093132134,0.000083798834,5.3635876e-8,0.000012604098,0.004718544,0.00047491805,0.9421995],"study_design_scores_gemma":[0.00045250077,0.00002849117,0.013026398,0.03556083,0.0018139434,0.000017258557,0.00008058471,0.0000024641079,0.0000147989085,0.0005448051,0.94799834,0.00045956945],"about_ca_topic_score_codex":0.0000083115,"about_ca_topic_score_gemma":0.0000068199984,"teacher_disagreement_score":0.9475234,"about_ca_system_score_codex":0.00004069832,"about_ca_system_score_gemma":0.00016186721,"threshold_uncertainty_score":0.99990803},"labels":[],"label_agreement":null},{"id":"W2590768478","doi":"10.1016/j.pharma.2017.01.003","title":"A survey of pharmacists’ knowledge and views of biosimilars in Quebec and France","year":2017,"lang":"en","type":"article","venue":"Annales Pharmaceutiques Françaises","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Biosimilar; Viewpoints; Medicine; Family medicine; Pharmacovigilance; Likert scale; Multiple choice; Medical education; Pharmacist; Pharmacy; Pharmacology; Psychology; Drug; Significant difference","score_opus":0.11549210676300678,"score_gpt":0.4157516035675008,"score_spread":0.30025949680449404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590768478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88324606,0.114486165,0.000023722847,0.00031738306,0.00017266654,0.00021540637,0.0001451249,0.000013717438,0.0013797586],"genre_scores_gemma":[0.9851042,0.013651823,0.00017120894,0.0002083736,0.000010788755,0.000008045241,0.000007921686,0.000011786292,0.00082587264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853647,0.0004193937,0.0004558411,0.00030516947,0.00003358277,0.00024953237],"domain_scores_gemma":[0.9988785,0.00036747858,0.0002844559,0.0002870292,0.00013721231,0.00004536165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000983173,0.00020480625,0.00058974733,0.00012390134,0.00015296214,0.00001808029,0.00028870688,0.00019502321,0.0001432644],"category_scores_gemma":[0.00025797036,0.00016895549,0.00006620973,0.00009499025,0.0017362402,0.00016606766,0.0001909268,0.00024864895,0.0000036967044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029924454,0.00028053805,0.7057785,0.00035357173,0.00013108525,0.000005813615,0.0008216125,1.037668e-7,0.15076928,0.000067047506,0.0021629229,0.13933028],"study_design_scores_gemma":[0.0013113221,0.00008216684,0.6353576,0.00013062538,0.000048259197,0.000007662527,0.000020529524,0.000033663062,0.31833366,0.00003855664,0.044461332,0.0001746106],"about_ca_topic_score_codex":0.0028364072,"about_ca_topic_score_gemma":0.0047792294,"teacher_disagreement_score":0.16756438,"about_ca_system_score_codex":0.0000051011166,"about_ca_system_score_gemma":0.00004812351,"threshold_uncertainty_score":0.68898046},"labels":[],"label_agreement":null},{"id":"W2593211227","doi":"10.1016/j.jaad.2016.12.014","title":"Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research","funders":"","keywords":"Adalimumab; Medicine; Psoriasis Area and Severity Index; Clinical endpoint; Confidence interval; Psoriasis; Internal medicine; Adverse effect; Randomized controlled trial; Biosimilar; Surgery; Dermatology; Disease","score_opus":0.05762649998465511,"score_gpt":0.40559744192652836,"score_spread":0.3479709419418732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593211227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98363316,0.0002193417,0.00011947598,0.0139188245,0.00022789877,0.0017903651,0.000063012965,0.0000026960452,0.00002523595],"genre_scores_gemma":[0.99722534,0.00027821117,0.0011161516,0.0012973364,0.000027594951,0.000027739869,0.0000010500878,0.00001283089,0.000013762018],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99483335,0.002441415,0.0019259325,0.00027598694,0.00018103576,0.0003423073],"domain_scores_gemma":[0.99495775,0.0010037448,0.003239682,0.0005149355,0.00020465473,0.00007923777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013754588,0.00028482036,0.0025249599,0.00022159092,0.00014619424,0.000012145608,0.0013032306,0.00023092786,0.000017548327],"category_scores_gemma":[0.00036273996,0.00013392341,0.0005131642,0.00023189172,0.001448872,0.000085067186,0.00017227406,0.0005996484,0.0000013272066],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86059856,0.010319478,0.11712756,0.000025436066,0.0024297708,0.000018185268,0.0017939031,0.000036610985,0.00057958195,0.000044040786,0.0005922294,0.0064346325],"study_design_scores_gemma":[0.8825285,0.0108180465,0.07451525,0.00021095086,0.0021706382,0.00020572511,0.0019776216,0.000051177863,0.025099864,0.00015517882,0.0019188762,0.00034815408],"about_ca_topic_score_codex":0.00012542812,"about_ca_topic_score_gemma":0.00004570865,"teacher_disagreement_score":0.042612303,"about_ca_system_score_codex":0.00003758103,"about_ca_system_score_gemma":0.00008609068,"threshold_uncertainty_score":0.54612386},"labels":[],"label_agreement":null},{"id":"W2593330344","doi":"10.1007/978-3-319-33703-6_47","title":"Biosimilars in the Treatment of Inflammatory Bowel Disease","year":2017,"lang":"en","type":"book-chapter","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Biosimilar; Infliximab; Medicine; Innovator; Inflammatory bowel disease; Biologic Agents; Monoclonal antibody; Tumor necrosis factor alpha; Disease; Intensive care medicine; Immunology; Rheumatoid arthritis; Internal medicine; Antibody","score_opus":0.03412152190006254,"score_gpt":0.29007605643304335,"score_spread":0.2559545345329808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593330344","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005196399,0.01881434,0.000011094444,0.003420368,0.00067326747,0.00083114573,0.00031690247,0.000031864416,0.9753814],"genre_scores_gemma":[0.010660815,0.006708809,0.00011933774,0.00083471835,0.00007832208,0.000023974699,0.000072889394,0.000032886648,0.98146826],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989844,0.00008351443,0.00036677314,0.0003014656,0.00004519955,0.00021864739],"domain_scores_gemma":[0.99866015,0.0001903281,0.00021922703,0.0008671673,0.000034940836,0.000028174245],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022287961,0.0003089198,0.00044198634,0.00010887865,0.0000888215,0.000012637246,0.00042748495,0.0005547221,0.0020064532],"category_scores_gemma":[0.00002869041,0.00016351757,0.00033840848,0.0000065221775,0.00063474843,0.000022437227,0.000041619343,0.00022319217,0.00011005744],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025473963,0.002730542,0.010195232,0.0005769115,0.0038803723,0.0008818976,0.0013844081,0.0000015928115,0.0051824497,0.6597332,0.123692326,0.18919371],"study_design_scores_gemma":[0.0007264972,0.00034164955,0.0049358727,0.000107005646,0.00028886937,0.0000055658134,0.000015717149,0.0000010243137,0.0011244728,0.00837977,0.9838253,0.00024825856],"about_ca_topic_score_codex":0.00001276622,"about_ca_topic_score_gemma":0.000073194366,"teacher_disagreement_score":0.860133,"about_ca_system_score_codex":0.000039910352,"about_ca_system_score_gemma":0.00008161947,"threshold_uncertainty_score":0.99890584},"labels":[],"label_agreement":null},{"id":"W2593485868","doi":"10.1007/s40265-017-0717-1","title":"The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects","year":2017,"lang":"en","type":"review","venue":"Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; Pfizer","keywords":"Biosimilar; Medicine; Clinical trial; Terminology; Risk analysis (engineering); Intensive care medicine; Internal medicine","score_opus":0.09806852305771535,"score_gpt":0.36849101172204035,"score_spread":0.270422488664325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593485868","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000044271114,0.99401575,0.000004084226,0.0003177706,0.00029565772,0.00025384783,0.00015126793,0.000019964671,0.0049372236],"genre_scores_gemma":[0.00006595623,0.9975688,0.0001619685,0.00007583801,0.000039856324,0.000024149625,0.00007856531,0.000017877317,0.001967032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861574,0.00043069953,0.00043974342,0.0002733236,0.00003517806,0.00020528956],"domain_scores_gemma":[0.9980306,0.00060542,0.0004761947,0.0008134845,0.000052781696,0.000021499704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008183816,0.00021733785,0.00081144937,0.00007114199,0.00036635494,0.000034416833,0.0004155644,0.0006207761,0.00006524892],"category_scores_gemma":[0.00028894952,0.0001247619,0.00025187826,0.00007312236,0.000834646,0.000026391535,0.00011713551,0.00043280888,0.00004798506],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000038776234,0.000023283774,0.0000014709708,0.0010660214,0.0002544672,0.0000011912383,0.00006793334,4.6966925e-10,0.00003637059,0.016663792,0.006880315,0.9750013],"study_design_scores_gemma":[0.00010706425,0.000020771422,0.000029033015,0.0012652572,0.000540268,0.000027300295,0.00008727413,4.8408314e-8,0.00019672076,0.0007907465,0.9967913,0.00014422709],"about_ca_topic_score_codex":0.000009177495,"about_ca_topic_score_gemma":0.0000059515687,"teacher_disagreement_score":0.98991096,"about_ca_system_score_codex":0.00001757473,"about_ca_system_score_gemma":0.000118872944,"threshold_uncertainty_score":0.5087642},"labels":[],"label_agreement":null},{"id":"W2596491583","doi":"","title":"Biosimilars regulations: Updates from Canada","year":2016,"lang":"en","type":"article","venue":"Journal of Bioanalysis & Biomedicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Computer science; Data science; Medicine","score_opus":0.010964908480154478,"score_gpt":0.2475670330854667,"score_spread":0.23660212460531224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596491583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50258744,0.08636181,0.018455166,0.38254952,0.007129138,0.00036760737,0.0010763924,0.00008435497,0.0013885861],"genre_scores_gemma":[0.99304944,0.0010477417,0.0020022318,0.002159954,0.0003135491,9.2908715e-7,0.000023248513,0.00001392115,0.0013889788],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979574,0.00024251414,0.00104064,0.00024164171,0.00019445045,0.0003233708],"domain_scores_gemma":[0.99788296,0.00058116706,0.0006978181,0.000349613,0.00037418318,0.00011426489],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007539074,0.00021761967,0.00074502773,0.00040757566,0.00009635571,0.000011137043,0.00040155018,0.00021320612,0.004020941],"category_scores_gemma":[0.0004630619,0.00010656616,0.0002776472,0.0006773054,0.00056204904,0.000103951934,0.000057058423,0.00020115446,0.000022604545],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002389253,0.00013161145,0.014573607,0.000006249392,0.002866436,0.00006972578,0.000029824336,3.41683e-7,0.7202153,0.00009031577,0.13552062,0.12625705],"study_design_scores_gemma":[0.0038017181,0.0005181099,0.05446355,0.0003618784,0.0025576442,0.0001652185,0.00039501095,0.00000753332,0.26497456,0.0014503984,0.6708755,0.00042889357],"about_ca_topic_score_codex":0.017500857,"about_ca_topic_score_gemma":0.018316709,"teacher_disagreement_score":0.53535485,"about_ca_system_score_codex":0.00016320209,"about_ca_system_score_gemma":0.00031989097,"threshold_uncertainty_score":0.9995965},"labels":[],"label_agreement":null},{"id":"W2596496142","doi":"10.1182/blood.v128.22.5391.5391","title":"Comparison of Pharmacokinetics and Pharmacodynamics of Two Anti-CD20 Monoclonal Antibodies (Candidate Biosimilar DRL-Rituximab and Innovator Reference Product Rituximab (Mabthera®) in a Randomised, Multi-Centre, Double-Blind, Parallel Group Study of CHOP with Rituximab Chemotherapy in Patients with CD20-Positive Diffuse Large B-Cell Lymphoma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Rituximab; Medicine; Pharmacodynamics; Cmax; Biosimilar; Internal medicine; Pharmacokinetics; Prednisone; Pharmacology; European union; CHOP; Cyclophosphamide; Vincristine; Gastroenterology; Oncology; Lymphoma; Chemotherapy","score_opus":0.02019780311363597,"score_gpt":0.30602112059193826,"score_spread":0.2858233174783023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596496142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956393,0.0016723595,0.00014826926,0.0000779967,0.000045874065,0.0020209716,0.0003654514,0.00001622735,0.000013498767],"genre_scores_gemma":[0.99650323,0.0007512642,0.0025556984,0.000048259197,0.000008951816,0.00003373689,0.000044554843,0.000038607894,0.000015667152],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972008,0.00040566624,0.0010011423,0.0007123781,0.00016432282,0.0005157219],"domain_scores_gemma":[0.9984577,0.0002017198,0.0006533798,0.00033022746,0.00030056984,0.00005644878],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048503015,0.00048762443,0.0015782694,0.0003385526,0.0000611599,0.000013508933,0.00026005413,0.00018240644,0.000017792067],"category_scores_gemma":[0.00002094051,0.00030857802,0.000053991902,0.00048743637,0.00064023904,0.00014838912,0.00014539248,0.00027216115,6.288433e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064962655,0.11589277,0.7351511,0.00017956665,0.0007322068,0.000008624788,0.0010819045,9.268086e-7,0.080300055,0.000026625725,0.0000050094336,0.0016585706],"study_design_scores_gemma":[0.6873783,0.00151618,0.16501051,0.0002516401,0.0003806781,0.000005090548,0.00021960754,0.000084916435,0.14477864,0.0000051397797,0.000020667288,0.00034861753],"about_ca_topic_score_codex":0.00013445479,"about_ca_topic_score_gemma":0.00023628127,"teacher_disagreement_score":0.62241566,"about_ca_system_score_codex":0.000025866626,"about_ca_system_score_gemma":0.000057482433,"threshold_uncertainty_score":0.99993664},"labels":[],"label_agreement":null},{"id":"W2598481489","doi":"10.1002/hep.27525","title":"Poster Session 3: Cost-Effectiveness; HCV: Diagnostics, Epidemiology, and Natural History","year":2014,"lang":"en","type":"article","venue":"Hepatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia; University of California, San Francisco; Université de Montréal; Monash University; Westmead Millennium Institute for Medical Research; University of New South Wales; Burnet Institute; Johns Hopkins University; Newcastle University; Gilead Sciences","keywords":"Session (web analytics); Natural history; Epidemiology; Virology; Medicine; Computer science; Internal medicine; World Wide Web","score_opus":0.050442967634978235,"score_gpt":0.3288191107609823,"score_spread":0.27837614312600406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598481489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8476613,0.11096618,0.005371952,0.010280523,0.014444986,0.0012888,0.00004021491,0.00036121806,0.009584784],"genre_scores_gemma":[0.99277264,0.00044687162,0.0005157602,0.005377914,0.000048688187,0.000034173616,0.000034727356,0.00001577768,0.00075345347],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959396,0.0027271968,0.0003286194,0.00048041256,0.00001746599,0.00050668477],"domain_scores_gemma":[0.99425554,0.005223486,0.0001215878,0.0002765962,0.00006497294,0.000057824447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013552211,0.0002231114,0.0006673701,0.00009238787,0.000108348,0.0000027093254,0.0001511697,0.00063475454,0.00046794146],"category_scores_gemma":[0.002874828,0.00016612926,0.000096525146,0.000047953446,0.0009495357,0.000045568093,0.00016463514,0.00051794155,0.00014669099],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029165568,0.0001264745,0.84703994,0.000081027596,0.00015905575,0.000015400476,0.00005580577,1.1272937e-7,0.014414501,0.020598792,0.032526765,0.08469047],"study_design_scores_gemma":[0.0012301957,0.00034368425,0.27675778,0.00004243181,0.000108141496,0.00021683949,0.000009645534,0.00013117945,0.004689306,0.0033046983,0.7128495,0.00031662043],"about_ca_topic_score_codex":0.00008350236,"about_ca_topic_score_gemma":0.000035024594,"teacher_disagreement_score":0.6803227,"about_ca_system_score_codex":0.00009141078,"about_ca_system_score_gemma":0.00003520077,"threshold_uncertainty_score":0.6774554},"labels":[],"label_agreement":null},{"id":"W2606513711","doi":"10.1016/j.clinthera.2017.03.014","title":"Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues","year":2017,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Arthritis Society; Pfizer","keywords":"Biosimilar; Medicine; Tolerability; Interchangeability; Pharmacovigilance; Comparability; Harmonization; Intensive care medicine; Risk analysis (engineering); Pharmacology; Adverse effect; Internal medicine; Computer science","score_opus":0.5280349009826678,"score_gpt":0.5524155657184614,"score_spread":0.02438066473579359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606513711","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025402458,0.99488246,0.000007963034,0.0023416206,0.0015350911,0.0007197348,0.000081670594,0.000026241165,0.000402702],"genre_scores_gemma":[0.000004685299,0.9952931,0.00050119165,0.003002611,0.00010746667,0.000013522552,0.000013984917,0.000029672938,0.001033767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953204,0.002003955,0.0017326808,0.00054237794,0.000060837636,0.00033979185],"domain_scores_gemma":[0.99524605,0.0017241889,0.001491615,0.0013736557,0.00012375665,0.00004075864],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0028436582,0.0004584087,0.0037077614,0.000040555897,0.00020522616,0.000024416526,0.0012104533,0.0013417493,0.00008961535],"category_scores_gemma":[0.001223432,0.0002191183,0.0012333249,0.00014431759,0.0021302865,0.00002408518,0.00058320136,0.0014148275,0.000027328306],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010029329,0.00011828992,0.00027870742,0.023200283,0.0010360294,0.0000014131369,0.0000035061587,8.7464863e-10,0.0000025340212,0.00058995275,0.0044426313,0.97031665],"study_design_scores_gemma":[0.0001932759,0.00015047174,0.000055850072,0.06241169,0.002812061,0.000028799011,0.0000021807705,7.1707916e-7,0.000014024798,0.0003208044,0.93374974,0.00026039124],"about_ca_topic_score_codex":0.0000017113398,"about_ca_topic_score_gemma":0.000001081794,"teacher_disagreement_score":0.97005624,"about_ca_system_score_codex":0.000020939337,"about_ca_system_score_gemma":0.0001776768,"threshold_uncertainty_score":0.9999547},"labels":[],"label_agreement":null},{"id":"W2606747790","doi":"10.13162/hro-ors.v5i1.2982","title":"Revising the Guidance Document for Biosimilar Agents","year":2017,"lang":"fr","type":"article","venue":"Health Reform Observer - Observatoire des Réformes de Santé","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Biosimilar; Computer science; Medicine; Data science; Internal medicine","score_opus":0.10883940744285545,"score_gpt":0.407574076997511,"score_spread":0.29873466955465555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606747790","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15462843,0.53135484,0.00688506,0.28189424,0.012565181,0.0058546094,0.0016717607,0.00028265425,0.00486323],"genre_scores_gemma":[0.30406314,0.29259443,0.14861827,0.14040992,0.004267874,0.0010498859,0.00045796784,0.0006407753,0.10789771],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99310535,0.0009740248,0.0016929674,0.0010214029,0.00022137813,0.0029848886],"domain_scores_gemma":[0.99466777,0.0005121128,0.0015297456,0.0025050738,0.00038751413,0.00039775818],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0059793866,0.0008667478,0.0013652081,0.00007559817,0.0070506753,0.00051319366,0.002284177,0.0011021429,0.000582814],"category_scores_gemma":[0.0010190625,0.0005833365,0.00086988887,0.00023910277,0.002574035,0.0010222386,0.00077792833,0.0010758506,0.00010353619],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008664491,0.00047874122,0.061284676,0.0062958817,0.0012172327,0.000039992083,0.0016178887,0.000005105002,0.0005859327,0.015982334,0.077554785,0.834071],"study_design_scores_gemma":[0.0017504465,0.00078436016,0.26973078,0.002392457,0.00019142237,0.0001121533,0.00043529316,0.0003669631,0.002295686,0.006526506,0.71479696,0.0006170033],"about_ca_topic_score_codex":0.0026624424,"about_ca_topic_score_gemma":0.0016977984,"teacher_disagreement_score":0.83345395,"about_ca_system_score_codex":0.002567138,"about_ca_system_score_gemma":0.0008900155,"threshold_uncertainty_score":0.9996618},"labels":[],"label_agreement":null},{"id":"W2607307651","doi":"10.1007/s12325-017-0523-x","title":"Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada); Université de Montréal","funders":"Merck","keywords":"Medicine; Rheumatoid arthritis; Crossover study; Randomized controlled trial; Crossover; Preference; Rheumatology; Health professionals; Health care; Internal medicine; Physical therapy; Alternative medicine; Statistics","score_opus":0.03973123510095347,"score_gpt":0.3763175813045308,"score_spread":0.3365863462035773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607307651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9155506,0.0739714,0.0009644715,0.0013622488,0.0011725246,0.006642239,0.00026235436,0.00005173441,0.000022460716],"genre_scores_gemma":[0.9814083,0.014815519,0.0021049897,0.00071002427,0.000017544224,0.00067396427,0.000015511338,0.000019638119,0.00023452449],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99824655,0.0003944862,0.0004926289,0.00044885094,0.000044546006,0.00037295168],"domain_scores_gemma":[0.9973216,0.0017954214,0.0003256167,0.00038207322,0.00014323015,0.00003207441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073787733,0.00022370163,0.00077614037,0.000053121654,0.00052102504,0.0000730912,0.00021065064,0.00021801353,0.000035097273],"category_scores_gemma":[0.0008163923,0.00015132425,0.00012769425,0.00003346009,0.00038758418,0.00032352554,0.00006889816,0.00018966415,0.0000012708623],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35492188,0.0021390715,0.024099056,0.00014550945,0.000583344,0.000004054116,0.0035009373,0.00001632753,0.0027666595,0.0042832275,0.00051490247,0.607025],"study_design_scores_gemma":[0.7597728,0.009130701,0.02136829,0.0012664875,0.000056337565,0.000019030567,0.0012269982,0.00052976096,0.02159519,0.039848838,0.14384277,0.0013428233],"about_ca_topic_score_codex":0.00007820901,"about_ca_topic_score_gemma":0.00015565573,"teacher_disagreement_score":0.6056822,"about_ca_system_score_codex":0.000019067795,"about_ca_system_score_gemma":0.000050348368,"threshold_uncertainty_score":0.61708236},"labels":[],"label_agreement":null},{"id":"W2610333505","doi":"10.1201/9781315119298-25","title":"Biologic therapies in the pipeline","year":2017,"lang":"en","type":"book-chapter","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pipeline (software); Computer science; Medicine; Intensive care medicine; Programming language","score_opus":0.06381193506163331,"score_gpt":0.3116979126017892,"score_spread":0.2478859775401559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610333505","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011226942,0.011520075,0.000060750128,0.0050388547,0.00041260364,0.0002033981,0.000035842426,0.000027574953,0.9826897],"genre_scores_gemma":[0.0060717682,0.0016535844,0.00021669717,0.0027766663,0.00008334246,0.0000055089863,0.000039460305,0.000013115053,0.98913985],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99911183,0.0001077215,0.00025009242,0.00028476413,0.000023637236,0.00022195997],"domain_scores_gemma":[0.99894243,0.00028198675,0.00013389553,0.00060503586,0.000029333398,0.000007336604],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006608746,0.00025125296,0.00039684225,0.00006837039,0.00013090795,0.000024804036,0.0006617808,0.00094134785,0.0070246486],"category_scores_gemma":[0.00006339586,0.00011346707,0.00017609393,0.000006803679,0.00058667216,0.000016442438,0.000092457405,0.0006917436,0.0005876128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011128852,0.00008134363,0.00012402542,0.000021564869,0.00031250739,0.00004409019,0.00016619402,2.7776522e-8,0.0027962662,0.6929117,0.1395593,0.16387174],"study_design_scores_gemma":[0.00022190128,0.00008922968,0.00019572857,0.000033100823,0.000042529446,0.000024417244,0.000024208179,3.3475433e-7,0.0002568345,0.050135158,0.94879526,0.00018131528],"about_ca_topic_score_codex":0.000023099588,"about_ca_topic_score_gemma":0.00010582877,"teacher_disagreement_score":0.80923593,"about_ca_system_score_codex":0.000010363173,"about_ca_system_score_gemma":0.00002194162,"threshold_uncertainty_score":0.9938831},"labels":[],"label_agreement":null},{"id":"W2613074462","doi":"10.1007/s40259-017-0219-4","title":"Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents","year":2017,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Concordance; Immunoassay; Cross-reactivity; Infliximab; Antibody; Rheumatoid arthritis; Internal medicine; Cross reactions; Immunology; Tumor necrosis factor alpha","score_opus":0.09935088227926661,"score_gpt":0.395455338091884,"score_spread":0.29610445581261735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613074462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984454,0.0005216785,0.00004309891,0.00016321879,0.00010755205,0.0003124876,0.00009989426,0.000008485511,0.00029819223],"genre_scores_gemma":[0.9988784,0.000033181546,0.0009355702,0.000030039528,0.000010417253,0.000003490185,0.000009248256,0.000007149959,0.00009246375],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983992,0.0005424585,0.00029728113,0.00037938525,0.00017108435,0.00021058021],"domain_scores_gemma":[0.9981078,0.00005668439,0.00048380147,0.00093180937,0.00039444407,0.000025462998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021486385,0.00016688331,0.0004513293,0.00010998522,0.000362895,0.000042305615,0.0003988792,0.00009680399,0.00004599263],"category_scores_gemma":[0.0005041592,0.00010022345,0.000087565284,0.00021549454,0.0008697678,0.00018870781,0.00021971768,0.00017154022,0.0000010758482],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011326941,0.00013216547,0.2865266,0.000018899882,0.0005997904,2.7796236e-7,0.0002406645,0.000023930143,0.7062696,0.000034893073,0.000016844471,0.006023066],"study_design_scores_gemma":[0.0004680688,0.00005410368,0.61408776,0.000036153113,0.0010068758,0.000004455067,0.00006823883,0.00024337858,0.38377386,0.000032924894,0.00012437317,0.0000997991],"about_ca_topic_score_codex":0.0009983102,"about_ca_topic_score_gemma":0.00012196144,"teacher_disagreement_score":0.32756117,"about_ca_system_score_codex":0.00003403135,"about_ca_system_score_gemma":0.00010141052,"threshold_uncertainty_score":0.40869936},"labels":[],"label_agreement":null},{"id":"W2618161433","doi":"10.1038/nrrheum.2017.79","title":"Biosimilar switching — “To set a form upon desired change”","year":2017,"lang":"en","type":"review","venue":"Nature Reviews Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Celltrion; GlaxoSmithKline; European Commission; Pfizer; Health Canada; Samsung; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Biosimilar; Set (abstract data type); MEDLINE; Internal medicine; Computer science; Programming language","score_opus":0.2596264671004778,"score_gpt":0.4620141243216886,"score_spread":0.20238765722121077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618161433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001156411,0.9900968,0.00015393406,0.0009325884,0.0042200633,0.0037932517,0.0001992986,0.00013529435,0.0004676044],"genre_scores_gemma":[0.000010346162,0.9949617,0.0015458419,0.0013862327,0.00013283711,0.0007922028,0.00031573648,0.00012793153,0.00072717614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925484,0.0022344422,0.0021659685,0.0015621652,0.0000984021,0.0013906357],"domain_scores_gemma":[0.9947728,0.0007735382,0.0018708842,0.0022561797,0.00012963406,0.0001969573],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0028131416,0.0014439429,0.009508192,0.00065733265,0.00058183726,0.00008500533,0.0022333611,0.0075031924,0.00062073686],"category_scores_gemma":[0.002318566,0.00094424904,0.0021035308,0.000511372,0.00020169956,0.00014485553,0.00075310183,0.004575685,0.002656169],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002678361,0.00005204618,0.0000042389634,0.014342733,0.0004957297,0.00002495467,0.000049521474,8.6769286e-10,0.000004988646,0.0006603005,0.02416541,0.9601733],"study_design_scores_gemma":[0.00031904102,0.00011519012,0.000002986814,0.028411457,0.0014639462,0.0016984631,0.0000042892275,4.909815e-7,0.000015084946,0.00014923574,0.9668573,0.0009625114],"about_ca_topic_score_codex":0.00003190002,"about_ca_topic_score_gemma":0.00007153443,"teacher_disagreement_score":0.95921075,"about_ca_system_score_codex":0.00017428609,"about_ca_system_score_gemma":0.00024352293,"threshold_uncertainty_score":0.999831},"labels":[],"label_agreement":null},{"id":"W2623521568","doi":"10.1136/annrheumdis-2016-210459","title":"Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Amgen","keywords":"Adalimumab; Medicine; Rheumatoid arthritis; Clinical endpoint; Internal medicine; Adverse effect; Bioequivalence; Pharmacokinetics; Gastroenterology; Randomized controlled trial","score_opus":0.04817295763684427,"score_gpt":0.32983176028224587,"score_spread":0.2816588026454016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623521568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946144,0.001138724,0.000031839772,0.0009839928,0.000083344145,0.0028596953,0.00021084277,0.000010846543,0.00006627565],"genre_scores_gemma":[0.99932444,0.00030628947,0.00006432802,0.00016866626,0.0000023827834,0.000065205786,0.000005867579,0.0000152462635,0.00004758706],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9980921,0.00043433733,0.00063650974,0.0003364708,0.00017348918,0.00032710168],"domain_scores_gemma":[0.9977791,0.00030325144,0.000595966,0.0010534606,0.00019486614,0.00007336909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004728189,0.0002737736,0.00084013934,0.00006441187,0.0004200886,0.00004917543,0.00077719893,0.00007733958,0.000057642854],"category_scores_gemma":[0.000289148,0.0001316971,0.000121822806,0.00016118404,0.0007523947,0.00013361497,0.00036980564,0.00016066029,0.0000015978092],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80253524,0.011619073,0.14647503,0.00033294552,0.0026165445,0.000004426699,0.002239121,0.00036852114,0.000171693,0.00019875955,0.00088624604,0.03255238],"study_design_scores_gemma":[0.45723638,0.0018733362,0.52995294,0.004701073,0.0003077409,0.000006915646,0.00064364035,0.00006926011,0.004459323,0.00025643545,0.00004324521,0.00044971853],"about_ca_topic_score_codex":0.00013351544,"about_ca_topic_score_gemma":0.0001092484,"teacher_disagreement_score":0.38347793,"about_ca_system_score_codex":0.000008738381,"about_ca_system_score_gemma":0.00008863415,"threshold_uncertainty_score":0.5370452},"labels":[],"label_agreement":null},{"id":"W2629949851","doi":"10.1016/j.clinthera.2017.05.014","title":"The Pharmacodynamic Effects of Rituximab at Very Low Doses","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Medicine; Rituximab; Pharmacokinetics; Biosimilar; Pharmacodynamics; Dosing; Pharmacology; Randomized controlled trial; Internal medicine; Immunogenicity; Gastroenterology; Immunology; Antibody; Lymphoma","score_opus":0.06536303396905699,"score_gpt":0.4256538472883188,"score_spread":0.3602908133192618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2629949851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96501815,0.016482757,0.00040824982,0.0053049866,0.008843136,0.0004915791,0.000034432578,0.00006517239,0.003351543],"genre_scores_gemma":[0.9884592,0.005894283,0.00021730603,0.0013081392,0.000101434714,0.0000054305174,0.0000026726866,0.00001465312,0.0039968323],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998459,0.00048482168,0.00048732193,0.00023067952,0.000042000833,0.00029619844],"domain_scores_gemma":[0.9950348,0.003759208,0.00032739036,0.0007831208,0.00006580972,0.000029666578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095872313,0.00014621965,0.0003999066,0.000013077643,0.0006698206,0.000029117338,0.00072242523,0.00035267428,0.00008564527],"category_scores_gemma":[0.00055290095,0.000083213905,0.00031059905,0.000028989954,0.001989577,0.00003348847,0.00028449408,0.00042854217,0.00010916512],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014798162,0.0014022146,0.025248805,0.00011761992,0.0020636336,0.000014184415,0.00004783778,3.055573e-7,0.20016831,0.002013023,0.0026005064,0.76484376],"study_design_scores_gemma":[0.008905085,0.0010092395,0.100684114,0.0001376534,0.0008649499,0.000016785953,0.000023234019,0.00024550164,0.3573823,0.0040864516,0.5262074,0.00043732263],"about_ca_topic_score_codex":0.0000033588922,"about_ca_topic_score_gemma":0.000006117741,"teacher_disagreement_score":0.76440644,"about_ca_system_score_codex":0.000015309093,"about_ca_system_score_gemma":0.000031253345,"threshold_uncertainty_score":0.7330679},"labels":[],"label_agreement":null},{"id":"W2684473450","doi":"10.1111/bjd.15756","title":"Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice","year":2017,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"AbbVie; Wyeth; Cilag; Amgen","keywords":"Psoriasis; Biosimilar; Medicine; Dermatology; Clinical Practice; Family medicine; Internal medicine","score_opus":0.2872613720546832,"score_gpt":0.5035942397088006,"score_spread":0.21633286765411736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2684473450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000636479,0.9857035,0.0022391423,0.00808128,0.0019770588,0.0011105322,0.0007836617,0.000014596235,0.000083852],"genre_scores_gemma":[0.000019348357,0.9561291,0.042135134,0.001121975,0.00023297995,0.00009069647,0.00007202156,0.0000620492,0.00013672505],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924779,0.0013473807,0.0049715834,0.0005612398,0.00006351557,0.0005784025],"domain_scores_gemma":[0.98590785,0.0055140965,0.00600933,0.0006461405,0.001793835,0.00012875882],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0023472672,0.00047164457,0.005206329,0.0003179947,0.00033977896,0.000054836673,0.0009950772,0.0020387284,0.000028268416],"category_scores_gemma":[0.012885429,0.00043509566,0.0018044333,0.00013660596,0.0010716184,0.00019542624,0.00020394252,0.00096855895,0.0000031097074],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013337226,0.00018024577,0.000026334332,0.0044127707,0.0018627088,0.000076603894,0.000003953795,1.3487849e-8,0.0000062085833,0.0014546631,0.12957904,0.8622641],"study_design_scores_gemma":[0.0017965604,0.00016169716,0.00015731048,0.005758405,0.005321839,0.1474739,0.000016382335,5.436e-7,0.000025750487,0.0012330079,0.8377468,0.00030781998],"about_ca_topic_score_codex":0.0000056802774,"about_ca_topic_score_gemma":0.00001687739,"teacher_disagreement_score":0.8619563,"about_ca_system_score_codex":0.000036410544,"about_ca_system_score_gemma":0.0008686036,"threshold_uncertainty_score":0.9998101},"labels":[],"label_agreement":null},{"id":"W2726607957","doi":"10.1136/annrheumdis-2017-eular.5524","title":"FRI0187 Radiographic progression by disease activity states in patients with rheumatoid arthritis treated with sb2 or reference infliximab","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Infliximab; Rheumatoid arthritis; Methotrexate; Internal medicine; Biosimilar; Adalimumab; Etanercept; Gastroenterology; Rheumatology; Clinical disease; Disease; Surgery","score_opus":0.026793230850410066,"score_gpt":0.3026051223582627,"score_spread":0.2758118915078526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726607957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951534,0.0026519955,0.000010471588,0.0009360283,0.00004073803,0.00052586093,0.00059759675,0.000028145625,0.000055717654],"genre_scores_gemma":[0.9971807,0.0024188121,0.000059379025,0.00008883297,0.0000015604379,0.000050398387,0.000064941356,0.000017060811,0.000118298325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853057,0.00033709238,0.00030721942,0.00031760216,0.00013901349,0.00036852775],"domain_scores_gemma":[0.9982462,0.00019151164,0.00049502513,0.0008313113,0.00013606479,0.00009987762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016932724,0.00026312613,0.0004992648,0.000080640144,0.00033990346,0.00006102494,0.00052880344,0.00009858134,0.00015227804],"category_scores_gemma":[0.00033757483,0.00012247032,0.000101693455,0.0001713714,0.00096948957,0.00025610055,0.00014088672,0.00017366163,0.000004356201],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0089786695,0.0020568622,0.88947874,0.00015958732,0.00039520994,0.000004842137,0.00004856103,0.0000027410756,0.00007260956,0.000049203856,0.0025322654,0.096220694],"study_design_scores_gemma":[0.0032845382,0.00074372394,0.9896117,0.0024807549,0.00006579973,0.0000012668949,0.00002573679,0.000020392099,0.002873025,0.0002644249,0.00038124132,0.00024738847],"about_ca_topic_score_codex":0.0001827465,"about_ca_topic_score_gemma":0.00006098839,"teacher_disagreement_score":0.10013296,"about_ca_system_score_codex":0.000008862791,"about_ca_system_score_gemma":0.00008330794,"threshold_uncertainty_score":0.49941945},"labels":[],"label_agreement":null},{"id":"W2726645172","doi":"","title":"Biosimilars in oncology : Is the absence of proof of difference a proof of absence of difference ?","year":2012,"lang":"fr","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Proof of concept; Structural proof theory; Biosimilar; Computer science; Internal medicine; Medicine; Oncology; Proof theory; Mathematics; Calculus (dental); Mathematical proof","score_opus":0.0306623112656527,"score_gpt":0.2824731157204146,"score_spread":0.2518108044547619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726645172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88355684,0.03056441,0.041746415,0.027089538,0.00089784426,0.0024866625,0.0010292393,0.000032127333,0.012596949],"genre_scores_gemma":[0.9788642,0.0020985752,0.014232381,0.00010916993,0.000008118416,0.00005224077,0.000043348573,0.000023406155,0.0045685675],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98606765,0.010352792,0.0019458781,0.00075864693,0.0002670658,0.0006079457],"domain_scores_gemma":[0.9870087,0.005606268,0.002552286,0.0023509744,0.002389026,0.00009273106],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.007485881,0.00047297706,0.0014983979,0.0002491373,0.00011488816,0.000014197017,0.0023716732,0.0010688787,0.00051428576],"category_scores_gemma":[0.002664855,0.00036593588,0.00042592228,0.00079176994,0.004454756,0.000062437,0.0017555639,0.0011904611,0.0000029970965],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028985494,0.0058587715,0.06598828,0.0024108768,0.0005084614,0.0000021174676,0.022880498,0.000014292933,0.67104405,0.07741743,0.00025173716,0.15333362],"study_design_scores_gemma":[0.00066210784,0.000013609221,0.11196732,0.004605707,0.00012889308,0.000012459407,0.00035157226,0.0007853907,0.8752973,0.0042443294,0.0016233056,0.0003080187],"about_ca_topic_score_codex":0.0016275794,"about_ca_topic_score_gemma":0.0016518654,"teacher_disagreement_score":0.20425323,"about_ca_system_score_codex":0.00009921046,"about_ca_system_score_gemma":0.0006157795,"threshold_uncertainty_score":0.99987924},"labels":[],"label_agreement":null},{"id":"W2731229649","doi":"10.1007/978-3-319-53763-4_13","title":"The Biosimilar Revolution: Coming to an IBD Patient Near You?","year":2017,"lang":"en","type":"book-chapter","venue":"Clinical gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Biosimilar; Medicine; Internal medicine","score_opus":0.06449084076317921,"score_gpt":0.35339578684582906,"score_spread":0.2889049460826498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731229649","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048262816,0.0232868,0.0051113293,0.22657959,0.094426066,0.010222862,0.0030199138,0.0013089657,0.58778167],"genre_scores_gemma":[0.075784005,0.003984578,0.011996329,0.070298575,0.0031167276,0.00016002919,0.00050985365,0.00044533593,0.8337046],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99573106,0.0007440759,0.0014542621,0.0010744645,0.000086766864,0.000909346],"domain_scores_gemma":[0.99624044,0.0006611189,0.00075763115,0.0018959007,0.00020865713,0.00023627546],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00166489,0.00055502215,0.0012132784,0.00007023595,0.0010279265,0.00008831821,0.0012916961,0.0017178617,0.00078251667],"category_scores_gemma":[0.0007834202,0.00037747528,0.0006702122,0.000012987862,0.00292005,0.000049862287,0.0007974281,0.0019223087,0.00083311246],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011525464,0.0009332779,0.012372584,0.000058489248,0.0036806378,0.00030226656,0.00020649003,0.0000041037088,0.0006042892,0.030509796,0.5080361,0.43176654],"study_design_scores_gemma":[0.0008247257,0.0057692667,0.0022984105,0.000089481684,0.00027118964,0.000093745955,0.000013789479,0.0000075041253,0.000023912798,0.0021666235,0.988179,0.00026231605],"about_ca_topic_score_codex":0.0000099359595,"about_ca_topic_score_gemma":0.00017483701,"teacher_disagreement_score":0.48014298,"about_ca_system_score_codex":0.000059063546,"about_ca_system_score_gemma":0.00008048742,"threshold_uncertainty_score":0.99994487},"labels":[],"label_agreement":null},{"id":"W2734326269","doi":"10.3821/1913-701x-143.sp1.s2","title":"Les produits biologiques: aperçu","year":2010,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.045811694343478364,"score_gpt":0.3049889494385003,"score_spread":0.25917725509502193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734326269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79405737,0.07036362,0.00033179097,0.009749395,0.092872985,0.0015173336,0.0076030726,0.000143278,0.023361163],"genre_scores_gemma":[0.93680274,0.01995351,0.0019357929,0.006531399,0.0032200254,0.000017207021,0.00005000135,0.000098441786,0.031390857],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942594,0.0010829497,0.0010877101,0.00085449545,0.00017798363,0.0025374526],"domain_scores_gemma":[0.9953201,0.00042049,0.00044082035,0.0005025638,0.00095030235,0.0023657316],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002053897,0.0008201546,0.00085281587,0.00045384836,0.0019375116,0.00026463118,0.0013796057,0.00087749574,0.027654922],"category_scores_gemma":[0.0010764801,0.00078856124,0.0004094478,0.0007558915,0.002019056,0.00034182915,0.00012348755,0.0050415127,0.00013015974],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001350958,0.00015125853,0.0028652486,0.00033444515,0.0008171051,0.037256945,0.00050239405,0.000014659583,0.087242834,0.0010713098,0.11695827,0.75265044],"study_design_scores_gemma":[0.0010742295,0.00010150978,0.00008073773,0.000036841626,0.00031086864,0.38812834,0.000010349135,0.00017119916,0.022842886,0.00017185464,0.5863636,0.00070757134],"about_ca_topic_score_codex":0.08725921,"about_ca_topic_score_gemma":0.41337687,"teacher_disagreement_score":0.7519429,"about_ca_system_score_codex":0.0017773983,"about_ca_system_score_gemma":0.006679678,"threshold_uncertainty_score":0.9994565},"labels":[],"label_agreement":null},{"id":"W2735513153","doi":"10.1038/aps.2017.69","title":"Section 6: Pharmaceutics, Pharmacokinetics, Drug Discovery","year":2017,"lang":"en","type":"article","venue":"Acta Pharmacologica Sinica","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Science and Technology Planning Project of Guangdong Province; Centre for Addiction and Mental Health; China Scholarship Council; Natural Sciences and Engineering Research Council of Canada; Ministry of Education of the People's Republic of China; National Natural Science Foundation of China; Ningxia University; Higher Education Discipline Innovation Project; Université de Sherbrooke; Ningxia Medical University; China Medical University; Heart and Stroke Foundation of Canada; Canadian Institutes of Health Research; American Heart Association; Leslie Dan Faculty of Pharmacy, University of Toronto; Huashan Hospital; Fundo para o Desenvolvimento das Ciências e da Tecnologia; Michael J. Fox Foundation for Parkinson's Research","keywords":"Pharmaceutics; Pharmacokinetics; Drug; Pharmacology; Section (typography); Medicine; Drug discovery; Bioinformatics; Biology; Computer science","score_opus":0.06037184508081807,"score_gpt":0.38077283811668544,"score_spread":0.3204009930358674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735513153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8467101,0.0045485743,0.00028746075,0.053213913,0.025291631,0.0013741348,0.00033738677,0.0006721714,0.06756463],"genre_scores_gemma":[0.97388005,0.0018169746,0.00042301576,0.0034721328,0.00060309994,0.00003172003,0.000025577154,0.000028811133,0.019718636],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975683,0.000445727,0.0004978634,0.0006885981,0.000086302294,0.0007131867],"domain_scores_gemma":[0.9982113,0.00040752054,0.00044903706,0.0007179122,0.00010991196,0.000104297265],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000851602,0.00037224533,0.0004923116,0.000081097045,0.0011654737,0.00023981888,0.0012283007,0.00034239743,0.005226266],"category_scores_gemma":[0.00036478162,0.00028594755,0.00028318373,0.00008381825,0.0009825795,0.0005069864,0.0005774845,0.0009806382,0.00026133415],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038813535,0.00042485577,0.0020296222,0.000017416727,0.0003816827,0.000023398079,0.000036084995,0.0000010240789,0.75834656,0.00012502301,0.22637066,0.011855501],"study_design_scores_gemma":[0.0021434475,0.00010364985,0.0072698696,0.000012446966,0.0003381657,0.000026561998,0.000030416622,0.000036752186,0.40760666,0.00015892017,0.5819434,0.00032969864],"about_ca_topic_score_codex":0.00004502506,"about_ca_topic_score_gemma":0.000007690194,"teacher_disagreement_score":0.35557273,"about_ca_system_score_codex":0.00006109692,"about_ca_system_score_gemma":0.000069820075,"threshold_uncertainty_score":0.9999593},"labels":[],"label_agreement":null},{"id":"W2736010401","doi":"10.1002/9781119413073.ch9","title":"Nonspecific Binding in LC–MS Bioanalysis","year":2017,"lang":"en","type":"other","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nucro Technics","funders":"","keywords":"Bioanalysis; Molecular biomarkers; Biomarker; Chemistry; Nanotechnology; Computational biology; Chromatography; Biology; Materials science; Biochemistry; Medicine; Internal medicine","score_opus":0.03313426440078781,"score_gpt":0.3107584605283986,"score_spread":0.2776241961276108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736010401","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015524787,0.007947675,0.00016776474,0.000346636,0.000852818,0.00014959702,0.00008659458,0.00011094712,0.9903225],"genre_scores_gemma":[0.0010036384,0.0013152651,0.0014274463,0.00011339512,0.00009608319,0.000007932034,0.0000663198,0.00013232966,0.99583757],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986599,0.00016123442,0.0002403586,0.0004994258,0.000032464373,0.00040658176],"domain_scores_gemma":[0.99894744,0.00007591968,0.00021312486,0.00072434713,0.000013159661,0.000026005531],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003371742,0.00030080677,0.000696976,0.00065944326,0.00008025943,0.000031762807,0.00049994106,0.0012445129,0.056002527],"category_scores_gemma":[0.00007923549,0.00021770038,0.0002295401,0.00016480632,0.00035318028,0.00001887597,0.00012755989,0.00048533556,0.002161621],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014311194,0.00007721555,0.0010694221,0.000024014753,0.00047792122,0.00002199622,0.000006683537,1.812653e-8,0.0035653908,0.00074574206,0.9719248,0.022072494],"study_design_scores_gemma":[0.00038264395,0.000025175668,0.00019377877,0.00015819285,0.00012277332,0.0000065643926,0.00001558439,0.0000011564458,0.0025216832,0.000040547064,0.9962268,0.0003051222],"about_ca_topic_score_codex":0.00081163127,"about_ca_topic_score_gemma":0.0022722322,"teacher_disagreement_score":0.053840905,"about_ca_system_score_codex":0.000036588954,"about_ca_system_score_gemma":0.000032782013,"threshold_uncertainty_score":0.9986153},"labels":[],"label_agreement":null},{"id":"W2742486699","doi":"10.1007/s11523-017-0518-1","title":"Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars","year":2017,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Pfizer","keywords":"Bevacizumab; Biosimilar; Medicine; Colorectal cancer; Oncology; Intensive care medicine; Internal medicine; Cancer; Chemotherapy","score_opus":0.060309267353295185,"score_gpt":0.4066597918623675,"score_spread":0.34635052450907233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742486699","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00058777636,0.9961729,0.0000017237385,0.00039760658,0.0010926209,0.0011523387,0.0002527379,0.000010456668,0.00033183815],"genre_scores_gemma":[0.002019324,0.9973257,0.00006265904,0.000029667402,0.000052969583,0.00031535386,0.000071907474,0.000020866617,0.00010151765],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623954,0.0018140128,0.0009208226,0.00050573435,0.00003289021,0.00048699035],"domain_scores_gemma":[0.99832743,0.00062732137,0.00065720995,0.0003188004,0.000037596314,0.000031652697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007954383,0.00043262896,0.0031160163,0.000302792,0.00009957594,0.000009956168,0.00044683972,0.0011349418,0.00022420051],"category_scores_gemma":[0.00015485915,0.00024317385,0.00041016663,0.00018100673,0.0013105513,0.000027411912,0.0002125662,0.0008149238,0.0000112032],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039994117,0.0003169263,0.00008070187,0.00051853096,0.00032970638,0.000017203041,0.000109357876,3.7023938e-7,0.0001441257,0.00018083508,0.00015502541,0.9977473],"study_design_scores_gemma":[0.0046762424,0.00049917906,0.00032037115,0.001152174,0.0009647781,0.00006897802,0.0000390077,0.000009159635,0.0001683835,0.00030581915,0.99154073,0.00025515558],"about_ca_topic_score_codex":0.0005726122,"about_ca_topic_score_gemma":0.0014330497,"teacher_disagreement_score":0.99749213,"about_ca_system_score_codex":0.00041465578,"about_ca_system_score_gemma":0.0006837382,"threshold_uncertainty_score":0.9916342},"labels":[],"label_agreement":null},{"id":"W2745225801","doi":"10.5740/jaoacint.17-0291","title":"Baseline Assessment of 25-Hydroxyvitamin D Reference Material and Proficiency Testing/External Quality Assurance Material Commutability: A Vitamin D Standardization Program Study","year":2017,"lang":"en","type":"article","venue":"Journal of AOAC International","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"National Institutes of Health","keywords":"External quality assessment; Standardization; Quality assurance; Medicine; Medical physics; Test (biology); Reference values; Vitamin D and neurology; Computer science; Internal medicine; Pathology","score_opus":0.06072874165889736,"score_gpt":0.421325785242373,"score_spread":0.36059704358347566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745225801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928368,0.000027614844,0.0038383512,0.00047604923,0.0016504362,0.0003219592,0.0003541287,0.000011138866,0.0004835656],"genre_scores_gemma":[0.9798044,0.000015640708,0.01988873,0.000022993845,0.00015426346,0.000008450629,0.000014771064,0.000008053738,0.00008270604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977504,0.0005996493,0.0010076985,0.00021919375,0.00024677554,0.0001762726],"domain_scores_gemma":[0.9970999,0.00027087654,0.0014153842,0.00028238562,0.0008944778,0.000036992522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036088133,0.00016244163,0.00046767903,0.00010045705,0.00020085552,0.00015352566,0.00054370915,0.00013716241,0.00033007291],"category_scores_gemma":[0.0014566702,0.00012069537,0.00007714277,0.000045816483,0.00036846043,0.0002657273,0.00020896431,0.00029322758,7.474659e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006424066,0.0024055946,0.50251484,0.00007432406,0.000351262,0.000018785437,0.00015266288,0.0000069527046,0.46225417,0.00063983485,0.00014014452,0.030799014],"study_design_scores_gemma":[0.0021614006,0.001957715,0.95507455,0.0001528474,0.00009498158,0.00010175729,0.00018056124,0.00020167888,0.03883147,0.0003129461,0.0007806341,0.00014947107],"about_ca_topic_score_codex":0.000100199315,"about_ca_topic_score_gemma":0.000022692237,"teacher_disagreement_score":0.45255968,"about_ca_system_score_codex":0.00007462668,"about_ca_system_score_gemma":0.00015149344,"threshold_uncertainty_score":0.49218142},"labels":[],"label_agreement":null},{"id":"W2753860164","doi":"10.1053/j.gastro.2017.08.049","title":"Is a Biosimilar Interchangeable With an Originator?","year":2017,"lang":"en","type":"letter","venue":"Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Biosimilar; Infliximab; Medicine; Drug; Pharmacology; Internal medicine; Disease","score_opus":0.04234443204730074,"score_gpt":0.3021830642448533,"score_spread":0.25983863219755254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753860164","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008735473,0.0006831101,0.00074001687,0.98360807,0.0027369652,0.0005385642,0.00075996807,0.00020256569,0.001995269],"genre_scores_gemma":[0.005082659,0.00007804034,0.0023006822,0.97311914,0.0012681433,0.00008019414,0.0005910297,0.000117089265,0.017363008],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996461,0.0006455611,0.00038368354,0.0011028876,0.00007996093,0.001326928],"domain_scores_gemma":[0.99775815,0.000070925744,0.0004076327,0.0015576633,0.00014230309,0.00006334044],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00033253263,0.0006609927,0.0010689831,0.00026221178,0.00028802984,0.00007592138,0.0012875469,0.0022820854,0.003009921],"category_scores_gemma":[0.00003248873,0.00047646317,0.00023883345,0.000051635845,0.001191542,0.0001346775,0.00026726388,0.0030379482,0.00039699365],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066577445,0.00008479243,0.0032990403,0.00006016202,0.00073749834,0.000549347,0.000056407902,2.6932666e-8,0.0005384372,0.000011509176,0.99332213,0.00067488424],"study_design_scores_gemma":[0.0013559117,0.004359882,0.00044182292,0.00009048688,0.0003620966,0.0010611098,0.000015191649,0.0000031660954,0.0015363138,0.00018208247,0.9902545,0.0003374414],"about_ca_topic_score_codex":0.00008204851,"about_ca_topic_score_gemma":0.000082742015,"teacher_disagreement_score":0.015367739,"about_ca_system_score_codex":0.000068402696,"about_ca_system_score_gemma":0.00006597458,"threshold_uncertainty_score":0.99976873},"labels":[],"label_agreement":null},{"id":"W2754190914","doi":"10.1136/annrheumdis-2017-eular.3348","title":"OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with rheumatoid arthritis","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Pfizer; Amgen","keywords":"Adalimumab; Medicine; Biosimilar; Rheumatoid arthritis; Trough level; Internal medicine; Gastroenterology","score_opus":0.05134418831104503,"score_gpt":0.332393368620422,"score_spread":0.281049180309377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754190914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948437,0.00096412725,0.000004210289,0.0004686375,0.00007607378,0.00096924783,0.002607477,0.000022267055,0.000044209766],"genre_scores_gemma":[0.99883235,0.00082794036,0.000045416324,0.000042430336,0.000008233798,0.000008577148,0.00020419592,0.000018075061,0.000012797632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732375,0.0006771975,0.0008522482,0.0004997186,0.00025666578,0.00039044386],"domain_scores_gemma":[0.9969307,0.00064640667,0.001369397,0.00069186126,0.00026384357,0.00009774693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046142447,0.0003587646,0.001032588,0.00006173756,0.00042655243,0.0001281555,0.00036503794,0.0001436867,0.000027615084],"category_scores_gemma":[0.00049398973,0.00022465411,0.00008319915,0.00012002823,0.00052524934,0.0004336984,0.00013948821,0.00024045334,8.8566804e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004609791,0.0024992437,0.981871,0.000049610222,0.0011950484,0.0000017962398,0.0014263077,0.000030323828,0.00012577209,0.00003261805,0.00014892677,0.008009566],"study_design_scores_gemma":[0.028520608,0.0028442743,0.962939,0.0017531314,0.0002305109,7.8106774e-7,0.00069633126,0.00010696812,0.002533008,0.00009297649,0.0000060282405,0.0002763424],"about_ca_topic_score_codex":0.0010732963,"about_ca_topic_score_gemma":0.0003031684,"teacher_disagreement_score":0.023910819,"about_ca_system_score_codex":0.000041163563,"about_ca_system_score_gemma":0.00012381749,"threshold_uncertainty_score":0.9161129},"labels":[],"label_agreement":null},{"id":"W2754739856","doi":"10.18433/j3vk90","title":"Biosimilars: State of Clinical and Regulatory Science","year":2017,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Western University; Health Canada","funders":"","keywords":"Regulatory science; Interchangeability; Biosimilar; Viewpoints; Marketing authorization; Authorization; Terminology; Medicine; Political science; Business; Engineering; Computer science; Bioinformatics","score_opus":0.1954540780110975,"score_gpt":0.5169129429236075,"score_spread":0.32145886491250997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754739856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856809,0.005233163,0.00009058622,0.005093649,0.0019652236,0.00009905354,0.00001141233,0.0000076750275,0.0018183385],"genre_scores_gemma":[0.9947812,0.0020171127,0.002221599,0.0007663279,0.00010925357,4.0334274e-7,5.5989588e-8,0.000004687951,0.00009938171],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975936,0.00030405298,0.0010515442,0.00031913823,0.00028655617,0.0004451386],"domain_scores_gemma":[0.99782366,0.0004317576,0.0009429289,0.00023683794,0.00033931757,0.00022549804],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.010032125,0.00015393438,0.0005354011,0.00018755144,0.0007497996,0.000116831965,0.0013587896,0.000065044704,0.00031715696],"category_scores_gemma":[0.001522444,0.00009853036,0.00019569657,0.00022441077,0.016772885,0.00069435383,0.00038847997,0.0005901854,0.0000064710052],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003679735,0.00023842609,0.1272671,0.000027754799,0.00010417708,0.000018850269,0.000054796477,0.0000014948334,0.44010592,0.0006842466,0.0010416238,0.43008763],"study_design_scores_gemma":[0.002958216,0.00046518116,0.121896006,0.000080288315,0.00018971763,0.00021739295,0.000046029156,0.00041678105,0.7487477,0.0013327152,0.123447254,0.0002027293],"about_ca_topic_score_codex":0.0000072912458,"about_ca_topic_score_gemma":9.789073e-7,"teacher_disagreement_score":0.42988488,"about_ca_system_score_codex":0.000013360067,"about_ca_system_score_gemma":0.00043613988,"threshold_uncertainty_score":0.9859029},"labels":[],"label_agreement":null},{"id":"W2754783592","doi":"10.1097/mib.0000000000001237","title":"Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort","year":2017,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Dr. Falk Pharma; Genentech; Mitsubishi Tanabe Pharma Corporation; Kyowa Hakko Kirin; Hungarian Scientific Research Fund; Pfizer; Amgen","keywords":"Medicine; Infliximab; Internal medicine; Ulcerative colitis; Interquartile range; Inflammatory bowel disease; Prospective cohort study; Cohort; Gastroenterology; Crohn's disease; Disease","score_opus":0.011177245439230842,"score_gpt":0.26974234055027857,"score_spread":0.25856509511104775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754783592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952437,0.002997729,0.00002505725,0.00020163566,0.00015944567,0.0005551623,0.00021724433,0.00003382053,0.0005661718],"genre_scores_gemma":[0.9990592,0.00041642145,0.00011332036,0.0000757096,0.000029455505,0.000041325504,0.000016410437,0.000016894635,0.00023125904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986022,0.0001702906,0.00047717392,0.00037758562,0.000079255406,0.00029350448],"domain_scores_gemma":[0.998846,0.00015036913,0.00025558696,0.0005824917,0.00010849563,0.000057060446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030281814,0.00021509737,0.0004181968,0.00012279402,0.00019486835,0.000044956967,0.00031107722,0.0002471861,0.00034770597],"category_scores_gemma":[0.0004998702,0.00019270612,0.0001363468,0.00005351037,0.00097197003,0.00019428706,0.00029585324,0.00021776262,0.000025847803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020758854,0.0003313946,0.9877944,0.00008628585,0.00028531972,0.0000310471,0.00008183644,5.1007146e-7,0.007800894,0.00035157986,0.000022440003,0.0011384237],"study_design_scores_gemma":[0.002558752,0.00007445644,0.9868301,0.00016534851,0.00016625882,0.0000049842397,0.000013697379,0.0000024047242,0.009506029,0.00028460778,0.0001674715,0.00022585466],"about_ca_topic_score_codex":0.000027769824,"about_ca_topic_score_gemma":0.000084487125,"teacher_disagreement_score":0.0038154698,"about_ca_system_score_codex":0.000045243643,"about_ca_system_score_gemma":0.000080991,"threshold_uncertainty_score":0.78583276},"labels":[],"label_agreement":null},{"id":"W2759170843","doi":"10.2174/2213476x03666151221210747","title":"Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities","year":2015,"lang":"en","type":"article","venue":"Applied Clinical Research Clinical Trials and Regulatory Affairs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Biopharmaceutical; Medicine; Business; Risk analysis (engineering); Biotechnology","score_opus":0.7556914656993441,"score_gpt":0.5835080839316263,"score_spread":0.17218338176771775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759170843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47856858,0.44932655,0.00011571353,0.032126274,0.012489232,0.0052636093,0.00042120114,0.00033534892,0.021353513],"genre_scores_gemma":[0.8461861,0.14741132,0.0014849729,0.00086225633,0.0028138822,0.00007000288,0.000044713965,0.00007787873,0.0010488987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9820869,0.011090096,0.0042535164,0.0012162647,0.00049643725,0.00085677294],"domain_scores_gemma":[0.9804465,0.016225852,0.0008533311,0.0010361192,0.0006074911,0.0008307131],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.10423187,0.00041817158,0.002818804,0.00023745422,0.00025952814,0.000060966147,0.00051968417,0.0016742282,0.00028553206],"category_scores_gemma":[0.011100551,0.0002830826,0.00065460504,0.0003647961,0.007297339,0.000102958205,0.0008183306,0.002388492,0.000028347615],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002923941,0.0011357665,0.004577055,0.0002872175,0.0007924234,0.000011411718,0.00010133055,1.3646975e-7,0.0007443383,0.083727084,0.080516234,0.82518303],"study_design_scores_gemma":[0.008624654,0.0019176063,0.025110522,0.00033122484,0.0004165037,0.000016757604,0.003349804,0.000015123297,0.0011720795,0.026797242,0.9316485,0.00059996446],"about_ca_topic_score_codex":0.000006341381,"about_ca_topic_score_gemma":0.0000068831423,"teacher_disagreement_score":0.8511323,"about_ca_system_score_codex":0.000035891604,"about_ca_system_score_gemma":0.000744536,"threshold_uncertainty_score":0.99996215},"labels":[],"label_agreement":null},{"id":"W2759477597","doi":"10.2147/ceor.s140063","title":"Drug tendering: drug supply and shortage implications for the uptake of biosimilars","year":2017,"lang":"en","type":"review","venue":"ClinicoEconomics and Outcomes Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"Pfizer","keywords":"Biosimilar; Procurement; Medicine; Economic shortage; Incentive; Health care; Business; Risk analysis (engineering); Pharmacology; Marketing; Economic growth","score_opus":0.38833538714832483,"score_gpt":0.5507725914305369,"score_spread":0.1624372042822121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759477597","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012619991,0.99187183,0.000015951438,0.0045688273,0.00042170746,0.0014459578,0.0011045501,0.000009836008,0.0004351621],"genre_scores_gemma":[0.00020485099,0.99202996,0.0005103744,0.00015563631,0.00005970371,0.00019800947,0.00005531219,0.000039379916,0.0067467866],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997403,0.00028104603,0.0011116868,0.00064436044,0.000030538875,0.000529324],"domain_scores_gemma":[0.99068266,0.007617261,0.00042195324,0.001072435,0.0001298947,0.000075774165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046970523,0.00032767316,0.0018436365,0.0002062824,0.0007309809,0.00012768651,0.00092335977,0.00051066984,0.00007922841],"category_scores_gemma":[0.0008714309,0.00019341962,0.00059624575,0.000064594904,0.0015870562,0.000050321923,0.00065747276,0.0009168393,0.000009606202],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014740166,0.00004185119,0.001246138,0.0014153086,0.00062333513,2.3957725e-7,0.000033475295,1.6774564e-8,0.000002493656,0.0033004344,0.008085651,0.9852363],"study_design_scores_gemma":[0.00036424075,0.000054083703,0.004243573,0.0003499147,0.0004351274,0.000010211286,0.000089944086,0.0000039058777,0.000007490733,0.0010472784,0.99319214,0.00020211625],"about_ca_topic_score_codex":0.0000235249,"about_ca_topic_score_gemma":0.00007959033,"teacher_disagreement_score":0.98510647,"about_ca_system_score_codex":0.00003283129,"about_ca_system_score_gemma":0.00027324999,"threshold_uncertainty_score":0.7887423},"labels":[],"label_agreement":null},{"id":"W2760720395","doi":"","title":"Solid Phase Microextraction as a Sample Preparation Tool for Targeted and Untargeted Analysis of Biological Matrices","year":2017,"lang":"en","type":"dissertation","venue":"UWSpace (University of Waterloo)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Concordia University","keywords":"Solid-phase microextraction; Sample preparation; Chromatography; Sample (material); Chemistry; Gas chromatography–mass spectrometry; Mass spectrometry","score_opus":0.023687929690736208,"score_gpt":0.33196319016361736,"score_spread":0.3082752604728812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760720395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971434,0.0007536538,0.00032893333,0.00014528584,0.00019893415,0.00039555895,0.00096279086,0.000021043212,0.000050393326],"genre_scores_gemma":[0.82758284,0.0015047604,0.009339164,0.000024949379,0.000029150136,0.000003523984,0.013298513,0.0000218454,0.14819527],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99902534,0.00012939582,0.00021807263,0.00038510558,0.00004145286,0.00020061193],"domain_scores_gemma":[0.9986048,0.00023073216,0.000662418,0.0002443463,0.0002323382,0.000025386333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026250654,0.00019877586,0.00075065385,0.0004079938,0.00026816915,0.000013984189,0.00021239526,0.000745064,0.0005699019],"category_scores_gemma":[0.00015759366,0.00018485694,0.0003421677,0.00017770502,0.00021447412,0.000116679024,0.000029104156,0.00015814955,0.0000037559378],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004561752,0.00030504295,0.0007247569,0.00018676867,0.0037466043,0.0000022189122,0.0059998543,0.0000030128128,0.9761123,0.00011731815,0.000943522,0.007296816],"study_design_scores_gemma":[0.006207763,0.003865461,0.029124362,0.00019055334,0.017172186,0.0000068682375,0.033303678,0.00061837037,0.8916261,0.0008431671,0.016031435,0.0010100302],"about_ca_topic_score_codex":0.008510825,"about_ca_topic_score_gemma":0.006418031,"teacher_disagreement_score":0.16956058,"about_ca_system_score_codex":0.000024909925,"about_ca_system_score_gemma":0.000049298105,"threshold_uncertainty_score":0.9980916},"labels":[],"label_agreement":null},{"id":"W2764033541","doi":"10.1002/dta.2320","title":"Immunomagnetic beads‐based isolation of erythropoietins from urine and blood for sports anti‐doping control","year":2017,"lang":"en","type":"article","venue":"Drug Testing and Analysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de la Recherche Scientifique","funders":"","keywords":"Chromatography; Chemistry; Biotinylation; Blot; Isoelectric focusing; Immunomagnetic separation; Streptavidin; Polyclonal antibodies; Antibody; Molecular biology; Biochemistry; Medicine; Biotin; Biology; Immunology; Enzyme","score_opus":0.01827883662086232,"score_gpt":0.2729009001005601,"score_spread":0.2546220634796978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764033541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895307,0.0021088854,0.0073049315,0.0006359966,0.000054855354,0.000113656315,0.00012527319,0.000021863558,0.000103857776],"genre_scores_gemma":[0.97808844,0.000037792153,0.021626666,0.00006439896,0.000023256009,0.000004190671,0.000034883593,0.000006755907,0.00011364255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991564,0.000070681905,0.0002914997,0.00028052594,0.000029284984,0.00017158322],"domain_scores_gemma":[0.9985059,0.00076023606,0.00032227044,0.00028474882,0.00010284444,0.000024000394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004128211,0.00012895677,0.00046861856,0.0001069118,0.0004041392,0.000043166994,0.00010180431,0.0001039333,0.000043883178],"category_scores_gemma":[0.00073236844,0.00010555385,0.00012381576,0.00010566851,0.00029748803,0.000042231957,0.000041162366,0.00008994448,2.7692408e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034856974,0.00007989585,0.80956733,0.000032258897,0.00085614517,0.0000017871419,0.000035083016,0.000010299199,0.17815271,0.00003133382,0.00001236694,0.011185912],"study_design_scores_gemma":[0.002680687,0.00017034031,0.9460477,0.00012198135,0.006884343,0.0000032254395,0.000084351814,0.012916777,0.030491825,0.00026199105,0.00008899596,0.00024775346],"about_ca_topic_score_codex":0.00066434895,"about_ca_topic_score_gemma":0.000029679439,"teacher_disagreement_score":0.1476609,"about_ca_system_score_codex":0.0000036723002,"about_ca_system_score_gemma":0.000014883533,"threshold_uncertainty_score":0.4304361},"labels":[],"label_agreement":null},{"id":"W2766513204","doi":"10.1016/j.jval.2017.08.958","title":"Biosimilar Discounts are Not Similar: A Comparison of The Prices and Discounts of Anti-Tnf Biosimilars Between Canada and Europe","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Infliximab; Drug prices; Reimbursement; Agency (philosophy); Medicine; Business; Economics; Public economics; Economic growth; Health care; Tumor necrosis factor alpha; Internal medicine","score_opus":0.06781305736739056,"score_gpt":0.3392838893712127,"score_spread":0.2714708320038221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766513204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835427,0.0033754408,0.0000101253245,0.0116603505,0.00035727277,0.00034730588,0.00058979343,0.0000045413653,0.00011248904],"genre_scores_gemma":[0.9981988,0.0007766549,0.00028348912,0.00063166587,0.000020179152,0.0000025083934,0.000004740863,0.0000133346475,0.00006859185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793965,0.00044993378,0.00072960934,0.00036574344,0.000118497024,0.0003965948],"domain_scores_gemma":[0.99797094,0.0003706947,0.0009230057,0.00060273113,0.00006933211,0.0000632977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000892133,0.00021707916,0.0008397326,0.00007076407,0.00037403466,0.000024578065,0.00048702265,0.0001811747,0.000018303748],"category_scores_gemma":[0.00042978465,0.00014172048,0.000050397943,0.0001402872,0.00090659305,0.00008074445,0.0003466468,0.00036676426,5.331882e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054169628,0.00009500144,0.99263823,0.0004033046,0.00007963624,0.0000015939065,0.0002564628,0.000009837278,0.003250077,0.0001518189,0.0014548171,0.001605031],"study_design_scores_gemma":[0.0006658942,0.00013714544,0.96744716,0.00047006484,0.00004908805,0.000003887656,0.00022079784,0.00008746488,0.02590324,0.00007861395,0.0047773677,0.00015926553],"about_ca_topic_score_codex":0.13018279,"about_ca_topic_score_gemma":0.0670976,"teacher_disagreement_score":0.06308519,"about_ca_system_score_codex":0.000044766708,"about_ca_system_score_gemma":0.00033032583,"threshold_uncertainty_score":0.9499254},"labels":[],"label_agreement":null},{"id":"W2767123116","doi":"10.1177/1352458517739976","title":"An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis","year":2017,"lang":"en","type":"review","venue":"Multiple Sclerosis Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Reimbursement; Multiple sclerosis; Business; Relevance (law); Public economics; Healthcare system; Competition (biology); Health care; Risk analysis (engineering); Industrial organization; Medicine; Economics; Political science; Economic growth; Immunology","score_opus":0.2728565278470762,"score_gpt":0.35153841585718654,"score_spread":0.07868188801011033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767123116","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04225534,0.9551712,0.000022468488,0.0005270303,0.00029287545,0.00070420536,0.0010066945,0.00001133895,0.000008844322],"genre_scores_gemma":[0.020567728,0.977663,0.00067008176,0.0008497587,0.000042961943,0.000020604053,0.000106451735,0.00004609297,0.000033334196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99600965,0.0015107301,0.0011000754,0.0006535705,0.00009037763,0.0006355836],"domain_scores_gemma":[0.9962361,0.0018188758,0.0008488998,0.0006485138,0.00024330158,0.00020433773],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017021334,0.0006577133,0.0020837907,0.00029130458,0.00065512024,0.00015789803,0.00079669413,0.0004657801,0.00003562512],"category_scores_gemma":[0.0009760133,0.00036924062,0.00015140543,0.0004429401,0.00081818964,0.000106902815,0.0004453115,0.001186264,0.0000015000741],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013708271,0.00014830011,0.007838142,0.0017718172,0.0004823499,0.000006712997,0.00037724298,0.0000043921423,0.0038492633,0.000007639842,0.0035145392,0.98186255],"study_design_scores_gemma":[0.0017131802,0.0003931689,0.08049279,0.011403985,0.0003509848,0.00015213033,0.00030315298,0.00018263288,0.00019253393,0.000019515288,0.904069,0.0007269061],"about_ca_topic_score_codex":0.06642189,"about_ca_topic_score_gemma":0.13676123,"teacher_disagreement_score":0.9811356,"about_ca_system_score_codex":0.00008975699,"about_ca_system_score_gemma":0.00026595168,"threshold_uncertainty_score":0.99987596},"labels":[],"label_agreement":null},{"id":"W2767217222","doi":"10.1071/ah17031","title":"Financial costs associated with monopolies on biologic medicines in Australia","year":2017,"lang":"en","type":"article","venue":"Australian Health Review","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"La Trobe University","keywords":"Pharmaceutical Benefits Scheme; Biosimilar; Government (linguistics); Monopoly; Listing (finance); Health economics; Subsidy; Medicine; Public economics; Business; Health care; Finance; Economics; Pharmacology; Economic growth","score_opus":0.14179708486309148,"score_gpt":0.4337335368431398,"score_spread":0.29193645198004836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767217222","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34090278,0.18367872,0.0000139072,0.45981562,0.003873826,0.0062559284,0.00053621066,0.00028537758,0.004637624],"genre_scores_gemma":[0.9176609,0.045800373,0.00026763705,0.023236636,0.00009792647,0.00008498261,0.0001074214,0.000023108132,0.012721042],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9979103,0.0005145409,0.0005291574,0.00036933177,0.000051864652,0.0006247909],"domain_scores_gemma":[0.9987639,0.00015390804,0.00045341157,0.0005121936,0.000050547944,0.0000660465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001325828,0.00024791382,0.00085539924,0.000062703446,0.00029457695,0.000017291903,0.00038469312,0.0002918125,0.0006304687],"category_scores_gemma":[0.0012931502,0.00015236813,0.00008589735,0.0001355532,0.0004593702,0.00005651199,0.00004087354,0.00053415465,0.00016704314],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039941198,0.00092126336,0.13315369,0.0038025226,0.00033084553,0.00015157096,0.00010747514,4.6165525e-7,0.0005469396,0.010539068,0.65284824,0.1971985],"study_design_scores_gemma":[0.0018001411,0.0022654682,0.7339256,0.020912854,0.00012289561,0.000032301017,0.000019138928,2.5203528e-7,0.0006873494,0.00055325206,0.2392034,0.00047737875],"about_ca_topic_score_codex":0.0007457897,"about_ca_topic_score_gemma":0.0008581018,"teacher_disagreement_score":0.6007719,"about_ca_system_score_codex":0.00013551599,"about_ca_system_score_gemma":0.00011679502,"threshold_uncertainty_score":0.690319},"labels":[],"label_agreement":null},{"id":"W2767375640","doi":"10.1016/j.aca.2017.11.014","title":"The effect of hematocrit on solid-phase microextraction","year":2017,"lang":"en","type":"article","venue":"Analytica Chimica Acta","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Solid-phase microextraction; Chemistry; Chromatography; Analyte; Hematocrit; Extraction (chemistry); Matrix (chemical analysis); Sample preparation; Coating; Analytical Chemistry (journal); Gas chromatography–mass spectrometry; Mass spectrometry","score_opus":0.0192323745169637,"score_gpt":0.37646560642594207,"score_spread":0.3572332319089784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767375640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9416489,0.00019288693,0.00004389979,0.022934267,0.0015191443,0.0007203226,0.00008088325,0.000081397586,0.03277832],"genre_scores_gemma":[0.9971975,0.00011577283,0.000046223762,0.0001688374,0.000051405586,0.00000828412,0.000007757178,0.000014007397,0.0023902277],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986809,0.0002517477,0.0003471801,0.00029512797,0.00005985454,0.00036519842],"domain_scores_gemma":[0.99752235,0.0010130667,0.00031786013,0.001055028,0.000051939624,0.000039769504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000734273,0.00020641439,0.00042508074,0.00005701333,0.0008472159,0.000075978176,0.00065938616,0.00023967991,0.00025249482],"category_scores_gemma":[0.0010197129,0.00011507125,0.00027279748,0.000056059875,0.0007167224,0.000074976604,0.000117344716,0.0003990839,0.00012044401],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011518713,0.00020389784,0.00052402396,0.000028237295,0.0005132897,0.0000039007373,0.000016989597,3.7202597e-8,0.9639237,0.0015324049,0.0221739,0.009927754],"study_design_scores_gemma":[0.0017747435,0.0014187901,0.0022027732,0.000054788958,0.00030154802,0.00002718588,0.000013450456,0.000096880554,0.93199944,0.00036456433,0.06158055,0.00016528124],"about_ca_topic_score_codex":0.000011423846,"about_ca_topic_score_gemma":0.000010644126,"teacher_disagreement_score":0.055548605,"about_ca_system_score_codex":0.000021608697,"about_ca_system_score_gemma":0.000022048202,"threshold_uncertainty_score":0.6516185},"labels":[],"label_agreement":null},{"id":"W2774120458","doi":"10.4155/bio-2017-4974","title":"2017 White Paper on Recent Issues in Bioanalysis: A Global Perspective on Immunogenicity Guidelines &amp; Biomarker Assay Performance (Part 3 – Lba: Immunogenicity, Biomarkers and PK Assays)","year":2017,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada); Health Canada; inVentiv Health Clinical","funders":"Health Canada; Genentech; Agence Nationale de Sécurité du Médicament et des Produits de Santé; Angelini Pharma; Sanofi; U.S. Food and Drug Administration; Bristol-Myers Squibb; Ministry of Health, Labour and Welfare; Pfizer; Amgen","keywords":"Bioanalysis; Immunogenicity; Biopharmaceutical; Excellence; Regulatory science; Biosimilar; Computer science; Nanotechnology; Chemistry; Political science; Medicine; Biotechnology; Biology; Chromatography","score_opus":0.08757148376182888,"score_gpt":0.3844078216666881,"score_spread":0.2968363379048592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774120458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6645098,0.16916542,0.00027674597,0.09892301,0.003584051,0.0018779902,0.0016695721,0.00041979615,0.05957366],"genre_scores_gemma":[0.9606473,0.029363161,0.0021070542,0.0018743105,0.00015087338,0.00006113277,0.00013777133,0.00005383306,0.0056046057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99454314,0.0011371223,0.0013063642,0.0016315673,0.00033210806,0.0010497222],"domain_scores_gemma":[0.995639,0.0002582426,0.0008139328,0.002421442,0.0007195714,0.0001477578],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034860477,0.0008677431,0.0014959367,0.0006041084,0.0011887577,0.00032765447,0.0012727468,0.00089467503,0.0016718779],"category_scores_gemma":[0.0019885502,0.0006697043,0.0007999687,0.0009735198,0.0013357354,0.0003598947,0.0006073808,0.0005989614,0.000375314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009462532,0.003412316,0.53456634,0.00013477173,0.040781975,0.00012254539,0.00060017686,0.000055525445,0.057398915,0.0026197215,0.053829584,0.2970156],"study_design_scores_gemma":[0.0052412194,0.0007792802,0.6054751,0.0005262241,0.004081029,0.000081746206,0.0013235518,0.00061046885,0.008158847,0.0006662992,0.3707253,0.0023309067],"about_ca_topic_score_codex":0.0038076383,"about_ca_topic_score_gemma":0.0034292052,"teacher_disagreement_score":0.31689572,"about_ca_system_score_codex":0.00067567674,"about_ca_system_score_gemma":0.000120981196,"threshold_uncertainty_score":0.99957544},"labels":[],"label_agreement":null},{"id":"W2774347927","doi":"10.4155/bio-2017-4973","title":"2017 White Paper on Recent Issues in Bioanalysis: Rise of Hybrid LBA/LCMS Immunogenicity Assays (Part 2: Hybrid LBA/LCMS Biotherapeutics, Biomarkers &amp; Immunogenicity Assays and Regulatory Agencies’ Inputs)","year":2017,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada); Health Canada","funders":"Health Canada; Genentech; Angelini Pharma; Sanofi; Amgen; Pfizer; U.S. Food and Drug Administration; Ministry of Health, Labour and Welfare; Bristol-Myers Squibb; Agence Nationale de Sécurité du Médicament et des Produits de Santé; GlaxoSmithKline","keywords":"Immunogenicity; Bioanalysis; Biopharmaceutical; Regulatory science; Computer science; Chemistry; Biotechnology; Medicine; Biology","score_opus":0.04165581480862591,"score_gpt":0.31142250469596533,"score_spread":0.26976668988733943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774347927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84023345,0.13765092,0.0005092759,0.0121678375,0.0018518271,0.0011636334,0.0017458199,0.00021896338,0.0044582565],"genre_scores_gemma":[0.96363425,0.029873839,0.0018416984,0.0007814819,0.000083887026,0.000035992387,0.0002159445,0.000080552134,0.0034523602],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929666,0.0016719601,0.0019864673,0.0017112436,0.00042314688,0.0012405847],"domain_scores_gemma":[0.9936788,0.00038792982,0.00160724,0.003755528,0.0003676152,0.00020287876],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042208517,0.001021071,0.0023061065,0.0010563062,0.0010027717,0.00023931221,0.001706202,0.0007190776,0.0023245774],"category_scores_gemma":[0.00080031715,0.0008572346,0.0012828808,0.00079650065,0.0027807301,0.0003955015,0.0007128304,0.00088858296,0.00015768163],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043751616,0.0032539857,0.18603286,0.00031122868,0.0432682,0.00016877276,0.0007718814,0.00005055799,0.63330907,0.0007172697,0.015231086,0.112509936],"study_design_scores_gemma":[0.0066361185,0.0008707651,0.21270375,0.0005789189,0.008977982,0.00013417052,0.0006455976,0.00058872846,0.343832,0.001254877,0.42039365,0.0033834316],"about_ca_topic_score_codex":0.0016499346,"about_ca_topic_score_gemma":0.00095643185,"teacher_disagreement_score":0.40516257,"about_ca_system_score_codex":0.0003654033,"about_ca_system_score_gemma":0.00019601278,"threshold_uncertainty_score":0.9999331},"labels":[],"label_agreement":null},{"id":"W2779036013","doi":"10.1016/j.biologicals.2017.12.002","title":"WHO informal consultation on development of guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 27–28 April 2017","year":2017,"lang":"en","type":"article","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Ministry of Food and Drug Safety; World Health Organization","keywords":"Harmonization; Standardization; Authorization; Licensure; Business; Quality (philosophy); Medicine; Public consultation; Medical education; Computer science; Engineering; Computer security","score_opus":0.3204473695739347,"score_gpt":0.4391512621598847,"score_spread":0.11870389258594999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2779036013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963909,0.0029268642,0.0010300138,0.025313593,0.0008165137,0.0036957671,0.0011570666,0.00007003742,0.0010811603],"genre_scores_gemma":[0.88050896,0.0010909527,0.10688557,0.00594486,0.00017741314,0.0001751619,0.00070583867,0.000027027676,0.004484192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987253,0.00006767599,0.0004850936,0.00044022547,0.00004716746,0.0002345533],"domain_scores_gemma":[0.99832916,0.00018712544,0.00045239844,0.0006730089,0.00033045057,0.000027843816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001186589,0.00017075265,0.00039958605,0.000079976984,0.00019725204,0.000022979193,0.0005310012,0.00025853497,0.000020282403],"category_scores_gemma":[0.0057438915,0.00010164776,0.00002541907,0.000052736737,0.00032811213,0.00006345075,0.0002658241,0.00006935794,0.000003822641],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017007744,0.00029650016,0.0014865604,0.00029969524,0.0003294212,2.653968e-7,0.00025214578,3.2685895e-7,0.7572313,0.0014873053,0.01907743,0.21783827],"study_design_scores_gemma":[0.0015817747,0.0022301823,0.045841042,0.00030930157,0.000058608915,0.0000032946396,0.00012056642,0.000020079377,0.59747744,0.00015124092,0.35191217,0.00029432337],"about_ca_topic_score_codex":0.000007784883,"about_ca_topic_score_gemma":0.000020738738,"teacher_disagreement_score":0.33283475,"about_ca_system_score_codex":0.000008629954,"about_ca_system_score_gemma":0.00007804469,"threshold_uncertainty_score":0.68763894},"labels":[],"label_agreement":null},{"id":"W2781139108","doi":"10.1208/s12248-017-0181-6","title":"Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment","year":2017,"lang":"en","type":"review","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"Alnylam Pharmaceuticals; Amgen","keywords":"Biosimilar; Immunogenicity; Drug development; Medicine; Pharmacology; Drug; Computational biology; Risk analysis (engineering); Immune system; Immunology; Biology","score_opus":0.2722218198343102,"score_gpt":0.4899556821618598,"score_spread":0.2177338623275496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781139108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004167527,0.9933156,0.0021550595,0.002852603,0.0006590533,0.0006082075,0.00009595585,0.0000029696419,0.00026892513],"genre_scores_gemma":[0.0002246621,0.99473524,0.0046681594,0.000054800043,0.00003747255,0.000017203023,0.00006162234,0.000012129443,0.0001886996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981636,0.00056307355,0.000905295,0.00013138195,0.000044373457,0.0001923081],"domain_scores_gemma":[0.9975942,0.0009197864,0.0011115794,0.00026665255,0.0000927482,0.0000150324895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041177208,0.00017271386,0.00080725306,0.0001236209,0.0003590974,0.000032679865,0.00045671864,0.0002292164,0.00010353632],"category_scores_gemma":[0.0001455024,0.000081404934,0.00022784859,0.00007745772,0.00021938948,0.000049737802,0.00010872353,0.000553428,9.9606e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014635383,0.00007883757,0.0000714588,0.0009288916,0.0006685545,7.28352e-7,0.0001582255,2.6219072e-7,0.0003484716,0.00059683813,0.0030995652,0.9940335],"study_design_scores_gemma":[0.0002825067,0.0000819724,0.000182169,0.0013972451,0.0006807066,0.00010838397,0.00006175613,9.567406e-7,0.0010669715,0.00020334644,0.99583584,0.0000981514],"about_ca_topic_score_codex":0.0000040913437,"about_ca_topic_score_gemma":0.000004433331,"teacher_disagreement_score":0.9939354,"about_ca_system_score_codex":0.000038002476,"about_ca_system_score_gemma":0.000313366,"threshold_uncertainty_score":0.3319597},"labels":[],"label_agreement":null},{"id":"W2781660650","doi":"10.1038/s41598-017-17934-6","title":"Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing","year":2018,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Rituximab; Dosing; Medicine; Biosimilar; Randomized controlled trial; Clinical trial; Internal medicine; CD20; Pharmacology; Gastroenterology; Lymphoma","score_opus":0.07680978617223842,"score_gpt":0.34229749635437634,"score_spread":0.2654877101821379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781660650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98667794,0.0023919286,0.0015071235,0.0026788134,0.004069997,0.002234455,0.000022127206,0.00007391665,0.00034371426],"genre_scores_gemma":[0.9895866,0.000015305493,0.009624408,0.00032127203,0.000057467045,0.00009864284,0.000019445717,0.000011784518,0.0002650584],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978606,0.00027520332,0.0006825507,0.00074649724,0.000039480925,0.00039567554],"domain_scores_gemma":[0.998102,0.0010333546,0.0002516246,0.00036061023,0.00019588097,0.000056548735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045417296,0.00015788512,0.0005499518,0.00021027107,0.00056584587,0.00015949717,0.00007314443,0.00015417527,0.000018569384],"category_scores_gemma":[0.0038808617,0.00012423683,0.00007320106,0.00042229157,0.0020034285,0.00010517597,0.00008997478,0.00014380089,0.0000014487306],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2593197,0.0017392178,0.006344556,0.00021373495,0.00016819501,0.000014829907,0.000503567,2.9012452e-7,0.692036,0.0007086543,0.0071039754,0.03184731],"study_design_scores_gemma":[0.83733267,0.0038072716,0.0057777977,0.00046097903,0.00043008622,0.0008817164,0.00018744735,0.0004355205,0.06748326,0.058840256,0.023425907,0.0009371091],"about_ca_topic_score_codex":0.00010384609,"about_ca_topic_score_gemma":0.00011749635,"teacher_disagreement_score":0.6245527,"about_ca_system_score_codex":0.000034833283,"about_ca_system_score_gemma":0.00011210541,"threshold_uncertainty_score":0.7381716},"labels":[],"label_agreement":null},{"id":"W2787423031","doi":"10.1136/esmoopen-2017-000319","title":"Extrapolation concept at work with biosimilar: a decade of experience in oncology","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Extrapolation; Work (physics); Medical physics; Computer science; Oncology; Data science; Medicine; Medical education; Internal medicine; Mathematics; Statistics; Engineering","score_opus":0.06550678048535025,"score_gpt":0.3813891271215389,"score_spread":0.31588234663618864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787423031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95949495,0.00055680366,0.0007552706,0.0023469732,0.000436722,0.0007044179,0.000017624106,0.0000239238,0.035663337],"genre_scores_gemma":[0.9921384,0.000015773754,0.0048739635,0.000670202,0.00001973039,0.000022872691,0.000008708044,0.000007544027,0.0022428227],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895096,0.00024380279,0.00026184917,0.00027206232,0.000027166852,0.0002441819],"domain_scores_gemma":[0.99940604,0.00016397709,0.000117273354,0.00023130569,0.000058449477,0.00002297916],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031388787,0.00011031598,0.00029959015,0.000060088663,0.000065228305,0.00000910289,0.00039744296,0.00026736662,0.0024938744],"category_scores_gemma":[0.00006775365,0.000078336474,0.00002908999,0.0003247078,0.0008971427,0.00008735267,0.00025226048,0.0001498261,0.000048076174],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009819904,0.0013299388,0.49332154,0.000026991534,0.0004365492,0.00005653526,0.020314367,0.000004426084,0.29221565,0.00765146,0.03735359,0.13746907],"study_design_scores_gemma":[0.0025838153,0.0015601971,0.14706747,0.00011001493,0.000034519388,0.00003904675,0.0006028953,0.000007695936,0.59784937,0.00023206178,0.24964266,0.00027027773],"about_ca_topic_score_codex":0.0002621156,"about_ca_topic_score_gemma":0.00080408686,"teacher_disagreement_score":0.34625405,"about_ca_system_score_codex":0.00005578972,"about_ca_system_score_gemma":0.00005672172,"threshold_uncertainty_score":0.998418},"labels":[],"label_agreement":null},{"id":"W2789498468","doi":"10.1007/s40258-018-0371-0","title":"Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching","year":2018,"lang":"en","type":"letter","venue":"Applied Health Economics and Health Policy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University; University of Ottawa","funders":"Janssen Pharmaceuticals","keywords":"Biosimilar; Infliximab; Inflammatory bowel disease; Medicine; Incentive; Intensive care medicine; Payment; Health economics; Public economics; Risk analysis (engineering); Disease; Business; Public health; Economics; Finance","score_opus":0.09600940158023422,"score_gpt":0.41344144705543284,"score_spread":0.31743204547519865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789498468","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045004755,0.006782873,0.0007564328,0.9854336,0.00052401907,0.003864323,0.0020745262,0.00005276014,0.00006143114],"genre_scores_gemma":[0.0013222995,0.026387144,0.004699207,0.960225,0.0050835037,0.001224079,0.00055464386,0.00013128798,0.00037284926],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950578,0.00020478747,0.0016642187,0.0011082201,0.000038282447,0.0019266752],"domain_scores_gemma":[0.9970162,0.00092782534,0.0010435292,0.00060993613,0.00007483563,0.0003276532],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023476563,0.0006071434,0.0012535026,0.0010579514,0.00091433077,0.00006816155,0.0004378347,0.0010989611,0.00002069736],"category_scores_gemma":[0.00022861661,0.0006249727,0.00025453308,0.00016750894,0.00029537815,0.00011060576,0.00021153803,0.0012346087,0.000019000612],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005425591,0.00008475119,0.0002491988,0.0065288753,0.0001928373,0.00000128399,0.0008984255,0.000018655604,0.00003195239,0.05495462,0.9090187,0.02747814],"study_design_scores_gemma":[0.0019472466,0.0003427051,0.0016187375,0.0004733847,0.000037762908,0.000005207534,0.000059210695,0.00026332162,0.000012882907,0.02145614,0.97322494,0.0005584674],"about_ca_topic_score_codex":0.0016347484,"about_ca_topic_score_gemma":0.0005835667,"teacher_disagreement_score":0.064206235,"about_ca_system_score_codex":0.0010985623,"about_ca_system_score_gemma":0.0057215383,"threshold_uncertainty_score":0.9999151},"labels":[],"label_agreement":null},{"id":"W2790028499","doi":"10.1093/ecco-jcc/jjx180.821","title":"P694 Non-medical mandatory reversed and back and forth switch between infliximab and its biosimilar: Early clinical outcomes","year":2018,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Biosimilar; Medicine; Infliximab; Inflammatory bowel disease; Concomitant; Cohort; Internal medicine; Ulcerative colitis; Disease","score_opus":0.0335502627924128,"score_gpt":0.3411447456736208,"score_spread":0.307594482881208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790028499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933696,0.0030967942,0.000078202764,0.0025828972,0.0003408168,0.00012037996,0.000043607793,0.000005267812,0.00036247825],"genre_scores_gemma":[0.99331737,0.0033455628,0.0006590971,0.0016480415,0.0002736239,9.3678335e-7,0.000001383931,0.000011308236,0.0007427063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842364,0.00020792555,0.0007197568,0.0002508666,0.00009592117,0.00030189974],"domain_scores_gemma":[0.9987199,0.0004946353,0.00026543278,0.00010767122,0.00016598254,0.00024643648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012652314,0.00018747323,0.0007197561,0.000091672104,0.00016949787,0.000056907425,0.00011804479,0.0005155934,0.00036840304],"category_scores_gemma":[0.00031204268,0.00012935435,0.00010047066,0.000066126304,0.00092560024,0.00015088018,0.00017410143,0.0005284405,0.00000859658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015075463,0.00011850889,0.9095306,0.00009736893,0.0007946617,0.000111465066,0.0002587938,1.4373499e-9,0.00026034756,0.0003536051,0.009157174,0.07780992],"study_design_scores_gemma":[0.0028691434,0.0012453255,0.9389897,0.00011275825,0.00018627099,0.0003623542,0.00006731821,0.000003893483,0.00043794233,0.00037269815,0.055192392,0.00016019937],"about_ca_topic_score_codex":0.00001707694,"about_ca_topic_score_gemma":0.000017806175,"teacher_disagreement_score":0.07764973,"about_ca_system_score_codex":0.000008355229,"about_ca_system_score_gemma":0.00007994964,"threshold_uncertainty_score":0.52749175},"labels":[],"label_agreement":null},{"id":"W2790630457","doi":"10.1093/jcag/gwy008.105","title":"A104 COST-EFFECTIVENESS OF INFLIXIMAB BIOSIMILAR FOR THE MANAGEMENT OF CROHN’S DISEASE","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Biosimilar; Infliximab; Medicine; Crohn's disease; Innovator; Observational study; Intensive care medicine; Disease; Internal medicine; Computer science","score_opus":0.01923842434431002,"score_gpt":0.2826813628186193,"score_spread":0.2634429384743093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790630457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96159697,0.00058881886,0.0030991395,0.027717259,0.004103307,0.0016430698,0.0008776476,0.000004853097,0.0003689639],"genre_scores_gemma":[0.9986872,0.00004314167,0.00039936675,0.00060334837,0.000042054075,0.0000073569367,0.0000022781323,0.0000068772915,0.00020835841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837166,0.00066544174,0.0005266124,0.00008901712,0.00007901225,0.00026824948],"domain_scores_gemma":[0.99758565,0.00040795244,0.0011375418,0.00020037057,0.00061232183,0.000056145404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021607587,0.0000963715,0.00037995214,0.00012293406,0.00011113521,0.0000043468085,0.00043425895,0.00014104896,0.000072814364],"category_scores_gemma":[0.0003177446,0.000057927155,0.00030904275,0.00011197921,0.0003770979,0.00003216449,0.000052672694,0.00017026994,8.552569e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016156137,0.00060521107,0.91239935,0.0006159157,0.010463956,0.000011826782,0.0002988086,0.00012177123,0.022075117,0.005224383,0.027175372,0.004852124],"study_design_scores_gemma":[0.0028074528,0.0009109808,0.9739706,0.00015582296,0.0007636125,0.000009703826,0.00006795732,0.000021303147,0.0091224685,0.00065280584,0.011469462,0.000047815618],"about_ca_topic_score_codex":0.00032684513,"about_ca_topic_score_gemma":0.007929619,"teacher_disagreement_score":0.061571237,"about_ca_system_score_codex":0.00027253252,"about_ca_system_score_gemma":0.00015416577,"threshold_uncertainty_score":0.44249138},"labels":[],"label_agreement":null},{"id":"W2791883034","doi":"10.1093/ecco-jcc/jjx180.669","title":"P542 Infliximab salvage therapy in acute severe ulcerative colitis: A systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Infliximab; Internal medicine; Ulcerative colitis; Salvage therapy; Meta-analysis; Odds ratio; Colectomy; Dosing; Surgery; Chemotherapy; Tumor necrosis factor alpha","score_opus":0.06532592840362832,"score_gpt":0.36487803813572195,"score_spread":0.2995521097320936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791883034","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012073393,0.9976749,0.000021662681,0.00034413836,0.00008794784,0.0012625986,0.00037622932,0.000005741127,0.00021471706],"genre_scores_gemma":[0.000056854922,0.9960462,0.00027391425,0.0013740526,0.00003659778,0.00009051826,0.000014053697,0.000024088598,0.0020837386],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9943426,0.0025647858,0.0021968402,0.0003973675,0.00011019436,0.00038820002],"domain_scores_gemma":[0.99674904,0.000643205,0.0018164633,0.0003547273,0.00033816966,0.0000984034],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022392408,0.0005678413,0.011036719,0.00046038948,0.00011039227,0.00010048747,0.00033598716,0.00062478054,0.0009240538],"category_scores_gemma":[0.00019583083,0.0003139529,0.0023693764,0.0006786273,0.00037057063,0.0001346018,0.000107953725,0.00079018506,0.0000094225],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041042824,0.00019639885,0.0000020421674,0.36868685,0.6036332,0.0004031611,0.0002121353,1.4523572e-8,2.9434165e-7,0.0006287237,0.004384875,0.021441832],"study_design_scores_gemma":[0.00053074013,0.0005063488,0.0001956542,0.025567787,0.7407917,0.0024430228,0.0000375937,1.6269625e-7,0.000002051407,0.00020605954,0.22931522,0.00040368186],"about_ca_topic_score_codex":0.000020720654,"about_ca_topic_score_gemma":0.000054040553,"teacher_disagreement_score":0.34311906,"about_ca_system_score_codex":0.00006774876,"about_ca_system_score_gemma":0.00018581562,"threshold_uncertainty_score":0.9999892},"labels":[],"label_agreement":null},{"id":"W2792338314","doi":"10.1093/jcag/gwy009.073","title":"A73 COST-EFFECTIVENESS OF INFLIXIMAB BIOSIMILAR COMPARED TO ORIGINATOR INFLIXIMAB FOR THE MANAGEMENT OF CROHN’S DISEASE","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Infliximab; Biosimilar; Medicine; Crohn's disease; Intensive care medicine; Internal medicine; Disease","score_opus":0.02114660282880905,"score_gpt":0.29576196750813166,"score_spread":0.2746153646793226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792338314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97693133,0.0002001025,0.0019363792,0.016300622,0.0023951535,0.0014107749,0.00067317445,0.000004180468,0.00014829943],"genre_scores_gemma":[0.9980201,0.000017895074,0.000751574,0.00096168055,0.000043691256,0.00001474138,0.000003083819,0.000009029419,0.00017818704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981527,0.0006614372,0.0006258648,0.000119089345,0.000105080806,0.0003358301],"domain_scores_gemma":[0.9973558,0.00041184467,0.0010662669,0.00024577393,0.00082142453,0.00009887075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002004658,0.00012613984,0.0005027074,0.00018583778,0.0001269268,0.0000069827083,0.00055008987,0.00014021578,0.00006949131],"category_scores_gemma":[0.00036301298,0.00007967713,0.00029618025,0.00017693211,0.00031233535,0.000039278035,0.00007309117,0.00018320177,0.0000017674732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026537579,0.0008119279,0.88791174,0.0006318716,0.010473212,0.000014530623,0.0005664156,0.0003143571,0.02238799,0.0064681596,0.04100201,0.0028802066],"study_design_scores_gemma":[0.004124094,0.0011342278,0.9519392,0.00020762817,0.0007521643,0.000009366643,0.00009880906,0.0000381427,0.010310115,0.0005026097,0.030807152,0.00007644333],"about_ca_topic_score_codex":0.00049841864,"about_ca_topic_score_gemma":0.009127638,"teacher_disagreement_score":0.0640275,"about_ca_system_score_codex":0.00043520413,"about_ca_system_score_gemma":0.00020815468,"threshold_uncertainty_score":0.5093436},"labels":[],"label_agreement":null},{"id":"W2792786951","doi":"10.1208/s12248-018-0189-6","title":"Correction to: Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment","year":2018,"lang":"en","type":"erratum","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Biosimilar; Babbitt; Psychology; Computer science; Medicine; Engineering; Internal medicine; Mechanical engineering","score_opus":0.05657685803591296,"score_gpt":0.3863369913463965,"score_spread":0.32976013331048354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792786951","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029721878,0.012237293,0.2778672,0.2003083,0.43953657,0.0084237335,0.0013066109,0.000099217345,0.030499227],"genre_scores_gemma":[0.3518751,0.034492712,0.2543418,0.0151353255,0.008763864,0.00053333334,0.0052363803,0.00057487487,0.3290466],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99846715,0.00039909588,0.000696354,0.00015653405,0.00006452964,0.00021631733],"domain_scores_gemma":[0.99840343,0.00061771495,0.00054780114,0.00018293277,0.00022750984,0.000020623918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00313408,0.00015837321,0.00035732027,0.00017430526,0.00029504672,0.000026392248,0.00028142834,0.00025975888,0.00023638719],"category_scores_gemma":[0.00022538293,0.00008725434,0.00010303004,0.00017721731,0.00017389418,0.000044491935,0.00009290898,0.00075807545,0.0000017769652],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000782903,0.00007979168,0.00034512408,0.00003718473,0.0002888406,2.8321782e-7,0.0005367424,0.000002160505,0.015248026,0.00008744313,0.97004426,0.013251874],"study_design_scores_gemma":[0.0004906441,0.00046779393,0.006306972,0.0003260984,0.00026754712,0.00008416444,0.00046833104,0.00003370131,0.056449324,0.00034919247,0.9346023,0.00015390744],"about_ca_topic_score_codex":0.000016686148,"about_ca_topic_score_gemma":0.00004488906,"teacher_disagreement_score":0.4307727,"about_ca_system_score_codex":0.00006374813,"about_ca_system_score_gemma":0.0002822874,"threshold_uncertainty_score":0.35581288},"labels":[],"label_agreement":null},{"id":"W2792915793","doi":"10.1093/ecco-jcc/jjx180.646","title":"P519 Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months results","year":2018,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Infliximab; Ulcerative colitis; Biosimilar; Internal medicine; Inflammatory bowel disease; Crohn's disease; Clinical endpoint; Gastroenterology; Demographics; Adverse effect; Observational study; Disease; Randomized controlled trial","score_opus":0.01213714846120796,"score_gpt":0.2598678414315272,"score_spread":0.24773069297031924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792915793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998439,0.00039438077,0.000012282309,0.0003166558,0.00021893355,0.00028885592,0.000103508435,0.0000062403424,0.00022013669],"genre_scores_gemma":[0.99901605,0.000035443816,0.0002811204,0.0002967824,0.00006751486,0.0000033848232,0.000005590877,0.000009600024,0.0002845386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985624,0.00024087973,0.00056058547,0.00024212994,0.00010538089,0.00028864335],"domain_scores_gemma":[0.9990245,0.00015267188,0.0002750836,0.0001948505,0.0002129936,0.00013990738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033522747,0.00016712882,0.00034702558,0.00011076405,0.00013687527,0.00003708913,0.00017030782,0.000078520876,0.00012711575],"category_scores_gemma":[0.00019553436,0.00011331731,0.000043307253,0.00007998878,0.00011153497,0.00012951427,0.00013661645,0.00029718125,0.000014366881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03617608,0.00082940416,0.9467547,0.000015881807,0.0002816253,0.00023688846,0.0021382272,0.000003261265,0.00032280548,0.000029157118,0.0016764824,0.011535482],"study_design_scores_gemma":[0.0060568294,0.0010423374,0.98177356,0.00017201135,0.00008799579,0.0000061115784,0.00043265073,0.000005217429,0.0003369318,0.000055519366,0.009873396,0.00015743819],"about_ca_topic_score_codex":0.00014973317,"about_ca_topic_score_gemma":0.0008486005,"teacher_disagreement_score":0.035018858,"about_ca_system_score_codex":0.000071536444,"about_ca_system_score_gemma":0.000059427242,"threshold_uncertainty_score":0.46209455},"labels":[],"label_agreement":null},{"id":"W2793290235","doi":"10.1093/ecco-jcc/jjx180.838","title":"P711 A pilot study using point of care testing for infliximab and faecal calprotectin in IBD patients with a secondary loss of response","year":2018,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Infliximab; Calprotectin; Faecal calprotectin; Internal medicine; Clinical endpoint; Point of care; Point-of-care testing; Prospective cohort study; Gastroenterology; Surgery; Inflammatory bowel disease; Immunology; Clinical trial; Pathology","score_opus":0.03027162593428769,"score_gpt":0.2996089309337857,"score_spread":0.26933730499949804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793290235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988701,0.00052983937,0.00011736027,0.000039902156,0.000054807508,0.00031074422,0.00005177295,0.00000134686,0.000024125371],"genre_scores_gemma":[0.99655604,0.0000035892547,0.0033700704,0.00003454064,0.00001801709,0.0000018413479,3.2957584e-7,0.0000066845373,0.0000088797615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900556,0.00024537442,0.00044492813,0.00010981745,0.00004246199,0.00015188806],"domain_scores_gemma":[0.9987372,0.0003320687,0.00032773748,0.00006756181,0.0005078356,0.000027577365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006264025,0.00009279342,0.0003963058,0.00011918448,0.000063676256,0.000008385577,0.000057026195,0.00006863109,0.000017025674],"category_scores_gemma":[0.0003556696,0.000064359185,0.000029409368,0.000111033965,0.00033254788,0.000057387573,0.00004715336,0.00017835318,3.7955132e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23964463,0.0022381824,0.66132945,0.00049159786,0.000569085,0.00010135946,0.0076538143,0.0000013504939,0.033743273,0.00008223092,0.000045413242,0.0540996],"study_design_scores_gemma":[0.0055667795,0.029536478,0.95491385,0.00025205314,0.00007005613,0.00012714263,0.0018156022,0.0000053791746,0.007373329,0.00012892178,0.000127873,0.00008255085],"about_ca_topic_score_codex":0.00012081352,"about_ca_topic_score_gemma":0.000110560046,"teacher_disagreement_score":0.29358438,"about_ca_system_score_codex":0.000022737164,"about_ca_system_score_gemma":0.0001115318,"threshold_uncertainty_score":0.26244915},"labels":[],"label_agreement":null},{"id":"W2793307100","doi":"10.22374/1710-6222.23.1.3","title":"Utilization of Biologics in Saskatchewan","year":2017,"lang":"en","type":"article","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Quality Council; University of Manitoba; University of Saskatchewan","funders":"","keywords":"Medicine","score_opus":0.08544272180592795,"score_gpt":0.3561344682357396,"score_spread":0.27069174642981164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793307100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92372334,0.0009245259,0.0033872472,0.0016710226,0.00065909117,0.0001964486,0.000020080397,0.0000353847,0.06938287],"genre_scores_gemma":[0.9953469,0.000036916354,0.0014699474,0.00009536105,0.000004161539,8.909148e-7,0.0000033725667,0.0000016723724,0.0030407934],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996109,0.00005466406,0.00013368804,0.000094761854,0.0000071766685,0.000098789635],"domain_scores_gemma":[0.999635,0.000041260133,0.000071511815,0.0002254526,0.000021696913,0.0000051026855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023515943,0.00004575572,0.0001293674,0.000028907702,0.000052463995,0.000004704513,0.00016330981,0.00016582549,0.0006353606],"category_scores_gemma":[0.00016364203,0.000030275505,0.000030624895,0.000025122068,0.000219746,0.00002739663,0.00005798866,0.00006884162,0.000015334186],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100731755,0.0002258903,0.24684885,0.000019882349,0.00005245066,0.0000022180689,0.00017134185,4.5433384e-7,0.4775414,0.015261977,0.001474494,0.2583003],"study_design_scores_gemma":[0.00062843895,0.00012522472,0.29345992,0.000016894865,0.000011472832,0.0000026967618,0.0004880892,0.000018390352,0.6917223,0.0032263007,0.010201205,0.00009910006],"about_ca_topic_score_codex":0.00018133162,"about_ca_topic_score_gemma":0.000408639,"teacher_disagreement_score":0.2582012,"about_ca_system_score_codex":0.0000042358447,"about_ca_system_score_gemma":0.000013890234,"threshold_uncertainty_score":0.6956753},"labels":[],"label_agreement":null},{"id":"W2793823183","doi":"10.1093/ecco-jcc/jjx180.620","title":"P493 Comparison of the efficacy of infliximab biosimilar (Remsima®) vs. infliximab original (Remicade®) in patients with inflammatory bowel disease","year":2018,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Infliximab; Medicine; Biosimilar; Internal medicine; Cohort; Ulcerative colitis; Inflammatory bowel disease; Prospective cohort study; Demographics; Crohn's disease; Retrospective cohort study; Cohort study; Disease; Demography","score_opus":0.010528512430882467,"score_gpt":0.27157948122300624,"score_spread":0.26105096879212375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793823183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99769163,0.001204958,0.000022641283,0.00041519455,0.00026485795,0.00019719295,0.000050168925,0.0000035400712,0.00014979197],"genre_scores_gemma":[0.9992849,0.000069012254,0.00031501372,0.00020766834,0.000056274752,0.0000014564671,0.0000018956235,0.000010874206,0.000052907053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983152,0.00023829612,0.00085913524,0.00015975807,0.00015279875,0.00027479336],"domain_scores_gemma":[0.99833715,0.00017663358,0.0007581141,0.00023379823,0.00041530174,0.00007897306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036312008,0.00018194923,0.00056551944,0.00015001741,0.000082374696,0.000012339082,0.00030279893,0.00018395159,0.0001310232],"category_scores_gemma":[0.00019201938,0.00010820536,0.00014396527,0.00021122207,0.0011166224,0.00011206075,0.00010287576,0.00040540125,0.0000016140806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017625976,0.0008497177,0.9738598,0.00011069225,0.00022737506,0.00000844731,0.00040338814,0.0000037843863,0.0011435037,0.0007159942,0.0015547657,0.0034965626],"study_design_scores_gemma":[0.0046692993,0.0010350761,0.96905565,0.0003531543,0.00015270109,0.000010014232,0.000066935485,0.0000101792575,0.012270795,0.00016786941,0.012076082,0.00013222476],"about_ca_topic_score_codex":0.000013404086,"about_ca_topic_score_gemma":0.0000152175235,"teacher_disagreement_score":0.012956677,"about_ca_system_score_codex":0.000036856505,"about_ca_system_score_gemma":0.00017950548,"threshold_uncertainty_score":0.44124863},"labels":[],"label_agreement":null},{"id":"W2794127362","doi":"10.1016/j.envpol.2018.01.036","title":"Dried blood spots for estimating mercury exposure in birds","year":2018,"lang":"en","type":"article","venue":"Environmental Pollution","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Research Council Canada; National Institutes of Health; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; Fulbright Canada","keywords":"Zebra finch; Dried blood; Methylmercury; Dried blood spot; Mercury (programming language); MERCURY EXPOSURE; Spots; Whole blood; Animal science; Chemistry; Biology; Medicine; Biomonitoring; Environmental chemistry; Surgery; Bioaccumulation; Chromatography","score_opus":0.014206689762903735,"score_gpt":0.26222138764999336,"score_spread":0.24801469788708963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794127362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908532,0.00079086213,0.0058224937,0.000718786,0.00082802644,0.00034640866,0.00009761249,0.0000416938,0.00050091563],"genre_scores_gemma":[0.9832797,0.000011690628,0.015561626,0.00032885803,0.00011436169,0.000016471407,0.000030815354,0.00001118038,0.0006452851],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99919665,0.00008576876,0.00020343119,0.00022982058,0.000025457048,0.0002588674],"domain_scores_gemma":[0.999756,0.000041098217,0.00005518706,0.0001271492,0.0000024281414,0.000018140212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002694175,0.00011093446,0.00014438652,0.000053384007,0.00012557636,0.000005682836,0.00008101439,0.00020895034,0.00054102833],"category_scores_gemma":[0.000044633754,0.00009967737,0.00006086136,0.0000583913,0.00030588597,0.00005471927,0.000044515582,0.00011708895,0.00010435875],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011097115,0.0002217622,0.0039773025,0.000007167637,0.000047745958,0.0000012935935,0.00012909887,0.0000030115177,0.95548594,0.0002568417,0.0005029734,0.039255913],"study_design_scores_gemma":[0.003778269,0.0011960866,0.16470243,0.000053273576,0.00015415753,0.000047792528,0.0002844863,0.000607042,0.81152284,0.0016894216,0.015541612,0.00042259146],"about_ca_topic_score_codex":0.000012285247,"about_ca_topic_score_gemma":0.000008124909,"teacher_disagreement_score":0.16072513,"about_ca_system_score_codex":0.000047275436,"about_ca_system_score_gemma":0.0000066436687,"threshold_uncertainty_score":0.5923881},"labels":[],"label_agreement":null},{"id":"W2794279877","doi":"10.1093/jcag/gwy008.124","title":"A123 INCREASING TIME ON TREATMENT IS PREDICTIVE OF IMPROVED LONG-TERM RETENTION FOR STABLE REMICADE® (INFLIXIMAB) INFLAMMATORY BOWEL DISEASE PATIENTS IN CANADA","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Infliximab; Medicine; Odds; Internal medicine; Odds ratio; Inflammatory bowel disease; Logistic regression; Surgery; Disease","score_opus":0.007600086820247636,"score_gpt":0.2207636618571736,"score_spread":0.21316357503692598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794279877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667394,0.00002005865,0.000012362159,0.002000077,0.00049977377,0.00026197356,0.0005057982,0.0000010743635,0.000024963785],"genre_scores_gemma":[0.9989504,0.000012411123,0.00006837024,0.0006263254,0.000042470885,0.000003438668,0.000015163315,0.000007819587,0.00027360025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984182,0.00048084414,0.00058869424,0.00011807391,0.00007938391,0.00031481488],"domain_scores_gemma":[0.99803084,0.00015990708,0.0011445975,0.00013291386,0.00044163954,0.000090109876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063102896,0.000115881354,0.0003459708,0.00015935177,0.00007462035,0.000004268325,0.00018183468,0.00014864386,0.000067458255],"category_scores_gemma":[0.00052046846,0.00008366455,0.00015875172,0.000059987124,0.00009852555,0.000050242405,0.000020229458,0.00016659615,7.7277707e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029081514,0.00008184507,0.99023175,0.000012529546,0.0003070044,0.0000010311022,0.00006364084,0.0000047566687,0.0041763103,0.0000035032547,0.0020221726,0.00018732155],"study_design_scores_gemma":[0.0028887617,0.0018123381,0.99052423,0.00008988644,0.00015437337,0.0000026445177,0.000013635785,0.00007437305,0.0040928237,0.00004183823,0.00026108735,0.00004398363],"about_ca_topic_score_codex":0.19656904,"about_ca_topic_score_gemma":0.92334694,"teacher_disagreement_score":0.7267779,"about_ca_system_score_codex":0.0034282822,"about_ca_system_score_gemma":0.001096555,"threshold_uncertainty_score":0.89648384},"labels":[],"label_agreement":null},{"id":"W2797505118","doi":"10.2533/chimia.2018.146","title":"Recent Regulatory Trends in Pharmaceutical Manufacturing and their Impact on the Industry","year":2018,"lang":"en","type":"article","venue":"CHIMIA International Journal for Chemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Marine Biosciences","funders":"","keywords":"Traceability; Guideline; Business; Quality (philosophy); Good manufacturing practice; Risk analysis (engineering); Pharmaceutical industry; Product (mathematics); Control (management); Identification (biology); Process management; Accounting; Computer science; Marketing; Medicine; Supply chain; Pharmacology","score_opus":0.04651344778359068,"score_gpt":0.37581238462582434,"score_spread":0.32929893684223366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797505118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98959166,0.00038167232,0.000019948944,0.0066079497,0.00079966977,0.000040576888,0.000042373642,0.000008817723,0.0025073246],"genre_scores_gemma":[0.99719214,0.0001503638,0.00004423619,0.0007497575,0.00049424235,0.0000041234193,0.000011312817,0.000009010399,0.0013448347],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993177,0.000047880952,0.00021246797,0.0001611771,0.000047338886,0.0002134083],"domain_scores_gemma":[0.9995014,0.00019672657,0.0000826824,0.00009811386,0.000075479504,0.000045568744],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043847223,0.00014488709,0.00013568469,0.00005576182,0.00012184641,0.00004297724,0.00028186938,0.00029543866,0.003029627],"category_scores_gemma":[0.000100129706,0.00007428118,0.00011581897,0.000042495063,0.0002516484,0.000036221554,0.00006316535,0.0008929131,0.000004522471],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016326752,0.0002436157,0.002277972,0.000009469114,0.0008730536,0.000013050309,0.00021137591,0.0000035655319,0.46419957,0.00026100758,0.02394246,0.50633216],"study_design_scores_gemma":[0.00086919573,0.0000679647,0.011752013,0.000049530747,0.000013742951,0.0003728859,0.00009179291,0.000052510673,0.89956737,0.0008132316,0.08624313,0.000106652165],"about_ca_topic_score_codex":9.1832806e-7,"about_ca_topic_score_gemma":6.049783e-7,"teacher_disagreement_score":0.5062255,"about_ca_system_score_codex":0.000112166716,"about_ca_system_score_gemma":0.000029443741,"threshold_uncertainty_score":0.9978817},"labels":[],"label_agreement":null},{"id":"W2800776653","doi":"10.1093/rheumatology/key075.444","title":"220 Cost per response for abatacept versus adalimumab in patients with seropositive erosive, early rheumatoid arthritis in the United States, Germany, Spain and Canada","year":2018,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"Eli Lilly and Company","keywords":"Abatacept; Medicine; Adalimumab; Rheumatoid arthritis; Antirheumatic Agents; Internal medicine; Immunology; Rituximab","score_opus":0.011139550292129137,"score_gpt":0.2473296718836191,"score_spread":0.23619012159148997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800776653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737114,0.00025632585,0.0000640106,0.0007503728,0.00015748035,0.00063661736,0.0007173224,0.000009186034,0.000037576967],"genre_scores_gemma":[0.9983872,0.00015569107,0.00029252586,0.0008052224,0.000010690675,0.000041463245,0.00020716785,0.000014797827,0.00008521101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819344,0.00086335605,0.0002236044,0.0002771327,0.00006046302,0.00038201603],"domain_scores_gemma":[0.9986108,0.00096258987,0.000082239974,0.00019716073,0.00011597496,0.00003122307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006418224,0.00016844778,0.00024573685,0.000092638475,0.00016215947,0.000028005623,0.00016360298,0.00015539082,0.000055481352],"category_scores_gemma":[0.00017198978,0.00011506723,0.000023302235,0.00019910555,0.0003301631,0.00006060523,0.000051307376,0.00028551318,0.0000048346756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17063785,0.001171749,0.7696124,0.000057009507,0.00092069723,0.00010913423,0.012224575,0.000010868713,0.0039468524,0.0010635576,0.018535383,0.021709932],"study_design_scores_gemma":[0.014593218,0.0026817704,0.91513324,0.000119026154,0.000027386975,0.000007135434,0.0011216595,0.00003009772,0.0012846944,0.00003641329,0.0646457,0.00031963622],"about_ca_topic_score_codex":0.14624314,"about_ca_topic_score_gemma":0.49178573,"teacher_disagreement_score":0.3455426,"about_ca_system_score_codex":0.000090442794,"about_ca_system_score_gemma":0.0001350535,"threshold_uncertainty_score":0.8594421},"labels":[],"label_agreement":null},{"id":"W2801498218","doi":"10.1038/s41571-018-0030-2","title":"Low-value approvals and high prices might incentivize ineffective drug development","year":2018,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Medicine; Drug development; Drug; Portfolio; Drug approval; Incentive; Pipeline (software); Clinical trial; Value (mathematics); Actuarial science; Risk analysis (engineering); Intensive care medicine; Public economics; Pharmacology; Finance; Business; Internal medicine; Economics; Microeconomics","score_opus":0.0935634486123407,"score_gpt":0.4775639335498192,"score_spread":0.3840004849374785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801498218","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001748353,0.98955005,0.00008904772,0.0003655692,0.005085318,0.003261625,0.000049615992,0.00007020661,0.0015110873],"genre_scores_gemma":[0.000004007436,0.9782373,0.015930401,0.0019461752,0.0008239819,0.0003311719,0.00019264588,0.00006573381,0.0024686027],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98326725,0.009816927,0.004048963,0.0019000235,0.0001110187,0.00085579144],"domain_scores_gemma":[0.98724425,0.0088256495,0.0026716026,0.000839744,0.00022129077,0.00019747092],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.01217801,0.001125142,0.009726153,0.00023478086,0.0002568031,0.00003412062,0.0009844571,0.008366371,0.00047248288],"category_scores_gemma":[0.0055465563,0.000654985,0.0015081698,0.0006113517,0.0015716937,0.0000782703,0.00090231077,0.006342596,0.0011269024],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059373164,0.0005939567,0.000012065637,0.008892972,0.0010950171,0.000017135331,0.000022931483,7.78097e-10,0.0000018252115,0.0007596085,0.030616887,0.95792824],"study_design_scores_gemma":[0.0008727359,0.00062592124,0.00007837261,0.01125212,0.0025097425,0.00010075324,0.0000033932474,1.4366125e-7,0.000035656183,0.00017124342,0.9836139,0.00073602545],"about_ca_topic_score_codex":0.000005602184,"about_ca_topic_score_gemma":0.000027366148,"teacher_disagreement_score":0.9571922,"about_ca_system_score_codex":0.0003029978,"about_ca_system_score_gemma":0.0010389726,"threshold_uncertainty_score":0.99965084},"labels":[],"label_agreement":null},{"id":"W2801567745","doi":"10.4155/bio-2017-0271","title":"Surface Plasmon Resonance as a Tool for Ligand-Binding Assay Reagent Characterization in Bioanalysis of Biotherapeutics","year":2018,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Surface plasmon resonance; Bioanalysis; Reagent; Combinatorial chemistry; Characterization (materials science); Ligand (biochemistry); Nanotechnology; Chemistry; Computer science; Materials science; Nanoparticle; Organic chemistry; Biochemistry","score_opus":0.029707607791575018,"score_gpt":0.3117426459981284,"score_spread":0.2820350382065534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801567745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856981,0.0035936532,0.007826782,0.0011844612,0.000386241,0.00044367462,0.0004916411,0.000049426424,0.0003260379],"genre_scores_gemma":[0.98991996,0.00083763927,0.0048526605,0.00028753237,0.000053699965,0.000015466956,0.00019872315,0.000025687323,0.0038086441],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978748,0.00032866912,0.00076222053,0.000523929,0.00009085923,0.000419511],"domain_scores_gemma":[0.9985664,0.00034462952,0.0003704897,0.00044861372,0.00023929554,0.000030581294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013467822,0.0002491692,0.0007113627,0.00039641283,0.00013488006,0.00002617595,0.00028725696,0.00043644838,0.00039270622],"category_scores_gemma":[0.00031178407,0.00020688435,0.00037312644,0.0014282173,0.00037550813,0.000082296,0.00006475755,0.00014667433,0.000055079207],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003697349,0.000235099,0.033720944,0.000034010016,0.00097306975,0.0000016086962,0.0001901363,0.000002463202,0.92540175,0.0005011199,0.00006868413,0.0385014],"study_design_scores_gemma":[0.0011165858,0.00039841508,0.011734826,0.00008227757,0.0009998968,0.0000034888799,0.00012926575,0.0013281859,0.9103509,0.00013940211,0.07332945,0.00038730016],"about_ca_topic_score_codex":0.00009335594,"about_ca_topic_score_gemma":0.000091597285,"teacher_disagreement_score":0.07326077,"about_ca_system_score_codex":0.000081582606,"about_ca_system_score_gemma":0.000059118498,"threshold_uncertainty_score":0.84364986},"labels":[],"label_agreement":null},{"id":"W2802249086","doi":"10.4155/bio-2018-0014","title":"11th GCC Closed Forum: Cumulative Stability; Matrix Stability; Immunogenicity assays; Laboratory Manuals; Biosimilars; Chiral methods; Hybrid LBA/LCMS Assays; Fit-for-Purpose Validation; China Food and Drug Administration Bioanalytical Method Validation","year":2018,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada); inVentiv Health Clinical; Grand Challenges Canada","funders":"","keywords":"Bioanalysis; Immunogenicity; Biosimilar; Food and drug administration; Medical education; Computer science; Chemistry; Medicine; Pharmacology; Chromatography; Internal medicine","score_opus":0.038646939676556476,"score_gpt":0.36644589330958643,"score_spread":0.32779895363302997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802249086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66032994,0.007596866,0.3062896,0.01193001,0.0014170862,0.0038735038,0.0071016815,0.00058948254,0.00087184913],"genre_scores_gemma":[0.8528113,0.00014948897,0.14509049,0.00037421187,0.00016369726,0.00012957254,0.0007934102,0.00007784718,0.0004100222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98878795,0.0055407993,0.002024869,0.002050336,0.0003722637,0.0012238027],"domain_scores_gemma":[0.9937224,0.0024254974,0.00095381687,0.0015378782,0.0010789433,0.00028146087],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009252373,0.0009962115,0.0017934383,0.00066207605,0.0010295174,0.00028451168,0.00070947985,0.0008420404,0.0014259643],"category_scores_gemma":[0.002541578,0.0008556334,0.0009736326,0.0017336578,0.0015662163,0.00060270814,0.0003910334,0.00075879315,0.000047380774],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008414765,0.0054130834,0.034234162,0.0009633095,0.023732975,0.000023474791,0.0030113305,0.000035541572,0.7764447,0.02253606,0.0063095354,0.1188811],"study_design_scores_gemma":[0.0024525896,0.0016956374,0.0031854545,0.00004204623,0.0037498132,0.00002646073,0.0008667135,0.0030916133,0.96351343,0.008123748,0.012070137,0.0011823312],"about_ca_topic_score_codex":0.00009018932,"about_ca_topic_score_gemma":0.00015064083,"teacher_disagreement_score":0.19248134,"about_ca_system_score_codex":0.00036048787,"about_ca_system_score_gemma":0.0003787277,"threshold_uncertainty_score":0.99948686},"labels":[],"label_agreement":null},{"id":"W2803745915","doi":"10.29315/gm.v3i3.102","title":"Biossimilares: Velhas Questões, Novos Desafios","year":2018,"lang":"pt","type":"article","venue":"Gazeta Médica","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Cluster (Canada)","funders":"","keywords":"Philosophy; European union; Medicine; Humanities; Business","score_opus":0.0400898487029774,"score_gpt":0.32421090804291774,"score_spread":0.28412105933994036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803745915","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.097114705,0.20466885,0.029958194,0.11779497,0.0627491,0.0072486475,0.005337029,0.002940039,0.47218847],"genre_scores_gemma":[0.8180551,0.0023523248,0.006357,0.01658935,0.0026418513,0.00004942143,0.0001482525,0.00019055829,0.15361615],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99534255,0.00090386777,0.0009425741,0.0011673727,0.00016507847,0.001478535],"domain_scores_gemma":[0.99747175,0.0003587324,0.00031778633,0.0012521453,0.0003363944,0.0002632037],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010991775,0.0007118385,0.0009636086,0.00027268284,0.0007693116,0.000117202064,0.001005637,0.0017549007,0.026970979],"category_scores_gemma":[0.00058811175,0.00059321814,0.00044255,0.0006750633,0.0031410372,0.0001413302,0.00049269694,0.0011018626,0.0074713165],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011129052,0.0015156353,0.002985867,0.0002088179,0.0018615434,0.0001347043,0.0009514083,1.3849171e-7,0.1051277,0.005011031,0.80350083,0.07758944],"study_design_scores_gemma":[0.0018310673,0.0016111146,0.0059308154,0.00026988433,0.0005857164,0.00016387155,0.0002458992,0.00006081684,0.06419027,0.00052614673,0.9236943,0.00089011743],"about_ca_topic_score_codex":0.00010924193,"about_ca_topic_score_gemma":0.00012316921,"teacher_disagreement_score":0.7209404,"about_ca_system_score_codex":0.000103229926,"about_ca_system_score_gemma":0.00034476398,"threshold_uncertainty_score":0.9996519},"labels":[],"label_agreement":null},{"id":"W2804564619","doi":"10.1016/j.bpg.2018.05.003","title":"Biosimilars in ulcerative colitis: When and for who?","year":2018,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"American Gastroenterological Association; Dr. Falk Pharma; Pfizer; Amgen","keywords":"Biosimilar; Infliximab; Medicine; Ulcerative colitis; Clinical trial; Interchangeability; Intensive care medicine; Pharmacology; Internal medicine; Disease","score_opus":0.33381954667827785,"score_gpt":0.5656493369924445,"score_spread":0.23182979031416662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804564619","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006145347,0.9890015,0.00027896417,0.0052199247,0.0010200441,0.0030246517,0.00040950876,0.000029979215,0.00095394114],"genre_scores_gemma":[0.000010596098,0.9900646,0.004781347,0.0019765864,0.00043204147,0.0006085321,0.000102860045,0.000072473595,0.0019509131],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.974558,0.019609755,0.0022032904,0.0016808127,0.00015810262,0.0017900692],"domain_scores_gemma":[0.97425056,0.023296965,0.00067962054,0.0007807811,0.0007730876,0.00021898621],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.020276334,0.00059535215,0.0032986184,0.00058309216,0.00028300422,0.000106683096,0.0008911892,0.0023656252,0.00036872108],"category_scores_gemma":[0.025667317,0.00046211813,0.00064264727,0.00032579177,0.004097747,0.00022977246,0.000978133,0.004363903,0.00025505916],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071658217,0.0026377423,0.0005268807,0.0033165656,0.0018544279,0.00012496187,0.00010078097,8.578644e-9,0.0000017428513,0.0011045715,0.12097857,0.8621879],"study_design_scores_gemma":[0.0021444072,0.011068069,0.00009405808,0.0029461388,0.00079170347,0.0003563093,0.00015208384,0.000002480763,0.0000010677796,0.00068007293,0.98151493,0.0002486974],"about_ca_topic_score_codex":0.000058858517,"about_ca_topic_score_gemma":0.0006466594,"teacher_disagreement_score":0.86193925,"about_ca_system_score_codex":0.00014742429,"about_ca_system_score_gemma":0.00048706864,"threshold_uncertainty_score":0.99978304},"labels":[],"label_agreement":null},{"id":"W2804981378","doi":"10.1007/s10067-018-4141-z","title":"Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data","year":2018,"lang":"en","type":"article","venue":"Clinical Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada); Memorial University of Newfoundland","funders":"","keywords":"Medicine; Etanercept; Discontinuation; Retrospective cohort study; Internal medicine; Proportional hazards model; Cohort; Retention rate; Cohort study; Psoriasis; Hazard ratio; Confidence interval; Immunology; Rheumatoid arthritis","score_opus":0.21851822334552592,"score_gpt":0.4059320531513955,"score_spread":0.1874138298058696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804981378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973611,0.00008101644,0.00043320467,0.00023926113,0.0007083749,0.0006421552,0.0004300864,0.000036344587,0.000068422836],"genre_scores_gemma":[0.9988623,0.00007505767,0.000118916716,0.000082080915,0.00002543294,0.000008973816,0.0005155238,0.000019476054,0.00029219818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687856,0.0010343707,0.000676274,0.0008849257,0.00005630257,0.00046954735],"domain_scores_gemma":[0.9981735,0.0005555804,0.00028525194,0.0006850744,0.00017001633,0.00013060794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010454707,0.00026727733,0.0008906207,0.000096795375,0.00032276232,0.000032656397,0.00028217994,0.00056757743,0.00061376824],"category_scores_gemma":[0.00075503346,0.00017972739,0.00007359909,0.0001490269,0.00094343344,0.000101369966,0.00015670512,0.00033996374,0.000016303395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009265726,0.0004557282,0.9952604,0.000001936427,0.0011210659,0.000014774566,0.00016577891,1.62255e-8,0.000029586534,0.000042870528,0.00010161558,0.0027135306],"study_design_scores_gemma":[0.001973293,0.0022856405,0.9944537,0.00006002003,0.0005003246,0.000039051698,0.0002704981,0.00006012911,0.000048671107,0.000031217984,0.0000528289,0.00022460359],"about_ca_topic_score_codex":0.013467379,"about_ca_topic_score_gemma":0.30450878,"teacher_disagreement_score":0.29104137,"about_ca_system_score_codex":0.00019210407,"about_ca_system_score_gemma":0.00018357926,"threshold_uncertainty_score":0.993102},"labels":[],"label_agreement":null},{"id":"W2806538628","doi":"10.1111/cts.12570","title":"<i>Assay Guidance Manual</i>: Quantitative Biology and Pharmacology in Preclinical Drug Discovery","year":2018,"lang":"en","type":"review","venue":"Clinical and Translational Science","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"U.S. National Library of Medicine; National Institute of General Medical Sciences; National Center for Advancing Translational Sciences; National Institute of Mental Health; National Institutes of Health","keywords":"Drug discovery; Drug development; Computational biology; Investigational Drugs; Preclinical testing; Preclinical research; Pharmacology; Computer science; Medicine; Drug; Medical physics; Bioinformatics; Biology; Clinical trial","score_opus":0.16964436320473275,"score_gpt":0.5264949632709308,"score_spread":0.35685060006619806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806538628","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038724282,0.99586004,0.00037782933,0.0009107515,0.0012936391,0.00041519204,0.00019287215,0.000016154443,0.0005462724],"genre_scores_gemma":[0.0013281783,0.9946061,0.0029197813,0.0004138735,0.00014262529,0.000027262688,0.000035774076,0.000010856969,0.00051558216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99536824,0.0015462375,0.001358232,0.0011931711,0.000066211585,0.00046793278],"domain_scores_gemma":[0.9930521,0.0063123023,0.0002784001,0.00017814216,0.00008327869,0.000095724805],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0062068896,0.00032245263,0.0014438088,0.00017716133,0.00021146792,0.000038986902,0.00045017555,0.0006620275,0.0001586233],"category_scores_gemma":[0.00072511897,0.00021442564,0.00024692973,0.00050201424,0.011041802,0.00020492917,0.00019678682,0.0008896064,0.000041614247],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016741469,0.00041496268,0.0067317863,0.0010428729,0.00023706825,0.000009966312,0.000067637586,7.7072684e-8,0.00008178698,0.04842934,0.0011015146,0.9417156],"study_design_scores_gemma":[0.00077780365,0.00026805096,0.0037880305,0.00093945256,0.00032266285,0.000035844307,0.000007189793,0.000021324036,0.000020425028,0.006859218,0.9865959,0.00036408915],"about_ca_topic_score_codex":0.000012065932,"about_ca_topic_score_gemma":0.000030617564,"teacher_disagreement_score":0.9854944,"about_ca_system_score_codex":0.000009645047,"about_ca_system_score_gemma":0.0004065883,"threshold_uncertainty_score":0.99164957},"labels":[],"label_agreement":null},{"id":"W2806905043","doi":"10.3899/jrheum.180139","title":"GRAPPA 2017 Project Report","year":2018,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research","keywords":"Psoriatic arthritis; Medicine; Biosimilar; Psoriasis; Medical physics; Comparative effectiveness research; Medical education; Family medicine; Alternative medicine; Internal medicine; Dermatology; Pathology","score_opus":0.03749978808574492,"score_gpt":0.331968302660581,"score_spread":0.29446851457483614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806905043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730133,0.0039737066,0.0039383164,0.00713262,0.004546262,0.00018193435,0.000006404987,0.00002867995,0.007178818],"genre_scores_gemma":[0.9958973,0.000594422,0.0013251752,0.0003688032,0.000030225514,8.25428e-7,0.0000013157878,0.000009125621,0.0017728035],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984586,0.00056345994,0.00057815,0.00009479579,0.00004266364,0.00026232845],"domain_scores_gemma":[0.99847823,0.00038110683,0.00057185756,0.00029278756,0.0002570828,0.000018953344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020274972,0.00011170818,0.00038781363,0.00010761338,0.00017234075,0.0000063177927,0.0004210739,0.0002134412,0.00042240007],"category_scores_gemma":[0.0005207773,0.000056368506,0.00012848336,0.00014081773,0.000990481,0.000045913002,0.000076224715,0.00039840522,0.00009534778],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019931507,0.00032016967,0.07768051,0.000038799044,0.0016846716,0.00018458016,0.00144875,3.06853e-7,0.057381608,0.0072532967,0.83673054,0.015283586],"study_design_scores_gemma":[0.0016556724,0.0018596252,0.006480184,0.000104357816,0.00036740513,0.32730293,0.0006071846,0.000006370287,0.031005558,0.005944427,0.6244005,0.00026576276],"about_ca_topic_score_codex":0.00010236061,"about_ca_topic_score_gemma":0.000034386085,"teacher_disagreement_score":0.32711837,"about_ca_system_score_codex":0.000011612544,"about_ca_system_score_gemma":0.00011903167,"threshold_uncertainty_score":0.46249846},"labels":[],"label_agreement":null},{"id":"W2808127185","doi":"10.3747/co.25.3942","title":"The Evolution of Biosimilars in Oncology, with a Focus on Trastuzumab","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University; University of Calgary","funders":"","keywords":"Biosimilar; Trastuzumab; Medicine; Breast cancer; Metastatic breast cancer; Disease; Oncology; Human Epidermal Growth Factor Receptor 2; Cancer; Intensive care medicine; Internal medicine; Pharmacology","score_opus":0.14408589405378577,"score_gpt":0.44797658950325536,"score_spread":0.30389069544946956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808127185","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001772856,0.9915064,0.00008764832,0.0005750115,0.0026040934,0.0010180492,0.00010146138,0.0000274076,0.0040622256],"genre_scores_gemma":[0.00020636788,0.9990039,0.00015113573,0.000035138408,0.00014084668,0.00019329296,0.000037096786,0.000035337962,0.00019691791],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949302,0.0024661743,0.0011477649,0.00068227143,0.000075374875,0.0006982346],"domain_scores_gemma":[0.99584174,0.0024942122,0.00087552716,0.00059950165,0.0001412986,0.000047718106],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015619259,0.00053511054,0.00241064,0.00037935685,0.00016956979,0.000008745294,0.00074137934,0.0015697656,0.00012830515],"category_scores_gemma":[0.000335641,0.00027683334,0.00045846353,0.0006674774,0.0019767382,0.000025633022,0.00017659669,0.0016268682,0.0001353717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030611022,0.00084125396,0.000022594839,0.00081900996,0.0003089696,0.000008649438,0.000044546883,4.733999e-8,0.000005503436,0.0020231742,0.01005483,0.9855653],"study_design_scores_gemma":[0.0010591588,0.004848873,0.00003243788,0.0035779309,0.0007644881,0.00011962337,0.00009859957,0.0000010612565,0.000030485162,0.00047201503,0.98869437,0.0003009848],"about_ca_topic_score_codex":0.000020963258,"about_ca_topic_score_gemma":0.00042925155,"teacher_disagreement_score":0.9852643,"about_ca_system_score_codex":0.0017272655,"about_ca_system_score_gemma":0.0016250536,"threshold_uncertainty_score":0.9999684},"labels":[],"label_agreement":null},{"id":"W2809709383","doi":"10.4155/bio-2017-0254","title":"Adaptation of Commercial Biomarker Kits and Proposal for ‘Drug Development Kits’ to Support Bioanalysis: Call for Action","year":2018,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Prince Edward Island","funders":"","keywords":"Adaptation (eye); Biomarker; Bioanalysis; Drug development; Computer science; Quality (philosophy); Resource (disambiguation); Process (computing); Risk analysis (engineering); Process management; Drug; Biochemical engineering; Medicine; Pharmacology; Business; Engineering; Biology; Nanotechnology","score_opus":0.08237224213466827,"score_gpt":0.35543199647984935,"score_spread":0.2730597543451811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809709383","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33138084,0.0038916876,0.64446515,0.012168819,0.0020981247,0.0041111587,0.0010475554,0.00019261261,0.0006440439],"genre_scores_gemma":[0.9248836,0.00003901912,0.07255272,0.00035521196,0.00009199104,0.00013210996,0.00022717936,0.000021132433,0.001697037],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983196,0.00014979903,0.0006200267,0.00048091938,0.000070422946,0.00035921586],"domain_scores_gemma":[0.99872625,0.00021841175,0.0002385807,0.00023965442,0.0005042366,0.00007287275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010040362,0.00022680566,0.0005606449,0.00041311164,0.00027213307,0.00002120497,0.00017614716,0.00024781396,0.00020379173],"category_scores_gemma":[0.00023883299,0.00018025383,0.00026398577,0.00054991577,0.0002921151,0.00006780608,0.000074429416,0.0000677273,0.000019899338],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016570536,0.0003990005,0.0061723236,0.00017319452,0.0043830234,5.7078864e-7,0.0011619149,0.0000030621106,0.07907621,0.0009606608,0.006197987,0.899815],"study_design_scores_gemma":[0.0034414085,0.0017371626,0.028126378,0.00006876535,0.005152104,0.0000092006485,0.0012197583,0.0022152688,0.43551263,0.000729158,0.52085453,0.0009336272],"about_ca_topic_score_codex":0.00013527441,"about_ca_topic_score_gemma":0.001745717,"teacher_disagreement_score":0.8988814,"about_ca_system_score_codex":0.00005482092,"about_ca_system_score_gemma":0.00016088378,"threshold_uncertainty_score":0.7350538},"labels":[],"label_agreement":null},{"id":"W2811463904","doi":"10.2196/resprot.9797","title":"Innovative Approach for Enhancing Testing of HIV, Hepatitis B, and Hepatitis C in the General Population: Protocol for an Acceptability and Feasibility Study (BaroTest 2016)","year":2018,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Context (archaeology); Hepatitis C; Human immunodeficiency virus (HIV); Hepatitis B virus; Dried blood spot; Virology; Hepatitis B; Protocol (science); Hepatitis C virus; Population; Immunology; Family medicine; Environmental health; Virus; Alternative medicine; Biology; Pathology","score_opus":0.3755801927589788,"score_gpt":0.5663908146646421,"score_spread":0.19081062190566334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811463904","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12025994,0.0000013546212,0.0012255952,0.00008693108,0.0000037138436,0.87816125,0.00007786463,0.0000146956945,0.00016863695],"genre_scores_gemma":[0.13937631,5.0529806e-8,0.021750722,0.00002702297,0.00007107196,0.8386917,0.000015327829,0.000011614049,0.00005616215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962818,0.001919513,0.00059003854,0.00061152334,0.00012393012,0.00047318044],"domain_scores_gemma":[0.99716526,0.0012430423,0.00015429944,0.00043841207,0.00096217525,0.000036827776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077290684,0.00017434414,0.00038019905,0.00012972916,0.00043415203,0.000071971874,0.00029847003,0.00020455291,0.000042644326],"category_scores_gemma":[0.0022833361,0.000113731745,0.000034385106,0.00062651304,0.0008588481,0.00018712577,0.00019949797,0.00038560198,4.0838094e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012155834,0.0018658018,0.96272373,0.00061508635,0.000022734203,2.582587e-7,0.00089033035,1.446691e-7,0.011686417,0.0003243014,0.00039943622,0.020256154],"study_design_scores_gemma":[0.0044366457,0.011957902,0.9656636,0.00017485186,0.000004129933,0.000004892764,0.0005224949,0.0004566532,0.0119536435,0.0023551343,0.0022919334,0.00017809124],"about_ca_topic_score_codex":0.00077798427,"about_ca_topic_score_gemma":0.0011356391,"teacher_disagreement_score":0.03946955,"about_ca_system_score_codex":0.000054850865,"about_ca_system_score_gemma":0.00011979203,"threshold_uncertainty_score":0.4637846},"labels":[],"label_agreement":null},{"id":"W2886945992","doi":"10.1111/apt.14860","title":"Editorial: antigenic response to <scp>CT</scp>‐P13 and infliximab originator in <scp>IBD</scp> shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply","year":2018,"lang":"en","type":"editorial","venue":"Alimentary Pharmacology & Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital","funders":"","keywords":"Biosimilar; Medicine; Epitope; Infliximab; Antigen; Immunology; Computational biology; Biology; Tumor necrosis factor alpha; Internal medicine","score_opus":0.031047618336150964,"score_gpt":0.347741876224587,"score_spread":0.3166942578884361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886945992","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29231825,0.004936189,0.00004743022,0.0039043098,0.6953689,0.0017132857,0.0015129349,0.00016003176,0.000038659127],"genre_scores_gemma":[0.012534408,0.011197706,0.009312697,0.073404856,0.8891403,0.0005917562,0.0008865035,0.00047289405,0.0024588692],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9883807,0.0033706352,0.0018600604,0.0031939417,0.0007747409,0.0024199747],"domain_scores_gemma":[0.9800068,0.016473886,0.0007756204,0.0012330012,0.00087519945,0.0006354824],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.008503455,0.0014742333,0.0018892463,0.0014315953,0.0009437261,0.00026482352,0.0022074191,0.0020054758,0.0006608352],"category_scores_gemma":[0.0010856485,0.0014255486,0.0003295402,0.0017086441,0.0017076967,0.000671332,0.0014928218,0.003424525,0.00055030646],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007506542,0.00026579952,0.00042412334,0.000029685434,0.0017894333,0.00009034703,0.0011464303,0.0000014989126,0.413324,5.369067e-7,0.58102906,0.0011484115],"study_design_scores_gemma":[0.0020026418,0.0014998438,0.00034473732,0.00030980044,0.0032608057,0.000024003237,0.00032060515,0.000011573263,0.27435368,0.00021261825,0.7172828,0.0003769436],"about_ca_topic_score_codex":0.000324348,"about_ca_topic_score_gemma":0.00009045471,"teacher_disagreement_score":0.27978384,"about_ca_system_score_codex":0.0008711698,"about_ca_system_score_gemma":0.0019237883,"threshold_uncertainty_score":0.9998007},"labels":[],"label_agreement":null},{"id":"W2889175163","doi":"10.2196/11025","title":"Web-Delivered Multimedia Training Materials for the Self-Collection of Dried Blood Spots: A Formative Project","year":2018,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Advancing Translational Sciences; University of Minnesota Foundation; Office of Research on Women's Health; National Institute on Aging; National Institutes of Health; University of Minnesota","keywords":"Usability; USable; Protocol (science); Formative assessment; Web application; Data collection; Medicine; Computer science; Multimedia; World Wide Web; Psychology; Alternative medicine; Human–computer interaction","score_opus":0.09258747987217593,"score_gpt":0.41617974349849846,"score_spread":0.32359226362632254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889175163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772229,0.00053355313,0.0018393096,0.0015656255,0.0014235954,0.0072050737,0.0010172045,0.00018169633,0.009011037],"genre_scores_gemma":[0.9955248,0.000104300125,0.0028056654,0.000057727702,0.00010991473,0.0006094488,0.000025702358,0.000017367687,0.000745054],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744976,0.0009544642,0.00051076896,0.0002332619,0.00018370416,0.00066802424],"domain_scores_gemma":[0.9964745,0.0018559683,0.0002023532,0.00026303978,0.0011751876,0.000028926666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004205952,0.00017739029,0.0003933917,0.00029512498,0.0007357695,0.000038061135,0.00038228504,0.0003034949,0.0005429287],"category_scores_gemma":[0.0006224951,0.00010660982,0.00013057394,0.0006860261,0.0010736096,0.00022638976,0.0001695198,0.00041182022,0.00005933734],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00379118,0.00094923255,0.000055389926,0.000391709,0.0019828484,0.0000013228938,0.13642047,1.427422e-7,0.7637414,0.0023344469,0.054654576,0.035677277],"study_design_scores_gemma":[0.004275751,0.0034707487,0.0018857908,0.000123699,0.000107294625,0.000027204456,0.01567682,0.00092651474,0.9431925,0.0007014896,0.029391143,0.00022105724],"about_ca_topic_score_codex":0.000055147408,"about_ca_topic_score_gemma":0.000025193858,"teacher_disagreement_score":0.1794511,"about_ca_system_score_codex":0.00008217575,"about_ca_system_score_gemma":0.0003362909,"threshold_uncertainty_score":0.59446883},"labels":[],"label_agreement":null},{"id":"W2889574927","doi":"10.3389/fphar.2018.01079","title":"Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines","year":2018,"lang":"en","type":"review","venue":"Frontiers in Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada; U.S. Food and Drug Administration; World Health Organization","keywords":"Biosimilar; Authorization; Marketing authorization; Quality (philosophy); Medicine; Regulatory science; Business; Bioinformatics; Computer science; Internal medicine; Computer security; Biology","score_opus":0.19784191096227582,"score_gpt":0.5028874777871456,"score_spread":0.3050455668248698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889574927","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008893008,0.9838852,0.0014211755,0.0010298454,0.010826076,0.001365769,0.00046479746,0.0000198661,0.0000979527],"genre_scores_gemma":[0.0000340535,0.93534184,0.05770477,0.004559084,0.000592696,0.00009421531,0.00016347767,0.00004981552,0.0014600478],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99262416,0.002021805,0.0033260712,0.0012253848,0.000077370605,0.00072521187],"domain_scores_gemma":[0.9954913,0.0029532977,0.00074698543,0.00031591958,0.00030748788,0.0001849951],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0044720448,0.0006238102,0.0034580033,0.00027815925,0.0003266712,0.000030844556,0.0003486086,0.0019042181,0.00028104256],"category_scores_gemma":[0.0013346006,0.0005287788,0.0003749713,0.00018812962,0.0021276001,0.000060313952,0.0003850406,0.0011032824,0.000007805478],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011221824,0.00014872587,0.011243961,0.0012279389,0.0018591939,0.000026620944,0.000014178643,4.19947e-8,0.000012532403,0.0000685572,0.7640405,0.22124551],"study_design_scores_gemma":[0.0019957577,0.0001698863,0.004669274,0.0005445047,0.0011929212,0.000094977884,0.000014701539,0.000027310723,0.0000406083,0.00022471327,0.990409,0.00061635196],"about_ca_topic_score_codex":0.0019588594,"about_ca_topic_score_gemma":0.019366516,"teacher_disagreement_score":0.22636847,"about_ca_system_score_codex":0.00012551606,"about_ca_system_score_gemma":0.0027978045,"threshold_uncertainty_score":0.9997164},"labels":[],"label_agreement":null},{"id":"W2890280370","doi":"10.1200/jco.2017.35.15_suppl.6607","title":"Impact of intravenous cancer drug wastage on economic evaluations.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Drug; Cancer drugs; Vial; Dosing; Revenue; Body surface area; Emergency medicine; Surgery; Internal medicine; Pharmacology; Accounting","score_opus":0.17522746253136742,"score_gpt":0.5663329527005595,"score_spread":0.39110549016919205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890280370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849181,0.0006830947,0.000049014216,0.005330452,0.0036959667,0.00009618895,0.00004494527,0.0000032240114,0.005178992],"genre_scores_gemma":[0.99663264,0.001003498,0.0006409863,0.00036735233,0.00044116154,0.0000014323523,9.587972e-7,0.000008353072,0.00090361683],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969814,0.0008381068,0.0017478908,0.00016061166,0.00005133739,0.000220696],"domain_scores_gemma":[0.9940828,0.002123159,0.003114719,0.000360153,0.00023366808,0.00008549319],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0048098695,0.0001268747,0.0012592336,0.00008543563,0.0001248577,0.000011725065,0.00054363796,0.00049449195,0.0024254392],"category_scores_gemma":[0.0031045019,0.00007833637,0.00079159555,0.0000192961,0.0007012386,0.00008627847,0.00008202876,0.0009129776,0.000059185404],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004804668,0.002011083,0.08215359,0.000012566782,0.0024429716,0.00004377453,0.00011487416,0.00012009693,0.0059429943,0.0010637504,0.033142835,0.8681468],"study_design_scores_gemma":[0.0058388524,0.012575836,0.93177676,0.00008182451,0.00047365262,0.00007096511,0.000039402432,0.000043721644,0.0037228777,0.0018093099,0.04340984,0.0001569389],"about_ca_topic_score_codex":0.00019481579,"about_ca_topic_score_gemma":0.000108134045,"teacher_disagreement_score":0.86798984,"about_ca_system_score_codex":0.00017172322,"about_ca_system_score_gemma":0.0015449926,"threshold_uncertainty_score":0.99848646},"labels":[],"label_agreement":null},{"id":"W2890610444","doi":"10.1188/18.cjon.s1.5-12","title":"Biosimilars: Exploring the History, Science, and Progress","year":2018,"lang":"en","type":"review","venue":"Clinical journal of oncology nursing","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Tolerability; Immunogenicity; Clinical trial; Health care; Intensive care medicine; Adverse effect; Pharmacology; Economic growth; Immunology; Internal medicine","score_opus":0.39507267220140085,"score_gpt":0.5180697305673746,"score_spread":0.12299705836597374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890610444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005582276,0.9766174,0.000023068536,0.0019310663,0.01989902,0.00027008489,0.0000037734335,0.0000128096,0.001186951],"genre_scores_gemma":[0.000027102136,0.99607116,0.001961068,0.00068525504,0.0010395,0.000008156485,9.1379525e-7,0.000026807382,0.00018003343],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946092,0.0020378642,0.0021757078,0.00047309208,0.00014934209,0.00055481715],"domain_scores_gemma":[0.993963,0.0028302402,0.0019765655,0.00040040287,0.00068366865,0.0001461272],"candidate_categories":["sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012246889,0.00035425238,0.0025145244,0.0003852946,0.00033878454,0.00003606097,0.0011553678,0.00095666945,0.00010198535],"category_scores_gemma":[0.0025985872,0.00018410117,0.0007266988,0.00041031517,0.018791763,0.00016976988,0.0002086011,0.0024359138,0.000025937461],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055034376,0.00025577322,0.00001967772,0.00020983636,0.0002849089,0.000027871376,0.0000833663,1.2492085e-9,0.0000026162759,0.000101621445,0.0657138,0.9332455],"study_design_scores_gemma":[0.00047153694,0.0018984508,0.000060216655,0.007737285,0.0021528853,0.0020244012,0.00008636821,4.247564e-7,0.0000071265567,0.00016028648,0.9851986,0.00020239346],"about_ca_topic_score_codex":2.7711923e-7,"about_ca_topic_score_gemma":3.6298258e-7,"teacher_disagreement_score":0.9330431,"about_ca_system_score_codex":0.0008759135,"about_ca_system_score_gemma":0.0030195974,"threshold_uncertainty_score":0.99986553},"labels":[],"label_agreement":null},{"id":"W2891439022","doi":"10.1016/j.cgh.2018.08.064","title":"Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease","year":2018,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Biosimilar; Inflammatory bowel disease; Inflammatory Bowel Diseases; Internal medicine; Disease","score_opus":0.042864263926867846,"score_gpt":0.345788306444199,"score_spread":0.3029240425173312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891439022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906207,0.0010543707,0.000436613,0.0068999766,0.0006431613,0.00016638024,0.000024433302,0.000050394156,0.00010402434],"genre_scores_gemma":[0.9890813,0.00060531596,0.0006518495,0.009438253,0.00014656135,0.000010463845,0.000013369581,0.000012405944,0.00004047159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965592,0.0012012478,0.00084297196,0.0007123038,0.000022127537,0.0006621304],"domain_scores_gemma":[0.9985251,0.00081735494,0.00017075012,0.00027570454,0.000047870162,0.00016322867],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0013137538,0.00026153936,0.0006925069,0.00015559736,0.0001651581,0.00001274956,0.00021288719,0.00078698434,0.0001448308],"category_scores_gemma":[0.0005087096,0.00020857538,0.000103656515,0.000065961685,0.0029215864,0.00005717104,0.00037156898,0.00081429054,0.00003859095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095157605,0.00009636315,0.9920613,0.000017398148,0.00010490454,0.00003456403,0.000026857242,2.1705764e-8,0.00041210005,0.000532526,0.0008726686,0.0048896824],"study_design_scores_gemma":[0.0018811391,0.0014334535,0.98540163,0.000024497005,0.00009893102,0.000060128143,0.000032551518,0.000048228016,0.00008796727,0.002915247,0.007863326,0.00015290373],"about_ca_topic_score_codex":0.000007864096,"about_ca_topic_score_gemma":0.00013996332,"teacher_disagreement_score":0.0069906577,"about_ca_system_score_codex":0.000012537033,"about_ca_system_score_gemma":0.00004022501,"threshold_uncertainty_score":0.9997919},"labels":[],"label_agreement":null},{"id":"W2893246991","doi":"10.1136/annrheumdis-2018-eular.5146","title":"AB0954 A randomised, double-blind trial comparing the efficacy, safety and immunogenicity of msb11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasis","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Adalimumab; Medicine; Psoriasis Area and Severity Index; Biosimilar; Psoriatic arthritis; Tolerability; Clinical endpoint; Bioequivalence; Internal medicine; Psoriasis; Interim analysis; Clinical trial; Adverse effect; Rheumatoid arthritis; Dermatology; Pharmacokinetics","score_opus":0.05245146854743497,"score_gpt":0.3175573006045067,"score_spread":0.2651058320570717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893246991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99600816,0.00070174865,0.000034226843,0.00052799354,0.00031429002,0.0021126138,0.00019032347,0.000011047085,0.00009961054],"genre_scores_gemma":[0.99960643,0.00011270809,0.00011596352,0.00007960775,0.000013053285,0.00002328675,0.000012756207,0.000016227195,0.000019981648],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99765253,0.00063126895,0.000905273,0.0002986665,0.00018215408,0.00033012283],"domain_scores_gemma":[0.9974744,0.000979402,0.0005717462,0.00060393335,0.00031302831,0.000057519577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007305533,0.00027113446,0.0009629517,0.00011132074,0.00017103353,0.00001650472,0.00054332166,0.00015136822,0.000089730274],"category_scores_gemma":[0.0005113623,0.00014021661,0.0002445409,0.000396454,0.00094781624,0.00007797106,0.00023188816,0.00017158435,0.00000214168],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9907688,0.0013368163,0.0029481244,0.0001523166,0.0012726281,2.2386895e-7,0.00049389753,0.000050787123,0.00021437557,0.00039875173,0.00017617122,0.0021871263],"study_design_scores_gemma":[0.88235575,0.0038809662,0.059680782,0.001210816,0.000965677,0.0000017992676,0.00026916742,0.0001953319,0.0504246,0.00036244403,0.00021253982,0.00044011624],"about_ca_topic_score_codex":0.00027062677,"about_ca_topic_score_gemma":0.0000742078,"teacher_disagreement_score":0.10841302,"about_ca_system_score_codex":0.000021463922,"about_ca_system_score_gemma":0.00016759512,"threshold_uncertainty_score":0.57178676},"labels":[],"label_agreement":null},{"id":"W2895726712","doi":"10.1136/annrheumdis-2018-eular.4382","title":"THU0201 A pooled analysis of three tnf-Α inhibitor biosimilar studies in patients with rheumatoid arthritis comparing radiographic progression by disease activity states","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Adalimumab; Infliximab; Etanercept; Rheumatoid arthritis; Internal medicine; Biosimilar; TNF inhibitor; Disease","score_opus":0.038792196765815586,"score_gpt":0.3229218672946032,"score_spread":0.2841296705287876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895726712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801572,0.018248111,0.000041558586,0.0005025632,0.000128839,0.000432339,0.00045820634,0.000022456325,0.000008752189],"genre_scores_gemma":[0.99729884,0.0024442552,0.00006664044,0.00009118909,0.0000039822903,0.000026318266,0.000047413818,0.00001344829,0.0000079253405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981123,0.00044883607,0.0005721417,0.00033320862,0.00017894588,0.0003545209],"domain_scores_gemma":[0.9981933,0.0003597364,0.0005310531,0.0005301916,0.00030885026,0.00007687398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036124923,0.00026447471,0.0010040744,0.0003246574,0.00015194,0.0000140010725,0.00034117617,0.00008501605,0.00007154085],"category_scores_gemma":[0.0003899117,0.00015068428,0.00035875526,0.0011945444,0.0017033614,0.0001290355,0.00020431781,0.00012450226,0.0000018425108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002143721,0.002005885,0.96230114,0.00023937604,0.0068700383,7.081324e-7,0.0002256681,0.000014759774,0.00031949382,0.000040479365,0.0029869615,0.022851791],"study_design_scores_gemma":[0.0016739158,0.000535639,0.9840185,0.0021759847,0.0011523489,2.081528e-7,0.00012310868,0.0003097643,0.00910043,0.00062110217,0.000045903453,0.00024307286],"about_ca_topic_score_codex":0.000062702304,"about_ca_topic_score_gemma":0.00012063249,"teacher_disagreement_score":0.022608718,"about_ca_system_score_codex":0.000011696468,"about_ca_system_score_gemma":0.000043241587,"threshold_uncertainty_score":0.6276106},"labels":[],"label_agreement":null},{"id":"W2897377957","doi":"10.1002/dta.2518","title":"Analysis of insulin and insulin analogs from dried blood spots by means of liquid chromatography–high resolution mass spectrometry","year":2018,"lang":"en","type":"article","venue":"Drug Testing and Analysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency","keywords":"Insulin aspart; Chromatography; Chemistry; Mass spectrometry; Insulin; Analyte; Liquid chromatography–mass spectrometry; Insulin analog; Ion suppression in liquid chromatography–mass spectrometry; Quantitative analysis (chemistry); Internal medicine; Human insulin; Medicine","score_opus":0.012978370189296802,"score_gpt":0.2494783571457034,"score_spread":0.23649998695640662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897377957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900417,0.0060344297,0.0028449919,0.00012535197,0.00003501467,0.000060871243,0.0006127886,0.000039245115,0.0002056419],"genre_scores_gemma":[0.9797747,0.00041474125,0.019445641,0.00005873707,0.000025578136,0.0000020655386,0.00021348926,0.000009987161,0.00005503081],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979747,0.00037176313,0.0006911776,0.000562598,0.00009473577,0.0003050346],"domain_scores_gemma":[0.998036,0.0008405651,0.00045275787,0.00037897952,0.00022579556,0.00006586414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075983006,0.0002384646,0.0011230562,0.0012615843,0.00016445406,0.000017818109,0.00018249622,0.0002617454,0.00023578158],"category_scores_gemma":[0.0005882741,0.00020315853,0.00032714722,0.0059218626,0.00086114835,0.000051421663,0.000093395356,0.00020942275,0.0000013794337],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002002863,0.0002902496,0.3222005,0.000028859344,0.022234041,0.0000027541714,0.0002741455,0.000015055848,0.65114856,0.00009960296,0.00008783932,0.0034180842],"study_design_scores_gemma":[0.0016967047,0.0007998185,0.63175577,0.0000868185,0.05724182,0.0000037447858,0.0004112763,0.0066566863,0.29998332,0.0007115136,0.000112198955,0.00054033473],"about_ca_topic_score_codex":0.0027646483,"about_ca_topic_score_gemma":0.00019263387,"teacher_disagreement_score":0.35116524,"about_ca_system_score_codex":0.000009031501,"about_ca_system_score_gemma":0.00001947954,"threshold_uncertainty_score":0.82845646},"labels":[],"label_agreement":null},{"id":"W2897416555","doi":"10.2196/11218","title":"The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study","year":2018,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Engineering and Physical Sciences Research Council; Centre For Medical Engineering, King’s College London; Wellcome Trust","keywords":"Medicine; Protocol (science); Infliximab; Disease; Clinical trial; Intensive care medicine; Therapeutic drug monitoring; Crohn's disease; Drug; Test (biology); Pharmacology; Alternative medicine; Internal medicine; Pathology","score_opus":0.38819278026291737,"score_gpt":0.6143314874573336,"score_spread":0.2261387071944162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897416555","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02586131,0.00000414889,0.00030398185,0.00006807927,0.000038718237,0.9736282,0.000051514402,0.000015241119,0.000028789018],"genre_scores_gemma":[0.08356547,3.659187e-7,0.00021100997,0.0000053869358,0.000079081125,0.91601366,0.000006721472,0.00001875037,0.000099561395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935551,0.004539043,0.0007263315,0.0004718365,0.00015511387,0.00055251736],"domain_scores_gemma":[0.9928349,0.005364936,0.00017336024,0.0004296096,0.0011299507,0.00006721772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012591362,0.00016956795,0.00037026298,0.00012679238,0.00043531274,0.00007444896,0.0003794248,0.00022923067,0.000014581935],"category_scores_gemma":[0.004152997,0.00010740492,0.00010944615,0.00026829378,0.0009113645,0.00010924692,0.0002779852,0.00043857773,0.0000031153845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07880366,0.010355548,0.78611475,0.0015699981,0.00023109661,0.0000020673262,0.00027712574,5.6777134e-7,0.010025243,0.000883156,0.0008855662,0.11085122],"study_design_scores_gemma":[0.024099367,0.009616543,0.8511561,0.001340161,0.0000112932685,2.3083948e-7,0.00013297072,0.00003901738,0.035817567,0.0020589798,0.07554469,0.00018307623],"about_ca_topic_score_codex":0.000011885861,"about_ca_topic_score_gemma":0.0000064028236,"teacher_disagreement_score":0.110668145,"about_ca_system_score_codex":0.00006618022,"about_ca_system_score_gemma":0.00016252745,"threshold_uncertainty_score":0.49718255},"labels":[],"label_agreement":null},{"id":"W2897971695","doi":"10.1515/cclm-2018-0905","title":"Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB)","year":2018,"lang":"en","type":"article","venue":"Clinical Chemistry and Laboratory Medicine (CCLM)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institute for Health and Care Research","keywords":"Hemolysis; Medicine; Troponin complex; Internal medicine; Intensive care medicine; Troponin I; Myocardial infarction","score_opus":0.029473460790394656,"score_gpt":0.3382444382886867,"score_spread":0.3087709774982921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897971695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96793574,0.015538968,0.000015680826,0.013551129,0.0010130096,0.00013634692,0.00059534685,0.000027988066,0.0011857963],"genre_scores_gemma":[0.99315906,0.0015391299,0.00036558197,0.0024423103,0.0017539939,0.000008513647,0.00016177897,0.000017144195,0.0005525198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724627,0.0008052216,0.00070885406,0.0007968588,0.00011604307,0.00032674088],"domain_scores_gemma":[0.9930385,0.005901167,0.00018677308,0.00047594562,0.00018217965,0.00021543706],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014601959,0.0003474101,0.00089373934,0.000027935897,0.00029932102,0.00003897184,0.00027305202,0.0006491131,0.0013608134],"category_scores_gemma":[0.002594301,0.00021300788,0.00013890796,0.00027202728,0.0057414253,0.000045081557,0.00018234823,0.00085981144,0.000020038511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018256423,0.00040309282,0.57974946,0.00010597411,0.0046871584,0.000013450783,0.00073814846,3.797448e-8,0.1200359,0.00076755777,0.26904145,0.022632103],"study_design_scores_gemma":[0.0062243063,0.0028863351,0.61148643,0.0010063407,0.004519896,0.0000149886055,0.0067405566,0.00009912816,0.07550955,0.003801985,0.28621048,0.0014999982],"about_ca_topic_score_codex":0.0001225522,"about_ca_topic_score_gemma":0.000006334331,"teacher_disagreement_score":0.044526357,"about_ca_system_score_codex":0.000026531188,"about_ca_system_score_gemma":0.00014336378,"threshold_uncertainty_score":0.9995521},"labels":[],"label_agreement":null},{"id":"W2899941886","doi":"10.1111/apt.14997","title":"Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab","year":2018,"lang":"en","type":"review","venue":"Alimentary Pharmacology & Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Robarts Clinical Trials; Western University","funders":"Allergan; Akebia Therapeutics; Janssen Pharmaceuticals; Ablynx","keywords":"Biosimilar; Medicine; Infliximab; MEDLINE; Intensive care medicine; Pharmacology; Internal medicine; Tumor necrosis factor alpha","score_opus":0.06518226559974113,"score_gpt":0.38392252269095883,"score_spread":0.31874025709121767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899941886","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021524525,0.99620956,0.000008601751,0.00020954972,0.00044935296,0.0024844361,0.0003433867,0.000029944653,0.000049900413],"genre_scores_gemma":[0.00010498898,0.9946312,0.00020880032,0.0045827236,0.00005157882,0.000054641747,0.00025435296,0.000044856813,0.00006688345],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952256,0.0019981032,0.0016195942,0.00062759744,0.0000788252,0.0004502581],"domain_scores_gemma":[0.9969475,0.0014621279,0.0010141167,0.00039761345,0.00011038156,0.00006825101],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009935817,0.0006405496,0.003469844,0.00016488072,0.00018513984,0.000010907922,0.000457615,0.0007372036,0.00020361772],"category_scores_gemma":[0.000005769768,0.0004475656,0.00023270017,0.00021542804,0.000638859,0.00006345808,0.0004043069,0.00074916886,0.000027301356],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018430148,0.00056657643,0.0002457286,0.81660354,0.06995705,0.0000054426596,0.00015975026,5.471207e-9,0.0006124628,0.000030049943,0.0013787854,0.110256314],"study_design_scores_gemma":[0.0025305517,0.0010313517,0.00007006294,0.17707941,0.23192506,0.000048185648,0.000015124408,5.914164e-7,0.00076388445,0.000027279777,0.5856998,0.00080872286],"about_ca_topic_score_codex":0.0000061499395,"about_ca_topic_score_gemma":5.9991754e-7,"teacher_disagreement_score":0.6395241,"about_ca_system_score_codex":0.00006257294,"about_ca_system_score_gemma":0.00007027435,"threshold_uncertainty_score":0.9997976},"labels":[],"label_agreement":null},{"id":"W2900514407","doi":"10.1136/annrheumdis-2018-eular.4362","title":"THU0184 Impact of immunogenicity on clinical efficacy and administration related reaction in tnf inhibitors: a pooled-analysis from three biosimilar studies in patients with rheumatoid arthritis","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Biosimilar; Adalimumab; Etanercept; Infliximab; Immunogenicity; Rheumatoid arthritis; Clinical endpoint; Internal medicine; Discontinuation; TNF inhibitor; Clinical efficacy; Clinical trial; Antibody; Immunology; Tumor necrosis factor alpha","score_opus":0.05998855447232843,"score_gpt":0.37815480077710734,"score_spread":0.3181662463047789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900514407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498165,0.0040998245,0.000003892658,0.00026813362,0.00011896329,0.00032024027,0.00018299448,0.000009878403,0.000014455899],"genre_scores_gemma":[0.9980558,0.001796824,0.00004035033,0.000048901387,0.0000052655996,0.000005373563,0.00003512978,0.000008133836,0.000004210909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977725,0.0006334422,0.0009974106,0.0002966055,0.000100529214,0.0001995125],"domain_scores_gemma":[0.9979424,0.000868438,0.00056162523,0.0004160494,0.00017813561,0.000033356348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059345766,0.00019550197,0.00081516406,0.0001901484,0.000062435094,0.000008606842,0.0001675862,0.00018161126,0.00005782313],"category_scores_gemma":[0.0013134067,0.00011338545,0.00031430574,0.0005743647,0.0009186598,0.000091879534,0.0000861556,0.00018384168,0.0000033241272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036311871,0.001992458,0.9663012,0.000027778473,0.006602329,8.383749e-7,0.00031350914,0.000008942403,0.00032408847,0.00003857175,0.00027492183,0.020484162],"study_design_scores_gemma":[0.0023322438,0.0019647903,0.99072874,0.001061272,0.00043969307,5.3622443e-7,0.00010119325,0.000028687897,0.0022707696,0.0009439359,0.0000029095306,0.00012523033],"about_ca_topic_score_codex":0.0003095623,"about_ca_topic_score_gemma":0.00042533752,"teacher_disagreement_score":0.024427526,"about_ca_system_score_codex":0.000020980799,"about_ca_system_score_gemma":0.000064472304,"threshold_uncertainty_score":0.46237245},"labels":[],"label_agreement":null},{"id":"W2900649681","doi":"10.1002/cpcy.53","title":"Flow Cytometry Method Validation Protocols","year":2018,"lang":"en","type":"article","venue":"Current Protocols in Cytometry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada)","funders":"","keywords":"Protocol (science); Computer science; Data validation; Data mining; Medical physics; Medicine; Database; Pathology","score_opus":0.09476345536470152,"score_gpt":0.46669307686522443,"score_spread":0.3719296215005229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900649681","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003148224,0.0008300268,0.32813737,0.0007501677,0.0028254855,0.65334904,0.0002450274,0.0006783667,0.010036303],"genre_scores_gemma":[0.051116027,0.000013474969,0.08494596,0.00057183224,0.00096553133,0.8607014,0.00010619632,0.00011168843,0.001467929],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996154,0.0010581189,0.0009078858,0.0008678106,0.0001773056,0.0008348606],"domain_scores_gemma":[0.9981571,0.00040167663,0.0002878263,0.000795403,0.0002707874,0.00008720593],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002820289,0.0004208291,0.0006624041,0.0009046389,0.00020771181,0.00009254854,0.00073530327,0.0005050387,0.0029436022],"category_scores_gemma":[0.0010215545,0.00034715928,0.00020880152,0.002307455,0.0004711737,0.00025039117,0.00031991472,0.00090559997,0.0007960422],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096512167,0.0018359827,0.08071384,0.0005607199,0.00011930719,0.0000099836925,0.00019231853,0.0000018215729,0.12108225,0.0012584447,0.015413987,0.7778462],"study_design_scores_gemma":[0.0031051475,0.0006817793,0.01237763,0.0007020219,0.00003133958,0.00003985357,0.00003683386,0.0003312251,0.47067106,0.0014490612,0.509982,0.00059204816],"about_ca_topic_score_codex":0.0000054857965,"about_ca_topic_score_gemma":0.0000030575081,"teacher_disagreement_score":0.77725416,"about_ca_system_score_codex":0.00019091164,"about_ca_system_score_gemma":0.00013552196,"threshold_uncertainty_score":0.99998194},"labels":[],"label_agreement":null},{"id":"W2900828482","doi":"10.1016/j.drudis.2018.11.011","title":"Advancing nonclinical innovation and safety in pharmaceutical testing","year":2018,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Policy Alternatives","funders":"National Academy of Sciences; Defense Advanced Research Projects Agency","keywords":"Human use; In silico; Drug discovery; Drug development; Pharmacology; Risk analysis (engineering); Drug; Medicine; Computer science; Biotechnology; Bioinformatics; Biology","score_opus":0.08038240903818748,"score_gpt":0.4101058111567351,"score_spread":0.3297234021185476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900828482","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016199128,0.9960986,0.00019569919,0.00020075068,0.0008617673,0.0004453532,0.00009666897,0.000035845722,0.0019033368],"genre_scores_gemma":[0.00012191891,0.9956592,0.0015325111,0.00043753584,0.00020228633,0.000023710101,0.00013166794,0.00003619534,0.001854982],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99681175,0.0007649434,0.0012045837,0.0006704155,0.000047556216,0.0005007527],"domain_scores_gemma":[0.9970353,0.0022886703,0.00030408206,0.00027680185,0.0000633363,0.00003177703],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002066226,0.0003940022,0.0014428576,0.00025646103,0.00011090438,0.000045868746,0.00023346201,0.00066289224,0.00015009231],"category_scores_gemma":[0.0017880592,0.0002841193,0.0001687884,0.00086914335,0.00044845557,0.0001780505,0.00031777503,0.0011176824,0.00007881362],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004774831,0.00010903714,0.00019835203,0.0020587752,0.00011940222,0.000011814822,0.000019683885,6.9621954e-8,0.00005552934,0.0013660518,0.0018447568,0.99416876],"study_design_scores_gemma":[0.0004490852,0.000056433993,0.00006148637,0.005201593,0.0002982349,0.000056730394,0.000015305764,0.0000056862464,0.000060707236,0.00026776866,0.9931692,0.00035777944],"about_ca_topic_score_codex":0.000012711711,"about_ca_topic_score_gemma":0.000013034275,"teacher_disagreement_score":0.993811,"about_ca_system_score_codex":0.0000962342,"about_ca_system_score_gemma":0.00021076301,"threshold_uncertainty_score":0.9999611},"labels":[],"label_agreement":null},{"id":"W2902268376","doi":"10.4155/bio-2018-0287","title":"2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on Bav (Part 3 – Lba/Cell-Based Assays: Immunogenicity, Biomarkers and Pk Assays)","year":2018,"lang":"en","type":"review","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; Caprion (Canada)","funders":"","keywords":"Bioanalysis; Immunogenicity; Biopharmaceutical; Computer science; Nanotechnology; Computational biology; Medicine; Biotechnology; Biology; Immune system; Immunology","score_opus":0.05972015392823208,"score_gpt":0.3313494038468652,"score_spread":0.2716292499186331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902268376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008345601,0.99242914,0.00010388905,0.0033330857,0.00048420185,0.00093546975,0.0008986948,0.00008526516,0.0016467981],"genre_scores_gemma":[0.00068773405,0.993125,0.0020800584,0.0011767074,0.00015543899,0.00015053198,0.00082617195,0.00011569282,0.0016826376],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9909353,0.0035496098,0.001894274,0.0022821554,0.00034781135,0.0009908204],"domain_scores_gemma":[0.995347,0.0011640595,0.0009890493,0.0020570157,0.00023916467,0.00020368036],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0031545095,0.0014402872,0.0037442048,0.0028148098,0.00047114762,0.00021118287,0.000865345,0.002333444,0.0020218769],"category_scores_gemma":[0.00041460793,0.0010326708,0.0014499481,0.00326906,0.0010205245,0.00009436778,0.00022292849,0.001246086,0.00044807605],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007111894,0.0023172232,0.0006128269,0.000787362,0.0164829,0.0000322232,0.00007333406,0.0000024883868,0.00058036606,0.00010410399,0.012708073,0.9655879],"study_design_scores_gemma":[0.0014629234,0.0010176746,0.00021033664,0.00169742,0.00611465,0.000013441288,0.000049067516,0.00006032569,0.0024215044,0.00008982942,0.9856362,0.0012266487],"about_ca_topic_score_codex":0.0002759274,"about_ca_topic_score_gemma":0.00029505958,"teacher_disagreement_score":0.9729281,"about_ca_system_score_codex":0.00037714306,"about_ca_system_score_gemma":0.00020904404,"threshold_uncertainty_score":0.9998347},"labels":[],"label_agreement":null},{"id":"W2902365578","doi":"10.1016/j.omtm.2018.10.013","title":"IPRF Reflection Paper on Biodistribution","year":2018,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Biodistribution; Session (web analytics); Dialog box; Political science; Globe; Panel discussion; Scopus; Position paper; Library science; Medicine; Medical education; Psychology; Computer science; MEDLINE; Business; Law; Pathology; Biology; Neuroscience; Biotechnology; World Wide Web","score_opus":0.12702297266073162,"score_gpt":0.48140785575434253,"score_spread":0.35438488309361094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902365578","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1799912,0.0030822535,0.7919031,0.006403616,0.00672089,0.0009556271,0.000019399133,0.00037768367,0.010546265],"genre_scores_gemma":[0.115006365,0.0006835301,0.85696846,0.023907648,0.00030165614,0.00008143878,0.00011123712,0.000061008992,0.0028786275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946663,0.0030638687,0.00092826993,0.0007332285,0.00009849634,0.00050988194],"domain_scores_gemma":[0.9984103,0.0006081457,0.00019477568,0.0004989118,0.00020049508,0.000087405846],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005052466,0.0003151108,0.0005088266,0.00009707225,0.0003122389,0.0000306419,0.00029695177,0.0007066787,0.0018721201],"category_scores_gemma":[0.0007456158,0.00023333494,0.00027997553,0.0003453605,0.0005249996,0.0000438461,0.000091358546,0.00057832967,0.0008672957],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005345088,0.00034235948,0.00026633078,0.0000026647476,0.0003232373,0.0000043512796,0.000042283875,9.569061e-8,0.3238874,0.0013189196,0.0014981012,0.67177975],"study_design_scores_gemma":[0.0008378869,0.0007174559,0.00761854,0.000016866241,0.000019326702,0.0000058023606,0.000008330018,0.0000022596637,0.49211606,0.0015847196,0.4968629,0.00020986621],"about_ca_topic_score_codex":0.000005918366,"about_ca_topic_score_gemma":0.000002541132,"teacher_disagreement_score":0.6715699,"about_ca_system_score_codex":0.000088440975,"about_ca_system_score_gemma":0.00013833128,"threshold_uncertainty_score":0.99991065},"labels":[],"label_agreement":null},{"id":"W2902584424","doi":"10.4155/bio-2018-0268","title":"2018 White Paper on Recent Issues in Bioanalysis: <i>‘A Global Bioanalytical Community Perspective on Last Decade of Incurred Samples Reanalysis (ISR)’</i> (Part 1 – Small Molecule Regulated Bioanalysis, Small Molecule Biomarkers, Peptides &amp; Oligonucleotide Bioanalysis)","year":2018,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Bioanalysis; Biopharmaceutical; Nanotechnology; Computer science; Chemistry; Biology; Biotechnology; Chromatography","score_opus":0.04670819109761333,"score_gpt":0.31502790300806993,"score_spread":0.2683197119104566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902584424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8316222,0.07115004,0.0041748183,0.039680615,0.0019529061,0.0036894204,0.0072692465,0.0015403002,0.038920496],"genre_scores_gemma":[0.97926426,0.006260161,0.0074283592,0.0026034229,0.00028162997,0.000085244006,0.0014831796,0.00018835742,0.0024054085],"study_design_codex":"meta_analysis","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98259646,0.006747922,0.004067236,0.003220828,0.0009492975,0.002418245],"domain_scores_gemma":[0.9888609,0.0013151186,0.0019871145,0.0049204486,0.002299237,0.00061719073],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.005058753,0.0021671148,0.0048453007,0.0042376146,0.0011179454,0.00028968786,0.0028549104,0.0017824124,0.0033877261],"category_scores_gemma":[0.003121557,0.001831557,0.0035707238,0.016305832,0.004598702,0.00028912304,0.0010046972,0.0018579699,0.0006899601],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02278766,0.040962145,0.2667345,0.0008514168,0.32825682,0.00042964253,0.0060089054,0.0018535458,0.18577437,0.01609161,0.039589807,0.090659566],"study_design_scores_gemma":[0.021564055,0.009487756,0.10065613,0.0033196965,0.13001044,0.00017885564,0.03692621,0.006133919,0.3457382,0.0059041358,0.32333848,0.016742127],"about_ca_topic_score_codex":0.016067483,"about_ca_topic_score_gemma":0.056991525,"teacher_disagreement_score":0.28374866,"about_ca_system_score_codex":0.0016154691,"about_ca_system_score_gemma":0.0003530801,"threshold_uncertainty_score":0.9995135},"labels":[],"label_agreement":null},{"id":"W2903785850","doi":"10.1007/978-3-319-99680-6_6","title":"Clinical Information Requirements for Biosimilar Biologic Drug Approvals in Canada","year":2018,"lang":"en","type":"book-chapter","venue":"AAPS advances in the pharmaceutical sciences series","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Context (archaeology); Medicine; Drug; Pharmacology; Pharmacovigilance; Risk analysis (engineering); Internal medicine","score_opus":0.10563326473178568,"score_gpt":0.40992796718194063,"score_spread":0.30429470245015494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903785850","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0112648085,0.15691873,0.00143867,0.05567398,0.029937208,0.01261888,0.0031440177,0.00025244424,0.72875124],"genre_scores_gemma":[0.4303885,0.26739854,0.04313665,0.12997997,0.0028830224,0.0014331479,0.0012448457,0.00023125032,0.12330406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972909,0.0003274248,0.0010571114,0.00050854526,0.00016471492,0.0006512741],"domain_scores_gemma":[0.9980277,0.0012520574,0.00033057082,0.00026394872,0.00008037642,0.00004536611],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0036252697,0.00034744068,0.00059453544,0.0001243754,0.00023192333,0.000044409346,0.0010914865,0.0003201377,0.00067491113],"category_scores_gemma":[0.00043814335,0.00020508867,0.00014302426,0.00018389428,0.002860691,0.0006078623,0.00020491134,0.0006560502,0.00003795963],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032056503,0.0004492041,0.015913334,0.0009781154,0.00045017278,0.00004403609,0.0017400937,0.00005837615,0.0006727162,0.3065505,0.06868438,0.60125345],"study_design_scores_gemma":[0.000553133,0.00029095192,0.000108266984,0.00011368643,0.000047847636,0.000012393226,0.00050827896,0.000039988194,0.00086193485,0.043064956,0.9540821,0.00031649537],"about_ca_topic_score_codex":0.0026941097,"about_ca_topic_score_gemma":0.1029149,"teacher_disagreement_score":0.8853977,"about_ca_system_score_codex":0.00017199773,"about_ca_system_score_gemma":0.00048613013,"threshold_uncertainty_score":0.99985296},"labels":[],"label_agreement":null},{"id":"W2907826353","doi":"10.1182/blood-2018-99-115341","title":"Biosimilar G-CSF Versus Originator G-CSF for Autologous Peripheral Blood Stem Cell Mobilization: A Comparative Analysis of Mobilization and Engraftment","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; Saskatchewan Cancer Agency","funders":"","keywords":"Biosimilar; Plerixafor; Medicine; Mobilization; Apheresis; Internal medicine","score_opus":0.034531517415535846,"score_gpt":0.3129585065225609,"score_spread":0.27842698910702507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907826353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909206,0.0033023034,0.0032729264,0.00012558336,0.00043401445,0.0007371846,0.00028095956,0.00006843799,0.0008579594],"genre_scores_gemma":[0.99534047,0.00010791126,0.0037796067,0.00010151518,0.00004150503,0.0000631573,0.000096721706,0.000012026911,0.00045711815],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99848706,0.00023567116,0.00042889448,0.0004785251,0.00005722286,0.00031263148],"domain_scores_gemma":[0.99875754,0.00031209906,0.00021673195,0.00030147788,0.000363816,0.000048310125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029232042,0.00024069696,0.00065640523,0.00020563186,0.00019627853,0.000023675706,0.00016019319,0.0003163758,0.00029382642],"category_scores_gemma":[0.000035366553,0.00019759146,0.00019552186,0.0006471222,0.0005203152,0.00007197209,0.00006422065,0.000104224244,0.0000045961187],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006589573,0.013034147,0.039457213,0.0006175834,0.042128637,0.000014582906,0.008140321,0.00013488205,0.85864645,0.020695377,0.0031527216,0.0073885173],"study_design_scores_gemma":[0.00943958,0.0038304296,0.0031586795,0.000022287648,0.011274857,0.000008162902,0.00082567765,0.0013301795,0.9593132,0.00011137705,0.010286856,0.0003987081],"about_ca_topic_score_codex":0.00001314692,"about_ca_topic_score_gemma":0.00005372495,"teacher_disagreement_score":0.10066676,"about_ca_system_score_codex":0.000021278633,"about_ca_system_score_gemma":0.0000537291,"threshold_uncertainty_score":0.80575466},"labels":[],"label_agreement":null},{"id":"W2910636195","doi":"10.1016/j.cgh.2018.12.036","title":"Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade","year":2019,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Hungarian Scientific Research Fund","keywords":"Medicine; Biosimilar; Inflammatory Bowel Diseases; Intensive care medicine; Inflammatory bowel disease; Internal medicine; Disease","score_opus":0.013441056449875652,"score_gpt":0.27615872632145355,"score_spread":0.2627176698715779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910636195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589247,0.00026019433,0.00025851233,0.002560334,0.00033884455,0.0004483505,0.00017517866,0.000035157726,0.000030960462],"genre_scores_gemma":[0.98964256,0.00013438391,0.0013593242,0.008661529,0.000016706188,0.00002104282,0.000046737812,0.000020628626,0.000097108175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975244,0.00054102397,0.0006878137,0.0006734626,0.000051593324,0.0005217435],"domain_scores_gemma":[0.9982754,0.0007154124,0.00029038667,0.00046704686,0.00012981353,0.00012191265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002493866,0.0003001312,0.0011070309,0.000088991954,0.00005177632,0.000004901349,0.0002901023,0.000468699,0.00036870805],"category_scores_gemma":[0.00012015064,0.0001774209,0.00013207186,0.000071446724,0.001091421,0.00004813655,0.0001487796,0.00046563696,0.00003893421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013564607,0.0005181222,0.9832315,0.0000122306465,0.00069221307,0.0000079401525,0.000029570043,4.178071e-7,0.00053777546,0.00010943536,0.0006304099,0.0006658039],"study_design_scores_gemma":[0.0072242976,0.0052722134,0.9839184,0.000032231892,0.00012704954,0.000007116201,0.000032373173,0.000003742912,0.00029069057,0.00014330824,0.002793582,0.00015494478],"about_ca_topic_score_codex":0.00001669982,"about_ca_topic_score_gemma":0.00007764596,"teacher_disagreement_score":0.0063403095,"about_ca_system_score_codex":0.000011331112,"about_ca_system_score_gemma":0.00004444882,"threshold_uncertainty_score":0.72350144},"labels":[],"label_agreement":null},{"id":"W2910647125","doi":"10.1016/j.taap.2019.01.012","title":"A multiplexed UPLC-MS/MS assay for the simultaneous measurement of urinary safety biomarkers of drug-induced kidney injury and phospholipidosis","year":2019,"lang":"en","type":"article","venue":"Toxicology and Applied Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Medicine; Nephrotoxicity; Urinary system; Phospholipidosis; Pharmacology; Lipocalin; Kidney; Biomarker; Renal function; Acute kidney injury; Creatinine; Internal medicine; Urology; Chemistry","score_opus":0.02143430691708027,"score_gpt":0.2941371551950889,"score_spread":0.2727028482780086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910647125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98739266,0.002507571,0.0002229721,0.0036713716,0.0018337567,0.0026717545,0.00031973905,0.00004453257,0.0013356425],"genre_scores_gemma":[0.99648386,0.00032897937,0.0007546012,0.001984848,0.00004253146,0.000119401215,0.000013701318,0.000019776848,0.00025230812],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979675,0.00041763418,0.0005878956,0.0004915496,0.00006067596,0.00047478967],"domain_scores_gemma":[0.9967667,0.002473416,0.00031788312,0.00023279441,0.0001282243,0.000080977945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017519228,0.0002905523,0.00076519,0.00010830958,0.00018737231,0.0000038728026,0.00027045558,0.00070786616,0.00087514095],"category_scores_gemma":[0.00018591227,0.00020638836,0.00012540631,0.00015976815,0.0009029505,0.000023431707,0.00021817305,0.00046387935,0.000008368833],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006114264,0.00043183396,0.000758352,0.00016447438,0.0012743848,0.0000010771037,0.00018230244,0.0000066306193,0.97155756,0.00082640885,0.0035795995,0.0151031045],"study_design_scores_gemma":[0.0059610703,0.001005608,0.002824594,0.000020262794,0.00068695424,0.000028691105,0.00018494033,0.00034225118,0.94866943,0.00015327644,0.03985225,0.00027066332],"about_ca_topic_score_codex":0.00002283753,"about_ca_topic_score_gemma":0.0000064148194,"teacher_disagreement_score":0.03627265,"about_ca_system_score_codex":0.00003752843,"about_ca_system_score_gemma":0.00011873444,"threshold_uncertainty_score":0.958218},"labels":[],"label_agreement":null},{"id":"W2911783008","doi":"10.1093/ecco-jcc/jjy222.533","title":"P409 Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring","year":2019,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Infliximab; Biosimilar; Ulcerative colitis; Inflammatory bowel disease; Internal medicine; Trough level; Crohn's disease; Disease; Surgery","score_opus":0.012671146645385606,"score_gpt":0.2972672392848751,"score_spread":0.2845960926394895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911783008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942022,0.003264044,0.00000328485,0.0019578566,0.00032046708,0.00021060665,0.000015308378,0.000003805175,0.000022437518],"genre_scores_gemma":[0.9981731,0.000993161,0.000043454267,0.00053747685,0.0000769443,0.0000022459712,7.4765103e-7,0.000010099161,0.00016275031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863124,0.00025954918,0.00054353406,0.00018613292,0.00013443187,0.0002450941],"domain_scores_gemma":[0.998835,0.00055088074,0.00023308392,0.00012418367,0.00011068503,0.00014614024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001002933,0.00016370426,0.00045848038,0.00007419415,0.00009308879,0.000036052657,0.00014791897,0.00021242541,0.00005418741],"category_scores_gemma":[0.0001329516,0.00008813485,0.000072930336,0.00006768626,0.0003168784,0.00011061698,0.00007390226,0.00064691517,0.0000025633165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009639437,0.00006777919,0.99218297,0.000040831135,0.00019664949,0.000024006791,0.00008768439,5.5859566e-8,0.000007686413,0.00008915486,0.0000937955,0.0062454334],"study_design_scores_gemma":[0.003293628,0.00028033718,0.9911708,0.00019977237,0.0001293052,0.000013092405,0.00009487975,0.000003918911,0.00006897079,0.0001547487,0.004464394,0.0001261079],"about_ca_topic_score_codex":0.000005728826,"about_ca_topic_score_gemma":0.000002630896,"teacher_disagreement_score":0.0061193258,"about_ca_system_score_codex":0.000018470248,"about_ca_system_score_gemma":0.00010324218,"threshold_uncertainty_score":0.35940352},"labels":[],"label_agreement":null},{"id":"W2912461211","doi":"10.1093/ecco-jcc/jjy222.025","title":"OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study","year":2019,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Western University","funders":"","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Internal medicine; Adverse effect; Exacerbation; Clinical endpoint; Inflammatory bowel disease; Gastroenterology; Surgery; Disease; Clinical trial","score_opus":0.024096599117632993,"score_gpt":0.29745493677453744,"score_spread":0.2733583376569044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912461211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428713,0.0029308489,0.00001749457,0.0011358889,0.00032112008,0.00037366475,0.0005133549,0.0000027744186,0.00041772577],"genre_scores_gemma":[0.99778646,0.0010112046,0.00009072366,0.00021583162,0.00007376843,0.0000030128178,0.000008691767,0.000007881485,0.0008024038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808633,0.00056478416,0.0007691365,0.00023598397,0.0000918522,0.00025191085],"domain_scores_gemma":[0.99833274,0.00083167333,0.00039353577,0.00021021016,0.00015782651,0.000074011325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079900655,0.00016850812,0.0005638884,0.00006923181,0.000098456265,0.000041426567,0.00019652002,0.00014680921,0.0002910334],"category_scores_gemma":[0.00022461425,0.00010709135,0.000100637946,0.00010730262,0.00033366086,0.00010526076,0.00012154959,0.00040884127,0.0000031973127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17176382,0.0019668574,0.6576576,0.00014606651,0.0016309139,0.0017618272,0.0074569676,0.0000043887067,0.0007178611,0.0021951601,0.0042718877,0.15042661],"study_design_scores_gemma":[0.005957065,0.0007511889,0.9892399,0.00025884897,0.00014060525,0.00009167942,0.0008982782,0.0000037068012,0.00023953336,0.00049652904,0.0017964551,0.00012624927],"about_ca_topic_score_codex":0.00019918766,"about_ca_topic_score_gemma":0.00042864602,"teacher_disagreement_score":0.33158222,"about_ca_system_score_codex":0.00003441579,"about_ca_system_score_gemma":0.00012242407,"threshold_uncertainty_score":0.43670586},"labels":[],"label_agreement":null},{"id":"W2912553198","doi":"10.1093/ecco-jcc/jjy222.653","title":"P529 Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1","year":2019,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Placebo; Internal medicine; Gastroenterology; Pharmacokinetics; Disease","score_opus":0.012350557891369013,"score_gpt":0.25746234629571874,"score_spread":0.24511178840434972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912553198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99831814,0.00056080223,0.000017188642,0.00018700998,0.00014677891,0.00022927817,0.000063760155,0.0000027753754,0.00047429954],"genre_scores_gemma":[0.9983739,0.000049737184,0.0003544656,0.000057727197,0.000012121324,0.0000026630137,0.0000028228799,0.000007826406,0.0011386864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870783,0.00045373247,0.00044872274,0.00012671329,0.00006391152,0.00019907288],"domain_scores_gemma":[0.998866,0.00049415405,0.0002832549,0.00011732454,0.00019874505,0.000040514453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033666356,0.00012847445,0.0004374599,0.00014404609,0.00004579505,0.000015059139,0.00007319032,0.00015625388,0.00032040072],"category_scores_gemma":[0.00008198937,0.00008541933,0.00007644746,0.00012747284,0.00014088546,0.00008648848,0.000017486907,0.00018236173,0.000005758979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19920628,0.0013600165,0.76406395,0.0000697799,0.0006316429,0.00022509783,0.0016860849,0.000013716228,0.0007789047,0.0034193383,0.00028000862,0.028265199],"study_design_scores_gemma":[0.0046512657,0.008014301,0.98252916,0.00011487182,0.00006345668,0.0001698587,0.00023821866,0.0000012301788,0.001776779,0.00036929082,0.0019709484,0.000100622565],"about_ca_topic_score_codex":0.0000342231,"about_ca_topic_score_gemma":0.000051313335,"teacher_disagreement_score":0.21846522,"about_ca_system_score_codex":0.000083676154,"about_ca_system_score_gemma":0.00013505471,"threshold_uncertainty_score":0.3508163},"labels":[],"label_agreement":null},{"id":"W2913552344","doi":"10.1093/ecco-jcc/jjy222.195","title":"P071 Supporting extrapolation of indications for ABP 501, the first adalimumab biosimilar: focus on Crohn’s disease","year":2019,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Adalimumab; Antibody-dependent cell-mediated cytotoxicity; Tumor necrosis factor alpha; Medicine; Peripheral blood mononuclear cell; Pharmacology; Immunology; Cytotoxicity; Chemistry; Cancer research; Monoclonal antibody; Antibody; In vitro; Biochemistry","score_opus":0.017971805539214625,"score_gpt":0.29347956686886845,"score_spread":0.2755077613296538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913552344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665162,0.0046229735,0.0017594463,0.023047304,0.00083867693,0.0009148128,0.00037244314,0.000012013645,0.0019161062],"genre_scores_gemma":[0.9982511,0.00017128904,0.00031246908,0.00061447587,0.00006981228,0.000008066154,0.000004468859,0.000008633315,0.0005597111],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990001,0.000084655774,0.0005240287,0.00012442017,0.000062019644,0.00020479326],"domain_scores_gemma":[0.9986272,0.0004455221,0.00055028853,0.00015932115,0.00016798604,0.00004968323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005608981,0.000107861466,0.00027499656,0.00009272867,0.00017318196,0.00002490888,0.00015458802,0.0001255236,0.00030982078],"category_scores_gemma":[0.00016850386,0.00006716532,0.0001911583,0.00009192776,0.0001688918,0.00007522612,0.00002812375,0.00019420349,0.000003826937],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045455966,0.0031338462,0.10555683,0.0013244308,0.004072834,0.00014393685,0.004115973,0.00003744028,0.01855089,0.25963685,0.09777375,0.46019724],"study_design_scores_gemma":[0.0015906325,0.00065603346,0.91628015,0.0001598767,0.00028303842,0.00005476962,0.0002092443,0.000031336178,0.0073382226,0.00963016,0.0636292,0.00013731554],"about_ca_topic_score_codex":0.000011383137,"about_ca_topic_score_gemma":0.0000117018635,"teacher_disagreement_score":0.81072336,"about_ca_system_score_codex":0.000019869232,"about_ca_system_score_gemma":0.00008665726,"threshold_uncertainty_score":0.33923206},"labels":[],"label_agreement":null},{"id":"W2914211697","doi":"10.1093/ecco-jcc/jjy222.459","title":"P335 Long-term follow-up of switching from original infliximab to infliximab biosimilar: real-world data","year":2019,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Infliximab; Medicine; Biosimilar; Ulcerative colitis; Internal medicine; Inflammatory bowel disease; Adverse effect; Demographics; Crohn's disease; Gastroenterology; Clinical endpoint; Disease; Clinical trial","score_opus":0.036630202603889446,"score_gpt":0.3272024794030693,"score_spread":0.29057227679917985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914211697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407566,0.001684415,0.00039493915,0.0011652366,0.0011649674,0.00018426853,0.00027214838,0.0000100526695,0.0010482924],"genre_scores_gemma":[0.99438375,0.00068687444,0.002462561,0.0007643818,0.00017464021,0.0000013262244,0.000024248586,0.000018914894,0.001483321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814296,0.00019444889,0.00083355955,0.00032740762,0.00012805537,0.0003735599],"domain_scores_gemma":[0.9982253,0.00033153468,0.00055385137,0.0005494256,0.00022047806,0.000119435295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072556274,0.00022578124,0.0008347894,0.00024983307,0.00008069694,0.00005942764,0.00062747515,0.00018300551,0.0008593324],"category_scores_gemma":[0.000119464436,0.00017202306,0.00016001772,0.00026024628,0.00015076566,0.0002717809,0.00035582075,0.0004661419,0.000030495981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02667047,0.00087149825,0.57709956,0.0003428483,0.0034226025,0.00040357502,0.001296629,0.0000041954463,0.12058107,0.0052618817,0.02822007,0.23582563],"study_design_scores_gemma":[0.0036180285,0.0008491389,0.9106944,0.000414478,0.0003296622,0.00014835373,0.00012545793,0.000012961473,0.018096589,0.00057871424,0.06482889,0.0003033117],"about_ca_topic_score_codex":0.00041224147,"about_ca_topic_score_gemma":0.0004783969,"teacher_disagreement_score":0.3335949,"about_ca_system_score_codex":0.000042282158,"about_ca_system_score_gemma":0.00014274575,"threshold_uncertainty_score":0.9409087},"labels":[],"label_agreement":null},{"id":"W2914570451","doi":"10.1093/ecco-jcc/jjy222.461","title":"P337 Switching from originator infliximab to CT-P13: single-centre experience from the UK","year":2019,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Infliximab; Ulcerative colitis; Biosimilar; Internal medicine; Cohort; Demographics; Inflammatory bowel disease; Retrospective cohort study; Gastroenterology; Crohn's disease; Disease; Surgery","score_opus":0.016334541303339386,"score_gpt":0.26788812559032527,"score_spread":0.2515535842869859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914570451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925144,0.002813925,0.00016509286,0.002808216,0.001029459,0.00011741398,0.000056949917,0.0000061690175,0.00048841425],"genre_scores_gemma":[0.9957001,0.000076486496,0.0009213662,0.0024875202,0.00016041151,0.0000013057052,0.0000019828062,0.000008083544,0.00064271304],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989601,0.00015333439,0.0003740503,0.00018235324,0.00007264846,0.00025755615],"domain_scores_gemma":[0.9989775,0.00045740136,0.00019875437,0.00018653592,0.000105469015,0.000074365045],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021836636,0.00013947497,0.00036097973,0.000035724177,0.00011714171,0.000084924846,0.00027020366,0.00010223713,0.0019689251],"category_scores_gemma":[0.00012161842,0.00008367539,0.00011172387,0.00009159494,0.00008723133,0.00009458841,0.00009578212,0.00033900296,0.00005431447],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00659245,0.0007818265,0.24994695,0.00003492882,0.0018539724,0.0005369362,0.015788417,0.0000068069376,0.4407365,0.0066648065,0.050685924,0.22637048],"study_design_scores_gemma":[0.0016981799,0.00034310805,0.44576636,0.00022743922,0.000118673604,0.000127885,0.0028233975,0.000006105378,0.048270937,0.0019044116,0.4984461,0.0002673908],"about_ca_topic_score_codex":0.00031054646,"about_ca_topic_score_gemma":0.00005060093,"teacher_disagreement_score":0.4477602,"about_ca_system_score_codex":0.000035548786,"about_ca_system_score_gemma":0.0000472119,"threshold_uncertainty_score":0.9989434},"labels":[],"label_agreement":null},{"id":"W2921198709","doi":"10.1093/jcag/gwz006.024","title":"A25 ASSOCIATION OF BIOLOGIC PRESCRIBING FOR INFLAMMATORY BOWEL DISEASE WITH INDUSTRY PAYMENTS TO PHYSICIANS","year":2019,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; University of Toronto","funders":"","keywords":"Medical prescription; Medicine; Payment; Medicaid; Family medicine; Medicare Part D; Receipt; Liberian dollar; Pharmacy; Actuarial science; Prescription drug; Business; Finance; Accounting; Health care; Nursing","score_opus":0.009596811182207721,"score_gpt":0.2335884960700855,"score_spread":0.22399168488787777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921198709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98714286,0.000018773359,0.00006491486,0.011467394,0.0007468939,0.00030181365,0.00019530147,0.0000023924274,0.000059651527],"genre_scores_gemma":[0.9959429,0.0000041564194,0.00027827002,0.0019955868,0.000048749956,0.000003965438,0.0000052389255,0.000008169241,0.0017129644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985227,0.0004446796,0.0004776912,0.00011289848,0.000095034935,0.00034699155],"domain_scores_gemma":[0.99762493,0.00018791475,0.0015156646,0.0001412158,0.00045019024,0.00008006805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011245669,0.00010680038,0.00036820697,0.00015700131,0.00006585295,0.0000071179097,0.00028097452,0.0003436092,0.000056901903],"category_scores_gemma":[0.0006430978,0.00007324166,0.00019259291,0.00009119773,0.000046926616,0.00005660358,0.000032426564,0.00039666594,0.0000029551777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063907856,0.000050238803,0.9816594,0.000019515679,0.0004919743,5.389951e-7,0.000059773705,0.000115087074,0.010304084,0.00005564095,0.00650345,0.000101182835],"study_design_scores_gemma":[0.0019157458,0.0012473186,0.98823345,0.000111348025,0.0002259345,0.0000035993112,0.00007501856,0.000010442016,0.0026412962,0.00010904262,0.005360977,0.00006585869],"about_ca_topic_score_codex":0.00030279942,"about_ca_topic_score_gemma":0.019432297,"teacher_disagreement_score":0.019129498,"about_ca_system_score_codex":0.00070436334,"about_ca_system_score_gemma":0.00025894077,"threshold_uncertainty_score":0.99846053},"labels":[],"label_agreement":null},{"id":"W2921678918","doi":"10.1093/jcag/gwz006.154","title":"A155 THE IMMUNOMODULATOR, LEFLUNOMIDE, REDUCES MITOCHONDRIAL FRAGMENTATION CAUSED BY ADHERENT–INVASIVE E. COLI AND PERSISTENCE OF THE PATHOBIONT WITHIN ENTERIC EPITHELIA","year":2019,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Biology; Mitochondrion; Leflunomide; Fragmentation (computing); Mitochondrial fission; Cell biology; Intracellular; Microbiology; Immunology","score_opus":0.00905231128103922,"score_gpt":0.21465132284622243,"score_spread":0.2055990115651832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921678918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761576,0.00021391512,0.0000075369658,0.009395789,0.002349894,0.00026051284,0.00012748528,0.0000011567291,0.000027951268],"genre_scores_gemma":[0.9977854,0.000048997073,0.00007800909,0.0010545868,0.000033526456,0.0000021486787,0.0000029051848,0.0000066710195,0.0009877466],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99788564,0.0010624852,0.0005876329,0.00012015961,0.00010501849,0.00023903683],"domain_scores_gemma":[0.99763113,0.00020737908,0.0016724318,0.00019003983,0.00025865604,0.00004038858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007372014,0.000119403325,0.00035101897,0.00006842333,0.00014928689,0.0000152643,0.00043367647,0.00019500835,0.0000997162],"category_scores_gemma":[0.00034382066,0.000063773005,0.00022770661,0.00009549031,0.00026921486,0.00005951512,0.00005666617,0.00037359065,0.0000023038124],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040852072,0.00005553658,0.3223656,0.000014027862,0.00067335373,5.1101796e-7,0.000916368,0.000021491081,0.6676223,0.00004346447,0.007768471,0.00011031815],"study_design_scores_gemma":[0.0048778444,0.002047935,0.8768077,0.0002175479,0.00058285834,0.00009546975,0.0017139214,0.000023819388,0.10995585,0.00028546105,0.0032471532,0.00014447936],"about_ca_topic_score_codex":0.0016602234,"about_ca_topic_score_gemma":0.021498214,"teacher_disagreement_score":0.5576665,"about_ca_system_score_codex":0.00033160028,"about_ca_system_score_gemma":0.00024401773,"threshold_uncertainty_score":0.9963569},"labels":[],"label_agreement":null},{"id":"W2921724680","doi":"10.14309/00000434-201810001-00676","title":"Efficacy and Tolerability of a Biosimilar Infliximab Switch - A Large Single-Centre Experience From the U.K.","year":2018,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Infliximab; Biosimilar; Ulcerative colitis; Tolerability; Internal medicine; Cohort; Demographics; Inflammatory bowel disease; Retrospective cohort study; Gastroenterology; Crohn's disease; Disease; Adverse effect","score_opus":0.018085701396641053,"score_gpt":0.27609933004506815,"score_spread":0.2580136286484271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921724680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989415,0.00045966444,0.000990133,0.008723532,0.00025398936,0.00010127032,0.000029965444,0.0000055301684,0.000020920457],"genre_scores_gemma":[0.9954107,0.00004192429,0.0009391181,0.0034817695,0.000104327526,0.0000010712577,8.5728635e-7,0.0000074694385,0.000012761783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775684,0.0010741041,0.00055935356,0.0001823461,0.000060598606,0.0003667594],"domain_scores_gemma":[0.99800754,0.00067643827,0.00074811635,0.00034666964,0.0001794457,0.00004178989],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0007830451,0.00015444752,0.0006297721,0.00004106947,0.0001336415,0.000010877207,0.0005291936,0.000061206934,0.0002314082],"category_scores_gemma":[0.00030570716,0.00007605961,0.00012590559,0.00014342848,0.003705588,0.0000434024,0.00019550794,0.0003651404,0.000004085235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044675753,0.0015661293,0.48273987,0.000008784262,0.0013766397,0.000015211652,0.010931341,0.0000010445879,0.43419966,0.00012331308,0.003645674,0.020716576],"study_design_scores_gemma":[0.011129763,0.050865274,0.8214227,0.00020027316,0.0008351759,0.0010848503,0.011626717,0.000048158614,0.07291528,0.00096409273,0.028559744,0.0003479743],"about_ca_topic_score_codex":0.000035462203,"about_ca_topic_score_gemma":0.00005250901,"teacher_disagreement_score":0.3612844,"about_ca_system_score_codex":0.00001737358,"about_ca_system_score_gemma":0.000023490644,"threshold_uncertainty_score":0.99900573},"labels":[],"label_agreement":null},{"id":"W2924683704","doi":"10.1007/s10067-019-04496-3","title":"PANLAR consensus statement on biosimilars","year":2019,"lang":"en","type":"article","venue":"Clinical Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Rheumatology Association","funders":"","keywords":"Biosimilar; Medicine; Pharmacovigilance; Traceability; Delphi; Delphi method; Family medicine; Actuarial science; Adverse effect; Pharmacology; Business; Internal medicine","score_opus":0.05225451284490387,"score_gpt":0.37858817921133114,"score_spread":0.32633366636642724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924683704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728861,0.0009980261,0.00008763702,0.012034848,0.0055156616,0.0004524899,0.0000498997,0.00014293274,0.007832417],"genre_scores_gemma":[0.98757434,0.00044624615,0.0009380569,0.0072506247,0.000015334692,0.00001130739,0.000025164934,0.000025549436,0.0037133817],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965234,0.0009977539,0.0011704459,0.0006638997,0.000051498897,0.00059303094],"domain_scores_gemma":[0.99599063,0.0029761137,0.0002554081,0.0006204229,0.00007526054,0.00008214332],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014925543,0.00025192468,0.00087917305,0.00008701384,0.000082548264,0.000010326939,0.00032270607,0.0007971051,0.005577973],"category_scores_gemma":[0.001030384,0.00018739644,0.00029577452,0.000128507,0.00068484223,0.000016208369,0.00014310045,0.0007445289,0.008605545],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024379918,0.0020269924,0.49484435,0.00012099735,0.0014995418,0.0000672753,0.000072082425,0.0000054109555,0.009101779,0.054641128,0.3891984,0.045984052],"study_design_scores_gemma":[0.006812364,0.0032423728,0.03937952,0.00014384085,0.00011846294,0.00020656786,0.00018591993,0.000050476036,0.0107862,0.004032621,0.9343349,0.00070678577],"about_ca_topic_score_codex":0.000008238365,"about_ca_topic_score_gemma":0.0000050962412,"teacher_disagreement_score":0.54513645,"about_ca_system_score_codex":0.000026544913,"about_ca_system_score_gemma":0.000086788554,"threshold_uncertainty_score":0.99533105},"labels":[],"label_agreement":null},{"id":"W2930500067","doi":"10.1007/s40259-019-00346-5","title":"Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting","year":2019,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Stockholms Läns Landsting","keywords":"Biosimilar; Market share; Medical prescription; Etanercept; Pharmacy; Prior authorization; Business; Reimbursement; Medicine; Quarter (Canadian coin); Marketing; Family medicine; Public economics; Health care; Economics; Economic growth; Nursing","score_opus":0.017447343844829443,"score_gpt":0.298849918284737,"score_spread":0.28140257443990757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2930500067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98848075,0.0022778704,0.0000046704167,0.007430138,0.00019207087,0.0003570336,0.00012701542,0.000023597937,0.0011068272],"genre_scores_gemma":[0.9974528,0.00058184273,0.00009741397,0.0011943354,0.000058572976,0.000013437797,0.00001897494,0.00000986662,0.0005727814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828607,0.0005907639,0.00030779906,0.0003675954,0.00008986209,0.00035793023],"domain_scores_gemma":[0.9986047,0.0008096507,0.00024391511,0.0002566737,0.00005121354,0.000033846398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010638373,0.00022297901,0.00033173015,0.00010602396,0.00013217297,0.000084733794,0.00022229238,0.00023593161,0.00008463009],"category_scores_gemma":[0.0004897172,0.00013488576,0.000044147346,0.00014559031,0.00036118831,0.00013661722,0.00013197692,0.00040294314,0.000012939128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111960326,0.00008851798,0.9771655,0.000115393814,0.00013753759,0.0000031066631,0.0011511046,1.5181092e-7,0.0023737985,0.0013117935,0.0029242462,0.014616856],"study_design_scores_gemma":[0.0010023745,0.00031742026,0.83815634,0.00013494081,0.00014029795,0.000029589664,0.0029270423,0.000048207516,0.0016914549,0.00060156797,0.15455413,0.00039664848],"about_ca_topic_score_codex":0.00020305539,"about_ca_topic_score_gemma":0.00009533692,"teacher_disagreement_score":0.15162988,"about_ca_system_score_codex":0.000052767144,"about_ca_system_score_gemma":0.000040235656,"threshold_uncertainty_score":0.5500482},"labels":[],"label_agreement":null},{"id":"W2930875443","doi":"10.3389/fphar.2019.00279","title":"Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?","year":2019,"lang":"en","type":"review","venue":"Frontiers in Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Biosimilar; Medicine; Health care; Guideline; Quality (philosophy); Market access; Business; Intensive care medicine; Economic growth","score_opus":0.07982178526645387,"score_gpt":0.39104433382246545,"score_spread":0.3112225485560116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2930875443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036805763,0.98492277,0.000021373875,0.0005049383,0.011222671,0.0019006408,0.00069003756,0.000102139405,0.0002673844],"genre_scores_gemma":[0.0002946469,0.99613667,0.00020371324,0.0013673875,0.00016631179,0.00049698446,0.0006861379,0.0000812712,0.0005668606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99217033,0.0033980317,0.0018169362,0.0011978738,0.00007807968,0.001338763],"domain_scores_gemma":[0.99764645,0.00096073677,0.00069522485,0.0005393868,0.000060403636,0.00009778077],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0009833663,0.0009812221,0.0043526706,0.0013801941,0.00009584943,0.00004310318,0.0018766893,0.0025505344,0.0014316359],"category_scores_gemma":[0.00025309908,0.0007442472,0.0006907711,0.0010799698,0.001227131,0.00014523156,0.00076465186,0.002356311,0.00009640738],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008038009,0.001073972,0.009341775,0.008503116,0.0033706245,0.00041344741,0.00028638245,0.0000031744942,0.0010131503,0.00010125361,0.18571545,0.7893739],"study_design_scores_gemma":[0.0020118533,0.00017063573,0.0006320285,0.0014418487,0.00077227515,0.00003182425,0.00012784301,0.0000057923517,0.00013245866,0.0001840588,0.9936084,0.0008809586],"about_ca_topic_score_codex":0.000030334342,"about_ca_topic_score_gemma":0.000012711714,"teacher_disagreement_score":0.807893,"about_ca_system_score_codex":0.00055090286,"about_ca_system_score_gemma":0.0007613194,"threshold_uncertainty_score":0.9999453},"labels":[],"label_agreement":null},{"id":"W2939550439","doi":"10.12927/hcpol.2019.25796","title":"Increase in Drug Spending in Canada Due to Extension of Data Protection for Biologics: A Descriptive Study","year":2019,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Competition (biology); Descriptive statistics; Extension (predicate logic); Descriptive research; Drug; Business; Public economics; Pharmacology; Economics; Medicine; Computer science; Statistics; Mathematics; Biology","score_opus":0.12383274704129667,"score_gpt":0.38398786715821004,"score_spread":0.2601551201169134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939550439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99312127,0.00027226203,0.000055847777,0.0036655443,0.00021295475,0.0022225007,0.00041071296,0.0000073816236,0.0000315422],"genre_scores_gemma":[0.99837023,0.000012276471,0.00072436983,0.00068520795,0.000025931675,0.000052682026,0.000033999124,0.00000783555,0.00008749422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827194,0.00054901,0.00038511053,0.00040627006,0.000031494823,0.00035618347],"domain_scores_gemma":[0.9992034,0.00018288053,0.00009323702,0.00041930715,0.000058953396,0.000042234697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009851058,0.000116053496,0.00038894432,0.00026733553,0.00003478037,0.0000024298145,0.0002398729,0.00010876831,0.000029835372],"category_scores_gemma":[0.0005230878,0.00009355503,0.000020334151,0.00037054514,0.000023489585,0.000051565938,0.00020438338,0.00023337078,0.000007468772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052578277,0.0013057371,0.64030516,0.0008727727,0.0001510362,0.00006427043,0.0050885063,0.000014914767,0.11837946,0.003547662,0.0021290693,0.22288355],"study_design_scores_gemma":[0.0039027093,0.0020256657,0.9582605,0.00039555065,0.000024787312,0.0000408347,0.014802703,0.00023884204,0.012025747,0.0012189335,0.006606876,0.0004568903],"about_ca_topic_score_codex":0.9864895,"about_ca_topic_score_gemma":0.97172344,"teacher_disagreement_score":0.3179553,"about_ca_system_score_codex":0.0005367118,"about_ca_system_score_gemma":0.0008708741,"threshold_uncertainty_score":0.38150632},"labels":[],"label_agreement":null},{"id":"W2940189035","doi":"10.5731/pdajpst.2019.010215","title":"PDA Biosimilars Workshop Report (September 27—28, 2018)—Getting It Right the First Time for Biosimilar Marketing Applications","year":2019,"lang":"en","type":"article","venue":"PDA Journal of Pharmaceutical Science and Technology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"AstraZeneca; Pfizer","keywords":"Biosimilar; Session (web analytics); Agency (philosophy); Panel discussion; Medical education; Regulatory agency; Quality (philosophy); Breakout; Event (particle physics); Medicine; Marketing; Computer science; Political science; Business; Public relations; World Wide Web; Sociology; Advertising","score_opus":0.021522726957345813,"score_gpt":0.33759112130499275,"score_spread":0.31606839434764694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940189035","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.123809606,0.027145386,0.014685603,0.80132455,0.0054367566,0.004795681,0.00009003346,0.00034002314,0.022372352],"genre_scores_gemma":[0.9376389,0.0018218321,0.030789882,0.021155434,0.0005651381,0.00013283029,0.000008493767,0.00008479821,0.0078027043],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772966,0.00011004564,0.0007677447,0.00048220885,0.00018642031,0.0007239039],"domain_scores_gemma":[0.9972113,0.001247477,0.00046939633,0.00039089532,0.0005786453,0.00010231534],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006186319,0.00022839413,0.00044767268,0.0003630829,0.0006809905,0.000072384835,0.0009609158,0.00040066516,0.0009459429],"category_scores_gemma":[0.0013031656,0.00013794808,0.00014745335,0.0012721379,0.002513829,0.00020140328,0.00034564585,0.00086208875,0.00009510565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005054911,0.000403825,0.0086339135,0.00013039308,0.0004648695,0.00006827989,0.00006688434,0.0000035187823,0.72025883,0.003360154,0.14639491,0.11970894],"study_design_scores_gemma":[0.00070668646,0.00014036939,0.00014728006,0.000075553515,0.00016339196,0.0013872971,0.00014448579,0.00020077554,0.091832794,0.001138732,0.90386355,0.00019906799],"about_ca_topic_score_codex":4.2846986e-7,"about_ca_topic_score_gemma":0.0000012852263,"teacher_disagreement_score":0.8138293,"about_ca_system_score_codex":0.00007299338,"about_ca_system_score_gemma":0.00016287016,"threshold_uncertainty_score":0.99996734},"labels":[],"label_agreement":null},{"id":"W2940236078","doi":"10.30895/1991-2919-2019-9-1-41-48","title":"Post-approval Variations to Dossiers for Vaccines: Analysis of Regulatory and Methodological Approaches Used in the Russian Federation and Abroad","year":2019,"lang":"en","type":"article","venue":"The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada","keywords":"Russian federation; Political science; Drug approval; Business; Medicine; Pharmacology; Economic policy","score_opus":0.24498558387229635,"score_gpt":0.44563681261964355,"score_spread":0.2006512287473472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940236078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88695824,0.005037775,0.00031812853,0.10169919,0.00043392487,0.005415855,0.000028475939,0.00000386184,0.00010456345],"genre_scores_gemma":[0.9977694,0.000029779749,0.0011153612,0.00011775425,0.0000678623,0.000121279736,0.000070743066,0.000006689512,0.00070111424],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9936149,0.0038998309,0.0006450781,0.00053538725,0.0010324715,0.0002723168],"domain_scores_gemma":[0.9950827,0.0025729178,0.00026650628,0.0005644541,0.001469588,0.000043877913],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07196752,0.00013993226,0.00047445876,0.00037457614,0.00039549856,0.000020805306,0.00029875975,0.00013440322,0.00024082707],"category_scores_gemma":[0.011317809,0.000065660766,0.000075655604,0.00091204385,0.0014763657,0.00003626318,0.00009123842,0.00017689294,4.1927197e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004153073,0.0007270794,0.003212862,0.0008657914,0.001598605,8.029817e-8,0.049086533,0.00065169466,0.72540617,0.030096997,0.027941855,0.15625925],"study_design_scores_gemma":[0.019720828,0.0050274404,0.6468115,0.0011022304,0.007664277,0.000025686646,0.06488931,0.07588686,0.12749037,0.02453307,0.026247453,0.00060100027],"about_ca_topic_score_codex":0.00007069026,"about_ca_topic_score_gemma":0.00004007275,"teacher_disagreement_score":0.6435986,"about_ca_system_score_codex":0.0000610383,"about_ca_system_score_gemma":0.00026006252,"threshold_uncertainty_score":0.9970103},"labels":[],"label_agreement":null},{"id":"W2940474131","doi":"10.4212/cjhp.v72i2.2885","title":"Biosimilar Drugs and the Hospital Formulary: A Canadian Experience","year":2019,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Athabasca University; Alberta Health Services","funders":"","keywords":"Formulary; Biosimilar; Medicine; Family medicine; Internal medicine","score_opus":0.009628505420556098,"score_gpt":0.2570898726288246,"score_spread":0.2474613672082685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940474131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91759217,0.010058885,0.0000061057594,0.0657616,0.002876022,0.00046534953,0.000049732847,0.000005994948,0.0031841565],"genre_scores_gemma":[0.9950912,0.00017402513,0.00005706836,0.0038683985,0.00010439061,0.000004165301,0.0000018431135,0.000015383213,0.000683515],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858177,0.0002312229,0.00035405354,0.00016699036,0.00007218907,0.0005937594],"domain_scores_gemma":[0.9988432,0.00019588301,0.00018865785,0.00025911318,0.00015755738,0.0003556031],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00093504967,0.00019704642,0.0003305503,0.00014444512,0.0005350148,0.0001121431,0.00070870924,0.000104825296,0.0010678038],"category_scores_gemma":[0.00015187217,0.00010139124,0.00018673857,0.00019509754,0.0011201056,0.00019808319,0.00004157593,0.00068130513,0.0000746377],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030368792,0.00046387324,0.26314732,0.00016491684,0.006680892,0.0013660706,0.15485017,0.000028232245,0.009615754,0.08943013,0.3532673,0.11794844],"study_design_scores_gemma":[0.0099424375,0.001093602,0.012777122,0.00011519588,0.00041391476,0.0006344197,0.005927341,0.000091178685,0.013229446,0.004260692,0.9507218,0.0007928583],"about_ca_topic_score_codex":0.14459342,"about_ca_topic_score_gemma":0.07639192,"teacher_disagreement_score":0.5974545,"about_ca_system_score_codex":0.00012719598,"about_ca_system_score_gemma":0.00096063945,"threshold_uncertainty_score":0.9998453},"labels":[],"label_agreement":null},{"id":"W2941839579","doi":"10.1007/s13318-019-00553-z","title":"Predictability of Capillary Blood Spot Toward Venous Whole Blood Sampling for Therapeutic Drug Monitoring of Tacrolimus in Solid Organ Transplant Recipients","year":2019,"lang":"en","type":"review","venue":"European Journal of Drug Metabolism and Pharmacokinetics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"","keywords":"Tacrolimus; Therapeutic drug monitoring; Medicine; Drug; Dried blood spot; Whole blood; Organ transplantation; Intensive care medicine; Venous blood; Internal medicine; Pharmacology; Transplantation; Chemistry; Chromatography","score_opus":0.07249983486276743,"score_gpt":0.34793842134482544,"score_spread":0.275438586482058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941839579","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.063727096,0.93286806,0.0001343583,0.0000357953,0.0020676334,0.00053070113,0.0006010085,0.0000068585286,0.000028458593],"genre_scores_gemma":[0.09241773,0.9055971,0.0014699113,0.000019402116,0.00032971767,0.0000023305442,0.0000233049,0.00006928039,0.000071201306],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951273,0.0018210721,0.0021216099,0.00036145077,0.00013814634,0.00043037639],"domain_scores_gemma":[0.99721074,0.00063497416,0.0015008502,0.00029413344,0.0002673934,0.00009188094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030070338,0.0004888772,0.0027401971,0.00033518331,0.00005307567,0.000016596712,0.0006362339,0.00017732548,0.00003018149],"category_scores_gemma":[0.00008863928,0.00035750566,0.0006511749,0.00026694115,0.00023922586,0.00006251962,0.00010959285,0.0010078646,0.0000016810585],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088516524,0.002534359,0.0020465525,0.023605295,0.006175382,0.00009604713,0.004266099,0.000024510513,0.059696645,0.000022437589,0.000099116674,0.9005484],"study_design_scores_gemma":[0.013574214,0.0012955369,0.005115549,0.020181354,0.047191743,0.00092293863,0.0002946723,0.0000049569617,0.0939997,0.00008166933,0.8161134,0.0012242644],"about_ca_topic_score_codex":0.000003605467,"about_ca_topic_score_gemma":2.3575932e-7,"teacher_disagreement_score":0.8993241,"about_ca_system_score_codex":0.000011933637,"about_ca_system_score_gemma":0.0001460167,"threshold_uncertainty_score":0.9998877},"labels":[],"label_agreement":null},{"id":"W2944589946","doi":"10.1136/ejhpharm-2019-eahpconf.403","title":"4CPS-254 Biosimilar rituximab – a year beyond","year":2019,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Kidney Foundation of Canada","keywords":"Biosimilar; Rituximab; Medicine; Discontinuation; Rheumatoid arthritis; Pharmacy; Retrospective cohort study; Internal medicine; Oncology; Lymphoma; Family medicine","score_opus":0.034963637577777165,"score_gpt":0.3810492240157845,"score_spread":0.34608558643800735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944589946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95383155,0.0023425687,0.00007077746,0.006162045,0.01508047,0.0006314881,0.000097552256,0.00037564445,0.021407917],"genre_scores_gemma":[0.9788494,0.00062476925,0.00079049886,0.012052721,0.00065611047,0.000011576367,0.00006177589,0.000036313446,0.0069168364],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750286,0.0005559264,0.00074861327,0.0006549348,0.00008267353,0.00045500023],"domain_scores_gemma":[0.99869657,0.00044159658,0.0002232749,0.00041575907,0.00012986302,0.00009291705],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011462474,0.00026056802,0.00054600375,0.000101427984,0.00015049189,0.000043212523,0.00039920406,0.00041233632,0.011528249],"category_scores_gemma":[0.00005099558,0.00021028204,0.00035209296,0.00031093962,0.00018060644,0.00020669182,0.00017374785,0.00087031943,0.0048630564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049050674,0.0053722397,0.51179725,0.00090528,0.0028740128,0.00002995037,0.00044052882,0.000011701624,0.30265576,0.002126279,0.082738124,0.086143814],"study_design_scores_gemma":[0.00615474,0.00034600735,0.012551292,0.000041843094,0.00018428166,0.000021011234,0.00017435462,0.00015581379,0.022209525,0.0007888894,0.9569972,0.0003750001],"about_ca_topic_score_codex":0.000104091465,"about_ca_topic_score_gemma":0.000033398424,"teacher_disagreement_score":0.8742591,"about_ca_system_score_codex":0.00002523202,"about_ca_system_score_gemma":0.00004630303,"threshold_uncertainty_score":0.9959118},"labels":[],"label_agreement":null},{"id":"W2945495993","doi":"10.1007/s10067-019-04592-4","title":"Correction to: PANLAR consensus statement on biosimilars","year":2019,"lang":"en","type":"erratum","venue":"Clinical Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Rheumatology Association","funders":"","keywords":"Statement (logic); Biosimilar; Medicine; Rheumatology; Internal medicine; Medical physics; Epistemology; Philosophy","score_opus":0.058333901941663845,"score_gpt":0.3901206355398377,"score_spread":0.3317867335981739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945495993","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036994035,0.005772432,0.0003877646,0.02698528,0.89209265,0.0020360486,0.00064139586,0.00043779536,0.06794722],"genre_scores_gemma":[0.00797132,0.006285377,0.00093637215,0.027586522,0.00051659666,0.00010192197,0.0011546054,0.0002161163,0.9552312],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926343,0.002127307,0.0024214275,0.0016101575,0.00012395147,0.0010828498],"domain_scores_gemma":[0.9919758,0.0055356794,0.00080298824,0.0012526258,0.00024018831,0.00019274249],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0021752524,0.0007494662,0.0025707337,0.00032879235,0.00018113069,0.00003060053,0.0007217116,0.003993115,0.0031944604],"category_scores_gemma":[0.0067651267,0.0006044153,0.0007590275,0.00028813587,0.00084231363,0.000016385817,0.0003879467,0.0043697217,0.011332957],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007124616,0.00046084655,0.0015930693,0.0000856528,0.00074849394,0.00002611911,0.000017738259,0.0000015786384,0.0000733076,0.00039234813,0.98341244,0.012475965],"study_design_scores_gemma":[0.0014332853,0.0025710629,0.0018201773,0.0006558678,0.00022333185,0.00013078857,0.000052176372,0.00002861327,0.00032816528,0.00022085347,0.99184626,0.0006894129],"about_ca_topic_score_codex":0.000049249247,"about_ca_topic_score_gemma":0.000078231635,"teacher_disagreement_score":0.89157605,"about_ca_system_score_codex":0.00014307826,"about_ca_system_score_gemma":0.0005831808,"threshold_uncertainty_score":0.9996407},"labels":[],"label_agreement":null},{"id":"W2947136960","doi":"10.1200/jco.2019.37.15_suppl.6550","title":"Minimizing drug wastage (DW) and cost of cabazitaxel used to treat metastatic castrate-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cabazitaxel; Vial; Medicine; Taxane; Prostate cancer; Internal medicine; Cancer; Androgen deprivation therapy; Breast cancer","score_opus":0.1360054522753275,"score_gpt":0.4651577656908596,"score_spread":0.3291523134155321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947136960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98911893,0.002749783,0.0000682386,0.0052273646,0.001427712,0.00042122396,0.000102143546,0.0000060736697,0.0008785321],"genre_scores_gemma":[0.9878717,0.00068308733,0.0057610436,0.0010831741,0.000091172995,0.000006519704,0.0000023942584,0.000019219488,0.004481666],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956663,0.00119814,0.0023392076,0.000298905,0.00010371928,0.0003937206],"domain_scores_gemma":[0.9943793,0.003387779,0.0014893971,0.00020947985,0.00033673563,0.000197336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003697183,0.00021696264,0.001964255,0.0001539749,0.00004710101,0.00001205152,0.0002556973,0.00034131098,0.00069568807],"category_scores_gemma":[0.0012004755,0.00014189225,0.00036097338,0.00017623938,0.0004172672,0.00009710542,0.00011100694,0.0008388484,0.000027863032],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023262307,0.0029763589,0.059280902,0.00044442294,0.0027553258,0.00064858055,0.0018121647,0.000094161136,0.5796012,0.00078643346,0.018930096,0.30940804],"study_design_scores_gemma":[0.04929459,0.044368878,0.16651306,0.0011905732,0.00421945,0.0010629143,0.006537766,0.000109505,0.13370647,0.0011854033,0.59039384,0.0014175498],"about_ca_topic_score_codex":0.00014556991,"about_ca_topic_score_gemma":0.00027679797,"teacher_disagreement_score":0.57146376,"about_ca_system_score_codex":0.00007207819,"about_ca_system_score_gemma":0.00066620664,"threshold_uncertainty_score":0.76172966},"labels":[],"label_agreement":null},{"id":"W2947268672","doi":"10.1007/s12325-019-00986-7","title":"Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto; Pfizer","keywords":"Medicine; Biosimilar; Rheumatoid arthritis; Methotrexate; Rheumatology; Internal medicine; Antirheumatic Agents; Arthritis; Intensive care medicine; Oncology; Pharmacology","score_opus":0.01538381736389248,"score_gpt":0.2861293139357488,"score_spread":0.2707454965718563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947268672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904567,0.0077326237,0.00012380208,0.000048023936,0.00015307832,0.0012981334,0.00009828744,0.000020905249,0.00006846313],"genre_scores_gemma":[0.98696285,0.010367367,0.002300513,0.0000938278,0.0000028567538,0.00019069882,0.000025040266,0.000021937012,0.000034924175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981781,0.00065981905,0.00029294664,0.00044311688,0.00004934229,0.00037666628],"domain_scores_gemma":[0.9988557,0.0005662025,0.00014913795,0.00031864483,0.000086946224,0.000023337345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003594614,0.00031151596,0.0006956474,0.00015554974,0.000024946927,0.000011405045,0.00017510152,0.00022580112,0.00025972378],"category_scores_gemma":[0.000016191474,0.00015029556,0.000059521448,0.00046352262,0.0002984789,0.00025694867,0.00002211755,0.00020113193,0.000006439521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01901097,0.0006057091,0.88531923,0.000023291974,0.00015912131,0.000007980833,0.00018998227,0.0000141412675,0.002567004,0.00007621506,0.0000017327042,0.09202463],"study_design_scores_gemma":[0.031717107,0.020748088,0.7621906,0.0010296799,0.000016073007,0.000010819326,0.00028195314,0.0000030895324,0.13365704,0.000671946,0.048912667,0.00076097425],"about_ca_topic_score_codex":0.0000322281,"about_ca_topic_score_gemma":0.00025710132,"teacher_disagreement_score":0.13109004,"about_ca_system_score_codex":0.00007879198,"about_ca_system_score_gemma":0.00005488522,"threshold_uncertainty_score":0.6128875},"labels":[],"label_agreement":null},{"id":"W2952089805","doi":"10.1111/bjd.18220","title":"<scp>AURIEL</scp> ‐PsO: a randomized, double‐blind phase <scp>III</scp> equivalence trial to demonstrate the clinical similarity of the proposed biosimilar <scp>MSB</scp> 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Fresenius Kabi; Merck","keywords":"Biosimilar; Equivalence (formal languages); Medicine; Double blind; Similarity (geometry); Adalimumab; Mathematics; Computer science; Internal medicine; Artificial intelligence; Discrete mathematics; Disease; Pathology","score_opus":0.03661824537907298,"score_gpt":0.32251316386995915,"score_spread":0.28589491849088616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952089805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98876345,0.0019893283,0.0005187858,0.0016659494,0.0021133586,0.004294319,0.00018222026,0.00002878109,0.00044382134],"genre_scores_gemma":[0.99546444,0.0005729523,0.0011899368,0.0021249123,0.00014395277,0.00005859232,0.000020787611,0.000056576228,0.0003678414],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9903391,0.0039749625,0.0029828178,0.00091636425,0.00047211966,0.0013146519],"domain_scores_gemma":[0.9908943,0.0052558426,0.0015539288,0.00084191316,0.0010975106,0.0003564671],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0033470362,0.00064242026,0.002808069,0.0003741717,0.00035079703,0.00014230111,0.0018608348,0.0011767541,0.00006221641],"category_scores_gemma":[0.005390784,0.00042838368,0.0006344426,0.0011742311,0.001050786,0.00028217828,0.00057689537,0.002468423,0.000057895515],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8164873,0.011305099,0.038081255,0.00055859674,0.0064002792,0.0011249566,0.0032451411,0.00071940967,0.013901809,0.0012911105,0.08654119,0.020343829],"study_design_scores_gemma":[0.91097915,0.0073959576,0.007944192,0.0012606705,0.0011012589,0.0038942015,0.0009032013,0.00009819673,0.05236165,0.00061542273,0.013165389,0.00028072632],"about_ca_topic_score_codex":0.000106385625,"about_ca_topic_score_gemma":0.0003441524,"teacher_disagreement_score":0.09449181,"about_ca_system_score_codex":0.00014491893,"about_ca_system_score_gemma":0.0012454287,"threshold_uncertainty_score":0.9998329},"labels":[],"label_agreement":null},{"id":"W2955764585","doi":"","title":"Безопасность биологических препаратов. Сообщение 2. Проблемы безопасности биоподобных препаратов","year":2016,"lang":"ru","type":"article","venue":"Biological Products Prevention Diagnosis Treatment","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Pharmacovigilance; Medicine; Infliximab; Interchangeability; Ulcerative colitis; Inflammatory bowel disease; Marketing authorization; Disease; Intensive care medicine; Pharmacology; Drug; Internal medicine; Bioinformatics","score_opus":0.10569599546046901,"score_gpt":0.33729123216130036,"score_spread":0.23159523670083135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955764585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55742663,0.17269611,0.0026165561,0.21785572,0.019310804,0.015043684,0.0035696612,0.002193967,0.009286862],"genre_scores_gemma":[0.87638086,0.053867668,0.0040875035,0.0010507467,0.0017700754,0.001533643,0.0003337016,0.00013465628,0.06084113],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9877427,0.0036884,0.0022013714,0.0035977643,0.0003171135,0.002452655],"domain_scores_gemma":[0.993964,0.0019612047,0.0009775499,0.0021207281,0.00049743615,0.00047905665],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0018031723,0.0018709797,0.0023051077,0.00040109336,0.0008309379,0.00015041098,0.0010946995,0.0025312367,0.015421697],"category_scores_gemma":[0.0023125368,0.0010266801,0.001511386,0.0009671995,0.002108088,0.00037690136,0.0006752801,0.0006404527,0.005118563],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015947182,0.016264455,0.038381733,0.00017305212,0.0040683667,0.00016169193,0.00017426789,9.5324145e-7,0.070494056,0.008336676,0.05432185,0.8060282],"study_design_scores_gemma":[0.0067089503,0.010722539,0.03260662,0.00081029884,0.0013035992,0.00009599084,0.000113482776,0.0000015753492,0.21978779,0.0042450326,0.7218658,0.0017383496],"about_ca_topic_score_codex":0.00014102395,"about_ca_topic_score_gemma":0.0000766269,"teacher_disagreement_score":0.8042898,"about_ca_system_score_codex":0.0011119698,"about_ca_system_score_gemma":0.00038510893,"threshold_uncertainty_score":0.9994035},"labels":[],"label_agreement":null},{"id":"W2957939626","doi":"10.1038/s41565-019-0523-x","title":"Publisher Correction: On the issue of transparency and reproducibility in nanomedicine","year":2019,"lang":"en","type":"erratum","venue":"Nature Nanotechnology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Transparency (behavior); Nanomedicine; Reproducibility; Nanotechnology; Computer science; Data science; Materials science; Computer security; Chemistry; Nanoparticle","score_opus":0.012157971710700384,"score_gpt":0.2733586332967566,"score_spread":0.2612006615860562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957939626","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007294216,0.14072718,0.000031548145,0.24695723,0.5127825,0.0029929962,0.00015938096,0.00033342422,0.088721484],"genre_scores_gemma":[0.1922287,0.004172892,0.00010953824,0.0059513445,0.00047744773,0.00006411458,0.00021167246,0.00007091104,0.79671335],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969249,0.00039693963,0.0006318467,0.0015550735,0.00008938194,0.00040190935],"domain_scores_gemma":[0.9967636,0.00046767923,0.0003078226,0.0023060578,0.0001399712,0.000014857159],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0021725718,0.00037115085,0.0010672504,0.00044886032,0.00006369837,0.000007996324,0.0006636033,0.009063511,0.0008937488],"category_scores_gemma":[0.004278402,0.00022088116,0.00012984347,0.0007549521,0.0011003355,0.000034256092,0.00014538519,0.008178343,0.000026497408],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013389111,0.00013541643,0.00075428846,0.00010972269,0.000110446854,0.000004636387,0.000039498358,6.889397e-8,0.002283878,0.0012598407,0.9779923,0.017176017],"study_design_scores_gemma":[0.00056025124,0.0006302163,0.0031066015,0.00023149762,0.000084886946,0.000045941906,0.0000642048,0.0000020348823,0.006045109,0.0020245695,0.9869749,0.00022978632],"about_ca_topic_score_codex":0.00006554853,"about_ca_topic_score_gemma":0.00010912246,"teacher_disagreement_score":0.7079919,"about_ca_system_score_codex":0.00006697202,"about_ca_system_score_gemma":0.00013762628,"threshold_uncertainty_score":0.9941098},"labels":[],"label_agreement":null},{"id":"W2958369991","doi":"10.1186/s12887-019-1590-8","title":"Parental perspectives on retention and secondary use of neonatal dried bloodspots: a Dutch mixed methods study","year":2019,"lang":"en","type":"article","venue":"BMC Pediatrics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Medicine; Focus group; Intervention (counseling); Parental consent; Informed consent; Perception; Population; Medical education; Nursing; Pediatrics; Environmental health; Psychology; Alternative medicine; Marketing","score_opus":0.03371346559586684,"score_gpt":0.3207610699277613,"score_spread":0.28704760433189447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958369991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511015,0.0024896113,0.00095354416,0.000028618248,0.00065505697,0.00043456725,0.000090256755,0.00003164368,0.00020654227],"genre_scores_gemma":[0.9744182,0.00018103448,0.024354272,0.00004145522,0.00004869476,0.0000076477845,0.000021143864,0.0000148878025,0.0009126294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980276,0.0009248523,0.00032849552,0.0004308608,0.00006166663,0.00022647655],"domain_scores_gemma":[0.9985305,0.0009007517,0.0001603616,0.00028820097,0.00008705292,0.000033104177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084533123,0.00017824833,0.0003767223,0.00016617027,0.00006685875,0.000019587702,0.00011920403,0.00025619383,0.00035965708],"category_scores_gemma":[0.00042995551,0.00014486106,0.00012299308,0.00024412133,0.00013884014,0.000096539865,0.00014329249,0.0003390073,0.000021164666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016534049,0.001983053,0.90770555,0.00021313758,0.000432782,0.000008971414,0.004370424,0.0000027388674,0.035661824,0.0016777443,0.0019421777,0.04434822],"study_design_scores_gemma":[0.00572123,0.0036100007,0.9256875,0.00002212981,0.0006514362,0.00004315052,0.041756384,0.00005258014,0.016676813,0.00036296522,0.0048197154,0.00059609476],"about_ca_topic_score_codex":0.000031587897,"about_ca_topic_score_gemma":0.000014455312,"teacher_disagreement_score":0.043752126,"about_ca_system_score_codex":0.000019453395,"about_ca_system_score_gemma":0.000055842633,"threshold_uncertainty_score":0.59072626},"labels":[],"label_agreement":null},{"id":"W2960106648","doi":"10.1007/s40120-019-0145-0","title":"Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?","year":2019,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Biopharmaceutical; Multiple sclerosis; Pharmacy; Intensive care medicine; Family medicine; Internal medicine; Psychiatry; Biotechnology","score_opus":0.037013532446487245,"score_gpt":0.2776106795977571,"score_spread":0.24059714715126984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960106648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934867,0.0014509632,0.00013055353,0.0027949307,0.0013747625,0.00040837788,0.00010272927,0.00006500733,0.00018598103],"genre_scores_gemma":[0.988175,0.0016274275,0.000705561,0.0084990105,0.000079967074,0.000034023982,0.000031554922,0.000021184294,0.0008262891],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987055,0.00034642505,0.00020832404,0.00042961506,0.000028883447,0.00028124673],"domain_scores_gemma":[0.9990504,0.00048939773,0.00010169115,0.00027066935,0.000051526677,0.000036349447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044647997,0.0001743201,0.00028140374,0.000090178204,0.00014469746,0.000015712036,0.00022590949,0.00044065405,0.0007538673],"category_scores_gemma":[0.00007012883,0.00012151566,0.000090825306,0.00006990565,0.00025152776,0.00008337277,0.000043995315,0.0002986419,0.000027267146],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04190328,0.0009800268,0.19585438,0.000027454777,0.0012312862,0.000005623169,0.0007960505,0.000007783105,0.49895626,0.0038388474,0.0065402607,0.24985875],"study_design_scores_gemma":[0.01856844,0.0069847,0.21170491,0.000019135361,0.00010368168,0.0000762035,0.00018671626,0.0008048499,0.09664088,0.0033662263,0.66090816,0.00063610805],"about_ca_topic_score_codex":0.000014654105,"about_ca_topic_score_gemma":0.00000990489,"teacher_disagreement_score":0.6543679,"about_ca_system_score_codex":0.000004059601,"about_ca_system_score_gemma":0.000021747781,"threshold_uncertainty_score":0.8254319},"labels":[],"label_agreement":null},{"id":"W2967873913","doi":"10.1016/j.jpba.2019.112802","title":"Part 2: Physicochemical characterization of bevacizumab in 2 mg/mL antibody solutions as used in human i.v. administration: Comparison of originator with a biosimilar candidate","year":2019,"lang":"en","type":"article","venue":"Journal of Pharmaceutical and Biomedical Analysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Chemistry; Biosimilar; Bevacizumab; Chromatography; Dilution","score_opus":0.026730115548474837,"score_gpt":0.37929976371065377,"score_spread":0.35256964816217895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967873913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974349,0.00033668973,0.0004178585,0.0015366483,0.00007786748,0.00010565885,0.00005443522,0.0000032346488,0.000032720774],"genre_scores_gemma":[0.99947315,0.0001357275,0.00014574766,0.000079937214,0.00003063437,0.0000013840178,0.00008945322,0.0000049427467,0.000039020404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806213,0.00024778733,0.0010267392,0.00021365269,0.00018753136,0.0002621373],"domain_scores_gemma":[0.9990392,0.00014979023,0.00045745555,0.000116050374,0.00013221486,0.000105315754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006423805,0.00015732541,0.00096409215,0.0004965178,0.00003397939,0.000009336151,0.0001600476,0.00023338952,0.00075885956],"category_scores_gemma":[0.000050469345,0.00010359136,0.00019160914,0.0012537304,0.00056849024,0.00009342838,0.000048338312,0.00045713666,0.0000021618073],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063513505,0.0012621892,0.12189616,0.000073980504,0.00075493386,0.000013265245,0.000089815425,0.0000012439452,0.8739414,0.00029058955,0.000020020077,0.001021215],"study_design_scores_gemma":[0.007589707,0.0027803045,0.09554979,0.00040536144,0.0028178568,0.00007161692,0.0003366008,0.0019551418,0.88097996,0.00019264924,0.0069417376,0.00037925367],"about_ca_topic_score_codex":0.000024649267,"about_ca_topic_score_gemma":0.000019284711,"teacher_disagreement_score":0.02634637,"about_ca_system_score_codex":0.000033357617,"about_ca_system_score_gemma":0.00011360163,"threshold_uncertainty_score":0.830898},"labels":[],"label_agreement":null},{"id":"W2971404000","doi":"10.33380//2305-2066-2019-8-3-91-100","title":"A Comparative Parallel Study of Pharmacokinetics and Immunogenicity Following Single Intravenous Administration of Bevacizumab Biosimilar RPH-001 (Manufactured by R-Pharm Group, Russia) and Avastin® (Manufactured by F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Male Volunteers","year":2019,"lang":"en","type":"article","venue":"Drug development & registration","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Public Health Association","funders":"","keywords":"Bevacizumab; Medicine; Pharmacokinetics; Immunogenicity; Biosimilar; Pharmacology; Antibody; Internal medicine; Immunology; Chemotherapy","score_opus":0.015063345169092792,"score_gpt":0.27465102252259677,"score_spread":0.25958767735350396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971404000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949386,0.0029254379,0.00037915658,0.0002843287,0.00016865063,0.0010699253,0.00005783808,0.00002016254,0.00015587357],"genre_scores_gemma":[0.9974439,0.00018539622,0.0014586548,0.00009591951,0.0000069674725,0.000027286935,0.00046205684,0.000015171595,0.00030461923],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976318,0.0004361753,0.00091535965,0.00052903855,0.0001525774,0.00033505313],"domain_scores_gemma":[0.9990533,0.00016986085,0.0004651214,0.00019730703,0.00005711127,0.000057292582],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071163685,0.00034009438,0.000714556,0.0001277429,0.00010698008,0.000034749475,0.00016146741,0.00026705736,0.000053114934],"category_scores_gemma":[0.000028595505,0.00030572392,0.000057003344,0.00014789228,0.00016799352,0.00013475645,0.00006320216,0.00033850333,0.0000023713114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045105107,0.004025992,0.0071712607,0.0002586308,0.0008196025,0.000012175037,0.01017181,0.000015760748,0.9640881,0.000023642899,0.0021391534,0.006763393],"study_design_scores_gemma":[0.017667389,0.0039099287,0.043343496,0.0001758681,0.00038664218,0.000066519264,0.005127229,0.00020906825,0.91680664,0.00006719563,0.011334606,0.00090539776],"about_ca_topic_score_codex":0.00014844007,"about_ca_topic_score_gemma":0.00025765487,"teacher_disagreement_score":0.047281407,"about_ca_system_score_codex":0.00008604735,"about_ca_system_score_gemma":0.000097996744,"threshold_uncertainty_score":0.9999395},"labels":[],"label_agreement":null},{"id":"W2972508118","doi":"","title":"Biosimilars versus biologics for inflammatory conditions.","year":2019,"lang":"en","type":"article","venue":"PubMed","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Biosimilar; Medicine; Computer science; Data science; World Wide Web; Internal medicine","score_opus":0.04090798055579421,"score_gpt":0.27433082721929813,"score_spread":0.23342284666350394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972508118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91216445,0.004719532,0.00082314847,0.009547001,0.02731041,0.00718968,0.0010186863,0.00065445225,0.036572658],"genre_scores_gemma":[0.9921293,0.00006046302,0.00061668805,0.0013528706,0.00008588335,0.0010722573,0.00011094291,0.00001784078,0.0045536994],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989608,0.00009087982,0.00020842107,0.00027262385,0.00002029995,0.0004470027],"domain_scores_gemma":[0.99896145,0.00063859427,0.000072734234,0.0002350074,0.000057696205,0.000034512694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004263016,0.00013461309,0.00022010646,0.00007017266,0.000082941624,0.000012863333,0.00018391163,0.0003335435,0.0004765364],"category_scores_gemma":[0.00033046276,0.000103842794,0.00014282831,0.00009823156,0.00017920458,0.00004937735,0.000054325486,0.00015003726,0.00021037593],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00608333,0.00073581,0.063464925,0.00031597272,0.0022264526,0.000008726242,0.000107315,0.000010781843,0.16035222,0.07459364,0.37648505,0.31561577],"study_design_scores_gemma":[0.00411684,0.00021365598,0.10476842,0.00000588507,0.000105915286,0.0000064125497,0.00006615072,0.000006902049,0.06570495,0.0013370509,0.8233269,0.0003409344],"about_ca_topic_score_codex":9.651782e-7,"about_ca_topic_score_gemma":0.000001883284,"teacher_disagreement_score":0.44684184,"about_ca_system_score_codex":0.000031600506,"about_ca_system_score_gemma":0.000017709961,"threshold_uncertainty_score":0.52177393},"labels":[],"label_agreement":null},{"id":"W2973451510","doi":"10.22270/jddt.v9i4-s.3334","title":"Challenges Faced During eCTD and CTD Filling Procedures for USFDA and Canada","year":2019,"lang":"en","type":"article","venue":"Journal of Drug Delivery and Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Agency (philosophy); CTD; Authorization; Business; Regulatory affairs; Political science; Computer science; Public administration; Computer security; Sociology","score_opus":0.02301051649082952,"score_gpt":0.25746372948361684,"score_spread":0.23445321299278732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973451510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9476486,0.050555028,0.000015613266,0.0013857342,0.00022162529,0.00009866075,0.000010537533,0.0000030046588,0.00006119931],"genre_scores_gemma":[0.98122567,0.017676724,0.00036447743,0.00036252214,0.000035819976,6.7919973e-7,5.051541e-7,0.000007282236,0.0003263357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994088,0.000059808306,0.00020762262,0.00012040842,0.00003095489,0.00017244415],"domain_scores_gemma":[0.99943876,0.00025814862,0.00013091588,0.000054459153,0.00008381371,0.000033904784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002563087,0.0001092839,0.00025222055,0.00004061882,0.0000989703,0.000016142318,0.000057212932,0.00010238482,0.000011466582],"category_scores_gemma":[0.00001783244,0.00007696206,0.000034891254,0.000018802222,0.00006699551,0.00006103813,0.00002941087,0.00018506237,1.8896603e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036235072,0.00022071725,0.04498786,0.002080951,0.004076113,0.000037208494,0.005601512,0.000022174125,0.7980332,0.0019633109,0.00073851534,0.13861497],"study_design_scores_gemma":[0.020558072,0.0032877363,0.16432925,0.0015244638,0.0021961096,0.0035232336,0.021971907,0.0005543819,0.5296778,0.00715455,0.24316593,0.0020565405],"about_ca_topic_score_codex":0.00055159646,"about_ca_topic_score_gemma":0.006502923,"teacher_disagreement_score":0.26835534,"about_ca_system_score_codex":0.000013768733,"about_ca_system_score_gemma":0.000081478174,"threshold_uncertainty_score":0.36287838},"labels":[],"label_agreement":null},{"id":"W2977861177","doi":"10.1002/cpt.1622","title":"The Future of Precision Medicine","year":2019,"lang":"en","type":"editorial","venue":"Clinical Pharmacology & Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"","keywords":"Pharmacogenomics; Precision medicine; Therapeutic drug monitoring; Personalized medicine; Medicine; Intensive care medicine; Key (lock); Clinical pharmacology; Drug; Medical physics; Pharmacology; Bioinformatics; Computer science; Biology; Pathology","score_opus":0.05672421129191929,"score_gpt":0.4516181753745289,"score_spread":0.3948939640826096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977861177","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010830527,0.06706346,0.000048405815,0.015221933,0.9162613,0.0004901693,0.00013071224,0.00003880655,0.00063692353],"genre_scores_gemma":[0.00015738988,0.10566321,0.00015560767,0.012849993,0.8644699,0.000020199806,0.00016714189,0.00007431804,0.016442271],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99437445,0.002543465,0.0016771976,0.0006570005,0.00018485631,0.00056299753],"domain_scores_gemma":[0.9711976,0.026511915,0.000941506,0.0007293989,0.0005651723,0.000054386077],"candidate_categories":["sts","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0038081144,0.0004618417,0.001466861,0.00007358418,0.00022143102,0.000009067097,0.001428815,0.0046552243,0.0012354251],"category_scores_gemma":[0.00034959443,0.00024378831,0.0005405284,0.00019992892,0.0031634879,0.00002401125,0.00032964753,0.0041349363,0.00022532622],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012131599,0.00021319327,0.000050607203,0.000040018356,0.002248,0.0000022812192,0.000023799454,1.7544085e-7,0.004409153,0.00003246679,0.94107467,0.050692454],"study_design_scores_gemma":[0.0027343114,0.0015638599,0.00008856449,0.00006216191,0.002575739,0.0000023259133,0.000046319903,0.0000060271855,0.0013593831,0.0004185239,0.9908949,0.00024785474],"about_ca_topic_score_codex":0.000003281012,"about_ca_topic_score_gemma":0.0000046072428,"teacher_disagreement_score":0.051791415,"about_ca_system_score_codex":0.00004365227,"about_ca_system_score_gemma":0.00039167012,"threshold_uncertainty_score":0.9996776},"labels":[],"label_agreement":null},{"id":"W2978074964","doi":"10.4155/bio-2019-0207","title":"GCC Consolidated Feedback to ICH on the 2019 ICH M10 Bioanalytical Method Validation Draft Guideline","year":2019,"lang":"de","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NEOMED Institute; Lambda Therapeutic Research; Pharma Medica Research (Canada); Grand Challenges Canada; Altasciences (Canada); Green Communities Canada; Royal Canadian Military Institute; Celerion (Canada)","funders":"","keywords":"Guideline; Bioanalysis; Attendance; Engineering; Political science; Nanotechnology; Law; Materials science","score_opus":0.02036949132567383,"score_gpt":0.32189882814242204,"score_spread":0.3015293368167482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978074964","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.077899456,0.06975008,0.08366418,0.67841756,0.02298365,0.011311386,0.0077066533,0.0010879368,0.04717911],"genre_scores_gemma":[0.5792427,0.0048069484,0.072282,0.08493954,0.002703546,0.00014461175,0.0038724148,0.0005056395,0.2515026],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99004585,0.0037089533,0.00222769,0.0020064046,0.00048034464,0.0015307881],"domain_scores_gemma":[0.9927662,0.0027211562,0.0006647881,0.002624211,0.0008646635,0.00035899042],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0055092745,0.0010848306,0.002070348,0.0009117824,0.0005064507,0.00029461976,0.0015470765,0.0016164711,0.032132864],"category_scores_gemma":[0.001551864,0.00071103463,0.0013834846,0.003236254,0.0006188715,0.00012168448,0.00062761584,0.0014453704,0.03169617],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031712814,0.0030203734,0.0051003685,0.00015178893,0.035516858,0.00006398109,0.0005105942,0.0005267189,0.17613195,0.0231754,0.6970634,0.05556731],"study_design_scores_gemma":[0.001645281,0.0009823518,0.0011754663,0.00015199766,0.008293572,0.000017104809,0.00043358587,0.0037402385,0.10450632,0.00045238156,0.87726647,0.0013352289],"about_ca_topic_score_codex":0.00040377746,"about_ca_topic_score_gemma":0.00003940836,"teacher_disagreement_score":0.593478,"about_ca_system_score_codex":0.00027951953,"about_ca_system_score_gemma":0.0002759113,"threshold_uncertainty_score":0.9996796},"labels":[],"label_agreement":null},{"id":"W2978147562","doi":"10.22270/ijdra.v7i3.341","title":"Regulatory architecture of biosimilars in Singapore: A critical overview","year":2019,"lang":"en","type":"article","venue":"International Journal of Drug Regulatory Affairs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Business; Biological drugs; Product (mathematics); Agency (philosophy); Medicine; Clinical trial; Traditional medicine; Disease","score_opus":0.013321512832161105,"score_gpt":0.29787116975175737,"score_spread":0.28454965691959627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978147562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97341025,0.011052544,0.000136912,0.0077631003,0.004259076,0.00017112502,0.00004651263,0.000016776972,0.0031436973],"genre_scores_gemma":[0.99743503,0.00012246828,0.0015182409,0.00037771862,0.000098707445,9.1817975e-7,0.0000035433297,0.000016911215,0.00042646955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979881,0.00033989773,0.00092880183,0.00022488864,0.00026437046,0.00025391346],"domain_scores_gemma":[0.9983731,0.00046437958,0.0004455396,0.00025749422,0.00040608365,0.000053434873],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011630489,0.0001928552,0.00052507606,0.00045272615,0.000021095042,0.000015078434,0.00063616084,0.00024871825,0.0011547004],"category_scores_gemma":[0.00033654674,0.00015368257,0.00035787828,0.0001777646,0.00042481037,0.00015761252,0.00012028224,0.0005813497,0.000021727441],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033651185,0.0021111765,0.084076256,0.0004564873,0.002809864,0.00037493024,0.002067261,0.0005498828,0.7755737,0.06140202,0.020985464,0.046227872],"study_design_scores_gemma":[0.011645158,0.0012313966,0.2555232,0.004574295,0.00047543016,0.0028012348,0.0037553536,0.00009855743,0.57756436,0.034765005,0.106187224,0.0013788192],"about_ca_topic_score_codex":0.0000043513483,"about_ca_topic_score_gemma":0.000007654693,"teacher_disagreement_score":0.19800934,"about_ca_system_score_codex":0.00010795705,"about_ca_system_score_gemma":0.00016231848,"threshold_uncertainty_score":0.99975836},"labels":[],"label_agreement":null},{"id":"W2980598391","doi":"10.1177/1715163519879411","title":"A brief overview of biosimilars and factors limiting their uptake","year":2019,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Biosimilar; Limiting; Risk analysis (engineering); Business; Medicine; Engineering; Internal medicine; Mechanical engineering","score_opus":0.06587248221263783,"score_gpt":0.2883134712677162,"score_spread":0.2224409890550784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980598391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850208,0.010693649,0.000014445077,0.00017926826,0.001851838,0.00024707455,0.0006984823,0.0000142822955,0.0012801612],"genre_scores_gemma":[0.9896633,0.0070219496,0.00013961828,0.0024171486,0.00009213395,0.0000020454763,0.0000182091,0.000032830027,0.0006127694],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780935,0.00026275218,0.0006179267,0.00036621167,0.00009273824,0.00085104984],"domain_scores_gemma":[0.99837095,0.00024949305,0.00029502518,0.00022053649,0.00026608678,0.0005978959],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065708125,0.00035121955,0.0005846611,0.00025926493,0.00037724225,0.000059944487,0.00043414705,0.00015313944,0.0025038668],"category_scores_gemma":[0.00016312143,0.00029509806,0.00018600884,0.00039215095,0.00032966796,0.00017066665,0.00006673436,0.0007047076,0.0000064032497],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003948919,0.00019019235,0.08159803,0.0014602495,0.0026176139,0.0075508547,0.003093183,0.0000943428,0.46289736,0.0008384329,0.043204974,0.39605987],"study_design_scores_gemma":[0.005142457,0.00030289308,0.002355886,0.0002074919,0.0005371532,0.24572945,0.00017037147,0.0006785453,0.19571863,0.00024833775,0.5473727,0.0015360753],"about_ca_topic_score_codex":0.0059311404,"about_ca_topic_score_gemma":0.014973379,"teacher_disagreement_score":0.50416774,"about_ca_system_score_codex":0.0004127269,"about_ca_system_score_gemma":0.0012631518,"threshold_uncertainty_score":0.9999501},"labels":[],"label_agreement":null},{"id":"W2981763433","doi":"","title":"Biosimilars in oncology in Canada and the role of nurses","year":2019,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Interchangeability; Medicine; Pharmacology; Internal medicine; Computer science","score_opus":0.10049858421584852,"score_gpt":0.5030752688098168,"score_spread":0.4025766845939683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981763433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9512526,0.039367147,0.0000016610402,0.0006645225,0.00066367886,0.00041654258,0.00003475872,0.0000029303756,0.0075961514],"genre_scores_gemma":[0.99303055,0.00603022,0.000052219857,0.0005774593,0.00001150654,0.000011336453,0.0000024715405,0.000011860998,0.0002723751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976549,0.000860706,0.00079386024,0.00027357237,0.000091764574,0.00032515425],"domain_scores_gemma":[0.9978956,0.0012237111,0.00047104686,0.0002826897,0.00008474723,0.000042209947],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015466989,0.00018281148,0.00093664223,0.000341731,0.00004575681,0.00004166354,0.0012129704,0.00019398108,0.0064085913],"category_scores_gemma":[0.0002865846,0.00011996335,0.000083592706,0.0005489864,0.0003989669,0.00025541938,0.0004901882,0.0005244902,0.0000033297836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006980152,0.00012507242,0.8364644,0.000025039053,0.000121396435,0.0000067552446,0.00012277499,0.000010113724,0.13852742,0.00029616038,0.003896376,0.019706491],"study_design_scores_gemma":[0.0023164835,0.000025332814,0.84734064,0.00020056672,0.00005344743,0.000017660353,0.000671458,0.000030593572,0.10159379,0.0053427834,0.04219216,0.00021505881],"about_ca_topic_score_codex":0.4336525,"about_ca_topic_score_gemma":0.37953287,"teacher_disagreement_score":0.05411964,"about_ca_system_score_codex":0.00014448867,"about_ca_system_score_gemma":0.0005310788,"threshold_uncertainty_score":0.9944997},"labels":[],"label_agreement":null},{"id":"W2981766175","doi":"10.1016/j.biologicals.2019.10.008","title":"Quality changes to approved biotherapeutic product: Simulated case studies on reporting categories &amp; supporting data requirements","year":2019,"lang":"en","type":"review","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"World Health Organization","keywords":"Quality (philosophy); Product (mathematics); Business; Process management; Process (computing); Order (exchange); Operations management; Risk analysis (engineering); Computer science; Engineering; Finance","score_opus":0.7420894449380853,"score_gpt":0.5846845918852744,"score_spread":0.15740485305281082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981766175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005952719,0.99347055,0.0000256936,0.0007160174,0.0017127316,0.0024607826,0.0006816925,0.00019435321,0.00014290753],"genre_scores_gemma":[0.00091068645,0.98991805,0.0013141843,0.0014694394,0.00027015616,0.00008930847,0.0016751159,0.00006393601,0.004289126],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99106985,0.0023568235,0.0033619374,0.002185539,0.000094904935,0.0009309708],"domain_scores_gemma":[0.9909974,0.0019533366,0.004229553,0.0025172657,0.0002236652,0.0000787813],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0087078,0.00087845256,0.0043286495,0.00020396398,0.00034229385,0.000054541986,0.0009768527,0.0011210685,0.00024278877],"category_scores_gemma":[0.017847743,0.00048842025,0.00037679417,0.0005380013,0.0004056999,0.000049481412,0.0013258035,0.00078332535,0.0004233769],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009183346,0.0002669553,0.000049171926,0.00706651,0.0027137804,0.00021059207,0.00012693454,6.160254e-7,0.002061877,0.00017083333,0.0030522982,0.9841886],"study_design_scores_gemma":[0.00018209829,0.00039637333,0.0000049501796,0.0017284062,0.00084868283,0.0004616077,0.00013298764,5.0967157e-7,0.00031987007,0.00007216753,0.9951104,0.0007419722],"about_ca_topic_score_codex":0.00004956696,"about_ca_topic_score_gemma":0.000052797175,"teacher_disagreement_score":0.9920581,"about_ca_system_score_codex":0.000121242556,"about_ca_system_score_gemma":0.0001337652,"threshold_uncertainty_score":0.99975675},"labels":[],"label_agreement":null},{"id":"W2982052459","doi":"","title":"Les médicaments biosimilaires en oncologie au canada : rôle des infirmières","year":2019,"lang":"fr","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Humanities; Art","score_opus":0.26218290964797836,"score_gpt":0.5544275177718251,"score_spread":0.2922446081238467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982052459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8119169,0.15504344,0.000072841416,0.0045068236,0.0070950994,0.0008125528,0.00045676398,0.00003507164,0.020060549],"genre_scores_gemma":[0.9538039,0.030040538,0.00084890815,0.0013767875,0.00036817038,0.000025682308,0.000023395622,0.00007049808,0.013442153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99396205,0.0020987208,0.0014644945,0.0008309022,0.00036099934,0.0012828121],"domain_scores_gemma":[0.9947316,0.0027091524,0.0010643695,0.0007606543,0.00039861526,0.00033563096],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023900792,0.0007005465,0.0017113222,0.0005285103,0.00060857914,0.0004954341,0.0040706885,0.00094373594,0.07796949],"category_scores_gemma":[0.0012101117,0.0005906852,0.00040250405,0.00094322505,0.0013433213,0.0011721713,0.002312627,0.0013558978,0.000092088565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004041803,0.0004876379,0.6596074,0.0003449635,0.0012318799,0.00007129223,0.00010397258,0.000030275305,0.10640058,0.000503426,0.1389487,0.09186567],"study_design_scores_gemma":[0.0008397085,0.00008124633,0.5541207,0.0010197058,0.00031421124,0.000046606267,0.00030311412,0.0000119677425,0.07964448,0.0018494531,0.3611763,0.0005924712],"about_ca_topic_score_codex":0.625271,"about_ca_topic_score_gemma":0.26857463,"teacher_disagreement_score":0.35669643,"about_ca_system_score_codex":0.0012662327,"about_ca_system_score_gemma":0.0024468044,"threshold_uncertainty_score":0.9996545},"labels":[],"label_agreement":null},{"id":"W2984022819","doi":"10.1182/blood-2019-122751","title":"Potential and Realized Cost Savings with the Use of the Biosimilar Grastofil Vs Neupogen","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Saskatchewan","funders":"","keywords":"Biosimilar; Filgrastim; Drug Utilization Review; Medicine; Reimbursement; Business; Health care; Drug; Pharmacology; Neutropenia; Economics; Internal medicine; Economic growth","score_opus":0.01717087098169331,"score_gpt":0.22453129569567026,"score_spread":0.20736042471397695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984022819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946693,0.00049892196,0.000049822236,0.0039128643,0.00016840138,0.00040583636,0.00006374572,0.000015848815,0.00021525196],"genre_scores_gemma":[0.9963343,0.000076219854,0.0005410016,0.0013664841,0.00001496389,0.000005879901,0.000004679789,0.000011216868,0.0016452351],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99920565,0.00023193184,0.00013864727,0.00018908587,0.000040205072,0.00019447732],"domain_scores_gemma":[0.99933904,0.00015137575,0.00009696151,0.00035101656,0.000046306533,0.000015273306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018992151,0.00011698353,0.00020626195,0.00002055822,0.00010866181,0.000017469942,0.00020021247,0.00015113177,0.00016931178],"category_scores_gemma":[0.000040346942,0.000050121864,0.00007441988,0.000120829915,0.00042027017,0.000036206737,0.0001288864,0.00019336028,0.000009109951],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065061136,0.00033847024,0.05264307,0.000038587532,0.0006911445,0.0000041376124,0.00017311516,0.0000026492712,0.93348515,0.0009809171,0.0076894048,0.0033027327],"study_design_scores_gemma":[0.0077302256,0.00085657556,0.22049057,0.0001056797,0.0014257819,0.00030670644,0.00017089641,0.000027206279,0.516034,0.00014996497,0.25231028,0.00039208587],"about_ca_topic_score_codex":0.000066263055,"about_ca_topic_score_gemma":0.000023138035,"teacher_disagreement_score":0.4174511,"about_ca_system_score_codex":0.000002963201,"about_ca_system_score_gemma":0.00002287083,"threshold_uncertainty_score":0.20439103},"labels":[],"label_agreement":null},{"id":"W2985705185","doi":"10.1186/s12913-019-4680-2","title":"Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis","year":2019,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Saskatchewan","funders":"U.S. Department of Veterans Affairs","keywords":"Biosimilar; Medicine; Insulin glargine; Filgrastim; Infliximab; Hypoglycemia; Internal medicine; Insulin","score_opus":0.04182438768228328,"score_gpt":0.34002401768794316,"score_spread":0.29819963000565985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985705185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912518,0.0031312462,0.00003275558,0.003965135,0.00016659511,0.0008859125,0.00053543854,0.0000059749677,0.000025143592],"genre_scores_gemma":[0.9963822,0.00048315176,0.00042279632,0.0024877314,0.000017699756,0.000017852768,0.000033449145,0.00000996034,0.00014520978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963997,0.001804523,0.00048604017,0.00043680292,0.000248034,0.00062487565],"domain_scores_gemma":[0.99761266,0.0013085386,0.00017276949,0.0006060387,0.00023562767,0.00006439633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015372627,0.00015211989,0.0005157795,0.000176029,0.0002303311,0.000034377455,0.0005558074,0.00018854618,0.00042523586],"category_scores_gemma":[0.00012859236,0.000085705884,0.00009537856,0.0017694508,0.00026685273,0.00007338947,0.00048941455,0.00087974657,0.0000069960874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029704426,0.00005975389,0.99504805,0.00010156283,0.0002509754,0.0000013265023,0.0004875276,0.00006657942,0.0017312905,0.000043000582,0.000387544,0.0015253642],"study_design_scores_gemma":[0.0008490623,0.00008650825,0.98846996,0.00009821876,0.00005097442,0.0000015966274,0.00089062675,0.0030970739,0.00080532045,0.000067134606,0.005497337,0.00008617974],"about_ca_topic_score_codex":0.83414435,"about_ca_topic_score_gemma":0.9233427,"teacher_disagreement_score":0.08919833,"about_ca_system_score_codex":0.000370172,"about_ca_system_score_gemma":0.0012531531,"threshold_uncertainty_score":0.46560347},"labels":[],"label_agreement":null},{"id":"W2989858130","doi":"10.3389/fphar.2019.01372","title":"The Clinical Implications of Nocebo Effects for Biosimilar Therapy","year":2019,"lang":"en","type":"review","venue":"Frontiers in Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Pfizer","keywords":"Nocebo Effect; Biosimilar; Nocebo; Medicine; Intensive care medicine; Psychosocial; Adverse effect; Disease; Psychological intervention; Rheumatoid arthritis; Alternative medicine; Pharmacology; Psychiatry; Immunology; Placebo; Internal medicine","score_opus":0.1281461086588577,"score_gpt":0.4769020353471043,"score_spread":0.3487559266882466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989858130","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002660277,0.98050374,0.0014817376,0.00082140206,0.013700817,0.0030888664,0.00018431857,0.000019468802,0.0001970166],"genre_scores_gemma":[0.000005993765,0.9948836,0.0025336072,0.0006742989,0.00015745749,0.000616829,0.00006598947,0.00004102735,0.0010211817],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99580586,0.0018399965,0.0012283415,0.0005489705,0.000025701358,0.00055110344],"domain_scores_gemma":[0.99363613,0.0051618726,0.0006160865,0.00046643446,0.00008597121,0.000033476525],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017104087,0.00037441266,0.0023902017,0.00019324404,0.0001308737,0.0000075088415,0.0009193934,0.0013174696,0.000056362594],"category_scores_gemma":[0.00022608951,0.0002224346,0.0010097872,0.00031574626,0.0008469536,0.000020857595,0.00012314625,0.0008692231,0.00002349478],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119922806,0.00015006115,0.00010396178,0.001313791,0.001092487,4.983067e-7,0.0000042412985,4.0001257e-8,0.00007136459,0.00022688022,0.24554525,0.7513715],"study_design_scores_gemma":[0.001644808,0.00039305125,0.00004253339,0.00030574127,0.0012276913,0.00000752339,0.000004421969,0.0000024879384,0.00036862213,0.0006892723,0.99508667,0.000227152],"about_ca_topic_score_codex":0.000001390548,"about_ca_topic_score_gemma":9.2458606e-7,"teacher_disagreement_score":0.75114435,"about_ca_system_score_codex":0.00006633477,"about_ca_system_score_gemma":0.0003123859,"threshold_uncertainty_score":0.999979},"labels":[],"label_agreement":null},{"id":"W2990117250","doi":"","title":"BioAdvance Patient Support Program Survey: Positive Perception of Intravenous Infusions of Infliximab.","year":2017,"lang":"en","type":"article","venue":"PubMed","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Memorial University of Newfoundland; McMaster University; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Infliximab; Interquartile range; Descriptive statistics; Logistic regression; Physical therapy; Family medicine; Disease; Internal medicine","score_opus":0.03329194563647538,"score_gpt":0.2972488877772865,"score_spread":0.2639569421408111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990117250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524695,0.0001383708,0.00007016513,0.00026045757,0.0004821675,0.00080130907,0.0003252312,0.000022032717,0.0026533152],"genre_scores_gemma":[0.99854153,0.00007174473,0.00085245864,0.000044593195,0.000009760812,0.00015026084,0.000054756772,0.000006914208,0.0002680045],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989691,0.00019367476,0.0003264638,0.0001878171,0.000040578398,0.00028237904],"domain_scores_gemma":[0.9989394,0.00013265776,0.00033533107,0.00037775884,0.00018268166,0.000032175896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004828782,0.000108286215,0.00029979035,0.000056796533,0.00012882253,0.000010067306,0.00022940812,0.00019274201,0.00012610211],"category_scores_gemma":[0.0006527319,0.00008464487,0.00008927414,0.00006216829,0.0006766668,0.0000690722,0.0001414267,0.00014496804,0.0000063841567],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022375275,0.0006596122,0.028708987,0.00001886471,0.00010609841,0.0000014167356,0.00020613678,1.720583e-7,0.018479874,0.00011114657,0.00027584413,0.9512081],"study_design_scores_gemma":[0.00040540376,0.0004485599,0.9498475,0.000010754032,0.00003868996,0.000006192105,0.000065820175,0.0000011345708,0.046066176,0.00006822181,0.002946755,0.00009476677],"about_ca_topic_score_codex":0.00024974055,"about_ca_topic_score_gemma":0.000056709527,"teacher_disagreement_score":0.95111334,"about_ca_system_score_codex":0.000019906112,"about_ca_system_score_gemma":0.00002462983,"threshold_uncertainty_score":0.34517175},"labels":[],"label_agreement":null},{"id":"W2990546292","doi":"10.23736/s1121-421x.19.02625-4","title":"Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease","year":2020,"lang":"en","type":"review","venue":"Minerva Gastroenterologica e Dietologica","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Vedolizumab; Medicine; Therapeutic drug monitoring; Inflammatory bowel disease; Intensive care medicine; Drug; Clinical trial; Clinical Practice; Disease; Internal medicine; Pharmacology; Physical therapy","score_opus":0.043945532222432235,"score_gpt":0.3034427132446421,"score_spread":0.25949718102220987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990546292","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014968733,0.9956563,0.000039417107,0.0007708758,0.00045390485,0.0010375004,0.00010467079,0.00021983056,0.00022060634],"genre_scores_gemma":[0.009138976,0.9886267,0.0006290907,0.00044478604,0.00013665514,0.00042160624,0.000103291444,0.000073779695,0.00042511098],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994506,0.0016064226,0.0011415337,0.0013640709,0.00012182909,0.0012601354],"domain_scores_gemma":[0.99805194,0.00038163818,0.0005781264,0.0007240626,0.000060264465,0.00020396318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000411025,0.0011505944,0.0028631447,0.0002506693,0.00015298818,0.00006270995,0.0011359473,0.000742094,0.00030665754],"category_scores_gemma":[0.0001646629,0.0006645193,0.0007624938,0.00035525934,0.00068144593,0.000082319064,0.0004672643,0.001785668,0.00019030459],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027350173,0.0011011672,0.07171921,0.006813715,0.0017350524,0.0027881367,0.00012586938,0.0000050477493,0.00008516987,0.00014644011,0.0017353962,0.9110098],"study_design_scores_gemma":[0.0013669557,0.0012409715,0.016426183,0.0054132836,0.001450479,0.00023395398,0.00007775578,0.00000451909,0.000009420068,0.00007158336,0.9729182,0.00078667456],"about_ca_topic_score_codex":0.0000068123904,"about_ca_topic_score_gemma":0.000008953145,"teacher_disagreement_score":0.9711828,"about_ca_system_score_codex":0.00016435405,"about_ca_system_score_gemma":0.00012419336,"threshold_uncertainty_score":0.9995806},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2993442462","doi":"10.4155/bio-2019-0260","title":"2019 White Paper on Recent Issues in Bioanalysis: Chromatographic Assays (Part 1 – Innovation in Small Molecules and Oligonucleotides &amp; Mass Spectrometric Method Development Strategies for Large Molecule Bioanalysis)","year":2019,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada)","funders":"Angelini Pharma; U.S. Food and Drug Administration; Bristol-Myers Squibb; Ministry of Health, Labour and Welfare; Agence Nationale de Sécurité du Médicament et des Produits de Santé; Biogen; GlaxoSmithKline; Health Canada; AstraZeneca","keywords":"Bioanalysis; Oligonucleotide; Small molecule; Chemistry; Chromatography; Biochemical engineering; Nanotechnology; Materials science; Biochemistry; DNA; Engineering","score_opus":0.025124744011580085,"score_gpt":0.29880668751176503,"score_spread":0.27368194350018493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993442462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80019987,0.093966804,0.08121224,0.013721347,0.0008883583,0.003707027,0.00057762046,0.00039337404,0.005333388],"genre_scores_gemma":[0.7823154,0.009294024,0.2001278,0.0019725943,0.00007835174,0.00027370686,0.0012815925,0.00013426073,0.0045222924],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99512047,0.00084392156,0.0015990073,0.0012968769,0.00018386301,0.00095584197],"domain_scores_gemma":[0.99794984,0.00042068903,0.00051477674,0.0007348695,0.00031077623,0.00006904818],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034375351,0.00062320614,0.0014802342,0.0054668444,0.00015852913,0.00015913509,0.0004329074,0.00059723796,0.0010655995],"category_scores_gemma":[0.0003269663,0.00052093965,0.00038578513,0.009687512,0.00013956797,0.00020574061,0.00013948727,0.0004621571,0.000104661696],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019321406,0.0048843143,0.34396827,0.00086840306,0.022705028,0.000054962584,0.0021136191,0.0012385885,0.4496663,0.067217276,0.0024976844,0.10285341],"study_design_scores_gemma":[0.013393202,0.0015515543,0.14953552,0.0007834249,0.0059485827,0.000028559378,0.0089373365,0.0051832306,0.10939908,0.011042655,0.688589,0.005607868],"about_ca_topic_score_codex":0.0002816191,"about_ca_topic_score_gemma":0.0025690882,"teacher_disagreement_score":0.6860913,"about_ca_system_score_codex":0.00017429476,"about_ca_system_score_gemma":0.00013457096,"threshold_uncertainty_score":0.9998476},"labels":[],"label_agreement":null},{"id":"W2993637233","doi":"10.1002/ajh.25701","title":"The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease","year":2019,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Allergan; Sanofi Genzyme; Sanofi; Pfizer; Amgen","keywords":"Biosimilar; Medicine; European union; Comparability; Orphan drug; Business; International trade; Bioinformatics","score_opus":0.047903286074954005,"score_gpt":0.3767017784107156,"score_spread":0.32879849233576164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993637233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002467508,0.9930356,0.00006168931,0.0049137445,0.0010895453,0.00034341277,0.00024190413,0.0000111373765,0.00005622514],"genre_scores_gemma":[0.0008330656,0.99725,0.00041348202,0.0010883432,0.000093032344,0.000021507787,0.000025887419,0.00005036412,0.00022427844],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955508,0.0018578838,0.0013942388,0.0004577496,0.00009109093,0.0006482285],"domain_scores_gemma":[0.995239,0.0025495351,0.001286026,0.0006211445,0.0001070203,0.00019727167],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051133294,0.0004906714,0.0034032417,0.0003589716,0.00012307496,0.00003548566,0.0010505423,0.00031425242,0.00022514448],"category_scores_gemma":[0.0009045982,0.0002776122,0.00096656306,0.0005667346,0.000792575,0.000050572165,0.0002465117,0.0011294443,0.00017475565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021681597,0.00013369112,0.00052529253,0.00037998884,0.00077129796,0.00021521404,0.000039046623,4.4921728e-7,0.0000062647896,0.0002766092,0.007316151,0.99011916],"study_design_scores_gemma":[0.00034418632,0.00030441213,0.0005946517,0.004487647,0.0015556285,0.00036583852,0.00021705139,5.118466e-7,0.000009754877,0.00020458981,0.9915548,0.00036091145],"about_ca_topic_score_codex":0.000042884192,"about_ca_topic_score_gemma":0.000032226068,"teacher_disagreement_score":0.98975825,"about_ca_system_score_codex":0.0001129694,"about_ca_system_score_gemma":0.00062944693,"threshold_uncertainty_score":0.99996763},"labels":[],"label_agreement":null},{"id":"W2994012024","doi":"10.1007/s43441-019-00015-3","title":"A Quantitative Study of US FDA Inspection Data for Drug Manufacturing Sites","year":2019,"lang":"en","type":"review","venue":"Therapeutic Innovation & Regulatory Science","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada); Alphora Research (Canada)","funders":"","keywords":"Pharmacy; Government (linguistics); Database; Good manufacturing practice; Business; Pharmaceutical manufacturing; Medicine; Computer science; Data science; Pharmacology; Marketing; Family medicine","score_opus":0.2871311540716608,"score_gpt":0.44947032410972815,"score_spread":0.16233917003806736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994012024","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021017417,0.97357017,0.0008935512,0.000037784663,0.0013889227,0.0026833948,0.00018608189,0.0000770839,0.0001455874],"genre_scores_gemma":[0.1748454,0.8085062,0.008223469,0.0007609763,0.0002707684,0.00031417984,0.0014121585,0.00020788705,0.0054589976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975033,0.00030137858,0.0009016272,0.0008195904,0.00015031603,0.00032377968],"domain_scores_gemma":[0.99703276,0.00043221217,0.00089065824,0.0012491479,0.00038305655,0.000012148639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032690985,0.00030519924,0.0010536042,0.00073691923,0.00031161163,0.000037460926,0.0012185932,0.00023378417,0.000053539818],"category_scores_gemma":[0.0001502027,0.00022089884,0.000093487426,0.0017451078,0.0008415694,0.00029677575,0.0002927793,0.0003288088,0.0000230413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085497304,0.00042564495,0.000042502175,0.0025074116,0.0005695231,2.9893934e-7,0.0003330851,0.0000017091652,0.006658593,0.011846215,0.00030582582,0.9772237],"study_design_scores_gemma":[0.0010285724,0.001138275,0.0010985576,0.0014556878,0.0013519609,0.000018748735,0.00085508404,0.00010854585,0.005420069,0.00070482376,0.9861337,0.0006860076],"about_ca_topic_score_codex":0.000015732285,"about_ca_topic_score_gemma":0.00000863203,"teacher_disagreement_score":0.98582786,"about_ca_system_score_codex":0.0001041468,"about_ca_system_score_gemma":0.00042224233,"threshold_uncertainty_score":0.9007994},"labels":[],"label_agreement":null},{"id":"W2995099757","doi":"10.1016/j.jval.2019.09.2178","title":"PNS278 A REVIEW OF HEALTH TECHNOLOGY ASSESSMENT GUIDELINES ON THE APPROVAL OF BIOSIMILARS","year":2019,"lang":"en","type":"review","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biosimilar; Medicine; Drug approval; Health technology; Pharmacology; Political science; Health care; Drug; Internal medicine; Law","score_opus":0.34093109077958933,"score_gpt":0.49828318519403947,"score_spread":0.15735209441445014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995099757","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.361112e-7,0.94819397,0.000053738087,0.04784663,0.00066329027,0.0027300646,0.00021364047,0.000023597207,0.00027421283],"genre_scores_gemma":[0.0000025853408,0.9870925,0.0034390222,0.009096699,0.000023441045,0.00008772572,0.000056750487,0.000036518886,0.0001647651],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9902736,0.0043692766,0.0039383634,0.000632987,0.0001433387,0.00064241426],"domain_scores_gemma":[0.99456376,0.0011773128,0.0028351892,0.0012040772,0.00018468255,0.00003497478],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010545772,0.00048459228,0.004952579,0.00052495254,0.000078522025,0.0000031474622,0.00085934,0.0010586338,0.00017996936],"category_scores_gemma":[0.0010891502,0.0002701235,0.0006407113,0.0012716205,0.00040132346,0.000011722837,0.00021736037,0.0017904631,0.000028231265],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000055542746,0.00016089971,0.0000055050423,0.19772646,0.00017384204,5.806625e-7,0.0000073756705,8.808049e-7,0.0000023546202,0.013848942,0.021345792,0.7667218],"study_design_scores_gemma":[0.0001609345,0.0007036725,0.00000271911,0.20383583,0.00012009305,0.00002399231,0.000027298252,0.00000438355,0.000010270053,0.00019797399,0.794755,0.00015787546],"about_ca_topic_score_codex":0.00022598328,"about_ca_topic_score_gemma":0.0000034645457,"teacher_disagreement_score":0.7734092,"about_ca_system_score_codex":0.0002680241,"about_ca_system_score_gemma":0.0028002984,"threshold_uncertainty_score":0.9999751},"labels":[],"label_agreement":null},{"id":"W2996253774","doi":"10.1136/jnnp-2019-abn-2.157","title":"177 Updated safety analysis of ocrelizumab in multiple sclerosis","year":2019,"lang":"en","type":"article","venue":"Journal of Neurology Neurosurgery & Psychiatry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ocrelizumab; Medicine; Multiple sclerosis; Clinical trial; Adverse effect; Population; Internal medicine; Immunology; Environmental health","score_opus":0.02441628927865399,"score_gpt":0.2506209571497512,"score_spread":0.2262046678710972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996253774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887115,0.0012442657,0.000060773033,0.0042379303,0.005243482,0.00012651566,0.000060151597,0.000014415999,0.00030098265],"genre_scores_gemma":[0.9956147,0.0003909565,0.0002865427,0.0035258965,0.000046711815,9.601583e-7,0.00001360862,0.000022823107,0.00009779911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622273,0.0010854111,0.0017116095,0.00039854777,0.00011097661,0.0004707103],"domain_scores_gemma":[0.9972843,0.0009308049,0.0010928399,0.0004622345,0.00016701316,0.000062842795],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010928612,0.00026874442,0.0014207414,0.001417742,0.000054958895,0.000009306932,0.00043402947,0.0005114638,0.0018981599],"category_scores_gemma":[0.00025746366,0.00021857333,0.00086682366,0.0017102082,0.00026536512,0.00012074824,0.00009365407,0.001149694,0.000029160305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036289473,0.00060073734,0.8817496,0.000017339667,0.0010858328,0.00002868017,0.000021757221,0.0003831436,0.10618296,0.00012524768,0.0054916935,0.00068408955],"study_design_scores_gemma":[0.0022869355,0.0010007591,0.98212546,0.000033341057,0.00078314333,0.00020600396,0.000030510228,0.00019080922,0.0029244085,0.00011616833,0.010094941,0.00020749043],"about_ca_topic_score_codex":0.000015969114,"about_ca_topic_score_gemma":0.000026826783,"teacher_disagreement_score":0.10325855,"about_ca_system_score_codex":0.0000147507035,"about_ca_system_score_gemma":0.00013586087,"threshold_uncertainty_score":0.99901426},"labels":[],"label_agreement":null},{"id":"W2996837618","doi":"10.1093/jcag/gwz043","title":"The Law and Ethics of Switching from Biologic to Biosimilar in Canada","year":2019,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Crohn's and Colitis Canada","keywords":"Biosimilar; Obligation; Business; Position (finance); Law and economics; Political science; Medicine; Law; Public relations; Economics; Finance","score_opus":0.010811322980661184,"score_gpt":0.2347926002966538,"score_spread":0.22398127731599263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996837618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9488905,0.00014063025,0.000006910223,0.049824327,0.00087797944,0.000083622566,0.000064662236,4.7145696e-7,0.0001109156],"genre_scores_gemma":[0.9926197,0.00003963771,0.00012896932,0.0071313186,0.000013870189,3.7194508e-7,7.3419056e-7,0.000003298424,0.00006207983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982936,0.00084081496,0.0004673366,0.00007969546,0.00006656976,0.00025202418],"domain_scores_gemma":[0.9982664,0.0007752316,0.0006273838,0.00012362903,0.00015816555,0.000049180766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016810816,0.00007338872,0.0003213861,0.00006865412,0.00008303202,0.0000057890043,0.0003041875,0.00019868587,0.00003818293],"category_scores_gemma":[0.0006946041,0.000042607684,0.00007014989,0.00008070479,0.00007028317,0.000020695996,0.000050312483,0.000603447,7.998792e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017358926,0.000009196703,0.9804961,0.000004313191,0.000182774,0.0000012622602,0.00015334236,0.000019669213,0.016716566,0.0004958975,0.0015988793,0.00014838639],"study_design_scores_gemma":[0.0013083467,0.0005933332,0.9742784,0.00008146986,0.00007096054,0.000019293244,0.00051467563,0.000013432512,0.00435072,0.00100028,0.01770072,0.00006835515],"about_ca_topic_score_codex":0.7864237,"about_ca_topic_score_gemma":0.99864906,"teacher_disagreement_score":0.21222539,"about_ca_system_score_codex":0.00058257807,"about_ca_system_score_gemma":0.00066040887,"threshold_uncertainty_score":0.26217106},"labels":[],"label_agreement":null},{"id":"W2997285364","doi":"10.1074/mcp.tir119.001820","title":"Concentration Determination of &gt;200 Proteins in Dried Blood Spots for Biomarker Discovery and Validation","year":2020,"lang":"en","type":"article","venue":"Molecular & Cellular Proteomics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria General Hospital; Jewish General Hospital; McGill University; University of British Columbia; University of Victoria","funders":"Genome British Columbia; Leading Edge Endowment Fund; Genome Canada","keywords":"Analyte; Biomarker discovery; Biomarker; Dried blood; Chemistry; Dried blood spot; Chromatography; Coefficient of variation; Peptide; Bioanalysis; Quantitative proteomics; Protein stability; Proteomics; Biochemistry","score_opus":0.020272407128666216,"score_gpt":0.25457144651534397,"score_spread":0.23429903938667776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997285364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7683028,0.00044080493,0.2292954,0.00057106535,0.000045380613,0.0012612637,0.000031406744,0.000011262213,0.000040594703],"genre_scores_gemma":[0.9764387,0.000022763636,0.023137184,0.00015096732,0.00001063819,0.00007337962,0.00010774976,0.000014724673,0.000043915028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99896353,0.00018990875,0.0003332572,0.00028880412,0.00004048562,0.00018398979],"domain_scores_gemma":[0.9996058,0.00004219054,0.00014625382,0.000121063895,0.000060007307,0.000024717374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030451122,0.00013245239,0.0002350346,0.00004374105,0.000039740575,0.00002338628,0.000087863176,0.00023965118,0.000013913301],"category_scores_gemma":[0.00021727942,0.00012672301,0.00007290074,0.00014188998,0.000120200224,0.00009998221,0.000041909207,0.000109446395,0.0000012501512],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021119993,0.00008266701,0.0006224659,0.000102540296,0.00003715471,0.000005146457,0.00010827185,0.0000025653735,0.9947681,0.0011271733,0.0000050473504,0.0029276772],"study_design_scores_gemma":[0.0015921259,0.00024072303,0.0005365376,0.000031017647,0.0000880949,0.0000036198014,0.000021605736,0.0012619242,0.99514496,0.0007031408,0.0002342207,0.00014203059],"about_ca_topic_score_codex":0.000007150004,"about_ca_topic_score_gemma":0.0000014146257,"teacher_disagreement_score":0.20813586,"about_ca_system_score_codex":0.000014452368,"about_ca_system_score_gemma":0.00003964414,"threshold_uncertainty_score":0.5167614},"labels":[],"label_agreement":null},{"id":"W2998576867","doi":"10.1111/bjd.18662","title":"How many people develop anti-drug antibodies to the biologic drug tildrakizumab, and what impact does this have on the effectiveness of their treatment","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug; Clinical trial; Adverse effect; Antibody; Pharmacokinetics; Incidence (geometry); Internal medicine; Psoriasis; Pharmacology; Immunology","score_opus":0.016572192714455206,"score_gpt":0.2646796761144864,"score_spread":0.2481074834000312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998576867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9384313,0.018182334,0.00012221352,0.042507734,0.00033988777,0.00030745103,0.000059964816,0.000009400196,0.00003972127],"genre_scores_gemma":[0.99041766,0.008279265,0.00011915946,0.0010732707,0.000036519654,0.000005919182,0.0000043137024,0.000011155772,0.000052740008],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99689156,0.0021364172,0.0003804502,0.00022695673,0.00004883267,0.00031576172],"domain_scores_gemma":[0.99722004,0.002095628,0.00028740277,0.00015360629,0.00018347523,0.0000598467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061918533,0.00023071512,0.00082633295,0.00006515547,0.0002327721,0.00012943064,0.00036291027,0.00016580144,0.00007561622],"category_scores_gemma":[0.0004797501,0.00009865976,0.0002298983,0.00017060454,0.00042519261,0.00014453166,0.00012473087,0.00037071988,0.0000062573286],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008433749,0.001702764,0.28705347,0.0006082179,0.010516905,0.0023840745,0.017366752,0.000021033931,0.22583452,0.0030953751,0.045763694,0.39721945],"study_design_scores_gemma":[0.0030933109,0.0014390944,0.2955636,0.00081557577,0.00036458453,0.026328571,0.009413654,0.000020302718,0.64154613,0.0009688678,0.01996597,0.0004803129],"about_ca_topic_score_codex":0.000071256705,"about_ca_topic_score_gemma":0.0001022497,"teacher_disagreement_score":0.4157116,"about_ca_system_score_codex":0.000029799834,"about_ca_system_score_gemma":0.00007006548,"threshold_uncertainty_score":0.40232283},"labels":[],"label_agreement":null},{"id":"W2999095294","doi":"10.1093/ecco-jcc/jjz203.553","title":"P424 Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada","year":2020,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Takeda (Canada)","funders":"","keywords":"Vedolizumab; Medicine; Golimumab; Ulcerative colitis; Adalimumab; Infliximab; Internal medicine; Disease","score_opus":0.045424011097627434,"score_gpt":0.30561315913313497,"score_spread":0.2601891480355075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999095294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99309474,0.0022983798,0.00016140187,0.0033358282,0.00021669158,0.0004016727,0.00027870707,6.4823473e-7,0.00021193788],"genre_scores_gemma":[0.99892914,0.0004907882,0.00020484871,0.00026725687,0.000042234202,0.000011244757,0.0000018711189,0.000004097801,0.000048507125],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99913114,0.00017806215,0.00042364394,0.00009035159,0.00004810773,0.00012868449],"domain_scores_gemma":[0.99918514,0.00029215065,0.00021683208,0.00005903247,0.00020806829,0.000038758844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031670585,0.00008262571,0.0003748759,0.000032242668,0.000042714542,0.00000736805,0.00007483552,0.000059602517,0.00019419045],"category_scores_gemma":[0.00006548587,0.000053037464,0.0000773524,0.00004685241,0.000066042405,0.000032499353,0.00001087248,0.00006399941,3.5747343e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06787376,0.0006224935,0.0056216195,0.00021174325,0.0031595111,0.00003976271,0.0075437636,0.00483588,0.003243177,0.008451493,0.018453488,0.8799433],"study_design_scores_gemma":[0.012410668,0.0057594054,0.8599857,0.00014815888,0.00080608856,0.00012534598,0.0029701665,0.0062208665,0.067649595,0.0026007479,0.041044604,0.00027863635],"about_ca_topic_score_codex":0.039901737,"about_ca_topic_score_gemma":0.16907887,"teacher_disagreement_score":0.87966466,"about_ca_system_score_codex":0.00024597716,"about_ca_system_score_gemma":0.00095100916,"threshold_uncertainty_score":0.96649164},"labels":[],"label_agreement":null},{"id":"W2999490023","doi":"10.1093/ecco-jcc/jjz203.570","title":"P441 Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis","year":2020,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Colectomy; Internal medicine; Infliximab; Ulcerative colitis; Colitis; Inflammatory bowel disease; Gastroenterology; Refractory (planetary science); Adverse effect; Interquartile range; Crohn's disease; Clinical endpoint; Disease; Clinical trial","score_opus":0.01675214129472696,"score_gpt":0.25337832386930736,"score_spread":0.2366261825745804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999490023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583834,0.0017147423,0.00009946404,0.0009873561,0.00020475144,0.00016945435,0.00010019507,0.000009943718,0.0008757748],"genre_scores_gemma":[0.99781704,0.0003617905,0.0004401743,0.0010923927,0.00007590132,0.0000018347891,0.000004180174,0.000016370903,0.00019031453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984825,0.0002279038,0.0006647751,0.00020238981,0.000116569725,0.00030585408],"domain_scores_gemma":[0.99866337,0.00020764451,0.0005699091,0.00013868632,0.00026996518,0.00015041193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023034502,0.00020636163,0.0006743581,0.00009311074,0.00009105371,0.000029729097,0.0002122337,0.00016437696,0.00042114107],"category_scores_gemma":[0.0001463861,0.00014575037,0.00015314917,0.00018455711,0.0004918371,0.00017269778,0.000086946166,0.00045459162,0.0000044013545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08235507,0.005637996,0.41860366,0.0021202324,0.010296648,0.0034814926,0.010029873,0.000076613505,0.036877584,0.0031477013,0.088643536,0.3387296],"study_design_scores_gemma":[0.0049161646,0.0028914479,0.9205362,0.00025593766,0.0002637245,0.00048464228,0.00038911228,0.000007616965,0.016186709,0.00008156767,0.053725187,0.00026167405],"about_ca_topic_score_codex":0.00003157,"about_ca_topic_score_gemma":0.000010736291,"teacher_disagreement_score":0.50193256,"about_ca_system_score_codex":0.000026166399,"about_ca_system_score_gemma":0.00010355601,"threshold_uncertainty_score":0.5943528},"labels":[],"label_agreement":null},{"id":"W2999642303","doi":"10.1016/j.biologicals.2019.12.008","title":"WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 25–26 June 2019","year":2020,"lang":"en","type":"article","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Ministry of Food and Drug Safety; World Health Organization","keywords":"Guideline; CLARITY; Product (mathematics); Business; Medicine; Medical education","score_opus":0.3059629528580957,"score_gpt":0.45261058716641406,"score_spread":0.14664763430831834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999642303","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14786828,0.013796714,0.0021665627,0.8242488,0.0011062085,0.0071105626,0.0031647645,0.00034262496,0.00019550424],"genre_scores_gemma":[0.62921363,0.011427842,0.093395896,0.24842241,0.0018678362,0.00077009405,0.0046128263,0.00019455339,0.010094902],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982858,0.00016815463,0.00042857937,0.0007674328,0.000046699188,0.0003033845],"domain_scores_gemma":[0.9989286,0.00023722231,0.00019050243,0.0004285836,0.00016602903,0.000049029644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007425033,0.0002092607,0.00041932028,0.00006674165,0.00008119338,0.000020308042,0.00038210838,0.000247633,0.000118235475],"category_scores_gemma":[0.0020872664,0.00012787254,0.000038834976,0.00022678576,0.00013739067,0.00004016487,0.00021844378,0.000101477264,0.000010528098],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009220583,0.00015097103,0.00027276628,0.0001095361,0.00021096451,3.3099715e-7,0.000082637205,3.987264e-7,0.5984354,0.0011600523,0.27884924,0.119805604],"study_design_scores_gemma":[0.0013160679,0.0034261658,0.0035193844,0.00012810087,0.00009816594,0.0000022522604,0.0002748923,0.000023948016,0.19147961,0.0002771951,0.79912925,0.00032494182],"about_ca_topic_score_codex":0.000008490864,"about_ca_topic_score_gemma":0.000017616208,"teacher_disagreement_score":0.57582635,"about_ca_system_score_codex":0.000010807412,"about_ca_system_score_gemma":0.000031129413,"threshold_uncertainty_score":0.5214491},"labels":[],"label_agreement":null},{"id":"W2999853201","doi":"10.1002/pds.4957","title":"A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia","year":2020,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biosimilar; Medicine; Etanercept; Infliximab; Rheumatoid arthritis; Cumulative incidence; Family medicine; Emergency medicine; Cohort; Internal medicine","score_opus":0.028736494549784247,"score_gpt":0.2975365821674436,"score_spread":0.2688000876176594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999853201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95308447,0.030295122,0.001630912,0.012117419,0.0010156189,0.00088118855,0.00079512154,0.00007939726,0.000100742145],"genre_scores_gemma":[0.9798166,0.01003454,0.0017305847,0.008043958,0.000111558365,0.000102549166,0.00010111505,0.000026995694,0.00003209024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960123,0.001383827,0.0009673078,0.0008451748,0.00003897392,0.0007524649],"domain_scores_gemma":[0.99571425,0.0038201471,0.0001293636,0.00014687952,0.000016071364,0.0001733055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024196263,0.0002547464,0.0011753843,0.00007337189,0.0002225032,0.000043749053,0.00025372367,0.00040542532,0.00036888648],"category_scores_gemma":[0.0013093146,0.00034209632,0.00021019935,0.00024932993,0.00015759005,0.00012946643,0.00017678943,0.00066792814,0.000016051099],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021262045,0.00021608412,0.7915314,0.000087239154,0.00036818656,0.00014018962,0.0033973297,0.000029109815,0.020339029,0.00004816837,0.016388169,0.16532892],"study_design_scores_gemma":[0.042604763,0.0007368508,0.53534746,0.0018061985,0.00019497522,0.00007413928,0.001806359,0.00065844593,0.013274568,0.0074414304,0.39360073,0.002454055],"about_ca_topic_score_codex":0.004971569,"about_ca_topic_score_gemma":0.0070051216,"teacher_disagreement_score":0.37721258,"about_ca_system_score_codex":0.000046813544,"about_ca_system_score_gemma":0.000044142602,"threshold_uncertainty_score":0.9999031},"labels":[],"label_agreement":null},{"id":"W2999916750","doi":"10.1136/rmdopen-2019-001096","title":"Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis","year":2020,"lang":"en","type":"article","venue":"RMD Open","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Regeneron Pharmaceuticals; Samsung; Celgene; Celltrion; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Adalimumab; Etanercept; Rheumatoid arthritis; Infliximab; Internal medicine; Erythrocyte sedimentation rate; Gastroenterology; Disease","score_opus":0.044834177934514594,"score_gpt":0.3436753370048442,"score_spread":0.2988411590703296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999916750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561011,0.038898308,0.00009024657,0.0039929254,0.00009903901,0.00051124766,0.00021307048,0.000031850956,0.00006220249],"genre_scores_gemma":[0.9921974,0.0069969282,0.0002952485,0.00036135054,0.000006225009,0.0000309381,0.00008097342,0.000010360469,0.000020564155],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983136,0.00048645405,0.00041963602,0.0004311094,0.000060781553,0.00028844137],"domain_scores_gemma":[0.9992436,0.00019924811,0.00018709817,0.00022438803,0.000061549894,0.00008412546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045807683,0.00019589394,0.0009799361,0.00020692383,0.00009926843,0.00003443087,0.00037442334,0.00012659687,0.00014442317],"category_scores_gemma":[0.00019476787,0.00015331658,0.00019960113,0.0012955156,0.00032336733,0.00014590986,0.0004581421,0.00024006718,0.000005695328],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004644088,0.001571916,0.6605407,0.00030123984,0.012605547,0.000044928343,0.0014986714,0.00007123629,0.23198807,0.00014953554,0.022527458,0.06405662],"study_design_scores_gemma":[0.014669259,0.0017585749,0.38597423,0.0018259428,0.003979575,0.000004371969,0.0024627652,0.0056524468,0.55034494,0.0006489543,0.030767774,0.0019111262],"about_ca_topic_score_codex":0.000109362016,"about_ca_topic_score_gemma":0.00012565493,"teacher_disagreement_score":0.3183569,"about_ca_system_score_codex":0.000020857764,"about_ca_system_score_gemma":0.000030701838,"threshold_uncertainty_score":0.6252069},"labels":[],"label_agreement":null},{"id":"W2999942204","doi":"10.1002/acr2.11106","title":"Patterns of Tumor Necrosis Factor Inhibitor (<scp>TNF</scp>i) Biosimilar Use Across United States Rheumatology Practices","year":2020,"lang":"en","type":"article","venue":"ACR Open Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada; University of British Columbia","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; Patient-Centered Outcomes Research Institute","keywords":"Biosimilar; Infliximab; Medicine; Rheumatoid arthritis; Etanercept; Rheumatology; Internal medicine; Medical prescription; Cohort; Tumor necrosis factor alpha; Pharmacology","score_opus":0.06740945790938267,"score_gpt":0.33967325561999234,"score_spread":0.27226379771060966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999942204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884726,0.0007807738,0.00045591642,0.0066297315,0.0009303781,0.0008117775,0.0016969499,0.00014849864,0.0000733746],"genre_scores_gemma":[0.9905792,0.0015524498,0.0019601323,0.004839108,0.000011760535,0.00006711384,0.00048364387,0.00008391488,0.00042268462],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944235,0.0014888993,0.0015336132,0.0011441413,0.0001156475,0.0012941695],"domain_scores_gemma":[0.99219865,0.0045380024,0.0018833207,0.0007728255,0.0003783917,0.0002288122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006507665,0.00064703095,0.001953775,0.00019086504,0.00036099667,0.00019079668,0.0017881484,0.0009285514,0.00087616144],"category_scores_gemma":[0.0063814186,0.0005389212,0.00027682292,0.0007396535,0.00081291876,0.00065248547,0.001756374,0.0009616041,0.0002934231],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010589847,0.0011699314,0.8241757,0.0009033796,0.002633165,0.00013084107,0.012356613,0.000009126529,0.08124806,0.0037072215,0.07012295,0.0024839973],"study_design_scores_gemma":[0.008947253,0.0024946118,0.043031696,0.0004703331,0.00039780806,0.0014826668,0.016440881,0.00034912274,0.44228098,0.0005380036,0.4824814,0.0010852504],"about_ca_topic_score_codex":0.0035297985,"about_ca_topic_score_gemma":0.00029584498,"teacher_disagreement_score":0.781144,"about_ca_system_score_codex":0.00003649343,"about_ca_system_score_gemma":0.00015926533,"threshold_uncertainty_score":0.9997062},"labels":[],"label_agreement":null},{"id":"W3000625420","doi":"10.1007/s40744-019-00190-7","title":"Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?","year":2020,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"AbbVie","keywords":"Nocebo Effect; Biosimilar; Nocebo; Discontinuation; Medicine; Adverse effect; Intensive care medicine; Internal medicine; Alternative medicine; Placebo; Pathology","score_opus":0.017435544185724097,"score_gpt":0.3083887121203034,"score_spread":0.2909531679345793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000625420","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12573601,0.8687414,0.00006371157,0.0035830834,0.000612452,0.0011241549,0.000090543,0.000043907945,0.0000047403328],"genre_scores_gemma":[0.023720987,0.9751985,0.00021128879,0.00053262163,0.000013149619,0.00022426168,0.000042147967,0.000042092637,0.000014949756],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947062,0.0026782725,0.00082334515,0.001062427,0.0000520449,0.00067772454],"domain_scores_gemma":[0.9963916,0.002790749,0.00028665946,0.00036360644,0.000014202926,0.00015317478],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006652876,0.00082331855,0.0031711399,0.00024379873,0.00025888518,0.000013197884,0.00033114743,0.0012755813,0.00012274433],"category_scores_gemma":[0.00019171942,0.00040799464,0.00024177441,0.00016912418,0.0006796285,0.000052977863,0.00023912307,0.000906606,0.000024536943],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001536514,0.00019542256,0.09039634,0.0011618803,0.0026080522,0.0000922139,0.0009226011,3.4084326e-8,0.00004545147,0.0005267357,0.00022098639,0.90229374],"study_design_scores_gemma":[0.0056985742,0.0026356915,0.0019102879,0.0036432287,0.0006373339,0.0015990803,0.00019550187,0.000008114931,0.00008074304,0.0005979816,0.98230207,0.0006913985],"about_ca_topic_score_codex":0.00038172936,"about_ca_topic_score_gemma":0.0002150208,"teacher_disagreement_score":0.98208106,"about_ca_system_score_codex":0.0000486711,"about_ca_system_score_gemma":0.00007699712,"threshold_uncertainty_score":0.9998372},"labels":[],"label_agreement":null},{"id":"W3001664763","doi":"10.1007/s10620-019-06036-0","title":"Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease","year":2020,"lang":"en","type":"review","venue":"Digestive Diseases and Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University; University of Alberta; Université de Montréal","funders":"Janssen Canada","keywords":"Biosimilar; Observational study; Medicine; Infliximab; Randomized controlled trial; Inflammatory bowel disease; Ulcerative colitis; Clinical trial; Intensive care medicine; Disease; Hepatology; Internal medicine","score_opus":0.021856990713766192,"score_gpt":0.3437954861377051,"score_spread":0.32193849542393893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001664763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037369976,0.99737155,0.000017441029,0.00043853594,0.00016812535,0.0013926816,0.00014821025,0.000016078322,0.0000736747],"genre_scores_gemma":[0.00110291,0.9978428,0.000030484409,0.0007837543,0.000023449047,0.00015605804,0.000015194984,0.000012009779,0.000033373526],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9970639,0.0006440141,0.0010703806,0.00064975297,0.00020544179,0.00036654947],"domain_scores_gemma":[0.9980818,0.0009023238,0.00039194498,0.0002474187,0.000053446398,0.00032307094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008982115,0.0003903498,0.0023900857,0.00021817129,0.00012632685,0.00003885437,0.0006434825,0.00013559834,0.000075280695],"category_scores_gemma":[0.0041616145,0.00023748448,0.00040906278,0.00057936367,0.00052341685,0.00008362071,0.0003357321,0.0003498579,0.00003414695],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021861852,0.00018747801,0.0070777233,0.92500895,0.0002596011,0.00020627277,0.00007444102,4.536947e-7,0.0000030237081,0.00047080033,0.0004838357,0.066205576],"study_design_scores_gemma":[0.00027099252,0.00019891026,0.007942513,0.92475873,0.002875774,0.000035780147,0.00011826621,0.0000315873,0.0000017051409,0.00007700674,0.06303119,0.0006575461],"about_ca_topic_score_codex":0.000015557434,"about_ca_topic_score_gemma":9.472091e-7,"teacher_disagreement_score":0.06554803,"about_ca_system_score_codex":0.000033678374,"about_ca_system_score_gemma":0.0007074948,"threshold_uncertainty_score":0.96843356},"labels":[],"label_agreement":null},{"id":"W3001684225","doi":"10.1016/j.clinbiochem.2020.01.006","title":"An in vitro comparison of four different immunoassays for the monitoring of Infliximab biosimilars drug levels","year":2020,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Alberta Hospital; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Biosimilar; Infliximab; Pharmacology; Drug; In vitro; Therapeutic drug monitoring; Chemistry; Medicine; Immunology; Tumor necrosis factor alpha; Internal medicine; Biochemistry","score_opus":0.14968651822089163,"score_gpt":0.420383235416336,"score_spread":0.27069671719544436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001684225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932803,0.0027817294,0.00058617326,0.0025054363,0.00037964707,0.00022967125,0.0001791086,0.000018077451,0.00003986519],"genre_scores_gemma":[0.99779856,0.00006917766,0.001732736,0.00022564601,0.000102952865,0.000012751983,0.000016636432,0.0000115738485,0.000029939647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980942,0.0001955417,0.0010609213,0.00034788798,0.00005195114,0.0002494705],"domain_scores_gemma":[0.9972678,0.0018701383,0.0003210268,0.00039881218,0.00009000828,0.000052244955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006880642,0.00017560874,0.0007000578,0.000017552939,0.000049432514,0.0000066820785,0.000536566,0.00040665935,0.00004677147],"category_scores_gemma":[0.0010413349,0.00011598105,0.00030828817,0.00012646151,0.0005248348,0.00002111485,0.00012624668,0.00050665415,0.0000015551024],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007263842,0.00040963208,0.03788592,0.000102485224,0.00013864509,3.7783013e-7,0.00009259027,0.0000018025484,0.9496972,0.000007830617,0.00046825787,0.010468865],"study_design_scores_gemma":[0.0013869451,0.00021804807,0.017019898,0.000049081376,0.000092984745,6.717287e-7,0.00049679796,0.0002276906,0.97978884,0.000053457672,0.00053743995,0.00012814],"about_ca_topic_score_codex":0.000004379723,"about_ca_topic_score_gemma":4.4824486e-7,"teacher_disagreement_score":0.030091634,"about_ca_system_score_codex":0.00001393888,"about_ca_system_score_gemma":0.00004498785,"threshold_uncertainty_score":0.472957},"labels":[],"label_agreement":null},{"id":"W3002426265","doi":"10.1093/jcag/gwz044","title":"The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta","year":2019,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Biosimilar; Medicine; Infliximab; Inflammatory bowel disease; Harm; Argument (complex analysis); Intensive care medicine; Health care; Disease; Family medicine; Psychology; Economics; Internal medicine; Social psychology; Economic growth","score_opus":0.0035735275475693245,"score_gpt":0.20851627058891442,"score_spread":0.2049427430413451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002426265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769373,0.00003236778,0.0000034830296,0.02224151,0.0003772379,0.00032947495,0.000029028564,8.4681125e-7,0.000048756698],"genre_scores_gemma":[0.99730104,0.000016163835,0.000038793452,0.002169741,0.000024721974,0.000005569944,0.0000023980847,0.000008634993,0.00043296284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838126,0.0004778163,0.00053065486,0.00010536071,0.00007963342,0.00042529614],"domain_scores_gemma":[0.9983945,0.00042985298,0.0007486111,0.00016479637,0.00019132948,0.00007091833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011638332,0.00011083661,0.00027759108,0.00025501722,0.0000826617,0.0000134521015,0.00032803207,0.00015056253,0.000014409701],"category_scores_gemma":[0.001034022,0.000065217806,0.00013076364,0.00011844172,0.00007740124,0.000059601927,0.000041088897,0.00032825384,0.0000018198995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077983295,0.00007172927,0.9977472,0.000010520851,0.00013679636,5.871528e-7,0.00010158202,0.00007849499,0.000098404016,0.00011281381,0.0007512695,0.000110799025],"study_design_scores_gemma":[0.0028272583,0.00043371174,0.9927703,0.000103647064,0.000031651383,0.0000011141719,0.000035724173,0.000027469712,0.000031283325,0.000097471806,0.0035931591,0.00004717601],"about_ca_topic_score_codex":0.0014441337,"about_ca_topic_score_gemma":0.3102524,"teacher_disagreement_score":0.30880827,"about_ca_system_score_codex":0.00095220195,"about_ca_system_score_gemma":0.0004731626,"threshold_uncertainty_score":0.7023337},"labels":[],"label_agreement":null},{"id":"W3002972298","doi":"10.31027/odprn.2020.01","title":"Current and prospective utilization of innovator biologics and biosimilars in Ontario","year":2020,"lang":"en","type":"report","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Innovator; Medicine; Business; Internal medicine","score_opus":0.11549367481383735,"score_gpt":0.35233933941006784,"score_spread":0.2368456645962305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002972298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54308236,0.2962405,0.0024520715,0.0072215083,0.0126323765,0.009021947,0.0017146871,0.00044951096,0.12718503],"genre_scores_gemma":[0.9604448,0.032090746,0.0028363008,0.00051022856,0.00007743461,0.00004608692,0.0005518638,0.000051159863,0.00339139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985978,0.00011812796,0.0005383594,0.00049441983,0.000051199546,0.00020010056],"domain_scores_gemma":[0.9992815,0.00009748219,0.00024067797,0.0001355672,0.00022013202,0.000024598183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048295496,0.00025794355,0.0007153352,0.00017086917,0.00002603884,0.000008820344,0.00008758558,0.0007495598,0.00024641745],"category_scores_gemma":[0.00035953996,0.00018351297,0.000053119926,0.0002535108,0.00040974698,0.000026988813,0.00020214543,0.00076010224,0.0000022165473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021155934,0.0002616442,0.93612856,0.000493782,0.00036512985,0.000005968408,0.0003369665,3.8008505e-8,0.010080554,0.0017325092,0.012992796,0.03739047],"study_design_scores_gemma":[0.0009536872,0.0005981134,0.513912,0.00031714333,0.00018452015,0.000048695092,0.00008869015,0.000003604022,0.016859254,0.0012387444,0.4653357,0.00045980632],"about_ca_topic_score_codex":0.0015693994,"about_ca_topic_score_gemma":0.014411661,"teacher_disagreement_score":0.4523429,"about_ca_system_score_codex":0.00012812194,"about_ca_system_score_gemma":0.0005216576,"threshold_uncertainty_score":0.80420446},"labels":[],"label_agreement":null},{"id":"W3003887243","doi":"10.1007/s40265-020-01256-5","title":"The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases","year":2020,"lang":"en","type":"review","venue":"Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Celltrion; Celltrion Healthcare","keywords":"Biosimilar; Medicine; Immune system; Pharmacotherapy; Intensive care medicine; Pharmacology; Immunology; Internal medicine","score_opus":0.021357099851742094,"score_gpt":0.3110286671542852,"score_spread":0.28967156730254306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003887243","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015127228,0.9952234,0.0000017808686,0.0007417313,0.0016069792,0.00053298625,0.0016468756,0.00008675886,0.00014435359],"genre_scores_gemma":[0.000020390735,0.9987144,0.000058637543,0.00023196368,0.00026978005,0.0000544077,0.0003307932,0.000060248312,0.00025940116],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99689853,0.0007056186,0.0011338146,0.00052745204,0.0000935645,0.00064101716],"domain_scores_gemma":[0.9971312,0.0012405814,0.0007367071,0.0007079872,0.000105981984,0.00007750511],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052868645,0.0005889109,0.0020562366,0.00006743111,0.00037321096,0.00004786149,0.0010154765,0.0010687644,0.00013075907],"category_scores_gemma":[0.00024229039,0.00033568393,0.001134516,0.00047003472,0.00067174586,0.00005098842,0.00050670485,0.0010092243,0.00018919108],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037935308,0.000041895848,0.000008582299,0.0026461594,0.000800694,0.000007312483,0.000117694675,4.6871218e-8,0.000028455257,0.0004163711,0.0037318312,0.992163],"study_design_scores_gemma":[0.00029478598,0.00005201015,0.000040886673,0.0023523665,0.0008367814,0.000017235878,0.00028878523,4.859996e-7,0.00012652286,0.000036279318,0.99558526,0.00036857682],"about_ca_topic_score_codex":0.0000029730718,"about_ca_topic_score_gemma":0.0000036282802,"teacher_disagreement_score":0.9918535,"about_ca_system_score_codex":0.000052293006,"about_ca_system_score_gemma":0.00023940322,"threshold_uncertainty_score":0.9999095},"labels":[],"label_agreement":null},{"id":"W3005936722","doi":"10.1016/j.jval.2019.12.003","title":"Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Rheumatoid arthritis; Methotrexate; Medicine; Internal medicine; Physical therapy","score_opus":0.09013654746989737,"score_gpt":0.34934846832493693,"score_spread":0.2592119208550396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005936722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99472404,0.001640533,0.00034993727,0.0020111443,0.00004899431,0.001046894,0.00017026404,0.000004857247,0.0000033373485],"genre_scores_gemma":[0.9890447,0.0005738343,0.009836565,0.00045056498,0.0000025541224,0.0000719228,0.000008304036,0.0000058852706,0.000005672573],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99776906,0.0011716522,0.00049980986,0.0003089916,0.000039584174,0.00021089229],"domain_scores_gemma":[0.9991137,0.0005196938,0.00015606712,0.00009335464,0.00006549732,0.00005173346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015662038,0.00011513565,0.00048210283,0.00009043283,0.000029790013,0.0000031522543,0.00008047483,0.000108758286,0.000030835046],"category_scores_gemma":[0.00047435286,0.00007926691,0.000022226479,0.00017392251,0.00008289466,0.000037523765,0.000026858059,0.00008220655,0.0000023354717],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08521817,0.0009709942,0.31590283,0.00043893157,0.00025667957,0.0000036410436,0.007923729,0.028849237,0.023311486,0.00056856085,0.00012681863,0.5364289],"study_design_scores_gemma":[0.029194858,0.028009932,0.84934837,0.0025013944,0.000037327023,0.000009093954,0.00049506343,0.017735148,0.06905112,0.0019915353,0.0009281724,0.0006980241],"about_ca_topic_score_codex":0.000530622,"about_ca_topic_score_gemma":0.000094969364,"teacher_disagreement_score":0.5357309,"about_ca_system_score_codex":0.000080268495,"about_ca_system_score_gemma":0.00021735973,"threshold_uncertainty_score":0.32324108},"labels":[],"label_agreement":null},{"id":"W3006421743","doi":"10.1093/jcag/gwz045","title":"A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn’s Disease","year":2019,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Institute for Clinical Evaluative Sciences; University of Toronto; SickKids Foundation; Hospital for Sick Children; Population Health Research Institute","funders":"","keywords":"Biosimilar; Infliximab; Medicine; Cohort; Quality-adjusted life year; Cost effectiveness; Internal medicine; Disease; Risk analysis (engineering)","score_opus":0.017665328851244964,"score_gpt":0.2595648579132957,"score_spread":0.24189952906205073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006421743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484885,0.000008214101,0.00013737347,0.0038852654,0.00017193655,0.00029975508,0.00057441054,0.0000022483125,0.00007193636],"genre_scores_gemma":[0.99648726,0.0000025324184,0.0007072853,0.0027241628,0.000006380484,0.0000034958668,0.000026571117,0.00000702998,0.000035288747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976279,0.00074587174,0.00082826545,0.00021972717,0.00016377737,0.00041443878],"domain_scores_gemma":[0.9974461,0.00023302564,0.0010693198,0.0003076174,0.0007495258,0.00019437203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008670374,0.00015854115,0.0008017586,0.00066895585,0.0000569932,0.000013187804,0.0004904649,0.000185948,0.00020248996],"category_scores_gemma":[0.00088825513,0.000114585506,0.00016345203,0.00056227343,0.000054934622,0.0000743265,0.00009019033,0.00047681603,0.000004525875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002737842,0.00010603972,0.9942115,0.0000055934224,0.00084152236,0.0000024638148,0.00029449313,0.0005745548,0.0007772747,0.000033790267,0.00023944637,0.00017547274],"study_design_scores_gemma":[0.0022342238,0.00042909873,0.9958278,0.00010347751,0.0004449679,5.36113e-7,0.00013394808,0.00010762752,0.0001408211,0.000036390506,0.00046619057,0.000074899726],"about_ca_topic_score_codex":0.008624301,"about_ca_topic_score_gemma":0.3343022,"teacher_disagreement_score":0.32567787,"about_ca_system_score_codex":0.000698904,"about_ca_system_score_gemma":0.000274933,"threshold_uncertainty_score":0.9979774},"labels":[],"label_agreement":null},{"id":"W3008982966","doi":"10.4212/cjhp.v73i1.2953","title":"Real-World Budget Impact of Listing a Biosimilar of Rituximab","year":2020,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"","keywords":"Biosimilar; Rituximab; Medicine; Health care; Actuarial science; Business; Internal medicine; Economic growth; Economics","score_opus":0.03768502336538441,"score_gpt":0.33383570470572826,"score_spread":0.29615068134034384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008982966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749651,0.0040252768,0.000038294507,0.017045785,0.00070902135,0.00019192565,0.00027449479,0.000007425828,0.002742703],"genre_scores_gemma":[0.9989036,0.00009728217,0.000328617,0.00045834342,0.000116558374,3.8983973e-7,0.0000025139445,0.000013309658,0.000079417616],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986959,0.00021359931,0.0006021018,0.00010820865,0.000059054237,0.0003211303],"domain_scores_gemma":[0.9986618,0.00017347082,0.000525909,0.00013858076,0.00027247806,0.00022776316],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005432826,0.00015432212,0.00049071905,0.00014445778,0.00011354886,0.00001472886,0.0005112765,0.000065287495,0.0010207468],"category_scores_gemma":[0.0003414362,0.00009520415,0.00040057697,0.00037013495,0.00050719036,0.00008557057,0.000034622604,0.00051470636,0.000009197155],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019617535,0.00079573033,0.22342202,0.00031673227,0.0063695875,0.0004759329,0.008043819,0.00012913295,0.5197309,0.0029250283,0.20543683,0.030392485],"study_design_scores_gemma":[0.015358345,0.009173645,0.10944268,0.0005633175,0.0021359003,0.0003429469,0.0009596433,0.00033506667,0.7767358,0.0025538644,0.08116545,0.0012333354],"about_ca_topic_score_codex":0.013283021,"about_ca_topic_score_gemma":0.00200795,"teacher_disagreement_score":0.25700486,"about_ca_system_score_codex":0.00007586326,"about_ca_system_score_gemma":0.0008599242,"threshold_uncertainty_score":0.9998925},"labels":[],"label_agreement":null},{"id":"W3010645847","doi":"10.12927/hcpol.2020.26133","title":"Lessons from the International Experience with Biosimilar Implementation: An Application of the Diffusion of Innovations Model","year":2020,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"University of Alberta","keywords":"Biosimilar; Context (archaeology); Business; Knowledge management; Marketing; Risk analysis (engineering); Computer science; Medicine; Geography","score_opus":0.0855200036463094,"score_gpt":0.4178667872870737,"score_spread":0.3323467836407643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010645847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.536182,0.00018014216,0.012864495,0.44896048,0.000084424966,0.00040660152,0.0012150278,0.000020358651,0.00008645303],"genre_scores_gemma":[0.9886307,0.000029529207,0.0012623853,0.009903125,0.000056252848,0.000023263381,0.000078822464,0.000005374203,0.0000105202325],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99928814,0.000112085036,0.00026539358,0.0001617533,0.00006357024,0.00010907097],"domain_scores_gemma":[0.99932325,0.000058016685,0.00018447664,0.00025626228,0.00015718049,0.00002080287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093757226,0.000072298884,0.00011611946,0.000025111101,0.00012473958,0.0000038789894,0.00035917325,0.00007496467,0.00006324602],"category_scores_gemma":[0.00004102645,0.00003839735,0.000033612992,0.0003219521,0.00021365438,0.000042386793,0.00009733074,0.00013311316,0.0000012349846],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023309917,0.00018449771,0.07476979,0.00003305286,0.00011839527,1.2874574e-7,0.01534872,0.000051698553,0.6603233,0.17709823,0.0021623385,0.06967673],"study_design_scores_gemma":[0.0024262026,0.0006686609,0.33162662,0.00007627997,0.000106434876,0.000009194729,0.014004871,0.009312891,0.59600013,0.008711087,0.036664475,0.0003931443],"about_ca_topic_score_codex":0.0031980157,"about_ca_topic_score_gemma":0.00059697375,"teacher_disagreement_score":0.45244873,"about_ca_system_score_codex":0.000021367376,"about_ca_system_score_gemma":0.00018927113,"threshold_uncertainty_score":0.48344645},"labels":[],"label_agreement":null},{"id":"W3011573122","doi":"10.1016/j.msard.2019.11.060","title":"Efficacy of a Fourth Alemtuzumab Course in RRMS Patients from CARE-MS II Who Experienced Disease Activity After Three Prior Courses","year":2020,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Alemtuzumab; Multiple sclerosis; Expanded Disability Status Scale; Internal medicine; Relapsing remitting; Physical therapy; Surgery; Immunology","score_opus":0.019191281974147045,"score_gpt":0.24445241318072583,"score_spread":0.22526113120657879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011573122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341387,0.004441741,0.000051487747,0.0010278209,0.00021395527,0.0005091494,0.00025519746,0.000035078087,0.000051690204],"genre_scores_gemma":[0.99897313,0.0005808883,0.00015063792,0.00015841523,0.00000854529,0.000035947665,0.00005175185,0.000019685423,0.000021023377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985459,0.00016634856,0.0003542462,0.0005195436,0.00007751081,0.00033645928],"domain_scores_gemma":[0.99926853,0.00019617371,0.00014112469,0.00022385853,0.000049924645,0.00012040415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006812685,0.00025532077,0.0004535895,0.00005059366,0.00015861692,0.000013843249,0.0001644878,0.0002935789,0.00026270412],"category_scores_gemma":[0.0002206928,0.00019715649,0.00016553827,0.00022200093,0.0005080941,0.000101404956,0.00017343317,0.0003305258,0.0000065983872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007213666,0.0018559438,0.7694547,0.00006290845,0.00039947082,0.0000038160697,0.010040453,0.000059321595,0.016634887,0.000012093888,0.00014710928,0.19411564],"study_design_scores_gemma":[0.008685512,0.00042384645,0.9866186,0.00015766741,0.00015044454,7.8951985e-8,0.0006149202,0.000601208,0.0019642476,0.000027537537,0.0004675242,0.0002884535],"about_ca_topic_score_codex":0.00038588975,"about_ca_topic_score_gemma":0.0002878866,"teacher_disagreement_score":0.21716388,"about_ca_system_score_codex":0.000021500327,"about_ca_system_score_gemma":0.000044833236,"threshold_uncertainty_score":0.8039808},"labels":[],"label_agreement":null},{"id":"W3012860972","doi":"10.1186/s12874-020-00941-z","title":"Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach","year":2020,"lang":"en","type":"article","venue":"BMC Medical Research Methodology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Immunogenicity; Statistic; Population; Drug; Immune system; Computational biology; Test statistic; Computer science; Medicine; Immunology; Statistical hypothesis testing; Statistics; Biology; Pharmacology; Mathematics","score_opus":0.3227665133978012,"score_gpt":0.4872711939285132,"score_spread":0.164504680530712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012860972","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15110375,0.0019736525,0.8412599,0.0039005198,0.00024315066,0.0005944207,0.00003244677,0.000042756878,0.0008493973],"genre_scores_gemma":[0.8249549,0.000063650725,0.17315419,0.0014846516,0.00010810124,0.000084045256,0.000027539112,0.000030508325,0.00009237333],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9437523,0.053498585,0.00064745184,0.0007451109,0.00054274005,0.000813845],"domain_scores_gemma":[0.91079897,0.08812066,0.00014115556,0.0005878492,0.00013522901,0.00021613688],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.026638482,0.0002704502,0.000950378,0.00013037935,0.00028344302,0.000027434431,0.001250847,0.00072331895,0.0014144892],"category_scores_gemma":[0.0736431,0.00015229433,0.00032086665,0.000525763,0.002127705,0.000026789285,0.00042739595,0.002165122,0.000056602577],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020518092,0.0008056992,0.0073182504,0.001459583,0.0015272362,0.000097602155,0.0008741852,0.0020257435,0.6793547,0.007255946,0.01119347,0.26756945],"study_design_scores_gemma":[0.008042351,0.00534005,0.0064597926,0.00033534248,0.00058041187,0.000033010027,0.00089746196,0.5030075,0.46246415,0.010157432,0.001980876,0.00070163305],"about_ca_topic_score_codex":0.00024839715,"about_ca_topic_score_gemma":0.000015014767,"teacher_disagreement_score":0.6738512,"about_ca_system_score_codex":0.00005230846,"about_ca_system_score_gemma":0.0007193472,"threshold_uncertainty_score":0.99949837},"labels":[],"label_agreement":null},{"id":"W3013519416","doi":"10.1016/j.biologicals.2020.02.005","title":"The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019","year":2020,"lang":"en","type":"review","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Ministry of Health and Welfare; World Health Organization","keywords":"Biosimilar; Business; Terminology; Competition (biology); Quality (philosophy); Risk analysis (engineering); Medicine","score_opus":0.04131380638215703,"score_gpt":0.33282749076361606,"score_spread":0.291513684381459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013519416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012687096,0.9962001,0.0000068981626,0.0011534508,0.000367076,0.0008850013,0.0010344124,0.000047892463,0.00017831501],"genre_scores_gemma":[0.000050047445,0.99792475,0.0004961799,0.0005231854,0.00011749007,0.000059997332,0.00014177918,0.000021273914,0.00066529517],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971155,0.0008576767,0.0008252501,0.0007031767,0.00005262771,0.00044578195],"domain_scores_gemma":[0.9977479,0.0011687013,0.00041085674,0.000526088,0.000051657506,0.000094791416],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006566815,0.00047426453,0.002153053,0.00006654664,0.0001437433,0.000032992786,0.00061414036,0.0013241053,0.00027329504],"category_scores_gemma":[0.00034124154,0.0002161501,0.00042715215,0.00026852384,0.0007391213,0.000016415292,0.00047674752,0.00048864214,0.00010077188],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055282755,0.00003906662,0.00008354548,0.0003625111,0.00047302785,0.0000062496842,0.000009748245,5.924029e-9,0.00018824618,0.00028319636,0.050401267,0.9480978],"study_design_scores_gemma":[0.0001510618,0.0003641763,0.0006248161,0.0015277477,0.00044940584,0.000015423093,0.000008695412,2.2445934e-7,0.00023909539,0.00018539983,0.996131,0.00030297518],"about_ca_topic_score_codex":0.000004249853,"about_ca_topic_score_gemma":0.0000013933796,"teacher_disagreement_score":0.94779485,"about_ca_system_score_codex":0.000015133163,"about_ca_system_score_gemma":0.000066167464,"threshold_uncertainty_score":0.9999724},"labels":[],"label_agreement":null},{"id":"W3015434285","doi":"10.1093/jcag/gwaa004","title":"Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease","year":2020,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Ottawa; McMaster University; Population Health Research Institute","funders":"McMaster University","keywords":"Biosimilar; Inflammatory bowel disease; Position statement; Medicine; Position (finance); Statement (logic); Inflammatory Bowel Diseases; Disease; Pharmacology; Internal medicine; Philosophy; Business; Family medicine; Epistemology","score_opus":0.018467847371823946,"score_gpt":0.2625422895375666,"score_spread":0.24407444216574264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015434285","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.458126,0.000009142743,0.000063701154,0.54074,0.0004855466,0.00026422844,0.00029059366,0.0000021235724,0.000018611392],"genre_scores_gemma":[0.8893885,0.0000053741614,0.000085532374,0.11028164,0.00004805222,0.0000068567037,0.0000043339683,0.00000828067,0.00017142107],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9977244,0.0013027794,0.00046421084,0.00011030312,0.00010127116,0.00029701454],"domain_scores_gemma":[0.9983915,0.00045096167,0.00063372037,0.00014197727,0.00020891917,0.00017291543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017642847,0.00011098224,0.00022260942,0.00011536524,0.00018723101,0.0000133200265,0.00033286223,0.00011552347,0.000080463564],"category_scores_gemma":[0.0015271168,0.000067965935,0.00021038878,0.00006918331,0.000062623134,0.00002539057,0.00003185549,0.00029627737,0.000009258581],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030429736,0.00018449132,0.15366076,0.000020885382,0.0009623477,0.000010930504,0.00047385856,0.00027475215,0.025790017,0.0005690354,0.78741604,0.0002071381],"study_design_scores_gemma":[0.005323756,0.0100551555,0.7024668,0.00016806937,0.00037409508,0.000010593512,0.00023413569,0.000062008265,0.009604424,0.0004362948,0.27108994,0.00017475395],"about_ca_topic_score_codex":0.000053210442,"about_ca_topic_score_gemma":0.0035382786,"teacher_disagreement_score":0.548806,"about_ca_system_score_codex":0.0007223929,"about_ca_system_score_gemma":0.0002200016,"threshold_uncertainty_score":0.27715704},"labels":[],"label_agreement":null},{"id":"W3015742209","doi":"10.1177/1078155219897959","title":"Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy Practice 2019","year":2020,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Pharmacy; Formulary; Product (mathematics); Pharmacology; Family medicine; Internal medicine","score_opus":0.0693095778245597,"score_gpt":0.4139647923595849,"score_spread":0.3446552145350252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015742209","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027477317,0.00243298,0.000037094953,0.91204816,0.005645997,0.00049684494,0.000040122955,0.000022024149,0.05179944],"genre_scores_gemma":[0.51853913,0.01707904,0.006757121,0.4486342,0.0026320142,0.00003394314,0.000009782197,0.00010773051,0.006207011],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99622834,0.0013381831,0.0012737196,0.00038594665,0.00032489546,0.0004489361],"domain_scores_gemma":[0.98640174,0.008410577,0.0034291653,0.00020050976,0.0014246708,0.00013333352],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004202939,0.00032261864,0.0006886158,0.00009424412,0.00032522876,0.000044829107,0.0016063984,0.00030643234,0.0014929988],"category_scores_gemma":[0.008670245,0.00018092852,0.00043908582,0.0004967106,0.0007696924,0.00081710366,0.0006490728,0.0028797546,0.00013637717],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016331814,0.001361917,0.00053408905,0.000018985982,0.0019353741,0.00008504593,0.0010322112,0.000028859375,0.41711584,0.0003770702,0.54383415,0.017344672],"study_design_scores_gemma":[0.005201527,0.0011307679,0.00007884956,0.00003560026,0.0014358999,0.0031883065,0.0013628072,0.000045825338,0.16192852,0.000023857052,0.82541275,0.00015527355],"about_ca_topic_score_codex":0.0000147994515,"about_ca_topic_score_gemma":0.0000029474352,"teacher_disagreement_score":0.49106184,"about_ca_system_score_codex":0.0004870356,"about_ca_system_score_gemma":0.0006446342,"threshold_uncertainty_score":0.99968016},"labels":[],"label_agreement":null},{"id":"W3015995016","doi":"10.1177/1078155219893441","title":"International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care","year":2020,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biosimilar; Medicine; Pharmacy; Pharmacovigilance; Health care; Position statement; Product (mathematics); Pharmacy practice; Family medicine; Pharmacology; Adverse effect; Internal medicine","score_opus":0.15815005056833825,"score_gpt":0.4658848871336269,"score_spread":0.30773483656528866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015995016","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47268674,0.0033364021,0.00022482828,0.51715344,0.001711917,0.0006491358,0.0005309566,0.000011254012,0.0036952891],"genre_scores_gemma":[0.95129246,0.018780774,0.005736697,0.023942351,0.00017133166,0.000014617159,0.000016592885,0.000011236827,0.000033948658],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976619,0.0011150008,0.0007473971,0.0001952622,0.000091227885,0.00018921008],"domain_scores_gemma":[0.99552447,0.0022513836,0.001538531,0.00007647189,0.00054728176,0.000061872204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006264932,0.00016874431,0.0004932313,0.0000635813,0.00006124038,0.000010273113,0.00018399765,0.00015738716,0.000498936],"category_scores_gemma":[0.0006397708,0.00011224068,0.00020660288,0.00021329074,0.0003897725,0.0004463272,0.00007049288,0.0006133604,0.000002589131],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038894422,0.0060270648,0.024539763,0.00012176409,0.0077049513,0.00031488578,0.010371684,0.00035606933,0.5186463,0.00067385216,0.12516461,0.26718464],"study_design_scores_gemma":[0.0071158903,0.0034058548,0.0011749248,0.00004287878,0.0008669737,0.0004602931,0.0034479073,0.0001347654,0.08534823,0.000018864874,0.8978756,0.000107830645],"about_ca_topic_score_codex":0.00017729639,"about_ca_topic_score_gemma":0.000015997482,"teacher_disagreement_score":0.772711,"about_ca_system_score_codex":0.000688891,"about_ca_system_score_gemma":0.0007638576,"threshold_uncertainty_score":0.5462999},"labels":[],"label_agreement":null},{"id":"W3016331201","doi":"10.4103/jpbs.jpbs_11_20","title":"Perspective, perceptions, and promulgation of biosimilars: A questionnaire-based study to assess and understand the current challenges of biosimilars to the potential and intended users","year":2020,"lang":"en","type":"article","venue":"Journal of Pharmacy And Bioallied Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Government (linguistics); Agency (philosophy); Globe; Marketing; Product (mathematics); Medicine; Revenue; Public relations; Business; Accounting; Political science; Social science","score_opus":0.12276653306086659,"score_gpt":0.39407215095784653,"score_spread":0.27130561789697993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016331201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8970016,0.012409292,0.00081375934,0.08919476,0.00015215753,0.00039642947,0.00001656624,0.0000041712256,0.000011230429],"genre_scores_gemma":[0.9964352,0.0021894595,0.0005131469,0.00082391617,0.000031679145,0.0000020188618,1.4367741e-7,0.0000030125257,0.0000013905749],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99875563,0.0004056441,0.00034728838,0.00022926451,0.00012509647,0.00013705989],"domain_scores_gemma":[0.99927795,0.00016779736,0.00021750806,0.000060977545,0.00019616363,0.000079578705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001431441,0.00012686825,0.00025796136,0.00012810003,0.0002560492,0.000049656734,0.00019489694,0.000032774096,0.000010061937],"category_scores_gemma":[0.00022312389,0.00006352951,0.000043139054,0.00026452052,0.00091737835,0.00011112702,0.00010286402,0.00022277371,1.3836069e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039537596,0.0017564256,0.07956756,0.0004712141,0.0008749795,0.000010764998,0.05341649,0.00010234331,0.71900237,0.003169315,0.0015077335,0.13616706],"study_design_scores_gemma":[0.009888415,0.014898329,0.58206147,0.00089519954,0.0018264585,0.00019504763,0.28848627,0.0026366604,0.09216163,0.0027538675,0.0033184635,0.0008781731],"about_ca_topic_score_codex":0.000010235643,"about_ca_topic_score_gemma":0.00003189981,"teacher_disagreement_score":0.6268407,"about_ca_system_score_codex":0.0000134748425,"about_ca_system_score_gemma":0.000076336735,"threshold_uncertainty_score":0.33801186},"labels":[],"label_agreement":null},{"id":"W3019503267","doi":"10.1093/rheumatology/keaa110.006","title":"O07 Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy","year":2020,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Rituximab; Tocilizumab; Internal medicine; TNF inhibitor; Randomized controlled trial; Population; Clinical trial; Rheumatology; Rheumatoid arthritis; Cohort; Immunology; Adalimumab; Lymphoma","score_opus":0.11116563099218164,"score_gpt":0.3746286409324721,"score_spread":0.2634630099402905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019503267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98580766,0.00020022914,0.000553811,0.007583138,0.0021130585,0.0033291632,0.00007765658,0.00007245594,0.0002628262],"genre_scores_gemma":[0.96769947,0.000039600593,0.019966634,0.0107775945,0.00029127506,0.00029376548,0.00003516216,0.00006150091,0.0008349778],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946812,0.0024294897,0.0011851345,0.00093572104,0.00013395998,0.00063450856],"domain_scores_gemma":[0.99718755,0.0017933885,0.00020410716,0.00044552598,0.00011155361,0.00025786902],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028789109,0.00035184354,0.0011152879,0.000119222525,0.0001958793,0.0001122523,0.0009138858,0.0005606573,0.0002145948],"category_scores_gemma":[0.006149135,0.0003049634,0.00022327006,0.00053508027,0.00013933412,0.00013247643,0.0006277738,0.0006486372,0.00021499916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.933294,0.0004236953,0.00016069625,0.000010403955,0.00014856967,0.000033083677,0.00074466725,0.0000020446555,0.046649784,0.0001142374,0.0031571388,0.015261711],"study_design_scores_gemma":[0.8337022,0.009595657,0.0008862482,0.00016489596,0.00009201125,0.0000012170433,0.0002416576,0.000031072097,0.0735506,0.00031741333,0.08061291,0.0008040962],"about_ca_topic_score_codex":0.00003242119,"about_ca_topic_score_gemma":0.00015650269,"teacher_disagreement_score":0.09959175,"about_ca_system_score_codex":0.0000896359,"about_ca_system_score_gemma":0.00019734656,"threshold_uncertainty_score":0.9999403},"labels":[],"label_agreement":null},{"id":"W3020398921","doi":"10.17511/ijoso.2019.i03.09","title":"A real life experience with novel biosimilar InfimabTM in biologic naive patients with active rheumatoid arthritis","year":2019,"lang":"en","type":"article","venue":"Surgical Update International Journal of Surgery and Orthopedics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Biosimilar; Erythrocyte sedimentation rate; Rheumatoid arthritis; Infliximab; Internal medicine; Adverse effect; Visual analogue scale; Methotrexate; Physical therapy; Disease","score_opus":0.014851527391208853,"score_gpt":0.25739482511318906,"score_spread":0.24254329772198022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020398921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974836,0.0006322476,0.000095658,0.0006789779,0.0006166592,0.00010701215,0.00010320883,0.000009240779,0.00027338247],"genre_scores_gemma":[0.9923973,0.0067093344,0.00032575673,0.000435029,0.000042571126,0.000003087423,0.000041863324,0.000011083419,0.000033993325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984666,0.00015714706,0.000632993,0.00026571288,0.00019708072,0.00028043948],"domain_scores_gemma":[0.998331,0.00058972836,0.00043712292,0.00010282453,0.00044406566,0.000095245334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005325167,0.00020939604,0.00055721146,0.00026149134,0.000046263525,0.00003379479,0.00019446817,0.00021112528,0.00049981783],"category_scores_gemma":[0.00015170353,0.00012541842,0.00010914291,0.00021370602,0.00038337213,0.0003143393,0.00008985325,0.00047917396,0.000008235809],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053215194,0.00043418538,0.97671753,0.000006986578,0.0003094603,0.00022164673,0.00014210568,0.00001107859,0.00030649116,0.00045999658,0.000086668166,0.015982345],"study_design_scores_gemma":[0.011718211,0.0012788115,0.91974014,0.00092877593,0.000041873944,0.0013603218,0.000777663,0.000026527034,0.0026272754,0.00010807258,0.060640376,0.00075194734],"about_ca_topic_score_codex":0.000020292844,"about_ca_topic_score_gemma":0.000009773885,"teacher_disagreement_score":0.060553707,"about_ca_system_score_codex":0.000035261586,"about_ca_system_score_gemma":0.00015269262,"threshold_uncertainty_score":0.54726547},"labels":[],"label_agreement":null},{"id":"W3021954828","doi":"10.1016/j.pharma.2020.04.004","title":"Interchangeabilité et substitution des biosimilaires","year":2020,"lang":"fr","type":"review","venue":"Annales Pharmaceutiques Françaises","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Humanities; Context (archaeology); Political science; Medicine; Philosophy; Geography","score_opus":0.173670899507864,"score_gpt":0.42924096161169534,"score_spread":0.2555700621038314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021954828","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031438173,0.9814738,0.0009108688,0.00838806,0.0021842213,0.0012440644,0.001009324,0.0003467208,0.0041285767],"genre_scores_gemma":[0.004336299,0.98408246,0.0021019008,0.006340673,0.00052898744,0.00015563182,0.00035839193,0.00012524718,0.0019704371],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99174124,0.0038493318,0.0015187982,0.0014611237,0.00016141708,0.0012680638],"domain_scores_gemma":[0.99663067,0.0014700403,0.00056801573,0.00061205745,0.00034581445,0.00037339033],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0014098436,0.0014573882,0.0028590949,0.00032893647,0.0006392868,0.00013697273,0.001091269,0.0018030409,0.008228999],"category_scores_gemma":[0.0008425245,0.0011851571,0.001687083,0.0008471289,0.0048519755,0.00041713088,0.00061582273,0.002521042,0.0022961367],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027919613,0.00052831834,0.0003179144,0.016576525,0.0018658638,0.00017792969,0.0010885072,5.814358e-7,0.0017764701,0.0047900416,0.015108907,0.9574897],"study_design_scores_gemma":[0.0006027804,0.0005482792,0.00012619642,0.00944946,0.0024445148,0.0003861159,0.00008702314,0.000020938365,0.01306045,0.00051917724,0.9715709,0.0011841533],"about_ca_topic_score_codex":0.00015579344,"about_ca_topic_score_gemma":0.00016740385,"teacher_disagreement_score":0.956462,"about_ca_system_score_codex":0.0002256356,"about_ca_system_score_gemma":0.0005443352,"threshold_uncertainty_score":0.99981755},"labels":[],"label_agreement":null},{"id":"W3024140734","doi":"10.1002/9781119187547.ch17","title":"Clinical Validation and Biomarker Translation","year":2020,"lang":"en","type":"other","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure","funders":"","keywords":"Biomarker; Biomarker discovery; Food and drug administration; Computer science; Translational research; Bench to bedside; Data science; Risk analysis (engineering); Medicine; Proteomics; Computational biology; Medical physics; Pathology; Biology","score_opus":0.1014800801377704,"score_gpt":0.37883957309877314,"score_spread":0.2773594929610027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024140734","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010549138,0.005903443,0.006285025,0.0023603314,0.00077208976,0.00022662584,0.00004310239,0.00018538542,0.9842135],"genre_scores_gemma":[0.0010426099,0.0016877296,0.016535096,0.0013522594,0.00015968848,0.000004273699,0.00019731831,0.00014956301,0.97887146],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99917024,0.0002339351,0.00021254136,0.00027040552,0.0000141818355,0.000098663455],"domain_scores_gemma":[0.9996878,0.00011049164,0.000071723654,0.00010236293,0.000005667294,0.000021937318],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020497285,0.00012580636,0.00027237457,0.000050977585,0.000017882978,0.0000104991395,0.000056065364,0.00080466154,0.016351577],"category_scores_gemma":[0.0000386179,0.00009020888,0.00007864084,0.00005534298,0.0001622272,0.000012882417,0.000021381753,0.00019082233,0.00025145247],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024875491,0.000023432816,0.00029565435,0.000022954802,0.00020487803,6.418599e-7,0.000004255741,6.2294797e-10,0.0020769206,0.00036814722,0.7378621,0.25911614],"study_design_scores_gemma":[0.00040541936,0.000055222794,0.0005233602,0.00002197346,0.00010991077,0.0000034114667,0.000005498733,0.000005259241,0.0008108946,0.00008271275,0.9978503,0.00012604098],"about_ca_topic_score_codex":0.00001947912,"about_ca_topic_score_gemma":0.00001023141,"teacher_disagreement_score":0.25998822,"about_ca_system_score_codex":0.0000019345612,"about_ca_system_score_gemma":0.000010741246,"threshold_uncertainty_score":0.9845476},"labels":[],"label_agreement":null},{"id":"W3025089949","doi":"10.1016/j.jval.2020.04.093","title":"PBI27 TRENDS IN AVERAGE SALES PRICES OF BIOLOGICS REIMBURSED BY THE MEDICARE PART B PROGRAM (FIRST QUARTER 2010-FIRST QUARTER 2020)","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Biosimilar; Medicine; Medicaid; Family medicine; Actuarial science; Business; Internal medicine; Health care; Economics","score_opus":0.048426148946019404,"score_gpt":0.3161614695657245,"score_spread":0.26773532061970506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025089949","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29574254,0.04520002,0.00033573806,0.6499808,0.002965445,0.0028035084,0.0007534197,0.00031939408,0.0018991416],"genre_scores_gemma":[0.9935315,0.0016603942,0.0008449969,0.003387723,0.00010944688,0.00007081101,0.00017017192,0.00001825852,0.00020664492],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99706274,0.00091612997,0.0008734682,0.00047243977,0.00008314071,0.0005920585],"domain_scores_gemma":[0.9986701,0.0006025209,0.0002880422,0.00032013797,0.00003387042,0.00008532382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013033071,0.0002392253,0.0006079704,0.00009889976,0.0001259825,0.000013641682,0.00041427417,0.00042620004,0.00044032533],"category_scores_gemma":[0.0001865031,0.0001471338,0.0001322085,0.00066865276,0.00044122478,0.000044195465,0.00007355124,0.0006867231,0.00003224145],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010569998,0.0023311349,0.09858924,0.001138535,0.00034790282,0.000048211794,0.013143524,0.0001501206,0.0023518128,0.0014695723,0.769499,0.109873936],"study_design_scores_gemma":[0.0037725165,0.0057138205,0.05665585,0.00050973723,0.000058797857,0.00003129006,0.002954678,0.0017230156,0.0013645475,0.00041132796,0.9261424,0.0006620248],"about_ca_topic_score_codex":0.0009261159,"about_ca_topic_score_gemma":0.00053293636,"teacher_disagreement_score":0.697789,"about_ca_system_score_codex":0.000054435233,"about_ca_system_score_gemma":0.000082105376,"threshold_uncertainty_score":0.59999424},"labels":[],"label_agreement":null},{"id":"W3027025576","doi":"10.1016/j.jval.2020.04.958","title":"PND66 RECENT EVOLUTION OF THE MARKET FOR DISEASE-MODIFYING DRUGS FOR MULTIPLE SCLEROSIS IN CANADA","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Teriflunomide; Fingolimod; Glatiramer acetate; Medical prescription; Dimethyl fumarate; Medicine; Multiple sclerosis; Ocrelizumab; Pediatrics; Family medicine; Internal medicine; Pharmacology; Psychiatry","score_opus":0.10127915638511291,"score_gpt":0.28736479265838666,"score_spread":0.18608563627327374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027025576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74027145,0.027636599,0.009958549,0.20836717,0.0031694472,0.00753949,0.0028625298,0.000041174382,0.00015357726],"genre_scores_gemma":[0.9962121,0.00023674658,0.0016491391,0.0017849465,0.000019241683,0.00005409235,0.0000081424605,0.000007619046,0.000027942619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875337,0.00035644608,0.00036888296,0.00019681803,0.00003188176,0.0002925947],"domain_scores_gemma":[0.9990153,0.00066778687,0.00011408388,0.00012313569,0.00003429029,0.000045417644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063749665,0.00007899786,0.00022903986,0.00002770295,0.00007129516,0.0000019242943,0.00013856842,0.0000656094,0.000025219175],"category_scores_gemma":[0.0006772268,0.000058079782,0.0000620695,0.0002023948,0.000043587006,0.000015238402,0.000037577578,0.00013117817,2.4962694e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011389164,0.0008878036,0.60541654,0.007421104,0.00025989916,0.0000015992684,0.0028089613,0.004591803,0.041683614,0.007417884,0.10894034,0.20918131],"study_design_scores_gemma":[0.0125549855,0.0007160387,0.6375237,0.0015691571,0.00009016876,0.0000014167293,0.002698467,0.14026843,0.019446883,0.0040583657,0.18040015,0.0006722026],"about_ca_topic_score_codex":0.38674632,"about_ca_topic_score_gemma":0.14590958,"teacher_disagreement_score":0.25594068,"about_ca_system_score_codex":0.000517431,"about_ca_system_score_gemma":0.0012141628,"threshold_uncertainty_score":0.86967534},"labels":[],"label_agreement":null},{"id":"W3029368205","doi":"10.1200/jco.2020.38.15_suppl.8525","title":"KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Population; Cohort; Multiple myeloma; Regimen; Refractory (planetary science); Oncology","score_opus":0.14089333641949836,"score_gpt":0.4538049989044175,"score_spread":0.31291166248491914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029368205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974164,0.00017510954,0.00001596017,0.0016078386,0.0002001593,0.00046761497,0.000029490424,0.0000049317996,0.00008249055],"genre_scores_gemma":[0.99832606,0.00013528463,0.0010376143,0.00040709547,0.00002547826,0.000004028831,0.0000031898476,0.00001153339,0.00004970616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958459,0.0012410446,0.0023189234,0.00028786255,0.000096358985,0.00020988352],"domain_scores_gemma":[0.99496716,0.0030778584,0.0014130737,0.00015781977,0.00021948476,0.00016459126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086872984,0.0002032217,0.0023012524,0.00016940729,0.00002895562,0.0000038185976,0.00014675099,0.00033634453,0.000037967187],"category_scores_gemma":[0.0012112024,0.0001204223,0.00013843687,0.00020109817,0.00023829244,0.000053052256,0.000095779964,0.00057868916,9.953279e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010531825,0.0067370553,0.9401542,0.000022487438,0.00069096993,0.000029112867,0.0012726686,0.000004562692,0.0004824735,0.00000396412,0.00012721775,0.039943494],"study_design_scores_gemma":[0.018239332,0.066926636,0.91151875,0.00006509216,0.00033359168,0.0000029369908,0.00078277825,0.000012090418,0.0005606471,0.0000061723645,0.0014458295,0.000106151594],"about_ca_topic_score_codex":0.00037324065,"about_ca_topic_score_gemma":0.002592441,"teacher_disagreement_score":0.060189582,"about_ca_system_score_codex":0.000060168353,"about_ca_system_score_gemma":0.00014762604,"threshold_uncertainty_score":0.4910679},"labels":[],"label_agreement":null},{"id":"W3030777068","doi":"10.3899/jrheum.200123","title":"Proceedings of the 2019 GRAPPA Collaborative Research Network Meeting","year":2020,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Library science; Medical physics; Family medicine; Medical education","score_opus":0.040104575538319656,"score_gpt":0.3177630868884238,"score_spread":0.27765851135010416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030777068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9415158,0.00877606,0.000067676934,0.046203613,0.00070007675,0.0002453088,0.00000883947,0.00000803777,0.002474559],"genre_scores_gemma":[0.99767834,0.0010269524,0.0005880694,0.0004672763,0.000023868668,8.224815e-7,2.1057573e-7,0.000008734412,0.00020572206],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99804914,0.00084955525,0.00055567845,0.000094561095,0.000095609685,0.00035543274],"domain_scores_gemma":[0.99735636,0.0011744807,0.00056471257,0.00009493422,0.0007782772,0.000031216423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037180325,0.00009855649,0.00043846015,0.00004377882,0.000268784,0.000007918073,0.00071665674,0.00019735507,0.00010425986],"category_scores_gemma":[0.0011936154,0.000044930126,0.000114911236,0.00075871195,0.0009834475,0.00004214568,0.00025059504,0.00096578395,0.000013057968],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021865708,0.00010938458,0.10353842,0.000085493564,0.0009961082,0.0000017903093,0.0047197477,0.00003457867,0.20739697,0.029398968,0.6499304,0.0016015499],"study_design_scores_gemma":[0.008653585,0.0076294346,0.031354904,0.001997174,0.0012156176,0.007874317,0.028495565,0.00015282954,0.49351534,0.043598156,0.3745762,0.00093687355],"about_ca_topic_score_codex":0.000025957565,"about_ca_topic_score_gemma":0.000006170906,"teacher_disagreement_score":0.28611836,"about_ca_system_score_codex":0.000012385484,"about_ca_system_score_gemma":0.00012088893,"threshold_uncertainty_score":0.41959044},"labels":[],"label_agreement":null},{"id":"W3031412128","doi":"10.1080/03009742.2020.1732458","title":"Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis","year":2020,"lang":"en","type":"article","venue":"Scandinavian Journal of Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Rheumatoid arthritis; Biosimilar; Etanercept; Internal medicine; Infliximab; Tolerability; Adalimumab; Immunogenicity; Rheumatology; Gastroenterology; Tumor necrosis factor alpha; Immunology; Antibody; Adverse effect","score_opus":0.04119759123436458,"score_gpt":0.33288732878088007,"score_spread":0.2916897375465155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031412128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825912,0.01637293,0.000045656096,0.00045654768,0.0001830345,0.00014897104,0.00018713885,0.0000053145027,0.000009221328],"genre_scores_gemma":[0.9934304,0.00627,0.0002484434,0.000029476298,0.0000035836467,0.0000011696719,0.000004370588,0.000010954905,0.0000016367821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639356,0.0007978153,0.0020737136,0.00029837902,0.000104769104,0.00033178373],"domain_scores_gemma":[0.9967363,0.0009721013,0.001585097,0.00023411041,0.00038042376,0.000091961294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007600363,0.00028882743,0.0029099362,0.0006523206,0.000046326753,0.000005191732,0.00029499468,0.00032757397,0.00021328751],"category_scores_gemma":[0.0015289099,0.000211008,0.00075590087,0.001040497,0.001187878,0.00008280732,0.00011705565,0.00048587992,8.937254e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002954153,0.0005805781,0.7850453,0.00015640173,0.008516528,0.000011469181,0.002202622,0.000055756183,0.19675611,0.000073046314,0.00016085357,0.0034871344],"study_design_scores_gemma":[0.005613331,0.0056052348,0.83700234,0.0012132094,0.00080412324,0.00020734899,0.000869411,0.000038519076,0.14814861,0.00020064622,0.00001424273,0.0002829711],"about_ca_topic_score_codex":0.00019301433,"about_ca_topic_score_gemma":0.000032864085,"teacher_disagreement_score":0.051956996,"about_ca_system_score_codex":0.000065491135,"about_ca_system_score_gemma":0.00010895616,"threshold_uncertainty_score":0.8604656},"labels":[],"label_agreement":null},{"id":"W3031883039","doi":"10.1007/s40265-020-01333-9","title":"Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases","year":2020,"lang":"en","type":"erratum","venue":"Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Biosimilar; Medicine; Immune system; Pharmacotherapy; Intensive care medicine; Immunology; Internal medicine","score_opus":0.010567851533116044,"score_gpt":0.26147632977104385,"score_spread":0.2509084782379278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031883039","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036935988,0.36377776,0.00009871364,0.04579029,0.5649326,0.002513428,0.0082558915,0.000692058,0.010245713],"genre_scores_gemma":[0.10199978,0.072553575,0.0013919013,0.06900632,0.04017459,0.0008937062,0.026284816,0.001365555,0.6863298],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753267,0.0004169301,0.0007169272,0.00060569186,0.00013247978,0.0005953089],"domain_scores_gemma":[0.99817175,0.00042213887,0.0004479317,0.00066685054,0.00020065263,0.000090700836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003987705,0.0005012208,0.00088587054,0.00010434402,0.00031344363,0.000044476506,0.0008158031,0.0012268955,0.00036653166],"category_scores_gemma":[0.0004536131,0.00033713883,0.00049020146,0.00053525675,0.0003388239,0.000058470156,0.00047522056,0.0018864624,0.00025021055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001971868,0.00006261425,0.00013135478,0.00013179448,0.00038302867,0.000004382934,0.00079383096,0.000003960691,0.001725354,0.00004024233,0.9704727,0.026053546],"study_design_scores_gemma":[0.0004089918,0.00014911685,0.0051899212,0.00039388897,0.000260266,0.000009641793,0.0013003276,0.00002261386,0.003872469,0.000020418918,0.98796743,0.00040488923],"about_ca_topic_score_codex":0.000030217752,"about_ca_topic_score_gemma":0.00006263372,"teacher_disagreement_score":0.67608404,"about_ca_system_score_codex":0.0000637121,"about_ca_system_score_gemma":0.00020086081,"threshold_uncertainty_score":0.9999081},"labels":[],"label_agreement":null},{"id":"W3032626619","doi":"10.1002/pds.5008","title":"Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia—An interim report","year":2020,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Ministry of Health","keywords":"Medicine; Biosimilar; Interim; Cohort; Etanercept; Christian ministry; Interim analysis; Family medicine; Demography; Cohort study; Health policy; Pharmacoepidemiology; Environmental health; Public health; Clinical trial; Internal medicine; Nursing; Geography","score_opus":0.05374257445547603,"score_gpt":0.36162163834700495,"score_spread":0.3078790638915289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032626619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811262,0.010876566,0.0010703461,0.0056336364,0.0006243544,0.00041986824,0.00015456261,0.00004304221,0.00005145404],"genre_scores_gemma":[0.99087656,0.002182553,0.0008957325,0.0057927314,0.00005602258,0.000015434363,0.00014844968,0.000016066468,0.00001647621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948974,0.0026487303,0.0012826779,0.0006791791,0.000042124433,0.00044986547],"domain_scores_gemma":[0.9984263,0.0009576253,0.000298027,0.00017158416,0.000022454135,0.00012401892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036546707,0.00018212915,0.0010342259,0.00007262607,0.0001231962,0.000019541885,0.00021886824,0.0002623914,0.00023065237],"category_scores_gemma":[0.00040124537,0.00023523,0.000101225836,0.00031760996,0.00012017014,0.0001695493,0.000170799,0.00045326762,0.0000033995723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004385037,0.00016055837,0.92472816,0.0001506881,0.000111694724,0.000058893962,0.0037771899,0.000019459361,0.009320181,0.000008408638,0.00039115403,0.06083512],"study_design_scores_gemma":[0.0042299675,0.00029993305,0.9718392,0.0006438966,0.00007896776,0.000029122446,0.0018939207,0.00031490816,0.005234105,0.00073740096,0.014237271,0.0004613389],"about_ca_topic_score_codex":0.015590911,"about_ca_topic_score_gemma":0.0068508214,"teacher_disagreement_score":0.060373783,"about_ca_system_score_codex":0.000045443423,"about_ca_system_score_gemma":0.000058149217,"threshold_uncertainty_score":0.99096435},"labels":[],"label_agreement":null},{"id":"W3034345646","doi":"10.1136/annrheumdis-2020-eular.1746","title":"THU0179 PERSISTENCE IN RHEUMATOID ARTHRITIS PATIENTS ON BIOSIMILAR AND BIO-ORIGINATOR ETANERCEPT: A POOLED ANALYSIS OF PAN-CANADIAN COHORTS","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Université de Sherbrooke; Mount Sinai Hospital; McGill University; Public Health Ontario; Montreal Heart Institute; McGill University Health Centre","funders":"","keywords":"Medicine; Etanercept; Rheumatoid arthritis; Cohort; Discontinuation; Internal medicine; Proportional hazards model; Hazard ratio; Biosimilar; Persistence (discontinuity); Cohort study; Demography; Confidence interval","score_opus":0.034141930845011374,"score_gpt":0.2731696901167273,"score_spread":0.23902775927171593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034345646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98818177,0.0059639025,0.0000033286924,0.0045450167,0.00008825021,0.0002716468,0.000718601,0.0000104961455,0.00021697974],"genre_scores_gemma":[0.99507916,0.003027706,0.000033846503,0.0017929614,0.0000019800088,0.000007468708,0.000028703053,0.000008794183,0.000019379724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845433,0.00032857424,0.0005182615,0.0002966416,0.000100190824,0.00030201222],"domain_scores_gemma":[0.9989211,0.00027669835,0.00024331007,0.00032324035,0.00010477524,0.00013085087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021046161,0.00019213508,0.0007464343,0.00025828969,0.00008354821,0.00001290309,0.00031456054,0.00013349754,0.00038239948],"category_scores_gemma":[0.0008094375,0.00013185015,0.0003370138,0.0008052095,0.00044004072,0.000054976143,0.00008104033,0.00012913242,0.000008195417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005074473,0.0010839868,0.8740875,0.00034631958,0.0067337197,0.000007606627,0.0015540053,0.000044039243,0.001063627,0.0016256758,0.0065232506,0.10642281],"study_design_scores_gemma":[0.00082449376,0.00034417008,0.9908437,0.0005934292,0.00072147895,9.650707e-7,0.00036403604,0.00026555045,0.0045663025,0.0003337488,0.00089511374,0.00024698948],"about_ca_topic_score_codex":0.0015253103,"about_ca_topic_score_gemma":0.0011968846,"teacher_disagreement_score":0.11675621,"about_ca_system_score_codex":0.000012981826,"about_ca_system_score_gemma":0.00008222408,"threshold_uncertainty_score":0.53766924},"labels":[],"label_agreement":null},{"id":"W3034961972","doi":"10.1136/annrheumdis-2020-eular.1233","title":"THU0207 SUSTAINABILITY OF RESPONSE TO UPADACITINIB AS MONOTHERAPY OR IN COMBINATION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Discontinuation; Placebo; Methotrexate; Post-hoc analysis; Gastroenterology; Pathology","score_opus":0.020795542196623648,"score_gpt":0.2992270094505657,"score_spread":0.278431467253942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034961972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826612,0.00046504484,0.00011398682,0.0155821545,0.000038828985,0.00092978147,0.00018886793,0.000012948138,0.0000071939107],"genre_scores_gemma":[0.99875134,0.00015154776,0.00014166713,0.00079813035,0.00000109614,0.00004422979,0.000005827752,0.000012409174,0.00009374666],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997386,0.0014447662,0.00053082674,0.0002728568,0.00013128613,0.00023426885],"domain_scores_gemma":[0.9977679,0.0013299296,0.00021607148,0.00027498472,0.00030536432,0.000105722116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009867016,0.00016696582,0.00045955236,0.00011644854,0.0000759179,0.0000146966195,0.00023262217,0.00008562039,0.00020793302],"category_scores_gemma":[0.007316905,0.00010542424,0.00009942789,0.00037682452,0.0004167466,0.00007767223,0.00012683372,0.00009627163,0.000004189838],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37418196,0.0037526262,0.20444174,0.0008583064,0.00079742534,0.000011733614,0.005132592,0.00010049715,0.0025868744,0.0016170754,0.0024501905,0.40406898],"study_design_scores_gemma":[0.0033820178,0.0024085515,0.98344916,0.0010195517,0.000023401786,0.0000019174897,0.00058863347,0.000033195913,0.0068519944,0.0015036734,0.00055737543,0.00018053642],"about_ca_topic_score_codex":0.00007223553,"about_ca_topic_score_gemma":0.000015687801,"teacher_disagreement_score":0.77900743,"about_ca_system_score_codex":0.000022878026,"about_ca_system_score_gemma":0.00020319002,"threshold_uncertainty_score":0.8759547},"labels":[],"label_agreement":null},{"id":"W3035652297","doi":"10.1002/bmc.4917","title":"Application of tail vein serial microsampling for plasma or dried plasma spots in toxicokinetic assessment in rats using acetaminophen as the model compound","year":2020,"lang":"en","type":"article","venue":"Biomedical Chromatography","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arbutus Biopharma (Canada)","funders":"","keywords":"Chemistry; Toxicokinetics; Acetaminophen; Chromatography; Urine; Plasma concentration; Dried blood; Blood plasma; Creatinine; Vein; Anesthesia; Tail vein; Pentobarbital; Pharmacology; Internal medicine; Medicine; Metabolism; Biochemistry","score_opus":0.04931670453722956,"score_gpt":0.33103298304377643,"score_spread":0.28171627850654685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035652297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97490114,0.000118123855,0.02142421,0.002295135,0.00019330434,0.0008949374,0.000102713115,0.000028866347,0.000041599294],"genre_scores_gemma":[0.97941417,0.000020354355,0.019822536,0.00051624386,0.00005306138,0.00007027752,0.00007702084,0.000018124429,0.000008203663],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998258,0.00016109116,0.000666369,0.00041721688,0.00010372599,0.0003935774],"domain_scores_gemma":[0.99911463,0.00038369175,0.00018095333,0.00020805249,0.00004206376,0.00007062029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050895126,0.00021395569,0.000506587,0.00019333673,0.0000887043,0.000020113173,0.00036608413,0.00042040824,0.000055837016],"category_scores_gemma":[0.00010804457,0.00014592502,0.00015518966,0.00084529485,0.0006231537,0.00004294666,0.00012054996,0.00033368595,0.0000031136321],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010096844,0.00041431072,0.0020842517,0.00015792414,0.00011345496,0.0000049480705,0.00030932747,0.00012542495,0.9905862,0.0007178107,0.00029005596,0.0041865883],"study_design_scores_gemma":[0.015030659,0.0017156382,0.012620665,0.00030892363,0.00029669967,0.000069944326,0.00095876347,0.52593327,0.4229203,0.0020141066,0.017197588,0.00093347114],"about_ca_topic_score_codex":0.000059112434,"about_ca_topic_score_gemma":0.000029853445,"teacher_disagreement_score":0.56766593,"about_ca_system_score_codex":0.00003790936,"about_ca_system_score_gemma":0.00016894986,"threshold_uncertainty_score":0.595065},"labels":[],"label_agreement":null},{"id":"W3036912484","doi":"10.1038/s41557-020-0496-2","title":"Crowdsourcing drug discovery for pandemics","year":2020,"lang":"en","type":"article","venue":"Nature Chemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emera (Canada)","funders":"Wellcome Trust","keywords":"Chemistry; Drug discovery; Crowdsourcing; Pandemic; Coronavirus disease 2019 (COVID-19); Drug; Computational biology; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Data science; Nanotechnology; Pharmacology; Biochemistry; World Wide Web; Virology; Disease; Computer science; Infectious disease (medical specialty); Internal medicine","score_opus":0.014385035185342308,"score_gpt":0.27561631463350306,"score_spread":0.26123127944816077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036912484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84023184,0.047438357,0.01728565,0.06569537,0.0024178338,0.0009520179,0.0010251735,0.0006747774,0.024278961],"genre_scores_gemma":[0.986504,0.000033378474,0.0016288458,0.005192024,0.00030170652,0.000008432922,0.000077153665,0.000015994203,0.006238435],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99930525,0.000018591778,0.00014492901,0.00028087237,0.000022577611,0.00022775444],"domain_scores_gemma":[0.9995551,0.00018542071,0.000052148895,0.00013152961,0.000039921393,0.00003586292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012266627,0.00012956634,0.00019859688,0.000005196917,0.00007846056,0.000019553514,0.00019738327,0.0006821244,0.00011729744],"category_scores_gemma":[0.00043853107,0.00010205847,0.00014028128,0.00007822377,0.0000896986,0.000042076932,0.0000624265,0.0007947558,0.00000675947],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112009744,0.000019352801,0.0004510784,0.00011128635,0.0000689281,0.0000014059339,0.000050461455,5.25064e-7,0.9536378,0.00011988751,0.04409447,0.0013327966],"study_design_scores_gemma":[0.00044368824,0.000011086293,0.000055039905,0.000013666416,0.00004137261,0.0000068014406,0.00007396034,0.000013537768,0.7826691,0.0001885963,0.21635923,0.00012386311],"about_ca_topic_score_codex":6.816824e-7,"about_ca_topic_score_gemma":2.5659082e-7,"teacher_disagreement_score":0.17226477,"about_ca_system_score_codex":0.000014866302,"about_ca_system_score_gemma":0.000029201386,"threshold_uncertainty_score":0.5261168},"labels":[],"label_agreement":null},{"id":"W3037698584","doi":"10.7554/elife.52687.sa2","title":"Author response: Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway","year":2020,"lang":"en","type":"peer-review","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Squalene; Antibody response; Antibody; CD8; Adjuvant; Biology; Chemistry; Immunology; Computational biology; Biochemistry; Immune system","score_opus":0.06947525752184332,"score_gpt":0.38132644575530306,"score_spread":0.31185118823345975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037698584","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035316725,0.24842323,0.009191586,0.6911943,0.015773114,0.0051784427,0.022943439,0.0012362958,0.0025279438],"genre_scores_gemma":[0.019896172,0.0065854597,0.00818622,0.06726652,0.00042758547,0.00012394463,0.0040199584,0.0002845787,0.8932096],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9870651,0.0062591434,0.0022666096,0.0023965118,0.00046932895,0.0015433092],"domain_scores_gemma":[0.99191344,0.0041666464,0.0009878763,0.0020183586,0.0006372573,0.00027640993],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0036343068,0.001635611,0.003470475,0.0003608114,0.0004654446,0.000081904116,0.0015674047,0.0030444693,0.016891655],"category_scores_gemma":[0.0038682779,0.0012142381,0.0011681913,0.00075951574,0.00032378442,0.00011644895,0.00076984754,0.00316169,0.0022959942],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011806871,0.0005075001,0.000021079994,0.0017107084,0.00042729976,0.0003420359,0.000026187392,0.0000028750383,0.308878,0.000037295114,0.67275107,0.0034890482],"study_design_scores_gemma":[0.0035306895,0.0014847218,0.00024681116,0.0018918986,0.0009433629,0.000057007484,0.000021871272,0.000051910327,0.19818985,0.000055938588,0.79223126,0.0012946939],"about_ca_topic_score_codex":0.00040941613,"about_ca_topic_score_gemma":0.0000421169,"teacher_disagreement_score":0.8906816,"about_ca_system_score_codex":0.00021470322,"about_ca_system_score_gemma":0.001033597,"threshold_uncertainty_score":0.9996391},"labels":[],"label_agreement":null},{"id":"W3046818137","doi":"10.1177/1078155220945374","title":"Off-label infusion of biosimilar bevacizumab: A provincial experience","year":2020,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Bevacizumab; Biosimilar; Medicine; Pharmacology; Surgery; Internal medicine; Chemotherapy","score_opus":0.09157931705200487,"score_gpt":0.4237562736411736,"score_spread":0.3321769565891687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046818137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82385075,0.015851539,0.0023806812,0.13810425,0.0042408183,0.0007384516,0.00006759245,0.000061126855,0.014704772],"genre_scores_gemma":[0.9609837,0.0027338546,0.01894616,0.016756028,0.00040839557,0.000004835355,0.0000023367954,0.000022328957,0.00014236802],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99713063,0.0011244619,0.0010711938,0.00022859618,0.00013596033,0.00030916758],"domain_scores_gemma":[0.9960798,0.0013531988,0.001637533,0.00014133466,0.0006607327,0.00012740625],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013522852,0.00019789733,0.0006749202,0.000119096185,0.000109564775,0.00001171027,0.0004952066,0.00026438126,0.0010080215],"category_scores_gemma":[0.0039627394,0.000150798,0.00018757452,0.00034110888,0.00042211407,0.0005683334,0.00019362081,0.0011046462,0.0000415756],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008512239,0.0011983018,0.0007057436,0.00004087066,0.00044229656,0.0002388289,0.0019820065,0.0000022690492,0.8342089,0.00016345773,0.018073665,0.13443144],"study_design_scores_gemma":[0.0054500974,0.002775508,0.00014234219,0.000023373559,0.00045854837,0.0010216215,0.0007919401,0.00006395536,0.22917508,0.00002264831,0.7599379,0.0001370292],"about_ca_topic_score_codex":0.000014883282,"about_ca_topic_score_gemma":0.0000015524539,"teacher_disagreement_score":0.7418642,"about_ca_system_score_codex":0.00008502458,"about_ca_system_score_gemma":0.0006019888,"threshold_uncertainty_score":0.99990517},"labels":[],"label_agreement":null},{"id":"W3049495976","doi":"10.1186/s13075-020-02267-z","title":"Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis","year":2020,"lang":"en","type":"article","venue":"Arthritis Research & Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Samsung","keywords":"Medicine; Biosimilar; Rheumatoid arthritis; Rheumatology; Internal medicine; TNF inhibitor; Etanercept; Infliximab; Tumor necrosis factor alpha; Radiography; Antirheumatic Agents; Baseline (sea); Arthritis; Surgery","score_opus":0.062068501103256145,"score_gpt":0.34842242205797014,"score_spread":0.286353920954714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049495976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574653,0.032776587,0.000077832636,0.0075851516,0.00030809498,0.0011665522,0.0004654788,0.00010138237,0.000053614443],"genre_scores_gemma":[0.9507841,0.045392714,0.0011391982,0.0021868618,0.0000963247,0.0001078438,0.00023816264,0.000043853954,0.00001093405],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99580383,0.001809219,0.00053561985,0.00074516085,0.0003410345,0.00076514925],"domain_scores_gemma":[0.997999,0.0009283375,0.00010731476,0.00039940132,0.00042767738,0.00013823883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012467407,0.00032829275,0.0006820694,0.00033014678,0.0003027628,0.00006100049,0.00031456244,0.0002993991,0.0006065163],"category_scores_gemma":[0.00067066884,0.00023593708,0.00011913886,0.0009327572,0.0010442629,0.000117941454,0.000094560055,0.0010278255,0.000079353355],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074124164,0.001561836,0.1818664,0.000025520845,0.00029969573,0.00012112304,0.0005940682,0.0000014427592,0.011740475,0.00004771312,0.009314765,0.78701454],"study_design_scores_gemma":[0.07745557,0.038171258,0.41140294,0.00933153,0.00002293272,0.000010155126,0.0010980946,0.0006863321,0.13388175,0.0007875125,0.32460254,0.002549357],"about_ca_topic_score_codex":0.00002858107,"about_ca_topic_score_gemma":0.000036873065,"teacher_disagreement_score":0.7844652,"about_ca_system_score_codex":0.000044318964,"about_ca_system_score_gemma":0.000086041466,"threshold_uncertainty_score":0.9621235},"labels":[],"label_agreement":null},{"id":"W3082103308","doi":"10.1111/dth.14258","title":"Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis","year":2020,"lang":"en","type":"article","venue":"Dermatologic Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Biosimilar; Medicine; Adalimumab; Psoriasis; Dermatology; Internal medicine","score_opus":0.013045273013249392,"score_gpt":0.24891633927974494,"score_spread":0.23587106626649554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082103308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958758,0.0010209478,0.00082960847,0.0016831304,0.00008991474,0.00038176318,0.000056905767,0.000028221175,0.000033746124],"genre_scores_gemma":[0.9967595,0.000100124584,0.0011111441,0.001993397,0.000005626044,0.000009686837,0.0000100753105,0.000009523517,9.603601e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988392,0.00038308545,0.00023429503,0.00030619174,0.000037462643,0.0001997466],"domain_scores_gemma":[0.9993923,0.00031683283,0.000073433395,0.00013577708,0.000040249917,0.00004145026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014230702,0.00016574423,0.00046168774,0.00005213132,0.000046360306,0.000006821907,0.0001448404,0.00018547893,0.000090188616],"category_scores_gemma":[0.000056872967,0.00010645858,0.000039095536,0.0002207792,0.00007966438,0.000043213557,0.00004663013,0.00017213385,0.0000066294297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008049224,0.00025403328,0.9240422,0.000044315475,0.00031517967,0.000009165313,0.0006581591,0.000003428482,0.03322638,0.000432895,0.00016188931,0.032803133],"study_design_scores_gemma":[0.0070241163,0.00074611633,0.86410254,0.000069196205,0.000025330679,0.0000022867382,0.00008193025,0.0000061748415,0.121311285,0.0002947411,0.0061069475,0.00022930649],"about_ca_topic_score_codex":0.000036211946,"about_ca_topic_score_gemma":0.0000029233647,"teacher_disagreement_score":0.08808491,"about_ca_system_score_codex":0.000013491863,"about_ca_system_score_gemma":0.000015588825,"threshold_uncertainty_score":0.43412548},"labels":[],"label_agreement":null},{"id":"W3082385452","doi":"","title":"2020 Market Analysis of Pharmaceutical Formulations & Drug Delivery Conference October 30-31, 2020 | Vancouver, Canada","year":2020,"lang":"en","type":"article","venue":"Journal of Pharmaceutics & Drug Delivery Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Globe; Pharmaceutical industry; Solvency; Medicine; Business; Engineering; Risk analysis (engineering); Pharmacology; Finance","score_opus":0.09417312631810189,"score_gpt":0.39802624826675875,"score_spread":0.3038531219486569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082385452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9519895,0.019714123,0.000560136,0.017916793,0.0026747214,0.00077448617,0.0011057728,0.000037336016,0.0052271876],"genre_scores_gemma":[0.9884778,0.005990673,0.00085290184,0.0019606084,0.0002286047,0.0000041970443,0.000021591382,0.000028484363,0.0024350912],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99454874,0.0016882635,0.0014514163,0.00046679718,0.00077480933,0.001069986],"domain_scores_gemma":[0.99382174,0.002195616,0.00053428946,0.00031939134,0.0025320146,0.0005969215],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032713066,0.000349267,0.0011187231,0.0004484216,0.00031396016,0.00005432441,0.0010779684,0.00023531604,0.012325502],"category_scores_gemma":[0.00054118794,0.00029343704,0.000574314,0.0023260752,0.0006136436,0.0002597004,0.0004862591,0.0025809966,0.000025216485],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020031065,0.00040726847,0.0070994827,0.00015140868,0.006864799,0.00029772308,0.0004950393,0.0002160559,0.116227865,0.000056865072,0.85572946,0.010450918],"study_design_scores_gemma":[0.0040559145,0.00031451497,0.0022516376,0.00011586072,0.005548905,0.00005116015,0.0017368724,0.034758896,0.20361525,0.00017507473,0.7467335,0.0006424551],"about_ca_topic_score_codex":0.005613617,"about_ca_topic_score_gemma":0.021665229,"teacher_disagreement_score":0.108996004,"about_ca_system_score_codex":0.0003387659,"about_ca_system_score_gemma":0.002356348,"threshold_uncertainty_score":0.9999518},"labels":[],"label_agreement":null},{"id":"W3082910282","doi":"10.1515/almed-2020-0040","title":"Evaluación crítica y meta-análisis de estudios de variación biológica para albúmina glicosilada, glucosa y HbA<sub>1c</sub>","year":2020,"lang":"es","type":"article","venue":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CARE Canada","funders":"","keywords":"Humanities; Philosophy","score_opus":0.029506133107721766,"score_gpt":0.3453670211682576,"score_spread":0.31586088806053586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082910282","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21656609,0.698447,0.009435898,0.06444062,0.0051404103,0.0022911278,0.0013819976,0.00052083953,0.0017760039],"genre_scores_gemma":[0.8100672,0.14546461,0.010045393,0.029850962,0.0037316543,0.0004450042,0.00010073347,0.00023272299,0.00006171897],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9845108,0.0063838544,0.0027250296,0.0024616045,0.0009000806,0.003018647],"domain_scores_gemma":[0.990045,0.004724302,0.0012640874,0.0014711161,0.0011984596,0.001297014],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.007865935,0.0019104123,0.0046386416,0.0005528646,0.0005758234,0.00009753361,0.0019350789,0.0020354725,0.0016088453],"category_scores_gemma":[0.01394481,0.0014846511,0.00048460663,0.005223504,0.0037482674,0.0009216472,0.0004313865,0.0036278535,0.00017394962],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004104066,0.0016499597,0.041076403,0.00321258,0.009712947,0.0029678687,0.012281956,0.00028262046,0.81722796,0.032731745,0.036929507,0.037822414],"study_design_scores_gemma":[0.0072466126,0.0045309854,0.005815703,0.0014557274,0.011597964,0.00012466808,0.0046276925,0.00040155352,0.18323919,0.0023955314,0.7764361,0.002128295],"about_ca_topic_score_codex":0.00009245879,"about_ca_topic_score_gemma":0.0001612183,"teacher_disagreement_score":0.73950654,"about_ca_system_score_codex":0.0009465036,"about_ca_system_score_gemma":0.002604774,"threshold_uncertainty_score":0.99936396},"labels":[],"label_agreement":null},{"id":"W3083932209","doi":"10.1254/jpssuppl.wcp2018.0_sy53-3","title":"Population Physiologically Based Pharmacokinetic Models (PBPK) for Macromolecular Drugs","year":2018,"lang":"en","type":"article","venue":"Proceedings for Annual Meeting of The Japanese Pharmacological Society","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Physiologically based pharmacokinetic modelling; Endocytic cycle; Pharmacokinetics; Monoclonal antibody; Chemistry; Extravasation; Population; Bioanalysis; Pharmacology; Small molecule; Endocytosis; Computational biology; Receptor; Biology; Medicine; Antibody; Biochemistry; Chromatography; Immunology","score_opus":0.027406586929592826,"score_gpt":0.31478954329759873,"score_spread":0.2873829563680059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083932209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907811,0.00036070216,0.0014237171,0.0029953502,0.00087051094,0.0022947737,0.0003446307,0.00017327072,0.0007559315],"genre_scores_gemma":[0.9842277,0.000015964013,0.01193615,0.0029527382,0.0002689784,0.0002449143,0.000023948398,0.000026749363,0.00030284416],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99804854,0.000097764525,0.00054095406,0.0005562061,0.00011806104,0.00063849374],"domain_scores_gemma":[0.9980777,0.0005601894,0.0003915503,0.00010476333,0.00080551044,0.00006030039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013947967,0.00031822184,0.00052530324,0.000025562475,0.000577453,0.000020623489,0.0006544843,0.00043706398,0.00012829997],"category_scores_gemma":[0.0004653503,0.00019053131,0.0008563752,0.00029821316,0.0007306121,0.00010399417,0.00022231709,0.00031157766,0.000002536143],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010891195,0.00033369908,0.00018085715,0.00021501974,0.00031588343,5.05234e-8,0.0008434095,0.00007053777,0.9813602,0.00045558112,0.013625406,0.0015102411],"study_design_scores_gemma":[0.005246886,0.001638611,0.0009975189,0.00011764556,0.0011082164,0.000005837648,0.001011848,0.03465257,0.93674946,0.010292417,0.007571668,0.0006073178],"about_ca_topic_score_codex":0.0000151314025,"about_ca_topic_score_gemma":1.7818819e-7,"teacher_disagreement_score":0.04461073,"about_ca_system_score_codex":0.00005882684,"about_ca_system_score_gemma":0.000023358418,"threshold_uncertainty_score":0.7769641},"labels":[],"label_agreement":null},{"id":"W3084337600","doi":"10.1002/cpt.2042","title":"Potential Cost Implications of Mandatory Non‐Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Institute for Clinical Evaluative Sciences; Women's College Hospital; University of Toronto","funders":"","keywords":"Biosimilar; Infliximab; Etanercept; Adalimumab; Medicine; Medical prescription; Market share; Business; Disease; Marketing; Pharmacology; Rheumatoid arthritis; Internal medicine","score_opus":0.0712620760253613,"score_gpt":0.40832476443640914,"score_spread":0.3370626884110478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084337600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9221973,0.0013447049,0.01079217,0.061971582,0.0011001722,0.0015448406,0.0010065761,0.000026909322,0.00001576523],"genre_scores_gemma":[0.94536805,0.0008307777,0.0004222798,0.053041812,0.000098941666,0.00013853615,0.00007350862,0.000013618996,0.000012470263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827886,0.00027147363,0.0007911205,0.00029659836,0.00003439096,0.00032757103],"domain_scores_gemma":[0.997253,0.002158026,0.00020632337,0.00011970381,0.00009679555,0.00016612813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051717303,0.00015755944,0.00043613632,0.000039891274,0.00013492204,0.0000047266262,0.00026343085,0.00029770218,0.00012870607],"category_scores_gemma":[0.00021839418,0.00013140711,0.00013935808,0.00007424229,0.00058771635,0.000027310542,0.00009665367,0.0003952575,0.0000015860862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054816795,0.001794699,0.67902386,0.0011431545,0.0040404396,0.000021792668,0.00049568224,0.00018893472,0.20415632,0.0028015347,0.066716135,0.034135744],"study_design_scores_gemma":[0.015428269,0.0012740556,0.87861425,0.00010777089,0.0024827137,0.000014100246,0.0004902219,0.01973467,0.0066398196,0.004336976,0.07008709,0.0007900353],"about_ca_topic_score_codex":0.0008952727,"about_ca_topic_score_gemma":0.0035944434,"teacher_disagreement_score":0.1995904,"about_ca_system_score_codex":0.00004607224,"about_ca_system_score_gemma":0.0009800637,"threshold_uncertainty_score":0.5358626},"labels":[],"label_agreement":null},{"id":"W3085906625","doi":"10.1007/s12325-020-01472-1","title":"The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Robarts Clinical Trials; Western University","funders":"AbbVie","keywords":"Biosimilar; Medicine; Narrative review; Interchangeability; Clinical Practice; Randomized controlled trial; Intensive care medicine; Risk analysis (engineering); Family medicine; Surgery; Internal medicine","score_opus":0.1170445249525093,"score_gpt":0.437350677947818,"score_spread":0.32030615299530873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085906625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012724806,0.9981267,0.000019429,0.0005263074,0.0003810955,0.00085843244,0.000021984026,0.0000117690715,0.00004157258],"genre_scores_gemma":[0.000492355,0.99899423,0.00024160038,0.000103042614,0.000028533144,0.00010945691,0.0000063898487,0.000022041038,0.0000023343594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960387,0.0020011538,0.0011188011,0.00046125753,0.00008220836,0.00029788495],"domain_scores_gemma":[0.99574465,0.0028855181,0.0007976776,0.00044717817,0.00010454059,0.000020435069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015108075,0.00038725638,0.0020457604,0.00012457184,0.00006614382,0.000008157488,0.0007503437,0.00024865853,0.00004520476],"category_scores_gemma":[0.000699149,0.0002116058,0.0003375255,0.00047573898,0.00026951582,0.00023604196,0.00008516755,0.0007679643,0.0000015330569],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006277016,0.00009694236,0.00011214898,0.016003896,0.00010308366,0.000001334883,0.0010629522,1.3222996e-7,0.00006555543,0.00022728243,0.00003068154,0.9822332],"study_design_scores_gemma":[0.00032176657,0.00032972652,0.000041784457,0.15336937,0.00006297748,0.00000457794,0.0005465762,0.0000033113902,0.00008877321,0.0003466414,0.8446436,0.00024089811],"about_ca_topic_score_codex":0.000002969861,"about_ca_topic_score_gemma":0.000098566816,"teacher_disagreement_score":0.9819923,"about_ca_system_score_codex":0.000035992267,"about_ca_system_score_gemma":0.00012980957,"threshold_uncertainty_score":0.8629034},"labels":[],"label_agreement":null},{"id":"W3092058913","doi":"10.1080/19466315.2020.1832567","title":"A Time-response Measure to Assess Clinical Equivalence in Rheumatoid Arthritis: an Assessment Using Data From Clinical Trials of Biosimilars","year":2020,"lang":"en","type":"article","venue":"Statistics in Biopharmaceutical Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); Eli Lilly (Canada)","funders":"","keywords":"Biosimilar; Equivalence (formal languages); Measure (data warehouse); Time point; Medicine; Clinical trial; Rheumatoid arthritis; Mathematics; Statistics; Computer science; Data mining; Internal medicine","score_opus":0.8318590791425474,"score_gpt":0.6923196274100802,"score_spread":0.13953945173246718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092058913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8917962,0.005596567,0.062083755,0.0113860555,0.0014968357,0.0031839807,0.024186553,0.00008071643,0.0001893491],"genre_scores_gemma":[0.8326985,0.004108941,0.16057776,0.0020284627,0.00017541194,0.00002784294,0.0003003479,0.000057913556,0.000024822422],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.944317,0.04780137,0.004361626,0.0016710175,0.00065015454,0.0011988446],"domain_scores_gemma":[0.9569241,0.040689483,0.00030147942,0.0010529695,0.00045571942,0.0005762687],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09372624,0.00031276583,0.0018746746,0.00034392643,0.000107024855,0.000069187365,0.0017728341,0.00079483254,0.0025185645],"category_scores_gemma":[0.09758192,0.00027352106,0.00015378188,0.0011641871,0.002008498,0.00015088532,0.0016673807,0.003226161,0.0001465386],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035142623,0.0044017886,0.06641638,0.00014073441,0.0006248494,0.00063528324,0.00026702177,0.000025459836,0.7062607,0.0016438895,0.018860921,0.16558039],"study_design_scores_gemma":[0.054955866,0.01596981,0.37894595,0.0046166624,0.00056221284,0.000058040794,0.0030648797,0.38109604,0.08104001,0.011231442,0.06443123,0.004027849],"about_ca_topic_score_codex":0.00009149829,"about_ca_topic_score_gemma":0.00005954375,"teacher_disagreement_score":0.62522066,"about_ca_system_score_codex":0.00011407975,"about_ca_system_score_gemma":0.001207178,"threshold_uncertainty_score":0.9999717},"labels":[],"label_agreement":null},{"id":"W3092235662","doi":"10.1016/j.jdin.2020.09.006","title":"Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council","year":2020,"lang":"en","type":"article","venue":"JAAD International","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"UCB Pharma; Janssen Biotech; LEO Pharma; Almirall; UCB; Arena Pharmaceuticals; Sandoz; Celgene; AbbVie; Sanofi; Novartis; Boehringer Ingelheim; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company","keywords":"Biosimilar; Medicine; Psoriasis; Pharmacovigilance; Product (mathematics); Pharmacy; Family medicine; Business; Pharmacology; Adverse effect; Dermatology; Internal medicine","score_opus":0.06521448596658885,"score_gpt":0.27068356302109675,"score_spread":0.2054690770545079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092235662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7080291,0.0049170256,0.004830092,0.24949168,0.014517288,0.0040890034,0.011921735,0.00008159398,0.0021225032],"genre_scores_gemma":[0.99319774,0.0002978718,0.0018984424,0.0038792011,0.00025805584,0.000089408735,0.00012662169,0.000019118124,0.00023355465],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986388,0.0001298361,0.00049113465,0.0002787186,0.00028885822,0.00017263541],"domain_scores_gemma":[0.9976925,0.0011565287,0.00040074176,0.00026701143,0.00046312116,0.000020080277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003222938,0.00018724606,0.00024577498,0.000020227451,0.00013677379,0.0000243313,0.00073711824,0.00010635896,0.00045195472],"category_scores_gemma":[0.00031238247,0.00007979269,0.00023873874,0.00012344937,0.00037882265,0.000026369606,0.000103755665,0.000120967095,0.0000034493653],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020933907,0.0054041706,0.52365303,0.00005522604,0.029460704,0.0000041693315,0.010365809,0.00025887595,0.035309974,0.0117389215,0.23957033,0.12324486],"study_design_scores_gemma":[0.006644709,0.00090802216,0.070870034,0.000082927945,0.00055270555,0.0000011864175,0.00079993636,0.0005596251,0.031822573,0.00041520057,0.8871473,0.00019578573],"about_ca_topic_score_codex":0.00007408504,"about_ca_topic_score_gemma":0.00009444985,"teacher_disagreement_score":0.6475769,"about_ca_system_score_codex":0.00017073711,"about_ca_system_score_gemma":0.00010928988,"threshold_uncertainty_score":0.4948587},"labels":[],"label_agreement":null},{"id":"W3092483376","doi":"10.1007/s11523-020-00748-4","title":"Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Amgen","keywords":"Medicine; Rituximab; Internal medicine; Follicular lymphoma; Clinical endpoint; Confidence interval; CD20; Randomized controlled trial; Lymphoma; Gastroenterology; Ofatumumab; Oncology","score_opus":0.030366827538506908,"score_gpt":0.2829847304425309,"score_spread":0.252617902904024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092483376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397635,0.0008601223,0.000037239086,0.0035704025,0.000090727655,0.0010171299,0.00014292379,0.000015628977,0.00028946775],"genre_scores_gemma":[0.9974738,0.000030707415,0.001803433,0.0004311252,0.000027957602,0.000016029046,0.00019142043,0.000009799661,0.000015763562],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99780667,0.00077270204,0.0006003626,0.00047618287,0.000058230355,0.00028583582],"domain_scores_gemma":[0.99862045,0.0007723157,0.00025005187,0.00025145107,0.000071421186,0.0000343104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042860562,0.0001877664,0.00075375516,0.000048658498,0.000048368864,0.000004591113,0.00021664712,0.00026876054,0.000056649995],"category_scores_gemma":[0.0004973854,0.000103487495,0.000025763396,0.00035277766,0.00043888995,0.000034800807,0.00009050237,0.00030187317,0.0000062889544],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8510591,0.00411478,0.09266313,0.000022679516,0.00041590576,0.000026483422,0.0021457383,0.000026050815,0.0057758065,0.00020295639,0.0012970262,0.04225034],"study_design_scores_gemma":[0.30204,0.008689594,0.66052413,0.00006969572,0.00013232413,0.0000023737575,0.00018712382,0.000040291034,0.0051865564,0.000038895694,0.022846965,0.0002420307],"about_ca_topic_score_codex":0.00038764172,"about_ca_topic_score_gemma":0.0004933921,"teacher_disagreement_score":0.567861,"about_ca_system_score_codex":0.00004937149,"about_ca_system_score_gemma":0.00012348067,"threshold_uncertainty_score":0.42200974},"labels":[],"label_agreement":null},{"id":"W3093529184","doi":"10.14309/01.ajg.0000714848.73122.58","title":"S3200 ABP 710, a Biosimilar to Infliximab Reference Product: Supporting Extrapolation of Indications With a Focus on Crohn’s Disease","year":2020,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Antibody-dependent cell-mediated cytotoxicity; Infliximab; Immunology; Peripheral blood mononuclear cell; Tumor necrosis factor alpha; Immune system; Pharmacology; Antibody; Monoclonal antibody; Biology; In vitro; Biochemistry","score_opus":0.023502399033147534,"score_gpt":0.28826664396343504,"score_spread":0.2647642449302875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093529184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93960005,0.00008885038,0.006147724,0.05377177,0.00005796889,0.00021183518,0.00003854351,0.000010087998,0.000073146395],"genre_scores_gemma":[0.99190277,0.000021447686,0.002665781,0.00531924,0.000054527947,0.000004991055,0.000002934906,0.000011802482,0.0000165266],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982878,0.0005264514,0.0005705325,0.00021140717,0.000084221305,0.00031961108],"domain_scores_gemma":[0.99828225,0.00013412324,0.0010336608,0.00024586526,0.00017555058,0.00012852933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045591648,0.0001571442,0.00051858753,0.00014159297,0.000071696966,0.000007779843,0.00040124418,0.00003227906,0.00010098586],"category_scores_gemma":[0.00030058718,0.000091834896,0.00010091144,0.0003007151,0.00066804385,0.000047567883,0.00006462462,0.00043287774,0.000010890172],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22220968,0.001944566,0.3251423,0.00009939161,0.0029723276,0.00025161932,0.005865875,0.00034337747,0.37452647,0.0029805016,0.008830071,0.05483383],"study_design_scores_gemma":[0.003577401,0.06202546,0.908315,0.00018434449,0.0009643656,0.0005756648,0.0013902545,0.00004034093,0.018185958,0.00065396365,0.003750562,0.00033670687],"about_ca_topic_score_codex":0.000008332893,"about_ca_topic_score_gemma":0.000006436947,"teacher_disagreement_score":0.5831727,"about_ca_system_score_codex":0.000021226107,"about_ca_system_score_gemma":0.00008553056,"threshold_uncertainty_score":0.37449184},"labels":[],"label_agreement":null},{"id":"W3093998083","doi":"10.14309/01.ajg.0000704948.53832.1a","title":"S0725 Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-Up Results From an Observational Real World Study Among Patients With Inflammatory Bowel Disease (ONWARD Study)","year":2020,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Science Network","funders":"","keywords":"Infliximab; Medicine; Ulcerative colitis; Biosimilar; Inflammatory bowel disease; Internal medicine; Adverse effect; Observational study; Prospective cohort study; Gastroenterology; Physical therapy; Disease","score_opus":0.048424838564226656,"score_gpt":0.33891956176964955,"score_spread":0.2904947232054229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093998083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743515,0.00001319753,0.000018959689,0.0014190667,0.00024180021,0.00058501214,0.0002621177,0.000017786811,0.000006924382],"genre_scores_gemma":[0.99793726,0.000013753595,0.00023927374,0.0016772781,0.000059505164,0.0000068453774,0.000029493045,0.000028061853,0.000008542764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944783,0.0024642774,0.001887763,0.00049344636,0.00025362265,0.00042257996],"domain_scores_gemma":[0.99564093,0.0006578177,0.0024817255,0.0005372613,0.0003865834,0.00029568054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009293267,0.0003836695,0.0013345389,0.00018039164,0.000115076,0.000022370952,0.00050763093,0.000074426105,0.00004304995],"category_scores_gemma":[0.00063782214,0.00021404919,0.000344467,0.00023726898,0.001479325,0.00016190106,0.00020227807,0.0008037259,0.0000020328437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13312349,0.0022531066,0.860002,0.0000021284352,0.0024847384,0.000053100986,0.0011275139,0.000037645288,0.000069739544,0.000001301392,0.00029400305,0.0005512412],"study_design_scores_gemma":[0.016207779,0.07814582,0.9034055,0.000026577554,0.000645342,0.00000359805,0.0013749277,0.0000148368035,0.000010263397,0.000015238939,0.000019915982,0.00013020304],"about_ca_topic_score_codex":0.00016901638,"about_ca_topic_score_gemma":0.00016244203,"teacher_disagreement_score":0.11691571,"about_ca_system_score_codex":0.00004225872,"about_ca_system_score_gemma":0.00012585905,"threshold_uncertainty_score":0.8728672},"labels":[],"label_agreement":null},{"id":"W3094171178","doi":"10.1053/j.seminoncol.2020.10.001","title":"Toward affordable cancer drugs: Do we need firmer price negotiation, me-too drugs, or a biosimilar silver bullet?","year":2020,"lang":"en","type":"editorial","venue":"Seminars in Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Biosimilar; Medicine; Cancer drugs; Negotiation; Cancer; Silver bullet; Drug prices; Pharmacology; Drug; Intensive care medicine; Internal medicine; Public economics","score_opus":0.019932946611267474,"score_gpt":0.3240218381404496,"score_spread":0.3040888915291821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094171178","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016986608,0.07319807,0.000086160646,0.053856835,0.86126435,0.0015730219,0.0011254995,0.00026065798,0.008465516],"genre_scores_gemma":[0.0017257709,0.23273627,0.012397783,0.01645758,0.576769,0.0016899315,0.002246431,0.0007051227,0.1552721],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99394554,0.0011181127,0.001455215,0.001661058,0.00030460468,0.0015154507],"domain_scores_gemma":[0.9929663,0.004859969,0.0008265997,0.00074281555,0.00042350515,0.00018082355],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013717425,0.0010424736,0.0024022732,0.0004724981,0.00024400289,0.000063850945,0.00133458,0.006678694,0.0075492063],"category_scores_gemma":[0.0024287845,0.0008335852,0.00045465425,0.0011178447,0.00081572495,0.00012052488,0.0006987206,0.00371784,0.00043045348],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021286635,0.000422832,0.00005767263,0.0003332479,0.0006637558,0.0001420377,0.0029824225,0.0000054157376,0.0022610805,0.000096329764,0.972661,0.018245533],"study_design_scores_gemma":[0.003269479,0.0013338991,0.000009395232,0.00065618946,0.0005381171,0.000022030314,0.0022897918,0.000016533106,0.0029509575,0.00059362064,0.98731965,0.0010003551],"about_ca_topic_score_codex":0.00039880638,"about_ca_topic_score_gemma":0.00017207277,"teacher_disagreement_score":0.28449535,"about_ca_system_score_codex":0.0013400064,"about_ca_system_score_gemma":0.0022078285,"threshold_uncertainty_score":0.9994115},"labels":[],"label_agreement":null},{"id":"W3096761668","doi":"10.3899/jrheum.200565","title":"Does Etanercept Biosimilar Prescription in a Rheumatology Center Bend the Medication Cost Curve?","year":2020,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer; Eli Lilly and Company","keywords":"Medicine; Biosimilar; Etanercept; Rheumatoid arthritis; Medical prescription; Rheumatology; Internal medicine; Average cost; Pharmacology","score_opus":0.024452529796698992,"score_gpt":0.27836254853273457,"score_spread":0.2539100187360356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096761668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77781445,0.0047847503,0.003999092,0.20953251,0.0030145615,0.0005294347,0.000033445733,0.000033467863,0.00025831157],"genre_scores_gemma":[0.99378705,0.003938134,0.00017592442,0.0019999146,0.000011286645,0.0000053883073,0.0000063867246,0.0000135171595,0.00006237444],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963696,0.002029637,0.0009554143,0.00018004526,0.00008442364,0.0003808883],"domain_scores_gemma":[0.99796987,0.0009782935,0.00062790484,0.00026394206,0.000104824845,0.00005514951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017060366,0.00019491979,0.00060605013,0.00010321345,0.00015047024,0.000012878717,0.0007630993,0.00036351688,0.0008108336],"category_scores_gemma":[0.00078076334,0.000076729884,0.00014659278,0.00023480385,0.00078743673,0.000095655945,0.00013446895,0.0009894456,0.000058794467],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040853107,0.0007007749,0.7895793,0.0002697003,0.0013813745,0.00003065312,0.011525134,0.00004132679,0.04437505,0.008087642,0.11876721,0.021156529],"study_design_scores_gemma":[0.022003606,0.003467282,0.13691118,0.0012335189,0.0014000967,0.036704123,0.015961519,0.0017467248,0.030087182,0.011880394,0.7369261,0.0016782766],"about_ca_topic_score_codex":0.00009285512,"about_ca_topic_score_gemma":0.00013401534,"teacher_disagreement_score":0.6526681,"about_ca_system_score_codex":0.000032300002,"about_ca_system_score_gemma":0.00007578946,"threshold_uncertainty_score":0.8878059},"labels":[],"label_agreement":null},{"id":"W3096892014","doi":"10.1016/j.jpba.2020.113750","title":"Evaluation of erythropoietin biosimilars Epotin™, Hemax® and Jimaixin™ by electrophoretic methods used for doping control analysis and specific N-glycan analysis revealed structural differences from original epoetin alfa drug Eprex®","year":2020,"lang":"en","type":"article","venue":"Journal of Pharmaceutical and Biomedical Analysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency; Agence Nationale de la Recherche","keywords":"Chemistry; Biosimilar; Glycan; Erythropoietin; Epoetin alfa; Sialic acid; Chromatography; Biochemistry; Internal medicine; Glycoprotein; Hemoglobin","score_opus":0.043645484670573914,"score_gpt":0.3793851311713537,"score_spread":0.3357396465007798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096892014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.859702,0.026384985,0.10032396,0.012679528,0.000112620015,0.000284744,0.00049491046,0.00001233736,0.000004921269],"genre_scores_gemma":[0.9794896,0.0020158573,0.017689096,0.0005604583,0.00011979945,0.0000063558036,0.000095381314,0.00001161242,0.0000118186335],"study_design_codex":"bench_or_experimental","study_design_gemma":"meta_analysis","domain_scores_codex":[0.994376,0.0023232466,0.0015538693,0.00071554276,0.0005380709,0.0004932467],"domain_scores_gemma":[0.9959447,0.001977263,0.00087524607,0.0001800002,0.00055558886,0.00046723432],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004338608,0.00040798887,0.0023875856,0.0008796593,0.00020490761,0.000079620135,0.00028790708,0.00033584482,0.001651731],"category_scores_gemma":[0.00072958664,0.00026846293,0.0010367504,0.003346842,0.001441715,0.0000984032,0.000098367855,0.0006100296,5.273614e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016678468,0.00030255996,0.14739127,0.00011943158,0.09940672,0.0000118961725,0.00047930158,0.000014553135,0.6872294,0.00006148736,0.0010826283,0.062232908],"study_design_scores_gemma":[0.014118372,0.0017423274,0.14530027,0.00008268674,0.5393411,0.00004933563,0.00092006725,0.183078,0.105827354,0.0026614508,0.0057088025,0.0011702367],"about_ca_topic_score_codex":0.00006753703,"about_ca_topic_score_gemma":0.000024793373,"teacher_disagreement_score":0.581402,"about_ca_system_score_codex":0.00005171513,"about_ca_system_score_gemma":0.00008075806,"threshold_uncertainty_score":0.99997675},"labels":[],"label_agreement":null},{"id":"W3097824528","doi":"10.1182/blood-2020-142723","title":"Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital","funders":"","keywords":"Medicine; Rituximab; Oncology; Pharmacology; Clinical trial; In vivo; Pharmacodynamics; Internal medicine; Biosimilar; Lymphoma; Pharmacokinetics; Biology","score_opus":0.11105793542711007,"score_gpt":0.32541391752517074,"score_spread":0.21435598209806067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097824528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939722,0.0012880071,0.0002534126,0.0037956177,0.00009794842,0.00026926727,0.0000204653,0.000008683876,0.00029438618],"genre_scores_gemma":[0.99209034,0.0000054583143,0.0072537665,0.0005937756,0.000007162763,0.000008900688,0.000002149404,0.0000029889054,0.000035457924],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998911,0.0002285447,0.00038441314,0.00023495484,0.00006337123,0.0001776671],"domain_scores_gemma":[0.9994216,0.00019609867,0.00007452182,0.00022262524,0.000062814,0.000022352982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010858281,0.00008557347,0.00024644853,0.000050810984,0.00005733496,0.000008644877,0.0003698536,0.00009591501,0.00012351711],"category_scores_gemma":[0.0005048529,0.000055023138,0.000060279777,0.00050078455,0.00022412224,0.000028622462,0.00012210003,0.0001282388,0.000029050168],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009757059,0.00090766343,0.0067416052,0.00010444869,0.00007553676,0.0000024015646,0.0035996013,3.102218e-7,0.9829963,0.00028924888,0.0007330825,0.004452217],"study_design_scores_gemma":[0.0008382592,0.00018362183,0.02982809,0.00010012532,0.00005374408,0.0000033098001,0.00031091334,0.0000016490848,0.96111196,0.000068051326,0.007408727,0.00009152649],"about_ca_topic_score_codex":0.0000071207446,"about_ca_topic_score_gemma":0.000023246881,"teacher_disagreement_score":0.023086485,"about_ca_system_score_codex":0.0000052460664,"about_ca_system_score_gemma":0.00008941478,"threshold_uncertainty_score":0.22437786},"labels":[],"label_agreement":null},{"id":"W3101044110","doi":"10.1016/j.envres.2020.110444","title":"Lead (Pb) exposure assessment in dried blood spots using Total Reflection X-Ray Fluorescence (TXRF)","year":2020,"lang":"en","type":"article","venue":"Environmental Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Fogarty International Center; Fonds de recherche du Québec – Nature et technologies; National Institutes of Health; Consejo Nacional de Ciencia y Tecnología; Canada Research Chairs; Canada Foundation for Innovation","keywords":"X-ray fluorescence; Spots; Fluorescence; Dried blood; X-ray; Radiochemistry; Lead (geology); Chemistry; Materials science; Environmental chemistry; Analytical Chemistry (journal); Optics; Physics; Chromatography; Biology","score_opus":0.10607711190799715,"score_gpt":0.39239711545642364,"score_spread":0.28632000354842646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101044110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958881,0.00080780766,0.00034006996,0.0013531441,0.00014581993,0.00034230883,0.000022473794,0.000023199776,0.0010770614],"genre_scores_gemma":[0.9939757,0.00016310961,0.0045388713,0.00014789304,0.000063580635,0.000014056996,0.000018475079,0.000018150724,0.001060149],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975441,0.0008485094,0.00029090513,0.0005186037,0.00020076575,0.0005971301],"domain_scores_gemma":[0.99947137,0.00018326871,0.0000407923,0.00021765052,0.000008980837,0.000077954086],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00086083234,0.00015857434,0.0002375906,0.00011155644,0.00021515593,0.000027271202,0.00022763337,0.00028803293,0.0018275429],"category_scores_gemma":[0.00011680707,0.00014402173,0.00007329607,0.00031071663,0.00048181586,0.000095743286,0.00029671384,0.0012414113,0.00018244816],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016059696,0.00035229835,0.01995606,0.000012724082,0.000045596367,0.000043370124,0.00017917778,0.00001638135,0.9690986,0.000046842724,0.00011157932,0.009976764],"study_design_scores_gemma":[0.0030248004,0.0017844621,0.20422041,0.00007498486,0.000053034,0.000060541468,0.0015692416,0.0010121178,0.7829026,0.0002580888,0.0045745927,0.0004651084],"about_ca_topic_score_codex":0.00004845064,"about_ca_topic_score_gemma":0.000008696498,"teacher_disagreement_score":0.186196,"about_ca_system_score_codex":0.00019549402,"about_ca_system_score_gemma":0.000053030413,"threshold_uncertainty_score":0.99908495},"labels":[],"label_agreement":null},{"id":"W3104122262","doi":"10.24018/ejbmr.2020.5.6.565","title":"Global Status of Biosimilars and Its Influential Factors","year":2020,"lang":"en","type":"article","venue":"European Journal of Business Management and Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Product (mathematics); Business; Medicine; Government (linguistics); International trade","score_opus":0.0988032733914623,"score_gpt":0.3462804947909919,"score_spread":0.24747722139952957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104122262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97817653,0.011335623,0.0005139966,0.0036109157,0.00027470413,0.00017420982,0.000026458803,0.000009098134,0.0058784583],"genre_scores_gemma":[0.9954794,0.0037785997,0.0003383805,0.00013885695,0.00004667278,1.3442758e-7,0.0000015664402,0.000008268186,0.00020809703],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983696,0.00068071677,0.0003519162,0.00015491695,0.00012929481,0.00031357582],"domain_scores_gemma":[0.9992942,0.00006653773,0.00013415888,0.000070341164,0.00033281065,0.00010193201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010859888,0.0001037193,0.00024125222,0.00014438097,0.00009960132,0.000034974495,0.00020223414,0.000039826635,0.0001368891],"category_scores_gemma":[0.00021920238,0.00006976136,0.000047046964,0.0005073742,0.00031386185,0.000089874346,0.00039828927,0.0002404375,0.0000054435545],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006989088,0.0011282251,0.21319357,0.0037563243,0.005116986,0.0018422512,0.0028000355,0.00006732027,0.13818085,0.009660776,0.09288972,0.52437484],"study_design_scores_gemma":[0.0023164193,0.0006345441,0.85345435,0.00014689138,0.0001411544,0.000028353665,0.00080231915,0.000015401576,0.004272663,0.00009600076,0.13793185,0.0001600516],"about_ca_topic_score_codex":0.0000026764174,"about_ca_topic_score_gemma":3.6787858e-7,"teacher_disagreement_score":0.6402608,"about_ca_system_score_codex":0.00001055285,"about_ca_system_score_gemma":0.000020476793,"threshold_uncertainty_score":0.28447855},"labels":[],"label_agreement":null},{"id":"W3107373271","doi":"10.1111/nyas.14522","title":"Regulatory challenges with biosimilars: an update from 20 countries","year":2020,"lang":"en","type":"article","venue":"Annals of the New York Academy of Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"World Health Organization","keywords":"Biosimilar; Interchangeability; Pharmacovigilance; Business; Risk analysis (engineering); Regulatory science; Quality (philosophy); Medicine; Pharmacology; Computer science; Adverse effect","score_opus":0.14022719422382712,"score_gpt":0.3386055666856391,"score_spread":0.198378372461812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107373271","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3119752,0.06625248,0.000030349272,0.620095,0.00018607831,0.00022204482,0.00013871928,0.00004728068,0.0010528666],"genre_scores_gemma":[0.9763865,0.002403859,0.0017425999,0.019221907,0.00009151476,0.0000011237203,0.0000013002867,0.0000073079736,0.0001439052],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998732,0.00021494391,0.00029526756,0.0003516141,0.00014269308,0.00026351132],"domain_scores_gemma":[0.9993118,0.00018069947,0.00027836143,0.0001280265,0.000036135993,0.00006499401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062508415,0.00014742241,0.00034546456,0.00003921675,0.00015328906,0.000011920428,0.0010483611,0.0002371645,0.00020561066],"category_scores_gemma":[0.00007930113,0.00007852552,0.00009519306,0.00029655918,0.0024758545,0.00015982064,0.00013418338,0.00023805258,0.000009987978],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016146472,0.0003181914,0.008946016,0.0001629156,0.0010780152,0.0000010615266,0.0050068568,0.0000979919,0.5166753,0.061916426,0.35031918,0.053863432],"study_design_scores_gemma":[0.00028668306,0.0004879368,0.011067192,0.0001174049,0.000060525726,0.000002233045,0.0005405986,0.000015231861,0.8340316,0.009573589,0.14365737,0.00015966577],"about_ca_topic_score_codex":0.00002658322,"about_ca_topic_score_gemma":0.0000073255933,"teacher_disagreement_score":0.6644113,"about_ca_system_score_codex":0.0000018917079,"about_ca_system_score_gemma":0.00007564223,"threshold_uncertainty_score":0.91223884},"labels":[],"label_agreement":null},{"id":"W3110075982","doi":"10.5639/gabij.2020.0903.022","title":"3rd Colombian educational workshop on regulatory assessment of biosimilars 2019 – Report","year":2020,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Pharmacovigilance; Workgroup; Medicine; Quality (philosophy); Health professionals; Political science; Medical education; Health care; Pharmacology; Adverse effect; Computer science; Law","score_opus":0.058383037059144174,"score_gpt":0.34017598766712337,"score_spread":0.2817929506079792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110075982","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15513977,0.012358349,0.0061872974,0.79902405,0.005639231,0.001110246,0.0009685517,0.00010510007,0.019467374],"genre_scores_gemma":[0.75357354,0.0053786584,0.024351845,0.21508415,0.0008348809,0.000019898902,0.00017001298,0.00008186448,0.0005051814],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997684,0.00041844617,0.0008258312,0.0004651626,0.00019779237,0.00040875407],"domain_scores_gemma":[0.9981544,0.00038632442,0.00067820615,0.00024620557,0.00034112396,0.00019370962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009029177,0.000318471,0.00057518604,0.00016616716,0.00032879322,0.00005340594,0.00027972952,0.00038158617,0.0005442948],"category_scores_gemma":[0.00043077726,0.00025107243,0.00022682245,0.00039292828,0.0005374479,0.00010743383,0.00014573337,0.00082951324,0.000006126875],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020025075,0.00038049612,0.012526432,0.000035880996,0.00059961696,0.00008410366,0.00022610869,0.000018142646,0.072797164,0.00046544833,0.90848285,0.004183509],"study_design_scores_gemma":[0.0051496886,0.0040546497,0.38402346,0.0005363307,0.0008081343,0.0023553648,0.0017536136,0.00038492423,0.12647307,0.004381931,0.46825626,0.0018225497],"about_ca_topic_score_codex":1.8215887e-7,"about_ca_topic_score_gemma":0.0000016126346,"teacher_disagreement_score":0.59843373,"about_ca_system_score_codex":0.00007127817,"about_ca_system_score_gemma":0.00041042818,"threshold_uncertainty_score":0.99999416},"labels":[],"label_agreement":null},{"id":"W3119874132","doi":"10.3390/ijerph18020677","title":"Erratum: Yang, X. et al. Optimization of Culture Conditions for Amoxicillin Degrading Bacteria Screened from Pig Manure. Int. J. Environ. Res. Public Health 2020, 17, 1973","year":2021,"lang":"en","type":"erratum","venue":"International Journal of Environmental Research and Public Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"INT; Amoxicillin; Manure; Bacteria; Public health; Microbiology; Veterinary medicine; Antibiotics; Biotechnology; Biology; Medicine; Computer science; Ecology; Genetics; Nursing","score_opus":0.08594549554308126,"score_gpt":0.3973311819743587,"score_spread":0.3113856864312774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119874132","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0070642238,0.1966073,0.02733205,0.70220315,0.022433393,0.002486381,0.038494796,0.00004537101,0.0033333348],"genre_scores_gemma":[0.064216115,0.6972806,0.04217178,0.0438299,0.0030832444,0.00012490342,0.06960347,0.00026476503,0.07942522],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944161,0.0020040318,0.0014542871,0.0005761755,0.0006802706,0.00086910394],"domain_scores_gemma":[0.9968639,0.00065773097,0.0012956648,0.00029876863,0.00038599066,0.0004979481],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0049259067,0.0003526834,0.0009344614,0.0006225935,0.00037773704,0.0002250992,0.0007881981,0.00065663015,0.0028064349],"category_scores_gemma":[0.00092578604,0.0002987778,0.0003036166,0.00021891994,0.0008196057,0.00039322727,0.0003596475,0.0024839577,0.0000057467937],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018460235,0.0009746663,0.00026764863,0.000056519304,0.001006265,0.000015998005,0.00024558976,0.0000041670514,0.0029747437,0.00041774355,0.9838382,0.010013854],"study_design_scores_gemma":[0.0016010738,0.0016380256,0.0036816522,0.0004489429,0.000020290885,0.00012873871,0.001050523,0.000073639545,0.0001570202,0.0006698327,0.99029714,0.00023310975],"about_ca_topic_score_codex":0.00023185286,"about_ca_topic_score_gemma":0.00015730737,"teacher_disagreement_score":0.65837324,"about_ca_system_score_codex":0.0008311902,"about_ca_system_score_gemma":0.0018015815,"threshold_uncertainty_score":0.9999464},"labels":[],"label_agreement":null},{"id":"W3119939393","doi":"10.2147/btt.s285610","title":"Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab","year":2021,"lang":"en","type":"article","venue":"Biologics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Discontinuation; Medicine; Biosimilar; Infliximab; Psoriatic arthritis; Rheumatoid arthritis; Internal medicine; Population; Disease","score_opus":0.0265783013926262,"score_gpt":0.2985141961853323,"score_spread":0.27193589479270613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119939393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959122,0.00018439826,0.0004872261,0.0009942164,0.00081863755,0.00069762085,0.00026748696,0.00016696754,0.000471236],"genre_scores_gemma":[0.99291945,0.00016078311,0.0015761731,0.0035615002,0.00010739527,0.00006335692,0.00028647488,0.000048108453,0.0012767366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964386,0.0006964817,0.0007042068,0.0011571504,0.00015435865,0.00084920734],"domain_scores_gemma":[0.9979575,0.0004853444,0.00029502262,0.0007384563,0.0003248489,0.00019879911],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00073413696,0.00060030166,0.00083603885,0.00023462967,0.00038760138,0.00014930312,0.00038512077,0.00081749354,0.0003657006],"category_scores_gemma":[0.0013409767,0.00040861688,0.00013948957,0.0005001848,0.00017341494,0.00027036617,0.00028981012,0.0006570338,0.00006451098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066160094,0.0051463703,0.6744809,0.00019653817,0.00094417523,0.00017435012,0.0018399064,0.00003132502,0.2129419,0.01306459,0.00397255,0.08059136],"study_design_scores_gemma":[0.009703467,0.009788986,0.4483771,0.00060532906,0.00027191895,0.000023086193,0.0010025285,0.00023508648,0.40600467,0.0011265987,0.120697536,0.0021636921],"about_ca_topic_score_codex":0.000059308393,"about_ca_topic_score_gemma":0.00014273696,"teacher_disagreement_score":0.22610381,"about_ca_system_score_codex":0.00018201074,"about_ca_system_score_gemma":0.00012461259,"threshold_uncertainty_score":0.99983656},"labels":[],"label_agreement":null},{"id":"W3121304865","doi":"10.4155/bio-2021-0005","title":"2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback ( <u>Part 2A</u> –Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation &amp; Innovation <u>Part 2B</u> –Regulatory Agencies’ Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene &amp; Cell Therapy and Vaccine)","year":2021,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Bioanalysis; Excellence; Biosimilar; Biopharmaceutical; Computer science; Regulatory science; Business; Biotechnology; Political science; Nanotechnology; Medicine; Biology","score_opus":0.0716324586553338,"score_gpt":0.31086882621317213,"score_spread":0.23923636755783834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121304865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8932092,0.079884954,0.00075511663,0.021769207,0.0008381755,0.0012997382,0.0008972831,0.00037332997,0.00097295584],"genre_scores_gemma":[0.91726923,0.058270995,0.013363904,0.0060511017,0.00023601229,0.000099226745,0.0030179275,0.00020227644,0.0014893126],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.987442,0.0039212247,0.0034100409,0.00299023,0.0008389618,0.0013975373],"domain_scores_gemma":[0.9922484,0.001181675,0.0015486022,0.003075047,0.001652702,0.00029354685],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.005444953,0.0015056321,0.0022634503,0.0031599603,0.0008990339,0.00046171373,0.000822316,0.0014155223,0.0038579814],"category_scores_gemma":[0.00087558484,0.0013559695,0.00082245615,0.014612637,0.0010974413,0.0004503063,0.00043628583,0.00097009545,0.000075349315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023324015,0.0046752715,0.21267809,0.00030219625,0.020631356,0.000023318498,0.00082117395,0.00014167852,0.66958946,0.00063349964,0.0036431279,0.08452842],"study_design_scores_gemma":[0.008419383,0.0011990785,0.16598874,0.0006695653,0.005409475,0.00005107989,0.0018148007,0.0009172035,0.48909736,0.0008683227,0.32174346,0.0038215432],"about_ca_topic_score_codex":0.00032435017,"about_ca_topic_score_gemma":0.0009725217,"teacher_disagreement_score":0.31810033,"about_ca_system_score_codex":0.0009658882,"about_ca_system_score_gemma":0.00039965837,"threshold_uncertainty_score":0.99988085},"labels":[],"label_agreement":null},{"id":"W3124773781","doi":"10.1111/cts.12967","title":"Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects","year":2021,"lang":"en","type":"article","venue":"Clinical and Translational Science","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Celltrion","keywords":"Adalimumab; Medicine; Pharmacokinetics; Biosimilar; Equivalence (formal languages); European union; Internal medicine; Randomized controlled trial; Pharmacology; Gastroenterology; Mathematics","score_opus":0.11323052653901182,"score_gpt":0.46096045532409496,"score_spread":0.34772992878508313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124773781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937926,0.0010505945,0.0009873769,0.0029198478,0.0003476681,0.0005307215,0.000032482476,0.0000110165265,0.0003276887],"genre_scores_gemma":[0.9974327,0.00023011661,0.0015556492,0.0006716191,0.0000218364,0.000016916827,0.00000917357,0.0000031463617,0.000058848138],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973744,0.00078224053,0.0008462074,0.00055952085,0.00014813026,0.00028946067],"domain_scores_gemma":[0.9979702,0.0014751047,0.00011061291,0.00015667532,0.00018509896,0.00010225521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003218071,0.00012297726,0.0005389291,0.00007134891,0.0001234933,0.000018668512,0.00020705802,0.000070113936,0.0003179126],"category_scores_gemma":[0.00078100845,0.00009323493,0.000076864235,0.00070814753,0.0013746625,0.0001161669,0.000053564232,0.00026597182,0.000008364439],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14178556,0.013521955,0.13768996,0.00018172951,0.0003487195,0.00012696213,0.0017615247,0.000110287714,0.36612222,0.045572314,0.00010681997,0.29267195],"study_design_scores_gemma":[0.4040523,0.0040515577,0.53030443,0.00024732578,0.00037987117,0.00005607978,0.00036941344,0.0018447696,0.044236798,0.012261935,0.0014401943,0.00075531413],"about_ca_topic_score_codex":0.00006559339,"about_ca_topic_score_gemma":0.000051867202,"teacher_disagreement_score":0.39261448,"about_ca_system_score_codex":0.000008353834,"about_ca_system_score_gemma":0.00035667588,"threshold_uncertainty_score":0.5065001},"labels":[],"label_agreement":null},{"id":"W3127478789","doi":"10.1186/s13075-020-02394-7","title":"Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study","year":2021,"lang":"en","type":"article","venue":"Arthritis Research & Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Muscular Dystrophy Canada; University of Toronto","funders":"Celltrion","keywords":"Adalimumab; Medicine; Rheumatoid arthritis; Internal medicine; Rheumatology; Clinical endpoint; Randomized controlled trial; Biosimilar; Bioequivalence; European union; Gastroenterology; Pharmacokinetics","score_opus":0.07480039588975368,"score_gpt":0.34718717036426844,"score_spread":0.27238677447451476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127478789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9245663,0.071409665,0.000016286951,0.0012200915,0.0001834731,0.0013984999,0.00027453798,0.000036500587,0.0008945984],"genre_scores_gemma":[0.8449382,0.15399966,0.00065968727,0.00007412955,0.00001593705,0.00007911816,0.00008635746,0.00002481941,0.00012209362],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99187154,0.0052650874,0.00091366516,0.0009041005,0.00029240557,0.0007532041],"domain_scores_gemma":[0.99247575,0.006141144,0.00015237853,0.00072717277,0.0004052426,0.000098326396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003910222,0.00030743616,0.0013161429,0.00024977955,0.0002542462,0.000068007204,0.00032939535,0.00021808289,0.00050613016],"category_scores_gemma":[0.0018093665,0.00023578586,0.00010849748,0.00076766993,0.0014450396,0.00012359724,0.00020761997,0.0010158025,0.000022080802],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7030669,0.0033384543,0.0013584907,0.000011585117,0.0013254349,0.0007286204,0.0027624932,0.0000018680868,0.04006215,0.0006252485,0.0007077283,0.24601103],"study_design_scores_gemma":[0.8908333,0.005680858,0.010112087,0.0011169483,0.000020767853,0.00008117399,0.004132871,0.0000111153695,0.071095094,0.0008933362,0.015490037,0.0005323919],"about_ca_topic_score_codex":0.001531635,"about_ca_topic_score_gemma":0.0042891875,"teacher_disagreement_score":0.24547864,"about_ca_system_score_codex":0.000042046693,"about_ca_system_score_gemma":0.00030065444,"threshold_uncertainty_score":0.96150684},"labels":[],"label_agreement":null},{"id":"W3128533013","doi":"10.4155/bio-2021-0007","title":"2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays)","year":2021,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Health Canada; U.S. Food and Drug Administration; Ministry of Health, Labour and Welfare","keywords":"Bioanalysis; Harmonization; Flow cytometry; ELISPOT; Computational biology; Chemistry; Medicine; Biology; Chromatography; Immunology","score_opus":0.030664485680787137,"score_gpt":0.3089061268995161,"score_spread":0.27824164121872896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128533013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29171157,0.22221784,0.29168403,0.16983233,0.0045580245,0.007835198,0.009457932,0.000978107,0.0017249581],"genre_scores_gemma":[0.76163936,0.14004622,0.05882595,0.006113905,0.0007463483,0.00054392713,0.026991935,0.00032673494,0.004765641],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98869216,0.0047672517,0.002746449,0.002265926,0.0004966638,0.0010315186],"domain_scores_gemma":[0.99333894,0.0017386572,0.001196027,0.0014315939,0.00206165,0.0002331568],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009066757,0.0011852375,0.0019267363,0.0011982007,0.00097211305,0.0006610966,0.00052093633,0.0012063863,0.0021803346],"category_scores_gemma":[0.0024146342,0.0010622989,0.0005338621,0.0036429917,0.00019868909,0.00072583155,0.0002999136,0.00083652016,0.000026855458],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028379306,0.0038938376,0.06291999,0.0003071467,0.011500563,0.00003177568,0.00084038486,0.0021479414,0.69445086,0.0007709972,0.08744648,0.13285209],"study_design_scores_gemma":[0.009308242,0.000749905,0.013891732,0.00024587556,0.003909982,0.00005637628,0.0013478467,0.005369904,0.6882938,0.00089538295,0.27355397,0.0023769718],"about_ca_topic_score_codex":0.00033574662,"about_ca_topic_score_gemma":0.0007488588,"teacher_disagreement_score":0.46992776,"about_ca_system_score_codex":0.00041116346,"about_ca_system_score_gemma":0.0003229629,"threshold_uncertainty_score":0.9991827},"labels":[],"label_agreement":null},{"id":"W3134358306","doi":"10.1093/jcag/gwab002.054","title":"A56 CLINICAL AND BIOCHEMICAL EFFICACY ARE NOT AFFECTED BY SWITCH FROM INFLIXIMAB ORIGINATOR TO RENFLEXIS IN PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS.","year":2021,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Medicine; Infliximab; Biosimilar; Interquartile range; Ulcerative colitis; Inflammatory bowel disease; Concomitant; Internal medicine; Discontinuation; Faecal calprotectin; Prospective cohort study; Disease; Calprotectin","score_opus":0.008988245745493296,"score_gpt":0.2598291813764856,"score_spread":0.2508409356309923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134358306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866598,0.00018625097,0.0000052215532,0.011950215,0.000809242,0.00012077643,0.00025800997,0.000002621146,0.000007855661],"genre_scores_gemma":[0.9965838,0.000057741694,0.0001511738,0.0029577622,0.00010388513,0.0000022149165,0.000016608972,0.000008650959,0.00011814227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758226,0.0010521114,0.0007494314,0.00019503412,0.000096225674,0.00032491802],"domain_scores_gemma":[0.99817294,0.00033377038,0.0007541276,0.00016257897,0.00033942147,0.0002371795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007728939,0.00012792724,0.00044749025,0.00015885259,0.00005666389,0.000013473021,0.0002345875,0.00033966644,0.000053047428],"category_scores_gemma":[0.003251186,0.00010164734,0.00018035716,0.00015260653,0.000100816666,0.000042035423,0.000081223756,0.0005887155,0.0000039043102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005534381,0.0002555047,0.97202027,0.0000075347893,0.0001410918,0.000010524309,0.00002646028,0.0000011989994,0.0020359252,0.0000068988097,0.024827095,0.000114086266],"study_design_scores_gemma":[0.0036705504,0.00022489605,0.99121684,0.000031512485,0.00014450254,0.000003387946,0.000010917902,0.0000023044324,0.0008136421,0.000047306985,0.003771153,0.00006298442],"about_ca_topic_score_codex":0.00045618962,"about_ca_topic_score_gemma":0.017657997,"teacher_disagreement_score":0.02105594,"about_ca_system_score_codex":0.00032693718,"about_ca_system_score_gemma":0.00032780578,"threshold_uncertainty_score":0.98535764},"labels":[],"label_agreement":null},{"id":"W3135575648","doi":"10.1093/jcag/gwab002.159","title":"A161 PREVALENCE OF FINANCIAL CONFLICTS OF INTEREST (FCOI) AMONG PROPENSITY-SCORE MATCHED RETROSPECTIVE STUDIES EVALUATING BIOLOGIC THERAPEUTICS FOR IBD","year":2021,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Propensity score matching; Medicine; MEDLINE; Retrospective cohort study; Internal medicine; Family medicine","score_opus":0.1345434276336528,"score_gpt":0.33397661040898463,"score_spread":0.19943318277533184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135575648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949271,0.0004503535,0.000059223374,0.003400394,0.00078570534,0.00020021212,0.00015577153,0.0000014829735,0.000019760726],"genre_scores_gemma":[0.99820215,0.00012697182,0.0006094833,0.00058936514,0.000038381968,0.0000025244135,0.000002402901,0.0000060269494,0.00042269076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780786,0.00093952526,0.000777661,0.00013170752,0.0000708321,0.00027240228],"domain_scores_gemma":[0.99532336,0.00034971506,0.0021546984,0.00015131895,0.001987963,0.00003294298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020904993,0.00011650262,0.0007226022,0.000105379564,0.00008611248,0.0000042846036,0.0002805627,0.00027384172,0.000037678605],"category_scores_gemma":[0.003626797,0.00007982016,0.00028462792,0.000120236655,0.00038108256,0.000039158298,0.000069937276,0.00034794616,2.4303884e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004372187,0.000067884874,0.92776537,0.00009941893,0.0008965333,0.0000015522368,0.00039779895,0.000006830892,0.06937197,0.00024739208,0.00052425044,0.0001837982],"study_design_scores_gemma":[0.0017029179,0.002145288,0.9442218,0.00020379125,0.0004777472,0.000028580323,0.00018319061,0.000008723347,0.04982736,0.0009721489,0.0001750076,0.000053457206],"about_ca_topic_score_codex":0.00018246128,"about_ca_topic_score_gemma":0.036232606,"teacher_disagreement_score":0.036050145,"about_ca_system_score_codex":0.00035704783,"about_ca_system_score_gemma":0.00036984327,"threshold_uncertainty_score":0.98135364},"labels":[],"label_agreement":null},{"id":"W3138344390","doi":"10.18433/jpps31491","title":"A Survey of the Regulatory Requirements for the Waiver of In Vivo Bioequivalence Studies of Generic Products in Certain Dosage Forms by Participating Regulators and Organisations of the International Pharmaceutical Regulators Programme","year":2021,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Bioequivalence; Dosage form; Medicine; Pharmacology; Waiver; Business; Risk analysis (engineering); Pharmacokinetics; Law; Political science","score_opus":0.25296795505692765,"score_gpt":0.44780678799288615,"score_spread":0.1948388329359585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138344390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851898,0.009046693,0.000026631837,0.004759239,0.0005368481,0.00036771793,0.00005716615,0.000001692116,0.00001421414],"genre_scores_gemma":[0.9985084,0.0008075705,0.00044316883,0.0001674182,0.000018935376,0.0000093442295,5.144743e-7,0.0000057364964,0.00003889501],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972089,0.0007559069,0.0011442547,0.00023038704,0.00033687695,0.00032370863],"domain_scores_gemma":[0.99719185,0.001273346,0.0007737302,0.00016637056,0.0005535212,0.000041194115],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00519415,0.00014505356,0.00043216496,0.00009158282,0.00012911658,0.000010837816,0.0006941294,0.000061150815,0.000088699635],"category_scores_gemma":[0.0023070078,0.000069945556,0.00013973819,0.0011057336,0.0028042705,0.00015941833,0.0003325202,0.00029275825,4.971948e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019592157,0.00032451266,0.2788447,0.00011699609,0.00021435299,5.987139e-7,0.0004997472,0.000030099085,0.7104218,0.00033091608,0.00025604744,0.008764311],"study_design_scores_gemma":[0.0014858041,0.00009411203,0.072494835,0.0001567611,0.00018835641,0.000013308871,0.0007288876,0.0012329093,0.921598,0.0002113239,0.0017177736,0.000077914985],"about_ca_topic_score_codex":0.00005389467,"about_ca_topic_score_gemma":0.000045115692,"teacher_disagreement_score":0.21117623,"about_ca_system_score_codex":0.00006251581,"about_ca_system_score_gemma":0.00033857865,"threshold_uncertainty_score":0.9999095},"labels":[],"label_agreement":null},{"id":"W3139590011","doi":"10.1186/s13643-021-01754-x","title":"Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Systematic Reviews","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Biosimilar; Medicine; Infliximab; Adalimumab; Etanercept; Rheumatoid arthritis; Randomized controlled trial; Meta-analysis; Protocol (science); MEDLINE; Intensive care medicine; Systematic review; Alternative medicine; Medical physics; Internal medicine; Disease; Pathology","score_opus":0.23918922713494312,"score_gpt":0.447034911195483,"score_spread":0.20784568406053988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139590011","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.9085287e-8,0.7142359,0.00053656136,0.000080911064,0.0000116455485,0.28498563,0.00011276454,0.000015789576,0.000020772473],"genre_scores_gemma":[4.0005736e-7,0.64472115,0.0016355986,0.00018345482,0.0000037585316,0.35329482,0.00002872491,0.000028650082,0.000103463695],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98241717,0.009872161,0.005795936,0.0012663236,0.00012398825,0.0005244126],"domain_scores_gemma":[0.9921353,0.0032965727,0.003158837,0.0011687283,0.00013457472,0.000106000014],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.011463439,0.0011220202,0.03233548,0.0003997206,0.00015523871,0.00015287702,0.00045346128,0.0007087458,0.0001152585],"category_scores_gemma":[0.004261389,0.00059039425,0.0022097959,0.00090367097,0.00017346992,0.000106911066,0.00032651643,0.0005969675,0.000013356249],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[8.221633e-7,0.00002005431,0.000001409354,0.9653199,0.030530443,0.000003910906,0.000024373565,2.351267e-9,6.3361273e-7,0.00017373756,0.00010476834,0.0038199846],"study_design_scores_gemma":[0.0001872625,0.000051458985,3.2399302e-7,0.62656796,0.32023397,0.0001805946,0.000021877355,9.935443e-7,7.836376e-7,0.000044823424,0.05224218,0.00046777347],"about_ca_topic_score_codex":0.000009611462,"about_ca_topic_score_gemma":0.000022701508,"teacher_disagreement_score":0.33875188,"about_ca_system_score_codex":0.00004715325,"about_ca_system_score_gemma":0.000087126595,"threshold_uncertainty_score":0.99965477},"labels":[],"label_agreement":null},{"id":"W3140555419","doi":"10.1111/bcp.14850","title":"Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects","year":2021,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Celltrion","keywords":"Pharmacokinetics; Medicine; Confidence interval; Area under the curve; Bioequivalence; Nuclear medicine; Urology; Gastroenterology; Internal medicine","score_opus":0.04880752646326203,"score_gpt":0.42273927062392597,"score_spread":0.37393174416066394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3140555419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629112,0.0319028,0.00003552084,0.0012693419,0.0029797503,0.0006472856,0.0000948176,0.000016231637,0.00014308357],"genre_scores_gemma":[0.9852521,0.011350339,0.0002981085,0.0026142944,0.00024532614,0.000015817948,0.000009191742,0.000029522316,0.00018530703],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99086577,0.0046692695,0.0031798845,0.0005582168,0.00014576766,0.0005811073],"domain_scores_gemma":[0.9950786,0.002952584,0.0011871912,0.00017030028,0.00038256607,0.00022872316],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0039475076,0.00029242167,0.0021042256,0.00018457552,0.00011473262,0.000025504725,0.000380425,0.00033728694,0.0018202533],"category_scores_gemma":[0.0015455213,0.00028612887,0.0003885323,0.00037351646,0.0005543781,0.00012113131,0.00019977735,0.0017569521,0.0000045437696],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11423651,0.043243222,0.01094994,0.0003902542,0.004698572,0.009568861,0.00035872377,0.000020978063,0.49056,0.000008495125,0.10157073,0.22439373],"study_design_scores_gemma":[0.7583649,0.021571256,0.02415777,0.000501309,0.0029766136,0.010744451,0.00091139844,0.00022018758,0.1146608,0.00015042517,0.06473719,0.001003685],"about_ca_topic_score_codex":0.000066879875,"about_ca_topic_score_gemma":0.000060622348,"teacher_disagreement_score":0.6441284,"about_ca_system_score_codex":0.00004530991,"about_ca_system_score_gemma":0.00038072548,"threshold_uncertainty_score":0.9999591},"labels":[],"label_agreement":null},{"id":"W3143513781","doi":"10.1007/s12325-021-01661-6","title":"Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Tolerability; Pharmacokinetics; Cmax; Confidence interval; Randomized controlled trial; Randomization; Adverse effect; Internal medicine; Pharmacology","score_opus":0.025623361726226656,"score_gpt":0.35381250518862584,"score_spread":0.3281891434623992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143513781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8907792,0.10549947,0.00014507862,0.0010607085,0.000632458,0.001271571,0.00006515047,0.000016567396,0.0005298201],"genre_scores_gemma":[0.96189725,0.036226414,0.0010203063,0.0004696277,0.000013107021,0.000067001754,0.0000178782,0.000010723213,0.0002776872],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99675673,0.0015710815,0.00092968997,0.00038140835,0.000044811397,0.0003162648],"domain_scores_gemma":[0.99822056,0.0013632607,0.0001572064,0.00019539525,0.000038189988,0.000025407811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001254631,0.00017968549,0.0013322775,0.000105393505,0.000025534693,0.0000065302524,0.00013444436,0.00017866211,0.0005231208],"category_scores_gemma":[0.00038351447,0.00013138218,0.00009457274,0.00030430083,0.00039053618,0.00007938167,0.000043972508,0.0003239114,9.497095e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96580976,0.0007922917,0.0023313474,0.000060573897,0.00006373927,0.0000071180407,0.00031050786,0.000018638668,0.008459738,0.00011883713,0.000034814395,0.021992652],"study_design_scores_gemma":[0.9514367,0.0012875665,0.00087742053,0.000102666876,0.000016281478,0.000009544309,0.00014026446,0.0002976203,0.018837374,0.0005441659,0.026237622,0.0002127794],"about_ca_topic_score_codex":0.0001274128,"about_ca_topic_score_gemma":0.0005771375,"teacher_disagreement_score":0.07111808,"about_ca_system_score_codex":0.000064588945,"about_ca_system_score_gemma":0.0001051481,"threshold_uncertainty_score":0.5727806},"labels":[],"label_agreement":null},{"id":"W3145525891","doi":"10.1016/j.clinbiochem.2021.03.011","title":"Corrigendum to “Quality assurance practices for point of care testing programs: Recommendations by the Canadian society of clinical chemists point of care testing interest group” [Clin. Biochem. 88 (2021) 11–17]","year":2021,"lang":"en","type":"erratum","venue":"Clinical Biochemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Canadian Electricity Association; Hôpital Maisonneuve-Rosemont; St. Paul's Hospital; London Health Sciences Centre; Horizon Health Network; Saint John Regional Hospital; Dalhousie University; University of Manitoba; University of Calgary; Kingston General Hospital; Calgary Laboratory Services","funders":"","keywords":"Point-of-care testing; Point of care; Quality assurance; Point (geometry); Medicine; Medical physics; Nursing; Pathology; Mathematics; External quality assessment","score_opus":0.23256448314886305,"score_gpt":0.46200534887138456,"score_spread":0.2294408657225215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145525891","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22740412,0.2813592,0.0021678265,0.120166406,0.16109443,0.021363426,0.11540153,0.0007412453,0.07030182],"genre_scores_gemma":[0.6251462,0.00350007,0.24129419,0.006499933,0.006951329,0.0008086524,0.046133984,0.00048731128,0.06917831],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921956,0.00085861376,0.0044423696,0.0015302482,0.00018188023,0.0007912753],"domain_scores_gemma":[0.98156446,0.008482437,0.0050863824,0.0014905371,0.0030577874,0.00031840277],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0049873632,0.0006430843,0.002374619,0.00004305654,0.00031914058,0.000050750594,0.0012750673,0.0035634593,0.00015995248],"category_scores_gemma":[0.06095028,0.00051977235,0.0016112732,0.00064386544,0.0018100023,0.000047025544,0.0005633137,0.0028792995,0.0000023817363],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025263775,0.0009061844,0.020213654,0.0058009475,0.0011842145,0.000002923844,0.00026124544,8.567179e-8,0.05201024,0.00001165324,0.85701746,0.062338743],"study_design_scores_gemma":[0.002027296,0.0017573581,0.0021044358,0.006112145,0.0013185221,0.000025591635,0.010438504,0.000015781743,0.3183617,0.000046602916,0.6565942,0.0011978392],"about_ca_topic_score_codex":0.005912094,"about_ca_topic_score_gemma":0.014168395,"teacher_disagreement_score":0.3977421,"about_ca_system_score_codex":0.0002058017,"about_ca_system_score_gemma":0.0032283454,"threshold_uncertainty_score":0.9997254},"labels":[],"label_agreement":null},{"id":"W3149855607","doi":"10.3390/ph14040306","title":"Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities","year":2021,"lang":"en","type":"article","venue":"Pharmaceuticals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Biosimilar; Regulatory science; Portfolio; Agency (philosophy); Medicine; Product (mathematics); Business; Distribution (mathematics); Pharmacology; Risk analysis (engineering); Finance","score_opus":0.051145122921824195,"score_gpt":0.32664297300518536,"score_spread":0.27549785008336114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149855607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686308,0.011871476,0.00069444213,0.0057712286,0.0011559281,0.0009712834,0.0005284172,0.00007824316,0.010298201],"genre_scores_gemma":[0.9952637,0.000055760705,0.0015472869,0.0011961866,0.000027869972,0.000016790524,0.000011186245,0.000015312287,0.0018659238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974677,0.00037020753,0.00070169003,0.0006779237,0.00025762283,0.00052488694],"domain_scores_gemma":[0.9980982,0.00023195926,0.00023947579,0.0009239924,0.00039838604,0.00010802085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019813827,0.00023127062,0.0007715776,0.0003105916,0.00019455554,0.00002034862,0.0006383473,0.00017423558,0.0008704382],"category_scores_gemma":[0.0005351537,0.00016400775,0.0003392876,0.0032041576,0.0019483776,0.00006362976,0.00042217172,0.00027589957,0.000007804661],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006931493,0.00031751272,0.0015745125,0.000062764986,0.0008872072,0.0000013319733,0.00012416518,0.000009327355,0.9846882,0.0033077027,0.0047202758,0.004237647],"study_design_scores_gemma":[0.00029907678,0.000035408717,0.010036065,0.000026035776,0.0013417639,0.000007770013,0.000114102404,0.000027068574,0.94539124,0.00021531309,0.042314358,0.00019178896],"about_ca_topic_score_codex":0.000004337604,"about_ca_topic_score_gemma":0.000001581199,"teacher_disagreement_score":0.03929699,"about_ca_system_score_codex":0.000059696496,"about_ca_system_score_gemma":0.0002458448,"threshold_uncertainty_score":0.95306873},"labels":[],"label_agreement":null},{"id":"W3153488758","doi":"10.4155/bio-2021-0046","title":"Recommendations for the Content and Management of Certificates of Analysis for Reference Standards from the GCC for Bioanalysis","year":2021,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand Challenges Canada","funders":"","keywords":"Bioanalysis; Guideline; Consistency (knowledge bases); Business; Computer science; Political science; Chemistry; Chromatography; Law","score_opus":0.18884809141776732,"score_gpt":0.36394263957749745,"score_spread":0.17509454815973013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153488758","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009518104,0.097320005,0.76874584,0.08000201,0.00041548235,0.0023499606,0.041415665,0.00003661914,0.0001963256],"genre_scores_gemma":[0.93755955,0.008465338,0.049182206,0.00042780713,0.00003168717,0.00041452024,0.0015753878,0.000019499803,0.0023240387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983444,0.00019965527,0.0007040522,0.00043420898,0.00008341376,0.00023426254],"domain_scores_gemma":[0.99499243,0.0030388488,0.00039092705,0.00064365816,0.00090990966,0.000024217266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001329187,0.00017568699,0.0007224223,0.00013359361,0.00030997331,0.000030194346,0.00033447932,0.00015205095,0.00032027255],"category_scores_gemma":[0.00038112066,0.000096230164,0.00094128656,0.0009967702,0.00038162933,0.000028860904,0.000102156504,0.00007493908,3.8008417e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002294406,0.0011320491,0.025282431,0.0005990253,0.34522584,0.0000010753901,0.0007901345,0.00011500423,0.072157465,0.04424856,0.01778296,0.49037105],"study_design_scores_gemma":[0.0031494135,0.00033766794,0.02510389,0.00010292154,0.13678047,9.833251e-7,0.009589767,0.0040933792,0.18773681,0.003745546,0.6288361,0.0005230615],"about_ca_topic_score_codex":0.00028936632,"about_ca_topic_score_gemma":0.0006289524,"teacher_disagreement_score":0.9280414,"about_ca_system_score_codex":0.000029732762,"about_ca_system_score_gemma":0.00004096377,"threshold_uncertainty_score":0.39241523},"labels":[],"label_agreement":null},{"id":"W3156218709","doi":"10.4212/cjhp.v74i2.3108","title":"Effect on Patients’ Outcomes of a Change to Biosimilar Filgrastim Product in Autologous Stem Cell Mobilization","year":2021,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta; Alberta Health Services","funders":"","keywords":"Filgrastim; Biosimilar; Medicine; Granulocyte colony-stimulating factor; Internal medicine; Autologous stem-cell transplantation; Formulary; Oncology; Pharmacology; Chemotherapy","score_opus":0.03301808305809579,"score_gpt":0.3007850103133421,"score_spread":0.2677669272552463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156218709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907974,0.0015833994,0.0000058422834,0.005687594,0.0013306745,0.00037424517,0.00006172405,0.0000034505156,0.00015569547],"genre_scores_gemma":[0.99860924,0.000022432117,0.000052634445,0.0011010704,0.000037217138,0.0000065307545,0.0000055619726,0.000011335314,0.00015395245],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99861616,0.00048955955,0.0003820084,0.00015653665,0.00006128872,0.00029446045],"domain_scores_gemma":[0.99910367,0.00020572449,0.0001866695,0.00017612486,0.00021597694,0.00011181194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059734983,0.00014988662,0.00036690204,0.00019936815,0.00008503211,0.000014749977,0.00026044605,0.00006629126,0.00018709975],"category_scores_gemma":[0.00021141926,0.000093977185,0.00013251194,0.0003315926,0.000115368886,0.00005966615,0.000027403228,0.0003406857,0.000016394284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005961675,0.0010006839,0.7799494,0.00016771122,0.0005060048,0.0003041125,0.0037601113,0.00007782473,0.023255354,0.00016683253,0.012743465,0.17747234],"study_design_scores_gemma":[0.0032507104,0.004832118,0.31811377,0.00015881343,0.00021420851,0.00003154093,0.0001583868,0.000010904999,0.65837836,0.000072642935,0.014461087,0.00031742163],"about_ca_topic_score_codex":0.00075070496,"about_ca_topic_score_gemma":0.0015969445,"teacher_disagreement_score":0.635123,"about_ca_system_score_codex":0.00009801151,"about_ca_system_score_gemma":0.0002425603,"threshold_uncertainty_score":0.38322783},"labels":[],"label_agreement":null},{"id":"W3158216971","doi":"10.1007/s00296-021-04874-8","title":"Patient perspectives on the British Columbia Biosimilars Initiative: a qualitative descriptive study","year":2021,"lang":"en","type":"article","venue":"Rheumatology International","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia Hospital; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Biosimilar; Medicine; Apprehension; Qualitative research; Government (linguistics); Family medicine; Perspective (graphical); Nursing; Medical education; Psychology; Internal medicine","score_opus":0.03965788259431681,"score_gpt":0.32349277424851863,"score_spread":0.28383489165420184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158216971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770918,0.0009966796,0.00018113607,0.010679931,0.0015314962,0.0003495904,0.00025172826,0.00005700961,0.008860619],"genre_scores_gemma":[0.99562174,0.00012521395,0.00036613873,0.0019883192,0.000011008588,0.00008408429,0.000037662667,0.000013973916,0.0017518805],"study_design_codex":"not_applicable","study_design_gemma":"qualitative","domain_scores_codex":[0.99684894,0.0018482193,0.00039985008,0.000513919,0.000107539476,0.00028150197],"domain_scores_gemma":[0.99774224,0.0013209335,0.00016673042,0.00023832679,0.0005056741,0.000026113657],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048856466,0.00015167317,0.0003334627,0.00004151411,0.0005557102,0.0002481279,0.0002831976,0.00019258179,0.0070461854],"category_scores_gemma":[0.001750046,0.00015118843,0.00014555489,0.00018983499,0.0005916413,0.000068075125,0.000180673,0.0005004937,0.00014327037],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005599895,0.009663315,0.09457717,0.000018050636,0.00921068,0.00065630756,0.20748903,0.0000031266486,0.004573873,0.027154189,0.6384109,0.007683368],"study_design_scores_gemma":[0.002770339,0.0011455419,0.03599038,0.0001917348,0.00011974442,0.0011013018,0.9205898,0.000021928734,0.0037748371,0.006311977,0.027421545,0.00056088343],"about_ca_topic_score_codex":0.0007859068,"about_ca_topic_score_gemma":0.003485321,"teacher_disagreement_score":0.71310073,"about_ca_system_score_codex":0.00011392273,"about_ca_system_score_gemma":0.000118513184,"threshold_uncertainty_score":0.9938615},"labels":[],"label_agreement":null},{"id":"W3159791832","doi":"10.1177/10781552211007535","title":"Education strategy for the implementation of oncology biosimilars essential for operational and patient safety in Alberta, Canada","year":2021,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Alberta Cancer Foundation","funders":"","keywords":"Biosimilar; Medicine; Pharmacy; Harm; Patient safety; Oncology; Internal medicine; Family medicine; Health care","score_opus":0.0369520180908905,"score_gpt":0.4361260698854512,"score_spread":0.3991740517945607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159791832","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28628498,0.019510876,0.007075451,0.6686357,0.011907021,0.0031032225,0.0005349684,0.0000058900473,0.0029418755],"genre_scores_gemma":[0.97634816,0.0017586291,0.010062518,0.011406918,0.00016569902,0.000049061793,0.000043728785,0.000011069198,0.00015423825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819565,0.0006590089,0.0007685887,0.00014310496,0.00005409922,0.00017956833],"domain_scores_gemma":[0.99268746,0.0056277732,0.00076623424,0.00007094377,0.00081538525,0.000032213014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010659796,0.00010027554,0.0003166849,0.00005889709,0.00012637027,0.000010544777,0.000106520594,0.000114008835,0.00028946894],"category_scores_gemma":[0.0009349245,0.00007317482,0.00007677864,0.00010626267,0.000106559724,0.0002012042,0.000034441895,0.0002984969,2.1775509e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006435655,0.0015781734,0.0013071032,0.00006800338,0.0012391745,0.000020816698,0.00088351005,0.00012741373,0.09918984,0.0037115936,0.07701407,0.80842465],"study_design_scores_gemma":[0.004675235,0.001077742,0.0013616702,0.00001036774,0.00048762266,0.0006569046,0.0059094764,0.00006196885,0.072485074,0.00014306542,0.91305226,0.00007862514],"about_ca_topic_score_codex":0.017323423,"about_ca_topic_score_gemma":0.11019644,"teacher_disagreement_score":0.8360382,"about_ca_system_score_codex":0.00025869004,"about_ca_system_score_gemma":0.007163127,"threshold_uncertainty_score":0.99846536},"labels":[],"label_agreement":null},{"id":"W3162185224","doi":"10.3899/jrheum.201510","title":"Unravelling the Cost of Biological Strategies in Rheumatoid Arthritis: A Kaleidoscope of Methodologies, Interpretations, and Interests","year":2021,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Rheumatoid arthritis; Antirheumatic drugs; Etanercept; Rheumatology; Medical prescription; Antirheumatic Agents; Internal medicine; Pharmacoeconomics; Physical therapy; Intensive care medicine; Pharmacology","score_opus":0.059916866642862575,"score_gpt":0.33739284069092845,"score_spread":0.2774759740480659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162185224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93331724,0.051161148,0.013263949,0.001669571,0.00036132903,0.00010268362,0.000009883374,0.0000041207622,0.00011004783],"genre_scores_gemma":[0.95848334,0.03690771,0.004510215,0.000079216385,0.0000015779963,0.0000016090596,0.0000013809157,0.0000047203744,0.000010222122],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99597794,0.0027060688,0.00097045314,0.0001100674,0.00003805425,0.00019742046],"domain_scores_gemma":[0.99448687,0.0044806474,0.0006219855,0.00019186495,0.00020273007,0.00001590035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025705243,0.00012583307,0.00072345405,0.00010186152,0.000054285676,0.000008803702,0.0003460026,0.00022857676,0.0001281504],"category_scores_gemma":[0.0017094457,0.00006265054,0.000104021696,0.00020792919,0.0012433514,0.000057534402,0.00016051135,0.000541874,0.0000012980915],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042718286,0.00069593743,0.27286753,0.00032603703,0.002490162,0.00006439469,0.012267246,0.00022716755,0.4678052,0.10287266,0.0016271513,0.13448466],"study_design_scores_gemma":[0.010442792,0.0042249514,0.12636775,0.0061942833,0.0003915679,0.052153125,0.12383691,0.00029085024,0.5343761,0.13352183,0.0072716735,0.00092818425],"about_ca_topic_score_codex":0.000095204094,"about_ca_topic_score_gemma":0.00021789558,"teacher_disagreement_score":0.1464998,"about_ca_system_score_codex":0.000010150824,"about_ca_system_score_gemma":0.00015245988,"threshold_uncertainty_score":0.458118},"labels":[],"label_agreement":null},{"id":"W3163292931","doi":"10.1093/rap/rkab026","title":"Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST)","year":2021,"lang":"en","type":"article","venue":"Rheumatology Advances in Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Clinical Research Institute","funders":"Hospira","keywords":"Medicine; Internal medicine; Adverse effect; Observational study; Infliximab; Prospective cohort study; Dosing; Cohort; Cohort study; Pediatrics; Disease","score_opus":0.013299653785010156,"score_gpt":0.2867051070826578,"score_spread":0.27340545329764765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163292931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99329334,0.0031418095,0.000045987756,0.0006642185,0.00015302369,0.0009351591,0.000032269534,0.000050686875,0.001683507],"genre_scores_gemma":[0.995787,0.0010668138,0.0023929544,0.00021002213,0.0000022752092,0.00020159854,0.00008829104,0.000021783539,0.00022925835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965814,0.0013857662,0.0005839809,0.0008228451,0.00015460697,0.00047144148],"domain_scores_gemma":[0.9965645,0.0021570772,0.00038343345,0.00041919932,0.00041592593,0.00005985728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048250618,0.00032547032,0.0008443915,0.00014345982,0.00017702427,0.000023937106,0.00022705656,0.00011436144,0.00018857849],"category_scores_gemma":[0.0024235575,0.00024053777,0.00005308626,0.0008357028,0.0005025022,0.0008240121,0.000091028036,0.0005656666,0.000022070013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019327154,0.0032173141,0.99212277,0.00005202323,0.0005719853,0.00014242512,0.000425589,0.00007071558,0.0000061587943,0.0010244291,0.000038905175,0.00039496936],"study_design_scores_gemma":[0.005300944,0.00051205,0.986651,0.00021397366,0.00032805328,0.0001462789,0.0059793703,0.000021416467,0.000069103415,0.00007320038,0.0003677971,0.00033678327],"about_ca_topic_score_codex":0.00023818131,"about_ca_topic_score_gemma":0.00075813424,"teacher_disagreement_score":0.005553781,"about_ca_system_score_codex":0.00018131269,"about_ca_system_score_gemma":0.00030995684,"threshold_uncertainty_score":0.98088455},"labels":[],"label_agreement":null},{"id":"W3163866919","doi":"10.1007/s40264-021-01078-8","title":"Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities","year":2021,"lang":"en","type":"review","venue":"Drug Safety","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada","keywords":"Pharmacovigilance; Medicine; Excellence; Best practice; Presentation (obstetrics); Knowledge management; Engineering ethics; Pharmacology; Engineering; Management; Adverse effect; Computer science","score_opus":0.119996193234862,"score_gpt":0.4177286110289148,"score_spread":0.2977324177940528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163866919","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021237884,0.994125,0.000022003731,0.0013384194,0.0031450002,0.00028111422,0.0004916117,0.00003177856,0.0005438051],"genre_scores_gemma":[0.000005382554,0.99695396,0.00019711323,0.0005647956,0.00085082214,0.000045875106,0.00035417092,0.00002076847,0.0010071042],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970572,0.001459243,0.0005621437,0.0005408438,0.000058609075,0.00032193126],"domain_scores_gemma":[0.99713707,0.001642748,0.0007089256,0.0004094893,0.000059046826,0.000042691572],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065868883,0.0003968807,0.001202578,0.00003009703,0.00033814026,0.00006478113,0.00040151307,0.00035378244,0.0013831274],"category_scores_gemma":[0.0001828637,0.00022137967,0.00029243357,0.00014219353,0.0003402281,0.00009477048,0.0002841623,0.0011307186,0.000025283336],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011600535,0.00003125057,0.000008991113,0.0007482154,0.00028220573,0.00001157443,0.0004922323,3.7433106e-9,0.000022594813,0.0002816494,0.0041881036,0.9939216],"study_design_scores_gemma":[0.00013359106,0.000007115514,0.000010562279,0.0025169298,0.00083741493,0.000050743616,0.0012387612,2.2466911e-7,0.00013570375,0.000010249872,0.9947728,0.0002858831],"about_ca_topic_score_codex":0.00004604901,"about_ca_topic_score_gemma":0.000019439334,"teacher_disagreement_score":0.9936357,"about_ca_system_score_codex":0.00003538374,"about_ca_system_score_gemma":0.00024673986,"threshold_uncertainty_score":0.9995297},"labels":[],"label_agreement":null},{"id":"W3163953444","doi":"10.1136/annrheumdis-2021-eular.2599","title":"AB0557 ACHIEVING TREATMENT TARGETS IN PSORIATIC ARTHRITIS WITH APREMILAST IN CANADIAN PRACTICE: REAL WORLD RESULTS FROM APPRAISE","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Windsor Regional Hospital; Amgen (Canada); Memorial University of Newfoundland; Université Laval; Vancouver Island University; Southlake Regional Health Center; Arthritis Society","funders":"Celgene; Amgen","keywords":"Medicine; Apremilast; Tolerability; Psoriatic arthritis; Internal medicine; Concomitant; Interim analysis; Clinical trial; Clinical endpoint; Observational study; Adverse effect; Physical therapy; Disease","score_opus":0.03231272302563403,"score_gpt":0.31874104812914017,"score_spread":0.28642832510350613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163953444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91371185,0.0354301,0.000015386384,0.036109928,0.00069994456,0.00086569507,0.0023749112,0.000037980204,0.010754213],"genre_scores_gemma":[0.9944751,0.003617302,0.0006723224,0.0005497956,0.0000134204365,0.00002372556,0.000099030956,0.00001287719,0.0005364262],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978919,0.00073307444,0.00054424437,0.0003199408,0.00007163278,0.00043918932],"domain_scores_gemma":[0.9977915,0.0013305292,0.000217027,0.00048083678,0.00008070483,0.0000993955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003620919,0.00019215529,0.0004844743,0.00013628574,0.00007989301,0.000023431174,0.00020318676,0.00009851719,0.00020423817],"category_scores_gemma":[0.0020654795,0.00012386034,0.00012201504,0.00044570697,0.00016284816,0.00010775228,0.000058088215,0.00016358655,0.000012320552],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062957257,0.0077497056,0.17362538,0.00036598477,0.0039720894,0.0009990297,0.0062659876,0.000558213,0.001935099,0.003783151,0.02002344,0.7744262],"study_design_scores_gemma":[0.007999333,0.00043749542,0.9397487,0.0048642955,0.00042236844,0.000031847725,0.0022130446,0.00017257368,0.012417975,0.0022291958,0.028784705,0.00067845726],"about_ca_topic_score_codex":0.16510242,"about_ca_topic_score_gemma":0.49594474,"teacher_disagreement_score":0.77374774,"about_ca_system_score_codex":0.00007235045,"about_ca_system_score_gemma":0.00053568376,"threshold_uncertainty_score":0.8404572},"labels":[],"label_agreement":null},{"id":"W3164234380","doi":"10.1136/annrheumdis-2021-eular.359","title":"POS0652 SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Pfizer (Canada); University of Alberta","funders":"Pfizer","keywords":"Tofacitinib; Medicine; Rheumatoid arthritis; Janus kinase inhibitor; Internal medicine; Discontinuation; Adalimumab; Post-hoc analysis; Placebo; Clinical trial; Methotrexate; Surgery; Alternative medicine; Pathology","score_opus":0.06071091670102527,"score_gpt":0.3499488817582679,"score_spread":0.28923796505724264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164234380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779542,0.019871525,0.000008930281,0.00082260906,0.00005211974,0.00027718244,0.0009996122,0.000002630266,0.000011188374],"genre_scores_gemma":[0.9843777,0.01528637,0.00002310244,0.0002127505,0.0000015511032,0.000005698948,0.000078583194,0.0000038113758,0.000010452453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969615,0.0015990417,0.0009682781,0.00021384661,0.00009072237,0.0001666626],"domain_scores_gemma":[0.99649507,0.0025301492,0.0004467147,0.00032840262,0.00017423641,0.000025457584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010198138,0.0001441294,0.0011209681,0.00016255879,0.000047768663,0.000012013633,0.0001829788,0.000094421826,0.00019892266],"category_scores_gemma":[0.0034994588,0.00007777037,0.00024729143,0.00050379557,0.00046702774,0.000049483628,0.0001240646,0.00009246588,2.2236979e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031160216,0.00561545,0.578617,0.00045913583,0.0028925266,0.000007628548,0.0021222362,0.0000032034134,0.0051509975,0.0005109355,0.0001859887,0.4013189],"study_design_scores_gemma":[0.003662366,0.00032307804,0.98969203,0.0010419516,0.00037043294,0.000003464403,0.0005727283,0.000018561304,0.003913137,0.00029655488,0.000010648274,0.000095056275],"about_ca_topic_score_codex":0.000055690605,"about_ca_topic_score_gemma":0.00006869704,"teacher_disagreement_score":0.41107506,"about_ca_system_score_codex":0.0000026966948,"about_ca_system_score_gemma":0.000039707356,"threshold_uncertainty_score":0.41894317},"labels":[],"label_agreement":null},{"id":"W3164373175","doi":"10.1093/clinchem/hvab074","title":"Broadening the Horizon of Antidoping Analytical Approaches Using Dried Blood Spots","year":2021,"lang":"en","type":"letter","venue":"Clinical Chemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency","keywords":"Dried blood; Spots; Chromatography; Chemistry","score_opus":0.2198762732898227,"score_gpt":0.3683143893273673,"score_spread":0.14843811603754462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164373175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48451063,0.023786994,0.00082700164,0.46883738,0.004268724,0.0008112057,0.00037365538,0.00022097774,0.016363429],"genre_scores_gemma":[0.5101778,0.0020518233,0.017811762,0.36664096,0.032505084,0.00005806048,0.003255958,0.0006482731,0.06685028],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99629056,0.000661685,0.0014192861,0.0008896569,0.00012786221,0.0006109367],"domain_scores_gemma":[0.99601924,0.0022438283,0.0005974486,0.00096117,0.00013228322,0.000046024332],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0011866471,0.00043377263,0.001376256,0.000029394932,0.00015432491,0.00003987446,0.00076414505,0.0040278793,0.00077641127],"category_scores_gemma":[0.0016129399,0.00030653502,0.0009824969,0.00026949073,0.0016939761,0.000025329868,0.00045333774,0.0054434375,0.000009414389],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002964981,0.0013012331,0.013666619,0.0034124875,0.010364429,0.0011495815,0.000058663063,0.0000050937338,0.114912495,0.0001487007,0.83360654,0.021077637],"study_design_scores_gemma":[0.002178214,0.00027581028,0.0003971139,0.0013276259,0.005583959,0.0006575853,0.00020151306,0.00029625485,0.38300654,0.00025579287,0.60445327,0.00136633],"about_ca_topic_score_codex":0.000005512811,"about_ca_topic_score_gemma":1.5949921e-7,"teacher_disagreement_score":0.26809403,"about_ca_system_score_codex":0.00002450299,"about_ca_system_score_gemma":0.0002496726,"threshold_uncertainty_score":0.99993867},"labels":[],"label_agreement":null},{"id":"W3164548357","doi":"10.1136/annrheumdis-2021-eular.282","title":"AB0197 EFFICACY AND SAFETY OF HLX01 COMBINED WITH METHOTREXATE IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD INADEQUATE RESPONSES TO METHOTREXATE: RESULTS OF A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of California, Los Angeles; University of Toronto","keywords":"Medicine; Rheumatoid arthritis; Placebo; Methotrexate; Internal medicine; Clinical endpoint; Rituximab; Rheumatology; Tolerability; Adverse effect; Clinical trial; Surgery; Lymphoma","score_opus":0.03450348972195552,"score_gpt":0.3363933706583125,"score_spread":0.30188988093635694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164548357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924134,0.0013032375,0.00014141647,0.0010719283,0.00005756055,0.0041585546,0.00074169686,0.0000145630665,0.00009761607],"genre_scores_gemma":[0.9980828,0.0005217408,0.00078714394,0.00015379704,0.0000019782249,0.00017038331,0.000031970943,0.000027166083,0.00022299917],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946923,0.0027651545,0.0013719609,0.0005396585,0.0002357396,0.00039515222],"domain_scores_gemma":[0.9940985,0.0036373264,0.0007756842,0.00068365835,0.00066296087,0.00014191036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015166928,0.00042219,0.0021401914,0.00028259656,0.000120823395,0.000025418722,0.00034859206,0.00012223235,0.000049099806],"category_scores_gemma":[0.0034879483,0.0002347564,0.0002117201,0.0009109389,0.00032202332,0.00012568681,0.00024108707,0.00021006954,0.0000017002197],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96755445,0.005111155,0.0016166231,0.000113271075,0.002275225,0.000009271496,0.0022726455,0.00024207978,0.0003698838,0.000040503503,0.000083645995,0.020311248],"study_design_scores_gemma":[0.7683861,0.0067532663,0.18669882,0.002726649,0.00046719308,0.000007685361,0.0010345071,0.00008233355,0.03309954,0.0002442912,0.00002742654,0.0004721377],"about_ca_topic_score_codex":0.00022899658,"about_ca_topic_score_gemma":0.00020484693,"teacher_disagreement_score":0.19916831,"about_ca_system_score_codex":0.000015603877,"about_ca_system_score_gemma":0.00022831923,"threshold_uncertainty_score":0.9573088},"labels":[],"label_agreement":null},{"id":"W3164610545","doi":"10.1136/annrheumdis-2021-eular.705","title":"POS0207 REAL-WORLD RETENTION OF JAK INHIBITORS IS LONGER THAN BDMARDS IN RHEUMATOID ARTHRITIS","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Tofacitinib; Abatacept; Discontinuation; Tocilizumab; Rheumatoid arthritis; Internal medicine; Janus kinase inhibitor; Hazard ratio; Certolizumab pegol; Rituximab; Adalimumab; Confidence interval","score_opus":0.03949495421658896,"score_gpt":0.3124648860336894,"score_spread":0.27296993181710044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164610545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785526,0.015085213,0.000010634956,0.003905302,0.0004988204,0.0001923372,0.00024980237,0.00001827465,0.0014870291],"genre_scores_gemma":[0.98812866,0.010075108,0.000111695816,0.0002888301,0.000007456873,0.000008390721,0.000024485607,0.000012439459,0.0013429292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981462,0.00050923176,0.00071600627,0.000245437,0.00010613919,0.0002769998],"domain_scores_gemma":[0.99867254,0.00028412987,0.00031739753,0.00050340436,0.00018349438,0.00003901469],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004182918,0.00016516654,0.00054516556,0.00011760927,0.000060584454,0.000011488671,0.00025088168,0.00013311605,0.0010766705],"category_scores_gemma":[0.00057781924,0.00011702895,0.0004169334,0.000490256,0.00035716512,0.00007835026,0.00017830789,0.00014716337,0.000016207183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009996735,0.0045978106,0.398494,0.0019274615,0.0027281328,0.00003706,0.0021069625,0.000015146359,0.055733643,0.014504297,0.14820425,0.37065154],"study_design_scores_gemma":[0.0012472689,0.000145015,0.5980244,0.0041804467,0.00009766262,0.000017095672,0.000662397,0.000021400116,0.38056245,0.012452885,0.002263265,0.00032571494],"about_ca_topic_score_codex":0.0002984898,"about_ca_topic_score_gemma":0.00020581255,"teacher_disagreement_score":0.37032583,"about_ca_system_score_codex":0.000010710513,"about_ca_system_score_gemma":0.000106380954,"threshold_uncertainty_score":0.9998365},"labels":[],"label_agreement":null},{"id":"W3165489527","doi":"10.1177/12034754211007814","title":"Biosimilars: Promises Made. Promises Kept?","year":2021,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Arthritis Patient Alliance; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Biosimilar; Intensive care medicine; Internal medicine","score_opus":0.04347359851706961,"score_gpt":0.29423066145134563,"score_spread":0.250757062934276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165489527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76191926,0.14107195,0.0003063009,0.0856421,0.0046461225,0.00024546086,0.000022328852,0.00005735297,0.006089107],"genre_scores_gemma":[0.94859475,0.02397298,0.002005753,0.013599663,0.0011712974,0.000003524839,0.000016355403,0.00004839313,0.010587301],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983364,0.0003049571,0.000764106,0.0001932405,0.000104484825,0.00029684333],"domain_scores_gemma":[0.99751395,0.0015457984,0.000343466,0.00016185112,0.00033498995,0.00009995676],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00081102265,0.00018704435,0.0008430985,0.0001823495,0.00009861912,0.00001769765,0.00010271837,0.00023565619,0.0016369554],"category_scores_gemma":[0.0018720105,0.00011633665,0.00020845576,0.00020981689,0.0004104184,0.00007423386,0.000041980264,0.00041708758,0.0000072810235],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071745575,0.0003557809,0.010247567,0.00022518019,0.0008970133,0.005429898,0.0004095875,4.7772915e-7,0.48249012,0.00017953756,0.43450955,0.06453784],"study_design_scores_gemma":[0.0014959729,0.0008970233,0.0021485311,0.0011910856,0.0007105127,0.0699189,0.0013815508,0.000004038501,0.16088338,0.0016966942,0.7592646,0.00040775276],"about_ca_topic_score_codex":0.0000030889346,"about_ca_topic_score_gemma":0.0000022127615,"teacher_disagreement_score":0.324755,"about_ca_system_score_codex":0.000017073662,"about_ca_system_score_gemma":0.00022545899,"threshold_uncertainty_score":0.9992757},"labels":[],"label_agreement":null},{"id":"W3165577823","doi":"10.1136/annrheumdis-2021-eular.325","title":"AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Adalimumab; Medicine; Internal medicine; Rheumatoid arthritis; Randomization; Immunogenicity; Biosimilar; Gastroenterology; Nuclear medicine; Randomized controlled trial; Immunology; Antibody","score_opus":0.030039323359740033,"score_gpt":0.2870993156697347,"score_spread":0.25705999230999466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165577823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889301,0.0018224684,0.00007970357,0.005590029,0.000056332854,0.001214587,0.0021738906,0.000029323211,0.00010353363],"genre_scores_gemma":[0.9966037,0.0013241852,0.00043224686,0.0011323789,0.0000052014557,0.00014225487,0.00022733922,0.000032834512,0.0000998564],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99660957,0.0010547931,0.00078488205,0.00073923974,0.00023548656,0.00057601137],"domain_scores_gemma":[0.9977451,0.0007871611,0.00026829288,0.0008120431,0.0002440628,0.0001433375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024984454,0.00049359543,0.0010223348,0.00013355182,0.00022509955,0.00007053429,0.00037775657,0.00012331812,0.00030412388],"category_scores_gemma":[0.0002412492,0.00025908215,0.00010757054,0.00056155486,0.00034667467,0.00016583143,0.00016377696,0.00031990767,0.000016169774],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5541578,0.022181317,0.080243155,0.0007436611,0.007484239,0.00036948736,0.02188603,0.0044499533,0.0015564209,0.0018133923,0.0063244468,0.29879013],"study_design_scores_gemma":[0.028349308,0.003950684,0.93720376,0.0076417946,0.0003842502,0.000030497073,0.005649714,0.00017896935,0.013072567,0.00080109946,0.0015620482,0.0011752883],"about_ca_topic_score_codex":0.00096334337,"about_ca_topic_score_gemma":0.0039926614,"teacher_disagreement_score":0.8569606,"about_ca_system_score_codex":0.00010520755,"about_ca_system_score_gemma":0.00027358095,"threshold_uncertainty_score":0.9999861},"labels":[],"label_agreement":null},{"id":"W3166447425","doi":"10.1016/j.jval.2021.04.081","title":"PBI10 Economic Impact of Originator-to-Biosimilar Non-Medical Switching on Health Care Resource Utilization in Rheumatic Patients in Quebec, Canada","year":2021,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada)","funders":"","keywords":"Biosimilar; Medicine; Psoriatic arthritis; Productivity; Health care; Rheumatoid arthritis; Indirect costs; Emergency medicine; Family medicine; Business; Accounting; Internal medicine","score_opus":0.021976219381300247,"score_gpt":0.3289181174072616,"score_spread":0.3069418980259614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166447425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924574,0.0015718195,0.000028766932,0.004983937,0.00035936036,0.0004143032,0.00006759385,0.0000071837794,0.00010965515],"genre_scores_gemma":[0.9968699,0.0003066326,0.00016945812,0.0025037052,0.000010522933,0.0000076181755,0.000081810234,0.000015689084,0.000034649667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968834,0.0010941444,0.0009753735,0.0003914766,0.00009909286,0.0005565175],"domain_scores_gemma":[0.9989399,0.000402385,0.00021230176,0.00027506516,0.000034800043,0.00013558855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010000148,0.00018151845,0.0006478568,0.00026732948,0.000055531615,0.0000069747553,0.00018036495,0.00023244036,0.00015459469],"category_scores_gemma":[0.0004501947,0.00016325469,0.00006317794,0.0004034126,0.000033949746,0.000032894724,0.00006303031,0.0005164694,0.0000050866356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007404699,0.0012278856,0.79128116,0.0020628409,0.00011868654,0.00006941646,0.009626451,0.0153634,0.00017559832,0.0011762673,0.02147154,0.1566863],"study_design_scores_gemma":[0.005800298,0.0015694018,0.9648398,0.004803366,0.000007845357,0.000009943619,0.0024444885,0.004440087,0.0014125274,0.00016890823,0.013912658,0.0005906507],"about_ca_topic_score_codex":0.9357038,"about_ca_topic_score_gemma":0.9459985,"teacher_disagreement_score":0.17355868,"about_ca_system_score_codex":0.0039798743,"about_ca_system_score_gemma":0.0072523993,"threshold_uncertainty_score":0.99984366},"labels":[],"label_agreement":null},{"id":"W3166743396","doi":"10.1093/rheumatology/keab460","title":"Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis","year":2021,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Celltrion","keywords":"Adalimumab; Medicine; Immunogenicity; Rheumatoid arthritis; Internal medicine; Nuclear medicine; Antibody; Immunology","score_opus":0.04388128521596943,"score_gpt":0.3137573164252346,"score_spread":0.2698760312092652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166743396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98710674,0.009333461,0.00041002454,0.00074786285,0.00030339413,0.0010006293,0.000077905,0.000032792726,0.0009871835],"genre_scores_gemma":[0.9957989,0.0019205541,0.001609443,0.00026485074,0.000022024851,0.000043096265,0.000055641023,0.000019463487,0.0002660449],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970473,0.0009768694,0.0008485663,0.0006384405,0.000089807654,0.0003990046],"domain_scores_gemma":[0.9979944,0.0011849635,0.00016103647,0.00049156067,0.000096554286,0.00007145422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011339593,0.00027136042,0.0012646207,0.00012916872,0.000117743904,0.00004130642,0.0002557391,0.00022583941,0.00054277066],"category_scores_gemma":[0.000409904,0.00022888614,0.00012073637,0.00034271268,0.00016264617,0.000080769925,0.0003282657,0.0005377468,0.00004172018],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6449256,0.005084859,0.016298657,0.000079447134,0.0025303038,0.00047883482,0.005840079,0.000023294562,0.19323169,0.0037367526,0.0007110114,0.1270595],"study_design_scores_gemma":[0.8988724,0.00080264785,0.031910922,0.00078383397,0.00023296099,0.00011644395,0.0020518494,0.000026612192,0.050300926,0.0013888538,0.012673,0.0008395716],"about_ca_topic_score_codex":0.0013291171,"about_ca_topic_score_gemma":0.0012773018,"teacher_disagreement_score":0.2539468,"about_ca_system_score_codex":0.00003074472,"about_ca_system_score_gemma":0.000075546646,"threshold_uncertainty_score":0.93337065},"labels":[],"label_agreement":null},{"id":"W3166958902","doi":"10.1093/crocol/otab038","title":"The Great Debate With IBD Biosimilars","year":2021,"lang":"en","type":"review","venue":"Crohn s & Colitis 360","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Biosimilar; Medicine; Internal medicine","score_opus":0.04654549297425101,"score_gpt":0.3287366330887108,"score_spread":0.2821911401144598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166958902","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000019841352,0.99174017,0.000048088747,0.00048204255,0.0010945225,0.00068287906,0.00027361125,0.000080443235,0.0055962424],"genre_scores_gemma":[0.0000027360481,0.9738232,0.00035021047,0.0006011222,0.00013457972,0.00016311537,0.0001786622,0.000077083365,0.024669327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623907,0.0011635253,0.00073037023,0.00081223814,0.000085702675,0.0009690919],"domain_scores_gemma":[0.9972926,0.0010569884,0.00033386596,0.0010451551,0.00018306966,0.000088360764],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005738038,0.00069586973,0.002114203,0.000096787226,0.0006853629,0.00018397723,0.0007765177,0.0011290616,0.0013312754],"category_scores_gemma":[0.00019356869,0.0003635669,0.0007732328,0.00054890476,0.0011068798,0.00004499147,0.00030492406,0.0011083644,0.00035783605],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003789974,0.0000388097,0.000002444203,0.0009700005,0.0010231392,0.00025590148,0.000010441499,1.1847651e-8,0.0000015376199,0.0017702646,0.04118473,0.9547048],"study_design_scores_gemma":[0.00028103674,0.00012916872,0.00004282433,0.0045951093,0.0016791965,0.0009979346,0.00002502822,1.1225295e-7,0.000055474124,0.00007902133,0.9915921,0.00052300264],"about_ca_topic_score_codex":0.000024794415,"about_ca_topic_score_gemma":0.00009637136,"teacher_disagreement_score":0.9541818,"about_ca_system_score_codex":0.00011612166,"about_ca_system_score_gemma":0.00057494873,"threshold_uncertainty_score":0.9998816},"labels":[],"label_agreement":null},{"id":"W3169076687","doi":"10.1200/jco.2021.39.15_suppl.e12569","title":"Trastuzumab-dkst versus trastuzumab: Real-world pCR rates in patients with HER2+ breast cancer treated with neoadjuvant chemotherapy plus trastuzumab from Alberta, Canada.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Baker Hughes (Canada)","funders":"","keywords":"Trastuzumab; Medicine; Biosimilar; Oncology; Breast cancer; Internal medicine; Anthracycline; Chemotherapy; Metastatic breast cancer; Cancer","score_opus":0.04144275719447472,"score_gpt":0.3705143256458127,"score_spread":0.329071568451338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169076687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98772943,0.00063577003,0.000038363,0.007899324,0.0016510047,0.0002718288,0.00023656728,0.000012059119,0.0015256392],"genre_scores_gemma":[0.9942314,0.0007334666,0.0011001981,0.0021391998,0.00032650793,0.000010710234,0.00006990953,0.00005323371,0.0013353523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946053,0.0013939262,0.0023772845,0.00064920436,0.00025291205,0.00072139705],"domain_scores_gemma":[0.99310595,0.0040548923,0.001495109,0.0003610272,0.0007099762,0.00027304364],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089151185,0.00046671482,0.0026776064,0.00014871256,0.0001098772,0.000025077097,0.0003714507,0.0007390871,0.0021550336],"category_scores_gemma":[0.00036241184,0.00029933828,0.0003169177,0.0005919474,0.0005672059,0.00014985356,0.000053096108,0.0018235483,0.000007298027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08930301,0.004914744,0.6920773,0.00002316562,0.0048880405,0.0011295459,0.00024230317,0.00009961277,0.00037548185,0.000042243137,0.008997,0.19790758],"study_design_scores_gemma":[0.04074538,0.007063153,0.92446864,0.00020898494,0.00061704323,0.000088752364,0.00028451305,0.000018341054,0.0011820423,0.000024799721,0.024886454,0.00041187924],"about_ca_topic_score_codex":0.2709047,"about_ca_topic_score_gemma":0.8890763,"teacher_disagreement_score":0.61817163,"about_ca_system_score_codex":0.001286336,"about_ca_system_score_gemma":0.007896309,"threshold_uncertainty_score":0.9999459},"labels":[],"label_agreement":null},{"id":"W3170732077","doi":"10.1016/j.jval.2021.04.079","title":"PBI8 Economic Impact of an Originator-to-Biosimilar Non-Medical Switch in the Real-World Setting: A Systematic Literature Review","year":2021,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ABB (Canada)","funders":"","keywords":"Biosimilar; Medicine; MEDLINE; Systematic review; Health care; Actuarial science; Business; Political science; Internal medicine","score_opus":0.02852181198879856,"score_gpt":0.3766476230798687,"score_spread":0.34812581109107016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170732077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5848048,0.3406521,0.00006134555,0.065500565,0.0015530712,0.005190779,0.00033405764,0.00006971618,0.0018335885],"genre_scores_gemma":[0.9126798,0.062443145,0.0023513238,0.021711461,0.00014834251,0.00013431236,0.00011998908,0.000047142315,0.00036447353],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99472106,0.0031864697,0.0011248878,0.00039621393,0.00008893439,0.0004824426],"domain_scores_gemma":[0.9981725,0.00079636433,0.00024744726,0.0006247623,0.00005355963,0.00010534346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062518255,0.00020865172,0.0010130082,0.00019296864,0.00005592786,0.000019065847,0.00042744237,0.00026276018,0.00024348819],"category_scores_gemma":[0.0006508057,0.00012630856,0.00018981105,0.00083434145,0.00006901732,0.000054112872,0.00006775994,0.0007200945,0.000025976435],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008479611,0.004856313,0.09779911,0.7318565,0.0015307904,0.0021772352,0.0154939825,0.0007027261,0.0061638798,0.037007637,0.082899235,0.018664617],"study_design_scores_gemma":[0.007009524,0.005093241,0.13972355,0.8102829,0.00044172961,0.0023178249,0.001456752,0.0065925126,0.003987993,0.0037062285,0.017246176,0.0021415446],"about_ca_topic_score_codex":0.0013960865,"about_ca_topic_score_gemma":0.00050235813,"teacher_disagreement_score":0.32787505,"about_ca_system_score_codex":0.00035310717,"about_ca_system_score_gemma":0.0011477945,"threshold_uncertainty_score":0.5150714},"labels":[],"label_agreement":null},{"id":"W3171527016","doi":"10.1093/ecco-jcc/jjab076.676","title":"P555 Outcomes of multiswitching from original infliximab to biosimilars in patients with inflammatory bowel disease","year":2021,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Infliximab; Inflammatory bowel disease; Ulcerative colitis; Internal medicine; Cohort; Discontinuation; Adverse effect; Retrospective cohort study; Pancolitis; Crohn's disease; Disease; Gastroenterology; Colorectal cancer; Colonoscopy","score_opus":0.008481972541966325,"score_gpt":0.2565659328500841,"score_spread":0.24808396030811777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171527016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755865,0.0009778626,0.000109890556,0.0009039447,0.00021451808,0.000085191474,0.00009921977,0.0000028668926,0.000047844565],"genre_scores_gemma":[0.99672085,0.00007331819,0.0023315866,0.0007460463,0.000020962943,0.0000015908735,0.00000474477,0.0000083704845,0.00009251911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989479,0.0001372054,0.00048151473,0.00014872683,0.000084063795,0.00020056941],"domain_scores_gemma":[0.9991793,0.00015096138,0.00021720988,0.00012787098,0.00022452064,0.00010015716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018113523,0.00013101374,0.00041180826,0.00011508229,0.00004320275,0.00002045778,0.000105497915,0.00010159402,0.00017318942],"category_scores_gemma":[0.00016097957,0.000091406335,0.00008956027,0.00010605535,0.00010052432,0.000105851715,0.00006386942,0.00023719133,0.000001783606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003199061,0.00026481732,0.9892457,0.000027282345,0.00021906315,0.00015787946,0.00017961038,0.000004286243,0.00066877314,0.00017692083,0.0003385696,0.0055180034],"study_design_scores_gemma":[0.0026441584,0.00022147385,0.9886317,0.00018487619,0.00008990211,0.000008191184,0.00010289663,0.0000019975357,0.0026335798,0.0003009234,0.0050611193,0.00011915326],"about_ca_topic_score_codex":0.000026003756,"about_ca_topic_score_gemma":0.000056829296,"teacher_disagreement_score":0.00539885,"about_ca_system_score_codex":0.000027967286,"about_ca_system_score_gemma":0.0001310648,"threshold_uncertainty_score":0.3727442},"labels":[],"label_agreement":null},{"id":"W3172413452","doi":"10.1200/jco.2021.39.15_suppl.9509","title":"Overall survival benefit from tebentafusp in patients with best response of progressive disease.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Cohort; Pembrolizumab; Progressive disease; Oncology; Interim analysis; Randomized controlled trial; Disease; Nuclear medicine; Cancer; Immunotherapy","score_opus":0.07157264237981696,"score_gpt":0.4179175306840169,"score_spread":0.3463448883041999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172413452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422103,0.0015606856,0.00002672808,0.002712372,0.0010419334,0.0001314118,0.00008611605,0.0000026765347,0.00021705934],"genre_scores_gemma":[0.99535733,0.00013733614,0.0032288246,0.00074076623,0.00012808215,0.0000023570817,0.000017232664,0.000011468173,0.000376608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954518,0.0020783124,0.0018590679,0.00024097666,0.0001263569,0.00024347613],"domain_scores_gemma":[0.9929487,0.004670577,0.0013979959,0.00023221385,0.0006216046,0.00012888259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021583815,0.00014415344,0.0013521182,0.00008218283,0.000025962476,0.000005925738,0.00024502433,0.0005056378,0.00088654045],"category_scores_gemma":[0.004612009,0.00009317858,0.00032770226,0.0001449567,0.00044074643,0.00007755033,0.00011210812,0.00087716366,0.000010965594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058843154,0.0058128294,0.90355825,0.00000936907,0.00056848745,0.00042951075,0.000031098643,0.0000048401234,0.00087902276,0.00019079757,0.00053541653,0.02913722],"study_design_scores_gemma":[0.010204305,0.006645468,0.96422124,0.00016324315,0.0002675583,0.000008375931,0.00006002118,0.0000016120026,0.0009332856,0.0007323536,0.016649833,0.00011272761],"about_ca_topic_score_codex":0.000016405485,"about_ca_topic_score_gemma":0.000049857284,"teacher_disagreement_score":0.060662966,"about_ca_system_score_codex":0.000058999925,"about_ca_system_score_gemma":0.0009877236,"threshold_uncertainty_score":0.9706996},"labels":[],"label_agreement":null},{"id":"W3173807129","doi":"10.1016/j.jpba.2021.114234","title":"Enhanced urinary stability of peptide hormones and growth factors by dried urine microsampling","year":2021,"lang":"en","type":"article","venue":"Journal of Pharmaceutical and Biomedical Analysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency","keywords":"Chemistry; Chromatography; Urine; Peptide; Tandem mass spectrometry; Growth hormone; Dried blood; Extraction (chemistry); Urinary system; Mass spectrometry; Hormone; Biochemistry; Internal medicine","score_opus":0.03137929185363556,"score_gpt":0.32693837192970304,"score_spread":0.29555908007606746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173807129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794037,0.0108022215,0.007069843,0.0024206133,0.000119476346,0.000037198013,0.0000954401,0.0000062207305,0.00004533955],"genre_scores_gemma":[0.99537754,0.0027077103,0.0015422539,0.00020885118,0.000036980528,4.6839816e-7,0.000026829408,0.0000051869747,0.00009419773],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981959,0.00031659502,0.000796932,0.00027270083,0.00013718201,0.00028068825],"domain_scores_gemma":[0.9985267,0.00061032135,0.0002562645,0.00010313903,0.0002782848,0.00022528782],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074714376,0.00018120435,0.00084319874,0.00017941282,0.0000904098,0.000017803717,0.00013064937,0.00024159598,0.0010744104],"category_scores_gemma":[0.00042864552,0.00011611468,0.0003489564,0.0007026417,0.0010183227,0.00006919977,0.0001586785,0.00047248922,7.506395e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000262052,0.0007209089,0.021490732,0.0000880262,0.0024021012,0.000022872446,0.00008983732,5.5797234e-8,0.9701216,0.0000615775,0.00029949346,0.004440745],"study_design_scores_gemma":[0.0013507996,0.00044977645,0.024053652,0.00003131832,0.0031874843,0.00011302477,0.00033275256,0.000060695656,0.96499103,0.0003539675,0.004892117,0.00018335423],"about_ca_topic_score_codex":0.000014314155,"about_ca_topic_score_gemma":0.0000015254891,"teacher_disagreement_score":0.015973873,"about_ca_system_score_codex":0.000016732125,"about_ca_system_score_gemma":0.00005055141,"threshold_uncertainty_score":0.99983877},"labels":[],"label_agreement":null},{"id":"W3174856630","doi":"10.1186/s12902-021-00797-4","title":"Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies","year":2021,"lang":"en","type":"article","venue":"BMC Endocrine Disorders","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"Biocon","keywords":"Medicine; Insulin glargine; Immunogenicity; Diabetes mellitus; Internal medicine; Insulin; Gastroenterology; Endocrinology; Antibody; Type 2 diabetes; Immunology","score_opus":0.024390254887420675,"score_gpt":0.2909738749663911,"score_spread":0.2665836200789704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174856630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9617092,0.033693448,0.000026928381,0.0034988802,0.00009061229,0.00070332666,0.0001910266,0.000032744792,0.000053853386],"genre_scores_gemma":[0.9937839,0.004917547,0.00062443846,0.00040923865,0.000018221406,0.00005108935,0.00012182689,0.000020951647,0.000052816915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977179,0.0006598022,0.0004641854,0.0005336034,0.00009754211,0.00052696787],"domain_scores_gemma":[0.9982306,0.0010034663,0.00014976744,0.0004313423,0.0001473742,0.000037474085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040615676,0.00035577573,0.00055320264,0.00007957349,0.00035000467,0.000043778084,0.00026870758,0.00012202044,0.000034900506],"category_scores_gemma":[0.00081028946,0.0001830444,0.00006712338,0.0004512571,0.0011516212,0.000113525086,0.00035541883,0.0005442081,0.0000027726776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068623153,0.0006900285,0.9399878,0.0001914489,0.00089416094,0.000005524127,0.00044661277,0.0000027429674,0.0027196931,0.0003152446,0.00032035817,0.0537402],"study_design_scores_gemma":[0.022669654,0.0016110936,0.8397311,0.0003041172,0.00070543645,0.00000904739,0.003924361,0.000037568352,0.09453224,0.001438486,0.034083184,0.00095372065],"about_ca_topic_score_codex":0.000040607458,"about_ca_topic_score_gemma":0.00030262762,"teacher_disagreement_score":0.10025666,"about_ca_system_score_codex":0.000026915155,"about_ca_system_score_gemma":0.00009310665,"threshold_uncertainty_score":0.7464334},"labels":[],"label_agreement":null},{"id":"W3183165891","doi":"","title":"Dried blood spot (DBS) Collection for SARS-CoV-2 antibodies","year":2021,"lang":"en","type":"article","venue":"Biopreservation and Biobanking","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Blood collection; Barcode; Dried blood spot; Data collection; Medicine; Computer science; Chromatography; Medical emergency; Chemistry; Mathematics","score_opus":0.0703962672082521,"score_gpt":0.32898697726660997,"score_spread":0.2585907100583579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183165891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873632,0.0032905703,0.0028883906,0.0038937444,0.0007078,0.00028876888,0.000052645984,0.00009492707,0.0014199358],"genre_scores_gemma":[0.9827683,0.00053636497,0.009870584,0.001897985,0.00011299522,0.000025048372,0.0001717647,0.000017163367,0.0045998245],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99910206,0.00009385758,0.00023300911,0.00030761995,0.00003362253,0.00022982746],"domain_scores_gemma":[0.9994452,0.0001319875,0.00007900465,0.00014508137,0.00018696628,0.000011764939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002914479,0.00012782558,0.00020967254,0.00007121803,0.00031560098,0.000058404752,0.00007420317,0.00025541725,0.000098877266],"category_scores_gemma":[0.00023016596,0.00011019448,0.000083006635,0.0002275504,0.00011438104,0.000089050176,0.00007299362,0.00010602291,0.0000069229154],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007697696,0.00007898353,0.0077462406,0.000040556934,0.00011578226,0.000002025918,0.000057228666,5.2806406e-8,0.9799479,0.0035874948,0.004943383,0.0034033323],"study_design_scores_gemma":[0.0009591101,0.00008789911,0.0103486115,0.000031960917,0.000096628144,0.000029270714,0.00008072889,0.00006726024,0.8905286,0.0014971095,0.09611997,0.00015283538],"about_ca_topic_score_codex":0.00003419647,"about_ca_topic_score_gemma":0.000068587884,"teacher_disagreement_score":0.091176584,"about_ca_system_score_codex":0.000011122314,"about_ca_system_score_gemma":0.00003576492,"threshold_uncertainty_score":0.44936004},"labels":[],"label_agreement":null},{"id":"W3189616149","doi":"10.1021/acs.analchem.1c01986","title":"Optimizing a High-Throughput Solid-Phase Microextraction System to Determine the Plasma Protein Binding of Drugs in Human Plasma","year":2021,"lang":"en","type":"article","venue":"Analytical Chemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Chemistry; Blood proteins; Pharmacokinetics; Ultrafiltration (renal); Plasma protein binding; Drug; Plasma; Chromatography; Blood plasma; Pharmacology; Biochemistry","score_opus":0.023846583535264514,"score_gpt":0.3292494269039266,"score_spread":0.3054028433686621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189616149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641466,0.00010197637,0.00036531984,0.00088132336,0.00008958539,0.00018058938,0.000040061404,0.000032858174,0.0018936326],"genre_scores_gemma":[0.9951078,0.0000040218138,0.0017166515,0.00006471626,0.000056138084,0.000022923201,0.00003819592,0.000017183507,0.0029723363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982319,0.0001545661,0.00063057384,0.0004638876,0.00008270676,0.00043640193],"domain_scores_gemma":[0.99901164,0.0002653369,0.00014538859,0.00040612536,0.00010626422,0.000065272056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004822036,0.00022304259,0.00051203725,0.00005859381,0.00013980616,0.000030805964,0.00025861897,0.0003930353,0.00039947993],"category_scores_gemma":[0.00027378398,0.00016972821,0.00016860539,0.0004645966,0.00021837113,0.00004780196,0.0001718047,0.00053639914,0.000028690614],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012780172,0.00024982344,0.000055406355,0.00018427914,0.00013057937,0.000049690418,0.0000910645,0.000017116257,0.99750596,0.00036729217,0.00020930148,0.0010116845],"study_design_scores_gemma":[0.0013684232,0.00007785381,0.000041459167,0.00028583565,0.000118157855,0.0000998479,0.00080349843,0.0009711932,0.9948256,0.000020622687,0.0011893075,0.00019817853],"about_ca_topic_score_codex":0.000043655044,"about_ca_topic_score_gemma":0.000011107976,"teacher_disagreement_score":0.0026803387,"about_ca_system_score_codex":0.00012944442,"about_ca_system_score_gemma":0.00007527303,"threshold_uncertainty_score":0.6921316},"labels":[],"label_agreement":null},{"id":"W3191058484","doi":"10.3389/fphar.2021.711361","title":"Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices","year":2021,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Benchmarking; China; Mandate; Business; Accounting; Regional science; Medicine; Political science; Marketing; Geography","score_opus":0.03494133850508291,"score_gpt":0.3575900183717308,"score_spread":0.3226486798666479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3191058484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728297,0.018457543,0.0013919725,0.0022840244,0.004340128,0.00024214131,0.00007470105,0.000014757972,0.0003650511],"genre_scores_gemma":[0.9845664,0.00068642606,0.012069009,0.0014571658,0.00007661384,0.000011547412,0.000030225781,0.000015253167,0.0010873816],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982212,0.00043123495,0.0004389497,0.0004081654,0.000074595875,0.0004258093],"domain_scores_gemma":[0.9988245,0.0003715116,0.0004364564,0.00017764616,0.00013467019,0.000055238634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036702902,0.0002050846,0.0006439111,0.00010408532,0.000095345225,0.0000124871995,0.00016764921,0.0005952376,0.0006866249],"category_scores_gemma":[0.0000943202,0.00017909438,0.000036158784,0.0002744877,0.0005419564,0.00007422513,0.00008983266,0.00096021616,0.0000011478572],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007753558,0.0003782038,0.7846389,0.00016822947,0.00089331483,0.00024245815,0.0003268384,0.00004913288,0.029346898,0.000115402756,0.17640527,0.0066600204],"study_design_scores_gemma":[0.0042753024,0.0007838954,0.056976285,0.0002026204,0.0010408816,0.0002719799,0.0025049401,0.00044059585,0.38806367,0.00026928054,0.5443854,0.0007851678],"about_ca_topic_score_codex":0.022694822,"about_ca_topic_score_gemma":0.06376293,"teacher_disagreement_score":0.72766256,"about_ca_system_score_codex":0.00010232176,"about_ca_system_score_gemma":0.0004361554,"threshold_uncertainty_score":0.98381317},"labels":[],"label_agreement":null},{"id":"W3193234131","doi":"10.51731/cjht.2021.98","title":"Initiation of Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Budget Impact Analysis","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Antirheumatic drugs; Rheumatoid arthritis; Biosimilar; Medicine; Jurisdiction; Antirheumatic Agents; Drug; Physical therapy; Pharmacology; Internal medicine; Political science","score_opus":0.0309432461624803,"score_gpt":0.3287337595575248,"score_spread":0.29779051339504453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193234131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57807845,0.39911592,0.009238843,0.012034493,0.0005088676,0.00032899095,0.00058810797,0.000068230474,0.000038070077],"genre_scores_gemma":[0.99034184,0.006738341,0.0026451699,0.0002009547,0.0000028961877,0.000006367828,0.000043749336,0.0000084576495,0.00001223862],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980089,0.0002792848,0.00097090716,0.00019328814,0.00004457177,0.0005030609],"domain_scores_gemma":[0.99809355,0.0003560568,0.00079864985,0.00027583574,0.00040834886,0.000067536355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011924099,0.00016412455,0.000888416,0.00086563156,0.00023977083,0.000023740384,0.00028258923,0.0002876792,0.00012208542],"category_scores_gemma":[0.0022677416,0.0001257434,0.00046466576,0.00091536884,0.0003742768,0.00008551063,0.000027109183,0.00032566083,0.0000020603036],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026271882,0.00022897017,0.14933775,0.0006825502,0.0049491306,0.00010401335,0.000741884,0.00015069566,0.006272193,0.0058520543,0.004458847,0.8269592],"study_design_scores_gemma":[0.015404323,0.0073980675,0.5912684,0.007658178,0.0026506884,0.0017268455,0.036222503,0.0008103491,0.11769437,0.1291331,0.086975805,0.0030573527],"about_ca_topic_score_codex":0.0007868925,"about_ca_topic_score_gemma":0.0012104249,"teacher_disagreement_score":0.82390183,"about_ca_system_score_codex":0.00016257634,"about_ca_system_score_gemma":0.0021620917,"threshold_uncertainty_score":0.5127668},"labels":[],"label_agreement":null},{"id":"W3194380886","doi":"10.51731/cjht.2021.133","title":"Utilization Patterns of Disease-Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis: Rationale for Improving the Harmonization of Coverage Criteria","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adalimumab; Infliximab; Leflunomide; Antirheumatic drugs; Etanercept; Rheumatoid arthritis; Tocilizumab; Hydroxychloroquine; Sulfasalazine; Antirheumatic Agents; Internal medicine; Disease","score_opus":0.0609078350527339,"score_gpt":0.32256263847655364,"score_spread":0.26165480342381975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194380886","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34125358,0.37366867,0.2579002,0.023612961,0.00086152036,0.0014667,0.0012128192,0.000019451441,0.00000407019],"genre_scores_gemma":[0.9842633,0.014480575,0.0011060454,0.000079051664,0.00000346461,0.000019733776,0.000026173939,0.0000067454293,0.000014921196],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893266,0.00011323278,0.00065130816,0.00008881577,0.000034943172,0.00017902063],"domain_scores_gemma":[0.9981963,0.0005579439,0.00066477957,0.00017780538,0.00038832548,0.000014844295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005152264,0.00008407353,0.00033688618,0.000111300724,0.00022192062,0.000011136266,0.00015901071,0.00009582226,0.000021596248],"category_scores_gemma":[0.00078739127,0.00005052069,0.0001302546,0.00012880156,0.00020058583,0.000046717967,0.000009509466,0.00006747537,6.3237415e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013817858,0.000117519645,0.0029651502,0.000706515,0.0002520964,0.000001187068,0.0012580161,0.000056490844,0.007984367,0.0041672783,0.0003603501,0.98199284],"study_design_scores_gemma":[0.008952794,0.0045795874,0.024108846,0.0034598194,0.00034589073,0.000121852114,0.03935947,0.0023124616,0.83895963,0.02219079,0.05512737,0.00048147552],"about_ca_topic_score_codex":0.00035885177,"about_ca_topic_score_gemma":0.00043640748,"teacher_disagreement_score":0.98151135,"about_ca_system_score_codex":0.000068114634,"about_ca_system_score_gemma":0.0009027661,"threshold_uncertainty_score":0.2060174},"labels":[],"label_agreement":null},{"id":"W3198411056","doi":"10.1093/ecco-jcc/jjab152","title":"Is Also the Patient Ready for Switching from Intravenous to Subcutaneous Biologics?","year":2021,"lang":"en","type":"letter","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Celltrion","keywords":"Vedolizumab; Medicine; Inflammatory bowel disease; Crohn's disease; Subcutaneous injection; Disease; Intensive care medicine; Internal medicine","score_opus":0.03467721961218399,"score_gpt":0.2884944352905215,"score_spread":0.2538172156783375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198411056","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08837847,0.022768416,0.0013425279,0.88041645,0.0039852043,0.00068404776,0.0019838584,0.000014206801,0.0004267901],"genre_scores_gemma":[0.041928887,0.0018624493,0.0031349005,0.94837755,0.0025140785,0.000018927636,0.000109631066,0.000043414962,0.002010183],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820346,0.00033111544,0.0006834405,0.00029136348,0.000074148775,0.00041648728],"domain_scores_gemma":[0.9978459,0.0010330076,0.00049669715,0.00024673494,0.0003308538,0.00004683245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035167777,0.00026682703,0.00077120896,0.0000775124,0.00021824805,0.00010414811,0.00030561755,0.0009418558,0.00044159897],"category_scores_gemma":[0.00021217685,0.00015279735,0.00030934802,0.00007335449,0.00012276557,0.000025464407,0.00011282269,0.0014142005,0.000007137752],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008029637,0.000050761704,0.000017778044,0.000034410597,0.0007322853,0.00095793186,0.0004702815,1.427844e-7,0.0012783848,0.00007848577,0.9198391,0.07573752],"study_design_scores_gemma":[0.0002976328,0.0014360007,0.001338828,0.0001682232,0.0003364594,0.0016968017,0.00019078684,8.223156e-7,0.002312163,0.0026961677,0.98930395,0.00022217123],"about_ca_topic_score_codex":0.00016247723,"about_ca_topic_score_gemma":0.000022067034,"teacher_disagreement_score":0.075515345,"about_ca_system_score_codex":0.00004453717,"about_ca_system_score_gemma":0.00010949149,"threshold_uncertainty_score":0.72644544},"labels":[],"label_agreement":null},{"id":"W3200182055","doi":"10.18549/pharmpract.2021.3.2377","title":"Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists","year":2021,"lang":"en","type":"article","venue":"Pharmacy Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Communications Research Centre Canada; BioPhage Pharma (Canada); Micropharma (Canada); University of British Columbia; Montreal Clinical Research Institute; Canadian Pharmacists Association; Montreal Heart Institute","funders":"","keywords":"Rheumatoid arthritis; Medicine; Consensus conference; Intensive care medicine; Medical physics; Family medicine; Internal medicine","score_opus":0.06595429840261208,"score_gpt":0.383882621057656,"score_spread":0.31792832265504395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200182055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9473233,0.030175377,0.00090025936,0.014557723,0.0033860442,0.0010134765,0.00039795908,0.000057562847,0.002188286],"genre_scores_gemma":[0.9904758,0.005943918,0.0020944446,0.0013324241,0.000035214125,0.000036942394,0.000019792215,0.000008782412,0.00005269106],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984232,0.0007192534,0.00036469428,0.00022926013,0.0000418575,0.00022169002],"domain_scores_gemma":[0.9970159,0.00238618,0.00018265292,0.0001450552,0.00025452473,0.000015679203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079905475,0.00011781445,0.00020750659,0.000032450364,0.00009620018,0.000010081084,0.00011475624,0.00007316049,0.000091854585],"category_scores_gemma":[0.0016740115,0.000086889835,0.000083166255,0.00016628837,0.00012560646,0.00007138529,0.000026483505,0.0002989506,0.000012266297],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008089746,0.0031663128,0.014904298,0.0001462683,0.0006198582,0.00005914453,0.0009950626,0.000058363952,0.680836,0.0014200422,0.0066362093,0.2830687],"study_design_scores_gemma":[0.0052026734,0.00012765302,0.001812077,0.00011062082,0.00004935465,0.000046648285,0.00024902078,0.0000597062,0.8783821,0.0002530783,0.11356333,0.00014375176],"about_ca_topic_score_codex":0.000011131463,"about_ca_topic_score_gemma":0.0000011560187,"teacher_disagreement_score":0.28292495,"about_ca_system_score_codex":0.000023242153,"about_ca_system_score_gemma":0.00004559959,"threshold_uncertainty_score":0.35432646},"labels":[],"label_agreement":null},{"id":"W3200575190","doi":"10.37285/ijpsn.2021.14.5.2","title":"Biosimilars: Novel Emerging Field of Biomedicine","year":2021,"lang":"en","type":"article","venue":"International Journal of Pharmaceutical Sciences and Nanotechnology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Product (mathematics); Competition (biology); Business; Quality (philosophy); Biomedicine; Marketing; Biotechnology","score_opus":0.045388962469404326,"score_gpt":0.40921239880770105,"score_spread":0.3638234363382967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200575190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69718206,0.028946724,0.028589157,0.23773459,0.006061036,0.00009716461,0.00004114114,0.000031275642,0.0013168706],"genre_scores_gemma":[0.9897934,0.0020936325,0.0058311555,0.0021468806,0.000063034015,3.452136e-7,6.9952654e-7,0.0000026300258,0.00006822673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990986,0.00005027327,0.0004200609,0.00014667379,0.000114066606,0.00017033228],"domain_scores_gemma":[0.9991007,0.00032249096,0.00019288968,0.000055902023,0.0002963163,0.000031694468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060525036,0.00007884746,0.00023549768,0.00023205043,0.00004898927,0.000010408403,0.0003709326,0.00018559018,0.00064736634],"category_scores_gemma":[0.0005966453,0.000054186963,0.00008299217,0.00030037828,0.0008598202,0.00006950769,0.00017084062,0.0002908719,0.0000015932999],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007175944,0.00013120563,0.0012476032,0.0000064646597,0.00015461358,0.000034949553,0.000021275502,9.673583e-7,0.8970259,0.007361662,0.0005678566,0.093375765],"study_design_scores_gemma":[0.00095313066,0.00035447036,0.00023619461,0.000066802306,0.000049731832,0.0010391732,0.0001598807,0.00008890774,0.8899317,0.00157243,0.105482675,0.000064933774],"about_ca_topic_score_codex":0.0000041943526,"about_ca_topic_score_gemma":0.0000015576427,"teacher_disagreement_score":0.29261136,"about_ca_system_score_codex":0.000011859198,"about_ca_system_score_gemma":0.000073655734,"threshold_uncertainty_score":0.7088207},"labels":[],"label_agreement":null},{"id":"W3202812249","doi":"10.18433/jpps32384","title":"Abstracts of poster presentations at the 2021 virtual annual of the Canadian Society for Pharmaceutical Sciences.","year":2021,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nobel laureate; Library science; Pharmaceutical sciences; Political science; Medicine; Art; Pharmacology; Computer science","score_opus":0.10220325158407427,"score_gpt":0.43419250961272876,"score_spread":0.3319892580286545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202812249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8755275,0.017656634,0.00023133935,0.09533082,0.0045038457,0.0007689629,0.0007334383,0.000008130522,0.005239359],"genre_scores_gemma":[0.9950715,0.00046785062,0.00077351084,0.0027097624,0.00014014232,0.0000037895356,0.0000018435884,0.000006701322,0.00082489965],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974354,0.00047872064,0.0008523812,0.00027549014,0.0003731781,0.0005848297],"domain_scores_gemma":[0.9971726,0.001477943,0.00044052184,0.00014343724,0.0005805339,0.00018499675],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003372947,0.00017458042,0.00035024213,0.000078605866,0.0010092679,0.00005023044,0.0009616486,0.000114281014,0.0024348875],"category_scores_gemma":[0.0005650955,0.00009098493,0.0006818369,0.000829535,0.0050672647,0.00024009247,0.0002507594,0.0006050931,0.000006604478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039509533,0.00064185506,0.021838488,0.000098546174,0.00082559604,0.000014545861,0.0010644313,0.00034638948,0.8751439,0.0033361558,0.054084674,0.04221032],"study_design_scores_gemma":[0.0014123153,0.00014944427,0.0025582889,0.000035087993,0.000387479,0.00020386913,0.0006639649,0.00033613463,0.7060143,0.00017089005,0.28795242,0.00011584035],"about_ca_topic_score_codex":0.0004309656,"about_ca_topic_score_gemma":0.00084485323,"teacher_disagreement_score":0.23386776,"about_ca_system_score_codex":0.0000805107,"about_ca_system_score_gemma":0.0016402409,"threshold_uncertainty_score":0.99847704},"labels":[],"label_agreement":null},{"id":"W3203232434","doi":"10.3748/wjg.v27.i37.6231","title":"Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring","year":2021,"lang":"en","type":"review","venue":"World Journal of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Therapeutic drug monitoring; Inflammatory bowel disease; Drug; Intensive care medicine; Clinical Practice; Narrative review; Ulcerative colitis; Disease; Immunology; Internal medicine; Pharmacology; Physical therapy","score_opus":0.037204272167128585,"score_gpt":0.33411389409152814,"score_spread":0.29690962192439957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203232434","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022559704,0.99437857,0.000027757294,0.00037263,0.002695245,0.00020863012,0.000016117645,0.0000054057023,0.000039659684],"genre_scores_gemma":[0.01444969,0.9844459,0.00020535925,0.000049691764,0.0003889259,0.000014726562,0.000003986161,0.00003648735,0.0004051798],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950887,0.0024366851,0.0015685194,0.000289608,0.00010508822,0.00051143207],"domain_scores_gemma":[0.9969527,0.0008119511,0.0015715366,0.00041922665,0.00017683426,0.00006774033],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014257504,0.00040517488,0.002045922,0.0005378608,0.0000704968,0.000019382996,0.0007490141,0.00024483778,0.00008454359],"category_scores_gemma":[0.00014320074,0.00025008086,0.00091401953,0.00026928922,0.0004272859,0.00007582162,0.00021657356,0.0020476088,0.00000428309],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019655435,0.0008062057,0.24958831,0.0043910644,0.006325503,0.00073172676,0.00040648243,0.000012581116,0.00072820636,0.00029523918,0.00093691505,0.7338122],"study_design_scores_gemma":[0.0017727636,0.0005728049,0.034163065,0.027507553,0.0037977276,0.00088340224,0.0003961747,5.5269885e-7,0.00037338093,0.00017542821,0.929975,0.0003821484],"about_ca_topic_score_codex":0.0000057998077,"about_ca_topic_score_gemma":0.000014301644,"teacher_disagreement_score":0.9290381,"about_ca_system_score_codex":0.00015249327,"about_ca_system_score_gemma":0.00023373225,"threshold_uncertainty_score":0.9999952},"labels":[],"label_agreement":null},{"id":"W3203654132","doi":"10.4212/cjhp.v74i4.3200","title":"Les médicaments qui interfèrent avec les bilans biologiques : revue de la littérature","year":2021,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Humanities; Gynecology; Philosophy; Medicine","score_opus":0.02616035912965199,"score_gpt":0.3217951188319492,"score_spread":0.29563475970229725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203654132","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32634395,0.43368822,0.0002889694,0.22488137,0.007437124,0.00020896297,0.00039475344,0.000014686359,0.0067419503],"genre_scores_gemma":[0.97615725,0.011746061,0.0010088634,0.0019591707,0.00092328264,0.0000023085402,0.000010531545,0.000026142643,0.008166382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961991,0.0022850349,0.0005727781,0.00022392013,0.00005299007,0.00066619605],"domain_scores_gemma":[0.99823916,0.0004691716,0.0003381642,0.0002340603,0.00034044954,0.00037897853],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015152246,0.0002853231,0.00046438584,0.00012490319,0.00043375432,0.00015368326,0.0006451009,0.0005111247,0.0033094864],"category_scores_gemma":[0.00064422813,0.00019663501,0.00041187182,0.0002655444,0.0016471976,0.00009948278,0.00008233719,0.0022338626,0.000025326612],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042745037,0.0010251981,0.12241461,0.00037625266,0.0051690047,0.007834169,0.0083146915,0.000020506735,0.037308034,0.024305817,0.22648971,0.5663146],"study_design_scores_gemma":[0.0010672121,0.00075840735,0.008859504,0.0007411318,0.0005810993,0.0028933096,0.0013757974,0.00001343414,0.04585517,0.0031201558,0.93438643,0.0003483402],"about_ca_topic_score_codex":0.008231698,"about_ca_topic_score_gemma":0.013967812,"teacher_disagreement_score":0.7078967,"about_ca_system_score_codex":0.00038925337,"about_ca_system_score_gemma":0.001617053,"threshold_uncertainty_score":0.99837255},"labels":[],"label_agreement":null},{"id":"W3207775405","doi":"10.1177/12034754211048674","title":"In Preparation for Biosimilar “Switch” Policy: How to Mitigate the Nocebo Effect","year":2021,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Biosimilar; Medicine; Nocebo Effect; Nocebo; Intensive care medicine; Pharmacology; Placebo; Internal medicine; Alternative medicine","score_opus":0.024570213221755618,"score_gpt":0.32499027862408425,"score_spread":0.30042006540232863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207775405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5522258,0.013339923,0.00093357067,0.4309611,0.0015994022,0.00040923082,0.000013934752,0.000009784857,0.0005072066],"genre_scores_gemma":[0.982398,0.001083595,0.00028242802,0.012346821,0.0006845103,0.0000072515645,0.0000045799716,0.000013678401,0.003179184],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988298,0.00035463032,0.00039770248,0.00013317264,0.000059233327,0.00022547357],"domain_scores_gemma":[0.99613625,0.0033582277,0.0001668897,0.00011904475,0.00016450275,0.00005508028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014802675,0.00012140753,0.0005390181,0.00019324181,0.00007434286,0.000015062882,0.0000750761,0.0001405859,0.00012384495],"category_scores_gemma":[0.0032464059,0.00006376874,0.00014046679,0.00025446064,0.00013251672,0.0000445597,0.000021979278,0.0002197899,0.0000025606266],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030323842,0.0001256225,0.0029496294,0.00017950476,0.00048102203,0.0009823018,0.0010226878,0.0000074736085,0.44071475,0.00031343187,0.48710147,0.06308971],"study_design_scores_gemma":[0.0013596541,0.002409784,0.0007778658,0.00049947255,0.00027891382,0.012078937,0.00041289366,0.000030305795,0.15236416,0.0012049043,0.8283628,0.00022026409],"about_ca_topic_score_codex":0.000008139577,"about_ca_topic_score_gemma":0.000018258377,"teacher_disagreement_score":0.43017212,"about_ca_system_score_codex":0.000023869894,"about_ca_system_score_gemma":0.0001385029,"threshold_uncertainty_score":0.38864857},"labels":[],"label_agreement":null},{"id":"W3209727209","doi":"10.14309/01.ajg.0000777252.35443.aa","title":"S930 Safety of Ustekinumab Across Approved Adult Indications: Pooled Safety Analysis in Crohn’s Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis Through up to 5 Years","year":2021,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. John’s Health Sciences Centre","funders":"","keywords":"Medicine; Ustekinumab; Psoriatic arthritis; Ulcerative colitis; Psoriasis; Internal medicine; Placebo; Dermatology; Surgery; Disease; Adalimumab; Alternative medicine; Pathology","score_opus":0.009414427878249457,"score_gpt":0.2839737848780415,"score_spread":0.274559356999792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209727209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854006,0.0009326446,0.0069775986,0.005892338,0.00026310992,0.00017990218,0.00033199883,0.0000051351917,0.000016643888],"genre_scores_gemma":[0.99284905,0.0017435896,0.0027862287,0.0024759234,0.000042147698,0.000008852652,0.000020565461,0.000011453333,0.00006220143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963016,0.0018722347,0.0009923597,0.0002911374,0.000091784044,0.00045091673],"domain_scores_gemma":[0.9980014,0.00040075468,0.0008363513,0.0003380822,0.0003316104,0.00009179381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082842034,0.00019075663,0.0011882195,0.00017365075,0.00010321597,0.000017816248,0.00032312656,0.000080132515,0.00013571934],"category_scores_gemma":[0.000523354,0.00014540787,0.00027124237,0.00081095955,0.0010426489,0.0000769618,0.00016909851,0.00044974728,0.0000029841872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24248351,0.002205836,0.4261342,0.00011032956,0.02680635,0.0007279992,0.027355462,0.000664094,0.009916009,0.004319377,0.002402335,0.25687447],"study_design_scores_gemma":[0.0030839203,0.0015496414,0.9884349,0.000079932724,0.00075484597,0.0002076557,0.0042147976,0.000013429864,0.0004302855,0.0005178529,0.00060620526,0.000106547806],"about_ca_topic_score_codex":0.00012208075,"about_ca_topic_score_gemma":0.0011264528,"teacher_disagreement_score":0.5623007,"about_ca_system_score_codex":0.000069808135,"about_ca_system_score_gemma":0.00011014705,"threshold_uncertainty_score":0.5929561},"labels":[],"label_agreement":null},{"id":"W3212141161","doi":"10.1016/s2152-2650(21)02314-4","title":"P-187: Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pomalidomide; Multiple myeloma; Clinical trial; Expert opinion; Facilitator; Oncology; Internal medicine; Lenalidomide; Intensive care medicine","score_opus":0.05124793519729414,"score_gpt":0.3540276618320754,"score_spread":0.30277972663478125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212141161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953939,0.0007480561,0.0008075893,0.0002907218,0.0007862149,0.0014307455,0.00016678387,0.000060475704,0.00031555298],"genre_scores_gemma":[0.9951451,0.00022767825,0.0020524461,0.00091151457,0.00022871101,0.00021292426,0.0006405467,0.00007007072,0.0005110258],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99429846,0.0018472486,0.0017950505,0.0010592676,0.00025449024,0.00074549654],"domain_scores_gemma":[0.9920419,0.0055667297,0.0007181651,0.00092303165,0.0006244392,0.00012575809],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016176855,0.00055074546,0.0012992778,0.00014195291,0.00023746568,0.00005008709,0.0005774593,0.0009243491,0.00018227255],"category_scores_gemma":[0.0021425495,0.00034557478,0.00045670292,0.0006488907,0.0008824509,0.00019071154,0.00011848279,0.00046753645,0.000030649466],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15532564,0.008381658,0.09439742,0.00010452284,0.001006243,0.0002457266,0.00052187964,0.0000034468865,0.026104962,0.0001485319,0.0013303552,0.71242964],"study_design_scores_gemma":[0.20983517,0.0113304565,0.72708297,0.0002585416,0.00041920162,0.000045187084,0.00036589144,0.00008033521,0.044224318,0.00006201656,0.005614214,0.0006817032],"about_ca_topic_score_codex":0.00009703247,"about_ca_topic_score_gemma":0.00029445358,"teacher_disagreement_score":0.7117479,"about_ca_system_score_codex":0.0003044949,"about_ca_system_score_gemma":0.0007755385,"threshold_uncertainty_score":0.9998996},"labels":[],"label_agreement":null},{"id":"W3212825246","doi":"10.51731/cjht.2021.197","title":"Biologics in Plaque Psoriasis","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ustekinumab; Biosimilar; Certolizumab pegol; Adalimumab; Infliximab; Etanercept; Secukinumab; Ixekizumab; Psoriasis; Dermatology; Internal medicine; Psoriatic arthritis; Tumor necrosis factor alpha","score_opus":0.039873739703723196,"score_gpt":0.3030348355283963,"score_spread":0.26316109582467306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212825246","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1743601,0.5970261,0.0009096835,0.22206876,0.0036568728,0.00024525338,0.00009249031,0.00012983513,0.0015108726],"genre_scores_gemma":[0.99413383,0.002148997,0.0023958455,0.0011318059,0.0000056943536,0.0000015833953,0.0000033808444,0.000006241999,0.00017263358],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985012,0.00026563852,0.0005751707,0.00014573096,0.000021810321,0.0004904387],"domain_scores_gemma":[0.99927276,0.00014352905,0.00022860989,0.00019241803,0.00013370291,0.000028990564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009303111,0.00010994535,0.00043482723,0.0004138433,0.00012229793,0.000013989984,0.0002997898,0.0004507179,0.00019314149],"category_scores_gemma":[0.0013397697,0.00008444222,0.000085985404,0.00047165793,0.0003243777,0.000043657565,0.000030433086,0.0007182751,0.000013057762],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027004653,0.000060611135,0.022967132,0.00005241879,0.000105260915,0.00058250455,0.00016704007,0.000004070273,0.0037803093,0.010112856,0.014603563,0.94753724],"study_design_scores_gemma":[0.00092098804,0.0004393856,0.017799603,0.00021445,0.000015557795,0.0011131815,0.004463279,0.0000012467867,0.040661752,0.016540024,0.9176074,0.00022309514],"about_ca_topic_score_codex":0.0010271637,"about_ca_topic_score_gemma":0.0063117975,"teacher_disagreement_score":0.94731414,"about_ca_system_score_codex":0.00018809034,"about_ca_system_score_gemma":0.0019571714,"threshold_uncertainty_score":0.3522131},"labels":[],"label_agreement":null},{"id":"W3213116899","doi":"10.1007/s12325-021-01944-y","title":"A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nexus Clinical Research (Canada); Memorial University of Newfoundland","funders":"Amgen","keywords":"Infliximab; Medicine; Biosimilar; Rheumatoid arthritis; Pharmacology; Internal medicine; Monoclonal antibody; Tumor necrosis factor alpha; Immunology; Antibody","score_opus":0.29922630501509223,"score_gpt":0.4893622988553286,"score_spread":0.19013599384023638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213116899","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025273059,0.99794084,0.00017303323,0.00015769775,0.00023398426,0.0013895578,0.000048903632,0.0000029817327,0.000027742806],"genre_scores_gemma":[0.000026951686,0.9961267,0.0033863485,0.00027385398,0.000012352375,0.00011006448,0.000009181025,0.0000119701035,0.00004259464],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975705,0.00082305714,0.0010442606,0.00031908118,0.000060711656,0.00018238157],"domain_scores_gemma":[0.9967089,0.0017812444,0.00076749845,0.0005894878,0.00014146202,0.000011391276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018691905,0.00025171772,0.0016239175,0.000039471473,0.00004793565,0.0000030322499,0.0005775704,0.0002554163,0.000044479948],"category_scores_gemma":[0.00051357306,0.00010671003,0.0003597987,0.0003462653,0.0006414801,0.00007354793,0.00012925877,0.00027107578,1.7319667e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000396736,0.0000955978,0.00003525594,0.03013265,0.00021221398,9.7294944e-8,0.000077197656,8.9215725e-8,0.0000967455,0.00036337442,0.00003540918,0.9689117],"study_design_scores_gemma":[0.0002704224,0.00014219413,0.000040952455,0.056520198,0.0002229581,0.000008726101,0.000036094265,3.828095e-7,0.0024788422,0.000121985264,0.94002366,0.00013356804],"about_ca_topic_score_codex":0.0000039922043,"about_ca_topic_score_gemma":0.000014919157,"teacher_disagreement_score":0.96877813,"about_ca_system_score_codex":0.000020882324,"about_ca_system_score_gemma":0.00026629394,"threshold_uncertainty_score":0.43515086},"labels":[],"label_agreement":null},{"id":"W3213207157","doi":"10.1016/j.clinbiochem.2021.11.006","title":"Evaluation of BD Barricor™ and PST™ blood collection tubes compared to serum for testing 11 therapeutic drugs on a Roche Cobas® 8000 platform","year":2021,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Horizon Health Network; Dalhousie University; Saint John Regional Hospital","funders":"","keywords":"Phenytoin; Carbamazepine; Therapeutic drug monitoring; Chromatography; Anticonvulsant; Digoxin; Phenobarbital; Medicine; Theophylline; Drug; Chemistry; Pharmacology; Internal medicine; Epilepsy","score_opus":0.15625549042930054,"score_gpt":0.4098722597609662,"score_spread":0.25361676933166566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213207157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963635,0.0012491817,0.00014373267,0.0007623152,0.00028338324,0.00030358668,0.000080433834,0.00002604609,0.00078779086],"genre_scores_gemma":[0.99661833,0.00002653742,0.0020323074,0.00069645344,0.00007132859,0.000031798074,0.00003750978,0.000010740906,0.000474968],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845356,0.00021201583,0.00055266276,0.0004600476,0.000096006865,0.00022573487],"domain_scores_gemma":[0.99718446,0.0018085515,0.00010524219,0.0002634064,0.00057545234,0.00006286871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002077234,0.00015656778,0.0003974318,0.00002679227,0.00012548734,0.00001525918,0.00010936103,0.00038823162,0.00014886128],"category_scores_gemma":[0.003903344,0.00013303936,0.0001360745,0.00024690304,0.00018695089,0.000016502825,0.000069665606,0.00023167988,0.000004761172],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003517167,0.0006632159,0.00911694,0.00010439275,0.00042390212,9.755826e-7,0.000055149565,0.0000037845411,0.9428753,0.000043517903,0.0013156283,0.04504548],"study_design_scores_gemma":[0.0026420073,0.00046446983,0.006116767,0.00012094744,0.0007221884,0.000019832718,0.00029696868,0.00061569427,0.9873798,0.0006641703,0.0007787695,0.0001783856],"about_ca_topic_score_codex":0.000004849618,"about_ca_topic_score_gemma":0.0000044782996,"teacher_disagreement_score":0.044867095,"about_ca_system_score_codex":0.000032788597,"about_ca_system_score_gemma":0.00023001364,"threshold_uncertainty_score":0.54251873},"labels":[],"label_agreement":null},{"id":"W3214657680","doi":"10.1007/s12325-021-01951-z","title":"The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; HEC Montréal; ABB (Canada); Université de Montréal","funders":"AbbVie Canada; AbbVie","keywords":"Biosimilar; Medicine; Systematic review; MEDLINE; Health care; Actuarial science; Business; Internal medicine","score_opus":0.020731650380400847,"score_gpt":0.41975871676771204,"score_spread":0.39902706638731117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214657680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010059776,0.99649245,0.000009941323,0.0005619032,0.00054388994,0.0019341045,0.00004177303,0.000009697553,0.00039617706],"genre_scores_gemma":[0.000035667534,0.9982936,0.00011044261,0.0010127837,0.00007105572,0.00029565516,0.000032683085,0.00003120502,0.000116903786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99406403,0.0031975657,0.0016129136,0.00051365,0.0001113355,0.0005005005],"domain_scores_gemma":[0.99444765,0.0038377522,0.00068356737,0.00094248867,0.000047808884,0.00004075121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052185,0.00052336464,0.003027936,0.00021071982,0.000105999905,0.000048606336,0.0013789423,0.0004873948,0.00012557382],"category_scores_gemma":[0.00052448525,0.00021982174,0.00091769005,0.0010315292,0.00015332625,0.00009082206,0.00010285299,0.0014875453,0.000017535645],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000328543,0.00008373746,0.00006294113,0.1324458,0.0005901213,0.00006590406,0.00023583368,0.0000016606904,0.0000041410485,0.0014825021,0.0014895751,0.86350495],"study_design_scores_gemma":[0.00020350901,0.000101984886,0.000009362468,0.34465805,0.00013185637,0.000082175735,0.000023841756,0.0000022847805,0.0000032328057,0.00011658019,0.654458,0.00020909941],"about_ca_topic_score_codex":0.000029200335,"about_ca_topic_score_gemma":0.00016598869,"teacher_disagreement_score":0.86329585,"about_ca_system_score_codex":0.00035270682,"about_ca_system_score_gemma":0.0006184288,"threshold_uncertainty_score":0.896407},"labels":[],"label_agreement":null},{"id":"W3215384357","doi":"10.1208/s12248-021-00649-y","title":"Anti-drug Antibody Validation Testing and Reporting Harmonization","year":2021,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); TransCanada (Canada)","funders":"","keywords":"Harmonization; Immunogenicity; Sample (material); Biotechnology; Computer science; Medicine; Chemistry; Biology; Chromatography; Antibody; Immunology","score_opus":0.07843213960607921,"score_gpt":0.3504298733020686,"score_spread":0.2719977336959894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215384357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862669,0.0030563085,0.0047095725,0.004246527,0.00056144793,0.00004729123,0.0000020425605,0.000022959797,0.0010869129],"genre_scores_gemma":[0.9926263,0.00024118068,0.005632838,0.0003461897,0.00012045786,3.4818333e-7,0.000007280969,0.0000072983717,0.0010181091],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988736,0.00035051806,0.0004600484,0.00011921173,0.00003363912,0.00016298195],"domain_scores_gemma":[0.9989005,0.0002481757,0.0005232055,0.0001121504,0.00019746632,0.000018531005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016519689,0.00007239462,0.00016034955,0.000027031008,0.0004562178,0.0000823907,0.00007124977,0.00006548397,0.0001811471],"category_scores_gemma":[0.002883544,0.000044125947,0.000041576375,0.00017696296,0.000089118046,0.00007541598,0.00006451033,0.00035143117,0.000009104226],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000066089333,0.000023221608,0.04553179,0.000006517685,0.0000613752,0.000041919888,0.00010658555,0.0000066721605,0.933384,0.00014258311,0.0009286328,0.0197601],"study_design_scores_gemma":[0.0006344608,0.000052443218,0.16207288,0.00012835565,0.00020644466,0.011594449,0.00046985675,0.00021756263,0.8122915,0.0040601986,0.008067459,0.00020437468],"about_ca_topic_score_codex":0.0000055540295,"about_ca_topic_score_gemma":5.5055995e-7,"teacher_disagreement_score":0.121092476,"about_ca_system_score_codex":0.00000967685,"about_ca_system_score_gemma":0.00004725117,"threshold_uncertainty_score":0.35089046},"labels":[],"label_agreement":null},{"id":"W3217724730","doi":"10.9778/cmajo.20210091","title":"Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis","year":2021,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institute for Work & Health; McMaster University; Women's College Hospital","funders":"","keywords":"Biosimilar; Medicine; Adalimumab; Reimbursement; Infliximab; Pharmacy; Family medicine; Internal medicine; Economic growth; Disease; Economics; Health care","score_opus":0.036212312408030224,"score_gpt":0.3243622385693566,"score_spread":0.28814992616132634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217724730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985215,0.00014175879,0.0000047314015,0.00020864226,0.00007487128,0.00019236418,0.00023848403,0.0000061317082,0.0006115089],"genre_scores_gemma":[0.99411416,0.000016357497,0.00023856394,0.00017743638,0.0000050531603,0.000007870669,0.00018962006,0.0000048515058,0.005246069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998948,0.00023554344,0.0002781177,0.0002800308,0.000044074575,0.00021428257],"domain_scores_gemma":[0.9993813,0.00015099236,0.00008528841,0.00020085325,0.00015088978,0.00003068426],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000270513,0.00013521564,0.0003849008,0.00013479065,0.00010148798,0.000088048444,0.0001457492,0.00015508829,0.0014120765],"category_scores_gemma":[0.00021290373,0.00010468732,0.00009666086,0.00053616543,0.00022306903,0.00017734298,0.00015430196,0.00022062205,0.0000030820772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032734525,0.000088373825,0.96807885,0.0000038689946,0.0006718122,0.0000126324485,0.00009946819,0.000020499514,0.02932233,0.0002866394,0.0010291388,0.000059064587],"study_design_scores_gemma":[0.000499608,0.00007905292,0.95972997,0.00001910083,0.00009670493,0.000019288891,0.00002584613,0.0000071467352,0.03807635,0.000021530299,0.0013063775,0.00011902853],"about_ca_topic_score_codex":0.97007185,"about_ca_topic_score_gemma":0.99060106,"teacher_disagreement_score":0.020529218,"about_ca_system_score_codex":0.0004394294,"about_ca_system_score_gemma":0.0011919616,"threshold_uncertainty_score":0.99950075},"labels":[],"label_agreement":null},{"id":"W34179070","doi":"10.15173/m.v1i18.767","title":"Small-molecule Inhibitors of Pseudomonas aeruginosa Biofilm Development","year":2012,"lang":"en","type":"article","venue":"The Meducator","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Pseudomonas aeruginosa; Biofilm; Microbiology; Biology; Chemistry; Bacteria; Genetics","score_opus":0.03913673266784607,"score_gpt":0.28078409359520046,"score_spread":0.2416473609273544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W34179070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894495,0.0051378477,0.000054320604,0.0015790306,0.001567544,0.00016483775,0.0000061100886,0.000025731955,0.0020150803],"genre_scores_gemma":[0.99539065,0.000021167187,0.002345974,0.00045098152,0.00010304485,0.00001618753,0.0000068812824,0.000010730856,0.0016543933],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989702,0.00020850803,0.00026629472,0.00012967776,0.0000358302,0.00038948987],"domain_scores_gemma":[0.9994146,0.00014081465,0.0000940467,0.00026575237,0.000035607125,0.000049162263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006813484,0.00013658546,0.00020951808,0.000051490297,0.00010825807,0.0000043332516,0.0002492855,0.00015249164,0.00085593696],"category_scores_gemma":[0.00006987078,0.000078594705,0.00008592239,0.00015402597,0.00029833833,0.000023220327,0.000102050755,0.00019185667,0.00023882902],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005799846,0.00052941975,0.016471952,0.000035306948,0.00032759583,5.474333e-7,0.0028959692,2.7568944e-8,0.93088055,0.0030788858,0.016359031,0.029362747],"study_design_scores_gemma":[0.00017643244,0.000029549037,0.008928795,0.000012415499,0.00004605183,0.000015591928,0.00064704596,5.2560523e-8,0.8848921,0.000026255038,0.105116054,0.0001096443],"about_ca_topic_score_codex":0.000028863373,"about_ca_topic_score_gemma":0.0000049757646,"teacher_disagreement_score":0.08875702,"about_ca_system_score_codex":0.000024986784,"about_ca_system_score_gemma":0.0001193591,"threshold_uncertainty_score":0.93719095},"labels":[],"label_agreement":null},{"id":"W367153446","doi":"","title":"Report to the Pharmaceutical Benefits Advisory Committee on the clinical and cost-effectiveness of the biological disease modifying anti-rheumatic drugs","year":2009,"lang":"en","type":"book","venue":"UEA Digital Repository (University of East Anglia)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Advisory committee; Rheumatic disease; Medicine; Biological drugs; Disease; Business; Intensive care medicine; Internal medicine; Political science; Public administration","score_opus":0.0760130323431085,"score_gpt":0.29912759503007647,"score_spread":0.22311456268696797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W367153446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8421259,0.008292534,0.00027763002,0.0062652533,0.0022063176,0.0048576994,0.0008568521,0.00013156574,0.13498624],"genre_scores_gemma":[0.960916,0.00014196227,0.00002521458,0.00031348717,0.000059615497,0.000002058038,0.00003503962,0.000017164502,0.0384895],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99768186,0.00090954377,0.0004366781,0.00052662246,0.00016569273,0.00027962224],"domain_scores_gemma":[0.99668777,0.0018396145,0.00042555833,0.00076033897,0.00017158374,0.00011510974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009508955,0.00031227258,0.00070916966,0.0000578321,0.00045680802,0.000034566685,0.00079803227,0.00047860682,0.000023248525],"category_scores_gemma":[0.00046901495,0.00017564521,0.00057646225,0.00013510698,0.0021401383,0.00007522915,0.0005855582,0.00083004055,0.000015829612],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022794174,0.008035733,0.2292917,0.0025162776,0.010765647,0.0019069535,0.0026008533,0.0002253786,0.005712375,0.06201558,0.17083432,0.48330098],"study_design_scores_gemma":[0.0039495504,0.0018405141,0.70734715,0.004974453,0.002211298,0.0005364775,0.0019266257,0.000101181926,0.0017685419,0.004390852,0.26938918,0.0015641741],"about_ca_topic_score_codex":0.000008640378,"about_ca_topic_score_gemma":0.000001879608,"teacher_disagreement_score":0.4817368,"about_ca_system_score_codex":0.00005457174,"about_ca_system_score_gemma":0.000179372,"threshold_uncertainty_score":0.7885429},"labels":[],"label_agreement":null},{"id":"W4200208170","doi":"10.22159/ijls.2021.v9i6.43430","title":"BIOSIMILARS: OPPORTUNITIES, CHALLENGES, AND THE GENERAL PRINCIPLES GOVERNING THEIR DEVELOPMENT AROUND THE GLOBE","year":2021,"lang":"en","type":"article","venue":"Innovare Journal of Life Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Globe; Agency (philosophy); European union; Medicine; Business; European market; International trade","score_opus":0.18433919910895252,"score_gpt":0.31571218571453524,"score_spread":0.13137298660558272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200208170","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3633875,0.426305,0.0005230655,0.19750278,0.0023095682,0.00018373209,0.00002481392,0.000019458106,0.009744081],"genre_scores_gemma":[0.9335104,0.039251354,0.009150652,0.01569252,0.0006753778,0.0000055962214,0.0000034044274,0.000015059408,0.0016956388],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998229,0.00063110504,0.0005642344,0.00017087488,0.0001439138,0.0002608324],"domain_scores_gemma":[0.99850416,0.00062911457,0.0004134129,0.00014501123,0.00027072648,0.000037544858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044556153,0.0001403222,0.00030352076,0.00005599653,0.0005626839,0.000082310755,0.0005106626,0.00010443601,0.00009417654],"category_scores_gemma":[0.0006642851,0.000057265235,0.00008270342,0.00025100054,0.0017065477,0.00012986163,0.00024258718,0.00037637967,0.0000022032752],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008884362,0.00052378926,0.0075847846,0.00015343768,0.0030326964,0.000226848,0.015611842,0.000041194824,0.032564715,0.2067297,0.028712993,0.70392954],"study_design_scores_gemma":[0.0009784233,0.00012938492,0.0070443563,0.00011165146,0.00004666309,0.0009668769,0.014465803,0.000026997199,0.0085402895,0.0014358286,0.9660939,0.00015983173],"about_ca_topic_score_codex":0.0000032308312,"about_ca_topic_score_gemma":0.000021801552,"teacher_disagreement_score":0.9373809,"about_ca_system_score_codex":0.00002400986,"about_ca_system_score_gemma":0.0007648457,"threshold_uncertainty_score":0.6287846},"labels":[],"label_agreement":null},{"id":"W4205536822","doi":"10.1016/j.jval.2021.11.081","title":"POSA6 Use of Real-World Evidence to Evaluate Infliximab Biosimilars: A Scoping Review","year":2022,"lang":"en","type":"review","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Biosimilar; Medicine; Infliximab; Tolerability; Rheumatoid arthritis; Observational study; Adverse effect; Clinical trial; Internal medicine; Intensive care medicine; Disease","score_opus":0.4610570349245248,"score_gpt":0.4993665742394198,"score_spread":0.038309539314895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205536822","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000018226162,0.99220103,0.000013687887,0.0019280668,0.00076083315,0.004776246,0.00016983747,0.00004511489,0.00010337103],"genre_scores_gemma":[4.2560563e-7,0.9914157,0.002916045,0.004704739,0.00003411553,0.0003568624,0.00006038145,0.000059228205,0.0004525531],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98690236,0.007953884,0.0030721312,0.0009943425,0.00020027418,0.0008770041],"domain_scores_gemma":[0.9927407,0.0045945407,0.0013053345,0.0011426195,0.000087250366,0.00012957823],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007660963,0.0005962619,0.0045478432,0.00082164386,0.0001441615,0.000019374536,0.0007751087,0.00038205527,0.0017396428],"category_scores_gemma":[0.0035705238,0.00047795227,0.00066835876,0.0024416333,0.00016409946,0.00011115398,0.00060313806,0.0012938541,0.00007825063],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003531292,0.0001337043,0.000022428114,0.3064878,0.00014306088,0.000010832343,0.00004784762,0.000008910513,0.0000036743213,0.00021118046,0.0065294905,0.6863657],"study_design_scores_gemma":[0.00010398858,0.00027011475,0.0000063720545,0.4483713,0.00025971257,0.000017820143,0.0000022075283,0.0000022101847,0.0000042917336,0.000014142563,0.5507004,0.00024743678],"about_ca_topic_score_codex":0.002121663,"about_ca_topic_score_gemma":0.0001877251,"teacher_disagreement_score":0.6861183,"about_ca_system_score_codex":0.0006841627,"about_ca_system_score_gemma":0.0027474961,"threshold_uncertainty_score":0.99976724},"labels":[],"label_agreement":null},{"id":"W4205926661","doi":"10.1038/s41587-021-01170-5","title":"The characteristics of patents impacting availability of biosimilars","year":2022,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Biosimilar; Business; Drug approval; Drug; Pharmacology; Medicine; Internal medicine","score_opus":0.01056651398639333,"score_gpt":0.2673655833208293,"score_spread":0.25679906933443597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205926661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97837275,0.007853536,0.00007159443,0.010212846,0.002155253,0.00034352092,0.00048560736,0.00009657204,0.00040830384],"genre_scores_gemma":[0.99892795,0.00019591795,0.00037215167,0.00027247422,0.000010558534,0.000008993015,0.000014720462,0.000009757505,0.0001875026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854344,0.00031123782,0.0004885343,0.000267219,0.00006893443,0.00032061752],"domain_scores_gemma":[0.9984721,0.0004611354,0.00040373782,0.0005567623,0.00009346195,0.0000127803205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010169233,0.00013946241,0.00037518868,0.0001169753,0.00030564185,0.000002954671,0.0006159931,0.00097302155,0.00037672903],"category_scores_gemma":[0.0010075882,0.00009293349,0.00014673288,0.00043855805,0.00089123426,0.000015272033,0.0005040064,0.0017230281,0.0000035893918],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033561102,0.00023475435,0.013664395,0.000032828026,0.00024116076,0.0000029221708,0.00004208362,2.3452942e-7,0.91296387,0.0062079313,0.0032380219,0.06303618],"study_design_scores_gemma":[0.0004707801,0.00056361797,0.02169168,0.00000987976,0.000070998045,0.000048422822,0.0003486503,0.000007227525,0.820748,0.0010838287,0.15480772,0.00014923039],"about_ca_topic_score_codex":0.000011479859,"about_ca_topic_score_gemma":0.0000032960318,"teacher_disagreement_score":0.1515697,"about_ca_system_score_codex":0.000045666053,"about_ca_system_score_gemma":0.000052276206,"threshold_uncertainty_score":0.75048333},"labels":[],"label_agreement":null},{"id":"W4206719484","doi":"10.1515/9783110718836-057","title":"Der Cluster für Industrielle Biotechnologie – CLIB<sup>2021</sup>","year":2021,"lang":"de","type":"book-chapter","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Cluster (Canada)","funders":"Bundesministerium für Bildung und Forschung","keywords":"Political science; Physics","score_opus":0.044501404100943,"score_gpt":0.29714372088851204,"score_spread":0.25264231678756904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206719484","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007900359,0.11100108,0.0067294054,0.07900938,0.0070734485,0.0026399805,0.0011210124,0.00090990344,0.79072577],"genre_scores_gemma":[0.004017372,0.01595894,0.007158571,0.00976212,0.00087073963,0.000027402952,0.0006616511,0.00020740974,0.9613358],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936032,0.0005340821,0.0016943144,0.002280883,0.0002019392,0.0016855249],"domain_scores_gemma":[0.9957312,0.0010225055,0.00049926876,0.0021140678,0.00041186681,0.00022112553],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0010104319,0.001610103,0.0022876172,0.0005678819,0.00055313803,0.00018908318,0.0012865487,0.01579793,0.15161407],"category_scores_gemma":[0.0006036744,0.0012961295,0.0012198609,0.00035604235,0.002426082,0.0001407902,0.0020934287,0.006224272,0.009273832],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077935494,0.00085376325,0.00026949798,0.00026852958,0.011374287,0.00089699554,0.00011618917,0.000014983612,0.00765169,0.34759256,0.30413905,0.3260431],"study_design_scores_gemma":[0.0016832814,0.00058099034,0.000015436406,0.00042994806,0.0015484018,0.00019455011,0.00039009927,0.00009304526,0.028150469,0.003041298,0.96223617,0.0016363162],"about_ca_topic_score_codex":0.000055199438,"about_ca_topic_score_gemma":0.00002160949,"teacher_disagreement_score":0.6580971,"about_ca_system_score_codex":0.0001836336,"about_ca_system_score_gemma":0.0005584086,"threshold_uncertainty_score":0.99966466},"labels":[],"label_agreement":null},{"id":"W4206907238","doi":"10.1093/ecco-jcc/jjab232.704","title":"P578 Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients – a multicentre study on efficacy and drug sustainability","year":2022,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Biosimilar; Medicine; Adalimumab; Inflammatory bowel disease; Internal medicine; Ulcerative colitis; Infliximab; Adverse effect; Crohn's disease; Disease","score_opus":0.008338829766213253,"score_gpt":0.27688887347246943,"score_spread":0.2685500437062562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206907238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868966,0.0011871763,0.000006299565,0.010510491,0.00027279602,0.0008580434,0.00025012725,0.000007797228,0.0000106766865],"genre_scores_gemma":[0.9974866,0.00011661805,0.000031716143,0.0022098185,0.000067099456,0.00002401236,0.0000065167824,0.000016642296,0.000040978623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997164,0.0010056557,0.0007157564,0.00040766664,0.000289274,0.0004176149],"domain_scores_gemma":[0.9978422,0.0011661262,0.00025044146,0.00025758895,0.00016865943,0.0003149781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013854975,0.0002643094,0.000526968,0.00015860189,0.00042670846,0.00007276038,0.00032181066,0.0001383784,0.0001519176],"category_scores_gemma":[0.0007627863,0.00018201163,0.00008920395,0.0001944029,0.00033429646,0.00009058954,0.0003730876,0.00090099487,9.2336427e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007811396,0.0013801353,0.9684902,0.000043810673,0.00029746085,0.00031570913,0.003034262,0.000002851596,0.000022682267,0.000049608578,0.0038739261,0.014677984],"study_design_scores_gemma":[0.0067626736,0.0011235524,0.9752542,0.000090651185,0.00019957389,0.000010920931,0.0045226426,0.00001010809,0.000050517832,0.00031986082,0.011442416,0.00021287818],"about_ca_topic_score_codex":0.00011549982,"about_ca_topic_score_gemma":0.000073464566,"teacher_disagreement_score":0.014465105,"about_ca_system_score_codex":0.00016809073,"about_ca_system_score_gemma":0.0002609088,"threshold_uncertainty_score":0.7422219},"labels":[],"label_agreement":null},{"id":"W4206930510","doi":"10.1093/ecco-jcc/jjab232.374","title":"P247 Comparison of discontinuation/switching between infliximab biosimilar and originator among Inflammatory Bowel Disease patients: a real-world analysis of two Canadian cohorts","year":2022,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McMaster University; McGill University Health Centre","funders":"","keywords":"Medicine; Infliximab; Discontinuation; Interquartile range; Ulcerative colitis; Inflammatory bowel disease; Internal medicine; Disease","score_opus":0.012865035751433669,"score_gpt":0.29372410220916545,"score_spread":0.2808590664577318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206930510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770516,0.0011382784,0.000036770598,0.00026762957,0.00013503304,0.00013961052,0.00041587534,0.0000030552224,0.00015855792],"genre_scores_gemma":[0.9995485,0.00010070571,0.00011889322,0.000081245424,0.000023116945,0.000004222019,0.000028640896,0.000008174079,0.00008651007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982909,0.0003253695,0.00086210115,0.00016246561,0.00012567687,0.00023350559],"domain_scores_gemma":[0.9984681,0.00019843195,0.00078978646,0.00014187572,0.00022129515,0.00018048243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006335823,0.00014100192,0.0007439495,0.00070617604,0.0002185038,0.000022332775,0.00014649336,0.00006478506,0.00021805998],"category_scores_gemma":[0.00008474411,0.000120268065,0.00018567443,0.00041495916,0.00025048823,0.00012781081,0.00009203596,0.00031875906,1.0353769e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003929847,0.000110223074,0.9931713,0.00002802974,0.0012052755,0.000013178346,0.00035568967,0.000016999795,0.000069561465,0.0007055313,0.0003421392,0.0035891281],"study_design_scores_gemma":[0.0009492887,0.00023148466,0.9921064,0.00004791237,0.0017865943,0.0000017631569,0.00027061856,0.000092224655,0.00043655897,0.0002540643,0.0036960845,0.00012705525],"about_ca_topic_score_codex":0.0072051818,"about_ca_topic_score_gemma":0.012722798,"teacher_disagreement_score":0.0055176155,"about_ca_system_score_codex":0.000084367115,"about_ca_system_score_gemma":0.00019027911,"threshold_uncertainty_score":0.9994059},"labels":[],"label_agreement":null},{"id":"W4206947552","doi":"10.1093/ecco-jcc/jjab232.738","title":"P612 Mirikizumab Pharmacokinetics and Exposure - Efficacy Relationships in Patients with Ulcerative Colitis","year":2022,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Ulcerative colitis; Pharmacokinetics; Placebo; Population; Internal medicine; Gastroenterology; Volume of distribution; Psoriasis; Immunology","score_opus":0.018857321582697865,"score_gpt":0.2679036466300737,"score_spread":0.24904632504737584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206947552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712265,0.0013722191,0.000028873903,0.00071722927,0.00017291591,0.00015848764,0.000075277916,0.0000034188604,0.00034892122],"genre_scores_gemma":[0.99877495,0.00014760169,0.0004248548,0.00025536283,0.00002322308,0.000004825065,0.0000061826086,0.000007593956,0.0003554293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876887,0.0005106388,0.00033687006,0.00012620905,0.00007243307,0.00018499303],"domain_scores_gemma":[0.9993529,0.00023460004,0.00019090548,0.000062286184,0.00011173767,0.00004757043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042661265,0.00010635998,0.0002723448,0.00011274854,0.00024121614,0.000023453058,0.00007601474,0.00007546398,0.0003925633],"category_scores_gemma":[0.000061999446,0.00008139149,0.000037317175,0.0001421703,0.00017611713,0.00007467936,0.000066693305,0.00060627953,6.1924663e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.084463134,0.0029740878,0.6942529,0.00013032871,0.001367732,0.0005377562,0.0060813697,0.000052721945,0.00035425584,0.01035266,0.016906783,0.18252623],"study_design_scores_gemma":[0.004867325,0.0013537026,0.9674069,0.000027988628,0.000072723335,0.00016065591,0.00035677536,0.0000030647006,0.00016613642,0.00033120575,0.02514714,0.00010632711],"about_ca_topic_score_codex":0.000010326746,"about_ca_topic_score_gemma":0.000018261631,"teacher_disagreement_score":0.27315402,"about_ca_system_score_codex":0.000040861418,"about_ca_system_score_gemma":0.000049896666,"threshold_uncertainty_score":0.4298293},"labels":[],"label_agreement":null},{"id":"W4206961888","doi":"10.1093/ecco-jcc/jjab232.102","title":"DOP63 Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease","year":2022,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Vedolizumab; Medicine; Cohort; Ulcerative colitis; Inflammatory bowel disease; Clinical endpoint; Internal medicine; Prospective cohort study; Surgery; Clinical trial; Disease","score_opus":0.01251110116569652,"score_gpt":0.2820852100135014,"score_spread":0.26957410884780486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206961888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911674,0.005850209,0.0007681215,0.0007327576,0.00048072552,0.00058388547,0.0002600862,0.00000793423,0.00014882819],"genre_scores_gemma":[0.9943747,0.0045906384,0.00033684497,0.00022572186,0.00007610412,0.000025120944,0.0000040054315,0.000016681342,0.00035019428],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986543,0.00032857858,0.00047480658,0.00019004404,0.00006798273,0.00028425254],"domain_scores_gemma":[0.99895704,0.00041632602,0.00027340857,0.000115941955,0.00012327712,0.00011399792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004879126,0.00017645734,0.00047491197,0.00013276347,0.00024856752,0.000019017643,0.0001250618,0.00005298943,0.00010942353],"category_scores_gemma":[0.000041448107,0.00013418804,0.00014842839,0.000092385395,0.00012411915,0.000038403807,0.000071730596,0.00020830761,3.0147265e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3076248,0.0013319354,0.00596753,0.00043342696,0.0017999613,0.0011543015,0.0017176087,0.00018386274,0.037602015,0.006770266,0.001215326,0.63419896],"study_design_scores_gemma":[0.013519881,0.011064042,0.75436,0.00024697275,0.00052346487,0.0016338656,0.00039364953,0.00008297633,0.014883871,0.0035659317,0.19923282,0.00049249805],"about_ca_topic_score_codex":0.000052966392,"about_ca_topic_score_gemma":0.000019232513,"teacher_disagreement_score":0.7483925,"about_ca_system_score_codex":0.00014312669,"about_ca_system_score_gemma":0.00014603544,"threshold_uncertainty_score":0.54720294},"labels":[],"label_agreement":null},{"id":"W4206970815","doi":"10.1093/ecco-jcc/jjab232.531","title":"P404 Underrepresentation of minorities and lack of race reporting in ulcerative colitis drug development clinical trials","year":2022,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Clinical trial; Ethnic group; Ulcerative colitis; Placebo; Race (biology); Internal medicine; Demography; Disease; Alternative medicine; Pathology","score_opus":0.20226121586472168,"score_gpt":0.45591068025828024,"score_spread":0.25364946439355857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206970815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629253,0.0021969352,0.000101255115,0.0006198612,0.00029713757,0.00013517916,0.000024719377,0.0000013907928,0.00033096227],"genre_scores_gemma":[0.9967398,0.0005183311,0.0019235307,0.0001060203,0.00003059513,0.000004078871,0.0000023957102,0.0000037501575,0.00067151093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99534535,0.0016936854,0.0026338624,0.000121598096,0.000076653625,0.00012882918],"domain_scores_gemma":[0.9959646,0.0012810652,0.0025101663,0.000060298844,0.00015406798,0.000029800496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008543847,0.00007849398,0.0008265568,0.000107980355,0.00008600827,0.00001025337,0.000064138636,0.00007976753,0.00020970151],"category_scores_gemma":[0.0016449495,0.000063774,0.00011627428,0.00009378651,0.00025395863,0.00005777634,0.00009234734,0.0002931884,9.115158e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032907967,0.0018384238,0.47750333,0.00078882376,0.0026203934,0.0005711385,0.019214734,0.00002365618,0.010120342,0.014524675,0.0139673315,0.42591918],"study_design_scores_gemma":[0.0020683366,0.0004043878,0.9656601,0.00009816747,0.000083971245,0.00030004577,0.0067229103,0.0000054708435,0.016414078,0.0021612414,0.005992028,0.00008926796],"about_ca_topic_score_codex":0.000084341526,"about_ca_topic_score_gemma":0.0000920615,"teacher_disagreement_score":0.48815677,"about_ca_system_score_codex":0.00002793482,"about_ca_system_score_gemma":0.00018531854,"threshold_uncertainty_score":0.2961144},"labels":[],"label_agreement":null},{"id":"W4207052422","doi":"10.1093/ecco-jcc/jjab232.445","title":"P318 Safety of Biological Therapies in Elderly IBD: a Systematic Review and Meta-analysis","year":2022,"lang":"en","type":"review","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Ustekinumab; Adverse effect; Vedolizumab; Internal medicine; MEDLINE; Cochrane Library; Inclusion and exclusion criteria; Meta-analysis; Inflammatory bowel disease; Adalimumab; Disease; Alternative medicine; Pathology","score_opus":0.1128001914579629,"score_gpt":0.3649552482273674,"score_spread":0.25215505676940453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207052422","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000867767,0.99873066,0.00001877381,0.00028108375,0.000049244085,0.0005838192,0.0002016751,0.0000021870621,0.00012389208],"genre_scores_gemma":[0.00010573774,0.9989037,0.00017939373,0.00030096772,0.0000083905215,0.000037494454,0.00000899916,0.000008665578,0.00044668507],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99471426,0.0026293087,0.002126846,0.00023679678,0.00007705496,0.00021573833],"domain_scores_gemma":[0.99677116,0.0011927161,0.0016684453,0.00023553651,0.000088749155,0.000043369026],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027923598,0.0003197862,0.009770377,0.00035509586,0.0000688073,0.000018867244,0.0002820182,0.0003561207,0.00306267],"category_scores_gemma":[0.0003029159,0.00016289031,0.0022857967,0.0005523131,0.0002634381,0.00003901697,0.00012041383,0.0006580007,0.0000010056597],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021722245,0.00023659714,0.0000072608336,0.58783597,0.32864633,0.00013267026,0.000110795714,4.2550298e-8,8.3024673e-7,0.0014505183,0.00040863716,0.08095313],"study_design_scores_gemma":[0.00017841379,0.00044649368,0.00011879265,0.008936859,0.5548441,0.0006925476,0.000072369534,4.6600377e-8,5.9971273e-7,0.00017617946,0.43434456,0.00018906321],"about_ca_topic_score_codex":0.000017616256,"about_ca_topic_score_gemma":0.000011029603,"teacher_disagreement_score":0.5788991,"about_ca_system_score_codex":0.00003140015,"about_ca_system_score_gemma":0.00008366486,"threshold_uncertainty_score":0.9978487},"labels":[],"label_agreement":null},{"id":"W4210434271","doi":"10.1021/cen-09039-notw5","title":"Pharmaceuticals: Boehringer Ingelheim will exit virology research, close Montreal site","year":2012,"lang":"en","type":"article","venue":"Chemical & Engineering News","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Chemistry; Virology; Medicine","score_opus":0.05757606540707753,"score_gpt":0.355421407200834,"score_spread":0.29784534179375644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210434271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97160786,0.017953496,0.0012696801,0.00219613,0.0014933415,0.00036188756,0.000040456143,0.00039746967,0.0046797018],"genre_scores_gemma":[0.9946379,0.00034939553,0.0030270047,0.0005619721,0.00054097734,0.000036152516,0.000027990027,0.000048913455,0.00076971576],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976561,0.00017828833,0.00036176198,0.0004048768,0.00008861661,0.0013103527],"domain_scores_gemma":[0.9986127,0.0006802247,0.00003914137,0.00038337574,0.000063525484,0.00022103153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008339008,0.0002790327,0.00042821327,0.00021718348,0.00008281707,0.000018919578,0.00031175805,0.0006281809,0.0008009151],"category_scores_gemma":[0.0006451029,0.00023454777,0.00015877839,0.00042972452,0.00031882958,0.00014615421,0.0002935315,0.0012949153,0.00046999086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000894136,0.00018371816,0.000982106,0.000030310313,0.00011639811,0.0000062620556,0.000115766125,0.0000034699494,0.9787726,0.0010362867,0.012872,0.0057917107],"study_design_scores_gemma":[0.00072136085,0.00005788536,0.0013744241,0.00002837749,0.000069472255,0.00005726222,0.000016151685,0.00014998848,0.625293,0.00020231157,0.3717118,0.0003179818],"about_ca_topic_score_codex":0.00005834671,"about_ca_topic_score_gemma":0.0000015988844,"teacher_disagreement_score":0.35883978,"about_ca_system_score_codex":0.000062171006,"about_ca_system_score_gemma":0.000014162835,"threshold_uncertainty_score":0.95645803},"labels":[],"label_agreement":null},{"id":"W4210485642","doi":"10.1016/j.yrtph.2020.104671","title":"Derivation of whole blood biomonitoring equivalents for titanium for the interpretation of biomonitoring data","year":2020,"lang":"en","type":"article","venue":"Regulatory Toxicology and Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Health Canada","funders":"Rijksinstituut voor Volksgezondheid en Milieu; Health Canada","keywords":"Biomonitoring; Pharmacokinetics; Biomarker; Environmental chemistry; Environmental science; Pharmacology; Medicine; Biology; Chemistry; Biochemistry","score_opus":0.09787634190086236,"score_gpt":0.38101771218998837,"score_spread":0.283141370289126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210485642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91003126,0.010599519,0.06336361,0.0077206194,0.0054007377,0.0019342804,0.00084712775,0.00005596058,0.000046857527],"genre_scores_gemma":[0.99693,0.00012437323,0.0022187633,0.00035396984,0.00021602133,0.000045918016,0.000049206057,0.000011696676,0.000050075472],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99890417,0.0001745412,0.00038041582,0.00029856898,0.000024759373,0.00021755052],"domain_scores_gemma":[0.9982645,0.001176373,0.0002394893,0.00018533297,0.000105401945,0.000028940829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055618974,0.00012357521,0.00032425078,0.000051675583,0.00012681076,0.0000034569473,0.00033904685,0.00029018548,0.000056240315],"category_scores_gemma":[0.00017834826,0.00009507021,0.00007101729,0.00010749059,0.00044516372,0.00007505628,0.00018529512,0.0001235738,9.3138465e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007571027,0.00009458142,0.0012662443,0.00021339412,0.00058574526,2.567927e-7,0.00015137835,0.0000114616005,0.9829745,0.0005970673,0.001720314,0.011627954],"study_design_scores_gemma":[0.0020914152,0.0007584276,0.0021120107,0.000017028313,0.0007701725,0.0000062229183,0.00013490256,0.0026543592,0.97460836,0.0001626152,0.01657925,0.00010525427],"about_ca_topic_score_codex":0.0000019850988,"about_ca_topic_score_gemma":9.52504e-7,"teacher_disagreement_score":0.08689869,"about_ca_system_score_codex":0.000008623943,"about_ca_system_score_gemma":0.00004275553,"threshold_uncertainty_score":0.38768506},"labels":[],"label_agreement":null},{"id":"W4210633796","doi":"10.1186/s41927-021-00235-x","title":"Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia","year":2022,"lang":"en","type":"article","venue":"BMC Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Ministry of Health, British Columbia","keywords":"Biosimilar; Medicine; Etanercept; Cohort; Cumulative incidence; Health care; Cohort study; Population; Incidence (geometry); Family medicine; Emergency medicine; Environmental health; Demography; Internal medicine; Rheumatoid arthritis","score_opus":0.022405480294571033,"score_gpt":0.30086997648313374,"score_spread":0.2784644961885627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210633796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959044,0.00066474336,0.00003359857,0.000284215,0.0013929169,0.0014161161,0.00023972937,0.000051209532,0.0000130766775],"genre_scores_gemma":[0.99666154,0.000046606638,0.002108098,0.0007584696,0.000009311303,0.00020907383,0.000049603274,0.00003118803,0.00012612899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99586016,0.0016222218,0.00097455556,0.0007334212,0.0001352873,0.00067436433],"domain_scores_gemma":[0.998704,0.00041515366,0.00023789189,0.00046891166,0.00007323482,0.00010077321],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010298964,0.0001998026,0.0011385812,0.00027801874,0.00034901587,0.000055349177,0.00052502035,0.00018664316,0.00046810522],"category_scores_gemma":[0.00025286447,0.00028172936,0.00014499598,0.0008800707,0.000053727323,0.00007902853,0.0005927063,0.0003637465,0.000021230986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009713997,0.0008111127,0.9927319,0.0000390451,0.00020028959,0.000009955593,0.0010607776,0.0000058707087,0.00053474394,0.0000059362533,0.0008300319,0.0036731947],"study_design_scores_gemma":[0.0018296584,0.00089962594,0.9893016,0.00011095949,0.000035226632,0.000014280482,0.0027662953,0.0000031495824,0.00013919262,0.00004169642,0.0046044793,0.0002538269],"about_ca_topic_score_codex":0.18066852,"about_ca_topic_score_gemma":0.049997006,"teacher_disagreement_score":0.13067152,"about_ca_system_score_codex":0.00024667638,"about_ca_system_score_gemma":0.00021307085,"threshold_uncertainty_score":0.99996346},"labels":[],"label_agreement":null},{"id":"W4210719544","doi":"10.1186/s41120-021-00050-1","title":"Best practices for the development and fit-for-purpose validation of biomarker methods: a conference report","year":2022,"lang":"en","type":"article","venue":"AAPS Open","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada); Canadian Nuclear Laboratories","funders":"","keywords":"Biomarker; Best practice; Biomarker discovery; Medicine; Data science; Medical physics; Computer science; Political science; Biology","score_opus":0.33646034908531747,"score_gpt":0.4844525017658601,"score_spread":0.1479921526805426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210719544","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33747342,0.024344547,0.49641082,0.071842015,0.0066708513,0.029540159,0.0014384261,0.00012904337,0.03215072],"genre_scores_gemma":[0.30881327,0.000096560725,0.65620273,0.00083144405,0.00002324809,0.0019069852,0.00018790743,0.000023889877,0.031913944],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99901116,0.0003354163,0.00028838546,0.00021496919,0.000025101976,0.00012496389],"domain_scores_gemma":[0.99775887,0.001524479,0.0004091358,0.00019392165,0.00010304636,0.000010569908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036771332,0.00007466502,0.00018541525,0.00002566926,0.00035308456,0.000033776614,0.00031479428,0.000061439176,0.00031718536],"category_scores_gemma":[0.0010130391,0.000048740592,0.000036605783,0.000077593795,0.00010367473,0.0000730145,0.0004229817,0.000087145076,0.00000111538],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012660273,0.00033270352,0.0011421567,0.00009607626,0.000982151,0.0000034081577,0.0012707248,0.0000021155236,0.17882717,0.005625859,0.010277474,0.8001741],"study_design_scores_gemma":[0.00054083555,0.0001786191,0.00064901775,0.000008927981,0.00013870145,0.000059427875,0.0010354562,0.000043929744,0.1612384,0.0007507917,0.83526635,0.00008953238],"about_ca_topic_score_codex":0.000121487494,"about_ca_topic_score_gemma":0.000021184713,"teacher_disagreement_score":0.8249889,"about_ca_system_score_codex":0.000012706916,"about_ca_system_score_gemma":0.00012405381,"threshold_uncertainty_score":0.3472957},"labels":[],"label_agreement":null},{"id":"W4210863439","doi":"10.4155/bio-2022-0010","title":"Recommendations on ELISpot Assay Validation by the GCC","year":2022,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand Challenges Canada; Caprion (Canada)","funders":"","keywords":"ELISPOT; Immunity; Immunology; Medicine; Computational biology; Biology; Immune system; T cell","score_opus":0.030875852825407658,"score_gpt":0.2956638180288257,"score_spread":0.264787965203418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210863439","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07187697,0.033622697,0.019734137,0.7438298,0.0099139055,0.0022851264,0.005697281,0.00089516735,0.112144925],"genre_scores_gemma":[0.96394235,0.00012201072,0.00039085024,0.004111791,0.000036583864,0.000084757594,0.0006256031,0.000013980519,0.030672068],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980116,0.0011823967,0.0002469508,0.00027344748,0.00007429979,0.00021129663],"domain_scores_gemma":[0.99901044,0.00044246967,0.00011528245,0.00037639646,0.000037420454,0.000017963524],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012595474,0.000119257966,0.00018332977,0.00011091396,0.00081860274,0.000025249174,0.00032135256,0.0000825491,0.013306992],"category_scores_gemma":[0.00014616236,0.00007812219,0.00019967373,0.0006175277,0.00010498181,0.000027922275,0.00012473844,0.00035355214,0.00016826275],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110321,0.00065256504,0.0017276338,0.0000036356905,0.0016713617,0.0000020243908,0.00016623213,0.000062107196,0.043160442,0.0061972034,0.6963802,0.2498663],"study_design_scores_gemma":[0.00023600359,0.00010685341,0.00028386936,0.0000015482636,0.0003159038,0.000005070456,0.00035525113,0.00007241361,0.017591946,0.00028320096,0.9806188,0.00012918102],"about_ca_topic_score_codex":0.00007508127,"about_ca_topic_score_gemma":0.000007729645,"teacher_disagreement_score":0.8920654,"about_ca_system_score_codex":0.000076090655,"about_ca_system_score_gemma":0.000019102894,"threshold_uncertainty_score":0.98759496},"labels":[],"label_agreement":null},{"id":"W4210946737","doi":"10.1080/03007995.2022.2037846","title":"Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab","year":2022,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Biosimilar; Infliximab; Innovator; Population; Rheumatoid arthritis; Discontinuation; Internal medicine; Disease","score_opus":0.11043825545334685,"score_gpt":0.4623763787597316,"score_spread":0.35193812330638474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210946737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955767,0.0015077795,0.00019856096,0.0011813467,0.0008458235,0.000427198,0.00015745703,0.000022880355,0.000082274004],"genre_scores_gemma":[0.9984111,0.0011386796,0.000031835956,0.00011063963,0.00009120187,0.00008970253,0.00006957282,0.000015525091,0.00004174112],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99707675,0.000878536,0.00044513145,0.00047510234,0.00043817257,0.00068632653],"domain_scores_gemma":[0.9984053,0.0008244031,0.00007815916,0.00030647352,0.00012455524,0.00026113848],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001982319,0.00021788439,0.00041781345,0.00046065412,0.00033621062,0.000026385595,0.0003424335,0.00017124526,0.0014469858],"category_scores_gemma":[0.0011174232,0.00014791526,0.00014499355,0.0006089618,0.00025624209,0.00005215726,0.0004781264,0.0011498678,0.000012292147],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014856772,0.0019021236,0.2799816,0.00010551048,0.00029464057,0.000015950127,0.0011626934,0.000005523933,0.011636067,0.00026268503,0.0040337103,0.6991138],"study_design_scores_gemma":[0.0064634965,0.023347836,0.8426701,0.0010213482,0.000029560975,0.000045345692,0.00045403317,0.00032137055,0.010266488,0.00031072996,0.11449978,0.0005699442],"about_ca_topic_score_codex":0.00034827398,"about_ca_topic_score_gemma":0.000022607648,"teacher_disagreement_score":0.69854385,"about_ca_system_score_codex":0.00030362015,"about_ca_system_score_gemma":0.0002625327,"threshold_uncertainty_score":0.9994658},"labels":[],"label_agreement":null},{"id":"W4212786196","doi":"10.1093/jcag/gwab049.146","title":"A147 SIMILAR OUTCOMES IN PATIENTS SWITCHED TO INFLIXIMAB BIOSIMILARS COMPARED TO THOSE REMAINING ON REMICADE IN A BRITISH COLUMBIA INFLAMMATORY BOWEL DISEASE PRACTICE","year":2022,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Biosimilar; Medicine; Infliximab; Inflammatory bowel disease; Ulcerative colitis; Adverse effect; Internal medicine; Retrospective cohort study; Disease","score_opus":0.009905478948594022,"score_gpt":0.2501827710273613,"score_spread":0.24027729207876727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212786196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9588672,0.000016994096,0.0000025713816,0.039753966,0.000726531,0.00037355287,0.0002153667,0.0000034283905,0.000040388324],"genre_scores_gemma":[0.9740048,0.0000043510786,0.00032252437,0.025398603,0.000015684911,0.000014598938,0.0000065967874,0.000013787523,0.0002190672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963267,0.0018438197,0.00089704257,0.00020811523,0.00020885393,0.00051551074],"domain_scores_gemma":[0.9980875,0.00035819988,0.00090238644,0.00020864532,0.00024332097,0.00019991708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002341073,0.00012243638,0.00052589865,0.0003978537,0.0001726182,0.00003852267,0.000514808,0.0001489445,0.00013038529],"category_scores_gemma":[0.004464766,0.00014445954,0.0001720567,0.00030351448,0.000048453654,0.00007937688,0.00016443398,0.0008805174,0.0000026439448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012292466,0.00028049754,0.97689354,0.0000050567896,0.0001370964,0.000033760614,0.0002762061,0.0005819462,0.00033576947,0.0000035210574,0.020119954,0.000103393926],"study_design_scores_gemma":[0.0033120343,0.0008534833,0.9849256,0.00007867823,0.000057371173,0.000012260381,0.00027151898,0.000008901034,0.000018307615,0.000049004582,0.010324091,0.00008874779],"about_ca_topic_score_codex":0.008952379,"about_ca_topic_score_gemma":0.61646694,"teacher_disagreement_score":0.60751456,"about_ca_system_score_codex":0.002204713,"about_ca_system_score_gemma":0.00035436338,"threshold_uncertainty_score":0.9976471},"labels":[],"label_agreement":null},{"id":"W4213218665","doi":"10.1136/bmjopen-2021-050949","title":"Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients’ satisfaction: a cross-sectional survey by patient organisations","year":2022,"lang":"en","type":"article","venue":"BMJ Open","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Society","funders":"","keywords":"Medicine; Biosimilar; Adalimumab; Cross-sectional study; Rheumatoid arthritis; Family medicine; Health care; Internal medicine; Pathology","score_opus":0.04187053370208662,"score_gpt":0.35647868591070153,"score_spread":0.31460815220861493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213218665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925105,0.0000060460693,0.00029802203,0.0005203638,0.00033288402,0.00363701,0.0025369974,0.000020490499,0.00013768856],"genre_scores_gemma":[0.9934745,4.94709e-7,0.0011291368,0.004214592,0.00000904801,0.00055216864,0.00051085465,0.000010145363,0.00009907248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811906,0.0005091458,0.00067201094,0.00030092537,0.00017946005,0.00021937487],"domain_scores_gemma":[0.99875546,0.0002968627,0.0002894742,0.0003543066,0.0002467537,0.000057127058],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008457516,0.00015750366,0.00026221605,0.00012772647,0.00051368703,0.000095756266,0.00042142256,0.00011611586,0.0013954118],"category_scores_gemma":[0.00087416655,0.0001440351,0.000050709536,0.00039942082,0.00003203287,0.00026654635,0.00076034566,0.00025432167,0.00010929461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019796707,0.00021498092,0.9514915,0.000010812034,0.000115189265,3.1798362e-7,0.0012665689,0.00088027964,0.027267823,0.00009898503,0.012001676,0.0046722027],"study_design_scores_gemma":[0.0009925781,0.0010616382,0.970772,0.000018436931,0.000010591754,0.0000016032942,0.00013319108,0.000006680143,0.017073324,0.00007033462,0.0096533485,0.00020623137],"about_ca_topic_score_codex":0.0040899995,"about_ca_topic_score_gemma":0.0002709278,"teacher_disagreement_score":0.019280547,"about_ca_system_score_codex":0.00019864498,"about_ca_system_score_gemma":0.00016787637,"threshold_uncertainty_score":0.99951744},"labels":[],"label_agreement":null},{"id":"W4213264205","doi":"10.9778/cmajo.20200319","title":"Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study","year":2022,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Ministry of Health, British Columbia","keywords":"Medicine; Biosimilar; Cohort; Infliximab; Psoriatic arthritis; Psoriasis; Internal medicine; Retrospective cohort study; Family medicine; Arthritis; Demography; Immunology; Disease","score_opus":0.007385127804799311,"score_gpt":0.24586361224554087,"score_spread":0.23847848444074157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213264205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967733,0.0004120069,0.0000072116422,0.00016971587,0.00029513848,0.0020368588,0.00017195597,0.000018749219,0.000115047624],"genre_scores_gemma":[0.9980015,0.000030530995,0.00036549708,0.0009583211,0.000015188053,0.00041391555,0.000046658504,0.000022676088,0.00014569717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777824,0.0006105321,0.00044810915,0.0006537952,0.00013270625,0.0003766232],"domain_scores_gemma":[0.9993657,0.0001354916,0.00008482399,0.0003008336,0.000032919586,0.000080218415],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011069473,0.00015264675,0.00056871143,0.0001049579,0.0002503389,0.00017448235,0.00048052624,0.00014704332,0.0017717353],"category_scores_gemma":[0.000118755976,0.00019451148,0.000027433765,0.00032630237,0.00010793541,0.00015768563,0.0011492879,0.00064722134,0.000011012713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026225107,0.00075831637,0.97234416,0.000004445824,0.00010982565,0.00012507517,0.00039557496,8.46499e-7,0.00006616997,0.0000035789615,0.0016663093,0.024263447],"study_design_scores_gemma":[0.007714828,0.0007395836,0.97628987,0.000093345436,0.000032729302,0.000007885059,0.0008692059,0.0000025246136,0.000025489051,0.000062786654,0.013883512,0.00027823533],"about_ca_topic_score_codex":0.025142746,"about_ca_topic_score_gemma":0.13015732,"teacher_disagreement_score":0.105014585,"about_ca_system_score_codex":0.00014540511,"about_ca_system_score_gemma":0.00010440617,"threshold_uncertainty_score":0.9991408},"labels":[],"label_agreement":null},{"id":"W4213329117","doi":"10.1093/jcag/gwab049.148","title":"A149 REAL WORLD OUTCOMES OF NON-MEDICAL SWITCHING OF INFLIXIMAB BIOSIMILAR IN BRITISH COLUMBIA FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD)","year":2022,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; University of British Columbia Hospital","funders":"","keywords":"Biosimilar; Infliximab; Medicine; Discontinuation; Inflammatory bowel disease; Internal medicine; Adverse effect; Ulcerative colitis; Retrospective cohort study; Disease","score_opus":0.008499605242350132,"score_gpt":0.24856394304210408,"score_spread":0.24006433779975395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213329117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902659,0.0001634186,0.000021002475,0.008272111,0.00064077694,0.00026121232,0.0003570022,0.0000010548455,0.000017506485],"genre_scores_gemma":[0.9987859,0.00012310644,0.00010826942,0.00059449323,0.000024414696,0.00001084017,0.000004136287,0.000008162137,0.00034066092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783444,0.0006328495,0.0009854726,0.00009927162,0.00016492992,0.00028302148],"domain_scores_gemma":[0.9974256,0.0005571201,0.0015733555,0.00016899605,0.00019676004,0.000078126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016214927,0.00008686866,0.0005944565,0.00018134214,0.00012495228,0.0000063638377,0.000421196,0.00012375462,0.00021648358],"category_scores_gemma":[0.00053941755,0.000075258744,0.00041467813,0.00013171534,0.00016053577,0.000029523822,0.000056285706,0.0002951662,8.415427e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004058859,0.0002830557,0.9938501,0.000022868118,0.0006369948,0.0000064704423,0.00016338505,0.00005940919,0.00095298165,0.000013899328,0.0028530874,0.0007518749],"study_design_scores_gemma":[0.0032242313,0.0010969265,0.9925085,0.000046068435,0.000232606,0.00001244415,0.00016406058,0.0000695429,0.00019024375,0.000115807605,0.0023005027,0.000039071165],"about_ca_topic_score_codex":0.03378218,"about_ca_topic_score_gemma":0.80859923,"teacher_disagreement_score":0.77481705,"about_ca_system_score_codex":0.0005987703,"about_ca_system_score_gemma":0.00058095856,"threshold_uncertainty_score":0.97265196},"labels":[],"label_agreement":null},{"id":"W4214523030","doi":"10.3390/ph15030298","title":"A Sex- and Gender-Based Analysis of Adverse Drug Reactions: A Scoping Review of Pharmacovigilance Databases","year":2022,"lang":"en","type":"review","venue":"Pharmaceuticals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Waterloo; University of British Columbia; British Columbia Centre of Excellence for Women's Health","funders":"","keywords":"Pharmacovigilance; Medicine; Adverse drug reaction; Drug reaction; Database; Drug; Adverse effect; Pharmacology; Computer science","score_opus":0.3252275046961626,"score_gpt":0.5177977323992277,"score_spread":0.1925702277030651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214523030","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000020537457,0.99624944,0.00015972715,0.000057706682,0.00018419542,0.001131798,0.0016957575,0.000029223458,0.000490115],"genre_scores_gemma":[0.00000928662,0.9975026,0.0007842058,0.0008015786,0.00001542428,0.00015909073,0.0005242586,0.000025124069,0.00017837979],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952173,0.002155848,0.0015492175,0.00061093224,0.00012417886,0.00034248395],"domain_scores_gemma":[0.99499744,0.0033715782,0.00094915234,0.00053910573,0.000069389724,0.000073352254],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002330397,0.00040802528,0.0036667578,0.0005225858,0.000098610646,0.000002617845,0.00034517332,0.0001385698,0.010184517],"category_scores_gemma":[0.00064398523,0.00032348267,0.0010360876,0.0015401075,0.00043251022,0.00005437603,0.00026417873,0.00068532693,0.000007655135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004834672,0.0004010631,0.000045198492,0.6245559,0.008952705,0.000011187047,0.000017416565,0.000001349581,0.0003084374,0.00016718986,0.0011494247,0.36434177],"study_design_scores_gemma":[0.00031635188,0.00001934116,0.0000010845611,0.07889983,0.037969545,0.000014760989,0.000008633496,0.000024605604,0.00088906166,0.0000035909954,0.8815735,0.00027967445],"about_ca_topic_score_codex":0.0000121805115,"about_ca_topic_score_gemma":0.0000011794978,"teacher_disagreement_score":0.8804241,"about_ca_system_score_codex":0.000047717665,"about_ca_system_score_gemma":0.0003174346,"threshold_uncertainty_score":0.99992174},"labels":[],"label_agreement":null},{"id":"W4214931193","doi":"10.1038/s41565-019-0538-3","title":"Publisher Correction: On the issue of transparency and reproducibility in nanomedicine","year":2019,"lang":"en","type":"article","venue":"Nature Nanotechnology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institute of Biomedical Imaging and Bioengineering; National Cancer Institute","keywords":"Transparency (behavior); Nanomedicine; Reproducibility; Nanotechnology; Computer science; Materials science; Chemistry; Computer security; Nanoparticle; Chromatography","score_opus":0.008632955545685815,"score_gpt":0.2598803779856528,"score_spread":0.25124742243996695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214931193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9000404,0.0067410273,0.000016258527,0.077010594,0.008998983,0.0006099142,0.000006556923,0.0000791236,0.0064971577],"genre_scores_gemma":[0.99264634,0.000103613216,0.00006387667,0.0014868659,0.000015905749,0.000007892362,0.000003290943,0.0000061284686,0.0056660734],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862695,0.00017206583,0.0002837792,0.00067343423,0.000038267284,0.00020549423],"domain_scores_gemma":[0.9985408,0.0003002589,0.000083220024,0.0010116582,0.000055697743,0.000008343929],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001378357,0.00012314164,0.0003476528,0.00016308039,0.00003224828,0.000003126899,0.00024991093,0.0014326875,0.0008567875],"category_scores_gemma":[0.0014540467,0.0000709663,0.000043547658,0.00048366314,0.00045847532,0.000030860552,0.00005348526,0.0014816463,0.000022461589],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095017516,0.00075471983,0.17950737,0.0001402746,0.00023549212,0.000009766184,0.0003608507,0.0000015085907,0.44297397,0.038650416,0.1682928,0.16812263],"study_design_scores_gemma":[0.0023020864,0.001775584,0.113982104,0.00013218977,0.00006042468,0.00010112867,0.00037450105,0.00001242861,0.3287771,0.012051067,0.5400925,0.00033882743],"about_ca_topic_score_codex":0.000028405337,"about_ca_topic_score_gemma":0.000029676768,"teacher_disagreement_score":0.37179974,"about_ca_system_score_codex":0.000020836229,"about_ca_system_score_gemma":0.000022052855,"threshold_uncertainty_score":0.9998637},"labels":[],"label_agreement":null},{"id":"W4220856531","doi":"10.1186/s40545-022-00420-4","title":"Trends in Canadian prescription drug purchasing: 2001–2020","year":2022,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Nova Scotia Health Authority; Queen Elizabeth II Health Sciences Centre; Université Laval; University of British Columbia; Public Health Ontario; University of Toronto; University of Calgary","funders":"","keywords":"Medicine; Medical prescription; Prescription drug; Pharmacy; Audit; Inpatient care; Emergency medicine; Family medicine; Medical emergency; Business; Health care; Accounting; Pharmacology","score_opus":0.07224898474257811,"score_gpt":0.4252484771502143,"score_spread":0.3529994924076362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220856531","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08428265,0.028525766,0.000120923534,0.79804885,0.0034604606,0.00031391936,0.00018723638,0.000028625514,0.085031584],"genre_scores_gemma":[0.9830927,0.00076406903,0.00061979756,0.012925306,0.00020146223,0.0000025213787,0.000003874511,0.000009692097,0.002380563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99736583,0.0015750953,0.00039372314,0.00013480424,0.00008123728,0.00044930953],"domain_scores_gemma":[0.9985821,0.00087535253,0.00019053977,0.00007571727,0.000062307205,0.00021395722],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032993378,0.000108883985,0.00022877056,0.0005136863,0.00021337262,0.000025959767,0.00016637529,0.00008864619,0.0018084169],"category_scores_gemma":[0.0017852661,0.0000933923,0.00008125071,0.00052050303,0.00013482779,0.0002542168,0.00008264322,0.0012656974,0.0000063599264],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008954746,0.0017988883,0.0048969816,0.00006702222,0.00094550103,0.0013795248,0.002898816,0.000108725995,0.13949586,0.026420077,0.35420874,0.45882514],"study_design_scores_gemma":[0.001128647,0.00021296399,0.0019751047,0.000007121536,0.00012619792,0.0031839807,0.00036442513,0.0000824824,0.0011285346,0.0005495337,0.9911325,0.0001085146],"about_ca_topic_score_codex":0.019368224,"about_ca_topic_score_gemma":0.0027922115,"teacher_disagreement_score":0.8988101,"about_ca_system_score_codex":0.00022884662,"about_ca_system_score_gemma":0.00031545362,"threshold_uncertainty_score":0.9991041},"labels":[],"label_agreement":null},{"id":"W4220960563","doi":"10.1093/rheumatology/keac190","title":"Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis","year":2022,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Society","funders":"Manchester Biomedical Research Centre; Versus Arthritis; British Society for Rheumatology; National Institute for Health and Care Research","keywords":"Medicine; Discontinuation; Rheumatoid arthritis; Internal medicine; Rheumatology; Rituximab; Biosimilar; Imputation (statistics); Etanercept; Abatacept; Physical therapy; Missing data; Lymphoma","score_opus":0.019139729793665027,"score_gpt":0.275605201525136,"score_spread":0.256465471731471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220960563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800996,0.015855037,0.002122755,0.00016802916,0.0004892615,0.0006093858,0.0005583911,0.000050609433,0.00004689136],"genre_scores_gemma":[0.9982299,0.0005909,0.0007422203,0.00007270977,0.000007320326,0.00013613202,0.00015265444,0.000014313016,0.000053809956],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982589,0.00077533565,0.00029064727,0.00033208387,0.00004298107,0.00030009166],"domain_scores_gemma":[0.9990165,0.0005789697,0.000121399105,0.00019881214,0.000043406042,0.00004088562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009826769,0.00015886921,0.00045596363,0.00008213467,0.00030121888,0.000011394409,0.00016696128,0.00010963882,0.00025029125],"category_scores_gemma":[0.00018584309,0.00013789228,0.00014581169,0.0001408879,0.00024947114,0.000043233875,0.00021538607,0.00019538573,0.0000032241146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002144234,0.00053358305,0.013012674,0.0009621635,0.0006983426,0.000014128203,0.00034474937,0.000063072155,0.95421124,0.006519055,0.00048185006,0.02101492],"study_design_scores_gemma":[0.035280712,0.004758087,0.20937765,0.0017072889,0.00070932246,0.00030985737,0.0020535656,0.0030695142,0.6433838,0.05574039,0.04052346,0.003086379],"about_ca_topic_score_codex":0.000034724893,"about_ca_topic_score_gemma":7.822051e-7,"teacher_disagreement_score":0.31082746,"about_ca_system_score_codex":0.000026685291,"about_ca_system_score_gemma":0.000044398854,"threshold_uncertainty_score":0.5623084},"labels":[],"label_agreement":null},{"id":"W4221019027","doi":"10.1007/s12325-022-02104-6","title":"Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Infliximab; Medicine; Biosimilar; Inflammatory bowel disease; Internal medicine; Ulcerative colitis; Observational study; Adverse effect; Disease","score_opus":0.03858910153886844,"score_gpt":0.35364014621390394,"score_spread":0.31505104467503553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221019027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974795,0.00033790251,2.6904604e-7,0.0002370916,0.00024139354,0.0013266238,0.00034770102,0.000009146944,0.000020368867],"genre_scores_gemma":[0.9989038,0.0001633106,0.000024796283,0.00069245993,0.000009332201,0.00010159857,0.00007401167,0.000014458411,0.00001624847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965223,0.0016284387,0.0008650996,0.0004947437,0.0002382909,0.00025112362],"domain_scores_gemma":[0.9977745,0.0011513783,0.0004018491,0.00055257935,0.000070209135,0.000049484213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000933407,0.0002497125,0.00043485887,0.00009688003,0.00020333484,0.000016730517,0.00031298402,0.000053649903,0.000032187712],"category_scores_gemma":[0.00021267556,0.00013137098,0.00006571795,0.00026824677,0.00035958883,0.0001596295,0.00010900717,0.0005035621,1.06057215e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00936185,0.0020775448,0.9838079,0.0000017008036,0.0002904535,0.000024534393,0.001643586,0.00014404145,0.0000062764875,0.000009274127,0.000056389275,0.0025763991],"study_design_scores_gemma":[0.013004082,0.0035687278,0.98069984,0.000012662209,0.00004873443,2.3266621e-7,0.001736967,0.0000135516775,0.000005058942,0.00010199743,0.00063735823,0.00017079929],"about_ca_topic_score_codex":0.06272872,"about_ca_topic_score_gemma":0.2815277,"teacher_disagreement_score":0.21879897,"about_ca_system_score_codex":0.00007935574,"about_ca_system_score_gemma":0.00019723119,"threshold_uncertainty_score":0.9435127},"labels":[],"label_agreement":null},{"id":"W4223568855","doi":"10.1016/j.ejps.2022.106181","title":"Overview of authorized drug products for subcutaneous administration: Pharmaceutical, therapeutic, and physicochemical properties","year":2022,"lang":"en","type":"article","venue":"European Journal of Pharmaceutical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"VINNOVA","keywords":"Drug; DrugBank; Pharmacology; Medicine; European union; Bioavailability; Drug development; Food and drug administration; Business","score_opus":0.16806187957223412,"score_gpt":0.38922586769715606,"score_spread":0.22116398812492194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223568855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85316896,0.09977617,0.00087697874,0.040311143,0.0025040535,0.0010001148,0.000102282116,0.000050563154,0.0022097493],"genre_scores_gemma":[0.9962495,0.00055513514,0.002049683,0.0007300249,0.000117043855,0.0000038167277,0.000001253434,0.00001106113,0.00028247328],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973432,0.001292595,0.000599836,0.00026736784,0.00018333593,0.0003136827],"domain_scores_gemma":[0.99902564,0.0003429861,0.0002981629,0.000093092225,0.0001638872,0.00007624195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035748451,0.00015629732,0.00036401642,0.000071833056,0.00037367735,0.00003473283,0.00047087413,0.000023162123,0.00038553344],"category_scores_gemma":[0.0002140676,0.000104346705,0.00014198515,0.00029790323,0.0012902061,0.00009767637,0.00017939096,0.00044643314,0.0000027591539],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013587661,0.00039533057,0.000059612656,0.000121052915,0.00014189273,0.000027010825,0.00020865253,0.0000029878072,0.95469874,0.0024288632,0.0016519402,0.03890513],"study_design_scores_gemma":[0.0017644061,0.0022885143,0.0000871966,0.000051126113,0.0002923623,0.0009934718,0.0003821204,0.0002098487,0.722672,0.00039132743,0.27065998,0.00020762997],"about_ca_topic_score_codex":4.950497e-7,"about_ca_topic_score_gemma":7.0365914e-8,"teacher_disagreement_score":0.26900804,"about_ca_system_score_codex":0.000020207717,"about_ca_system_score_gemma":0.00014584727,"threshold_uncertainty_score":0.47538182},"labels":[],"label_agreement":null},{"id":"W4224225336","doi":"10.1503/cmaj.211478","title":"Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data","year":2022,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; AIDS Vancouver; British Columbia Centre of Excellence for Women's Health; Women's College Hospital; University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Biosimilar; Per capita; Medical prescription; Drug prices; Medicine; Business; Public economics; Environmental health; Economics; Pharmacology; Internal medicine; Population","score_opus":0.015485631348758279,"score_gpt":0.25804367506038856,"score_spread":0.24255804371163028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224225336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808819,0.0012827341,0.000010295877,0.014634729,0.0004527967,0.00007692526,0.0021700046,0.000002011007,0.0004885619],"genre_scores_gemma":[0.99733526,0.000094478004,0.00005994624,0.0022943527,0.00003706194,0.0000012967795,0.000054491753,0.0000039699926,0.00011915224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832517,0.0003910777,0.00055722566,0.00014165288,0.0002892769,0.00029561014],"domain_scores_gemma":[0.99904484,0.00025494315,0.00028901602,0.00014556239,0.00009166752,0.00017399783],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026746613,0.00007406794,0.00039267223,0.0003984819,0.00014061751,0.0000060992816,0.0004020899,0.0001508409,0.00388754],"category_scores_gemma":[0.0010922829,0.00006701167,0.00005587344,0.00073860935,0.00008103468,0.000037995684,0.00012819828,0.00064777705,3.4228557e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054321037,0.00009830154,0.8566395,0.00001844701,0.002735258,0.000078418554,0.0008522186,0.000021154001,0.0011499444,0.0004861811,0.0745862,0.06328005],"study_design_scores_gemma":[0.0009791687,0.000084462554,0.761171,0.00001670344,0.00058054796,0.000052102117,0.003249413,0.0006105948,0.00025995428,0.000059462276,0.23276971,0.00016691221],"about_ca_topic_score_codex":0.8567964,"about_ca_topic_score_gemma":0.9889579,"teacher_disagreement_score":0.15818352,"about_ca_system_score_codex":0.000786787,"about_ca_system_score_gemma":0.006934455,"threshold_uncertainty_score":0.9986953},"labels":[],"label_agreement":null},{"id":"W4224288018","doi":"10.1016/j.biologicals.2022.03.001","title":"WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June – 2 July 2021","year":2022,"lang":"en","type":"article","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Ministry of Health and Welfare; World Health Organization","keywords":"CLARITY; Biosimilar; Flexibility (engineering); Standardization; Medicine; Engineering ethics; Risk analysis (engineering); Management science; Business; Medical education; Engineering management; Political science; Engineering; Law; Management","score_opus":0.1113743065632104,"score_gpt":0.378385527609463,"score_spread":0.2670112210462526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224288018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792576,0.009270835,0.0001076505,0.004124962,0.0013251671,0.0015365332,0.0004434108,0.000050879058,0.0038829567],"genre_scores_gemma":[0.9948007,0.0006749075,0.0011537516,0.0018308456,0.00007187572,0.000027335615,0.00016970912,0.000010795532,0.0012600641],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971786,0.0013203092,0.0007722111,0.00033711805,0.00018327241,0.00020847014],"domain_scores_gemma":[0.9981054,0.00050456397,0.00047445725,0.00028377635,0.00061545294,0.000016365351],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004077255,0.0001750627,0.00044251356,0.00012254946,0.00014390824,0.0000045565716,0.00021237516,0.00022829167,0.0025481067],"category_scores_gemma":[0.0035870485,0.000114453265,0.00011069423,0.00032645828,0.00025371654,0.00002645929,0.000105714826,0.0002399272,0.00003753913],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014390727,0.0006444837,0.00032247626,0.00004654291,0.00024376929,8.0422444e-7,0.00018674626,0.0009876632,0.7396649,0.0031265623,0.021714386,0.23162256],"study_design_scores_gemma":[0.0022788416,0.005963675,0.0029369507,0.00016981331,0.00021240958,0.000005562741,0.00033526623,0.0005520739,0.5207384,0.0003157232,0.4661825,0.00030875634],"about_ca_topic_score_codex":0.000005483879,"about_ca_topic_score_gemma":3.7753063e-7,"teacher_disagreement_score":0.4444681,"about_ca_system_score_codex":0.00003317699,"about_ca_system_score_gemma":0.00007530706,"threshold_uncertainty_score":0.9983637},"labels":[],"label_agreement":null},{"id":"W4226230176","doi":"10.18433/jpps32433","title":"Biosimilars: A Comparative Study of Regulatory, Safety and Pharmacovigilance Monograph in the Developed and Developing Economies","year":2022,"lang":"en","type":"review","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Pharmacovigilance; Business; Risk analysis (engineering); Medicine; Pharmacology; Adverse effect","score_opus":0.3142194182936775,"score_gpt":0.49441166339444886,"score_spread":0.18019224510077136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226230176","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011619884,0.9863458,0.000012003776,0.00068148575,0.00038287873,0.00073317427,0.000024744066,0.000005704299,0.00019429269],"genre_scores_gemma":[0.016924256,0.98196,0.0004484835,0.0005849754,0.00004244198,0.000017650915,0.0000013026139,0.000009447358,0.000011468475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947998,0.0025208697,0.0016274675,0.00043002196,0.00020447835,0.00041737038],"domain_scores_gemma":[0.99646384,0.0022693593,0.0010065472,0.000121026154,0.000064610205,0.00007462729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054664263,0.00040047537,0.0018364816,0.00048223324,0.00039456863,0.000063761574,0.00094789884,0.00010195188,0.00028030892],"category_scores_gemma":[0.00009767413,0.00022832055,0.00021836451,0.001033658,0.0014160813,0.00023335482,0.0003267811,0.0012521807,9.967656e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004625594,0.0006713617,0.002202843,0.0014747117,0.001032155,0.00005191157,0.0024307494,0.0000034975133,0.00016383607,0.00033776372,0.00067317346,0.99049544],"study_design_scores_gemma":[0.0018514311,0.00036323702,0.00028257637,0.00053264014,0.0009348725,0.00043358767,0.0019725226,0.000024062914,0.0002462749,0.00004594696,0.9930269,0.00028591356],"about_ca_topic_score_codex":0.000009741399,"about_ca_topic_score_gemma":0.0000066565267,"teacher_disagreement_score":0.99235374,"about_ca_system_score_codex":0.0000758167,"about_ca_system_score_gemma":0.00042799418,"threshold_uncertainty_score":0.9310642},"labels":[],"label_agreement":null},{"id":"W4226349190","doi":"10.51731/cjht.2022.302","title":"Sacituzumab Govitecan (Trodelvy)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Metastatic breast cancer; Family medicine; Breast cancer; Cancer; Internal medicine; Political science; Health care","score_opus":0.028862155386624497,"score_gpt":0.27560738489170655,"score_spread":0.24674522950508204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226349190","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.106390946,0.5909424,0.0038693834,0.28676802,0.0073088477,0.0007295176,0.00050137925,0.00044602455,0.003043482],"genre_scores_gemma":[0.9971491,0.00012539384,0.0007845521,0.0014514178,0.0000051506822,0.0000060786297,0.0000034499735,0.0000105083,0.00046431465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840415,0.00029104683,0.00054295297,0.00014687347,0.00005191365,0.0005630457],"domain_scores_gemma":[0.99919534,0.00007748062,0.00036940823,0.00024241721,0.000076915225,0.000038467042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012705494,0.000121765275,0.00039181495,0.000568182,0.000849595,0.000014575467,0.0006215158,0.00015659691,0.00090798526],"category_scores_gemma":[0.0003336902,0.00010201163,0.00011910273,0.0004102472,0.00038033607,0.000046875517,0.00007560591,0.0010919916,0.0000115922285],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046570003,0.000045711313,0.001611079,0.000030106776,0.000145682,0.00011626094,0.0002251906,0.000022827993,0.0016419067,0.0114075,0.07024319,0.914464],"study_design_scores_gemma":[0.00041448316,0.0008087193,0.00085974275,0.000018352874,0.000014845357,0.0008657704,0.00308227,0.0000020405412,0.0019714336,0.0063281446,0.985507,0.00012718323],"about_ca_topic_score_codex":0.0019046556,"about_ca_topic_score_gemma":0.00084124453,"teacher_disagreement_score":0.91526383,"about_ca_system_score_codex":0.00051164936,"about_ca_system_score_gemma":0.0018807829,"threshold_uncertainty_score":0.9941802},"labels":[],"label_agreement":null},{"id":"W4229003246","doi":"10.1016/j.semarthrit.2022.152023","title":"Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases","year":2022,"lang":"en","type":"review","venue":"Seminars in Arthritis and Rheumatism","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Mylan","keywords":"Biosimilar; Medicine; Biological drugs; Intensive care medicine; European union; Pharmacology; Immunology; Internal medicine; Rheumatoid arthritis","score_opus":0.019520373799472256,"score_gpt":0.30792206769014024,"score_spread":0.288401693890668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229003246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029413057,0.9936421,0.0000010165608,0.00018459244,0.0017280023,0.00066963345,0.0006826997,0.0000656154,0.000085025706],"genre_scores_gemma":[0.00057004945,0.99842846,0.00010637972,0.000089737914,0.000101457495,0.00019541042,0.0003481586,0.00007775633,0.00008257642],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99524933,0.0014420314,0.001378512,0.0009950112,0.00013339819,0.0008016953],"domain_scores_gemma":[0.9950456,0.0040035937,0.00028273405,0.0005168055,0.00002391202,0.0001273708],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000835314,0.00078852015,0.0024263803,0.0006223011,0.00027423672,0.00009875897,0.00031668658,0.0012340631,0.0009424111],"category_scores_gemma":[0.001024913,0.0006732907,0.0003102948,0.00034366417,0.001035153,0.00021889035,0.00044889882,0.001943805,0.000029847126],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031089206,0.00014896748,0.00060828443,0.0030377922,0.000115601615,0.00035963702,0.00013026567,1.4745045e-7,0.000033944238,0.001495839,0.001092408,0.992946],"study_design_scores_gemma":[0.0013876391,0.00034149663,0.004528153,0.06176126,0.00015101819,0.00036611833,0.00016638923,0.0000068247236,0.000009478467,0.00008953761,0.9303178,0.0008742778],"about_ca_topic_score_codex":0.000027204724,"about_ca_topic_score_gemma":0.000073947434,"teacher_disagreement_score":0.99207175,"about_ca_system_score_codex":0.00019281128,"about_ca_system_score_gemma":0.00029384668,"threshold_uncertainty_score":0.99997085},"labels":[],"label_agreement":null},{"id":"W4229454042","doi":"10.1208/s12248-022-00707-z","title":"Biomarker Assay Validation by Mass Spectrometry","year":2022,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Native Health Society","funders":"","keywords":"Biomarker; Bioanalysis; Context (archaeology); Biomarker discovery; Computational biology; Chemistry; Chromatography; Proteomics; Biology","score_opus":0.024091079122455263,"score_gpt":0.2840727474356391,"score_spread":0.2599816683131838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229454042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.478198,0.060110845,0.1918712,0.17146598,0.021636985,0.0011475052,0.0007089508,0.00034613413,0.074514404],"genre_scores_gemma":[0.981807,0.00015914402,0.0014398951,0.0016545032,0.00010927435,0.0000060977477,0.000025182646,0.000016123122,0.014782784],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808747,0.0012526558,0.00021009099,0.00011626743,0.000074383635,0.00025910806],"domain_scores_gemma":[0.9994525,0.00020135586,0.00012737494,0.0001673131,0.0000283672,0.00002308842],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024817637,0.00009149067,0.00013367755,0.00007130679,0.000763748,0.000036642643,0.00035533062,0.00006561575,0.013916925],"category_scores_gemma":[0.000091263326,0.000055039487,0.00011274947,0.00023918813,0.00011568142,0.000041673215,0.00010804105,0.0007794001,0.000082650935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008021186,0.00005558564,0.00042762177,9.292123e-7,0.00016780681,0.0000061177984,0.000032813667,0.0000013391995,0.78845495,0.0003395295,0.20334356,0.0070895255],"study_design_scores_gemma":[0.0010309076,0.00034271233,0.0024636858,0.0000049191276,0.00015552025,0.0019637668,0.00047158657,0.000029962732,0.17870972,0.009007047,0.80559,0.000230205],"about_ca_topic_score_codex":0.0000040449277,"about_ca_topic_score_gemma":1.3627009e-7,"teacher_disagreement_score":0.60974526,"about_ca_system_score_codex":0.00006712562,"about_ca_system_score_gemma":0.000027806711,"threshold_uncertainty_score":0.9869845},"labels":[],"label_agreement":null},{"id":"W4229584754","doi":"10.5639/gabij.2014.0401.012","title":"Comparison of biosimilars guidelines","year":2014,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Business; Medicine; Internal medicine","score_opus":0.14024363653818273,"score_gpt":0.40170539137391414,"score_spread":0.2614617548357314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229584754","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2513455,0.10981876,0.18425664,0.40295744,0.015164405,0.0015383427,0.0008915845,0.0003578446,0.033669483],"genre_scores_gemma":[0.82636,0.0049005346,0.055849932,0.112111844,0.00053351093,0.000007608195,0.00002949478,0.000060796858,0.00014628553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779284,0.00045689143,0.0009378687,0.00029070734,0.000113481656,0.00040823309],"domain_scores_gemma":[0.9983089,0.00029166465,0.00054458977,0.00020455902,0.00055547914,0.00009483897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001316108,0.00027804205,0.0006797032,0.00020088533,0.00031723498,0.000043890162,0.00027438762,0.00033791224,0.0003336965],"category_scores_gemma":[0.00065346836,0.00019947668,0.00019019145,0.00027871018,0.00054731645,0.0000923758,0.00014375454,0.00051278435,0.000007740598],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012300974,0.0002445807,0.02584405,0.00003855157,0.00037200138,0.000004019304,0.00027402653,0.000012039701,0.17586389,0.00025552124,0.75339067,0.04357762],"study_design_scores_gemma":[0.0017884736,0.0014313632,0.01146044,0.00015211401,0.00029349455,0.00026676845,0.0007741733,0.00073280855,0.38370395,0.0034946625,0.5953315,0.00057024957],"about_ca_topic_score_codex":2.8757154e-7,"about_ca_topic_score_gemma":0.0000026266541,"teacher_disagreement_score":0.5750145,"about_ca_system_score_codex":0.000020580543,"about_ca_system_score_gemma":0.000059263413,"threshold_uncertainty_score":0.8134423},"labels":[],"label_agreement":null},{"id":"W4230452634","doi":"10.1093/rheumatology/kex389","title":"BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs","year":2017,"lang":"en","type":"erratum","venue":"Lara D. Veeken","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital; Arthritis Society","funders":"","keywords":"Medicine; Guideline; Medical prescription; Rheumatic disease; Intensive care medicine; Disease; Internal medicine; Pharmacology; Pathology","score_opus":0.040881375414976044,"score_gpt":0.3337434337747749,"score_spread":0.29286205835979884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230452634","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.082150355,0.7620714,0.019418819,0.015475927,0.10232201,0.008432062,0.0036974472,0.0003228939,0.0061090863],"genre_scores_gemma":[0.6501618,0.11222149,0.027118303,0.001230497,0.0049597477,0.0005620926,0.0018730237,0.00028651813,0.2015865],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998491,0.00014057313,0.00051835884,0.0004499834,0.00005119838,0.00034889183],"domain_scores_gemma":[0.9984037,0.00040885582,0.00045197183,0.00056488364,0.00012546545,0.00004511002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088901876,0.0003133141,0.0006945126,0.000070040085,0.00042868775,0.00006294525,0.00038717166,0.0007245536,0.000024588153],"category_scores_gemma":[0.0005737793,0.00019481045,0.00016163614,0.000038300743,0.00053040736,0.00006682289,0.0002616791,0.0005496675,0.0000025767893],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079955417,0.00021818627,0.012915588,0.0038613738,0.0023752993,0.000009879039,0.00070458,0.0000034325121,0.052694365,0.00033458535,0.76419026,0.1618929],"study_design_scores_gemma":[0.0027022534,0.00047251076,0.084139004,0.0022519599,0.0021537216,0.000026358883,0.00045195507,0.0014112635,0.0028526986,0.0027974767,0.8998029,0.00093790534],"about_ca_topic_score_codex":0.00007540325,"about_ca_topic_score_gemma":0.0000033157742,"teacher_disagreement_score":0.6498499,"about_ca_system_score_codex":0.000017637076,"about_ca_system_score_gemma":0.00006077105,"threshold_uncertainty_score":0.7944139},"labels":[],"label_agreement":null},{"id":"W4230666570","doi":"10.4103/1947-2714.128482","title":"Western blot: Technique, theory and trouble shooting","year":2014,"lang":"en","type":"article","venue":"North American Journal of Medical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":230,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Trouble shooting; Medicine; Data science; Computer science; Engineering","score_opus":0.020281564672442222,"score_gpt":0.32223895671067027,"score_spread":0.301957392038228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230666570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649871,0.0013667837,0.026259976,0.006278059,0.00034353396,0.000052920877,0.0000012631575,0.000014259653,0.00069613266],"genre_scores_gemma":[0.994716,0.00012820617,0.003812727,0.0011672028,0.0001169496,8.951999e-7,1.5869561e-7,0.0000031020857,0.000054793487],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983467,0.0006866866,0.0003267791,0.00012944925,0.00021448132,0.0002959006],"domain_scores_gemma":[0.99863446,0.00084506103,0.00027318212,0.00006336704,0.000035343124,0.00014857727],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0073466273,0.000089511304,0.00031034532,0.00008534919,0.00014487604,0.000019633248,0.0004129681,0.00007251299,0.00029982976],"category_scores_gemma":[0.0009764671,0.00005073427,0.000060253336,0.00030869368,0.002752411,0.00007546223,0.00007984733,0.00044027288,0.000004624219],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051864437,0.00006138389,0.27335486,0.000005411485,0.000037603684,0.0000046457276,0.00009179976,3.5721632e-7,0.0010101676,0.002062246,0.0001601834,0.7231595],"study_design_scores_gemma":[0.0032304726,0.015274416,0.72647464,0.00058611116,0.0004904797,0.006762523,0.0029550393,0.00009456041,0.02180623,0.00675605,0.21439236,0.001177092],"about_ca_topic_score_codex":0.000019398884,"about_ca_topic_score_gemma":0.000022674558,"teacher_disagreement_score":0.72198236,"about_ca_system_score_codex":0.000007016218,"about_ca_system_score_gemma":0.00007993708,"threshold_uncertainty_score":0.99996156},"labels":[],"label_agreement":null},{"id":"W4231118242","doi":"10.1093/ecco-jcc/jjx180.643","title":"P516 Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trials","year":2018,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Tofacitinib; Octave (electronics); Ulcerative colitis; Maintenance therapy; Clinical trial; Open label; Surgery; Internal medicine; Chemotherapy; Rheumatoid arthritis","score_opus":0.12657783373225187,"score_gpt":0.4222906470315133,"score_spread":0.29571281329926147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231118242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98597914,0.0029326174,0.0006298285,0.0045596696,0.0008891512,0.0007109971,0.0038181222,0.000004813754,0.00047566087],"genre_scores_gemma":[0.9940129,0.0026907427,0.0015474937,0.00046417184,0.0005377276,0.000012403975,0.00002127828,0.0000073903316,0.00070590177],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969649,0.0011821911,0.0014022958,0.00021386139,0.000047061356,0.00018970152],"domain_scores_gemma":[0.99442273,0.0043595284,0.0006952627,0.00016084146,0.00029510207,0.00006653274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002516297,0.00016293103,0.0008655614,0.000033609864,0.00013634813,0.000033291104,0.00007969299,0.00023808508,0.00035942715],"category_scores_gemma":[0.0011902285,0.000084040876,0.00029957347,0.00004594176,0.0007718318,0.000050391824,0.000042976506,0.00015350863,0.0000020146526],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29659826,0.0007985741,0.0023225602,0.00001878893,0.004038036,0.000049186434,0.0033049874,6.672904e-8,0.00044277564,0.0018899095,0.0100317225,0.6805051],"study_design_scores_gemma":[0.01695827,0.009166868,0.7248885,0.00025731057,0.000865959,0.00013239981,0.0006851568,0.0000047086855,0.007344055,0.0016449839,0.2379057,0.00014606964],"about_ca_topic_score_codex":0.000060636816,"about_ca_topic_score_gemma":0.00011053214,"teacher_disagreement_score":0.72256595,"about_ca_system_score_codex":0.000039381994,"about_ca_system_score_gemma":0.00007916905,"threshold_uncertainty_score":0.39354753},"labels":[],"label_agreement":null},{"id":"W4231136064","doi":"10.1093/ecco-jcc/jjw019.552","title":"P433. Canadian patient and caregiver perspectives on subsequent entry biologics / biosimilars for inflammatory bowel disease","year":2016,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Inflammatory bowel disease; Medicine; Intensive care medicine; Disease; Internal medicine","score_opus":0.012679446100973043,"score_gpt":0.2467566722902664,"score_spread":0.23407722618929336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231136064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97971535,0.010772468,0.00009875595,0.008088761,0.00042643966,0.00021856569,0.0004010312,0.0000062464833,0.00027236875],"genre_scores_gemma":[0.9954113,0.0031095445,0.00014175863,0.00096641306,0.000067365436,0.000005466488,0.0000014249142,0.0000076754895,0.00028907473],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99912274,0.000111638554,0.0002623327,0.00017772369,0.000036278634,0.00028929228],"domain_scores_gemma":[0.9991671,0.00019128884,0.00015083302,0.00009583099,0.00018086433,0.00021407081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020982341,0.00013718462,0.00022334541,0.00012283267,0.0001474579,0.000023330287,0.00008010886,0.00016067275,0.00011281035],"category_scores_gemma":[0.00018130224,0.00007827454,0.00010963605,0.0000304211,0.00036541565,0.000062609535,0.000026209806,0.00012332296,0.0000016892507],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038811848,0.0011619206,0.10652561,0.00048345633,0.0033563161,0.001832779,0.010692923,0.0000033051303,0.022065496,0.120346464,0.15766484,0.5370551],"study_design_scores_gemma":[0.0024816783,0.0018694834,0.69964856,0.0003097487,0.00018950466,0.00018148737,0.0029001406,0.0000022791223,0.0058283145,0.0034492987,0.28277782,0.00036171832],"about_ca_topic_score_codex":0.00011535064,"about_ca_topic_score_gemma":0.00036924667,"teacher_disagreement_score":0.59312296,"about_ca_system_score_codex":0.00009595729,"about_ca_system_score_gemma":0.00016495073,"threshold_uncertainty_score":0.31919432},"labels":[],"label_agreement":null},{"id":"W4231898760","doi":"10.1515/iupac.83.0423","title":"Negative Assay Control","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Glossary; Context (archaeology); Field (mathematics); Process (computing); Computer science; Multidisciplinary approach; Data science; Component (thermodynamics); Management science; Engineering; Sociology; Biology; Linguistics; Mathematics; Social science","score_opus":0.0157302173952543,"score_gpt":0.40006756099114116,"score_spread":0.38433734359588684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231898760","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004228569,0.0025279105,0.0011225607,0.0026107603,0.0019081539,0.0003434304,0.99124265,0.000064929205,0.00017539386],"genre_scores_gemma":[0.000047220332,0.0006504071,0.00010573361,0.0018322463,0.00043054365,0.00001611372,0.9933578,0.000030654868,0.0035292865],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970565,0.0008612836,0.0005794182,0.000653306,0.00018609532,0.0006633968],"domain_scores_gemma":[0.9973463,0.0009934312,0.00032891467,0.0007674031,0.00048447936,0.00007947586],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014125422,0.0005508203,0.0011087985,0.00017587126,0.0001636588,0.000030357149,0.00055740244,0.0014593132,0.023322215],"category_scores_gemma":[0.00224671,0.00034075676,0.00034725675,0.00015284505,0.00068608427,0.000049931168,0.00015644498,0.001035189,0.00002965663],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004957797,0.00021073454,0.000006012019,0.00003955373,0.0007495918,0.000029247802,0.0000033295514,3.9684814e-8,0.0005409704,0.0000319109,0.98936397,0.008528888],"study_design_scores_gemma":[0.0029114191,0.00040880832,0.000033426084,0.00022155183,0.0004559453,0.000029392642,0.000012651047,4.8180004e-7,0.00092320767,0.00046576178,0.994054,0.0004833347],"about_ca_topic_score_codex":0.00007525059,"about_ca_topic_score_gemma":0.00021300053,"teacher_disagreement_score":0.023292558,"about_ca_system_score_codex":0.00022434384,"about_ca_system_score_gemma":0.00047494084,"threshold_uncertainty_score":0.99990445},"labels":[],"label_agreement":null},{"id":"W4231957853","doi":"10.1016/j.cgh.2015.04.022","title":"Increased Risk of Venous Thromboembolic Events With Corticosteroid Versus Biologic Therapy for Inflammatory Bowel Disease","year":2015,"lang":"en","type":"letter","venue":"Clinical Gastroenterology and Hepatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Odds ratio; Inflammatory bowel disease; Corticosteroid; Internal medicine; Cohort; Disease; Gastroenterology","score_opus":0.057107183416522045,"score_gpt":0.3343660144199183,"score_spread":0.27725883100339627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231957853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9493939,0.004495881,0.00022125238,0.041013345,0.0025323164,0.0011447794,0.0010853679,0.00007264109,0.000040500916],"genre_scores_gemma":[0.6037944,0.008172039,0.0017030679,0.38178673,0.001502527,0.00044928625,0.0020432347,0.00017653716,0.0003721554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934975,0.0030359859,0.0013446871,0.0010735859,0.00007171554,0.0009765085],"domain_scores_gemma":[0.9955427,0.0021148003,0.0011525564,0.0007303612,0.00029080143,0.00016878828],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013221719,0.0006307149,0.0021568916,0.00017331506,0.00015209832,0.000007039878,0.00053044263,0.0029116054,0.00015948767],"category_scores_gemma":[0.0008107168,0.00043671837,0.00047553892,0.000060616756,0.0030708464,0.000039346603,0.00021717222,0.0024523751,0.000026187967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037912514,0.0007560379,0.7833816,0.00014668555,0.0024997462,0.00011240908,0.000018279154,2.4705622e-7,0.00006405078,0.000028509578,0.17363426,0.0014457019],"study_design_scores_gemma":[0.03549125,0.05113244,0.5039413,0.0001422806,0.0037049358,0.00023216735,0.000028281525,0.00003819929,0.000081107966,0.0021892248,0.4021793,0.00083949504],"about_ca_topic_score_codex":0.000030296183,"about_ca_topic_score_gemma":0.000054005806,"teacher_disagreement_score":0.3455995,"about_ca_system_score_codex":0.000034233228,"about_ca_system_score_gemma":0.00030597718,"threshold_uncertainty_score":0.999849},"labels":[],"label_agreement":null},{"id":"W4233454438","doi":"10.1136/annrheumdis-2017-eular.6361","title":"SAT0195 Rituximab shows better sustainability than tnf inhibitors when used following initial biologic dmard failure in the treatment of rheumatoid arthritis: 8 years of real-world observations from the rhumadata® clinical database and registry","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Osteoporosis Canada; Montreal Clinical Research Institute","funders":"Chugai Pharmaceutical","keywords":"Medicine; Discontinuation; Rheumatoid arthritis; Rituximab; Internal medicine; Ustekinumab; TNF inhibitor; Hazard ratio; Proportional hazards model; Adalimumab; Confidence interval","score_opus":0.11409654221495438,"score_gpt":0.38338819610129793,"score_spread":0.2692916538863436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233454438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98579836,0.0030863506,0.0000069720927,0.008827982,0.00020532135,0.00052738126,0.0015204237,0.000007983944,0.000019252564],"genre_scores_gemma":[0.99622756,0.003080143,0.00023379778,0.00026073866,0.000022848402,0.000029425251,0.00011409858,0.000008163747,0.000023250961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972039,0.001281227,0.00086976046,0.00029678916,0.000105211955,0.0002431242],"domain_scores_gemma":[0.99491173,0.002801459,0.00066308596,0.0015101758,0.00008164461,0.000031881296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001118073,0.00018925777,0.00070159655,0.000037802252,0.00026976824,0.000038847746,0.0008256914,0.00014585948,0.000043001528],"category_scores_gemma":[0.0025410394,0.00009612219,0.00042854695,0.00008421236,0.0016781058,0.00014763027,0.00026235712,0.00018139437,8.3950346e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003353306,0.0019151809,0.9272188,0.000084941865,0.0007394775,0.0000072163957,0.0009513408,6.443664e-7,0.00027421062,0.0007590852,0.005950247,0.061763544],"study_design_scores_gemma":[0.0019132977,0.00024720348,0.9784853,0.0007351869,0.00015530139,0.0000014150237,0.0014411206,0.0000065960403,0.0011951774,0.013742856,0.0019384451,0.00013813772],"about_ca_topic_score_codex":0.0034085216,"about_ca_topic_score_gemma":0.002819567,"teacher_disagreement_score":0.061625406,"about_ca_system_score_codex":0.000013265835,"about_ca_system_score_gemma":0.00011282591,"threshold_uncertainty_score":0.618305},"labels":[],"label_agreement":null},{"id":"W4233896371","doi":"10.29176/2590843x.287","title":"Actualización en biosimilares: una reflexión sobre la reglamentación en Colombia de los medicamentos biológicos y biosimilares","year":2015,"lang":"es","type":"article","venue":"Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada)","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.015333780045337688,"score_gpt":0.3443819579834302,"score_spread":0.3290481779380925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233896371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63812333,0.12130481,0.006696029,0.12854293,0.0035311508,0.011401749,0.010059943,0.004643094,0.07569695],"genre_scores_gemma":[0.9515758,0.022585034,0.005251162,0.017572314,0.0004238957,0.00049250753,0.00057107274,0.000439417,0.0010887658],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9640878,0.024595158,0.0032619156,0.002540913,0.0009149324,0.0045992965],"domain_scores_gemma":[0.9846974,0.008621713,0.0018300052,0.002262977,0.00055377086,0.0020341075],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts","research_integrity"],"category_scores_codex":[0.008263494,0.0025304484,0.004221771,0.00083691516,0.001307522,0.0017023406,0.003460169,0.008135981,0.0010680167],"category_scores_gemma":[0.0053279265,0.0025153123,0.0016430535,0.0020967806,0.0052170074,0.0006024058,0.0015472479,0.0044790814,0.0005218358],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025207417,0.004351847,0.07701257,0.004054498,0.006640771,0.0069292183,0.006776168,0.000009415864,0.037981413,0.06333758,0.7763649,0.014020863],"study_design_scores_gemma":[0.0077263545,0.00080621464,0.0067342184,0.0028783842,0.0026494968,0.011815934,0.005104267,0.00052573264,0.037826024,0.0042561158,0.91655076,0.003126515],"about_ca_topic_score_codex":0.00023889354,"about_ca_topic_score_gemma":0.00003590021,"teacher_disagreement_score":0.31345248,"about_ca_system_score_codex":0.0034802947,"about_ca_system_score_gemma":0.003546103,"threshold_uncertainty_score":0.99999267},"labels":[],"label_agreement":null},{"id":"W4235055282","doi":"10.1007/s40265-017-0719-z","title":"Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview","year":2017,"lang":"en","type":"erratum","venue":"Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Medicine; Inflammatory bowel disease; Pharmacotherapy; Drug; Antibody; Incidence (geometry); Disease; Biological drugs; Pharmacology; Immunology; Intensive care medicine; Internal medicine","score_opus":0.030616717790005837,"score_gpt":0.34854795751473017,"score_spread":0.3179312397247243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235055282","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17045307,0.6458716,0.00023887132,0.017449375,0.048370346,0.0075351885,0.0010004847,0.00035277952,0.108728305],"genre_scores_gemma":[0.197335,0.36257145,0.0031957496,0.0020567724,0.00046053188,0.00019841015,0.00082967494,0.00018438807,0.43316802],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99733424,0.0005401211,0.0007140808,0.0007276211,0.00015653971,0.0005274202],"domain_scores_gemma":[0.9983599,0.00013853467,0.0005286386,0.0007810573,0.00010796546,0.00008391156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010125382,0.0004953228,0.0009404001,0.0003196056,0.00020314417,0.00008143672,0.0004468917,0.0006033212,0.00006659176],"category_scores_gemma":[0.00013786415,0.0004117704,0.00023658665,0.00013421984,0.00064992154,0.00019441934,0.00062616356,0.0009375423,0.00003450109],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005507643,0.00084251934,0.027631236,0.010162357,0.002179288,0.00034458347,0.00079440244,0.0000013166906,0.0021338172,0.0068364465,0.91983473,0.028688554],"study_design_scores_gemma":[0.0010091814,0.000103121776,0.43491614,0.008172512,0.0008092526,0.000011768841,0.00042713256,0.000022269904,0.00044026406,0.002070177,0.5511725,0.00084568484],"about_ca_topic_score_codex":0.000027928343,"about_ca_topic_score_gemma":0.00004816761,"teacher_disagreement_score":0.4072849,"about_ca_system_score_codex":0.00005128831,"about_ca_system_score_gemma":0.00020836991,"threshold_uncertainty_score":0.9998334},"labels":[],"label_agreement":null},{"id":"W4237374677","doi":"10.1142/s0219030313000074","title":"INSIDE INDUSTRY","year":2013,"lang":"en","type":"article","venue":"Asia-Pacific Biotech News","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Sign (mathematics); Management; Engineering; Business; Biotechnology; Economics; Biology","score_opus":0.022400207014021605,"score_gpt":0.26652671339306877,"score_spread":0.24412650637904718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237374677","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31430393,0.0069573554,0.002519743,0.097704284,0.005554213,0.0023337794,0.0001552655,0.0013446937,0.5691267],"genre_scores_gemma":[0.9630872,0.000125628,0.004657715,0.0017104254,0.0001192823,0.000041251278,0.00003111306,0.00003190273,0.03019551],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983767,0.00020657745,0.00036301804,0.00044922862,0.00004845683,0.00055597763],"domain_scores_gemma":[0.99908656,0.0001106181,0.00009778251,0.0005578373,0.000067409295,0.00007981076],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022593168,0.00025792248,0.0003415463,0.00013102792,0.00015412233,0.00005304607,0.00032443504,0.0019692837,0.007519022],"category_scores_gemma":[0.00012463029,0.00019429956,0.00014276919,0.00035750552,0.00036146468,0.00012746059,0.00012735685,0.001405911,0.0035341613],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021855336,0.000145049,0.0024574392,0.000011195876,0.00013449363,0.000006885215,0.000055238663,1.4792607e-7,0.48530242,0.001280922,0.34248698,0.16809738],"study_design_scores_gemma":[0.00051372696,0.00015830043,0.0055810018,0.000023881492,0.00003809918,0.000080649785,0.0010608406,0.000005571356,0.3843124,0.002288518,0.60558337,0.00035363168],"about_ca_topic_score_codex":0.00030509912,"about_ca_topic_score_gemma":0.000013694369,"teacher_disagreement_score":0.64878327,"about_ca_system_score_codex":0.000035794492,"about_ca_system_score_gemma":0.00004916825,"threshold_uncertainty_score":0.99932635},"labels":[],"label_agreement":null},{"id":"W4237577048","doi":"10.1200/jco.2015.33.15_suppl.e13528","title":"Development of a proposed biosimilar product based on the demonstration of physicochemical, pharmacologic and clinical similarity to filgrastim.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Filgrastim; Biosimilar; Medicine; Clinical endpoint; Pharmacology; Clinical trial; Oncology; Internal medicine; Neutropenia; Chemotherapy","score_opus":0.27554359687456065,"score_gpt":0.49068665412606977,"score_spread":0.21514305725150912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237577048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777862,0.0002492144,0.0013160442,0.018316109,0.0011896383,0.00046075936,0.000012968162,0.000008132555,0.00066095276],"genre_scores_gemma":[0.9547946,0.0000482578,0.042267695,0.0026918515,0.00015901745,0.0000029292162,0.0000021730887,0.000007749079,0.000025745654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9943777,0.0019347649,0.003014516,0.00028154178,0.0001604723,0.00023100604],"domain_scores_gemma":[0.992322,0.004711437,0.0018516582,0.00021922727,0.0007167722,0.00017885676],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011796711,0.00017781484,0.0013693861,0.00009226481,0.000056388806,0.0000050498443,0.00036354805,0.0005338804,0.00009317037],"category_scores_gemma":[0.009263644,0.00009710389,0.00034433164,0.00022221397,0.0010211243,0.00004137197,0.00011206358,0.0010868516,0.0000061575706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027616713,0.020289958,0.051500987,0.0001693119,0.002466101,0.000048416656,0.00048133568,0.00006427292,0.4384033,0.00084587926,0.0658879,0.39222583],"study_design_scores_gemma":[0.014271128,0.03335224,0.085763134,0.00031528735,0.0012661413,0.00006158311,0.00048414434,0.00062149944,0.76556915,0.0010934978,0.09670706,0.0004951331],"about_ca_topic_score_codex":0.0000018781885,"about_ca_topic_score_gemma":0.000004906127,"teacher_disagreement_score":0.3917307,"about_ca_system_score_codex":0.000044890796,"about_ca_system_score_gemma":0.0017521798,"threshold_uncertainty_score":0.99908173},"labels":[],"label_agreement":null},{"id":"W4238025275","doi":"10.12688/gatesopenres.12855.2","title":"Optimization of extraction of genomic DNA from archived dried blood spot (DBS): potential application in epidemiological research &amp; bio banking","year":2019,"lang":"en","type":"preprint","venue":"Gates Open Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Tata Memorial Centre; Bill and Melinda Gates Foundation","keywords":"genomic DNA; Genotyping; Biology; Computational biology; DNA; Genetics; Genotype; Gene","score_opus":0.2037761519590353,"score_gpt":0.4620180368664788,"score_spread":0.2582418849074435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238025275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731428,0.0021155977,0.015690414,0.0012821278,0.000340638,0.0040287576,0.00038474178,0.000021601283,0.0029933248],"genre_scores_gemma":[0.97139883,0.0016595555,0.024376052,0.000018995186,0.000077933706,0.00021646956,0.0013823053,0.0000341488,0.00083571393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9888596,0.007511654,0.0012646512,0.0012276712,0.0003037003,0.0008327239],"domain_scores_gemma":[0.9933815,0.0041627144,0.00047679446,0.001191963,0.00072683225,0.000060199047],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.014973074,0.0002831428,0.0011424447,0.000838104,0.00018122728,0.00007633556,0.0020187397,0.0014649502,0.0017377037],"category_scores_gemma":[0.0018870124,0.00024267989,0.00020107455,0.00044951146,0.0011971003,0.000088531895,0.004087403,0.0034870878,0.00011188272],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017880332,0.00077252724,0.011262057,0.00020030454,0.00031884963,0.000003998316,0.00024869794,0.007058115,0.9727738,0.000827771,0.00044137103,0.004304513],"study_design_scores_gemma":[0.0064126034,0.0012814272,0.26829693,0.0017303515,0.00033371826,0.00002605674,0.00097002764,0.018989136,0.6036211,0.09288064,0.004204055,0.0012539452],"about_ca_topic_score_codex":0.0067240037,"about_ca_topic_score_gemma":0.0003058922,"teacher_disagreement_score":0.36915267,"about_ca_system_score_codex":0.00013703146,"about_ca_system_score_gemma":0.00041325868,"threshold_uncertainty_score":0.9998903},"labels":[],"label_agreement":null},{"id":"W4239339813","doi":"10.1093/jcag/gwy009.173","title":"A173 HOME BASED FECAL CALPROTECTIN TESTING: A CANADIAN USER PERFORMANCE EVALUATION STUDY OF IBDOC®","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Calprotectin; Feces; Computer science; Statistics; Medicine; Biology; Mathematics; Internal medicine; Microbiology","score_opus":0.029299171833194238,"score_gpt":0.27075068666932384,"score_spread":0.2414515148361296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239339813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950611,0.000019131588,0.000013561219,0.0033311776,0.0010430468,0.0002769331,0.000034598314,0.0000020744355,0.00021839884],"genre_scores_gemma":[0.9986548,0.0000011508611,0.00028769157,0.0007736749,0.000077641984,0.000003320535,0.0000013786582,0.000008291035,0.00019207379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973884,0.0012908697,0.0006322062,0.00012438891,0.0001608533,0.0004032381],"domain_scores_gemma":[0.9970406,0.00015755616,0.0011017594,0.00019662999,0.0013827822,0.00012062884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032965818,0.000117840376,0.00039255698,0.00027314032,0.00020325198,0.000008865478,0.00036224938,0.0002534904,0.0004101824],"category_scores_gemma":[0.0014050112,0.00008717264,0.00012014835,0.00022513769,0.00016171565,0.00006279033,0.000023655737,0.00038446352,0.0000041320995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002663643,0.00012236251,0.992872,0.000006314653,0.00030204965,0.0000016787686,0.0001846885,0.0000559199,0.0026970073,0.0000053601793,0.0024110181,0.0010752443],"study_design_scores_gemma":[0.0028944523,0.004961128,0.9883154,0.000043803724,0.00028340128,0.000043077212,0.00016204483,0.00037366277,0.0016143929,0.000029236997,0.0012132426,0.00006616732],"about_ca_topic_score_codex":0.15109439,"about_ca_topic_score_gemma":0.96141267,"teacher_disagreement_score":0.8103183,"about_ca_system_score_codex":0.0013603395,"about_ca_system_score_gemma":0.0012095921,"threshold_uncertainty_score":0.8545585},"labels":[],"label_agreement":null},{"id":"W4240219195","doi":"10.1515/iupac.84.1054","title":"Popliteal Lymph Node Assay (PLNA)","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Immunotoxicology; Glossary; Disease; Immunology; Medicine; Immune system; Pathology; Philosophy; Linguistics","score_opus":0.018665673507729273,"score_gpt":0.4003128371443619,"score_spread":0.3816471636366326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240219195","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027108354,0.0040639993,0.0005080455,0.0030157373,0.0026127538,0.00022716665,0.9891986,0.00010063724,0.00024593037],"genre_scores_gemma":[0.00001684673,0.0013229697,0.000274974,0.001799581,0.0005905979,0.000012993226,0.98975813,0.000046815185,0.00617706],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965459,0.0006910499,0.0007166926,0.0008784349,0.00026176585,0.00090612867],"domain_scores_gemma":[0.9974296,0.00047635857,0.00033951428,0.0011762136,0.0004636762,0.00011460365],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001682124,0.00068993086,0.0011822263,0.0002510148,0.00021381117,0.000051569004,0.0008042272,0.0020012625,0.018905126],"category_scores_gemma":[0.0013402315,0.00045310223,0.00043059894,0.00021476689,0.00064112537,0.00006504141,0.0003838779,0.0009643327,0.000046978366],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033890948,0.00030559977,0.000045056062,0.00009031695,0.0004959135,0.00004617005,0.0000029926478,4.1599368e-8,0.00075984286,0.000042910273,0.98410434,0.013767914],"study_design_scores_gemma":[0.001758604,0.00017289967,0.00014618193,0.00031666976,0.00038157534,0.000079979895,0.000011333941,4.6099066e-7,0.00057563453,0.00025130538,0.9956618,0.0006435419],"about_ca_topic_score_codex":0.000109140055,"about_ca_topic_score_gemma":0.00010496496,"teacher_disagreement_score":0.018858148,"about_ca_system_score_codex":0.00036112053,"about_ca_system_score_gemma":0.0006592706,"threshold_uncertainty_score":0.9997921},"labels":[],"label_agreement":null},{"id":"W4241113968","doi":"10.1310/hpj4401-15","title":"Letter to the Editor","year":2009,"lang":"en","type":"letter","venue":"Hospital Pharmacy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Family medicine","score_opus":0.01934144669111644,"score_gpt":0.3031762626115907,"score_spread":0.28383481592047427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241113968","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003338581,0.0016148837,0.00007446821,0.96818817,0.026098005,0.00049138657,0.00013100046,0.00008936272,0.003279325],"genre_scores_gemma":[0.00031426994,0.00005098223,0.00019528145,0.89817405,0.07448047,0.0000346826,0.00012254508,0.000036135276,0.026591614],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808085,0.0002960616,0.0003117115,0.0005310758,0.00009164324,0.0006886816],"domain_scores_gemma":[0.99906665,0.00020587278,0.0001027621,0.0005289328,0.00006114602,0.000034653087],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00026406554,0.0004060856,0.00040747586,0.00008050409,0.00017688425,0.000060008213,0.00084575266,0.0007338639,0.0023266748],"category_scores_gemma":[0.00008072017,0.00024082787,0.00031121218,0.00016659767,0.00017466623,0.00004983542,0.00016932085,0.0032125674,0.0039712237],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017795943,0.000042826858,0.000008426692,0.000011786246,0.00015067097,0.000061587765,0.00003927165,7.7038344e-8,0.0007114384,0.0000058633873,0.98695654,0.011993735],"study_design_scores_gemma":[0.0003689966,0.00017162718,0.00005386772,0.000025139694,0.0001470219,0.000012173157,0.0000023094515,4.939523e-7,0.004359876,0.000081179394,0.9943791,0.00039818606],"about_ca_topic_score_codex":0.000024107872,"about_ca_topic_score_gemma":7.416153e-7,"teacher_disagreement_score":0.070014164,"about_ca_system_score_codex":0.000040608473,"about_ca_system_score_gemma":0.00003701715,"threshold_uncertainty_score":0.99908704},"labels":[],"label_agreement":null},{"id":"W4241619766","doi":"10.1200/jco.2004.22.90140.2512","title":"Re-importation of pharmaceuticals may be unsafe: Lessons learned from the RADAR assessment of erythropoietin (EPO)-associated pure red cell aplasia (PRCA)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Erythropoietin; Pure red cell aplasia; Adverse effect; Incidence (geometry); Anemia; Darbepoetin alfa; Epoetin alfa; Internal medicine; Pharmacovigilance; Pediatrics","score_opus":0.2513401943261482,"score_gpt":0.5258195532516994,"score_spread":0.2744793589255512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241619766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.729158,0.002392982,0.0014816643,0.25791755,0.0034740437,0.00054211594,0.00022110975,0.000021255017,0.004791259],"genre_scores_gemma":[0.98523444,0.0022837291,0.009680208,0.0023572787,0.00016613351,0.0000027302997,0.000026661353,0.000017428603,0.00023140069],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99248135,0.0031194375,0.003548667,0.00029067404,0.00021583299,0.00034402654],"domain_scores_gemma":[0.98701215,0.007681478,0.004332166,0.00030667667,0.000557713,0.00010981981],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0079712225,0.00021584528,0.0018261708,0.000078219186,0.00009769694,0.000007653197,0.0005363411,0.0012520313,0.0009968245],"category_scores_gemma":[0.004525372,0.00013304553,0.00077373255,0.00026358585,0.001073419,0.00007487697,0.0001090776,0.0020160084,0.000005452925],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013381918,0.024779161,0.1332226,0.0001507334,0.009422471,0.00039724036,0.0011676515,0.00024979553,0.5677622,0.00984125,0.074723564,0.1649014],"study_design_scores_gemma":[0.03992554,0.01914144,0.44268656,0.0004204936,0.004624504,0.00007319672,0.0030446977,0.000050415718,0.15921776,0.023387995,0.30678725,0.000640121],"about_ca_topic_score_codex":0.00006751109,"about_ca_topic_score_gemma":0.0001119877,"teacher_disagreement_score":0.40854445,"about_ca_system_score_codex":0.00013506856,"about_ca_system_score_gemma":0.0014303576,"threshold_uncertainty_score":0.9999164},"labels":[],"label_agreement":null},{"id":"W4241819020","doi":"10.1186/s12913-019-4829-z","title":"Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis","year":2019,"lang":"en","type":"erratum","venue":"BMC Health Services Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Saskatchewan","funders":"","keywords":"Biosimilar; Medicine; Mistake; Insulin glargine; Infliximab; Internet portal; Filgrastim; Insulin; Internal medicine; Intensive care medicine; Hypoglycemia; World Wide Web; The Internet; Law","score_opus":0.043445751945585184,"score_gpt":0.3464683807633722,"score_spread":0.303022628817787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241819020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6023334,0.115984075,0.0013081759,0.06921736,0.14564638,0.029565277,0.033927877,0.00017230063,0.0018451322],"genre_scores_gemma":[0.86139905,0.017452471,0.0022200206,0.03215811,0.0013416639,0.00048002848,0.0032479763,0.00025772114,0.08144296],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9938842,0.0030614587,0.00083045673,0.0008412171,0.00045023844,0.00093239883],"domain_scores_gemma":[0.9959735,0.0019712858,0.000413655,0.000978835,0.00054819154,0.00011452192],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019948175,0.00034120865,0.001110726,0.00047822195,0.000398686,0.00007321655,0.00094367866,0.0006607657,0.00030611583],"category_scores_gemma":[0.0005133758,0.00020631973,0.0001945662,0.0030307937,0.0002986503,0.00007093461,0.0008901333,0.00331157,0.000009687655],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011100986,0.00017877898,0.33489615,0.0006688198,0.0013000587,0.00000552684,0.0012698665,0.00021619503,0.0004024327,0.000010372172,0.6539122,0.0060295556],"study_design_scores_gemma":[0.00060420315,0.00017663879,0.84442973,0.000660649,0.00017036419,0.0000030241065,0.00074682804,0.003980792,0.00012411333,0.000018565937,0.14889237,0.00019270182],"about_ca_topic_score_codex":0.92820174,"about_ca_topic_score_gemma":0.98300964,"teacher_disagreement_score":0.50953364,"about_ca_system_score_codex":0.0012313147,"about_ca_system_score_gemma":0.0046981936,"threshold_uncertainty_score":0.99898785},"labels":[],"label_agreement":null},{"id":"W4243495076","doi":"10.1007/bf03294092","title":"Ranibizumab launched for wet AMD in Canada","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Launched; Medicine; Ranibizumab; Pharmacy; Optometry; Family medicine; Internal medicine; Engineering","score_opus":0.023996872037995158,"score_gpt":0.29786394733083654,"score_spread":0.2738670752928414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243495076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563684,0.0047149286,0.0066294014,0.011806082,0.005128769,0.0013504412,0.00034455396,0.000113414775,0.013544015],"genre_scores_gemma":[0.9939723,0.00001882544,0.001285893,0.00248157,0.00005182563,0.000012258147,0.000022388134,0.000013275153,0.002141666],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988143,0.00007758897,0.00032927244,0.00023877466,0.00003412545,0.00050597277],"domain_scores_gemma":[0.9992922,0.00040868038,0.000057196463,0.00015195717,0.000048231617,0.000041720203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006871261,0.00013844698,0.00025956778,0.00007054822,0.000059491133,0.0000059902977,0.00018916784,0.00015710013,0.0007830871],"category_scores_gemma":[0.000119424025,0.00011671745,0.00006804072,0.00016467605,0.00006699482,0.000033615648,0.00003601076,0.00024874142,0.00003184923],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022566393,0.0002966361,0.026746215,0.00009098788,0.0003068502,0.00012823123,0.00019268296,0.0000035193368,0.5886529,0.0018712331,0.23068418,0.14876993],"study_design_scores_gemma":[0.0046298183,0.00012917996,0.038184788,0.000023326238,0.0000505014,0.00003743777,0.00033312995,0.000037615366,0.3192799,0.00045002773,0.6365044,0.00033987442],"about_ca_topic_score_codex":0.23057891,"about_ca_topic_score_gemma":0.63213414,"teacher_disagreement_score":0.40582022,"about_ca_system_score_codex":0.00021381491,"about_ca_system_score_gemma":0.0003296029,"threshold_uncertainty_score":0.85742545},"labels":[],"label_agreement":null},{"id":"W4244693063","doi":"10.3410/f.718339908.793555480","title":"Faculty Opinions recommendation of New insights into the DT40 B cell receptor cluster using a proteomic proximity labeling assay.","year":2019,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Key Research and Development Program of China; Biotechnology and Biological Sciences Research Council; Ministry of Science and Technology of the People's Republic of China; Medical Research Council; Directorate for Biological Sciences; Chinese Academy of Sciences; Semmelweis Egyetem; National Natural Science Foundation of China; Wellcome Trust; DePaul University","keywords":"Cluster (spacecraft); Computational biology; Computer science; Biology","score_opus":0.05047223613688111,"score_gpt":0.36360713100016434,"score_spread":0.3131348948632832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244693063","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000389064,0.0034811073,0.00024057916,0.16256411,0.0017957728,0.0024376858,0.82942295,0.000023427856,0.000030474785],"genre_scores_gemma":[0.0000065454133,0.00044705736,0.005151259,0.0061828005,0.00025017522,0.00010275024,0.9843463,0.000028959972,0.0034841623],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994585,0.0019150963,0.0017661604,0.0008032591,0.00048728572,0.0004431959],"domain_scores_gemma":[0.9927737,0.00035464973,0.0018934325,0.0016534147,0.0031825951,0.00014221529],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0025651862,0.00061652035,0.0011752603,0.00027104493,0.00039991445,0.00010992538,0.0019529667,0.001604052,0.00081937056],"category_scores_gemma":[0.0056565097,0.00031726877,0.00073063624,0.0015979509,0.0005734384,0.00029068041,0.00085632165,0.002063319,0.00012082328],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004109364,0.00031260983,0.0000036184092,0.0038653782,0.00023840599,4.916879e-8,0.00026616786,1.6767244e-7,0.00042995,0.00006162472,0.99302375,0.0017572029],"study_design_scores_gemma":[0.0009388691,0.00015137526,0.00008350474,0.00638974,0.00038470374,0.000016147915,0.000041523494,0.00001834015,0.0010513434,0.0000511216,0.9905095,0.00036382928],"about_ca_topic_score_codex":0.00015170201,"about_ca_topic_score_gemma":0.000008607962,"teacher_disagreement_score":0.15638131,"about_ca_system_score_codex":0.00015550456,"about_ca_system_score_gemma":0.00086512184,"threshold_uncertainty_score":0.99992794},"labels":[],"label_agreement":null},{"id":"W4245526990","doi":"10.14205/2309-4435","title":"Journal of Applied Biopharmaceutics and Pharmacokinetics","year":2013,"lang":"en","type":"paratext","venue":"Journal of Applied Biopharmaceutics and Pharmacokinetics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Biopharmaceutics; Pharmacokinetics; Pharmacology; Medicine; Chemistry; Pharmacognosy","score_opus":0.033479479272058806,"score_gpt":0.33140994513275224,"score_spread":0.29793046586069344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245526990","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25187454,0.5639476,0.003321353,0.00543962,0.07031915,0.006418499,0.0035735487,0.00014555865,0.09496014],"genre_scores_gemma":[0.44021195,0.5201122,0.014572806,0.0081078755,0.0059089065,0.000025600479,0.00012348901,0.00047064174,0.01046651],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937193,0.00030988088,0.003540442,0.000692332,0.0005573871,0.0011806875],"domain_scores_gemma":[0.992417,0.000733221,0.0044448175,0.000404837,0.0012980531,0.00070209714],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0020473567,0.0014024836,0.0027596185,0.0010965294,0.00029110556,0.00025506338,0.0012387718,0.0015957982,0.0041304375],"category_scores_gemma":[0.00005400458,0.0011013297,0.00058104546,0.0006482112,0.0014712494,0.00014790347,0.000629521,0.004969948,0.00020285675],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029053108,0.0005493763,0.000012164697,0.0009796809,0.0032815298,0.00007148567,0.00047800888,0.00010062365,0.6640392,0.00022371883,0.2575356,0.06982329],"study_design_scores_gemma":[0.0070687714,0.00049640954,0.000019896694,0.00018803087,0.0037599783,0.00080824597,0.00024657833,0.00016573184,0.35599613,0.00022070028,0.6302049,0.0008246386],"about_ca_topic_score_codex":0.0000020129967,"about_ca_topic_score_gemma":1.67676e-7,"teacher_disagreement_score":0.3726693,"about_ca_system_score_codex":0.00012414751,"about_ca_system_score_gemma":0.00041759567,"threshold_uncertainty_score":0.99987257},"labels":[],"label_agreement":null},{"id":"W4247681342","doi":"10.17504/protocols.io.rv3d68n","title":"Global Standards for Biosimilars v1","year":2018,"lang":"en","type":"preprint","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Biopharmaceutical; Biological drugs; Business; Risk analysis (engineering); Pharmaceutical industry; Pharmacology; Biotechnology; Medicine","score_opus":0.03654376306522028,"score_gpt":0.36456064754347617,"score_spread":0.3280168844782559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247681342","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014358351,0.026853891,0.5353005,0.031860035,0.044066068,0.006843282,0.07070624,0.001719299,0.26829234],"genre_scores_gemma":[0.39132258,0.0023649773,0.46045822,0.043718528,0.0039941533,0.0010784925,0.0038725191,0.00038299675,0.09280751],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797946,0.00016950698,0.00044490554,0.00076557253,0.000070495524,0.0005700686],"domain_scores_gemma":[0.99851406,0.00014459476,0.00015715114,0.0006316127,0.000502753,0.000049856724],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009946554,0.00040104438,0.0006552574,0.00006144183,0.00015377956,0.00005246071,0.0005505576,0.0017171844,0.004077175],"category_scores_gemma":[0.00036390725,0.0002976622,0.00047382084,0.000108504726,0.0005560098,0.000021055555,0.0007854569,0.00036798202,0.00007752294],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038730487,0.00012175284,0.0006863519,0.00017264026,0.0007574205,0.0000016884012,0.000014157173,0.0000010063283,0.0011847639,0.004417245,0.97871864,0.013537012],"study_design_scores_gemma":[0.0010257493,0.00041880872,0.0007774569,0.00010747484,0.00035174706,0.000015525917,0.000026874188,0.00003327978,0.023114877,0.034368467,0.93918616,0.00057356275],"about_ca_topic_score_codex":0.000026170366,"about_ca_topic_score_gemma":0.000055120512,"teacher_disagreement_score":0.37696424,"about_ca_system_score_codex":0.00019990887,"about_ca_system_score_gemma":0.00042879413,"threshold_uncertainty_score":0.99994755},"labels":[],"label_agreement":null},{"id":"W4251234362","doi":"10.1093/ecco-jcc/jju027.432","title":"P314. Biosimilar infliximab in inflammatory bowel diseases: first interim Results from a prospective nationwide observational cohort","year":2015,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Infliximab; Medicine; Observational study; Inflammatory Bowel Diseases; Interim; Inflammatory bowel disease; Internal medicine; Cohort; Interim analysis; Prospective cohort study; Clinical trial; Tumor necrosis factor alpha; Disease; Political science","score_opus":0.031030652274971114,"score_gpt":0.2880386089473571,"score_spread":0.257007956672386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251234362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99212974,0.0027240203,0.00009318245,0.003129554,0.0005433076,0.00020646505,0.00036984234,0.000011029165,0.00079286617],"genre_scores_gemma":[0.99794847,0.0002411313,0.0007935915,0.0005609659,0.00013544635,0.000009092953,0.000027234903,0.000009131859,0.00027491624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985849,0.0001762133,0.00073075417,0.00019754568,0.0001045328,0.00020603987],"domain_scores_gemma":[0.99871105,0.00032223202,0.00035181726,0.00012435166,0.00039126643,0.00009927192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063066924,0.00014754172,0.00035737964,0.00013968424,0.0000726819,0.000055857017,0.00016196715,0.0002001367,0.00008982786],"category_scores_gemma":[0.0009517398,0.00011694549,0.00009465744,0.00012706254,0.00023559955,0.00024028763,0.00008085435,0.0003265345,0.000006210106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011938932,0.00044055775,0.96080846,0.000027910966,0.00050003023,0.00018607052,0.0013237445,0.000012166026,0.00038806265,0.0021365134,0.020114465,0.0021230923],"study_design_scores_gemma":[0.003422457,0.00025090086,0.9617882,0.00013651433,0.000070307426,0.00005906817,0.00030203463,0.00003140665,0.00080799084,0.0050827605,0.027909651,0.00013870976],"about_ca_topic_score_codex":0.00011986644,"about_ca_topic_score_gemma":0.00016655138,"teacher_disagreement_score":0.008516475,"about_ca_system_score_codex":0.00011395395,"about_ca_system_score_gemma":0.00023064445,"threshold_uncertainty_score":0.47688988},"labels":[],"label_agreement":null},{"id":"W4252497502","doi":"10.1093/ecco-jcc/jjw019.551","title":"P432. Patient perspectives on biosimilars: a European Federation of Crohn’s and Colitis Associations survey","year":2016,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Foothills Medical Centre; St. Paul's Hospital; McMaster University Medical Centre; University of British Columbia; University of Alberta; Canadian Society of Intestinal Research","funders":"","keywords":"Biosimilar; Medicine; Colitis; Internal medicine; Gastroenterology","score_opus":0.02536138059954286,"score_gpt":0.2803906156591049,"score_spread":0.25502923505956204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252497502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915833,0.0023590368,0.0002754357,0.0024988058,0.00027534243,0.00013329709,0.00048149884,0.0000073066376,0.0023860026],"genre_scores_gemma":[0.9974472,0.0014838331,0.00025169956,0.0003358203,0.00005242037,0.0000012057603,0.000003164041,0.00000995815,0.0004146982],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982168,0.0008456349,0.00049661915,0.0001662501,0.00007356807,0.00020113973],"domain_scores_gemma":[0.99846905,0.0005192266,0.00043365144,0.000096991076,0.0004214242,0.000059644313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008964784,0.00013023855,0.00035921307,0.00010925676,0.0001695622,0.000046825087,0.0000758901,0.00013243302,0.00016363188],"category_scores_gemma":[0.0006099285,0.000083020386,0.00009649275,0.00008158666,0.00027840558,0.00010651349,0.00004446108,0.00016440179,0.0000033121771],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02894576,0.00407232,0.10465148,0.00021348303,0.0049510817,0.00050027005,0.015724242,0.0000017507166,0.05154246,0.051492754,0.09804495,0.63985944],"study_design_scores_gemma":[0.0009725571,0.001046511,0.9826965,0.00013123473,0.00005992288,0.000084797975,0.0005838227,5.0438797e-7,0.0064735366,0.00047880568,0.0073565957,0.00011524426],"about_ca_topic_score_codex":0.000046422192,"about_ca_topic_score_gemma":0.00007963597,"teacher_disagreement_score":0.87804496,"about_ca_system_score_codex":0.00005305357,"about_ca_system_score_gemma":0.000053759246,"threshold_uncertainty_score":0.3385473},"labels":[],"label_agreement":null},{"id":"W4254719029","doi":"10.3410/f.725287422.793521144","title":"Faculty Opinions recommendation of The therapeutic monoclonal antibody market.","year":2016,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Monoclonal antibody; Antibody; Business; Medicine; Immunology","score_opus":0.036392043351768016,"score_gpt":0.3783521049302346,"score_spread":0.3419600615784666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254719029","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.5458205e-7,0.002787276,0.000046439287,0.27392727,0.0018786521,0.00085165654,0.7203278,0.000020044892,0.00016073335],"genre_scores_gemma":[0.0000068952904,0.0007182542,0.00024890288,0.008781127,0.00018690943,0.000091025206,0.9824914,0.00002231683,0.007453196],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99513024,0.0016772718,0.0015462426,0.0006801926,0.00050559593,0.00046044315],"domain_scores_gemma":[0.99299234,0.00041888945,0.0015499176,0.0017800359,0.003149548,0.00010928694],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020918169,0.00056291337,0.0010358806,0.00020775762,0.0003558317,0.00006165898,0.0023928739,0.0013635883,0.0035934465],"category_scores_gemma":[0.0047553456,0.00025058642,0.0010534665,0.0013790299,0.0010850845,0.00016313946,0.0007698867,0.0014031499,0.00006879114],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030866842,0.00031716644,0.000014763848,0.0018796383,0.00040551863,8.019207e-8,0.000020003761,3.231708e-9,0.00007787492,0.00041992564,0.9909054,0.0059287683],"study_design_scores_gemma":[0.00069984765,0.00010709254,0.0038513076,0.006925261,0.00036256417,0.000048983835,0.000010328914,9.537407e-7,0.00019485866,0.00010084462,0.98739296,0.00030500776],"about_ca_topic_score_codex":0.000024993105,"about_ca_topic_score_gemma":0.000003204829,"teacher_disagreement_score":0.26514614,"about_ca_system_score_codex":0.000085801046,"about_ca_system_score_gemma":0.00045197195,"threshold_uncertainty_score":0.99999464},"labels":[],"label_agreement":null},{"id":"W4256503590","doi":"10.1128/jb.00323-13","title":"Training the Biofilm Generation—a Tribute to J. W. Costerton","year":2013,"lang":"en","type":"article","venue":"Journal of Bacteriology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; St. Francis Xavier University","funders":"","keywords":"Tribute; Biology; Biofilm; Microbiology; Computational biology; Bacteria; Art history; Genetics","score_opus":0.06244578370784941,"score_gpt":0.30321762033120636,"score_spread":0.24077183662335694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256503590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95149374,0.00066573423,0.002356549,0.042495176,0.0023208025,0.0001945466,0.000010942228,0.000009161241,0.0004533638],"genre_scores_gemma":[0.9882029,0.00005431198,0.0029544232,0.00654444,0.00038744905,0.0000075262224,0.000005574203,0.000008964054,0.001834355],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987029,0.0004233162,0.0004769469,0.00011191333,0.00002495338,0.00026000562],"domain_scores_gemma":[0.9991704,0.00023047162,0.00022331993,0.00014796281,0.00018073151,0.00004710142],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006442365,0.00011075292,0.0003331819,0.000087432534,0.000106312145,0.000027717255,0.00027460323,0.00020804537,0.0019419168],"category_scores_gemma":[0.00025509132,0.000057912825,0.00013187263,0.00010680552,0.00014494882,0.00007900318,0.00005393623,0.00034323832,0.00021212858],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046704008,0.000023102277,0.000266488,0.0000013231922,0.0001203002,0.0000031256398,0.00022908623,0.0000017562994,0.9114279,0.00010130278,0.039146382,0.04863249],"study_design_scores_gemma":[0.0010692636,0.0017390548,0.03321026,0.000025329613,0.000106502506,0.0014892758,0.00045817523,0.000025810452,0.109119855,0.00049844,0.8520338,0.00022421339],"about_ca_topic_score_codex":0.000011746908,"about_ca_topic_score_gemma":0.0000055062465,"teacher_disagreement_score":0.81288743,"about_ca_system_score_codex":0.000023526389,"about_ca_system_score_gemma":0.000052465843,"threshold_uncertainty_score":0.99897045},"labels":[],"label_agreement":null},{"id":"W4280494337","doi":"10.4155/bio-2022-0081","title":"2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 &amp; CAR-T Immunogenicity; PCR &amp; Vaccine Assay Performance; ADA Assay Comparability &amp; Cut Point Appropriateness ( <u>Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization)","year":2022,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Health Canada; U.S. Food and Drug Administration; Ministry of Health, Labour and Welfare","keywords":"Bioanalysis; Immunogenicity; Context (archaeology); Biotechnology; Computational biology; Biology; Nanotechnology; Immunology; Immune system","score_opus":0.04166831171770948,"score_gpt":0.29180055319748255,"score_spread":0.2501322414797731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280494337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9490703,0.036175847,0.0047608917,0.004461151,0.0009711099,0.0014701112,0.0027542203,0.00011473677,0.00022168172],"genre_scores_gemma":[0.960722,0.029202512,0.004230927,0.00072212913,0.0000864337,0.0001761808,0.0033246789,0.00011460294,0.0014204842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9890672,0.00470434,0.0029691348,0.0016172099,0.0005910542,0.0010510581],"domain_scores_gemma":[0.9941005,0.001070152,0.0015964063,0.0021408068,0.0009584895,0.00013362683],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006447734,0.0011596739,0.00271784,0.0012777465,0.0008402054,0.00010401943,0.0011646578,0.0007169828,0.006482677],"category_scores_gemma":[0.00029764208,0.00096965843,0.0010283298,0.0035828433,0.00039249673,0.0003182652,0.0005779901,0.0015724738,0.000019683928],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007950113,0.0075098104,0.061936546,0.00013136615,0.010088178,0.0000026069868,0.0016773185,0.0021148443,0.881812,0.00013262739,0.00083917973,0.025805444],"study_design_scores_gemma":[0.016779654,0.0024710537,0.042654734,0.000331153,0.003572979,0.000045315086,0.0026134455,0.0030239248,0.6683033,0.00025624895,0.25654125,0.00340691],"about_ca_topic_score_codex":0.004123887,"about_ca_topic_score_gemma":0.0015524195,"teacher_disagreement_score":0.25570208,"about_ca_system_score_codex":0.0007767521,"about_ca_system_score_gemma":0.00030774233,"threshold_uncertainty_score":0.9992754},"labels":[],"label_agreement":null},{"id":"W4280523378","doi":"10.1186/s12916-022-02377-2","title":"Data-sharing and re-analysis for main studies assessed by the European Medicines Agency—a cross-sectional study on European Public Assessment Reports","year":2022,"lang":"en","type":"article","venue":"BMC Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Agence Nationale de la Recherche; Yale University","keywords":"Medicine; Protocol (science); Family medicine; Receipt; Clinical trial; Interquartile range; European commission; Trial registration; Agency (philosophy); Transparency (behavior); Cross-sectional study; Checklist; Alternative medicine; European union; Accounting; Surgery; Pathology","score_opus":0.30111279732662044,"score_gpt":0.4564789689756282,"score_spread":0.15536617164900773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280523378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9042755,0.018223694,0.017968446,0.026184138,0.006019615,0.00369177,0.0010694683,0.00031687788,0.022250488],"genre_scores_gemma":[0.99441624,0.000057932062,0.0002890275,0.0013085358,0.00024826525,0.000062384424,0.0006459938,0.000026794038,0.0029448532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994859,0.0027139953,0.0008659105,0.0009953075,0.00023410284,0.0003317053],"domain_scores_gemma":[0.9969676,0.0012899691,0.00037910804,0.0011889576,0.00012225306,0.000052095096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021270208,0.00023895342,0.0005637871,0.00019038269,0.0010494434,0.00004378174,0.0006959828,0.00003845045,0.00063243497],"category_scores_gemma":[0.0021682216,0.00013384153,0.00009831727,0.000510911,0.00049823016,0.00006061514,0.0011104452,0.00046100933,0.000002352169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010030736,0.00051377754,0.91525596,0.000038937895,0.0044371323,0.00008842228,0.00048764254,0.000011647432,0.004824797,0.00021181777,0.07255355,0.0014760243],"study_design_scores_gemma":[0.0016694003,0.0012126925,0.9409636,0.000012895408,0.001500515,0.000088523826,0.0048742653,0.000096442556,0.000019504094,0.00019215938,0.04918321,0.00018675218],"about_ca_topic_score_codex":0.000032555523,"about_ca_topic_score_gemma":0.00008641852,"teacher_disagreement_score":0.09014071,"about_ca_system_score_codex":0.00006519607,"about_ca_system_score_gemma":0.00004287496,"threshold_uncertainty_score":0.8071576},"labels":[],"label_agreement":null},{"id":"W4280547561","doi":"10.4155/bio-2022-0078","title":"2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid &amp; Rare Matrices; Regulatory Inputs ( <u>Part 1A</u> – Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC &amp; <u>Part 1B</u> - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene &amp; Cell Therapy and Vaccine)","year":2022,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; Seagen (Canada)","funders":"World Health Organization","keywords":"Bioanalysis; White paper; Excellence; Computer science; Computational biology; Political science; Nanotechnology; Biology","score_opus":0.04661098129259345,"score_gpt":0.2895291604763159,"score_spread":0.24291817918372244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280547561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69734526,0.25802788,0.015325898,0.012706508,0.002149518,0.00606329,0.005610672,0.00046908142,0.0023018937],"genre_scores_gemma":[0.7812488,0.0660162,0.11614869,0.0038202498,0.00068750686,0.00071890955,0.020669036,0.00069501274,0.009995597],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9825138,0.0073499214,0.004280774,0.0030362087,0.0010537414,0.0017655443],"domain_scores_gemma":[0.9913266,0.0006026433,0.0031182403,0.0036921958,0.00087038585,0.00038996563],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0062615997,0.0018819948,0.0039909636,0.0045555355,0.0010781718,0.00013932992,0.0016950623,0.0011766218,0.00412039],"category_scores_gemma":[0.00028988218,0.0017496275,0.0018787199,0.0076551,0.0007474558,0.00019999025,0.0007125966,0.0016824616,0.000046538684],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041453126,0.003786524,0.0018390954,0.00022230844,0.011505644,0.00006240229,0.00044390414,0.001105203,0.96921116,0.00018398733,0.0037269967,0.003767477],"study_design_scores_gemma":[0.008578439,0.0026211964,0.0035095264,0.00044147257,0.0076826024,0.000083468265,0.0011643714,0.001086878,0.60978967,0.00022147204,0.36171117,0.0031097122],"about_ca_topic_score_codex":0.0014360409,"about_ca_topic_score_gemma":0.001872672,"teacher_disagreement_score":0.35942146,"about_ca_system_score_codex":0.0010558206,"about_ca_system_score_gemma":0.00037291046,"threshold_uncertainty_score":0.99939245},"labels":[],"label_agreement":null},{"id":"W4281697694","doi":"10.1021/acs.molpharmaceut.2c00376","title":"Introducing the Molecular Pharmaceutics Special Issue on “Tiny Things, Big Impact: Nanomedicine in Canada”","year":2022,"lang":"en","type":"article","venue":"Molecular Pharmaceutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pharmaceutics; Citation; Library science; World Wide Web; Computer science; Medicine; Pharmacology","score_opus":0.02359115191943469,"score_gpt":0.3211142780800686,"score_spread":0.2975231261606339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281697694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85217404,0.027885895,0.0012773593,0.07635091,0.019954672,0.0028179549,0.00055303116,0.00018097786,0.018805161],"genre_scores_gemma":[0.961526,0.000233696,0.0002171099,0.03628163,0.00085246033,0.000042788728,0.00006365109,0.00006375611,0.0007189408],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965249,0.0011348777,0.0005602016,0.0005746146,0.00030550532,0.0008999202],"domain_scores_gemma":[0.9988293,0.00025294692,0.0001797348,0.00056326756,0.00006582678,0.00010894118],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013051498,0.00040516912,0.00047932807,0.00019074077,0.00040450774,0.00002618283,0.0007695226,0.00012924003,0.0041191992],"category_scores_gemma":[0.00018004223,0.0003054055,0.00018473556,0.000772456,0.00021694039,0.000031719694,0.00047589053,0.002097514,0.000035833375],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006420216,0.0004177239,0.0012883985,0.000046041034,0.0006865406,0.001233275,0.0007586769,0.005347113,0.8374622,0.0009152974,0.034680683,0.11652205],"study_design_scores_gemma":[0.0016842185,0.00017165324,0.00017651849,0.000014835017,0.00017712779,0.000118188895,0.00047423938,0.0008476728,0.354386,0.00009985147,0.64152133,0.00032838847],"about_ca_topic_score_codex":0.030420981,"about_ca_topic_score_gemma":0.004620412,"teacher_disagreement_score":0.6068406,"about_ca_system_score_codex":0.0009778225,"about_ca_system_score_gemma":0.00078888214,"threshold_uncertainty_score":0.9999398},"labels":[],"label_agreement":null},{"id":"W4281718991","doi":"10.51731/cjht.2022.356","title":"Utilization of Old- Versus New-Generation Biologics for Plaque Psoriasis for Public and Private Payers in Canada","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Institute for Health Information","funders":"","keywords":"Biosimilar; Medicine; Formulary; Ustekinumab; Generic drug; Orphan drug; Family medicine; Infliximab; Pharmacology; Drug; Internal medicine","score_opus":0.1329166001152631,"score_gpt":0.31660010990601506,"score_spread":0.18368350979075196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281718991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72102296,0.096399404,0.015901381,0.1577425,0.0057205986,0.0019510412,0.001191777,0.000047080044,0.000023252815],"genre_scores_gemma":[0.995627,0.00043026335,0.0035409862,0.0003234506,0.000006774426,0.000017721419,0.00002674807,0.000005916915,0.000021173157],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894744,0.00011642878,0.0004714715,0.00012134465,0.000026338626,0.000316992],"domain_scores_gemma":[0.9992091,0.00022059312,0.00035868055,0.00009539945,0.00008608881,0.000030105835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079694396,0.000083797066,0.00029812794,0.00032579203,0.0002292428,0.000006915,0.00019999359,0.00013043637,0.000020353149],"category_scores_gemma":[0.001001823,0.000071449074,0.000039435632,0.0002355554,0.00010424524,0.000039453214,0.000024744366,0.00022139867,2.5595018e-8],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031490807,0.000022323931,0.008477156,0.000086945416,0.00012228401,0.0000033761853,0.00013534403,0.00007443608,0.002421099,0.020248437,0.01758616,0.9505075],"study_design_scores_gemma":[0.006090859,0.0039793067,0.0050073448,0.000051536957,0.000054999142,0.00006992416,0.009457819,0.000377835,0.027008792,0.009163026,0.9383936,0.0003449931],"about_ca_topic_score_codex":0.24745373,"about_ca_topic_score_gemma":0.7804248,"teacher_disagreement_score":0.95016253,"about_ca_system_score_codex":0.00060796173,"about_ca_system_score_gemma":0.004628594,"threshold_uncertainty_score":0.82109267},"labels":[],"label_agreement":null},{"id":"W4283366803","doi":"10.1016/j.jpba.2022.114911","title":"A state of the art in analytical quality-by-design and perspectives in characterization of nano-enabled medicinal products","year":2022,"lang":"en","type":"review","venue":"Journal of Pharmaceutical and Biomedical Analysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Horizon 2020; Horizon 2020 Framework Programme; European Commission","keywords":"Quality by Design; Terminology; Robustness (evolution); Computer science; Quality (philosophy); Protocol (science); Risk analysis (engineering); Management science; Characterization (materials science); Biochemical engineering; Nanotechnology; Chemistry; Engineering","score_opus":0.12057223831134851,"score_gpt":0.40760910221851976,"score_spread":0.28703686390717126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283366803","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005107482,0.9906596,0.0006872321,0.0028655524,0.0001583873,0.00036463866,0.00013772375,0.0000026591067,0.000016742917],"genre_scores_gemma":[0.007317977,0.99210733,0.00018037828,0.00008315461,0.000032097112,0.0000056843505,0.000030433379,0.000009866115,0.0002330874],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941861,0.0028782159,0.0019831716,0.0003579123,0.0002997521,0.00029486432],"domain_scores_gemma":[0.9975088,0.0010783931,0.0010291092,0.00015905619,0.000119283075,0.00010535892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044909036,0.00027806003,0.0026718935,0.00090814586,0.00004591439,0.000009848188,0.00032562265,0.00028846142,0.0006454118],"category_scores_gemma":[0.00088486564,0.00014611194,0.0004922923,0.0029052366,0.0013021949,0.00005624337,0.00020408028,0.0011787169,4.6625985e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008693196,0.0025273266,0.0007637044,0.0060453773,0.007529023,0.00005999871,0.00054337084,9.4003445e-7,0.030422352,0.0002321054,0.00041185948,0.9505946],"study_design_scores_gemma":[0.0027344476,0.00088829984,0.0021660046,0.0024586446,0.015461199,0.00023415123,0.0002942299,0.00027785162,0.0015287481,0.00023024126,0.9732387,0.0004874636],"about_ca_topic_score_codex":0.000012669296,"about_ca_topic_score_gemma":0.0000021779952,"teacher_disagreement_score":0.97282684,"about_ca_system_score_codex":0.00007671296,"about_ca_system_score_gemma":0.00025728135,"threshold_uncertainty_score":0.70668066},"labels":[],"label_agreement":null},{"id":"W4283372505","doi":"10.1016/j.lanwpc.2022.100506","title":"Monoclonal antibodies and Fc-fusion protein biologic medicines: A multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020","year":2022,"lang":"en","type":"article","venue":"The Lancet Regional Health - Western Pacific","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Health and Medical Research Fund; Li Ka Shing Faculty of Medicine, University of Hong Kong; National Health and Medical Research Council; Merck Sharp and Dohme; GlaxoSmithKline; University of Hong Kong; Research Grants Council, University Grants Committee; Bristol-Myers Squibb; Electrochemical Society; Novartis; European Commission; Amgen; Pfizer; Bayer","keywords":"Consumption (sociology); Per capita; Population; Economics; Business; Medicine; Environmental health","score_opus":0.09816593607048849,"score_gpt":0.37465985570502675,"score_spread":0.2764939196345383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283372505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698104,0.0028671052,0.00007876931,0.026038317,0.000117335345,0.0006479296,0.00038813928,0.00002312062,0.0000288322],"genre_scores_gemma":[0.99810016,0.00034829485,0.0007358542,0.0002832603,0.00008903294,0.000070411705,0.0002093281,0.000006587749,0.0001570926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747145,0.000958281,0.00059932144,0.00051674154,0.00013375054,0.00032046984],"domain_scores_gemma":[0.9985623,0.00071322033,0.00034433242,0.00023960946,0.000076107615,0.00006443859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029543259,0.00018953354,0.00051061326,0.000106392356,0.0005832766,0.00002209246,0.00017715733,0.00016739049,0.000034064597],"category_scores_gemma":[0.00013107416,0.0001286323,0.000043894564,0.0002443115,0.00183934,0.00009673731,0.00022470353,0.0006105344,7.8003427e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038761276,0.000062172236,0.99133736,0.00015675764,0.000026307112,6.274475e-7,0.00047255546,9.1915564e-7,0.0053011007,0.0005612537,0.0003090898,0.001384244],"study_design_scores_gemma":[0.001075286,0.00039048388,0.99030393,0.000054617747,0.00000965299,0.00008150647,0.0006265108,0.00003774599,0.00014484327,0.0056996383,0.0014533771,0.00012240552],"about_ca_topic_score_codex":0.00015389972,"about_ca_topic_score_gemma":0.00008329533,"teacher_disagreement_score":0.028289685,"about_ca_system_score_codex":0.000069878944,"about_ca_system_score_gemma":0.00013501276,"threshold_uncertainty_score":0.67771244},"labels":[],"label_agreement":null},{"id":"W4283382967","doi":"10.3389/fvets.2022.887163","title":"Suitability of Dried Blood Spots for Accelerating Veterinary Biobank Collections and Identifying Metabolomics Biomarkers With Minimal Resources","year":2022,"lang":"en","type":"article","venue":"Frontiers in Veterinary Science","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Mars Petcare","keywords":"Biobank; Dried blood; Medicine; Veterinary medicine; Biology; Bioinformatics; Chemistry","score_opus":0.04813269396272362,"score_gpt":0.3005118165231641,"score_spread":0.2523791225604405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283382967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958888,0.0016396554,0.0009216549,0.0001042935,0.0007745603,0.00036285148,0.000094455645,0.000015978181,0.00019774787],"genre_scores_gemma":[0.92600393,0.000021834461,0.073686406,0.00003791254,0.000007098684,0.00005458124,0.000003154304,0.000007869484,0.000177235],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99842525,0.00026442704,0.00032485515,0.00051351887,0.00008518552,0.0003867675],"domain_scores_gemma":[0.9993882,0.0001500601,0.00014474675,0.00022613094,0.000056313496,0.00003453847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017241441,0.00014172823,0.00032106537,0.00048040415,0.0009539506,0.000040923198,0.00038187308,0.00006847894,0.000034369932],"category_scores_gemma":[0.00017998272,0.000127766,0.00005670748,0.0014474827,0.0016094159,0.0001480235,0.00039969335,0.00019352185,7.110882e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001750313,0.00021781442,0.02177907,0.00007308006,0.00011009479,0.000014416358,0.0006453139,0.000009460377,0.97108865,0.000095001895,0.00022018423,0.003996577],"study_design_scores_gemma":[0.014846513,0.04698685,0.5673015,0.0003094836,0.0008834716,0.0033968964,0.041851703,0.0049488232,0.24159303,0.0023389026,0.0730031,0.002539711],"about_ca_topic_score_codex":0.000033163575,"about_ca_topic_score_gemma":0.0000023095263,"teacher_disagreement_score":0.72949564,"about_ca_system_score_codex":0.00005967708,"about_ca_system_score_gemma":0.00012618239,"threshold_uncertainty_score":0.7337113},"labels":[],"label_agreement":null},{"id":"W4283514070","doi":"10.1016/j.jval.2022.04.751","title":"EE505 Canada's Evolving Market for Biosimilars and What It Means for Payers","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Business; Public economics; Medicine; Economics","score_opus":0.03955446445295664,"score_gpt":0.3009156528136979,"score_spread":0.2613611883607413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283514070","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057372693,0.17561458,0.0074076247,0.72755873,0.015439641,0.010902316,0.004206809,0.00018578711,0.001311797],"genre_scores_gemma":[0.8092,0.008568797,0.0447749,0.12731907,0.000243281,0.0015049971,0.0002992132,0.0001625722,0.0079271775],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982402,0.0004673156,0.0003712102,0.00034180545,0.000045561334,0.0005339057],"domain_scores_gemma":[0.9985007,0.0011409747,0.000107760374,0.0001625847,0.00003338947,0.00005461147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019487138,0.00013448171,0.00032181345,0.00008810923,0.00043170273,0.000024646732,0.00015397526,0.00009357765,0.00032328043],"category_scores_gemma":[0.00026748434,0.0001246972,0.000063422944,0.00014457197,0.00006974053,0.00006850358,0.00008664342,0.00024244687,2.2646806e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097521296,0.00022561378,0.0032842064,0.00091475487,0.00022371308,0.0000066662938,0.00094549754,0.0003233835,0.0022370557,0.0027091731,0.9033391,0.08481563],"study_design_scores_gemma":[0.001694455,0.00066870684,0.0014476241,0.000098212135,0.00002776337,0.000025156252,0.003589297,0.0054544006,0.0006129498,0.0013208914,0.9848077,0.00025278822],"about_ca_topic_score_codex":0.055891085,"about_ca_topic_score_gemma":0.048157636,"teacher_disagreement_score":0.7518273,"about_ca_system_score_codex":0.0003249245,"about_ca_system_score_gemma":0.00061401166,"threshold_uncertainty_score":0.969211},"labels":[],"label_agreement":null},{"id":"W4283692756","doi":"10.1136/annrheumdis-2022-eular.2682","title":"POS1563-PARE SELF-MANAGEMENT STRATEGIES FOR ADVERSE DRUG REACTIONS AS REPORTED BY TNF-ALPHA INHIBITOR USERS: AN OBSERVATIONAL STUDY","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital","funders":"","keywords":"Medicine; Etanercept; Adalimumab; Injection site; Cohort; Drug reaction; Observational study; Cohort study; Internal medicine; Drug; Disease; Pharmacology; Tumor necrosis factor alpha","score_opus":0.11691705678361215,"score_gpt":0.37676686132037535,"score_spread":0.2598498045367632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283692756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992488,0.00090928463,0.000042951786,0.0030355726,0.00059956656,0.0014773873,0.0009930291,0.000097442746,0.00035676357],"genre_scores_gemma":[0.9956822,0.000059579004,0.00033780865,0.0007101694,0.0000124053495,0.00033002387,0.00022172043,0.000016506829,0.002629605],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9982294,0.0005107174,0.00056935835,0.00030157386,0.00014540892,0.00024354638],"domain_scores_gemma":[0.9986122,0.00029782552,0.00038145622,0.0005191908,0.00014359078,0.000045728826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005659134,0.00017148827,0.00029451604,0.00006510642,0.00053896854,0.00002462552,0.00040209707,0.00004147219,0.000634999],"category_scores_gemma":[0.00019448955,0.00012565083,0.0002356644,0.00023481592,0.000117961645,0.00019602684,0.00021942364,0.00012754451,0.000005023177],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002836126,0.034370087,0.021774571,0.0012403701,0.0147071825,0.000024789879,0.0056207925,0.00069719483,0.004476817,0.037904706,0.85907257,0.017274804],"study_design_scores_gemma":[0.011781191,0.006023021,0.32209918,0.0007001713,0.0065317946,0.00007677667,0.27909088,0.00069186144,0.010347493,0.102699414,0.25768825,0.002269977],"about_ca_topic_score_codex":0.00012329406,"about_ca_topic_score_gemma":0.000011887356,"teacher_disagreement_score":0.60138434,"about_ca_system_score_codex":0.000024395013,"about_ca_system_score_gemma":0.00012381091,"threshold_uncertainty_score":0.6952794},"labels":[],"label_agreement":null},{"id":"W4283694519","doi":"10.1136/annrheumdis-2022-eular.3408","title":"POS1434 USE OF BIOLOGIC OR TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AND THE RISK OF LYMPHOMA IN RHEUMATOID ARTHRITIS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Abatacept; Leflunomide; Rheumatoid arthritis; Tofacitinib; Hydroxychloroquine; Tocilizumab; Internal medicine; Rituximab; Etanercept; Sulfasalazine; Lymphoma; Diagnosis code; Infliximab; Adalimumab; Disease; Population","score_opus":0.03884315260165726,"score_gpt":0.276547160552637,"score_spread":0.23770400795097973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283694519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705546,0.026609994,0.000024166487,0.0010767254,0.00017152814,0.00056506955,0.0009697084,0.000016476377,0.000011727967],"genre_scores_gemma":[0.98225695,0.01728584,0.000105379884,0.00019951489,0.0000015875454,0.000059265843,0.000014317076,0.000015324205,0.000061800536],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956905,0.0025411271,0.0009992803,0.000284342,0.00015054048,0.00033420193],"domain_scores_gemma":[0.99519587,0.0031409129,0.0008433975,0.00067622674,0.0000878972,0.00005569231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012020105,0.000243012,0.00094528863,0.00015285326,0.00026301452,0.000014873301,0.0005588375,0.000076081385,0.00041097894],"category_scores_gemma":[0.003766206,0.0001245055,0.00040153114,0.000446949,0.0016349521,0.00008509824,0.0005501989,0.00016994792,0.0000017785891],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02493378,0.01100081,0.442946,0.005063216,0.007877998,0.00003120722,0.009407322,0.0030364995,0.005952852,0.021324936,0.005139837,0.46328557],"study_design_scores_gemma":[0.013058508,0.00077683927,0.92362934,0.004952867,0.00090986176,0.000069281574,0.0052176667,0.0048463694,0.011543935,0.033412904,0.0006464291,0.00093599403],"about_ca_topic_score_codex":0.000626215,"about_ca_topic_score_gemma":0.000014616268,"teacher_disagreement_score":0.48068336,"about_ca_system_score_codex":0.000012497183,"about_ca_system_score_gemma":0.0001292874,"threshold_uncertainty_score":0.6024049},"labels":[],"label_agreement":null},{"id":"W4283695675","doi":"10.1136/annrheumdis-2022-eular.2614","title":"POS0648 SEX DIFFERENCES IN ADVERSE DRUG REACTIONS FROM BIOLOGICAL USE IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"UCB Pharma","keywords":"Medicine; Adalimumab; Etanercept; MedDRA; Rheumatoid arthritis; Internal medicine; Pharmacovigilance; Adverse effect","score_opus":0.03339306425167516,"score_gpt":0.25445691319523933,"score_spread":0.22106384894356418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283695675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963688,0.001296218,0.0000010399444,0.0004548559,0.00017062858,0.0003348294,0.0013308858,0.000024294119,0.000018403673],"genre_scores_gemma":[0.9991671,0.0001425829,0.00001912138,0.00025015304,0.0000031640686,0.00005928997,0.0001889874,0.000008774867,0.00016081485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778616,0.0010511836,0.00051907165,0.00025861716,0.00010808101,0.0002768883],"domain_scores_gemma":[0.9981549,0.0011263347,0.00026002686,0.00037227737,0.000043591303,0.000042907057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018350522,0.00018130822,0.00044142897,0.00012456399,0.00014447194,0.00000958552,0.00039957697,0.00006675656,0.000786666],"category_scores_gemma":[0.0007083647,0.00010565662,0.00015540943,0.0003075797,0.00038387725,0.000109836175,0.00029493045,0.00025809763,0.0000073055057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005968599,0.0013042813,0.9960403,0.000020966649,0.0001716767,0.0000026006444,0.0001478856,0.000020874699,0.00012826154,0.000069350936,0.0005028119,0.0009941255],"study_design_scores_gemma":[0.0011366024,0.000121398145,0.9967149,0.00015492093,0.00005079055,3.2717907e-7,0.0005563078,0.000020265772,0.00016011404,0.00069674896,0.00023428428,0.00015332551],"about_ca_topic_score_codex":0.00060817116,"about_ca_topic_score_gemma":0.000051003135,"teacher_disagreement_score":0.002798267,"about_ca_system_score_codex":0.000024368424,"about_ca_system_score_gemma":0.00006678869,"threshold_uncertainty_score":0.86134416},"labels":[],"label_agreement":null},{"id":"W4283698327","doi":"10.1136/annrheumdis-2022-eular.2168","title":"POS1422 USE OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AND RISK OF MULTIPLE MYELOMA IN PERSONS WITH RHEUMATOID ARTHRITIS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Abatacept; Leflunomide; Tocilizumab; Rheumatoid arthritis; Hydroxychloroquine; Internal medicine; Rituximab; Sulfasalazine; Incidence (geometry); Etanercept; Infliximab; Medical prescription; Tofacitinib; Antirheumatic drugs; Antirheumatic Agents; Disease; Lymphoma; Pharmacology","score_opus":0.034062120496429184,"score_gpt":0.2689386530115542,"score_spread":0.234876532515125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283698327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862201,0.011512995,0.00004448919,0.0004643066,0.00007531094,0.00036810842,0.001288033,0.00001302497,0.0000135840755],"genre_scores_gemma":[0.99411404,0.0053923475,0.00029925298,0.0000716103,0.0000011365009,0.000032562122,0.000016062897,0.000016874605,0.0000561003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781054,0.00086598773,0.0006377845,0.00025039027,0.0001516385,0.00028367224],"domain_scores_gemma":[0.9976248,0.0011566947,0.0005872524,0.00048712225,0.00007777536,0.000066352004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004605896,0.00020064619,0.00068372994,0.00015793194,0.0001927832,0.000011005522,0.00030940544,0.000051050643,0.00020233562],"category_scores_gemma":[0.0009912408,0.00013588616,0.00022815209,0.0003299734,0.0007135808,0.00011530954,0.00031687279,0.00020322413,7.959793e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002044957,0.0022584088,0.919043,0.0013035127,0.00163464,0.0000058918417,0.0034457608,0.00094949413,0.0020085077,0.0008541006,0.001376205,0.065075494],"study_design_scores_gemma":[0.0031054593,0.00047143508,0.9796846,0.0026893152,0.00030321156,0.000017272669,0.0039447257,0.001750134,0.005810727,0.0016054984,0.00022214932,0.00039547728],"about_ca_topic_score_codex":0.0006328556,"about_ca_topic_score_gemma":0.00003030465,"teacher_disagreement_score":0.06468002,"about_ca_system_score_codex":0.000009603035,"about_ca_system_score_gemma":0.000098473975,"threshold_uncertainty_score":0.5541277},"labels":[],"label_agreement":null},{"id":"W4283789080","doi":"10.1016/j.annonc.2022.04.119","title":"P-28 Real-world observational study of MVASI in metastatic colorectal cancer patients in Canada: Baseline patient characteristics","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Amgen (Canada); Centre Intégré de Santé et de Services Sociaux des Laurentides; Nova Scotia Health Authority; Queen Elizabeth II Health Sciences Centre; Southlake Regional Health Center; Grand River Hospital; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Amgen","keywords":"Biosimilar; Bevacizumab; Medicine; Colorectal cancer; Internal medicine; Oncology; Observational study; Real world evidence; Monoclonal antibody; Antibody; Cancer; Chemotherapy; Immunology","score_opus":0.13708244977754078,"score_gpt":0.3839199649749954,"score_spread":0.24683751519745464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283789080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971809,0.00013484799,6.968558e-7,0.00094773655,0.00048288846,0.0004063158,0.0006347217,0.00000260033,0.00020933693],"genre_scores_gemma":[0.9986392,0.00010214344,0.00008248922,0.00087570824,0.0000061712217,0.000107036016,0.00011977725,0.0000076595115,0.000059817055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973237,0.0011668995,0.0008981344,0.0002297028,0.00010283542,0.00027875337],"domain_scores_gemma":[0.9985998,0.0006507287,0.00042437937,0.00011439633,0.00018812524,0.000022514228],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007108321,0.00012513335,0.0006432875,0.00020599671,0.00004300908,8.9220566e-7,0.00017929156,0.000052304185,0.0010363664],"category_scores_gemma":[0.00022611002,0.00011606277,0.000045606143,0.00047756245,0.00008108448,0.000024977824,0.00017146878,0.00032234922,5.4347527e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008998208,0.004364761,0.9629686,0.000020054007,0.00015605356,0.00002810932,0.0005136328,0.00009768325,0.0016291126,0.000121595825,0.00289518,0.026305404],"study_design_scores_gemma":[0.0017667146,0.0035697643,0.98234093,0.000011422623,0.000035122383,0.0000010573577,0.00086097256,0.00006646896,0.0024270734,0.00005430756,0.008751736,0.000114400864],"about_ca_topic_score_codex":0.61546946,"about_ca_topic_score_gemma":0.8907795,"teacher_disagreement_score":0.27531007,"about_ca_system_score_codex":0.00031906797,"about_ca_system_score_gemma":0.0011995746,"threshold_uncertainty_score":0.9998768},"labels":[],"label_agreement":null},{"id":"W4285389549","doi":"10.1080/00365521.2022.2090275","title":"Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study","year":2022,"lang":"en","type":"article","venue":"Scandinavian Journal of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Biosimilar; Infliximab; Medicine; Discontinuation; Inflammatory bowel disease; Concomitant; Internal medicine; Observational study; Disease; Pharmacoepidemiology; Adverse effect; Pharmacology","score_opus":0.03772343192871048,"score_gpt":0.30181664582656,"score_spread":0.2640932138978495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285389549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157315,0.00024840824,0.000048928567,0.0044290707,0.002343307,0.0005195947,0.00080770196,0.000016011232,0.00001380639],"genre_scores_gemma":[0.99772704,0.000012560093,0.00031546532,0.0015785802,0.00019919149,0.000037442285,0.00006820458,0.000022403927,0.000039087354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960073,0.0017328856,0.0010187621,0.00046705824,0.0002297317,0.0005442409],"domain_scores_gemma":[0.99774307,0.00087025104,0.000760983,0.00039660378,0.00011959146,0.00010951019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012882017,0.00029769304,0.000551191,0.00030512418,0.0002793398,0.0000438984,0.0008366984,0.0000865532,0.00020088341],"category_scores_gemma":[0.0006604251,0.0002158719,0.00019414279,0.00028103843,0.00012482262,0.000118584605,0.0002969596,0.001294893,0.000009536911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054806538,0.00058108196,0.9372047,0.0000024638277,0.0004495637,0.00029205935,0.0017650513,0.00016712012,0.0009876476,0.000050405855,0.0029940228,0.00069933984],"study_design_scores_gemma":[0.013172299,0.0059141116,0.9656979,0.000086891756,0.00017550717,0.00002040173,0.0019001011,0.000024768406,0.00009067095,0.00011871506,0.012626328,0.00017231231],"about_ca_topic_score_codex":0.00016855099,"about_ca_topic_score_gemma":0.0004327571,"teacher_disagreement_score":0.04163424,"about_ca_system_score_codex":0.0003057953,"about_ca_system_score_gemma":0.00013652835,"threshold_uncertainty_score":0.88030005},"labels":[],"label_agreement":null},{"id":"W4289526142","doi":"10.1016/j.dld.2022.07.004","title":"Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study","year":2022,"lang":"en","type":"article","venue":"Digestive and Liver Disease","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Janssen Pharmaceuticals; Takeda Canada; Emberi Eroforrások Minisztériuma; Ferring Pharmaceuticals; Semmelweis Egyetem; Meso Scale Diagnostics; Merck; AbbVie; Gilead Sciences; Pfizer","keywords":"Biosimilar; Medicine; Adalimumab; Inflammatory bowel disease; Intensive care medicine; Disease; Internal medicine","score_opus":0.010634672913510406,"score_gpt":0.2642036419642729,"score_spread":0.2535689690507625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289526142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99071807,0.0044064866,0.000012007178,0.002376477,0.00011302018,0.0012570935,0.001075854,0.000019761941,0.000021241658],"genre_scores_gemma":[0.99835706,0.00010861685,0.000029298577,0.0012070356,0.000035716537,0.0001427661,0.000036293462,0.00001674409,0.00006645438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980509,0.00051436626,0.00033628574,0.00058474595,0.0001821338,0.00033153465],"domain_scores_gemma":[0.9986153,0.00060476444,0.000091818874,0.00030752964,0.000058331,0.00032225568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000468712,0.000252,0.00034814657,0.00011015378,0.00030352335,0.000022063055,0.00030204532,0.00008982162,0.00037547338],"category_scores_gemma":[0.00035325016,0.00018154582,0.00007810225,0.00024318144,0.00043542223,0.00006943372,0.00049789133,0.00046639756,0.000005727283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015576364,0.0008136627,0.9929927,0.000029189325,0.00022187507,0.00017651667,0.0017691695,0.000001959798,0.000265346,0.00008607529,0.00062715984,0.0014587371],"study_design_scores_gemma":[0.0024804021,0.00031297872,0.9919817,0.00006463523,0.0003439357,8.934342e-7,0.0018576649,0.000054006843,0.00017996758,0.00014268988,0.0023442642,0.00023687325],"about_ca_topic_score_codex":0.00022603117,"about_ca_topic_score_gemma":0.000056138026,"teacher_disagreement_score":0.0076390165,"about_ca_system_score_codex":0.000056845693,"about_ca_system_score_gemma":0.0001852528,"threshold_uncertainty_score":0.7403224},"labels":[],"label_agreement":null},{"id":"W4290342819","doi":"10.1080/10408363.2022.2103085","title":"DropWise: current role and future perspectives of dried blood spots (DBS), blood microsampling, and their analysis in sports drug testing","year":2022,"lang":"en","type":"review","venue":"Critical Reviews in Clinical Laboratory Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency","keywords":"Dried blood; Whole blood; Drug detection; Blood testing; Analyte; Blood collection; Drug; Dried blood spot; Medicine; Pharmacology; Chemistry; Chromatography; Immunology; Internal medicine; Emergency medicine","score_opus":0.1193709924205625,"score_gpt":0.4540927923290558,"score_spread":0.3347217999084933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290342819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0053380174,0.99307704,0.0000032580867,0.00014775214,0.0004886214,0.0005663628,0.00025766986,0.000015082917,0.00010617898],"genre_scores_gemma":[0.0010662968,0.9967729,0.0018553293,0.00009161712,0.000121746256,0.000051185092,0.000015215013,0.000015592843,0.000010155327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99123627,0.0037126231,0.0028156983,0.0015014823,0.00013997788,0.0005939211],"domain_scores_gemma":[0.98903567,0.009497639,0.0006859971,0.00049698487,0.0001365729,0.00014714521],"candidate_categories":["metaresearch","metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.012326958,0.0005516056,0.004405316,0.00053749856,0.00023817708,0.00005706224,0.0006509391,0.00054470997,0.00036655585],"category_scores_gemma":[0.012336018,0.00036037242,0.00060424,0.004030853,0.0040794406,0.00011174473,0.00048038852,0.0020137946,0.0000019427757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008649831,0.00088437105,0.018118827,0.003676618,0.0001886663,0.000016939111,0.00020689619,4.343518e-8,0.000016233402,0.0016098002,0.000025370866,0.97524756],"study_design_scores_gemma":[0.00032049668,0.00022277687,0.0028917755,0.004784991,0.0032828979,0.000019703737,0.000957964,0.000003963586,0.000009423087,0.00072461256,0.9862543,0.00052713667],"about_ca_topic_score_codex":0.000009903544,"about_ca_topic_score_gemma":0.00002614787,"teacher_disagreement_score":0.9862289,"about_ca_system_score_codex":0.000025989706,"about_ca_system_score_gemma":0.00047120682,"threshold_uncertainty_score":0.99988484},"labels":[],"label_agreement":null},{"id":"W4291020097","doi":"10.1126/scitranslmed.abo7793","title":"The past, present, and future of antibiotics","year":2022,"lang":"en","type":"review","venue":"Science Translational Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":616,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Antibiotics; Risk analysis (engineering); Intensive care medicine; Business; Reimbursement; Investment (military); Medicine; Political science; Biology; Health care; Economic growth; Economics","score_opus":0.07061422966179243,"score_gpt":0.38520187126828725,"score_spread":0.31458764160649483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291020097","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.667765e-7,0.99038297,0.00002793828,0.0063644648,0.0009922106,0.00023471037,0.00004516599,0.000006596645,0.0019451567],"genre_scores_gemma":[0.000018031873,0.9988821,0.00020162194,0.000041250736,0.00044024072,0.0000011088173,0.000024543253,0.000005837108,0.00038524592],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987333,0.00020705201,0.00040359702,0.00027634783,0.00016497668,0.0002147607],"domain_scores_gemma":[0.9985017,0.0010380583,0.00017319039,0.00020765624,0.00005023752,0.000029123234],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0015997174,0.00015349996,0.0005723814,0.00012843848,0.0004451248,0.0000064264086,0.0004437355,0.00010911448,0.00067546894],"category_scores_gemma":[0.000046419103,0.0000724061,0.000092781316,0.00067527813,0.003947249,0.00003194745,0.000058605223,0.00038354212,0.0000020347952],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000053205995,0.000011579772,0.000008758224,0.00046559807,0.00004422932,4.973122e-7,0.00003639479,2.7548783e-8,0.000037657595,0.0064796507,0.0009692992,0.991941],"study_design_scores_gemma":[0.00013900566,0.000091082424,0.00011507228,0.00032545446,0.00026963596,0.000042714866,0.00005455258,0.0000015937205,0.0000074282702,0.0004670619,0.9984099,0.00007648581],"about_ca_topic_score_codex":0.0000041971275,"about_ca_topic_score_gemma":7.1199577e-7,"teacher_disagreement_score":0.99744064,"about_ca_system_score_codex":0.000010846958,"about_ca_system_score_gemma":0.00021710419,"threshold_uncertainty_score":0.99876344},"labels":[],"label_agreement":null},{"id":"W4294026392","doi":"10.3899/jrheum.220811","title":"From Canadian Living Guidelines to Global Living Guidelines: A Post Pandemic Effort","year":2022,"lang":"en","type":"letter","venue":"The Journal of Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Discontinuation; Pandemic; Rheumatoid arthritis; Rheumatology; Family medicine; Internal medicine; Physical therapy; Disease; Coronavirus disease 2019 (COVID-19)","score_opus":0.04447046280983015,"score_gpt":0.3288656533046769,"score_spread":0.28439519049484674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294026392","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06320058,0.01547129,0.0005844989,0.910356,0.008894722,0.00032964192,0.0007421398,0.000048639962,0.00037249518],"genre_scores_gemma":[0.016282434,0.0025083597,0.004088886,0.9737197,0.0009310637,0.00001166572,0.00009259964,0.00009540271,0.0022698622],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944297,0.0017081265,0.002224277,0.00040662568,0.0001916491,0.0010396265],"domain_scores_gemma":[0.9940828,0.0028937855,0.0011564494,0.00067824515,0.001037552,0.00015113776],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003467009,0.0005558352,0.0015819909,0.00039069512,0.00044080336,0.000040114533,0.0020400234,0.0016037115,0.0075662592],"category_scores_gemma":[0.005937339,0.00036179036,0.00050850376,0.00035993158,0.00029050763,0.000065022,0.000583789,0.003553499,0.00016784953],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008957169,0.00001583187,0.018708006,0.000023685316,0.0009490176,0.000097153956,0.00026061377,0.000012201601,0.00021473787,0.000016858034,0.97686875,0.0027436016],"study_design_scores_gemma":[0.00024535228,0.00041709407,0.0012497484,0.0008207981,0.0005820627,0.014571402,0.0006201657,0.000009547581,0.000009282491,0.00034106098,0.9806956,0.00043786812],"about_ca_topic_score_codex":0.16916317,"about_ca_topic_score_gemma":0.05178025,"teacher_disagreement_score":0.117382914,"about_ca_system_score_codex":0.00047589626,"about_ca_system_score_gemma":0.0014438927,"threshold_uncertainty_score":0.9998834},"labels":[],"label_agreement":null},{"id":"W4294992329","doi":"10.1093/jlb/lsac022","title":"Biological patent thickets and delayed access to biosimilars, an American problem","year":2022,"lang":"en","type":"article","venue":"Journal of Law and the Biosciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Internal medicine","score_opus":0.0801436779493731,"score_gpt":0.33198517026902263,"score_spread":0.25184149231964953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294992329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688465,0.002555913,0.00012561951,0.027071372,0.00047835693,0.00020348294,0.000030737832,0.000010641844,0.00067739224],"genre_scores_gemma":[0.9886646,0.00037208974,0.00096425944,0.009928054,0.000028804152,0.0000047314466,6.230382e-7,0.0000027967178,0.000034037803],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998484,0.0007041728,0.00030366494,0.00019525106,0.0000894404,0.00022346554],"domain_scores_gemma":[0.99926275,0.00027013267,0.00023844047,0.00009878642,0.000054279608,0.00007562843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022700808,0.00010716762,0.00029939655,0.00007138428,0.0006549155,0.00009481865,0.0005281436,0.000045189132,0.0000777329],"category_scores_gemma":[0.000068364665,0.00004896261,0.00006420446,0.00024929905,0.0020134866,0.00012986116,0.0003845499,0.00029634038,5.5221284e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0127625475,0.0018668753,0.035696987,0.00003857278,0.0010229093,0.00012555633,0.0075906934,0.000039040653,0.46598324,0.3056728,0.009353203,0.15984756],"study_design_scores_gemma":[0.009958939,0.036449824,0.081809916,0.00009770368,0.0006032446,0.0053374167,0.012362332,0.00017900352,0.05595402,0.07386198,0.72183216,0.001553478],"about_ca_topic_score_codex":0.00009647123,"about_ca_topic_score_gemma":0.000027108259,"teacher_disagreement_score":0.71247894,"about_ca_system_score_codex":0.000011375933,"about_ca_system_score_gemma":0.000035321384,"threshold_uncertainty_score":0.74187756},"labels":[],"label_agreement":null},{"id":"W4295315491","doi":"10.5281/zenodo.7070750","title":"Biolyte CBD Gummies\\t Reviews (Pros &amp; Cons) (Cost, Scam Exposed 2022) Gummies | Shocking Fraud Alert! | Does It Really Work | Where to Buy??","year":2022,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Order (exchange); Quality (philosophy); Work (physics); Plan (archaeology); Aside","score_opus":0.06784111166193306,"score_gpt":0.2970067032407727,"score_spread":0.22916559157883964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295315491","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.077986665,0.050738227,0.039115652,0.12231112,0.009541805,0.022908188,0.009390453,0.0066527138,0.6613552],"genre_scores_gemma":[0.4718432,0.013888953,0.0143104,0.023418874,0.0013273354,0.000016598859,0.009042269,0.0058733495,0.460279],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956571,0.0019399783,0.00064178766,0.0008102908,0.00020334411,0.00074750563],"domain_scores_gemma":[0.99833614,0.00012403815,0.00022439017,0.00081921543,0.0003364421,0.00015975698],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0022854519,0.00031565732,0.00048577518,0.00030706206,0.003601229,0.0003641533,0.0015081177,0.00017895845,0.16906865],"category_scores_gemma":[0.0013029963,0.00026156395,0.00016840895,0.0012018686,0.00034408545,0.0001364687,0.0028123334,0.00084820454,0.014941248],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032129546,0.00016933505,0.000036348192,0.000061091945,0.00012273087,0.000009668886,0.0008621206,0.000009417004,0.07195956,0.00073904364,0.8349756,0.09073376],"study_design_scores_gemma":[0.0005879987,0.00033620186,0.00017317795,0.0000990387,0.000048919734,0.00006618511,0.00068376074,0.00000448554,0.0030363777,0.00009762244,0.9945024,0.00036381805],"about_ca_topic_score_codex":0.00001582474,"about_ca_topic_score_gemma":0.0000051306715,"teacher_disagreement_score":0.39385656,"about_ca_system_score_codex":0.0002046368,"about_ca_system_score_gemma":0.000007159958,"threshold_uncertainty_score":0.99998367},"labels":[],"label_agreement":null},{"id":"W4296000957","doi":"10.5281/zenodo.7085599","title":"Biolyte CBD Gummies Reviews (Pros &amp; Cons) (Cost, Scam Exposed 2022) Gummies | Shocking Fraud Alert! | Does It Really Work | Where to Buy??","year":2022,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"cons; Business; Computer security; Work (physics); Internet privacy; Computer science; Engineering","score_opus":0.06788448412718397,"score_gpt":0.2968247141335369,"score_spread":0.22894023000635294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296000957","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09393489,0.059989657,0.035704512,0.12881319,0.009492861,0.022715386,0.009586561,0.0069640065,0.6327989],"genre_scores_gemma":[0.501592,0.014810169,0.013702658,0.020063717,0.0012184576,0.000015690312,0.008018501,0.0053184214,0.43526042],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99583477,0.0018663605,0.00061739486,0.0007727719,0.0001956183,0.0007131045],"domain_scores_gemma":[0.99841654,0.00012581502,0.00021637701,0.0007683654,0.00032736926,0.00014555483],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002154872,0.00030764844,0.00047555464,0.00030444845,0.0036035036,0.0003730982,0.001435838,0.00016861205,0.15252613],"category_scores_gemma":[0.0012942427,0.00025257404,0.00016242037,0.0011214251,0.00036143837,0.0001388705,0.0027183604,0.00079036306,0.013259252],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031394308,0.0001617516,0.000042169344,0.00006464161,0.00012516699,0.000008992441,0.0009869038,0.000009576295,0.07300601,0.000794583,0.83570284,0.08878342],"study_design_scores_gemma":[0.000536435,0.00032449226,0.00019255845,0.00010082041,0.000047961665,0.00006197437,0.0007994969,0.0000038204594,0.0034218268,0.000106850945,0.9940513,0.0003524743],"about_ca_topic_score_codex":0.000015147814,"about_ca_topic_score_gemma":0.0000053848735,"teacher_disagreement_score":0.4076571,"about_ca_system_score_codex":0.00018304023,"about_ca_system_score_gemma":0.000006568093,"threshold_uncertainty_score":0.99999267},"labels":[],"label_agreement":null},{"id":"W4296642322","doi":"10.1007/s12325-022-02303-1","title":"Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); University of Saskatchewan; Université de Montréal; University of Toronto; St. Joseph's Hospital; Mount Sinai Hospital; Western University","funders":"","keywords":"Medicine; Etanercept; Rheumatoid arthritis; Internal medicine; Rheumatology; Erythrocyte sedimentation rate; Adverse effect; Observational study; Biosimilar; Methotrexate; Concomitant; Prospective cohort study; Physical therapy","score_opus":0.01895463268009967,"score_gpt":0.3013498490173185,"score_spread":0.2823952163372188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296642322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906528,0.00704791,0.000043253604,0.00008305596,0.00032527605,0.0013718761,0.00036340303,0.000019087689,0.00009333884],"genre_scores_gemma":[0.9982787,0.00060896046,0.00038671584,0.000086423606,0.00000481113,0.00040142352,0.00016422269,0.000017470806,0.00005127947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976994,0.0010437127,0.00037555624,0.00043044033,0.00017401502,0.00027690784],"domain_scores_gemma":[0.9985875,0.0008202146,0.00016583317,0.00019645091,0.00020728687,0.000022711214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007075952,0.00020286282,0.00043051268,0.00015575049,0.00013478943,0.0000072716325,0.0001913598,0.00006253809,0.0005781001],"category_scores_gemma":[0.00014726387,0.00016746315,0.000059426133,0.0005018691,0.00020580822,0.0002132612,0.000078382815,0.00033680693,0.000001360309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019518303,0.0032591217,0.96057504,0.000016887543,0.00014000399,0.000010824423,0.0005118919,0.0002947376,0.0033825962,0.0006824629,0.0000063100006,0.011601803],"study_design_scores_gemma":[0.019156752,0.0021559054,0.97399354,0.000060329778,0.0000076025917,0.0000013177075,0.0006826776,0.000018705829,0.0013406132,0.00043552517,0.0019227741,0.00022422842],"about_ca_topic_score_codex":0.00005987763,"about_ca_topic_score_gemma":0.00015264652,"teacher_disagreement_score":0.013418511,"about_ca_system_score_codex":0.00014383183,"about_ca_system_score_gemma":0.00009963881,"threshold_uncertainty_score":0.68289495},"labels":[],"label_agreement":null},{"id":"W4297463011","doi":"10.1111/apt.17188","title":"Editorial: the immunogenicity to second anti‐TNF therapy (IMSAT) therapeutic drug monitoring study—defining the risk of the in‐class switch","year":2022,"lang":"en","type":"editorial","venue":"Alimentary Pharmacology & Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Immunogenicity; Drug class; Drug; Intensive care medicine; Pharmacotherapy; Tumor necrosis factor alpha; Pharmacology; Immunology; Oncology; Internal medicine; Antibody","score_opus":0.020953354389105297,"score_gpt":0.33003013455532393,"score_spread":0.30907678016621865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297463011","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15082926,0.024622522,0.0000015512179,0.0031264934,0.8181291,0.0025302467,0.0006444782,0.00005302564,0.00006331777],"genre_scores_gemma":[0.34303543,0.013383899,0.00004013487,0.009628129,0.6310227,0.0009459279,0.00011999967,0.0002808655,0.0015429282],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9871115,0.008587386,0.0014216661,0.0010814471,0.0006322326,0.0011657793],"domain_scores_gemma":[0.9896703,0.0073680244,0.0010680036,0.0015747782,0.00026459436,0.000054345343],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005525027,0.0009979237,0.0013333821,0.00020266589,0.0015909305,0.00007112237,0.004023724,0.0010440262,0.0017780873],"category_scores_gemma":[0.000016500298,0.00052749715,0.00071449514,0.0010014682,0.0009992437,0.00009111923,0.0015001674,0.0066147996,0.00003124417],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002266444,0.0017991245,0.018589789,0.000027537357,0.03745728,0.000007154658,0.0059134173,0.00008395252,0.079305515,0.000013844455,0.85118264,0.0033533336],"study_design_scores_gemma":[0.0037707724,0.0008440887,0.0051100464,0.00003065439,0.007865595,0.0000052862238,0.0032585787,0.000005078401,0.0506658,0.00012649667,0.9277343,0.00058331166],"about_ca_topic_score_codex":0.0010071179,"about_ca_topic_score_gemma":0.00020191164,"teacher_disagreement_score":0.19220617,"about_ca_system_score_codex":0.0004189652,"about_ca_system_score_gemma":0.00056107435,"threshold_uncertainty_score":0.99971765},"labels":[],"label_agreement":null},{"id":"W4301183139","doi":"10.4155/bio-2022-0129","title":"Efficient interactions with bioanalytical contract research organizations: inside scoop","year":2022,"lang":"en","type":"editorial","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nucro Technics","funders":"","keywords":"SCOOP; Bioanalysis; Business; Nanotechnology; Computer science; Materials science","score_opus":0.03292697951996681,"score_gpt":0.3619217649774175,"score_spread":0.3289947854574507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301183139","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006586839,0.024708109,0.0015831589,0.004755223,0.949468,0.0015133042,0.0034406118,0.0005111547,0.013361764],"genre_scores_gemma":[0.18187612,0.0038786978,0.006994877,0.0009825798,0.6274654,0.00094345375,0.014402464,0.00092968263,0.16252668],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.993538,0.0022029656,0.00096988055,0.0014484373,0.000775432,0.0010652677],"domain_scores_gemma":[0.9903815,0.005491351,0.00039541724,0.0013247671,0.0022592894,0.00014767454],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027721094,0.0006218246,0.0013497164,0.0016646498,0.0012549738,0.00018810984,0.0010185337,0.0012737277,0.026392322],"category_scores_gemma":[0.00623104,0.00046405874,0.00045247457,0.0055302256,0.0012988982,0.00005183727,0.00064103975,0.0045972406,0.00061741343],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033500802,0.0009022056,0.00018876803,0.00005203621,0.005031254,0.00008533132,0.00010448045,0.00013683422,0.0007903105,0.00049622345,0.9896028,0.0022747219],"study_design_scores_gemma":[0.00081743946,0.00036370894,0.000056247067,0.00008069135,0.0025472438,0.00001922518,0.0004044066,0.00035358727,0.00051904493,0.000036880552,0.9942035,0.00059804355],"about_ca_topic_score_codex":0.00088991533,"about_ca_topic_score_gemma":0.0005473981,"teacher_disagreement_score":0.32200256,"about_ca_system_score_codex":0.0007200175,"about_ca_system_score_gemma":0.0012337366,"threshold_uncertainty_score":0.99978113},"labels":[],"label_agreement":null},{"id":"W4301283258","doi":"10.1136/annrheumdis-2022-eular.787","title":"OP0269 BIOMARKERS TO PREDICT RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Sanofi Genzyme; Horizon Therapeutics; Sanofi; European Commission; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Tofacitinib; Etanercept; Internal medicine; Adalimumab; Rheumatoid arthritis; Hazard ratio; Rheumatoid factor; Pulmonary embolism; Gastroenterology; Surgery; Confidence interval","score_opus":0.0197678037723394,"score_gpt":0.262929628155183,"score_spread":0.24316182438284362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301283258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940482,0.0013933704,0.00000843832,0.0005222212,0.00032572623,0.00059553114,0.003038914,0.000022723512,0.00004489896],"genre_scores_gemma":[0.9989754,0.00053635397,0.00012990617,0.00021235578,0.0000032323503,0.000050057588,0.000029272956,0.000021501428,0.000041907955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977318,0.0007386238,0.00067109644,0.00029199864,0.00018949014,0.00037697665],"domain_scores_gemma":[0.99846476,0.00047714723,0.0004701599,0.0004142239,0.00010513155,0.00006859097],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039802748,0.00022163993,0.00071629207,0.00016571347,0.00022053834,0.000012975728,0.00047144666,0.000075139425,0.0009554586],"category_scores_gemma":[0.0010479123,0.00013752164,0.00021784214,0.00055874523,0.00028920211,0.0000773526,0.0003649106,0.00020872115,0.000004065716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039808606,0.004879481,0.7479483,0.0003475925,0.0023337156,0.0000039431034,0.002342764,0.00023500125,0.0012643058,0.00007906002,0.015824882,0.2207601],"study_design_scores_gemma":[0.0017755349,0.001242621,0.98567116,0.0010311145,0.000075652155,0.0000033318513,0.00058776146,0.00001100924,0.008393324,0.0003504556,0.00060709,0.00025094612],"about_ca_topic_score_codex":0.00038843957,"about_ca_topic_score_gemma":0.000039871786,"teacher_disagreement_score":0.23772287,"about_ca_system_score_codex":0.000024432165,"about_ca_system_score_gemma":0.000115870156,"threshold_uncertainty_score":0.9999578},"labels":[],"label_agreement":null},{"id":"W4307713717","doi":"10.1208/s12248-022-00762-6","title":"Anti-drug Antibody Sample Testing and Reporting Harmonization","year":2022,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Canadian Nuclear Laboratories","funders":"Bill and Melinda Gates Foundation","keywords":"Immunogenicity; Harmonization; Computer science; Scope (computer science); Bioanalysis; Sample (material); Medicine; Chemistry; Antibody; Chromatography; Immunology","score_opus":0.07532404115153642,"score_gpt":0.33930565057632084,"score_spread":0.26398160942478444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307713717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872469,0.0031271195,0.0037129072,0.0043551624,0.000801266,0.00009867523,0.00001569625,0.00003507769,0.0006072379],"genre_scores_gemma":[0.9942264,0.000067547444,0.00452121,0.0005882013,0.0000845623,0.0000014439432,0.000005851072,0.00000888947,0.00049588445],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987281,0.00044300949,0.00045693832,0.00011876273,0.000046122517,0.00020705303],"domain_scores_gemma":[0.9987078,0.00048686872,0.0006109575,0.00011482168,0.000060325372,0.000019244428],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0026697598,0.00007633357,0.00016951977,0.000043699692,0.0013817524,0.00004435852,0.00015110658,0.00003100914,0.00057414756],"category_scores_gemma":[0.0020890783,0.00004761189,0.00004572909,0.00019004075,0.00010933892,0.00004487629,0.00019221325,0.0006226924,0.0000032510518],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004951766,0.0000815408,0.17043605,0.000009754968,0.00016052747,0.000055120807,0.00053104915,0.000074484604,0.7751968,0.0004572511,0.006318237,0.046629667],"study_design_scores_gemma":[0.0036732038,0.0009718612,0.5430298,0.00014229357,0.00077671435,0.050652012,0.0056941863,0.002419,0.10664913,0.03500079,0.24979044,0.0012005506],"about_ca_topic_score_codex":0.000039051447,"about_ca_topic_score_gemma":7.2250407e-7,"teacher_disagreement_score":0.6685477,"about_ca_system_score_codex":0.00001862556,"about_ca_system_score_gemma":0.00003480994,"threshold_uncertainty_score":0.99991834},"labels":[],"label_agreement":null},{"id":"W4307887193","doi":"10.1186/s41927-022-00295-7","title":"Adherence patterns in naïve and prevalent use of infliximab and its biosimilar","year":2022,"lang":"en","type":"article","venue":"BMC Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Biosimilar; Medicine; Infliximab; Internal medicine; Pharmacy; Family medicine; Pharmacology; Disease","score_opus":0.05615643155585728,"score_gpt":0.2873580588120808,"score_spread":0.23120162725622354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307887193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99240756,0.0066714734,0.00007269545,0.0002688577,0.00021540705,0.0002183984,0.00010095998,0.000014709754,0.00002993363],"genre_scores_gemma":[0.9981668,0.0009087852,0.00050279964,0.00015885927,0.0000011020292,0.00003622848,0.000008750036,0.000008146665,0.000208541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842316,0.0005943018,0.00037837666,0.0003146625,0.000031230204,0.0002582855],"domain_scores_gemma":[0.999153,0.0005056689,0.00012802644,0.00016377305,0.00002583732,0.000023686163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032966997,0.00013408434,0.00042286637,0.00013422084,0.00008418655,0.0000054878033,0.0001254778,0.00016571715,0.00061922433],"category_scores_gemma":[0.0002131281,0.00011957936,0.000038773385,0.000120185076,0.00020640141,0.00005046468,0.0003880447,0.00027598857,0.0000033900026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034105135,0.00022271945,0.9724836,0.00027998202,0.00007880543,0.000009457022,0.00043450747,0.0000044078297,0.017778933,0.0050091874,0.00047413816,0.002883237],"study_design_scores_gemma":[0.008870758,0.0025217829,0.9024116,0.00029686195,0.0001694745,0.002445378,0.0014580924,0.001149978,0.05246209,0.0016435517,0.02553838,0.0010320474],"about_ca_topic_score_codex":0.00010858064,"about_ca_topic_score_gemma":0.000094528914,"teacher_disagreement_score":0.070071965,"about_ca_system_score_codex":0.000014948874,"about_ca_system_score_gemma":0.000035418543,"threshold_uncertainty_score":0.67800725},"labels":[],"label_agreement":null},{"id":"W4308842006","doi":"10.1186/s12909-022-03847-0","title":"Challenges associated with the integration of immuno-oncology agents in clinical practice","year":2022,"lang":"en","type":"article","venue":"BMC Medical Education","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"Bristol-Myers Squibb","keywords":"Pulmonologists; Medicine; Oncology; Internal medicine; Family medicine; Qualitative research; MEDLINE; Oncology nursing; Medical education; Intensive care medicine; Nurse education","score_opus":0.1388900316325979,"score_gpt":0.4617965982131657,"score_spread":0.3229065665805678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308842006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7904463,0.020432593,0.0015453739,0.1521183,0.0063674645,0.0012171036,0.000017435359,0.0000630655,0.027792383],"genre_scores_gemma":[0.99421084,0.0005067778,0.00092193525,0.0034567746,0.000049805476,0.00009835806,0.0000590135,0.0000070433834,0.0006894452],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953348,0.0037592908,0.0004387585,0.00019151754,0.00013115427,0.0001444452],"domain_scores_gemma":[0.9958038,0.003573343,0.0002967038,0.00018958803,0.000109614404,0.00002698943],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0056296415,0.000075016695,0.00022432592,0.00005651343,0.00011319786,0.0000036542526,0.00024890856,0.00022887583,0.0012970077],"category_scores_gemma":[0.012675351,0.000045269902,0.00005476134,0.0002203015,0.00035875503,0.000039937724,0.00008743872,0.00064763677,0.0000059954664],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012741439,0.008866151,0.0071681603,0.000029948209,0.00030316674,0.0000050131835,0.0034655116,0.000003900286,0.000994385,0.013368758,0.03635073,0.92817014],"study_design_scores_gemma":[0.0035593598,0.0030038892,0.3757507,0.00017612052,0.00029070987,0.00015137409,0.03813825,0.00023120326,0.0006042011,0.00087322935,0.5769382,0.00028275594],"about_ca_topic_score_codex":0.00008171078,"about_ca_topic_score_gemma":0.00069075,"teacher_disagreement_score":0.9278874,"about_ca_system_score_codex":0.00010638887,"about_ca_system_score_gemma":0.0020628974,"threshold_uncertainty_score":0.99961597},"labels":[],"label_agreement":null},{"id":"W4310776690","doi":"10.1007/s40259-022-00568-0","title":"The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries","year":2022,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; China; Medicine; Biopharmaceutical; European union; Business; Product (mathematics); International trade; Biotechnology; Geography","score_opus":0.02814807893878446,"score_gpt":0.29967549266217763,"score_spread":0.2715274137233932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310776690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955738,0.0389355,0.000005541793,0.0014889966,0.00048199622,0.0002817951,0.0020473404,0.00001712591,0.0010036689],"genre_scores_gemma":[0.99692917,0.0020375797,0.00020858672,0.000540913,0.000009607562,0.000008297285,0.000034615605,0.0000056577055,0.00022557237],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863935,0.00049507624,0.00035134165,0.00023138236,0.000071242735,0.0002116311],"domain_scores_gemma":[0.9989986,0.00036630893,0.0002556318,0.00029831397,0.00005856195,0.00002261427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078237406,0.00015023677,0.00038443276,0.000045337692,0.00017468602,0.000005230463,0.00030737495,0.00015577719,0.00051796983],"category_scores_gemma":[0.000084480176,0.000090059824,0.00012337376,0.00016197606,0.0006261227,0.000021917713,0.0002019718,0.0001433439,0.0000018056439],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032361206,0.0036493368,0.32958132,0.002025615,0.0073927147,0.0000404014,0.0031776107,0.000023516573,0.2710113,0.12815534,0.12279215,0.09978949],"study_design_scores_gemma":[0.0047077457,0.0047517866,0.17416413,0.00012873112,0.00057789986,0.000058284088,0.004804013,0.000030427627,0.40140444,0.0066099176,0.40210506,0.0006575485],"about_ca_topic_score_codex":0.000046953464,"about_ca_topic_score_gemma":0.000015938833,"teacher_disagreement_score":0.2793129,"about_ca_system_score_codex":0.000018030221,"about_ca_system_score_gemma":0.000040829138,"threshold_uncertainty_score":0.56714064},"labels":[],"label_agreement":null},{"id":"W4311626261","doi":"10.3390/pharmaceutics14122721","title":"Biosimilars in Oncology: Latest Trends and Regulatory Status","year":2022,"lang":"en","type":"review","venue":"Pharmaceutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Licensure; Health care; Intensive care medicine; Economic growth; Internal medicine; Nursing","score_opus":0.1877940009608717,"score_gpt":0.4593003992351504,"score_spread":0.2715063982742787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311626261","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028832033,0.9951289,4.2710852e-7,0.00023494576,0.0010382998,0.00043257332,0.00023743317,0.000056576115,0.002842007],"genre_scores_gemma":[0.000066232875,0.9973162,0.00012992109,0.00048264663,0.000039185164,0.00008814328,0.00014084899,0.000053202064,0.0016836487],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623287,0.0016159,0.0007623011,0.00064345717,0.00006092728,0.00068451854],"domain_scores_gemma":[0.9984314,0.0008083026,0.0002840879,0.00037230234,0.000014721298,0.00008917474],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011138591,0.00049043604,0.0017475873,0.00060756365,0.00014817192,0.000018110728,0.00032674472,0.0007147691,0.0039985706],"category_scores_gemma":[0.000088655055,0.00040363803,0.00025923242,0.0007650361,0.0003304826,0.000038371556,0.0004589235,0.001976952,0.000034002867],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002619496,0.0004043275,0.00018461474,0.00085042906,0.00034208508,0.00007905967,0.00008982262,9.2057604e-8,0.000012113398,0.00003192396,0.0035154019,0.9944639],"study_design_scores_gemma":[0.00092290394,0.00024933778,0.000080241276,0.00024871106,0.0014518929,0.00011677543,0.00007342894,0.0000029619016,0.000017010547,0.00001566102,0.99639714,0.00042394898],"about_ca_topic_score_codex":0.000012336047,"about_ca_topic_score_gemma":0.000021026148,"teacher_disagreement_score":0.99404,"about_ca_system_score_codex":0.00033431532,"about_ca_system_score_gemma":0.000256277,"threshold_uncertainty_score":0.9998416},"labels":[],"label_agreement":null},{"id":"W4312114408","doi":"10.1002/cpt.2782","title":"Advancing Innovations in Biosimilars","year":2022,"lang":"en","type":"editorial","venue":"Clinical Pharmacology & Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Pharmacology; Business; Internal medicine","score_opus":0.06304985624685244,"score_gpt":0.44777936023714354,"score_spread":0.3847295039902911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114408","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007077519,0.0058086035,0.00006522059,0.011801081,0.9797366,0.0005588259,0.00049305434,0.00013119007,0.000697632],"genre_scores_gemma":[0.0007294072,0.025330156,0.0025984237,0.20196268,0.75665265,0.00042490332,0.0021117819,0.00033738115,0.0098525975],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99357903,0.0023901865,0.0018456678,0.001055675,0.00015556012,0.00097388256],"domain_scores_gemma":[0.99098563,0.0075754765,0.00058981625,0.0005281469,0.00025395598,0.00006696157],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003431332,0.0005554603,0.0013573852,0.00039550534,0.000287002,0.00001911837,0.0010731657,0.003311186,0.0088660745],"category_scores_gemma":[0.00048659713,0.0005194861,0.00044363656,0.00085979025,0.0010065134,0.00006204448,0.0006169632,0.007889473,0.0001519751],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003981177,0.00090668973,0.0006337837,0.000029909866,0.0011306048,0.00004130544,0.00003459164,0.000004827086,0.0045445827,0.000011283003,0.98739785,0.0048664724],"study_design_scores_gemma":[0.002887564,0.0006074957,0.00026632345,0.000024956416,0.0010423452,0.0000044211984,0.000052644544,0.000016106218,0.0007769816,0.00024928153,0.9935442,0.0005276501],"about_ca_topic_score_codex":0.000011406308,"about_ca_topic_score_gemma":0.000026918418,"teacher_disagreement_score":0.22308397,"about_ca_system_score_codex":0.0002683777,"about_ca_system_score_gemma":0.0008038574,"threshold_uncertainty_score":0.9997257},"labels":[],"label_agreement":null},{"id":"W4312210901","doi":"10.1021/acsnano.2c09249","title":"The Issue of Reliability and Repeatability of Analytical Measurement in Industrial and Academic Nanomedicine","year":2022,"lang":"en","type":"review","venue":"ACS Nano","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Division of Chemical, Bioengineering, Environmental, and Transport Systems; National Institute of General Medical Sciences; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases; Office of Science; Chan Zuckerberg Initiative; Henry Moore Foundation; U.S. Department of Agriculture; Alfred P. Sloan Foundation; Camille and Henry Dreyfus Foundation; Burroughs Wellcome Fund; Philomathia Foundation; Gordon and Betty Moore Foundation; U.S. Department of Energy; National Institutes of Health; National Science Foundation","keywords":"Nanomedicine; Reliability (semiconductor); Repeatability; Field (mathematics); Key (lock); Perspective (graphical); Data science; Nanotechnology; Computer science; Materials science; Artificial intelligence; Computer security; Mathematics; Physics","score_opus":0.1684319624370758,"score_gpt":0.37928133958376137,"score_spread":0.21084937714668556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312210901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011011795,0.99733275,0.0000010752941,0.0004646978,0.00029494512,0.0005732462,0.00006401344,0.0000046906025,0.00016339973],"genre_scores_gemma":[0.0012743005,0.9984289,0.000025541258,0.000028372924,0.000028642635,0.000023953946,0.000012076019,0.000008840354,0.00016937601],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99647415,0.0015339656,0.0011923397,0.000437968,0.000119553646,0.00024200063],"domain_scores_gemma":[0.9972094,0.0018118822,0.0003878626,0.0005009195,0.000060207618,0.000029719788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006941382,0.00022818815,0.0016293976,0.00010239215,0.00007640253,0.0000028034674,0.0002911702,0.0007767223,0.00018127481],"category_scores_gemma":[0.004112505,0.00012839555,0.0001406709,0.00037207012,0.0012301803,0.000018852154,0.00038226112,0.0012274021,7.7322494e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001163548,0.00008608581,0.0010259576,0.0019834617,0.00018861426,9.870606e-7,0.000034854253,1.2039765e-8,0.00011882385,0.00021439046,0.0008122977,0.99541813],"study_design_scores_gemma":[0.00049902714,0.00025955756,0.0002551495,0.0008015225,0.0005760394,0.000015317572,0.000045563687,3.0436522e-7,0.00015122093,0.00014322664,0.99713844,0.0001146293],"about_ca_topic_score_codex":0.00007182751,"about_ca_topic_score_gemma":0.000008449637,"teacher_disagreement_score":0.99632615,"about_ca_system_score_codex":0.000094625575,"about_ca_system_score_gemma":0.00022107107,"threshold_uncertainty_score":0.5990794},"labels":[],"label_agreement":null},{"id":"W4313418791","doi":"10.1016/j.vascn.2022.107239","title":"An electrochemiluminescence assay for quantification of Denileukin Diftitox and its anti-drug antibodies in rat serum","year":2022,"lang":"en","type":"article","venue":"Journal of Pharmacological and Toxicological Methods","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Immunogenicity; Biotinylation; Streptavidin; Electrochemiluminescence; Diphtheria toxin; Pharmacokinetics; Antibody; Chemistry; Molecular biology; Chromatography; ELISPOT; Pharmacology; Medicine; Detection limit; Biotin; Biology; Immunology; Toxin; Biochemistry; In vitro","score_opus":0.05607673240112326,"score_gpt":0.4083875046212947,"score_spread":0.35231077222017143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313418791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98406345,0.007391037,0.0061352747,0.0014631527,0.0005164382,0.0003523582,0.00003570371,0.000012738285,0.000029853809],"genre_scores_gemma":[0.9671773,0.0009324057,0.031264137,0.00044326702,0.000052278898,0.000026885318,0.0000036114961,0.0000068260415,0.00009332554],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99578154,0.0026688988,0.00078422565,0.00033307963,0.00008211485,0.00035012822],"domain_scores_gemma":[0.9970448,0.0021614956,0.00047809657,0.00007500016,0.00015433252,0.000086285974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005328293,0.00019876173,0.0007673341,0.00016004074,0.00020520492,0.000015352987,0.00031455723,0.00022166508,0.00042633977],"category_scores_gemma":[0.00090668525,0.00012998775,0.00014111231,0.0002811296,0.00030689727,0.00011167569,0.00017153348,0.0007333695,2.4459075e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008015357,0.0008187337,0.0045184097,0.000035976824,0.000087702254,0.000014567371,0.00006036169,0.000014546021,0.97385883,0.0010159116,0.00024421277,0.01852923],"study_design_scores_gemma":[0.0018903773,0.0026410648,0.022981664,0.0000135531,0.00021483423,0.00021289043,0.00025688543,0.0007370955,0.9646042,0.0022527142,0.0039887754,0.00020593668],"about_ca_topic_score_codex":0.000001174694,"about_ca_topic_score_gemma":8.519736e-7,"teacher_disagreement_score":0.025128864,"about_ca_system_score_codex":0.00003830705,"about_ca_system_score_gemma":0.000043427666,"threshold_uncertainty_score":0.53007466},"labels":[],"label_agreement":null},{"id":"W4313464260","doi":"10.22270/ijdra.v10i2.518","title":"A Comparative Study of Biologic Regulation in US, Canada, Australia, Europe and Singapore","year":2022,"lang":"en","type":"article","venue":"International Journal of Drug Regulatory Affairs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Regulatory science; Product (mathematics); Regulatory authority; Order (exchange); Business; Quality (philosophy); Control (management); New product development; Developed country; International trade; Political science; Public administration; Marketing; Medicine; Economics; Environmental health; Management; Finance","score_opus":0.030783674348117927,"score_gpt":0.30298779999825287,"score_spread":0.27220412565013496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313464260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980291,0.000371412,0.0000055385594,0.00047404828,0.0007606968,0.00010164489,0.000029480794,0.0000023244315,0.00022574048],"genre_scores_gemma":[0.9991342,0.00000674317,0.000098215416,0.00004302012,0.000026549682,0.0000018373426,0.000005852926,0.000003886176,0.000679724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984788,0.0005563081,0.00055197877,0.00013813317,0.00016347272,0.00011135666],"domain_scores_gemma":[0.99902976,0.00014334398,0.00047851182,0.000086144755,0.00023973749,0.000022519293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068968185,0.00010099435,0.00030202817,0.00020173694,0.00005771167,0.000006946926,0.00028657643,0.000038801867,0.00042972542],"category_scores_gemma":[0.000053277017,0.00008320534,0.000045261568,0.0001504865,0.00013212113,0.000064171465,0.00013282741,0.00032764295,5.488052e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029062864,0.0029680622,0.800583,0.00002371962,0.0023988327,0.0003982603,0.006686024,0.00454458,0.15430045,0.003174354,0.019018283,0.00299816],"study_design_scores_gemma":[0.0026375675,0.0007749413,0.96429807,0.00004074673,0.00007192601,0.00033292678,0.011809189,0.000042173913,0.011288464,0.00035230856,0.008179413,0.00017229446],"about_ca_topic_score_codex":0.006406193,"about_ca_topic_score_gemma":0.026137445,"teacher_disagreement_score":0.16371505,"about_ca_system_score_codex":0.00014065746,"about_ca_system_score_gemma":0.00013024763,"threshold_uncertainty_score":0.991633},"labels":[],"label_agreement":null},{"id":"W4313855510","doi":"10.18433/jpps33421","title":"The 2022 Canadian Society for Pharmaceutical Sciences/Canadian Chapter of Controlled Release Society Annual Symposium was held virtually from June 1-2, 2022.","year":2023,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.05575016226620621,"score_gpt":0.3783270135529703,"score_spread":0.3225768512867641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313855510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49082726,0.057307497,0.000639129,0.4170396,0.020616673,0.003872553,0.0041398564,0.00016680709,0.005390623],"genre_scores_gemma":[0.97179055,0.012498877,0.0014909052,0.0113287615,0.00073530286,0.000036713078,0.000015473988,0.00003583922,0.0020675764],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955174,0.00046894298,0.0012643551,0.00058937166,0.0005181571,0.0016417956],"domain_scores_gemma":[0.9949899,0.0029533019,0.00047543502,0.00019404003,0.0004939905,0.00089338585],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["sts"],"category_scores_codex":[0.008422648,0.00039077504,0.00081868627,0.0002833698,0.0021721765,0.00015510259,0.0016381486,0.00026030015,0.0018950247],"category_scores_gemma":[0.0005331924,0.00024389206,0.0013964887,0.001286954,0.004255215,0.0004009635,0.00018009281,0.0011613359,0.000048715283],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029046633,0.00041133497,0.0047070784,0.000081294354,0.0029257014,0.000072819996,0.0014360494,0.00015207836,0.67695767,0.00959452,0.2211426,0.07961416],"study_design_scores_gemma":[0.008646991,0.0005066947,0.00022637336,0.000057007997,0.0007839921,0.00006979859,0.0015628469,0.015197288,0.07686187,0.0008618087,0.89479464,0.00043071026],"about_ca_topic_score_codex":0.010254427,"about_ca_topic_score_gemma":0.009664885,"teacher_disagreement_score":0.673652,"about_ca_system_score_codex":0.00020118532,"about_ca_system_score_gemma":0.002132692,"threshold_uncertainty_score":0.99912685},"labels":[],"label_agreement":null},{"id":"W4318539099","doi":"10.1093/ecco-jcc/jjac190.0858","title":"P728 Real world evidence for adalimumab biosimilar, MSB 11022, therapy in inflammatory bowel diseases: Adherence analysis","year":2023,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adalimumab; Biosimilar; Ulcerative colitis; Interquartile range; Internal medicine; Inflammatory bowel disease; Crohn's disease; Mesalazine; Population; Disease","score_opus":0.051486269103077395,"score_gpt":0.3487193998681134,"score_spread":0.297233130765036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318539099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840001,0.012544771,0.00023483206,0.0020047678,0.00050380017,0.0003369375,0.00014263397,0.00002940512,0.00020279022],"genre_scores_gemma":[0.9819372,0.015344761,0.00046903998,0.0005843657,0.00010779093,0.000025586407,0.000008169675,0.000013633826,0.0015094243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833316,0.0002664633,0.00068262644,0.00024157937,0.00008773447,0.00038841672],"domain_scores_gemma":[0.99838436,0.00083482056,0.00032720328,0.0001840482,0.00019230926,0.0000772907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083653524,0.00017744474,0.0005542686,0.00050519273,0.00012287502,0.000060472703,0.00024938275,0.00017117598,0.00028706898],"category_scores_gemma":[0.00023214289,0.00013336907,0.0003561859,0.00089385256,0.00023590004,0.00020783894,0.000057755416,0.00026985304,0.000005423607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04152311,0.0010837313,0.6606863,0.00054306176,0.009141039,0.0009911767,0.002047716,0.000082251216,0.016763886,0.008219694,0.0725349,0.18638313],"study_design_scores_gemma":[0.0018496362,0.0006100611,0.9718533,0.00019771562,0.00047474596,0.000018136185,0.00022286417,0.00006409338,0.0015322063,0.002093849,0.020888176,0.00019519935],"about_ca_topic_score_codex":0.00010363719,"about_ca_topic_score_gemma":0.00031202642,"teacher_disagreement_score":0.311167,"about_ca_system_score_codex":0.000048071488,"about_ca_system_score_gemma":0.0001456607,"threshold_uncertainty_score":0.5438633},"labels":[],"label_agreement":null},{"id":"W4318539850","doi":"10.1093/ecco-jcc/jjac190.0547","title":"P417 Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort Study","year":2023,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Biosimilar; Infliximab; Adalimumab; Internal medicine; Inflammatory bowel disease; Ulcerative colitis; Nocebo; Adverse effect; Faecal calprotectin; Observational study; Therapeutic drug monitoring; Nocebo Effect; Crohn's disease; Calprotectin; Prospective cohort study; Clinical trial; Disease; Placebo; Pathology; Alternative medicine","score_opus":0.05769409734213311,"score_gpt":0.33155148397561884,"score_spread":0.27385738663348574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318539850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969222,0.000934706,0.000035480232,0.00044436817,0.00032219343,0.0008318563,0.00048031332,0.00001682085,0.000012045919],"genre_scores_gemma":[0.9992454,0.00007779612,0.0001822525,0.00026302307,0.0000482972,0.0000119510305,0.00007487351,0.000020507781,0.00007591039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753696,0.0006256008,0.0008387799,0.0004696892,0.00020396347,0.000324993],"domain_scores_gemma":[0.9983145,0.0007188872,0.00033579834,0.00034048717,0.00015823294,0.00013210488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017709312,0.00023936336,0.0005847213,0.00015615443,0.00018793908,0.000065973894,0.00031710017,0.00015264722,0.00006427496],"category_scores_gemma":[0.00018770223,0.00017291901,0.00009631476,0.00017253862,0.00031750556,0.00021363431,0.00029351283,0.00044639377,0.0000040284813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076341913,0.00066818687,0.98773885,0.000016629272,0.0011364917,0.000289144,0.00018122616,4.5893225e-7,0.000038502356,0.000030365323,0.00046586708,0.0018001132],"study_design_scores_gemma":[0.006511641,0.0007331196,0.9908898,0.0001855796,0.0004145043,0.000007989162,0.0002848383,0.00005261055,0.000015028406,0.00044353397,0.00024190183,0.00021948112],"about_ca_topic_score_codex":0.000050855502,"about_ca_topic_score_gemma":0.00004280226,"teacher_disagreement_score":0.0031509479,"about_ca_system_score_codex":0.000054978274,"about_ca_system_score_gemma":0.00015742646,"threshold_uncertainty_score":0.7051433},"labels":[],"label_agreement":null},{"id":"W4318539865","doi":"10.1093/ecco-jcc/jjac190.0648","title":"P518 Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)","year":2023,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Discontinuation; Adverse effect; Medicine; Ulcerative colitis; Incidence (geometry); Internal medicine; Disease","score_opus":0.12167949768426314,"score_gpt":0.404908083524012,"score_spread":0.28322858583974886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318539865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956874,0.001103217,0.00011186907,0.0012569579,0.0003626051,0.00045018905,0.0008050969,0.000005648511,0.00021699027],"genre_scores_gemma":[0.9979387,0.00095977774,0.00016295158,0.000317795,0.0000731804,0.000004399639,0.00005651665,0.000010448579,0.00047624818],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978538,0.0007876976,0.00074351206,0.00026761103,0.00008716095,0.0002602149],"domain_scores_gemma":[0.9981729,0.0008102918,0.00038973428,0.00040030634,0.00017970098,0.000047100035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017134582,0.00015251407,0.0006007119,0.00008329544,0.00016065915,0.00006487606,0.0006822343,0.00014390117,0.00048549613],"category_scores_gemma":[0.0002958897,0.0000946898,0.00004450334,0.0002833869,0.00028532516,0.00025438232,0.00057323114,0.00042007936,0.0000074772224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1567138,0.016148215,0.09564987,0.00014973128,0.0050693215,0.004112943,0.008285779,0.000003465257,0.040793385,0.0022322075,0.07286431,0.597977],"study_design_scores_gemma":[0.010035483,0.0012506483,0.9794321,0.00022973171,0.00013977439,0.00009925794,0.0017657167,0.000019603023,0.0020299146,0.00054054,0.0043306164,0.00012662898],"about_ca_topic_score_codex":0.00029674012,"about_ca_topic_score_gemma":0.00055493123,"teacher_disagreement_score":0.8837822,"about_ca_system_score_codex":0.000024359344,"about_ca_system_score_gemma":0.00010863555,"threshold_uncertainty_score":0.5315842},"labels":[],"label_agreement":null},{"id":"W4319460993","doi":"10.1002/acr.25099","title":"Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis","year":2023,"lang":"en","type":"article","venue":"Arthritis Care & Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto; University of Calgary; University of British Columbia","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Biosimilar; Etanercept; Medicine; Psoriatic arthritis; Infliximab; Rheumatoid arthritis; Medical prescription; Ankylosing spondylitis; Psoriasis; Internal medicine; Arthritis; Pharmacology; Dermatology; Tumor necrosis factor alpha","score_opus":0.04352270525580827,"score_gpt":0.3408438282387279,"score_spread":0.29732112298291963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319460993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127185,0.0066596735,0.0000029225484,0.0014377682,0.000043099124,0.00017049734,0.0000955441,0.000028203884,0.0002904308],"genre_scores_gemma":[0.9968568,0.002192269,0.00014227215,0.00019719977,0.000023586586,0.000010880865,0.000031870048,0.000015177179,0.0005299127],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980852,0.00044509833,0.00026651673,0.00047391324,0.0001221071,0.00060716894],"domain_scores_gemma":[0.9993218,0.00026739616,0.000025858855,0.00020035161,0.000058943348,0.00012564064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065622,0.00017702817,0.00040184127,0.0006638524,0.00021641703,0.00010107447,0.000114792485,0.00016525174,0.0003566384],"category_scores_gemma":[0.00013736641,0.00015596958,0.00003704348,0.0008780018,0.00028482915,0.00015231628,0.00028249467,0.0005134253,0.000011572748],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094352156,0.000052270152,0.43199757,0.000104196944,0.00071745005,0.00060054194,0.018255495,0.00000828313,0.062903814,0.000545558,0.0022927956,0.48157853],"study_design_scores_gemma":[0.0012440312,0.0005720572,0.96633124,0.00018674856,0.00006406342,0.00004928006,0.017215082,0.00012984662,0.004339282,0.00024684556,0.0092805065,0.00034099093],"about_ca_topic_score_codex":0.20626009,"about_ca_topic_score_gemma":0.7908613,"teacher_disagreement_score":0.5846012,"about_ca_system_score_codex":0.00011790575,"about_ca_system_score_gemma":0.000160667,"threshold_uncertainty_score":0.7990255},"labels":[],"label_agreement":null},{"id":"W4321795859","doi":"10.1177/23814683231156433","title":"Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"MDM Policy & Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"Hospital for Sick Children; Canada Research Chairs","keywords":"Infliximab; Medicine; Biosimilar; Inflammatory bowel disease; Willingness to pay; Ulcerative colitis; Intensive care medicine; Family medicine; Internal medicine; Disease; Economics","score_opus":0.10322591411669334,"score_gpt":0.48652066261796045,"score_spread":0.3832947485012671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321795859","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019469982,0.9776442,0.000008280785,0.016825942,0.00035487686,0.0037353435,0.00025788334,0.00006861225,0.001085409],"genre_scores_gemma":[0.00003836467,0.99104124,0.00011907091,0.006859056,0.00009856516,0.0010014302,0.00012618228,0.000046708094,0.000669366],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947359,0.001838963,0.0020627792,0.00064603414,0.00012366824,0.0005926792],"domain_scores_gemma":[0.99470526,0.0033577508,0.0010242705,0.0006491963,0.0001342489,0.0001292841],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0046442663,0.0005588705,0.0020869644,0.0016673086,0.00011458946,0.00017324692,0.0009703198,0.00053361413,0.0001001108],"category_scores_gemma":[0.027075626,0.00043048922,0.00028790653,0.0011027632,0.00024096931,0.0005440344,0.0008852909,0.0008540763,0.00058082235],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015896313,0.0003337178,0.0002505252,0.92407566,0.0017846961,0.00009209387,0.0006388285,0.000020731668,0.0000056342706,0.011674499,0.0040203463,0.05694433],"study_design_scores_gemma":[0.0004781096,0.00006373262,0.00026438083,0.2456196,0.0020455068,0.000100331534,0.00014191483,0.00002699987,0.0000013433121,0.0002615264,0.75034183,0.0006547255],"about_ca_topic_score_codex":0.0009256723,"about_ca_topic_score_gemma":0.00023290042,"teacher_disagreement_score":0.7463215,"about_ca_system_score_codex":0.0010129338,"about_ca_system_score_gemma":0.0013174945,"threshold_uncertainty_score":0.9998147},"labels":[],"label_agreement":null},{"id":"W4322721258","doi":"10.1155/2023/2794220","title":"Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study","year":2023,"lang":"en","type":"article","venue":"Gastroenterology Research and Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"University of British Columbia; Ministry of Health, British Columbia","keywords":"Biosimilar; Medicine; Infliximab; Cohort; Inflammatory Bowel Diseases; Inflammatory bowel disease; Population; Internal medicine; Family medicine; Intensive care medicine; Environmental health; Tumor necrosis factor alpha; Disease","score_opus":0.023287963568184977,"score_gpt":0.364555049673507,"score_spread":0.341267086105322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322721258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948241,0.000079046345,0.00006266,0.0037043924,0.00017719144,0.0009946639,0.000072977775,0.000061374776,0.00002356775],"genre_scores_gemma":[0.9984853,0.000027180218,0.00041032655,0.0006914667,0.00009117927,0.00017096178,0.00006787872,0.00002357208,0.000032086446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956173,0.0021893543,0.00037588333,0.00065143657,0.00028037553,0.0008856822],"domain_scores_gemma":[0.9971711,0.0019401414,0.000094486146,0.00038074036,0.00019529715,0.0002182573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002392348,0.00022040431,0.00037267292,0.00075238955,0.0002879536,0.00005708628,0.00027644594,0.00020336431,0.000059222348],"category_scores_gemma":[0.002708162,0.00017630872,0.00003391363,0.0005946707,0.00021143907,0.00023802381,0.00028878974,0.00094723975,0.0000626957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00798212,0.0008145255,0.9893999,0.000015763591,0.00023097062,0.000077521414,0.00020429102,0.0000061806263,0.00024578138,0.000009590011,0.00028727914,0.0007260789],"study_design_scores_gemma":[0.004082965,0.0022743838,0.99187154,0.000060795654,0.00005761661,0.000003475671,0.000502662,0.000021921482,0.000033333185,0.00005053372,0.0009246464,0.00011615436],"about_ca_topic_score_codex":0.0007619417,"about_ca_topic_score_gemma":0.00015545488,"teacher_disagreement_score":0.0038991545,"about_ca_system_score_codex":0.00014656538,"about_ca_system_score_gemma":0.00015191497,"threshold_uncertainty_score":0.71896607},"labels":[],"label_agreement":null},{"id":"W4323351148","doi":"10.1093/jcag/gwac036.175","title":"A175 REAL-WORLD EXPERIENCE ON SWITCHING FROM ADALIMUMAB TO BIOSIMILARS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – AN OBSERVATIONAL STUDY FROM THREE TERTIARY CARE CENTRES","year":2023,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Western University; Kelowna General Hospital; University of British Columbia","funders":"","keywords":"Biosimilar; Medicine; Adalimumab; Ulcerative colitis; Inflammatory bowel disease; Infliximab; Internal medicine; Crohn's disease; Faecal calprotectin; Calprotectin; Disease","score_opus":0.022869142803211485,"score_gpt":0.2722432630754599,"score_spread":0.2493741202722484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323351148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929215,0.0000090173835,0.000004549232,0.0058071325,0.0005688955,0.00025584578,0.00042039866,0.0000063192647,0.000006399275],"genre_scores_gemma":[0.9975136,0.0000025524387,0.000093692266,0.0022457954,0.00004787063,0.0000057342127,0.000048546204,0.000011772048,0.000030467458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807465,0.0006620809,0.0005262314,0.00020567399,0.00018236252,0.00034902786],"domain_scores_gemma":[0.9986509,0.00018295593,0.0005441584,0.00023504496,0.00023041747,0.00015649428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038719174,0.0001463669,0.00029870274,0.00034559262,0.00013000987,0.000018074737,0.00041568402,0.00011043804,0.00006898079],"category_scores_gemma":[0.00026099483,0.00010437099,0.00009025582,0.00019403921,0.000046543766,0.00010773976,0.000060046197,0.00034712366,0.000003956901],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011989957,0.00013651246,0.9958291,0.0000021509488,0.00018560939,0.00001178071,0.0011650613,0.0001998848,0.00023431427,0.000006213041,0.00090036815,0.00013000207],"study_design_scores_gemma":[0.0022339867,0.00060864916,0.996111,0.0000706612,0.00006996642,1.5234303e-7,0.00051920617,0.000013962224,0.000059568858,0.00007767625,0.00016588598,0.00006929339],"about_ca_topic_score_codex":0.009702082,"about_ca_topic_score_gemma":0.7537191,"teacher_disagreement_score":0.744017,"about_ca_system_score_codex":0.00072418124,"about_ca_system_score_gemma":0.00022310654,"threshold_uncertainty_score":0.9968924},"labels":[],"label_agreement":null},{"id":"W4327698971","doi":"10.51731/cjht.2023.599","title":"Formulary Management of Targeted Immune Modulators in Ulcerative Colitis","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Golimumab; Medicine; Ulcerative colitis; Infliximab; Biosimilar; Tofacitinib; Adalimumab; Ustekinumab; Formulary; Vedolizumab; Pharmacology; Immunology; Internal medicine; Rheumatoid arthritis; Disease","score_opus":0.02723269619042964,"score_gpt":0.29722217123173855,"score_spread":0.26998947504130894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327698971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86706877,0.0946342,0.0005145531,0.03411687,0.0016558575,0.0008077191,0.00017432083,0.00018603691,0.00084168743],"genre_scores_gemma":[0.99739826,0.0013541651,0.0009504332,0.000095151714,0.0000015576359,0.0000044681983,0.0000058165124,0.000007778463,0.0001823805],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99846846,0.00015484123,0.00072433986,0.00011908577,0.000037411195,0.0004958908],"domain_scores_gemma":[0.99933976,0.00006391933,0.0003139754,0.00018149245,0.00007550305,0.000025349396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011744461,0.00011190258,0.00046628187,0.0008744666,0.00010779696,0.0000056999625,0.00032485905,0.0002507247,0.0000620111],"category_scores_gemma":[0.00013517642,0.00009138333,0.00009047228,0.0008295226,0.00032813312,0.000056424302,0.00004427115,0.0004128388,0.0000090419035],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014660934,0.0000654423,0.007916734,0.00044377413,0.0005598015,0.00050808024,0.00076391274,0.000046661753,0.0021895445,0.023360768,0.00658306,0.95741564],"study_design_scores_gemma":[0.0034924636,0.001702502,0.756194,0.0016552516,0.00006968332,0.00025673694,0.028075421,0.00005536764,0.057508122,0.041547354,0.108893536,0.00054958224],"about_ca_topic_score_codex":0.0013952315,"about_ca_topic_score_gemma":0.0016012318,"teacher_disagreement_score":0.956866,"about_ca_system_score_codex":0.00017551384,"about_ca_system_score_gemma":0.0003961453,"threshold_uncertainty_score":0.37265038},"labels":[],"label_agreement":null},{"id":"W4360601016","doi":"10.1007/s40259-023-00589-3","title":"Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health and Medical Research Fund; Medical Research Council; University of Hong Kong; National Institute for Health and Care Research; Australian Government; National Health and Medical Research Council; European Commission; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Biosimilar; Infliximab; Medicine; Interrupted time series; Interrupted Time Series Analysis; Consumption (sociology); Demography; Internal medicine; Tumor necrosis factor alpha","score_opus":0.02306556960911271,"score_gpt":0.3292944411009679,"score_spread":0.3062288714918552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360601016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974874,0.000816495,0.000040207677,0.00069416617,0.0001785104,0.0003072545,0.00019378678,0.0001269895,0.00015513663],"genre_scores_gemma":[0.9975277,0.00048482325,0.0010184323,0.0001407549,0.000039524057,0.000026888036,0.00026006316,0.000026026215,0.0004757694],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997708,0.00032426568,0.0006715362,0.0006737819,0.000099075485,0.00052333187],"domain_scores_gemma":[0.99866855,0.00031887883,0.00028055822,0.0005397827,0.00011423528,0.00007797431],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007631847,0.00036612927,0.0008152126,0.0013793914,0.00012025315,0.000049309056,0.0002478213,0.00044546716,0.000497718],"category_scores_gemma":[0.0003135783,0.0002836912,0.00027380115,0.0018755028,0.0005981078,0.00032765372,0.00016756999,0.00037277158,0.000109507826],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058801365,0.001864076,0.41155076,0.00027825395,0.0069570174,0.00006377898,0.005128696,0.00027297068,0.5338472,0.003214245,0.0076407003,0.023302162],"study_design_scores_gemma":[0.005162547,0.0028184494,0.8990749,0.0002533766,0.0010765357,0.000060672417,0.00061656896,0.0016788145,0.082233176,0.0005326861,0.005372234,0.0011200529],"about_ca_topic_score_codex":0.00015183205,"about_ca_topic_score_gemma":0.00004966936,"teacher_disagreement_score":0.48752415,"about_ca_system_score_codex":0.0001225996,"about_ca_system_score_gemma":0.00007527038,"threshold_uncertainty_score":0.9999615},"labels":[],"label_agreement":null},{"id":"W4361205476","doi":"10.51731/cjht.2023.608","title":"Formulary Management of Biologics in Plaque Psoriasis","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ustekinumab; Biosimilar; Medicine; Formulary; Plaque psoriasis; Biologic Agents; Infliximab; Psoriasis; Family medicine; Tumor necrosis factor alpha; Internal medicine; Dermatology; Disease","score_opus":0.04817312372920696,"score_gpt":0.31702777676995286,"score_spread":0.2688546530407459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361205476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6961749,0.19351313,0.00089152204,0.10266907,0.0034117212,0.0009298552,0.00019682493,0.00033947203,0.0018734882],"genre_scores_gemma":[0.9938541,0.004223338,0.0016073064,0.00017787021,0.0000023265561,0.000003338168,0.0000041991184,0.000006304915,0.0001211851],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998609,0.000119581964,0.00064853125,0.000118080134,0.00002913768,0.00047568872],"domain_scores_gemma":[0.9993448,0.000097349985,0.00029551034,0.00018339888,0.000057051395,0.000021836482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013502327,0.00010419246,0.00041481797,0.0008835017,0.000084648505,0.0000046507375,0.00039947894,0.00032382374,0.00004107743],"category_scores_gemma":[0.00017798685,0.00007789869,0.00008507933,0.0007826695,0.00030480514,0.000039335493,0.00004890192,0.00040657353,0.000012723817],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004862782,0.000036677917,0.01207357,0.00025692672,0.0002077778,0.00026484593,0.00014981008,0.0000131050265,0.00089071185,0.014822554,0.010800539,0.96043485],"study_design_scores_gemma":[0.0034587653,0.0023803446,0.16302955,0.0016476811,0.000087530556,0.00040310505,0.022343611,0.00001910515,0.037010282,0.0761947,0.6927955,0.0006298238],"about_ca_topic_score_codex":0.0007229564,"about_ca_topic_score_gemma":0.00080021017,"teacher_disagreement_score":0.959805,"about_ca_system_score_codex":0.000118571355,"about_ca_system_score_gemma":0.0003346157,"threshold_uncertainty_score":0.31766164},"labels":[],"label_agreement":null},{"id":"W4362459170","doi":"10.4212/cjhp.3272","title":"A Framework for Evaluating the Implementation of Biosimilar Drugs","year":2023,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Cancer Care Ontario; Alberta Health Services; Canadian Pharmacists Association; Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Biosimilar; Computer science; Medicine; Data science; Internal medicine","score_opus":0.07292815816171819,"score_gpt":0.43169258429392016,"score_spread":0.35876442613220194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362459170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92091525,0.002804726,0.0005165359,0.07215482,0.0027058907,0.0005846839,0.00018133462,0.0000099237595,0.00012683615],"genre_scores_gemma":[0.9979799,0.000053530253,0.0008276922,0.00089206954,0.0001183786,0.0000072079415,0.000004593308,0.000010580156,0.00010608562],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99898314,0.00021400648,0.0003707629,0.000077257115,0.0000587253,0.00029611375],"domain_scores_gemma":[0.998665,0.00062844984,0.00029859957,0.00012977829,0.00021966358,0.000058534213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020022057,0.00009062115,0.00017223987,0.000098433535,0.00035382342,0.000024754489,0.0003973783,0.000055204175,0.0004592379],"category_scores_gemma":[0.00033063683,0.00004807807,0.00018437764,0.00028406165,0.0002645407,0.00005399581,0.000021334647,0.0003113945,0.000012009781],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007656351,0.0001417468,0.021258768,0.00017160534,0.004098882,0.00003583373,0.03261115,0.00009203331,0.100276515,0.048151612,0.29851145,0.49388477],"study_design_scores_gemma":[0.00934463,0.0071334764,0.035873797,0.0003758019,0.0023943437,0.00014273393,0.031918734,0.0004484623,0.48619074,0.16986006,0.2553952,0.0009220033],"about_ca_topic_score_codex":0.0012322795,"about_ca_topic_score_gemma":0.0006892029,"teacher_disagreement_score":0.49296275,"about_ca_system_score_codex":0.000042101827,"about_ca_system_score_gemma":0.0004891657,"threshold_uncertainty_score":0.5028333},"labels":[],"label_agreement":null},{"id":"W4364857199","doi":"10.2139/ssrn.4415094","title":"Effect of Biosolids Amendment on the Fate and Mobility of Non-Steroidal Anti-Inflammatory Drugs (Nsaids) in a Field-Based Lysimeter Cell Study","year":2023,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Lysimeter; Amendment; Naproxen; Biosolids; Field (mathematics); Pharmacology; Anti-inflammatory; Medicine; Environmental science; Law; Soil science; Political science; Mathematics; Environmental engineering; Soil water","score_opus":0.012198067542883044,"score_gpt":0.29263988090713094,"score_spread":0.2804418133642479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364857199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694556,0.0009658209,0.00028722436,0.00050044106,0.00034540505,0.0008659517,0.0000192967,0.000011025083,0.00005924962],"genre_scores_gemma":[0.9990482,0.0005637051,0.000020410049,0.00007196901,0.00002747037,0.00003190432,0.000003835119,0.000021703774,0.00021083262],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955237,0.0020456254,0.00078803656,0.00044087094,0.00012226411,0.0010794867],"domain_scores_gemma":[0.99749047,0.0014304754,0.0004966615,0.0004929171,0.000062471016,0.00002701391],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008413046,0.0003569856,0.0009042827,0.00027816527,0.000079801284,0.00001724244,0.0004689396,0.00045905603,0.000042605112],"category_scores_gemma":[0.00013732904,0.00021365794,0.0003241651,0.00016217095,0.00021616595,0.000019060893,0.000316416,0.0038583495,0.0000067050655],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012768428,0.007885391,0.2159637,0.002827133,0.008851694,0.00006392259,0.0034725673,0.000760636,0.686998,0.0010516136,0.00034193593,0.05901494],"study_design_scores_gemma":[0.0060923873,0.016671723,0.010600399,0.0005004539,0.00080031593,0.000016793332,0.0016530833,0.00022048675,0.9580692,0.0047899634,0.00004619346,0.0005390115],"about_ca_topic_score_codex":0.00012927456,"about_ca_topic_score_gemma":0.000094307376,"teacher_disagreement_score":0.27107114,"about_ca_system_score_codex":0.00021125172,"about_ca_system_score_gemma":0.00051181356,"threshold_uncertainty_score":0.9984398},"labels":[],"label_agreement":null},{"id":"W4378347895","doi":"10.1080/13543784.2023.2212155","title":"Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study","year":2023,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Celltrion","keywords":"Tocilizumab; Medicine; Bioequivalence; Clinical endpoint; Cmax; Pharmacokinetics; Adverse effect; Internal medicine; Confidence interval; Pharmacology; Randomized controlled trial; European union; Area under the curve; Rheumatoid arthritis; Gastroenterology","score_opus":0.11854610921628209,"score_gpt":0.39229762798865775,"score_spread":0.2737515187723757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378347895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9388909,0.010353015,0.00027779563,0.02342641,0.008124186,0.007672591,0.00129491,0.00063371466,0.009326501],"genre_scores_gemma":[0.9949911,0.0019031417,0.000603562,0.0008583356,0.00013632607,0.0002611595,0.0006416105,0.0000341703,0.0005705427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971442,0.0007680795,0.0008337185,0.0006163443,0.00023905876,0.00039857387],"domain_scores_gemma":[0.9975952,0.001463035,0.0002707266,0.0003521128,0.00018900089,0.00012992883],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011032177,0.00036126273,0.0007388143,0.00028722172,0.00026403708,0.000031573494,0.0002849498,0.0001878562,0.00047117606],"category_scores_gemma":[0.00044202394,0.00029089773,0.00015371834,0.0005472699,0.0011204333,0.00010635315,0.00018710959,0.00038433753,0.00007378054],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83804905,0.0025549876,0.00010024087,0.00008500206,0.0016881347,0.000019723213,0.0046398235,0.000056176308,0.065806754,0.031211177,0.028403966,0.02738496],"study_design_scores_gemma":[0.82020605,0.002203794,0.00017518623,0.0001759269,0.00010047864,0.000016404643,0.0016328099,0.00058785256,0.08821864,0.0012752292,0.084756,0.0006516436],"about_ca_topic_score_codex":0.00014749248,"about_ca_topic_score_gemma":0.000007716559,"teacher_disagreement_score":0.05635204,"about_ca_system_score_codex":0.000078134544,"about_ca_system_score_gemma":0.00015583805,"threshold_uncertainty_score":0.99995434},"labels":[],"label_agreement":null},{"id":"W4379282976","doi":"10.1200/jco.2023.41.16_suppl.e15555","title":"Real-world safety and effectiveness of MVASI in metastatic colorectal cancer patients in Canada.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Centre Hospitalier Universitaire de Sherbrooke; Queen Elizabeth II Health Sciences Centre; Markham Stouffville Hospital; Southlake Regional Health Center; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Victoria Hospital; Ottawa Hospital; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Nova Scotia Health Authority; Centre Intégré de Santé et de Services Sociaux des Laurentides; London Health Sciences Centre; Amgen (Canada); Grand River Hospital","funders":"Amgen","keywords":"Medicine; Bevacizumab; Colorectal cancer; Internal medicine; Biosimilar; Adverse effect; Oncology; Medical record; Cancer; Surgery; Chemotherapy","score_opus":0.06881814776288293,"score_gpt":0.4400968442127952,"score_spread":0.3712786964499123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972124,0.00026254673,0.0000038170715,0.00066459854,0.0012346787,0.00014352158,0.00002997685,0.0000020561122,0.0004463851],"genre_scores_gemma":[0.9975225,0.0020584986,0.00018619059,0.00014675455,0.000022642153,0.0000030697624,0.0000033494025,0.0000063589932,0.000050657974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950845,0.002590977,0.0018502771,0.00015833441,0.00006697489,0.00024888554],"domain_scores_gemma":[0.98963016,0.0093371095,0.0007648837,0.00006120973,0.00014802399,0.00005863994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005620278,0.00010467848,0.0014402356,0.00022195264,0.000016771079,0.0000014327076,0.00014335268,0.0002097681,0.00009437841],"category_scores_gemma":[0.0023596883,0.00007399419,0.00011737909,0.00047256958,0.0002408641,0.000041068983,0.00007563237,0.0007386623,0.0000015691842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046857004,0.00038510605,0.9550286,0.000050627827,0.00020560338,0.00009011103,0.000026947817,0.000026426367,0.0010960493,0.0001366582,0.0003569809,0.03791118],"study_design_scores_gemma":[0.0052157217,0.0014787486,0.98829377,0.00012768754,0.000075659125,0.00000535673,0.000052252006,0.000024479132,0.0012693179,0.00035749158,0.0030267432,0.00007275411],"about_ca_topic_score_codex":0.19344182,"about_ca_topic_score_gemma":0.77781534,"teacher_disagreement_score":0.58437353,"about_ca_system_score_codex":0.00032603514,"about_ca_system_score_gemma":0.0022858272,"threshold_uncertainty_score":0.8119291},"labels":[],"label_agreement":null},{"id":"W4379521519","doi":"10.1136/annrheumdis-2023-eular.1722","title":"POS0232 POST-MARKETING SAFETY SURVEILLANCE OF TOFACITINIB OVER 9 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"UCB Pharma; Medac; Eisai; Celgene; Biogen; Ortho Dermatologics; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company","keywords":"Tofacitinib; Medicine; Psoriatic arthritis; Rheumatoid arthritis; Adverse effect; Internal medicine; Safety profile; Ulcerative colitis; Dermatology","score_opus":0.011433446367392599,"score_gpt":0.25199623909436375,"score_spread":0.24056279272697115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379521519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99301404,0.0051794243,0.0000017705122,0.00047690546,0.0001267324,0.00024997385,0.0008772506,0.000020779773,0.000053149826],"genre_scores_gemma":[0.9940524,0.0056628967,0.000046552155,0.0001299375,0.0000023433697,0.0000066922084,0.000045181976,0.000012684022,0.00004130761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984108,0.00048665228,0.0005147429,0.00020225132,0.00010321214,0.0002823494],"domain_scores_gemma":[0.9984732,0.00084131304,0.00026154058,0.0002810827,0.00010850999,0.00003431648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006630353,0.00014516003,0.0004906423,0.000098775796,0.00005863343,0.00000954376,0.00018143283,0.000086534536,0.00023133341],"category_scores_gemma":[0.0013708308,0.00010024629,0.00011029003,0.00035218045,0.0003532358,0.000051998548,0.000135677,0.00010214301,0.000006664784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009894106,0.00030816978,0.58503276,0.00024199147,0.0003168296,0.0000023491036,0.00025479426,0.000010196822,0.000112627014,0.00025481643,0.0015242762,0.4109518],"study_design_scores_gemma":[0.0016608951,0.00013408634,0.9954373,0.0016516147,0.000009561127,0.0000017084642,0.00012490299,0.000012872929,0.00025702134,0.0003929486,0.00018868169,0.00012841183],"about_ca_topic_score_codex":0.000080723374,"about_ca_topic_score_gemma":0.00004757427,"teacher_disagreement_score":0.41082337,"about_ca_system_score_codex":0.0000047527133,"about_ca_system_score_gemma":0.00003990817,"threshold_uncertainty_score":0.4087925},"labels":[],"label_agreement":null},{"id":"W4379523042","doi":"10.1136/annrheumdis-2023-eular.3343","title":"POS0566 SURVIVAL ON TREATMENT AFTER SWITCHING TO A BIOSIMILAR: POPULATION-BASED EVIDENCE FROM A NATURAL EXPERIMENT DUE TO A POLICY CHANGE","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Research Canada; University of British Columbia","funders":"University of British Columbia; Simon Fraser University; Arthritis Society; Canadian Rheumatology Association","keywords":"Biosimilar; Medicine; Psoriatic arthritis; Etanercept; Discontinuation; Infliximab; Rheumatoid arthritis; Medical prescription; Internal medicine; Pharmacy; Family medicine; Disease; Pharmacology","score_opus":0.12199417997306101,"score_gpt":0.3917912002071095,"score_spread":0.2697970202340485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379523042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96089333,0.0018890328,0.000028157503,0.03558646,0.0004901087,0.00065932627,0.00038021922,0.00006157888,0.000011779544],"genre_scores_gemma":[0.9936914,0.000066628534,0.0001677823,0.0055376887,0.00005362336,0.00024499436,0.000027811133,0.000016698013,0.00019340677],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984844,0.00036660608,0.00033174144,0.00032708695,0.00012183328,0.00036834067],"domain_scores_gemma":[0.9983574,0.0008485722,0.00010095606,0.0005367419,0.00005475032,0.00010153489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019277558,0.00024244671,0.00043385196,0.00025882086,0.00012087671,0.00002676153,0.0003142735,0.000079015816,0.0001931348],"category_scores_gemma":[0.0009044202,0.0001398855,0.00030388826,0.00061342056,0.000039287595,0.00005400281,0.00014721099,0.00006970228,0.00013712753],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017435739,0.0062569343,0.15761544,0.0007716343,0.005422365,0.000108204935,0.018834539,0.00061322044,0.08791967,0.0022242952,0.029768232,0.6730297],"study_design_scores_gemma":[0.000531114,0.0006366432,0.9433181,0.0018944012,0.00012705331,9.062278e-7,0.00017173748,0.00017140408,0.0516329,0.0006811466,0.0005270225,0.0003075702],"about_ca_topic_score_codex":0.0020559423,"about_ca_topic_score_gemma":0.00012269414,"teacher_disagreement_score":0.78570265,"about_ca_system_score_codex":0.00006039898,"about_ca_system_score_gemma":0.00006365592,"threshold_uncertainty_score":0.5704365},"labels":[],"label_agreement":null},{"id":"W4379523514","doi":"10.1136/annrheumdis-2023-eular.2415","title":"POS0826 SAFETY PROFILE OF UPADACITINIB UP TO 6.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Chugai Pharmaceutical; Samsung; Genentech; Medac; H. Lundbeck A/S; Eisai; Astellas Pharma; Mylan; Gigtforeningen; Eli Lilly and Company; AstraZeneca; Kræftens Bekæmpelse; Daiichi-Sankyo; Teva Pharmaceutical Industries; Celgene; Biogen; Gilead Sciences; Kowa Company; Sanofi; Amgen; Pfizer","keywords":"Medicine; Adverse effect; Discontinuation; Internal medicine; Adalimumab; Rheumatoid arthritis; MedDRA; Population; Clinical trial; Pharmacovigilance","score_opus":0.021755609586488558,"score_gpt":0.27879290885957425,"score_spread":0.2570372992730857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379523514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746597,0.00076573755,0.000007940631,0.00039426849,0.00014149968,0.00037500486,0.00073373265,0.000014266584,0.000101598],"genre_scores_gemma":[0.9990938,0.00043252524,0.00011082131,0.000087571076,0.0000014758878,0.000012287876,0.000035376623,0.000010640717,0.00021550087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875695,0.0002171168,0.00053481886,0.00015652615,0.000105680185,0.00022891202],"domain_scores_gemma":[0.99894166,0.0002935725,0.00024031171,0.00035575603,0.00013510503,0.000033605975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000285412,0.00011417281,0.00046494656,0.00012054736,0.000028405258,0.000003005393,0.00028494565,0.00008018749,0.00025978708],"category_scores_gemma":[0.000590479,0.000075575634,0.00013782002,0.00050608057,0.0002531071,0.000040513947,0.00013384053,0.00007455363,0.000019250281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004254153,0.0017989115,0.6130694,0.0009458349,0.0010725209,0.0000027491233,0.002405328,0.0001367889,0.001927519,0.0022934717,0.025507944,0.34658536],"study_design_scores_gemma":[0.0012774921,0.00041316645,0.98636276,0.0013516478,0.000018527388,5.235273e-7,0.00029215778,0.000003301801,0.00935986,0.00046790394,0.00034525478,0.00010743226],"about_ca_topic_score_codex":0.000052677216,"about_ca_topic_score_gemma":0.000011770195,"teacher_disagreement_score":0.3732933,"about_ca_system_score_codex":0.000004045147,"about_ca_system_score_gemma":0.000054047985,"threshold_uncertainty_score":0.3081885},"labels":[],"label_agreement":null},{"id":"W4379523616","doi":"10.1136/annrheumdis-2023-eular.2446","title":"POS0564 THE IMPACT OF BIOSIMILAR SWITCHING POLICIES IN INFLAMMATORY ARTHRITIS ON UPTAKE AND SPENDING IN BRITISH COLUMBIA, CANADA","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Centre for Advancing Health Outcomes; University of Toronto; Providence Health Care; University of British Columbia","funders":"","keywords":"Biosimilar; Medicine; Inflammatory arthritis; Arthritis; Antirheumatic Agents; Internal medicine","score_opus":0.028388044956145803,"score_gpt":0.3001521578998069,"score_spread":0.2717641129436611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379523616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553853,0.0030204337,2.0662239e-7,0.0008593241,0.000099804274,0.00019376972,0.00022105135,0.000008333167,0.000058559453],"genre_scores_gemma":[0.9982672,0.0014590588,0.0000034344816,0.00016586577,0.0000043503237,0.000006478875,0.0000042858883,0.000008110073,0.000081230246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879646,0.00027822066,0.0004325818,0.00013706282,0.000069446956,0.0002862531],"domain_scores_gemma":[0.9989764,0.0005822462,0.00015757399,0.00023070013,0.000024967982,0.000028119592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046213414,0.00009575083,0.0003376341,0.00006953793,0.00009231651,0.000036036672,0.00024786795,0.00006779836,0.00009798122],"category_scores_gemma":[0.00053037377,0.00007657305,0.00012705919,0.0003245817,0.00021349169,0.000041801843,0.00012564656,0.00014792141,0.0000011782483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006847768,0.00020402855,0.8843053,0.00021895456,0.0003400898,0.000022655953,0.0005262373,0.00013691346,0.001864001,0.00017337764,0.013971252,0.09816872],"study_design_scores_gemma":[0.00032834557,0.000052563897,0.99545544,0.0011486149,0.000011932716,0.000008231486,0.0006430226,0.000051202,0.00053552265,0.0016290224,0.000052314757,0.00008377301],"about_ca_topic_score_codex":0.5760395,"about_ca_topic_score_gemma":0.70121884,"teacher_disagreement_score":0.12517934,"about_ca_system_score_codex":0.00002157316,"about_ca_system_score_gemma":0.00015833645,"threshold_uncertainty_score":0.42678368},"labels":[],"label_agreement":null},{"id":"W4379523942","doi":"10.1136/annrheumdis-2023-eular.3373","title":"POS0567 COMPARISON OF SURVIVAL ON TREATMENT AMONG NEW USERS OF BIOSIMILAR VS. ORIGINATOR BIOLOGICS IN INFLAMMATORY ARTHRITIS: POPULATION-BASED EVIDENCE FROM A NATURAL EXPERIMENT DUE TO A POLICY CHANGE","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Research Canada; University of British Columbia","funders":"University of British Columbia; Simon Fraser University; Arthritis Society; Canadian Rheumatology Association","keywords":"Medicine; Biosimilar; Etanercept; Infliximab; Psoriatic arthritis; Discontinuation; Hazard ratio; Internal medicine; Rheumatoid arthritis; Population; Adalimumab; Tumor necrosis factor alpha; Environmental health; Confidence interval","score_opus":0.12592058147037297,"score_gpt":0.3951156928155578,"score_spread":0.2691951113451848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379523942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99049854,0.0048716622,0.0000044617973,0.0035227626,0.00026294592,0.00052268425,0.00028813243,0.000024564575,0.0000042375445],"genre_scores_gemma":[0.9991161,0.0003960419,0.00010316623,0.000245909,0.000016341633,0.000041469433,0.00004069873,0.000009823568,0.000030447485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832946,0.00044938715,0.00061637873,0.00023463536,0.000108990454,0.00026117582],"domain_scores_gemma":[0.9981644,0.000966857,0.00034031074,0.00040091592,0.00006485607,0.000062661165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022085506,0.00020727859,0.00072594313,0.00029787954,0.000044012253,0.000007333245,0.00030813497,0.00012412178,0.00006163379],"category_scores_gemma":[0.0009421922,0.00012987627,0.00024894893,0.0005642039,0.00018446898,0.000054460583,0.00008598164,0.00007870116,0.0000073175574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014210804,0.001032092,0.9551054,0.00018422316,0.00050199346,0.0000043157756,0.0017184385,0.0002485344,0.0069645448,0.00084036594,0.0013972494,0.030581763],"study_design_scores_gemma":[0.0006768249,0.00058079476,0.89569724,0.002047466,0.000046966725,1.4128133e-7,0.0002634051,0.00018674218,0.099832155,0.00046471463,0.00006221215,0.00014131343],"about_ca_topic_score_codex":0.004116025,"about_ca_topic_score_gemma":0.0003001637,"teacher_disagreement_score":0.09286761,"about_ca_system_score_codex":0.000046123707,"about_ca_system_score_gemma":0.00013113287,"threshold_uncertainty_score":0.62222254},"labels":[],"label_agreement":null},{"id":"W4379648580","doi":"10.1136/annrheumdis-2023-eular.268","title":"AB0402 PHARMACOKINETICS AND SAFETY OF CT-P47, A PROPOSED TOCILIZUMAB BIOSIMILAR, IN COMPARISON WITH EU-APPROVED TOCILIZUMAB; A PHASE 1, RANDOMIZED, DOUBLE-BLIND, TWO-ARM, SINGLE-DOSE STUDY IN HEALTHY SUBJECTS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Pfizer Pharmaceuticals; Sanofi Genzyme; Biogen; Gilead Sciences; Chugai Pharmaceutical; Celltrion; Sanofi; Amgen; Pfizer; Samsung; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Tocilizumab; Pharmacokinetics; Bioequivalence; Clinical endpoint; Area under the curve; Internal medicine; Pharmacodynamics; Nuclear medicine; Gastroenterology; Urology; Pharmacology; Randomized controlled trial; Rheumatoid arthritis","score_opus":0.10114464188552591,"score_gpt":0.39424986641269333,"score_spread":0.2931052245271674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379648580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879575,0.004214126,0.000023883205,0.0027743576,0.0001583115,0.0045195622,0.0001348794,0.000045482324,0.00017191173],"genre_scores_gemma":[0.99867296,0.00063296035,0.00011863736,0.00030046215,0.000006649049,0.00014201991,0.000028139984,0.000025691754,0.00007250216],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99572396,0.0016405792,0.0014156881,0.0004699405,0.00019783272,0.00055201165],"domain_scores_gemma":[0.99724096,0.0013903342,0.00060761184,0.0005172106,0.00015353892,0.000090355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016874399,0.0003712586,0.0016758573,0.000336761,0.000104686565,0.000022967128,0.00042922224,0.00009785858,0.00008553456],"category_scores_gemma":[0.0005970944,0.00022808329,0.00023758454,0.0011126021,0.00090821186,0.000089779045,0.00024266097,0.00031721956,0.0000038499047],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93507314,0.016479991,0.009505795,0.0011798728,0.0014813216,0.000030796393,0.0026007886,0.00019356624,0.0024914136,0.00040045625,0.0010879092,0.029474935],"study_design_scores_gemma":[0.9526799,0.004664158,0.008284301,0.0015581687,0.0009093005,0.0000194445,0.0035757336,0.002487415,0.023855198,0.0011863654,0.00016261975,0.0006174094],"about_ca_topic_score_codex":0.0004629023,"about_ca_topic_score_gemma":0.00050102064,"teacher_disagreement_score":0.028857525,"about_ca_system_score_codex":0.000031176693,"about_ca_system_score_gemma":0.00019005634,"threshold_uncertainty_score":0.9300966},"labels":[],"label_agreement":null},{"id":"W4379650075","doi":"10.1136/annrheumdis-2023-eular.4884","title":"POS1069 SYSTEMATIC LITERATURE REVIEW INFORMING THE EULAR POINTS TO CONSIDER TASK FORCE ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Debreceni Egyetem; Hôpitaux Universitaires de Genève; Diakonhjemmet; Hacettepe Üniversitesi; Universita degli Studi di Bari Aldo Moro; Universität Wien; Celltrion; Aarhus Universitet; Medizinische Universität Wien; Aarhus Universitetshospital; Institut Gustave-Roussy; Gilead Sciences; Karolinska Institutet; Rigshospitalet; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Oncology; Task force; Cancer; Inflammatory arthritis; MEDLINE; Hazard ratio; Physical therapy; Rheumatoid arthritis; Confidence interval","score_opus":0.0248120749477799,"score_gpt":0.2841204645295113,"score_spread":0.2593083895817314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379650075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80706924,0.18780228,0.0000014522793,0.0037390448,0.0000876828,0.0011365255,0.00012350206,0.000008449676,0.000031801792],"genre_scores_gemma":[0.9864216,0.011023259,0.0000099195095,0.002376513,0.0000018650138,0.00007420084,0.000008229739,0.0000073414644,0.0000770858],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.99871385,0.00050222717,0.00047308777,0.00009131392,0.00009526723,0.00012425092],"domain_scores_gemma":[0.9982775,0.000856551,0.0003811569,0.00029192428,0.00017825994,0.000014596031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006133329,0.000115847324,0.00040244457,0.00007375209,0.000042028783,0.0000048860984,0.00017554505,0.000047598623,0.000035695186],"category_scores_gemma":[0.0012221981,0.000046816916,0.00008806073,0.0002499212,0.0002699559,0.000057651916,0.000061644976,0.00008902517,0.0000014714935],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00377297,0.0018594322,0.27779427,0.47839522,0.0096451,0.000009628902,0.05352601,0.00015892801,0.007643645,0.025517762,0.103683986,0.037993044],"study_design_scores_gemma":[0.0013955352,0.0005220978,0.6336957,0.3538537,0.00056612206,0.0000027205124,0.0011983784,0.000036078814,0.0048418166,0.0029959953,0.0005695118,0.00032232417],"about_ca_topic_score_codex":0.000014161157,"about_ca_topic_score_gemma":0.000011491693,"teacher_disagreement_score":0.35590145,"about_ca_system_score_codex":0.00001203819,"about_ca_system_score_gemma":0.00006156924,"threshold_uncertainty_score":0.19091384},"labels":[],"label_agreement":null},{"id":"W4379650122","doi":"10.1136/annrheumdis-2023-eular.2062","title":"AB0396 DISCONTINUATION AND EFFECTIVENESS OF ORIGINATOR AND BIOSIMILAR TNFI IN PATIENTS WITH RHEUMATOID ARTHRITIS: REAL WORLD DATA FROM A RHEUMATOID ARTHRITIS REGISTRY IN CANADA","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University of Toronto; Ministry of Health and Long Term Care","funders":"Canadian Institutes of Health Research","keywords":"Biosimilar; Medicine; Discontinuation; Rheumatoid arthritis; Internal medicine; Real world data; Arthritis; Physical therapy; Data science","score_opus":0.025077973140227573,"score_gpt":0.2789506569275707,"score_spread":0.2538726837873431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379650122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909609,0.006525125,0.0000028062566,0.00036161143,0.00010590328,0.00037160053,0.001641547,0.000011405222,0.000019134306],"genre_scores_gemma":[0.98644876,0.0132093225,0.000042279302,0.000038715312,0.0000015781463,0.000018307352,0.0002198903,0.000012995809,0.000008121363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815464,0.0005699942,0.00051998,0.00036404884,0.000118164586,0.00027317583],"domain_scores_gemma":[0.9981242,0.0008882362,0.00030707955,0.0005712912,0.00006249111,0.000046690006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005380943,0.00018982109,0.0006528891,0.00013528127,0.00005409676,0.000015699212,0.0003229793,0.00006055927,0.000025417055],"category_scores_gemma":[0.0005213452,0.00013196866,0.00003641214,0.00048226636,0.00043670303,0.00014742572,0.0002692043,0.00013426655,9.541815e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005568184,0.0002049669,0.96897995,0.00017277265,0.00015012488,0.000003548258,0.00006167033,0.000003738971,0.00008057536,0.00020437445,0.0008623981,0.028719028],"study_design_scores_gemma":[0.0020521225,0.00007861784,0.99038404,0.004807112,0.000012466094,9.0944985e-7,0.00020589955,0.00006407673,0.0012536343,0.0008985576,0.0000837226,0.00015883107],"about_ca_topic_score_codex":0.22733532,"about_ca_topic_score_gemma":0.42002225,"teacher_disagreement_score":0.19268695,"about_ca_system_score_codex":0.000024870405,"about_ca_system_score_gemma":0.00024669114,"threshold_uncertainty_score":0.7778099},"labels":[],"label_agreement":null},{"id":"W4379650226","doi":"10.1136/annrheumdis-2023-eular.2772","title":"AB0409 TIME TO FIRST REMISSION AND PREVALENCE OF SUSTAINED REMISSION AFTER ETANERCEPT BIOSIMILAR (ETA-B) OR ORIGINATOR (ETA-O) INITIATION IN RHEUMATOID ARTHRITIS (RA)","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Alberta; Université de Sherbrooke; McGill University Health Centre","funders":"","keywords":"Medicine; Etanercept; Rheumatoid arthritis; Internal medicine; Hydroxychloroquine; Body mass index; Methotrexate; Cohort; Disease","score_opus":0.028991236289722642,"score_gpt":0.3059786104500527,"score_spread":0.27698737416033004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379650226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832621,0.0073319124,0.000015307376,0.008060484,0.00014113313,0.00064616575,0.00031971393,0.000057374113,0.00016577575],"genre_scores_gemma":[0.98830295,0.008562499,0.0001569802,0.0003525399,0.0000059607455,0.000037753027,0.0000169986,0.000018731807,0.002545562],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99811584,0.00040470218,0.0006773067,0.0003256866,0.0001344559,0.00034198872],"domain_scores_gemma":[0.99841285,0.00064917014,0.00025750673,0.00044667927,0.00014369114,0.000090133326],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006812055,0.00021858266,0.00054141483,0.00019868079,0.000102956496,0.000014603393,0.00030121053,0.00018618256,0.0021710952],"category_scores_gemma":[0.002271285,0.00013415886,0.00015889188,0.0006325496,0.00026203366,0.000118362565,0.0002483542,0.00012781113,0.00006153768],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014913295,0.0036043918,0.13178088,0.016980505,0.0016846718,0.00011939706,0.006050722,0.00015501639,0.09231787,0.0011081623,0.30577677,0.42550832],"study_design_scores_gemma":[0.004209117,0.0014142726,0.7888406,0.02303664,0.00034900545,0.000056245335,0.0009863485,0.00094995124,0.14863521,0.006204888,0.024039418,0.0012783344],"about_ca_topic_score_codex":0.000017723834,"about_ca_topic_score_gemma":0.000006656434,"teacher_disagreement_score":0.65705967,"about_ca_system_score_codex":0.000015828093,"about_ca_system_score_gemma":0.00008808703,"threshold_uncertainty_score":0.99874103},"labels":[],"label_agreement":null},{"id":"W4379650819","doi":"10.1136/annrheumdis-2023-eular.1464","title":"AB1591 POLICY DRIVERS FOR MARKET PENETRATION OF ANTI-TNF BIOSIMILARS: MULTI-COUNTRY COMPARISONS","year":2023,"lang":"en","type":"article","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University of Calgary; Centre for Advancing Health Outcomes; University of British Columbia","funders":"UCB Pharma; Jazz Pharmaceuticals; Nordic Pharma Group; Mylan; Biogen; Sanofi; Merck; Canadian Institutes of Health Research; Novartis; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biosimilar; Procurement; Infliximab; Medicine; Penetration (warfare); Market penetration; Market share; Business; Marketing; Operations research; Tumor necrosis factor alpha; Internal medicine; Engineering","score_opus":0.04815369307898426,"score_gpt":0.3436926202255529,"score_spread":0.29553892714656865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379650819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5905412,0.0044261306,0.2046807,0.07640939,0.011164139,0.010361281,0.0088181235,0.0034720767,0.090126954],"genre_scores_gemma":[0.96256256,0.00036463208,0.019380666,0.0016676057,0.000088243294,0.000034358072,0.00026727922,0.000030855346,0.01560382],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99884367,0.00012811323,0.00034743213,0.00027169747,0.00003691405,0.0003721944],"domain_scores_gemma":[0.9991689,0.0003684795,0.000108891385,0.00022916721,0.000094724135,0.000029859037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050490856,0.00015712182,0.00035405133,0.00023944712,0.00012335076,0.0000118310445,0.00019872635,0.00033329809,0.0007633558],"category_scores_gemma":[0.00025737783,0.00012509032,0.00015669553,0.0005129605,0.00026796653,0.000057025914,0.000067359986,0.000133249,0.000060849572],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000173331,0.0002846536,0.01235642,0.00009475762,0.00036726063,0.0000013991845,0.00009124716,0.000010317555,0.435949,0.0055195885,0.541377,0.0037750502],"study_design_scores_gemma":[0.0047347876,0.00050401554,0.19742443,0.00006223186,0.00023847014,0.000012087276,0.0009322536,0.0038804896,0.40256277,0.00046737588,0.38861352,0.0005675688],"about_ca_topic_score_codex":0.000077549215,"about_ca_topic_score_gemma":0.000070011796,"teacher_disagreement_score":0.37202135,"about_ca_system_score_codex":0.000024009045,"about_ca_system_score_gemma":0.00007689327,"threshold_uncertainty_score":0.8358211},"labels":[],"label_agreement":null},{"id":"W4380149473","doi":"10.1016/j.jval.2023.03.1261","title":"HPR114 Formulary Management of Biologics in Plaque Psoriasis in Canada","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Biosimilar; Formulary; Plaque psoriasis; Medicine; Psoriasis; Dermatology; Intensive care medicine; Family medicine; Internal medicine","score_opus":0.05714793715616513,"score_gpt":0.3078940492575455,"score_spread":0.25074611210138037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380149473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914855,0.0022812786,0.00002378989,0.004441498,0.0006453556,0.0004276924,0.000054867825,0.00001823302,0.00062181073],"genre_scores_gemma":[0.99553674,0.0027960367,0.000913716,0.0005560545,0.0000061638416,0.00001613316,0.000022649137,0.00000646086,0.00014605443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831444,0.00043531903,0.0005504294,0.00021924888,0.000034539593,0.0004460159],"domain_scores_gemma":[0.9994615,0.00025645155,0.000083805964,0.00016781359,0.000008657402,0.000021814394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012738166,0.00009889623,0.00034059474,0.00022871596,0.000020728292,0.0000012711034,0.00015937637,0.0001403338,0.000050370698],"category_scores_gemma":[0.00004421268,0.00008289768,0.000029773471,0.000776862,0.00004147857,0.000016519443,0.000085759515,0.00026225817,0.000008769273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007073727,0.00067705143,0.752891,0.0027212133,0.00022565201,0.0005500554,0.0010361338,0.0063025863,0.0029392675,0.04123638,0.011601403,0.17911188],"study_design_scores_gemma":[0.0038963987,0.00044232563,0.9496293,0.0009876832,0.0000123544105,0.000011497446,0.002630861,0.002406007,0.004769314,0.008352511,0.02642752,0.00043423564],"about_ca_topic_score_codex":0.7902571,"about_ca_topic_score_gemma":0.54173917,"teacher_disagreement_score":0.24851793,"about_ca_system_score_codex":0.00037796507,"about_ca_system_score_gemma":0.00036235922,"threshold_uncertainty_score":0.46662286},"labels":[],"label_agreement":null},{"id":"W4380184439","doi":"10.1016/j.jval.2023.03.2621","title":"HPR144 Coverage of Biologics for Rheumatoid Arthritis in Canada","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Medicine; Guideline; Rheumatoid arthritis; Antirheumatic drugs; Equity (law); Actuarial science; Antirheumatic Agents; Business; Internal medicine","score_opus":0.05111866706465138,"score_gpt":0.30295467291690203,"score_spread":0.25183600585225063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380184439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98385507,0.008985282,0.00019517414,0.0046445196,0.00104598,0.00060058606,0.00042299827,0.000028075596,0.00022229904],"genre_scores_gemma":[0.98837614,0.010252758,0.00053955894,0.0006673881,0.0000068005547,0.000019516347,0.000040469775,0.000007098167,0.000090294896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859834,0.00030195172,0.00049986923,0.00018402375,0.000022960672,0.00039284994],"domain_scores_gemma":[0.99902004,0.00070878403,0.00010259911,0.00012712512,0.000018842717,0.000022611173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010468485,0.00008366152,0.00037767453,0.00011120953,0.0000348606,0.0000015920851,0.00010791679,0.00012713813,0.000053884884],"category_scores_gemma":[0.000309538,0.000071571696,0.000039201666,0.00036124288,0.000054789743,0.000012694125,0.00003438962,0.00016752776,0.000005851047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073885004,0.000451967,0.446559,0.0012798494,0.00015175785,0.000058503978,0.00082470995,0.0034528845,0.017470697,0.033866983,0.05053761,0.44460717],"study_design_scores_gemma":[0.0135991825,0.0026670054,0.46617308,0.002414318,0.000008625675,0.000071730334,0.0019857828,0.0062123677,0.03530935,0.037423402,0.43288937,0.0012457998],"about_ca_topic_score_codex":0.742477,"about_ca_topic_score_gemma":0.5368046,"teacher_disagreement_score":0.44336137,"about_ca_system_score_codex":0.00017383612,"about_ca_system_score_gemma":0.0008837198,"threshold_uncertainty_score":0.47164747},"labels":[],"label_agreement":null},{"id":"W4380361363","doi":"10.1080/00085030.2023.2171022","title":"Simultaneous screening and quantitation of stimulant drugs in dried blood spot (DBS) samples using ultra-high performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS)","year":2023,"lang":"en","type":"article","venue":"Canadian Society of Forensic Science Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Laurentian University","funders":"","keywords":"Chromatography; Dried blood spot; Analyte; Dried blood; Chemistry; Mass spectrometry; Whole blood; Quadrupole time of flight; Drug detection; Elution; High-performance liquid chromatography; Blood sampling; Sample preparation; Tandem mass spectrometry; Medicine","score_opus":0.021386559929984464,"score_gpt":0.27097894527736927,"score_spread":0.24959238534738482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380361363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983049,0.0006265884,0.00049745105,0.00019931518,0.00016519337,0.000098376004,0.000058681224,0.000008559119,0.0000409225],"genre_scores_gemma":[0.9544072,0.0003377097,0.045133058,0.00006740205,0.000021478956,2.906386e-7,0.000006128116,0.000008834207,0.000017863284],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984047,0.000069605754,0.0005266678,0.00025325394,0.0001757871,0.00057003077],"domain_scores_gemma":[0.99882823,0.00033549537,0.00032787872,0.00015441787,0.00021028583,0.00014366432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00166716,0.00015116934,0.0004399892,0.00064512447,0.00032403113,0.000024323257,0.00029822488,0.00022281038,0.0000794431],"category_scores_gemma":[0.00020328413,0.00013470183,0.00016111351,0.0019123527,0.002010853,0.00017101361,0.000029320287,0.00032732546,0.0000013942043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005441952,0.000022151371,0.010602065,0.000058734862,0.000107644904,0.000005670907,0.0015243313,0.00041138055,0.98486775,0.000116385956,0.00009583535,0.002133611],"study_design_scores_gemma":[0.0011444096,0.0007550561,0.033345334,0.00043350234,0.00012367082,0.00018266684,0.004153219,0.010167281,0.94912875,0.00024634562,0.000051048755,0.00026873383],"about_ca_topic_score_codex":0.0036260819,"about_ca_topic_score_gemma":0.0005106558,"teacher_disagreement_score":0.04463561,"about_ca_system_score_codex":0.000067786,"about_ca_system_score_gemma":0.0005037687,"threshold_uncertainty_score":0.74090713},"labels":[],"label_agreement":null},{"id":"W4380785854","doi":"10.1007/s13318-023-00835-7","title":"Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study","year":2023,"lang":"en","type":"article","venue":"European Journal of Drug Metabolism and Pharmacokinetics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Adalimumab; Medicine; Internal medicine; Pharmacokinetics; Population; Dosing; Gastroenterology; Rheumatoid arthritis","score_opus":0.05780076161012206,"score_gpt":0.3190729579071068,"score_spread":0.2612721962969848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380785854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991397,0.0051142997,0.0004757823,0.00068388385,0.0013506119,0.00029318462,0.000048611364,0.00002057853,0.00061604404],"genre_scores_gemma":[0.99701387,0.0010561079,0.0008884943,0.00019422585,0.00015157295,9.5129167e-7,0.0000020631796,0.000024223375,0.00066850777],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968913,0.0014783712,0.00091770286,0.00021003501,0.00022313962,0.00027944506],"domain_scores_gemma":[0.99873435,0.00014562052,0.00035976843,0.00018732005,0.00044894882,0.00012396937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034982415,0.00019281848,0.00048397764,0.00022835917,0.00013576246,0.000028530878,0.00032132337,0.000021788801,0.000137138],"category_scores_gemma":[0.00018921318,0.00014262472,0.0000981889,0.00040346722,0.000119583485,0.00006417771,0.00021323255,0.00027494098,0.000041986856],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073594763,0.00064138515,0.002441219,0.000021800832,0.0004985014,0.000062122446,0.0019700285,0.00006226772,0.95167285,0.00004737691,0.022707948,0.019138534],"study_design_scores_gemma":[0.0093067605,0.0031201807,0.43396124,0.00015345306,0.0013096002,0.00008536225,0.0006334089,0.000020329764,0.2349302,0.000046021934,0.3160324,0.0004010187],"about_ca_topic_score_codex":0.0000064214264,"about_ca_topic_score_gemma":0.0000014691765,"teacher_disagreement_score":0.71674263,"about_ca_system_score_codex":0.000018012663,"about_ca_system_score_gemma":0.00004149355,"threshold_uncertainty_score":0.5816067},"labels":[],"label_agreement":null},{"id":"W4381273483","doi":"10.21518/ms2023-052","title":"Bioequivalence and immunogenicity of insulin LisPro biosimilar compared to reference drug","year":2023,"lang":"en","type":"article","venue":"Meditsinskiy sovet = Medical Council","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Defence Medical Centre","funders":"","keywords":"Bioequivalence; Medicine; Pharmacokinetics; Insulin lispro; Insulin; Crossover study; Immunogenicity; Area under the curve; Confidence interval; Pharmacodynamics; Cmax; Pharmacology; Internal medicine; Hypoglycemia; Immune system; Immunology","score_opus":0.09385972665149749,"score_gpt":0.3159028409374231,"score_spread":0.2220431142859256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381273483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567408,0.01024481,0.0004950404,0.022801192,0.0032059662,0.0007915491,0.0007116812,0.00046877004,0.0045401854],"genre_scores_gemma":[0.99097806,0.0025544427,0.00092908874,0.003308847,0.000121457626,0.00003513696,0.000064113236,0.000030894753,0.0019779336],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966505,0.00039831866,0.00078640477,0.0006602918,0.0007974598,0.00070703076],"domain_scores_gemma":[0.99749213,0.0009183353,0.00016199314,0.0005451311,0.00059807644,0.00028432586],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042700055,0.0003269608,0.0007743539,0.00015734296,0.00017599126,0.00001943744,0.0007250195,0.0005936003,0.0016746947],"category_scores_gemma":[0.0069420678,0.00025141521,0.0001194801,0.0010006151,0.0012454954,0.00007741297,0.0005498471,0.0007135966,0.0003789772],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016443719,0.0009096567,0.004061462,0.0006400243,0.0008132772,0.00016293638,0.00322744,0.0000030071012,0.36697537,0.0027581255,0.5203887,0.098415576],"study_design_scores_gemma":[0.0042631305,0.00071109843,0.023067113,0.0006792106,0.0002447058,0.00009568685,0.0008570595,0.0003350416,0.12710378,0.0014413524,0.8402173,0.0009845246],"about_ca_topic_score_codex":0.0004249348,"about_ca_topic_score_gemma":0.00030379562,"teacher_disagreement_score":0.31982857,"about_ca_system_score_codex":0.00013650558,"about_ca_system_score_gemma":0.0007972013,"threshold_uncertainty_score":0.9999938},"labels":[],"label_agreement":null},{"id":"W4383265608","doi":"10.1016/j.dld.2023.06.022","title":"Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study","year":2023,"lang":"en","type":"article","venue":"Digestive and Liver Disease","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Biosimilar; Nocebo; Internal medicine; Discontinuation; Inflammatory bowel disease; Nocebo Effect; Calprotectin; Observational study; Biomarker; Prospective cohort study; Adverse effect; Therapeutic drug monitoring; Ulcerative colitis; Clinical trial; Adalimumab; Drug; Infliximab; Disease; Placebo; Pharmacology; Pathology; Pharmacokinetics","score_opus":0.023658101272286743,"score_gpt":0.3193033824295685,"score_spread":0.2956452811572818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383265608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973674,0.0007302531,0.000009370707,0.00027823608,0.00015840502,0.0013053567,0.0000721978,0.000055154997,0.00002362962],"genre_scores_gemma":[0.9992574,0.00007202851,0.000018968909,0.00031185604,0.000037588266,0.000081887665,0.000088217996,0.000018867127,0.0001131881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798894,0.0004888119,0.00034284758,0.0006492102,0.00017196708,0.00035824862],"domain_scores_gemma":[0.99833584,0.0010159385,0.000071227834,0.00019546854,0.000068138266,0.000313406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008003434,0.00026885877,0.00038915497,0.00012653423,0.00018352206,0.000028349104,0.00012768863,0.00016318946,0.000049503054],"category_scores_gemma":[0.0009578407,0.00018827044,0.00009351301,0.0002753497,0.0003931546,0.00012823284,0.0002074609,0.00038480465,0.000025823676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003329531,0.0010485039,0.99198234,0.0000534715,0.00029997755,0.0003026285,0.00016774768,8.262853e-7,0.000008767722,0.000032315522,0.00021940478,0.0025544958],"study_design_scores_gemma":[0.008041164,0.001009867,0.9898716,0.00019146915,0.000313465,3.742357e-7,0.00005321253,0.000089613066,0.0000060285524,0.00003629534,0.00012899844,0.00025790907],"about_ca_topic_score_codex":0.000011972686,"about_ca_topic_score_gemma":0.000009972297,"teacher_disagreement_score":0.004711633,"about_ca_system_score_codex":0.000025557545,"about_ca_system_score_gemma":0.00014726292,"threshold_uncertainty_score":0.7677446},"labels":[],"label_agreement":null},{"id":"W4383620165","doi":"10.1208/s12248-023-00830-5","title":"Neutralizing Antibody Validation Testing and Reporting Harmonization","year":2023,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); TransCanada (Canada)","funders":"Strong","keywords":"Harmonization; Immunogenicity; Food and drug administration; Computer science; Robustness (evolution); Medicine; Risk analysis (engineering); Antibody; Chemistry; Immunology","score_opus":0.1436484235687656,"score_gpt":0.38147501636485437,"score_spread":0.23782659279608878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383620165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99237543,0.0005417465,0.0021667618,0.003509189,0.0005421638,0.00006972783,0.0000014904986,0.0000745683,0.0007189168],"genre_scores_gemma":[0.99721336,0.00016752524,0.0016429346,0.00019383045,0.00011877406,7.328934e-7,0.0000065073446,0.000008589842,0.0006477142],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99903667,0.00022104346,0.0004217483,0.00009723569,0.00002980401,0.00019352288],"domain_scores_gemma":[0.99906933,0.0002891984,0.00046368098,0.000083752966,0.000077278084,0.00001677524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023532026,0.00006642071,0.00011927528,0.000059904385,0.0005180363,0.00006800772,0.000081927225,0.00007185466,0.000054839955],"category_scores_gemma":[0.0019371179,0.000039428476,0.00003448613,0.00030189322,0.00008128974,0.000075139,0.00005468093,0.00030089138,0.000025798086],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011752825,0.000008245891,0.03326816,0.0000072505586,0.000049360435,0.000018634239,0.00016951398,0.000023788438,0.93195957,0.00022368539,0.0015036508,0.0327564],"study_design_scores_gemma":[0.0012742296,0.0002928252,0.56817937,0.0002774963,0.0003360033,0.0076673697,0.0011301001,0.002059176,0.38662088,0.016318256,0.01537352,0.0004707885],"about_ca_topic_score_codex":0.000007768793,"about_ca_topic_score_gemma":2.9422674e-7,"teacher_disagreement_score":0.5453387,"about_ca_system_score_codex":0.0000084833855,"about_ca_system_score_gemma":0.000017191816,"threshold_uncertainty_score":0.3984369},"labels":[],"label_agreement":null},{"id":"W4383683847","doi":"10.58931/cibdt.2023.117","title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease","year":2023,"lang":"en","type":"article","venue":"Canadian IBD Today","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Therapeutic drug monitoring; Medicine; Vedolizumab; Inflammatory bowel disease; Ulcerative colitis; Monoclonal antibody; Drug; Infliximab; Crohn's disease; Biosimilar; Certolizumab pegol; Pharmacokinetics; Disease; Immunology; Pharmacology; Tumor necrosis factor alpha; Intensive care medicine; Internal medicine; Antibody","score_opus":0.025557850001566292,"score_gpt":0.27335403774548345,"score_spread":0.24779618774391715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383683847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917935,0.0035743176,0.0000040876052,0.002230368,0.0009952212,0.00017082575,0.00009437769,0.00005180443,0.0010854612],"genre_scores_gemma":[0.99736136,0.00015653344,0.000043992404,0.00025136024,0.000032395106,0.000010656069,0.000015859025,0.000009856744,0.0021179789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900436,0.00015915267,0.000214012,0.00019063176,0.000021071972,0.00041077813],"domain_scores_gemma":[0.9994655,0.00013483212,0.0000396544,0.00021482538,0.000027775155,0.00011737952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036800423,0.00011039948,0.00016351872,0.00028297902,0.000062892526,0.0000071751856,0.00019382758,0.00016642353,0.00022852303],"category_scores_gemma":[0.00011541667,0.00009277785,0.00006784186,0.00029385113,0.00018011281,0.000027855942,0.000031136,0.0002028133,0.0001320442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003870554,0.000020986769,0.9647421,0.00004279785,0.00006696634,0.00007750032,0.00024413942,0.000013285045,0.018241018,0.0026689847,0.002985277,0.010858239],"study_design_scores_gemma":[0.00029475385,0.000022144905,0.95108163,0.00005256982,0.00002012406,0.0000012937631,0.00024344404,0.000017332273,0.007869832,0.0015570609,0.038676534,0.00016330651],"about_ca_topic_score_codex":0.004000253,"about_ca_topic_score_gemma":0.0060593006,"teacher_disagreement_score":0.035691254,"about_ca_system_score_codex":0.000075887365,"about_ca_system_score_gemma":0.00023350441,"threshold_uncertainty_score":0.60472125},"labels":[],"label_agreement":null},{"id":"W4383683871","doi":"10.58931/cdet.2023.118","title":"The use of biosimilar insulins in 2023","year":2023,"lang":"en","type":"article","venue":"Canadian Diabetes & Endocrinology Today","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Biosimilar; Medicine; Drug; Intensive care medicine; Pharmacology; Internal medicine","score_opus":0.05139916307993134,"score_gpt":0.2681650018123653,"score_spread":0.21676583873243396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383683871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97225666,0.0047643958,0.0000025969825,0.018506091,0.001877513,0.00038398243,0.00040933315,0.00009825587,0.0017011556],"genre_scores_gemma":[0.98945904,0.0012051336,0.00015410982,0.0024305906,0.00003554139,0.00005542212,0.00006843226,0.000028477378,0.006563282],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.997432,0.00038079897,0.00042123545,0.00033209374,0.000033428605,0.0014004698],"domain_scores_gemma":[0.99810827,0.0011739966,0.000079221405,0.00047320523,0.00006581844,0.00009948312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003528036,0.000194625,0.00037077078,0.0005025966,0.00021634939,0.000018621733,0.0004364696,0.0003280355,0.0003562203],"category_scores_gemma":[0.0008102126,0.00014385593,0.00011645916,0.0008886481,0.0008201911,0.0000602245,0.00011392234,0.0004566542,0.00039094887],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006745024,0.00010424683,0.5112698,0.000050001847,0.0006996106,0.00021384435,0.00023598195,0.000045819383,0.07231024,0.017893348,0.27256486,0.12454476],"study_design_scores_gemma":[0.00050212786,0.00009429272,0.18164483,0.000024548312,0.000030201812,0.000006018601,0.00008563208,0.000049064904,0.024468558,0.00073673297,0.79215866,0.00019933294],"about_ca_topic_score_codex":0.00865036,"about_ca_topic_score_gemma":0.07815223,"teacher_disagreement_score":0.5195938,"about_ca_system_score_codex":0.00008148592,"about_ca_system_score_gemma":0.00021195979,"threshold_uncertainty_score":0.99795115},"labels":[],"label_agreement":null},{"id":"W4385442519","doi":"10.4155/bio-2023-0135","title":"2022 White Paper on Recent Issues in Bioanalysis: Fda Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, Lnp &amp; Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, Ada Affinity, Risk-Based Approaches, Ngs, Qpcr, Ddpcr Assays ( <u>Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity &amp; Technologies; Immunogenicity &amp; Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)","year":2023,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Excellence; Bioanalysis; Regulatory science; Medicine; Computer science; Political science; Nanotechnology","score_opus":0.04790826792381044,"score_gpt":0.30126749099843664,"score_spread":0.2533592230746262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385442519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96835005,0.019981395,0.0031500754,0.0027617528,0.00056853046,0.0026838875,0.0018354218,0.000512634,0.00015625912],"genre_scores_gemma":[0.93513995,0.052033316,0.0066223918,0.0004884801,0.000045117373,0.0005841175,0.004583033,0.000116325464,0.00038728592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9891469,0.004678871,0.0027883349,0.001562584,0.0006325661,0.00119075],"domain_scores_gemma":[0.9936322,0.0012328944,0.0022558842,0.0021905259,0.00060708495,0.00008141466],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00727012,0.0014067615,0.0020865297,0.0025565138,0.0007781666,0.00026098007,0.0012737722,0.0013990402,0.00026462413],"category_scores_gemma":[0.00063050725,0.001125459,0.0009001604,0.004862301,0.00048272536,0.0005700464,0.00038631062,0.002281863,0.000040314764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013639384,0.011709658,0.27995896,0.00038207733,0.014347313,0.0000027651504,0.0030396169,0.018610226,0.5076159,0.00038582264,0.0010299187,0.14927836],"study_design_scores_gemma":[0.0365399,0.0052253744,0.21144144,0.000986613,0.005513254,0.000018641073,0.004071245,0.036559023,0.5762821,0.0016727232,0.115270704,0.0064190193],"about_ca_topic_score_codex":0.0060850084,"about_ca_topic_score_gemma":0.0037105668,"teacher_disagreement_score":0.14285932,"about_ca_system_score_codex":0.0008476942,"about_ca_system_score_gemma":0.00025976426,"threshold_uncertainty_score":0.99989736},"labels":[],"label_agreement":null},{"id":"W4385898364","doi":"10.1093/ibd/izad168","title":"Approval Timelines for Advanced Therapeutics in Inflammatory Bowel Disease: A Comparison Between the European Medicines Agency and the Food and Drug Administration","year":2023,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Western Ontario; Statistics Canada; Western University; University of Calgary","funders":"","keywords":"Medicine; Family medicine; Food and drug administration; Pediatric gastroenterology; Timeline; Agency (philosophy); Library science; Hepatology; Internal medicine; Sociology; History; Pharmacology","score_opus":0.026631856202214366,"score_gpt":0.3045720988032804,"score_spread":0.27794024260106603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385898364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756059,0.015702177,0.0001430627,0.006540635,0.00027289925,0.0012419937,0.0002393301,0.00014171023,0.000112311296],"genre_scores_gemma":[0.998313,0.0005758587,0.000042434935,0.00041066867,0.00017017279,0.00013877354,0.000085151834,0.000028507551,0.00023541616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977694,0.0009141251,0.0005392193,0.00035721925,0.00008431967,0.00033569173],"domain_scores_gemma":[0.99804735,0.0013100605,0.0001788761,0.00032089578,0.00006365903,0.00007917446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011953104,0.00025982142,0.00030662434,0.00008801824,0.00035137509,0.00005972601,0.00026302272,0.000089981106,0.000011329462],"category_scores_gemma":[0.0003125194,0.00014549487,0.00011568891,0.0001293417,0.0010989201,0.00009871779,0.000112829126,0.00022508357,0.000010437204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004748769,0.0002378488,0.8266494,0.00095996517,0.00092048675,0.000052803687,0.002995365,0.00004135412,0.0025788974,0.0050422666,0.006417422,0.1493554],"study_design_scores_gemma":[0.0035096316,0.00011304649,0.97683984,0.000111086796,0.00045210155,0.0000030144795,0.0007394483,0.0004932506,0.00045251133,0.0033006805,0.013708979,0.0002764267],"about_ca_topic_score_codex":0.0000017366618,"about_ca_topic_score_gemma":0.000024017136,"teacher_disagreement_score":0.1501904,"about_ca_system_score_codex":0.000011383585,"about_ca_system_score_gemma":0.000079236765,"threshold_uncertainty_score":0.5933109},"labels":[],"label_agreement":null},{"id":"W4386052468","doi":"10.1016/j.ijpharm.2023.123342","title":"Real-time algorithmic exchange and processing of pharmaceutical quality data and information","year":2023,"lang":"en","type":"review","venue":"International Journal of Pharmaceutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Interoperability; Workflow; Digitization; Information exchange; Computer science; Data exchange; Health information exchange; Pharmaceutical industry; Product (mathematics); Process management; Application programming interface; Quality (philosophy); Health care; Knowledge management; Data science; Business; World Wide Web; Database; Medicine; Telecommunications","score_opus":0.2487301281636788,"score_gpt":0.5218463251077662,"score_spread":0.2731161969440874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386052468","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006136288,0.9970115,0.0003149919,0.00031139932,0.0009407559,0.00019403992,0.0009855059,0.000015451287,0.00016503078],"genre_scores_gemma":[0.00004624777,0.99766827,0.0016895472,0.00009095265,0.00019275764,0.0000016960569,0.00016249184,0.000016380269,0.00013165694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977019,0.00040782514,0.0013570584,0.00017318837,0.00018206294,0.00017800019],"domain_scores_gemma":[0.9974179,0.0005975363,0.001340144,0.00015409208,0.00042521599,0.00006511089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00216843,0.00022987094,0.0009803761,0.0003638708,0.000040483792,0.00005211021,0.0007121866,0.00032289702,0.00013473677],"category_scores_gemma":[0.00037628703,0.00017105744,0.00013552049,0.00015303386,0.00029648628,0.0005121482,0.0005979969,0.0006564042,0.000017565644],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006397778,0.000047322832,0.000008020784,0.0036715383,0.0009535808,0.000011133486,0.000068481284,5.9885785e-8,0.00048631904,0.000066499255,0.00048930285,0.9941338],"study_design_scores_gemma":[0.0008319053,0.000044245546,0.000015117551,0.0028155008,0.0012361039,0.0005779263,0.000030968473,0.00025718933,0.00034312642,0.00005686654,0.9936187,0.00017229773],"about_ca_topic_score_codex":0.000005413623,"about_ca_topic_score_gemma":2.9783726e-7,"teacher_disagreement_score":0.99396145,"about_ca_system_score_codex":0.000051648123,"about_ca_system_score_gemma":0.00020900361,"threshold_uncertainty_score":0.69755197},"labels":[],"label_agreement":null},{"id":"W4386164976","doi":"10.3389/fphar.2023.1188368","title":"An international comparative analysis and roadmap to sustainable biosimilar markets","year":2023,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada","funders":"","keywords":"Biosimilar; Sustainability; Business; Sustainable development; Environmental economics; Medicine; Economics; Political science","score_opus":0.018973658528293982,"score_gpt":0.35661256720624557,"score_spread":0.3376389086779516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386164976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97158843,0.0011132464,0.008211084,0.0078453375,0.0052929567,0.00071675977,0.000119371856,0.00019208602,0.0049207355],"genre_scores_gemma":[0.9871827,0.0002975054,0.0054054772,0.0021209354,0.000056489043,0.000058637335,0.00008800192,0.000008958746,0.0047813226],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826026,0.000491528,0.0002590678,0.00044755364,0.000037065653,0.00050449616],"domain_scores_gemma":[0.9995394,0.00011320225,0.000052096628,0.00014531036,0.000074407326,0.0000756108],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072303694,0.00015931985,0.00043878204,0.0011519372,0.00010235314,0.000020414915,0.0003194184,0.00021202848,0.0009493773],"category_scores_gemma":[0.000034341592,0.00014692862,0.000072145,0.0015125963,0.00022120758,0.00012292438,0.00016549717,0.00024679484,0.0000413307],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015924767,0.00038929653,0.29931852,0.000024363546,0.004244276,0.00019333434,0.001510359,0.00022448052,0.09897972,0.0007617958,0.5797144,0.013046944],"study_design_scores_gemma":[0.002510281,0.0003656172,0.40978613,0.000006022968,0.0008088304,0.000011376776,0.003701816,0.0052493624,0.061522245,0.0009510869,0.51458186,0.00050537667],"about_ca_topic_score_codex":0.000030942985,"about_ca_topic_score_gemma":0.000013096157,"teacher_disagreement_score":0.11046758,"about_ca_system_score_codex":0.00007438436,"about_ca_system_score_gemma":0.000027799813,"threshold_uncertainty_score":0.9999639},"labels":[],"label_agreement":null},{"id":"W4386212943","doi":"10.1200/op.23.00224","title":"Changing Tides? Anticancer Biologic and Biosimilar Use in Medicare Part B, 2019-2021","year":2023,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biosimilar; Medicine; Internal medicine","score_opus":0.061402533689737956,"score_gpt":0.37587693381592385,"score_spread":0.3144744001261859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386212943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7379963,0.019804973,0.0003024173,0.20613241,0.010147335,0.0019383454,0.00036139513,0.00072536897,0.022591474],"genre_scores_gemma":[0.9005469,0.03393849,0.010063835,0.038290944,0.0006780622,0.00020614454,0.00031762745,0.00009834251,0.015859665],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691576,0.0013143121,0.0004138971,0.00056540995,0.000055144013,0.0007354525],"domain_scores_gemma":[0.9944879,0.0048465086,0.00020687551,0.00030014056,0.00009518023,0.000063412015],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027538955,0.0002231648,0.00050988345,0.00038514263,0.00018636757,0.00002753072,0.00019804967,0.0007951175,0.0009785886],"category_scores_gemma":[0.005107738,0.00017661869,0.000069410715,0.0009379193,0.0005639276,0.00029929858,0.00033734014,0.00076655037,0.0004473906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002680556,0.001826374,0.07992514,0.0001653743,0.0017868262,0.0028736098,0.003578557,0.000010585317,0.14744551,0.008200452,0.34920204,0.40230495],"study_design_scores_gemma":[0.0013023341,0.00047545932,0.014840665,0.000055343044,0.00016201114,0.00020431654,0.0021418082,0.000043280892,0.0033539645,0.00018003603,0.97696054,0.00028026747],"about_ca_topic_score_codex":0.00008069745,"about_ca_topic_score_gemma":0.000094078896,"teacher_disagreement_score":0.62775844,"about_ca_system_score_codex":0.00008719831,"about_ca_system_score_gemma":0.000111524416,"threshold_uncertainty_score":0.9999347},"labels":[],"label_agreement":null},{"id":"W4386332198","doi":"10.20944/preprints202308.2094.v1","title":"Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus","year":2023,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Lunenfeld-Tanenbaum Research Institute; Western University","funders":"UCB Pharma; Janssen Pharmaceuticals; Genentech; Norgine; Celltrion; Astellas Pharma; Eisai; Mitsubishi Tanabe Pharma Corporation; Celgene; Pfizer; Biogen; EA Pharma Co., Ltd.; Gilead Sciences; Seres Therapeutics; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb; Dr. Falk Pharma; Vifor Pharma; Hospital for Sick Children; Kyorin Pharmaceutical; Tillotts Pharma; Amgen; Novo Nordisk; Falk Foundation; National Science Foundation","keywords":"Biosimilar; Inflammatory bowel disease; Delphi method; Medicine; Delphi; Health care; Inflammatory Bowel Diseases; Knowledge management; Intensive care medicine; Disease; Business; Computer science; Economics; Economic growth","score_opus":0.239380236649462,"score_gpt":0.43122212320554676,"score_spread":0.19184188655608475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386332198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950781,0.00017971992,0.00010515079,0.0014125176,0.0011615168,0.0006450516,0.0010163737,0.00009371758,0.0003078925],"genre_scores_gemma":[0.99643403,0.00078195054,0.0017827739,0.00016019406,0.000029364988,0.00005775573,0.0002710859,0.000027928168,0.00045493268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963621,0.0011806496,0.0008216148,0.0011029779,0.00013643927,0.000396203],"domain_scores_gemma":[0.99792993,0.00044561512,0.00033584444,0.0009708443,0.00018287497,0.00013489956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002169675,0.0003693363,0.0004973942,0.00017539033,0.000050131774,0.000031280175,0.0005158887,0.00063724496,0.00031793214],"category_scores_gemma":[0.0011700874,0.00035943414,0.00014713459,0.00014493045,0.00058682315,0.00009512209,0.002904572,0.00080148695,0.000119933204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001172759,0.00042641934,0.9936785,0.00024860076,0.0007455499,0.00023519424,0.00004679422,0.000031532334,0.00080306124,0.0021628698,0.00023989282,0.00020882869],"study_design_scores_gemma":[0.0008670764,0.00002509281,0.99486226,0.0002623167,0.00014785244,0.000012221851,0.0000783806,0.00016130654,0.00088486855,0.0014940702,0.0008690721,0.0003354909],"about_ca_topic_score_codex":0.00046265905,"about_ca_topic_score_gemma":0.00029606704,"teacher_disagreement_score":0.0023886836,"about_ca_system_score_codex":0.00012404787,"about_ca_system_score_gemma":0.00016434128,"threshold_uncertainty_score":0.99988574},"labels":[],"label_agreement":null},{"id":"W4386347132","doi":"10.1080/13543784.2023.2254684","title":"Investigational monoclonal antibodies in early development for psoriatic arthritis: beyond the biosimilars","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Memorial University of Newfoundland","funders":"","keywords":"Psoriatic arthritis; Biosimilar; Medicine; Psoriasis; Investigational Drugs; Clinical trial; Ixekizumab; Monoclonal antibody; Arthritis; Intensive care medicine; Immunology; Secukinumab; Internal medicine; Antibody","score_opus":0.11954500560529793,"score_gpt":0.3821567219202426,"score_spread":0.2626117163149446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386347132","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003531208,0.9902495,0.000048535065,0.004612428,0.0027847579,0.0015457466,0.00045205763,0.00009898523,0.00017269004],"genre_scores_gemma":[0.0000067160045,0.98467946,0.0064931214,0.0034508058,0.0004722227,0.0016793623,0.0023857856,0.00008805288,0.0007444468],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99611324,0.00069899525,0.0014670906,0.0008498597,0.0002621221,0.00060871465],"domain_scores_gemma":[0.9960557,0.0028626379,0.00046668848,0.00037462937,0.00013954242,0.0001007784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013108731,0.00067391095,0.0013011219,0.0004836533,0.0005070143,0.00008080976,0.0006372579,0.0008371205,0.00011375719],"category_scores_gemma":[0.0008547608,0.0004667492,0.00046312762,0.0006469689,0.00093000603,0.0001051935,0.00017418565,0.0008115233,0.00037626651],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058805508,0.00021788856,0.000042427982,0.0016969901,0.001048193,0.000003230957,0.0017270584,0.000007878712,0.000027330241,0.07154204,0.14662388,0.77700424],"study_design_scores_gemma":[0.0006495447,0.000091118694,0.00023482711,0.0076949145,0.000027434467,0.000012026507,0.00006872201,0.000012590485,0.00020602542,0.010737905,0.9796986,0.0005663171],"about_ca_topic_score_codex":0.000015781972,"about_ca_topic_score_gemma":0.00000942375,"teacher_disagreement_score":0.8330747,"about_ca_system_score_codex":0.00021638797,"about_ca_system_score_gemma":0.001211631,"threshold_uncertainty_score":0.99977845},"labels":[],"label_agreement":null},{"id":"W4386531039","doi":"10.4155/bio-2023-0092","title":"Volumetric Absorptive Microsampling Coupled with Hybridization LC–MS/MS for Quantitation of Antisense Oligonucleotides","year":2023,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"","keywords":"Oligonucleotide; Chromatography; Chemistry; DNA; Biochemistry","score_opus":0.035182981114477395,"score_gpt":0.3022029868536173,"score_spread":0.2670200057391399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386531039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9227847,0.0021567254,0.073365286,0.00042694274,0.00026106648,0.00046173728,0.00026451476,0.0001421398,0.00013691651],"genre_scores_gemma":[0.9854856,0.0003318957,0.012773653,0.00005740374,0.00002574233,0.000018332295,0.00031658384,0.000023509356,0.00096726115],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870586,0.00011554414,0.00042779048,0.00037089578,0.00006661705,0.0003132732],"domain_scores_gemma":[0.99852943,0.0005415672,0.00028261225,0.00024531712,0.0003736603,0.000027420156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061710575,0.00017715168,0.0004837822,0.00067744026,0.00016271255,0.00002319948,0.000140226,0.00017263087,0.00013883958],"category_scores_gemma":[0.00044295966,0.00013761182,0.00023716096,0.0024260117,0.00024343064,0.000070567694,0.000036983405,0.00008992479,0.00005475114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060861284,0.00027807307,0.02979484,0.00022566167,0.0034269642,0.000006949989,0.0002840007,0.0007913351,0.9447644,0.0021881834,0.0019639183,0.01566709],"study_design_scores_gemma":[0.005696304,0.001588077,0.1360963,0.00023505838,0.0056294245,0.00003188084,0.0014905749,0.059118044,0.772364,0.0010337125,0.015370898,0.0013456882],"about_ca_topic_score_codex":0.00019708765,"about_ca_topic_score_gemma":0.00006123136,"teacher_disagreement_score":0.17240033,"about_ca_system_score_codex":0.000029815856,"about_ca_system_score_gemma":0.000039039405,"threshold_uncertainty_score":0.5611647},"labels":[],"label_agreement":null},{"id":"W4387007546","doi":"10.1101/2023.09.22.23295633","title":"Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Rituximab; Repurposing; Biosimilar; Medicine; Drug repositioning; Immunology; Drug; Lymphoma; Pharmacology; Internal medicine; Engineering","score_opus":0.03858788093529037,"score_gpt":0.3008245527119206,"score_spread":0.26223667177663024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387007546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9212218,0.043809343,0.0014958638,0.012025973,0.008947549,0.002532278,0.0051023364,0.0013707919,0.0034940955],"genre_scores_gemma":[0.9719826,0.0023104688,0.004171063,0.001370166,0.00015334776,0.00017678185,0.0009416157,0.00020846172,0.018685522],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968524,0.00056203164,0.00091050495,0.0009409054,0.00011453505,0.000619599],"domain_scores_gemma":[0.9976651,0.000545204,0.00036558334,0.0011503701,0.00016655105,0.0001071937],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006364949,0.00051952084,0.0012747997,0.00041736598,0.00011997621,0.00002908424,0.00080032815,0.00102583,0.00083171536],"category_scores_gemma":[0.0007533614,0.00042729898,0.00049062294,0.00048334282,0.00036792338,0.000028715858,0.0012761743,0.00082374696,0.000593519],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066684344,0.0017321456,0.04205797,0.0014730741,0.00078930805,0.00012957954,0.0005228053,0.00005895682,0.8885256,0.00010067732,0.05537669,0.008566351],"study_design_scores_gemma":[0.0033636587,0.0006773861,0.12879072,0.0011937707,0.0018247471,0.000017270078,0.00018423979,0.00011314852,0.740714,0.0015772822,0.119815744,0.0017279953],"about_ca_topic_score_codex":0.00009063218,"about_ca_topic_score_gemma":0.000008642204,"teacher_disagreement_score":0.14781156,"about_ca_system_score_codex":0.00006516465,"about_ca_system_score_gemma":0.00015088925,"threshold_uncertainty_score":0.9998179},"labels":[],"label_agreement":null},{"id":"W4387311003","doi":"10.3390/jcm12196350","title":"Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; McGill University Health Centre; Lunenfeld-Tanenbaum Research Institute; Western University","funders":"","keywords":"Biosimilar; Medicine; Inflammatory bowel disease; Delphi method; Delphi; Intensive care medicine; Pharmacovigilance; Disease; Risk analysis (engineering); Drug; Pharmacology; Internal medicine","score_opus":0.18479566265910286,"score_gpt":0.49285345328185715,"score_spread":0.3080577906227543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387311003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847665,0.00042115455,0.00012177848,0.012627949,0.0016847862,0.00012729176,0.00006307582,0.000010791958,0.00017671382],"genre_scores_gemma":[0.99431384,0.0023730695,0.0022118741,0.0008152684,0.0001700457,0.000001070768,0.000015064248,0.0000075861685,0.000092186616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966794,0.0011006821,0.0016506573,0.00020956657,0.00015789975,0.00020178595],"domain_scores_gemma":[0.9962469,0.0025505035,0.0005795546,0.00018968208,0.00025332248,0.00018007826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064844186,0.00012900861,0.00056189887,0.00014518622,0.000022844528,0.000008596313,0.00019945519,0.0002153188,0.00013561982],"category_scores_gemma":[0.007205244,0.00008618934,0.00010801937,0.00022734975,0.00079841283,0.00010544554,0.00012306927,0.0004723506,0.0000053715275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039985967,0.00039930042,0.97664416,0.000053734326,0.0004683355,0.0008781362,0.000020256672,0.0000027545095,0.00018680196,0.0014974333,0.009220351,0.006630143],"study_design_scores_gemma":[0.0037595788,0.0006962598,0.9897657,0.00029843897,0.00014984398,0.00006965616,0.00015368316,0.000139905,0.000017264601,0.00069459475,0.004172027,0.000083069885],"about_ca_topic_score_codex":0.000020493355,"about_ca_topic_score_gemma":0.000031904125,"teacher_disagreement_score":0.013121522,"about_ca_system_score_codex":0.000020952912,"about_ca_system_score_gemma":0.0000991069,"threshold_uncertainty_score":0.8625871},"labels":[],"label_agreement":null},{"id":"W4387618984","doi":"10.1016/j.jcjd.2023.10.401","title":"Dried Blood Spot Test for Glycated Hemoglobin Measurement in Pediatric Diabetes Care","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Glycated hemoglobin; Diabetes mellitus; Phlebotomy; Venous blood; Dried blood spot; Population; Hemoglobin; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.025397804136542523,"score_gpt":0.24491511168455396,"score_spread":0.21951730754801144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387618984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872071,0.009918705,0.0000018938557,0.0013730064,0.0008400748,0.00023447003,0.00021364733,0.000017682793,0.00019337918],"genre_scores_gemma":[0.99916345,0.000039078193,0.00021707655,0.00028307378,0.00013852096,0.000012921081,0.000023799763,0.000022104905,0.00009995839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828756,0.00012696881,0.0005237534,0.00019874635,0.000069482216,0.0007934719],"domain_scores_gemma":[0.99858814,0.00043384108,0.00018514675,0.00015443051,0.00042739353,0.00021106125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010373936,0.00018706288,0.00044719878,0.0006729865,0.00013452586,0.000034485267,0.00032851062,0.00026778405,0.00012348367],"category_scores_gemma":[0.0017260779,0.00016166885,0.00019261602,0.00071095274,0.00012443395,0.00006522264,0.000018236862,0.00032404775,0.000057969017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007133728,0.000056333374,0.9299478,0.00014321087,0.00018474282,0.000015364443,0.00022271482,0.000006768724,0.051343054,0.000037397585,0.013882354,0.0041531287],"study_design_scores_gemma":[0.005865132,0.0017414073,0.68447876,0.00030879214,0.00089945557,0.0000059361128,0.0008912496,0.000027052762,0.2694869,0.0010275716,0.034533944,0.00073379755],"about_ca_topic_score_codex":0.0000542409,"about_ca_topic_score_gemma":0.0031462403,"teacher_disagreement_score":0.24546903,"about_ca_system_score_codex":0.00014216856,"about_ca_system_score_gemma":0.00072941545,"threshold_uncertainty_score":0.6592664},"labels":[],"label_agreement":null},{"id":"W4387733501","doi":"10.14309/01.ajg.0000953556.82432.e9","title":"S979 A Nationwide Comparison of Ozanimod and Upadacitinib Adverse Events in Ulcerative Colitis Patients: A Pharmacovigilance Investigation","year":2023,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brandon University","funders":"","keywords":"Medicine; Adverse Event Reporting System; Internal medicine; Adverse effect; Ulcerative colitis; Odds ratio; Pharmacovigilance","score_opus":0.022049506626983,"score_gpt":0.318345225083906,"score_spread":0.296295718456923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387733501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770474,0.00003848332,0.00021827649,0.0017194558,0.00015908196,0.00011272875,0.000027357291,0.000005344331,0.000014535969],"genre_scores_gemma":[0.99864066,0.00008584755,0.0005188905,0.00069958303,0.000017240192,0.000004242025,0.000006786949,0.000005765637,0.000021012753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802285,0.0010439608,0.00054166594,0.000111456786,0.000056555164,0.00022351218],"domain_scores_gemma":[0.99869376,0.00028928858,0.00076794345,0.00007687593,0.00014222591,0.000029873203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069211563,0.000101879545,0.0005015202,0.0001893173,0.000045481724,0.0000013668053,0.00016687262,0.000037283204,0.00002352957],"category_scores_gemma":[0.0001623837,0.00006986274,0.00006398433,0.0002704234,0.0007217952,0.00006272792,0.00005958913,0.00029320986,0.0000032152384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062816045,0.000115362534,0.98037124,0.000009311835,0.00017171312,0.000002700254,0.0009338502,0.000038236216,0.008824431,0.000050365245,0.00039552042,0.0028056826],"study_design_scores_gemma":[0.0024853484,0.0048812386,0.98796177,0.00004940679,0.00005837994,0.000042315474,0.0010934375,0.00011482362,0.0026790018,0.00040775776,0.0001763093,0.00005021174],"about_ca_topic_score_codex":0.000024196142,"about_ca_topic_score_gemma":0.00006539378,"teacher_disagreement_score":0.007590547,"about_ca_system_score_codex":0.000023797436,"about_ca_system_score_gemma":0.000026604746,"threshold_uncertainty_score":0.284892},"labels":[],"label_agreement":null},{"id":"W4387811267","doi":"10.1016/j.annonc.2023.09.2157","title":"1018O Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stephenson Cancer Center; Chugai Pharmaceutical; University of Texas MD Anderson Cancer Center; Genentech; Foundation Medicine; Sierra Oncology; INCLIVA Instituto de Investigación Sanitaria; Sun Pharma; PharmaMar; University of Toronto; European Society for Medical Oncology; FibroGen; Cytokinetics; Astellas Pharma; Eisai; Pfizer; Moderna; Incyte; BeiGene; Natera; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; CRIS Cancer Foundation; Servier; Gilead Sciences; Ribon Therapeutics; Array BioPharma; Iterion Therapeutics; Sanofi; Amgen; G1 Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Rash; Mucositis; Gastroenterology; Internal medicine; Colorectal cancer; Phases of clinical research; Diarrhea; Toxicity; Adverse effect; Cancer; Oncology","score_opus":0.07137095289724445,"score_gpt":0.4252981760145111,"score_spread":0.35392722311726665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977435,0.00051409873,0.0000015082645,0.0005094378,0.0002516695,0.0004977349,0.000070880655,0.000018301023,0.0003928799],"genre_scores_gemma":[0.9990828,0.0004073648,0.000058226517,0.00024808192,0.000009202362,0.00005104102,0.000020340955,0.000010987894,0.00011196908],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986252,0.0003669797,0.00039026455,0.000249661,0.00005004617,0.00031782844],"domain_scores_gemma":[0.9991489,0.00025281956,0.00021043346,0.00015905757,0.00020661132,0.000022193815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037940603,0.00013792644,0.0005820573,0.00017909172,0.000032943546,0.0000012818513,0.00017564281,0.00022224618,0.00027538638],"category_scores_gemma":[0.00006255875,0.0000967992,0.000058992027,0.00049078313,0.00025277116,0.00003871096,0.000057908434,0.00019244257,0.0000074945574],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014463621,0.0124404775,0.36941,0.000026374231,0.00086830935,0.000019975107,0.0020839255,0.00003500021,0.08688751,0.000070329246,0.0029576935,0.51073676],"study_design_scores_gemma":[0.02718424,0.059381444,0.77698326,0.000037978647,0.00005212384,0.0000013210173,0.0011650043,0.0000068445024,0.11894999,0.000106424624,0.015887477,0.00024391244],"about_ca_topic_score_codex":0.00022728095,"about_ca_topic_score_gemma":0.00035634797,"teacher_disagreement_score":0.51049286,"about_ca_system_score_codex":0.000017355987,"about_ca_system_score_gemma":0.000094853596,"threshold_uncertainty_score":0.3947357},"labels":[],"label_agreement":null},{"id":"W4387934183","doi":"10.1093/jcag/gwad027","title":"An Update on Anti-TNF Biosimilar Switching—Real-World Clinical Effectiveness and Safety","year":2023,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biosimilar; Medicine; Adalimumab; Infliximab; Adverse effect; Ulcerative colitis; Inflammatory bowel disease; Internal medicine; Disease","score_opus":0.017732026882527542,"score_gpt":0.3134796128733935,"score_spread":0.2957475859908659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387934183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98297447,0.000016049536,0.000025838019,0.015037542,0.0016384651,0.000112351685,0.000079254896,0.000008330653,0.00010771007],"genre_scores_gemma":[0.9972358,0.00017203651,0.000083239094,0.0022831871,0.00008273288,7.509429e-7,0.0000048970533,0.000010347304,0.0001270318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962436,0.0024938807,0.0006491307,0.00016116722,0.00007852027,0.0003737007],"domain_scores_gemma":[0.99814385,0.0005611551,0.00080283993,0.00018583228,0.00018426524,0.000122030375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004867355,0.00012596027,0.0005508843,0.00033369876,0.0001838699,0.0000143583975,0.0003149529,0.00028572168,0.000058503545],"category_scores_gemma":[0.00054652547,0.00008689703,0.00022126849,0.00022235577,0.00014485644,0.000057794576,0.00004281709,0.0006156588,0.000010386792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006468785,0.00006746201,0.98716635,0.000009321363,0.0004469333,0.000008366168,0.000026088823,0.000026304771,0.003519602,0.0002969814,0.005733036,0.0020526787],"study_design_scores_gemma":[0.0016170355,0.00089261,0.9898153,0.00004420088,0.00011805453,0.000022166845,0.000018203047,0.000019690546,0.0007500704,0.00030249223,0.0063474313,0.000052748335],"about_ca_topic_score_codex":0.00096317707,"about_ca_topic_score_gemma":0.0737973,"teacher_disagreement_score":0.07283412,"about_ca_system_score_codex":0.0002739866,"about_ca_system_score_gemma":0.0001558235,"threshold_uncertainty_score":0.9431035},"labels":[],"label_agreement":null},{"id":"W4387968834","doi":"10.1159/000534626","title":"Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study","year":2023,"lang":"en","type":"article","venue":"Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Trastuzumab; Postmarketing surveillance; Medicine; Oncology; Internal medicine; Environmental health; Intensive care medicine; Marketing; Business; Adverse effect; Cancer; Breast cancer","score_opus":0.012664839698004445,"score_gpt":0.3002756927398671,"score_spread":0.2876108530418626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387968834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764925,0.00027719684,0.000007886273,0.00032516115,0.0003163435,0.0005201314,0.000072925926,0.00003709586,0.00079397776],"genre_scores_gemma":[0.99959564,0.00009391423,0.00006928462,0.00010242244,0.000008122413,0.000017091259,0.000039775252,0.0000119103515,0.000061817256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99544567,0.0034079826,0.00040487555,0.00036339372,0.000035567966,0.00034250028],"domain_scores_gemma":[0.9964566,0.0031064618,0.00011395631,0.00017445949,0.00012445879,0.000024059684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039655077,0.00015541865,0.0006150839,0.00019657669,0.00007357829,0.0000033517447,0.0001377791,0.0002932723,0.0000802194],"category_scores_gemma":[0.0012423199,0.00012626342,0.000055355744,0.00045318741,0.0002621683,0.000020772772,0.00016247561,0.0002579938,0.000013805669],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035305875,0.0014836341,0.9318489,0.00011065666,0.00018140694,0.000025289386,0.00040266427,0.0000034154837,0.031532746,0.00007957105,0.00017693281,0.030624237],"study_design_scores_gemma":[0.0035384267,0.002755449,0.9889583,0.000038053357,0.000026525697,0.0000059046856,0.00062576163,0.000009628971,0.0022081046,0.000045682656,0.0016530117,0.00013513233],"about_ca_topic_score_codex":0.00009328545,"about_ca_topic_score_gemma":0.0002815978,"teacher_disagreement_score":0.05710946,"about_ca_system_score_codex":0.0000778039,"about_ca_system_score_gemma":0.000055789085,"threshold_uncertainty_score":0.5148873},"labels":[],"label_agreement":null},{"id":"W4388035195","doi":"10.1111/cts.13676","title":"<scp>Time‐dependent</scp> clearance can confound <scp>exposure–response</scp> analysis of therapeutic antibodies: A comprehensive review of the current literature","year":2023,"lang":"en","type":"review","venue":"Clinical and Translational Science","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Clearance; Spurious relationship; Population; Pharmacokinetics; Drug; Antibody; Pharmacology; Immunology; Computer science; Urology","score_opus":0.1121145288813808,"score_gpt":0.4335412296875174,"score_spread":0.3214267008061366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388035195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006587313,0.9965367,0.000041124364,0.00023358384,0.00057148637,0.0006438694,0.001173941,0.000016849956,0.00012374541],"genre_scores_gemma":[0.00075580296,0.9979991,0.00008409166,0.00035218272,0.000035794546,0.000013069014,0.00008734632,0.000013481331,0.00065918465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948223,0.0019128787,0.0017471042,0.00079217314,0.00032376318,0.0004017344],"domain_scores_gemma":[0.98694384,0.011045638,0.0008806352,0.0005203827,0.0005227686,0.000086760556],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0038268168,0.00038806186,0.0025447945,0.0002912838,0.00025446274,0.00003706962,0.0009259152,0.00044216303,0.000033955646],"category_scores_gemma":[0.0020713094,0.00021911689,0.0014242445,0.0034923798,0.0044056852,0.000068833164,0.00015402288,0.001028831,0.000016697859],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045874287,0.0004542444,0.0019603486,0.034200486,0.0053575444,0.0000050712188,0.00033849047,0.000004206805,0.00024907067,0.0019816868,0.0007748168,0.95462817],"study_design_scores_gemma":[0.0003963292,0.00018472355,0.042226285,0.029765135,0.0070425803,0.00001595397,0.000016210324,0.00002726642,0.000023973971,0.0005875857,0.9196044,0.00010956224],"about_ca_topic_score_codex":0.000004344442,"about_ca_topic_score_gemma":0.000005718233,"teacher_disagreement_score":0.9545186,"about_ca_system_score_codex":0.000011445351,"about_ca_system_score_gemma":0.00067051227,"threshold_uncertainty_score":0.9983038},"labels":[],"label_agreement":null},{"id":"W4388105377","doi":"10.7748/cnp.22.6.14.s6","title":"A guide to the benefits of CAR-T immunotherapy","year":2023,"lang":"en","type":"article","venue":"Cancer Nursing Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Medicine; Immunotherapy; Immunology; Immune system","score_opus":0.04417580895719486,"score_gpt":0.40478248255406196,"score_spread":0.3606066735968671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388105377","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0826967,0.099438466,0.005456551,0.7078291,0.01948726,0.0018581044,0.0003149659,0.00057184737,0.08234699],"genre_scores_gemma":[0.79494405,0.017150901,0.016962396,0.051997088,0.0012952973,0.00035214398,0.000054804754,0.00021045133,0.117032856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99905324,0.00024796935,0.00020709397,0.00018776604,0.00004568691,0.0002582186],"domain_scores_gemma":[0.99875903,0.00066891586,0.0001075437,0.00030675886,0.00013961644,0.00001810626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070801575,0.0000965014,0.00017064091,0.000060327384,0.0001423388,0.000012630201,0.00024174557,0.00011709869,0.00025066547],"category_scores_gemma":[0.0004923328,0.00006385127,0.000065260756,0.0005301903,0.00015030077,0.00006338452,0.000030254128,0.00020090428,0.00014949881],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004621513,0.00008500914,0.00006890548,0.000009086307,0.00024240934,0.0000013831092,0.0019651116,0.0001246687,0.11428777,0.0023311204,0.2504414,0.629981],"study_design_scores_gemma":[0.00030114327,0.00011266579,0.0026358978,0.00011000772,0.00009387405,0.000018214121,0.00081420515,0.0000069570006,0.049260687,0.00010073433,0.9464511,0.00009446496],"about_ca_topic_score_codex":0.00031431054,"about_ca_topic_score_gemma":0.000014297994,"teacher_disagreement_score":0.7122474,"about_ca_system_score_codex":0.00005352407,"about_ca_system_score_gemma":0.00006478922,"threshold_uncertainty_score":0.27446112},"labels":[],"label_agreement":null},{"id":"W4388204778","doi":"10.1200/op.2023.19.11_suppl.9","title":"Cost-effectiveness analysis of bevacizumab biosimilars for metastatic colorectal cancer: A comparative study using real-world data.","year":2023,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Biosimilar; Bevacizumab; Medicine; Population; Colorectal cancer; Oncology; Internal medicine; Cost effectiveness; Propensity score matching; Quality-adjusted life year; Cohort; Cancer; Environmental health; Chemotherapy; Risk analysis (engineering)","score_opus":0.38408174310378035,"score_gpt":0.5530617835706201,"score_spread":0.16898004046683973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388204778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986118,0.00054098107,0.002139751,0.0019060437,0.0012237187,0.004340187,0.0027104686,0.00014621692,0.0008746087],"genre_scores_gemma":[0.99011284,0.00024028833,0.008084883,0.00035230644,0.00003658667,0.00045570196,0.00048976415,0.000027819915,0.00019979369],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99365383,0.004156274,0.00072371383,0.00081504975,0.00010204009,0.00054907514],"domain_scores_gemma":[0.9820365,0.015945073,0.0008645396,0.00061910955,0.0004801858,0.000054643577],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0048927306,0.00030237815,0.0017327822,0.00086622685,0.0002982175,0.000020432019,0.00057883904,0.00020008937,0.00014352398],"category_scores_gemma":[0.0015043545,0.00025625483,0.00023644371,0.0039720573,0.0005998482,0.0003062394,0.0004334514,0.0004488732,0.000018804994],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0677265,0.024991281,0.13187566,0.00057450344,0.2625941,0.0004564701,0.013120733,0.0060485266,0.3737707,0.0033112646,0.027440397,0.08808986],"study_design_scores_gemma":[0.023640744,0.014130389,0.31533062,0.00012801541,0.16369204,0.00010378675,0.046832155,0.052767634,0.075509615,0.00031714988,0.30547488,0.0020729562],"about_ca_topic_score_codex":0.0018195014,"about_ca_topic_score_gemma":0.0078954855,"teacher_disagreement_score":0.29826108,"about_ca_system_score_codex":0.00033313912,"about_ca_system_score_gemma":0.00042689723,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W4388598609","doi":"10.1007/s12325-023-02706-8","title":"Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Clinical Research Institute","funders":"Novartis Pharma","keywords":"Medicine; Etanercept; Discontinuation; Biosimilar; Rheumatoid arthritis; Internal medicine; Psoriatic arthritis; Clinical endpoint; Pharmacology; Clinical trial","score_opus":0.023877749858004328,"score_gpt":0.3366253561703939,"score_spread":0.31274760631238957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388598609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970449,0.0014898562,0.000018912377,0.000032041306,0.00014697388,0.00071751873,0.00046988687,0.00003376429,0.00004610301],"genre_scores_gemma":[0.9970163,0.0024512773,0.0002642381,0.000044763572,0.0000054238217,0.00001577332,0.00016501448,0.000015394371,0.000021806236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786764,0.0009333388,0.00043750802,0.000425793,0.000069252455,0.0002664416],"domain_scores_gemma":[0.99847335,0.0009982018,0.00014702516,0.00031011866,0.000041131963,0.000030205714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005635543,0.0002118866,0.00054861343,0.00019186959,0.000060857976,0.000008506969,0.00018062531,0.00010101087,0.00003513078],"category_scores_gemma":[0.000079051846,0.00014411681,0.00003156439,0.00059699203,0.00028201946,0.00018563367,0.00003392988,0.00022210702,0.0000025786587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011328021,0.0015707966,0.9533858,0.000026402773,0.00011450058,0.000006207641,0.0006941883,0.000121209596,0.0006290498,0.00001711019,0.000007265586,0.032099452],"study_design_scores_gemma":[0.015961908,0.0012441508,0.98099846,0.00020783607,0.00002331295,2.0312896e-7,0.0004231491,0.00006953888,0.0004658368,0.00020572652,0.00021321472,0.00018665272],"about_ca_topic_score_codex":0.00059333054,"about_ca_topic_score_gemma":0.0017931951,"teacher_disagreement_score":0.0319128,"about_ca_system_score_codex":0.00004015721,"about_ca_system_score_gemma":0.000023505201,"threshold_uncertainty_score":0.5876913},"labels":[],"label_agreement":null},{"id":"W4388845961","doi":"10.17148/iarjset.2023.101105","title":"REVIEW ARTICLE ELISA: THE IMMUNOLOGICAL DIGNOSTIC TOOL","year":2023,"lang":"en","type":"article","venue":"IARJSET","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Computational biology; Biology","score_opus":0.0405479057563873,"score_gpt":0.32369074267103354,"score_spread":0.28314283691464626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388845961","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34175852,0.48023582,0.00059183594,0.15122135,0.004559516,0.0024343168,0.00038410703,0.001755695,0.01705884],"genre_scores_gemma":[0.8882126,0.05774979,0.00036801727,0.03910106,0.00017899026,0.00016555988,0.00015725597,0.000040062056,0.014026659],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987878,0.00034045955,0.00025017935,0.00021646981,0.00003328485,0.0003717782],"domain_scores_gemma":[0.99884653,0.00067861885,0.000045236244,0.00037707534,0.000037519025,0.000015006598],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00081070315,0.00012205363,0.00023014378,0.000024959776,0.00018168474,0.000015552438,0.00030129607,0.00016195474,0.0018639232],"category_scores_gemma":[0.0010545271,0.000063424304,0.0001289807,0.000428259,0.00029780777,0.000033103413,0.00016291543,0.0003173205,0.0054065064],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053562053,0.00011111634,0.0011094118,0.00012630802,0.00021993599,0.000025450065,0.00007086306,8.625247e-7,0.07276448,0.006572699,0.83878696,0.08015834],"study_design_scores_gemma":[0.0003661252,0.00010545382,0.027482629,0.0002504644,0.00013274263,0.000057187695,0.000048265647,0.000014552796,0.009239718,0.0038927349,0.9582103,0.00019982684],"about_ca_topic_score_codex":0.00000667064,"about_ca_topic_score_gemma":0.0000019842807,"teacher_disagreement_score":0.5464541,"about_ca_system_score_codex":0.000011211892,"about_ca_system_score_gemma":0.000016986123,"threshold_uncertainty_score":0.99904853},"labels":[],"label_agreement":null},{"id":"W4388902238","doi":"10.1007/s40259-023-00630-5","title":"Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Celltrion","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Clinical endpoint; Biosimilar; Dosing; Adverse effect; Randomized controlled trial; Psoriasis; Tolerability; Internal medicine; Dermatology; Adalimumab","score_opus":0.04463726408912411,"score_gpt":0.3397974502253265,"score_spread":0.2951601861362024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388902238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993409,0.0004862133,0.000021140766,0.0007897529,0.00067497534,0.0034503753,0.00070156105,0.000057838704,0.00040917078],"genre_scores_gemma":[0.9986297,0.00030590556,0.00014201154,0.00006628539,0.00003286802,0.00013928165,0.00007320533,0.000024640278,0.0005861078],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967947,0.00064605614,0.001177886,0.00069975073,0.0001251358,0.00055646914],"domain_scores_gemma":[0.9977064,0.0011776754,0.00036820935,0.0004917154,0.00015068693,0.000105310675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016611059,0.00039268186,0.0014738557,0.00053229346,0.00012939154,0.000019916806,0.0003186022,0.00026650957,0.00007587575],"category_scores_gemma":[0.00037292644,0.0003031415,0.0001913711,0.0009531698,0.00024454907,0.000096257005,0.00020023026,0.00035929077,0.000025971585],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97088146,0.0017030275,0.00006996475,0.000042893684,0.0012190156,0.00004067534,0.0016780547,0.000036109806,0.01743956,0.00008598217,0.0012626789,0.0055405498],"study_design_scores_gemma":[0.90951216,0.00222271,0.00043901685,0.0001039162,0.00043830715,0.000008593705,0.0017558326,0.00008279959,0.08051165,0.000022850056,0.0045234496,0.00037870198],"about_ca_topic_score_codex":0.0005211662,"about_ca_topic_score_gemma":0.00024532247,"teacher_disagreement_score":0.06307209,"about_ca_system_score_codex":0.00007088396,"about_ca_system_score_gemma":0.0001617998,"threshold_uncertainty_score":0.99994206},"labels":[],"label_agreement":null},{"id":"W4389020697","doi":"10.1096/fasebj.31.1_supplement.955.13","title":"Palmitic and Stearic Free Fatty Acids Are Consistently Found in Materials used for Dried Blood Spot Collection","year":2017,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"","keywords":"Chromatography; Chemistry; Formic acid; Fatty acid; Stearic acid; Dried blood spot; Palmitic acid; Biochemistry; Organic chemistry","score_opus":0.042754321235183315,"score_gpt":0.29602628568505995,"score_spread":0.25327196444987665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389020697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957612,0.0005826512,0.00024527436,0.002060331,0.00088189665,0.00025724593,0.00006381746,0.00000839556,0.00013916162],"genre_scores_gemma":[0.9980737,0.00007345816,0.0005336271,0.00018941765,0.00008924043,0.000009468366,0.0000026688613,0.00000934698,0.0010190754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892825,0.00032337694,0.00028382632,0.00014916365,0.000034112294,0.0002812911],"domain_scores_gemma":[0.9990095,0.00029107285,0.00028358633,0.00030776422,0.00007637687,0.000031715987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011189166,0.00012366187,0.00030248254,0.00006251133,0.00094503874,0.00019756361,0.00030127657,0.00019516917,0.00019406597],"category_scores_gemma":[0.00062325306,0.00007818046,0.00006700897,0.000045629753,0.0003860058,0.00007464823,0.00009215537,0.00027764827,0.0000049720215],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039924498,0.000084186955,0.019127809,0.000022553777,0.00023745248,0.000018783434,0.00012529492,2.912113e-7,0.9785637,0.00037300703,0.0005986465,0.00044900336],"study_design_scores_gemma":[0.0068064,0.00039317305,0.19495247,0.00012212041,0.0003999733,0.0009404207,0.00038044833,0.0000095111,0.788716,0.0063956752,0.0006853011,0.00019849707],"about_ca_topic_score_codex":0.00002848734,"about_ca_topic_score_gemma":0.00008721587,"teacher_disagreement_score":0.18984772,"about_ca_system_score_codex":0.00002353346,"about_ca_system_score_gemma":0.00004653354,"threshold_uncertainty_score":0.72685695},"labels":[],"label_agreement":null},{"id":"W4389486878","doi":"10.1007/s40259-023-00636-z","title":"Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Research Foundation of Korea","keywords":"Biosimilar; Adalimumab; Medicine; Significant difference; Intensive care medicine; Internal medicine; Rheumatoid arthritis","score_opus":0.027742553902886852,"score_gpt":0.2830068196293937,"score_spread":0.25526426572650684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389486878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995486,0.0006208299,0.000035236248,0.002315116,0.000102294885,0.00021172348,0.00097642216,0.00004547678,0.00020687141],"genre_scores_gemma":[0.99791807,0.00019385265,0.000055037013,0.00038845194,0.000004478104,0.000012094774,0.000068457186,0.000008501201,0.0013510763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809825,0.00043935428,0.0005607676,0.0003856901,0.0001287622,0.00038719745],"domain_scores_gemma":[0.9977171,0.0011927106,0.0003170219,0.00053272664,0.00021621614,0.000024236002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001058391,0.00021817406,0.00079425506,0.00032302964,0.00009309051,0.000011766145,0.0004147982,0.00031659592,0.0005671155],"category_scores_gemma":[0.00047424436,0.00012344585,0.0002401112,0.0024630835,0.0010929288,0.000024363433,0.00012860603,0.00025185235,0.000016016182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049116754,0.0004337815,0.9187063,0.000091483904,0.0039073923,0.0000042200472,0.0021866688,0.0000038225307,0.06920481,0.0006245242,0.0025375308,0.0018082805],"study_design_scores_gemma":[0.00070216315,0.00020899207,0.93412524,0.00008383821,0.0009937539,6.6921837e-7,0.00039680648,0.00015054368,0.062062137,0.0002494786,0.00084533886,0.00018105794],"about_ca_topic_score_codex":0.00024189753,"about_ca_topic_score_gemma":0.00044009698,"teacher_disagreement_score":0.015418904,"about_ca_system_score_codex":0.000041910997,"about_ca_system_score_gemma":0.00008745382,"threshold_uncertainty_score":0.6209517},"labels":[],"label_agreement":null},{"id":"W4389508203","doi":"10.1002/cpt.3133","title":"Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics","year":2023,"lang":"en","type":"review","venue":"Clinical Pharmacology & Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Dosing; Medicine; Bridging (networking); Comparability; Pharmacology; Patient safety; Intensive care medicine; Risk analysis (engineering); Computer science","score_opus":0.33356432890633997,"score_gpt":0.539773575557006,"score_spread":0.20620924665066603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389508203","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008865399,0.9779503,0.0011749166,0.009461656,0.0069939024,0.0034227327,0.00038625882,0.00029189565,0.00022969459],"genre_scores_gemma":[0.00018478862,0.9838054,0.0003379339,0.013054417,0.0011463731,0.00041234714,0.00006380507,0.00013144923,0.0008634966],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99418217,0.0020485807,0.0014266307,0.0012031986,0.00006657792,0.0010728596],"domain_scores_gemma":[0.98730206,0.011284788,0.00052405574,0.0005654135,0.00022251694,0.00010115268],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0021216404,0.0008130638,0.0025267852,0.00022272921,0.00067890325,0.000051143947,0.0012283721,0.0018394487,0.00010247775],"category_scores_gemma":[0.00016215023,0.00047910083,0.0013995732,0.00046774992,0.0011155087,0.000026922831,0.00045981383,0.002636678,0.00051394996],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001145312,0.0010931885,0.0000025868642,0.0015388444,0.010517321,0.00013877318,0.00063933193,0.00003114845,0.00017913054,0.0023834393,0.011387008,0.9709439],"study_design_scores_gemma":[0.0008018809,0.0036086242,0.000008501288,0.0008690458,0.006260714,0.00013527455,0.00086040155,0.00007254294,0.000023592296,0.0014899324,0.9851598,0.0007096558],"about_ca_topic_score_codex":0.000008277344,"about_ca_topic_score_gemma":0.000010519296,"teacher_disagreement_score":0.9737728,"about_ca_system_score_codex":0.00023663127,"about_ca_system_score_gemma":0.00045900748,"threshold_uncertainty_score":0.99976605},"labels":[],"label_agreement":null},{"id":"W4390125958","doi":"10.1016/j.jval.2023.09.391","title":"EE121 Cost-Efficiency and the Opportunity for Expanded Treatment Access with Incremental Increases in Biosimilar Adalimumab and Tocilizumab Use: A European Perspective","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Biosimilar; Tocilizumab; Adalimumab; Perspective (graphical); Medicine; Internal medicine; Computer science; Rheumatoid arthritis; Artificial intelligence","score_opus":0.15026313276785994,"score_gpt":0.3781046183827965,"score_spread":0.22784148561493658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390125958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872188,0.0032057543,0.00009331321,0.006288185,0.00006147115,0.0025865484,0.00020552859,0.000052591604,0.00028783156],"genre_scores_gemma":[0.9962391,0.0023742232,0.0002054779,0.0008805325,0.000014506228,0.00013163117,0.00002805648,0.000015768665,0.00011066175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728703,0.0015498145,0.00032497072,0.00038844722,0.0000433106,0.00040642903],"domain_scores_gemma":[0.99849737,0.0011083591,0.00010368655,0.00018167256,0.00003917002,0.00006974235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017759266,0.0001837613,0.00038715612,0.00016981494,0.00022840695,0.000044482997,0.00012886425,0.00007959392,0.000018445347],"category_scores_gemma":[0.00037087128,0.0001067007,0.00003878907,0.00037607434,0.00048137916,0.000088926725,0.00012453072,0.00017026396,0.0000013823652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06394411,0.009746188,0.49785042,0.0017387415,0.002189774,0.00059696694,0.049938925,0.00062859803,0.0059535094,0.11352906,0.00663393,0.24724978],"study_design_scores_gemma":[0.14626433,0.018499255,0.72757083,0.00171902,0.0003993555,0.0006397187,0.055607464,0.011260926,0.0060323295,0.010621608,0.019176872,0.0022082673],"about_ca_topic_score_codex":0.015283137,"about_ca_topic_score_gemma":0.0011304688,"teacher_disagreement_score":0.2450415,"about_ca_system_score_codex":0.00022797172,"about_ca_system_score_gemma":0.00021395269,"threshold_uncertainty_score":0.9912742},"labels":[],"label_agreement":null},{"id":"W4390662933","doi":"10.1016/j.rmra.2023.11.092","title":"Impact réel du switch d’autres biologiques vers mépolizumab chez les patients asthmatiques sévères","year":2024,"lang":"fr","type":"article","venue":"Revue des Maladies Respiratoires Actualités","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Gynecology; Medicine; Humanities; Art","score_opus":0.03853227993899993,"score_gpt":0.3203406464467799,"score_spread":0.28180836650777996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390662933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7609873,0.22293216,0.00036612805,0.0053357794,0.003119431,0.0006451372,0.0014826396,0.00052890874,0.004602542],"genre_scores_gemma":[0.9213369,0.04551246,0.0020472885,0.0008504967,0.0011972097,0.00008746168,0.00024052638,0.00018614947,0.02854154],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.992993,0.0024672279,0.001371669,0.0013099225,0.00015823374,0.0016999525],"domain_scores_gemma":[0.9960924,0.0021516709,0.0003131891,0.00079431565,0.00038978143,0.00025864027],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012360513,0.0011559973,0.0014365936,0.00052867836,0.00073061825,0.00047645002,0.0008198014,0.002012488,0.0078015886],"category_scores_gemma":[0.0018461201,0.0008931397,0.0011315107,0.00074388256,0.0034075917,0.00056400435,0.00053330977,0.0013507685,0.0004245106],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001319977,0.0012429651,0.09052829,0.006179604,0.0048287157,0.00040682708,0.007757511,0.000019283812,0.0132504385,0.024166532,0.06187661,0.78842324],"study_design_scores_gemma":[0.001119329,0.0042134295,0.07058234,0.0048238724,0.000677511,0.000313042,0.0009426111,0.00023053208,0.015849525,0.0034700288,0.8961952,0.0015826235],"about_ca_topic_score_codex":0.0015247687,"about_ca_topic_score_gemma":0.0006026303,"teacher_disagreement_score":0.8343185,"about_ca_system_score_codex":0.00069942523,"about_ca_system_score_gemma":0.00028741985,"threshold_uncertainty_score":0.9993519},"labels":[],"label_agreement":null},{"id":"W4390910595","doi":"10.4155/bio-2023-0180","title":"Validation of Mitra <sup>®</sup> VAMS <sup>®</sup> as a Blood Collection Technique for Trace Elements Analysis Using ICP-MS/MS","year":2024,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; Institut National de Santé Publique du Québec","funders":"","keywords":"Venipuncture; Inductively coupled plasma mass spectrometry; Blood sampling; Chromatography; Sampling (signal processing); TRACE (psycholinguistics); Chemistry; Mass spectrometry; Computer science; Medical physics; Medicine; Surgery; Internal medicine","score_opus":0.026691903612765064,"score_gpt":0.31614820196782806,"score_spread":0.289456298355063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390910595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67877847,0.018017784,0.29488882,0.001381693,0.00044168695,0.002959355,0.0012831574,0.00049491355,0.0017541237],"genre_scores_gemma":[0.96325254,0.00034221413,0.03177109,0.00010339321,0.00010440771,0.00017178938,0.0003961454,0.000054585194,0.0038038243],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963547,0.00060337025,0.0012338877,0.0009918805,0.0001930976,0.0006230387],"domain_scores_gemma":[0.99811083,0.00048703834,0.00034136488,0.000631474,0.0003465118,0.00008275296],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001763182,0.00046585407,0.0011484412,0.0016725105,0.0003391115,0.000104987106,0.00037771848,0.00079790805,0.0021311827],"category_scores_gemma":[0.00032809647,0.00039953174,0.0016286364,0.0050285943,0.00027579349,0.0001874889,0.00009685748,0.0003784836,0.000030084599],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008074117,0.002139432,0.015042622,0.00079894974,0.09189248,0.00003586603,0.0016008327,0.007360468,0.8545544,0.0016447061,0.002435914,0.021686876],"study_design_scores_gemma":[0.0015035054,0.0007699449,0.00027404242,0.00016395697,0.0561346,0.000059596416,0.0007715692,0.0845952,0.83493596,0.0012095616,0.018702017,0.00088003103],"about_ca_topic_score_codex":0.0006194077,"about_ca_topic_score_gemma":0.000031358042,"teacher_disagreement_score":0.2844741,"about_ca_system_score_codex":0.00016777022,"about_ca_system_score_gemma":0.00016227929,"threshold_uncertainty_score":0.9998457},"labels":[],"label_agreement":null},{"id":"W4391162032","doi":"10.1093/ecco-jcc/jjad212.0919","title":"P789 Impact of risk factors for Janus kinase inhibitor use identified by the Pharmacovigilance Risk Assessment Committee on the safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis","year":2024,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of British Columbia","funders":"","keywords":"Pharmacovigilance; Medicine; Risk assessment; Janus kinase inhibitor; Adverse effect; Environmental health; Janus kinase; Internal medicine","score_opus":0.019657966786932383,"score_gpt":0.31710741265653264,"score_spread":0.29744944586960026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391162032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947368,0.00028795344,0.00039893488,0.00028248137,0.0001438259,0.00064190105,0.003466678,0.000002555606,0.000038851435],"genre_scores_gemma":[0.9993545,0.00034109096,0.00012213319,0.00008303386,0.000019127125,0.000009029314,0.000008369826,0.000010783911,0.000051956056],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99848175,0.0005716095,0.00047003664,0.00017517604,0.00009345332,0.00020798769],"domain_scores_gemma":[0.99670583,0.002509149,0.0003694959,0.00011052033,0.00025293295,0.000052083575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058110605,0.00018019919,0.0004554746,0.00008249793,0.00015886046,0.00007241886,0.00011673163,0.00010361357,0.00003653894],"category_scores_gemma":[0.00024343492,0.000084963,0.00014024746,0.00014917596,0.00024675849,0.00014521506,0.000043481912,0.00047709272,1.8699153e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6332776,0.0039899233,0.16843516,0.00033705574,0.011146569,0.00006232511,0.01436859,0.00044403705,0.0032832576,0.005462145,0.022441665,0.13675168],"study_design_scores_gemma":[0.0024978877,0.002155535,0.9845648,0.00019424655,0.0002112084,0.0000065356558,0.00032610827,0.00006387212,0.008722749,0.00030803235,0.0008409775,0.00010807445],"about_ca_topic_score_codex":0.00034827614,"about_ca_topic_score_gemma":0.00006931883,"teacher_disagreement_score":0.8161296,"about_ca_system_score_codex":0.000079517835,"about_ca_system_score_gemma":0.00009624242,"threshold_uncertainty_score":0.34646907},"labels":[],"label_agreement":null},{"id":"W4391162067","doi":"10.1093/ecco-jcc/jjad212.1138","title":"P1008 Efficacy and safety of retreatment with upadacitinib after treatment interruption in ulcerative colitis: Data from the phase 3 open-label extension study U-ACTIVATE","year":2024,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ulcerative colitis; Medicine; Open label; Phase (matter); Extension (predicate logic); Colitis; Pharmacology; Internal medicine; Gastroenterology; Computer science; Adverse effect; Chemistry","score_opus":0.09873069000829178,"score_gpt":0.39499244525075033,"score_spread":0.29626175524245857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391162067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922166,0.0054522897,0.0001405774,0.000891725,0.00014180654,0.00055269897,0.00052287854,0.0000032981388,0.00007812501],"genre_scores_gemma":[0.9975675,0.0016249006,0.00042909427,0.000100052275,0.00003761434,0.000011425772,0.000022052165,0.000008333102,0.00019906631],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99866486,0.00043208493,0.00043973283,0.00026409494,0.000053079842,0.00014613142],"domain_scores_gemma":[0.9990822,0.00042691705,0.00014969734,0.00023197997,0.00007311922,0.000036089798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004978042,0.00015524382,0.0004392248,0.000055697146,0.00007447093,0.00009002595,0.00015105226,0.00008181713,0.00015364152],"category_scores_gemma":[0.00003774009,0.000076937875,0.0000247929,0.0001018901,0.00021634692,0.00020519395,0.00016423716,0.00020212114,9.244445e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25521287,0.011299992,0.008605622,0.00006843725,0.0053453287,0.0025124613,0.010294058,0.0000012492789,0.004795973,0.0005645432,0.0018728882,0.6994266],"study_design_scores_gemma":[0.02104244,0.011843959,0.9488403,0.0009602589,0.00065643614,0.00036932735,0.0027690725,0.00006109775,0.0018459252,0.00027283875,0.011171526,0.00016680651],"about_ca_topic_score_codex":0.0003522562,"about_ca_topic_score_gemma":0.00061623246,"teacher_disagreement_score":0.94023466,"about_ca_system_score_codex":0.00006090126,"about_ca_system_score_gemma":0.00007809291,"threshold_uncertainty_score":0.31374356},"labels":[],"label_agreement":null},{"id":"W4391162386","doi":"10.1093/ecco-jcc/jjad212.0802","title":"P672 Occurrence of malignancy among infliximab biosimilar and bio-originator initiators in Canada: a comparative population-based analysis","year":2024,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; University of British Columbia; Hamilton Health Sciences; Mount Sinai Hospital; University of Manitoba; McGill University Health Centre","funders":"","keywords":"Biosimilar; Infliximab; Malignancy; Medicine; Population; Internal medicine; Tumor necrosis factor alpha; Environmental health","score_opus":0.018152424616367797,"score_gpt":0.2877145619167409,"score_spread":0.2695621373003731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391162386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98947936,0.009517681,0.00011037096,0.00029794584,0.0002131752,0.00007098713,0.00023981073,0.0000030324138,0.00006766079],"genre_scores_gemma":[0.99941087,0.0002341112,0.0001996289,0.00011582949,0.0000114468485,0.0000018305477,0.000007645242,0.0000030419496,0.000015587731],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988874,0.0001656166,0.00055108493,0.00015134113,0.00006662765,0.00017790645],"domain_scores_gemma":[0.99925506,0.00029629227,0.00020993862,0.00007189313,0.00011332975,0.000053464297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002985544,0.00012655798,0.00055708265,0.0003749525,0.00004260271,0.000026059495,0.00007931412,0.00010707658,0.00013906622],"category_scores_gemma":[0.000044938108,0.00009600205,0.00010157505,0.0005716076,0.0001730832,0.00009890267,0.00002157137,0.00023782035,2.3324871e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048535736,0.000083295265,0.98924154,0.00017923652,0.0011177185,0.00020375408,0.0002977235,0.000022837768,0.00027244037,0.0018520372,0.0009552151,0.0052888263],"study_design_scores_gemma":[0.00044852134,0.00012835622,0.99323606,0.00021542775,0.00038958463,0.000025716556,0.00022573711,0.00029280924,0.002842588,0.00024517777,0.0018321405,0.00011789317],"about_ca_topic_score_codex":0.061511062,"about_ca_topic_score_gemma":0.111792855,"teacher_disagreement_score":0.050281793,"about_ca_system_score_codex":0.00008713282,"about_ca_system_score_gemma":0.00045765415,"threshold_uncertainty_score":0.9447384},"labels":[],"label_agreement":null},{"id":"W4391165493","doi":"10.1093/ecco-jcc/jjad212.1211","title":"P1081 Pharmacokinetics and immunogenicity of the ustekinumab biosimilar candidate ABP 654 in patients with moderate-to-severe plaque psoriasis","year":2024,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Ustekinumab; Biosimilar; Plaque psoriasis; Medicine; Immunogenicity; Pharmacokinetics; Psoriasis; Dermatology; Internal medicine; Pharmacology; Immunology; Adalimumab; Immune system; Disease","score_opus":0.00855860430933333,"score_gpt":0.25117824204352607,"score_spread":0.24261963773419273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391165493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99469227,0.0033729577,0.0000657495,0.0010370238,0.00037206244,0.00017621857,0.00013566992,0.0000033878844,0.00014464206],"genre_scores_gemma":[0.9986142,0.00054975157,0.00024233319,0.00033519306,0.000026930084,0.0000019955849,0.0000015147824,0.000009762146,0.00021830252],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990182,0.00015756486,0.0004027459,0.000145918,0.00007111059,0.00020447864],"domain_scores_gemma":[0.99949133,0.00010010719,0.00012729551,0.00010474561,0.00013024594,0.000046270994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029090178,0.00013787416,0.0003392965,0.00010921773,0.00006934243,0.00004095772,0.00013499892,0.00013437479,0.000112749905],"category_scores_gemma":[0.000030167028,0.00007819155,0.00007256589,0.00020208412,0.00018725362,0.00007564363,0.000080898644,0.0003367638,7.7307106e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13810502,0.0039607417,0.35119572,0.002432701,0.010636981,0.00078931183,0.009307567,0.00036572947,0.052263778,0.008083163,0.053058494,0.3698008],"study_design_scores_gemma":[0.0039190366,0.00088443584,0.9375241,0.0005138213,0.00030525203,0.00021647656,0.00010391109,0.0000526998,0.033283636,0.0005207401,0.022455096,0.00022080506],"about_ca_topic_score_codex":0.00006196347,"about_ca_topic_score_gemma":0.000044883294,"teacher_disagreement_score":0.5863284,"about_ca_system_score_codex":0.0000306018,"about_ca_system_score_gemma":0.00008005462,"threshold_uncertainty_score":0.3188559},"labels":[],"label_agreement":null},{"id":"W4391264910","doi":"10.1016/j.jpba.2024.115993","title":"Generic UPLC-MS/MS and Gyrolab assays with blood microsampling for pharmacokinetic assessments of therapeutic antibodies in mice","year":2024,"lang":"en","type":"article","venue":"Journal of Pharmaceutical and Biomedical Analysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Pharmacokinetics; Chemistry; Blood sampling; Pharmacology; Antibody; Whole blood; Chromatography; Therapeutic drug monitoring; Immunology; Internal medicine; Medicine","score_opus":0.04122010452379741,"score_gpt":0.38470999369644326,"score_spread":0.34348988917264583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391264910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9083476,0.056943983,0.029074397,0.0049356455,0.00032170516,0.00020023373,0.000110137764,0.000014911953,0.00005140107],"genre_scores_gemma":[0.98911446,0.0042849816,0.0059376564,0.00046155218,0.00008557094,0.0000034141246,0.000010933965,0.000011366486,0.000090079906],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983067,0.00020580488,0.00072238577,0.00029334764,0.0001357459,0.00033600692],"domain_scores_gemma":[0.99877363,0.00074228266,0.00017024454,0.000065796674,0.00012086407,0.00012715445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011771852,0.00021095412,0.0007625734,0.00059163413,0.000062042425,0.00004247659,0.00015545596,0.0002558926,0.00024587606],"category_scores_gemma":[0.000049907194,0.000121317724,0.00025406815,0.0009862022,0.0006769211,0.00008185978,0.000067113666,0.0006033821,6.8944365e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006450365,0.00063573057,0.013217307,0.0004430469,0.0089681195,0.000070637565,0.00008850386,0.0000044324293,0.90215033,0.00014225631,0.0002251198,0.07340948],"study_design_scores_gemma":[0.022049041,0.00676861,0.070027016,0.001431526,0.09041823,0.00214695,0.0006535175,0.039790094,0.5976175,0.0027887123,0.16457504,0.0017337683],"about_ca_topic_score_codex":0.000015128362,"about_ca_topic_score_gemma":0.0000049133455,"teacher_disagreement_score":0.30453283,"about_ca_system_score_codex":0.00001647037,"about_ca_system_score_gemma":0.000062209954,"threshold_uncertainty_score":0.4947193},"labels":[],"label_agreement":null},{"id":"W4391317775","doi":"10.1007/978-3-031-30023-3","title":"Pharmaceutical Biotechnology","year":2024,"lang":"en","type":"book","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","keywords":"Biotechnology; Biology","score_opus":0.03658400606171987,"score_gpt":0.33367973697225106,"score_spread":0.2970957309105312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391317775","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010593033,0.027667774,0.000309099,0.006491971,0.002548259,0.00017157858,0.000094788076,0.0005361834,0.9621793],"genre_scores_gemma":[0.000046715522,0.0008587288,0.00066814746,0.001651294,0.00013393273,0.00000723303,0.00007598162,0.000046956568,0.996511],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861246,0.000063177,0.0003148063,0.0005702392,0.000030042766,0.00040925323],"domain_scores_gemma":[0.99937654,0.00016007658,0.000042429256,0.0003632451,0.000028020066,0.000029712492],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022767588,0.00034014095,0.0005123673,0.0002219201,0.000047722417,0.000018653443,0.00033840325,0.0029855126,0.023781847],"category_scores_gemma":[0.000039306466,0.00023726017,0.0002829269,0.000085999,0.0006978794,0.000012480387,0.00030393447,0.0017871722,0.018232545],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014109226,0.000020084324,2.276955e-7,0.00006345651,0.00040355476,0.00003395541,0.0000026006765,4.095651e-9,0.006502021,0.20707306,0.7499182,0.035968676],"study_design_scores_gemma":[0.00016532258,0.00008854555,4.1052814e-7,0.00006713784,0.0003604858,0.00013096417,0.0000028292925,0.0000028071456,0.031744123,0.025504414,0.9416453,0.0002876505],"about_ca_topic_score_codex":0.0000015873106,"about_ca_topic_score_gemma":0.0000022233248,"teacher_disagreement_score":0.19172706,"about_ca_system_score_codex":0.00008396899,"about_ca_system_score_gemma":0.0001772973,"threshold_uncertainty_score":0.99830884},"labels":[],"label_agreement":null},{"id":"W4391386792","doi":"10.22541/au.170670892.22092232/v1","title":"Early model-based precision-dosing at home to guide adalimumab therapy","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Adalimumab; Medicine; Dosing; Prospective cohort study; Internal medicine; Pharmacokinetics; Therapeutic drug monitoring; Population; Disease","score_opus":0.04282159200818242,"score_gpt":0.3346772948019855,"score_spread":0.2918557027938031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391386792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66770715,0.04606792,0.16857314,0.029754097,0.014107824,0.0041072713,0.0013264053,0.0017272618,0.06662896],"genre_scores_gemma":[0.71892226,0.0005158264,0.09100079,0.010722435,0.00023884686,0.00019239995,0.00017002103,0.00019139417,0.17804602],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99723464,0.000290659,0.0006483059,0.001141065,0.00009825636,0.0005870858],"domain_scores_gemma":[0.99834096,0.0003187431,0.00009946693,0.0010040104,0.00014271817,0.00009412127],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00074387837,0.00053734286,0.00074587285,0.0002859634,0.0001529946,0.00010767695,0.0006738261,0.0013993708,0.002485675],"category_scores_gemma":[0.0000837967,0.00037540324,0.0005041168,0.0001997141,0.00016883832,0.000018423232,0.0018833338,0.0011768691,0.0012206837],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002793716,0.0005621668,0.000404483,0.00032706375,0.0020050684,0.000053608877,0.0006961976,0.00406858,0.4334903,0.0035309675,0.33856866,0.2134992],"study_design_scores_gemma":[0.0036291755,0.0012898612,0.001430756,0.0014887368,0.0006325282,0.000040332594,0.00005265176,0.016449245,0.49932536,0.06940937,0.4030131,0.003238885],"about_ca_topic_score_codex":0.00014689732,"about_ca_topic_score_gemma":0.00002791738,"teacher_disagreement_score":0.21026032,"about_ca_system_score_codex":0.00024859223,"about_ca_system_score_gemma":0.0002808934,"threshold_uncertainty_score":0.999897},"labels":[],"label_agreement":null},{"id":"W4391391181","doi":"10.1007/s40261-024-01341-7","title":"Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance","year":2024,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Etanercept; Medicine; Adalimumab; Biosimilar; Rheumatoid arthritis; Internal medicine; Infliximab; Observational study; Disease; Arthritis","score_opus":0.041359489177806366,"score_gpt":0.3287282879898965,"score_spread":0.28736879881209015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391391181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997123,0.00084791123,0.00018591156,0.0002821193,0.00051234616,0.0007523573,0.00020512604,0.00008310995,0.000008111073],"genre_scores_gemma":[0.99775285,0.0008930468,0.00095903967,0.00004648019,0.00007770866,0.000049144386,0.00012684969,0.000023356226,0.00007155758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975594,0.00045334545,0.0009950501,0.00061269867,0.000083937186,0.00029555534],"domain_scores_gemma":[0.99813634,0.0011448135,0.0002512758,0.00021405242,0.00012335824,0.0001301804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016190347,0.00024977117,0.0006202898,0.00014184244,0.000117207404,0.000031836116,0.00009867221,0.00036362268,0.000012428174],"category_scores_gemma":[0.0005294888,0.00016315696,0.0001212359,0.00030769056,0.0009028821,0.00030304457,0.000047818437,0.0005035202,0.000004722146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002335531,0.00023028906,0.98534954,0.00015346172,0.00012410269,0.0000020666994,0.00002291186,0.0000025704144,0.00015868909,0.00002639456,0.00014825283,0.011446216],"study_design_scores_gemma":[0.0031253605,0.002434237,0.98722583,0.0012620976,0.00010314809,0.0000011120742,0.00001104088,0.0007268694,0.004445861,0.000117060205,0.00032753957,0.0002198422],"about_ca_topic_score_codex":0.000009050748,"about_ca_topic_score_gemma":0.0000056157232,"teacher_disagreement_score":0.011226374,"about_ca_system_score_codex":0.00005943228,"about_ca_system_score_gemma":0.00009666967,"threshold_uncertainty_score":0.66533476},"labels":[],"label_agreement":null},{"id":"W4391782265","doi":"10.53555/sfs.v10i1s.2158","title":"Microbial Remediation of Diverse Antibiotics","year":2023,"lang":"en","type":"article","venue":"Journal of Survey in Fisheries Sciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Antibiotics; Environmental remediation; Microbiology; Environmental science; Biology; Ecology; Contamination","score_opus":0.22008367710831336,"score_gpt":0.32512096370707905,"score_spread":0.10503728659876568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391782265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749106,0.00015856007,0.00005256639,0.00063618843,0.0013577322,0.000030024628,0.000024580857,0.000004469931,0.0002448044],"genre_scores_gemma":[0.9986209,0.00028405443,0.0007901813,0.000049331615,0.00002329477,2.4250172e-8,0.000002822562,0.0000020001885,0.00022735864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889034,0.0003852617,0.00040639704,0.00008478121,0.000070297705,0.00016291655],"domain_scores_gemma":[0.9990149,0.0005030855,0.00027755805,0.000054584565,0.00013657262,0.00001325552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042041116,0.00005805696,0.0002282374,0.00021562727,0.000060098406,0.000013373227,0.0002476516,0.000104789535,0.00013731714],"category_scores_gemma":[0.0011131455,0.000040586376,0.000058127403,0.00085218175,0.0009774654,0.00014046831,0.00005409457,0.00014752262,0.000007308783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007980038,0.000042333704,0.8830832,0.0000089039595,0.000019228655,0.000005436992,0.0001808833,0.000010067426,0.1048122,0.00003860808,0.0095426515,0.0021766347],"study_design_scores_gemma":[0.00035273333,0.00036008752,0.9202404,0.000036159305,0.000010268486,0.000015823996,0.00044971582,0.000004763037,0.07598075,0.00021294875,0.002270175,0.00006616162],"about_ca_topic_score_codex":0.00008917937,"about_ca_topic_score_gemma":0.00019284416,"teacher_disagreement_score":0.037157156,"about_ca_system_score_codex":0.000012633182,"about_ca_system_score_gemma":0.000086570566,"threshold_uncertainty_score":0.3601512},"labels":[],"label_agreement":null},{"id":"W4391873217","doi":"10.1093/jcag/gwad061.252","title":"A252 DRUG DISCONTINUATION AND PERSISTENT SYMPTOMS AMONG THE USERS OF BIOSIMILAR AND LEGACY ANTI-TNF DRUGS IN A REAL-WORLD CANADIAN IBD COHORT","year":2024,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; University of British Columbia; McGill University; University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Biosimilar; Discontinuation; Cohort; Medicine; Drug; Infliximab; Tumor necrosis factor alpha; Pharmacology; Internal medicine","score_opus":0.007170871140938479,"score_gpt":0.23317791886816996,"score_spread":0.22600704772723149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391873217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96567965,0.00040005462,0.0000015215556,0.032902494,0.0005914313,0.00016393933,0.000065630855,0.0000019406098,0.0001933396],"genre_scores_gemma":[0.99856395,0.00017983536,0.000026787762,0.0006152059,0.000028955466,0.0000017499643,0.0000033981296,0.0000079656165,0.0005721672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827003,0.000657458,0.00052613654,0.00013713722,0.00007907245,0.00033013782],"domain_scores_gemma":[0.99899226,0.00020647253,0.000447819,0.000119748634,0.00013226666,0.00010140309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019638236,0.00011694654,0.00038648036,0.00046620413,0.00011261873,0.000037893362,0.00020544368,0.00015846305,0.000036943864],"category_scores_gemma":[0.00018964912,0.000074741845,0.00016651161,0.00020841401,0.00033400612,0.000115587885,0.00003305644,0.00044264866,4.3918595e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003932536,0.000013542276,0.99439764,0.000012924592,0.0005380476,0.0000034324664,0.0006625989,0.0000079943175,0.0005065793,0.00020100428,0.00327748,0.00033945043],"study_design_scores_gemma":[0.0005469071,0.0001790934,0.99568695,0.000120368706,0.00030501108,0.000028215727,0.00046012437,0.000079621,0.0002138388,0.000066773224,0.0022629353,0.00005018941],"about_ca_topic_score_codex":0.1989446,"about_ca_topic_score_gemma":0.95524544,"teacher_disagreement_score":0.7563008,"about_ca_system_score_codex":0.0005400199,"about_ca_system_score_gemma":0.00033142787,"threshold_uncertainty_score":0.8063897},"labels":[],"label_agreement":null},{"id":"W4391873380","doi":"10.1093/jcag/gwad061.229","title":"A229 DRUG PERSISTENCE WITH THERAPY OF ADALIMUMAB BIOSIMILAR, IDACIO, IN INFLAMMATORY BOWEL DISEASES","year":2024,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Adalimumab; Inflammatory Bowel Diseases; Medicine; Persistence (discontinuity); Drug; Inflammatory bowel disease; Pharmacology; Immunology; Internal medicine; Tumor necrosis factor alpha; Disease","score_opus":0.009279761584070055,"score_gpt":0.22377210555655377,"score_spread":0.2144923439724837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391873380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98003924,0.0015747915,0.000013873364,0.017324712,0.0007180818,0.00011037899,0.00010642752,0.0000038703192,0.000108610286],"genre_scores_gemma":[0.99857515,0.00017539933,0.00009599797,0.00079530996,0.000029726027,0.0000013241985,0.0000017434065,0.000008335926,0.00031701126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984313,0.0005799866,0.0005025046,0.00010994174,0.000094041294,0.0002821742],"domain_scores_gemma":[0.99890924,0.00017392344,0.00052864687,0.00013137975,0.00019788505,0.00005890704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082132884,0.00011205179,0.00034804377,0.000305509,0.00004913638,0.000012404083,0.00030817557,0.00015924172,0.00012616783],"category_scores_gemma":[0.00015709347,0.000070182155,0.00021821623,0.00015477907,0.00021869036,0.000072161114,0.000022358323,0.00039123514,0.0000014638537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006596983,0.00007158586,0.9849221,0.000033159384,0.0006164876,0.000019178306,0.00032324053,0.000033269363,0.0053659733,0.00014876391,0.0074062143,0.00040030177],"study_design_scores_gemma":[0.0027982388,0.0012465841,0.97645044,0.00036518602,0.00020332343,0.00012266732,0.00035098125,0.00003223468,0.004545685,0.00028558337,0.013485711,0.00011337248],"about_ca_topic_score_codex":0.00072124123,"about_ca_topic_score_gemma":0.06102413,"teacher_disagreement_score":0.060302887,"about_ca_system_score_codex":0.00039848866,"about_ca_system_score_gemma":0.00044807774,"threshold_uncertainty_score":0.95610976},"labels":[],"label_agreement":null},{"id":"W4392107106","doi":"10.4155/bio-2024-0024","title":"2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard <u>(Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity &amp; Technologies; Biotherapeutics Immunogenicity &amp; Risk Assessment; ADA/NAb Assay/Reporting Harmonization)","year":2024,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada); Health Canada","funders":"","keywords":"Excellence; Bioanalysis; White paper; Regulatory science; Political science; Medicine; Engineering ethics; Medical education; Nanotechnology; Engineering","score_opus":0.05395239857254657,"score_gpt":0.3813431374030369,"score_spread":0.3273907388304903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392107106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4462642,0.18883598,0.16358656,0.124564655,0.008214822,0.011493555,0.053675037,0.0016784196,0.0016867564],"genre_scores_gemma":[0.78585726,0.17358609,0.028667428,0.001002568,0.00026232717,0.0006562848,0.005772911,0.00019362097,0.0040015164],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99275106,0.0014688921,0.0029543105,0.0014209751,0.000596331,0.00080845325],"domain_scores_gemma":[0.9917018,0.0018204752,0.002407845,0.0014811739,0.0025258332,0.00006289496],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008605408,0.0008363185,0.0014981763,0.0011545587,0.000692013,0.0003994656,0.0011769627,0.000799115,0.0015632387],"category_scores_gemma":[0.001962055,0.00059751025,0.00096470397,0.0025231342,0.00024468693,0.0003863215,0.00025888337,0.0010749128,0.00001413983],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069758836,0.0032479675,0.0649136,0.00020586744,0.024109118,0.000008504305,0.00046278466,0.0010007459,0.50308824,0.0015646147,0.018906001,0.37551665],"study_design_scores_gemma":[0.0040114,0.0010691045,0.0069327597,0.00027661896,0.0018801504,0.000008851531,0.0008520119,0.0008968644,0.16777773,0.0007996161,0.81453425,0.0009606662],"about_ca_topic_score_codex":0.00064623286,"about_ca_topic_score_gemma":0.0006602193,"teacher_disagreement_score":0.79562825,"about_ca_system_score_codex":0.00077315565,"about_ca_system_score_gemma":0.00071376585,"threshold_uncertainty_score":0.9996476},"labels":[],"label_agreement":null},{"id":"W4392516312","doi":"10.1080/19420862.2024.2323706","title":"Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge","year":2024,"lang":"en","type":"article","venue":"mAbs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Structural Genomics Consortium; Montreal Neurological Institute and Hospital","funders":"NIHR Leicester Biomedical Research Centre; Biotechnology and Biological Sciences Research Council; National Institute of General Medical Sciences; Directorate for Biological Sciences; Ontario Genomics; National Institute for Health and Care Research; Genome Canada","keywords":"Context (archaeology); Computer science; Quality (philosophy); Exploit; Data science; Biochemical engineering; Risk analysis (engineering); Business; Engineering; Computer security; Biology","score_opus":0.3319024866860573,"score_gpt":0.4848507462807238,"score_spread":0.15294825959466646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392516312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92181903,0.051148076,0.00009143469,0.02482722,0.00037521106,0.00055573374,0.00031316784,0.00012331562,0.0007468089],"genre_scores_gemma":[0.99769104,0.0012573454,0.00048324052,0.000043542612,0.000046197794,0.0000055637774,0.000011144384,0.0000075364983,0.00045441647],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982258,0.00027028506,0.00019384224,0.0010190343,0.000050256007,0.00024077714],"domain_scores_gemma":[0.9976409,0.00038577107,0.00002880783,0.0018683404,0.00005636258,0.000019808025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064195846,0.00009518011,0.000195889,0.00009713993,0.00015881279,0.000059309063,0.0004731145,0.00021009306,0.000056911947],"category_scores_gemma":[0.0016461754,0.000054147215,0.000029719464,0.00019390564,0.0017402836,0.00008986727,0.0020328527,0.0008714429,0.0000030128065],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029756303,0.0007014987,0.05994617,0.0015749072,0.00027944968,0.000029045492,0.0017201465,1.3670176e-8,0.5523998,0.051739372,0.01208528,0.31922674],"study_design_scores_gemma":[0.0018570625,0.003408552,0.3893181,0.0018848171,0.0008452047,0.0007212553,0.0073203356,0.00057011476,0.25234196,0.07220928,0.26815286,0.0013704704],"about_ca_topic_score_codex":0.0017446835,"about_ca_topic_score_gemma":0.00023357729,"teacher_disagreement_score":0.32937193,"about_ca_system_score_codex":0.000017073875,"about_ca_system_score_gemma":0.000062091625,"threshold_uncertainty_score":0.6412147},"labels":[],"label_agreement":null},{"id":"W4392858819","doi":"10.21203/rs.3.rs-4088062/v1","title":"Rigorous Quality Assessment of Clinical Practice Guidelines for Microfluidic Technologies as Rapid Tests during COVID-19 using the AGREE II Instrument","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of Toronto","keywords":"Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Clinical Practice; Quality (philosophy); Microfluidics; Medical physics; Computer science; Medicine; Virology; Nanotechnology; Materials science; Physics; Internal medicine; Family medicine","score_opus":0.5188351172130501,"score_gpt":0.6363066520693178,"score_spread":0.11747153485626771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392858819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45210537,0.22114402,0.0040527373,0.30343854,0.0049150554,0.00962365,0.0023640383,0.0007546992,0.0016018657],"genre_scores_gemma":[0.82820284,0.045157284,0.11882331,0.0027730486,0.0007741903,0.0009999984,0.00026986818,0.00016719686,0.0028322549],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99081916,0.004132895,0.0023296871,0.0012921472,0.00047818347,0.0009479531],"domain_scores_gemma":[0.9858227,0.008542905,0.0007115089,0.0016953221,0.0031040148,0.00012358536],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.026703386,0.00044191707,0.0011908441,0.00041550776,0.0009888625,0.00011013796,0.0013909333,0.0018767635,0.0002030852],"category_scores_gemma":[0.10057248,0.00027768285,0.0007369778,0.00053414254,0.001742099,0.000054877,0.007436585,0.004495186,0.000014135691],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047552427,0.0043383273,0.0072527267,0.027096117,0.010128821,0.00023525093,0.0011939033,0.00009545925,0.42917442,0.032142535,0.16896123,0.31462598],"study_design_scores_gemma":[0.0039483598,0.003417845,0.0042771217,0.0035923684,0.0011453979,0.00033066995,0.016807005,0.00040957547,0.1220945,0.05969914,0.7829574,0.0013206268],"about_ca_topic_score_codex":0.00093297876,"about_ca_topic_score_gemma":0.000034507393,"teacher_disagreement_score":0.61399615,"about_ca_system_score_codex":0.00048557698,"about_ca_system_score_gemma":0.0038302215,"threshold_uncertainty_score":0.9999675},"labels":[],"label_agreement":null},{"id":"W4393098859","doi":"10.1016/j.ejca.2024.113958","title":"A randomized, double-blind, phase III study in India to evaluate efficacy, safety, pharmacokinetics (PK), and immunogenicity of ZRC-3277 (pertuzumab biosimilar) in comparison with Perjeta® (pertuzumab) in patients with HER2-positive metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Pertuzumab; Biosimilar; Immunogenicity; Pharmacokinetics; Medicine; Double blind; Pharmacology; Internal medicine; Trastuzumab; Placebo; Immunology; Antibody; Cancer; Pathology","score_opus":0.03121014927277414,"score_gpt":0.3622070905831796,"score_spread":0.33099694131040547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393098859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98224634,0.014718698,0.00017810793,0.0007389962,0.00027398404,0.0015608281,0.00014618655,0.000007733112,0.00012915285],"genre_scores_gemma":[0.99850106,0.0008369731,0.00028372483,0.00021747939,0.000032613614,0.000026265187,0.0000071667887,0.000047081216,0.000047615096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99493885,0.002480611,0.0014866842,0.000425384,0.00024741588,0.00042108243],"domain_scores_gemma":[0.9985348,0.00039921518,0.00045636244,0.00018443739,0.00032957937,0.000095616306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029771514,0.0003925918,0.001493377,0.00064788054,0.000050810293,0.00004601456,0.0003088227,0.00006162432,0.00024885367],"category_scores_gemma":[0.000047253943,0.00024119695,0.00013393088,0.00085724756,0.00035941193,0.0001468276,0.00012276748,0.0008981396,0.0000027678557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89600587,0.0039928737,0.03800069,0.00008984221,0.0028101446,0.0003349922,0.007534238,0.0010038487,0.0020965498,0.000008068694,0.000113882634,0.048008975],"study_design_scores_gemma":[0.78422177,0.0044883164,0.20179413,0.0020481849,0.001615096,0.00007555383,0.00075070804,0.00030550515,0.003872214,0.0000030238082,0.0003551544,0.000470341],"about_ca_topic_score_codex":0.00042084174,"about_ca_topic_score_gemma":0.0005088048,"teacher_disagreement_score":0.16379344,"about_ca_system_score_codex":0.00028663978,"about_ca_system_score_gemma":0.00028874064,"threshold_uncertainty_score":0.9835726},"labels":[],"label_agreement":null},{"id":"W4393110617","doi":"10.1093/jcag/gwae011","title":"Outcomes of a mandatory non-medical switch of infliximab to a biosimilar for inflammatory bowel disease in British Columbia, Canada","year":2024,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Association of Gastroenterology","keywords":"Biosimilar; Infliximab; Medicine; Discontinuation; Inflammatory bowel disease; Adverse effect; Internal medicine; Observational study; Disease","score_opus":0.004894062226645064,"score_gpt":0.2297162564921015,"score_spread":0.22482219426545644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393110617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98363626,0.00016765548,0.000041329287,0.014285186,0.0010907963,0.00020231628,0.00056231895,0.0000014325336,0.000012691064],"genre_scores_gemma":[0.99737227,0.00001849633,0.00012820704,0.0020433944,0.000027879269,0.0000050187214,0.0000035508435,0.000009067747,0.00039208893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998296,0.00027146397,0.0008472133,0.00011551995,0.00015437372,0.0003153965],"domain_scores_gemma":[0.99863994,0.00028154193,0.00051127747,0.000124455,0.0002803499,0.00016241579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013655496,0.00008153264,0.000503953,0.000177565,0.000040568062,0.000012330166,0.00035401838,0.000219327,0.00014256687],"category_scores_gemma":[0.001410104,0.00008379421,0.00023497229,0.00012437302,0.00011257985,0.00003755538,0.00004784761,0.0003201624,3.2232023e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014031204,0.00004862525,0.9637658,0.000092264,0.0003867384,0.000023875391,0.000047615245,0.0000104518695,0.0005558937,0.000009738672,0.034640837,0.00027786972],"study_design_scores_gemma":[0.0013190622,0.0003253146,0.9901937,0.00025805229,0.000118174736,0.000019731538,0.000045334702,0.000034949288,0.00016596867,0.00008430404,0.0073846187,0.00005077056],"about_ca_topic_score_codex":0.51405346,"about_ca_topic_score_gemma":0.9980212,"teacher_disagreement_score":0.48396775,"about_ca_system_score_codex":0.00065683475,"about_ca_system_score_gemma":0.002641011,"threshold_uncertainty_score":0.48918253},"labels":[],"label_agreement":null},{"id":"W4393143300","doi":"10.1016/j.cca.2024.117890","title":"LC-MS/MS measurement of endogenous steroid hormones and phase II metabolites in blood volumetric absorptive microsampling (VAMS) for doping control purposes","year":2024,"lang":"en","type":"article","venue":"Clinica Chimica Acta","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministero dell’Istruzione, dell’Università e della Ricerca; World Anti-Doping Agency; Partnership for Clean Competition","keywords":"Chemistry; Chromatography; Analyte","score_opus":0.07670242077501588,"score_gpt":0.33283536391352164,"score_spread":0.25613294313850576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393143300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94761884,0.048222777,0.00048246887,0.0010566982,0.00070407294,0.0011054167,0.0005742336,0.00006710654,0.00016837899],"genre_scores_gemma":[0.9948631,0.0022753808,0.0023503643,0.0002231456,0.00009146689,0.00006645232,0.000024213054,0.000029896786,0.0000759724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997516,0.00026675762,0.0010161736,0.0006278968,0.00007586675,0.00049733836],"domain_scores_gemma":[0.99746895,0.0017858064,0.00022816139,0.0002995862,0.00016232637,0.00005514773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001843859,0.00029680328,0.0009348104,0.00034886555,0.00015491755,0.000046569778,0.0002765323,0.00036781293,0.000075930235],"category_scores_gemma":[0.0013192862,0.00023487098,0.00030335394,0.00036825813,0.00037325197,0.00009375181,0.00014304415,0.0004167132,0.000003366127],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050658145,0.00084512203,0.00061436725,0.00018309684,0.0010118713,0.0000031314637,0.00022353535,2.2155322e-7,0.98533905,0.00016135204,0.00025424073,0.0108574405],"study_design_scores_gemma":[0.01295537,0.003355199,0.003187371,0.00048642783,0.0020761613,0.000094464165,0.00015249914,0.0002561395,0.9412082,0.0008423495,0.034782685,0.0006031281],"about_ca_topic_score_codex":0.000029078525,"about_ca_topic_score_gemma":0.000018809587,"teacher_disagreement_score":0.04724426,"about_ca_system_score_codex":0.000029916131,"about_ca_system_score_gemma":0.000105307525,"threshold_uncertainty_score":0.95777607},"labels":[],"label_agreement":null},{"id":"W4393673708","doi":"10.5281/zenodo.8008094","title":"CFdb: chromatograms","year":2023,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chromatography; Chemistry","score_opus":0.05145542196333285,"score_gpt":0.29169949163390274,"score_spread":0.24024406967056988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393673708","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015733016,0.0003600648,0.000096068885,0.0006070931,0.0007066913,0.00035650705,0.98933685,0.00091945985,0.0076015145],"genre_scores_gemma":[0.000042887397,0.00054133515,0.00006223306,0.00026712185,0.00014861069,4.6061604e-8,0.9935641,0.0010566115,0.0043170108],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975739,0.00075499463,0.00035620644,0.0006132667,0.00012420137,0.0005774141],"domain_scores_gemma":[0.99860215,0.000074730655,0.0001583095,0.0007878122,0.00028976207,0.00008725502],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00093169534,0.00027424106,0.00036476133,0.00031057326,0.0017607932,0.00038541746,0.0016014302,0.0005630081,0.042211454],"category_scores_gemma":[0.0009589472,0.0002518185,0.00014681264,0.00061922544,0.00043967675,0.00006228207,0.0018913298,0.0008849901,0.17434268],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036359612,0.00011582701,5.440801e-8,0.000098648,0.00018982774,0.000022537872,0.000019731982,2.8927292e-7,0.0010696765,0.00013448157,0.97631156,0.022001019],"study_design_scores_gemma":[0.00038450555,0.0002597781,0.000033114327,0.00006244022,0.00008423823,0.00015779515,0.00004871038,0.0000018742694,0.000291911,0.00008843228,0.99830145,0.0002857713],"about_ca_topic_score_codex":0.000075977645,"about_ca_topic_score_gemma":0.0000012812834,"teacher_disagreement_score":0.13213123,"about_ca_system_score_codex":0.00008854356,"about_ca_system_score_gemma":0.000004859204,"threshold_uncertainty_score":0.9999934},"labels":[],"label_agreement":null},{"id":"W4393773264","doi":"10.5281/zenodo.3245502","title":"Optimisation of viability assay for DIPG patient-derived cell lines","year":2019,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium","funders":"","keywords":"Viability assay; Computational biology; Computer science; Cell culture; Biology; Genetics","score_opus":0.04375743927569752,"score_gpt":0.27902739891926126,"score_spread":0.23526995964356373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393773264","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006382969,0.00030112168,0.0012169293,0.00026797917,0.00046608847,0.0011237917,0.99404854,0.000110617846,0.0018266515],"genre_scores_gemma":[0.0033078177,0.00019707506,0.0006843533,0.00013405745,0.00006678541,1.5011724e-7,0.9944511,0.000440205,0.00071842637],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99762356,0.0008947068,0.00049094314,0.00053089525,0.000104803556,0.00035510925],"domain_scores_gemma":[0.9978833,0.00020482835,0.00036615282,0.00070788857,0.00078673277,0.00005106614],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010338558,0.0002362207,0.0004195402,0.00018535618,0.00062692375,0.000106416024,0.0008695848,0.00048497054,0.016955538],"category_scores_gemma":[0.0015507239,0.00021238787,0.00016609735,0.00022469868,0.00031452518,0.000075702694,0.00082705414,0.00042809892,0.0015296019],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019342163,0.00027960565,2.78514e-7,0.00038133736,0.00009714713,5.109287e-7,0.000055247252,0.000005531849,0.063490964,0.000021075519,0.92009664,0.01537823],"study_design_scores_gemma":[0.000622889,0.00072897365,0.000017144112,0.00004552277,0.000106981206,0.00000974522,0.00006984233,0.000014985487,0.029626314,0.00004449387,0.9684969,0.000216205],"about_ca_topic_score_codex":0.00001634514,"about_ca_topic_score_gemma":2.971384e-7,"teacher_disagreement_score":0.048400253,"about_ca_system_score_codex":0.00007907295,"about_ca_system_score_gemma":0.000009295915,"threshold_uncertainty_score":0.99924785},"labels":[],"label_agreement":null},{"id":"W4394058682","doi":"10.5281/zenodo.3245503","title":"Optimisation of viability assay for DIPG patient-derived cell lines","year":2019,"lang":"en","type":"dataset","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium","funders":"","keywords":"Viability assay; Computational biology; Computer science; Cell culture; Biology; Genetics","score_opus":0.05501456524466697,"score_gpt":0.3074884759689034,"score_spread":0.2524739107242364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394058682","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021945565,0.0007120571,0.0000040089362,0.00004788419,0.0003912556,0.0007812434,0.99796665,0.000013416208,0.00006154824],"genre_scores_gemma":[0.00015522407,0.000013329839,0.0004122178,0.00018206205,0.000050176634,0.00013154912,0.998734,0.000013228941,0.00030824382],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986887,0.0002288733,0.00041017745,0.00038454396,0.00004030677,0.00024742624],"domain_scores_gemma":[0.9978589,0.0009230226,0.0004003571,0.0005350547,0.00026140144,0.00002125405],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014217992,0.00024846933,0.00051910634,0.00006448617,0.000049214912,0.0000104719065,0.00031619487,0.0010551752,0.1377401],"category_scores_gemma":[0.0020336774,0.00019621872,0.0002628014,0.00007208047,0.00003073662,0.00003292664,0.00016378915,0.00031204073,0.0006037156],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006691348,0.00013351135,8.791914e-7,0.0011938891,0.00007053848,2.731648e-7,0.000006152775,0.0000013666421,0.010581474,1.436274e-7,0.986663,0.0012818509],"study_design_scores_gemma":[0.00035030994,0.00028472338,0.000022151342,0.00034742957,0.00009091952,0.0000010115448,0.000009042135,0.0000042626575,0.09625129,0.000011489979,0.9024236,0.00020374531],"about_ca_topic_score_codex":0.000008689241,"about_ca_topic_score_gemma":0.0000048150587,"teacher_disagreement_score":0.13713638,"about_ca_system_score_codex":0.000025549445,"about_ca_system_score_gemma":0.000084175845,"threshold_uncertainty_score":0.86304814},"labels":[],"label_agreement":null},{"id":"W4394258771","doi":"10.6084/m9.figshare.24448336","title":"Supplementary Material for: Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Trastuzumab; Postmarketing surveillance; Medicine; Business; Internal medicine; Adverse effect; Cancer; Breast cancer","score_opus":0.017201913181690176,"score_gpt":0.28943256989466964,"score_spread":0.27223065671297947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394258771","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004614089,0.00012714145,5.1290463e-8,0.000026243155,0.00034900758,0.0018284704,0.99303734,0.000015459105,0.0000021851704],"genre_scores_gemma":[0.003356314,0.000025652233,0.000014054002,0.000057975707,0.00003356508,0.00021304659,0.99626374,0.000028408576,0.000007225567],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967883,0.0015742963,0.00059051526,0.0005808434,0.00006429066,0.0004017126],"domain_scores_gemma":[0.9965945,0.002605927,0.00025411282,0.00033192203,0.00018669142,0.000026883914],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001170959,0.00035683054,0.00087414146,0.00019719177,0.000091987626,0.000017830733,0.0003178786,0.0004989717,0.022060253],"category_scores_gemma":[0.002572201,0.00030477115,0.00011890339,0.00019069518,0.000039283088,0.000021451626,0.0003861865,0.0003154733,0.0000329492],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029220306,0.00041200023,0.001490746,0.0021118578,0.00027577917,0.000008289093,0.000016062095,2.1038854e-7,0.00018274147,9.028489e-8,0.9919988,0.00058139063],"study_design_scores_gemma":[0.00613156,0.0024180703,0.38169664,0.0032880465,0.00016909762,0.0000044370195,0.00018320988,0.0000011415441,0.0017497997,0.000005767652,0.6036518,0.0007003879],"about_ca_topic_score_codex":0.00027925405,"about_ca_topic_score_gemma":0.0010833493,"teacher_disagreement_score":0.38834697,"about_ca_system_score_codex":0.00006786983,"about_ca_system_score_gemma":0.000061785635,"threshold_uncertainty_score":0.99994045},"labels":[],"label_agreement":null},{"id":"W4394282603","doi":"10.6084/m9.figshare.24449218","title":"Supplementary Material for: Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Trastuzumab; Postmarketing surveillance; Business; Medicine; Marketing; Pharmacology; Internal medicine; Adverse effect","score_opus":0.017201913181690176,"score_gpt":0.28943256989466964,"score_spread":0.27223065671297947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394282603","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004614089,0.00012714145,5.1290463e-8,0.000026243155,0.00034900758,0.0018284704,0.99303734,0.000015459105,0.0000021851704],"genre_scores_gemma":[0.003356314,0.000025652233,0.000014054002,0.000057975707,0.00003356508,0.00021304659,0.99626374,0.000028408576,0.000007225567],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967883,0.0015742963,0.00059051526,0.0005808434,0.00006429066,0.0004017126],"domain_scores_gemma":[0.9965945,0.002605927,0.00025411282,0.00033192203,0.00018669142,0.000026883914],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001170959,0.00035683054,0.00087414146,0.00019719177,0.000091987626,0.000017830733,0.0003178786,0.0004989717,0.022060253],"category_scores_gemma":[0.002572201,0.00030477115,0.00011890339,0.00019069518,0.000039283088,0.000021451626,0.0003861865,0.0003154733,0.0000329492],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029220306,0.00041200023,0.001490746,0.0021118578,0.00027577917,0.000008289093,0.000016062095,2.1038854e-7,0.00018274147,9.028489e-8,0.9919988,0.00058139063],"study_design_scores_gemma":[0.00613156,0.0024180703,0.38169664,0.0032880465,0.00016909762,0.0000044370195,0.00018320988,0.0000011415441,0.0017497997,0.000005767652,0.6036518,0.0007003879],"about_ca_topic_score_codex":0.00027925405,"about_ca_topic_score_gemma":0.0010833493,"teacher_disagreement_score":0.38834697,"about_ca_system_score_codex":0.00006786983,"about_ca_system_score_gemma":0.000061785635,"threshold_uncertainty_score":0.99994045},"labels":[],"label_agreement":null},{"id":"W4394318233","doi":"10.6084/m9.figshare.24448345","title":"Supplementary Material for: Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Trastuzumab; Postmarketing surveillance; Business; Medicine; Internal medicine; Marketing; Adverse effect; Cancer","score_opus":0.017201913181690176,"score_gpt":0.28943256989466964,"score_spread":0.27223065671297947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394318233","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004614089,0.00012714145,5.1290463e-8,0.000026243155,0.00034900758,0.0018284704,0.99303734,0.000015459105,0.0000021851704],"genre_scores_gemma":[0.003356314,0.000025652233,0.000014054002,0.000057975707,0.00003356508,0.00021304659,0.99626374,0.000028408576,0.000007225567],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967883,0.0015742963,0.00059051526,0.0005808434,0.00006429066,0.0004017126],"domain_scores_gemma":[0.9965945,0.002605927,0.00025411282,0.00033192203,0.00018669142,0.000026883914],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001170959,0.00035683054,0.00087414146,0.00019719177,0.000091987626,0.000017830733,0.0003178786,0.0004989717,0.022060253],"category_scores_gemma":[0.002572201,0.00030477115,0.00011890339,0.00019069518,0.000039283088,0.000021451626,0.0003861865,0.0003154733,0.0000329492],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029220306,0.00041200023,0.001490746,0.0021118578,0.00027577917,0.000008289093,0.000016062095,2.1038854e-7,0.00018274147,9.028489e-8,0.9919988,0.00058139063],"study_design_scores_gemma":[0.00613156,0.0024180703,0.38169664,0.0032880465,0.00016909762,0.0000044370195,0.00018320988,0.0000011415441,0.0017497997,0.000005767652,0.6036518,0.0007003879],"about_ca_topic_score_codex":0.00027925405,"about_ca_topic_score_gemma":0.0010833493,"teacher_disagreement_score":0.38834697,"about_ca_system_score_codex":0.00006786983,"about_ca_system_score_gemma":0.000061785635,"threshold_uncertainty_score":0.99994045},"labels":[],"label_agreement":null},{"id":"W4395450028","doi":"10.1053/j.gastro.2024.04.020","title":"Basket, Umbrella, and Platform Trials: The Potential for Master Protocol–Based Trials in Inflammatory Bowel Disease","year":2024,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Inflammatory bowel disease; Medicine; Protocol (science); Clinical trial; Disease; Intensive care medicine; Internal medicine; Pathology; Alternative medicine","score_opus":0.07373650700413996,"score_gpt":0.3538731137210565,"score_spread":0.28013660671691654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395450028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56858915,0.0072301016,0.114057414,0.071065694,0.009570053,0.22668688,0.0019090661,0.00052314566,0.00036846427],"genre_scores_gemma":[0.9137079,0.000043969183,0.0025902756,0.0078271255,0.0007427606,0.07297537,0.00012087162,0.00008820744,0.0019034821],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99576753,0.002157882,0.0010690377,0.00044428514,0.000039839066,0.00052141846],"domain_scores_gemma":[0.99763656,0.0018486687,0.00017719288,0.00024860635,0.000031597076,0.000057377685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007985016,0.00024122957,0.0007707974,0.00017830697,0.00009427513,0.00006933726,0.00020468027,0.00026900778,0.00046835694],"category_scores_gemma":[0.0011481777,0.00013732204,0.00038786986,0.000058615897,0.0003858847,0.00006307998,0.00009147781,0.00036376028,0.000019636107],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24141075,0.0020024993,0.15735404,0.0050699,0.004690531,0.00061102427,0.00064743264,0.00022650984,0.21856466,0.011372886,0.1866517,0.17139806],"study_design_scores_gemma":[0.052335937,0.0068442337,0.17706938,0.0008885833,0.0024777816,0.00026403595,0.00035235737,0.0130348755,0.0075972304,0.01456394,0.72353566,0.0010360075],"about_ca_topic_score_codex":0.0000047280732,"about_ca_topic_score_gemma":0.000026186675,"teacher_disagreement_score":0.53688395,"about_ca_system_score_codex":0.000026681739,"about_ca_system_score_gemma":0.000075737014,"threshold_uncertainty_score":0.5599831},"labels":[],"label_agreement":null},{"id":"W4396541919","doi":"10.2139/ssrn.4810665","title":"Real-Time Nanopore Sequencing and Evidence-Based Reporting to Prevent Adverse Drug Reactions","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; Vancouver General Hospital","funders":"","keywords":"Nanopore; Drug reaction; Drug; Adverse drug reaction; Nanopore sequencing; Adverse effect; Medicine; Intensive care medicine; Business; Computer science; Risk analysis (engineering); Pharmacology; Nanotechnology; Chemistry; DNA sequencing; Materials science; DNA","score_opus":0.03407098937027214,"score_gpt":0.32286605177459043,"score_spread":0.2887950624043183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396541919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.900282,0.06812072,0.0015777894,0.022860255,0.0033564689,0.0013116726,0.000044107153,0.0003535238,0.0020934336],"genre_scores_gemma":[0.9251283,0.020452326,0.0048145354,0.00044542583,0.00054927287,0.000058504953,0.000029570563,0.00010878723,0.048413277],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9952656,0.0005653968,0.00139942,0.0007415492,0.00011136985,0.0019166513],"domain_scores_gemma":[0.9978115,0.00029756565,0.0011835975,0.0004315836,0.00017017094,0.00010558969],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008190582,0.00039985846,0.00065076957,0.00031140185,0.0003247656,0.00007685282,0.00031656376,0.00056880224,0.0001851926],"category_scores_gemma":[0.0013984612,0.00032018527,0.00039515612,0.0002137529,0.00013406486,0.00006820424,0.000544381,0.00674919,0.00009878587],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004898993,0.00023554465,0.0004298246,0.0008477388,0.003363099,0.00023847171,0.00071950804,0.00045608086,0.9331202,0.013246793,0.005059001,0.04179385],"study_design_scores_gemma":[0.0016732482,0.0022819035,0.00084422395,0.024661746,0.0053677303,0.01351593,0.005700523,0.0009792952,0.17757285,0.74213463,0.02150707,0.0037608491],"about_ca_topic_score_codex":0.00043841885,"about_ca_topic_score_gemma":0.0002152606,"teacher_disagreement_score":0.75554734,"about_ca_system_score_codex":0.0019866636,"about_ca_system_score_gemma":0.0062762043,"threshold_uncertainty_score":0.999925},"labels":[],"label_agreement":null},{"id":"W4396871427","doi":"","title":"Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment","year":2015,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Calgary","funders":"","keywords":"Clinical Practice; Computer science; Medicine; Computational biology; Biology; Family medicine","score_opus":0.573995184115697,"score_gpt":0.6230099557210517,"score_spread":0.04901477160535461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396871427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9176627,0.067765824,0.0023681875,0.0041847085,0.0019693794,0.00091084844,0.00016392648,0.00004322384,0.0049311896],"genre_scores_gemma":[0.9688252,0.011007505,0.01307873,0.00620985,0.00023505885,0.0000415359,0.000031971816,0.000035574685,0.0005345407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957838,0.0019642906,0.0010605594,0.0005502087,0.00014698671,0.00049411936],"domain_scores_gemma":[0.99687225,0.001782804,0.00057806866,0.0004685732,0.000118213415,0.00018010211],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005414286,0.00027567605,0.0009529974,0.00055921223,0.00012077606,0.00020171536,0.0017541047,0.00033911894,0.009165341],"category_scores_gemma":[0.0021091786,0.00020730283,0.00017990835,0.0006868453,0.00038925034,0.0005732429,0.0013697202,0.0007090239,0.0001518342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028040076,0.0023516098,0.6678127,0.000018300068,0.0012474102,0.00010094909,0.0013999111,0.000031928972,0.14523466,0.0005133997,0.0460054,0.13247971],"study_design_scores_gemma":[0.0017753693,0.000133235,0.52200204,0.00019768105,0.0001441158,0.000020378218,0.0011288993,0.000017909142,0.013943907,0.013615727,0.4464621,0.0005586427],"about_ca_topic_score_codex":0.00076254364,"about_ca_topic_score_gemma":0.000033225595,"teacher_disagreement_score":0.4004567,"about_ca_system_score_codex":0.00008647124,"about_ca_system_score_gemma":0.00007986552,"threshold_uncertainty_score":0.9917404},"labels":[],"label_agreement":null},{"id":"W4398198890","doi":"10.1016/j.jcyt.2024.03.339","title":"THYMUS-DERIVED REGULATORY T CELLS AS A UNIVERSAL OFF-THE-SHELF ANTI-INFLAMMATORY THERAPY: TECHNOLOGY TRANSFER IN PREPARATION FOR A PHASE I CLINICAL TRIAL","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; University of British Columbia; BC Children's Hospital","funders":"","keywords":"Off the shelf; Clinical trial; Phase (matter); Medicine; Immunology; Chemistry; Internal medicine; Computer science","score_opus":0.042339644382727,"score_gpt":0.37754759292847145,"score_spread":0.3352079485457444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398198890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97416675,0.015133727,0.0032639154,0.0032856446,0.0018150035,0.0019340055,0.000042095,0.00020553383,0.00015332602],"genre_scores_gemma":[0.99012256,0.0057241484,0.00046900136,0.0012600716,0.00031364174,0.00020956928,0.000025134112,0.00006133562,0.0018145615],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.997947,0.0004884474,0.00060374744,0.0005392669,0.000047438043,0.00037412008],"domain_scores_gemma":[0.9989021,0.00056968216,0.000052958105,0.00039619446,0.000050606202,0.000028458604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012571872,0.00024123208,0.0004660389,0.0002263362,0.00012438369,0.000036013287,0.0003055192,0.00082002365,0.00039922842],"category_scores_gemma":[0.000043377695,0.00016529145,0.00034499945,0.00031645258,0.0006425167,0.00008741915,0.00001788208,0.0004857534,0.00005158276],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03127156,0.00055117754,0.000028473318,0.000017509661,0.00043301372,0.000015973199,0.0004618483,0.000001224473,0.76002467,0.005777695,0.0013748907,0.200042],"study_design_scores_gemma":[0.04929923,0.003869148,0.00006535656,0.000043388787,0.00006168784,0.000014940481,0.00016773092,0.0001674113,0.43047467,0.001816089,0.5137505,0.0002698815],"about_ca_topic_score_codex":0.0000044495796,"about_ca_topic_score_gemma":0.0000123593245,"teacher_disagreement_score":0.5123756,"about_ca_system_score_codex":0.000048967526,"about_ca_system_score_gemma":0.00024467404,"threshold_uncertainty_score":0.674039},"labels":[],"label_agreement":null},{"id":"W4398210924","doi":"10.1080/17576180.2024.2340961","title":"2023 White Paper on Recent Issues in Bioanalysis: EU IVDR 2017/746 Implementation/Impact, IVD/CDx/CLIA Approved Assays, High Dimensional Cytometry, Multiplexing Technologies, LBA Tissue Analysis, Vaccine Study Endpoints, Cell-Based Assays for Biomarkers, Cell Therapy and Vaccines ( <u>PART 2</u> – Recommendations on Development &amp; Validation of Biomarkers, IVD, CDx, Cell-Based, Flow Cytometry, Ligand-Binding and Enzyme Assays; Advanced Critical Reagents Strategies)","year":2024,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"U.S. Food and Drug Administration; Ministry of Health, Labour and Welfare; Exelixis; Biogen; Sanofi; Health Canada; Spark Therapeutics; Genentech; AstraZeneca","keywords":"Bioanalysis; Chemistry; Computational biology; Biology; Chromatography","score_opus":0.039892838548765776,"score_gpt":0.3678123926781478,"score_spread":0.327919554129382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398210924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81153566,0.06328421,0.07784262,0.025796246,0.0023053014,0.0090968935,0.008712326,0.0010622874,0.00036446945],"genre_scores_gemma":[0.9563236,0.002171598,0.035892706,0.00017318012,0.000040537358,0.00029524148,0.0047793537,0.00007630794,0.0002474239],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9933082,0.0012376461,0.002053375,0.0019571984,0.00046826102,0.0009753275],"domain_scores_gemma":[0.99541175,0.0023303432,0.00067701,0.0009441377,0.00046441826,0.00017235274],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036512804,0.0010061534,0.0017596252,0.004743074,0.00057044544,0.0003269052,0.00048730357,0.0006889977,0.0010368407],"category_scores_gemma":[0.00048795747,0.000814378,0.0005294542,0.0057927673,0.00020542998,0.00035693301,0.00020874137,0.0005539884,0.000020630894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067511043,0.010455275,0.08394007,0.0010364176,0.032064535,0.00007336205,0.0008632705,0.0034771159,0.66610414,0.00009390954,0.01488934,0.18025148],"study_design_scores_gemma":[0.011405914,0.0026499445,0.01434215,0.00039667543,0.007417385,0.0000050839067,0.006149633,0.007003058,0.9182936,0.000127066,0.030188004,0.0020214864],"about_ca_topic_score_codex":0.00043367888,"about_ca_topic_score_gemma":0.0011569913,"teacher_disagreement_score":0.25218946,"about_ca_system_score_codex":0.00041908954,"about_ca_system_score_gemma":0.00027953848,"threshold_uncertainty_score":0.9998763},"labels":[],"label_agreement":null},{"id":"W4399273590","doi":"10.3899/jrheum.2024-0001","title":"Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective Registry","year":2024,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Discontinuation; Biosimilar; Medicine; Adalimumab; Etanercept; Hazard ratio; Internal medicine; Adverse effect; Concomitant; Proportional hazards model; Rheumatoid arthritis; Retrospective cohort study; Confidence interval","score_opus":0.019949641265375122,"score_gpt":0.2916780996843627,"score_spread":0.2717284584189876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399273590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99087226,0.002534691,0.00037947216,0.0023032124,0.0031110244,0.00025460016,0.00043727728,0.000033440807,0.000074039745],"genre_scores_gemma":[0.9988962,0.00027514133,0.00044951346,0.00011761191,0.000028257971,0.0000020947207,0.000008731139,0.000024634024,0.00019780741],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973125,0.0007044163,0.0011747961,0.00029467553,0.00011528501,0.00039832716],"domain_scores_gemma":[0.9968498,0.0018526468,0.0005602572,0.0003893011,0.00026572257,0.00008228776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007471919,0.0002804277,0.00091552193,0.00020665758,0.00009669107,0.000030902072,0.00059445074,0.00027659215,0.00027416836],"category_scores_gemma":[0.0006044069,0.0001670851,0.0002797912,0.00031064943,0.000552892,0.000078578545,0.00015243625,0.0007555009,0.00005397357],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026755994,0.0010076115,0.54697114,0.00037605752,0.005545583,0.00069809135,0.008481713,0.00001558987,0.3841532,0.0007857774,0.021409642,0.0037996022],"study_design_scores_gemma":[0.014381143,0.0056665572,0.17844054,0.005801482,0.0021405914,0.021543102,0.0030031407,0.00012253522,0.7461775,0.0022484951,0.018625017,0.0018499105],"about_ca_topic_score_codex":0.0003041418,"about_ca_topic_score_gemma":0.00012801848,"teacher_disagreement_score":0.36853063,"about_ca_system_score_codex":0.000090552356,"about_ca_system_score_gemma":0.00014157448,"threshold_uncertainty_score":0.68135333},"labels":[],"label_agreement":null},{"id":"W4399274302","doi":"10.9734/bpi/prrat/v2/778","title":"Addressing Gaps in Early Drug Development: A Focus on Preclinical and CMC Phases","year":2024,"lang":"en","type":"book-chapter","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Drug development; Drug; Focus (optics); Medicine; Pharmacology; Physics","score_opus":0.0948553397880184,"score_gpt":0.3573682612062028,"score_spread":0.2625129214181844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399274302","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017013269,0.023231957,0.000022574064,0.0013008907,0.0006948171,0.000327093,0.00005375031,0.00010708318,0.9725605],"genre_scores_gemma":[0.021869466,0.00050963415,0.0014396217,0.00053231325,0.00006842411,0.000009312029,0.000024293684,0.000043654676,0.97550327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984438,0.00005874101,0.0005358253,0.0006192576,0.000044949385,0.00029743934],"domain_scores_gemma":[0.9990734,0.0005828807,0.00008174878,0.00019669702,0.00002490469,0.00004039431],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042387345,0.0003524639,0.0006039458,0.00022272147,0.00006800802,0.000044232955,0.00014225945,0.0009133874,0.001770099],"category_scores_gemma":[0.00006203171,0.00025075607,0.000119835524,0.000032431704,0.00032192952,0.000027967442,0.00017463895,0.0010818733,0.00039310192],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010975692,0.0003782617,0.00040084214,0.00039398644,0.0016368537,0.00035567884,0.0008047872,9.5802136e-8,0.002464594,0.39836976,0.03153633,0.5625612],"study_design_scores_gemma":[0.0011257911,0.00029331713,0.00037579928,0.0021501635,0.00019320466,0.00004417836,0.00001842207,0.0000015111921,0.011937502,0.048700612,0.9344573,0.000702191],"about_ca_topic_score_codex":0.000019392062,"about_ca_topic_score_gemma":0.000117306554,"teacher_disagreement_score":0.90292096,"about_ca_system_score_codex":0.00003795179,"about_ca_system_score_gemma":0.000079678946,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W4399359525","doi":"10.2147/ppa.s455791","title":"Patient Experience with the SensoReady® Autoinjector Pen versus a Comparator Device: Results from a Canadian Patient Survey in Rheumatoid Arthritis and Crohn´s Disease","year":2024,"lang":"en","type":"article","venue":"Patient Preference and Adherence","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Population Health Research Institute; Université de Montréal","funders":"","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Activities of daily living; Physical therapy; Visual analogue scale; Internal medicine","score_opus":0.06358661044022383,"score_gpt":0.28350244833106425,"score_spread":0.2199158378908404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399359525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98582435,0.011255594,0.000009473474,0.00028278993,0.00033188713,0.00050319696,0.0015309255,0.0000341071,0.00022770472],"genre_scores_gemma":[0.9983464,0.0010136104,0.00012084738,0.00023279974,0.000006137278,0.00009631602,0.00013866396,0.000011947283,0.000033293047],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99786097,0.00046281848,0.00040626968,0.0007046272,0.00009982618,0.00046549214],"domain_scores_gemma":[0.99851924,0.0007811678,0.00009273039,0.0003238972,0.000081731414,0.0002012597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001738947,0.00028717305,0.0003106136,0.00008867551,0.00022053866,0.00014722219,0.00015433505,0.00013362641,0.00015831256],"category_scores_gemma":[0.00021770365,0.00017843794,0.000032157546,0.0002717645,0.00045410587,0.00014648643,0.00012247545,0.0003655505,0.00003208214],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01158717,0.0004900498,0.16211057,0.00010625657,0.0004161076,0.00064559944,0.046427436,0.000020311354,0.0020463315,0.0007751138,0.0063609043,0.7690141],"study_design_scores_gemma":[0.0031965035,0.0026198353,0.95745534,0.0020242175,0.00005268281,0.000031054264,0.0046068593,0.0005920619,0.003438761,0.00015071416,0.024781093,0.0010508779],"about_ca_topic_score_codex":0.06529393,"about_ca_topic_score_gemma":0.14369227,"teacher_disagreement_score":0.79534477,"about_ca_system_score_codex":0.00005350983,"about_ca_system_score_gemma":0.0002682835,"threshold_uncertainty_score":0.94093037},"labels":[],"label_agreement":null},{"id":"W4399481328","doi":"10.1200/jco.2024.42.16_suppl.e19002","title":"Real-world barriers to CAR-T access: A Canadian referral center perspective.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Referral; Perspective (graphical); Family medicine; Medical emergency","score_opus":0.16079550675472445,"score_gpt":0.5149049176788891,"score_spread":0.3541094109241647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481328","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16518968,0.0045767617,0.0003777974,0.35587904,0.041070662,0.00063717674,0.00019435145,0.00010790378,0.43196663],"genre_scores_gemma":[0.9709922,0.00078782183,0.0018268533,0.017364744,0.0011763796,0.000003703706,0.0000029235032,0.000027601509,0.007817746],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99644935,0.0010341849,0.0015866854,0.00033726796,0.00007693037,0.0005155691],"domain_scores_gemma":[0.9967659,0.0015178494,0.00030420808,0.00020529088,0.00038621266,0.0008205521],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036213214,0.00018253506,0.0010994896,0.00052293786,0.00010231778,0.000053416767,0.00057446625,0.00069999404,0.004114294],"category_scores_gemma":[0.0043364502,0.00012382296,0.0006144414,0.00044300072,0.00033732146,0.0001612246,0.00011983446,0.0017992208,0.00019993108],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002463521,0.0004483338,0.034915563,0.000035031986,0.002260829,0.0019305857,0.0006957025,0.0000052340056,0.0019576955,0.024427518,0.77623063,0.15462935],"study_design_scores_gemma":[0.0010172841,0.0023027977,0.022288924,0.000085399704,0.00020852216,0.0002060907,0.00036622703,0.000006806702,0.0002522417,0.0018146663,0.97129166,0.00015939955],"about_ca_topic_score_codex":0.014635004,"about_ca_topic_score_gemma":0.08335967,"teacher_disagreement_score":0.8058025,"about_ca_system_score_codex":0.00061632495,"about_ca_system_score_gemma":0.0044662454,"threshold_uncertainty_score":0.9967961},"labels":[],"label_agreement":null},{"id":"W4399481771","doi":"10.1136/annrheumdis-2024-eular.1667","title":"OP0015 THE ROLE OF MULTI-CRITERIA DECISION ANALYSIS IN THE DEVELOPMENT OF CANDIDATE CLASSIFICATION CRITERIA FOR ANTISYNTHETASE SYNDROME: ANALYSIS FROM THE CLASS PROJECT","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Antisynthetase syndrome; Computer science; Class (philosophy); Artificial intelligence; Linguistics; Philosophy","score_opus":0.08484319331023812,"score_gpt":0.3968394934648648,"score_spread":0.31199630015462665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797066,0.011366318,0.0033353835,0.0023870298,0.00017072396,0.0007934001,0.002201153,0.000011486403,0.000027926262],"genre_scores_gemma":[0.9980811,0.00026218075,0.0012804791,0.00011255298,0.000004608769,0.00007497978,0.00014299873,0.000008245778,0.00003285936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99753255,0.0009833038,0.0008691319,0.0002685063,0.0001379264,0.00020857749],"domain_scores_gemma":[0.9959096,0.0028401024,0.00033665728,0.00076705636,0.00013120823,0.000015402211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016302513,0.00017577622,0.0005965239,0.00022397425,0.00015690854,0.000046029174,0.000874844,0.000098947276,0.00016488029],"category_scores_gemma":[0.0007549258,0.00006890946,0.00066974637,0.0016037456,0.00038084216,0.000059029695,0.00013303572,0.00011145349,0.0000022239508],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029500162,0.0056299237,0.081892364,0.0014916193,0.100285985,0.0000063380744,0.028621163,0.00032016778,0.07699597,0.0047596996,0.0192966,0.6777502],"study_design_scores_gemma":[0.000712706,0.00013051605,0.8949063,0.0009800316,0.015096384,0.000003948796,0.006791834,0.03567389,0.035565816,0.0053906008,0.0044232523,0.00032473923],"about_ca_topic_score_codex":0.0003594501,"about_ca_topic_score_gemma":0.00040667376,"teacher_disagreement_score":0.8130139,"about_ca_system_score_codex":0.000011216017,"about_ca_system_score_gemma":0.00012700862,"threshold_uncertainty_score":0.28100464},"labels":[],"label_agreement":null},{"id":"W4399481889","doi":"10.1136/annrheumdis-2024-eular.1852","title":"POS0149 DO POLICIES THAT IMPROVE BIOSIMILAR UPTAKE ALSO HELP ACHIEVE GREATER EXPENDITURE CONTROL? A CROSS-COUNTRY POLICY ANALYSIS","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary; University of British Columbia; Centre for Advancing Health Outcomes","funders":"","keywords":"Biosimilar; Control (management); Business; Computer science; Medicine; Artificial intelligence; Internal medicine","score_opus":0.030416221144762702,"score_gpt":0.3427143278562319,"score_spread":0.3122981067114692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8391201,0.09315505,0.0005677268,0.049056903,0.0025170436,0.0012472743,0.011418463,0.00037633692,0.0025411302],"genre_scores_gemma":[0.9930458,0.00092495204,0.000040433963,0.003439431,0.000093186274,0.000031867265,0.000048457016,0.000031194813,0.0023446567],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9976438,0.00039934664,0.00063529366,0.0004957424,0.00017245032,0.00065331237],"domain_scores_gemma":[0.99814415,0.00050546264,0.00024289972,0.00088409893,0.0001235239,0.000099863275],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049860316,0.000415685,0.00088235777,0.00040498166,0.0002453407,0.0002304208,0.00074257917,0.00033506643,0.0010259628],"category_scores_gemma":[0.00046929653,0.00023254869,0.0012141687,0.00088521885,0.0008919373,0.00018832741,0.00023592329,0.00028836422,0.00006519356],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005120355,0.0037235345,0.17491563,0.005433001,0.14026849,0.00011588458,0.006440987,0.000475927,0.055133224,0.06670586,0.27923527,0.26243186],"study_design_scores_gemma":[0.0035300576,0.00097637536,0.7709129,0.0020849567,0.015521398,0.00009101396,0.0017177182,0.00093971984,0.10753489,0.03560739,0.05892611,0.002157509],"about_ca_topic_score_codex":0.00034239932,"about_ca_topic_score_gemma":0.00001579136,"teacher_disagreement_score":0.5959972,"about_ca_system_score_codex":0.0000259297,"about_ca_system_score_gemma":0.00014680123,"threshold_uncertainty_score":0.9998872},"labels":[],"label_agreement":null},{"id":"W4399482262","doi":"10.1136/annrheumdis-2024-eular.1845","title":"POS0874 COMPARABLE SAFETY AND EFFECTIVENESS AMONG NEW USERS OF BIOSIMILAR VS ORIGINATOR ANTI-TNFS IN INFLAMMATORY ARTHRITIS: POPULATION-BASED EVIDENCE FROM A POLICY CHANGE","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Research Canada; University of British Columbia","funders":"","keywords":"Biosimilar; Medicine; Population; Arthritis; Computer science; Pharmacology; Internal medicine; Environmental health","score_opus":0.04622181934063255,"score_gpt":0.3329080716615825,"score_spread":0.2866862523209499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399482262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9554537,0.041608017,0.00005505163,0.0019591132,0.00020321454,0.00042023958,0.00026529512,0.000028198017,0.0000072017365],"genre_scores_gemma":[0.9975449,0.0021036183,0.000062774125,0.00021135228,0.000016731521,0.000014924506,0.000016305632,0.000012658048,0.000016744409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983607,0.00060708856,0.00046558393,0.00025609205,0.00007940353,0.0002311364],"domain_scores_gemma":[0.99785644,0.0015664075,0.00016230381,0.00030677495,0.000050923594,0.000057144276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004479292,0.0001813314,0.00056733825,0.00018377323,0.00006053752,0.000025966274,0.00023481138,0.000132221,0.000101407124],"category_scores_gemma":[0.00069548097,0.0001267125,0.00017397954,0.00037686393,0.00032546924,0.0002368647,0.00008377482,0.00013053308,0.000004116825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005917036,0.00018473127,0.9727686,0.0013917251,0.0004100427,0.0000050647463,0.00028119105,0.00008176637,0.0018829119,0.0017729083,0.00044529547,0.020184051],"study_design_scores_gemma":[0.00050119555,0.000075928314,0.9760886,0.009889364,0.0000903496,0.0000010292651,0.000031680087,0.0004255664,0.010089597,0.0025179584,0.00014697142,0.00014179574],"about_ca_topic_score_codex":0.0046856687,"about_ca_topic_score_gemma":0.000114627,"teacher_disagreement_score":0.04209122,"about_ca_system_score_codex":0.000022280967,"about_ca_system_score_gemma":0.00017529739,"threshold_uncertainty_score":0.70833606},"labels":[],"label_agreement":null},{"id":"W4399482514","doi":"10.1136/annrheumdis-2024-eular.40","title":"AB0222 THE IMPACT OF BIOSIMILAR USE ON HEALTHCARE UTILIZATION AMONG NEW USERS OF ETANERCEPT FOR INFLAMMATORY ARTHRITIS: A POPULATION-BASED REGRESSION DISCONTINUITY ANALYSIS","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Research Canada; Simon Fraser University","funders":"","keywords":"Biosimilar; Etanercept; Regression discontinuity design; Regression analysis; Population; Discontinuity (linguistics); Health care; Regression; Computer science; Medicine; Statistics; Economics; Environmental health; Machine learning; Rheumatoid arthritis; Internal medicine; Mathematics","score_opus":0.08979890712339454,"score_gpt":0.3908102563034888,"score_spread":0.30101134918009426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399482514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896708,0.006322731,0.0005008159,0.001831822,0.00013619877,0.0005239503,0.0009856835,0.000022831131,0.00000517971],"genre_scores_gemma":[0.99916923,0.0004174324,0.000067375724,0.00010439486,0.000007958678,0.000012791411,0.000109206616,0.000012271163,0.00009936236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838513,0.0004948308,0.00062191946,0.00020469469,0.000103498045,0.00018994526],"domain_scores_gemma":[0.9977758,0.0011146216,0.00042347744,0.00049970305,0.00014111448,0.000045267327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039910045,0.00017410642,0.000517495,0.00018207204,0.00009942642,0.000021832157,0.0002540016,0.0001323925,0.00014606034],"category_scores_gemma":[0.00092008774,0.0000837889,0.0009932463,0.0005486608,0.00027261054,0.000099820674,0.000042804044,0.00010269455,6.3785035e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017834855,0.000866491,0.77006847,0.0020314362,0.008477061,0.0000013510582,0.0011048521,0.005460608,0.0025399213,0.0034818705,0.019997753,0.1841867],"study_design_scores_gemma":[0.00035530335,0.0002555954,0.98294604,0.0023428337,0.00083379436,3.5653756e-7,0.00013702252,0.0032391741,0.007940559,0.0017698403,0.00005603455,0.00012343128],"about_ca_topic_score_codex":0.001109472,"about_ca_topic_score_gemma":0.00017481092,"teacher_disagreement_score":0.21287759,"about_ca_system_score_codex":0.000017405495,"about_ca_system_score_gemma":0.00016359334,"threshold_uncertainty_score":0.34168124},"labels":[],"label_agreement":null},{"id":"W4399482868","doi":"10.1136/annrheumdis-2024-eular.1846","title":"AB0192 COMPARABLE SAFETY AND EFFECTIVENESS AFTER TRANSITION TO A BIOSIMILAR ANTI-TNF IN INFLAMMATORY ARTHRITIS: POPULATION-BASED EVIDENCE FROM A POLICY CHANGE","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Research Canada; University of British Columbia","funders":"","keywords":"Biosimilar; Inflammatory arthritis; Arthritis; Transition (genetics); Medicine; Tumor necrosis factor alpha; Population; Immunology; Internal medicine; Chemistry; Environmental health","score_opus":0.040275142744125414,"score_gpt":0.32882825811243993,"score_spread":0.2885531153683145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399482868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9527066,0.03952214,0.00023588243,0.006349037,0.0001598647,0.0005300475,0.00045939075,0.000032095973,0.000004950146],"genre_scores_gemma":[0.9976297,0.0010542767,0.00006373792,0.0011215787,0.000018486655,0.00007787369,0.00001830506,0.000010715899,0.000005297225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985228,0.00060572964,0.00033986257,0.0002552801,0.00006148789,0.00021483177],"domain_scores_gemma":[0.9987074,0.0009204583,0.000052835607,0.00023547956,0.000037655696,0.00004618145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040231136,0.0001560192,0.0003752039,0.00016848854,0.000060304756,0.000034223875,0.0001361173,0.00010338583,0.00011179692],"category_scores_gemma":[0.00031424602,0.00010918778,0.00013676542,0.00032431787,0.00013211808,0.00014818773,0.000049316586,0.000103436556,0.000012354328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007603715,0.0014987031,0.56990016,0.008387438,0.0016429571,0.00006853505,0.00544117,0.00095019955,0.018259425,0.0025077085,0.0014796848,0.3822603],"study_design_scores_gemma":[0.00034587458,0.000072080446,0.982001,0.010415273,0.00006670951,0.0000018107555,0.000032630123,0.00050936156,0.00468415,0.0015674914,0.00015649306,0.00014712589],"about_ca_topic_score_codex":0.0010589381,"about_ca_topic_score_gemma":0.000093120594,"teacher_disagreement_score":0.41210082,"about_ca_system_score_codex":0.000020558258,"about_ca_system_score_gemma":0.00006329155,"threshold_uncertainty_score":0.44525483},"labels":[],"label_agreement":null},{"id":"W4399483084","doi":"10.1136/annrheumdis-2024-eular.1527","title":"AB1428 ADALIMUMAB AND TOCILIZUMAB BIOSIMILARS IN EUROPE: BUDGET-IMPACT AND OPPORTUNITY FOR EXPANDED PATIENT ACCESS","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Biosimilar; Adalimumab; Tocilizumab; Medicine; Internal medicine; Rheumatoid arthritis","score_opus":0.07246973880904191,"score_gpt":0.38171561327561515,"score_spread":0.30924587446657326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399483084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95836973,0.0338999,0.000046852725,0.005732057,0.00030108273,0.00065058423,0.00073425897,0.00003700471,0.0002285454],"genre_scores_gemma":[0.99659455,0.0023503008,0.000046992907,0.00079700164,0.0000054630364,0.000028548398,0.000015095251,0.000013887249,0.00014817523],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99880654,0.00026986623,0.00036372064,0.00024995033,0.000050475304,0.0002594603],"domain_scores_gemma":[0.9988986,0.0006064401,0.00009316659,0.00024438094,0.00008239271,0.00007498882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031279505,0.00017690938,0.00035493146,0.00009559607,0.00008476238,0.00006326971,0.00021739888,0.00009686157,0.00014219292],"category_scores_gemma":[0.0009185916,0.00010212744,0.00013607681,0.00024013316,0.00032854217,0.00013237774,0.00022772493,0.00011276198,0.0000014079662],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001302148,0.0009264755,0.00915371,0.0022838293,0.0013585548,0.00001371793,0.0010589722,0.000010588418,0.0024086155,0.0020982784,0.08497977,0.89440536],"study_design_scores_gemma":[0.009571244,0.004765386,0.7205509,0.01000279,0.0017772012,0.00022826152,0.002301078,0.0033692606,0.08414043,0.102434345,0.05833272,0.0025263987],"about_ca_topic_score_codex":0.000054706292,"about_ca_topic_score_gemma":0.0000149978505,"teacher_disagreement_score":0.89187896,"about_ca_system_score_codex":0.000009131166,"about_ca_system_score_gemma":0.00012756254,"threshold_uncertainty_score":0.4164636},"labels":[],"label_agreement":null},{"id":"W4399483155","doi":"10.1136/annrheumdis-2024-eular.651","title":"AB1435 BUDGET IMPACT ANALYSIS OF A TOCILIZUMAB BIOSIMILAR: A UK PAYER PERSPECTIVE","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Biosimilar; Tocilizumab; Perspective (graphical); Computer science; Medicine; Rheumatoid arthritis; Artificial intelligence; Internal medicine","score_opus":0.03591416034762759,"score_gpt":0.37284060070753955,"score_spread":0.336926440359912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399483155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85808855,0.11850993,0.00046170602,0.012487891,0.00084799476,0.00077345315,0.0046417927,0.00013347915,0.0040552053],"genre_scores_gemma":[0.9984003,0.0006090264,0.000062969404,0.0002770391,0.000008129108,0.000010558597,0.000017170294,0.000011640548,0.0006031864],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99850255,0.00033923239,0.00047903968,0.00028516946,0.00010309113,0.000290929],"domain_scores_gemma":[0.9983523,0.00066568726,0.00017406623,0.0005472839,0.00021180396,0.000048857022],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035235126,0.00021071667,0.0007062113,0.00030472214,0.00007008529,0.000023493494,0.0004005685,0.0001361348,0.0027765522],"category_scores_gemma":[0.00068232755,0.00011277439,0.0014765164,0.0012461517,0.00049673516,0.000058057645,0.00014192743,0.00014660133,0.0000194169],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031619046,0.005293914,0.048876137,0.0028617082,0.25908387,0.00003734936,0.009325536,0.0006623324,0.036827862,0.102988005,0.3583027,0.17257866],"study_design_scores_gemma":[0.002080263,0.001799312,0.7476769,0.0031573107,0.038269207,0.00003929852,0.0052249567,0.0048687933,0.11133539,0.07947002,0.0045447997,0.0015337308],"about_ca_topic_score_codex":0.0003355791,"about_ca_topic_score_gemma":0.000023482655,"teacher_disagreement_score":0.6988008,"about_ca_system_score_codex":0.000029179038,"about_ca_system_score_gemma":0.00014059503,"threshold_uncertainty_score":0.99813503},"labels":[],"label_agreement":null},{"id":"W4399483383","doi":"10.1136/annrheumdis-2024-eular.618","title":"POS0899 FIRST-IN-HUMAN SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS DATA WITH MK-6194, A MODIFIED FORM OF INTERLEUKIN-2, DESIGNED TO SELECTIVELY ACTIVATE REGULATORY T-CELLS – SINGLE ASCENDING DOSE AND MULTIPLE ASCENDING DOSE TRIALS","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"","keywords":"Pharmacokinetics; Pharmacodynamics; Pharmacology; Chemistry; Medicine","score_opus":0.09399967121303109,"score_gpt":0.36951362545309985,"score_spread":0.27551395424006875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399483383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902913,0.0054593426,0.00096584985,0.0010213738,0.00029168514,0.0009875196,0.0008592603,0.000041868214,0.00008180178],"genre_scores_gemma":[0.99817806,0.0009144811,0.0005606839,0.0001587611,0.000015381947,0.000010607637,0.000030992378,0.000030437948,0.00010061151],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99768645,0.0005676731,0.00078247784,0.0004829511,0.00010885889,0.00037159232],"domain_scores_gemma":[0.99728036,0.0017990274,0.0003134772,0.00044231894,0.00007270344,0.000092097216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014764948,0.0002927394,0.000816963,0.00024596334,0.00014473041,0.000053979882,0.00046785717,0.00011118697,0.000044239932],"category_scores_gemma":[0.00063304737,0.00018928053,0.0001266919,0.00033695746,0.00037811595,0.00021588006,0.000480867,0.00019423976,9.635885e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043122885,0.00097438967,0.001019323,0.001998469,0.002375819,0.000010064549,0.0014130535,0.0001920512,0.9001299,0.0006541327,0.0018818537,0.085038625],"study_design_scores_gemma":[0.0080052465,0.0012783441,0.021618927,0.007695958,0.0020079508,0.000038533264,0.0007134181,0.018972732,0.93519145,0.0024794627,0.0010524411,0.00094553124],"about_ca_topic_score_codex":0.00006696273,"about_ca_topic_score_gemma":0.000029844166,"teacher_disagreement_score":0.084093094,"about_ca_system_score_codex":0.00003628831,"about_ca_system_score_gemma":0.0000629374,"threshold_uncertainty_score":0.77186364},"labels":[],"label_agreement":null},{"id":"W4399484120","doi":"10.1136/annrheumdis-2024-eular.209","title":"AB0027 PHARMACOKINETICS AND SAFETY OF CT-P47, A PROPOSED TOCILIZUMAB BIOSIMILAR, IN COMPARISON WITH INTRAVENOUS EU-APPROVED TOCILIZUMAB AND US-LICENSED TOCILIZUMAB; A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THREE-ARM, SINGLE-DOSE STUDY IN HEALTHY JAPANESE SUBJECTS","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Tocilizumab; Biosimilar; Medicine; Pharmacokinetics; Pharmacology; Internal medicine; Rheumatoid arthritis","score_opus":0.06634039404615578,"score_gpt":0.35883441166264973,"score_spread":0.29249401761649396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399484120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680022,0.023795698,0.00003187897,0.0021738298,0.00018395517,0.005439066,0.00017620825,0.000046946665,0.00015020437],"genre_scores_gemma":[0.9982437,0.0010773252,0.00013707721,0.0002761255,0.000010164665,0.00015353887,0.000022036933,0.00003674846,0.0000433097],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956321,0.0013163205,0.0015512562,0.0006709275,0.00022850113,0.0006008873],"domain_scores_gemma":[0.99716586,0.00155388,0.00045200725,0.00053630985,0.00016480422,0.00012714209],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014466083,0.00051112374,0.0019200613,0.00034717037,0.000121140714,0.000063015934,0.00038577593,0.00016535443,0.000102940285],"category_scores_gemma":[0.00044532985,0.000316407,0.0002383057,0.00078125024,0.0012992421,0.00013651903,0.00023558353,0.0004708669,0.0000018427195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89332676,0.015883716,0.0037794295,0.0034526917,0.0023942485,0.0000790324,0.007599605,0.00006453769,0.0027199604,0.00042074325,0.00035375624,0.06992552],"study_design_scores_gemma":[0.9360204,0.012346838,0.01149355,0.0049796654,0.0025257883,0.00017556407,0.006358234,0.006996774,0.01586637,0.0016288646,0.00031309514,0.0012948962],"about_ca_topic_score_codex":0.0011305723,"about_ca_topic_score_gemma":0.0015743225,"teacher_disagreement_score":0.06863062,"about_ca_system_score_codex":0.00005497216,"about_ca_system_score_gemma":0.00027142343,"threshold_uncertainty_score":0.9999288},"labels":[],"label_agreement":null},{"id":"W4399571906","doi":"10.1007/s13346-024-01646-2","title":"Toward an international standardisation roadmap for nanomedicine","year":2024,"lang":"en","type":"article","venue":"Drug Delivery and Translational Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada","funders":"HORIZON EUROPE Framework Programme; Conseil Régional, Île-de-France; European Commission; European Partnership on Metrology; Bpifrance","keywords":"European commission; Commission; Nanomedicine; Test (biology); Political science; Engineering management; Engineering; Member states; Business; European union","score_opus":0.1286212649432285,"score_gpt":0.43008834228291687,"score_spread":0.30146707733968836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399571906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7671015,0.052854735,0.051083136,0.093739375,0.0051939557,0.0022386606,0.0032590092,0.00034712977,0.024182463],"genre_scores_gemma":[0.99565786,0.00046409736,0.0012093906,0.00009810288,0.00018061695,0.000028430139,0.00029630229,0.00000907847,0.0020561104],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989993,0.00017239615,0.0001685795,0.000290918,0.00013558545,0.00023320806],"domain_scores_gemma":[0.99889404,0.00075730786,0.000008997293,0.000074570766,0.00022241347,0.000042704243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018027091,0.00007955485,0.00010831365,0.0001990453,0.0001782386,0.000062689774,0.00011496852,0.00011075152,0.00086802023],"category_scores_gemma":[0.0000655476,0.00006199064,0.00005663604,0.00014010679,0.00026838577,0.00022183855,0.00001869882,0.00026028548,0.000021013657],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018110911,0.00024370551,0.002375616,0.0002863473,0.00071747566,0.000020891099,0.0030518866,0.000014190522,0.06501051,0.19093758,0.014546614,0.7209841],"study_design_scores_gemma":[0.0015286878,0.0003442254,0.009126383,0.0001236601,0.000064380394,0.000036474117,0.00052649324,0.00461342,0.013127466,0.040107433,0.93017423,0.00022715193],"about_ca_topic_score_codex":0.000023263226,"about_ca_topic_score_gemma":0.000014903824,"teacher_disagreement_score":0.9156276,"about_ca_system_score_codex":0.000019305626,"about_ca_system_score_gemma":0.000110081266,"threshold_uncertainty_score":0.9504213},"labels":[],"label_agreement":null},{"id":"W4399577440","doi":"10.1080/17576180.2024.2342691","title":"16 <sup>th</sup> GCC Closed Forum: ICH M10 implementation; NGS, qPCR/dPCR, flow cytometry validation; tissue biomarkers; IS response; immunogenicity harmonization; bioanalytical industry status","year":2024,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand Challenges Canada; Pharma Medica Research (Canada); Aptose Biosciences (Canada)","funders":"","keywords":"Bioanalysis; Harmonization; Immunogenicity; Flow cytometry; Computational biology; Chemistry; Medicine; Biology; Chromatography; Molecular biology; Immunology; Physics","score_opus":0.02447590168580123,"score_gpt":0.3404678279722946,"score_spread":0.31599192628649336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399577440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65855235,0.1369542,0.09996454,0.07531163,0.0040365066,0.0038947572,0.014215009,0.002606434,0.0044645923],"genre_scores_gemma":[0.98048633,0.0008953798,0.006915872,0.001663375,0.00016772232,0.00006596072,0.0015653492,0.00010614091,0.008133842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99355376,0.001512417,0.0015699014,0.0015267952,0.00040516735,0.0014319466],"domain_scores_gemma":[0.9967871,0.00106088,0.00028940997,0.0011404944,0.00044208148,0.00028007454],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0021643848,0.00077270286,0.0010566501,0.0016219018,0.0006556827,0.00043540724,0.0007270516,0.0016298302,0.024990216],"category_scores_gemma":[0.0005073841,0.000668441,0.000838769,0.005052608,0.0007098092,0.00043568536,0.00038945465,0.0012030149,0.0010314666],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033761,0.0014820988,0.07233778,0.00036631388,0.038598195,0.0002266688,0.0013472228,0.000108458065,0.2587781,0.0021138457,0.23141827,0.38984698],"study_design_scores_gemma":[0.002693018,0.00050671207,0.0092568295,0.00010768612,0.005315884,0.00009220282,0.004156315,0.0049293996,0.3972706,0.00073762034,0.5733813,0.0015524521],"about_ca_topic_score_codex":0.0005383706,"about_ca_topic_score_gemma":0.000054134834,"teacher_disagreement_score":0.38829452,"about_ca_system_score_codex":0.0006823808,"about_ca_system_score_gemma":0.00051824097,"threshold_uncertainty_score":0.9997463},"labels":[],"label_agreement":null},{"id":"W4399628176","doi":"10.13162/hro-ors.v11i2.5711","title":"Implementing a Medication Switching Policy: Analysis of the Saskatchewan Biosimilars Initiative","year":2024,"lang":"en","type":"article","venue":"Health Reform Observer - Observatoire des Réformes de Santé","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Authority","funders":"","keywords":"Biosimilar; Medicine; Business; Internal medicine","score_opus":0.04524062438025573,"score_gpt":0.3579668235505265,"score_spread":0.3127261991702708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399628176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95639056,0.015876733,0.003488327,0.020775845,0.0006965323,0.00075384666,0.00046734067,0.00026683317,0.0012839749],"genre_scores_gemma":[0.9881593,0.00095741893,0.002435067,0.007930568,0.000079536374,0.00003517413,0.000115385265,0.000035765046,0.00025178434],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99651814,0.0005396276,0.0010981519,0.0004955776,0.00017295963,0.0011755548],"domain_scores_gemma":[0.9983963,0.00032721812,0.00042661643,0.0006077311,0.0001306182,0.000111515925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026707693,0.00033342725,0.0007640566,0.0004158297,0.0007205011,0.00005244329,0.0005639035,0.00034441068,0.00020637341],"category_scores_gemma":[0.0001741811,0.00020413722,0.00062215206,0.0030347914,0.00038273007,0.00031175528,0.00035308045,0.0006283936,0.00000843555],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020665901,0.00036001691,0.32280993,0.0028237668,0.010797011,0.000013392803,0.029544076,0.000017403907,0.029154312,0.007952401,0.004038836,0.5922822],"study_design_scores_gemma":[0.00065593305,0.00028374465,0.9062063,0.00088166614,0.0014283557,0.00003702063,0.009117599,0.002752779,0.020641018,0.0037682785,0.053735424,0.0004918574],"about_ca_topic_score_codex":0.004096613,"about_ca_topic_score_gemma":0.010078649,"teacher_disagreement_score":0.5917903,"about_ca_system_score_codex":0.0011479061,"about_ca_system_score_gemma":0.0013715607,"threshold_uncertainty_score":0.8324474},"labels":[],"label_agreement":null},{"id":"W4399699830","doi":"10.1016/j.jval.2024.03.671","title":"EE375 Cost Savings and the Opportunity for Expanded Treatment Access with Increased Use of Biosimilar Adalimumab in the United States","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Brampton Civic Hospital","funders":"","keywords":"Biosimilar; Adalimumab; Business; Medicine; Expanded access; Internal medicine","score_opus":0.16194609539653945,"score_gpt":0.37661123023996423,"score_spread":0.21466513484342478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399699830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97121626,0.004222571,0.00027505882,0.021658551,0.00011242011,0.0021119877,0.0003510261,0.000026380472,0.000025771878],"genre_scores_gemma":[0.9917388,0.0035167572,0.00042968994,0.003984721,0.000011397647,0.00013898165,0.00011594893,0.000013249094,0.000050457416],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99769276,0.0013973671,0.00037034845,0.00022230386,0.000038471215,0.00027876123],"domain_scores_gemma":[0.9961478,0.0034754348,0.00009007015,0.0002184876,0.00003437716,0.00003379636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018931787,0.0001458448,0.0003484096,0.00016959044,0.00009908018,0.00004665477,0.00016359439,0.00010884593,0.000017139397],"category_scores_gemma":[0.00019782477,0.000063690655,0.00004859846,0.0004417747,0.0003991469,0.00006418968,0.00003710409,0.00020334838,3.1744528e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07211459,0.010617365,0.25179276,0.010304904,0.0056495583,0.0003607354,0.10134153,0.0035799518,0.00846216,0.18170199,0.036907814,0.31716663],"study_design_scores_gemma":[0.06621282,0.014756819,0.104611225,0.005169086,0.00101125,0.0004444774,0.017021254,0.06158455,0.02506264,0.021111643,0.6812089,0.0018053446],"about_ca_topic_score_codex":0.02934546,"about_ca_topic_score_gemma":0.0009099032,"teacher_disagreement_score":0.64430106,"about_ca_system_score_codex":0.00007525202,"about_ca_system_score_gemma":0.0002485062,"threshold_uncertainty_score":0.9771182},"labels":[],"label_agreement":null},{"id":"W4399706325","doi":"10.1016/j.jval.2024.03.2422","title":"MT48 Assessment of a Patient-Centric Web Application Tool for Potential Adverse Events of Oral Corticosteroids","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Adverse effect; Web application; Medicine; Intensive care medicine; Computer science; World Wide Web; Pharmacology","score_opus":0.025073692238496686,"score_gpt":0.34496624451340396,"score_spread":0.31989255227490726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399706325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96455455,0.0032725427,0.027720379,0.00123571,0.0012450814,0.001584684,0.00029501462,0.000032490498,0.00005954923],"genre_scores_gemma":[0.9925814,0.00017450353,0.006985117,0.00011289675,0.000009963915,0.000037980273,0.000035854024,0.000008246695,0.000054036587],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986668,0.00026271492,0.00059539854,0.00021100484,0.000047671307,0.00021636026],"domain_scores_gemma":[0.9994882,0.00014220287,0.00015363934,0.00015071507,0.00004572021,0.00001954618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061926845,0.0000866493,0.00027835614,0.00013409159,0.000026514082,0.000001496427,0.000082114224,0.0001290886,0.000043871823],"category_scores_gemma":[0.00003739247,0.00007154599,0.000101955644,0.00023592135,0.00005420796,0.000029749854,0.00003669109,0.00013511885,0.0000035235516],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001213525,0.0036428017,0.098019704,0.0067861504,0.00074033457,0.000008176408,0.000637715,0.001995436,0.41768453,0.04122127,0.0029817054,0.42506865],"study_design_scores_gemma":[0.022100536,0.018776469,0.29209784,0.0041600335,0.0009937054,0.00013771658,0.0011667552,0.38039532,0.11909038,0.019866759,0.13929287,0.0019216336],"about_ca_topic_score_codex":0.00019445425,"about_ca_topic_score_gemma":0.0000038421613,"teacher_disagreement_score":0.42314702,"about_ca_system_score_codex":0.000087495086,"about_ca_system_score_gemma":0.00024848938,"threshold_uncertainty_score":0.2917561},"labels":[],"label_agreement":null},{"id":"W4399883248","doi":"10.1080/14712598.2024.2321360","title":"Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Biological Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Celltrion","keywords":"Pharmacokinetics; Medicine; Biosimilar; Bioequivalence; Syringe; Immunogenicity; Pharmacology; Open label; Safety profile; Adverse effect; Anesthesia; Internal medicine; Antibody; Immunology","score_opus":0.12781426508065188,"score_gpt":0.4271629290048784,"score_spread":0.29934866392422654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399883248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.682299,0.284662,0.0013179238,0.009173263,0.006146947,0.012683872,0.0017591977,0.00067216234,0.0012856348],"genre_scores_gemma":[0.8995632,0.09672629,0.00065131055,0.0019451274,0.00010783466,0.00030220905,0.0001452945,0.00004001778,0.00051870296],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955891,0.0019306083,0.00094319024,0.00094602164,0.00010199704,0.00048913306],"domain_scores_gemma":[0.9975991,0.0016098697,0.00019511818,0.00041472682,0.00006917763,0.000111983456],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010722257,0.00053142523,0.0014331245,0.00012224507,0.0001983189,0.000110872694,0.00057855697,0.00033813698,0.002424127],"category_scores_gemma":[0.00030079897,0.00028240058,0.00019489616,0.00031827192,0.00077524973,0.0000810819,0.00028914493,0.00043656354,0.000014749501],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3247708,0.0063337917,0.000037086484,0.000016915224,0.0014480896,0.000036802357,0.0006970986,1.4168258e-7,0.42388076,0.00035582672,0.010660476,0.23176222],"study_design_scores_gemma":[0.23945858,0.019261358,0.000056381097,0.0001863967,0.000020058427,0.00006165642,0.0002804277,0.00020514641,0.11366157,0.00010667183,0.6260844,0.0006173779],"about_ca_topic_score_codex":0.000047542853,"about_ca_topic_score_gemma":0.0000017810843,"teacher_disagreement_score":0.6154239,"about_ca_system_score_codex":0.00005582937,"about_ca_system_score_gemma":0.000069650196,"threshold_uncertainty_score":0.9999628},"labels":[],"label_agreement":null},{"id":"W4399975217","doi":"10.2139/ssrn.4872346","title":"Data Fabrication in Rheumatology Randomized Controlled Trials: Evidence from a Systematic Review and Sampling Analysis","year":2024,"lang":"en","type":"review","venue":"SSRN Electronic Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Randomized controlled trial; Rheumatology; Medicine; Internal medicine; Sampling (signal processing); Medical physics; Computer science","score_opus":0.14303744538011035,"score_gpt":0.44016126480252293,"score_spread":0.2971238194224126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399975217","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.798839e-7,0.98527336,0.0095601715,0.0004885968,0.0003608108,0.0041520414,0.00013356541,0.000024355411,0.0000063070634],"genre_scores_gemma":[0.000024082936,0.9986199,0.00021922556,0.000059537037,0.000038316513,0.00031428295,0.00026448473,0.000030553347,0.00042960516],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.967429,0.024266683,0.005913795,0.0008867708,0.000106166415,0.001397625],"domain_scores_gemma":[0.9698239,0.025455728,0.0035414665,0.0010051625,0.00012637007,0.000047399182],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.08901512,0.00064844266,0.032425355,0.0009055635,0.00010313328,0.00011419471,0.0011331557,0.0007750893,0.00014794368],"category_scores_gemma":[0.054765012,0.0003215413,0.0030572016,0.0011042088,0.0001994779,0.00013136702,0.0002938669,0.004254409,0.000058249734],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005117033,0.0001011304,0.000004397085,0.68596995,0.21838276,0.0000073885417,0.00004532162,1.6652255e-7,0.0000026492705,0.004982933,0.00030969348,0.08507659],"study_design_scores_gemma":[0.019608878,0.00004311544,1.0034232e-7,0.44453257,0.5232142,0.00059385784,0.000055134795,0.000051045976,6.064538e-8,0.0071283197,0.0043856385,0.00038706625],"about_ca_topic_score_codex":0.00013492313,"about_ca_topic_score_gemma":0.00030047487,"teacher_disagreement_score":0.30483145,"about_ca_system_score_codex":0.0004677281,"about_ca_system_score_gemma":0.0020193139,"threshold_uncertainty_score":0.99992365},"labels":[{"model":"gemma","categories":["metaresearch","research_integrity"],"domain":"methods","study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":["metaresearch","research_integrity"],"domain":"methods","study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4400378609","doi":"10.51731/cjht.2024.927","title":"National and International Policies on the Use of Biosimilars: An Environmental Scan","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Environmental policy; Business; Medicine; Environmental planning; Environmental science; Internal medicine","score_opus":0.11366115682620082,"score_gpt":0.3321419509867425,"score_spread":0.21848079416054167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400378609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5062826,0.10746413,0.00018209098,0.38252762,0.0019462698,0.00028339436,0.0008843528,0.00008464431,0.0003448867],"genre_scores_gemma":[0.99710983,0.00080052693,0.00036861748,0.0015761388,0.000008722341,0.0000011586654,0.0000037981592,0.000005404636,0.00012581647],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992736,0.00010199738,0.0003007454,0.000096785785,0.000046210935,0.00018067198],"domain_scores_gemma":[0.9995128,0.00022514908,0.00011580166,0.000090683396,0.000034560064,0.00002102284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005395202,0.00008141987,0.00015347161,0.00037716818,0.00012361439,0.00003957123,0.00022914622,0.00013982302,0.00015917247],"category_scores_gemma":[0.00031928872,0.000049305505,0.00004723205,0.00010198529,0.0007099839,0.00010130013,0.000023139039,0.00034139518,0.0000037500872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005379866,0.00008221168,0.0044660633,0.000051624975,0.00048046737,0.000027024815,0.00068520446,0.000014867709,0.009214126,0.06285041,0.08843045,0.83364373],"study_design_scores_gemma":[0.00017486083,0.0006731779,0.013679184,0.000220523,0.000018222723,0.00033698106,0.0018713465,0.000051530624,0.0077301688,0.0060755285,0.96905327,0.00011519821],"about_ca_topic_score_codex":0.00027864595,"about_ca_topic_score_gemma":0.00028886992,"teacher_disagreement_score":0.8806228,"about_ca_system_score_codex":0.00012673564,"about_ca_system_score_gemma":0.0004228557,"threshold_uncertainty_score":0.26159653},"labels":[],"label_agreement":null},{"id":"W4400462617","doi":"10.1080/14712598.2024.2378090","title":"Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Pfizer","keywords":"Biosimilar; Infliximab; Medicine; Inflammatory bowel disease; Adverse effect; Intensive care medicine; Ulcerative colitis; Disease; Internal medicine; Pharmacology","score_opus":0.03492524527650228,"score_gpt":0.34824673445929305,"score_spread":0.3133214891827908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400462617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010750527,0.9949048,0.000011664665,0.00008879745,0.00026262054,0.0034402553,0.00015432939,0.00005109769,0.0000113476335],"genre_scores_gemma":[0.0009856041,0.99810725,0.000046631936,0.00031886093,0.00003933017,0.00032176578,0.00013567969,0.00004115574,0.0000037313205],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.995077,0.002383753,0.0012124568,0.00084801705,0.00010723673,0.00037152818],"domain_scores_gemma":[0.9975251,0.0013796503,0.00046966586,0.00045758838,0.0000653156,0.00010268931],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012420112,0.0007570373,0.0033585087,0.0002517674,0.00008603235,0.000025099684,0.00030709736,0.00078485097,0.000029490448],"category_scores_gemma":[0.00032050954,0.00036591353,0.00032462957,0.0003011192,0.00037957684,0.000060299106,0.00016909257,0.0007447197,0.000010323032],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029014463,0.00090157025,0.009750668,0.5515539,0.0036337997,0.000019417934,0.00013013657,7.837143e-8,0.00003225667,0.0015915717,0.00023823383,0.4292469],"study_design_scores_gemma":[0.0025966577,0.0015419121,0.008414841,0.542623,0.00014879763,0.00000548697,0.00000887026,5.184969e-7,0.000019378394,0.00012647129,0.44366598,0.0008481289],"about_ca_topic_score_codex":0.0000023086009,"about_ca_topic_score_gemma":1.0173216e-7,"teacher_disagreement_score":0.44342774,"about_ca_system_score_codex":0.00009038397,"about_ca_system_score_gemma":0.00007627386,"threshold_uncertainty_score":0.9998793},"labels":[],"label_agreement":null},{"id":"W4400576516","doi":"10.3390/ph17070925","title":"Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments","year":2024,"lang":"en","type":"review","venue":"Pharmaceuticals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Biopharmaceutical; Medicine; Artificial intelligence; Risk analysis (engineering); Computer science; Biotechnology; Biology; Internal medicine","score_opus":0.3703154797720838,"score_gpt":0.5024762722797308,"score_spread":0.132160792507647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400576516","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005602337,0.9929543,0.000044521425,0.0050703343,0.00050719886,0.0009176486,0.00015050035,0.000010253155,0.00028919423],"genre_scores_gemma":[0.0011174184,0.9976153,0.00028154944,0.00062994,0.000044463748,0.00011844223,0.00003699473,0.000010707729,0.0001452349],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968772,0.001615404,0.000855103,0.00033921687,0.00006918682,0.00024390989],"domain_scores_gemma":[0.9965099,0.0031088316,0.0001280171,0.00021010762,0.000024966112,0.000018160026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014821063,0.00025362973,0.0009089326,0.00014935668,0.000047248355,0.000047765527,0.00040368715,0.00040446746,0.00036288137],"category_scores_gemma":[0.00042398396,0.00010682069,0.00029952527,0.0004369765,0.000962099,0.000038362305,0.00015952464,0.0010893113,0.0000404903],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001051629,0.0003018476,0.00002366034,0.00030875174,0.0004213437,0.000021629194,0.00013725953,6.463761e-7,0.000012748503,0.017952302,0.0006390805,0.98007554],"study_design_scores_gemma":[0.00035983362,0.00004791041,0.00006362338,0.0013382765,0.0016857554,0.000071494826,0.00006384999,0.00015878365,0.00005055411,0.004761248,0.99123794,0.00016075646],"about_ca_topic_score_codex":0.000016663682,"about_ca_topic_score_gemma":0.000024830097,"teacher_disagreement_score":0.99059886,"about_ca_system_score_codex":0.000058008027,"about_ca_system_score_gemma":0.00006250618,"threshold_uncertainty_score":0.47325763},"labels":[],"label_agreement":null},{"id":"W4400587065","doi":"10.52711/0974-360x.2024.00378","title":"A Systematic Review of Regulatory requirements of Biosimilar Products: WHO, India, European Union and USFDA","year":2024,"lang":"en","type":"review","venue":"Research Journal of Pharmacy and Technology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Innovator; License; Biopharmaceutical; Product (mathematics); European union; Business; Interchangeability; Quality (philosophy); Medicine; Biotechnology; Risk analysis (engineering); Engineering; International trade; Finance; Computer science","score_opus":0.11902033608580515,"score_gpt":0.4601811171710643,"score_spread":0.34116078108525916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400587065","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005577925,0.9974749,0.0000050710187,0.0010159924,0.00019420603,0.0010048756,0.000057240606,0.0000133889835,0.00017856531],"genre_scores_gemma":[0.00048458765,0.9989295,0.0001458856,0.000030842235,0.00004025907,0.000011664856,0.0000050665944,0.000034659402,0.00031751525],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99206156,0.0047768643,0.0021577866,0.00037996564,0.00022009405,0.00040373995],"domain_scores_gemma":[0.996887,0.00041416605,0.0013482037,0.0004611253,0.0008270944,0.00006237158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014403838,0.000330324,0.003145687,0.0017852196,0.00007862311,0.000013795909,0.0006941908,0.00037515437,0.00004930429],"category_scores_gemma":[0.0021966663,0.00020250912,0.00028025624,0.001538358,0.0015870018,0.00008103061,0.0006229568,0.0020531544,0.000008391779],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013838252,0.00009006576,0.0000052907008,0.8339344,0.0015000792,0.00007370497,0.0000146125385,5.089764e-10,0.0016805523,0.0005752525,0.0032426256,0.15886956],"study_design_scores_gemma":[0.0003304716,0.00045256133,8.4187997e-7,0.62448895,0.0036760983,0.0013291786,0.000034702836,1.779024e-7,0.0033439233,0.00024825928,0.36594248,0.00015236042],"about_ca_topic_score_codex":0.0000019859904,"about_ca_topic_score_gemma":1.4149902e-7,"teacher_disagreement_score":0.36269987,"about_ca_system_score_codex":0.000055943266,"about_ca_system_score_gemma":0.00035054417,"threshold_uncertainty_score":0.8920048},"labels":[],"label_agreement":null},{"id":"W4400598666","doi":"10.1208/s12248-024-00955-1","title":"Neutralizing Antibody Sample Testing and Report Harmonization","year":2024,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Immunogenicity; Harmonization; Sample (material); Computer science; Scope (computer science); Medicine; Antibody; Immunology; Chemistry","score_opus":0.053643398283271346,"score_gpt":0.3451334748050669,"score_spread":0.29149007652179554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400598666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78477734,0.06241662,0.11158598,0.028656222,0.006278724,0.00033238047,0.000035214012,0.00032016748,0.0055973665],"genre_scores_gemma":[0.99034137,0.00036201774,0.0076260194,0.00037383498,0.00023840742,7.119051e-7,0.0000059920026,0.000012553776,0.0010391143],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99934375,0.00014678344,0.00020236846,0.00011402081,0.00002442973,0.00016864818],"domain_scores_gemma":[0.99925286,0.0005361997,0.000054355613,0.00009000685,0.00004744574,0.000019122788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009784853,0.0000726241,0.00009967226,0.000042976295,0.00030741922,0.00012382846,0.00008632077,0.00007405426,0.00014088592],"category_scores_gemma":[0.0005759682,0.00003972098,0.000039823823,0.00015823066,0.0001209873,0.00007094557,0.000045098357,0.00040996989,0.000013574445],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026643638,0.000025760304,0.012352874,0.000032191067,0.0002547451,0.0003285519,0.0002922544,0.000005425938,0.8698971,0.0027432728,0.007422947,0.10661822],"study_design_scores_gemma":[0.0011191776,0.0005879695,0.09331556,0.00083591824,0.0009428849,0.13195929,0.0006304399,0.0023274256,0.11853211,0.06726437,0.58168244,0.0008023734],"about_ca_topic_score_codex":0.000022859811,"about_ca_topic_score_gemma":8.9123296e-7,"teacher_disagreement_score":0.751365,"about_ca_system_score_codex":0.000010578144,"about_ca_system_score_gemma":0.00003132629,"threshold_uncertainty_score":0.23644511},"labels":[],"label_agreement":null},{"id":"W4400622862","doi":"10.1016/j.taap.2024.117034","title":"Can we do better with Mylotarg? Model-based assessment of opportunities to improve therapeutic index","year":2024,"lang":"en","type":"article","venue":"Toxicology and Applied Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fractal Systems (Canada)","funders":"","keywords":"Dosing; Pharmacology; Clinical trial; Toxicity; Pharmacokinetics; Adverse effect; Drug; Therapeutic index; Schedule; Medicine; Prioritization; Food and drug administration; Pharmacodynamics; Dose; Intensive care medicine; Internal medicine; Computer science","score_opus":0.03795955727374511,"score_gpt":0.3382090716434077,"score_spread":0.3002495143696626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400622862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8754766,0.005509929,0.039997645,0.062027358,0.0020913326,0.0021557545,0.00041232503,0.00031772692,0.012011336],"genre_scores_gemma":[0.9843024,0.00010559913,0.0021623094,0.012300923,0.00005108578,0.00019487237,0.000012885026,0.00002577005,0.00084414525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847466,0.00019393631,0.00032087704,0.0005018076,0.00004252268,0.00046620917],"domain_scores_gemma":[0.9992719,0.00036929586,0.000070199865,0.00016542316,0.0000419543,0.00008119937],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003682133,0.00027575152,0.0005088108,0.00022430976,0.000110290726,0.000015379068,0.00019104713,0.00044717742,0.0013408695],"category_scores_gemma":[0.000002263186,0.00019922553,0.000061665494,0.00013758661,0.000788127,0.000023937868,0.00009765863,0.00055362226,0.000008391216],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006477398,0.00024435794,0.0004301961,0.0001621017,0.0007584682,0.000023822791,0.00019432402,0.00032436635,0.9152862,0.021331863,0.0022079858,0.058388572],"study_design_scores_gemma":[0.006137953,0.004007374,0.0030575572,0.00009187132,0.0016928769,0.0000972473,0.0005235473,0.013580313,0.8682806,0.011395611,0.08994831,0.0011867632],"about_ca_topic_score_codex":0.000003775674,"about_ca_topic_score_gemma":0.000008314053,"teacher_disagreement_score":0.10882582,"about_ca_system_score_codex":0.00004511965,"about_ca_system_score_gemma":0.00031811197,"threshold_uncertainty_score":0.99957204},"labels":[],"label_agreement":null},{"id":"W4400741621","doi":"10.1080/13696998.2024.2379212","title":"Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Fresenius Kabi","keywords":"Biosimilar; Medicine; Tocilizumab; Adalimumab; Intensive care medicine; Rheumatoid arthritis; Internal medicine","score_opus":0.08273379655443044,"score_gpt":0.3413688276508669,"score_spread":0.2586350310964365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400741621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.576734,0.030087398,0.16451527,0.21623172,0.0039517945,0.001989465,0.00036080403,0.0001005452,0.006029012],"genre_scores_gemma":[0.9835742,0.0064432505,0.0030479394,0.006115079,0.00041378918,0.000011939665,0.0000043266245,0.00004846123,0.000341006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99890625,0.00019876109,0.00044344008,0.00018624529,0.000058739133,0.00020654668],"domain_scores_gemma":[0.99869597,0.00074845325,0.00018131349,0.00011192609,0.00012923579,0.00013309461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017856992,0.00013569248,0.0003061437,0.00006991759,0.0001262749,0.00010674278,0.00035542503,0.00016084457,0.000310239],"category_scores_gemma":[0.00037738818,0.00006484593,0.00012002486,0.000060985312,0.00036406206,0.00013887863,0.000121438155,0.00059331034,0.0000021311118],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012559231,0.0009578685,0.00019301777,0.00052848435,0.006692414,0.00091387983,0.009607535,0.002662713,0.00038516396,0.06441485,0.07388407,0.8272008],"study_design_scores_gemma":[0.0057895766,0.0051114694,0.00006828432,0.0010458325,0.00088209915,0.0047173197,0.009522727,0.08102007,0.0020224152,0.011519849,0.87764096,0.000659413],"about_ca_topic_score_codex":0.00002701142,"about_ca_topic_score_gemma":0.000019938032,"teacher_disagreement_score":0.82654136,"about_ca_system_score_codex":0.000089942994,"about_ca_system_score_gemma":0.00046125692,"threshold_uncertainty_score":0.33968994},"labels":[],"label_agreement":null},{"id":"W4400830732","doi":"10.5639/gabij.2022.1103.018","title":"Key factors for successful uptake of biosimilars: Europe and the US","year":2022,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Key (lock); Business; Medicine; Computer science; Computer security; Internal medicine","score_opus":0.039403864860124246,"score_gpt":0.2793923534529661,"score_spread":0.23998848859284183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400830732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8418385,0.049835566,0.0057099923,0.09134991,0.004153075,0.0016764982,0.00311008,0.000061811406,0.0022645814],"genre_scores_gemma":[0.9160567,0.010920298,0.0054178494,0.066990666,0.00022016956,0.000065633074,0.00006456032,0.00007192002,0.00019218959],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99789464,0.00069277803,0.000603505,0.0003018051,0.00011433299,0.00039292005],"domain_scores_gemma":[0.99834365,0.0006946336,0.00046628152,0.00017281258,0.00025628906,0.00006636287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017193088,0.00026381738,0.000532087,0.00014945546,0.0011316324,0.00006317471,0.0003317276,0.00013612282,0.000307633],"category_scores_gemma":[0.00039268972,0.00015693739,0.00019866558,0.00034505027,0.000992359,0.000083072155,0.0003683352,0.00062053924,3.955348e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065930816,0.0011412746,0.042149536,0.00025183847,0.004598694,0.000064532775,0.008506111,0.00008030868,0.19572507,0.0057794377,0.70379794,0.03131216],"study_design_scores_gemma":[0.009301324,0.0023309921,0.023125974,0.00004682897,0.0007833984,0.0007511149,0.0049156477,0.00029217466,0.05592681,0.0051417723,0.896676,0.0007079309],"about_ca_topic_score_codex":8.2556465e-7,"about_ca_topic_score_gemma":0.0000031989628,"teacher_disagreement_score":0.19287807,"about_ca_system_score_codex":0.000025294343,"about_ca_system_score_gemma":0.000095588686,"threshold_uncertainty_score":0.8703716},"labels":[],"label_agreement":null},{"id":"W4401026462","doi":"10.5639/gabij.2023.1202.008","title":"Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars","year":2023,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Perception; Medicine; Psychology; Internal medicine; Neuroscience","score_opus":0.039198613817649,"score_gpt":0.3057897446700765,"score_spread":0.2665911308524275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401026462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.735314,0.028239245,0.00068726356,0.21527527,0.0051931133,0.0010957288,0.0022523438,0.00036323132,0.011579789],"genre_scores_gemma":[0.89985746,0.031555135,0.003916426,0.06335044,0.00034092084,0.000026531428,0.00010851943,0.00007656997,0.0007679846],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.997969,0.00031506462,0.00042128522,0.00042622254,0.00009165423,0.0007767816],"domain_scores_gemma":[0.9990078,0.00017430981,0.00014047843,0.00018365674,0.00017995443,0.00031378574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078753,0.00032525006,0.00039411304,0.0005155073,0.0010890567,0.00018080072,0.00022810025,0.00041673574,0.0007247805],"category_scores_gemma":[0.00015744446,0.00025896935,0.00013064645,0.0005421172,0.00056247285,0.00017218453,0.00016733985,0.0006909252,0.000054901415],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006516959,0.00009612698,0.07973417,0.000057846002,0.00066032965,0.00023212048,0.0011407214,0.0000046867,0.077419996,0.00012180206,0.829183,0.011284076],"study_design_scores_gemma":[0.0024124146,0.0009734675,0.7326333,0.0002881951,0.0004280968,0.0035890853,0.003261081,0.00020976373,0.009667594,0.003764775,0.24133596,0.0014362793],"about_ca_topic_score_codex":0.00005402226,"about_ca_topic_score_gemma":0.0012766707,"teacher_disagreement_score":0.65289915,"about_ca_system_score_codex":0.00009937698,"about_ca_system_score_gemma":0.0002240171,"threshold_uncertainty_score":0.99998623},"labels":[],"label_agreement":null},{"id":"W4401034735","doi":"10.5639/gabij.2023.1201.006","title":"Non-medical switching of biologicals/biosimilars: Canada, Europe and the US – a webinar report","year":2023,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Business; Medicine; Internal medicine","score_opus":0.025111266278451654,"score_gpt":0.27459839568875927,"score_spread":0.24948712941030762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401034735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73611146,0.013843768,0.0018375843,0.24093637,0.0030371542,0.00065797917,0.00022660919,0.00008113575,0.0032679636],"genre_scores_gemma":[0.88148344,0.025827128,0.001265367,0.09079572,0.00034023784,0.000016767612,0.00003325153,0.000047125734,0.00019099457],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974793,0.00058937975,0.0008193578,0.0003753115,0.00021668256,0.00051993405],"domain_scores_gemma":[0.9981494,0.00070349127,0.00048623548,0.00022827547,0.00028318848,0.0001493866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031926972,0.00029093464,0.0006534833,0.00013644884,0.000553308,0.00005252012,0.00034549666,0.00034328067,0.00017288806],"category_scores_gemma":[0.0013878911,0.00015757966,0.00013088131,0.00060124614,0.0008632025,0.0000624979,0.00041042475,0.0008847802,0.000002878451],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007762004,0.00017572248,0.033673517,0.00009265411,0.00132589,0.0024188608,0.00052593526,0.000007289879,0.06569889,0.0003124132,0.8814104,0.013582204],"study_design_scores_gemma":[0.01181457,0.0016530233,0.20233801,0.00061459374,0.00081287866,0.018409973,0.002277947,0.00194031,0.04461482,0.0041451147,0.7097931,0.0015856969],"about_ca_topic_score_codex":0.00019958013,"about_ca_topic_score_gemma":0.0014890553,"teacher_disagreement_score":0.17161736,"about_ca_system_score_codex":0.000028582934,"about_ca_system_score_gemma":0.00050126563,"threshold_uncertainty_score":0.6425912},"labels":[],"label_agreement":null},{"id":"W4401134684","doi":"10.1002/art.42963","title":"Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022","year":2024,"lang":"en","type":"article","venue":"Arthritis & Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; Agency for Healthcare Research and Quality; National Institutes of Health; Pfizer","keywords":"Biosimilar; Infliximab; Medicaid; Private insurance; Business; Reimbursement; Actuarial science; Pharmacology; Medicine; Internal medicine; Economics; Health care; Tumor necrosis factor alpha; Economic growth","score_opus":0.011272224588276957,"score_gpt":0.2678203226603281,"score_spread":0.25654809807205115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401134684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8834148,0.094296075,0.007247223,0.009255964,0.002479087,0.00055493985,0.0024947121,0.0001303283,0.00012687554],"genre_scores_gemma":[0.98203003,0.013392046,0.0030741922,0.0010264756,0.000026641303,0.00009346323,0.00009674451,0.000029761755,0.0002306662],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981006,0.00018091484,0.0006436058,0.00056389655,0.00006060717,0.0004503884],"domain_scores_gemma":[0.99851805,0.0009373148,0.00008776831,0.0003030053,0.000066076485,0.00008780215],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046345592,0.00022613879,0.00069770345,0.00016678796,0.00008981273,0.00001697631,0.00025646074,0.00044887533,0.0010583608],"category_scores_gemma":[0.00045937172,0.00018751482,0.00012159637,0.00017020688,0.00035816457,0.00006961231,0.00018177302,0.00027432936,0.000059591563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040773838,0.00018497831,0.053333584,0.00043018576,0.0010749456,0.00006401505,0.0010962588,2.2223665e-7,0.08286468,0.026076967,0.046498004,0.7879684],"study_design_scores_gemma":[0.003497075,0.0008717421,0.026684778,0.0018869316,0.00008784706,0.00036893424,0.00021885667,0.000039374678,0.053162728,0.008496542,0.90414727,0.00053795264],"about_ca_topic_score_codex":0.00016724497,"about_ca_topic_score_gemma":0.00014524945,"teacher_disagreement_score":0.8576492,"about_ca_system_score_codex":0.000012415675,"about_ca_system_score_gemma":0.000071054965,"threshold_uncertainty_score":0.9998548},"labels":[],"label_agreement":null},{"id":"W4401475055","doi":"10.1016/j.jval.2024.07.018","title":"Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Occupational Cancer Research Centre; Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"Kementerian Kesihatan Malaysia; Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-Term Care; Ontario Institute for Cancer Research; Ministry of Long-Term Care; Johns Hopkins University; Ministry of Health, Ontario","keywords":"Bevacizumab; Biosimilar; Medicine; Colorectal cancer; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.37779171903743725,"score_gpt":0.5155538795367467,"score_spread":0.13776216049930945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401475055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98179317,0.0066243857,0.0016708826,0.00041904522,0.0015295035,0.0035505553,0.0043109534,0.000066365596,0.00003515471],"genre_scores_gemma":[0.9963563,0.00030385057,0.0027975116,0.000042121974,0.000025164638,0.00018770577,0.00023937384,0.000024107547,0.000023872482],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9954215,0.0021839528,0.00084909983,0.0008654263,0.00010776452,0.0005722343],"domain_scores_gemma":[0.9952929,0.0037030391,0.00027633252,0.00053868204,0.00012235239,0.00006671535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031216894,0.00030108157,0.0015292976,0.0010070292,0.00015931645,0.000030802905,0.00045048923,0.000099508245,0.00007749989],"category_scores_gemma":[0.0001613582,0.00025083005,0.00020737993,0.003260199,0.00029948898,0.0001286771,0.00017902761,0.00037127789,0.0000028733007],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11485667,0.02323089,0.20711325,0.016415602,0.20282188,0.00036400228,0.038428593,0.09733974,0.061440576,0.04902101,0.007769264,0.18119854],"study_design_scores_gemma":[0.027682682,0.013675533,0.07879355,0.0020611952,0.026278092,0.000020472076,0.009457589,0.7817259,0.033419922,0.0009099975,0.023725824,0.0022492472],"about_ca_topic_score_codex":0.016727006,"about_ca_topic_score_gemma":0.011010646,"teacher_disagreement_score":0.68438613,"about_ca_system_score_codex":0.00075277046,"about_ca_system_score_gemma":0.00081237586,"threshold_uncertainty_score":0.9999944},"labels":[],"label_agreement":null},{"id":"W4401585408","doi":"10.7554/elife.100211","title":"Antibody characterization is critical to enhance reproducibility in biomedical research","year":2024,"lang":"en","type":"review","venue":"eLife","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; Biotechnology and Biological Sciences Research Council; National Institute on Aging; National Institutes of Health; University of Leicester; Wellcome Trust","keywords":"Reproducibility; Computational biology; Characterization (materials science); Biology; Nanotechnology; Chemistry; Materials science; Chromatography","score_opus":0.16844118151846543,"score_gpt":0.5691097740130054,"score_spread":0.40066859249454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401585408","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031090123,0.9929581,0.0004133043,0.0038647945,0.0013688749,0.0006532968,0.0003098422,0.000053563777,0.00034712921],"genre_scores_gemma":[0.000049971262,0.99440247,0.00035087054,0.00056447316,0.00032111417,0.000082213075,0.00080926996,0.000035183857,0.0033844279],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99448335,0.0016911246,0.00090686727,0.0020958602,0.00016368541,0.00065913814],"domain_scores_gemma":[0.9976001,0.00067405845,0.00005020165,0.0014185772,0.00016423239,0.00009284111],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.007975097,0.00030682952,0.0013319593,0.0005405822,0.00008465575,0.00004681582,0.00045314556,0.0011492589,0.0010735375],"category_scores_gemma":[0.007267731,0.00021345276,0.00026524425,0.0015453143,0.0005440365,0.000037399168,0.0005002092,0.0019186916,0.0038437373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023552884,0.00031801953,0.0000087673125,0.007878759,0.00011191503,0.000044359967,0.000110053355,3.6427633e-10,0.013232328,0.00045987355,0.011055567,0.9667568],"study_design_scores_gemma":[0.000031050837,0.00013178847,0.000041229574,0.006015588,0.00014731585,0.000022717206,0.000008546219,4.671443e-7,0.00097118097,0.000060790997,0.99234617,0.00022316934],"about_ca_topic_score_codex":0.00001828824,"about_ca_topic_score_gemma":0.0000026018786,"teacher_disagreement_score":0.9812906,"about_ca_system_score_codex":0.00012991487,"about_ca_system_score_gemma":0.00032277958,"threshold_uncertainty_score":0.9998396},"labels":[],"label_agreement":null},{"id":"W4402068618","doi":"10.1007/s40121-024-01036-8","title":"Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI","year":2024,"lang":"en","type":"erratum","venue":"Infectious Diseases and Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Victoria; University of Calgary; Western University","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Microbiome; Clinical trial; Intensive care medicine; Internal medicine; Bioinformatics; Biology","score_opus":0.06418841119723868,"score_gpt":0.4115239399001146,"score_spread":0.34733552870287593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402068618","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026807776,0.86833626,0.005400536,0.00070192065,0.07598987,0.004685819,0.01696598,0.00023042738,0.0008814039],"genre_scores_gemma":[0.5254977,0.39060605,0.00045237996,0.00194448,0.0022512248,0.00053741655,0.0071481927,0.00042466685,0.07113792],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977433,0.0005587748,0.0009232422,0.00048763797,0.000042543157,0.00024450137],"domain_scores_gemma":[0.9977922,0.001257201,0.0004507561,0.00022839583,0.00020762287,0.000063845626],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006395919,0.00039237444,0.0015667148,0.00039892708,0.00009810012,0.00003511869,0.00010502615,0.0004744168,0.00024198653],"category_scores_gemma":[0.00045679763,0.00025837257,0.00058322574,0.00037298206,0.0003185622,0.000025976482,0.00004434164,0.00037090183,0.0000019592617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008084134,0.0015413708,0.0000825224,0.00051362114,0.0052168192,0.0000012803853,0.00013972221,7.825066e-7,0.1113081,0.00013720611,0.19317849,0.679796],"study_design_scores_gemma":[0.0071394406,0.007781191,0.0006623494,0.0010733728,0.0029217803,0.00002651934,0.00006170087,0.000063212654,0.016723895,0.00095898705,0.96209687,0.00049067277],"about_ca_topic_score_codex":0.00012464174,"about_ca_topic_score_gemma":0.000019981942,"teacher_disagreement_score":0.7689184,"about_ca_system_score_codex":0.000032609812,"about_ca_system_score_gemma":0.00015737566,"threshold_uncertainty_score":0.9999868},"labels":[],"label_agreement":null},{"id":"W4402563246","doi":"10.1016/j.clinthera.2024.08.007","title":"The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab","year":2024,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Hexal AG","keywords":"Medicine; Biosimilar; Pharmacology; Intensive care medicine; Internal medicine","score_opus":0.8425130437616768,"score_gpt":0.6390781168110089,"score_spread":0.2034349269506679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402563246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000022428374,0.9933433,0.0006303116,0.0017172039,0.0023497646,0.0013942958,0.00034605002,0.000067162866,0.00014967403],"genre_scores_gemma":[0.000024934829,0.99418133,0.0014836155,0.0011782264,0.00017602787,0.00012822624,0.000019563555,0.000052042866,0.0027560482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951189,0.0013668272,0.0021236883,0.00077325705,0.00008604438,0.0005312391],"domain_scores_gemma":[0.9839657,0.014109998,0.00047758812,0.0011400513,0.00023528041,0.00007140195],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0043515135,0.0004883952,0.002218144,0.000071765986,0.00018641287,0.000056865894,0.0012687737,0.0015519967,0.000048064307],"category_scores_gemma":[0.0020191697,0.00022198149,0.0015636558,0.00041862804,0.0009083496,0.000024771109,0.00038638094,0.0012653078,0.00021057394],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001390599,0.000098490826,0.0000030602976,0.0030348774,0.0015287789,0.0000010956245,0.000012970892,1.4919548e-8,0.000017627875,0.0022321213,0.008325589,0.9846063],"study_design_scores_gemma":[0.00015976214,0.0007578047,0.000005818426,0.0060748695,0.0048889695,0.000010360964,0.000011805691,0.0000024275162,0.000051648323,0.0011259486,0.98660487,0.00030571324],"about_ca_topic_score_codex":0.000003191931,"about_ca_topic_score_gemma":0.000007732947,"teacher_disagreement_score":0.9843006,"about_ca_system_score_codex":0.0000556373,"about_ca_system_score_gemma":0.00041755446,"threshold_uncertainty_score":0.9997442},"labels":[],"label_agreement":null},{"id":"W4402580922","doi":"10.1093/jlb/lsae020","title":"Biosimilar approval pathways: comparing the roles of five medicines regulators","year":2024,"lang":"en","type":"article","venue":"Journal of Law and the Biosciences","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Government of Canada; Australian Government; Arnold Ventures","keywords":"Biosimilar; Drug approval; Medicine; Agency (philosophy); Public economics; Pharmacology; Business; Drug; Economics","score_opus":0.029730687031938013,"score_gpt":0.2831647801321844,"score_spread":0.25343409310024634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402580922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8422407,0.113148004,0.0003256816,0.033253044,0.0035233828,0.00021404917,0.00001543862,0.00002123504,0.007258452],"genre_scores_gemma":[0.99850684,0.0005859742,0.00014510653,0.0005509192,0.00008877502,4.999832e-7,1.3563971e-7,0.0000024216706,0.00011933532],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990965,0.00023332426,0.0003444299,0.0001032274,0.00008831993,0.00013419215],"domain_scores_gemma":[0.9990464,0.00060754694,0.00016719346,0.000097201686,0.00006189905,0.000019753876],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.002306119,0.000087181754,0.0002889249,0.000053748165,0.00020040169,0.000043145865,0.00034586262,0.00007222559,0.000020344634],"category_scores_gemma":[0.000105679195,0.00002969412,0.00013046198,0.00017531961,0.0033108646,0.00008047753,0.000070314905,0.00022029357,8.924071e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006933234,0.00010426262,0.0007676312,0.000115665935,0.0006428124,0.000017322118,0.0057222527,0.000007888473,0.14870119,0.82706773,0.0036334053,0.012526491],"study_design_scores_gemma":[0.004550601,0.0018797801,0.004874276,0.0016274027,0.0014267311,0.0021101458,0.017012464,0.0022253147,0.5343342,0.11883374,0.31058317,0.000542213],"about_ca_topic_score_codex":0.00001899165,"about_ca_topic_score_gemma":0.000018443448,"teacher_disagreement_score":0.708234,"about_ca_system_score_codex":0.000004616917,"about_ca_system_score_gemma":0.00004467241,"threshold_uncertainty_score":0.99940157},"labels":[],"label_agreement":null},{"id":"W4402801136","doi":"10.1097/01.tp.0001064316.25419.d4","title":"221.6: Development of a calculated panel reactive antibody calculator for the United Arab Emirates.","year":2024,"lang":"en","type":"article","venue":"Transplantation","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Calculator; Panel reactive antibody; Antibody; Medicine; Ancient history; Immunology; History; Computer science; Antigen","score_opus":0.05534100254929517,"score_gpt":0.33902622768263835,"score_spread":0.28368522513334316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402801136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83288234,0.0018429961,0.16319637,0.00047874617,0.00052867807,0.0005799718,0.00023342845,0.00008831302,0.00016916885],"genre_scores_gemma":[0.99699473,0.00017331824,0.0017622559,0.00008808429,0.0000142135295,0.0000265197,0.0006016625,0.000011341985,0.0003278579],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99929905,0.000074986296,0.00026141145,0.000173967,0.000031345353,0.00015921504],"domain_scores_gemma":[0.99932146,0.00046968905,0.000040667037,0.00008803702,0.000068246205,0.000011912907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003046766,0.00010852833,0.00014886307,0.00009038003,0.000105725965,0.000011008872,0.00008357923,0.00016878176,0.00008017815],"category_scores_gemma":[0.000016652855,0.00006578146,0.000078109515,0.00025951944,0.000101639926,0.000036032583,0.0000045566485,0.00013484745,0.000015924432],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004555319,0.00005654765,0.00021017618,0.00029081196,0.000600245,0.0000048625384,0.0021694228,0.000016840064,0.98230237,0.0027078725,0.00014137194,0.011043949],"study_design_scores_gemma":[0.0010099071,0.0001024363,0.021349065,0.00022184059,0.0005721101,0.000038654343,0.0002274136,0.0017664353,0.9543366,0.00018928484,0.019996373,0.00018991134],"about_ca_topic_score_codex":0.00005751708,"about_ca_topic_score_gemma":0.000015166285,"teacher_disagreement_score":0.16411242,"about_ca_system_score_codex":0.000019233496,"about_ca_system_score_gemma":0.000067631125,"threshold_uncertainty_score":0.268249},"labels":[],"label_agreement":null},{"id":"W4402851415","doi":"10.22541/au.172724768.89080170/v1","title":"Endocrine toxicities in Chimeric Antigen Receptor T-Cell Therapy: A pharmacovigilance study from 2017 to 2023 Quarter 1","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Natural Science Foundation of China; Shanghai Municipal Health Commission","keywords":"Pharmacovigilance; Chimeric antigen receptor; Quarter (Canadian coin); Medicine; Endocrine system; Pharmacology; Oncology; Immunology; Internal medicine; Immunotherapy; Adverse effect; Cancer; Hormone","score_opus":0.04251896766246037,"score_gpt":0.3453353232989682,"score_spread":0.30281635563650783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402851415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9539802,0.023086304,0.000098926146,0.0036038386,0.0055415677,0.0018755656,0.0008831866,0.00019655703,0.010733867],"genre_scores_gemma":[0.9575482,0.002631526,0.001975556,0.0023071964,0.00031406689,0.0002831304,0.0001631192,0.000057119636,0.034720093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99707276,0.0005692857,0.00061026745,0.001111589,0.000071645976,0.00056443573],"domain_scores_gemma":[0.9989203,0.00021896242,0.000105567255,0.0006508664,0.000046821224,0.000057470836],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00041078322,0.0005346148,0.0009088584,0.00028946792,0.00006134601,0.00008072538,0.0006607876,0.0004120413,0.008348551],"category_scores_gemma":[0.000025009535,0.00039375472,0.00023004768,0.00025731412,0.00011046115,0.000026469193,0.0010464302,0.0014701209,0.0021871415],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006212427,0.0017641674,0.010192153,0.00009177706,0.0013878188,0.00009664123,0.0022384182,0.0000075322705,0.6834414,0.000032913937,0.28922802,0.010897934],"study_design_scores_gemma":[0.005110318,0.0020036502,0.02428078,0.00046398063,0.00032116426,0.000011099207,0.0041296207,0.000046472214,0.5924111,0.0025575145,0.36621183,0.0024524475],"about_ca_topic_score_codex":0.0015581921,"about_ca_topic_score_gemma":0.00020715885,"teacher_disagreement_score":0.09103027,"about_ca_system_score_codex":0.00006123543,"about_ca_system_score_gemma":0.00009613782,"threshold_uncertainty_score":0.9998514},"labels":[],"label_agreement":null},{"id":"W4402960439","doi":"10.1186/s41927-024-00415-5","title":"Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data","year":2024,"lang":"en","type":"article","venue":"BMC Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University of Alberta; Centre Hospitalier de l’Université de Montréal; McGill University; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Biosimilar; Infliximab; Etanercept; Incidence (geometry); Medicine; Population; Immunology; Environmental health; Internal medicine; Tumor necrosis factor alpha; Mathematics","score_opus":0.02677707771730346,"score_gpt":0.3060094944558463,"score_spread":0.2792324167385428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402960439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522126,0.0022530325,0.0012591934,0.00039585197,0.00022735451,0.000243165,0.00025475287,0.000068867696,0.00007649558],"genre_scores_gemma":[0.99781245,0.00015865374,0.0016011796,0.00007012824,0.0000066915663,0.0000058636556,0.00031430848,0.000018146879,0.0000125601855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829865,0.00033249293,0.00048522808,0.0005097487,0.00004604598,0.00032786423],"domain_scores_gemma":[0.99869704,0.00064329186,0.00013205195,0.0003799463,0.000053541433,0.000094125644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048386457,0.00022186835,0.00059179176,0.00035640772,0.00016626561,0.00003326343,0.0001754416,0.0004704959,0.0000907537],"category_scores_gemma":[0.00019033013,0.00017615885,0.000031052183,0.00033734879,0.0006889666,0.00017741545,0.000104253195,0.00033201164,0.000005770048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005357572,0.0000206508,0.9946949,0.00022415118,0.00014619475,0.000004450355,0.000072258845,0.0000042063502,0.00007795399,0.000640875,0.0002261526,0.00383465],"study_design_scores_gemma":[0.00060472597,0.00024755212,0.9917807,0.00030972116,0.00020778878,0.00010602385,0.000060036826,0.0013258191,0.0008625742,0.00014875997,0.004077173,0.00026912492],"about_ca_topic_score_codex":0.058578186,"about_ca_topic_score_gemma":0.13244416,"teacher_disagreement_score":0.07386598,"about_ca_system_score_codex":0.00005638935,"about_ca_system_score_gemma":0.0003021763,"threshold_uncertainty_score":0.94769084},"labels":[],"label_agreement":null},{"id":"W4403498878","doi":"10.1002/jcph.6139","title":"Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT‐P47 and Reference Tocilizumab: A Randomized, Double‐Blind, Phase 1 Study","year":2024,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Celltrion","keywords":"Tocilizumab; Medicine; Adverse effect; Internal medicine; Pharmacokinetics; Randomized controlled trial; Bioequivalence; Clinical endpoint; Area under the curve; Confidence interval; Pharmacodynamics; Gastroenterology; Pharmacology; Rheumatoid arthritis","score_opus":0.09548188791577344,"score_gpt":0.4630843294698259,"score_spread":0.3676024415540525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403498878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96592623,0.023566663,0.00042282089,0.0055619036,0.00308395,0.001037564,0.000059504953,0.000019211648,0.00032216645],"genre_scores_gemma":[0.9780284,0.020398399,0.00014647555,0.000948793,0.00027294477,0.000006411296,0.0000020909326,0.00001581636,0.0001806793],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939121,0.003301677,0.0021072086,0.00026843502,0.0000977758,0.000312781],"domain_scores_gemma":[0.9932301,0.005654101,0.0006306695,0.00016296207,0.00020425106,0.000117935204],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009623537,0.00024969774,0.0015254652,0.00015521495,0.00011888844,0.000019796697,0.0003699793,0.00020280373,0.0009163134],"category_scores_gemma":[0.00034433333,0.00013548041,0.00023616207,0.00020163025,0.002229538,0.000077435834,0.00021615395,0.0015303466,0.000008338116],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84320444,0.0024828962,0.00028996266,0.00016496301,0.006787366,0.00030775074,0.0010434537,0.000007836598,0.052777916,0.00052483554,0.010007119,0.08240147],"study_design_scores_gemma":[0.867583,0.009208482,0.0005257805,0.00017468561,0.0118858,0.0022828677,0.0007153847,0.0005093905,0.035677377,0.0017333594,0.06924223,0.00046165223],"about_ca_topic_score_codex":0.000031224175,"about_ca_topic_score_gemma":0.0000074366453,"teacher_disagreement_score":0.08193982,"about_ca_system_score_codex":0.000016186077,"about_ca_system_score_gemma":0.00017284733,"threshold_uncertainty_score":0.99999696},"labels":[],"label_agreement":null},{"id":"W4403665664","doi":"10.1093/bjd/ljae402","title":"Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Amgen","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Randomized controlled trial; Clinical endpoint; Adverse effect; Internal medicine; Psoriasis; Randomization; Gastroenterology; Dermatology; Adalimumab; Disease","score_opus":0.027337013886964728,"score_gpt":0.3263798375749371,"score_spread":0.29904282368797236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403665664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99291545,0.002411777,0.00021733443,0.0011452644,0.0007384775,0.002379774,0.000047706835,0.000011068727,0.00013312495],"genre_scores_gemma":[0.99917424,0.00018002467,0.00026445385,0.00026606556,0.000028454147,0.000027092714,0.0000030510457,0.000016482438,0.000040145005],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99413824,0.0032786825,0.0017503025,0.0003629157,0.00012959311,0.00034026112],"domain_scores_gemma":[0.996721,0.0021768096,0.0005488913,0.00018909574,0.00028958434,0.00007458192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012690085,0.0002661756,0.0025164296,0.00022797054,0.00012059744,0.00005494701,0.00032645022,0.000413294,0.000095221854],"category_scores_gemma":[0.00036024678,0.00016655702,0.00032355133,0.0003622419,0.00063410477,0.00013785674,0.00013199434,0.0011622717,0.0000028631434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9659307,0.0023596499,0.019484194,0.000039523096,0.0044837873,0.00033719544,0.0009152445,0.000025174597,0.00008481951,0.00022023208,0.0012725182,0.0048469664],"study_design_scores_gemma":[0.8218519,0.00102928,0.17091896,0.0006421021,0.0010153087,0.0024956022,0.00037850082,0.00008345824,0.00076952047,0.00016485379,0.00037536293,0.0002751803],"about_ca_topic_score_codex":0.00003987394,"about_ca_topic_score_gemma":0.00015429157,"teacher_disagreement_score":0.15143475,"about_ca_system_score_codex":0.000039351336,"about_ca_system_score_gemma":0.000208081,"threshold_uncertainty_score":0.6791998},"labels":[],"label_agreement":null},{"id":"W4403725300","doi":"10.14309/01.ajg.0001033616.34362.32","title":"S1062 Real-World Outcomes of a Mandatory Adalimumab Non-Medical Biosimilar Switch for Patients With Inflammatory Bowel Disease: A Single Center Retrospective Study","year":2024,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Biosimilar; Adalimumab; Inflammatory bowel disease; Single Center; Retrospective cohort study; Center (category theory); Disease; Intensive care medicine; Internal medicine","score_opus":0.007551006124394666,"score_gpt":0.27211841204318843,"score_spread":0.26456740591879374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403725300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949333,0.00013704905,0.0010993299,0.002681396,0.00056430086,0.00041744017,0.00012976334,0.000016930113,0.000020493151],"genre_scores_gemma":[0.99853384,0.00004158289,0.00032208167,0.0008859749,0.00007390883,0.000015960977,0.0000067620476,0.000030343099,0.00008952388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977268,0.0005762182,0.0007528991,0.00028943727,0.00020058018,0.0004540517],"domain_scores_gemma":[0.9983533,0.00031762716,0.00062082004,0.00032281,0.0002689451,0.00011647457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009130045,0.0002628762,0.0009106835,0.00027563117,0.00008558004,0.000016330721,0.000507246,0.0000614157,0.000119375545],"category_scores_gemma":[0.00013612659,0.00014067005,0.0003086689,0.0001875169,0.0012206888,0.00009081741,0.00013273135,0.0005367344,0.0000033155036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017495353,0.0015587542,0.97577745,0.00003353163,0.0020024437,0.000051491064,0.00024344205,0.0000012129225,0.0003142016,0.00003136056,0.0014147026,0.0010760899],"study_design_scores_gemma":[0.0041266647,0.027931457,0.96561843,0.00015425624,0.0005783012,0.000057573772,0.00038359745,0.00001534326,0.000072732335,0.000094332434,0.0008508189,0.0001164842],"about_ca_topic_score_codex":0.000014930607,"about_ca_topic_score_gemma":0.00009721221,"teacher_disagreement_score":0.026372703,"about_ca_system_score_codex":0.00009689906,"about_ca_system_score_gemma":0.00012228495,"threshold_uncertainty_score":0.5736358},"labels":[],"label_agreement":null},{"id":"W4403810817","doi":"10.1136/bmj-2024-079830","title":"Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline","year":2024,"lang":"en","type":"article","venue":"BMJ","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bruyère; University of Ottawa; Alberta Bone and Joint Health Institute; Impact; University of Calgary; McMaster University","funders":"HORIZON EUROPE Framework Programme; Danmarks Grundforskningsfond; Norges Forskningsråd; National Research Foundation; European Commission; National Institute for Health and Care Research","keywords":"Medicine; Inflammatory bowel disease; Psoriasis; Guideline; Drug; Inflammatory arthritis; Arthritis; Psoriatic arthritis; Intensive care medicine; Therapeutic drug monitoring; Disease; Clinical Practice; Inflammatory Bowel Diseases; Internal medicine; Dermatology; Pharmacology; Physical therapy; Pathology","score_opus":0.023878900214986804,"score_gpt":0.35241343279022663,"score_spread":0.32853453257523985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403810817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805813,0.011215158,0.000132865,0.0033780313,0.0022808977,0.0016404645,0.00010600999,0.00016764668,0.00049764535],"genre_scores_gemma":[0.9918097,0.0012873176,0.00536013,0.0006163606,0.00029848292,0.00015496249,0.000035003482,0.000037259582,0.00040074575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968183,0.00096477213,0.0012134688,0.00051772385,0.00011695767,0.0003687679],"domain_scores_gemma":[0.99779356,0.001129695,0.00029038978,0.0003588255,0.00036039323,0.00006714636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016780549,0.00026749432,0.0004405914,0.00015203138,0.000058999816,0.000024143668,0.00022424632,0.00031403446,0.00009150349],"category_scores_gemma":[0.0014007872,0.00016635182,0.00014478313,0.00026555627,0.00038761532,0.00023122592,0.000105798485,0.0006367048,0.000040896964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008731148,0.0011078643,0.8537563,0.00026512682,0.00136996,0.00013492774,0.00069117243,0.0000058767037,0.00055154687,0.0012130949,0.0056807734,0.12649219],"study_design_scores_gemma":[0.0049456414,0.0008690062,0.9335692,0.0016116642,0.00045917192,0.000018408382,0.001777666,0.000066717665,0.002727222,0.0004376513,0.05284181,0.00067583536],"about_ca_topic_score_codex":0.000019359779,"about_ca_topic_score_gemma":0.000019529247,"teacher_disagreement_score":0.12581636,"about_ca_system_score_codex":0.000054627522,"about_ca_system_score_gemma":0.00034061956,"threshold_uncertainty_score":0.6783631},"labels":[],"label_agreement":null},{"id":"W4404387688","doi":"10.1080/17576180.2024.2411925","title":"Harmonization of Vaccine Ligand Binding Assays Validation","year":2024,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; Ministry of Health, Labour and Welfare; U.S. Food and Drug Administration; Sanofi","keywords":"Harmonization; Computational biology; Chemistry; Biochemical engineering; Virology; Chromatography; Biology; Engineering; Physics","score_opus":0.022318986982197257,"score_gpt":0.29318371679120414,"score_spread":0.2708647298090069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404387688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7281247,0.117643215,0.12694997,0.009282681,0.004391126,0.00067758956,0.00044351717,0.00074583915,0.011741386],"genre_scores_gemma":[0.9946577,0.00040290225,0.001426676,0.000034702993,0.000033144952,0.0000029881176,0.000102272774,0.000010163151,0.0033294538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99913454,0.00012252713,0.00031056235,0.00024128803,0.000042661042,0.0001484237],"domain_scores_gemma":[0.9995242,0.00014363749,0.000069056216,0.00017157065,0.000075584,0.00001596311],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047565188,0.00010721008,0.00025128116,0.0003127167,0.000058343627,0.000028953358,0.000103275546,0.00018496769,0.0009657089],"category_scores_gemma":[0.00011631411,0.000080102,0.00017749415,0.00091058837,0.00004806283,0.00007267535,0.00003655785,0.00011276541,0.00013393819],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002510137,0.00006880733,0.0063188705,0.00007970441,0.0013247221,0.0000043810983,0.000077626595,0.000008016655,0.93294936,0.0025347462,0.0025378221,0.054070827],"study_design_scores_gemma":[0.00021222999,0.00006324228,0.0011981945,0.00005690214,0.0009893659,0.000006263957,0.00005763412,0.0006075171,0.9597439,0.00030505942,0.03661776,0.0001418965],"about_ca_topic_score_codex":0.000022596838,"about_ca_topic_score_gemma":0.000003528927,"teacher_disagreement_score":0.26653302,"about_ca_system_score_codex":0.0000260065,"about_ca_system_score_gemma":0.000022379198,"threshold_uncertainty_score":0.99994755},"labels":[],"label_agreement":null},{"id":"W4404417581","doi":"10.21203/rs.3.rs-5289961/v1","title":"Disease Remission and Sustained Remission After Etanercept Biosimilar or Originator Initiation in Rheumatoid Arthritis: An Interim Real-World Analysis","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Canadian Arthritis Patient Alliance; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; McGill University; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre","funders":"","keywords":"Biosimilar; Etanercept; Rheumatoid arthritis; Medicine; Interim; Interim analysis; Internal medicine; Disease; Immunology; Clinical trial; Political science; Law","score_opus":0.058991147044761,"score_gpt":0.43026782724061835,"score_spread":0.37127668019585736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404417581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95107794,0.03599123,0.00012220457,0.0069413865,0.0007199165,0.0021405485,0.0010488847,0.00031926692,0.001638605],"genre_scores_gemma":[0.97368383,0.021106135,0.00047483278,0.000101978694,0.00008010668,0.00022796147,0.0007338069,0.000061582265,0.0035297854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934929,0.0028817127,0.00085016637,0.0015421506,0.0003153259,0.00091773993],"domain_scores_gemma":[0.99748695,0.00054685713,0.00013755859,0.0010171206,0.00043969593,0.00037179267],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033130697,0.0005069013,0.000963251,0.0026140276,0.00021800838,0.00026637892,0.00042918362,0.0010335181,0.0030439063],"category_scores_gemma":[0.0011293996,0.00036991978,0.00031025478,0.0021741954,0.00052405894,0.00013521471,0.001840243,0.003067479,0.000043309814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07283645,0.0069393837,0.3903323,0.027642364,0.009205191,0.0146502685,0.010547389,0.0001049987,0.08263894,0.010721501,0.04549043,0.32889077],"study_design_scores_gemma":[0.009702676,0.0043604276,0.61062986,0.056556035,0.0028583803,0.00011166617,0.01176895,0.012014278,0.032645956,0.07728491,0.17487736,0.0071894936],"about_ca_topic_score_codex":0.00038733613,"about_ca_topic_score_gemma":0.0013382091,"teacher_disagreement_score":0.32170126,"about_ca_system_score_codex":0.00047258943,"about_ca_system_score_gemma":0.00068532786,"threshold_uncertainty_score":0.99987525},"labels":[],"label_agreement":null},{"id":"W4404505874","doi":"10.3748/wjg.v30.i46.4904","title":"Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease","year":2024,"lang":"en","type":"article","venue":"World Journal of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"British Columbia Centre on Substance Use; Western University; St. Paul's Hospital; Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"","keywords":"Adalimumab; Biosimilar; Inflammatory bowel disease; Medicine; Disease; Crohn's disease; Infliximab; Intensive care medicine; Ulcerative colitis; Internal medicine","score_opus":0.013067198095836549,"score_gpt":0.315956796969488,"score_spread":0.3028895988736514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404505874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937267,0.0011262929,0.00027732298,0.0037753633,0.00087468873,0.00014351206,0.000027740103,0.000008985057,0.00003941495],"genre_scores_gemma":[0.9979862,0.00035461062,0.00043537698,0.00089634414,0.00004118726,0.0000067510778,0.0000018709704,0.000016415514,0.00026124678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977498,0.00030109196,0.0011046663,0.00028312844,0.000148353,0.00041296377],"domain_scores_gemma":[0.9989259,0.00024221576,0.000292319,0.00023000059,0.00009878238,0.00021076547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000869668,0.00022723078,0.0007687449,0.0009656336,0.000027785869,0.0000116420815,0.0003860351,0.0001357115,0.00045124727],"category_scores_gemma":[0.00014279237,0.00016939403,0.00020698576,0.00026496826,0.0006297613,0.000106278916,0.00019237475,0.00056450913,0.0000036587967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002426328,0.00022746017,0.98458004,0.00018594967,0.00027849263,0.00045196648,0.00024331379,0.0000017325389,0.009095503,0.00022114706,0.0010466583,0.0012414145],"study_design_scores_gemma":[0.001667446,0.00085810834,0.99278855,0.0006452276,0.00012103546,0.00012706283,0.000050571787,0.000015650496,0.0022341004,0.00007970869,0.0013068506,0.000105681254],"about_ca_topic_score_codex":0.000013588741,"about_ca_topic_score_gemma":0.00041261484,"teacher_disagreement_score":0.0082085235,"about_ca_system_score_codex":0.000060665072,"about_ca_system_score_gemma":0.00016370491,"threshold_uncertainty_score":0.69076884},"labels":[],"label_agreement":null},{"id":"W4404524533","doi":"10.1007/s40268-024-00496-0","title":"In-Use Physicochemical Stability of Sandoz Rituximab Biosimilar in 0.9% Sodium Chloride Solution After Prolonged Storage at Room Temperature Conditions","year":2024,"lang":"en","type":"article","venue":"Drugs in R&D","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sandoz Canada","keywords":"Relative humidity; Chemistry; Chromatography; Shelf life; Sodium; Humidity; Sodium dodecyl sulfate; Food science; Organic chemistry","score_opus":0.013969203204884036,"score_gpt":0.27798644947447765,"score_spread":0.2640172462695936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404524533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947198,0.0020414237,0.0000068197864,0.0019951018,0.00048915297,0.00033583338,0.00028393607,0.00003053384,0.00009741291],"genre_scores_gemma":[0.99907136,0.000061565865,0.00015058031,0.00030168402,0.00003180692,0.000081501035,0.00007896857,0.000013447241,0.00020905958],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984079,0.00026802215,0.0004468881,0.00045229078,0.00005389889,0.00037101356],"domain_scores_gemma":[0.99929523,0.00032940495,0.000043576012,0.0002711938,0.00003657307,0.000024010675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005406609,0.00019527195,0.00043100954,0.00020506748,0.000032908414,0.000017433309,0.00013106807,0.00048747702,0.00048152622],"category_scores_gemma":[0.00014372739,0.00016530693,0.00012386401,0.00046809477,0.00032061376,0.0001740973,0.00012327354,0.0007410679,0.000031054253],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011361986,0.00087088736,0.012437275,0.00018149252,0.000050793973,0.000051280334,0.0011622986,0.0000018804071,0.98140633,0.000290962,0.0022763736,0.00013425473],"study_design_scores_gemma":[0.0024104991,0.00008483924,0.046625815,0.00029465242,0.000042636122,0.000012922514,0.00015235275,0.00013993129,0.9450877,0.000935937,0.003920209,0.0002925273],"about_ca_topic_score_codex":0.00008029901,"about_ca_topic_score_gemma":0.00030669,"teacher_disagreement_score":0.036318626,"about_ca_system_score_codex":0.00022313533,"about_ca_system_score_gemma":0.000062832114,"threshold_uncertainty_score":0.6741021},"labels":[],"label_agreement":null},{"id":"W4404532483","doi":"10.1093/bjd/ljae454","title":"Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Portugal; Janssen Australia; Caisse nationale de l'Assurance Maladie; Bristol-Myers Squibb Canada; AbbVie Canada; Psoriasis Association; LEO Pharma; Assistance publique-Hôpitaux de Paris; Cilag; University of Manchester; British Association of Dermatologists; Almirall; Boehringer Ingelheim España; Assistance Publique - Hôpitaux de Paris; Manchester Biomedical Research Centre","keywords":"Biosimilar; Adalimumab; Medicine; Psoriasis; Multinational corporation; Cohort; Internal medicine; Cohort study; Oncology; Family medicine; Dermatology; Business; Disease","score_opus":0.013596104107275651,"score_gpt":0.2890731079822312,"score_spread":0.27547700387495555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404532483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98360956,0.010094313,0.00279118,0.0016243928,0.0008753392,0.0005693349,0.00020392935,0.00002543594,0.00020651775],"genre_scores_gemma":[0.9956036,0.00024505542,0.003923827,0.000049803628,0.00003688082,0.0000105343215,0.0000110918745,0.000016567605,0.0001026057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983423,0.00041294182,0.00070341036,0.00022689927,0.00008083282,0.00023361342],"domain_scores_gemma":[0.9982743,0.0010171181,0.00026170525,0.00007950086,0.00032555708,0.000041786236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000681839,0.0001487503,0.0007223734,0.00015754347,0.00012928768,0.00003458748,0.00014917382,0.0001412618,0.00008582582],"category_scores_gemma":[0.00019307822,0.00012516101,0.00012589178,0.00016552402,0.0003159332,0.000099369136,0.000038879458,0.0002977845,8.64652e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066608037,0.0026331886,0.85012037,0.0008373484,0.011210697,0.0029786306,0.0014716414,0.0000148118725,0.009880121,0.00459328,0.021253806,0.0883453],"study_design_scores_gemma":[0.046459675,0.003556345,0.6526658,0.0028474499,0.0052373977,0.16000037,0.009492441,0.0011384295,0.050346393,0.0018906733,0.06476641,0.0015985995],"about_ca_topic_score_codex":0.000039549308,"about_ca_topic_score_gemma":0.000120661505,"teacher_disagreement_score":0.19745456,"about_ca_system_score_codex":0.000027949753,"about_ca_system_score_gemma":0.000117864896,"threshold_uncertainty_score":0.5103918},"labels":[],"label_agreement":null},{"id":"W4404610816","doi":"10.1002/psp4.13280","title":"Clinical study design strategies to mitigate confounding effects of time‐dependent clearance on dose optimization of therapeutic antibodies","year":2024,"lang":"en","type":"article","venue":"CPT Pharmacometrics & Systems Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of British Columbia; Killam Trusts","keywords":"Confounding; Medicine; Sample size determination; Population; Clinical trial; Internal medicine; Statistics; Mathematics","score_opus":0.06467598173167563,"score_gpt":0.42622265070390564,"score_spread":0.36154666897223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404610816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7138231,0.063476175,0.17833138,0.0003868186,0.03381663,0.0084427465,0.0001624809,0.0004297005,0.001130976],"genre_scores_gemma":[0.99730897,0.0010741418,0.00046051785,0.0002505402,0.00015113373,0.0000817247,0.000006163032,0.000041603016,0.0006251896],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99419403,0.003240381,0.001262763,0.00064236653,0.00017186007,0.0004885786],"domain_scores_gemma":[0.99377656,0.0052654897,0.00034152993,0.00024620388,0.00027656692,0.00009364139],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028796534,0.00036077594,0.0011323694,0.0011773206,0.00010685769,0.000056430737,0.00048485692,0.00031805536,0.00029780142],"category_scores_gemma":[0.00022161641,0.00029023198,0.00020241289,0.0019144495,0.00032771513,0.00013009786,0.00013169023,0.00061154924,0.00011393201],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001491587,0.001876786,0.00090726116,0.001179943,0.0036881,0.00010471449,0.0005007328,0.029183304,0.94489944,0.00041438805,0.00423395,0.011519817],"study_design_scores_gemma":[0.010203342,0.012691462,0.003088096,0.0008404662,0.0043752263,0.00008233745,0.0009901149,0.039677676,0.91922474,0.000085974236,0.007532475,0.001208097],"about_ca_topic_score_codex":0.000022364,"about_ca_topic_score_gemma":1.8673921e-7,"teacher_disagreement_score":0.2834859,"about_ca_system_score_codex":0.000076524026,"about_ca_system_score_gemma":0.00015713218,"threshold_uncertainty_score":0.999955},"labels":[],"label_agreement":null},{"id":"W4404692022","doi":"10.1001/jama.2024.16911","title":"Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US","year":2024,"lang":"en","type":"article","venue":"JAMA","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Heart, Lung, and Blood Institute; Arnold Ventures","keywords":"Medicine; Biosimilar; Revenue; Drug development; Competition (biology); Clinical trial; Reimbursement; Drug prices; Drug; Finance; Pharmacology; Public economics; Business; Health care; Internal medicine; Economics; Economic growth","score_opus":0.025126327673231127,"score_gpt":0.294798512688436,"score_spread":0.26967218501520485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404692022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93275994,0.0027005763,0.0138576375,0.03840259,0.0025714145,0.0016826944,0.0002197572,0.00020750046,0.0075979074],"genre_scores_gemma":[0.99569976,0.000026068083,0.00049013674,0.00096790644,0.00012572297,0.00014825209,0.000026737373,0.000008060916,0.0025073248],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99917525,0.0002099707,0.0001534161,0.00021275849,0.000015661331,0.00023293987],"domain_scores_gemma":[0.9995319,0.00028108223,0.000017888424,0.00013854074,0.000021789587,0.0000087532035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031103462,0.00010065272,0.00013379588,0.000059336104,0.00010776523,0.00007210388,0.00017963733,0.0002785185,0.00020741709],"category_scores_gemma":[0.00012799927,0.00005481677,0.00012640646,0.00016690858,0.00012943624,0.00002701532,0.000041509273,0.0003802088,0.00003945254],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010441315,0.00069200504,0.0006407737,0.0002439443,0.00054248003,0.00003417326,0.0010144988,0.0000018442591,0.6386625,0.15297672,0.04348318,0.16066375],"study_design_scores_gemma":[0.001402771,0.00079151493,0.0059678815,0.000071070055,0.00012917808,0.000075554126,0.00027102858,0.0003211297,0.13969842,0.0036149144,0.84737116,0.000285358],"about_ca_topic_score_codex":0.00005697929,"about_ca_topic_score_gemma":0.00004248234,"teacher_disagreement_score":0.803888,"about_ca_system_score_codex":0.000016176995,"about_ca_system_score_gemma":0.000027175858,"threshold_uncertainty_score":0.22710718},"labels":[],"label_agreement":null},{"id":"W4404924122","doi":"10.2196/56553","title":"An Educational Digital Tool to Improve the Implementation of Switching to a Biosimilar (Rapid Switch Trainer): Tool Development and Validation Study","year":2024,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Biosimilar; Nocebo Effect; Focus group; Trainer; Medicine; Quality (philosophy); Medical education; Health care; Health professionals; Resource (disambiguation); Knowledge management; Alternative medicine; Psychology; Computer science; Business; Internal medicine; Marketing","score_opus":0.048608423452570784,"score_gpt":0.441791703582826,"score_spread":0.3931832801302552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404924122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923035,0.00010028601,0.0012605042,0.0043818844,0.00016716518,0.0015078603,0.00008912885,0.000019253994,0.00017040239],"genre_scores_gemma":[0.9985781,0.000003875167,0.0006685237,0.00013803178,0.000040028393,0.00036248588,0.00003952518,0.0000104360815,0.0001590038],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984388,0.0003235751,0.00040970673,0.00029971756,0.00018837156,0.00033988146],"domain_scores_gemma":[0.99908596,0.0004105399,0.00003746656,0.00019730238,0.00022121394,0.000047492813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021990454,0.00013183327,0.00016318489,0.00030547666,0.00029334007,0.0002031083,0.0002231259,0.00007243055,0.00026836377],"category_scores_gemma":[0.00009454163,0.000083144056,0.000037271824,0.0005600519,0.00007275496,0.0003935086,0.00017965848,0.0003062192,0.000055697954],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015583783,0.0004835835,0.0011661822,0.00009343622,0.00025587145,0.0000010096218,0.056886822,7.544416e-7,0.1815434,0.0022712196,0.00386876,0.7532731],"study_design_scores_gemma":[0.001664536,0.007090578,0.2519,0.00018467319,0.000059277667,0.000025514106,0.08416696,0.00014109445,0.5880806,0.0020082663,0.06401094,0.000667566],"about_ca_topic_score_codex":0.000023884773,"about_ca_topic_score_gemma":0.000017219832,"teacher_disagreement_score":0.75260556,"about_ca_system_score_codex":0.00009315461,"about_ca_system_score_gemma":0.00022940096,"threshold_uncertainty_score":0.3390516},"labels":[],"label_agreement":null},{"id":"W4404935841","doi":"10.1111/1475-6773.14410","title":"Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registry","year":2024,"lang":"en","type":"article","venue":"Health Services Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; Agency for Healthcare Research and Quality","keywords":"Biosimilar; Medicine; Infliximab; Medicaid; Rheumatology; Family medicine; Internal medicine; Health care","score_opus":0.16603421149433628,"score_gpt":0.49234952491397854,"score_spread":0.32631531341964226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404935841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9360188,0.03626828,0.0007555488,0.016516257,0.0010993313,0.0013245192,0.0010043993,0.00012526163,0.0068875556],"genre_scores_gemma":[0.997083,0.001114366,0.0012829243,0.0002496052,0.000013115717,0.000015452451,0.00011647533,0.000009348672,0.000115692266],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99684376,0.00091564516,0.00092845346,0.0004657259,0.00027763043,0.0005688113],"domain_scores_gemma":[0.9971585,0.0017630379,0.00026427582,0.00030399725,0.00042089113,0.00008926475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023620743,0.0001703396,0.00081708137,0.0020510706,0.00015078131,0.000024023653,0.00042301932,0.0003661312,0.0005435253],"category_scores_gemma":[0.00014262728,0.00015125095,0.0001874475,0.004417247,0.00031591702,0.00012784317,0.0001776865,0.00085613487,0.000022939335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014862673,0.0047219363,0.16194607,0.025570849,0.049110666,0.0001493263,0.255394,0.0024843724,0.12992899,0.25116616,0.060735956,0.043929003],"study_design_scores_gemma":[0.024706958,0.007218323,0.42302686,0.00964441,0.002505279,0.00010162459,0.10535328,0.12353944,0.064681806,0.012090734,0.22453924,0.002592053],"about_ca_topic_score_codex":0.0029189694,"about_ca_topic_score_gemma":0.0039321627,"teacher_disagreement_score":0.26108077,"about_ca_system_score_codex":0.0001996117,"about_ca_system_score_gemma":0.0012982555,"threshold_uncertainty_score":0.61678344},"labels":[],"label_agreement":null},{"id":"W4405040930","doi":"10.1182/blood-2024-208943","title":"Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Chimeric antigen receptor; Health technology; Medicine; Health care; Cancer; Immunotherapy; Internal medicine; Political science","score_opus":0.0311121393473149,"score_gpt":0.37298388317416625,"score_spread":0.34187174382685137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749476,0.017409865,0.00018432205,0.0061909854,0.0004314505,0.0003415618,0.0002139846,0.000060623926,0.00021964224],"genre_scores_gemma":[0.99505675,0.0012418915,0.0029492816,0.00045249166,0.0000190969,0.00001660629,0.000010685865,0.000009049291,0.00024416464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988174,0.00014151713,0.00032498458,0.00034215604,0.000038835547,0.00033512572],"domain_scores_gemma":[0.9996204,0.00006193175,0.00006110463,0.00018974402,0.000032809385,0.000034002936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003525383,0.00015756945,0.00039155412,0.0001621801,0.000050115734,0.000032228687,0.00023342868,0.00027471493,0.000249135],"category_scores_gemma":[0.0000169542,0.00012397734,0.000047074376,0.0005936306,0.00024459156,0.000051091927,0.00013574709,0.00020306856,0.000018239669],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014509699,0.0012036079,0.5821712,0.00066870556,0.0009863024,0.000027867798,0.0006519348,0.0000017061295,0.36370158,0.012429741,0.014711421,0.023300853],"study_design_scores_gemma":[0.0040808003,0.0033399279,0.35760558,0.00065007136,0.00026946512,0.000114106304,0.0017720155,0.0000068312047,0.33031228,0.0022153275,0.29874766,0.0008859349],"about_ca_topic_score_codex":0.00034338754,"about_ca_topic_score_gemma":0.00015923497,"teacher_disagreement_score":0.28403625,"about_ca_system_score_codex":0.000042009488,"about_ca_system_score_gemma":0.00013507812,"threshold_uncertainty_score":0.5055649},"labels":[],"label_agreement":null},{"id":"W4405139084","doi":"10.2147/jir.s478529","title":"Assessing Functional Similarity of Biosimilar ABP 654 and Ustekinumab in Samples from Patients with Crohn’s Disease","year":2024,"lang":"en","type":"article","venue":"Journal of Inflammation Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"Amgen","keywords":"Ustekinumab; Biosimilar; Crohn's disease; Medicine; Crohn disease; Similarity (geometry); Disease; Internal medicine; Immunology; Infliximab; Artificial intelligence; Computer science","score_opus":0.0883939579232651,"score_gpt":0.374831963070583,"score_spread":0.2864380051473179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405139084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948235,0.002146428,0.0007643957,0.0017811969,0.00018352033,0.0001462679,0.00004421973,0.000005710326,0.000104723746],"genre_scores_gemma":[0.9983446,0.00010717555,0.0013585148,0.000026260803,0.00007275727,0.0000027974856,0.000017227341,0.000008439978,0.00006225307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982871,0.00056066294,0.00053208997,0.00016973913,0.00024304187,0.0002073667],"domain_scores_gemma":[0.99805814,0.001052154,0.00014194724,0.000114081864,0.0005731649,0.00006052518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018122853,0.0000996731,0.00024646925,0.0004988773,0.00008810449,0.000101853446,0.000116579955,0.00014861004,0.00049781287],"category_scores_gemma":[0.00068658544,0.000066271634,0.00006321446,0.00035717376,0.0003266719,0.00031175403,0.00006517658,0.0006837024,0.0000038066185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048218905,0.00064369245,0.77799284,0.00061724416,0.0008241017,0.00027856315,0.00076459243,0.0001493023,0.10083772,0.0025689732,0.0054513724,0.10504968],"study_design_scores_gemma":[0.0010642572,0.00014087243,0.98542136,0.00049007183,0.000045648976,0.000004990009,0.00018525615,0.00022155362,0.007441419,0.0021823624,0.002718617,0.000083584855],"about_ca_topic_score_codex":0.000031741572,"about_ca_topic_score_gemma":0.000024051104,"teacher_disagreement_score":0.2074285,"about_ca_system_score_codex":0.00007563168,"about_ca_system_score_gemma":0.00026564475,"threshold_uncertainty_score":0.5450702},"labels":[],"label_agreement":null},{"id":"W4405181189","doi":"10.1158/1538-8514.cancerchem24-a001","title":"Abstract A001: Navigating the future of therapeutic development: innovations in safety and efficacy through advanced research methodologies and nanotechnology","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacogenomics; Risk analysis (engineering); SAFER; Drug delivery; Computer science; Medicine; Nanotechnology; Pharmacology","score_opus":0.10169475308274675,"score_gpt":0.42888031368134283,"score_spread":0.32718556059859605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5367224,0.43080854,0.006585363,0.024557559,0.00047875728,0.0005317384,0.000023298626,0.00008152736,0.00021076071],"genre_scores_gemma":[0.97602564,0.012144174,0.010691396,0.0010039677,0.000018149487,0.00003595849,0.0000059691574,0.000023102133,0.00005161776],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984966,0.00041848648,0.00036392556,0.0003241561,0.000068027184,0.00032878475],"domain_scores_gemma":[0.9987376,0.0008771258,0.000059508602,0.00022364587,0.0000936799,0.000008484093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013005829,0.0001611977,0.00027081202,0.0000965303,0.00018486663,0.000025690693,0.00020547197,0.00035677562,0.000030767333],"category_scores_gemma":[0.00005066108,0.000104411454,0.000035912228,0.00075894035,0.00082804955,0.000048934337,0.00013818947,0.001138819,0.000001338903],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007520642,0.000018654215,0.00009446761,0.00005293475,0.00020315852,0.000004049065,0.0010602128,0.0000056148897,0.3704331,0.015822284,0.000004773778,0.6122256],"study_design_scores_gemma":[0.0010306062,0.00015936796,0.013665456,0.00039409415,0.00009479468,0.0000306571,0.0022113852,0.000038524453,0.6588185,0.022427572,0.3008163,0.00031275794],"about_ca_topic_score_codex":0.000039269424,"about_ca_topic_score_gemma":0.000048153608,"teacher_disagreement_score":0.6119128,"about_ca_system_score_codex":0.000044768185,"about_ca_system_score_gemma":0.00011980856,"threshold_uncertainty_score":0.4947665},"labels":[],"label_agreement":null},{"id":"W4405352415","doi":"10.18433/j37305","title":"13th Canadian Society for Pharmaceutical Sciences (CSPS) Annual Meeting and AFPC's First Annual Canadian Pharmacy Education and Research Conference (CPERC), Vancouver, BC, Canada. International Symposium: New Frontiers in Pharmaceutical Sciences","year":2010,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical sciences; Pharmacy; Library science; Political science; Medicine; Pharmacology; Law; Computer science","score_opus":0.23286956596967853,"score_gpt":0.5658636532000836,"score_spread":0.332994087230405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405352415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9095875,0.032569505,0.00011781022,0.034245346,0.011193261,0.0016794612,0.0014219899,0.000022876986,0.009162259],"genre_scores_gemma":[0.98472035,0.009223717,0.0031085077,0.0020022895,0.00024330815,0.000033747372,0.000015563463,0.000020032501,0.00063251075],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971819,0.00032011996,0.0005451426,0.000683143,0.00030923716,0.00096049247],"domain_scores_gemma":[0.99770427,0.00072146597,0.00016745429,0.00013452671,0.0005162947,0.00075596594],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004297927,0.00026429034,0.00045756667,0.00072874845,0.0012641813,0.00065685745,0.0017705056,0.00021682303,0.0020086726],"category_scores_gemma":[0.00063330756,0.00023527419,0.000079208985,0.0008620591,0.0019317684,0.0011860383,0.00039729924,0.0010871423,8.271743e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015054591,0.00011499377,0.399471,0.00005789424,0.00018071222,0.0000082165525,0.0006358238,0.0000075793782,0.022224749,0.00042767668,0.52149135,0.055229444],"study_design_scores_gemma":[0.001378845,0.000032978023,0.045446277,0.00022807685,0.00009657111,0.00004812771,0.0029268502,0.0012099536,0.01622287,0.0011917697,0.9306951,0.00052255165],"about_ca_topic_score_codex":0.96042603,"about_ca_topic_score_gemma":0.9861942,"teacher_disagreement_score":0.40920377,"about_ca_system_score_codex":0.0003569673,"about_ca_system_score_gemma":0.010576533,"threshold_uncertainty_score":0.99890363},"labels":[],"label_agreement":null},{"id":"W4405750458","doi":"10.1016/j.jval.2024.10.2187","title":"HTA362 The Cost of Innovation: Evaluating the Evolution of Willingness-to-Pay for CAR-T Therapies in Germany","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Network for Business Sustainability","funders":"","keywords":"Willingness to pay; Business; Economics; Marketing; Industrial organization; Microeconomics","score_opus":0.10340659088591199,"score_gpt":0.4114694174890013,"score_spread":0.3080628266030893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405750458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9174209,0.027326947,0.011399772,0.039922826,0.0014922083,0.0021862355,0.00009436141,0.000024365318,0.00013235355],"genre_scores_gemma":[0.99803245,0.00010068518,0.0011586439,0.00046076905,0.000036862915,0.000055942975,0.000003738636,0.0000070037654,0.00014391654],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9984166,0.00058081356,0.00060994644,0.00015085115,0.00004534753,0.00019644998],"domain_scores_gemma":[0.99840796,0.0011848807,0.000122008896,0.00016955072,0.00010977196,0.0000058550922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049778745,0.000074115174,0.00020758488,0.0001288383,0.0000697804,0.0000056313593,0.00015133688,0.0000980742,0.000022142449],"category_scores_gemma":[0.0003718203,0.000035929548,0.000039396644,0.0009964705,0.00012582558,0.000023666906,0.000029392382,0.00023512897,0.0000018995341],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074440136,0.00030102968,0.028264133,0.0019175283,0.00025954688,8.986416e-7,0.015292407,0.004285468,0.22258799,0.45092627,0.0019361177,0.2734842],"study_design_scores_gemma":[0.0050234236,0.0065616574,0.5394963,0.005755268,0.00018679097,0.00004798871,0.01197931,0.093894064,0.048435755,0.1632821,0.12441872,0.00091864786],"about_ca_topic_score_codex":0.0010789421,"about_ca_topic_score_gemma":0.00006675741,"teacher_disagreement_score":0.51123214,"about_ca_system_score_codex":0.000109414555,"about_ca_system_score_gemma":0.00032148705,"threshold_uncertainty_score":0.17252418},"labels":[],"label_agreement":null},{"id":"W4405915963","doi":"10.1016/j.jor.2024.12.045","title":"Clinical evaluation of therapeutic efficacy of Teriparatide in osteoporotic patients with vertebral degeneration","year":2024,"lang":"en","type":"article","venue":"Journal of Orthopaedics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"IMRIS (Canada)","funders":"","keywords":"Medicine; Degeneration (medical); Osteoporosis; Pathology","score_opus":0.04480320940096454,"score_gpt":0.36182511585919114,"score_spread":0.3170219064582266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405915963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947791,0.0033418133,0.00072093063,0.00017318568,0.0007475351,0.0001569814,0.000006816789,0.0000027583542,0.00007088384],"genre_scores_gemma":[0.99861974,0.00007841517,0.0011467005,0.00006712037,0.000047120408,8.6669803e-7,0.0000075548537,0.0000069334296,0.000025556817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809664,0.00060708704,0.0009182464,0.00010361767,0.00016824127,0.000106177446],"domain_scores_gemma":[0.998827,0.00029511514,0.00034929672,0.00010130544,0.0004073565,0.000019949632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026673346,0.0000873377,0.00034899882,0.00015793664,0.0000140152015,0.0000062769336,0.000091254355,0.00016140386,0.00014181834],"category_scores_gemma":[0.0002906721,0.000054039265,0.00015445915,0.00021791762,0.00015610605,0.00008850418,0.000014696072,0.00031100202,0.0000021221733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012010813,0.0011342315,0.56425005,0.00010332619,0.0006261892,0.000008760249,0.00029989117,0.0001368987,0.014741529,0.00038754987,0.0004609386,0.41664958],"study_design_scores_gemma":[0.0075344495,0.0037725198,0.96900535,0.0005615717,0.0011359054,0.000037725393,0.000072896015,0.0012836406,0.014612074,0.0004268909,0.0014019185,0.00015506637],"about_ca_topic_score_codex":0.0000022008426,"about_ca_topic_score_gemma":0.000012053064,"teacher_disagreement_score":0.41649452,"about_ca_system_score_codex":0.000029727606,"about_ca_system_score_gemma":0.00026254286,"threshold_uncertainty_score":0.22036572},"labels":[],"label_agreement":null},{"id":"W4406163584","doi":"","title":"The safety of biological preparations. Part 2. Safety issues of biosimilars","year":2018,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Safety profile; Risk analysis (engineering); Business; Medicine; Pharmacology; Biotechnology; Biology; Adverse effect","score_opus":0.27501726295372514,"score_gpt":0.562361806301287,"score_spread":0.2873445433475618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406163584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6933105,0.23889676,0.002285047,0.009001416,0.006091391,0.0028147232,0.0014365002,0.00012901431,0.04603468],"genre_scores_gemma":[0.9448613,0.051611997,0.0010369665,0.0006025789,0.00018290113,0.000018082825,0.000026633086,0.000026599651,0.0016329653],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964182,0.0011195712,0.0015006615,0.0003914172,0.00015909658,0.0004110579],"domain_scores_gemma":[0.99631757,0.0012462315,0.0010934036,0.0006546788,0.00061656826,0.000071552975],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031502144,0.00027867948,0.000968674,0.00022678464,0.0004742894,0.00011266817,0.002296803,0.00037154346,0.01327839],"category_scores_gemma":[0.0011005014,0.00016623348,0.00031356316,0.00071687764,0.0021493814,0.00037196756,0.00088907336,0.00037443792,0.000021175923],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028850944,0.00055300986,0.11830929,0.000049084734,0.0011345099,0.0000028392633,0.00018466663,0.0000043543773,0.6493714,0.0023505525,0.19475967,0.030395571],"study_design_scores_gemma":[0.00048285155,0.0001049969,0.16066805,0.00017885822,0.00011384573,0.00001071675,0.00009067692,0.000007418786,0.46443695,0.003923337,0.3697651,0.00021717693],"about_ca_topic_score_codex":0.00012117974,"about_ca_topic_score_gemma":0.00003878604,"teacher_disagreement_score":0.2515508,"about_ca_system_score_codex":0.000032124375,"about_ca_system_score_gemma":0.000113616865,"threshold_uncertainty_score":0.98762363},"labels":[],"label_agreement":null},{"id":"W4406201240","doi":"10.1002/alz.092369","title":"A‐T+ PET participants in preclinical AD: Clinical progression and concordance with fluid markers","year":2024,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; McGill University; Douglas Mental Health University Institute","funders":"","keywords":"Concordance; Medicine; Psychology; Internal medicine; Oncology","score_opus":0.08326197567222347,"score_gpt":0.4106226141933638,"score_spread":0.32736063852114033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406201240","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42386213,0.56891817,0.0002546424,0.0031246443,0.0017034187,0.00067659986,0.000026044052,0.00015014886,0.0012842166],"genre_scores_gemma":[0.99417436,0.0009552456,0.004294111,0.00042644568,0.000031572206,0.00003407534,0.000011231163,0.000017327877,0.000055618584],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979407,0.00047086022,0.0005537515,0.0005473849,0.000050225874,0.0004370538],"domain_scores_gemma":[0.9991435,0.00048486312,0.000058649934,0.00021958904,0.000025462787,0.000067980596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012960492,0.00017991955,0.00034230718,0.00005323898,0.000060841256,0.00003860549,0.00013379916,0.00018555309,0.00052877166],"category_scores_gemma":[0.00008962549,0.00011945572,0.00007465853,0.00015837215,0.00056646654,0.00009026888,0.000121803256,0.00044266207,0.00008507671],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016138632,0.00048017257,0.14127523,0.000034250137,0.013200733,0.00026639496,0.00009791793,3.5381464e-7,0.0053182137,0.00078021776,0.012138544,0.8247941],"study_design_scores_gemma":[0.0065891664,0.0046440684,0.46604848,0.0012194589,0.026118524,0.00028847,0.00023369405,0.0014798373,0.032214325,0.0011244417,0.45865852,0.0013810139],"about_ca_topic_score_codex":0.000007818457,"about_ca_topic_score_gemma":0.000052450145,"teacher_disagreement_score":0.8234131,"about_ca_system_score_codex":0.0000027416386,"about_ca_system_score_gemma":0.00006780905,"threshold_uncertainty_score":0.5789679},"labels":[],"label_agreement":null},{"id":"W4406450127","doi":"10.1016/s1541-9800(10)70394-x","title":"10.1016/s1541-9800(10)70394-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Biomarker; Internal medicine; Medicine; Environmental science; Biology","score_opus":0.009610656548735141,"score_gpt":0.21086357194718275,"score_spread":0.2012529153984476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406450127","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016387593,0.0005168627,0.000002829893,0.0013155477,0.0000065477675,0.00014404453,0.000040850828,0.00011323905,0.9976962],"genre_scores_gemma":[0.000080379614,0.0000010933712,0.00043333304,0.00033013686,0.00006496466,0.0000102501435,0.000026275708,0.000018012264,0.99903554],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988273,0.00016899541,0.00023179846,0.0003182729,0.00003567309,0.0004179922],"domain_scores_gemma":[0.99940777,0.000117569834,0.00002939749,0.0003359051,0.000043225784,0.00006615126],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00026782014,0.00018342884,0.00028335734,0.00006506098,0.000115510724,0.000019239988,0.00027231887,0.00028776386,0.99961025],"category_scores_gemma":[0.00007305265,0.00014787723,0.000117749834,0.00019603274,0.00013841547,0.000041816173,0.00006266696,0.00022152509,0.9970906],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016687244,0.0000641548,7.381628e-8,0.0000028130282,0.000055026958,0.0000028498912,0.0000046393234,7.532911e-7,0.0030968105,0.0000029247667,0.5768024,0.41980073],"study_design_scores_gemma":[0.00038763662,0.0002979024,0.00003457369,0.000012853607,0.000050867602,0.000023855708,9.96973e-7,0.0000074575028,0.005832176,0.000025637573,0.99311143,0.00021458881],"about_ca_topic_score_codex":0.000014554466,"about_ca_topic_score_gemma":2.2482207e-7,"teacher_disagreement_score":0.41958615,"about_ca_system_score_codex":0.000022119017,"about_ca_system_score_gemma":0.000022826518,"threshold_uncertainty_score":0.60302585},"labels":[],"label_agreement":null},{"id":"W4406466075","doi":"10.1016/s1553-3212(07)70050-x","title":"10.1016/s1553-3212(07)70050-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Postmarketing surveillance; Medicine; Pharmacology; Adverse effect","score_opus":0.00937191591486463,"score_gpt":0.21166875381272537,"score_spread":0.20229683789786074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406466075","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021359682,0.00051302544,0.0000038081066,0.0013998231,0.0000070677734,0.00014461459,0.0000358617,0.00011272668,0.9975695],"genre_scores_gemma":[0.00011935805,0.0000012146738,0.00044961102,0.00039439485,0.00006328697,0.000009729145,0.000021283287,0.000017068562,0.9989241],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988828,0.00015529664,0.00022018237,0.00030259133,0.00003375076,0.00040543717],"domain_scores_gemma":[0.99944854,0.00010691152,0.000027241795,0.00031710128,0.000036550737,0.000063679225],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025418145,0.00017338996,0.0002690517,0.00005907151,0.000109797256,0.000017961373,0.00025841684,0.00026847204,0.9994363],"category_scores_gemma":[0.000060772887,0.00013965956,0.00011029935,0.00016834239,0.00013068256,0.000040455427,0.000057738638,0.00023104191,0.9974958],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000140051,0.00006500749,1.167624e-7,0.0000027398924,0.000055155924,0.000003036576,0.0000055075666,9.0576555e-7,0.00323586,0.000003879631,0.5012872,0.4952005],"study_design_scores_gemma":[0.00035351783,0.00025951094,0.00004521724,0.000012168896,0.000046159763,0.000026906098,0.0000010330943,0.0000063776297,0.0051357253,0.000026052567,0.993883,0.00020431605],"about_ca_topic_score_codex":0.000016047215,"about_ca_topic_score_gemma":1.9549512e-7,"teacher_disagreement_score":0.49499622,"about_ca_system_score_codex":0.00002099909,"about_ca_system_score_gemma":0.000020962761,"threshold_uncertainty_score":0.56951517},"labels":[],"label_agreement":null},{"id":"W4406473343","doi":"10.1016/s1541-9800(08)70342-9","title":"10.1016/s1541-9800(08)70342-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunogenicity; Medicine; Pharmacology; Immunology; Antigen","score_opus":0.00913122987995965,"score_gpt":0.20965189393067324,"score_spread":0.2005206640507136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406473343","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017473062,0.0005299435,0.00000342859,0.0013874087,0.0000070012866,0.0001939536,0.000038708135,0.00011284466,0.997552],"genre_scores_gemma":[0.0000920178,0.0000012706803,0.0004642349,0.00037770558,0.000061362385,0.000015217221,0.000021859205,0.00001713281,0.99894917],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888223,0.00015635192,0.00022076849,0.00030396896,0.00003349039,0.00040321532],"domain_scores_gemma":[0.99944514,0.00010852111,0.000026953678,0.00031923674,0.00003684706,0.000063318534],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025261592,0.00017397104,0.0002697841,0.000062778534,0.000110003275,0.000018030314,0.00026000448,0.00026923823,0.99930304],"category_scores_gemma":[0.000059493468,0.00014002755,0.00011129645,0.00019246792,0.00013099542,0.0000404085,0.00005819116,0.00023209148,0.99644625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012717304,0.000060388644,1.260927e-7,0.000002636625,0.000052280357,0.0000028164231,0.0000050524204,8.2750717e-7,0.0033996732,0.000003473974,0.49576816,0.5005774],"study_design_scores_gemma":[0.0003712918,0.0002550811,0.000043439763,0.000012585128,0.00004685208,0.00002609715,0.0000010127834,0.0000066594316,0.0059556053,0.000027298867,0.9930495,0.00020458874],"about_ca_topic_score_codex":0.00001418593,"about_ca_topic_score_gemma":1.9945426e-7,"teacher_disagreement_score":0.5003728,"about_ca_system_score_codex":0.00002043255,"about_ca_system_score_gemma":0.000020640335,"threshold_uncertainty_score":0.5710158},"labels":[],"label_agreement":null},{"id":"W4406505271","doi":"10.1016/s0765-2046(98)80159-7","title":"10.1016/s0765-2046(98)80159-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Beacon; Tuberculosis; Drug; Molecular beacon; Medicine; Computer science; Pharmacology; Biology; Pathology; Genetics; Telecommunications","score_opus":0.0113738391525474,"score_gpt":0.22242719644164313,"score_spread":0.21105335728909574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406505271","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018433614,0.0004952348,0.000002679828,0.0014074031,0.0000064649744,0.00013952877,0.000032337728,0.00009129215,0.9976407],"genre_scores_gemma":[0.00010185799,0.0000010332111,0.00046484655,0.00036015103,0.00006365146,0.00000937518,0.000017892145,0.000016261049,0.9989649],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989282,0.00014866069,0.00021126446,0.00029210246,0.00003308078,0.00038673205],"domain_scores_gemma":[0.9994683,0.00010017453,0.000025811498,0.0003066668,0.000037254795,0.000061743034],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00024134782,0.00016711607,0.00026888534,0.00006066645,0.000102200196,0.00001739531,0.0002481186,0.0002606482,0.99946415],"category_scores_gemma":[0.00005380431,0.00013476818,0.00010509877,0.00018769584,0.00012347152,0.000038246275,0.000055012923,0.00022296002,0.99692893],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012459744,0.00006186702,1.2244487e-7,0.0000027142914,0.000054388296,0.0000026917946,0.0000051892516,7.707886e-7,0.0030155792,0.0000037014095,0.53848124,0.45824713],"study_design_scores_gemma":[0.00034327325,0.00024196443,0.000053024505,0.000012152104,0.000046869653,0.000021388807,9.880218e-7,0.0000062222316,0.0052442257,0.000029959105,0.99380296,0.00019699267],"about_ca_topic_score_codex":0.000018204311,"about_ca_topic_score_gemma":2.531593e-7,"teacher_disagreement_score":0.45805013,"about_ca_system_score_codex":0.000020679041,"about_ca_system_score_gemma":0.0000202961,"threshold_uncertainty_score":0.54956865},"labels":[],"label_agreement":null},{"id":"W4406535520","doi":"10.1155/ijcp/2248512","title":"Understanding Community Pharmacists’ Knowledge, Attitudes, and Practices Regarding Biosimilar Drugs: A Cross‐Sectional Survey","year":2025,"lang":"en","type":"article","venue":"International Journal of Clinical Practice","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Biosimilar; Cross-sectional study; Family medicine; Internal medicine; Pathology","score_opus":0.3979202703520576,"score_gpt":0.582202450166058,"score_spread":0.18428217981400036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406535520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7068896,0.02162576,0.04570024,0.03221779,0.05521678,0.00065533933,0.0002773879,0.0001361607,0.13728091],"genre_scores_gemma":[0.99133915,0.0018541254,0.0029160604,0.0024848673,0.0003128158,0.0000012030928,0.00001089836,0.000009889932,0.0010709697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992681,0.005060735,0.0016186914,0.0002413176,0.00019563918,0.00020257455],"domain_scores_gemma":[0.9632755,0.032491542,0.0022731188,0.00018778008,0.0017003826,0.00007168882],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.020293277,0.00017451576,0.00047424727,0.00024340424,0.00033331965,0.00023086955,0.00068885117,0.00036493948,0.00020011718],"category_scores_gemma":[0.059545647,0.00014149882,0.00025206644,0.00020568268,0.0006012557,0.00083648716,0.00034686303,0.0024559142,0.000016671711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0088019455,0.0027714958,0.9379354,0.00006253338,0.006213562,0.00008263469,0.00019719431,0.000007522363,0.0015408864,0.0059895935,0.024961269,0.011435965],"study_design_scores_gemma":[0.0065245894,0.00047970665,0.724235,0.00025429213,0.00038710143,0.0012536863,0.000615442,0.00007096405,0.0010428982,0.003842623,0.26098737,0.0003063484],"about_ca_topic_score_codex":0.00004347307,"about_ca_topic_score_gemma":0.000019544996,"teacher_disagreement_score":0.28444955,"about_ca_system_score_codex":0.00015689475,"about_ca_system_score_gemma":0.0003465119,"threshold_uncertainty_score":0.99984545},"labels":[],"label_agreement":null},{"id":"W4406545871","doi":"10.1016/s1541-9800(12)70314-9","title":"10.1016/s1541-9800(12)70314-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Tocilizumab; Medicine; Computational biology; Internal medicine; Biology; Rheumatoid arthritis","score_opus":0.009857382314568636,"score_gpt":0.20762953871421927,"score_spread":0.19777215639965062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406545871","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001624928,0.00042897707,0.0000033438532,0.0012872756,0.0000069869566,0.00014523655,0.00003494922,0.00011123956,0.9978195],"genre_scores_gemma":[0.00010939412,0.0000011962302,0.0004499176,0.0003897983,0.00006172897,0.000009704132,0.00002115388,0.000017116945,0.99894],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888223,0.00015778092,0.00022038331,0.00030272495,0.000033794593,0.00040308104],"domain_scores_gemma":[0.99945444,0.000105965686,0.00002688885,0.00031821613,0.000031871663,0.00006264004],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002540006,0.00017364303,0.00026878412,0.00006183684,0.00010993411,0.00001793812,0.00025825796,0.00026608614,0.9992191],"category_scores_gemma":[0.00005982489,0.0001397748,0.000109980305,0.00015142847,0.00013151854,0.000040134863,0.0000580689,0.00022974354,0.9950936],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013784785,0.00006104925,1.5907148e-7,0.0000026521282,0.00005314897,0.000002836726,0.0000053319104,7.611484e-7,0.0034068672,0.000003178052,0.5083975,0.48792866],"study_design_scores_gemma":[0.00036848377,0.00027141135,0.00005655353,0.000012452043,0.00004699894,0.000026063406,9.688594e-7,0.0000062478803,0.0054582013,0.000027860404,0.9935205,0.00020424357],"about_ca_topic_score_codex":0.00001732283,"about_ca_topic_score_gemma":3.5644896e-7,"teacher_disagreement_score":0.48772442,"about_ca_system_score_codex":0.000020658304,"about_ca_system_score_gemma":0.000020300738,"threshold_uncertainty_score":0.5699851},"labels":[],"label_agreement":null},{"id":"W4406545994","doi":"10.1016/s1541-9800(12)70188-6","title":"10.1016/s1541-9800(12)70188-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Tumor necrosis factor alpha; Medicine; Internal medicine","score_opus":0.009876707573613775,"score_gpt":0.20780807914667004,"score_spread":0.19793137157305626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406545994","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001594905,0.00042867401,0.0000036024783,0.0012919232,0.0000069392645,0.00014498457,0.00003516663,0.000111091016,0.9978181],"genre_scores_gemma":[0.00010165807,0.0000011774089,0.00047332284,0.0003906233,0.00006217585,0.000009633968,0.000021041347,0.000017080522,0.9989233],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888456,0.00015674449,0.00022005835,0.00030260222,0.00003374471,0.000402304],"domain_scores_gemma":[0.9994545,0.000106733794,0.000026836715,0.00031696842,0.000031866683,0.00006310348],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025242867,0.00017318288,0.0002674623,0.00006169367,0.00011029834,0.000017912216,0.00025781087,0.00026557106,0.9992393],"category_scores_gemma":[0.000059233374,0.00013946804,0.00010937523,0.00015180068,0.0001335531,0.000040034185,0.000057927085,0.00022691074,0.99515754],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014035695,0.00006151407,1.4808835e-7,0.0000026821788,0.000054532327,0.0000027844935,0.000005433728,7.513621e-7,0.0034355079,0.0000033705805,0.5026789,0.49361405],"study_design_scores_gemma":[0.00036428464,0.0002776709,0.00005313531,0.000012602332,0.000047214355,0.000025956186,9.51296e-7,0.000006261304,0.0055109994,0.000028153901,0.99346906,0.00020372718],"about_ca_topic_score_codex":0.000016944521,"about_ca_topic_score_gemma":3.4370314e-7,"teacher_disagreement_score":0.49341032,"about_ca_system_score_codex":0.00002059718,"about_ca_system_score_gemma":0.000020571786,"threshold_uncertainty_score":0.56873417},"labels":[],"label_agreement":null},{"id":"W4406546592","doi":"10.1016/s1541-9800(10)70628-1","title":"10.1016/s1541-9800(10)70628-1","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Biosimilar; Agency (philosophy); Medicine; Internal medicine; Philosophy; Epistemology","score_opus":0.009582615820716445,"score_gpt":0.21071425739873179,"score_spread":0.20113164157801533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406546592","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017251539,0.0005026506,0.0000027527806,0.0012912073,0.000006414154,0.00014639668,0.00004129872,0.00011252097,0.99772424],"genre_scores_gemma":[0.00009029417,0.0000011363062,0.000423458,0.00033028037,0.00006544394,0.000010282576,0.000026702353,0.00001766463,0.99903476],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988316,0.00016617503,0.00023109862,0.00031620858,0.000035459547,0.00041941952],"domain_scores_gemma":[0.9994148,0.00011403338,0.000029410132,0.00033267718,0.000043390468,0.0000656883],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025897453,0.00018232013,0.0002825839,0.00006544086,0.000115520816,0.000018829529,0.000270446,0.00028592788,0.9995975],"category_scores_gemma":[0.00006804104,0.00014739552,0.000117368916,0.00019068172,0.00013928319,0.000041649957,0.00006282249,0.00022296149,0.9970887],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016846025,0.00006468753,9.281286e-8,0.0000029049074,0.000055181485,0.0000028905608,0.0000047560798,7.250344e-7,0.0033429384,0.0000030300382,0.5850643,0.41129005],"study_design_scores_gemma":[0.00039023816,0.0002976063,0.000042477433,0.000012569891,0.00005091167,0.00002409581,9.840635e-7,0.0000068716804,0.0062471377,0.000023913093,0.9926895,0.00021368085],"about_ca_topic_score_codex":0.000015328218,"about_ca_topic_score_gemma":2.2659587e-7,"teacher_disagreement_score":0.41107637,"about_ca_system_score_codex":0.000022231388,"about_ca_system_score_gemma":0.000022892047,"threshold_uncertainty_score":0.60106146},"labels":[],"label_agreement":null},{"id":"W4406547396","doi":"10.1016/s1541-9800(05)70520-2","title":"10.1016/s1541-9800(05)70520-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Etanercept; Medicine; Internal medicine; Rheumatoid arthritis","score_opus":0.009479817351905088,"score_gpt":0.2114260403328414,"score_spread":0.2019462229809363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406547396","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016584978,0.00046621714,0.000003971472,0.0015129076,0.000007908712,0.0001443967,0.000029820585,0.000111785725,0.99755716],"genre_scores_gemma":[0.00009233416,0.0000011333516,0.0005541009,0.0004375848,0.000060111663,0.000009057456,0.000022280543,0.000016835322,0.99880654],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888766,0.00015689834,0.00021859487,0.0003007345,0.000033534594,0.00040256488],"domain_scores_gemma":[0.99947876,0.000083046856,0.000026700478,0.0003121837,0.000036361915,0.0000629262],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025135893,0.00017265226,0.00026765573,0.00006070353,0.000109523884,0.000017905137,0.0002553273,0.000266593,0.99905294],"category_scores_gemma":[0.000059947997,0.00013874737,0.00011063795,0.0001873768,0.00013106843,0.000039827013,0.00005654982,0.00022853017,0.99428076],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008816879,0.000057386,7.797198e-8,0.0000024671288,0.000047611953,0.0000031929137,0.0000047133703,7.438446e-7,0.0036528953,0.00000388574,0.52382606,0.4723128],"study_design_scores_gemma":[0.00036486977,0.00027871045,0.000047530742,0.000012465663,0.000046099613,0.000032632586,9.890326e-7,0.000006566253,0.006261515,0.000027585382,0.9927191,0.00020191474],"about_ca_topic_score_codex":0.000014044138,"about_ca_topic_score_gemma":1.823082e-7,"teacher_disagreement_score":0.4721109,"about_ca_system_score_codex":0.0000204206,"about_ca_system_score_gemma":0.00002021984,"threshold_uncertainty_score":0.56579536},"labels":[],"label_agreement":null},{"id":"W4406551040","doi":"10.1016/s1541-9800(09)70188-7","title":"10.1016/s1541-9800(09)70188-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Etanercept; Medicine; Political science; Intensive care medicine; Internal medicine; Tumor necrosis factor alpha","score_opus":0.009349754625385428,"score_gpt":0.21086569483836126,"score_spread":0.20151594021297584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406551040","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001873432,0.00051489077,0.000003706263,0.0013980663,0.0000070243814,0.00014557513,0.000036628375,0.00011179469,0.99759495],"genre_scores_gemma":[0.00007944426,0.0000011361176,0.00049759663,0.00029562402,0.00006420573,0.000009759953,0.000020736392,0.00001709235,0.9990144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988819,0.0001582203,0.00022038215,0.00030389868,0.000033704586,0.0004019083],"domain_scores_gemma":[0.999452,0.00010533896,0.00002624716,0.0003174072,0.00003585495,0.000063128624],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002563647,0.00017324634,0.00026772372,0.00006143423,0.00011428672,0.000018501138,0.00025597922,0.0002685307,0.999187],"category_scores_gemma":[0.00005921551,0.00013955923,0.00011058799,0.00018502203,0.00013351162,0.000039139253,0.000057907564,0.0002295437,0.99600804],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012306758,0.000060038663,1.1272615e-7,0.0000025684328,0.000052114498,0.0000027293938,0.000004995022,7.892621e-7,0.0035845484,0.0000037760203,0.44435638,0.5518089],"study_design_scores_gemma":[0.00036047443,0.00026245587,0.000040745075,0.000012403236,0.00004746063,0.00002643809,9.818609e-7,0.00000697375,0.0064092637,0.000028094066,0.992601,0.00020371936],"about_ca_topic_score_codex":0.000016723134,"about_ca_topic_score_gemma":2.3132655e-7,"teacher_disagreement_score":0.55160517,"about_ca_system_score_codex":0.000020491123,"about_ca_system_score_gemma":0.00002066408,"threshold_uncertainty_score":0.56910604},"labels":[],"label_agreement":null},{"id":"W4406578690","doi":"10.1016/s1541-9800(11)70654-8","title":"10.1016/s1541-9800(11)70654-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Allele; Genetics; Computational biology; Biology; Gene","score_opus":0.009056394119286867,"score_gpt":0.20966101764385858,"score_spread":0.2006046235245717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406578690","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002984624,0.00042880137,0.0000035580838,0.0015897832,0.0000075161824,0.00014707091,0.000037970553,0.00011400799,0.9973728],"genre_scores_gemma":[0.00012039522,9.827304e-7,0.0004978111,0.00036235686,0.00006362642,0.00000987448,0.000021366126,0.000017046143,0.99890655],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888,0.00016037107,0.00022102502,0.00030353054,0.000033877946,0.00040116286],"domain_scores_gemma":[0.9994358,0.00011639968,0.000026907333,0.00032184675,0.000036753296,0.00006229022],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00026106945,0.00017294698,0.00026721958,0.00006222509,0.000111963185,0.000018291177,0.00026430274,0.00026969868,0.99923426],"category_scores_gemma":[0.000063116,0.0001393967,0.00011005384,0.00018962109,0.00013708821,0.000039191364,0.000059099453,0.00019937167,0.994512],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010203629,0.000065222725,2.689831e-7,0.0000029568337,0.000045794503,0.000003054937,0.000005609653,9.4630354e-7,0.0029736082,0.0000048987413,0.5371055,0.4596901],"study_design_scores_gemma":[0.0003559923,0.00020770669,0.000053758733,0.0000125492425,0.00004630282,0.000026085332,0.0000010448788,0.000006635942,0.005507428,0.00002639138,0.9935524,0.00020370597],"about_ca_topic_score_codex":0.000023043887,"about_ca_topic_score_gemma":4.696659e-7,"teacher_disagreement_score":0.4594864,"about_ca_system_score_codex":0.000020394215,"about_ca_system_score_gemma":0.000020519705,"threshold_uncertainty_score":0.56844324},"labels":[],"label_agreement":null},{"id":"W4406578946","doi":"10.1016/s1541-9800(06)71201-7","title":"10.1016/s1541-9800(06)71201-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Etanercept; Phase (matter); Medicine; Internal medicine; Chemistry; Tumor necrosis factor alpha","score_opus":0.009272158118633451,"score_gpt":0.21044059397000303,"score_spread":0.2011684358513696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406578946","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020732924,0.00050886313,0.0000033771191,0.0014245829,0.000005148117,0.00014375737,0.00004055517,0.00010941232,0.997557],"genre_scores_gemma":[0.000100947174,0.0000011949791,0.00043895745,0.000376202,0.00006083324,0.000009328402,0.000027973001,0.000016807468,0.99896777],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988987,0.00015628585,0.00021531098,0.00029740873,0.000033187196,0.00039914568],"domain_scores_gemma":[0.9994496,0.00010307638,0.000026431857,0.0003194982,0.000037241214,0.00006415059],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025855863,0.0001704939,0.00026421636,0.00006118102,0.00010789003,0.00001746774,0.0002568539,0.0002691438,0.9991581],"category_scores_gemma":[0.00006012072,0.00013647636,0.00010740899,0.00017560438,0.00013137756,0.00003973744,0.00005732374,0.00022780344,0.9969702],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009607474,0.00005755788,1.2481871e-7,0.0000024959484,0.00004967226,0.0000022580468,0.000004674941,7.2981044e-7,0.0032778177,0.000003502285,0.5677354,0.4287697],"study_design_scores_gemma":[0.00035363284,0.00022001765,0.000043807777,0.000012238077,0.00004580413,0.000024321476,9.68725e-7,0.000007473787,0.0050118575,0.000027346388,0.9940514,0.00020114669],"about_ca_topic_score_codex":0.0000138641835,"about_ca_topic_score_gemma":1.6338798e-7,"teacher_disagreement_score":0.42856857,"about_ca_system_score_codex":0.000019560546,"about_ca_system_score_gemma":0.000020310765,"threshold_uncertainty_score":0.5565344},"labels":[],"label_agreement":null},{"id":"W4406579323","doi":"10.1016/s1541-9800(11)70567-1","title":"10.1016/s1541-9800(11)70567-1","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Biosimilar; Drug approval; Medicine; Business; Pharmacology; Drug; Internal medicine","score_opus":0.009376585117663799,"score_gpt":0.2105459954395594,"score_spread":0.20116941032189561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579323","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031262086,0.00043094013,0.0000034397349,0.0015157745,0.0000074142067,0.00014675168,0.000039001363,0.00011291124,0.99743116],"genre_scores_gemma":[0.00012598479,9.787004e-7,0.0005042254,0.0003639644,0.000061240775,0.000009630579,0.000022190261,0.00001670229,0.9988951],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888545,0.00016011069,0.00021937076,0.00030221592,0.000033644872,0.00039922894],"domain_scores_gemma":[0.99943817,0.000115763454,0.000026820293,0.00032022689,0.00003691247,0.0000621129],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002586728,0.00017245642,0.00026685838,0.00006131054,0.00010964184,0.000018083376,0.0002629904,0.00026992607,0.99923956],"category_scores_gemma":[0.00006295753,0.0001390589,0.00010895774,0.0001857112,0.00013431004,0.000038625072,0.000058202426,0.00019939015,0.99475706],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010429138,0.00006495698,2.7996452e-7,0.0000029097503,0.00004546101,0.0000029733928,0.0000054661878,9.059354e-7,0.002840798,0.000004510856,0.55473727,0.44219014],"study_design_scores_gemma":[0.00035555943,0.00021187897,0.000054438653,0.000012411112,0.00004614109,0.000025217238,0.0000010707653,0.000006737746,0.005393575,0.000025493275,0.99366426,0.0002032405],"about_ca_topic_score_codex":0.000023211449,"about_ca_topic_score_gemma":4.865262e-7,"teacher_disagreement_score":0.44198692,"about_ca_system_score_codex":0.000019659918,"about_ca_system_score_gemma":0.000020213696,"threshold_uncertainty_score":0.5670657},"labels":[],"label_agreement":null},{"id":"W4406579413","doi":"10.1016/s1541-9800(07)70460-x","title":"10.1016/s1541-9800(07)70460-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Tumor necrosis factor alpha; Medicine; Intensive care medicine; Immunology","score_opus":0.009426016563133403,"score_gpt":0.21152625834978506,"score_spread":0.20210024178665165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579413","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020448519,0.0005106546,0.0000034483633,0.0013667212,0.0000071362074,0.0001446205,0.000037912017,0.00011260008,0.9976124],"genre_scores_gemma":[0.00011103001,0.0000012160489,0.00046135526,0.00038155908,0.000061979925,0.00000975811,0.000021091517,0.000017096569,0.9989349],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888116,0.00015800101,0.00022050958,0.000303448,0.00003383887,0.0004030323],"domain_scores_gemma":[0.99944526,0.00010863236,0.00002691447,0.00031839128,0.000037493377,0.000063336265],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025465686,0.00017360547,0.00026932324,0.000059072358,0.00011060921,0.00001820296,0.00025939275,0.00026891197,0.9994394],"category_scores_gemma":[0.00006234816,0.00013983114,0.00010923579,0.00017424196,0.00013202125,0.000040655737,0.000058490274,0.00023176138,0.997407],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013134169,0.00006300985,1.2903809e-7,0.0000026980772,0.00005381554,0.0000030502129,0.0000050751637,7.986117e-7,0.0031179562,0.0000037238146,0.5044742,0.4921442],"study_design_scores_gemma":[0.00036122507,0.0002592788,0.000045407847,0.000012586185,0.000046819085,0.000027072723,9.836319e-7,0.0000061381875,0.0054726647,0.000029233259,0.99353415,0.00020444786],"about_ca_topic_score_codex":0.000016443713,"about_ca_topic_score_gemma":1.9513706e-7,"teacher_disagreement_score":0.49193975,"about_ca_system_score_codex":0.000020711142,"about_ca_system_score_gemma":0.000021147986,"threshold_uncertainty_score":0.5702148},"labels":[],"label_agreement":null},{"id":"W4406579913","doi":"10.1016/s1541-9800(07)70327-7","title":"10.1016/s1541-9800(07)70327-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Class (philosophy); Test (biology); Latent class model; Computer science; Artificial intelligence; Machine learning; Biology","score_opus":0.009410613518366253,"score_gpt":0.21139509387392555,"score_spread":0.2019844803555593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579913","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021214988,0.0005150599,0.000003234677,0.0015025244,0.000006832502,0.00014468399,0.000037271202,0.00011263308,0.9974656],"genre_scores_gemma":[0.000105486426,0.000001126565,0.000461963,0.0003662356,0.000061686376,0.000009548154,0.000020522062,0.000017089607,0.9989563],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988816,0.00015808693,0.00022097313,0.00030322498,0.000033830973,0.00040232303],"domain_scores_gemma":[0.9994465,0.00010723257,0.000026965738,0.00031881573,0.000037279493,0.00006318729],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000255319,0.00017340215,0.00026938337,0.00005905424,0.00011086138,0.000017966144,0.00025874635,0.00026905903,0.9994606],"category_scores_gemma":[0.00006149145,0.00013963824,0.000111028035,0.00017148706,0.000132193,0.000039581508,0.000057948,0.00023205856,0.9974509],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012956225,0.00006199777,1.1810622e-7,0.0000026743037,0.000052956922,0.0000029880755,0.0000051935194,7.871415e-7,0.0030349393,0.0000036461836,0.52758276,0.46912238],"study_design_scores_gemma":[0.0003597533,0.00025773715,0.000045140245,0.000012493125,0.000046790832,0.000027267522,0.0000010393661,0.0000062711006,0.0054373075,0.000029469487,0.99357253,0.00020417928],"about_ca_topic_score_codex":0.000015977012,"about_ca_topic_score_gemma":1.868606e-7,"teacher_disagreement_score":0.4689182,"about_ca_system_score_codex":0.000020529968,"about_ca_system_score_gemma":0.000020556341,"threshold_uncertainty_score":0.5694282},"labels":[],"label_agreement":null},{"id":"W4406580181","doi":"10.1016/s1541-9800(06)71295-9","title":"10.1016/s1541-9800(06)71295-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Etanercept; Medicine; Internal medicine; Tumor necrosis factor alpha","score_opus":0.009241267710088435,"score_gpt":0.21111526313821388,"score_spread":0.20187399542812545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406580181","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023061728,0.00049497315,0.0000035562084,0.0013977482,0.0000049576624,0.00014541225,0.000037497088,0.00011315639,0.99757206],"genre_scores_gemma":[0.00012569774,0.0000011524533,0.00042525138,0.00039335192,0.000060141727,0.000009725263,0.00002769374,0.00001713249,0.9989399],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998872,0.00015812904,0.00022066143,0.00030322134,0.000033867967,0.0004121367],"domain_scores_gemma":[0.9994451,0.0001073074,0.000026427362,0.00031822672,0.000037354614,0.00006561417],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002549962,0.00017365057,0.00026917114,0.00006261388,0.000110277484,0.000017964692,0.00025882744,0.00026975607,0.999165],"category_scores_gemma":[0.00006215338,0.0001398613,0.000111185436,0.00018805685,0.0001321075,0.000040173367,0.000058122412,0.0002325921,0.99661005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105816594,0.00006504103,1.7942065e-7,0.0000028732939,0.0000557149,0.0000028274444,0.000005377285,8.9452755e-7,0.0033334692,0.000004579835,0.578212,0.41821122],"study_design_scores_gemma":[0.0003580411,0.00022624148,0.000051894862,0.000012552044,0.00004676261,0.000025758018,0.000001011011,0.0000070292376,0.0053578634,0.000030019333,0.9936784,0.00020446014],"about_ca_topic_score_codex":0.000014072292,"about_ca_topic_score_gemma":1.7937134e-7,"teacher_disagreement_score":0.41800675,"about_ca_system_score_codex":0.000020866028,"about_ca_system_score_gemma":0.000021596776,"threshold_uncertainty_score":0.57033783},"labels":[],"label_agreement":null},{"id":"W4406656811","doi":"10.1016/b978-0-443-10303-2.50022-9","title":"10.1016/b978-0-443-10303-2.50022-9","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immune system; Line (geometry); Biology; Immunology; Mathematics","score_opus":0.013885505321999107,"score_gpt":0.20930941002210754,"score_spread":0.19542390470010843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406656811","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.7409683e-7,0.002470217,0.0000019117513,0.0006510509,0.000021980939,0.0003411677,0.00032274018,0.00016235076,0.9960284],"genre_scores_gemma":[4.788187e-7,0.0000049652544,0.00022964198,0.00038092144,0.00019790657,0.000011836442,0.00019451114,0.00009082519,0.9988889],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980769,0.00009426787,0.00049998023,0.00069353275,0.00007684847,0.0005584469],"domain_scores_gemma":[0.99880254,0.0001888739,0.00013614324,0.00068335567,0.00008202966,0.00010705633],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002810521,0.00057578256,0.0008412047,0.00022720796,0.00014033017,0.000030100726,0.0005238929,0.0014955654,0.9993316],"category_scores_gemma":[0.000045861947,0.0004961251,0.000382668,0.00005772899,0.00031026272,0.000035071418,0.00019944689,0.0008851733,0.99657243],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001785905,0.0000311748,3.7548853e-9,0.000010797787,0.00027576572,0.000013369695,0.000002796636,2.3294051e-7,0.00027725144,0.00020158841,0.48969692,0.5093115],"study_design_scores_gemma":[0.00035646517,0.00040534665,9.014623e-7,0.00010931531,0.00028358895,0.000056823228,2.3901214e-7,8.9237403e-7,0.00049435673,0.0006231385,0.9970379,0.00063102326],"about_ca_topic_score_codex":0.000010891654,"about_ca_topic_score_gemma":4.3858995e-7,"teacher_disagreement_score":0.50868046,"about_ca_system_score_codex":0.00006292605,"about_ca_system_score_gemma":0.000067639005,"threshold_uncertainty_score":0.9998007},"labels":[],"label_agreement":null},{"id":"W4406687500","doi":"10.1093/ecco-jcc/jjae190.0894","title":"P0720 Cost-effectiveness of vedolizumab vs. ustekinumab as first-line biologic in treatment sequencing for ulcerative colitis in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Takeda (Canada)","funders":"","keywords":"Vedolizumab; Medicine; Ustekinumab; Ulcerative colitis; Internal medicine; Gastroenterology; Crohn's disease; Tofacitinib; Dermatology; Infliximab; Disease","score_opus":0.03199449956713621,"score_gpt":0.31493651625906427,"score_spread":0.2829420166919281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406687500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952066,0.0022293872,0.00026029607,0.00059300166,0.00038306895,0.00064167887,0.00015673315,0.0000020223113,0.00052719255],"genre_scores_gemma":[0.99844515,0.0008956652,0.0001865158,0.00019594979,0.00001685073,0.000041217147,0.0000059003437,0.0000049287596,0.00020782267],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984866,0.0004295057,0.00059030723,0.00017143073,0.000034343262,0.00028783598],"domain_scores_gemma":[0.99833846,0.0011430488,0.00022127417,0.0000868518,0.00017650178,0.00003384506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057151995,0.00015789016,0.00073313847,0.00017469077,0.00006304794,0.000010784301,0.00010401042,0.00017347101,0.00005745907],"category_scores_gemma":[0.0002345744,0.000115786825,0.000102419785,0.00020139581,0.00013633595,0.000048299116,0.000030772488,0.00018848883,2.1939388e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20710732,0.0020612804,0.14719005,0.0029790155,0.004156795,0.0022989367,0.0022377193,0.0010583177,0.013281548,0.057206616,0.0026603886,0.557762],"study_design_scores_gemma":[0.009177616,0.0028121085,0.90835744,0.0010611883,0.00012899151,0.00022309105,0.00086554646,0.00008125477,0.05693344,0.0058247517,0.014323409,0.00021116583],"about_ca_topic_score_codex":0.20294794,"about_ca_topic_score_gemma":0.5454446,"teacher_disagreement_score":0.7611674,"about_ca_system_score_codex":0.0013851805,"about_ca_system_score_gemma":0.0016732438,"threshold_uncertainty_score":0.8023597},"labels":[],"label_agreement":null},{"id":"W4406687881","doi":"10.1093/ecco-jcc/jjae190.1004","title":"P0830 Use of FK-adalimumab biosimilar (MSB 11022) in context of biologic switch in Inflammatory Bowel Diseases : 6 months data of the real-world IDEA study","year":2025,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Biosimilar; Adalimumab; Context (archaeology); Inflammatory bowel disease; Internal medicine; Tumor necrosis factor alpha","score_opus":0.038111501515814494,"score_gpt":0.3165345878130037,"score_spread":0.2784230862971892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406687881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405146,0.004368859,0.0000062376675,0.0005686937,0.00024124297,0.00031787634,0.00033486134,0.000002342393,0.000108445456],"genre_scores_gemma":[0.9982671,0.0012647887,0.000075687036,0.00019627876,0.000011581831,0.0000029494956,0.0000036362317,0.000005390495,0.00017255919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976167,0.0006648185,0.0012226683,0.00020222999,0.0000787478,0.00021482418],"domain_scores_gemma":[0.998034,0.00062772195,0.00066415645,0.000466815,0.00017816035,0.000029151206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000893731,0.00015728339,0.00075829105,0.00031724753,0.000041902742,0.0000125054885,0.0005239765,0.00016319445,0.000051223276],"category_scores_gemma":[0.0004689885,0.000098079145,0.00013241317,0.00038910858,0.000504493,0.00013044542,0.00037264408,0.00033326758,1.434971e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032388452,0.0009980653,0.978732,0.00014378612,0.00036734244,0.000043679887,0.00026050716,0.0000036289268,0.0057454878,0.001418677,0.0012046486,0.0078433445],"study_design_scores_gemma":[0.0020033203,0.0003430594,0.98696095,0.00038477578,0.00017836348,0.000006692612,0.0011360628,0.000011528937,0.005774228,0.0005792289,0.0025328356,0.00008898654],"about_ca_topic_score_codex":0.0012505291,"about_ca_topic_score_gemma":0.004085795,"teacher_disagreement_score":0.008228932,"about_ca_system_score_codex":0.00003299537,"about_ca_system_score_gemma":0.00020768792,"threshold_uncertainty_score":0.39995515},"labels":[],"label_agreement":null},{"id":"W4406687944","doi":"10.1093/ecco-jcc/jjae190.1005","title":"P0831 Improving efficiency in early phase clinical trials for inflammatory bowel disease through use of external control arms","year":2025,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Calgary","funders":"","keywords":"Medicine; Inflammatory bowel disease; Clinical trial; Disease; Crohn's disease; Internal medicine; Intensive care medicine; Gastroenterology","score_opus":0.07409164227096139,"score_gpt":0.40775619866233287,"score_spread":0.3336645563913715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406687944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9519715,0.005659507,0.040392358,0.0006284642,0.00079449464,0.0003904469,0.0001360941,0.000003719154,0.00002345042],"genre_scores_gemma":[0.9973989,0.00044441377,0.0012580565,0.0005430808,0.000099180994,0.0000074642007,8.2426186e-7,0.000005688008,0.00024237885],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970984,0.00077601126,0.001677066,0.00016171324,0.00004781824,0.00023899492],"domain_scores_gemma":[0.99653906,0.002338314,0.0007260133,0.0001210079,0.00021229642,0.00006334068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035458563,0.00012635556,0.0008294858,0.00011863535,0.000057242232,0.00003808816,0.0001391709,0.00021264874,0.000038099224],"category_scores_gemma":[0.003183257,0.00008820338,0.00040455707,0.00007626376,0.0003157695,0.00015688916,0.000034878838,0.00032107887,3.680938e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20145132,0.0055702874,0.2528408,0.001056283,0.001909181,0.0005001977,0.0008116097,0.000025094812,0.06602335,0.024785105,0.00520112,0.43982568],"study_design_scores_gemma":[0.025011534,0.0019470884,0.9442168,0.000623972,0.00073693995,0.000032429463,0.00011476135,0.00025501504,0.006842881,0.006161402,0.013839284,0.0002178772],"about_ca_topic_score_codex":0.00002739054,"about_ca_topic_score_gemma":0.00000491829,"teacher_disagreement_score":0.69137603,"about_ca_system_score_codex":0.0000185449,"about_ca_system_score_gemma":0.00022590844,"threshold_uncertainty_score":0.38108858},"labels":[],"label_agreement":null},{"id":"W4406688089","doi":"10.1093/ecco-jcc/jjae190.1286","title":"P1112 Pharmacokinetic comparability and safety between original and citrate-free mirikizumab formulations for subcutaneous injections: Results from three clinical trials in healthy participants","year":2025,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Comparability; Pharmacokinetics; Clinical trial; Bioequivalence; Pharmacology; Intensive care medicine; Internal medicine","score_opus":0.1648612863726028,"score_gpt":0.4596053593337135,"score_spread":0.2947440729611107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406688089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868168,0.004368881,0.0023152633,0.0047338163,0.00042684222,0.00045530626,0.00078154803,0.000006133186,0.00009536474],"genre_scores_gemma":[0.9957959,0.0013805865,0.00230791,0.00031527947,0.000117960546,0.0000072786347,0.000011368611,0.000004545814,0.00005918469],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965419,0.0009822273,0.0019073102,0.0002473251,0.000040696694,0.00028053304],"domain_scores_gemma":[0.99201196,0.0071508535,0.0004594158,0.00014081049,0.00014181552,0.00009516378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004986077,0.00013751062,0.0010110855,0.00011827864,0.00018200927,0.000041413005,0.00010507855,0.00024698616,0.000033382436],"category_scores_gemma":[0.0024727038,0.000103960265,0.00013772375,0.00012799451,0.00033764754,0.00007661767,0.00005797711,0.0004145749,3.1835694e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27275613,0.0008759646,0.2832692,0.0002529662,0.002029869,0.00006708232,0.000449879,0.000008044704,0.00045742214,0.0062557305,0.0065538823,0.42702386],"study_design_scores_gemma":[0.010625802,0.0012003765,0.9373345,0.00012137348,0.00045376414,0.000060081675,0.00006995915,0.00011425722,0.00018433365,0.03082866,0.01889624,0.00011068198],"about_ca_topic_score_codex":0.00016601692,"about_ca_topic_score_gemma":0.0006205784,"teacher_disagreement_score":0.6540653,"about_ca_system_score_codex":0.00003565927,"about_ca_system_score_gemma":0.00015401166,"threshold_uncertainty_score":0.42393765},"labels":[],"label_agreement":null},{"id":"W4406698128","doi":"10.1093/ecco-jcc/jjae190.1303","title":"P1129 Comparison of discontinuation/switching between adalimumab biosimilar and originator in Inflammatory Bowel Disease patients: Preliminary data from CAN-AIM","year":2025,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; McMaster University; Thunder Bay Regional Health Sciences Centre; McGill University; University of Calgary; NOSM University; McGill University Health Centre","funders":"","keywords":"Medicine; Biosimilar; Adalimumab; Inflammatory bowel disease; Discontinuation; Infliximab; Internal medicine; Disease; Oncology; Gastroenterology","score_opus":0.0229693386672265,"score_gpt":0.3177806211486827,"score_spread":0.2948112824814562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406698128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899516,0.007292942,0.0002578078,0.0014362797,0.00023645167,0.00013732843,0.000626819,0.000003692511,0.000057078356],"genre_scores_gemma":[0.99903923,0.0003181472,0.0003175804,0.00015921015,0.0000371691,0.0000015987935,0.000054296474,0.0000059062486,0.00006687423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986088,0.00022421517,0.0007218228,0.00020276579,0.00006561603,0.000176761],"domain_scores_gemma":[0.99885637,0.0003743014,0.00036501038,0.00022296963,0.00011687915,0.000064479485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038774995,0.00013628464,0.00046636016,0.00015919369,0.00008018628,0.000034013665,0.00024630147,0.00014814115,0.000039833085],"category_scores_gemma":[0.00024260454,0.00010773918,0.000051078467,0.000091369046,0.00017841613,0.00018727368,0.0002207957,0.0003083797,2.894976e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018694709,0.00025734113,0.9642483,0.00008151402,0.0002602905,0.000015650092,0.00024207924,8.027953e-7,0.00018034104,0.00042239806,0.0024650837,0.029956723],"study_design_scores_gemma":[0.0017351593,0.0002250357,0.9868595,0.00042455198,0.00026374095,0.0000014152228,0.00028929612,0.00007015966,0.0008269414,0.0013595128,0.0078352615,0.000109406414],"about_ca_topic_score_codex":0.00010746497,"about_ca_topic_score_gemma":0.00007362977,"teacher_disagreement_score":0.029847316,"about_ca_system_score_codex":0.000028111062,"about_ca_system_score_gemma":0.00012977984,"threshold_uncertainty_score":0.43934762},"labels":[],"label_agreement":null},{"id":"W4406823881","doi":"10.1080/17576180.2025.2450194","title":"2024 White Paper on Recent Issues in Bioanalysis: Three Way-Cross Validation; Urine Clinical Analysis; Automated Methods; Regulatory Queries on Plasma Protein Binding; Automated Biospecimen Management; ELN Migration; Ultra-Sensitivity Mass Spectrometry ( <u>Part 1A</u> – Recommendations on Advanced Strategies for Mass Spectrometry Assays, Chromatography, Sample Preparation and BMV/Regulated Bioanalysis <u>Part 1B</u> - Regulatory Agencies’ Inputs on Regulated Bioanalysis/BMV)","year":2025,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Revolution Medicines; Regeneron Pharmaceuticals; Biogen; GlaxoSmithKline; Health Canada; AstraZeneca; U.S. Food and Drug Administration; Ministry of Health, Labour and Welfare; Eli Lilly and Company","keywords":"Bioanalysis; Mass spectrometry; Urine; Chemistry; Chromatography; Computational biology; Biochemistry; Biology","score_opus":0.025474177395062653,"score_gpt":0.36084530964528516,"score_spread":0.3353711322502225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406823881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90885425,0.0064924597,0.03471983,0.023398587,0.0027999913,0.008873822,0.005201455,0.0051491125,0.0045105135],"genre_scores_gemma":[0.89545584,0.0037217361,0.08378815,0.000798967,0.00019269007,0.00069389225,0.0077614984,0.00019420407,0.007393006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9842566,0.0048676133,0.004350232,0.0039727218,0.0008539005,0.0016988833],"domain_scores_gemma":[0.99101275,0.0024515926,0.0021412857,0.0031131895,0.00095196936,0.0003291952],"candidate_categories":["metaepi_narrow","bibliometrics","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0076570814,0.0018823113,0.0039475174,0.01037496,0.0013038736,0.0007590998,0.00088215707,0.0016964864,0.0015243907],"category_scores_gemma":[0.0012988858,0.0016786252,0.002274991,0.022341669,0.0013532556,0.00077426434,0.00020715687,0.0012049301,0.0000732118],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021256378,0.013143334,0.06413815,0.0012055262,0.2737077,0.00019028212,0.00071865413,0.0384124,0.49061477,0.031449057,0.027038023,0.038125724],"study_design_scores_gemma":[0.016679214,0.006682133,0.16839193,0.0022410802,0.059626628,0.000017723296,0.0035984183,0.15074481,0.51355404,0.0071759773,0.063472256,0.007815775],"about_ca_topic_score_codex":0.0003012452,"about_ca_topic_score_gemma":0.0021843535,"teacher_disagreement_score":0.21408108,"about_ca_system_score_codex":0.0012073354,"about_ca_system_score_gemma":0.00027688526,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W4406824892","doi":"10.1080/17576180.2024.2442218","title":"2024 White paper on recent issues in bioanalysis: Impact of LDT in US and IVDR in EU; AI/ML for High Parameter Flow Cytometry; The rise of Olink Technology; CDx for AAV Gene Therapies; Integrative Bioanalysis by Multiple Platforms; Super Sensitive ADA/NAb LBA ( <u>PART 2A</u> – Recommendations on Advanced Strategies for Biomarkers, IVD/CDx Assays (BAV), Cell Based Assays (CBA), and Ligand-Binding Assays (LBA) <u>PART 2B</u> – Regulatory Agencies’ Input on Biomarkers, IVD/CDx, and Biomarker Assay Validation)","year":2025,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Bioanalysis; Flow cytometry; Nanotechnology; Chemistry; Chromatography; Materials science; Molecular biology; Biology","score_opus":0.01702756591390475,"score_gpt":0.3036685285899941,"score_spread":0.28664096267608935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406824892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.952329,0.01247704,0.013260971,0.012238404,0.000366482,0.0036957366,0.0053539453,0.00008085872,0.00019760037],"genre_scores_gemma":[0.98478854,0.0022262943,0.010996657,0.00042110813,0.000017673892,0.00040177253,0.0008352857,0.000052238836,0.00026042922],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99490917,0.0009363802,0.0016739479,0.0014204963,0.0002230811,0.00083692564],"domain_scores_gemma":[0.9935567,0.0042812517,0.00072262523,0.00081582024,0.00052484416,0.000098761026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004135712,0.0008515391,0.0018291842,0.0037299872,0.00035602655,0.00012584068,0.0003719646,0.0009274227,0.000089614325],"category_scores_gemma":[0.001313208,0.0005916744,0.00064495,0.004295386,0.0010385573,0.00036599376,0.0001354343,0.0005021775,0.0000011041649],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02032369,0.0041201003,0.19004114,0.00061567343,0.032296717,0.00001652597,0.0020895877,0.0011899673,0.5611726,0.0018951942,0.008169224,0.17806958],"study_design_scores_gemma":[0.02222916,0.0047738464,0.03999445,0.0018292017,0.0066623176,0.000008513672,0.020586286,0.057328366,0.82754344,0.0038262194,0.0125776855,0.0026405214],"about_ca_topic_score_codex":0.00039071322,"about_ca_topic_score_gemma":0.0016521392,"teacher_disagreement_score":0.26637083,"about_ca_system_score_codex":0.00045628662,"about_ca_system_score_gemma":0.00022814544,"threshold_uncertainty_score":0.99965346},"labels":[],"label_agreement":null},{"id":"W4406824986","doi":"10.1080/17576180.2024.2439229","title":"2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation <u>(PART 3A</u> – Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment &amp; Clinical Relevance <u>PART 3B</u> – Regulatory Agencies’ Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell &amp; Vaccine Therapies)","year":2025,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Esri (Canada); Frontier Geosciences (Canada); Health Canada","funders":"","keywords":"Bioanalysis; Immunogenicity; Computational biology; Chemistry; Nanotechnology; Biology; Genetics; Chromatography; Materials science; Immune system","score_opus":0.0365078794490103,"score_gpt":0.32365501259434454,"score_spread":0.28714713314533424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406824986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90594697,0.06755191,0.018302562,0.0032308581,0.00087083766,0.0026584896,0.0009957367,0.00014759153,0.00029506165],"genre_scores_gemma":[0.91850215,0.06047566,0.01897669,0.00024932867,0.00004637872,0.00016873293,0.0007198671,0.00009746207,0.00076375355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99025464,0.0030486234,0.003602455,0.0018070485,0.00045743867,0.00082982006],"domain_scores_gemma":[0.9921169,0.0014398743,0.0027528533,0.0023192163,0.0012929549,0.00007818159],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004156431,0.0011547895,0.002710262,0.0014970751,0.0004952898,0.00007302117,0.00074140367,0.001483055,0.00014567967],"category_scores_gemma":[0.00020814221,0.0010228454,0.0013668502,0.0024249027,0.0005656552,0.00032061862,0.00021460227,0.0012463813,0.0000036964955],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010391256,0.0041463813,0.004247692,0.00011037674,0.0084719015,0.0000013662659,0.00036314322,0.0030151557,0.94149566,0.00063724344,0.00016204978,0.026957756],"study_design_scores_gemma":[0.019782223,0.003223525,0.057008352,0.00048037007,0.004441984,0.000015002844,0.005021443,0.0046326,0.88568145,0.0023359882,0.015426396,0.0019506433],"about_ca_topic_score_codex":0.0004616005,"about_ca_topic_score_gemma":0.00025633685,"teacher_disagreement_score":0.05581421,"about_ca_system_score_codex":0.0009731349,"about_ca_system_score_gemma":0.0005980576,"threshold_uncertainty_score":0.99981326},"labels":[],"label_agreement":null},{"id":"W4407285619","doi":"10.1093/jcag/gwae059.191","title":"A191 REAL WORLD USE OF ADALIMUMAB BIOSIMILAR AMGEVITA® (ABP-501) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN CANADA","year":2025,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Biosimilar; Adalimumab; Inflammatory bowel disease; Medicine; Inflammatory Bowel Diseases; Internal medicine; Disease; Gastroenterology; Pharmacology","score_opus":0.005826618595907135,"score_gpt":0.20474749667324135,"score_spread":0.19892087807733422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407285619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99227214,0.000034098503,0.0000025540194,0.0068412647,0.0005025446,0.00014633397,0.00014991451,9.0599224e-7,0.000050240993],"genre_scores_gemma":[0.99809355,0.000018534018,0.0000777257,0.0014779744,0.0000079600395,0.000001451949,0.000005306344,0.0000060177676,0.0003114813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792403,0.0007294055,0.0007617702,0.00011549067,0.0001091864,0.00036009814],"domain_scores_gemma":[0.9983826,0.00019681096,0.00088292174,0.0001749867,0.0002818938,0.000080771504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059767265,0.00012395853,0.00044217295,0.0005108882,0.00004123375,0.0000057936563,0.0002866112,0.0001255413,0.000043569114],"category_scores_gemma":[0.00041789952,0.00009043047,0.00010243902,0.00027294108,0.00010949739,0.00007487361,0.000041313026,0.000435558,2.242968e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001212163,0.00007215658,0.9934627,0.000018957098,0.00020404781,0.00000775632,0.000021321264,0.00015103114,0.00006790771,0.000055914647,0.004646721,0.0000793254],"study_design_scores_gemma":[0.0025602176,0.00017554342,0.99538654,0.00015199515,0.0000813147,6.2420895e-7,0.000020684613,0.000009224591,0.00012224868,0.000044647928,0.0014002026,0.000046767906],"about_ca_topic_score_codex":0.5490739,"about_ca_topic_score_gemma":0.9984319,"teacher_disagreement_score":0.44935805,"about_ca_system_score_codex":0.0022660866,"about_ca_system_score_gemma":0.002248963,"threshold_uncertainty_score":0.59257376},"labels":[],"label_agreement":null},{"id":"W4407636047","doi":"10.1016/j.bpg.2025.101992","title":"Biobetters and biosimilars in inflammatory bowel disease","year":2025,"lang":"en","type":"article","venue":"Best Practice & Research Clinical Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Biosimilar; Inflammatory bowel disease; Medicine; Inflammatory Bowel Diseases; Gastroenterology; Internal medicine; Intensive care medicine; Disease","score_opus":0.0722861784055998,"score_gpt":0.463917414269884,"score_spread":0.39163123586428417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407636047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82521653,0.0041704583,0.00031545418,0.16608681,0.0011336745,0.00075974147,0.000034273773,0.00005482406,0.002228256],"genre_scores_gemma":[0.9568125,0.004411446,0.0022555795,0.034541804,0.00011344787,0.000116243,0.00001957909,0.000030086374,0.0016993154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9907444,0.0062773535,0.00095463183,0.0008429283,0.000119761,0.0010609066],"domain_scores_gemma":[0.99391675,0.004931962,0.00014074626,0.00056834536,0.00025212322,0.0001901009],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008369069,0.0002282941,0.00046700408,0.00052437687,0.00018870337,0.00006524062,0.00048047994,0.00050328637,0.00018678154],"category_scores_gemma":[0.012946008,0.00019660125,0.0001433456,0.00033073477,0.0026003297,0.00022770235,0.0007554628,0.0024136463,0.00012517677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00832871,0.002056481,0.94003224,0.00007571415,0.00027958516,0.00027313072,0.000030209634,9.3743944e-7,0.0023169904,0.0013500261,0.031501055,0.013754936],"study_design_scores_gemma":[0.0055619474,0.002890667,0.5275179,0.00023301758,0.00020542832,0.00005650129,0.0005886896,0.00008076692,0.00020660569,0.0015993236,0.4608248,0.00023435868],"about_ca_topic_score_codex":0.000041824693,"about_ca_topic_score_gemma":0.00010562835,"teacher_disagreement_score":0.42932373,"about_ca_system_score_codex":0.00006290508,"about_ca_system_score_gemma":0.00019986511,"threshold_uncertainty_score":0.9998878},"labels":[],"label_agreement":null},{"id":"W4407753578","doi":"10.1038/s41433-025-03732-2","title":"Aflibercept 2 mg biosimilars—will they lead the Anti-VEGF biosimilar world globally","year":2025,"lang":"en","type":"article","venue":"Eye","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"University of California, Irvine; Research to Prevent Blindness","keywords":"Biosimilar; Aflibercept; Medicine; Bevacizumab; Internal medicine","score_opus":0.013685154340724015,"score_gpt":0.29645387277245305,"score_spread":0.282768718431729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407753578","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11400825,0.040849347,0.0030540505,0.36870328,0.013752941,0.002443575,0.0006273051,0.0012763435,0.45528492],"genre_scores_gemma":[0.85145044,0.0006941317,0.0016765158,0.042886887,0.00018450488,0.000036112036,0.000041163355,0.00004399398,0.10298626],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99762464,0.0005210161,0.0004711647,0.0005786006,0.000087297405,0.0007172713],"domain_scores_gemma":[0.99856806,0.00035194014,0.000112908674,0.0008232696,0.00010266489,0.00004115332],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008206947,0.000370221,0.00049504306,0.00019064912,0.0004992057,0.00008215218,0.0009906207,0.00043117383,0.0017259028],"category_scores_gemma":[0.00020063497,0.00022667651,0.00032619774,0.0007315016,0.0006971853,0.00009861811,0.00038221345,0.00067823456,0.00043426856],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024078334,0.00053934846,0.017258804,0.00007172688,0.0011598654,0.000026714222,0.00032979329,0.0000042218244,0.24405749,0.022870012,0.67504245,0.0383988],"study_design_scores_gemma":[0.00080113433,0.0000787764,0.024131749,0.00009326484,0.00021447346,0.000008125,0.00014907881,0.000017609898,0.04868115,0.0032704875,0.9222175,0.0003366862],"about_ca_topic_score_codex":0.00004313144,"about_ca_topic_score_gemma":0.00023280115,"teacher_disagreement_score":0.7374422,"about_ca_system_score_codex":0.000059348222,"about_ca_system_score_gemma":0.00009430496,"threshold_uncertainty_score":0.99918664},"labels":[],"label_agreement":null},{"id":"W4407922422","doi":"10.1007/s40259-025-00709-1","title":"Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries","year":2025,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of Calgary; University of British Columbia; University of Toronto; Providence Health Care","funders":"Canadian Institutes of Health Research; National Research Foundation of Korea; Michael Smith Health Research BC","keywords":"Biosimilar; Infliximab; Adalimumab; Etanercept; Descriptive statistics; Medicine; Antirheumatic Agents; Pharmacology; Business; Rheumatoid arthritis; Internal medicine; Tumor necrosis factor alpha","score_opus":0.011238142126732919,"score_gpt":0.28803591462183653,"score_spread":0.2767977724951036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407922422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99014497,0.0053044935,0.00004101775,0.0024366118,0.000033444798,0.00017993027,0.00031598218,0.000016251397,0.001527306],"genre_scores_gemma":[0.9970738,0.0019399326,0.0001221055,0.0004950829,0.000008718791,0.000008715795,0.0000065632357,0.0000057063708,0.00033933402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998789,0.0003300955,0.00030083378,0.00030053747,0.00003090783,0.00024859078],"domain_scores_gemma":[0.998938,0.00070703286,0.00009545024,0.0001813733,0.000046649857,0.00003145222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004691872,0.00023348132,0.00056961965,0.00077600003,0.00009344663,0.000037057478,0.00008382883,0.0002784346,0.00013767453],"category_scores_gemma":[0.00020041878,0.00015091087,0.0000957423,0.00050501234,0.0006883396,0.00006627827,0.0000836208,0.00014009365,0.0000010686417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070570093,0.0006897164,0.63056076,0.00057429046,0.0088198865,0.000007587357,0.011875921,0.00001037097,0.24417192,0.013377474,0.0054469765,0.0774081],"study_design_scores_gemma":[0.0010400501,0.00032012316,0.86355984,0.00013921846,0.0006153382,0.000008436791,0.0023807155,0.00020189803,0.12818685,0.0008623166,0.0023915535,0.000293635],"about_ca_topic_score_codex":0.001386874,"about_ca_topic_score_gemma":0.00036283766,"teacher_disagreement_score":0.23299912,"about_ca_system_score_codex":0.000051178118,"about_ca_system_score_gemma":0.00007136162,"threshold_uncertainty_score":0.6153967},"labels":[],"label_agreement":null},{"id":"W4407976072","doi":"10.3390/jcm14051561","title":"Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Hexal AG","keywords":"Biosimilar; Medicine; Inflammatory bowel disease; Intensive care medicine; Infliximab; Tumor necrosis factor alpha; Disease; Formulary; Crohn's disease; Immunology; Pharmacology; Internal medicine","score_opus":0.168548071039021,"score_gpt":0.4946549485358143,"score_spread":0.32610687749679335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976072","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037840407,0.9873293,0.00011259254,0.007876112,0.001715406,0.0009977677,0.000017716693,0.0000062288236,0.00156649],"genre_scores_gemma":[0.0005506903,0.9943875,0.000537722,0.0037461617,0.00046266385,0.000017911256,0.00000915501,0.000019787562,0.00026842926],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99346346,0.0015726687,0.0039373017,0.00036939178,0.00031228724,0.0003448776],"domain_scores_gemma":[0.99408036,0.002972476,0.001987911,0.0005508414,0.00025351314,0.00015491569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065548182,0.00042369528,0.0033813256,0.0004895234,0.00006148825,0.0000171521,0.0015391074,0.00045977885,0.00032540294],"category_scores_gemma":[0.0018333226,0.00017906715,0.00056877703,0.00074218697,0.00060084625,0.00008337852,0.0002853714,0.0015840405,0.0000051216657],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047716184,0.00043094077,0.004198429,0.01679258,0.0020505746,0.0006776288,0.00007002434,0.0000014661751,0.00000146077,0.000102403326,0.032072343,0.943125],"study_design_scores_gemma":[0.0022895571,0.0009924223,0.0343381,0.10701723,0.005326256,0.00005395002,0.00016895862,0.0000011963522,0.0000024684816,0.00006464331,0.849523,0.00022218775],"about_ca_topic_score_codex":0.000002815727,"about_ca_topic_score_gemma":0.000003045394,"teacher_disagreement_score":0.9429028,"about_ca_system_score_codex":0.000028693355,"about_ca_system_score_gemma":0.00034916043,"threshold_uncertainty_score":0.73021466},"labels":[],"label_agreement":null},{"id":"W4408026290","doi":"10.1111/dom.16278","title":"What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Biosimilar; Simple (philosophy); Intensive care medicine; Medical physics; Internal medicine; Epistemology","score_opus":0.09275575179041569,"score_gpt":0.381834232375524,"score_spread":0.2890784805851083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408026290","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007981186,0.98610705,0.000012064055,0.003100058,0.0008512904,0.0013361799,0.0005504509,0.000018455432,0.000043286404],"genre_scores_gemma":[0.0011209566,0.99407375,0.00071930623,0.0035893894,0.00008574516,0.00011203649,0.000075254466,0.000024797744,0.00019879146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959599,0.0012172515,0.0013494347,0.000760431,0.00008413028,0.00062889874],"domain_scores_gemma":[0.9958046,0.0027247092,0.0003301891,0.00066572137,0.00033987506,0.00013488776],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010364009,0.00055818603,0.002180163,0.0005137441,0.00031520426,0.00022885624,0.00025361028,0.00075768965,0.00026600683],"category_scores_gemma":[0.003690533,0.00033398997,0.00047011834,0.0004506125,0.0003657196,0.00020649288,0.0002941061,0.0008013462,0.0000070695946],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029569559,0.00068545796,0.0020479816,0.0014137697,0.0016265605,0.000015238852,0.0020206938,0.0000023496561,0.00008928205,0.011107093,0.0144177675,0.9665442],"study_design_scores_gemma":[0.00029373815,0.00006532378,0.0030097575,0.002955104,0.00073183066,0.0000047111666,0.0006099811,0.0000034011287,0.00019242591,0.00059998967,0.99115723,0.00037648348],"about_ca_topic_score_codex":0.003814224,"about_ca_topic_score_gemma":0.011434687,"teacher_disagreement_score":0.97673947,"about_ca_system_score_codex":0.00008408241,"about_ca_system_score_gemma":0.0005226963,"threshold_uncertainty_score":0.9999112},"labels":[],"label_agreement":null},{"id":"W4408045731","doi":"10.1016/b978-0-443-23848-2.00005-x","title":"Basics of process validation and equipment qualification protocols (DQ, IQ, OQ, PQ) in FDA-regulated industries","year":2025,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Process (computing); Computer science; Reliability engineering; Engineering","score_opus":0.04117282563924691,"score_gpt":0.33191075094190603,"score_spread":0.29073792530265913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408045731","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00077727943,0.0015906391,0.000046258552,0.00050461915,0.00023897126,0.014590419,0.00020151048,0.000060996295,0.9819893],"genre_scores_gemma":[0.0049844612,0.00007126251,0.0002908078,0.00014887369,0.000029877609,0.0010996707,0.00016465661,0.000029511111,0.9931809],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827784,0.00017252256,0.0007926173,0.00044930604,0.0000795394,0.000228189],"domain_scores_gemma":[0.99886346,0.00014538255,0.00043337082,0.00034429476,0.00018788973,0.000025583544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006338861,0.00032700575,0.0006759861,0.000245069,0.00006384868,0.00002004963,0.00020163786,0.0011791035,0.00019902017],"category_scores_gemma":[0.00009921971,0.00027866208,0.00008100079,0.00005005947,0.0003922756,0.000035906844,0.00010768703,0.00058387325,0.0000074382447],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019023157,0.00005059594,0.00013254398,0.00058207754,0.0001991903,0.0000016563978,0.00018131727,3.7124434e-7,0.0032430147,0.012672865,0.00021572222,0.9825304],"study_design_scores_gemma":[0.0011403064,0.00025586208,0.0003298761,0.002609383,0.00023658191,0.000007025169,0.00005001541,0.0000033689396,0.119833216,0.013583674,0.86146706,0.00048364972],"about_ca_topic_score_codex":0.000001300578,"about_ca_topic_score_gemma":0.000011356838,"teacher_disagreement_score":0.9820468,"about_ca_system_score_codex":0.00005995914,"about_ca_system_score_gemma":0.0002768654,"threshold_uncertainty_score":0.99996656},"labels":[],"label_agreement":null},{"id":"W4408047297","doi":"10.1016/b978-0-443-23848-2.00006-1","title":"Case studies in validation and protocols of pharmaceutical industry","year":2025,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Pharmaceutical industry; Computer science; Medicine; Pharmacology","score_opus":0.11954541321216078,"score_gpt":0.4161467154293389,"score_spread":0.2966013022171781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408047297","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00059623696,0.0049370313,0.0000016230767,0.00013626547,0.00025365778,0.0058630225,0.000085695094,0.000020276035,0.9881062],"genre_scores_gemma":[0.0022779573,0.00014477536,0.0003158791,0.00022171655,0.00003017821,0.00053256855,0.00000640139,0.000014435918,0.9964561],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887836,0.00013548882,0.00047783364,0.00030457368,0.00003121514,0.00017251183],"domain_scores_gemma":[0.9992953,0.00025452662,0.0001467238,0.00019917406,0.00008354459,0.00002071727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047920796,0.00023592694,0.0006335517,0.00016109046,0.000043202053,0.000005413683,0.00008784288,0.0011624612,0.00020314187],"category_scores_gemma":[0.00009744091,0.0001882866,0.000084727035,0.000017235872,0.00064121943,0.000013937152,0.00017553288,0.0010642537,0.0000050587437],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008391379,0.000023017485,0.000066075125,0.0005670028,0.00038939543,0.00024568234,0.000098255914,2.3198423e-8,0.001028142,0.005440219,0.00027785051,0.9917804],"study_design_scores_gemma":[0.0011621558,0.00016846813,0.000010115068,0.0018495934,0.00037657225,0.00090188714,0.00005232272,0.0000010343643,0.02422297,0.006831477,0.9640947,0.0003287123],"about_ca_topic_score_codex":3.623285e-7,"about_ca_topic_score_gemma":0.0000040241844,"teacher_disagreement_score":0.9914517,"about_ca_system_score_codex":0.00003299118,"about_ca_system_score_gemma":0.00006897596,"threshold_uncertainty_score":0.89659655},"labels":[],"label_agreement":null},{"id":"W4408121967","doi":"10.2340/actadv.v105.42572","title":"Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study","year":2025,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Sanofi Genzyme; LEO Pharma; Bausch Health; Novo Nordisk; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; Ortho Dermatologics; Cilag; Mylan; UCB Pharma; Kongelig Hofbuntmager Aage Bangs Fond; Regeneron Pharmaceuticals; Simon Spies Fonden; Les Laboratories Pierre Fabre; Celgene; Sanofi; Pfizer; Samsung; Galápagos; National Psoriasis Foundation; Amgen","keywords":"Medicine; Biosimilar; Adalimumab; Psoriasis; Cohort; Cohort study; Drug; Family medicine; Internal medicine; Pharmacology; Dermatology","score_opus":0.014887189020757474,"score_gpt":0.31828730339637146,"score_spread":0.303400114375614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408121967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98774,0.0007068602,0.00073656865,0.0039589787,0.002634047,0.0013927554,0.00018361,0.00013643072,0.0025107749],"genre_scores_gemma":[0.99523056,0.00016805728,0.0013684023,0.0011736752,0.00007594005,0.00023391847,0.00012044314,0.000023889457,0.0016051411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684054,0.00067919854,0.0009187044,0.0007714876,0.00021522834,0.00057487335],"domain_scores_gemma":[0.9969339,0.0017863634,0.00030681168,0.0007118144,0.00017340196,0.000087709246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016771918,0.00039819514,0.0011912391,0.00028153977,0.00034079765,0.00003104101,0.0008613645,0.000562904,0.00054080936],"category_scores_gemma":[0.0008937673,0.00030816998,0.00042636532,0.00046611406,0.00029336964,0.00010601646,0.00033891358,0.0004720641,0.000019047053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001285539,0.0018397194,0.9289453,0.000113550836,0.004158623,0.00008055983,0.00027256313,7.9984864e-7,0.014890027,0.0021632982,0.043714877,0.002535169],"study_design_scores_gemma":[0.014526269,0.00062568183,0.7032783,0.0005042466,0.002714876,0.000013391668,0.0015119751,0.00025372,0.08882984,0.005591486,0.18086167,0.0012885567],"about_ca_topic_score_codex":0.0005440565,"about_ca_topic_score_gemma":0.0005341002,"teacher_disagreement_score":0.225667,"about_ca_system_score_codex":0.00008388233,"about_ca_system_score_gemma":0.00034246908,"threshold_uncertainty_score":0.99993706},"labels":[],"label_agreement":null},{"id":"W4408206616","doi":"10.1007/s12325-025-03138-2","title":"A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Biosimilar; Randomized controlled trial; Internal medicine; Clinical endpoint; Adverse effect; Psoriasis; Dermatology; Infliximab; Disease","score_opus":0.021678752856792344,"score_gpt":0.3021284946839793,"score_spread":0.28044974182718696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408206616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906574,0.0031060644,0.00032027383,0.0014059803,0.00028001453,0.0034552864,0.000058029804,0.000013379479,0.000703612],"genre_scores_gemma":[0.9976778,0.00082885136,0.00042768245,0.0007843172,0.000009492265,0.0001149528,0.000008857792,0.000013497541,0.00013452198],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979854,0.0005669252,0.0005427911,0.00045239445,0.0001034379,0.00034900673],"domain_scores_gemma":[0.99849796,0.00065628183,0.00016705785,0.000536644,0.00011561247,0.000026427613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053712295,0.00028994321,0.00066433725,0.00013957966,0.00017765014,0.000024347464,0.00054831547,0.00014953285,0.000044521727],"category_scores_gemma":[0.00006032979,0.00013671965,0.00007000412,0.00083917,0.00035608822,0.000097911434,0.0001465379,0.00044263463,0.000001550127],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97035635,0.00043885648,0.012421772,0.000016411102,0.00021764074,7.6870094e-7,0.00040283724,0.00081815297,0.00034650989,0.0005695457,0.000034490215,0.014376674],"study_design_scores_gemma":[0.901688,0.0020031915,0.056564484,0.0005160558,0.00009710499,0.0000043600717,0.0003405991,0.000018473982,0.017720735,0.00036354933,0.020204274,0.00047922484],"about_ca_topic_score_codex":0.00012343311,"about_ca_topic_score_gemma":0.0010660919,"teacher_disagreement_score":0.06866839,"about_ca_system_score_codex":0.0000659921,"about_ca_system_score_gemma":0.00010348873,"threshold_uncertainty_score":0.5575265},"labels":[],"label_agreement":null},{"id":"W4408243951","doi":"10.1093/rheumatology/keaf128","title":"Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting","year":2025,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Erik och Edith Fernströms Stiftelse för Medicinsk Forskning; Vetenskapsrådet; Reumatikerförbundet; Linköpings Universitet; Svenska Läkaresällskapet; Gilead Sciences; GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Ulla och Gustaf af Ugglas Stiftelse; Stiftelsen Konung Gustaf V:s 80-årsfond; Karolinska Institutet; Amgen; Nyckelfonden","keywords":"Belimumab; Medicine; Adverse effect; Internal medicine; Serology; Immunogenicity; Drug; Immunology; Pharmacology; Antibody; B-cell activating factor","score_opus":0.00930358386182029,"score_gpt":0.2902217957412761,"score_spread":0.2809182118794558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408243951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467677,0.0012183913,0.0003103171,0.0015403025,0.00023867186,0.00044558774,0.000022955413,0.000022246215,0.0015247477],"genre_scores_gemma":[0.99803203,0.00010112447,0.00095786556,0.00028644895,0.000006925672,0.000021289112,0.0000155508,0.0000050267313,0.0005737337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868864,0.00050087966,0.00030148865,0.00028475368,0.000020519457,0.00020369793],"domain_scores_gemma":[0.99926174,0.00052105467,0.000045275166,0.00012764115,0.000025165746,0.00001909895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010264262,0.00011046874,0.0002508136,0.00014220843,0.000111988134,0.00001880877,0.000066212255,0.0001273965,0.000016075304],"category_scores_gemma":[0.00019897165,0.00010239495,0.000024464376,0.00040977413,0.0001019413,0.00006909019,0.00009835032,0.00029185874,0.0000025448733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014248523,0.00018116091,0.74855584,0.00013114394,0.00014851187,0.000012802155,0.0019441252,0.00007273822,0.2184543,0.01693425,0.0002863447,0.0118539315],"study_design_scores_gemma":[0.0018690448,0.000040413415,0.9787181,0.00024377811,0.000031567004,0.000003613597,0.0001622959,0.00013279944,0.015724292,0.0015092719,0.0014344272,0.00013037701],"about_ca_topic_score_codex":0.00081297156,"about_ca_topic_score_gemma":0.0033353064,"teacher_disagreement_score":0.2301623,"about_ca_system_score_codex":0.000081321574,"about_ca_system_score_gemma":0.000041621206,"threshold_uncertainty_score":0.4175545},"labels":[],"label_agreement":null},{"id":"W4408320811","doi":"10.1111/dom.16278/v1/review5","title":"Review for \"What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives\"","year":2025,"lang":"en","type":"peer-review","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Simple (philosophy); Medicine; Computer science; Internal medicine; Epistemology; Philosophy","score_opus":0.1755794320571133,"score_gpt":0.4445223122925183,"score_spread":0.268942880235405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408320811","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028074966,0.5583646,0.0003286723,0.4339067,0.0012444541,0.0040812646,0.001598509,0.000021533539,0.00042618846],"genre_scores_gemma":[0.000104744155,0.7333845,0.0047465507,0.24769956,0.00011068115,0.00053255237,0.00056433363,0.00004053481,0.012816526],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946838,0.0009806511,0.0024759937,0.0010180814,0.00011922648,0.00072222046],"domain_scores_gemma":[0.9923856,0.004058088,0.00052086666,0.0012093158,0.0016925784,0.00013352782],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021160175,0.00064999587,0.0019860882,0.0003337819,0.00027571525,0.00012654047,0.00041505977,0.00079286844,0.0036136354],"category_scores_gemma":[0.015650311,0.0003781171,0.00071118155,0.00046627346,0.0002792495,0.00012908257,0.00026780774,0.00094255025,0.000013805446],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042399082,0.00018850698,0.000039461454,0.0012908876,0.00042998814,0.000004435958,0.00011739187,0.0000012208991,0.00004904446,0.0021806278,0.9678482,0.02780786],"study_design_scores_gemma":[0.00041345457,0.00028231565,0.00008567786,0.017236212,0.0005225405,0.000015493193,0.00041532936,0.000010799608,0.0002482594,0.0004310519,0.97991645,0.00042241783],"about_ca_topic_score_codex":0.020208335,"about_ca_topic_score_gemma":0.13186061,"teacher_disagreement_score":0.18620715,"about_ca_system_score_codex":0.00032232708,"about_ca_system_score_gemma":0.0013179572,"threshold_uncertainty_score":0.9998671},"labels":[],"label_agreement":null},{"id":"W4408320837","doi":"10.1111/dom.16278/v1/review6","title":"Review for \"What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives\"","year":2025,"lang":"en","type":"peer-review","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Simple (philosophy); Medicine; Insulin; Medical physics; Computer science; Internal medicine; Epistemology","score_opus":0.1755794320571133,"score_gpt":0.4445223122925183,"score_spread":0.268942880235405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408320837","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028074966,0.5583646,0.0003286723,0.4339067,0.0012444541,0.0040812646,0.001598509,0.000021533539,0.00042618846],"genre_scores_gemma":[0.000104744155,0.7333845,0.0047465507,0.24769956,0.00011068115,0.00053255237,0.00056433363,0.00004053481,0.012816526],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946838,0.0009806511,0.0024759937,0.0010180814,0.00011922648,0.00072222046],"domain_scores_gemma":[0.9923856,0.004058088,0.00052086666,0.0012093158,0.0016925784,0.00013352782],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021160175,0.00064999587,0.0019860882,0.0003337819,0.00027571525,0.00012654047,0.00041505977,0.00079286844,0.0036136354],"category_scores_gemma":[0.015650311,0.0003781171,0.00071118155,0.00046627346,0.0002792495,0.00012908257,0.00026780774,0.00094255025,0.000013805446],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042399082,0.00018850698,0.000039461454,0.0012908876,0.00042998814,0.000004435958,0.00011739187,0.0000012208991,0.00004904446,0.0021806278,0.9678482,0.02780786],"study_design_scores_gemma":[0.00041345457,0.00028231565,0.00008567786,0.017236212,0.0005225405,0.000015493193,0.00041532936,0.000010799608,0.0002482594,0.0004310519,0.97991645,0.00042241783],"about_ca_topic_score_codex":0.020208335,"about_ca_topic_score_gemma":0.13186061,"teacher_disagreement_score":0.18620715,"about_ca_system_score_codex":0.00032232708,"about_ca_system_score_gemma":0.0013179572,"threshold_uncertainty_score":0.9998671},"labels":[],"label_agreement":null},{"id":"W4408320861","doi":"10.1111/dom.16278/v1/review4","title":"Review for \"What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives\"","year":2024,"lang":"en","type":"peer-review","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Simple (philosophy); Medicine; Insulin; Family medicine; Internal medicine; Epistemology","score_opus":0.18959406876240917,"score_gpt":0.4452067584349151,"score_spread":0.25561268967250594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408320861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033268072,0.5660698,0.0001351959,0.4270917,0.0015475006,0.0032527458,0.0016128904,0.000025512663,0.00023140362],"genre_scores_gemma":[0.00017198767,0.7586202,0.003931644,0.222083,0.00019581403,0.0005868616,0.0006045988,0.000075770295,0.013730146],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99480593,0.0007959111,0.002429055,0.0011020023,0.00013190357,0.0007352082],"domain_scores_gemma":[0.99394214,0.0030652403,0.0004164639,0.0011161877,0.0013072388,0.00015275419],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022233827,0.0006760509,0.0018624474,0.00032249262,0.00021813238,0.00018185852,0.0003703669,0.0007745647,0.004553593],"category_scores_gemma":[0.010143666,0.00037785334,0.00077140634,0.00045179497,0.00029268573,0.00013089649,0.000270498,0.0011034416,0.000046678055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003298177,0.0001476518,0.000016341522,0.0016189438,0.00048095337,0.000009613871,0.0001848931,9.643322e-7,0.00006796467,0.0021476273,0.97471225,0.020579826],"study_design_scores_gemma":[0.00027934293,0.00033487138,0.0000409886,0.018377,0.0006513201,0.000036427435,0.00046691875,0.000015426993,0.00021157238,0.0007068328,0.9784228,0.0004564965],"about_ca_topic_score_codex":0.01784872,"about_ca_topic_score_gemma":0.1349704,"teacher_disagreement_score":0.20500869,"about_ca_system_score_codex":0.00032853457,"about_ca_system_score_gemma":0.0010049379,"threshold_uncertainty_score":0.9998673},"labels":[],"label_agreement":null},{"id":"W4408320862","doi":"10.1111/dom.16278/v2/review1","title":"Review for \"What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives\"","year":2025,"lang":"en","type":"peer-review","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Simple (philosophy); Medicine; Insulin; Family medicine; Internal medicine; Epistemology","score_opus":0.1755794320571133,"score_gpt":0.4445223122925183,"score_spread":0.268942880235405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408320862","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028074966,0.5583646,0.0003286723,0.4339067,0.0012444541,0.0040812646,0.001598509,0.000021533539,0.00042618846],"genre_scores_gemma":[0.000104744155,0.7333845,0.0047465507,0.24769956,0.00011068115,0.00053255237,0.00056433363,0.00004053481,0.012816526],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946838,0.0009806511,0.0024759937,0.0010180814,0.00011922648,0.00072222046],"domain_scores_gemma":[0.9923856,0.004058088,0.00052086666,0.0012093158,0.0016925784,0.00013352782],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021160175,0.00064999587,0.0019860882,0.0003337819,0.00027571525,0.00012654047,0.00041505977,0.00079286844,0.0036136354],"category_scores_gemma":[0.015650311,0.0003781171,0.00071118155,0.00046627346,0.0002792495,0.00012908257,0.00026780774,0.00094255025,0.000013805446],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042399082,0.00018850698,0.000039461454,0.0012908876,0.00042998814,0.000004435958,0.00011739187,0.0000012208991,0.00004904446,0.0021806278,0.9678482,0.02780786],"study_design_scores_gemma":[0.00041345457,0.00028231565,0.00008567786,0.017236212,0.0005225405,0.000015493193,0.00041532936,0.000010799608,0.0002482594,0.0004310519,0.97991645,0.00042241783],"about_ca_topic_score_codex":0.020208335,"about_ca_topic_score_gemma":0.13186061,"teacher_disagreement_score":0.18620715,"about_ca_system_score_codex":0.00032232708,"about_ca_system_score_gemma":0.0013179572,"threshold_uncertainty_score":0.9998671},"labels":[],"label_agreement":null},{"id":"W4408320863","doi":"10.1111/dom.16278/v1/review3","title":"Review for \"What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives\"","year":2024,"lang":"en","type":"peer-review","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Simple (philosophy); Medicine; Family medicine; Internal medicine; Epistemology; Philosophy","score_opus":0.18959406876240917,"score_gpt":0.4452067584349151,"score_spread":0.25561268967250594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408320863","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033268072,0.5660698,0.0001351959,0.4270917,0.0015475006,0.0032527458,0.0016128904,0.000025512663,0.00023140362],"genre_scores_gemma":[0.00017198767,0.7586202,0.003931644,0.222083,0.00019581403,0.0005868616,0.0006045988,0.000075770295,0.013730146],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99480593,0.0007959111,0.002429055,0.0011020023,0.00013190357,0.0007352082],"domain_scores_gemma":[0.99394214,0.0030652403,0.0004164639,0.0011161877,0.0013072388,0.00015275419],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022233827,0.0006760509,0.0018624474,0.00032249262,0.00021813238,0.00018185852,0.0003703669,0.0007745647,0.004553593],"category_scores_gemma":[0.010143666,0.00037785334,0.00077140634,0.00045179497,0.00029268573,0.00013089649,0.000270498,0.0011034416,0.000046678055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003298177,0.0001476518,0.000016341522,0.0016189438,0.00048095337,0.000009613871,0.0001848931,9.643322e-7,0.00006796467,0.0021476273,0.97471225,0.020579826],"study_design_scores_gemma":[0.00027934293,0.00033487138,0.0000409886,0.018377,0.0006513201,0.000036427435,0.00046691875,0.000015426993,0.00021157238,0.0007068328,0.9784228,0.0004564965],"about_ca_topic_score_codex":0.01784872,"about_ca_topic_score_gemma":0.1349704,"teacher_disagreement_score":0.20500869,"about_ca_system_score_codex":0.00032853457,"about_ca_system_score_gemma":0.0010049379,"threshold_uncertainty_score":0.9998673},"labels":[],"label_agreement":null},{"id":"W4408321062","doi":"10.1111/dom.16278/v1/review2","title":"Review for \"What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives\"","year":2024,"lang":"en","type":"peer-review","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Simple (philosophy); Medicine; Computer science; Internal medicine; Epistemology; Philosophy","score_opus":0.18959406876240917,"score_gpt":0.4452067584349151,"score_spread":0.25561268967250594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408321062","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033268072,0.5660698,0.0001351959,0.4270917,0.0015475006,0.0032527458,0.0016128904,0.000025512663,0.00023140362],"genre_scores_gemma":[0.00017198767,0.7586202,0.003931644,0.222083,0.00019581403,0.0005868616,0.0006045988,0.000075770295,0.013730146],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99480593,0.0007959111,0.002429055,0.0011020023,0.00013190357,0.0007352082],"domain_scores_gemma":[0.99394214,0.0030652403,0.0004164639,0.0011161877,0.0013072388,0.00015275419],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022233827,0.0006760509,0.0018624474,0.00032249262,0.00021813238,0.00018185852,0.0003703669,0.0007745647,0.004553593],"category_scores_gemma":[0.010143666,0.00037785334,0.00077140634,0.00045179497,0.00029268573,0.00013089649,0.000270498,0.0011034416,0.000046678055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003298177,0.0001476518,0.000016341522,0.0016189438,0.00048095337,0.000009613871,0.0001848931,9.643322e-7,0.00006796467,0.0021476273,0.97471225,0.020579826],"study_design_scores_gemma":[0.00027934293,0.00033487138,0.0000409886,0.018377,0.0006513201,0.000036427435,0.00046691875,0.000015426993,0.00021157238,0.0007068328,0.9784228,0.0004564965],"about_ca_topic_score_codex":0.01784872,"about_ca_topic_score_gemma":0.1349704,"teacher_disagreement_score":0.20500869,"about_ca_system_score_codex":0.00032853457,"about_ca_system_score_gemma":0.0010049379,"threshold_uncertainty_score":0.9998673},"labels":[],"label_agreement":null},{"id":"W4408321092","doi":"10.1111/dom.16278/v2/decision1","title":"Decision letter for \"What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives\"","year":2025,"lang":"en","type":"peer-review","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Simple (philosophy); Medicine; Medical physics; Computer science; Internal medicine","score_opus":0.14237147198874825,"score_gpt":0.4300584700689597,"score_spread":0.2876869980802115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408321092","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009700854,0.13089588,0.0044957916,0.84974706,0.005130304,0.0055689034,0.0026352473,0.00004098995,0.0005157299],"genre_scores_gemma":[0.0033428785,0.19165766,0.04657118,0.70636964,0.00065829436,0.0010788062,0.0013548724,0.0001511195,0.04881554],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955236,0.00063086057,0.0020404733,0.0009854733,0.0001378546,0.0006817527],"domain_scores_gemma":[0.9910736,0.006102673,0.00036846322,0.0010467673,0.0012963224,0.00011215733],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001508666,0.00057914184,0.0013865035,0.00045505544,0.00029376097,0.000184706,0.00037098047,0.00092848134,0.0027691429],"category_scores_gemma":[0.010973007,0.00033369334,0.00056643557,0.00035300493,0.00025615797,0.00013885593,0.00028161294,0.00088203343,0.0000133094445],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011756871,0.00018512859,0.000091269285,0.0001062422,0.00032047048,0.0000065990903,0.00019232387,0.0000058018513,0.00017291444,0.0013735924,0.96065885,0.036769245],"study_design_scores_gemma":[0.0006141993,0.00028810828,0.00028367896,0.0024183234,0.00024133896,0.000011109079,0.00045712385,0.00003266969,0.00075736456,0.00092146866,0.9935854,0.00038918518],"about_ca_topic_score_codex":0.017430216,"about_ca_topic_score_gemma":0.1816698,"teacher_disagreement_score":0.16423959,"about_ca_system_score_codex":0.0003135237,"about_ca_system_score_gemma":0.0008156138,"threshold_uncertainty_score":0.9999115},"labels":[],"label_agreement":null},{"id":"W4408321126","doi":"10.1111/dom.16278/v1/review1","title":"Review for \"What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives\"","year":2024,"lang":"en","type":"peer-review","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Simple (philosophy); Medicine; Insulin; Intensive care medicine; Internal medicine; Epistemology; Philosophy","score_opus":0.18959406876240917,"score_gpt":0.4452067584349151,"score_spread":0.25561268967250594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408321126","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033268072,0.5660698,0.0001351959,0.4270917,0.0015475006,0.0032527458,0.0016128904,0.000025512663,0.00023140362],"genre_scores_gemma":[0.00017198767,0.7586202,0.003931644,0.222083,0.00019581403,0.0005868616,0.0006045988,0.000075770295,0.013730146],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99480593,0.0007959111,0.002429055,0.0011020023,0.00013190357,0.0007352082],"domain_scores_gemma":[0.99394214,0.0030652403,0.0004164639,0.0011161877,0.0013072388,0.00015275419],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022233827,0.0006760509,0.0018624474,0.00032249262,0.00021813238,0.00018185852,0.0003703669,0.0007745647,0.004553593],"category_scores_gemma":[0.010143666,0.00037785334,0.00077140634,0.00045179497,0.00029268573,0.00013089649,0.000270498,0.0011034416,0.000046678055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003298177,0.0001476518,0.000016341522,0.0016189438,0.00048095337,0.000009613871,0.0001848931,9.643322e-7,0.00006796467,0.0021476273,0.97471225,0.020579826],"study_design_scores_gemma":[0.00027934293,0.00033487138,0.0000409886,0.018377,0.0006513201,0.000036427435,0.00046691875,0.000015426993,0.00021157238,0.0007068328,0.9784228,0.0004564965],"about_ca_topic_score_codex":0.01784872,"about_ca_topic_score_gemma":0.1349704,"teacher_disagreement_score":0.20500869,"about_ca_system_score_codex":0.00032853457,"about_ca_system_score_gemma":0.0010049379,"threshold_uncertainty_score":0.9998673},"labels":[],"label_agreement":null},{"id":"W4408321132","doi":"10.1111/dom.16278/v2/response1","title":"Author response for \"What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives\"","year":2025,"lang":"en","type":"peer-review","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Simple (philosophy); Medicine; Psychology; Family medicine; Internal medicine; Epistemology; Philosophy","score_opus":0.19018037517669203,"score_gpt":0.4537396144984064,"score_spread":0.2635592393217143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408321132","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014519319,0.102549635,0.0009497418,0.8833759,0.0026513347,0.005013158,0.0037102804,0.000045272245,0.00025273612],"genre_scores_gemma":[0.010748486,0.13570474,0.047199856,0.48116064,0.0006903443,0.0027820806,0.0019510258,0.0002994402,0.3194634],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99399763,0.0018237949,0.0022001278,0.0010568039,0.00013636131,0.0007852762],"domain_scores_gemma":[0.9876692,0.008984646,0.00044450045,0.0011831746,0.0015655203,0.00015292162],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003361165,0.00063867716,0.0015404997,0.0005672905,0.0003584758,0.0001889229,0.00040187282,0.0010773249,0.0024702372],"category_scores_gemma":[0.027268117,0.00038520954,0.0006032314,0.000462556,0.00034692662,0.00013229404,0.0002795758,0.0009999087,0.000011565874],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068286015,0.0002500591,0.00007361467,0.00015385041,0.000468038,0.000010173258,0.0004965747,0.000004886481,0.0003984537,0.0024927533,0.98249435,0.012474377],"study_design_scores_gemma":[0.000636365,0.0005306749,0.0005631574,0.0020736433,0.00030360953,0.000015890764,0.0015818051,0.00003530816,0.0010652568,0.0005890823,0.9921593,0.0004458775],"about_ca_topic_score_codex":0.019335913,"about_ca_topic_score_gemma":0.12937087,"teacher_disagreement_score":0.40221527,"about_ca_system_score_codex":0.0004221813,"about_ca_system_score_gemma":0.0018946435,"threshold_uncertainty_score":0.99986},"labels":[],"label_agreement":null},{"id":"W4408321157","doi":"10.1111/dom.16278/v1/decision1","title":"Decision letter for \"What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives\"","year":2025,"lang":"en","type":"peer-review","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Simple (philosophy); Medicine; Psychology; Epistemology; Internal medicine; Philosophy","score_opus":0.14237147198874825,"score_gpt":0.4300584700689597,"score_spread":0.2876869980802115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408321157","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009700854,0.13089588,0.0044957916,0.84974706,0.005130304,0.0055689034,0.0026352473,0.00004098995,0.0005157299],"genre_scores_gemma":[0.0033428785,0.19165766,0.04657118,0.70636964,0.00065829436,0.0010788062,0.0013548724,0.0001511195,0.04881554],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955236,0.00063086057,0.0020404733,0.0009854733,0.0001378546,0.0006817527],"domain_scores_gemma":[0.9910736,0.006102673,0.00036846322,0.0010467673,0.0012963224,0.00011215733],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001508666,0.00057914184,0.0013865035,0.00045505544,0.00029376097,0.000184706,0.00037098047,0.00092848134,0.0027691429],"category_scores_gemma":[0.010973007,0.00033369334,0.00056643557,0.00035300493,0.00025615797,0.00013885593,0.00028161294,0.00088203343,0.0000133094445],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011756871,0.00018512859,0.000091269285,0.0001062422,0.00032047048,0.0000065990903,0.00019232387,0.0000058018513,0.00017291444,0.0013735924,0.96065885,0.036769245],"study_design_scores_gemma":[0.0006141993,0.00028810828,0.00028367896,0.0024183234,0.00024133896,0.000011109079,0.00045712385,0.00003266969,0.00075736456,0.00092146866,0.9935854,0.00038918518],"about_ca_topic_score_codex":0.017430216,"about_ca_topic_score_gemma":0.1816698,"teacher_disagreement_score":0.16423959,"about_ca_system_score_codex":0.0003135237,"about_ca_system_score_gemma":0.0008156138,"threshold_uncertainty_score":0.9999115},"labels":[],"label_agreement":null},{"id":"W4408323049","doi":"10.1208/s12248-025-01033-w","title":"Best Practices and Recommendations for Non-Liquid Matrices Bioanalysis","year":2025,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nuclear Laboratories","funders":"","keywords":"Bioanalysis; Best practice; Computer science; Drug development; Engineering ethics; Subject matter; Process (computing); Nanotechnology; Data science; Political science; Drug; Engineering; Medicine; Pharmacology; Materials science","score_opus":0.05830798396820661,"score_gpt":0.39239985292044177,"score_spread":0.33409186895223514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408323049","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12415537,0.074849434,0.043395948,0.7325849,0.004464687,0.00096029986,0.0001617544,0.00006679824,0.019360842],"genre_scores_gemma":[0.8516628,0.029530486,0.039719857,0.01059721,0.0006147134,0.000061096514,0.000035542897,0.000034733024,0.06774352],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992156,0.00021813296,0.00024401686,0.00012125158,0.000018989509,0.00018202882],"domain_scores_gemma":[0.99864495,0.0008027122,0.00029321568,0.0001357126,0.000104640734,0.000018748813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011443637,0.00008818786,0.00017489918,0.00011670737,0.0006303692,0.00007823402,0.00021144067,0.00010847104,0.00029438283],"category_scores_gemma":[0.00042634452,0.000049178623,0.000102110804,0.00021173978,0.00016041072,0.000092333685,0.00006680073,0.0003116691,0.000014797065],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022414823,0.00067851366,0.0017707509,0.00012192798,0.006215338,0.000006789506,0.0007199723,0.0000037252285,0.18701589,0.013212382,0.30942267,0.47859055],"study_design_scores_gemma":[0.0008245411,0.00034923878,0.0002835363,0.000070650334,0.0012268126,0.00016673982,0.0011431366,0.00006195504,0.020133782,0.003098302,0.9725175,0.00012378521],"about_ca_topic_score_codex":0.000026583177,"about_ca_topic_score_gemma":0.000016614502,"teacher_disagreement_score":0.7275075,"about_ca_system_score_codex":0.000013923949,"about_ca_system_score_gemma":0.000044912056,"threshold_uncertainty_score":0.4848354},"labels":[],"label_agreement":null},{"id":"W4408727992","doi":"10.1016/j.biologicals.2025.101821","title":"Global availability of critical reagents for biologicals testing - Current status, challenges and possible solutions","year":2025,"lang":"en","type":"article","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Humane Society International","keywords":"Current (fluid); Biochemical engineering; Risk analysis (engineering); Computational biology; Data science; Biology; Medicine; Computer science; Engineering; Oceanography; Geology","score_opus":0.20636856003758755,"score_gpt":0.41314882603169506,"score_spread":0.2067802659941075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408727992","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40368524,0.5661851,0.0077107656,0.0070640743,0.0020102756,0.0017696493,0.002619106,0.00030692085,0.008648849],"genre_scores_gemma":[0.98648363,0.003711213,0.009370865,0.00021663558,0.000026909727,0.00006227149,0.000029668787,0.0000032797118,0.00009554655],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99784714,0.00049670663,0.00051845005,0.00053983484,0.000024286757,0.00057357305],"domain_scores_gemma":[0.99677056,0.002621735,0.00009678305,0.00024114824,0.00021549193,0.000054284254],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011163185,0.00019625324,0.0005297743,0.00004529968,0.00019600912,0.000010003169,0.00018630919,0.0004734519,0.00010819189],"category_scores_gemma":[0.0090299165,0.00012286325,0.00013094107,0.00019627312,0.001332787,0.000028456092,0.0002755363,0.00014940488,0.0000062692466],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037150164,0.0014885461,0.050013486,0.00047878345,0.0002188377,8.973336e-7,0.00002717505,3.0303238e-7,0.067888275,0.19919693,0.00232028,0.67799497],"study_design_scores_gemma":[0.0017051741,0.0021679641,0.6671163,0.00027494782,0.0003135911,0.000012426688,0.00024561558,0.00004481867,0.012574324,0.22986248,0.08513083,0.0005515273],"about_ca_topic_score_codex":0.000011506244,"about_ca_topic_score_gemma":0.000005113696,"teacher_disagreement_score":0.67744344,"about_ca_system_score_codex":0.00003555855,"about_ca_system_score_gemma":0.00005735871,"threshold_uncertainty_score":0.99931747},"labels":[],"label_agreement":null},{"id":"W4408730910","doi":"10.1007/s12325-025-03158-y","title":"Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Eli Lilly and Company","keywords":"Medicine; Comparability; Pharmacokinetics; Clinical trial; Rheumatology; Pharmacology; Intensive care medicine; Internal medicine; Medical physics","score_opus":0.12910321262455474,"score_gpt":0.47651952724574037,"score_spread":0.3474163146211856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408730910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8922382,0.066019595,0.031481393,0.004100392,0.0013747041,0.0019469068,0.0019324125,0.000074888725,0.0008315225],"genre_scores_gemma":[0.9693259,0.016277468,0.013500601,0.00043941007,0.000117231175,0.000054150038,0.000106160056,0.000009368702,0.00016972287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759996,0.00073832326,0.0009915662,0.0004327313,0.000024870396,0.00021256699],"domain_scores_gemma":[0.98946065,0.01001554,0.00017085319,0.0002715896,0.00005499951,0.000026343892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002343508,0.00016132115,0.0006727364,0.00007509229,0.0001642871,0.000017602999,0.00016443261,0.00024019176,0.000046516318],"category_scores_gemma":[0.0011396045,0.00012078597,0.00010583693,0.00016650991,0.00044291254,0.00009777631,0.000045562778,0.00029410238,0.0000010166646],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020280961,0.00021010346,0.09083763,0.000023109922,0.00041384672,0.0000013898006,0.00007617779,0.000012089532,0.0016554534,0.0032938328,0.00043422417,0.8827612],"study_design_scores_gemma":[0.026989348,0.001154019,0.25084183,0.00009642168,0.00025444455,0.000009298402,0.000060597522,0.00032140134,0.0041372725,0.31186083,0.4039071,0.00036745847],"about_ca_topic_score_codex":0.00005278074,"about_ca_topic_score_gemma":0.00031186943,"teacher_disagreement_score":0.8823937,"about_ca_system_score_codex":0.000023800281,"about_ca_system_score_gemma":0.000041088017,"threshold_uncertainty_score":0.49255088},"labels":[],"label_agreement":null},{"id":"W4408957204","doi":"10.1002/dta.3889","title":"Analysis of Testosterone Esters in Serum and DBS Samples—Results From an Interlaboratory Study","year":2025,"lang":"en","type":"article","venue":"Drug Testing and Analysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency","keywords":"Chromatography; Urine; Chemistry; Matrix (chemical analysis); Biochemistry","score_opus":0.029033118326265782,"score_gpt":0.3127103407830056,"score_spread":0.2836772224567398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408957204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99814045,0.0008019322,0.00018797659,0.00024297572,0.00003819737,0.00008838238,0.00035230146,0.000026832095,0.00012095516],"genre_scores_gemma":[0.99789983,0.00001584076,0.0016216408,0.00017679682,0.0000046859977,0.00000367486,0.00007990941,0.000004534257,0.00019307395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981062,0.0005138127,0.0005814754,0.0005541782,0.000038790975,0.00020557072],"domain_scores_gemma":[0.99787456,0.0014675688,0.0001710188,0.0003572778,0.00009348995,0.000036074805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000920993,0.00017959955,0.0008337109,0.0011126352,0.000088305176,0.000033108678,0.0001483163,0.00011803473,0.000026139352],"category_scores_gemma":[0.0007603982,0.000148257,0.000099756064,0.0039097373,0.00020076735,0.00006253845,0.00013254053,0.00019954394,4.4883288e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007161044,0.00028249228,0.968682,0.0000077755085,0.0054370523,0.0000036692984,0.0008462829,0.00006283782,0.0055548474,0.000006822613,0.0000131671895,0.01903144],"study_design_scores_gemma":[0.0010094707,0.000111675494,0.97969764,0.000035470144,0.011135532,2.3053525e-7,0.0027242952,0.0041350545,0.00090181653,0.00005938937,0.00003645953,0.00015298523],"about_ca_topic_score_codex":0.0040071546,"about_ca_topic_score_gemma":0.0045005083,"teacher_disagreement_score":0.018878454,"about_ca_system_score_codex":0.0000151149825,"about_ca_system_score_gemma":0.000023636674,"threshold_uncertainty_score":0.60576457},"labels":[],"label_agreement":null},{"id":"W4409360170","doi":"10.1016/j.lana.2025.101058","title":"The impact of biosimilar use on healthcare utilization among new users of etanercept for inflammatory arthritis: a population-based regression discontinuity analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Regional Health - Americas","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia; Research Canada; Arthritis Research Centre of Canada; Simon Fraser University","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; University of British Columbia; Arthritis Society","keywords":"Biosimilar; Etanercept; Medicine; Regression discontinuity design; Population; Regression analysis; Arthritis; Rheumatoid arthritis; Immunology; Environmental health; Internal medicine; Computer science; Machine learning; Pathology","score_opus":0.1130884909217401,"score_gpt":0.43076291191455585,"score_spread":0.31767442099281573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409360170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91873467,0.008486948,0.0073436555,0.06306329,0.00028680803,0.001541632,0.0004419729,0.00006289291,0.000038147304],"genre_scores_gemma":[0.99555767,0.0014143115,0.0005787881,0.0019433813,0.00004108627,0.000022681585,0.00016306486,0.000009540714,0.00026947094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978421,0.0008300176,0.0006220958,0.00025617774,0.00008773682,0.0003618987],"domain_scores_gemma":[0.9969529,0.0016262071,0.00069125067,0.0005354262,0.00014402674,0.00005018517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000873656,0.00017838339,0.0007388664,0.00016053187,0.00034324112,0.000013419748,0.00026563313,0.00015503382,0.000020420328],"category_scores_gemma":[0.00032390916,0.000090683134,0.00042309525,0.0007919637,0.00048069132,0.00004507478,0.00003200698,0.0002466549,5.620835e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051286677,0.0002618542,0.80387306,0.0002646484,0.0017907117,6.7804814e-7,0.00051152846,0.0014569297,0.00084074686,0.008752889,0.053362004,0.1237563],"study_design_scores_gemma":[0.0010345193,0.0005286971,0.99091053,0.00044790146,0.00015395666,8.2571006e-7,0.00017351893,0.0010861292,0.0005937173,0.00095684046,0.003997137,0.00011624639],"about_ca_topic_score_codex":0.0048746318,"about_ca_topic_score_gemma":0.0014419331,"teacher_disagreement_score":0.18703747,"about_ca_system_score_codex":0.00011288475,"about_ca_system_score_gemma":0.0004279768,"threshold_uncertainty_score":0.73690176},"labels":[],"label_agreement":null},{"id":"W4409566295","doi":"10.1080/17576180.2025.2471243","title":"Recommendations on biomarker assay validation (BAV) in tissues by GCC","year":2025,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada); Green Communities Canada; Royal Canadian Military Institute; Altasciences (Canada)","funders":"","keywords":"Biomarker; Computational biology; Chemistry; Chromatography; Biology; Biochemistry","score_opus":0.029880232097949454,"score_gpt":0.33936287186063835,"score_spread":0.3094826397626889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409566295","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11367235,0.06828034,0.053212777,0.35945797,0.0082229795,0.0025382396,0.0016961689,0.00097209285,0.39194706],"genre_scores_gemma":[0.95783377,0.00056645233,0.001572591,0.0015190317,0.000012408721,0.00003062323,0.0004536424,0.000010417501,0.038001046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984214,0.00058072264,0.000370037,0.00035490494,0.000036143403,0.00023683601],"domain_scores_gemma":[0.99917114,0.0003784218,0.0000790086,0.00030313246,0.000050344435,0.000017948696],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007735174,0.00015239633,0.00030568178,0.00045402485,0.00011127514,0.000028209299,0.00018078454,0.0002789181,0.0023412912],"category_scores_gemma":[0.00028606018,0.00012397008,0.00014524523,0.0010501968,0.00010677849,0.00004842129,0.000050790295,0.00018432165,0.00021264984],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012732753,0.000797958,0.014845884,0.000020480362,0.0015077301,0.0000031588766,0.000059275608,0.0000033344772,0.07531515,0.0047001108,0.27830917,0.62431043],"study_design_scores_gemma":[0.0006881936,0.00005584179,0.0072998703,0.000056969395,0.00034400573,7.2735867e-7,0.00012439869,0.00012002408,0.11825833,0.00082708563,0.8719912,0.00023333184],"about_ca_topic_score_codex":0.00014876248,"about_ca_topic_score_gemma":0.00006985096,"teacher_disagreement_score":0.84416145,"about_ca_system_score_codex":0.00007523827,"about_ca_system_score_gemma":0.000022284325,"threshold_uncertainty_score":0.9985707},"labels":[],"label_agreement":null},{"id":"W4409626611","doi":"10.1158/1538-7445.am2025-4039","title":"Abstract 4039: An isogenic CRISPR screen identifies novel MYC-driven vulnerabilities","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"CRISPR; Biology; Computational biology; Genetics; Cancer research; Gene","score_opus":0.12796377370158396,"score_gpt":0.4667443649151886,"score_spread":0.33878059121360465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409626611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9426308,0.018834839,0.0008561023,0.0097866785,0.0017981005,0.0008389655,0.0007081709,0.00016992552,0.024376377],"genre_scores_gemma":[0.9612608,0.0005126615,0.00034120755,0.0004621062,0.00011532207,0.00009430178,0.000035995225,0.000017806748,0.037159786],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979404,0.00042016842,0.00030703074,0.00051934196,0.00011682143,0.00069623394],"domain_scores_gemma":[0.99844956,0.0005410931,0.00003572467,0.00054215366,0.00037171482,0.00005974071],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015696875,0.00016329337,0.0003001079,0.00028866032,0.00046834894,0.0000906753,0.00060586055,0.00036483648,0.0046749674],"category_scores_gemma":[0.00037743032,0.0001318076,0.00012035766,0.00047572333,0.0010681463,0.00014267156,0.00026234117,0.0010095743,0.00018251361],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025440124,0.000206198,0.0013415747,0.00008766164,0.00027289038,0.0000037014318,0.00018332897,0.0000060952975,0.9367059,0.0056546046,0.044346236,0.010937415],"study_design_scores_gemma":[0.0013790027,0.00024625717,0.05257727,0.00021905081,0.00007119637,0.0000057280386,0.001441932,0.000027475098,0.78209424,0.0050248336,0.1565395,0.0003735338],"about_ca_topic_score_codex":0.002508946,"about_ca_topic_score_gemma":0.0009706475,"teacher_disagreement_score":0.15461168,"about_ca_system_score_codex":0.00013789663,"about_ca_system_score_gemma":0.00032691495,"threshold_uncertainty_score":0.9962349},"labels":[],"label_agreement":null},{"id":"W4409980294","doi":"10.1002/bcp.70086","title":"A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease","year":2025,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Service Executive; Wellcome Trust; Canadian Institute for Theoretical Astrophysics","keywords":"Medicine; Adalimumab; Biosimilar; Inflammatory bowel disease; Internal medicine; Ulcerative colitis; Adverse effect; Nocebo; Faecal calprotectin; Disease; Infliximab; Anxiety; Calprotectin; Placebo; Psychiatry; Pathology; Alternative medicine","score_opus":0.047385330626193926,"score_gpt":0.4026851161154693,"score_spread":0.3552997854892754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409980294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97618806,0.01240577,0.0026254037,0.0051917434,0.002781852,0.00053063995,0.00011494065,0.000017347893,0.0001442407],"genre_scores_gemma":[0.9928658,0.00083553593,0.0027311682,0.0031497432,0.00014450785,0.00001042139,0.000012136557,0.000012807588,0.00023785798],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99565643,0.0010992184,0.0024211647,0.00030769684,0.00006532653,0.00045018233],"domain_scores_gemma":[0.99613583,0.0023409314,0.00090406387,0.00012664607,0.0003829907,0.00010955934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002880127,0.0001654172,0.0012210918,0.00043013075,0.00006637092,0.000021140162,0.00039665605,0.00040534642,0.00029359647],"category_scores_gemma":[0.0024432074,0.00016233092,0.0010960004,0.00060070225,0.00037367092,0.000095943426,0.00010322732,0.00079551566,0.0000010759811],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016519615,0.010483096,0.25136334,0.000624262,0.023610016,0.001034502,0.00017560572,0.00025410854,0.08034584,0.0007823508,0.047354482,0.5674528],"study_design_scores_gemma":[0.04697297,0.0021887776,0.5909792,0.0017021226,0.031877127,0.00016277963,0.0006482298,0.0024201002,0.023482725,0.0070576007,0.29144755,0.0010608323],"about_ca_topic_score_codex":0.000015370819,"about_ca_topic_score_gemma":0.00008039253,"teacher_disagreement_score":0.56639194,"about_ca_system_score_codex":0.00004755949,"about_ca_system_score_gemma":0.00033600855,"threshold_uncertainty_score":0.6619663},"labels":[],"label_agreement":null},{"id":"W4410303297","doi":"10.1080/1750743x.2025.2493039","title":"Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medac; Cilag; Mylan; Celgene; Biogen; Gilead Sciences; Chugai Pharmaceutical; Celltrion; Sanofi; Eli Lilly and Company; AstraZeneca; Edwards Lifesciences; Amgen","keywords":"Biosimilar; Etanercept; Medicine; Plain language; Pharmacology; Internal medicine; Intensive care medicine; Oncology; Physical therapy; Rheumatoid arthritis; Linguistics","score_opus":0.02248146023747329,"score_gpt":0.35650275953216726,"score_spread":0.334021299294694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410303297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931316,0.0027823197,0.000066367385,0.001382366,0.0000707864,0.0010471743,0.000026178532,0.00005848519,0.0014347733],"genre_scores_gemma":[0.9974996,0.00034582993,0.0002621873,0.0009272581,0.000008791638,0.00009521981,0.000054490272,0.000024324076,0.0007822963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972142,0.0014745125,0.00040658147,0.0004046139,0.00008234615,0.00041775344],"domain_scores_gemma":[0.9985458,0.0006675157,0.00011457755,0.0006256286,0.000025108584,0.00002135678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061661477,0.00034350625,0.000655392,0.00033486157,0.00019827603,0.00011789329,0.00037566538,0.00012222845,0.00013751896],"category_scores_gemma":[0.000015223756,0.00017478362,0.00007398703,0.00093859853,0.00021935752,0.0001659757,0.00002661186,0.00033490622,0.0000039248243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00484022,0.008751292,0.85918045,0.000061501225,0.0013210967,0.00019659573,0.026291128,0.00003874691,0.019728815,0.00047729825,0.00029135402,0.07882151],"study_design_scores_gemma":[0.007919597,0.0021812355,0.96664375,0.00035469185,0.00014066049,0.000015215741,0.019785205,0.00007198228,0.0012258055,0.00006663934,0.0012644043,0.00033082438],"about_ca_topic_score_codex":0.006525782,"about_ca_topic_score_gemma":0.04162815,"teacher_disagreement_score":0.1074633,"about_ca_system_score_codex":0.00020774918,"about_ca_system_score_gemma":0.00017212219,"threshold_uncertainty_score":0.98650736},"labels":[],"label_agreement":null},{"id":"W4410512993","doi":"10.3899/jrheum.2025-0390.pv267","title":"REAL-WORLD EXPERIENCE OF EFFECTIVENESS OF NONMEDICAL SWITCH FROM ORIGINATOR TO BIOSIMILAR RITUXIMAB AND BETWEEN BIOSIMILARS IN CONNECTIVE TISSUE DISEASES AND VASCULITIS","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Rituximab; Vasculitis; Connective tissue; Immunology; Intensive care medicine; Internal medicine; Pathology; Lymphoma; Disease","score_opus":0.010441297408989697,"score_gpt":0.3126655893757405,"score_spread":0.3022242919667508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410512993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259794,0.004795154,0.0007809625,0.0012257452,0.00027023096,0.00020158484,0.000080505575,0.0000043138934,0.000043587097],"genre_scores_gemma":[0.9974864,0.0019191696,0.00047640014,0.00009223899,0.000003636824,0.000004069996,0.0000020613325,0.0000062369304,0.000009773864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766093,0.0011971579,0.0006632276,0.0001947669,0.000062029125,0.00022186628],"domain_scores_gemma":[0.99500203,0.0043471996,0.00028021418,0.00018974714,0.00012209862,0.000058698904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001008618,0.0001633124,0.0010878494,0.0002973224,0.0000557022,0.0000042635775,0.0002808964,0.00020871242,0.000051017883],"category_scores_gemma":[0.0005855809,0.00010632278,0.000067449204,0.00036204746,0.0010219566,0.00005280352,0.0001692606,0.0002979391,7.684358e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00143644,0.00021110091,0.94915646,0.00020712525,0.0005652832,0.000007723757,0.0009111599,6.250383e-7,0.040273424,0.0019323285,0.0001928299,0.0051055118],"study_design_scores_gemma":[0.003951957,0.0006207634,0.82171905,0.0012243567,0.00039149477,0.000109435496,0.00082308776,0.0000040426817,0.16486867,0.005051882,0.0010731535,0.00016212775],"about_ca_topic_score_codex":0.00095183554,"about_ca_topic_score_gemma":0.00012451806,"teacher_disagreement_score":0.12743741,"about_ca_system_score_codex":0.000031882068,"about_ca_system_score_gemma":0.00009362249,"threshold_uncertainty_score":0.43357173},"labels":[],"label_agreement":null},{"id":"W4410785032","doi":"10.1093/9780199289011.003.0065","title":"Overview","year":2011,"lang":"en","type":"book-chapter","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Geography","score_opus":0.09931609167791068,"score_gpt":0.29619949079344055,"score_spread":0.19688339911552988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410785032","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.1348748e-7,0.025585327,0.00010580987,0.00018575808,0.00058177736,0.000092704366,0.000031115214,0.000065734836,0.97335154],"genre_scores_gemma":[0.000046613884,0.0029700985,0.0005859745,0.0014202658,0.000039809645,0.0000015354793,0.00002497014,0.000025479016,0.99488527],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.999265,0.000023474964,0.00022629536,0.00027945984,0.000016657863,0.00018912007],"domain_scores_gemma":[0.9994838,0.00005260775,0.00007957253,0.00032558333,0.000038364553,0.000020037427],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013409198,0.00023806177,0.0003982212,0.00005471255,0.00004008408,0.000004492093,0.00019098308,0.0010242488,0.17908971],"category_scores_gemma":[0.0000106367415,0.00016411935,0.0002343055,0.000008496137,0.0002049986,0.000013057778,0.0001074704,0.00042245194,0.0070214584],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013364418,0.000010741196,0.0000015703909,0.000020067437,0.00022802965,0.000004702782,0.000004200449,2.6870847e-10,0.00031269688,0.85653937,0.09272614,0.05013911],"study_design_scores_gemma":[0.00011529423,0.000068500995,0.000013338618,0.000055652636,0.00013224037,0.000021909887,5.295246e-7,1.721198e-8,0.0016367137,0.07988295,0.9178575,0.00021533367],"about_ca_topic_score_codex":0.000009953489,"about_ca_topic_score_gemma":0.000007308537,"teacher_disagreement_score":0.82513136,"about_ca_system_score_codex":0.000012554575,"about_ca_system_score_gemma":0.00002455846,"threshold_uncertainty_score":0.9937517},"labels":[],"label_agreement":null},{"id":"W4411046742","doi":"10.1007/s40259-025-00727-z","title":"Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings","year":2025,"lang":"en","type":"review","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada","funders":"Sandoz; Diakonhjemmet","keywords":"Biosimilar; Real world evidence; Intensive care medicine; Medicine; Pharmacotherapy; Internal medicine","score_opus":0.11594011786904149,"score_gpt":0.39974440582842885,"score_spread":0.2838042879593874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411046742","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015949662,0.99348676,8.380548e-7,0.00087187736,0.0007885649,0.0009201423,0.0009227095,0.000026965583,0.0028226685],"genre_scores_gemma":[0.000027150745,0.9965358,0.0006684523,0.0013059397,0.00002601024,0.000056635356,0.00017219268,0.000018482713,0.0011893404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967851,0.00070979516,0.0014712762,0.00063467753,0.000053332555,0.00034583197],"domain_scores_gemma":[0.99705,0.0018918085,0.000481796,0.00045775872,0.00007397722,0.00004468493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007371716,0.00039870295,0.0019452503,0.00047393847,0.00007036121,0.000012247503,0.00027785392,0.000959281,0.00007835758],"category_scores_gemma":[0.0004562026,0.00029724737,0.0004240191,0.0007631338,0.0004443775,0.00002609701,0.00023265352,0.0007715413,0.000017858534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028402841,0.00023081312,0.00073643913,0.0022519398,0.0001958949,0.0000020017478,0.000023028235,5.997183e-8,0.000003821516,0.0032606267,0.016182423,0.9770846],"study_design_scores_gemma":[0.00038847554,0.00021939744,0.0016630928,0.009563596,0.00047035428,0.000002732951,0.000015520545,2.4942307e-7,0.00007370167,0.00012210537,0.9872003,0.00028045732],"about_ca_topic_score_codex":0.000036087356,"about_ca_topic_score_gemma":0.000079118065,"teacher_disagreement_score":0.9768041,"about_ca_system_score_codex":0.000045267097,"about_ca_system_score_gemma":0.00020385231,"threshold_uncertainty_score":0.99994797},"labels":[],"label_agreement":null},{"id":"W4411394543","doi":"10.1016/j.ard.2025.06.020","title":"POS0659 EFFICACY, SAFETY AND IMMUNOGENICITY OF THE PROPOSED TOCILIZUMAB BIOSIMILAR RGB-19, INTRAVENOUSLY ADMINISTERED TO PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS: WEEK 24 DATA FROM A PHASE 3 STUDY","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Biosimilar; Tocilizumab; Immunogenicity; Rheumatoid arthritis; Pharmacology; Immunology; Internal medicine; Antibody","score_opus":0.09250792226928192,"score_gpt":0.3679126803776471,"score_spread":0.2754047581083652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411394543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98385984,0.005724841,0.0001031509,0.0041242586,0.0002364225,0.0018406966,0.0040409165,0.000024685378,0.00004519391],"genre_scores_gemma":[0.9983816,0.0006696284,0.0001483808,0.00060992525,0.00000392603,0.00002304676,0.00004752843,0.0000143705265,0.00010160779],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99710214,0.0010176402,0.0008229712,0.0005078126,0.00014882979,0.00040061254],"domain_scores_gemma":[0.99680007,0.0008419471,0.00041103712,0.001701058,0.0001566457,0.00008923445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052159117,0.0002956028,0.0008417165,0.000065569446,0.00030532308,0.000031086474,0.0012659469,0.00011488994,0.000155476],"category_scores_gemma":[0.0016937352,0.00015819084,0.00016715452,0.00040908816,0.0007725242,0.000093498056,0.001076224,0.00020478191,0.00000409641],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12124506,0.07539288,0.042189058,0.0014041384,0.036783274,0.000033568147,0.016868787,0.000044886197,0.03731119,0.0013719792,0.02183325,0.64552194],"study_design_scores_gemma":[0.030044995,0.007406262,0.6946745,0.007712558,0.0026354757,0.000024823961,0.012188546,0.00018593963,0.23843949,0.0031960916,0.002428061,0.0010632642],"about_ca_topic_score_codex":0.00048539575,"about_ca_topic_score_gemma":0.0002991331,"teacher_disagreement_score":0.65248543,"about_ca_system_score_codex":0.000016425149,"about_ca_system_score_gemma":0.000356578,"threshold_uncertainty_score":0.64508355},"labels":[],"label_agreement":null},{"id":"W4411428627","doi":"10.1016/j.ard.2025.06.528","title":"POS1178 DRUG DISCONTINUATION IN INFLAMMATORY ARTHRITIS FOLLOWING MANDATORY NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR IN QUEBEC, CANADA","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke; Montreal Clinical Research Institute; McGill University Health Centre","funders":"","keywords":"Medicine; Biosimilar; Discontinuation; Drug; Arthritis; Drug approval; Rheumatoid arthritis; Intensive care medicine; Pharmacology; Dermatology; Internal medicine","score_opus":0.007377121633257179,"score_gpt":0.277455790872275,"score_spread":0.27007866923901785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411428627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97955525,0.004746009,0.000057574653,0.014364527,0.0007899781,0.00029835972,0.00006868324,0.000011222388,0.00010839198],"genre_scores_gemma":[0.9967691,0.00015512592,0.000042739408,0.0025568665,0.0000088877205,0.000026954975,0.000013819353,0.000008181957,0.00041832845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829,0.00036931943,0.00062979583,0.00025968588,0.00014011783,0.00031108657],"domain_scores_gemma":[0.9988587,0.0005846179,0.00011929082,0.00033819716,0.000034858793,0.000064372456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051038293,0.00017268157,0.0004555849,0.00014825244,0.00007369345,0.000022781827,0.0004483052,0.0001234831,0.00017801838],"category_scores_gemma":[0.0012393637,0.00012643157,0.00015617651,0.0003153472,0.000079045814,0.00010075293,0.00019031976,0.00022705916,0.0000049357723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048115692,0.0011284662,0.56968886,0.00041348895,0.0010979323,0.000101921316,0.0015397872,0.000043563545,0.004387335,0.0021471805,0.10781101,0.3111593],"study_design_scores_gemma":[0.001998211,0.00002581988,0.9604015,0.008295126,0.00008385253,6.431998e-7,0.0010452349,0.00015900725,0.01762569,0.002994841,0.006975688,0.00039443123],"about_ca_topic_score_codex":0.3435594,"about_ca_topic_score_gemma":0.78331846,"teacher_disagreement_score":0.43975905,"about_ca_system_score_codex":0.000067158915,"about_ca_system_score_gemma":0.0007808896,"threshold_uncertainty_score":0.6608119},"labels":[],"label_agreement":null},{"id":"W4411621246","doi":"10.1007/s11096-025-01956-6","title":"Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: a systematic review of real-world evidence","year":2025,"lang":"en","type":"review","venue":"International Journal of Clinical Pharmacy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Sydney","keywords":"Biosimilar; Medicine; Observational study; Rheumatoid arthritis; CINAHL; Adverse effect; MEDLINE; Intensive care medicine; Family medicine; Internal medicine; Psychological intervention; Nursing","score_opus":0.2861957787491073,"score_gpt":0.5490243562708481,"score_spread":0.2628285775217408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411621246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045141022,0.9968015,0.000018955267,0.00013140432,0.0013179564,0.00084960734,0.00017928393,0.000004278627,0.00024560958],"genre_scores_gemma":[0.0059742397,0.993663,0.00019177093,0.000057607293,0.000040657673,0.000025984698,0.000019751378,0.000006758299,0.000020228385],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99079216,0.0039823377,0.0046335054,0.0002909719,0.00015154725,0.00014950833],"domain_scores_gemma":[0.97972584,0.015488517,0.0038276415,0.00019159606,0.00072168343,0.000044731292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035724621,0.00031839055,0.005191538,0.00040008494,0.000025799305,0.000009363365,0.0005642138,0.0002272135,0.00011590991],"category_scores_gemma":[0.0043069692,0.00020581494,0.0008095059,0.00033445595,0.00034701428,0.000118202355,0.00016023948,0.0006666812,0.000002871456],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005668421,0.0011035724,0.0011779618,0.7697861,0.007805861,0.00012580019,0.000048508227,0.0000013128735,0.00009279475,0.00055373774,0.00011786882,0.21351805],"study_design_scores_gemma":[0.0038722209,0.0004968441,0.00053948,0.9768977,0.001312538,0.000099429024,0.000009427679,8.9841507e-7,0.0004101706,0.00004329777,0.016135812,0.00018217012],"about_ca_topic_score_codex":0.000021588537,"about_ca_topic_score_gemma":0.000015338068,"teacher_disagreement_score":0.21333587,"about_ca_system_score_codex":0.00018413085,"about_ca_system_score_gemma":0.00059926615,"threshold_uncertainty_score":0.839289},"labels":[],"label_agreement":null},{"id":"W4411839965","doi":"10.1038/s41409-025-02672-5","title":"Correction: Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium","year":2025,"lang":"en","type":"erratum","venue":"Bone Marrow Transplantation","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Bioproduction; Medicine; Control (management); Computer science; Biotechnology; Biology; Artificial intelligence","score_opus":0.026267859225672208,"score_gpt":0.2972623132131521,"score_spread":0.2709944539874799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411839965","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3029329,0.03653425,0.04596809,0.07241893,0.47932613,0.022856722,0.03545294,0.00037066563,0.0041394024],"genre_scores_gemma":[0.96435124,0.0027493269,0.0003470179,0.00044510348,0.0006406985,0.00015606516,0.0036968312,0.00003290951,0.027580837],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971251,0.0009936949,0.0011273746,0.00043344905,0.00013989807,0.00018046511],"domain_scores_gemma":[0.996869,0.0008725887,0.0012606554,0.00043126373,0.0005549596,0.000011533556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011363963,0.00025932293,0.0006418951,0.00010294244,0.00017716126,0.0000060856723,0.00022404832,0.0009841345,0.00005379685],"category_scores_gemma":[0.0004482742,0.00017317361,0.0003222963,0.000314627,0.00048493186,0.000092618684,0.000013895161,0.00076919317,8.3577424e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017436435,0.00011237502,0.0005162891,0.0008157861,0.00035827712,1.254652e-7,0.00040665435,0.000026096535,0.88885945,0.00026583456,0.1043805,0.0025149651],"study_design_scores_gemma":[0.001674607,0.00021937214,0.047526903,0.001228079,0.0028461728,0.00001960348,0.00029470318,0.00004277748,0.93241423,0.0010628751,0.012420469,0.0002501877],"about_ca_topic_score_codex":0.00073918444,"about_ca_topic_score_gemma":0.00029846537,"teacher_disagreement_score":0.6614183,"about_ca_system_score_codex":0.000061657665,"about_ca_system_score_gemma":0.00025300204,"threshold_uncertainty_score":0.75905466},"labels":[],"label_agreement":null},{"id":"W4412108571","doi":"10.3899/jrheum.2025-0314.pod09","title":"Comparative Safety and Effectiveness of Biosimilar and Originator Rituximab for Induction or Maintenance in ANCA-Associated Vasculitis: 6-Month Results of a Longitudinal Cohort Study","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia; Alberta Hospital Edmonton; Western University; University of Toronto; Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre; University of Ottawa; Mount Sinai Hospital; University of Calgary; St. Joseph’s Healthcare Hamilton; Lawson Health Research Institute; University of Alberta","funders":"","keywords":"Medicine; Biosimilar; Rituximab; Internal medicine; Granulomatosis with polyangiitis; Cohort; Vasculitis; Adverse effect; Maintenance therapy; Microscopic polyangiitis; Tolerability; Surgery; Chemotherapy; Disease; Lymphoma","score_opus":0.021386730429274848,"score_gpt":0.3217244021310459,"score_spread":0.30033767170177106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412108571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844025,0.013941527,0.0005818577,0.00016308612,0.00020247638,0.0006436818,0.000043058008,0.000003122429,0.000018736218],"genre_scores_gemma":[0.9923002,0.0074961614,0.0001675525,0.0000071107033,8.6011045e-7,0.00000665993,0.0000017068289,0.000003639307,0.000016088185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712944,0.0016865461,0.0008136579,0.00015879574,0.000035335896,0.00017623545],"domain_scores_gemma":[0.9961807,0.0028535249,0.00059330027,0.00012506843,0.00023270807,0.000014665807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039991047,0.00013543974,0.0013314616,0.00018025002,0.00007222121,0.0000031295403,0.00013980523,0.00018455484,0.0000039123815],"category_scores_gemma":[0.000845204,0.00007591068,0.00007359712,0.00028657124,0.000554152,0.000051989653,0.00005889232,0.0002713236,1.00596814e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050773617,0.0020354795,0.9305685,0.00069600134,0.0041648634,0.0000059904205,0.001310331,0.0000053755803,0.0026575776,0.0030187368,0.00020948455,0.0045540174],"study_design_scores_gemma":[0.023560839,0.0032254918,0.96271557,0.0014739886,0.0008416756,0.00048031553,0.0018110377,0.000026058076,0.003988008,0.0012141122,0.0005245592,0.00013836165],"about_ca_topic_score_codex":0.00016317381,"about_ca_topic_score_gemma":0.00025319142,"teacher_disagreement_score":0.032147028,"about_ca_system_score_codex":0.00004539847,"about_ca_system_score_gemma":0.00009494712,"threshold_uncertainty_score":0.30955476},"labels":[],"label_agreement":null},{"id":"W4412387313","doi":"10.1002/acr.25610","title":"Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?","year":2025,"lang":"en","type":"article","venue":"Arthritis Care & Research","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Arthritis Research Centre of Canada; Centre for Advancing Health Outcomes","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Michael Smith Health Research BC","keywords":"Biosimilar; Business; Medicine; Resource (disambiguation); Lead (geology); Arthritis; Intensive care medicine; Immunology; Internal medicine; Computer science","score_opus":0.03354943901015619,"score_gpt":0.3863419439335702,"score_spread":0.352792504923414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412387313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787013,0.0141357975,0.00008272456,0.0029958053,0.0001717278,0.0024541572,0.00027159008,0.000092799004,0.0010940892],"genre_scores_gemma":[0.9930211,0.0029401125,0.00021024817,0.0029388184,0.00006830742,0.00019923448,0.00048648423,0.000043040647,0.00009266961],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.993284,0.0027342497,0.00093937543,0.0010778768,0.00040868841,0.0015557957],"domain_scores_gemma":[0.99775493,0.00053000194,0.0001260705,0.00077163556,0.00052090193,0.00029646573],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022774842,0.0004191516,0.0008239069,0.0013586158,0.00057138735,0.00009438718,0.00067717064,0.00090311526,0.0002578325],"category_scores_gemma":[0.0014502638,0.0003366645,0.000094434676,0.0020114372,0.0007687648,0.00023740373,0.00053954066,0.0019425673,0.000022233407],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002483141,0.000755665,0.3948299,0.00031514314,0.000083727704,0.0003963394,0.005136355,0.0000066049333,0.00059462606,0.00036504076,0.0026711677,0.5923623],"study_design_scores_gemma":[0.029716596,0.005426828,0.85503775,0.007725086,0.000025482135,0.0000499738,0.025498284,0.00009088822,0.0050934423,0.00016658321,0.06985663,0.0013124811],"about_ca_topic_score_codex":0.0019838528,"about_ca_topic_score_gemma":0.03729956,"teacher_disagreement_score":0.5910498,"about_ca_system_score_codex":0.0006903325,"about_ca_system_score_gemma":0.0019520586,"threshold_uncertainty_score":0.99990857},"labels":[],"label_agreement":null},{"id":"W4412490411","doi":"10.1186/s13075-025-03607-7","title":"Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis","year":2025,"lang":"en","type":"article","venue":"Arthritis Research & Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Arthritis Patient Alliance; Centre Hospitalier de l’Université de Montréal; McGill University; Université de Sherbrooke; University of Alberta; Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Internal medicine; Rheumatoid arthritis; Etanercept; Hazard ratio; Confidence interval; Proportional hazards model; Odds ratio; Log-rank test; Interim analysis; Logistic regression; Gastroenterology; Rheumatology; Multivariate analysis; Clinical trial","score_opus":0.045163626680807575,"score_gpt":0.40049992579847543,"score_spread":0.35533629911766784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412490411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9579496,0.03368022,0.00019657964,0.0057099457,0.00019729306,0.0008657231,0.00008533523,0.00011194616,0.0012033597],"genre_scores_gemma":[0.86686665,0.12961784,0.00042575,0.0005628812,0.000023164532,0.00011984043,0.00009367346,0.000021485319,0.0022687179],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953514,0.002238978,0.0006249794,0.0008278769,0.00018614586,0.0007706217],"domain_scores_gemma":[0.99827117,0.0005179202,0.00007673784,0.00061887834,0.0003018951,0.00021338975],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002319585,0.00028981265,0.000605251,0.0015066321,0.00034701958,0.00013880696,0.0002983883,0.0003309685,0.0026942722],"category_scores_gemma":[0.0005196344,0.00022196806,0.00014831543,0.002539438,0.0005884581,0.00031302564,0.00018102414,0.0007639778,0.000014155818],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015769944,0.0011597432,0.118034504,0.000080350874,0.0006763655,0.00051531056,0.00091171294,0.000001838281,0.08632619,0.0028901112,0.00483778,0.76879615],"study_design_scores_gemma":[0.017145827,0.002779541,0.47418228,0.0039624795,0.00011821123,0.000034140296,0.003379683,0.0008514689,0.057751287,0.016128635,0.42199358,0.0016728669],"about_ca_topic_score_codex":0.00032030194,"about_ca_topic_score_gemma":0.001950744,"teacher_disagreement_score":0.7671233,"about_ca_system_score_codex":0.00015148682,"about_ca_system_score_gemma":0.00028918337,"threshold_uncertainty_score":0.9982174},"labels":[],"label_agreement":null},{"id":"W4412661821","doi":"10.1093/humrep/deaf144","title":"Methodological concerns and clinical relevance: a critical appraisal of the meta-analysis on biosimilars versus originator follitropin alfa in ART","year":2025,"lang":"en","type":"letter","venue":"Human Reproduction","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Conversant (Canada)","funders":"","keywords":"Critical appraisal; Biosimilar; Meta-analysis; Relevance (law); Medicine; MEDLINE; Intensive care medicine; Internal medicine; Alternative medicine; Political science; Pathology; Law","score_opus":0.36833543517543865,"score_gpt":0.4976417602416229,"score_spread":0.12930632506618422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412661821","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003121888,0.008840498,0.00055556756,0.97263944,0.011267222,0.0010042958,0.00031031496,0.00009731829,0.0021634656],"genre_scores_gemma":[0.10579936,0.0057929605,0.033151343,0.7052301,0.01760971,0.00092724885,0.0018139613,0.00038083876,0.12929444],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9909921,0.0055290954,0.0012009521,0.0016876078,0.00016164438,0.00042855972],"domain_scores_gemma":[0.9896996,0.008244421,0.00041073473,0.0014492737,0.0001710108,0.00002498513],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003472553,0.0004330616,0.002374324,0.0003459359,0.00016641014,0.000023737393,0.00041862958,0.0019778358,0.00072353764],"category_scores_gemma":[0.011852056,0.0002655119,0.0018855586,0.00074404845,0.0018395879,0.00003526018,0.00021648593,0.0032909676,0.0000111992495],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008460714,0.0003668787,0.0006453272,0.00019549724,0.052544132,0.000030164569,0.000031010004,0.000003774623,0.0009857396,0.005365196,0.93736124,0.001624987],"study_design_scores_gemma":[0.0008727829,0.0006148741,0.0016260823,0.000031405933,0.08697398,0.000007997372,0.000022182385,0.0000030167193,0.003077352,0.0014242128,0.90500367,0.00034244213],"about_ca_topic_score_codex":0.000037286063,"about_ca_topic_score_gemma":0.000040008763,"teacher_disagreement_score":0.2674093,"about_ca_system_score_codex":0.000064568674,"about_ca_system_score_gemma":0.00007135487,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W4413116692","doi":"10.1208/s12248-025-01118-6","title":"Assessment of Neutralizing Antibody Activity in Clinical Studies: Use of Surrogate Measurements Instead of Stand-alone Assays","year":2025,"lang":"en","type":"review","venue":"The AAPS Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Neutralizing antibody; Antibody; Virology; Immunology; Medicine","score_opus":0.4557701382744787,"score_gpt":0.5553614931886626,"score_spread":0.09959135491418386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413116692","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031766237,0.9948177,0.00020338532,0.00006862754,0.0009984553,0.0004145537,0.00011121625,0.0000038881194,0.00020559212],"genre_scores_gemma":[0.0070014643,0.99205303,0.00071368826,0.000019403042,0.00003004841,0.0000029999062,0.0000052914156,0.000012867197,0.00016120868],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911185,0.005873038,0.0022759694,0.00025660035,0.00015814327,0.00031778662],"domain_scores_gemma":[0.993845,0.0030761734,0.002226178,0.00045625333,0.0003676864,0.000028696128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009365406,0.00032043844,0.003530525,0.00028235183,0.000081725826,0.00001073616,0.0005478285,0.0005277889,0.000039070255],"category_scores_gemma":[0.0012480324,0.00017674264,0.00093628565,0.0004668744,0.00064515596,0.00008151999,0.0002878282,0.0017670221,7.494941e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003346747,0.0019161057,0.010116239,0.02045397,0.011570858,0.000021971744,0.00011383807,0.0000049706664,0.00645679,0.00036177482,0.00082779553,0.947821],"study_design_scores_gemma":[0.011356379,0.0043073003,0.054471243,0.2673198,0.024402184,0.00045817858,0.0006627699,0.000011705941,0.008344792,0.0008941458,0.6259193,0.00185218],"about_ca_topic_score_codex":0.000028558487,"about_ca_topic_score_gemma":0.00001605141,"teacher_disagreement_score":0.9459688,"about_ca_system_score_codex":0.00010759623,"about_ca_system_score_gemma":0.0007292487,"threshold_uncertainty_score":0.767693},"labels":[],"label_agreement":null},{"id":"W4413177238","doi":"10.3389/fphar.2025.1599013","title":"Contextual factors in value-based decision support to enhance health technologies adoption: the case of biosimilars","year":2025,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"King Khalid University; Mahidol University; Ewha Womans University","keywords":"Biosimilar; Operationalization; Stakeholder; Multiple-criteria decision analysis; Knowledge management; Context (archaeology); Stakeholder engagement; Business; Management science; Process management; Medicine; Computer science; Political science; Public relations; Economics; Engineering; Operations research","score_opus":0.01692070132280413,"score_gpt":0.36625977853145864,"score_spread":0.3493390772086545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413177238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8082451,0.01750475,0.10028147,0.05835702,0.012106242,0.0024639904,0.0002132015,0.00019179682,0.0006363997],"genre_scores_gemma":[0.984528,0.00026310974,0.009072666,0.0058846874,0.0000058382543,0.00005511844,0.000008412207,0.000008211386,0.00017393375],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787927,0.00057378906,0.0006312687,0.00040302938,0.000031064323,0.00048159718],"domain_scores_gemma":[0.9989269,0.00060100516,0.00013693859,0.00026558957,0.000049197748,0.000020387894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010361401,0.00020078788,0.0005833207,0.00062372035,0.00010380262,0.0000052368882,0.000431742,0.00039226035,0.00015580427],"category_scores_gemma":[0.00024257475,0.0001425342,0.00009539809,0.0008746965,0.0006085413,0.000034817098,0.0001575303,0.0005603529,0.000004427071],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021481381,0.0008372774,0.03769082,0.0001196486,0.0002892127,0.00028049445,0.0005748787,0.00027054935,0.051609483,0.0011318674,0.46134797,0.44369966],"study_design_scores_gemma":[0.0041922266,0.0012399722,0.007836614,0.00019842156,0.00012498075,0.000068447465,0.0069716545,0.00049063057,0.81076247,0.0026550274,0.1650007,0.00045887948],"about_ca_topic_score_codex":0.00009696772,"about_ca_topic_score_gemma":0.0001324093,"teacher_disagreement_score":0.75915295,"about_ca_system_score_codex":0.00017718135,"about_ca_system_score_gemma":0.00023028214,"threshold_uncertainty_score":0.5812376},"labels":[],"label_agreement":null},{"id":"W4413287453","doi":"10.1080/17576180.2025.2529119","title":"17th GCC Closed Forum: Integrative Bioanalysis, Patient-centric Sampling, Emerging Technologies, Data Integrity, Sample Reconciliation, Discrepancies of ELISpot Data, Cross-validation Harmonization, Ultrasensitive Platforms for ADA Assays, Remote Regulatory Assessments, Shedding Assays by PCR, and Biomarker Tissue Assays","year":2025,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada); Grand Challenges Canada; Natural Sciences and Engineering Research Council of Canada; Altasciences (Canada)","funders":"","keywords":"Bioanalysis; Harmonization; ELISPOT; Sample (material); Sampling (signal processing); Computer science; Medicine; Chemistry; Immunology; Chromatography; Telecommunications","score_opus":0.06044166139963062,"score_gpt":0.38217707512592086,"score_spread":0.3217354137262902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413287453","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025414493,0.02264799,0.9238949,0.0035894357,0.0006902246,0.0014710252,0.021815475,0.0003119498,0.00016451372],"genre_scores_gemma":[0.85213387,0.0035703199,0.09983472,0.00033310775,0.000031549862,0.00003575627,0.043245777,0.0000588132,0.0007561053],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950757,0.00044871794,0.0017164198,0.0017662361,0.00028651484,0.0007064037],"domain_scores_gemma":[0.9932887,0.0020331866,0.0012425318,0.002180129,0.0011862473,0.00006923143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030511487,0.00063037203,0.0013036003,0.0010105936,0.0007032667,0.00020853215,0.0012857771,0.00087441073,0.00011874335],"category_scores_gemma":[0.007640901,0.0004998549,0.0002410667,0.0025950314,0.0008511146,0.0008981606,0.0011841082,0.0005679608,0.000002735804],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070044526,0.0006555426,0.077651285,0.00032721882,0.012285417,0.000003367158,0.00026832268,0.000023927203,0.0844204,0.0036780774,0.028464716,0.7915213],"study_design_scores_gemma":[0.00614773,0.0007311569,0.012181262,0.0009999718,0.013063239,0.000019128453,0.018009873,0.07725786,0.5971833,0.012502634,0.2590333,0.00287053],"about_ca_topic_score_codex":0.0021059432,"about_ca_topic_score_gemma":0.0007895056,"teacher_disagreement_score":0.82671934,"about_ca_system_score_codex":0.00031053415,"about_ca_system_score_gemma":0.0002690836,"threshold_uncertainty_score":0.9997453},"labels":[],"label_agreement":null},{"id":"W4413442348","doi":"10.30683/1929-2279.2025.14.13","title":"Real-World Clinical Outcomes of Ujvira® (Trastuzumab Emtansine Biosimilar) in HER2-Positive Breast Cancer: A Retrospective Observational Study in Indian Patients","year":2025,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Biosimilar; Trastuzumab; Medicine; Observational study; Trastuzumab emtansine; Breast cancer; Retrospective cohort study; Oncology; Internal medicine; Real world evidence; Cancer","score_opus":0.09948385518210313,"score_gpt":0.4922922593312986,"score_spread":0.3928084041491955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413442348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898503,0.0008266683,0.0000026851324,0.007670748,0.00051203114,0.00053955015,0.00038548326,0.000004079046,0.00020849919],"genre_scores_gemma":[0.99698216,0.001997373,0.00015830595,0.00030989273,0.000052180945,0.000027563685,0.000009550307,0.000012133454,0.0004508451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99567944,0.0016810519,0.0014890545,0.00034113595,0.00031856104,0.00049077213],"domain_scores_gemma":[0.9968787,0.0010985524,0.00043846623,0.00021355101,0.0013115007,0.00005926056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035469881,0.00019632632,0.0009860111,0.0011437393,0.00008865244,0.00002512545,0.00044991996,0.00023041958,0.0004173702],"category_scores_gemma":[0.0007934936,0.00014348968,0.0001900746,0.001794844,0.0005538288,0.00018529601,0.00019724965,0.0015986537,0.0000019289685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023491748,0.002330458,0.98426414,0.000027124272,0.0007443765,0.000037273967,0.0002502067,0.000007238389,0.0006177124,0.00016235762,0.002739477,0.006470487],"study_design_scores_gemma":[0.0037409507,0.0008665907,0.991103,0.00046888986,0.00006107529,0.0000017108249,0.00042765008,0.000004066174,0.0021359108,0.0006585734,0.0004129672,0.00011862904],"about_ca_topic_score_codex":0.004885099,"about_ca_topic_score_gemma":0.028016975,"teacher_disagreement_score":0.023131877,"about_ca_system_score_codex":0.0007248963,"about_ca_system_score_gemma":0.0011036503,"threshold_uncertainty_score":0.98971915},"labels":[],"label_agreement":null},{"id":"W4413870770","doi":"10.1016/j.jaad.2025.05.1165","title":"65106 Safety profile of Rezpegaldesleukin, A Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, versus Placebo Based on Aggregate Safety Evaluation of 746 Subjects Enrolled Across 9 Studies","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Placebo; Conjugate; Interleukin; Safety profile; Internal medicine; Pharmacology; Oncology; Cytokine; Adverse effect; Pathology; Alternative medicine","score_opus":0.03453460692454409,"score_gpt":0.37269818288710704,"score_spread":0.33816357596256297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413870770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884015,0.0035416214,0.00018092897,0.0054677175,0.0007157233,0.00057326624,0.000054551878,0.000009975938,0.0010547175],"genre_scores_gemma":[0.9979856,0.00027857727,0.0009589517,0.0006195645,0.000018044157,0.0000077479,0.0000016326397,0.0000139722615,0.00011591003],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944007,0.0030817734,0.0016078908,0.00028185704,0.00024487518,0.0003829323],"domain_scores_gemma":[0.99272066,0.0025608093,0.0037025325,0.0002787453,0.00070378254,0.0000334954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002380135,0.00027900102,0.0016829617,0.00032688092,0.00015621042,0.0000031987506,0.0005792897,0.00033775152,0.000035684676],"category_scores_gemma":[0.0019738777,0.00018676504,0.00046925418,0.00076233695,0.0021947515,0.000068861526,0.00019349939,0.0010022924,0.0000015498076],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06988495,0.00075297675,0.006612014,0.00049512426,0.005545116,0.000007742254,0.0014937227,0.0009417027,0.88985974,0.00086214324,0.0063169487,0.01722784],"study_design_scores_gemma":[0.011269646,0.0008799406,0.015072853,0.0006711864,0.0009570042,0.00012120393,0.0016800679,0.00036450347,0.9675628,0.0003327844,0.00091081206,0.00017718569],"about_ca_topic_score_codex":0.000015763499,"about_ca_topic_score_gemma":0.000006340066,"teacher_disagreement_score":0.07770309,"about_ca_system_score_codex":0.00025833916,"about_ca_system_score_gemma":0.0004986145,"threshold_uncertainty_score":0.80866534},"labels":[],"label_agreement":null},{"id":"W4414022399","doi":"10.1080/17576180.2025.2554568","title":"An interview with <i>Bioanalysis</i> : speaking with the 2025 international reid bioanalytical forum bursary award winners","year":2025,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Intertek (Canada)","funders":"","keywords":"Bioanalysis; Bursary; Chemistry; Political science; Chromatography","score_opus":0.019839422442080618,"score_gpt":0.30509439254253545,"score_spread":0.28525497010045486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414022399","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027424252,0.050466552,0.27366543,0.5550436,0.002978784,0.0021237095,0.0004697925,0.0010317551,0.08679616],"genre_scores_gemma":[0.9746285,0.00042504986,0.004811033,0.008805431,0.000097320255,0.000044940214,0.0001768967,0.000039643142,0.01097119],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99662256,0.00074539945,0.0006655271,0.0010056039,0.00023318587,0.0007277081],"domain_scores_gemma":[0.99768245,0.0003369092,0.00028459882,0.0012270487,0.00037411082,0.00009486275],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011930285,0.00053015293,0.00091002206,0.00063310406,0.00044733664,0.00019316282,0.0013749691,0.0003497369,0.0011900463],"category_scores_gemma":[0.00009239877,0.00027825058,0.0005380629,0.0024071638,0.0012136676,0.00023167388,0.00025405473,0.0006639585,0.00007269505],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004158901,0.003095243,0.16131507,0.00025404047,0.099475935,0.0003402527,0.0007369332,0.00054320146,0.020297714,0.028807547,0.056301903,0.62467325],"study_design_scores_gemma":[0.0025305029,0.0007517359,0.0073677436,0.0003419918,0.012192068,0.000074370284,0.00509474,0.0023175543,0.01178508,0.00037726745,0.9560187,0.0011482743],"about_ca_topic_score_codex":0.00022206485,"about_ca_topic_score_gemma":0.0010675086,"teacher_disagreement_score":0.94720423,"about_ca_system_score_codex":0.00014423656,"about_ca_system_score_gemma":0.0001519669,"threshold_uncertainty_score":0.999967},"labels":[],"label_agreement":null},{"id":"W4414026299","doi":"10.1080/14712598.2025.2557626","title":"Efficacy and safety of biosimilars in gastroenterology: a focus on inflammatory bowel disease management","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Biosimilar; Inflammatory bowel disease; Medicine; Gastroenterology; Internal medicine; Disease; Inflammatory Bowel Diseases; Intensive care medicine","score_opus":0.06055974414817065,"score_gpt":0.3647163946971899,"score_spread":0.30415665054901925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414026299","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008040347,0.99620235,0.000024000594,0.0008444082,0.0006724227,0.0014221387,0.000121148485,0.00004770973,0.0005854043],"genre_scores_gemma":[0.00022700478,0.9975343,0.0001491981,0.0016604185,0.00004898839,0.00018966205,0.00011402872,0.000018998733,0.00005741862],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99616075,0.0015306656,0.0008982314,0.00087411044,0.000060626466,0.0004756479],"domain_scores_gemma":[0.9981951,0.0009103025,0.00027277812,0.0005253349,0.000020598252,0.00007586581],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005227475,0.0006167632,0.0016288196,0.00039989673,0.00007952973,0.000009911457,0.00045255414,0.000901873,0.00023657657],"category_scores_gemma":[0.00010506421,0.00036376703,0.00045949646,0.00021597816,0.0005222047,0.000015870832,0.00020653296,0.0006304575,0.000018572999],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005299668,0.00081645575,0.00015694332,0.0003793447,0.00044799654,0.000015633323,0.000014733849,2.6691214e-7,0.000022289474,0.0032134913,0.0014814716,0.9881517],"study_design_scores_gemma":[0.0025910425,0.0015172958,0.0029061849,0.0067614513,0.000008588047,0.0000034111163,0.000009050465,3.424934e-7,0.00003166577,0.00025275687,0.9856142,0.00030402496],"about_ca_topic_score_codex":0.0000012645238,"about_ca_topic_score_gemma":3.238897e-7,"teacher_disagreement_score":0.9878477,"about_ca_system_score_codex":0.00006694451,"about_ca_system_score_gemma":0.00004048523,"threshold_uncertainty_score":0.99988145},"labels":[],"label_agreement":null},{"id":"W4414377911","doi":"10.1101/2025.09.16.676687","title":"What Could Go Wrong? Promoting Success by Planning for Failure in Label-Free Biosensor Assay Development","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Killam Trusts; CMC Microsystems","keywords":"Troubleshooting; Workflow; Biosensor; Intersection (aeronautics); Identification (biology)","score_opus":0.02326347310264085,"score_gpt":0.27981911647108054,"score_spread":0.25655564336843967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414377911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9071429,0.040846232,0.016746048,0.008504672,0.014347052,0.0077480334,0.003304596,0.0012841556,0.000076303586],"genre_scores_gemma":[0.9125954,0.00044191125,0.083706364,0.0013258103,0.00028605273,0.00088088325,0.000017126713,0.00021045526,0.0005360107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99549055,0.00045359723,0.0011584298,0.0015293696,0.00014034685,0.0012276911],"domain_scores_gemma":[0.99706876,0.00065918185,0.00055717956,0.0011595686,0.00043048302,0.0001248267],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0030854077,0.00084258977,0.001161375,0.00041871952,0.00030845747,0.0003063156,0.0012550405,0.0019031834,0.000050392588],"category_scores_gemma":[0.0010233455,0.00081995846,0.00018535806,0.00054399733,0.0002355497,0.00021814337,0.0011353627,0.0016822643,0.00001931563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022240487,0.0005271747,0.011984921,0.0015322964,0.0008115547,0.00004340612,0.00007812973,0.0000054153475,0.97264194,0.0004108198,0.011640624,0.000101287405],"study_design_scores_gemma":[0.0022195284,0.00008708873,0.0075147836,0.0029061956,0.00019349111,5.5697317e-8,0.0000357162,0.00008418557,0.8622421,0.000008069607,0.12349957,0.0012092066],"about_ca_topic_score_codex":0.000021932405,"about_ca_topic_score_gemma":0.000034071185,"teacher_disagreement_score":0.11185895,"about_ca_system_score_codex":0.0004212251,"about_ca_system_score_gemma":0.00072662224,"threshold_uncertainty_score":0.9994251},"labels":[],"label_agreement":null},{"id":"W4414447185","doi":"10.1097/ftd.0000000000001372","title":"Abstract for 22nd International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Banff, Alberta, Canada, September 15–18, 2024","year":2025,"lang":"en","type":"article","venue":"Therapeutic Drug Monitoring","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Therapeutic drug monitoring; Drug; Safety monitoring; MEDLINE; Monitoring and evaluation","score_opus":0.03824448603303193,"score_gpt":0.3659102081550008,"score_spread":0.32766572212196887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414447185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92741203,0.016021056,0.00020994006,0.0036341548,0.044438444,0.0008400221,0.000093951414,0.000060428116,0.0072899875],"genre_scores_gemma":[0.9663747,0.0003857906,0.00044096616,0.0002285339,0.00033480383,0.00003651027,0.0000068438358,0.00002569789,0.032166176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979084,0.00023101932,0.0007896433,0.00049746124,0.000094682,0.00047881028],"domain_scores_gemma":[0.99695694,0.0022400036,0.00023253192,0.0003291532,0.00018208381,0.000059302285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092157116,0.00030739687,0.00060909684,0.00012052927,0.00018246904,0.000037904323,0.00043751308,0.0003240424,0.00035742248],"category_scores_gemma":[0.00010074801,0.00026268465,0.00019797159,0.00014146576,0.00037167248,0.0000837098,0.00014633813,0.0005495897,0.0000064358996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009971267,0.0005769327,0.7139011,0.00029445754,0.0061302963,0.0000093496155,0.00043530946,0.000012018007,0.089271806,0.0012629889,0.016584555,0.17052408],"study_design_scores_gemma":[0.0041031204,0.00014150269,0.5468377,0.0005442107,0.00087701075,0.000014484971,0.0015464517,0.00009167265,0.27705958,0.0017131834,0.16637914,0.0006919775],"about_ca_topic_score_codex":0.013321809,"about_ca_topic_score_gemma":0.0078335,"teacher_disagreement_score":0.18778779,"about_ca_system_score_codex":0.00011865335,"about_ca_system_score_gemma":0.00026186323,"threshold_uncertainty_score":0.99998254},"labels":[],"label_agreement":null},{"id":"W4414472615","doi":"10.64490/eltx4741","title":"Programme d’évaluation externe de la qualité en biochimie – 2024","year":2025,"lang":"fr","type":"report","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Quality assurance; Public health","score_opus":0.06297720083385523,"score_gpt":0.3898720430618859,"score_spread":0.32689484222803067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414472615","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055502984,0.07153962,0.020433338,0.012405275,0.012789822,0.0018848965,0.00038964205,0.0003134199,0.8746937],"genre_scores_gemma":[0.002554365,0.012255851,0.024078086,0.0013100387,0.00043541906,0.00010586173,0.00036162973,0.00004142066,0.95885736],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99127346,0.0054310765,0.0011200171,0.00095818006,0.00016149071,0.0010557837],"domain_scores_gemma":[0.9956157,0.002990854,0.0003387041,0.0006528226,0.00028972444,0.00011214823],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009395793,0.0006585942,0.0011042617,0.00030407525,0.00019405149,0.00010980262,0.000495933,0.004572297,0.014015041],"category_scores_gemma":[0.0024997208,0.0005264929,0.00067206554,0.00044067,0.0009828092,0.000048012662,0.00036912327,0.0018324006,0.0003218109],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013505043,0.00080294436,0.0025103122,0.00095545547,0.001935639,0.000068369256,0.00022020514,0.0000010119088,0.019261058,0.021179538,0.08678689,0.8661435],"study_design_scores_gemma":[0.0007380098,0.0003424427,0.0046676868,0.000677908,0.0014188626,0.0004333615,0.00021823177,0.00004837118,0.011521708,0.0050672055,0.9742507,0.000615566],"about_ca_topic_score_codex":0.0013751717,"about_ca_topic_score_gemma":0.0001613712,"teacher_disagreement_score":0.88746375,"about_ca_system_score_codex":0.000462923,"about_ca_system_score_gemma":0.0021025778,"threshold_uncertainty_score":0.99971867},"labels":[],"label_agreement":null},{"id":"W4414478367","doi":"10.1002/psp4.70120","title":"Model‐Informed Drug Development of Subcutaneous Nivolumab: Comparison of Pharmacokinetic Analysis Methodologies Using Clinical Trial Simulation","year":2025,"lang":"en","type":"article","venue":"CPT Pharmacometrics & Systems Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"NONMEM; Pharmacokinetics; Population; Clinical trial; Population pharmacokinetics; Drug development; Pooled analysis; Drug","score_opus":0.3510040612031019,"score_gpt":0.5559946688922948,"score_spread":0.20499060768919286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414478367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7907421,0.008989962,0.19077644,0.000054573684,0.00727304,0.0015112794,0.00008630272,0.00009869413,0.00046763272],"genre_scores_gemma":[0.9794142,0.00025245096,0.019247519,0.00015202358,0.00008778699,0.00004508814,0.000045314464,0.000024103952,0.00073148904],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9913592,0.0028279026,0.0041420213,0.00072359625,0.00023209341,0.0007152394],"domain_scores_gemma":[0.9889574,0.007945462,0.0018514612,0.00038594392,0.0007567645,0.000102940096],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004864727,0.00048658362,0.0027483548,0.0032998596,0.00023272111,0.000020517504,0.0008665094,0.00063332636,0.00035622378],"category_scores_gemma":[0.000917044,0.00043652405,0.000754815,0.00583881,0.00063659117,0.00011409031,0.00039296647,0.00082860974,0.000008472332],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03526812,0.0027076285,0.010962241,0.0011915977,0.022109905,0.000012745894,0.0008388748,0.38888037,0.48464125,0.0001806603,0.005006286,0.048200306],"study_design_scores_gemma":[0.034440137,0.00041394978,0.00030222748,0.00005596535,0.01158928,0.0000069092794,0.00032746352,0.64785844,0.29500833,0.000040698058,0.009408907,0.00054766034],"about_ca_topic_score_codex":0.000046251545,"about_ca_topic_score_gemma":0.0000041015264,"teacher_disagreement_score":0.2589781,"about_ca_system_score_codex":0.00025611607,"about_ca_system_score_gemma":0.0007056079,"threshold_uncertainty_score":0.99980867},"labels":[],"label_agreement":null},{"id":"W4414828950","doi":"10.1177/17562848251358168","title":"Adalimumab around the world: comparative analysis of products characteristics and patient support systems","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Adalimumab; Usability; Biosimilar; Dosing; MEDLINE; Patient safety; Patient satisfaction; Psychological intervention","score_opus":0.04039737541785968,"score_gpt":0.36537673269169263,"score_spread":0.324979357273833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414828950","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016104306,0.9973076,0.00022385191,0.00011126252,0.0008369597,0.0008059878,0.00030283778,0.00001245422,0.00023798698],"genre_scores_gemma":[0.008470662,0.9903924,0.00009776185,0.0002751148,0.000022609353,0.00011888808,0.000149301,0.000010832839,0.0004624578],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960408,0.001727892,0.0011646874,0.00055327074,0.000054244352,0.00045906627],"domain_scores_gemma":[0.9975988,0.00096200325,0.0008122215,0.000517931,0.00008978026,0.00001924499],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044450525,0.00043782816,0.0032935694,0.0007082981,0.00006736823,0.000013304927,0.00039874105,0.00026422023,0.00006273859],"category_scores_gemma":[0.00003533025,0.00026007424,0.00027923836,0.001009736,0.0009365844,0.000047437396,0.00018130864,0.000605874,0.0000032007497],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005833518,0.00037460666,0.0019258368,0.005523825,0.00881563,0.000009082329,0.00029467454,0.000012714509,0.000011808297,0.0019378619,0.00013109337,0.9803795],"study_design_scores_gemma":[0.00032268107,0.0005658869,0.00031634083,0.0012403876,0.0070629856,0.00003516588,0.00016751065,0.00001397663,0.000005615921,0.000039389375,0.99006915,0.00016088877],"about_ca_topic_score_codex":0.000006583548,"about_ca_topic_score_gemma":0.000088436514,"teacher_disagreement_score":0.9899381,"about_ca_system_score_codex":0.000058136193,"about_ca_system_score_gemma":0.00007661649,"threshold_uncertainty_score":0.99998516},"labels":[],"label_agreement":null},{"id":"W4414997731","doi":"10.1080/17576180.2025.2572289","title":"Patient centric blood sampling and analysis for diagnostics and laboratory medicine","year":2025,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Workflow; Sampling (signal processing); Blood collection; Blood sampling; Medical laboratory; Process (computing); Health care; Resource (disambiguation)","score_opus":0.01770404337630626,"score_gpt":0.2957425062102035,"score_spread":0.2780384628338972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414997731","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39612204,0.5177178,0.070108734,0.011857873,0.000930768,0.0010055334,0.0010322481,0.00016769546,0.0010573247],"genre_scores_gemma":[0.98330426,0.0074277073,0.00705848,0.0014000374,0.000030889692,0.000029652494,0.00009986323,0.000009675706,0.0006394529],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881387,0.00013928897,0.00035869482,0.00040200955,0.000034605426,0.0002515548],"domain_scores_gemma":[0.99833477,0.0011285174,0.0001036371,0.00023379794,0.0001552484,0.000044053853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039167562,0.00017081105,0.0005715022,0.0005934492,0.00019707532,0.0000193872,0.00007929601,0.00021274171,0.00012671751],"category_scores_gemma":[0.00088317395,0.00012515455,0.00014053575,0.0016140296,0.0003407458,0.000024057968,0.00008550455,0.000112576534,0.0000011108824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017568463,0.00043836236,0.77271825,0.00021162654,0.03542271,0.000008162084,0.0003241225,0.000010850402,0.017506469,0.009492696,0.002225973,0.16146511],"study_design_scores_gemma":[0.0059422664,0.001029118,0.38455793,0.00018933191,0.13202368,0.000007850173,0.0015921298,0.0010720621,0.027876694,0.003318213,0.44121027,0.0011804609],"about_ca_topic_score_codex":0.000055700162,"about_ca_topic_score_gemma":0.00003720931,"teacher_disagreement_score":0.58718216,"about_ca_system_score_codex":0.000014900815,"about_ca_system_score_gemma":0.000022656328,"threshold_uncertainty_score":0.5103654},"labels":[],"label_agreement":null},{"id":"W4415019943","doi":"10.1016/j.aca.2025.344765","title":"Analytical and usability comparison of microsampling dried blood spot devices for glucocorticoid detection in sports using ultra-high-performance liquid chromatography–tandem mass spectrometry","year":2025,"lang":"en","type":"article","venue":"Analytica Chimica Acta","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency; National Science and Technology Council","keywords":"Usability; Dried blood spot; Dried blood; Triamcinolone acetonide; Glucocorticoid; Whole blood; Matrix (chemical analysis)","score_opus":0.020069111172928488,"score_gpt":0.3061300304735689,"score_spread":0.2860609193006404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415019943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974982,0.00021879526,0.001076669,0.00020354055,0.00020795294,0.00049508916,0.000026596343,0.000034426947,0.00023870842],"genre_scores_gemma":[0.9951418,0.000122056066,0.0045365733,0.00010388284,0.000021391785,0.000008512229,0.000017106333,0.000016834718,0.000031819975],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975013,0.00013555028,0.001034712,0.00067069643,0.000088295994,0.0005694231],"domain_scores_gemma":[0.9984514,0.0006761469,0.00029081604,0.00041506527,0.000113794,0.000052777217],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007500847,0.00031730818,0.0010408093,0.0005594692,0.00015949273,0.000031177642,0.000245101,0.0004619202,0.000063650165],"category_scores_gemma":[0.00027250595,0.0002879645,0.00021961593,0.0011306119,0.0005067603,0.00011833199,0.00006764754,0.00044347628,7.8972124e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051161397,0.0003370884,0.23365308,0.00023100489,0.00033090293,6.019923e-7,0.00002943217,0.000003963872,0.76411957,0.00024926884,0.0000055646165,0.0005279347],"study_design_scores_gemma":[0.0013857342,0.0004599392,0.17787468,0.00019645263,0.0008586193,0.000011841653,0.00015734897,0.004409096,0.8139883,0.00027246913,0.00010507757,0.0002803823],"about_ca_topic_score_codex":0.00003395984,"about_ca_topic_score_gemma":0.00006254726,"teacher_disagreement_score":0.055778388,"about_ca_system_score_codex":0.00006310242,"about_ca_system_score_gemma":0.00009367518,"threshold_uncertainty_score":0.99995726},"labels":[],"label_agreement":null},{"id":"W4415444549","doi":"10.1158/1535-7163.targ-25-b102","title":"Abstract B102: Using subclonal dynamics to detect and quantify fitness advantages of resistant subclones in tumors under treatment","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Selection (genetic algorithm); Population; Genetic drift; Dynamics (music); Mutation Accumulation; Evolutionary dynamics; Distribution (mathematics); Cancer","score_opus":0.038737620427158496,"score_gpt":0.36027169737587644,"score_spread":0.32153407694871794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415444549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751777,0.017041445,0.0060601104,0.0011113647,0.00018857731,0.00023229267,0.00008711158,0.00001288917,0.00008852546],"genre_scores_gemma":[0.99667823,0.0006228092,0.0019468887,0.0006071098,0.0000041862704,0.00001231637,0.0000066958005,0.000014428839,0.000107320855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99897444,0.00012172628,0.00030890686,0.00028463517,0.000040163926,0.00027011908],"domain_scores_gemma":[0.9995424,0.00010866199,0.00007205541,0.00020594761,0.000049799917,0.000021099704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016103582,0.00019326177,0.0003686683,0.00016125059,0.000056675133,0.000011809878,0.00011571319,0.00018898344,0.000030719755],"category_scores_gemma":[0.00000879862,0.00015747469,0.00008114256,0.00028008517,0.00017974214,0.000018625795,0.00004970823,0.00013760035,6.0709453e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005633188,0.00008343039,0.008282116,0.00006467262,0.00045083486,0.000019805957,0.00007047464,0.00023782667,0.9596615,0.0021056675,0.0000020638613,0.028458335],"study_design_scores_gemma":[0.001502298,0.000303368,0.09843532,0.00027111743,0.0003017599,0.0000076040765,0.00031812614,0.00028821494,0.8942176,0.0025913643,0.0014466529,0.00031655788],"about_ca_topic_score_codex":0.0005529023,"about_ca_topic_score_gemma":0.000977645,"teacher_disagreement_score":0.0901532,"about_ca_system_score_codex":0.0001870939,"about_ca_system_score_gemma":0.00011792068,"threshold_uncertainty_score":0.64216316},"labels":[],"label_agreement":null},{"id":"W4415453799","doi":"10.1210/jendso/bvaf149.1533","title":"SAT-050 Other hormone defficiencies and side effects IN a cohort of adults IN TREATMENT WITH a biosimilar HUMAN GROWTH HORMONE","year":2025,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Instituto de Salud Carlos III; Massachusetts General Hospital; University of Victoria; Brigham and Women's Hospital","keywords":"Cohort; Hormone; Adverse effect; Biosimilar; Growth hormone; Cohort study; Human growth hormone; Cancer","score_opus":0.006825970405884735,"score_gpt":0.2588039722101429,"score_spread":0.25197800180425817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415453799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98868585,0.009143976,0.00009294787,0.0014729658,0.000068387126,0.00026341624,0.000007463163,0.000004211658,0.0002608052],"genre_scores_gemma":[0.9969092,0.0010950185,0.0014100319,0.00035869548,0.000012258297,0.0000057506845,4.908452e-7,0.0000070366855,0.00020153495],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989141,0.00022351596,0.00041428526,0.0001485374,0.000059447935,0.00024009617],"domain_scores_gemma":[0.99928504,0.0002590913,0.00021925835,0.00014824423,0.000069593996,0.000018788964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000407981,0.00016238776,0.00049138983,0.00008852036,0.00006680438,0.0000072040652,0.00017611492,0.00009614878,0.0000034454984],"category_scores_gemma":[0.000079002646,0.000083924155,0.00021243491,0.00035604354,0.000361829,0.000039788763,0.00007903045,0.0003173953,2.4637038e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001215975,0.0013276399,0.3615122,0.00014122273,0.0011993949,0.000037831793,0.0013449992,0.00000981463,0.6280901,0.0010319118,0.0014030868,0.0026858004],"study_design_scores_gemma":[0.008261809,0.0021277482,0.8592051,0.00039291274,0.0002867891,0.00011502039,0.00068996917,0.000022256881,0.1273574,0.0006692455,0.000723199,0.00014851315],"about_ca_topic_score_codex":0.00021666712,"about_ca_topic_score_gemma":0.00012445363,"teacher_disagreement_score":0.5007327,"about_ca_system_score_codex":0.000101990656,"about_ca_system_score_gemma":0.0000612959,"threshold_uncertainty_score":0.34223276},"labels":[],"label_agreement":null},{"id":"W4415453884","doi":"10.1210/jendso/bvaf149.806","title":"SAT-251 Massive Tissue Deposition Of Cholesterol Leading To Multi-organ Failure In Cholestatic Hypercholesterolemia","year":2025,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto Rehabilitation Institute; University of Toronto; Robarts Clinical Trials; Western University","funders":"","keywords":"Plasmapheresis; Cholesterol; Retinal; Kidney disease; Disease","score_opus":0.014430415123770251,"score_gpt":0.31656259613381055,"score_spread":0.3021321810100403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415453884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97397447,0.00055978965,0.006711627,0.017604128,0.0007282496,0.00029074168,0.000018425158,0.000009210918,0.00010333524],"genre_scores_gemma":[0.9831399,0.000045882654,0.013373765,0.0021117995,0.000035908895,0.0000032135385,0.0000015920486,0.000010665225,0.001277293],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99858534,0.0003040061,0.0006161342,0.00015475322,0.00007037893,0.00026941235],"domain_scores_gemma":[0.9991484,0.00016916814,0.00029253878,0.00021946523,0.00013780194,0.000032573036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004385218,0.0001575147,0.0004372758,0.00009923865,0.000083969535,0.000017058646,0.00040844866,0.0001417271,0.000032988275],"category_scores_gemma":[0.00020721936,0.0001034444,0.00029617597,0.00039307703,0.00014985996,0.00008785272,0.00016457579,0.00071876455,0.000007038806],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000723154,0.00019956064,0.018060384,0.0000891526,0.00024355881,0.0000061448472,0.0009165416,0.00008922189,0.9662344,0.000064141925,0.005866137,0.008158479],"study_design_scores_gemma":[0.0035341298,0.0002767746,0.09686189,0.0008918155,0.00024930976,0.00019105976,0.0017994145,0.000030991945,0.88664764,0.00019551239,0.009138839,0.00018259039],"about_ca_topic_score_codex":0.000020860394,"about_ca_topic_score_gemma":0.00006569476,"teacher_disagreement_score":0.07958669,"about_ca_system_score_codex":0.00012335995,"about_ca_system_score_gemma":0.00006633012,"threshold_uncertainty_score":0.421834},"labels":[],"label_agreement":null},{"id":"W4415517684","doi":"10.1038/s41564-025-02192-4","title":"Author Correction: Discovery and artificial intelligence-guided mechanistic elucidation of a narrow-spectrum antibiotic","year":2025,"lang":"en","type":"article","venue":"Nature Microbiology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Population Health Research Institute; McMaster University","funders":"","keywords":"Antibiotics; Drug discovery; Bacteria","score_opus":0.018124123405708056,"score_gpt":0.3136622417404824,"score_spread":0.29553811833477434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415517684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68174034,0.0526239,0.1585156,0.04317501,0.05279987,0.0025353457,0.0007320959,0.00046163608,0.007416224],"genre_scores_gemma":[0.99386543,0.000043417578,0.00069767813,0.0007097291,0.000042415508,0.000002853731,0.00008607832,0.000008328584,0.0045440523],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845463,0.00030514676,0.00046869193,0.00045046885,0.000015806565,0.00030528483],"domain_scores_gemma":[0.99917454,0.00032707056,0.00015277366,0.00024058422,0.00008805087,0.000017010827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042481106,0.00020729171,0.00046216536,0.00024844648,0.00013857169,0.000018696777,0.00018400824,0.0012169336,0.00018856123],"category_scores_gemma":[0.00039111424,0.00016591247,0.000105876214,0.00039545842,0.0004980458,0.000051187726,0.00011735587,0.0007496919,0.000016656732],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020857048,0.000106411986,0.0002264544,0.000046322468,0.0001493245,0.0000022943293,0.00004348172,0.0000012566062,0.9001519,0.075549,0.010297848,0.013217141],"study_design_scores_gemma":[0.00017800495,0.0002470664,0.0005725155,0.00007105387,0.00014576917,0.00014266041,0.00017174918,0.000042965723,0.97182816,0.011549325,0.014869828,0.00018089372],"about_ca_topic_score_codex":0.000027860273,"about_ca_topic_score_gemma":0.00006882534,"teacher_disagreement_score":0.31212512,"about_ca_system_score_codex":0.000040754618,"about_ca_system_score_gemma":0.000079473684,"threshold_uncertainty_score":0.9386106},"labels":[],"label_agreement":null},{"id":"W4415778201","doi":"10.1136/bmjophth-2025-002509","title":"Comparative outcomes of aflibercept biosimilars and reference aflibercept in nAMD: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"BMJ Open Ophthalmology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Brampton Civic Hospital; Dalhousie University","funders":"","keywords":"Aflibercept; Biosimilar; MEDLINE; Clinical trial; Clinical Practice","score_opus":0.31802348585291046,"score_gpt":0.5154239258367296,"score_spread":0.19740043998381912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415778201","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000069853404,0.98609674,0.0000047801814,0.0004941952,0.00006513474,0.0089066615,0.00062532176,0.000010822467,0.00378938],"genre_scores_gemma":[0.00012019556,0.98530036,0.000965859,0.0007156693,0.0000019150584,0.0019264985,0.00014823121,0.000022477105,0.010798773],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9894488,0.0060919104,0.002710915,0.0011812637,0.00007909584,0.00048803334],"domain_scores_gemma":[0.9939825,0.003095474,0.0015123028,0.0012024662,0.0001424662,0.00006480138],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029248241,0.0009006433,0.025532905,0.0007638805,0.000090594585,0.000042905063,0.0012370506,0.0012027681,0.00257722],"category_scores_gemma":[0.00068973476,0.0005477537,0.0015023762,0.0014084696,0.0007562948,0.00009512366,0.0015128484,0.00080896355,0.000028504423],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003151072,0.00026431354,0.00008226167,0.7714774,0.22543614,0.00008419332,0.00011124511,7.99805e-8,0.0000015027593,0.0005866118,0.000883953,0.001040791],"study_design_scores_gemma":[0.00037957652,0.00024655025,0.00024177798,0.02916056,0.955212,0.001064512,0.000086004235,4.212099e-7,0.0000031130269,0.00016326089,0.01265273,0.0007894752],"about_ca_topic_score_codex":0.00016066241,"about_ca_topic_score_gemma":0.000067238885,"teacher_disagreement_score":0.74231684,"about_ca_system_score_codex":0.000045992743,"about_ca_system_score_gemma":0.0002287432,"threshold_uncertainty_score":0.9996974},"labels":[],"label_agreement":null},{"id":"W4416137363","doi":"10.3389/fphar.2025.1659395","title":"A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability","year":2025,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ministry of Food and Drug Safety","keywords":"Biosimilar; Sustainability; Health care; Healthcare system; Sustainable development; Dynamics (music)","score_opus":0.0116924310199034,"score_gpt":0.3299239551258698,"score_spread":0.3182315241059664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416137363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93292516,0.021493247,0.019081498,0.0078430325,0.004054538,0.0017114062,0.0006477482,0.00006112807,0.012182211],"genre_scores_gemma":[0.99510574,0.0010739535,0.0018235573,0.0009531679,0.000005171719,0.000033573648,0.000042552314,0.0000034438137,0.00095882185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764407,0.0009793923,0.0005420578,0.000413459,0.000023270408,0.00039773723],"domain_scores_gemma":[0.9990018,0.00057114835,0.00012750257,0.00016447416,0.00011325918,0.000021809672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010604259,0.00019179203,0.0010712469,0.0009735712,0.000050218117,0.000004908076,0.00022903773,0.00045274722,0.00034891802],"category_scores_gemma":[0.00014884984,0.00016670022,0.00010833521,0.0012690412,0.0012025553,0.000040309566,0.00015420966,0.00040924895,3.556571e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015386512,0.00034152984,0.95804656,0.00010516702,0.002397277,0.000012206822,0.00029680377,0.00006801125,0.0007596933,0.0022024694,0.03239916,0.0018324697],"study_design_scores_gemma":[0.008719201,0.0006551762,0.7574164,0.00006029189,0.005022362,0.000005503594,0.012814153,0.07117115,0.0134215085,0.017270932,0.11257272,0.0008705597],"about_ca_topic_score_codex":0.00013053378,"about_ca_topic_score_gemma":0.000637038,"teacher_disagreement_score":0.20063011,"about_ca_system_score_codex":0.00043405648,"about_ca_system_score_gemma":0.00014468237,"threshold_uncertainty_score":0.67978376},"labels":[],"label_agreement":null},{"id":"W4416175662","doi":"10.17235/reed.2025.11653/2025","title":"Biosimilar Switching in IBD: Safety, Efficacy, and Immunogenicity in 10,812 Patients � A Systematic Review and Meta-analysis","year":2025,"lang":"en","type":"article","venue":"Revista Española de Enfermedades Digestivas","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Immunogenicity; Biological drugs; Drug; Clinical trial; Interchangeability","score_opus":0.02301623661059654,"score_gpt":0.3123278830371655,"score_spread":0.289311646426569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416175662","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16141133,0.8273241,0.0006366447,0.0055868914,0.000063401814,0.003987307,0.00014194827,0.00009507502,0.00075333315],"genre_scores_gemma":[0.9868259,0.009865889,0.0003837816,0.0017535974,0.000003215063,0.0001057997,0.00003674747,0.000020310707,0.0010047731],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99563795,0.0018242897,0.0012507781,0.00067276263,0.000076811164,0.000537408],"domain_scores_gemma":[0.9979765,0.0010540582,0.00027037584,0.0005564513,0.000079362624,0.00006324246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023681794,0.00043234066,0.0031405082,0.0005480799,0.00012560889,0.00009636168,0.00031918226,0.0003633316,0.0002589422],"category_scores_gemma":[0.0022107211,0.00031243244,0.00046722475,0.00135792,0.00025228024,0.000103193954,0.0002960648,0.0005670774,0.000009102465],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020259812,0.0042846547,0.22893322,0.3914144,0.3247439,0.00016487623,0.001690976,0.000024199071,0.018945046,0.022420939,0.0011606665,0.0041911257],"study_design_scores_gemma":[0.0051725395,0.00034142777,0.28592667,0.018391298,0.6806105,0.000051563133,0.0001875047,0.00007067777,0.0031286592,0.0006131129,0.0037746017,0.001731457],"about_ca_topic_score_codex":0.000083938074,"about_ca_topic_score_gemma":0.00005925483,"teacher_disagreement_score":0.82541454,"about_ca_system_score_codex":0.00014895426,"about_ca_system_score_gemma":0.00007242716,"threshold_uncertainty_score":0.99993277},"labels":[],"label_agreement":null},{"id":"W4416411816","doi":"10.1093/jnci/djaf335","title":"Uptake of oncology-related biosimilars: a global analysis of usage data","year":2025,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"Canada Foundation for Innovation","keywords":"Biosimilar; Usage data; Quality (philosophy); Data source; Measure (data warehouse)","score_opus":0.09661028781747728,"score_gpt":0.4275638917499583,"score_spread":0.330953603932481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416411816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7618013,0.056338098,0.004861507,0.07213236,0.031744394,0.0010141962,0.015353531,0.000042309726,0.05671229],"genre_scores_gemma":[0.9957319,0.00042850283,0.0017044691,0.0015129974,0.000054659486,0.0000014194238,0.000025551657,0.0000029630219,0.00053753564],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984007,0.00019872066,0.0009350613,0.00015731143,0.0001742166,0.00013398252],"domain_scores_gemma":[0.9979421,0.00016834869,0.00086504803,0.00026532097,0.00074009254,0.000019105062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013330168,0.00011084104,0.0005571279,0.0002265457,0.00007498714,0.000005597282,0.001047303,0.0002541729,0.00029011347],"category_scores_gemma":[0.0007216071,0.0000687884,0.00035387545,0.0017733795,0.00054454716,0.00014369929,0.00026871395,0.00031688335,9.388607e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032178464,0.003243965,0.1108551,0.00025516804,0.11329241,0.00001980517,0.00036191512,0.00939689,0.23350307,0.06996913,0.28900623,0.16687846],"study_design_scores_gemma":[0.0034675165,0.00026193637,0.3488457,0.0003880065,0.012188347,0.00006148522,0.00007092095,0.0007270754,0.027889177,0.005622362,0.60025173,0.00022576742],"about_ca_topic_score_codex":0.00005109841,"about_ca_topic_score_gemma":0.00024754528,"teacher_disagreement_score":0.31124547,"about_ca_system_score_codex":0.0002234992,"about_ca_system_score_gemma":0.0012700952,"threshold_uncertainty_score":0.3176539},"labels":[],"label_agreement":null},{"id":"W4416640743","doi":"10.5256/f1000research.26110.r69397","title":"Referee report. For: Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol [version 1; peer review: 1 approved with reservations]","year":2020,"lang":"en","type":"article","venue":"Faculty of 1000 Research Ltd","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Affect (linguistics); Protocol (science); Translation (biology); Knowledge translation; Protocol analysis","score_opus":0.2876073593083834,"score_gpt":0.4455725364228844,"score_spread":0.15796517711450103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416640743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56771916,0.0018558291,0.0054697716,0.252312,0.00008384269,0.16975619,0.0024646546,0.000056889276,0.00028164516],"genre_scores_gemma":[0.98832387,0.0000894228,0.0014488258,0.0004795537,0.000026688567,0.008132671,0.00049805763,0.000031106036,0.0009698293],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775165,0.0011081162,0.00028700932,0.0002722303,0.00039600296,0.00018496026],"domain_scores_gemma":[0.9969622,0.0013902789,0.00015599413,0.00029292493,0.001169236,0.000029374616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034831665,0.000112431895,0.00026548124,0.0000418288,0.00031757267,0.00002811973,0.00028077525,0.000085423075,0.000057680827],"category_scores_gemma":[0.0020357515,0.000051050825,0.00005616275,0.00039751755,0.00028455476,0.000090461486,0.00009988932,0.0003028273,0.0000011029708],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007228557,0.0009665366,0.5093757,0.0020094013,0.0019779385,0.0000042842375,0.03758561,0.000001590716,0.13867372,0.0003456351,0.29555967,0.0062713833],"study_design_scores_gemma":[0.006030053,0.005781933,0.33081478,0.0022277574,0.00035511045,0.00000113382,0.05965603,0.00002450597,0.06320058,0.0005261291,0.5309531,0.0004288948],"about_ca_topic_score_codex":0.00023366095,"about_ca_topic_score_gemma":0.00025435124,"teacher_disagreement_score":0.42060468,"about_ca_system_score_codex":0.00003625216,"about_ca_system_score_gemma":0.000056154917,"threshold_uncertainty_score":0.24425444},"labels":[],"label_agreement":null},{"id":"W4416756903","doi":"10.1016/j.jcvp.2025.100236","title":"Impact of dried blood spot vs. venous sample collection on SARS-CoV-2 antibody test results in the CLSA serological study of older Canadians","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Virology Plus","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Alberta; McGill University","funders":"Fonds de Recherche du Québec - Santé; Canadian Blood Services","keywords":"Serology; Dried blood spot; Population; Confidence interval; Antibody; Odds ratio; Dried blood; Venous blood; Population study","score_opus":0.07327596737449306,"score_gpt":0.44380702590636034,"score_spread":0.3705310585318673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416756903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566317,0.00016535445,0.000053472006,0.0027461052,0.0005901207,0.00034120248,0.00009712925,0.000004544935,0.00033893465],"genre_scores_gemma":[0.9981773,0.000105910985,0.00012486195,0.0014592891,0.000059372,0.0000024481135,0.0000064494034,0.0000064384735,0.00005794616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99453294,0.0024383324,0.0022925036,0.00028883788,0.00009581017,0.000351566],"domain_scores_gemma":[0.9880231,0.010322782,0.0010438208,0.000359428,0.00021574239,0.000035118883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046380977,0.00019768254,0.0014079238,0.00031445723,0.0000920468,0.0000068270706,0.00052171986,0.0008294585,0.000040810995],"category_scores_gemma":[0.0083182845,0.00011411012,0.000460282,0.00054545683,0.00058677874,0.000030709998,0.000064390755,0.0015695001,0.0000022444376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040783178,0.032725576,0.8231299,0.0000349042,0.0033389619,0.0003651295,0.0015732046,0.00015941064,0.0855456,0.00019649121,0.00885111,0.0032965306],"study_design_scores_gemma":[0.011304011,0.03801996,0.9468391,0.000048364884,0.00048640533,0.00010004397,0.0002129934,0.00002551926,0.001793185,0.00038734218,0.0006882899,0.00009481789],"about_ca_topic_score_codex":0.0018505328,"about_ca_topic_score_gemma":0.002969761,"teacher_disagreement_score":0.12370917,"about_ca_system_score_codex":0.000050099483,"about_ca_system_score_gemma":0.00048557413,"threshold_uncertainty_score":0.99583644},"labels":[],"label_agreement":null},{"id":"W4416837248","doi":"10.1007/s40290-025-00593-8","title":"Considerations for Biosimilar Adoption in Pediatrics: A Scoping Review","year":2025,"lang":"en","type":"review","venue":"Pharmaceutical Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Biosimilar; Pharmacovigilance; New product development; Product (mathematics); Key (lock); MEDLINE; Drug development","score_opus":0.23519607778497048,"score_gpt":0.5185248198969498,"score_spread":0.2833287421119793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416837248","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.03483755e-8,0.9873013,0.00055748556,0.0054505374,0.0012446216,0.00426941,0.000112363276,0.000052782958,0.0010115202],"genre_scores_gemma":[4.9572895e-7,0.9910878,0.0011573544,0.0063039437,0.00025186577,0.0006744149,0.00016125158,0.000023529577,0.0003393231],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965501,0.0008171505,0.0014324446,0.00061759487,0.00006604287,0.00051667757],"domain_scores_gemma":[0.99206275,0.0071755657,0.00024788693,0.00031363507,0.00012328094,0.00007685589],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017687624,0.00046128864,0.0028325606,0.0004121802,0.000109748005,0.000008017783,0.00021581007,0.0006518074,0.00216077],"category_scores_gemma":[0.00676569,0.0003151144,0.0004027376,0.0006807882,0.00033642797,0.000035775647,0.00010087042,0.00092109793,0.000046432335],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012887615,0.000085785774,0.0000014873995,0.35125348,0.000106429856,0.000008316328,0.000005764948,1.6145819e-8,0.000006374902,0.0013222155,0.026487116,0.62071013],"study_design_scores_gemma":[0.00067912735,0.000076373515,2.733902e-7,0.36354795,0.0033464374,0.000029930909,0.0000026564692,0.0000014639625,0.0000064979076,0.00023763774,0.6318633,0.00020837333],"about_ca_topic_score_codex":0.0000027495537,"about_ca_topic_score_gemma":0.0000048844054,"teacher_disagreement_score":0.62050176,"about_ca_system_score_codex":0.000093748706,"about_ca_system_score_gemma":0.000489741,"threshold_uncertainty_score":0.9999301},"labels":[],"label_agreement":null},{"id":"W4417183456","doi":"10.1016/j.gastha.2025.100821","title":"Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar Anti–tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-world Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC Registry","year":2025,"lang":"en","type":"article","venue":"Gastro Hep Advances","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; NOSM University; University of British Columbia; McGill University; McGill University Health Centre; University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Biosimilar; Infliximab; Discontinuation; Adalimumab; Inflammatory bowel disease; Inflammatory Bowel Diseases; Drug; Ulcerative colitis; Thiopurine methyltransferase","score_opus":0.020922583193016264,"score_gpt":0.32765356000810103,"score_spread":0.30673097681508477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417183456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652255,0.025764741,0.0009367438,0.003118447,0.0008143484,0.0010272114,0.002897437,0.00003477637,0.00018078618],"genre_scores_gemma":[0.99184304,0.00052665273,0.0066380994,0.0002948076,0.00004373476,0.00006639635,0.00038130546,0.000018627567,0.00018731819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774086,0.00049376773,0.00058866927,0.00067395763,0.000056872293,0.00044587578],"domain_scores_gemma":[0.9978414,0.0010423771,0.00031485967,0.0006176593,0.00006568077,0.00011801215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000789135,0.00029895193,0.0005225543,0.00016829847,0.00037082157,0.000059553844,0.00048019984,0.00012147661,0.000017580362],"category_scores_gemma":[0.00020346981,0.0002229827,0.00011219817,0.00022708524,0.0010106614,0.0004135942,0.00044476613,0.00031890802,3.9732052e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054050767,0.000055441196,0.9818191,0.00014252005,0.00029096968,0.0000038968665,0.00036629158,0.000012746599,0.0013510113,0.00057819666,0.001811382,0.013027934],"study_design_scores_gemma":[0.001856939,0.000109341025,0.9735435,0.0009935554,0.0002751443,0.0000012125778,0.0026481287,0.0007628551,0.0019063585,0.002308439,0.015190518,0.00040398227],"about_ca_topic_score_codex":0.003362231,"about_ca_topic_score_gemma":0.039225653,"teacher_disagreement_score":0.035863418,"about_ca_system_score_codex":0.000086557084,"about_ca_system_score_gemma":0.00026339185,"threshold_uncertainty_score":0.978306},"labels":[],"label_agreement":null},{"id":"W4417480112","doi":"10.1016/j.jval.2025.09.230","title":"CO128 Health Technology Assessment, Reimbursement, and Funding Landscape Challenges for Oncology Companion Diagnostics in Europe and Canada","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Precision oncology; Biomarker; Selection (genetic algorithm); Precision medicine; Biomarker discovery; Health technology","score_opus":0.0730116779306706,"score_gpt":0.38458019095373086,"score_spread":0.31156851302306027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417480112","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28941476,0.26919064,0.0016581385,0.4315854,0.0025538863,0.00284248,0.0002166449,0.0000988436,0.0024391983],"genre_scores_gemma":[0.9130694,0.077774875,0.0044713113,0.004371617,0.000023355466,0.00006191581,0.000032637006,0.000015264079,0.00017961899],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978009,0.0007607851,0.0005122397,0.0003753941,0.000025120273,0.00052557496],"domain_scores_gemma":[0.99817276,0.0014358257,0.00015388445,0.0001476905,0.00004210119,0.00004774027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001807742,0.00014432904,0.00054589205,0.00030683886,0.00016618795,0.0000070898263,0.00010462702,0.00022138408,0.0000070019923],"category_scores_gemma":[0.0004519838,0.00013176957,0.0000122044885,0.00030906478,0.00013354207,0.000019958376,0.00010836083,0.0004875531,2.4265304e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019489894,0.00057258236,0.44865227,0.0020427692,0.00014896605,0.000022742059,0.00046344317,0.000044274675,0.00057800283,0.2535388,0.017891604,0.27584967],"study_design_scores_gemma":[0.005940397,0.0024922518,0.3197528,0.0011314926,0.000031464144,0.000053273798,0.0045251027,0.0014130087,0.00023059118,0.0049732877,0.6590507,0.00040557925],"about_ca_topic_score_codex":0.10086971,"about_ca_topic_score_gemma":0.29113707,"teacher_disagreement_score":0.6411591,"about_ca_system_score_codex":0.0003107895,"about_ca_system_score_gemma":0.0013280065,"threshold_uncertainty_score":0.9051177},"labels":[],"label_agreement":null},{"id":"W4417497569","doi":"10.1080/14712598.2025.2606897","title":"Ranibizumab biosimilar (Oceva) – real-world experience from India (RORE study)","year":2025,"lang":"en","type":"article","venue":"Expert Opinion on Biological Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Electrovaya (Canada)","funders":"","keywords":"Biosimilar; Ranibizumab; Population; Clinical trial; Pharmacogenetics; MEDLINE","score_opus":0.09086108873478276,"score_gpt":0.39661812815289293,"score_spread":0.30575703941811017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417497569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9027239,0.048434243,0.00056898553,0.009208851,0.010105514,0.002596382,0.00017532526,0.00086623663,0.02532058],"genre_scores_gemma":[0.9431206,0.044816416,0.00066873786,0.010211092,0.00020526284,0.0001780807,0.00009321647,0.000018996234,0.00068756985],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99683005,0.0010026073,0.0005526345,0.0009845252,0.00008603193,0.00054414506],"domain_scores_gemma":[0.9983277,0.0007422443,0.00012387609,0.0006766299,0.00006578123,0.00006378415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040442278,0.0004464451,0.00068110635,0.00020173665,0.00034460952,0.000042971693,0.0006904612,0.00059619197,0.0036012144],"category_scores_gemma":[0.00014479796,0.00027417648,0.00024853277,0.00059123005,0.00051634543,0.000051193063,0.00015981904,0.00051462895,0.0001412644],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009109007,0.007138268,0.114691556,0.0000031325758,0.0014448742,0.000034922152,0.0031054576,9.320729e-7,0.43404415,0.018753564,0.06355545,0.34811866],"study_design_scores_gemma":[0.003433872,0.0016180873,0.14332104,0.000053332114,0.0000014495896,0.0000011749083,0.000976199,0.0000033703434,0.08306164,0.001380983,0.76570994,0.0004389122],"about_ca_topic_score_codex":0.0001855799,"about_ca_topic_score_gemma":0.000008832667,"teacher_disagreement_score":0.7021545,"about_ca_system_score_codex":0.00007367494,"about_ca_system_score_gemma":0.000041380496,"threshold_uncertainty_score":0.99997103},"labels":[],"label_agreement":null},{"id":"W49093681","doi":"10.2310/7750.2013.13006","title":"Preparing for Subsequent Entry Biologies in Dermatology and Rheumatology in Canada","year":2013,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Amgen (Canada); Centre Hospitalier de l’Université de Montréal; Moncton Hospital; University of British Columbia","funders":"Health Canada","keywords":"Medicine; Authorization; Declaration; Marketing authorization; Agency (philosophy); Alternative medicine; Prior authorization; Clinical trial; Family medicine; Pathology; Pharmacology; Bioinformatics; Law","score_opus":0.0224351369086598,"score_gpt":0.2614748119278012,"score_spread":0.2390396750191414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W49093681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773533,0.015235214,0.000029465658,0.0066997474,0.0004829397,0.00010893258,0.0000015784926,0.0000025201034,0.00008633029],"genre_scores_gemma":[0.99412143,0.0050105574,0.00015900485,0.0006526894,0.000013688413,0.000004468584,0.000001564154,0.0000044887906,0.00003209575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868065,0.00017929052,0.0007019086,0.00012492793,0.00002691434,0.0002863307],"domain_scores_gemma":[0.99666935,0.002956872,0.00021147267,0.000061295315,0.000059031285,0.00004197219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004103636,0.00011277373,0.0007535112,0.00021794635,0.000026710553,0.0000037143177,0.00006195867,0.00015790497,0.000070061506],"category_scores_gemma":[0.00091308827,0.00007307386,0.00003664409,0.00007465698,0.00021854282,0.000039467286,0.000026635973,0.00024006091,3.4141448e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032517922,0.00004202638,0.92253613,0.00016502663,0.00011858966,0.0004438581,0.00022716663,0.0000019344516,0.009076781,0.00017569053,0.02889639,0.0379912],"study_design_scores_gemma":[0.013499337,0.0022864516,0.3935405,0.004592359,0.0004732996,0.34711105,0.021093465,0.0007175048,0.023400826,0.02222532,0.16908087,0.0019790232],"about_ca_topic_score_codex":0.08739642,"about_ca_topic_score_gemma":0.117485344,"teacher_disagreement_score":0.52899563,"about_ca_system_score_codex":0.000056291017,"about_ca_system_score_gemma":0.0002726458,"threshold_uncertainty_score":0.91868067},"labels":[],"label_agreement":null},{"id":"W5945574","doi":"","title":"Reduced drug costs from switching hemodialysis patients from epoetin alfa in multidose vials to pre-filled syringes.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epoetin alfa; Medicine; Vial; Hemodialysis; Drug holiday; Internal medicine; Emergency medicine; Erythropoietin; Surgery; Family medicine","score_opus":0.012193004604480565,"score_gpt":0.2436496030420074,"score_spread":0.23145659843752683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W5945574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465,0.00020556053,0.00007143145,0.0011798519,0.0022410883,0.0009564079,0.00020669715,0.000066555695,0.00042240592],"genre_scores_gemma":[0.99531966,0.000018031631,0.0027173231,0.0007179842,0.00013254519,0.00049599627,0.00013979764,0.000027598962,0.00043104275],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974773,0.00047294958,0.0005904546,0.0006955062,0.000082546554,0.00068125833],"domain_scores_gemma":[0.9981474,0.00094282074,0.00016500513,0.00052846805,0.00007398845,0.00014231322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008200006,0.00028464902,0.00061586447,0.00018744192,0.00010552805,0.000045729415,0.0004289156,0.00044294863,0.000450177],"category_scores_gemma":[0.0021583475,0.00023948058,0.00015730683,0.00027300132,0.000077532684,0.000086122716,0.00025559662,0.00068827067,0.000112849106],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005637845,0.000459056,0.07913835,0.000004077004,0.00024506223,0.0000052433697,0.00067539077,0.0000013705151,0.3704259,0.000011332628,0.0013935867,0.5470768],"study_design_scores_gemma":[0.0021456985,0.000014612135,0.77576613,0.00001794054,0.00007776986,3.8337356e-7,0.000034267177,0.000011145265,0.2166006,0.00023652558,0.0047897627,0.00030512892],"about_ca_topic_score_codex":0.0038997629,"about_ca_topic_score_gemma":0.0019686704,"teacher_disagreement_score":0.6966278,"about_ca_system_score_codex":0.00008584314,"about_ca_system_score_gemma":0.000019193703,"threshold_uncertainty_score":0.9765734},"labels":[],"label_agreement":null},{"id":"W612086590","doi":"10.1097/mog.0000000000000184","title":"Biosimilars in inflammatory bowel disease","year":2015,"lang":"en","type":"review","venue":"Current Opinion in Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Infliximab; Inflammatory bowel disease; Ankylosing spondylitis; Rheumatoid arthritis; Clinical trial; Intensive care medicine; Disease; Internal medicine","score_opus":0.10259076885967774,"score_gpt":0.3973268672409257,"score_spread":0.2947360983812479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W612086590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000039979022,0.9866636,0.000030838713,0.0002450431,0.011901545,0.00080526917,0.00022995361,0.000043806784,0.000040004168],"genre_scores_gemma":[0.000019552484,0.9987325,0.000054343025,0.00009754723,0.0002011596,0.00023509018,0.0005596756,0.00004694572,0.000053206055],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99465233,0.0019686131,0.0014111963,0.0009032015,0.00007617923,0.000988451],"domain_scores_gemma":[0.9986195,0.0001615811,0.00041200776,0.0005981312,0.000055231416,0.00015352778],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010335557,0.0006750345,0.0019339873,0.00091066706,0.000035270903,0.000019469051,0.00068938086,0.00079954375,0.00025284968],"category_scores_gemma":[0.0001902787,0.00055603037,0.00047628453,0.0002845991,0.00046147648,0.000071030896,0.0004206616,0.0017213085,0.00023081378],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006519067,0.0012213872,0.046149567,0.021531394,0.00023696943,0.00003539427,0.00006176876,0.000003053642,0.0000013306299,0.00039617534,0.065911956,0.8637991],"study_design_scores_gemma":[0.0012547746,0.00018247486,0.0018520982,0.008453109,0.00012637072,0.00003765042,0.000008367863,0.000004270857,1.3096721e-7,0.00013791524,0.9876458,0.00029700575],"about_ca_topic_score_codex":0.000002869384,"about_ca_topic_score_gemma":0.000010237535,"teacher_disagreement_score":0.92173386,"about_ca_system_score_codex":0.00028250943,"about_ca_system_score_gemma":0.00031631583,"threshold_uncertainty_score":0.9996891},"labels":[],"label_agreement":null},{"id":"W6885452136","doi":"10.1371/journal.pgph.0003320.s001","title":"Search strategy MeSH terms and keywords.","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Predictive validity; Measure (data warehouse); Face validity; External validity; Quality (philosophy); MEDLINE","score_opus":0.06550157669273304,"score_gpt":0.33406270187617226,"score_spread":0.2685611251834392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6885452136","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010543432,0.13637581,0.000038312937,0.006171233,0.0015517882,0.0012041936,0.6021272,0.0013357579,0.24065226],"genre_scores_gemma":[0.9580069,0.00009131049,0.00017125193,0.0005865713,0.00013476775,0.000043387558,0.019120637,0.000028364922,0.021816779],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993817,0.00006684306,0.000093813804,0.00022622837,0.000019947061,0.00021145641],"domain_scores_gemma":[0.99968326,0.00015531272,0.0000075114745,0.000109100554,0.00001945266,0.00002538554],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006993846,0.000093023955,0.000113154434,0.000045635057,0.00005663238,0.00006423942,0.000093889896,0.00019398455,0.25516504],"category_scores_gemma":[0.00009078827,0.00006597894,0.00004666358,0.00010607691,0.000027655964,0.000048560654,0.00009157151,0.00027113943,0.0026294156],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013174305,0.00001984072,0.000041086878,0.00023968231,0.000112046546,0.00005069279,0.00006739147,1.722524e-7,0.012730635,0.00084377074,0.8182142,0.16766733],"study_design_scores_gemma":[0.00016032909,0.0001275998,0.0021544055,0.0006362227,0.0000210548,0.00009125491,0.000050776325,0.000093246366,0.03481079,0.00032099214,0.96135473,0.00017858198],"about_ca_topic_score_codex":0.000002819415,"about_ca_topic_score_gemma":0.0000018405663,"teacher_disagreement_score":0.9474635,"about_ca_system_score_codex":0.000008239966,"about_ca_system_score_gemma":0.00002878232,"threshold_uncertainty_score":0.99814713},"labels":[],"label_agreement":null},{"id":"W6901869858","doi":"10.6084/m9.figshare.10297469","title":"MOESM3 of Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis","year":2019,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Infliximab; Insulin glargine; Retrospective cohort study; Insulin; MEDLINE","score_opus":0.024890258997745232,"score_gpt":0.22859118140100737,"score_spread":0.20370092240326215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901869858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70385253,0.0017330885,0.00000451375,0.0013353057,0.00013846056,0.00056667184,0.29229888,0.000007476223,0.00006302882],"genre_scores_gemma":[0.9966078,0.000018348466,0.00009315186,0.0005745402,0.0000073351493,0.000011959366,0.002576042,0.000006692731,0.0001041266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899346,0.00020370331,0.0003025808,0.00023874703,0.00007121311,0.00019029809],"domain_scores_gemma":[0.9988415,0.00045823504,0.00021079261,0.00035935058,0.00011373085,0.000016357819],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000691858,0.00013360012,0.00040491487,0.000059098897,0.000041649,0.000008952328,0.0002785105,0.0001693139,0.024312912],"category_scores_gemma":[0.0007709008,0.0000756268,0.00013016156,0.0005904697,0.00006223552,0.00004678749,0.00023694006,0.0003115302,0.000008398075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000551547,0.00022354253,0.7717737,0.0001212042,0.0035894485,0.000012839552,0.0005193492,0.0004973018,0.05525195,0.000042854273,0.16188836,0.00552792],"study_design_scores_gemma":[0.0006627861,0.000035636738,0.97153616,0.00019471622,0.00019218445,0.0000017465763,0.00006495819,0.00060424546,0.01464979,0.000023137894,0.011930656,0.000103979444],"about_ca_topic_score_codex":0.13168953,"about_ca_topic_score_gemma":0.2573407,"teacher_disagreement_score":0.29275525,"about_ca_system_score_codex":0.00007781717,"about_ca_system_score_gemma":0.00019337452,"threshold_uncertainty_score":0.976579},"labels":[],"label_agreement":null},{"id":"W6902009905","doi":"10.6084/m9.figshare.10297463.v1","title":"MOESM2 of Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis","year":2019,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Infliximab; Insulin glargine; Retrospective cohort study; Insulin; MEDLINE","score_opus":0.024890258997745232,"score_gpt":0.22859118140100737,"score_spread":0.20370092240326215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902009905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70563495,0.001727043,0.0000045237102,0.0013185744,0.00013748225,0.00056329597,0.29054546,0.0000074225422,0.00006124225],"genre_scores_gemma":[0.9966032,0.000018383804,0.000092620015,0.00057534996,0.0000073499027,0.000011967125,0.0025793177,0.0000066963958,0.0001051468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998993,0.00020385747,0.00030270813,0.00023884521,0.00007124765,0.00019035736],"domain_scores_gemma":[0.99884105,0.00045840588,0.00021085897,0.00035955242,0.00011379,0.000016367976],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008015933,0.00013363222,0.00040509115,0.000059122,0.000041675168,0.00000895465,0.00027861347,0.0001692189,0.024328485],"category_scores_gemma":[0.00077093975,0.00007564064,0.00013017819,0.00059115863,0.00006226524,0.000046801273,0.00023719204,0.00031167438,0.00000839928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051136856,0.00020680428,0.79702365,0.00011194001,0.0033159987,0.000011865814,0.00048055965,0.0004565067,0.043058474,0.000040306524,0.14968663,0.005095884],"study_design_scores_gemma":[0.00067210867,0.0000360591,0.9714717,0.0001966472,0.00019415219,0.000001756119,0.00006724635,0.00061575393,0.014295029,0.00002338347,0.012321119,0.00010500087],"about_ca_topic_score_codex":0.13212276,"about_ca_topic_score_gemma":0.26446387,"teacher_disagreement_score":0.2909682,"about_ca_system_score_codex":0.00007794336,"about_ca_system_score_gemma":0.00019351559,"threshold_uncertainty_score":0.9765634},"labels":[],"label_agreement":null},{"id":"W6902084783","doi":"10.6084/m9.figshare.18281248.v1","title":"Diagnostic accuracy of dried blood spots for serology of vaccine-preventable diseases: a systematic review","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Serology; Dried blood spot; Diagnostic accuracy; Dried blood; Diagnostic test; Antibody; Confidence interval; Blood test; Rubella","score_opus":0.028869669416566778,"score_gpt":0.3077441904642681,"score_spread":0.27887452104770133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902084783","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00278098,0.36916947,0.00001419474,0.00074314367,0.00029089948,0.0061057885,0.620658,0.00006415816,0.00017335288],"genre_scores_gemma":[0.84263647,0.0012409815,0.0004429338,0.0042723618,0.000059591395,0.008522462,0.14069961,0.00008271046,0.0020428752],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99843234,0.00047118578,0.000596176,0.00022257262,0.000045573564,0.0002321698],"domain_scores_gemma":[0.9958786,0.0031138915,0.0004826849,0.0003784518,0.00012085802,0.000025554316],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002233633,0.00013739782,0.0008628351,0.000054828055,0.00008778038,0.0000024062138,0.00038794414,0.00009060221,0.09658221],"category_scores_gemma":[0.011965845,0.0001119222,0.0002702637,0.00020755662,0.000012626993,0.000032131968,0.0002554827,0.00014549923,0.000037194615],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017985505,0.0009794136,0.00032092663,0.57266,0.0011860507,0.000012704754,0.00005807526,0.0000046769273,0.0048354957,0.00019156844,0.4192623,0.00030891807],"study_design_scores_gemma":[0.014394222,0.006021954,0.008551674,0.72680604,0.024776908,0.00064734765,0.0005936428,0.00009333089,0.105968274,0.0024854129,0.10752599,0.0021352032],"about_ca_topic_score_codex":0.000003979663,"about_ca_topic_score_gemma":0.0000014663153,"teacher_disagreement_score":0.8398555,"about_ca_system_score_codex":0.000013103958,"about_ca_system_score_gemma":0.00006813448,"threshold_uncertainty_score":0.9963568},"labels":[],"label_agreement":null},{"id":"W6902093402","doi":"10.6084/m9.figshare.14853224.v1","title":"Additional file 1 of Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"","keywords":"Immunogenicity; Biosimilar; Insulin glargine; Diabetes mellitus; Insulin; Clinical trial","score_opus":0.03648264879626843,"score_gpt":0.2728259093846413,"score_spread":0.23634326058837285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902093402","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08168113,0.006124257,1.0027434e-7,0.00048598787,0.000014557107,0.00035319064,0.9112775,0.000013242972,0.00005003965],"genre_scores_gemma":[0.2935839,0.0002383562,0.00065450923,0.00056667667,0.000042994583,0.00037182946,0.7044111,0.00002312821,0.000107531334],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986361,0.00034259495,0.00034265613,0.0003271263,0.00008301914,0.00026846497],"domain_scores_gemma":[0.9959645,0.003265652,0.00018904971,0.00026504477,0.0002902386,0.00002548491],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012066875,0.00021578326,0.000399024,0.000048762733,0.00020167162,0.00002234922,0.00019899565,0.00018617573,0.26054472],"category_scores_gemma":[0.0039201956,0.000111833055,0.00004726246,0.00031517242,0.00030616552,0.00008467304,0.00029272292,0.00040398058,0.000018911109],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023900215,0.00037303808,0.0035307556,0.00024624335,0.0007531236,0.0000057679927,0.00018389785,3.1263446e-7,0.0006063752,0.000010468679,0.9685883,0.025462711],"study_design_scores_gemma":[0.0047263247,0.00092848146,0.23811385,0.0035119762,0.00017366442,0.0000052420714,0.00054711243,0.000013265301,0.06456806,0.00016152325,0.6867691,0.0004813694],"about_ca_topic_score_codex":0.00000227414,"about_ca_topic_score_gemma":0.000013911362,"teacher_disagreement_score":0.28181916,"about_ca_system_score_codex":0.000019092944,"about_ca_system_score_gemma":0.00011693596,"threshold_uncertainty_score":0.74013126},"labels":[],"label_agreement":null},{"id":"W6920144360","doi":"10.60692/cz7cn-9f046","title":"PANLAR consensus statement on biosimilars","year":2019,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Rheumatology Association","funders":"","keywords":"Biosimilar; Pharmacovigilance; Delphi method; Delphi; Pharmacy; Pharmacoeconomics; Clinical trial","score_opus":0.03698233551938615,"score_gpt":0.24411058038445443,"score_spread":0.20712824486506828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920144360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672712,0.000021395135,0.0011171151,0.00093367585,0.0024022716,0.0008439385,0.00037956098,0.00028396773,0.026746841],"genre_scores_gemma":[0.9968024,2.0933967e-7,0.00022466287,0.0014874799,0.000014550327,0.000015065739,0.000022355922,0.000007126885,0.0014261857],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987253,0.00016386187,0.0005674063,0.00016697183,0.00007404233,0.00030244436],"domain_scores_gemma":[0.9992684,0.000024110406,0.00021701658,0.00036322602,0.00009290208,0.00003432097],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004971085,0.00018137577,0.00027229456,0.00016462759,0.000088321984,0.00004613365,0.0001397996,0.00022880847,0.00060648524],"category_scores_gemma":[0.000018183642,0.00012678774,0.00009469549,0.00012558555,0.000060433194,0.00008939041,0.000047264337,0.00015928257,0.011154258],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048600594,0.0001162136,0.7623857,0.0034183064,0.003467191,0.00004322181,0.07603422,0.00035217727,0.006277705,0.02144576,0.10667993,0.014919516],"study_design_scores_gemma":[0.018802213,0.0027612979,0.19120865,0.0012718429,0.0004054283,0.0003686793,0.052001018,0.0010201748,0.2811634,0.000024015548,0.44835705,0.0026162507],"about_ca_topic_score_codex":0.0000016591487,"about_ca_topic_score_gemma":4.0712205e-8,"teacher_disagreement_score":0.57117707,"about_ca_system_score_codex":0.00008150558,"about_ca_system_score_gemma":0.0000251064,"threshold_uncertainty_score":0.9896157},"labels":[],"label_agreement":null},{"id":"W6920727404","doi":"10.6084/m9.figshare.13724963.v1","title":"Additional file 1 of Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Adalimumab; Biosimilar; Table (database); Adverse effect; Randomized controlled trial; Rheumatoid arthritis","score_opus":0.039167351567345764,"score_gpt":0.2645597193182086,"score_spread":0.22539236775086283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920727404","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005168617,0.0017573525,2.3353726e-7,0.000054862572,0.0000375115,0.0003899252,0.9913627,0.000015878939,0.0012129132],"genre_scores_gemma":[0.21431388,0.00016410835,0.0010500333,0.000049673148,0.000010636594,0.00020980442,0.78399754,0.000014385255,0.00018993144],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980866,0.00063066394,0.00058057916,0.0004132901,0.00007960397,0.0002092644],"domain_scores_gemma":[0.98819214,0.011019805,0.0002771642,0.0002911744,0.00018793931,0.000031797434],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000143792,0.00018501142,0.000820995,0.000071890034,0.000052147956,0.0000097761895,0.0001396664,0.00015040308,0.8453942],"category_scores_gemma":[0.00973284,0.00014443962,0.00007961586,0.00025371966,0.00011945022,0.00004981354,0.0001376649,0.000282245,0.00006973889],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10476187,0.0008791416,0.000006580968,0.000037333757,0.00052599265,0.00008953805,0.0002176601,0.0000012018515,0.0003993145,0.000008480374,0.88930076,0.003772135],"study_design_scores_gemma":[0.6294724,0.0022411,0.01855115,0.016702145,0.00012505583,0.00007220897,0.0017553038,0.00002568222,0.022046028,0.0000863339,0.30814683,0.0007757762],"about_ca_topic_score_codex":0.00004491349,"about_ca_topic_score_gemma":0.0003776608,"teacher_disagreement_score":0.84532446,"about_ca_system_score_codex":0.00001469181,"about_ca_system_score_gemma":0.00019871452,"threshold_uncertainty_score":0.9986086},"labels":[],"label_agreement":null},{"id":"W6920875477","doi":"10.6084/m9.figshare.10297469.v1","title":"MOESM3 of Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis","year":2019,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Infliximab; Insulin glargine; Retrospective cohort study; Insulin; MEDLINE","score_opus":0.024890258997745232,"score_gpt":0.22859118140100737,"score_spread":0.20370092240326215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920875477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70385253,0.0017330885,0.00000451375,0.0013353057,0.00013846056,0.00056667184,0.29229888,0.000007476223,0.00006302882],"genre_scores_gemma":[0.9966078,0.000018348466,0.00009315186,0.0005745402,0.0000073351493,0.000011959366,0.002576042,0.000006692731,0.0001041266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899346,0.00020370331,0.0003025808,0.00023874703,0.00007121311,0.00019029809],"domain_scores_gemma":[0.9988415,0.00045823504,0.00021079261,0.00035935058,0.00011373085,0.000016357819],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000691858,0.00013360012,0.00040491487,0.000059098897,0.000041649,0.000008952328,0.0002785105,0.0001693139,0.024312912],"category_scores_gemma":[0.0007709008,0.0000756268,0.00013016156,0.0005904697,0.00006223552,0.00004678749,0.00023694006,0.0003115302,0.000008398075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000551547,0.00022354253,0.7717737,0.0001212042,0.0035894485,0.000012839552,0.0005193492,0.0004973018,0.05525195,0.000042854273,0.16188836,0.00552792],"study_design_scores_gemma":[0.0006627861,0.000035636738,0.97153616,0.00019471622,0.00019218445,0.0000017465763,0.00006495819,0.00060424546,0.01464979,0.000023137894,0.011930656,0.000103979444],"about_ca_topic_score_codex":0.13168953,"about_ca_topic_score_gemma":0.2573407,"teacher_disagreement_score":0.29275525,"about_ca_system_score_codex":0.00007781717,"about_ca_system_score_gemma":0.00019337452,"threshold_uncertainty_score":0.976579},"labels":[],"label_agreement":null},{"id":"W6920993657","doi":"10.6084/m9.figshare.19076418","title":"Additional file 1 of Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia","year":2022,"lang":"en","type":"article","venue":"Open MIND","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biosimilar; Cohort; Cohort study; Cumulative incidence; Table (database); Cumulative dose; Off-label use","score_opus":0.028200985542118782,"score_gpt":0.3201328406559849,"score_spread":0.2919318551138661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920993657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7878326,0.000030346047,4.6432226e-7,0.00007618139,0.00016205928,0.0009511921,0.21086189,0.0000014514849,0.000083788604],"genre_scores_gemma":[0.97787434,0.0000034064328,0.01040336,0.0004908445,0.00002703493,0.00046375478,0.009342652,0.000020836656,0.0013737427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981265,0.0005056099,0.0005381642,0.00042670267,0.000120935874,0.00028206303],"domain_scores_gemma":[0.9989326,0.0005121364,0.00018040053,0.00024851988,0.00006895549,0.000057368386],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004611723,0.00010449622,0.0005375903,0.00011184056,0.0001808563,0.00006848584,0.0004887802,0.000075654,0.43536097],"category_scores_gemma":[0.00021659925,0.00014550098,0.000078047575,0.0005794273,0.000026729169,0.00010109462,0.00063957705,0.0001854535,0.00003275639],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009692119,0.001389739,0.7522428,0.000009847605,0.00027653394,0.0000097876755,0.00093877845,0.0000027177962,0.001026046,1.07466455e-7,0.19129021,0.052716527],"study_design_scores_gemma":[0.000708592,0.00080296735,0.7898149,0.00018474615,0.000022924167,0.0000010710513,0.001931367,7.2568446e-7,0.00029367208,0.0000052940195,0.20610008,0.00013367868],"about_ca_topic_score_codex":0.045965128,"about_ca_topic_score_gemma":0.0143201575,"teacher_disagreement_score":0.43532822,"about_ca_system_score_codex":0.0001338975,"about_ca_system_score_gemma":0.00019412274,"threshold_uncertainty_score":0.9603879},"labels":[],"label_agreement":null},{"id":"W6929278557","doi":"10.4224/20377992","title":"Evaluation of the effectiveness of different photoluminescent stairwell installations for the evacuation of office building occupants","year":2007,"lang":"en","type":"report","venue":"NPARC","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Field (mathematics); Field research; Research council; Public access","score_opus":0.09419224723217853,"score_gpt":0.3906692482926683,"score_spread":0.2964770010604898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929278557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.943644,0.005878693,0.016596887,0.00017187787,0.004465335,0.00837723,0.00095293834,0.000022569458,0.019890506],"genre_scores_gemma":[0.99920183,0.00018621393,0.000255164,0.000007805231,0.000034172936,0.000050332917,0.00005595199,0.0000144493615,0.0001940533],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974152,0.0010672896,0.00068791106,0.00023330176,0.00041254156,0.00018374226],"domain_scores_gemma":[0.9940619,0.0024370095,0.000847336,0.00044877047,0.0021949157,0.000010055136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009996506,0.00018692795,0.0005498418,0.00010630357,0.000092555456,0.000003085165,0.00028461192,0.00044395932,0.00020928856],"category_scores_gemma":[0.002313902,0.00009854386,0.00034270188,0.00020986152,0.00032455946,0.000017087315,0.00009103084,0.0002444177,3.6969644e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006211916,0.00033921318,0.003433777,0.000982246,0.0010123979,4.1023874e-8,0.00004449332,0.000037429985,0.9630737,0.0006025549,0.00071555824,0.029137444],"study_design_scores_gemma":[0.000976123,0.00016408243,0.16404848,0.00065239787,0.0024467953,0.0000035569183,0.000040827523,0.00034019724,0.82771504,0.0011189075,0.0023751056,0.00011848513],"about_ca_topic_score_codex":0.00008309322,"about_ca_topic_score_gemma":0.00004403484,"teacher_disagreement_score":0.1606147,"about_ca_system_score_codex":0.0001856518,"about_ca_system_score_gemma":0.00058387703,"threshold_uncertainty_score":0.4018502},"labels":[],"label_agreement":null},{"id":"W6931497447","doi":"10.5281/zenodo.5800955","title":"Andricus columbiensis Melika, Nicholls & Stone 2021, sp. nov.","year":2021,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Holotype; Antenna (radio); Genus; Key (lock); SPINE (molecular biology)","score_opus":0.03312136970137358,"score_gpt":0.2667821844675039,"score_spread":0.23366081476613032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931497447","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12984063,0.009212158,0.009071431,0.017007139,0.0025069292,0.0014300701,0.0020657168,0.0018551785,0.82701075],"genre_scores_gemma":[0.88829523,0.0017966917,0.0042604106,0.002952146,0.0004207036,1.4149248e-7,0.004063037,0.0022396534,0.09597196],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979451,0.00074012263,0.0002741005,0.0004931518,0.00010211777,0.00044544684],"domain_scores_gemma":[0.9986181,0.00006163289,0.00008136017,0.000488496,0.00066112354,0.00008927472],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00066871656,0.00014603595,0.0002437728,0.00010563152,0.0014406309,0.00029588045,0.00052139064,0.00018804465,0.1041518],"category_scores_gemma":[0.0009805457,0.00014642619,0.00009716677,0.0006625994,0.00029189952,0.00010580424,0.00094423053,0.00040472276,0.011354078],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008383771,0.0003189655,0.000016082977,0.00002680953,0.0002035682,0.00006276712,0.00022737772,0.0000022603374,0.27495694,0.0019721093,0.5689894,0.1531399],"study_design_scores_gemma":[0.0006988747,0.00014544046,0.0009836969,0.00002015385,0.00004726427,0.00031260512,0.00023398691,0.000011675874,0.036665484,0.00012032806,0.9605776,0.00018287472],"about_ca_topic_score_codex":0.00001487075,"about_ca_topic_score_gemma":0.0000012996549,"teacher_disagreement_score":0.7584546,"about_ca_system_score_codex":0.00007338744,"about_ca_system_score_gemma":0.000007734796,"threshold_uncertainty_score":0.99985933},"labels":[],"label_agreement":null},{"id":"W6931640950","doi":"10.5281/zenodo.6238237","title":"Anopheles mosquito","year":2007,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Extant taxon; Anopheles; Fossil Record; Cretaceous; Biogeography; Phylogenetic tree","score_opus":0.040460148131341016,"score_gpt":0.28296868829969674,"score_spread":0.2425085401683557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931640950","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0879666,0.0017256796,0.03425262,0.0034151687,0.0010160024,0.0007801744,0.0003480737,0.0022198579,0.8682758],"genre_scores_gemma":[0.9888239,0.00008106208,0.0013449852,0.0006875565,0.00014336928,9.277563e-9,0.0005196922,0.000743346,0.007656086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99879503,0.00023590651,0.00020666463,0.00028606132,0.00006997584,0.0004063312],"domain_scores_gemma":[0.99931777,0.000047906127,0.000054462977,0.00028411002,0.00023198657,0.00006375248],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013175727,0.00010463719,0.00012844827,0.00012880866,0.0012552509,0.00015199783,0.0006225518,0.00014059896,0.029957375],"category_scores_gemma":[0.00044360352,0.00009389335,0.00005443672,0.0003219573,0.00027310653,0.00007528489,0.0005649918,0.00026790865,0.00788071],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001706734,0.00018265346,0.000013753954,0.00002432954,0.00009302918,0.000015206289,0.00027466717,9.905472e-7,0.29727086,0.012080856,0.29962003,0.39025295],"study_design_scores_gemma":[0.00036309767,0.0001826682,0.0011803252,0.000009297367,0.000014153772,0.0001083544,0.00020966365,0.000004250593,0.03232325,0.0002480608,0.96523833,0.00011855372],"about_ca_topic_score_codex":0.000006129638,"about_ca_topic_score_gemma":2.582854e-7,"teacher_disagreement_score":0.90085727,"about_ca_system_score_codex":0.000050766812,"about_ca_system_score_gemma":0.0000014752065,"threshold_uncertainty_score":0.9928918},"labels":[],"label_agreement":null},{"id":"W6939390286","doi":"10.6084/m9.figshare.12812511.v1","title":"Additional file 1 of Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Rheumatoid arthritis; Confidence interval; TNF inhibitor; Radiography; Coverage probability","score_opus":0.031202565369390464,"score_gpt":0.25986130397516544,"score_spread":0.22865873860577496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939390286","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00094890856,0.00044809765,6.406926e-7,0.00021431714,0.000039683273,0.0002143263,0.9980687,0.000029622439,0.000035720623],"genre_scores_gemma":[0.04409005,0.00002014373,0.0012710295,0.00097002083,0.000041691084,0.00021817829,0.95336366,0.000015896281,0.000009318066],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989479,0.00017296622,0.0003097494,0.00030055575,0.000082490405,0.0001863414],"domain_scores_gemma":[0.9979494,0.0015052913,0.00018823196,0.00013884115,0.00017861639,0.000039620598],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003336921,0.00017933141,0.00037759327,0.00008848308,0.000053158794,0.0000071418076,0.00011561998,0.00018483131,0.91325235],"category_scores_gemma":[0.0035660001,0.00013040136,0.00007937353,0.0002844079,0.00007433016,0.000042177984,0.00005562895,0.0002492059,0.00023678826],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036742145,0.00023317861,0.0007200101,0.000052820626,0.00006296734,0.000007379489,0.000021172942,4.045951e-7,0.000055196833,2.5592752e-7,0.98976713,0.008712082],"study_design_scores_gemma":[0.003020172,0.0016838084,0.08958949,0.019719027,0.000014533843,8.3911385e-7,0.000040374598,0.00019076462,0.0044797235,0.00000665023,0.8808463,0.0004082863],"about_ca_topic_score_codex":6.146022e-7,"about_ca_topic_score_gemma":0.0000022214504,"teacher_disagreement_score":0.91301554,"about_ca_system_score_codex":0.000012762472,"about_ca_system_score_gemma":0.00004416649,"threshold_uncertainty_score":0.5317613},"labels":[],"label_agreement":null},{"id":"W6939656168","doi":"10.6084/m9.figshare.13724963","title":"Additional file 1 of Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Adalimumab; Biosimilar; Table (database); Adverse effect; Randomized controlled trial; Rheumatoid arthritis","score_opus":0.039167351567345764,"score_gpt":0.2645597193182086,"score_spread":0.22539236775086283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939656168","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005168617,0.0017573525,2.3353726e-7,0.000054862572,0.0000375115,0.0003899252,0.9913627,0.000015878939,0.0012129132],"genre_scores_gemma":[0.21431388,0.00016410835,0.0010500333,0.000049673148,0.000010636594,0.00020980442,0.78399754,0.000014385255,0.00018993144],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980866,0.00063066394,0.00058057916,0.0004132901,0.00007960397,0.0002092644],"domain_scores_gemma":[0.98819214,0.011019805,0.0002771642,0.0002911744,0.00018793931,0.000031797434],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000143792,0.00018501142,0.000820995,0.000071890034,0.000052147956,0.0000097761895,0.0001396664,0.00015040308,0.8453942],"category_scores_gemma":[0.00973284,0.00014443962,0.00007961586,0.00025371966,0.00011945022,0.00004981354,0.0001376649,0.000282245,0.00006973889],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10476187,0.0008791416,0.000006580968,0.000037333757,0.00052599265,0.00008953805,0.0002176601,0.0000012018515,0.0003993145,0.000008480374,0.88930076,0.003772135],"study_design_scores_gemma":[0.6294724,0.0022411,0.01855115,0.016702145,0.00012505583,0.00007220897,0.0017553038,0.00002568222,0.022046028,0.0000863339,0.30814683,0.0007757762],"about_ca_topic_score_codex":0.00004491349,"about_ca_topic_score_gemma":0.0003776608,"teacher_disagreement_score":0.84532446,"about_ca_system_score_codex":0.00001469181,"about_ca_system_score_gemma":0.00019871452,"threshold_uncertainty_score":0.9986086},"labels":[],"label_agreement":null},{"id":"W6957311411","doi":"10.60692/2c36r-3rz15","title":"WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June – 2 July 2021","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"CLARITY; Biosimilar; Standardization; Product (mathematics); Best practice; MEDLINE; Excellence","score_opus":0.08225290411359372,"score_gpt":0.30795954127450403,"score_spread":0.22570663716091033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957311411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98098123,0.00032959174,0.0019397776,0.00092838926,0.0029539925,0.0026552794,0.0011108358,0.0001161185,0.008984788],"genre_scores_gemma":[0.99864835,0.0000029014418,0.000301766,0.00042126066,0.0000344637,0.000027827244,0.00010518087,0.000008429036,0.00044981515],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973511,0.00063789677,0.0012761265,0.00017854056,0.00036752594,0.00018879113],"domain_scores_gemma":[0.9974735,0.00005391693,0.0009450361,0.00035726026,0.0011515158,0.000018780767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034170626,0.00018822221,0.0003913494,0.00035101807,0.00018489458,0.000017455888,0.00017992473,0.00015787824,0.0004068388],"category_scores_gemma":[0.0004882559,0.00014468329,0.000095771305,0.0003965038,0.00008518468,0.0001837359,0.00007185689,0.00019219484,0.00013881596],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017511021,0.0005259058,0.019665956,0.0068550147,0.0041339,0.000004789125,0.26888546,0.078736,0.024253765,0.014336557,0.07364064,0.491451],"study_design_scores_gemma":[0.020683339,0.00720829,0.014528841,0.0031398893,0.0014279293,0.0000870365,0.05406278,0.0355119,0.5797117,0.000014190563,0.2820298,0.0015943324],"about_ca_topic_score_codex":0.0000041711887,"about_ca_topic_score_gemma":6.0928905e-8,"teacher_disagreement_score":0.5554579,"about_ca_system_score_codex":0.00008834513,"about_ca_system_score_gemma":0.00010448085,"threshold_uncertainty_score":0.59000134},"labels":[],"label_agreement":null},{"id":"W6957940510","doi":"10.60692/10ajh-wrk96","title":"Compatibility of Stabilized Whole Blood Products with CD4 Technologies and Their Suitability for Quality Assessment Programs","year":2014,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Enumeration; External quality assessment; Standardization; Quality assessment; Compatibility (geochemistry); Quality assurance","score_opus":0.05941014530680419,"score_gpt":0.27742861315425027,"score_spread":0.21801846784744608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957940510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974392,0.000017535323,0.023312911,0.00023518711,0.00009239958,0.0013043255,0.0002534734,0.00020646161,0.00018569092],"genre_scores_gemma":[0.9936124,1.0078021e-7,0.0061730836,0.000016339787,0.0000050538492,0.00012065864,0.000046871053,0.000004549059,0.00002092554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998479,0.00032581494,0.0006731694,0.00023846216,0.00005250299,0.00023102033],"domain_scores_gemma":[0.9985816,0.00008546694,0.0003888468,0.0005205225,0.00040610525,0.000017486645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021965057,0.0001823262,0.0005153228,0.00006690913,0.00011096175,0.000035587705,0.00014463636,0.00020920204,0.000004240679],"category_scores_gemma":[0.00019205299,0.00010184814,0.000060138354,0.00014957818,0.00039555662,0.00016845725,0.00007668891,0.000121227546,0.0000033782785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069705065,0.000097818265,0.95209706,0.004328885,0.00038195567,4.793082e-8,0.010789116,0.000001962023,0.0022451144,0.002396575,0.000018836765,0.026945565],"study_design_scores_gemma":[0.010532741,0.0031348253,0.61518234,0.00043721875,0.0003365964,0.00004002592,0.07324526,0.0006740405,0.29174912,0.00018425405,0.003651396,0.0008321829],"about_ca_topic_score_codex":0.000008929679,"about_ca_topic_score_gemma":0.0000014040816,"teacher_disagreement_score":0.33691472,"about_ca_system_score_codex":0.000028464414,"about_ca_system_score_gemma":0.000036879155,"threshold_uncertainty_score":0.41532466},"labels":[],"label_agreement":null},{"id":"W6958110223","doi":"10.6084/m9.figshare.12812511","title":"Additional file 1 of Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Rheumatoid arthritis; Confidence interval; TNF inhibitor; Radiography; Coverage probability","score_opus":0.031202565369390464,"score_gpt":0.25986130397516544,"score_spread":0.22865873860577496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958110223","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00094890856,0.00044809765,6.406926e-7,0.00021431714,0.000039683273,0.0002143263,0.9980687,0.000029622439,0.000035720623],"genre_scores_gemma":[0.04409005,0.00002014373,0.0012710295,0.00097002083,0.000041691084,0.00021817829,0.95336366,0.000015896281,0.000009318066],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989479,0.00017296622,0.0003097494,0.00030055575,0.000082490405,0.0001863414],"domain_scores_gemma":[0.9979494,0.0015052913,0.00018823196,0.00013884115,0.00017861639,0.000039620598],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003336921,0.00017933141,0.00037759327,0.00008848308,0.000053158794,0.0000071418076,0.00011561998,0.00018483131,0.91325235],"category_scores_gemma":[0.0035660001,0.00013040136,0.00007937353,0.0002844079,0.00007433016,0.000042177984,0.00005562895,0.0002492059,0.00023678826],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036742145,0.00023317861,0.0007200101,0.000052820626,0.00006296734,0.000007379489,0.000021172942,4.045951e-7,0.000055196833,2.5592752e-7,0.98976713,0.008712082],"study_design_scores_gemma":[0.003020172,0.0016838084,0.08958949,0.019719027,0.000014533843,8.3911385e-7,0.000040374598,0.00019076462,0.0044797235,0.00000665023,0.8808463,0.0004082863],"about_ca_topic_score_codex":6.146022e-7,"about_ca_topic_score_gemma":0.0000022214504,"teacher_disagreement_score":0.91301554,"about_ca_system_score_codex":0.000012762472,"about_ca_system_score_gemma":0.00004416649,"threshold_uncertainty_score":0.5317613},"labels":[],"label_agreement":null},{"id":"W6958164583","doi":"10.60692/bw3ys-35y80","title":"Compatibility of Stabilized Whole Blood Products with CD4 Technologies and Their Suitability for Quality Assessment Programs","year":2014,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Enumeration; External quality assessment; Standardization; Quality assessment; Compatibility (geochemistry); Quality assurance","score_opus":0.05941014530680419,"score_gpt":0.27742861315425027,"score_spread":0.21801846784744608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958164583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974392,0.000017535323,0.023312911,0.00023518711,0.00009239958,0.0013043255,0.0002534734,0.00020646161,0.00018569092],"genre_scores_gemma":[0.9936124,1.0078021e-7,0.0061730836,0.000016339787,0.0000050538492,0.00012065864,0.000046871053,0.000004549059,0.00002092554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998479,0.00032581494,0.0006731694,0.00023846216,0.00005250299,0.00023102033],"domain_scores_gemma":[0.9985816,0.00008546694,0.0003888468,0.0005205225,0.00040610525,0.000017486645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021965057,0.0001823262,0.0005153228,0.00006690913,0.00011096175,0.000035587705,0.00014463636,0.00020920204,0.000004240679],"category_scores_gemma":[0.00019205299,0.00010184814,0.000060138354,0.00014957818,0.00039555662,0.00016845725,0.00007668891,0.000121227546,0.0000033782785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069705065,0.000097818265,0.95209706,0.004328885,0.00038195567,4.793082e-8,0.010789116,0.000001962023,0.0022451144,0.002396575,0.000018836765,0.026945565],"study_design_scores_gemma":[0.010532741,0.0031348253,0.61518234,0.00043721875,0.0003365964,0.00004002592,0.07324526,0.0006740405,0.29174912,0.00018425405,0.003651396,0.0008321829],"about_ca_topic_score_codex":0.000008929679,"about_ca_topic_score_gemma":0.0000014040816,"teacher_disagreement_score":0.33691472,"about_ca_system_score_codex":0.000028464414,"about_ca_system_score_gemma":0.000036879155,"threshold_uncertainty_score":0.41532466},"labels":[],"label_agreement":null},{"id":"W6958228504","doi":"10.6084/m9.figshare.13175906.v1","title":"Knowledge and awareness of biosimilars and shared decision-making among gastroenterology team members in Colorado, USA","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Nocebo Effect; Reading (process); Nocebo; Quarter (Canadian coin)","score_opus":0.03882943514673702,"score_gpt":0.3126654341597372,"score_spread":0.27383599901300015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958228504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9410393,0.006248791,0.000033469507,0.00083695544,0.00018535243,0.00061659684,0.049668502,0.00005836964,0.0013126121],"genre_scores_gemma":[0.9978515,0.000027917016,0.00051268813,0.0006199608,0.000014624117,0.000023174904,0.00091785967,0.000012324007,0.000019942367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883497,0.00016919957,0.0003139228,0.00037396056,0.000026849519,0.00028112836],"domain_scores_gemma":[0.9991304,0.0005202798,0.00010965767,0.0001245333,0.000059308248,0.000055790828],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010504385,0.0001706153,0.0004213365,0.000097966935,0.000057294223,0.00001429202,0.0001751041,0.0002938384,0.022131369],"category_scores_gemma":[0.0010723432,0.00014653018,0.00005325881,0.00019616992,0.00011323078,0.00007807736,0.00032237935,0.00025579298,0.0000355955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014640733,0.00028210957,0.63555604,0.0008587469,0.00027964154,0.000056415633,0.0017474794,0.00001252088,0.013092567,0.000030211888,0.3206004,0.026019815],"study_design_scores_gemma":[0.003156496,0.0010903333,0.9359449,0.0034188852,0.000086115506,0.00006561885,0.00039517978,0.0013370333,0.008242363,0.00013274248,0.04563959,0.0004907105],"about_ca_topic_score_codex":0.000006879843,"about_ca_topic_score_gemma":0.00020225177,"teacher_disagreement_score":0.30038893,"about_ca_system_score_codex":0.000013235456,"about_ca_system_score_gemma":0.000030901807,"threshold_uncertainty_score":0.9787625},"labels":[],"label_agreement":null},{"id":"W6958281618","doi":"10.6084/m9.figshare.10297454","title":"MOESM1 of Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis","year":2019,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Infliximab; Insulin glargine; Retrospective cohort study; Insulin; MEDLINE","score_opus":0.024890258997745232,"score_gpt":0.22859118140100737,"score_spread":0.20370092240326215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958281618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7088845,0.001706606,0.0000043178848,0.0013133085,0.00013585336,0.00055664114,0.28733099,0.0000073348942,0.000060495007],"genre_scores_gemma":[0.99659866,0.00001838708,0.000092795926,0.00057541096,0.000007350761,0.000011969642,0.0025835894,0.000006697738,0.000105164014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989928,0.00020385502,0.00030266633,0.00023884501,0.00007123803,0.0001905759],"domain_scores_gemma":[0.9988417,0.00045865888,0.00021085044,0.00035953376,0.00011285332,0.000016388669],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008025814,0.00013362923,0.00040509176,0.00005912023,0.000041675812,0.000008954361,0.00027860652,0.00016921313,0.024320142],"category_scores_gemma":[0.0007729782,0.000075638854,0.00013018408,0.00059114123,0.00006226606,0.000046796373,0.00023718765,0.00031159804,0.00000839825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005129006,0.00020793975,0.79569143,0.00011256827,0.0033341572,0.000011931961,0.00048371247,0.00046682006,0.043147497,0.00004066347,0.15089612,0.0050942665],"study_design_scores_gemma":[0.0006713327,0.000036126094,0.9712977,0.00019704715,0.0001945434,0.0000017674463,0.000067435154,0.00062755094,0.014400901,0.00002344442,0.012376933,0.00010521834],"about_ca_topic_score_codex":0.13212489,"about_ca_topic_score_gemma":0.26414812,"teacher_disagreement_score":0.28771418,"about_ca_system_score_codex":0.00007793045,"about_ca_system_score_gemma":0.0001935113,"threshold_uncertainty_score":0.97657174},"labels":[],"label_agreement":null},{"id":"W6958397419","doi":"10.6084/m9.figshare.18281248","title":"Diagnostic accuracy of dried blood spots for serology of vaccine-preventable diseases: a systematic review","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Serology; Dried blood spot; Diagnostic accuracy; Dried blood; Diagnostic test; Antibody; Confidence interval; Blood test; Rubella","score_opus":0.028869669416566778,"score_gpt":0.3077441904642681,"score_spread":0.27887452104770133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958397419","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00278098,0.36916947,0.00001419474,0.00074314367,0.00029089948,0.0061057885,0.620658,0.00006415816,0.00017335288],"genre_scores_gemma":[0.84263647,0.0012409815,0.0004429338,0.0042723618,0.000059591395,0.008522462,0.14069961,0.00008271046,0.0020428752],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99843234,0.00047118578,0.000596176,0.00022257262,0.000045573564,0.0002321698],"domain_scores_gemma":[0.9958786,0.0031138915,0.0004826849,0.0003784518,0.00012085802,0.000025554316],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002233633,0.00013739782,0.0008628351,0.000054828055,0.00008778038,0.0000024062138,0.00038794414,0.00009060221,0.09658221],"category_scores_gemma":[0.011965845,0.0001119222,0.0002702637,0.00020755662,0.000012626993,0.000032131968,0.0002554827,0.00014549923,0.000037194615],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017985505,0.0009794136,0.00032092663,0.57266,0.0011860507,0.000012704754,0.00005807526,0.0000046769273,0.0048354957,0.00019156844,0.4192623,0.00030891807],"study_design_scores_gemma":[0.014394222,0.006021954,0.008551674,0.72680604,0.024776908,0.00064734765,0.0005936428,0.00009333089,0.105968274,0.0024854129,0.10752599,0.0021352032],"about_ca_topic_score_codex":0.000003979663,"about_ca_topic_score_gemma":0.0000014663153,"teacher_disagreement_score":0.8398555,"about_ca_system_score_codex":0.000013103958,"about_ca_system_score_gemma":0.00006813448,"threshold_uncertainty_score":0.9963568},"labels":[],"label_agreement":null},{"id":"W6959056778","doi":"10.1021/ac3018229.s001","title":"Reusable Solid-Phase Microextraction\\nCoating for Direct\\nImmersion Whole-Blood Analysis and Extracted Blood Spot Sampling Coupled\\nwith Liquid Chromatography–Tandem Mass Spectrometry and Direct\\nAnalysis in Real Time–Tandem Mass Spectrometry","year":2016,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Mass spectrometry; Detection limit; Dried blood spot; Extraction (chemistry); Liquid chromatography–mass spectrometry; Analytical Chemistry (journal); Matrix (chemical analysis); Sample preparation; Coating","score_opus":0.0270525187348146,"score_gpt":0.31632726254833476,"score_spread":0.28927474381352014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6959056778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.912049,0.011528547,0.004162481,0.00085344503,0.00021318697,0.0016594041,0.06687292,0.0004631721,0.0021978808],"genre_scores_gemma":[0.967164,0.001004853,0.019698177,0.000105064784,0.00018005742,0.00014302156,0.009990594,0.00009660865,0.0016176137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963114,0.0003289858,0.00092639576,0.0012300386,0.0001518762,0.0010512675],"domain_scores_gemma":[0.99661654,0.0019085506,0.00057014846,0.00052515056,0.0002080965,0.00017151404],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00090949645,0.0005742511,0.0013880391,0.0014031808,0.00046399218,0.00012639223,0.0002990798,0.0007570295,0.01486944],"category_scores_gemma":[0.0012704727,0.00043894458,0.00048538958,0.0025316214,0.00011667106,0.00030151027,0.00014960402,0.0004634664,0.000045347304],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038850887,0.00037769735,0.0075757364,0.000102023994,0.0033284456,0.000030578798,0.000030030438,0.0000014851798,0.98650986,0.000004449524,0.0009062412,0.000744947],"study_design_scores_gemma":[0.010225179,0.002014737,0.03181829,0.0017529627,0.0082741175,0.00012368588,0.00023091926,0.00052461267,0.93940085,0.00012615528,0.0039352938,0.0015731915],"about_ca_topic_score_codex":0.000060154158,"about_ca_topic_score_gemma":0.00008298846,"teacher_disagreement_score":0.056882318,"about_ca_system_score_codex":0.000097405056,"about_ca_system_score_gemma":0.00007005651,"threshold_uncertainty_score":0.9998062},"labels":[],"label_agreement":null},{"id":"W6965810099","doi":"10.3899/jrheum.2025-0314.149","title":"Injection Site Pain and Adherence in Patients Switching from Reference Adalimumab to AVT02 - EASE PAIN Trial","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Arthritis Research Centre of Canada; Dalhousie University; Micromolding Solutions (Canada); Centre hospitalier de l'Université Laval","funders":"","keywords":"Adalimumab; Visual analogue scale; Ankylosing spondylitis; Psoriatic arthritis; Population; Ulcerative colitis; Quality of life (healthcare); Injection site; Etanercept","score_opus":0.016160424980553062,"score_gpt":0.2784093558315459,"score_spread":0.2622489308509929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6965810099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991451,0.0007572844,0.005635409,0.0012461249,0.0006541003,0.00018258134,0.000007391198,0.000006771635,0.000059321577],"genre_scores_gemma":[0.99833876,0.000115416806,0.00046084894,0.0009947122,0.0000047615013,0.000002553762,0.000002898515,0.0000043744412,0.00007568983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579555,0.0032033927,0.0006027491,0.00014274985,0.00004010787,0.00021543891],"domain_scores_gemma":[0.99731916,0.0021423618,0.00026367244,0.00015607603,0.00008802809,0.00003069412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003852414,0.00012672195,0.00043062147,0.00018334627,0.00009733795,0.0000121466355,0.00022818331,0.00023878459,0.00009613501],"category_scores_gemma":[0.002248198,0.000080232785,0.000048957118,0.00020119386,0.00009389801,0.000054186177,0.000099321325,0.00055599486,0.000008991055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06731823,0.00052938354,0.6654479,0.00004723903,0.00040543135,0.0000055217743,0.0016865012,0.0000143753505,0.009560556,0.0007929483,0.0073403623,0.24685158],"study_design_scores_gemma":[0.23821662,0.041681577,0.609016,0.0048688794,0.0011704328,0.0006075206,0.005807567,0.0009748233,0.00676661,0.0533645,0.03552623,0.0019992362],"about_ca_topic_score_codex":0.0009427697,"about_ca_topic_score_gemma":0.00047899145,"teacher_disagreement_score":0.24485235,"about_ca_system_score_codex":0.000036995592,"about_ca_system_score_gemma":0.00006648698,"threshold_uncertainty_score":0.32717982},"labels":[],"label_agreement":null},{"id":"W6968408985","doi":"10.5281/zenodo.15615538","title":"Biosimilars in the Era of Artificial Intelligence: Canada's Health Regulations and Their Role in the Approval Process","year":2025,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Process (computing); Product (mathematics); Quality (philosophy); Key (lock); Health care; Healthcare system","score_opus":0.03221565830325024,"score_gpt":0.290833726371683,"score_spread":0.25861806806843274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6968408985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5631914,0.008404655,0.011054587,0.3289117,0.0005528467,0.005202298,0.0011177447,0.00028373837,0.08128104],"genre_scores_gemma":[0.9986356,0.000059008744,0.000049385104,0.0010811382,0.000008723163,9.47182e-8,0.00008097872,0.000043487464,0.000041580217],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985023,0.00083263125,0.0002471557,0.00017227288,0.000053158,0.00019249372],"domain_scores_gemma":[0.99952894,0.00010576419,0.000057327237,0.00020166744,0.00009415393,0.00001213926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013961138,0.00007197481,0.00012095467,0.00009224257,0.00056931906,0.00006560068,0.00053398253,0.000056304467,0.00035472584],"category_scores_gemma":[0.00031658311,0.000043510103,0.000018066026,0.00068781583,0.000258108,0.00003096207,0.00015082667,0.0003524517,0.000008162064],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002077047,0.0005039924,0.00013848253,0.00015614399,0.000073536874,0.0000033875713,0.013928056,0.00006757893,0.006147172,0.060795933,0.043180775,0.8747972],"study_design_scores_gemma":[0.0005817263,0.0005175702,0.032546923,0.00020494037,0.000026987569,0.000099438366,0.05141536,0.0012726296,0.011792716,0.019738533,0.88150203,0.00030115535],"about_ca_topic_score_codex":0.0027909067,"about_ca_topic_score_gemma":0.0017931781,"teacher_disagreement_score":0.8744961,"about_ca_system_score_codex":0.000041223215,"about_ca_system_score_gemma":0.000028909395,"threshold_uncertainty_score":0.43787995},"labels":[],"label_agreement":null},{"id":"W6976422627","doi":"10.60692/j9m7n-n5054","title":"The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019","year":2020,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Terminology; Competition (biology); Biopharmaceutical; Product (mathematics); Member states","score_opus":0.020852287530561838,"score_gpt":0.22368758561273347,"score_spread":0.20283529808217163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976422627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907747,0.0007915008,0.001529305,0.0039484776,0.00050813326,0.0007042484,0.00076064136,0.00011913002,0.0008638475],"genre_scores_gemma":[0.9985498,0.0000016914373,0.00028124836,0.0009771585,0.000033637138,0.000012698694,0.000016830652,0.0000052149276,0.00012169905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905515,0.000112536596,0.0004551176,0.00013053867,0.00005886473,0.0001877913],"domain_scores_gemma":[0.99942535,0.000027967248,0.00018690935,0.00022555298,0.000078372774,0.000055859862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029977478,0.00012886064,0.00025607776,0.000052037874,0.000112526686,0.000051452815,0.00016143172,0.00018052367,0.000033493543],"category_scores_gemma":[0.000029684694,0.00007577286,0.000054187058,0.00013400057,0.00010692702,0.00011954144,0.00009781048,0.00009867562,0.00013735164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026461007,0.000016523736,0.7050651,0.0011146332,0.0014455449,0.0000067123615,0.11215158,0.000020810658,0.0022627846,0.0018690117,0.13470776,0.038693476],"study_design_scores_gemma":[0.0040034647,0.0007595994,0.7667823,0.00067008706,0.00031000635,0.0000488084,0.01586937,0.0008741169,0.10277863,0.00001300261,0.107082374,0.00080826756],"about_ca_topic_score_codex":0.0000024961637,"about_ca_topic_score_gemma":1.1443819e-7,"teacher_disagreement_score":0.10051584,"about_ca_system_score_codex":0.000009024022,"about_ca_system_score_gemma":0.000014845803,"threshold_uncertainty_score":0.30899277},"labels":[],"label_agreement":null},{"id":"W6976568214","doi":"10.6084/m9.figshare.14853224","title":"Additional file 1 of Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"","keywords":"Immunogenicity; Biosimilar; Insulin glargine; Diabetes mellitus; Insulin; Clinical trial","score_opus":0.03648264879626843,"score_gpt":0.2728259093846413,"score_spread":0.23634326058837285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976568214","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08168113,0.006124257,1.0027434e-7,0.00048598787,0.000014557107,0.00035319064,0.9112775,0.000013242972,0.00005003965],"genre_scores_gemma":[0.2935839,0.0002383562,0.00065450923,0.00056667667,0.000042994583,0.00037182946,0.7044111,0.00002312821,0.000107531334],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986361,0.00034259495,0.00034265613,0.0003271263,0.00008301914,0.00026846497],"domain_scores_gemma":[0.9959645,0.003265652,0.00018904971,0.00026504477,0.0002902386,0.00002548491],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012066875,0.00021578326,0.000399024,0.000048762733,0.00020167162,0.00002234922,0.00019899565,0.00018617573,0.26054472],"category_scores_gemma":[0.0039201956,0.000111833055,0.00004726246,0.00031517242,0.00030616552,0.00008467304,0.00029272292,0.00040398058,0.000018911109],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023900215,0.00037303808,0.0035307556,0.00024624335,0.0007531236,0.0000057679927,0.00018389785,3.1263446e-7,0.0006063752,0.000010468679,0.9685883,0.025462711],"study_design_scores_gemma":[0.0047263247,0.00092848146,0.23811385,0.0035119762,0.00017366442,0.0000052420714,0.00054711243,0.000013265301,0.06456806,0.00016152325,0.6867691,0.0004813694],"about_ca_topic_score_codex":0.00000227414,"about_ca_topic_score_gemma":0.000013911362,"teacher_disagreement_score":0.28181916,"about_ca_system_score_codex":0.000019092944,"about_ca_system_score_gemma":0.00011693596,"threshold_uncertainty_score":0.74013126},"labels":[],"label_agreement":null},{"id":"W6976711216","doi":"10.60692/spxza-v7t82","title":"The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019","year":2020,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Terminology; Competition (biology); Biopharmaceutical; Product (mathematics); Member states","score_opus":0.020852287530561838,"score_gpt":0.22368758561273347,"score_spread":0.20283529808217163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976711216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907747,0.0007915008,0.001529305,0.0039484776,0.00050813326,0.0007042484,0.00076064136,0.00011913002,0.0008638475],"genre_scores_gemma":[0.9985498,0.0000016914373,0.00028124836,0.0009771585,0.000033637138,0.000012698694,0.000016830652,0.0000052149276,0.00012169905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905515,0.000112536596,0.0004551176,0.00013053867,0.00005886473,0.0001877913],"domain_scores_gemma":[0.99942535,0.000027967248,0.00018690935,0.00022555298,0.000078372774,0.000055859862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029977478,0.00012886064,0.00025607776,0.000052037874,0.000112526686,0.000051452815,0.00016143172,0.00018052367,0.000033493543],"category_scores_gemma":[0.000029684694,0.00007577286,0.000054187058,0.00013400057,0.00010692702,0.00011954144,0.00009781048,0.00009867562,0.00013735164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026461007,0.000016523736,0.7050651,0.0011146332,0.0014455449,0.0000067123615,0.11215158,0.000020810658,0.0022627846,0.0018690117,0.13470776,0.038693476],"study_design_scores_gemma":[0.0040034647,0.0007595994,0.7667823,0.00067008706,0.00031000635,0.0000488084,0.01586937,0.0008741169,0.10277863,0.00001300261,0.107082374,0.00080826756],"about_ca_topic_score_codex":0.0000024961637,"about_ca_topic_score_gemma":1.1443819e-7,"teacher_disagreement_score":0.10051584,"about_ca_system_score_codex":0.000009024022,"about_ca_system_score_gemma":0.000014845803,"threshold_uncertainty_score":0.30899277},"labels":[],"label_agreement":null},{"id":"W6976880958","doi":"10.6084/m9.figshare.13175906","title":"Knowledge and awareness of biosimilars and shared decision-making among gastroenterology team members in Colorado, USA","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Nocebo Effect; Reading (process); Nocebo; Quarter (Canadian coin)","score_opus":0.03882943514673702,"score_gpt":0.3126654341597372,"score_spread":0.27383599901300015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976880958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9410393,0.006248791,0.000033469507,0.00083695544,0.00018535243,0.00061659684,0.049668502,0.00005836964,0.0013126121],"genre_scores_gemma":[0.9978515,0.000027917016,0.00051268813,0.0006199608,0.000014624117,0.000023174904,0.00091785967,0.000012324007,0.000019942367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883497,0.00016919957,0.0003139228,0.00037396056,0.000026849519,0.00028112836],"domain_scores_gemma":[0.9991304,0.0005202798,0.00010965767,0.0001245333,0.000059308248,0.000055790828],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010504385,0.0001706153,0.0004213365,0.000097966935,0.000057294223,0.00001429202,0.0001751041,0.0002938384,0.022131369],"category_scores_gemma":[0.0010723432,0.00014653018,0.00005325881,0.00019616992,0.00011323078,0.00007807736,0.00032237935,0.00025579298,0.0000355955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014640733,0.00028210957,0.63555604,0.0008587469,0.00027964154,0.000056415633,0.0017474794,0.00001252088,0.013092567,0.000030211888,0.3206004,0.026019815],"study_design_scores_gemma":[0.003156496,0.0010903333,0.9359449,0.0034188852,0.000086115506,0.00006561885,0.00039517978,0.0013370333,0.008242363,0.00013274248,0.04563959,0.0004907105],"about_ca_topic_score_codex":0.000006879843,"about_ca_topic_score_gemma":0.00020225177,"teacher_disagreement_score":0.30038893,"about_ca_system_score_codex":0.000013235456,"about_ca_system_score_gemma":0.000030901807,"threshold_uncertainty_score":0.9787625},"labels":[],"label_agreement":null},{"id":"W6977061073","doi":"10.6084/m9.figshare.10297463","title":"MOESM2 of Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis","year":2019,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Infliximab; Insulin glargine; Retrospective cohort study; Insulin; MEDLINE","score_opus":0.024890258997745232,"score_gpt":0.22859118140100737,"score_spread":0.20370092240326215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977061073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70563495,0.001727043,0.0000045237102,0.0013185744,0.00013748225,0.00056329597,0.29054546,0.0000074225422,0.00006124225],"genre_scores_gemma":[0.9966032,0.000018383804,0.000092620015,0.00057534996,0.0000073499027,0.000011967125,0.0025793177,0.0000066963958,0.0001051468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998993,0.00020385747,0.00030270813,0.00023884521,0.00007124765,0.00019035736],"domain_scores_gemma":[0.99884105,0.00045840588,0.00021085897,0.00035955242,0.00011379,0.000016367976],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008015933,0.00013363222,0.00040509115,0.000059122,0.000041675168,0.00000895465,0.00027861347,0.0001692189,0.024328485],"category_scores_gemma":[0.00077093975,0.00007564064,0.00013017819,0.00059115863,0.00006226524,0.000046801273,0.00023719204,0.00031167438,0.00000839928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051136856,0.00020680428,0.79702365,0.00011194001,0.0033159987,0.000011865814,0.00048055965,0.0004565067,0.043058474,0.000040306524,0.14968663,0.005095884],"study_design_scores_gemma":[0.00067210867,0.0000360591,0.9714717,0.0001966472,0.00019415219,0.000001756119,0.00006724635,0.00061575393,0.014295029,0.00002338347,0.012321119,0.00010500087],"about_ca_topic_score_codex":0.13212276,"about_ca_topic_score_gemma":0.26446387,"teacher_disagreement_score":0.2909682,"about_ca_system_score_codex":0.00007794336,"about_ca_system_score_gemma":0.00019351559,"threshold_uncertainty_score":0.9765634},"labels":[],"label_agreement":null},{"id":"W6977393001","doi":"10.6084/m9.figshare.19076418.v1","title":"Additional file 1 of Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biosimilar; Cohort; Cohort study; Cumulative incidence; Table (database); Cumulative dose; Off-label use","score_opus":0.02540190930525595,"score_gpt":0.28904897434118165,"score_spread":0.2636470650359257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977393001","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25951216,0.00006156214,3.5401754e-8,0.000041010197,0.00008573321,0.0005883499,0.73967665,0.000013955878,0.000020532349],"genre_scores_gemma":[0.47691008,0.000001217406,0.0008054313,0.0008136916,0.00003623674,0.0012190329,0.5198433,0.000023311071,0.00034770992],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99832237,0.00038276878,0.00047514174,0.00037806557,0.00013884714,0.00030282236],"domain_scores_gemma":[0.99870825,0.0007172254,0.00017949443,0.00023218588,0.0001038975,0.000058955957],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013066857,0.00011288609,0.0004709286,0.00012896181,0.0001646583,0.00003285183,0.0003109033,0.00009040566,0.90265405],"category_scores_gemma":[0.00088282657,0.00016152457,0.000109501474,0.0006358525,0.0000072182274,0.00006970755,0.00038884638,0.00021794107,0.00007467609],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002165893,0.00047584184,0.13345362,0.000036539015,0.000116651965,0.0000057765847,0.00022473306,0.0000018507162,0.000107872,3.92233e-8,0.8619302,0.003625245],"study_design_scores_gemma":[0.00038396698,0.00050313555,0.7277867,0.0008848277,0.000009484459,8.0472813e-7,0.0005430218,8.254857e-7,0.00007798054,0.0000028803504,0.26968598,0.00012036138],"about_ca_topic_score_codex":0.011474562,"about_ca_topic_score_gemma":0.004219305,"teacher_disagreement_score":0.90257937,"about_ca_system_score_codex":0.00014457264,"about_ca_system_score_gemma":0.00015664796,"threshold_uncertainty_score":0.9951081},"labels":[],"label_agreement":null},{"id":"W6981568813","doi":"","title":"Equity valuation : WestJet Airlines","year":2019,"lang":"en","type":"dissertation","venue":"Repositório Institucional da Universidade Católica Portuguesa (Universidade Católica Portuguesa)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Valuation (finance); Discounted cash flow; Pre-money valuation; Equity (law); Market value; Cash flow; Market price; Intrinsic value (animal ethics)","score_opus":0.04158037999897821,"score_gpt":0.3083020295044996,"score_spread":0.26672164950552135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981568813","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20426829,0.025760068,0.002314572,0.015057087,0.030455489,0.010002892,0.0052250205,0.0035289398,0.7033876],"genre_scores_gemma":[0.6856302,0.0024218636,0.002041526,0.00161592,0.00080295413,0.00006857311,0.037854243,0.0004241264,0.26914063],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99049115,0.0007434255,0.0020632187,0.0033461992,0.0011515862,0.0022044145],"domain_scores_gemma":[0.99213517,0.0005498712,0.0024929494,0.002554978,0.0015475582,0.00071944745],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0013670243,0.0021631583,0.0027094493,0.0020229574,0.0012501233,0.00023398436,0.0025964181,0.004482016,0.003994755],"category_scores_gemma":[0.00048667224,0.0023245786,0.0017692833,0.0018323947,0.00094071653,0.0012080136,0.0009350109,0.003343691,0.0012091025],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008303247,0.0049120774,0.0024693562,0.0033689474,0.015941426,0.004848846,0.005225163,0.00033871585,0.4183742,0.14161187,0.2678387,0.12676746],"study_design_scores_gemma":[0.0061155655,0.0013013028,0.024353357,0.001650495,0.0054962756,0.0013261363,0.0069417134,0.00019314115,0.021991419,0.0011428995,0.92413795,0.0053497576],"about_ca_topic_score_codex":0.0007271363,"about_ca_topic_score_gemma":0.0004587129,"teacher_disagreement_score":0.65629923,"about_ca_system_score_codex":0.0017480328,"about_ca_system_score_gemma":0.003306042,"threshold_uncertainty_score":0.9995686},"labels":[],"label_agreement":null},{"id":"W6982667939","doi":"","title":"Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results","year":2017,"lang":"en","type":"other","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Payment; Term (time); Work (physics); Financial Audit","score_opus":0.031457721045606096,"score_gpt":0.317004787028174,"score_spread":0.28554706598256785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6982667939","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000016563293,0.00879044,0.00056987983,0.001163236,0.0042837877,0.0002606696,0.0002169133,0.00021194591,0.9845015],"genre_scores_gemma":[0.00011514021,0.0011718209,0.003166289,0.0011879486,0.0003870159,0.0000074762565,0.00007506306,0.000112056165,0.9937772],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982576,0.00013370956,0.00040721407,0.00069344835,0.000050528735,0.00045751024],"domain_scores_gemma":[0.99771595,0.00006913561,0.00065941276,0.0014768182,0.000043894714,0.000034814882],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045263607,0.000394043,0.00066719047,0.0001294049,0.00016451407,0.000038236547,0.0004051882,0.001959998,0.0021009643],"category_scores_gemma":[0.00024996823,0.00028088005,0.00023909283,0.00004379782,0.00050937675,0.00002644354,0.000095258525,0.0005658346,0.00057949655],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077105,0.000058684982,0.000024289222,0.000021740272,0.00018932733,0.000081426835,0.00001079394,6.3807226e-9,0.0012461074,0.00029644356,0.9906956,0.007298457],"study_design_scores_gemma":[0.0005370552,0.000119896715,0.00018765284,0.00017995348,0.00010199741,0.00011677654,0.0000031014345,3.3123234e-7,0.0023902503,0.00033201923,0.9956209,0.00041007673],"about_ca_topic_score_codex":0.00016994828,"about_ca_topic_score_gemma":0.00039190555,"teacher_disagreement_score":0.009275718,"about_ca_system_score_codex":0.000018794915,"about_ca_system_score_gemma":0.0001088968,"threshold_uncertainty_score":0.99996436},"labels":[],"label_agreement":null},{"id":"W6991917940","doi":"","title":"Intellipharmaceutics Announces Third Quarter 2017 Results","year":2017,"lang":"en","type":"other","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Period (music); Work (physics)","score_opus":0.06580398014300567,"score_gpt":0.364965401759808,"score_spread":0.29916142161680237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6991917940","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.7454554e-7,0.009283856,0.0002500385,0.0013456683,0.0030128665,0.00019076045,0.0004499769,0.00020590243,0.9852604],"genre_scores_gemma":[0.000081308885,0.0027375794,0.0013981157,0.00075716275,0.0002784111,0.0000050040294,0.000117217955,0.00008214146,0.9945431],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986314,0.00017780176,0.00026398635,0.00048763352,0.000041723462,0.000397458],"domain_scores_gemma":[0.998629,0.000118197444,0.00032992868,0.0008447968,0.000040137522,0.00003798637],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00041706473,0.00034295357,0.0005241789,0.00013351257,0.0001349046,0.00004819017,0.0006710945,0.0013212382,0.005420714],"category_scores_gemma":[0.00014684703,0.00022778906,0.00017890241,0.000033452947,0.0006034099,0.000027123571,0.00013410056,0.0006193975,0.0029204327],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080685255,0.0000482213,0.000013571527,0.000026248246,0.0003452635,0.000010262752,0.00001832131,5.7390057e-9,0.00066468416,0.000278643,0.9919444,0.0065697203],"study_design_scores_gemma":[0.0006173397,0.000096243355,0.000016474114,0.00015129943,0.00013520829,0.00002102455,0.000024681185,0.0000016935662,0.002400895,0.000111497204,0.9960871,0.0003365457],"about_ca_topic_score_codex":0.00012826778,"about_ca_topic_score_gemma":0.00018477405,"teacher_disagreement_score":0.009282602,"about_ca_system_score_codex":0.000013870736,"about_ca_system_score_gemma":0.0000462398,"threshold_uncertainty_score":0.99997526},"labels":[],"label_agreement":null},{"id":"W6995632458","doi":"","title":"The Pegasus spyware scandal: a critical review of Citizen Lab's \"CatalanGate\"","year":2023,"lang":"en","type":"other","venue":"London School of Economics and Political Science Research Online (London School of Economics and Political Science)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Universidad de Córdoba; Universidad Nacional de Educación a Distancia","keywords":"Politics; National security; Interrogation; Public opinion; Variety (cybernetics); Public trust","score_opus":0.06620927868947948,"score_gpt":0.39941448544437486,"score_spread":0.3332052067548954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995632458","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33600435,0.1312037,0.000031799056,0.14803466,0.005319573,0.0058645383,0.019638954,0.0002905273,0.3536119],"genre_scores_gemma":[0.57719755,0.36808136,0.0032020481,0.0036822844,0.0014059525,0.00010020744,0.00011644688,0.0006165509,0.04559761],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925499,0.00042944084,0.0017724929,0.0013815109,0.0003084256,0.0035582378],"domain_scores_gemma":[0.99174005,0.0035555528,0.00044069558,0.0011238308,0.0008832258,0.0022566344],"candidate_categories":["metaresearch","metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0115730725,0.00052483054,0.0016562046,0.0009805425,0.0005916542,0.00025457444,0.0020554913,0.0006127107,0.0010189923],"category_scores_gemma":[0.01594933,0.0003771603,0.00031840708,0.0010193414,0.028183449,0.00033202049,0.0016400227,0.0013524151,0.00008774495],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000095505195,0.00016803165,0.001062071,0.0010420268,0.00008730866,0.00000342284,0.000006871164,4.0776231e-7,0.0005041328,0.9869105,0.007593329,0.0025263836],"study_design_scores_gemma":[0.0046898774,0.003906366,0.024260381,0.010177098,0.00065247726,0.00030844743,0.0015564924,0.0011380056,0.016089968,0.22635649,0.7079595,0.0029049243],"about_ca_topic_score_codex":0.0039548874,"about_ca_topic_score_gemma":0.00074414036,"teacher_disagreement_score":0.760554,"about_ca_system_score_codex":0.0004497505,"about_ca_system_score_gemma":0.0039022963,"threshold_uncertainty_score":0.9998942},"labels":[],"label_agreement":null},{"id":"W6996047524","doi":"","title":"Real-World Safety Data from Patients With Rheumatic Diseases Treated With CT-P13, An Infliximab Biosimilar: An Interim Analysis from an Observational Study","year":2019,"lang":"en","type":"article","venue":"Oxford University Research Archive (ORA) (University of Oxford)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Infliximab; Observational study; Interim analysis; Adverse effect; Ankylosing spondylitis; Rheumatoid arthritis; Pneumonia; Psoriatic arthritis; Tuberculosis","score_opus":0.08152729118823879,"score_gpt":0.3232313010287865,"score_spread":0.2417040098405477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6996047524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98389465,0.000014691296,0.0012006868,0.00018999398,0.000031561573,0.000903446,0.01250758,0.00008253495,0.0011748527],"genre_scores_gemma":[0.9701765,0.00013333427,0.007177075,0.000031043583,0.000011492595,3.3647254e-7,0.021450516,0.000026384841,0.0009932778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950298,0.002215037,0.00027675062,0.0013522896,0.0004568447,0.00066925393],"domain_scores_gemma":[0.99604267,0.00072621024,0.00028662966,0.0020712307,0.00052814995,0.00034509072],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005693394,0.00038515564,0.0009428978,0.0011170533,0.0007981405,0.000057656118,0.0025623243,0.0001298228,0.0024833253],"category_scores_gemma":[0.000044772205,0.0003511999,0.00014851095,0.0018990575,0.001217988,0.001727443,0.0013518382,0.0006949015,0.000013939171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009780822,0.0034956157,0.9783634,0.000019000616,0.0038274399,0.00007491786,0.000995094,0.000059417398,0.00054788927,0.00021521302,0.00019560728,0.0024255824],"study_design_scores_gemma":[0.006328438,0.0038764148,0.96510375,0.00007258874,0.0015754127,5.918411e-7,0.014309258,0.003071509,0.000045468856,0.00013375995,0.00502437,0.00045846147],"about_ca_topic_score_codex":0.0194104,"about_ca_topic_score_gemma":0.04693552,"teacher_disagreement_score":0.02752512,"about_ca_system_score_codex":0.00020763377,"about_ca_system_score_gemma":0.00031252622,"threshold_uncertainty_score":0.999894},"labels":[],"label_agreement":null},{"id":"W7000798929","doi":"","title":"Growth strategy for an emerging biopharmaceutcal company","year":2006,"lang":"en","type":"dissertation","venue":"Summit (Simon Fraser University)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Simon Fraser University","keywords":"Commercialization; Negotiation; Resource (disambiguation); Biopharmaceutical; Drug development; Human resources; Pharmaceutical industry; Public health; Work (physics)","score_opus":0.040956481863518905,"score_gpt":0.30781967371617486,"score_spread":0.26686319185265595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000798929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86421776,0.00518449,0.0025817025,0.0005034474,0.007306284,0.0026004608,0.00266245,0.0007998496,0.11414358],"genre_scores_gemma":[0.8099351,0.0003165222,0.001079472,0.00026515144,0.0002819884,0.000006150267,0.012529362,0.000115129944,0.17547111],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982383,0.0002313834,0.0002847025,0.000655138,0.00005757734,0.00053285976],"domain_scores_gemma":[0.9990797,0.00012620601,0.00020761896,0.00026881078,0.00023863236,0.0000790415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017996655,0.00041604487,0.0005479944,0.00046986624,0.00034752954,0.00003386208,0.00053192733,0.0010416907,0.00054281484],"category_scores_gemma":[0.000022381091,0.00042840804,0.0003236837,0.00041396503,0.00014317238,0.0001691052,0.00003688506,0.0006003073,0.000048859212],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010734154,0.0030103403,0.08203672,0.0018139165,0.0038652474,0.00034322162,0.000108436674,0.00008234191,0.034550115,0.037020817,0.74734807,0.07908661],"study_design_scores_gemma":[0.004089843,0.0007352631,0.0024317838,0.000121801335,0.0013271226,3.852105e-8,0.0150470855,0.00010430325,0.12287351,0.0008142114,0.8511182,0.0013368039],"about_ca_topic_score_codex":0.00035846836,"about_ca_topic_score_gemma":0.02456199,"teacher_disagreement_score":0.10377015,"about_ca_system_score_codex":0.000087045686,"about_ca_system_score_gemma":0.00011904747,"threshold_uncertainty_score":0.9998168},"labels":[],"label_agreement":null},{"id":"W7001394037","doi":"","title":"Intellipharmaceutics Announces First Quarter 2017 Results","year":2017,"lang":"en","type":"other","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Period (music); Government (linguistics); Work (physics)","score_opus":0.06284510629534533,"score_gpt":0.35458654178769333,"score_spread":0.291741435492348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7001394037","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.7747554e-7,0.008830234,0.00022119073,0.0024210748,0.0027892848,0.00019199024,0.0005101974,0.0001799131,0.9848557],"genre_scores_gemma":[0.00012789508,0.0034590403,0.0010830434,0.0005378113,0.0002751502,0.000005927086,0.00012326016,0.000094156174,0.9942937],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873126,0.00011461663,0.00025144476,0.00047747025,0.000037974376,0.00038720996],"domain_scores_gemma":[0.9986611,0.000134798,0.0003103642,0.0008204684,0.00003561084,0.00003768158],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00033894816,0.00033520293,0.0004934549,0.00012844645,0.0001784883,0.00004704339,0.00064977293,0.0012071915,0.010139668],"category_scores_gemma":[0.00014857706,0.00022699444,0.00016916699,0.000033263543,0.00058635883,0.000025293146,0.0001317587,0.00052018324,0.0027529374],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072619216,0.000051265284,0.000019657322,0.00003632811,0.0003190698,0.000010215261,0.000018556402,1.1267248e-8,0.00016183265,0.00014894338,0.9940677,0.005093791],"study_design_scores_gemma":[0.0006473852,0.00009239295,0.000020952784,0.00019094249,0.00012606513,0.000019714671,0.000018846402,0.0000022177906,0.0012736795,0.000055333807,0.99721813,0.00033434315],"about_ca_topic_score_codex":0.00020759109,"about_ca_topic_score_gemma":0.0006892113,"teacher_disagreement_score":0.009437979,"about_ca_system_score_codex":0.000015576745,"about_ca_system_score_gemma":0.00003554127,"threshold_uncertainty_score":0.9980235},"labels":[],"label_agreement":null},{"id":"W7001809268","doi":"","title":"L'inspection des établissements industriels et la lutte contre les accidents du travail : de l'Acte des manufactures (1885) à la Loi sur les accidents du travail (1909)","year":2023,"lang":"fr","type":"other","venue":"Archipelago (University of Quebec in Montreal)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Poison control; Political action; Preventive action","score_opus":0.022416576582208653,"score_gpt":0.24459608589662135,"score_spread":0.2221795093144127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7001809268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722987,0.004192512,0.002115489,0.0007030609,0.00041677745,0.00066933007,0.00038714183,0.0002193651,0.01899766],"genre_scores_gemma":[0.8094078,0.018472467,0.00079848256,0.00012481723,0.0000978172,0.000003957744,0.00011577446,0.00019409785,0.1707848],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9938121,0.0034697999,0.00058567594,0.0009124961,0.000210438,0.001009492],"domain_scores_gemma":[0.99698645,0.0015596864,0.00059796654,0.0004862301,0.0001665847,0.00020306402],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014814399,0.000779713,0.0012446401,0.00081295404,0.00069252,0.000090067624,0.001022991,0.0023087675,0.0031028292],"category_scores_gemma":[0.00051168806,0.0008398204,0.00048766934,0.00049195817,0.0033418527,0.00038329835,0.0004480943,0.0016892563,0.000093947056],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010962083,0.0008893485,0.26086146,0.00026831107,0.0016574343,0.0006034027,0.012763692,0.000041775715,0.0020784503,0.000786346,0.009159663,0.7097939],"study_design_scores_gemma":[0.0037529166,0.00022521507,0.95381194,0.0012727982,0.00067803136,0.00008738195,0.017595604,0.00004260798,0.00091194885,0.0027791592,0.018151565,0.00069082837],"about_ca_topic_score_codex":0.66691434,"about_ca_topic_score_gemma":0.9795147,"teacher_disagreement_score":0.70910305,"about_ca_system_score_codex":0.0004087651,"about_ca_system_score_gemma":0.00027711358,"threshold_uncertainty_score":0.99940526},"labels":[],"label_agreement":null},{"id":"W7008058012","doi":"","title":"ADMA Biologics Provides Corporate Update and Reports Second Quarter 2017 Financial Results","year":2017,"lang":"en","type":"other","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Financial Audit; Earnings; Payment","score_opus":0.03941729289040248,"score_gpt":0.2852185978463663,"score_spread":0.2458013049559638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7008058012","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028516795,0.018109627,0.00017011623,0.001406948,0.0033983751,0.00075821346,0.0012550029,0.00028234706,0.9743342],"genre_scores_gemma":[0.0012760519,0.0012749386,0.0024092942,0.00082815473,0.00020956204,0.0000134706925,0.00030748034,0.00007967197,0.9936014],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981164,0.00019441218,0.00043286895,0.00080965395,0.000029449768,0.00041724526],"domain_scores_gemma":[0.9977414,0.00006897301,0.0012006034,0.0008876891,0.000050018043,0.00005129788],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006245995,0.00041636382,0.0007294349,0.0001295571,0.00018126275,0.000059018785,0.00025480668,0.001795535,0.0035153052],"category_scores_gemma":[0.0004093389,0.00027312708,0.00012326046,0.00003466846,0.0008154465,0.00004151168,0.00018560937,0.00048776885,0.00019681049],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010274955,0.000035916248,0.00020128953,0.00004467129,0.00013781954,0.00014275275,0.0000055631835,1.9509383e-9,0.0012271943,0.00043870264,0.98960805,0.008055292],"study_design_scores_gemma":[0.00057469704,0.00023498743,0.0009987319,0.00011818818,0.00008623426,0.00023994819,0.0000045910638,3.4665237e-7,0.0016820799,0.0018107092,0.993827,0.00042247318],"about_ca_topic_score_codex":0.000083258274,"about_ca_topic_score_gemma":0.00072268053,"teacher_disagreement_score":0.019267173,"about_ca_system_score_codex":0.000010398048,"about_ca_system_score_gemma":0.000109092514,"threshold_uncertainty_score":0.9999721},"labels":[],"label_agreement":null},{"id":"W7010589370","doi":"","title":"Intégration des médicaments biosimilaires à la pratique de l’oncologie","year":2022,"lang":"fr","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cancer treatment; Colonic disease; Drug industry","score_opus":0.26898431156639263,"score_gpt":0.5677113646052262,"score_spread":0.29872705303883357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7010589370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5844341,0.37127218,0.0038056006,0.014298323,0.005925485,0.0016179878,0.0008207231,0.00011276924,0.01771282],"genre_scores_gemma":[0.88927555,0.09076526,0.0051088533,0.0052161287,0.00028821055,0.00022781343,0.00005529566,0.000092382135,0.008970512],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99070024,0.0062312526,0.0012470463,0.00065867376,0.00028028432,0.0008824793],"domain_scores_gemma":[0.996123,0.0017707353,0.0011013335,0.0005083965,0.0002749691,0.00022152599],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0058439053,0.00048802438,0.0010835512,0.0006818532,0.0011792996,0.00069527846,0.0031039335,0.0006273289,0.063564196],"category_scores_gemma":[0.0014499766,0.00045515154,0.00038888142,0.0012799206,0.0015143477,0.0011795626,0.0029343748,0.0018317656,0.000023557104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008266579,0.0017293681,0.19144827,0.00019917132,0.0010907273,0.00016111403,0.00038307204,0.00011474708,0.36461732,0.0015165801,0.2797073,0.15820566],"study_design_scores_gemma":[0.0012636312,0.00023585849,0.40368506,0.0005027288,0.00054801255,0.0003074257,0.00057573995,0.00009486719,0.1398954,0.029980315,0.42216378,0.0007471467],"about_ca_topic_score_codex":0.0013253754,"about_ca_topic_score_gemma":0.00013221095,"teacher_disagreement_score":0.30484146,"about_ca_system_score_codex":0.0007981249,"about_ca_system_score_gemma":0.0009754835,"threshold_uncertainty_score":0.99979},"labels":[],"label_agreement":null},{"id":"W7017295300","doi":"","title":"Assessing Functional Similarity of Biosimilar ABP 654 and Ustekinumab in Samples from Patients with Crohn&amp;rsquo;s Disease","year":2024,"lang":"en","type":"article","venue":"Dove Medical Press (Taylor and Francis Group)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ustekinumab; Biosimilar; Potency; Peripheral blood mononuclear cell; STAT4; Crohn disease; Clinical trial","score_opus":0.03510796267378329,"score_gpt":0.2859883953730435,"score_spread":0.2508804326992602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7017295300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8059816,0.037492312,0.15137228,0.0014364617,0.0013338142,0.00058725907,0.0013418038,0.00010257857,0.00035192023],"genre_scores_gemma":[0.9983249,0.000019565676,0.00080443866,0.0005188305,0.00007566712,0.000018055885,0.00021329914,0.000018951914,0.000006293883],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99815804,0.00025744468,0.00044265186,0.0005971915,0.0002041914,0.00034048202],"domain_scores_gemma":[0.9985347,0.0009284781,0.000069657144,0.00022423382,0.0000598752,0.00018309314],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048172192,0.0002606292,0.00048226703,0.000106695785,0.00010128757,0.000077231045,0.00014333765,0.00040007665,0.0010763713],"category_scores_gemma":[0.0004565836,0.00017591043,0.000082007056,0.00016887534,0.0008722972,0.00016629361,0.00015789115,0.0006000371,0.0000037171062],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00198093,0.0010517807,0.3708443,0.00065140444,0.00060590275,0.000106304826,0.0003962443,0.0000035173077,0.002741608,0.0019493024,0.000313794,0.6193549],"study_design_scores_gemma":[0.003557534,0.00016987877,0.97832036,0.00011080868,0.00036177176,0.00000835157,0.00007318729,0.0074747484,0.0005237081,0.002885713,0.0060439683,0.00046995093],"about_ca_topic_score_codex":0.0002839619,"about_ca_topic_score_gemma":0.000105081665,"teacher_disagreement_score":0.6188849,"about_ca_system_score_codex":0.000019717283,"about_ca_system_score_gemma":0.0000075613953,"threshold_uncertainty_score":0.9998368},"labels":[],"label_agreement":null},{"id":"W7018090948","doi":"","title":"Current perspectives on integrating biosimilars in oncology practice in Canada","year":2022,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Healthcare system; Immunogenicity; Health care; Alternative medicine; Clinical Practice; Clinical trial; Biological drugs","score_opus":0.19979706513910175,"score_gpt":0.5670853791953796,"score_spread":0.3672883140562778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7018090948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80630916,0.16448115,0.000052908043,0.0078105773,0.0037202598,0.0010665497,0.00022248075,0.000025390653,0.016311523],"genre_scores_gemma":[0.9871542,0.010399282,0.00027964226,0.0019297046,0.000037771035,0.00007427465,0.000010890357,0.000025691086,0.00008852874],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99514306,0.002626231,0.00093686086,0.0005560716,0.00021612576,0.00052168214],"domain_scores_gemma":[0.99644506,0.002300127,0.0007061509,0.0003215504,0.0001536866,0.000073431824],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002902729,0.00028487446,0.0008489856,0.0008483182,0.00025468323,0.000110011264,0.0018174873,0.00012506942,0.012501533],"category_scores_gemma":[0.002080069,0.00024899826,0.00011860785,0.0013279174,0.00016403254,0.00051134266,0.0011320658,0.0021371848,0.000004236318],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003144921,0.0039421683,0.44074744,0.000071135764,0.0005728446,0.0005386376,0.003403992,0.00050269085,0.12751636,0.0015895239,0.13717315,0.28079715],"study_design_scores_gemma":[0.0027334157,0.00021949466,0.37786135,0.00046256595,0.00013463637,0.00014677577,0.029794052,0.00008095958,0.022703972,0.0022882076,0.5626187,0.00095588405],"about_ca_topic_score_codex":0.2618573,"about_ca_topic_score_gemma":0.20846806,"teacher_disagreement_score":0.42544556,"about_ca_system_score_codex":0.0017207856,"about_ca_system_score_gemma":0.0015241422,"threshold_uncertainty_score":0.99999624},"labels":[],"label_agreement":null},{"id":"W7019686608","doi":"","title":"Integrating biosimilars into oncology practice","year":2022,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Infliximab; Health care; Healthcare system; Pharmacy; Alternative medicine","score_opus":0.2542726559425994,"score_gpt":0.5985677180986461,"score_spread":0.34429506215604666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7019686608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38581815,0.32902116,0.0061834627,0.049436543,0.019846633,0.004098717,0.0006581299,0.0004777935,0.2044594],"genre_scores_gemma":[0.9605018,0.009453722,0.011247794,0.015757093,0.00021273473,0.0001873971,0.0000620595,0.00010537804,0.0024720558],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945369,0.0028766063,0.0011432342,0.0006203112,0.0002450215,0.0005779726],"domain_scores_gemma":[0.9955948,0.0021569177,0.0012252257,0.00054233545,0.00035778873,0.00012295836],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004819847,0.00036381476,0.0010268964,0.00070782343,0.0009672525,0.0003375829,0.003279707,0.0002964277,0.052223224],"category_scores_gemma":[0.00234888,0.00030941918,0.00030104214,0.0013034989,0.00043477747,0.0011304502,0.0032398673,0.0018159967,0.00003917463],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097145734,0.0009910488,0.020431047,0.000039104772,0.00083050306,0.000105856074,0.000501759,0.000024036242,0.6330961,0.0010051235,0.23627944,0.105724536],"study_design_scores_gemma":[0.0009087933,0.00015266263,0.012029857,0.000079874444,0.00030614642,0.0002697044,0.0017938243,0.000021746697,0.08313605,0.0066082375,0.89418864,0.0005044894],"about_ca_topic_score_codex":0.00071616913,"about_ca_topic_score_gemma":0.000052564817,"teacher_disagreement_score":0.65790915,"about_ca_system_score_codex":0.00031891634,"about_ca_system_score_gemma":0.00035059592,"threshold_uncertainty_score":0.9999358},"labels":[],"label_agreement":null},{"id":"W7023629530","doi":"","title":"Perspectives actuelles sur l’intégration des médicaments biosimilaires à la pratique de l’oncologie au Canada","year":2022,"lang":"fr","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Work (physics); European union; Limiting","score_opus":0.17738408688313737,"score_gpt":0.5191764912986376,"score_spread":0.3417924044155003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7023629530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7058049,0.26243463,0.0006401559,0.015561109,0.0037657802,0.000975363,0.0009251,0.00004888935,0.009844063],"genre_scores_gemma":[0.9360062,0.05667791,0.001083976,0.0016160914,0.00021468331,0.000100582365,0.000029316303,0.000056828474,0.004214417],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9917894,0.0051426915,0.0010489287,0.00070712424,0.00034356967,0.0009682561],"domain_scores_gemma":[0.9952662,0.002613603,0.0010106493,0.00046319442,0.00039740323,0.00024894372],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038135755,0.0005268318,0.0010885559,0.00047409046,0.0014616479,0.00048770817,0.002675347,0.00045353596,0.038299564],"category_scores_gemma":[0.0020593966,0.00048793992,0.00031461177,0.0010043602,0.0014041949,0.0009668077,0.0019769834,0.0015182925,0.000004427267],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001083601,0.0020501502,0.2912202,0.0002692963,0.0021387031,0.00031359534,0.0017337645,0.00028730292,0.2312568,0.002675451,0.40291622,0.06405492],"study_design_scores_gemma":[0.0011304904,0.00016043772,0.57218605,0.00045034479,0.00048166834,0.00023214663,0.004860379,0.000068731555,0.08013483,0.0058720955,0.33362958,0.00079325243],"about_ca_topic_score_codex":0.3947292,"about_ca_topic_score_gemma":0.18900168,"teacher_disagreement_score":0.28096583,"about_ca_system_score_codex":0.0028551272,"about_ca_system_score_gemma":0.0064255586,"threshold_uncertainty_score":0.9998383},"labels":[],"label_agreement":null},{"id":"W7024029596","doi":"","title":"Protalix BioTherapeutics Reports 2017 Third Quarter Results and Provides Corporate Update","year":2017,"lang":"en","type":"other","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Risk management; Payment; Key (lock)","score_opus":0.04871906888237188,"score_gpt":0.3090232978968216,"score_spread":0.2603042290144497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7024029596","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024840818,0.012393687,0.0002205499,0.0029738983,0.0016613863,0.0012558881,0.00035033314,0.00032423995,0.9807952],"genre_scores_gemma":[0.00035559395,0.0018828769,0.003567305,0.0007861962,0.00013168015,0.000025152292,0.00012507325,0.00013805318,0.99298805],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818057,0.00019843178,0.00042275045,0.00075528433,0.000046247227,0.0003966914],"domain_scores_gemma":[0.99752784,0.000048179932,0.001209651,0.0011151391,0.000050397393,0.000048813632],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005969965,0.00042645045,0.0006603794,0.00014113255,0.00016764313,0.00009417016,0.00025305364,0.001376161,0.0008835472],"category_scores_gemma":[0.00009866747,0.00028132717,0.00011441507,0.000038024024,0.0008284475,0.000044147702,0.00013223507,0.00043741154,0.0001804855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011282673,0.00005352434,0.00016514634,0.000072888106,0.0004330454,0.00008493581,0.000014085113,2.5778715e-9,0.0028769812,0.00032697443,0.9890133,0.006846297],"study_design_scores_gemma":[0.0006111848,0.00017693952,0.0001564068,0.00021732324,0.00015701826,0.00024767482,0.000008335768,0.0000013229242,0.0031076602,0.0008355962,0.9940567,0.00042384182],"about_ca_topic_score_codex":0.0001646649,"about_ca_topic_score_gemma":0.00022778506,"teacher_disagreement_score":0.012192894,"about_ca_system_score_codex":0.00001155574,"about_ca_system_score_gemma":0.00007629771,"threshold_uncertainty_score":0.9999639},"labels":[],"label_agreement":null},{"id":"W7030255881","doi":"","title":"Monitorización farmacocinética de anticuerpos monoclonales","year":2016,"lang":"es","type":"dissertation","venue":"Deposito de Investigacion Universidad de Sevilla (University of Seville)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Population; STAT2","score_opus":0.011343900712257387,"score_gpt":0.2605217824161099,"score_spread":0.24917788170385252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7030255881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96408033,0.0053077447,0.005550377,0.003968451,0.0011323133,0.00077275647,0.0005113911,0.0002326908,0.01844396],"genre_scores_gemma":[0.9493669,0.014938064,0.01358871,0.000513053,0.00024617102,0.0000011769939,0.00027978275,0.00011323872,0.020952854],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99511015,0.0015135799,0.0006034766,0.001091896,0.00027275947,0.0014081303],"domain_scores_gemma":[0.99637735,0.0007512356,0.0009426049,0.0007287241,0.00058914605,0.0006109266],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.000763012,0.0009107994,0.0014213626,0.0008652662,0.0010924431,0.000057176225,0.001375466,0.0029608204,0.00086781057],"category_scores_gemma":[0.00022770997,0.0009907935,0.0008992406,0.00069845654,0.001530928,0.00035016242,0.0003245028,0.0012768673,0.00016451412],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023230102,0.00042512975,0.03773832,0.001370811,0.0028690516,0.0008937247,0.0047957688,0.000028525159,0.9168554,0.00976507,0.005916083,0.017019117],"study_design_scores_gemma":[0.010536135,0.0022462925,0.14626929,0.008112923,0.00952799,0.0012050136,0.04605186,0.0012285742,0.58019507,0.0024157937,0.18706018,0.0051508984],"about_ca_topic_score_codex":0.001613255,"about_ca_topic_score_gemma":0.00015750369,"teacher_disagreement_score":0.33666036,"about_ca_system_score_codex":0.00097654277,"about_ca_system_score_gemma":0.0013300556,"threshold_uncertainty_score":0.9992542},"labels":[],"label_agreement":null},{"id":"W7033133086","doi":"","title":"Ontario Pickling Cucumber &amp; Pepper Cultivar Trials 1982","year":2014,"lang":"en","type":"report","venue":"The Atrium (University of Guelph)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cultivar; Pickling; Loam; Harrow; Pepper; Irrigation","score_opus":0.09175038680183455,"score_gpt":0.31292794355277126,"score_spread":0.2211775567509367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7033133086","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18999033,0.029795764,0.021288065,0.019195555,0.023578566,0.0047207084,0.0019364239,0.0005751189,0.70891947],"genre_scores_gemma":[0.39900595,0.0016041812,0.0029079688,0.00023663243,0.0004494228,6.978021e-7,0.0004006348,0.00004564006,0.5953489],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969908,0.0012790962,0.0005478429,0.0005197905,0.00020026354,0.0004622106],"domain_scores_gemma":[0.99659985,0.0010555742,0.00094378006,0.00088449405,0.00046130715,0.000055020155],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005464038,0.00038687384,0.00164678,0.00016808802,0.00041343053,0.000014991094,0.0009352323,0.0012876614,0.010370073],"category_scores_gemma":[0.00080878945,0.00028697756,0.0009387704,0.000188151,0.0007618885,0.00006070648,0.0004638846,0.0012602797,0.000676952],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012325802,0.00030429848,0.0035890536,0.00036082996,0.005202005,0.000030241497,0.0026202623,0.0000061498367,0.2007216,0.0005360851,0.76949626,0.015900625],"study_design_scores_gemma":[0.0009451644,0.00010675413,0.009139673,0.00012582059,0.0018260892,0.0000684139,0.00029050309,0.0000012491159,0.000445115,0.0002049161,0.9864923,0.0003540055],"about_ca_topic_score_codex":0.092790775,"about_ca_topic_score_gemma":0.06083193,"teacher_disagreement_score":0.21699603,"about_ca_system_score_codex":0.00029469424,"about_ca_system_score_gemma":0.0007989745,"threshold_uncertainty_score":0.9999582},"labels":[],"label_agreement":null},{"id":"W7037608134","doi":"","title":"Edgefield County 2021-2022 Piedmont Technical College annual report","year":2023,"lang":"en","type":"article","venue":"The South Carolina State Library Digital Collections (South Carolina State Library)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Annual report; Technical report; Affect (linguistics); Statistical analysis; Quarter (Canadian coin)","score_opus":0.010656758749501376,"score_gpt":0.22861971206727547,"score_spread":0.2179629533177741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7037608134","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37250254,0.0049275155,0.0019982376,0.0401428,0.012378976,0.008156437,0.1602542,0.011369899,0.3882694],"genre_scores_gemma":[0.6064634,0.00024177684,0.00029256754,0.0014091666,0.00037858522,0.0002408506,0.0017052117,0.00025978335,0.3890087],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936669,0.00070099405,0.0017408095,0.0015769355,0.00040329772,0.0019111],"domain_scores_gemma":[0.99614114,0.000979811,0.0005992468,0.0017413286,0.00016958517,0.00036889713],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006000279,0.0010339804,0.0012749285,0.0010304446,0.0019031928,0.00058175117,0.0014565405,0.0007440451,0.0017690762],"category_scores_gemma":[0.00037344682,0.00078919367,0.00091807934,0.0070625413,0.0013486041,0.0025254674,0.0016875458,0.002021118,0.00075172447],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023743878,0.00044342503,0.0129417125,0.00011818064,0.0011157679,0.0018864044,0.0033263825,0.00018664458,0.0007197622,0.0017017402,0.9731066,0.0020789956],"study_design_scores_gemma":[0.0037173254,0.001484315,0.014850552,0.00014495326,0.00047502268,0.0015365637,0.0042745722,0.00024839843,0.010007229,0.026878444,0.9339982,0.002384418],"about_ca_topic_score_codex":0.000027162518,"about_ca_topic_score_gemma":0.000005927173,"teacher_disagreement_score":0.2339608,"about_ca_system_score_codex":0.00008806863,"about_ca_system_score_gemma":0.00096023007,"threshold_uncertainty_score":0.99945587},"labels":[],"label_agreement":null},{"id":"W7044976277","doi":"","title":"AltaGas Canada (TSE:ACI) Hits New 12-Month High After Analyst Upgrade","year":2019,"lang":"en","type":"other","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Upgrade; Key (lock); Focus (optics); Term (time)","score_opus":0.009673382048420621,"score_gpt":0.22770477410019785,"score_spread":0.21803139205177724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7044976277","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030659005,0.012096409,0.0004133786,0.0041213743,0.0037565317,0.0005139766,0.0005399552,0.00017138869,0.9783563],"genre_scores_gemma":[0.0016808924,0.00023930676,0.0014671377,0.0038247895,0.00032392808,0.000010115553,0.00016504263,0.00023257262,0.9920562],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99788594,0.00020700113,0.0003987063,0.0007278812,0.00009108538,0.0006894054],"domain_scores_gemma":[0.9987695,0.00010822284,0.00019946051,0.0007776388,0.00002826372,0.000116865674],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012731354,0.0005579997,0.00096871814,0.00019906023,0.000043507065,0.000023047729,0.00045899648,0.0013546826,0.10707518],"category_scores_gemma":[0.000043892174,0.00039617514,0.00022695433,0.0001749143,0.00014472516,0.00002064692,0.00015382428,0.00062168017,0.0010547409],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005906629,0.0000438831,0.00028771284,0.000039657112,0.00068975997,0.000029080176,0.0000045915995,1.5329954e-7,0.0003891086,0.00049078884,0.9958537,0.0021124992],"study_design_scores_gemma":[0.00072031806,0.000095986885,0.0007715171,0.000093549424,0.00024036897,0.000015017809,0.000015012775,9.187205e-7,0.0014085452,0.00005435262,0.9960299,0.00055451907],"about_ca_topic_score_codex":0.60244894,"about_ca_topic_score_gemma":0.78152555,"teacher_disagreement_score":0.1790766,"about_ca_system_score_codex":0.00011439242,"about_ca_system_score_gemma":0.00074475346,"threshold_uncertainty_score":0.99994177},"labels":[],"label_agreement":null},{"id":"W7067771594","doi":"","title":"New budget offers Canada a chance to get employee ownership right","year":2022,"lang":"en","type":"article","venue":"UVic’s Research and Learning Repository (University of Victoria)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Work (physics); Legislation; Payment","score_opus":0.025087729938060927,"score_gpt":0.26825520759737015,"score_spread":0.2431674776593092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7067771594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862368,0.0013399315,0.00024567882,0.0034596722,0.0012020706,0.000319533,0.000028520755,0.000057044355,0.007110727],"genre_scores_gemma":[0.9152449,0.000031949974,0.00068693305,0.000074953954,0.00008987241,0.0000011015517,0.000012488558,0.000011560765,0.083846256],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752975,0.0011946284,0.00012587279,0.00040587466,0.00025283193,0.0004910543],"domain_scores_gemma":[0.9989354,0.00041089542,0.00006850554,0.00023602048,0.00016110965,0.00018804897],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010337918,0.00012220436,0.00026755556,0.00017037675,0.0018473642,0.000020355514,0.0004351021,0.00011861672,0.0013253085],"category_scores_gemma":[0.00016881598,0.00012962589,0.000059083846,0.00046689244,0.0002046336,0.000056637487,0.00047673102,0.0014334822,0.000011965676],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004459182,0.00034353507,0.09105385,0.00022034656,0.0011144079,0.00087838457,0.011948818,0.0002114814,0.42014772,0.0015590427,0.4509853,0.01707791],"study_design_scores_gemma":[0.0007463642,0.0012350582,0.018890753,0.000024741013,0.000025942025,0.000041458174,0.0050786077,0.000017323682,0.005425032,0.00007924649,0.9682247,0.0002107403],"about_ca_topic_score_codex":0.14622457,"about_ca_topic_score_gemma":0.02061626,"teacher_disagreement_score":0.5172394,"about_ca_system_score_codex":0.00024835058,"about_ca_system_score_gemma":0.0005812045,"threshold_uncertainty_score":0.9995876},"labels":[],"label_agreement":null},{"id":"W7068187024","doi":"","title":"Fort Desolation","year":2022,"lang":"en","type":"article","venue":"Vědecká knihovna v Olomouci (Research Library in Olomouc)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Join (topology); Mercantilism; Government (linguistics)","score_opus":0.0901311856137442,"score_gpt":0.3646497111815568,"score_spread":0.27451852556781264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7068187024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8361242,0.013454354,0.00022860244,0.019365221,0.0022972827,0.002448952,0.00044457076,0.0007612464,0.12487558],"genre_scores_gemma":[0.9612284,0.00025516946,0.0017720617,0.0011893768,0.00010359872,0.0003774478,0.00033850074,0.000077592435,0.034657884],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933362,0.0031984495,0.00071865617,0.0009225726,0.0003509324,0.0014731976],"domain_scores_gemma":[0.99770087,0.0012494944,0.00011710751,0.00074418134,0.000067369154,0.00012096461],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030783345,0.00032367912,0.00051533745,0.0010512158,0.0009284682,0.00007846259,0.0011967875,0.0003803454,0.030737044],"category_scores_gemma":[0.000350832,0.00029853283,0.00020653575,0.0022529846,0.0006417948,0.0006239792,0.001734535,0.0026048736,0.0005704959],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030859886,0.0034372963,0.13830018,0.0001635126,0.0004869988,0.0006630411,0.0017478766,0.00012968546,0.18840373,0.066097304,0.465551,0.13193342],"study_design_scores_gemma":[0.0024409494,0.0013961667,0.021490246,0.00003509786,0.00002490259,0.0001953344,0.0011608743,0.0004020719,0.044385202,0.016776077,0.91100824,0.00068481924],"about_ca_topic_score_codex":0.00011083225,"about_ca_topic_score_gemma":0.000014587858,"teacher_disagreement_score":0.44545728,"about_ca_system_score_codex":0.00017594718,"about_ca_system_score_gemma":0.00031357727,"threshold_uncertainty_score":0.99994665},"labels":[],"label_agreement":null},{"id":"W7086628342","doi":"","title":"As Students Become Adults: The Role Of Occupational Therapy In The Transition Process","year":2010,"lang":"en","type":"article","venue":"Sound Ideas (University of Puget Sound)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Process (computing); Occupational therapy; Transition (genetics); Work (physics)","score_opus":0.016885076783068106,"score_gpt":0.29993340862674717,"score_spread":0.28304833184367906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7086628342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977643,0.000282471,0.00020001682,0.0007120998,0.000121133795,0.00023841563,0.00004455411,0.000009614015,0.00062740024],"genre_scores_gemma":[0.9994726,0.000039425686,0.00010315832,0.0002188962,0.00001716003,8.4567955e-7,0.000024063793,0.000003928233,0.00011992808],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9991936,0.00022649016,0.00014155734,0.00016489376,0.00011425718,0.0001592184],"domain_scores_gemma":[0.99932307,0.0002062857,0.00012002916,0.00021673943,0.0001205693,0.000013294141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006127924,0.000099582016,0.0001802587,0.00007468135,0.00020347074,0.0000109307375,0.00062345155,0.00019257644,0.0006105821],"category_scores_gemma":[0.000041295236,0.00006727019,0.000118677,0.00022887047,0.0005654339,0.000105248524,0.000035389472,0.00035039734,0.000019271505],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006288989,0.0030839178,0.31248182,0.00011397216,0.0010070907,0.000011813536,0.07256665,0.000020377,0.018508026,0.5804234,0.00056504126,0.0049289213],"study_design_scores_gemma":[0.0014195498,0.00024883504,0.12828399,0.000015370506,0.00004663383,0.000013097877,0.021618525,0.0000140255925,0.00024005074,0.8469909,0.0010041787,0.00010482142],"about_ca_topic_score_codex":0.000374961,"about_ca_topic_score_gemma":0.00089541054,"teacher_disagreement_score":0.26656753,"about_ca_system_score_codex":0.000010375051,"about_ca_system_score_gemma":0.000047452348,"threshold_uncertainty_score":0.6685446},"labels":[],"label_agreement":null},{"id":"W7114932358","doi":"10.3390/jcm14248819","title":"Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Biosimilar; Adalimumab; Logistic regression; Adverse effect; Confidence interval; Retrospective cohort study; Inflammatory bowel disease","score_opus":0.05164266589261287,"score_gpt":0.45054122487020176,"score_spread":0.3988985589775889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7114932358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98399776,0.0068454794,0.0027515145,0.0045368634,0.0011771998,0.00052325707,0.000013985275,0.000008543043,0.00014539473],"genre_scores_gemma":[0.9977605,0.0008115245,0.0007469369,0.00047130417,0.0001018837,0.0000012160463,0.0000010253643,0.000007388593,0.00009823492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99598604,0.0017476901,0.0017292795,0.00024898982,0.00008664892,0.00020136718],"domain_scores_gemma":[0.9918979,0.006878299,0.0005813688,0.00018342647,0.00036963762,0.00008939938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076925745,0.00018151385,0.0015344378,0.00019130087,0.000062453524,0.000005155148,0.00018377107,0.00032191788,0.000050949828],"category_scores_gemma":[0.0049557425,0.00010593149,0.00013407358,0.00020868452,0.00085600466,0.000057705198,0.00012741578,0.000752433,5.668622e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005162527,0.0009598739,0.9388163,0.00030352332,0.0017267,0.00003093742,0.00015288878,1.6817789e-7,0.003654274,0.00013922447,0.00038987512,0.04866368],"study_design_scores_gemma":[0.021927126,0.0044383006,0.9597143,0.0009742833,0.0011658107,0.000017417811,0.00079462334,0.000013582126,0.001566057,0.0002725812,0.009010508,0.00010539407],"about_ca_topic_score_codex":0.000014107075,"about_ca_topic_score_gemma":0.0000041876583,"teacher_disagreement_score":0.048558287,"about_ca_system_score_codex":0.000020384654,"about_ca_system_score_gemma":0.00008908752,"threshold_uncertainty_score":0.5932844},"labels":[],"label_agreement":null},{"id":"W7116122509","doi":"10.5281/zenodo.17976351","title":"In Vivo CRO Market - Size & Upcoming Industry Trends (2024-2032) | #in Vivo CRO Market","year":2025,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Outsourcing; In vivo; Government (linguistics); Pharmaceutical industry; Food and drug administration; Preclinical research; Drug development","score_opus":0.023892605085640277,"score_gpt":0.2884278590626329,"score_spread":0.2645352539769926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116122509","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013701128,0.00092539506,0.00013691845,0.005298939,0.0011501295,0.00051359955,0.0005946867,0.00018524415,0.98982495],"genre_scores_gemma":[0.014680551,0.0004763684,0.00032998752,0.0012256402,0.000121601384,2.1745763e-7,0.0000039931083,0.0007356428,0.982426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99295956,0.00298185,0.0011409364,0.001298921,0.00021325251,0.0014054695],"domain_scores_gemma":[0.99771845,0.00048429784,0.0002654207,0.0009664357,0.00036577453,0.00019961422],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0033681747,0.0005671986,0.0008086172,0.0012266012,0.0016328914,0.0006956258,0.0018371345,0.001442611,0.96494997],"category_scores_gemma":[0.0022347225,0.00060417247,0.00022720099,0.0028936844,0.0009608142,0.0003562367,0.0026689218,0.0029459747,0.0002256842],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012347234,0.0006624162,0.00026057984,0.00017043688,0.00025218388,0.00010548355,0.00053764635,0.000007452512,0.0019806419,0.00088763307,0.98072296,0.013177842],"study_design_scores_gemma":[0.0025248788,0.00033197587,0.0053656027,0.00037744475,0.00009805797,0.00007201807,0.00060337776,0.00025798194,0.004220046,0.00028557706,0.9853234,0.00053961214],"about_ca_topic_score_codex":0.00042718774,"about_ca_topic_score_gemma":0.000086588465,"teacher_disagreement_score":0.9647243,"about_ca_system_score_codex":0.0007668866,"about_ca_system_score_gemma":0.00005439215,"threshold_uncertainty_score":0.99985373},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["insufficient_payload"],"domain":null,"study_design":"not_applicable","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W7116186900","doi":"10.5281/zenodo.17976352","title":"In Vivo CRO Market - Size & Upcoming Industry Trends (2024-2032) | #in Vivo CRO Market","year":2025,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Outsourcing; In vivo; Government (linguistics); Pharmaceutical industry; Food and drug administration; Preclinical research; Drug development","score_opus":0.023892605085640277,"score_gpt":0.2884278590626329,"score_spread":0.2645352539769926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116186900","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013701128,0.00092539506,0.00013691845,0.005298939,0.0011501295,0.00051359955,0.0005946867,0.00018524415,0.98982495],"genre_scores_gemma":[0.014680551,0.0004763684,0.00032998752,0.0012256402,0.000121601384,2.1745763e-7,0.0000039931083,0.0007356428,0.982426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99295956,0.00298185,0.0011409364,0.001298921,0.00021325251,0.0014054695],"domain_scores_gemma":[0.99771845,0.00048429784,0.0002654207,0.0009664357,0.00036577453,0.00019961422],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0033681747,0.0005671986,0.0008086172,0.0012266012,0.0016328914,0.0006956258,0.0018371345,0.001442611,0.96494997],"category_scores_gemma":[0.0022347225,0.00060417247,0.00022720099,0.0028936844,0.0009608142,0.0003562367,0.0026689218,0.0029459747,0.0002256842],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012347234,0.0006624162,0.00026057984,0.00017043688,0.00025218388,0.00010548355,0.00053764635,0.000007452512,0.0019806419,0.00088763307,0.98072296,0.013177842],"study_design_scores_gemma":[0.0025248788,0.00033197587,0.0053656027,0.00037744475,0.00009805797,0.00007201807,0.00060337776,0.00025798194,0.004220046,0.00028557706,0.9853234,0.00053961214],"about_ca_topic_score_codex":0.00042718774,"about_ca_topic_score_gemma":0.000086588465,"teacher_disagreement_score":0.9647243,"about_ca_system_score_codex":0.0007668866,"about_ca_system_score_gemma":0.00005439215,"threshold_uncertainty_score":0.99985373},"labels":[],"label_agreement":null},{"id":"W7117291427","doi":"10.3748/wjg.v31.i48.114355","title":"Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease","year":2025,"lang":"en","type":"article","venue":"World Journal of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Ustekinumab; Biosimilar; Inflammatory bowel disease; Drug; Crohn's disease; Inflammatory Bowel Diseases; Ulcerative colitis; Crohn disease","score_opus":0.006078753538397578,"score_gpt":0.30947431461362945,"score_spread":0.30339556107523186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117291427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9507028,0.0007227189,0.0006373627,0.04622569,0.0014308381,0.0002200575,0.000023025792,0.0000093661865,0.000028146142],"genre_scores_gemma":[0.9833684,0.000087307664,0.0007644709,0.015148253,0.00006918908,0.000012501555,0.0000021256053,0.000010841942,0.0005369424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965704,0.0010246749,0.0013501055,0.00040650234,0.000103190316,0.00054509344],"domain_scores_gemma":[0.9982105,0.0007445624,0.00025110738,0.0003189752,0.00019424513,0.0002806057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020535418,0.00025879237,0.000861702,0.0005513066,0.000051387164,0.000022387698,0.00042516913,0.00024695814,0.0004438772],"category_scores_gemma":[0.0012078385,0.0001933059,0.0002949285,0.00018761592,0.00059523823,0.00008511053,0.00034456968,0.0011363109,0.000007683617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072540212,0.00037663867,0.98122346,0.000033622582,0.00028573253,0.00034714208,0.00005042378,0.0000014200386,0.000044098753,0.00006642908,0.007533778,0.0027832498],"study_design_scores_gemma":[0.003574002,0.00033358755,0.9758623,0.00015145358,0.00013825308,0.00001831114,0.00008724159,0.000009467807,0.000031719683,0.0012515082,0.01843947,0.00010263433],"about_ca_topic_score_codex":0.000031555417,"about_ca_topic_score_gemma":0.0007409336,"teacher_disagreement_score":0.032665573,"about_ca_system_score_codex":0.00013238363,"about_ca_system_score_gemma":0.00031215244,"threshold_uncertainty_score":0.7882786},"labels":[],"label_agreement":null},{"id":"W7118798759","doi":"10.1080/17576180.2025.2586976","title":"2025 White Paper on Recent Issues in Bioanalysis: Redosing Patients with AAV Gene Therapy; CRS Immunogenicity Risk; Shedding Assays; NHP Studies Immunogenicity; CMC vs Bioanalytical Assays; Artificial Intelligence-Powered Genomic Pipelines for NGS ( <u>PART 3A</u> – Recommendations on Gene, Cell, and Vaccine Therapies Immunogenicity &amp; Technologies; Biotherapeutics &amp; Biosimilars Immunogenicity Assessment &amp; Clinical Relevance <u>PART 3B</u> – Regulatory Agencies’ Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell &amp; Vaccine Therapies)","year":2025,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Frontier Geosciences (Canada); Esri (Canada); Health Canada","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Health Canada; Eisai; U.S. Food and Drug Administration; Moderna; Daiichi Sankyo Europe; Exelixis; Regeneron Pharmaceuticals; Alnylam Pharmaceuticals; Alexion Pharmaceuticals; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"White paper; Excellence; Harmonization; Regulatory science; Agency (philosophy); Bioanalysis; Human use; Best practice","score_opus":0.060267720877984446,"score_gpt":0.36392681598259663,"score_spread":0.3036590951046122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7118798759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7990583,0.17557392,0.0065528,0.011064382,0.001632634,0.0034229902,0.0019069673,0.00070844847,0.000079516176],"genre_scores_gemma":[0.58313376,0.3682774,0.043295305,0.0021049955,0.00015474699,0.00041423322,0.0012257393,0.0002976474,0.0010961795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98390746,0.003180529,0.0060201534,0.003731321,0.00087624695,0.0022842889],"domain_scores_gemma":[0.98563987,0.004011988,0.003385651,0.0048817797,0.0019196098,0.00016110243],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.006504219,0.0026156798,0.004897913,0.0030715803,0.001825788,0.0003485014,0.0026504244,0.0026777077,0.000427645],"category_scores_gemma":[0.001479369,0.0020732067,0.002166924,0.005025556,0.0023287477,0.00039396403,0.0010388086,0.0028261743,0.000051557243],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03358873,0.014066171,0.113979794,0.0004266434,0.060129296,0.000009853774,0.0019851124,0.0010144251,0.575567,0.00076932297,0.0038988832,0.19456474],"study_design_scores_gemma":[0.014366719,0.005588769,0.030027268,0.0013726663,0.011746111,0.000016667185,0.0061455183,0.00058107136,0.55304474,0.004121549,0.36682582,0.0061631165],"about_ca_topic_score_codex":0.0003257853,"about_ca_topic_score_gemma":0.0018112967,"teacher_disagreement_score":0.36292693,"about_ca_system_score_codex":0.0014002221,"about_ca_system_score_gemma":0.00057281874,"threshold_uncertainty_score":0.99947435},"labels":[],"label_agreement":null},{"id":"W7126048515","doi":"10.1080/17576180.2025.2599698","title":"2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators &amp; Stability; Evaluation of NULISA; Neurofilament &amp; Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot &amp; FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A – Recommendations on Biomarkers Discovery, Development, Validation &amp; Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B – Regulatory Agencies’ Input on Biomarkers, IVD/CDx and Biomarker Assay Validation (BAV))","year":2025,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Health Canada; Eisai; U.S. Food and Drug Administration; Moderna; Regeneron Pharmaceuticals; Alnylam Pharmaceuticals; Alexion Pharmaceuticals; Daiichi Sankyo Europe; Exelixis; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"White paper; Excellence; Harmonization; Agency (philosophy); Bioanalysis; Best practice; Quality (philosophy); Expert opinion","score_opus":0.0952726767801078,"score_gpt":0.34582114803132485,"score_spread":0.25054847125121704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7126048515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9614438,0.005789266,0.021120448,0.0050058714,0.0011408589,0.0018453868,0.0005236529,0.00022932464,0.0029014351],"genre_scores_gemma":[0.98104835,0.0012649925,0.011580411,0.00050466345,0.0000448583,0.00014236169,0.003919689,0.00010658569,0.0013880652],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.983484,0.0074387537,0.003293365,0.0031403014,0.0013660943,0.0012774284],"domain_scores_gemma":[0.99072105,0.002606725,0.0029324458,0.002379932,0.0010460471,0.0003137848],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.018761316,0.0014235015,0.0020391846,0.008296857,0.00094221596,0.00079445314,0.0007703525,0.0009861048,0.0010830674],"category_scores_gemma":[0.0041390946,0.0013323388,0.0008438837,0.012007955,0.0010077484,0.0011873257,0.0004705767,0.0007850423,0.000046410136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020045496,0.0033792278,0.253141,0.0005694749,0.012477609,0.0000064374467,0.0005139861,0.00039647266,0.6782392,0.0000743044,0.0035318772,0.045665875],"study_design_scores_gemma":[0.009927419,0.0006332441,0.15363522,0.0034332946,0.029098287,0.000015423915,0.0050942358,0.014150154,0.68002594,0.0001974387,0.09871286,0.0050764917],"about_ca_topic_score_codex":0.00041533273,"about_ca_topic_score_gemma":0.0007391528,"teacher_disagreement_score":0.09950576,"about_ca_system_score_codex":0.0018516321,"about_ca_system_score_gemma":0.00065670314,"threshold_uncertainty_score":0.9998515},"labels":[],"label_agreement":null},{"id":"W7128773366","doi":"10.1080/17576180.2026.2617084","title":"2025 White Paper on Recent Issues in Bioanalysis: What is the Future of Bioanalytical LIMS? AI/ML Integration in Bioanalysis; Tear Sample Collection; Radiolabeled Mass Balance Studies; Chiral Assays; Bioanalysis of Antibody-Oligonucleotide &amp; Bicycle Drug Conjugates ( <u>PART 1A</u> – Recommendations on Mass Spectrometry Assays, Chromatography, Sample Preparation and Regulated Bioanalysis Sampling, Validating, Analyzing &amp; Reporting <u>PART 1B</u> – Regulatory Agencies’ Input on Regulated Bioanalysis/BMV)","year":2025,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Agência Nacional de Vigilância Sanitária","keywords":"Bioanalysis; White paper; Excellence; Harmonization; Agency (philosophy); Sample (material); Best practice; Regulatory science","score_opus":0.029927622621568374,"score_gpt":0.3526246322477707,"score_spread":0.3226970096262023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7128773366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7544989,0.15922004,0.010084625,0.065405995,0.0024224727,0.004326586,0.0023154595,0.00070824195,0.0010176831],"genre_scores_gemma":[0.89139885,0.07570135,0.021089355,0.0019365741,0.0002957476,0.00021286636,0.0042201816,0.00018609167,0.004959016],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98069847,0.004762881,0.008056151,0.003572127,0.0011937664,0.0017166017],"domain_scores_gemma":[0.984283,0.0036557463,0.006040845,0.0037538481,0.001978935,0.0002876315],"candidate_categories":["metaepi_narrow","bibliometrics","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.010044791,0.0019117169,0.0056845304,0.010280637,0.0012581197,0.00055726664,0.0013587435,0.0013754015,0.0014745916],"category_scores_gemma":[0.005412085,0.0015098557,0.0026877623,0.031195266,0.0018608286,0.000894031,0.00039811,0.0019016169,0.000028274388],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005594717,0.007000209,0.65990835,0.0009827607,0.115840666,0.00004191913,0.0047317524,0.008670734,0.13598299,0.0046639014,0.013558355,0.043023627],"study_design_scores_gemma":[0.02271453,0.0043577985,0.107996546,0.0167421,0.11982264,0.00006504367,0.06174859,0.08853851,0.3141316,0.016777169,0.23319718,0.013908293],"about_ca_topic_score_codex":0.0027804454,"about_ca_topic_score_gemma":0.010736734,"teacher_disagreement_score":0.55191183,"about_ca_system_score_codex":0.0012417391,"about_ca_system_score_gemma":0.00041034532,"threshold_uncertainty_score":0.999921},"labels":[],"label_agreement":null},{"id":"W7133198000","doi":"10.2310/6620.2006.x0002j","title":"Patch Testing Patients On Etanercept","year":2006,"lang":"en","type":"article","venue":"Dermatitis","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"","score_opus":0.017981115747095214,"score_gpt":0.24492952743104543,"score_spread":0.22694841168395022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133198000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7557337,0.0004877076,0.00057031814,0.0032928588,0.0012056162,0.00028127845,0.00014847818,0.00022909878,0.23805092],"genre_scores_gemma":[0.99219316,0.0000041904677,0.0018183858,0.0035115588,0.000039396065,0.0000054424568,0.000060242313,0.000009039373,0.0023586063],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9993122,0.000104425155,0.00018646357,0.00014907296,0.000029992414,0.0002178269],"domain_scores_gemma":[0.99957883,0.00017373578,0.00005064378,0.00013376444,0.000050849998,0.000012187921],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000073011324,0.00010050818,0.00013388637,0.000038874947,0.00010602865,0.0000136765575,0.0000888284,0.00014423612,0.00094886974],"category_scores_gemma":[0.000097727236,0.000080132566,0.00004593617,0.00011145831,0.000075220516,0.0000311287,0.000027226828,0.00014553766,0.0006179259],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000083901405,0.00041063872,0.3008653,0.00002594843,0.00005016716,0.000015193217,0.00004568508,0.000004340696,0.0062723383,0.0018007059,0.563652,0.1268493],"study_design_scores_gemma":[0.0006515674,0.00015188928,0.73793447,0.000032712353,0.00002211928,0.000014332165,0.00000832346,0.000016394379,0.02949197,0.0011119054,0.23038018,0.00018416511],"about_ca_topic_score_codex":0.00019230071,"about_ca_topic_score_gemma":0.000027564209,"teacher_disagreement_score":0.43706915,"about_ca_system_score_codex":0.000015553898,"about_ca_system_score_gemma":0.0000067949713,"threshold_uncertainty_score":0.9999644},"labels":[],"label_agreement":null},{"id":"W76024419","doi":"10.1177/135965350701200114","title":"HIV-1 drug resistance surveillance using dried whole blood spots","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; Public Health Agency of Canada","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Drug resistance; Dried blood spot; Drug; Virology; Internal medicine; Pharmacology; Biology; Chemistry; Microbiology; Chromatography","score_opus":0.02623441622039107,"score_gpt":0.29876182322360295,"score_spread":0.2725274070032119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W76024419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984665,0.0066826954,0.0015425492,0.0011579905,0.00057088747,0.00017523055,0.000035503504,0.00009170588,0.005078482],"genre_scores_gemma":[0.9766661,0.00032208744,0.0030362087,0.0006716581,0.00009104394,0.0000012349407,0.000015955593,0.000021859798,0.019173866],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985605,0.00023470797,0.00029559893,0.0003465582,0.000049181137,0.0005134938],"domain_scores_gemma":[0.999296,0.00020750784,0.000107657135,0.00030557605,0.000058770907,0.000024492405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010394773,0.00019873785,0.00032278243,0.00006926941,0.00019270266,0.000021095111,0.00022571076,0.00021433322,0.00018122104],"category_scores_gemma":[0.000034493514,0.00016020355,0.00013192474,0.000269146,0.00029375072,0.00007464749,0.00003571721,0.0002698843,0.000103537284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053976104,0.0001919043,0.028869571,0.0000069157873,0.00016829753,0.00002822358,0.00011213674,1.3937905e-7,0.95555425,0.00080680917,0.0040558996,0.009666114],"study_design_scores_gemma":[0.0018672985,0.000047938425,0.048609816,0.00003185341,0.000020372314,0.000013421387,0.00006120571,0.0000028346942,0.66485,0.00060497865,0.28353557,0.00035472645],"about_ca_topic_score_codex":0.000016493324,"about_ca_topic_score_gemma":0.00005160903,"teacher_disagreement_score":0.29070422,"about_ca_system_score_codex":0.000014703986,"about_ca_system_score_gemma":0.000023848135,"threshold_uncertainty_score":0.6532911},"labels":[],"label_agreement":null},{"id":"W86393321","doi":"","title":"BioPartnering North America--Spotlight on Canada.","year":2010,"lang":"en","type":"other","venue":"PubMed","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Investigational Drugs; Pipeline (software); Medicine; Library science; Engineering; Clinical trial; Computer science","score_opus":0.015622319357544379,"score_gpt":0.218985654244983,"score_spread":0.20336333488743863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W86393321","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015241488,0.0023219604,0.00002450417,0.0026075612,0.0061008288,0.0006797593,0.0005409181,0.0002509946,0.9873211],"genre_scores_gemma":[0.0023603216,0.000121265664,0.00014650593,0.0020371617,0.00029812014,0.00027889648,0.000103443606,0.00020643673,0.9944478],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987143,0.00008647862,0.0001833552,0.00039663166,0.00004956087,0.00056967465],"domain_scores_gemma":[0.99926245,0.0000944591,0.00014530189,0.00041318592,0.000014558484,0.00007002309],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008490916,0.00028836558,0.0004243731,0.00012459015,0.000053461095,0.000011306681,0.00030290333,0.0005884251,0.0033077619],"category_scores_gemma":[0.00011216086,0.00021536204,0.00008408246,0.0001446539,0.00018910442,0.0000064510205,0.000068313726,0.0007199052,0.000150114],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017431577,0.00003256823,0.00011936539,0.0000135480095,0.00016443325,0.000012503439,0.0000018207655,4.8446992e-8,0.00007592829,0.00006062875,0.8387042,0.16079749],"study_design_scores_gemma":[0.00018735518,0.000011442788,0.0059334645,0.000011173092,0.00005450417,0.000005576925,0.000002650577,1.2835164e-7,0.0013031579,0.00000343285,0.99220854,0.00027859787],"about_ca_topic_score_codex":0.060445238,"about_ca_topic_score_gemma":0.56236684,"teacher_disagreement_score":0.5019216,"about_ca_system_score_codex":0.000046615143,"about_ca_system_score_gemma":0.00009105246,"threshold_uncertainty_score":0.99760336},"labels":[],"label_agreement":null},{"id":"W96869817","doi":"10.20506/rst.26.2.1751","title":"Armonización internacional de los requisitos reglamentarios","year":2007,"lang":"es","type":"article","venue":"Revue Scientifique et Technique de l OIE","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Authorization; Pharmacovigilance; Guideline; European union; Business; Principal (computer security); Working group; Traceability; Animal health; Marketing authorization; Political science; Medicine; Veterinary medicine; Engineering; Computer science; Pharmacology; Law; International trade; Computer security","score_opus":0.02581380128380236,"score_gpt":0.3379442781951045,"score_spread":0.31213047691130213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W96869817","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11581334,0.0053933915,0.82798934,0.017323824,0.0036303245,0.002957889,0.0005049266,0.00068816013,0.025698816],"genre_scores_gemma":[0.8131888,0.0015973567,0.14451453,0.0070284056,0.0005999067,0.0001730557,0.00012676907,0.00013994564,0.032631237],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956883,0.00096124783,0.00084617746,0.0009917571,0.00013891749,0.0013735932],"domain_scores_gemma":[0.9977309,0.0005773941,0.00036112545,0.00084261916,0.0002486423,0.00023932186],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010108721,0.00047500155,0.00059848046,0.00050179573,0.00029800803,0.00017938616,0.00092711207,0.0014204814,0.0011535916],"category_scores_gemma":[0.00070496043,0.00046512237,0.0004304759,0.00069216464,0.00085603556,0.00015643482,0.00047301195,0.0017220667,0.00012752923],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025919353,0.00047377727,0.005125891,0.0013522878,0.0002176373,0.00037098333,0.0003931738,0.0000010407717,0.92887384,0.036832124,0.01608548,0.01001457],"study_design_scores_gemma":[0.0004814096,0.0002223783,0.0043129427,0.0043926104,0.00015622722,0.0011690919,0.00007461076,0.000040414157,0.8506865,0.007253701,0.130619,0.0005911418],"about_ca_topic_score_codex":0.0001098066,"about_ca_topic_score_gemma":0.000143298,"teacher_disagreement_score":0.6973755,"about_ca_system_score_codex":0.0006636258,"about_ca_system_score_gemma":0.00036479335,"threshold_uncertainty_score":0.9998759},"labels":[],"label_agreement":null}]}